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Elements of strict liability
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Definition ofdefect
Strict liabilitysfocus on the product risksibenefits
Strict liability defendantsburden
Manufacturersduty to investigate test and research
Negligent failure to warn adequate warning requires defense verdict
Elements of a negligent failure to warn
Negligent failure to warn definition of a defective product
Negligent failure to warn manufacturersduty to warn
Negligent failure to warn duty to warn
Negligent failure to warn duty to investigate test and research
Negligent failure to warn elements
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Proximate cause
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Harm increased in extent by othersunforeseeable physical condition
Compliance with standards regulations and statutes
FHSA Requirements
2 Counsel are working together to develop a set of stipulated facts
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Co pliance ith standards, regulations and statutes 
 e ire e ts 
2 Counsel are working together to develop a set of stipulated facts. 
LAINTIF 'S  y  -  
INSTRUCTIONNO
This is a product liability lawsuit brought by the Plaintiff Billie Major against the
Defendant Security Equipment Corporation also referred to as SEC In her complaint filed in this
Court Billie Major alleges that SEC is the manufacturer of pepper spray products that she was
exposed to during her employment as a prison guard
Ms Major alleges that certain of SECspepper spray products are defective because the
product labels do not warn that exposure to the pepper spray products create a risk of injury to the
respiratory system She also alleges that certain SEC pepper spray products are defective by design
because they create an unreasonable danger ofinjury Ms Major also alleges that SEC is negligent
in failing to provide adequate warning on its pepper spray product labels
SEC denies Ms Major allegations and asserts that its pepper spray products only cause
temporary effects SEC claims that its pepper spray products do not cause the kind of longterm
injury claimed by MsMajor SEC also claims that even if its pepper spray products caused
Ms Major injuries SEC did not know and that it should not have known that its pepper spray
products could cause a longterm injury to the respiratory system SEC also claims that the






PLAINTIFFSPROPOSED JURY INSTRUCTIONS 5
001531
 . 
is i   t li ilit  l it t  t  l intif , illi  j r, i t t  
f t, rit  i t r r ti n, l  r f rr  t   C. I  r l i t file  i  t i  
ourt, illie ajor alleges that S  is the anufacturer of pepper spray products that she as 
exposed to during her e ploy ent as a prison guard. 
s. ajor alleges that certain of SEC's pepper spray products are defective because the 
product labels do not arn that exposure to the pepper spray products create a risk of injury to the 
respiratory syste . he also alleges that certain  pepper spray products are defective by design 
se t  r t   r l  r f i j r . . j r l  ll  t t  i  li t 
in failing to provide adequate arning on its pepper spray product labels. 
S  denies s. ajor's allegations and asserts that its pepper spray products only cause 
t r r  ff t .  l i s t t it  r r  r t   t  t  i  f l -ter  
injury clai ed by s. ajor. SEC also clai s that, even if its pepper spray products caused 
s. ajor's injuries, SE  did not kno , and that it should not have kno n, that its pepper spray 
products could cause a long-ter  injury to the respiratory system.      






I TIFF'S   I S -  
INSTRUCTION NO
SEC admits that it is the manufacturer of a line of pepper spray products sold under the
name of SABRE Red SEC also admits that it markets its SABRE Red products to law
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 ts  t   a t rer   line    ts  r  
   .  l  its t t it ets its   t  t  l  






I TIF 'S  y I S -  
INSTRUCTION NO
Plaintiff Billie Major has brought her claims under two different legal theories The first
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l i tiff illie ajor  r t r l i s r t  iffere t l l t ri .  fir t 







I TIF 'S   S -  
INSTRUCTION NO
Under a theory of strict liability in order to prove the claim of product liability by a
manufacturer the plaintiff has the burden of proving each of the following propositions
The defendant was a manufacturer ofthe product as explained in these instructions
The product was defective as explained in these instructions
The defect existed when the product left the defendantscontrol
The defect was a proximate cause of injury to the plaintiff and
Thenature and extent ofthe injuries the elements of damages and the amount thereof
If you find from your consideration of all of the evidence that each ofthese propositions has
been proved then on the verdict form you should answer the question Yes If you find that any
of these propositions has not been proved you should answer the questionNo
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  the  f ct il ,  e  t   the    ia t    
a fact rer, t e lai tiff as t e r e  f r i   f t e f ll i  r siti s: 
e fe a t as  "manufa t r r" f t  r t, s l i e  i  t s  i str ti s; 
e r ct as "defective," as e laine  i  t ese i str cti s; 
e f t ist   t  r t l ft t e f ndant's trol; 
The defect as a proxi ate cause of injury to the plaintiff; and 
 t re  t t  t  i j ri , t e l t   ,  t  t t r of. 
If  fin  fr  r si r ti  f ll f t  i  t t  f t es  r sitions s 
 r , t e   t  r ict f r   s l  s r t e sti  "Y s." If  fi  t t  
f t ese r sitions as t ee  r ed,  s l  a s er t e esti  "N ." 






I TIFF'S  y  -  
INSTRUCTION NO
Under a theory of strict liability a product may be defective because ofa defect in its design
or manufacture or because of a failure to adequately warn the consumer of a hazard involved in the
foreseeable use of the product A product has a defect when it exposes a user or bystander to an
unreasonable risk of physical injury or if it is more dangerous than would be expected by an
ordinary person who may reasonably be expected to use it The law does not say what would be
expected by an ordinary person or who may reasonably be expected to use the product Both of
these issues are for you to decide
IDJI 1001 Product liability definition of defective product Modified only to the extent of






PLAINTIFFSPROPOSED JURY INSTRUCTIONS 9
001535
 . 
n   t   t ict lia ilit ,  r t   ti e ause   t i  it  i  
 a t re  se   ailur  t  t l   t e     i lve  i  t  
foreseeable use of the product.  product has a defect hen it exposes a user or bystander to an 
reas le is   i l i j ,  i  it is   t  l   t    
         .   s t     
expected by an ordinary person or ho ay reasonably be expected to use the product. oth of 
s       i . 
J  0.0 .1 - Product liability - i ition  ti e t. i ie  l  t  t  t t  






LAINTIF 'S    -  
INSTRUCTION NO
Under the theory of strict liability in determining whether a product is defective your
determination must be on the condition of the product when it left the product seller hands and
not on whether the product seller acted reasonably or unreasonably That is the focus is on the
condition of the product at the time of sale and not on the seller conduct You may find that a
product is defective and unreasonably dangerous even though the product seller has exercised all
possible care in the preparation and sale of his product
In making the determination of whether a product is defective you should weigh a number
of factors You may evaluate the adequacy of a products design by weighing the benefits of the
challenged design against the risk of danger inherent in that design including warnings on the label
and the instructions that come with the product You should consider the product as a whole when
making this consideration You may consider any label warnings or absence thereof You may
consider the likelihood that harm will occur and the gravity of the danger posed by the
challenged design You should consider whether the gravity of harm inherent to the product
outweighs the feasibility of a design that eliminates or reduces the risk of harm You should
consider whether a different design was feasible You should consider the economic costs
associated with a different design as compared to the costs associated with any danger posed by
the product as it was sold Any adverse consequences of altering the design of the product
should also be considered
A manufacturersplacement of warnings on a product may suffice to avoid liability under
a negligent failure to warn theory However a manufacturer may still be found liable under a
strict liability design defect theory if you determine upon balancing all pertinent factors
including the availability of safer alternative designs which are not at issue under a negligent
failure to warn theory a design defect exists
Hansen v Sunnyside Prods 55 Cal App 4th 1497 1518 Cal App 3d Dist 1997 a warning
does not automatically preclude liability In a design defect case the defendant retains the burden
to prove the absence of a design defect under a balancing of all relevant factors Citing
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r t  t r  f tri t li bility, i  t nni i  t r  r t i  "def tive" ur 
detennination ust be on the condition of the product hen it left the product seller's hands and 
t  t r t  r t ll r ct  r o abl  r r asonably. t is, t  f  i   t  
iti   t  t t t  ti   l   t  t  eller's nduct.   fi  t t  
product is defective and unreasonably dangerous even though the product seller has exercised all 
i l   i  t  r ti   l   i  uct. 
I  i  t  t nni ti   t r  r t i  f ctive,  l  i   r 
of factors. ou ay evaluate the adequacy of a product's design by eighing the benefits of the 
challenged design against the risk of danger inherent in that design, including arnings on the label, 
and the instructions that co e ith the product. ou should consider the product as a hole hen 
aking this consideration. ou ay consider any label arnings or absence thereof ou ay 
consider the likelihood that har  ill occur and the gravity of the danger posed by the 
lle e  sign. ou should consider hether the gravity of har  inherent to the product 
t i s t  f si ilit    i  t t li inate  r r  t  ri   r .  l  
i r t r  iffere t i   f i l .       
associated ith a different design as co pared to the costs associated ith any danger posed by 
t  r t s it s s l . ny adverse consequences of altering the design of the product 
s l  ls   si r . 
 anufacturer's place ent of arnings on a product ay suffice to avoid liability under 
 li e t f il r  t  r  t ory. r,  f t r r  still  f  li l  r  
strict liability design defect theory if you detennine upon balancing all pertinent factors, 
including the availability of safer alternative designs (which are not at issue under a negligent 
il  t   t ory),  i  t i t . 
ansen v. Sunnyside Prods., 55 Cal. pp. 4th 1497, 1518 (Cal. pp. 3d ist. 1997) (a arning 
es t t ti ll  r l e lia ilit . "In  si  f t s , t  f t r t i s t  r  
t  r  the s  f  si  f t er  l i  f ll r l t f t rs.") (Citing 






P I F'S P P S  J  I S IO S -  
INSTRUCTION NO
Under a strict liability theory the burden of showing the effect of an alternative design falls
on the defendant and not on the plaintiff Once a plaintiff shows a productsdesign was a cause of
her injury the burden shifts to the defendant to show that the product is not defective because the
benefits ofthe product outweigh its risks
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nder  strict lia ility t r , the rden  s ing t e fect   lte ti e i  lls 
on the defendant and not on the plaintiff. nce a plaintiff sho s a product's design as a cause of 
her injury, the burden shifts to the defendant to sho  that the product is not "defective" because the 
benefits of the product out eigh its risks. 






LAINTIF 'S  J y I I  -  
INSTRUCTION NO
Under a theory of strict liability a manufacturersfailure to adequately warn of its
productsreasonably foreseeable dangers renders that product defective A manufacturer has a
duty to warn A manufacturer has a duty to keep abreast of the current state of knowledge of its
products as acquired through research adverse reaction reports scientific literature testing and
other available methods A product related danger may be regarded as knowable if the available
scientific data gave rise to a reasonable inference that the danger is likely to exist A
manufacturer is held to the knowledge and skill of an expert and is required to test his products and
keep abreast of scientific discoveries related to its products but it has a duty to warn only of
dangers that the reasonable foresight of an expert could reveal
Richter v Limax Intern Inc 45 F3d 1464 146869 10Cir 1995 see also Mercer v Pittway
Corp 616NW2d602 624 Iowa 2000 the inquiry in a negligent failure to warn case is
whether a reasonable manufacturer knew or should have known of the danger in light of the
generally recognized and prevailing best scientific knowledge yet failed to provide adequate
warning to users or customers Pfeiffer v Eagle Mfg Co 771 F Supp 1133 1139DKan
1991 Bernier v Raymark Industries Inc 516A2d 534 53839 Me 1986 OwenIllinois Inc
v Zenibia 601 A2d633 63940Md 1992 see 402A RESTATEMENT SECOND OFTORTS 1965
strict product liability Potter v Chicago Pneumatic Tools Co 694A2d 1319 132829 Conn
1997 strict liability relieves plaintiff of burden ofproving manufacturer was negligent and allows
plaintiff to establish instead defective condition ofproduct as principal basis of liability Lohrmann
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 . 
nder a theory of strict liability, a anufacturer's failure to adequately arn of its 
duct's l  res l    t t t f ti .  t    
duty to arn.  anufacturer has a duty to keep abreast of the current state f kno ledge of its 
products as acquired through research, adverse reaction reports, scientific literature, testing, and 
t  il le t .  t- l t       l  i  t  il l  
scientific data gave rise to a reasonable inference that the danger is likely to exist.  
a fact rer is el  t  t e le e a  s ill f a  e ert, a  is re ire  t  test is r cts a  
keep abreast of scientific discoveries related to its products, but it has a duty to arn only of 
dangers that the reasonable foresight of an expert could reveal. 
i t r v. i  I tern., I c.,   , -69 (lOth ir. 995); s  lso, r r v. itt  
orp., 616 .W.2d 602, 624 (Iowa 2000) (the inquiry in a negligent failure to arn case "is 
hether a reasonable anufacturer kne  or should have kno n of the danger, in light of the 
generally recognized and prevailing best scientific kno ledge, yet failed to provide adequate 
arning to users or custo ers."); Pfeiffer v. Eagle fg. o., 771 F. Supp. 1133, 1139 (D.Kan. 
1991»; Bernierv. Ray arkIndustries, Inc., 516 .2d 534, 538-39 ( e. 1986); wen-Illinois, Inc. 
v. e i i , 601 .2d , -40 (M . 92); see  S  (S D) F S (1 ) 
(strict product liability); Potter v. Chicago Pneu atic Tools Co., 694 .2d 1319, 1328-29 (Conn. 
1997) (strict liability relieves plaintiff of burden of proving anufacturer as negligent and allo s 
plaintiff to establish instead defective condition of product as principal basis of liability); Lohr ann 




e e  
t  
I TIFF'S  y  -  
INSTRUCTION NO
Under a negligent failure to warn theory if you find that the product included adequate
warnings and instructions youmust find for the defendant and against the plaintiff on that cause of
action






PLAINTIFFSPROPOSED JURY INSTRUCTIONS 13
001539
INS ION . 
nder a negligent failure to arn theory, if you find that the product included adequate 
arnings and instructions, you ust find for the defendant and against the plaintiff on that cause of 
a . 






PLAINTIF 'S PROPOSE  JU y I I  - 13 
INSTRUCTIONNO
Under a theory of negligent failure to warn the plaintiff has the burden of proving each of
the following propositions
1 SEC manufactured the SABRE Red OC Spray product or products that Ms Major
was exposed to and
2 The Defendant knew or should have known that danger to users or bystanders could
result from a particular use of the product and
3 TheDefendant failed to give adequate warning ofsuch danger and
4 The failure to give adequate warning was a proximate cause of injury to the
Plaintiff and
5 The nature and extent of the injuries the elements of damage and the amount
thereof
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 . 
er a t e r  f e li e t fail re t  ar , t e lai tiff as t e r e  f r i  eac  f 
the follo ing propositions: 
.  f t r  t   e   r  r t r r ts t t s. j r 
as exposed to; and 
. e efe a t e  r s l  a e  t at a er t  sers r sta ers c l  
result fro  a particular use ofthe product; and 
.  efe t f il  t  i  t  r i  f s  er;  
.  f il r  t  i  t  r i  as  r i ate s  f i j r  t  t  
l intiff;  
. he nature and extent f the injuries, the ele ents f da age, and the a ount 
reof. 






LAINTIF 'S  y  -  
INSTRUCTIONNO
Under a theory of negligent failure to warn a product is defective if it is reasonably
foreseeable that the product could be used in a manner that involves a substantial danger that would
not be readily recognized by the ordinary user of the product and that the manufacturer knows or
should have known of the danger associated with such use but that the manufacturer fails to give
adequate warning of such danger
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r  t r  f lige t failure t  r ,  r t is f ti e if it is r s l  
orese l  t t t  t l    i    t t i lve   t ti l  t t l  
not be readily recognized by the ordinary user of the product, and that the anufacturer kno s or 
should have kno n f the danger associated ith such use, but that the anufacturer fails to give 
adequate arning of such danger. 






L I TIFF'S    -  
INSTRUCTIONNO
Under a theory ofnegligent failure to warn a product manufacturer or product seller has a
duty to provide an adequate warning to the user on how to use the product if a reasonably
foreseeable use of the product involves a substantial danger ofwhich the supplier either is aware or
should be aware and that would not be readily recognized by the ordinary user
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Under a theory of negligent failure to warn, a product anufacturer or product seller has a 
duty to provide an adequate warning to the user on how to use the product if a reasonably 
foreseeable use of the product involves a substantial danger of hich the supplier either is a are or 
should be a are, and that ould not be readily recognized by the ordinary user. 






PLAINTIF 'S PR P SE  JURY I T I  - 16 
INSTRUCTION NO
Under a theory of negligent failure to warn a supplier has a duty to provide an adequate
warning of potential risks or side effects which may follow the foreseeable use of the product and
which are known or knowable in light of the generally recognized and prevailing best scientific and
medical knowledge at the time of the distribution
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 . 
  t   li t il  t  ,  lier   t  t  ide  t  
arning of potential risks or side effects hich ay follo  the foreseeable use of the product, and 
i  r   r a le i  lig t  t e r ll  r i   r ili  t i tifi   
edical kno ledge at the ti e f the distribution. 






LAINTIF 'S    -  
INSTRUCTION NO
Under a theory of negligent failure to warn a manufacturersfailure to adequately warn of
its product reasonably foreseeable dangers renders that product defective A manufacturer has a
duty to warn A manufacturer has a duty to keep abreast of the current state of knowledge of its
products as acquired through research adverse reaction reports scientific literature testing and
other available methods A product related danger may be regarded as knowable if the available
scientific data gave rise to a reasonable inference that the danger is likely to exist A manufacturer
is held to the knowledge and skill ofan expert and is required to test his products and keep abreast
of scientific discoveries related to his products but it has a duty to warn only of dangers that the
reasonable foresight of an expert could reveal
Richter v Limax Intern Inc 45 1 1464 146869 10 Cir 1995 see also Mercer v Pittway
Corp 616NW2d602 624 Iowa 2000 the inquiry in a negligent failure to warn case is
whether a reasonable manufacturer knew or should have known of the danger in light of the
generally recognized and prevailing best scientific knowledge yet failed to provide adequate
warning to users or customers Pfeiffer v Eagle Mfg Co 771 F Supp 1133 1139DKan
1991 Bernier v Raymark Industries Inc 516A2d 534 538 39 Me 1986 OwenIllinois
Inc v Zenibia 601A2d 633 63940 Md 1992 see 402A RESTATEMENT SECOND OF TORTS
1965 strict product liability Potter v Chicago Pneumatic Tools Co 694A2d 1319 132829
Conn 1997 strict liability relieves plaintiff ofburden ofproving manufacturer was negligent
and allows plaintiff to establish instead defective condition of product as principal basis of






PLAINTIFFSPROPOSED JURY INSTRUCTIONS 18
001544
NS ION . 
Under a theory of negligent failure to warn, a anufacturer's failure to adequately warn of 
its product's reasonably foreseeable dangers renders that product defective.  anufacturer has a 
duty to arn.  anufacturer has a duty to keep abreast of the current state of kno ledge of its 
products as acquired through research, adverse reaction reports, scientific literature, testing, and 
other a aila le et s.  r ct-relate  a ger a  e re arded as a le if t e a aila le 
scientific data gave rise to a reasonable inference that the danger is likely to exist.  anufacturer 
is held to the kno ledge and skill of an expert, and is required to test his products and keep abreast 
f scie tific iscoveries relate  t  is r cts, t it as a t  t  ar  l  f a ers t at t e 
reasonable foresight of an expert could reveal. 
ic ter v. i x I tern., I c.,  F3d , -69 (loth ir. 95); see lso, ercer v. itt y 
Corp., 616 .W.2d 602,624 (Iowa 2000) (the inquiry in a negligent failure to arn case "is 
et er  e       t  er,    
generally recognized and prevailing best scientific knowledge, yet failed to provide adequate 
warning to users or customers."); feiffer v. le f . o.,  . p. 3,  (D.Kan. 
991)); er ier v. y rk I stries, I c.,  .2d ,5 -3  (Me. 986); en-Illi is, 
Inc. v. enibia, 601 .2d 633,639-40 ( d. 1992); see 402  ESTATE E T (S D) F T TS 
(1965) (strict product liability); Potter v. Chicago Pneumatic Tools Co., 694 A.2d 1319, 1328-29 
(Conn. 1997) (strict liability relieves plaintiff of burden of proving manufacturer was negligent 
and allows plaintiff to establish instead defective condition of product as principal basis of 






LAINTIF 'S SED  I I  - 18 
INSTRUCTION NO
Under a theory of negligent design the plaintiff has the burden of proving each of the
following propositions
1 SEC manufactured the SABRE Red OC Spray product or products that Ms Major
was exposed to and
2 The Defendant knew or should have known that danger to users or bystanders could
result from a particular use ofthe product and
3 The Defendant was negligent in designing or manufacturing the product and
4 The Defendantsnegligence was a proximate cause ofinjury to the Plaintiff and
5 The nature and extent of the injuries the elements of damage and the amount
thereof
Ifyou find from your consideration of all of the evidence that each of these propositions has
been proved then you should answer Yes to Question No 3 on the verdict form If any ofthese
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INS ION . 
nder a theory of negligent design, the plaintiff has the burden of proving each of the 
following propositions: 
1.  anufactured the  e    t r ucts  . ajor 
as exposed to; and 
. he efe a t kne  r s ld   t at  t  s s r sta ers  
result fro  a particular use of the product; and 
. he efe da t as li t i  i i  r a fa t ring t e r t;  
. e efe ant's e lige ce as a r i ate ca se f i j r  t  t e laintiff; a  
. e at re a  e te t f t e i j ries, t e ele e ts f a a e, a  t e a t 
t of. 
If  fi  fr  r c si erati  f all f t e e i e ce t at eac  f t ese r siti s as 
been proved, then you should answer "Yes" to Question No.3 on the verdict form. If any of these 






LAINTIF 'S PR POSED J y  - 19 
INSTRUCTION NO
A manufacturer or seller of a product is required to foresee some degree of misuse and
abuse of his product and to take reasonable precautions to minimize the harm that may result from
misuse and abuse
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 . 
 t re   ller   t i  ire  t  ores     i   
  is t  t  t  le ti  t  i i ize t   t t  lt  
isuse  . 






LAINTIF 'S  y  -  
INSTRUCTION NO
The law does not require SEC to warn against every conceivable health problem associated
with the use of its product Whether a warning is adequate depends upon several factors among
them the normal expectations of the consumer as to how a product will perform degrees of
simplicity or complication in its operation or use the nature and magnitude of the danger to which
the user is exposed the likelihood of injury and the feasibility and beneficial effect of including
additional warnings
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S  . 
The la  does not require SEC to arn against every conceivable health proble  associated 
ith the use of its product. hether a arning is adequate depends upon several factors, a ong 
the  the nonnal expectations of the consu er as to ho  a product ill perfonn, degrees of 
si plicity or co plication in its operation or use, the nature and agnitude of the danger to hich 
the user is exposed, the likelihood of injury, and the feasibility and beneficial effect of including 
additional warnings. 






LAINTIF 'S SE    - 1 
INSTRUCTION NO
When I use the expression proximate cause I mean a cause which in natural or probable
sequence produced the damage complained of It need not be the only cause It is sufficient if it is
a substantial factor concurring with some other cause acting at the same time which in
combination with it causes the damage
While expert testimony may assist in determining whether proximate cause has been
established expert testimony is not required so long as the evidence shows a chain of circumstances
from which proximate cause can reasonably and naturally be inferred
IDJI230 Modified as instructed in Fussell v St Clair 120 Idaho 591 595 1991 reaffirmed by







PLAINTIFFSPROPOSED JURY INSTRUCTIONS 22
001548
INS  . 
he  I se the ression "proximate se," I ea   cause i , i  t r l r r l  
sequence, produced the da age co plained of. It need not be the only cause. It is sufficient if it is 
a substantial factor concurring ith so e other cause acting at the sa e ti e, hich, in 
co bination ith it, causes the da age. 
hile expert testi ony ay assist in deter ining hether proxi ate cause has been 
established, expert testi ony is not required so long as the evidence sho s a chain f circu stances 
from which proximate cause can reasonably and naturally be inferred. 
I Jl .3 .2 ifie   i tr t  i  ll . t. l ir,  I  ,  (1 1) (reaffir   
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INSTRUCTION NO
If you find that the Defendantsnegligence proximately caused the Plaintiff to suffer a
foreseeable injury you may award damages in an amount to compensate her for that injury If you
make such a determination youmay then and only then award her damages that compensate her for
consequential injuries caused by the Defendantsnegligence but which were not necessarily
foreseeable at the time the Defendant acted negligently Such damages may be awarded where
there are circumstances in which the consequences of a foreseeable injury leads to injury or injuries
that are not always foreseeable in the beginning
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 . 
If  fin  t t t e f dant's lige ce r i ately s  t e l i tiff t  s ffer  
f reseea le i j r ,  a  a ar  a ages i  a  a t t  c e sate er f r t at i j ry. If  
a e s c  a eter i ati ,  a  t e  a  l  t e  a ar  er a a es t at c e sate er f r 
s ti l i j ries se   t  f ndant's li  t i  r  t ss ril  
f res l  t t  ti  t  f t t  li ntl .  a es   r  r  
t r  r  ircu sta ces i  i  t  s s f  f res l  i j r  l s t  i j r  r i j ri s 
t t r  t l s f res l  i  t  i i . 






LAINTIF 'S  y I S -  
INSTRUCTION NO
A defendant in a personal injury action takes the plaintiff as the defendant finds her A
negligent actor is subject to liability for harm to another although a physical condition of the other
which is neither known nor should be known to the actor makes the injury greater than that which
the actor as a reasonable man should have foreseen as a probable result ofhis conduct
RESTATEMENT SECOND OF TORTS 461 Harm Increased In Extent By OthersUnforeseeable
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 f t i   r l i j r  ti  t  t  l i tiff  t  f t fi s r.  
li t t r is s j t t  li ilit  f r nn t  t r lt   si l iti  f t  t r 
i  is it r  r s l    t  t  t r es t  i j r  r t r t  t t i  
t  t r s  r s l   s l   f res  s  r l  r s lt f is uct. 
REST TE E T (SEC ) F T RTS,-r 461 (Hann Increased In xtent y ther's nforeseeable 
Physical ondition); ushong v. a iah rain, 96 Idaho 659 (1975); laine v. yers, 91 Idaho 




e e  
ther 
I TIFF'S  y  -  
INSTRUCTIONNO
Compliance with governmental standards regulations or statutes does not preclude
imposition of liability for a defective product Compliance with government standards regulations
or statutes is merely to be considered by you as some evidence on the issue of adequacy of
warnings Violation of a statute is negligence as a matter of law If you find that the Defendant has
violated a government statute you must find that the Defendant was negligent
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liance it  r t l st r s, r l ti s r st t t s s t r l  
i iti  fli ilit  f r  f ti  r t. lia ce it  r t t ards, r l ti s, 
or statutes is erely to be considered by you as so e evidence on the issue of adequacy of 
i . i latio    t t te i  li    tt  l .   i  t t t  t  
violated a govern ent statute, you ust find that the efendant as negligent. 






I TIFF'S   I S -  
INSTRUCTION NO
There was a certain statute in force at the time of the occurrence in question which provided
that a manufacturer of a hazardous substance must include on the label certain warnings and
directions Under the statute a hazardous substance means any substance or mixture of
substances which is toxic is corrosive or is an irritant if such substances or mixture of substances
may cause substantial personal injury or substantial illness during or as a proximate result of any
customary or reasonably foreseeable handling or use including reasonably foreseeable ingestion by
children
Under the statute the word toxic means any substance other than a radioactive
substance which has the capacity to produce personal injury or illness to a person through
ingestion inhalation or absorption through anybody surface
Under the statute the word corrosive means any substance which in contact with living
tissue will cause destruction of tissue by chemical action but shall not refer to action on inanimate
surfaces
Under the statute the word irritant means any substance that is not a corrosive as
defined in these instructions which on immediate prolonged or repeated contact with normal
living tissue will induce a local inflammatory reaction
The statute requires manufacturers of products containing toxic corrosive andorirritant
substances to include conspicuous warnings and instructions on the label that include
1 An affirmative statement of the principal hazard or hazards such as Flammable
Combustible Vapor Harmful Causes Burns Absorbed Through Skin or similar wording
descriptive of the hazard
2 An affirmative statement of precautionary measures describing the action to be
followed or avoided
3 Instructions when necessary or appropriate for firstaid treatment and
4 Instructions for handling and storage of packages which require special care in
handling or storage
The statements must be located prominently in conspicuous and legible type in contrast by
typography layout or color with other printed matter on the label
PLAINTIFFSPROPOSED JURY INSTRUCTIONS 26
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 . 
r  s  rt i  st t te i  f r  t t  ti  f t  rr  i  sti  i  r i  
t at a a fact rer f  r s s st e st i l   t  l l rt i  r i s  
.   ,  "hazard  tance"       
t ces i  i  t i , is rr i , r i   irrit t, i   t  r i t r   t  
 se t ti l l i j   t ti l illne  i     i at  lt   
custo ary or reasonably foreseeable handling or use, including reasonably foreseeable ingestion by 
il . 
nder the statute, the ord "toxic" eans "any substance (other than a radioactive 
s sta ce) ic  as t e ca acit  t  r ce persO!lal i j r  r illness t  [a erson] t r  
ingestion, inhalation, or absorption through any body surface." 
 t  t t t , t   "corr i e"  "any t  i  i  t t it  li i  
tissue ill cause destruction of tissue by che ical action; but shall not refer to action on inani ate 
rfaces. " 
 t  t t t , t   "i rit t"   t  t t i  t  "corr i e"  
defined in these instructions "which on i ediate, prolonged, or repeated contact ith nor al 
living tissue ill induce a local infla atory reaction." 
he statute requires anufacturers of products containing toxic, corrosive, and/or irritant 
substances to include conspicuous arnings and instructions on the label that include: 
. n affir ative state ent of the principal hazard or hazards, such as "Flam able", 
"Combus e", "Vapor ar ful", "Causes ", "Absorbed hrough Skin", or si ilar ording 
descriptive f the hazard; 
.  affir ati e state e t f reca ti ar  eas res escri i  t e acti  t  e 
  i d; 
. Instructions, hen necessary or appropriate, for first-aid treat ent; and 
. Instructions for handling and storage of packages hich require special care in 
a li  r st ra e. 
he state ents ust be located pro inently in conspicuous and legible type in contrast by 
t ra y, la t, r c l r it  t er ri te  atter  t e la el. 
I TIFF'S  y  -  
Under the statute a principal hazard or hazards means the principal or primary hazard or
hazards associated with a hazardous substance A hazardous substance may have more than one
principal hazard
A violation of the statute is negligence
IDJI 22 Violation ofstatute or ordinance negligence per se
15USC 1261 16 CFR 15003Walton v Potlach Corp 116 Idaho 892 898 nl
1989 Mattis v Carlon Electrical Products 295 F3d 856 8 Cir 2002 Milanese v Rust
Oleum Corp 244 F3d 104 10910 2d Cir 2001 Sanchez v Galey 112 Idaho 609 61718
1987 OSHA violation may be evidence of negligence per se citing Dixon v International
Harvester Co 754 F2d 573 581 5th Cir 1985 we reiterated that a violation of an OSHA
regulation can be evidence of negligence or even in appropriate circumstances negligence per
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nder the statute, a "principal hazard or hazards" eans the principal or pri ary hazard or 
r s i t  ith  r s t .  r  t    re t a   
principal hazard. 
 violation of the statute is negligence. 
I JI . 2 - iolation  te  na  - negligence per se. 
 .S.C. § ;  .F.R. § 50 .3; t  .  orp.,   ,  & .l 
(19 9); ttis v. rlo  l tri l r ts,  .3d  (8th ir. 02); ilanese v. st-
leu  orp., 244 F.3d 104, 109-10 (2d ir. 2001); Sanchez v. aley, 112 Idaho 609, 617-18 
(1987) (OS  violation ay be evidence of negligence per se) (citing ixon v. International 
rvest r o.,  .2d ,  (5th ir. 5) ("we r it r t  t t  i l ti  f   
regulation can be evidence of negligence or even, in appropriate circu stances, negligence per 
")); see eibstein v. rge rt  er.,  . up .2d , -90 (E.D.N.Y. 0) (state 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual
Case No CV PI 1003515
Plaintiff




We the Jury answer the special interrogatories as follows
Question No 1 Did SEC manufacture the SABRE Red OC Spray that Ms Major was
exposed to
Answer to Question No 1 Yes No
Instruction No 1 If you answered Yes to Question No 1 proceed to Question No 2
If you answered No to Question No 1 skip Questions No 2 3 and 4 and proceed to Question
No 5
Question No 2 At the time that SEC sold SABRE Red OC Spray to Ms Major
employer did SEC know or should it have known that danger to users or bystanders could result
from a particular use of the product
Answer to Question No 2 Yes No
Instruction No 2 If you answered Yes to Question No 2 proceed to Question No 3
If you answered No to Question No 2 skip Questions No 3 and 4 and proceed to Question
No 5
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 E         
E   I , I        
I IE J  J , and individual, 
l i tiff, 
vs. 
I  I  A I , 
a issouri corporation, 
nt. 
ase .    
I  I   
e, the Jury, ans er the special interrogatories as follo s: 
uestion o.1: id S  anufacture the S  ed  Spray that s. ajor as 
exposed to? 
s r t  ti  . : es [ ] o [ ] 
Instruction o 1: If you ans ered "Yes" to uestion o.1, proceed to uestion o.2. 
If you ans ered "No" to uestion o.1, skip uestions o.2, 3, and 4, and proceed to uestion 
. . 
uestion . : t the ti e that  sold  ed  pray to s. ajor's 
e ployer, did SE  kno  or should it have kno n that danger to users or bystanders could result 
fro  a particular use of the product? 
s er t  esti  . : es [ ] o [ ] 
I str ti  . : If  a s ere  "Yes" t  esti  . , r cee  t  esti  .3. 
If you ans ered "No" to uestion o.2, skip uestions o. 3 and 4, and proceed to uestion 
. . 
LAINTIF 'S  y  -  
Question No 3 Did SEC fail to give adequate warning of a danger that it knew or
should have known of
Answer to Question No 3 Yes No
Instruction No 3 If you answered Yes to Question No 3 proceed to Question No 4
If you answered No to Question No 3 skip Question No 4 and proceed to Question No 5
Question No 4 Was SECs failure to give adequate warning a proximate cause of
injury to Ms Major
Answer to Question No 4 Yes No
Instruction No 4 Proceed to Question No 5
Question No 5 Was SEC a product seller of the SABRE Red OC spray that
Ms Major was exposed to
Answer to Question No 5 Yes No
Instruction No 5 If you answered Yes to Question No 5 proceed to Question No 6
If you answered No to Question No 5 skip Questions No 6 and 7 and proceed to Instruction
No 7
Question No 6 Was the SABRE Red OC Spray that Ms Major was exposed to in a
defective and unreasonably dangerous condition when it left the hands ofSEC
Answer to Question No 6 Yes No
Instruction No 6 If you answered Yes to Question No 6 proceed to Question No 7
If you answered No to Question No 6 skip Question No 7 and proceed to InstructionNo 7
Question No 7 Was the defective condition a proximate cause of the injuries sustained
byMs Major
Answer to Question No 7 Yes No
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 .3:   il     f     w,  
   f? 
   . :  [ ] o [ ] 
I str ti  . : If  s r  "Yes" t  sti  . , r  t  sti  .4. 
If  a s ere  "N " t  esti  . , s i  esti  . , a  r cee  t  esti  .5. 
 . : as EC's fail re t  i e a e ate ar i  a r i ate ca se f 
  . jor? 
   . :  [ ] o [ ] 
I str ti  . : r cee  t  esti  .5. 
 .5: s   "prod t seller" f t     s r  t t 
.    ? 
s er t  esti  . : es [ ] o [ ] 
I str ti  . : If  s r  "Yes" t  sti  . , r  t  sti  . . 
If  a s ere  "N " t  esti  . , s i  esti s .  a  , a  r cee  t  I str cti  
. . 
esti  . : as t e  e   ra  t at s. aj r as e se  t  i  a 
defective and unreasonably dangerous condition hen it left the hands f C? 
s  t  ti n . : e  [ ]  [ ] 
Instruction o.6: If you ans ered "Yes" to uestion o.6, proceed to uestion o.7. 
If you ans ered "No" to uestion o.6, skip uestion o.7, and proceed to Instruction o.7. 
uestion o.7: as the defective condition a proxi ate cause of the injuries sustained 
 . jor? 
ns er to uestion o.7: es [ ] o [ ] 
I TIFF'S  J Ry  -  
Instruction No 7 If you have answered yes to Question No 4 or Question No 7 or if
you answered yes to both Question No 4 and Question No 7 proceed to Question No 8 If
you have not answered yes to either Question No 4 or Question No 7 sign the verdict form
and let the bailiffknow that you have reached a verdict
Question No 8 What were the economic damages sustained by the Plaintiff Billie
Major
Answer to Question No 8
Instruction No 8 Proceed to Question No 9
Question No 9 What were the non economic damages sustained by the Plaintiff Billie
Major
Answer to Question No 9
Instruction No 9 Sign the verdict form and let the bailiffknow that you have reached a
verdict
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t ti  .7: If   r  "ye " t  ti  .  r ti  . , r if 
 r  "ye " t  t  ti  .   ti  . , r e  t  ti  .8. If 
you have not ans ered "yes" to either uestion o. 4 or uestion o.7, sign the verdict for  
and let the bailiff kno  that you have reached a verdict. 
i  .8: t  t  i   t i   t  l i ti  illie 
ajor? 
 t  ti  . : $ --------------------------------
t ti  . :  t  ti  . . 
estio  o.9: hat ere the non-econo ic da ages sustained by the laintiff illie 
ajor? 
ns er to uestion o.9: $ ______________________________ __ 
Instruction o.9: Sign the verdict for  and let the bailiffkno  that you have reached a 
r ict. 
  _ a f __________ ,2011. 
By _____________ __ 
  
y he Jury 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR and individual






We the Jury answer the special interrogatories as follows
Question No 1 Is SEC liable for damages under a theory of strict liability
Answer to Question No 1 Yes No
Question No 2 Is SEC liable for damages under a theory of negligent failure to warn
Answer to Question No 2 Yes No
Question No 3 Is SEC liable for damages under a theory of negligent design
Answer to Question No3 Yes No
Instruction If you answered Yes to Question No 1 Question No 2 or Question
No 3 proceed to Question No 4 If you answered No to each of those three questions skip
Question No 4 and Question No 5 sign the verdict form and let the bailiff know you have
reached a verdict
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I  E IS    E     
E E  I ,  D  E    
I IE J  J , a  i i i l, 
ase .  I  
lai tiff, 
vs.   
I  I  I , 
a issouri corporation, 
nt. 
e, the Jury, ans er the special interrogatories as follo s: 
estion . : Is  lia le f r a a es er a t e r  f strict lia ility? 
s r t  sti  . : es [ ] o [ ] 
sti  . : Is  li l  f r es r  t r  f li t f il r  t  rn? 
s r t  sti  . : es [ ]  [ ] 
uestion o.3: Is SEC liable for da ages under a theory of negligent design? 
ns er to uestion o.3: es [ ] o [ ] 
tr ction: If you ans ered "Yes" to uestion .1, uestion .2, or uestion 
No.3, proceed to Question No.4. If you answered "No" to each of those three questions, skip 
Question No.4 and Question No.5, sign the verdict form and let the bailiff know you have 
  rdict. 
LAINTIF 'S  y  - 32 
Question No 4 What are the economic damages sustained by the Plaintiff Billie Major
Answer to Question No 4
Question No 5 What were the non economic damages sustained by the Plaintiff Billie
Major
Answer to Question No 5
Instruction After you have answered Question No 4 and Question No 5 sign the
verdict form and let the bailiffknow that you have reached a verdict
DATED this day of 92011
JURY FOREPERSON
By The Jury
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 . :         l i t  ie jor? 
 t  ti  . : $, _______________ _ 
esti  . : hat ere the non-econo ic da ages sustained by the laintiff illie 
jor? 
ns er to uestion o.5: $, _______________ _ 
t ction: fter  a e a s ere  esti  .  a  esti  . , si  t e 
verdict for  and let the bailiff kno  that you have reached a verdict. 
 s _ dayof ______ ,2 . 
By ____________ _ 
  
y The Jury 
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 15th day of September 2011 a true and correct copy
of the foregoing document was served on the following individualsbythe method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
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I EREB  CERTIF  that on this 15th day of Septe ber, 2011, a true and correct copy 
f t  f r i  t s s r   t  f ll i  i dividual(s)  t  t  i i t : 
rist er . r e 
as J. l  III 
     
 .  t,   
,   
I TIFF'S  y I S -  
[ ] .S. il 
[ ] Fax: 319-2601 ~ , / Lf'~ 
J-rMessenger DeliveryI'  A. 
[ ] ail: burke erlaw.com 
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CHRISTOPHER D RICH ClerkBy JAMIE RANDALL
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OFADA






Case No CV PI 1003515
PLAINTIFFS
MOTIONS IN LIMINE
Plaintiff Billie Jo Major by and through her counsel of record and pursuant to this
CourtsMay 13 2011 Order Governing Proceedings Rules 6b7b1and 8c of the Idaho
Rules of Civil Procedure and Rules 401 402 and 403 ofthe Idaho Rules of Evidence hereby
moves to exclude and prevent the presentation of the following evidence and arguments by the
Defendant and its counsel at the trial of this matter
1 Evidence or testimony ofherpes
2 Evidence or testimony of Plaintiffs performance and disciplinary personnel
records
PLAINTIFFSMOTIONS IN LIMINE 1
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702






Attorneys for Plaintiff Billie Jo Major
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r  verson, I  #58  
 . artz, I  #639  
 &  L  
 . horeli  ri e, i   [ 02] 
st ffice   
, I   
l one: (2 8) -8  
csi ile: (2 ) -8  
ail: r i jonesandswartzlaw.com 
ri jonesandswartzlaw.com 
tt r e  f r laintiff, illie  j  
AN.OM·.=_--File~~"9-_ _ Flleo~L = ----_-P.M._~ .......... ___  
SEP t  2011 
CHRISTOPHER 0 
By JAMIE RAN~HJ l r  
DEPUTY 
       I I    
   ,        
I   ,  l, 
l intif , 
vs. 
  RATI , 
 is  ti , 
f nt. 
 .    
I TIFF'S 
   
Plaintiff Billie Jo ajor, by and through her counsel of record, and pursuant to this 
Court's ay 13, 2011 Order Governing Proceedings, Rules 6(b), 7(b)(1), and 8(c) of the Idaho 
Rules of Civil Procedure, and Rules 401, 402, and 403 of the Idaho Rules of Evidence, hereby 
oves to exclude and prevent the presentation of the follo ing evidence and argu ents by the 
efendant  its ns l t the trial  t is : 
. vidence r testi  f her s; 
. Evidence or testimony of Plaintiffs performance and disciplinary personnel 
re ; 
P I I F'S OTIONS IN LIMINE - 1 
0
3 Evidence or testimony of SECshealth questionnaire
4 Evidence testimony or argument that the Federal Hazardous Substances Act
preempts Idaho law
5 Evidence or testimony about articles or studies related to whether OC spray causes
inmate death
This Motion is made and supported by the pleading of record herein and by the
Memorandum and supporting Affidavit filed contemporaneously herewith
DATED this 15th day of September 2011




I HEREBY CERTIFY that on this 15th day of September 2011 a true and correct copy
of the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BuxKE SHOEMAKER PA










3.   ti  f EC's alt  estionnaire; 
. i ce, t sti ony,  r t t t t  r l r  t  t 
ree ts I a  la ; 
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i ate eath. 
This otion is ade and supported by the pleading of record herein and by the 
e ra  a  s rti  ffi a it file  c te ra e sl  erewith. 
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CHRISTOPHER D RICH ClerkBY JAMIE RANDALL
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OFADA









Case No CV PI 1003515
AFFIDAVIT OF COUNSEL IN
SUPPORT OF PLAINTIFFS
MOTIONS INLIMINE
I Darwin L Overson being first duly sworn upon oath depose and state upon my own
personal knowledge as follows
1 I am an attorney with the law firm of Jones Swartz PLLC and am authorized to
practice law before this and all courts of the State of Idaho
2 I am counsel of record for Plaintiff Billie Jo Major in the above action
AFFIDAVIT OF COUNSEL IN SUPPORT OF PLAINTIFFSMOTIONS INLIMINE 1
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC











z -<!J -a: 
o 
in on,  #5887 
c . rt ,  #6396 
 &   
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Telephone: (208) 489-8989 
acsi ile: (20 ) -8988 
E ail: dar in jonesandswartzlaw.com 
eric jonesandswartzlaw.com 
ttorne s f r laintiff, illie J  aj r 
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----- .M bZ? -= 
   
I T  0 
By JAMIE RAN~~H. l rk 
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l intif , 
vs. 
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a issouri corporation, 
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  LAINTIF 'S 
I S  I I  
I, ar in L. verson, being first duly s orn upon oath, depose and state upon y o n 
personal kno ledge as follo s: 
. I   tt r  it  t  l  fir  f J s & rt  ,   t rize  t  
practice law before this and all courts of the State of Idaho. 
. I a  counsel of record for Plaintiff Billie Jo ajor in the above action. 
      L I TIFF'S I S  INE -  
3 Attached hereto as Exhibit 1 is a true and correct copy of the May 18 2011 email
that Plaintiffscounsel sent to counsel for Defendant requesting supplementation of SECs
discovery responses pursuant to Idaho Rule of Civil Procedure 37
4 Attached hereto as Exhibit 2 is a true and correct copy of the June 2 2011 letter
sent by counsel for Defendant in response to Plaintiffs counsels Rule 37 request for
supplementation
FURTHER YOUR AFFIANT SAYETH N
SUBSCRIBED AND SWORN TO before me this 15th day ofSeptember 2011
oTIB l
ui pTA r Notary Public for Idaho
My Commission expires T 8 z
UBLt
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.  r t   i i   i        t   ,20  ail 
t at laintiffs c sel se t t  c sel f r efendant, re esti  supple entati  f EC's 
  t   l   i il  . 
. tta  r t  s i it  is  tr   rr t  f t  Ju  ,  l tt r 
sent by counsel for efendant in response to Plaintiffs counsel's Rule 37 request for 
l ntation. 
  I  AUGHT. 
S S I   S   before e this 15th day of Septe ber, 2011. 
~k-u;<~~~~ 
/ otary ublic for Idaho 
y Co ission expires 1- ~ ·1& 
F  F C NSEL IN S P  F P IFF'S OTIONS IN LIMINE -  
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 15th day of September 2011 a true and correct copy
of the foregoing document was served on the following indiviqualsb method indicated
Christopher CBurke UMail
Thomas J Lloyd III KFax 3192601
GREENER BURKE SHOEMAKER PA 71tiessenger Delivery
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Eric Swartz
From Eric Swartz
Sent Wednesday May 18 2011 414 PM
To Chris Burke Thomas J Lloyd III
Cc Christina Morrow Mat Cundiff Darwin Overson
Subject 2257 Major v SEC Rule 37 Request for Supplementation
Counsel
am writing to request that SEC supplement its responses to Request for Production Nos 56 and 57 RFP 56
asks your client to produce the survey reports that SEC designee Robert Nance testified SEC relies on to as part
of its ongoing evaluation and review of SECs OC spray products RFP 57 requests production of the
contamination reports that Mr Nance testified SEC relies on to as part of its ongoing evaluation and review
of SECs OC spray products
Your clients response to both of these RFPs was identical SEC objected stating that the requests are
argumentative overly broad unduly burdensome vague not limited in scope that it is not relevant and that
there are too many to produce Subject to these objections your client produced a sample Instructor
Feedback Questionnaire and Course Evaluation forms
We are asking again for the actual surveys and contamination reports that Mr Nance testified about Based
upon Mr Nancesown testimony these surveys and contamination reports are part of what SEC reviews and
relies on to learn about how its product impacts its users and those who are otherwise exposed to such
products These materials will show what SEC knew or should have known about its products Further in an
attempt to address your clients objections about to volume of surveys we are happy to limit our request to
the years 2000 to 2008
Please have SEC produce the requested surveys and contamination reports by May 31 2011 If we do not








NOTICE DO NOT read copy or disseminate this communication unless you are the intended addressee This
communication may contain confidential andor legally privileged information intended only for the addressee All parties
entities or individuals privy to or in any way using or disclosing any protected health information in conjunction with this e
mail shall comply with all federal and state laws and regulations including HIPAA regulations with regard to the
confidentiality handling and use of such protected health information If you are not the intended recipient you are
hereby notified that any disclosure copying distribution or the taking of any action in reliance upon the contents of this
information is strictly prohibited If you have received this communication in error please call us collect immediately at
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1673 W Shoreline Drive Suite 200
PO Box 7808
Boise Idaho 83702
Re Billie Jo Major v Security Equipment Corporation
Gentlemen
I am writing to respond to Ericsemail to me of May 16 2011 wherein he requested
that SEC supplement its responses to Document Request Nos 56 and 57 to provide
questionnaires filled out by trainees who received exposure to OC during Sabre Red instructor
training classes
As I discussed with Eric last week we have some of these questionnaires for 2011 and
2010 After checking with SEC we have determined that SEC did not implement this
questionnaire process until March 14 2008 in a training session in Tennessee For all training
sessions prior to that date SEC did not use the questionnaire forms or ask or require its trainees
to fill out forms to provide written descriptions of their experience in being exposed to OC
Therefore SEC does not have documentation of any trainee response to pepper spray exposure
prior to the date ofBillie Jo Majorslast exposure to OC March 3 2008
As I also discussed with Eric last week and as we documented in our objections to
Document Request Nos 56 and 57 we do not believe these questionnaires are relevant to the
issues raised by this litigation First the questionnaires are only filled out by prospective OC
trainees who have had direct Level I inthe face exposure to OC This is different than the
indirect Level III exposures which Major had during her employment at IDOC Second the
comments relate to the trainees acute reactions only Trainees routinely recover from the affects
of OC exposure within minutes to an hour SEC has no record of any trainee ever having
experienced the adverse affects of OC exposure for a period longer than one day Since the
focus ofMajorsclaims against SEC is that her exposure to SECsOC products caused her long
term chronic cough and GERD symptoms or chronically aggravated her preexisting cough and
GERD symptoms the questionnaire responses relating to acute exposures are not relevant
950w bannock street suite 9001 bolse Idaho 837021 t208 319 26011 o208 319 2600
14542011 394878doc
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Finally and perhaps most importantly SEC has no records of questionnaires of trainees
who have been exposed to OC prior to the date ofMajors last exposure Questionnaires filled
out by trainees after March 2008 are simply not relevant to what SEC knew or should have
known prior to the date ofMajorslast exposure
For these reasons SEC will stand by its objections and will not be producing postMarch
2008 trainee questionnaires in response to Document Request Nos 56 and 57 SEC is not aware
ofany other documents responsive to these requests other than those which have already been
produced in discovery in this case
Very truly yours
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Case No CV PI 1003515
MEMORANDUM IN SUPPORT OF
PLAINTIFFSMOTIONS INLIMINE
I INTRODUCTION
Defendant should be precluded from presenting evidence that is not relevant and which
will only serve to prejudice the Plaintiff waste time and confuse the jury An example of
Plaintiffsirrelevant medical condition is being diagnosed with herpes This medical condition
has no relevance to Plaintiffsrespiratory injury at issue in this case There is no probative value
to this medical condition and allowing any evidence or testimony of the same will only prejudice
the Plaintiff
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I TIFF'S   LIMINE 
.  
Defendant should be precluded from presenting evidence that is not relevant and which 
will only serve to prejudice the Plaintiff, waste time, and confuse the jury.  l  f 
laintiffs irrelevant edical condition is being diagnosed ith herpes. his edical condition 
has no relevance to Plaintiffs respiratory injury at issue in this case. There is no probative value 
to this edical condition, and allo ing any evidence or testi ony of the sa e ill only prejudice 
 laintif . 
 I    LAINTIF 'S I  I  I I  - 1 
Plaintiffs personnel materials from her employment with the Idaho Department of
Correction IDOC should also be excluded Plaintiffsperformance or disciplinary records are
not probative of any issue in this case and it does not make any issue more or less probable
Defendant Security Equipment Corporation SEC and its attorneys should also be
prevented from presenting any evidence or testimony about SECs health questionnaires or
contamination reports or its use of the same SEC refused to produce these documents in
discovery SEC claimed they were temporally and substantively irrelevant SEC should not now
be able to testify or present evidence of its use of these forms for any reason
SEC and its counsel should also be precluded from presenting any evidence testimony or
argument that the Federal Hazardous Substances Act FHSA preempts Idaho law SEC has
never raised this as an affirmative defense To allow SEC to raise this at trial would be a waste
of time and confusing and prejudicial to the Plaintiff
SEC should also be precluded from presenting evidence or testimony about articles or
studies related to whether OC spray can cause death of an inmate by asphyxiation or delirium
SEC produced a number of this type of articles in discovery None of the articles are relevant to
the respiratory injury at issue in this case This type ofmaterial would be a waste of time and
confuse the jury Additionally they make no issue in this matter more or less probable
II ARGUMENT
A Evidence and Testimony of Plaintiffs Irrelevant Medical Condition Should Be
Excluded
That Plaintiff has been diagnosed with herpes is not related to any of the issues in this
case SEC and its attorneys should be precluded from presenting any evidence or testimony
about this medical condition or that Plaintiff has been diagnosed with the same This medical
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SEC produced a number of this type of articles in discovery. None of the articles are relevant to 
the respiratory injury at issue in this case. This type of material would be a waste of time and 
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 I  S PORT  LAINTIF 'S I  I  I I  - 2 
condition is not relevant Idaho Rule of Evidence 401 defines relevant evidence as evidence
having anytendency to make the existence ofany fact that is ofconsequence to the determination
of the action more probable or less probable than it would be without the evidence IRE401
Evidence which is not relevant is not admissibleIRE402
Additionally any evidence or testimony of this medical condition will only serve to
prejudice the Plaintiff waste time and confuse the jury There is no probative value to this
medical condition and allowing any evidence or testimony of the same will only prejudice the
Plaintiff Idaho Rule of Evidence 403 provides evidence may be excluded if its probative value
is substantially outweighed by the danger of unfair prejudice confusion of the issues or
misleading the jury or by considerations of undue delay waste of time or needless presentation
ofcumulative evidence IRE403
B Evidence and Testimony ofPlaintiffs Performance and Disciplinary Personnel
Records Should be Excluded
How the Plaintiff performed or was disciplined during her employment with the IDOC
are not probative of any issue in this case Such evidence or testimony does not have the
tendency to make the existence of any fact that is of consequence to the determination of the
action more probable or less probable than it would be without the evidence IRE401
Evidence which is not relevant is not admissibleIRE 402
SEC and its attorneys should be precluded from presenting evidence or testimony about
Plaintiffs performance discipline or termination of her employment Such testimony and
evidence will only waste time confuse the jury and prejudice the Plaintiff Idaho Rule of
Evidence 403 provides evidence may be excluded if its probative value is substantially
outweighed by the danger of unfair prejudice confusion of the issues or misleading the jury or
MEMORANDUM IN SUPPORT OF PLAINTIFFSMOTIONS INLIMINE 3
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S  and its attorneys should be precluded fro  presenting evidence or testi ony about 
Plaintiff's performance, discipline, or termination of her employment.  t ti   
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 I  S P   LAINTIF 'S   I INE -  
by considerations of undue delay waste of time or needless presentation of cumulative
evidence IRE403 As such it should be excluded from trial
C Evidence and Testimony of SECsHealth Questionnaire and Contamination
Reports Should Be Excluded
Plaintiff asked SEC to produce copies of completed health questionnaires and
contamination reports that SECs designee testified SEC relied on in its ongoing evaluation of
its OC spray products SEC objected stating that the requests are argumentative overly broad
unduly burdensome vague not limited in scope that it is not relevant and that there are too
many to produce Subject to these objections SEC produced only a sample Instructor Feedback
Questionnaire and Course Evaluation forms
Plaintiff asked that SEC provide copies of the actual reports and SEC reiterated its
objections SEC also stated that the reports were irrelevant and that they postdate the incident
that gave rise to the Plaintiffs complaint SEC also claimed that the reports concerned
exposures that were different than the OC spray exposure alleged by the Plaintiff SEC also
claimed that the reports concerned acute reactions only
SEC should not now be able to present any evidence or testimony about these reports or
SECs use of such reports SEC chose to prevent the Plaintiff from conducting discovery on
these materials ThePlaintiff would be prejudiced if SEC was permitted to present the materials
or the existence or its use of the materials at trial
Ex 1 to Affidavit of Counsel in Support of PlaintiffsMotions in Limine filed contemporaneously
herewith Aff ofCounsel May 18 2011 Rule 37 Request for Supplementation
2 Id
3 Id




MEMORANDUM IN SUPPORT OF PLAINTIFFSMOTIONS IN LIMINE 4
001576
by considerations of undue delay, aste of ti e, or needless presentation of cu ulative 
i nce." I.R.E. . s s , it s ld  luded fro  tri l. 
c. idence  esti  f C's lt  sti i e  t i tio  
eports Should Be Excluded 
laintiff asked  to produce copIes f co pleted health questionnaires and 
conta ination reports that C's designee testified  relied on in its on-going evaluation f 
its OC spray products.! SEC objected, stating that the requests are argumentative, overly broad, 
unduly burdenso e, vague, not li ited in scope, that it is not relevant, and that there are too 
any to produce.2 Subject to these objections, SEC produced only a sa ple Instructor Feedback 
Questionnaire and Course Evaluation forms.3 
laintiff asked that  provide copies f the actual reports, and  reiterated its 
objections.4 SEC also stated that the reports were irrelevant and that they post-date the incident 
that gave rise to the Plaintiffs co plaint.s  ls  l i  t t t  r rts r  
exposures that were different than the OC spray exposure alleged by the Plaintiff.6 SEC also 
clai ed that the reports concerned acute reactions, only.7 
 s l  t  e a le t  rese t a  e i e ce r testi  a t t ese re rts r 
SEC's use of such reports. S  chose to prevent the Plaintiff fro  conducting discovery on 
these aterials. he laintiff ould be prejudiced if  as per itted to present the aterials 
  st   s      trial. 
1 Ex. 1 to ffidavit of ounsel in Support of Plaintiff's otions in Li ine filed conte poraneously 
r it  ("Aff. f l"), ay 18,2011 ule 37 equest for Supple entation. 
2Id. 
I . 




 I  S PORT  LAINTIF 'S I  I  I I  -  
Additionally if the reports were as SEC states so temporally and substantively irrelevant
during discovery they are still temporally and substantively irrelevant They have no tendency
to make the existence of any fact that is of consequence to the determination of the action more
probable or less probable than it would be without the evidence IRE401 Evidence which
is not relevant is not admissible IRE402 Also such testimony and evidence will only waste
time confuse the jury and prejudice the Plaintiff and it should be excluded IRE 403
D Evidence Testimony and Argument that the Federal Hazardous Substances Act
Preempts Idaho Law Should Be Excluded
In the products liability case of Sherman v Winco Fireworks Inc the defendant
manufacturer sought to amend its answer just before trial asserting that the FHSA preempted
state law on products liability 532 F3d 709 8 Cir 2008 The Eighth Circuit Court of
Appeals held that the defendant was not timely the deadline to amend pleadings had passed and
defendants delay in seeking the amendment and the prejudice to the plaintiff of such a late
amendment overcame any good cause that is necessary to amend a scheduling order so as to
allow such an amendment Sherman 532F3d at 71617 Idahosstandard of seeking to amend
after the deadline therefore is higher than the good cause standard cited in Sherman In Idaho
the moving party must show excusable neglect before untimely leave to amend can be granted
IRCP6b
Sherman also holds that FHSA preemption is an affirmative defense that must be pled
Id at 715 Rule 8 of the Idaho Rules of Civil Procedure requires that affirmative defenses must
be pled or they are waived IRCP8c see also Bluestone v Mathewson 103 Idaho 453
1982 unpled affirmative defense can be allowed for the first time on summary judgment if the
8 Sherman is attached as Exhibit A to this Memorandum
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party against whom it is being asserted has ample time to prepare for and respond to the new
defense
SEC did not plead FHSA preemption in its answer and SEC has not sought leave to
amend its answer SEC also did not raise this issue in a manner that gave the Plaintiff sufficient
time to retain an FHSA expert or conduct discovery on SECsunpled preemption affirmative
defense Allowing SEC to argue that the FHSA preempts Idaho law would be highly prejudicial
to the Plaintiff Allowing SEC to argue that compliance with the FHSA excuses noncompliance
with Idaho law should also be precluded Any such argument testimony or evidence is not only
untimely but is an inaccurate statement of the law See Hansen v Sunnyside Prods 55 Cal
App 4th 1497 1507 fn 5 Cal App 3d Dist 1997 Compliance with governmental standards
or regulations does not preclude imposition of liability for a defective product It is merely to be
considered byyou as some evidence on the issue of adequacy ofwarnings
E Evidence and Testimony About Articles or Studies Related to Whether OC Spray
Causes Inmate Death Should be Excluded
SEC produced a number of articles in discovery that speak to whether OC spray can cause
death of an inmate by asphyxiation or delirium SEC should also be precluded from presenting
evidence or testimony about this type of article or study These articles are irrelevant to whether
SECsOC spray can cause respiratory injury This type ofmaterial would be a waste oftime and
confuse the jury and it should be excluded IRE 403 Additionally these articles make no
issue in this matter more or less probable and are therefore irrelevant See IRE 401
Evidence which is not relevant is not admissible IRE 402
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SEC's  spray can cause respiratory injury. his type of aterial ould be a aste of ti e and 
confuse the jury, and it should be excluded. I.RE. 403. Additionally, these articles make no 
iss e i  t is atter re r less r a le a  are, t erefore, irrele ant.  .RE. 1. 
"Evidence      t dmis ible." .RE. 2. 
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El
III CONCLUSION
For the foregoing reasons Plaintiff respectfully requests this Court to grant her motions
in limine in full and exclude from the trial of this matter all evidence and testimony of the
following
1 Evidence and testimony ofPlaintiffsirrelevant medical condition
2 Evidence and testimony of Plaintiffs performance and disciplinary personnel
records
3 Evidence and testimony of SECshealth questionnaire and contamination reports
4 Evidence testimony and argument that the Federal Hazardous Substances Act
preempts Idaho law
5 Evidence and testimony about articles or studies related to whether OC Spray
causes inmate death
DATED this 15th day of September 2011
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For the foregoing reasons, Plaintiff respectfully requests this ourt to grant her otions 
i  limine in ll,  l e  t e t i l  t is tter ll ide ce  t ti   t  
follo ing: 
. idence  t ti   l intiffs irreleva t i l iti . 
. idence  t sti  f l i tiffs rf r a ce  is i lin r  rs l 
. 
. Evidence and testi ony of SEC's health questionnaire and conta ination reports. 
. i , t sti ny,  r t t t t  r l r s st s t 
pree pts Idaho law. 
. ide ce  t ti  t ti les  t i  l t  t  t    
 ate th. 
TE  this 15th day of Septe ber, 2011. 
 .  
 . W Z 
 I  S PORT  LAINTIF 'S   I INE -  
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 15th day of September 2011 a true and correct copy
of the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA






MEMORANDUM IN SUPPORT OF PLAINTIFFSMOTIONS IN LIMINE 8
ERIC B SWARTZ
001580
ICATE F  
I ERE Y IF  that n this th a  of t r, , a true  rre t  
of the foregoing docu ent as served on the follo ing individual(s) by the ethod indicated: 
hristopher . urke 
homas J. loyd III 
EE ER RKE E    
950 . annock treet, ite  
oise, I  83702 
[ ] .S.  
~ 319-2601 
[ ] esse er li er  




Ic .  
A  I  SU PORT  LAINTIF 'S  I  I  - 8 
Exhibit A
to Memorandum in Support ofPlaintiff s Motions in Limine
001581
Exhibit A 
to Memorandum in Support of Plaintiff's Motions in Limine 
bit  
to e orandu  in Support of Plaintiff's otions in Limine 
Page 1
LexisNexis
1 of 12 DOCUMENTS
Positive
As of Sep 15 2011
Margaret Sherman Richard Sherman AppellantsCross Appellees v
Winco Fireworks Inc Winco Fireworks International LLCAppel
leesCross Appellants
Nos 072267393
UNITED STATES COURT OF APPEALS FOR THE EIGHTH
CIRCUIT
532F3d 709 2008 USApp LEXIS 14199 70 Fed R Sere 3d Cal
laghan 1543 CCHProd Liab Rep P18033
March 13 2008 Submitted
July 3 2008 Filed
PRIORHISTORY 1
Appeal from the United States District Court
for the District of Nebraska District 08678
804cv00300LSC Trial Judge Laurie Smith
CampUS District Judge
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CASE SUMMARY
PROCEDURAL POSTURE Plaintiffs a
husband and his wife sued defendant an al
leged fireworks distributor in the United States
District Court for the District of Nebraska for
claims that included negligent failure to warn
under Nebraska law The district court allowed
the distributor to belatedly amend its answer
and awarded plaintiffs attorney fees under 28
USCS 1927 A jury found for the distribu
tor Plaintiffs appealed the distributor
cross appealed
OVERVIEW The wife was allegedly injured
by a firework that the distributor sold to a re
tailer The distributor was allowed to amend its
answer after the scheduling deadline to assert a
affirmative defense of preemption under the
Federal Hazardous Substances Act which the
district court held partially preempted the neg
ligent failure to warn claim and required exclu
sion of expert testimony offered by plaintiffs
The district court awarded fees to plaintiffs
based on the distributor belated amendment
The court of appeals held that the district court
erred by allowing the amendment in the ab
sence of good cause under Fed R Civ P 16b
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order Fed R Civ P 15a did not apply The
error required a new trial only on the negligent
failure to warn claim and required reconsidera
tion of the admissibility of the expert testimo
ny A refusal to give an allocation of negli
gence instruction under Neb Rev Stat
252118509was not error pursuant to Neb
Rev Stat 252118507 such an instruction
was required only when contributory negli
gence was a defense The distributor was en
titled to reduction but not elimination of the fee
award
OUTCOME The district courtsgrant of leave
to amend was reversed as was the portion of
the attorneysfee award attributable to plain
tiffs costs of preparing expert testimony The
district courts judgment was otherwise af
firmed The matter was remanded for a new
trial on the negligent failure to warn claim
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HN1 While a court of appeals reviews a dis
trict courtsdecision allowing a party to amend
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Governments Courts Rule Application
Interpretation
HN2 Interpreting the Federal Rules of Civil
Procedure presents a question of law subject to
denovo review
Civil Procedure Pleading Practice De
fenses Demurrers Objections Affirmative
Defenses General Overview
Civil Procedure Pleading Practice
Pleadings Answers
Constitutional Law Supremacy Clause
Federal Preemption
HN3 Because preemption is an affirmative
defense Fed R Civ P 8c requires a defen
dant to plead a preemption defense in its an
swer
Civil Procedure Pleading Practice De
fenses Demurrers Objections Affirmative
Defenses General Overview
Civil Procedure Pleading Practice De
fenses Demurrers Objections Waiver
Preservation
HN4 Generally failure to plead an affirma
tive defense results in a waiver ofthat defense
However when an affirmative defense is raised
in the trial court in a manner that does not re
sult in unfair surprise technical failure to
comply with Fed R Civ P 8c is not fatal
Rule 8c is not an absolute bar to a partys be
lated attempt to plead an affirmative defense
Civil Procedure Pleading Practice
Pleadings Amended Pleadings General
Overview
Civil Procedure Pleading Practice
Pleadings Amended Pleadings Leave of
Court
HN5 Fed R Civ P 15a governs the pretri
al amendment of pleadings and states that
where an amendment is not sought as a matter
of course as defined by the Rule a party may
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amend its pleading only with the opposing par
tyswritten consent or the courtsleave Fed R
Civ P15a2
Civil Procedure Pleading Practice
Pleadings Amended Pleadings Leave of
Court
HN6 Fed R Civ P 15 provides that a court
should freely give leave to amend when justice
so requires Rule 152But parties do not
have an absolute right to amend their pleadings
even under this liberal standard
Civil Procedure Pleading Practice
Pleadings Amended Pleadings Leave of
Court
HN7 A district court appropriately denies a
movant leave to amend if there are compelling
reasons such as undue delay bad faith or dila
tory motive repeated failure to cure deficien
cies by amendments previously allowed undue
prejudice to the non moving party or futility of
the amendment
Civil Procedure Pretrial Matters Confe
rences Pretrial Orders
Civil Procedure Pretrial Matters Confe
rences Scheduling Conferences
HN8 Fed R Civ P 16b guides a district
courts issuance and modification of pretrial
scheduling orders and provides that except in
categories of actions exempted by local rule
the district judgemust issue a scheduling order
which must limit the time to join other parties
amend the pleadings complete discovery and
file motions Fed R Civ P 16b3A
This schedule may be modified only for good
cause and with the judgesconsent Fed R Civ
P 16b4In addition Rule 16d states that a
pretrial order controls the course of the action
unless the court modifies it
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Civil Procedure Pleading Practice
Pleadings Amended Pleadings Leave of
Court
Civil Procedure Pretrial Matters Confe
rences Scheduling Conferences
HN9 If a party files for leave to amend out
side of the courtsscheduling order the party
must show cause to modify the schedule
Moreover Fed R Civ P 16bsgoodcause
standard governs when a party seeks leave to
amend a pleading outside of the time period
established by a scheduling order not the more
liberal standard ofFed R Civ P 15a
Civil Procedure Pleading Practice
Pleadings Amended Pleadings Leave of
Court
Civil Procedure Pretrial Matters Confe
rences Scheduling Conferences
HN10 The plain language of Fed R Civ P
16b states both that district courts must issue
a scheduling order limiting the time to amend
the pleadings and that a scheduling order may
be modified only for good cause When a party
seeks to amend a pleading after the scheduling
deadline for doing so the application of Rule
16bsgoodcause standard is not optional To
permit district courts to consider motions to
amend pleadings under Fed R Civ P 15a
without regard to Rule 16b would render
scheduling orders meaningless and effectively
read Rule 16b and its good cause requirement
out of the Federal Rules ofCivil Procedure
Civil Procedure Pleading Practice
Pleadings Amended Pleadings Leave of
Court
Civil Procedure Pretrial Matters Confe
rences Scheduling Conferences
HN11 Once a scheduling orders deadline
passes a plaintiff first must show good cause
under Fed R Civ P 16b for failure earlier to
seek leave to amend before a court will consid
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er whether amendment is proper under Fed R
Civ P 15a
Civil Procedure Pretrial Matters Confe
rences Scheduling Conferences
HN12 The primary measure of good cause
under Fed R Civ P 16b is a movantsdili
gence in attempting to meet a scheduling or
ders requirements Under Rule 16b advisory
committee note 1983 amendment a court
may modify the schedule on a showing of good
cause if it cannot reasonably be met despite the
diligence of the party seeking the extension
While the prejudice to the nonmovant resulting
from modification of the scheduling order may
also be a relevant factor generally a reviewing
court will not consider prejudice if the movant
has not been diligent in meeting the scheduling
ordersdeadlines Cases reviewing Rule 16b
rulings focus in the first instance and usually
solely on the diligence of the party who sought
modification of the order
Civil Procedure Remedies Costs Attor
ney Fees Attorney Expenses Fees Sta
tutory Awards
Civil Procedure Sanctions General Over
view
HN13 28USC 1927 provides for attor
neysfees against an attorney who so multiplies
the proceedings in any case unreasonably and
vexatiously
Civil Procedure Pleading Practice De
fenses Demurrers Objections Affirmative
Defenses General Overview
Constitutional Law Supremacy Clause
Federal Preemption
HN14 The very fact that preemption is treated
as an affirmative defense presupposes that in a
typical case a diligent defendant will be able to
plead the defense on the basis of the complaint
alone at the onset of the litigation
Civil Procedure Appeals Standards ofRe
view Reversible Errors
HN15 Reversal is not mandated unless a dis
trict courtserror affects a substantial right of
the objecting party
Antitrust Trade Law Consumer Protec
tion General Overview
Torts Negligence Proof Burdens of
Proof
Torts Negligence Standards of Care
Reasonable Care General Overview
Torts Products Liability Duty to Warn
Torts Products Liability Negligence
HN16 To establish a Nebraska commonlaw
negligent failuretowarn claim plaintiffs are
required to establish the relevant standard of
care by proving that the defendant failed to ex
ercise reasonable care to inform expected users
of a product dangerous condition or of the
facts which make it likely to be dangerous Un
like the more concrete Federal Hazardous Sub
stances Act FHSA standard of care the Ne
braska commonlaw standard does not establish
the form in which the warning must be com
municated to the user and it also does not limit
the warning requirement to principal hazards
Instead Nebraska law vests a jury with the task
of determining the dangers that require a warn
ing and the form that the warning must take
Accordingly the FHSA standard of care is not
necessarily equal to or greater than the standard
of care that Nebraska law imposes upon a de
fendant
Civil Procedure Trials Jury Trials Jury
Instructions General Overview
Civil Procedure Trials Jury Trials Jury
Instructions Requests for Instructions
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HN17 A court of appeals reviews a district
courtsrefusal to submit proffered jury instruc
tions and its decision to give certain instruc
tions for an abuse ofdiscretion
Civil Procedure Federal State Interrela
tionships ErieDoctrine
Civil Procedure Trials Jury Trials Jury
Instructions Requests for Instructions
Civil Procedure Trials Jury Trials Jury
Instructions Supplemental Instructions
HN18 A federal district court presiding over a
diversity case is not bound to give a jury in
struction requested by the litigants nor is the
court constrained to follow the language con
tained in a state uniform instructions
Civil Procedure Trials Jury Trials Jury
Instructions General Overview
Civil Procedure Appeals Standards ofRe
view General Overview
Civil Procedure Appeals Standards of Re
view Reversible Errors
HN19 In conducting a review of a district
courtsjury instructions a court of appeals must
determine simply whether the instructions
taken as a whole and viewed in light of the
evidence and applicable law fairly and ade
quately submitted the issues in the case to the
jury Reversal is only warranted if a partys
substantial rights are prejudiced by instruction
al error The court of appeals will order a new
trial only if the error misled the jury or had a
probable effect on its verdict
Torts Negligence Defenses Contributory
Negligence Procedure General Overview
Torts Procedure Multiple Defendants
Alternative Liability
HN20 Neb Rev Stat 252118507restricts
the applicability of Neb Rev Stat
252118509 and 2521185
252118507 to 25211852 shall apply to all
Page 5
civil actions to which contributory negligence
may be pursuant to law a defense By ex
pressly narrowing the application of these sta
tutes to cases in which contributory negligence
is at issue 252118507 impliedly excludes
the statutes application outside of that context
Torts Negligence Defenses Contributory
Negligence Procedure General Overview
Torts Procedure Multiple Defendants
Alternative Liability
HN21 Consistent with Neb Rev Stat
252118507 Nebraska cases construing Neb
Rev Stat 252118507 through
25211852 limit those statutes to the contri
butorynegligence context For cases involving
multiple defendants where contributory negli
gence is a defense the Nebraska Legislature
has altered the common law
Civil Procedure Trials Jury Trials Jury
Instructions General Overview
Civil Procedure Appeals Standards ofRe
view Reversible Errors
HN22 A court of appeals will not order a new
trial after the jury has passed on the evidence
merely because there is a metaphysical possi
bility that the jurysverdict was affected by the
district courtsfailure to give an instruction
Torts Products Liability General Overview
HN23 While the drafting committeescom
ments to the Nebraska Model Jury Instructions
indicate that in almost all cases the issue of
whether a plaintiff was among those expected
to be endangered by a product will be resolved
as a question of law Nebraska law also indi
cates that the determination of whether a legal
duty exists is a question of law dependent on
the facts in a particular case
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jury. Reversal is only warranted if a party's 
substantial rights are prejudiced by instruction-
al error. The court of appeals will order a new 
trial only if the error misled the jury or had a 
probable effect on its verdict. 
ts> Negligence> efenses> tri t r  
Negligence> e> r l  
 >  > Multiple Defendants > 
lter tive i ility 
[H 20] eb. ev. Stat. § 25-21,185.07 restricts 
 applicability  b. ev. tat. §§ 
25-21,185.09  25-21,185.11(2): §§ 
25-21,185.07 to 25-21,185.12 shall apply to all 
i il tions t  hich t i t  ligence 
a  e, rs a t t  la , a efe se. y e -
ressl  arr ing t e a licati  f t ese sta-
te  t  ases in ich  igence 
is t is , § - 1,185.07 i lie l  ludes 
t e t t t ' li ti  t i   t t t t. 
rts> egligence> fenses>  
ligence> ocedure> r l r i  
t  >  > lti l  efe ts > 
lte tive i ility 
[HN21]  t  . v. . § 
- 1,185.07, as a  t i  . 
v. t. §§ - 1,185.07 t r  
- 1,185.12 li it t se stat tes t  t e c tri-
butory-negligence context. For cases involving 
lti l  t   t i t  gli-
gence is a defense, the ebraska egislature 
 tere    . 
 oce re> s>  ials>  
io s> r l i  
 ce e> ls> s  e-
> r i l   
[H ]  rt  l  ill t    
tri l, ft r t  j     t  i e, 
r l   t r  i   t i l ssi-
ilit  t t t  j ry's r i t s ff t   t  
istrict c urt's fail re t  i e a  i str ction. 
ts> r ts i ility> r l i  
[H 23] hile the drafting co mittee's com-
t  t  t   l r  t ti  
t   i  l  l    i  f 
t r  l i tiff s  t s  t  
t   r    r t ill  r sol  
as a esti  f law, e ras a la  als  i di-
cates t at t e eter i ati  f et er a le al 
t  e ists is a esti  f la  e e e t  
the facts in a particular case. 
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Civil Procedure Remedies Costs Attor
ney Fees Attorney Expenses Fees Sta
tutoryAwards
Civil Procedure Sanctions General Over
view
HN24 28 USCS 1927 authorizes a district
court to require an attorney to reimburse the
excess costs and attorneysfees reasonably in
curred by the opposing party as a result of an
attorneysunreasonable and vexatious multip
lication of the proceedings That statutory au
thority for the award of attorney fees focuses
on the conduct of the movantsopposing coun
sel
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Daniel Mary Elizabeth Frankman BRA
SHEAR LLPOmaha NE
JUDGES Before WOLLMAN HANSEN
and MELLOY Circuit Judges
OPINION BY HANSEN
OPINION
712 HANSEN 2 Circuit Judge
Margaret and Richard Sherman appeal the
district courtsgrant of Winco Fireworks Incs
motion to amend its answer which allowed
Winco to plead an affirmative federallaw
preemption defense more than seventeen
months after the deadline for amending plead
ings The Shermans also challenge the district
courts exclusion of expert testimony and the
district courts 713 failure to give several
jury instructions On cross appeal Winco chal
lenges the district courtsattorney fees award
We reverse the district court order granting
Winco leave to amend and remand for a new
trial on the Shermans failuretowarn claim in
addition to Mr Shermanspendent consortium
claim We do not reach the district courts ex
clusion of expert testimony and we affirm on
the juryinstruction issues Finally we reverse
in part the district courtsattorney fees award
I
On July 3 2002 the Shermans were
watching their grandson Nate Kapustka set off
fireworks in Mrs Sherman daughtersback
yard Nate ignited a Saturn Missile that er
rantly struck and injured Mrs Sherman eye
Natesfather Stanley Kapustka had purchased
the Saturn Missile from Hale Fireworks Inc
in Nixa Missouri 3 prior to the accident
Winco is allegedly the fireworks distributor
that sold the Saturn Missile to Hale Fireworks
On July 2 2004 the Shermans filed this
suit in the District of Nebraska asserting nine
causes of action against several businesses in
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 oc  > e edies> sts & r-
ney ees> ttorney xpenses & ees> t -
tutory A ards 
  > ons > l er-
e  
[H 24] 28 S.c.s. §  ize    
court to require an attorney to rei burse the 
excess costs and attorney's fees reasonably in-
curred by the opposing party as a result of an 
attorney's unreasonable and vexatious ultip-
lication f t  r i s. hat st t t r  u-
thority for the a ard of attorney's fees focuses 
on the conduct of the ovant's opposing coun-
l. 
S L: For argaret Sher an, ichard 
r  (0 - 67), l i tiff - ll ts: -
trick S. ooper, ichael Francis oyle, avid 
J. t sta , a e e J. s ar,  & 
, , . 
  , c.,  r r s 
t ti al,  (0 - 67), t - -
pellees: ark Joseph aly, cott ugene a-
niel, ary lizabeth Frank an, S  
, , . 
For Shiu Fung Fire orks, Co. LT . (07-2267), 
efe ant: eat er lla  sc tz, ert 
ic l l k,  & K, a, 
. 
For Shangli Jin in xport Fire orks Factory 
(07-2267), efendant: onald E. readore, 
  I ,  rk, . 
 argaret Sher an,   
(07-2393), Plaintiff - Appellees: Patrick S. 
ooper,  Francis oyle,  . 
t t ,  . ar,  & 
, a a, . 
r i c  ire r s, I C., i c  ire r s 
International, . (07-2393), efendant -
Appellants: ark Joseph Daly, Scott Eugene 
i l, ar  liza t  , -
 , , . 
:  , , 
 ,  s. 
 :  
 
[*71 ] , [**2] ir it J e. 
ar ar t  i r  r  l t  
i tri t urt's r t f i  ir r , I c.'s 
    r,   
i c  t  lea  a  affir ati e fe eral-la  
pree ption     
onths after the deadline for a ending plead-
i .  r  l  ll  t  i tri t 
urt's l i  f rt t ti   t  
 urt's [*7 ] fail re t  i e se eral 
j r  i str cti s.  cr ss-a eal, i c  c al-
le es t e istrict c urt's attorney's fees a ard. 
e reverse the district court order granting 
         
   r ' -to-wa    
addition to r. Sher an's pendent consortiu  
l i .       ourt's x-
l i  f rt t ti ,  e ffir   
t e j ry-i str cti  iss es. i ally, e re erse, 
in part, the district court's attorney's fees a ard. 
. 
n July 3, 2002, the Sher ans ere 
t i  t ir r  t  t  t ff 
fir r  i  r . erman's ughter's  
yard. ate ignited a "Saturn issile" that er-
ra tl  str c  a  i j re  rs. herman's eye. 
ate's father, Stanley apustka, had purchased 
t  t  i il   l  i , c., 
i  i , i uri, [**3] prior to the accident. 
i  is ll l  t  fir r s istri t r 
 l   t     rks. 
 J l  , 04, t e er a s file  t is 
suit in the istrict of ebraska, asserting nine 
causes of action against several businesses in 
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the fireworks industry allegedly responsible for
the manufacture distribution andorsale of the
Saturn Missile The Shermans nine claims in
cluded a Nebraska law negli
gent failuretowarn claim among others In its
initial scheduling order the district court di
rected the parties to file motions to amend their
pleadings by May 6 2005 A later progression
order directed the parties to file motions to
amend their pleadings by August 9 2005 The
district court directed the parties to complete
discovery and to file motions for summary
judgment by December 15 2006
On December 15 2006 Winco filed a mo
tion for summary judgment and argued for the
first time that the Shermans negligence and
warranty claims counts two through sev
enwere label based claims preempted by the
Federal Hazardous Substances Act FHSA and
FHSA regulations See 15 USC 1261p
defining misbranded hazardous substance
16 CFR 150047xiv 4 de
scribing the label required formissiletype
rockets pursuant to the Consumer Product
Safety Commission authority under 15 USC
1262b to establish label requirements addi
tional to those mandated by 15 USC
1261pOn January 22 2007 more than
seventeen months after the August 9 2005
deadline for amending pleadings Winco filed a
motion for leave to file and serve an amended
answer formally pleading this affirmative
preemption defense The district court granted
Wincos motion for leave to amend its answer
noting that allowing the amendment was
somewhat prejudicial and that Wincosdelay
was unwarranted Shermans Add at 10 In
an attempt to mitigate the prejudice resulting
from the belated amendment the district court
permitted the Shermans to file a supplementary
brief on the preemption issue allowed the
Shermans to seek leave to conduct additional
discovery permitted the Shermans to seek re
levant time extensions and invited the Sher
mans to file a motion for attorneysfees and
costs incurred as a result of the belated
Page 7
amendment The district court subsequently
awarded the Shermans 3201987in attorney
fees costs and other expenses 5 based on
28USC 1927 which permits the award of
fees if an attorney multiplies the proceedings
in any case unreasonably and vexatiously
1 For ease of reference in the re
mainder of this opinion the Shermans
addendum will be cited as SA and
Wincos addendum will be cited at
WA
714 In a February 2007 order the dis
trict court addressed Wincos sum
maryjudgment motion and considered Wincos
affirmative preemption defense concluding
that only the Shermans third cause of action for
negligent failure to warn was preempted insofar
as the Shermans sought to hold Winco to a
higher standard of care than the standard estab
lished by federal law See Mattis v Carlon
Elec Prods 295F3d 856 862 8th Cir 2002
quoting 15 USC 1261 note b1A
NoState may establish or continue in
effect a cautionary labeling requirement appli
cable to such substance or packaging and de
signed to protect against the same risk of illness
or injury unless such cautionary labeling re
quirement is identical to the labeling require
ment under 1261p or 1262 Spe
cifically the district court concluded that the
Saturn Missile warning label satisfied the re
quirements of 16 CFR150047xiv
6 as a matter of law but found that genuine
issues of material fact remained with respect to
whether the fireworkswarning label complied
with the requirements of 15 USC
1261pErequiring hazardous substances
to bear a label including among other things
an affirmative statement of the products
principal hazard or hazards The district court
expressly rejected Wincoscontention that the
preemption defense affected the Shermans re
maining claims but the district court did dis
miss all but four of the nine original causes of
action on grounds not challenged on appeal
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t e fire orks industr  lle l  re i le f r 
the anufacture, distribution, and/or sale of the 
 is i . he ' ine lai s i -
lude   ebraska-la  li-
t-f ilure-to-warn l i , ng t rs. I  its 
initial scheduling order, the district court di-
rected the parties to file otions to a end their 
pleadings by ay 6, 2005.  later progression 
order directed the parties to file otions to 
a end their pleadings by ugust 9, 2005. he 
district court directed the parties to co plete 
discovery and to file otions for su ary 
judg ent by ece ber 15, 2006. 
 e er , , i  file   -
tion for su ary judg ent and argued, for the 
first ti e, that the Sher ans' negligence and 
arranty --   t r  v-
en--were label-based clai s pree pted by the 
ederal azardous ubstances ct (F ) and 
FHSA regulations. See 15 U.S.C § 261(P)(1) 
(definin  "misbrande  azar s s sta ce"); 
 F.R. § 1500.14(b)(7)(xiv) [**4] (de-
scribing the label required for "[ m ]issile-type 
rockets, " pursuant to the onsu er Product 
Safety o ission's authority under 15 .S.C 
§ 1262(b) to establish label require ents addi-
tional to those andated by 15 U.S.C § 
1261 (P)(1)). On January 22, 2007, ore than 
seventeen onths after the ugust 9, 2005, 
deadline for a ending pleadings, inco filed a 
         
 formally pleading  f  
pree ption defense. The district court granted 
i co's ti  f r lea e t  a e  its a s er, 
noting that allowing the   
"some hat prejudicial" and that inco's delay 
 "un rr nted." ( r ' . t 0.) I I  
an attempt to mitigate the prejudice resulting 
fr  t  l t  nd ent, t  istri t rt 
per itted the Sher ans to file a supple entary 
brief on the pree ption issue; allowed the 
     t dditi l 
discovery; per itted the Sher ans to seek re-
levant ti e extensions; and invited the Sher-
ans to file a otion for attorney's fees and 
 i    r sult f t  l  
t.   t  
 t e a s $ 2,019.87 in rney's 
fees, c sts, a  t er e enses [**5]   
 .S.C § , ic  ts t e   
e  f   "multiplies   
  ase re   tiously." 
 r   ,  t  -
i r f t is i i  t  r ' 
   te   "S ,"  
i co's  ill  ite  t 
"WA." 
[*71 ] I   r r   r er, t  is-
   co's su -
ary-judgment ti   i  i co's 
affir ative pree ption defense, l  
t t l  t  r s' t ir  s  f ti  f r 
       
as the her ans sought to hold inco to a 
i  t    t  t  t  t b-
li   l l .  tti  V. l  
l c. ds.,  .3d 6,  (8t  ir. 2) 
(quoting 15 U. S. C §   (b)(1 )( A) 
("[N]o t t  ...  t li  r ti  i  
effect a ca ti ar  la eli  re ire e t appli-
ca le t  s c  s sta ce r ac a i  a  e-
   i      lnes  
 i j  les   ti  l li  -
ir t i  i ti l t  t  l li  r uire-
  (§ 1261(P) or § 262(b)]."). pe-
ifi lly, t  istri t rt l  t t t  
at r  issile's ar i  la el satisfie  t e re-
ire e ts f  F.R. 500.14(b)(7)(xiv) 
[**6] as a atter flaw, t f  t at e i e 
issues f aterial fact re ained ith respect to 
t r t  fir work's r i  l l li  
  require ents f  u.s. C § 
261 (P)(1 )(E) (re iri  r  t  
t  ear a la el i cl i g, a  t er t i s, 
"a  affir ati e state e t f t e [pr duct's] 
principal hazard or hazards").  i tri  rt 
expressly rejected inco's contention that the 
pree ption defense affected the her ans' re-
i i  l i s, t t  i tri t rt i  is-
iss all t f r f t e i e ri i al ca ses f 
acti   r s t c alle e   appeal. 
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The following four causes of action remained
for trial 1 negligent failure to use reasonable
care to see that goods are safe for intended use
2 negligent failure to warn as limited by the
district courtspreemption ruling 3 breach of
implied warranty of merchantability and 4
loss ofconsortium
Prior to trial Winco filed a motion in li
mine to exclude the testimony of the Shermans
expert Dr Christine Wood The district court
granted Wincosmotion concluding that Dr
Woodstestimony concerning the development
ofwarning labels would not assist the jury be
cause as a result of its preemption 7 rul
ing the warnings the Product label was re
quired to include hadalready been developed
and stated in the federal regulations SA at
18
At trial a jury found for Winco on all four
claims and the district court entered judgment
in favor of Winco The Shermans filed a re
newed motion for judgment as a matter of law
or in the alternative a new trial which the dis
trict court denied This appeal and Wincos
conditional cross appeal of the attorneysfees
award followed
II
First we consider the Shermans argument
that the district court erred by applying the
wrong standard in ruling on Wincosmotion to
amend its answer which was filed well after
the Rule 16 scheduling deadline for amending
the pleadings HN1 While we review the dis
trict courtsdecision allowing a party to amend
a pleading for an abuse of discretion see Po
poalii v Corr Med Servs 512 FM 488 497
8th Cir 2008 standard of review we review
whether the district court applied the correct
legal standard in exercising that discretion de
novo see Ind Lumbermens Mut Ins Co v
Timberland Pallet Lumber Co 195 F3d
368 374 8th Cir 1999 HN2 Interpreting
the Federal Rules ofCivil Procedure 8
Page 8
presents a question of law subject to de novo
review internal marks omitted
Wincosbelated motion to amend its answer
and plead its affirmative preemption defense
implicated three different federal rules of civil
procedure First HN3 because 715
preemption is an affirmative defense see
Wuebker v WilburEllis Co 418 F3d 883
886 8th Cir 2005 Rule 8c required Winco
to plead the preemption defense in its answer
HN4 Generally failure to plead an affirma
tive defense results in a waiver of that defense
First Union NatlBank v Pictet Overseas Trust
Corp 477 F3d 616 622 8th Cir 2007
However when an affirmative defense is
raised in the trial court in a manner that does
not result in unfair surprise technical failure to
comply with Rule 8c is not fatal Id internal
marks omitted Here consistent with govern
ing caselaw the district court recognized that
Rule 8cis not an absolute bar to a partysbe
lated attempt to plead an affirmative defense
concluding that Winco had not waived its af
firmative preemption defense in this particular
case Because the Shermans do not meaning
fully contest this discretionary determination Z
we do not address the district courts 9
Rule8canalysis further
2 In their brief the Shermans argue
that the district court erred by concluding
as a matter of law that an affirmative
preemption defense can never be waived
But the district courtsorder is not so ca
tegorical Rather the orders plain lan
guage indicates that the district court
concluded in its discretion that waiver
of the preemption defense was not war
ranted in this particular case
In addition to Rule 8c Wincosmotion
implicated both Rule 15a and Rule 16b
HN5 Rule 15a governs the pretrial amend
ment of pleadings and states that where an
amendment is not sought as a matter of
course as defined by the Rule a party may
001589
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The following four causes of action remained 
for trial: (1) negligent failure to use reasonable 
care to see that goods are safe for intended use; 
(2) negligent failure to warn (as limited by the 
district court's pree ption ruling); (3) breach of 
implied warranty of merchantability; and (4) 
loss  . 
rior t  tri l, inc  filed a otion in li-
ine to exclude the testi ony of the Sher ans' 
expert, Dr. Christine ood. The district court 
granted inco's otion, concluding that r. 
d's testi  c cer i  the e el e t 
of warning labels would not assist the jury be-
cause, as a result of its pree ption [**7] r l-
ing, "the arnings the Product's label as re-
quired to include ha[ d] already been developed 
and stated in the federal regulations." (SA at 
18.) 
At trial, a jury found for inco on all four 
claims, and the district court entered judgment 
in   . e  le   -
ne ed otion for judg ent as a atter of la , 
or in the alternative, a ne  trial, hich the dis-
trict court denied. This appeal, and inco's 
conditional cross-appeal of the attorney's fees 
award, followed. 
I. 
First, we consider the Shermans' argument 
that the district court erred by applying the 
rong standard in ruling on inco's otion to 
a end its ans er, hich as filed ell after 
the ule 16 scheduling deadline for a ending 
the pleadings. [HNl] hile e revie  the dis-
trict court's decision allowing a party to a end 
a pleading for an abuse of discretion, see Po-
poalii v. Corr. ed. Servs., 512 F.3d 488, 497 
(8th Or. 2008) (standard of review), we review 
whether the district court applied the correct 
legal standard in exercising that discretion de 
novo, see Ind. Lu ber ens ut. Ins. Co. v. 
r  ll t & r o.,  .3d 
368, 374 (8th Or. 1999) ([HN2] "Interpreting 
t  r l l  f ivil r e. .. [**8] 
presents a question of la  subject to de novo 
r i w." (internal a s itted». 
i o's late  tion to e d its s er 
a d lead its affirmative ree tion efense 
i plicated three different federal rules f civil 
procedure. t, [HN ] because [*71 ] 
pree ption is an ir ative , see 
 . l -E lis o.,  .3d , 
6 (8th . 5), e (c) re ire  inc  
to lea  the re tion efense in its s r. 
[H ] "Gen ll , r     -
tive fense lts in  i e   t at f nse." 
irs   at'l k . t  s   
rp., 77 .3d ,  (8t  Or. 07). 
r, "when  ir a i e ense  
r i  i  t  trial rt i   r t t  
t r s lt i  f ir s r ris , t i l f il r  t  
co ply ith le (c) is not fatal." Id. (internal 
 itted). r ,   rn-
i  casela , t e istrict c rt rec ize  t at 
 (c) s   l     arty's -
lated atte pt to plead an affir ative defense, 
concluding that inco had not aived its af-
fir ti  r ti  f  i  t i  rti l r 
.      ning-
f ll  t st t is is r ti r  t r i ati n, 2 
      ourt's [**9] 
l  (c) a al sis f rt er. 
   ri f,   r  
t t t  i t i t t   l i  
   f    f  
r ti  f   r  i d. 
  i t  ourt's  i  t  a-
t gorical. ther, t  rder's l i  l n-
a e i icates t at t e istrict c rt 
cl ed, i  i  i cretion, t t i r 
 t  ti  f   t ar-
ranted in this particular case. 
 dditi  t  l  (c), inco's oti  
i plicated both Rule 15(a) and Rule 16(b). 
[ ] l  5(a) g r s t  r tri l end-
e t f lea i s a  states t at ere an 
 i  t sou t "a  a tt  f 
course"--as defined by the ule--"a party ay 
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amend its pleading only with the opposing par
tys written consent or the courtsleave Fed
R Civ P 15a2HN6 The Rule provides
that he court should freely give leave when
justice so requires Id But parties do not have
an absolute right to amend their pleadings even
under this liberal standard United States ex rel
Lee v FairviewHealth Sys 413 F3d 748 749
8th Cir 2005 HN7 A district court appro
priately denies the movant leave to amend if
there are compelling reasons such as undue
delay bad faith or dilatory 10 motive
repeated failure to cure deficiencies by
amendments previously allowed undue preju
dice to the non moving party or futility of the
amendment Mosesc mSec Inc v Compre
hensive Software Sys Inc 406 F3d 1052
1065 8th Cir 2005 internal marks omitted
HN8 Rule 16bon the other hand guides
the district courtsissuance and modification of
pretrial scheduling orders and provides that
xcept in categories of actions exempted by
local rule the district judge must issue a
scheduling order which must limit the time
to join other parties amend the pleadings
complete discovery and file motions Fed R
Civ P 16b3AThis schedule may be
modified only for good cause and with the
judgesconsent Fed R Civ P 16b4em
phasis added In addition Rule 16d states
that a pretrial order controls the course of the
action unless the court modifies it
Relying on the plain language of Rule 16
the Shermans argue that the district court erred
by failing to apply Rule 16bsgood cause
standard in ruling on Wincosmotion to amend
But as a threshold matter Winco contends that
the Shermans waived this argument by failing
to raise it before 11 the district court
Wincosposition is unsupported by the record
In the Shermans brief in opposition to Wincos
motion to amend its answer albeit in a lengthy
footnote the Shermans directed the district
court to a district court case applying the same
approach now advocated by the Shermans the
Page 9
primacy ofRule 16b over Rule 15a in cases
in which the deadline to amend pleadings
716 has past See Fin Holding Corp v
Garnac Grain Co 127FRD 165 16566
WDMo 1989 We conclude that this foot
note raised the issue in the district court in a
way sufficient to avoid waiver on appeal
The interplay between Rule 15a and Rule
16b is settled in this circuit In Popoalii we
stated that HN9 ifa party files for leave to
amend outside of the courtsscheduling order
the party must show cause to modify the sche
dule 512 F3d at 497 citing Rule 16b em
phasis added Moreover we said so in the
context of a discussion of the Rule 15 amend
ment standard unmistakably concluding that
Rule 16bsgoodcause standard governs when
a party seeks leave to amend a pleading outside
of the time period established by a scheduling
order not the more liberal standard of Rule
15a Id 12 Because Popoalii filed her
motion to amend her complaint five months
after the scheduling deadline for amending
pleadings under Rule 16b Popoalii
needed to show cause in order to be given leave
to amend Id
The approach taken in Popoalii is derived
directly from HN10 the plain language of
Rule 16bwhich states both that district courts
must issue a scheduling order limiting the time
to amend the pleadings and that a scheduling
order may be modified only for good cause
When a party seeks to amend a pleading after
the scheduling deadline for doing so the appli
cation of Rule 16bsgoodcause standard is
not optional To permit district courts to con
sider motions to amend pleadings under Rule
15a without regard to Rule 16b would
render scheduling orders meaningless and ef
fectively read Rule 16b and its good cause
requirement out of the Federal Rules of Civil
Procedure Sosa v Airprint Sys Inc 133
F3d 1417 1419 11th Cir 1998 see also
Leary v Daeschner 349 F3d 888 909 6th
Cir 2003 HN11 Once the scheduling or
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a end its pleading only ith the opposing par-
ty's ritten consent or the court's leave." Fed. 
R. iv. P. 15(a)(2). [HN6] The Rule provides 
that "[t]he court should freely give leave hen 
justice s  re ires." I . t arties  t a e 
an absolute right to a end their pleadings, even 
er t is iberal r . nited t   i. 
Lee v. airvie  ealth Sys., 413 .3d 748, 749 
(8th Cir. 2005). [HN7] A district court appro-
priately denies the movant leave to amend if 
"there are co pelling reasons such as undue 
delay, bad faith, or dilatory [**1 ] ti , 
repeated  t   ie e  by 
a end ents previously allo ed, undue preju-
dice to the non- oving party, or futility of the 
a endment." oses.com Sec., Inc. v. o pre-
hensive Soft are Sys., Inc., 406 3d 1052, 
1065 (8th ir. 2005) (internal arks o itted). 
[H 8] Rule 16(b), on the other hand, guides 
t e s ict urt's iss e  ication  
pretrial scheduling orders and provides that 
"[e]xcept in categories of actions exe pted by 
local rule, the district judge . . .    
scheduling order," which "must li it the ti e 
to join other parties, amend the pleadings, 
co plete discovery, and file otions." ed. . 
iv. . 16(b)(1), (3)(A). his schedule "may be 
odified only for good cause and ith the 
judge's consent." Fed.  Civ. P. 16(b)(4) (e -
phasis added). In addition, Rule 16(d) states 
that a pretrial order "controls the course of the 
ti  les  t  t i ie  it." 
Relying on the plain language of Rule 16, 
the Shermans argue that the district court erred 
by failing to apply Rule 16(b)'s "good cause" 
standard in ruling on inco's otion to a end. 
t as a t res l  atter, i c  c te s t at 
the Sher ans waived this argu ent by failing 
   f  [**11] the district court. 
inco's position is unsupported by the record. 
In the Shermans' brief in opposition to inco's 
otion to a end its ans er--albeit in a lengthy 
--th    t  i t  
court to a district court case applying the same 
approach now advocated by the Shermans--the 
ri acy  le 6(b) er le 5(a) in  
i  ic  t e li e t  e d lea ings 
[*71 ] s st.  i . l i  r . . 
  o.,  R.D. , -66 
(W.D. . 89). e de  t is f t-
t  is  t  issue i  t  ist ict t in  
ay sufficient to avoid aiver on appeal. 
 t  ee   5(a)  e 
6(b) s e    it.  poali ,  
t t  t at [H ] "[i]f  t  iles  l e t  
 t i   t  urt's li  r r, 
t  t  t  se t  i  t  e-
le."  3d t  (citing l  6(b) (e -
i  ded». r r,  i   i  t  
        end-
ent standard, un istakably concluding that 
l  6(b)'s -cause t  s  
 t   l  t    l i  t i  
f t e ti  ri  st lis    s li  
r r, t t  r  liber l st r  f l  
5(a). I . [**1 ] eca se alii file  er 
ti  t   r l i t fi  t s 
ft r t  s li  li  f r i  
pleadings, "[u]nder [R l ] 16(b), l  
needed to sho  cause in order to be given leave 
 end." . 
  t  i  oalii i  i  
ir tl  fr  [HNI ] t  l i  l   
l  6(b), i  st t s t  t t istri t rts 
ust issue a scheduling order li iting the ti e 
to a end the pleadings, and that a scheduling 
r er "ma  e ifie  l  f r  cause." 
hen a party seeks to a end a pleading after 
 l  l   i  o,  ppli-
cation of ule 16(b)'s good-cause standard is 
not optional. To per it district courts to con-
si er ti s t  a e  lea i s er l  
5(a) it t re ar  t  le 6(b) "wo l  
render scheduling orders eaningless and ef-
ti l  ... read ule 16(b) and its good cause 
r ir t t  t  r l l  f i il 
r cedure." osa v. i i t ys., Inc.,  
.3d 417,  (l t  ir. 9 8)); s  ls  
r  v. schner,  .3d 88,  (6t  
ir. 2003) ([HNll] "Once the scheduling or-
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dersdeadline passes a plaintiff first must show
good cause under Rule 16b for failure earlier
to seek leave to amend before a court will
13 consider whether amendment is proper
under Rule 15a Hawthorne Land Co v
Occidental Chem Corp 431 F3d 221 227
5th Cir 2005 cert denied 127 S Ct 48 166
L Ed 2d 20 2006 applying the same ap
proachOConnell v Hyatt Hotels ofPR357
EM 152 15455 1st Cir 2004 same Park
er v Columbia Pictures Indus 204F3d 326
340 2d Cir 2000 same Johnson v Mam
moth Recreations Inc 975 F2d 604 609 9th
Cir 1992 same
Because Wincosmotion to amend was
filed more than seventeen months after the es
tablished scheduling deadline for amending
pleadings the district court was required to ap
ply Rule 16bsgoodcause standard in ruling
on Wincosmotion Winco argues that even if
the district court was required to apply Rule
16b the district courts analysis was tanta
mount to a goodcause finding Were we satis
fied that the substance of the district courts
ruling was in fact a goodcause analysis giving
due consideration to Wincosdiligence in at
tempting to comply with the scheduling dead
line we would not disapprove of a functional
reading of the district courtsorder a formal
citation of Rule 16bsgood cause require
ment is not what counts But as we explain
14 below we are not satisfied that the dis
trict court effectively engaged in a goodcause
analysis as required by Rule 16b
The goodcause inquiry required under Rule
16b is more narrow than the analysis under
taken by the district court HN12 The pri
mary measure of good cause is the movants
diligence in attempting to meet the ordersre
quirements Rahn v Hawkins 464 F3d 813
822 8th 717 Cir 2006 see also Fed R
Civ P 16b advisory committee note 1983
Amendment The court may modify the
schedule on a showing of good cause if it can
not reasonably be met despite the diligence of
Page 10
the party seeking the extension While the
prejudice to the nonmovant resulting from
modification of the scheduling order may also
be a relevant factor generally we will not con
sider prejudice if the movant has not been dili
gent in meeting the scheduling ordersdead
lines See Bradford v DANA Corp 249 F3d
807 809 8th Cir 2001 concluding that there
was no need to explore beyond the first crite
rion diligence because the record clearly
demonstrate that Bradford made only mi
nimal efforts to satisfy the scheduling orders
requirements Our cases reviewing Rule 16b
rulings focus 15 in the first instance and
usually solely on the diligence of the party
who sought modification of the order See eg
Rahn 464 F3d at 822 affirming the district
courtsdenial of Rahnsrequest for a modifica
tion of the scheduling order because the record
made clear that Rahn did not act diligently to
meet the orders deadlines Barstad v Murray
County 420F3d 880 883 8th Cir 2005 af
firming the district courts denial of leave to
amend the Barstads complaint under Rule
16b because the Barstads had eight months to
request an amendment of the scheduling order
and knew of the claims they sought to add
when they filed the original complaint
Freeman v Busch 349F3d 582 589 8th Cir
2003 affirming under Rule 16b the district
courtsdenial of Freemansmotion to amend
her complaint because she provided no reasons
why the amendment could not have been made
earlier or why hermotion to amend was filed so
late
The district courts order ruling on Wincos
motion to amend cannot be read consistently
with Rule 16bsgoodcause standard as this
court has interpreted and applied that standard
The district court characterized Wincosdelay
in seeking to add the 16 preemption de
fense as unwarranted SA at 10 The district
court also found that Winco admitted
awareness of the affirmative defense at
least as early as May 16 2006 idbut Win
co still waited until January of 2007 to seek
001591
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der's ea line asses, a lai tiff first ust s  
good cause under ule 16(b) for failure earlier 
to  lea e t   f re  rt ill 
[**13] consider hether a end ent is proper 
under le 5(a)."); t rne nd . . 
ccidental he . orp., 431 F.3d 221, 227 
(5th Cir. 2005), cert. denied, 127 S. Ct. 48, 166 
. .  0 (20 ) (applying the s e -
proach); 'Connell v. yatt otels of P.R., 357 
F.3d , -55 (ist ir. ) (sa e); rk-
 .  ictures I s.,  .3d , 
340 (2d Cir. 2000) (same); Johnson v. am-
oth ecreations, Inc., 975 .2d 604, 609 (9th 
ir. 1992) (sa e). 
eca se co's ion   as 
ile   t  t  t  t  t  -
tablished scheduling deadline for a ending 
pleadings, the district court as required to ap-
ply Rule 16(b)'s good-cause standard in ruling 
on inco's otion. inco argues that even if 
the district court as required to apply Rule 
16(b), the district court's analysis as tanta-
ount to a good-cause finding. ere e satis-
       urt's 
ruling was in fact a good-cause analysis, giving 
due consideration to inco's diligence in at-
te pting to co ply ith the scheduling dead-
line, e ould not disapprove of a functional 
reading of the district court's order; a for al 
citation of Rule 16(b)'s "good cause" require-
ent is not what counts. But as we explain 
[**14] below, we are not satisfied that the dis-
trict court effectively engaged in a good-cause 
analysis as required by Rule 16(b). 
The good-cause inquiry required under Rule 
16(b) is ore narro  than the analysis under-
taken by the district court. [ 12] "The pri-
mary measure of good cause is the movant's 
diligence in atte pting to eet the order's re-
quirements." Rahn v. Hawkins, 464 F.3d 813, 
822 (8th [*717] ir. 2006); see also ed. R. 
Civ. P. 16(b), advisory committee note (1983 
A end ent) (" [T]he court ay odify the 
schedule on a showing of good cause if it can-
not reasonably be met despite the diligence of 
t e t  i  t  t i . "). ile t e 
r j ice t  the a t r lti  fr  
ification f t  s li  r r  ls  
  rele a t f t r, rally, e ill t -
si r r jUdice if t e ant as t  ili-
t   the l  er's d-
lin .  f d .  rp.,  .3d 
,  (8th ir. ) (conclu in    
as "no   re   irs  rite-
i , [dilige ce,] s  t   l l  
onstrate [ d] t t   l  i-
i l ts t  ti  t e [sche li  rder's] 
require ents"). r  r i i  le 6(b) 
r li  f cus [**1 ] i  t  first i st  (an  
s all  s lely)  t e ilige ce f t e art  
ho sought odification f the order. ee, e.g, 
,  .3d t  (a firmin  t  i t i t 
urt's i l  ahn's t   ifi a-
ti   t  li  r r  t  r r  
 l r t t  i  t t ilig tl  t  
  rder's adlines); s  .  
nty,  .3d ,  (8t  ir. 05) (af-
fir in  t e istrict court's e ial f lea e t  
  '    
6(b)     i t t s  
r t  t  t  eduli  r r 
 "kne  f t  l i s t  t t   
hen they fil  t  ri i l l i t"); 
re  v. sch,  .3d ,  (8t  ir. 
03) (affir i , er le 6(b), t e istrict 
ourt's i  f r eman's    
her co plaint because she provided no reasons 
 t  t l  t    
rli r r  r ti  t    fil   
late). 
 i tri t ourt's  l   inco's 
t  t      i t tl  
ith ule 16(b)'s good-cause standard as this 
court has interpreted and applied that standard. 
 i tri t rt r t i  inco's l  
in seeking to add the [**1 ] r ti  e-
f s  s "un rr nted." (S  t 0.)  istri t 
rt l  f  t t i  "admitt[ed] 
 f  . . . f i ti  f  t 
least as early as ay 16, 2006," (id.), but in-
 still it  til an r  f  t  see  
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leave to plead the affirmative defense The dis
trict courtsorder makes clear that in its analy
sis Winco was anything but diligent in com
plying with the scheduling deadline Wincos
argument that the district court effectively ap
plied and found good cause for the modifica
tion of the scheduling order is also at odds with
the district courts attorneys fees award The
award of attorney fees was based on HN13
28 USC 1927 which in the words of the
district court provides for attorneysfees
against an attorney who so multiplies the pro
ceedings in any case unreasonably and vex
atiously WA at 74 Thus the very basis for
the district courtsfee award was Winco lack
of diligence in seeking to amend its answer For
these reasons we conclude that the district
court did not implicitly apply Rule 16bsgood
cause standard when ruling on Wincosmotion
to amend and erred by failing to do so
Moreover the record provides no support
for 17 a finding of good cause here Even
though preemption is a purely legal defense
based on readily available federal law Winco
waited to seek leave to plead the affirmative
defense until two and a half years after the suit
was filed a month after the close of discovery
a month after it raised the defense in its sum
mary judgment motion almost eighteen months
after the deadline for amending pleadings and
eight full months after it was actually aware of
the preemption defense applicability Wincos
explanation for its inadvertent failure to plead
pre emption as an 718 affirmative de
fense was that at the close of discovery and
during research and preparation for Wino
summary judgment motion Winco deter
mined the merits of the pre emption argument
Appellants App at 609 But this is effective
ly a concession that Winco did not explore the
applicability of the preemption defense before
the summary judgment stage of the litigation
Had Winco been diligent it would have per
formed this research at the outset of the litiga
tion and at least prior to the scheduled deadline
for adding affirmative defenses HN14 The
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very fact that our court treats preemption as an
affirmative defense 18 presupposes that
in a typical case a diligent defendant will be
able to plead the defense on the basis of the
complaint alone at the onset of the litigation
Here no change in the law no newly discov
ered facts or any other changed circumstance
made the preemption defense more viable after
the scheduling deadline for amending plead
ings Given the absence of good cause we must
conclude that the district court abused its dis
cretion in allowing Winco to amend its answer
so long after the scheduling deadline
Despite the district courts error HN15
reversal is not mandated unless the error af
fects a substantial right of the objecting par
ty Crane v Crest Tankers Inc 47F3d 292
296 8th Cir1995 Here the district courts
error was not harmless In its summary judg
ment order the district court concluded that the
Shermans negligentfailuretowarn claim was
preempted insofar as that claim sought to im
pose warning requirements that were different
from or in addition to federal standards Ap
pellants App 1705 As a result of the impro
perly allowed preemption defense the Sher
mans were precluded from demonstrating that
under Nebraska law the Saturn Missile cau
tionary 19 warning label should have in
cluded more than that which is required by the
federal standards Id at 1706 Consistent
with this limitation that it placed on the Sher
mans statelaw failure towarn claim and re
lying on its preemption discussion the district
court excluded the proffered expert testimony
ofDr Wood The district court reasoned that
because Dr Wood could not testify to a
standard of care that requires more than the
federal regulations her testimony concerning
the development of warning labels was irre
levant to this case SA at 18 The exclusion
of Dr Woodsexpert testimony followed di
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leave to plead the affir ative defense. he dis-
trict urt's r er es l r t t i  its ly-
sis, inc  as a t i  t ilige t i  c -
l i  it  t e sc e li  ea li e. i co's 
ar e t t at t e istrict c rt effecti el  a -
plied and found good cause for the odifica-
tion f the scheduling order is also at odds ith 
t  ist i t urt's tt rney's  r . he 
a ard of attorney's fees as based on [H 13] 
 u.s.c. § , i --in t  r s f t  
istri t urt--"provides f r ... tt rney's f s 
a ai st a  att r e   so lti lies t e r -
ceedings in any case unreasonably and vex-
atiously." (W  at 74.) hus, the very basis for 
 t urt's   as i co's  
of diligence in seeking to a end its ans er. For 
t es  r s s,  l de t t t  istri t 
c rt i  t i licitl  a l  ule 16(b)'s  
cause standard when ruling on inco's otion 
to a end, and erred by failing to do so. 
oreover, the record provides no support 
 [**17] a finding of good cause here. Even 
though pree ption is a purely legal defense 
based on readily available federal la , inco 
aited to seek leave to plead the affir ative 
fe s  til t    lf rs ft r t  s it 
as file ; a t  after t e cl se f isc ery; 
         -
ary judg ent otion; al ost eighteen onths 
after the deadline for a ending pleadings; and 
eight full onths after it as actually a are of 
the pree ption defense's applicability. inco's 
explanation for its "inadvertent failure to plead 
pre-e ption as an [*71 ] f  e-
fense" was that "at the close of discovery and 
during research and preparation for [ inco's] 
su ary judg ent otion ... [ inco] deter-
ined the erits of the pre-e ption argument." 
(Appellants' pp. at 609.) ut this is effective-
ly a concession that inco did not explore the 
applicability of the pree ption defense before 
the su ary judg ent stage of the litigation. 
Had inco been diligent, it would have per-
for ed this research at the outset of the litiga-
tion, and at least prior to the scheduled deadline 
for adding affir ative defenses. [H 14] The 
r  f t t t r rt treats r ti    
r  e s  [**1 ] ses t, 
  ic  ,  ige     
able to plead the defense on the basis f the 
l i t l , t t  t  t  liti ti . 
r ,  e i  t  l ,  l  i cov-
ered facts, or any other changed circu stance 
 t  r ti  fe s  r  i l  ft r 
t  li  li  f r i  l ad-
i s. i e  t e a se ce f  ca se, e st 
e      t  i -
creti  i  all i  i c  t  a e  its a s er 
so long after the scheduling deadline. 
espite the district court's error, [H 15] 
   t     "af-
fect[ s] a substantial right of the objecting par-
ty." r  V. r st ers, I c.,  .3d 2, 
296 (8th ir.1995). ere, t e istrict c urt's 
error as not har less. I  its su ary judg-
 r,       
r ' li nt-f il r -to-war  l i   
r t  i f r  t t l i  t "to i -
s  r i  r ir ts t t [were] iff r t 
fro  r i  iti  t  f r l st ndards." (A -
ll ts' . 05.) s  r s lt f t  i ro-
erl  all e  ree ti  efe se, t e er-
a s ere recl e  fr  e strati  t at 
     sile's "c u-
tionary [**19] arning label should have in-
cluded ore than that hich is required by the 
f r l st ndards." (I . t 706.) sist t 
ith this li itation that it placed on the Sher-
' -la  r -to-wa  i ,  -
l i   its ree ti  isc ssion, t e istrict 
court excluded the proffered expert testi ony 
 r. .      
because "Dr. ood [could not] testify to a 
standard of care that requires ore than the 
federal regulations," her "testi ony concerning 
t  l t f r i  l ls [ s] irre-
t   se." (S  t 8.)  x l i  
f r. ood's e ert testi  f ll e  i-
rectly fro  the district court's pree ption 
analysis. 
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At oral argument Winco suggested that the
district courtsallowance of the preemption de
fense made no real difference in the case con
tending that the Shermans evidence would
have been the same with or without the
amendment Winco asserts that in fact the al
lowance of the amendment lightened the Sher
mans burden of proof because they were not
required to prove the applicable Nebraska
standard of care at trial We respectfully disag
ree Winosargument assumes that the stan
dard of care in Nebraska is the same as 20
the standard of care set out in the FHSA But
the standards are not necessarily the same in all
cases In fact Winco recognized as much when
it argued for the applicability of the preemption
defense for the first time Appellants App at
228 To hold that Winco is liable for
not having provided additional label language
would be contrary to the express purpose of
Congress to develop uniform safety standards
internal marks omitted The FHSA standard
of care that was submitted to the jury required
the Saturn Missile label to conspicuously
state
A The name and place of the
manufacturer packer distributor
or seller
719 B The signal word
WARNING or CAUTION on
all other hazardous substances C
An affirmative statement of the
principal hazards such as
Flammable Combustible
Vapor Harmful Causes Burns
Absorbed Through Skin or sim
ilar wording descriptive of the ha
zardsD Precautionary meas
ures describing the action to be
followed or avoided E Instruc
tion when necessary or appropri
ate for first aid treatment and F
Adequate directions for the protec
tion of children from the hazards
Page 12
SA at 35 In contrast had the Shermans
21 been permitted to proceed on the basis
of an unrestricted HN16 Nebraska com
monlaw negligent failuretowarn claim they
would have been required to establish the rele
vant standard of care by proving that Winco
failed to exercise reasonable care to inform
expected users of the Saturn Missile dan
gerous condition or of the facts which make it
likely to be dangerous Erickson v UHaul
Intl Inc 274 Neb 236 738 NW2d 453 460
Neb 2007 see also NJI2d Civ 11Un
like the more concrete FHSA standard of care
the Nebraska commonlaw standard does not
establish the form in which the warning must
be communicated to the user and it also does
not limit the warning requirement to principal
hazards Instead Nebraska law vests the jury
with the task of determining the dangers that
require a warning and the form that the warning
must take Accordingly the FHSA standard of
care is not necessarily equal to or greater than
the standard of care that Nebraska law imposes
upon the distributor of the Saturn Missile that
injured Mrs Sherman Theoretically under
Nebraska law the Shermans could prove that
Winco failed to comply with a standard of care
different than the FHSA standard that the jury
22 may have concluded Winco did not
breach For these reasons we conclude that as a
result of the district courts error in granting
Winco motion to amend the Shermans
statelaw failuretowarn claim was prejudi
cially limited
The Shermans contend that this error re
quires a new trial on all of their claims But the
record unambiguously indicates that the Win
cos affirmative preemption defense affected
only the Shermans negligent failuretowarn
claim The district courtssummary judgment
order explicitly rejected Wincos contention
that claims other than the failuretowarn claim
were preempted Likewise in its attorney fees
order the district court recognized that ulti
001593
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t r l r nt, inc  t  t t t e 
istrict c urt's allo ance f t e ree tion e-
fense a e  real ifference i  t e case, c -
te i  t at t e er a s' e idence l  
 e    th r th   
t. i  ts t t, i  t, t  l-
lo ance of the a end ent lightened the Sher-
ans' burden of proof because they ere not 
r ire  t  rove t  lica le ras a 
standard of care at trial. e respectfully disag-
r . inco's r e t ss es t t t  st n-
   i  e ras a is t    [**2 ] 
    t t n  .  
t e sta ards are t ecessaril  t e sa e i  all 
cases. In fact, inco recognized as uch hen 
it argued for the applicability of the pree ption 
defense for the first ti e. (Appellants' pp. at 
228.) ("To hold that ... inco [is] liable for 
not having provided additional label language . 
. . ould be contrary to the express purpose f 
ongress to develop unifor  safety standards." 
(internal arks o itted)}. he F S  standard 
of care that as sub itted to the jury required 
the Saturn issile's label to conspicuously 
t : 
(A) e a e a  lace f t e 
a fact rer, ac er, istri t r 
or seller; 
[*719] (B) The signal ord 
"WAR "  "C "  
all other hazardous substances; (C) 
 r a e    
principal azard( s},   
"Fla able," "Co stible," 
"Vapor armful," "Causes ms," 
"Absorbed Through Skin," or si -
ilar wording descriptive of the ha-
zard(s}; (D) Precautionary meas-
ures describing the action to be 
f llo e  r a i ed; (E) I str c-
tion, hen necessary or appropri-
ate, f r first ai  treat ent; a  (F) 
Adequate directions for the protec-
tion of children fro  the hazard( s} 
(S  t 5.)  t,    
[**21] been per itted to proceed on the basis 
  t icte  [H ] e ras a -
-la  li t- ilure-to-warn l i , t  
l    r ire  t  st lis  t  r l -
t st r  f r   r i  t t i  
le  "to is  e    
[expecte  sers] f [the at r  issile's] an-
er s c iti  r f t e facts ic  a e it 
   ngerous." icks  . -Ha  
!'l, c.,  b. 6,   .2d 3,  
(Neb. 2007); see also JI2d iv. § 1. 1. n-
ike   ete    re, 
t  r  -la  t r   t 
esta lis  t e f r  i  ic  t e ar i  st 
 cate    r,     
 i t     "princip  
zards." I t d, r  l  t  t  j r  
it  t  t   t i i  t   t t 
r ir   r i   t  f r  t t t  r i  
t t . r i gly, t   t r   
r  i  t aril  l t  r r t r t  
        
 t  istri t r f t  t r  issil  t t 
i jure  rs. er an. e reticall , er 
ebraska la , the her ans could prove that 
inco failed to co ply ith a standard f care 
different than the F S  standard that the jury 
[**2 ]   l  i  i  t 
r ch. r t s  r s ns,  l  t t s  
result of the district court's error in granting 
i co's   end,  ' 
state-la  fail re-to-war  clai  as rej di-
cially li ited. 
      -
quires a ne  trial on all of their clai s. ut the 
record una biguously indicates that the in-
o's ffir ti  r ti  f s  ff t  
l  t e er a s' e li e t-fail re-to- ar  
l i .  istri t ourt's s r  j t 
r er explicitl  rejecte  i co's c te ti  
     -to- a  i  
ere pree pted. ike ise, in its attorney's fees 
order, the district court recognized that "ulti-
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mately the Shermans first second and
fourth through ninth causes of action were un
affected by Wincosuntimely filing WA at
75 There is no indication in the record and
the Shermans make no showing that the legal
elements of any claim other than the fail
uretowarn claim were affected and there is
no indication that Dr Woodsexpert testimony
was relevant to any claim other than the fail
uretowarn claim and by extension Mr Sher
manspendent consortium claim Accordingly
the prejudicial effect 23 of the district
courts error was limited to the failuretowarn
claim and the consortium claim A remand for a
new trial on all of the Shermans claims is un
warranted
III
The Shermans also argue that the district
court committed reversible error by excluding
the expert testimony of Dr Wood Because we
conclude in part II that a new trial is required
on the Shermans statelaw failuretowarn
claim and because Dr Woodstestimony was
relevant only to that claim we do not reach this
evidentiary issue It is for the district court now
to determine in the first instance whether Dr
Woodsexpert testimony is properly admissible
under the Nebraska 720 commonlaw
theory under which the case will proceed on
remand
IV
Next we consider the Shermans challenge
to the district courts jury instructions HN17
We review the district courts refusal to submit
proffered jury instructions and its decision to
give certain instructions for an abuse of discre
tion The Shaw Group Inc v Marcum 516
F3d 1061 1068 8th Cir 2008 Bennett v
Hidden Valley Golf Ski Inc 318 F3d 868
873 8th Cir 2003 HN18 A federal district
court presiding over a diversity case is not
bound to give the jury instruction 24 re
quested by the litigants nor is the court con
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strained to follow the language contained in a
state uniform instructions Fin Holding
Corp v Garnac Grain Co 965F2d591 594
8th Cir 1992 HN19 In conducting our re
view we must determine simply whether the
instructions taken as a whole and viewed in
light of the evidence and applicable law fairly
and adequately submitted the issues in the case
to the jury The Shaw Group Inc 516F3dat
1068 internal marks omitted Reversal is only
warranted if a partyssubstantial rights are pre
judiced by instructional error Burry v Eustis
Plumbing Heating Inc 243 F3d 432 434
8th Cir 2001 We will order a new trial only
if the error misled the jury or had a probable
effect on its verdict internal marks omitted
A The Effect of the Jurys Allocation of Neg
ligence
First the Shermans argue that the district
court abused its discretion by declining to give
an instruction on the effect of the jurysalloca
tion of negligence among Winco and nonpar
ties whom Winco argued were responsible for
Mrs Sherman injuries
In Instruction No 20 the district court in
structed the jury that if it found that Winco
proximately caused 25 some of Mrs
Shermansinjury it was required to consider
and assign the respective shares of fault if any
of the Winco Defendants against the persons or
entities with whom the Shermans have set
tled SA at 48 Consistent with this instruc
tion section B ofthe final verdict form directed
the juryif it reached that section to assign
negligence on a percentage basis According to
the Shermans the district courts instructions
are deficient because the jury was not in
structed on the effect of its allocation of negli
gence between Winco and the nonparties
The Shermans rely on two Nebraska sta
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t  t e istrict c urt's jury i str cti s. [H ] 
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proffered jury instructions and its decision to 
give certain instructions for an abuse of discre-
ti .   , I . . ,  
.3d ,  (8t  ir. 008); tt v. 
idden Valley olf & id, c.,  .3d , 
 (8t  ir. 03). [H ] "A fe eral istrict 
court presiding over a diversity case is not 
bound to give the jury instruction [**24] re-
quested by the litigants, nor is the court con-
strained to follo  the language contained in a 
tate's nn tructions." . olding 
orp. v. arnac rain o., 965 .2d 591,594 
(8t  ir. 92). [H ] I  ti  r r -
i , "we st t r i  si l  t r t  
i str ti s, t  s  l   i  i  
li t f t  i e   li l  l , f irl  
a  a e atel  s itte  t e iss es i  t e case 
t  t e j ry." e  r , I c.,  . 3d t 
 (internal ar s itted). e ersal is l  
arranted if a party's substantial rights are pre-
judiced by instructional error. urry v. ustis 
lu bing & ti g, c.,  .3d 2,  
(8th ir. 2001) ("We ill order a ne  trial only 
if the error isled the jury or had a probable 
effect on its verdict." (internal arks o itted». 
.  e    ury's loc   g-
ligence 
ir t, t  nn  r  t t t  i tri t 
court abused its discretion by declining to give 
an instruction on the effect of the jury's alloca-
tion of negligence a ong inco and nonpar-
ties ho  inco argued ere responsible for 
rs. erman's i j ri s. 
  . ,  t   -
structed the jury that if it found that inco 
proximately caused [**2 ]   . 
Shennan's injury, it as "required to consider 
and assign the respective shares of fault, if any, 
of the inco Defendants against the persons or 
 t    [Shennans] have set-
tled." (S  at 8.) siste t it  t is i struc-
ti , secti   f t e fi al er ict f nn irecte  
the jury--if it reached that section--to assign 
negligence on a percentage basis. ccording to 
t  r s, t  istri t urt's i str ti s 
are deficient because the jury as not in-
str cte   t e effect f its all cati  f egli-
gence bet een inco and the nonparties. 
The Shermans rely on two Nebraska sta-
t t , t  irst  i --N . v. t t. § 
25-21,185.09--provides: 
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Any contributory negligence
chargeable to the claimant shall
diminish proportionately the
amount awarded as damages for an
injury attributable to the claimant
contributory negligence but shall
not bar recovery except that if the
contributory negligence of the
claimant is equal to or greater than
the total negligence of all persons
against whom recovery is sought
the claimant shall be totally barred
from recovery The jury shall be
instructed on the effects of the al
location ofnegligence
The second statute that the 26 Shermans
rely on is Neb Rev Stat 2521185
which states
A release covenant not to sue
or similar agreement entered into
by a claimant and a person liable
shall preclude that person from
being made a party or if an action
is pending shall be a basis for that
persons dismissal but the persons
negligence if any shall be consi
dered in accordance with section
252118509
According to the Shermans Neb Rev Stat
2521185sinstruction that a settling
721 partys negligence be considered in
accordance with section 252118509 requires
that the district court instruct the jury on the
effect of its allocation of negligence among the
defendant and the nonparties even when con
tributory negligence is not at issue
The Shermans legal position is inconsistent
with our reading of Nebraska law Crucially
the Shermans ignore HN20 Neb Rev Stat
252118507 which restricts the applicability
of the two Nebraska statutes on which they de
pend Sections 252118507 to 25211852
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shall apply to all civil actions to which contri
butory negligence may be pursuant to law a
defense Emphasis added By expressly
narrowing the application of these statutes to
cases 27 in which contributory negligence
is at issue 252118507 impliedly excludes
the statutes application outside of that context
See Chapin v Neuhoff BroadGrand Island
Inc 268 Neb 520 684 NW2d 588 593 Neb
2004 recognizing and applying the expressio
unius est exclusio alterius canon of statutory
construction HN21 Consistent with this sta
tute Nebraska cases construing 252118507
through 25211852 limit these statutes to
the contributory negligence context See eg
Tadros v City of Omaha 273 Neb 935 735
NW2d 377 380 Neb 2007 for cases in
volving multiple defendants where contributory
negligence is a defense the Legislature has al
tered the common law citing
252118507 to 25211852 Although the
Nebraska cases that the Shermans rely on have
held that it is prejudicial error for the district
court not to instruct the jury on the effects of its
allocation of negligence in accordance with
252118509 they have done so where the
plaintiffs own contributory negligence was a
defense at issue See Russell v Stricker 262
Neb 853 635 NW2d 734 737 740 Neb
2001 Wheeler v Bagley 254 Neb 232 575
NW2d616 620 Neb 1998
Early in this litigation in Wincosanswer
Winco alleged 28 that Margaret Sherman
was contributorily negligent But by the time of
trial that affirmative defense was apparently
abandoned The district court did not give a
contributorynegligence instruction to the jury
and in its brief Winco concedes that contribu
tory negligence was not at issue at trial Be
cause contributory negligence was not at issue
at trial and because the Shermans cite no per
suasive Nebraska authority applying Neb Rev
Stat 252118509 and 2521185out
side of the contributorynegligence context we
conclude that the district court committed no
001595
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25-21,185.07 to 25-21,185.12)). lthough the 
ebraska cases that the Sher ans rely on have 
held that it is prejudicial error for the district 
court not to instruct the jury on the effects of its 
allocation of negligence in accordance ith § 
25-21,185.09, they have done so here the 
lai tiffs  c tri t r  e lige ce as a 
  e.  ll . tri er,  
eb. 853, 635 . .2d 734, 737, 740 (Neb. 
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Early in this litigation, in inco's ans er, 
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trial, that affir ative defense was apparently 
abandoned. he district court did not give a 
contributory-negligence instruction to the jury, 
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cause contributory negligence as not at issue 
at trial, and because the Sher ans cite no per-
suasive ebraska authority applying eb. ev. 
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side of the contributory-negligence context, e 
lude   t  tt   
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prejudicial error by denying the requested in
struction
B The Effect of a Violation of a Statute or
Regulation
The Shermans also contend that the district
court committed reversible error by failing to
instruct the jury on the effect of a violation of a
statute or regulation The Shermans argue that
the district court should have instructed the jury
that the violation of a statute or regulation is
merely evidence of negligence and does not
constitute negligence per se According to the
Shermans because the jury was not given this
instruction it may have found for Winco be
cause it erroneously concluded that Stanley
29 and Nate Kapustka were automatically
negligent by virtue of their violation of a regu
lation issued by the Nebraska Fire Marshals
Office and should therefore bear the entire
brunt of fault under the law Shermans Br at
46 In response Winco contends that the
Shermans failed to preserve this issue and
therefore our review is for plain error
Even under the more lenient harmlesserror
standard we find insufficient prejudice to jus
tify reversal for the district courts failure to
give the instruction 722 While it may
have been appropriate for the district court to
give such an instruction there is no basis in the
record to conclude that the lack of such an in
struction had a probable effect on the jurys
verdict Burry 243 F3d at 434 HN22 We
will not order a new trial here after the jury has
passed on the evidence merely because there is
a metaphysical possibility that the jurysverdict
was affected by the district courts failure to
give the instruction
Winco presented many theories under
which the jury may have found that Winco was
not liable Among other arguments Winco ar
gued that it had not sold the Saturn Missile that
there was no evidence that the Saturn Missile
was 30 prone to an erratic flight path that
the warning label was legally sufficient and
that Wincojust one of several companies in
the chain of distribution was not the proximate
cause of Mrs Sherman injuries Winco did
introduce the Nebraska fireworks regulation
into the record when examining Stanley Ka
pustka and during its closing argument Winco
argued that if Stanley Kapustka had not brought
the illegal firework into Nebraska Mrs Sher
man would not have been injured But beyond
these two isolated references to the regulation
the Shermans cite to no other time during the
fiveday trial in which the illegality of the
presence of the Saturn Missile in Nebraska was
brought to the jurysattention Moreover Win
co did not argue to the jury that the Kapustkas
illegal conduct was per se negligence legally
barring the Shermans claims For these rea
sons we conclude that the district court did not
commit reversible error by failing to give the
instruction on the effect ofa violation of a sta
tute or regulation
3 To demonstrate prejudice the Sher
mans rely on an affidavit from the jury
foreperson In ruling on the Shermans
post verdict motions however the dis
trict court concluded 31 that the af
fidavit is not competent evidence under
Fed R Evid 606b That determination
is not challenged on appeal and accor
dingly we do not consider the affidavit
further
C Instruction Requiring the Jury to Find that
Mrs Sherman was Among Those Reasonably
Expected to be Endangered by the Saturn Mis
sile
The Shermans also contend that the district
court erred by instructing the jury that it was
required to find that Mrs Sherman was among
the group of people that the Winco Defendants
should reasonably have expected would be en
dangered by the probable use of the Saturn
Missile SA at 31 33 According to the
Shermans the district court ought to have con
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was among those expected to be endangered by
the firework
HN23 We recognize that the drafting
committeescomments to the Nebraska Model
Jury instructions indicate that in almost all
cases this issue will be resolved as a question of
law see NJI2d Civ 11 10 comments au
thorities but Nebraska law also indicates that
the determination of whether a legal duty exists
is a question of law dependent on the facts in a
particular case Erickson 738 NW 2d at 459
In Erickson for 32 example the Nebraska
Supreme Court characterized the question of
whether the plaintiff was a person whom the
productssupplier should have expected to be
endangered by using the product as an issue of
material fact Id at 46263 Here we conclude
that even if the district court improperly sub
mitted the question to the jury on this record
the Shermans cannot meet the standard re
quired to justify reversal Slidell Inc v Mil
lennium Inorganic Chems Inc 460 F3d
1047 1054 8th Cir 2006 new trial is
necessary only when the errors in 723
the district courts instructions misled the jury
or had a probable effect on the jurysverdict
The instruction submitted by the district court
did not misstate the law or mislead the jury in
any way And there is no indication in this
record that the submission of the instruction
prejudicially influenced the jurys verdict As
discussed above there were many theories un
der which the jury may have concluded that
Winco was not liable for Mrs Sherman inju
ries The Shermans assignment of prejudice is
speculative Moreover if the evidence at trial
so clearly showed that Mrs Sherman was
among the group of people reasonably expected
33 to be endangered by the firework as the
Shermans claim then the district courts sub
mission of this question to the jury was hardly
prejudicial because the jury would have
reached the same conclusion Because we find
no prejudice on this record we conclude that
the district court committed no reversible error
by permitting the jury to determine whether
Page 16
Mrs Sherman was among the group of people
that Winco should have reasonably expected to
be endangered by the probable use of the Sa
turn Missile
V
Finally we address Winco cross appeal of
the district courtsattorney fees award which
totaled 3201987 Winco argues that if we
conclude that the district court abused its dis
cretion by allowing Wincosbelated preemp
tion amendment and reverse and remand for a
new trial then the attorneysfees award should
be reversed and vacated in its entirety The
Shermans do not agree that the full award
should be vacated but concede that ifthis
Court orders a new trial and allows Dr Wood
to testify at the new trial Winco should not
be required to pay 1542637 related to Dr
Woodsfees Shermans Reply Br at 24
Part of the attorneys fees award
1542637 worth accounted 34 for costs
incurred by the Shermans in preparing Dr
Woodsexpert testimony Those costs were in
curred unnecessarily and that testimony be
came irrelevant as a result ofWincos belated
preemption amendment But because we re
verse and remand for a new trial on the
state law failuretowarn claim it is no longer
true that those costs were unnecessarily in
curred as a result ofWinco counselsconduct
As a result of our decision on remand the
Shermans will again be allowed to offer Dr
Woods expert testimony in support of their
statelaw failuretowarn claim effectively re
turning the Shermans to the status quo ante
Because we concluded in part II that the district
court abused its discretion in allowing the
preemption amendment and because
1542637 worth of the fee award was based on
costs associated with Dr Woodsimproperly
excluded expert testimony the admissibility of
which will be considered anew on remand we
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Winco also urges us to reverse and vacate
the remaining portion of the award amounting
to 165930But Winco makes no claim that
the district court improperly awarded the
Shermans attorney fees in the first 35
instance effectively conceding that its conduct
and the fee award meet the standard set out at
1927 Instead Wincosposition on appeal is
that a reversal of the district courtsdecision
allowing the amendment requires a reversal of
the related fee award
The district court based its award of attor
neys fees on HN24 1927 which authorizes
a district court to require an attorney to reim
burse the excess costs and attorneysfees rea
sonably incurred by the opposing party as a re
sult of an attorneysunreasonable and vex
atious multiplication 724 of the
proceedings That statutory authority for the
award ofattorney fees focuses on the conduct
of the movants opposing counsel Here Win
Page 17
cos counsel has not multiplied the proceedings
to any lesser degree and its conduct is no less
unreasonabl and vexatious just because
we conclude in part II that the district court
improperly permitted Winco to amend its an
swer Wincos untimely pleading of the
preemption defense after the scheduling dead
line without good cause to do so still caused
the Shermans to incur fees unnecessarily Our
resolution of the amendment issue above does
not undermine the district courts statutory
36 rationale for the remaining 165930
portion of the fee award in any way rather it
reinforces the validity of the award Accor
dingly we affirm the award in the amount of
165930
The judgment of the district court is af
firmed in part reversed in part and remanded
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inco also urges us to reverse and vacate 
the re aining portion of the a ard, a ounting 
t  $ 16,593.50. ut inco akes no clai  that 
the district court i properly a arded the 
Sher ans attorney's fees in the first [**35] 
instance, effectively conceding that its conduct 
a d e ee  t t e rd t   § 
. I stea , i co's sitio   a eal is 
that     s ict urt's  
allo ing the a end ent requires a reversal of 
the at   . 
e t rt  ts   r-
ney's fees on [HN24] § , i  t rizes 
a district court to require an attorney to rei -
burse the excess costs and attorney's fees rea-
sonably incurred by the opposing party as a re-
sult of an attorney's "unreasonable[]" and "vex-
atious[]" "multipli[cation] [*724]   
proceedings." That statutory authority for the 
a ard of attorney's fees focuses on the conduct 
f t  vant's si  sel. r , i -
o's l as t ltiplied t e i s 
t   less r ree  its t is  less 
"unr sonabl[ e]"  "ve tious[]" just s  
e clude in rt II t t t e istrict rt 
 tte  inc    ts -
r. i co's ti el  lea i  of the 
ree ti  efense after t e sc e li  ead-
i , itho t  se   , til   
     saril .  
   e t ss e   
t i  t  i t i t urt's t t t  
[**3 ] e    $ 6,593.50 
rti   t  f  r  i   y; r t r, it 
r i forces t  li it  f t  rd. r-
i l , e ffir  t  r  i  t  t f $ 
6,593.50. 
e jud e t f t e istrict c rt is af-
r   rt,   rt,   
for further proceedings consistent ith this 
OpInIOn. 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff
0




CORPORATION a Missouri corporation
Defendant
Defendant Security Equipment Corporation SEC by and through its counsel of
record Greener Burke Shoemaker PA pursuant to Idaho Rule of Civil Procedure 7bhereby
respectfully requests that this Court clarify its in court decision on September 5 2011 as to
whether any aspect of Plaintiffs case survived Defendants successful Motions for Summary
Judgment
The basis for this Motion is that at no point throughout this litigation have Plaintiffs
claims been about alleged acute injuries suffered by Plaintiff following her exposure to oleoresin
capsicum OC during her employment with the Idaho Department of Corrections
Throughout this litigation Plaintiff has repeatedly admitted to the fact that she knew of the acute




Christopher C. Burke, ISB #2098 
Thomas J. Lloyd III, ISB #7772 
GREENER URKE S AKER P  
950 . a  Stre t, Suite  
oise, Idaho 83702 
Tel: (208) 319-2600 
Fax: (208) 319-2601 




  0\  
CHRISTOPHER o. RICH, Clerk 
By eARLY LATIMORE 
D!!I"UT'f 
 E          
  I , TN       
I LIE  J ,  i i i l, 
laintiff, 
v. 
I  I  
CORPORATION, a issouri corporation, 
nt. 
 o.: - I-  
FENDANT'S   
I I I  
efendant ecurity quip ent orporation ("SE "),     l  
record, reener urke Shoe aker P.A., pursuant to Idaho ule of ivil Procedure 7(b), hereby 
respectfully requests that this Court clarify its in-court decision on September '5, 2011 as to 
hether any aspect of Plaintiffs case survived efendant's successful otions for Su ary 
Judg ent. 
 i      t at, t  i t t t i  ti n,  laintiffs 
clai s been about alleged acute injuries suffered by Plaintiff follo ing her exposure to oleoresin 
capsicum ("O ") during her e ploy ent with the Idaho Depart ent of Corrections. 
Throughout this litigation, Plaintiff has repeatedly ad itted to the fact that she kne  of the acute 
EFENDANT'S I  F  CLA IFI ATI N - Page I 14542·  ( 14570.doc) 
health effects of exposure to OC and has repeatedly asserted that the injuries complained in this
action and in her parallel workerscompensation claim case are longterm chronic respiratory
illnesses Plaintiff should not be permitted to following the entry of summary judgment on all
causes of action asserted in her Complaint long after the deadline for submitting and hearing
additional motions for summary judgment suddenly and materially alter the substance of her
claims
This Motion is supported by the Memorandum and Affidavit of Counsel filed herewith
as well as the pleadings motions and other documents on file in this litigation Specifically
SEC relies on the following
1 PlaintiffsComplaint and Demandfor Jury Trial filed in this action on February
24 2010
2 Affidavit ofBillie Jo Major in Support ofPlaintiffsMotion to Reconsider filed in
this action on July 26 2011
3 Plaintiff s assertions in discovery specifically her Supplemental Answer to SECs
Interrogatory No 14 served on counsel for SEC on or about June 25 2010 and
4 Plaintiffs Worker Compensation Complaint filed on or about September 28
2009
Each of the aforementioned documents as well as the complete record in this action
demonstrates that Plaintiff has alleged injuries as a result of exposure to OC that are chronic
longterm andor permanent The evidence demonstrates that Plaintiff was fully aware of any
and all acute andortemporary injuries that are expected to result from exposure to OC spray
and that she willingly allowed herself to be subjected to training sessions involving OC in full
DEFENDANTSMOTION FOR CLARIFICATION Page 2 14542011 414570doc
001600
lt  e ts   t  ~C,   t l  t  t t t  i j ie  l ine  i  t i  
action (and in her parallel orker's co pensation clai  case) are long-ter , chronic respiratory 
illnesses. lai tiff s l  t e er itte  t , f ll i  t e e tr  f s ar  j e t  all 
ca ses f acti  asserte  i  er lai t l  after t e ea li e f r s itti  a  eari  
additional otions for su ary judg ent, suddenly and aterially alter the substance f her 
. 
is ti  is s rte   t e e ra  a  ffida it f sel file  erewith, 
as ell as the pleadings, otions, and other docu ents on file in this litigation. Specifically, 




laintiffs o plaint and e andfor Jury rial, filed in this action on ebruary 
Affidavit of Billie Jo ajor in Support of Plaintiff's otion to Reconsider, filed in 
this action on July 26, 2011; 
. laintiffs assertions in discovery, specifically her le e t l s er t  EC's 
Int rr t r  . , s r   s l f r   r t J  , 0;  
. lai tiffs orker's e s ti  plaint, file   r a t e te er , 
9. 
Each of the afore entioned docu ents, as ell as the co plete record in this action, 
de onstrates that laintiff has alleged injuries as a result f exposure to  that are chronic, 
long-ter , and/or per anent. The evidence de onstrates that Plaintiff as fully a are of any 
and all acute and/or te porary injuries that are expected to result fro  exposure to OC spray, 
and that she illingly allo ed herself to be subjected to training sessions involving C in full 
ENDANT'S I   I I I  - Page 2 14542-011 (414S70.doc) 
anticipation and acceptance of those effects SEC has prevailed on all of Plaintiffsclaims and
Plaintiff should not be permitted to proceed to trial on injuries not previously complained of
For these reasons SEC respectfully requests that this Court clarify its decision on
summary judgment that SEC has prevailed on summary judgment as to the entirety of Plaintiff s
case and enter judgment as a matter of law in favor of Defendant SEC on all claims for relief in
Plaintiff s Complaint
Oral argument is hereby requested
DATED this day of September 2011
GREE ER BURKE SHOEMAKERPA
Christopher C Burke
Thomas J Lloyd III
Attorneys for Defendant
DEFENDANTSMOTION FOR CLARIFICATION Page 3 14542011 414570doc
001601
anticipation and acceptance of those effects. SEC has prevailed on all of Plaintiff s clai s, and 
Plaintiff should not be per itted to proceed to trial on injuries not previously co plained of. 
r t es  re ,  tf  requests t at t is   ts   
su ary judg ent, that SE  has prevailed on su ary judg ent as to the entirety of Plaintiff s 
case, and enter judg ent as a atter of law in favor of Defendant SEC on all clai s for relief in 
Plaintiff s Co plaint. 
r l r e t is r  r st . 
 s z.tr day of Septe ber, 2011. 
 .  
as 1.   
ttorneys for efendant 
FENDANT'S    - Page 3 14542-011 (414570.doc) 
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing DEFENDANTSMOTION FOR
PARTIAL CLARIFICATION on the following named personson the date indicated below in
the manner indicated below
Darwin Overson Esq ViaUSMail
Eric B Swartz Esq ViaHand Delivery
JONES SWARTZ PLLC x Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O Box 7808
Boise Idaho 83707
DATED thisZI day of September 2011
Christopher C Burke
Thomas J Lloyd III
DEFENDANTSMOTION FOR CLARIFICATION Page 4 14542011 414570doc
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IC TE   
I hereby certify that I caused to be served the foregoing NDANT'S I   
 FIC ION  t e f llo ing  rson(s)  t  te i icate  l , i  
  indicated l : 
ar in verson, Esq. 
Eric . S artz, Esq. 
 & ,  
 . r line ri , ite  
. .   
oise, Idaho 83707 
 s2t1'- day of September, 2011. 
[ ] ia .S.  
[ ] i   li r  
[  ] i  si il  (20 /489-89 ) 
[ ] ia r i t li r  
-Cr<:4J"E? 
rist er . r e 
as 1. l  III 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
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I Thomas J Lloyd III being first duly sworn upon oath state as follows
1 I am one of the attorneys of record for Defendant Security Equipment Corporation
SEC or Defendant and make this Affidavit in support of SECs Motion for Partial
Reconsideration based upon personal knowledge
2 Attached to this Affidavit as Exhibit A is a true and correct copy of Deposition
Exhibit 20 to the deposition of Plaintiff Billie Jo Major This deposition exhibit is a copy of the
Complaint filed by Ms Major in her Workers Compensation action
AFFIDAVIT OF COUNSEL IN SUPPORT OF DEFENDANTSMOTION FOR CLARIFICATION Page 1
14542011 414583doc
001603
\ \ l : ___ FL~I~L{;W't 
Christopher C. urke, IS  #2098 
Thomas 1. Lloyd III, ISB #7772 
EE ER R E S KER P  
950 . annock treet, uite 900 
ise, Idaho  
Tel: (208) 319-2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
P   201  
I ER . , l r  
By e  L I  
DI!PUTY 
 E      J  IS I    
   ,        
I IE J  J , an individual, 
Plaintiff, 
v. 
SE IT  E IP E T 
C RPORATI N, a issouri corporation, 
ant. 
   ) 
)ss. 
County of Ada ) 
 o.: -PI-  
    
  FENDANT'S  
  
I, Thomas J. Lloyd III, being first duly sworn upon oath, state as follows: 
. I   f t  tt r s f r r  f r f t ecurit  i t r r ti  
("S "  "Defend t"),   t i  id it i  rt f EC's ti  f r arti l 
econsideration, based upon personal kno ledge. 
.      i i     t  a    f siti  
Exhibit 20 to the deposition of Plaintiff Billie Jo Major. This deposition exhibit is a copy of the 
Complaint filed by s. ajor in her orkers' Compensation action. 
FFI I  F S  I  S PP  F EFENDANT'S I  F R CLA IFI I  - Page 1 
14542-011 ( 14583 doc) 
3 Attached hereto as Exhibit B are true and correct excerpts from the deposition
transcript of Billie Jo Major volume II taken on January 6 2011
4 Attached hereto as Exhibit C is a true and correct excerpts of Plaintiffs
Supplemental Answers and Responses to Defendants First Set of Interrogatories and Requests
for Production of Documents dated June 24 2010
Further your Affiant sayeth naught
AFFIDAVIT OF COUNSEL IN SUPPORT OF DEFENDANTSMOTION FORCLARIFICATION Page 2
14542 011 414583doc
IL
Thomas J Lloyd III
SUBSCRIBED AND SWORN TO before me this day of September 2011









3. tached hereto as i it  are true and correct e cerpts from the de tion 
transcript of Billie Jo Major, volume II, taken on January 6, 2011. 
4. tached hereto as i it  is  true a d c rrect cerpts  P a iffs 
Supplemental Answers and Responses to Defendant's First Set of Interrogatories and Requests 
for Pro ction f ocuments ated J e , . 
Further your ffiant sayeth naught. 
ho as 1. loyd III 
E     ore   ~   t ber, . 
~~ 
 lI  ZO 
Residing at . l ,~ 
Co ission Expires: v -;>-~ • .::;::J.;C.:::t. 
FFIDA VI  F S L I  SUPP  F EFENDANT'S TI  FOR CLA IFI ATI  - Page 2 
14542-011 (414583.doc) 
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing Affidavit of Counsel in Support
of DefendantsMotion for Clarification to be served on the following named persons on the
date indicated below in the manner indicated below
Darwin Overson Esq ViaUSMail
Eric B Swartz Esq ViaHand Delivery
JONES SWARTZ PLLC J Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O BOX 7808
Boise Idaho 83707
DATED this 20 day of September 2011
Christopher C Burke
Thomas J Lloyd III
AFFIDAVIT OF COUNSEL IN SUPPORT OF DEFENDANTSMOTION FOR CLARIFICATION Page 3
14542 011 414583doc 001605
CE IFICATE F  
I hereby certify that I caused to be served the foregoing Affidavit of Counsel in Support 
of dant's otion for Clarification to be served on the following a ed p rson(s) n the 
date indicated belo , in the anner indicated belo : 
Darwin Overson, Esq. 
Eric B. S artz, Esq. 
J S & ,  
3 . reline ri e, ite  
P. . ox 7808 
oise, Idaho 83707 
[ ] ia .S. a  
[a] ia a d liver  
p<] ia i ile (208/489-89 ) 
[ ] ia t ive  
 this 211'-day of Septe ber, 2011. 
----rr:= s ~i ~ 
rist er . r e 
as J. lo  III 
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you not to answer questions that would require
you to disclose communications with your
attorneys in the Social Security Law Group
Q BY MR BURKE And I can get around
that Im just interested in your understanding
ofwhat would happen if you got Social Security
Disability benefits Would that cause your
benefits under the disability insurance policy to
somehow be reduced
A Yes by the amount that I would get
from Social Security
Q All right Lets talk about your
workers compensation claim You have in fact
submitted a claim to the state workers
compensation liability carrier In other words
the carrier for the IDOC which I think is the
State Insurance Fund You initially did that in
June or prior to June of 2009
A Yes Im not sure of the date but
yes
Q And initially that claim was denied by
the compensation carrier correct
A Yes
Q And the basis for the denial as you
understand it was that thev are saving there
Page 252
wasntan accident injury or condition that was
covered under the workers comp statutes
MR OVERSON And Illdirect you that
if you can answer this question if you can
answer it without disclosing our communications
Q BYMR BURKE Imasking for your
understanding
MR OVERSON And if that understanding
is based on conversations between you and IIm
directing you to assert your privilege
THE WITNESS I will have to assert my
privilege because I dontunderstand the
difference between
Q BY MR BURKE Wellget to it a
different way Somebody on your behalf or you
have filed an actual complaint with the Idaho
Industrial Commission on your workers
compensation claim is that correct
A Yes
Exhibits 20 and 21 marked
Q BY MR BURKE So let me hand you
Exhibit No 20 first Do you recognize that as
a copy of the workers compensation complaint
that was filed on your behalf with the Idaho
20 Pages 249 to 252
Page 249
1 A Principal Financial Group put me in 1
2 touch with Social Security Law Group And Social 2
3 Security Law Group is who is doing my Social 3
4 Security Disability claim 4
5 Q So is it your understanding that you 5
6 made an application for that disability 6
7 A Yes 7
8 Q And how was it received Was it 8
9 approved rejected or is it still pending 9
10 A It was rejected until now Imwaiting 10
11 for a hearing 11
12 Q So I take it you or somebody on your 12
13 behalf appealed that rejection 13
14 A Yes they did 14
15 Q Okay 15
16 A I filled outpaperwork for them and 16
17 then they just contact my doctors and get me any 17
18 information 18
19 Q Do you have a hearing date yet 19
20 A No 20
21 Q Is this Victor Aruta from this Social 21
22 Security Disability Law Group that you mentioned 22
23 A Idon know 23
24 Q Okay So I take it to date you have 24
25 not received any Social Security Disability 25
Page 250
1 benefits is that true 1
2 A Correct 2
3 Q Now if you were to receive Social 3
4 Security Disability benefits would that cause 4
5 your disability benefits from Principal Life 5
6 Financial Group to be diminished any more 6
7 A Say that again 7
8 MR OVERSON Hold on a second Who is 8
9 they 9
10 THE WITNESS From what I 10
11 understand 11
12 MR OVERSON Who is they thats 12
13 telling you this 13
14 Q BY MR BURKE The Principal Life 14
15 people or the Principal Financial people 15
16 MR OVERSON Or the lawyers over at 16
17 Social Security 17
18 THE WITNESS They send me brochures 18
19 Q BYMR BURKE Who is they 19
20 A Sorry The lawyers from Social 20
21 Security Law Group 21
22 Q Okay 22
23 MR OVERSON And youre in 23
24 communications with the attorneys at the law 24
25 group would be privileged And so I would direct 25
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 . rincipal inancial roup put e in 1 
 touch ith cial ec rit  a  r .  cial 2 
 rit  a  r  is  is i   ial  
 Security isability clai . 4 
 . O is it r rst i , t t   
 ade an application for that disability? 6 
 . .  
 . nd ho  as it received? as it 8 
 approved, rejected, or is it still pending?  
 A. It was rejected until now. I'm waiting  
 for a hearing. 11 
 . SO I take it you or so ebody on your  
 behalf appealed that rejection?  
 . es, they did. 14 
 . kay. 15 
 . I filled out paper ork for the , and  
 then they just contact y doctors, and get e any 17 
 ti .  
 . o you have a hearing date yet?  
 . .  
 . Is this ictor ruta fro  this Social  
 Security isability La  roup that you entioned? 22 
 .  n't .  
 Q. Okay. So I take it, to date, you have  
 not received any Social Security isability  
 efits; is t t tr e? 




 . o , if you ere to receive Social  
 Security isability benefits, ould that cause 4 
 your disability benefits from Principal Life  
 i a cial r p t  e i i ishe  a  re?  
 A. Say that, again.  
 . :    cond.  · 8 
 "they"?  
  :     
  --  
 . S N: ho is "they," that's 12 
 telling you this?  
 . (B  R. B R E) The Principal Life  
 people, or the Principal Financial people? 15 
 R. OVERSON: Or the lawyers over at  
  i l ecurity? 1 7 
 T E IT ESS: They send e brochures. 18 
 Q. (BY R. BURKE) ho is "they"?  
 . Sorry. The la yers fro  Social  
 ecurity a  roup.  
 Q. Okay.  
 R. ERS : nd you're in  
 co unications ith the attorneys at the la   
 group would be privileged. And so I would direct  
  
ou    s  d re 
ou to is lose ca ions th r 
tt r e s i  t  i l rit  a  r . 
. (BY . )      
t. 'm just tere    ng 
 t l   i   t i l rit  
isability benefits? ould that cause your 
its  t  i bilit  i s ra  li  t  
s   r ced? 
. ,  t  t t t I ld t 
fro  Social Security. 
. ll right. et's talk about your 
r ers' s ti  l i .  , i  f t, 
tte     e  ' 
c e sati  lia ilit  carrier. I  t er r s, 
e    , c      
  d.  i l ,    
J e, r ri r t  J e f 09? 
. , I'm t r   t  t , t, 
yes. 
.  i itiall , t at clai  as e ie   
t e ti  rri r; rrect? 
. . 
. nd the basis for the denial, as you 
sta  ,   y  y   
  
sn't  i nt, i j ry, r iti  t t s 
r  r t  r r '  t t tes? 
. : nd I'll direct you that 
if you can ans er this question -- if  n, 
ans er it ithout disclosing our co unications. 
. (B  . ) I'm asking for your 
erstandi g. 
. N:  if t t r t i  
is based on conversations bet een you and I, I'm 
directing you to assert your privilege. 
 I : I ill a e t  assert  
privilege, because I don't understand the 
iffer  t  --
. (B  . ) e'll et t  it a 
i fere t .    half,   
have filed an actual co plaint ith the Idaho 
I strial issi   r r ers' 
co pensation clai ; is that correct? 
. . 
(Exhibits    arked.) 
. (B  . E) So let e hand you 
xhibit o. 20, first. o you recognize that as 
a copy of the orkers' co pensation co plaint 
that as filed on your behalf ith the Idaho 
Industrial Commission? 
 (Pa   t  52) 
21 Pages 253 to 256
Page 253 Page 255
1 A It looks like it yes 1 his examination ofyou
2 Q Okay And did you review that before 2 A I have not
3 it was filed 3 MR BURKE And I might ask you too
4 A Yes 4 Darwin have you received a report on that yet
5 Q So far as you know does it accurately 5 MROVERSON I have yes
6 state the basis foryour claim 6 MR BURKE So I can followup in
7 A Yes 7 discovery and ask you for that and write you a
8 Q Then hand you what wev marked as 8 letter
9 Exhibit No 21 Do you recognize that letter 9 MR OVERSON Dontworry about the
10 A Yes I recognize it 10 letter
11 Q And for the record its a letter dated 11 MR BURKE Okay Because we would
12 June 11 2009 directed to you from the Idaho 12 request a copy
13 State Insurance Fund 13 Q BY MRBURKE You have had some other
14 A Yes 14 workers compensation claims in the past and I
15 Q And is it your understanding that is a 15 think you and I talked about a couple of those
16 letter that informed you that your workers 16 earlier this afternoon And as I recall one of
17 compensation claim was being denied 17 them related to your elbow injury is that right
18 A Yes 18 A Yes my left elbow
19 Q Does it accurately state what you 19 Q And one of them related to an ankle or
20 understand the reasons for the denial to be 20 a foot injury
21 A Well what was that again 21 A Left knee
22 Q Does it accurately state what you 22 Q Its a knee injury Thats right left
23 understand the reasons for the denial to be 23 knee Were there any other compensation claims
24 A Yes 24 that you filed other than those two prior to
25 Q Now you had your deposition taken in 25 the one that relates to your work comp
Page 254 Page 256
1 the workers compensation proceeding is that 1 A I think I had one at the prison for my
2 correct 2 wrist
3 A Yes 3 Q Tell me about that
4 Q So far as you know have any other 4 A Iasked I remember I asked a guy to
5 depositions been taken in that proceeding 5 go get a sandbag for me And he said they were
6 A Iam I donknow 6 too heavy So I went and threw a sandbag up like
7 Q As I understand it you have also had 7 this indicating
8 an independent medical examination with a 8 Q Over your shoulder
9 physician or maybe more than one physician 9 A Over my shoulder and my wrist just
10 chosen by the carrier for the Idaho Department of 10 stopped And they told me I needed to see a
11 Insurance or Corrections 11 doctor for it
12 A That I go to a doctor that they wanted 12 Q Who did you see
13 me to go to 13 A I went to I think Dr Robinson
14 Q Yes 14 Q The chiropractor
15 A I dontremember that 15 A Yeah just thought ifhe could put it
16 Q Do you remember going to a doctor in 16 back in it would be fine I wore a brace on it
17 Oregon 17 for about three weeks but I never drew workmens
18 A Oh yes Portland 18 comp money for it I went right back to work
19 Q Okay Do you remember the doctors 19 Q Were your healthcare bills paid for by
20 name 20 workers comp
21 A No 21 A Ido not remember
22 Q Did you just see one doctor at that 22 MR BURKE Okay Well you will be
23 time or more than one 23 happy to know that I think I am finished at
24 A One 24 this time
25 Q And do you recall seeing an re ort of 25 THE WITNESS Good because mX head is
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a e 253 e  
 . It looks like it, yes. 1 s o   ? 
 . kay. nd did ou revie  that before 2 .  e t. 
 it as d?  . : nd I ight  , , 
 . e .  r in, e  e ved   n t t? 
 . SO far as you know, does it accurately  . : I , . 
 state the basis for your clai ?  . :    lo -up n 
 . es. 
 . Then hand you hat e've arked as 
7 i r , a d  ou f r t t,  rite   
 le r? 
 Exhibit o. 21. o you recognize that letter? 9 . : n't    
 A. Yes, !recognize it.  t r. 
 . nd for the record, it's a letter dated  . : kay. ecause e ould 
 June 11,2009, directed to you fro  the Idaho 
 tate Insurance . 
12 r st  . 
 . (BY . )  e   t  
 . e .  r ers' c e sation clai s i  t e ast, a  I 
 .  is it r ersta i , t at is a 15 t i    I t l  t  le  t s  
 letter that infor ed you that your orkers' 16 rli r t i  ft r on.   I r ll   
 7 co pensation clai  as being denied?    ate     ; s at ht? 
 . .  . ,  t l . 
 Q. Does it accurately state what you 19 .    t  r l t  t   kl , r 
 erstand e s or    e?   f t i j ry? 
 . ell, hat as that, again?  .  . 
 Q. Does it accurately state what you  . It's   i j ry? at's ri t, l ft 
 erstand e e s  e   ? 
 . . 
 knee. ere there any other co pensation clai s 
 t t  fil , t r t  t s  t , ri r t  


























a e 254 
the orkers' co pensation proceeding; is that 1 
rrect?  
. . 3 
Q. SO far as you know, have any other  
depositions been taken in that proceeding?  
.   --  n't . 6 
Q. As I understand it, you have also had  
an independent medical examination with a  
physician, or aybe ore than one physician  
chosen by the carrier for the Idaho Department of 10 
s ra e  rrections?  
A. That I go to a doctor that they anted  
me to go to? 13 
. es.  
.  on't  t at.  
. o you re e ber going to a doctor in  
Oregon?  
A. Oh, yes. Portland.  
Q. Okay. Do you remember the doctor's  
ame?  
. o.  
Q. Did you just see one doctor at that  
time, or more than one?  
. e.  
O. And do vou recall seeing anv reDort of  
  
. I think I had one at the prison for y 
i t. 
. ell e about that. 
.   -- I  I    t  
 et a sa a  f r e.  e sai  t e  ere 
t  avy.  I t  t     li  
this (indicating). 
. ver your shoulder? 
A. Over y shoulder, and y wrist just 
stopped. nd they told e I needed to see a 
  t. 
.  i   see? 
. I t to, I t i k, r. i on. 
.  i practor? 
. h, j st t t if  l  t it 
 i , it l   fi . I r   r   it 
   eks, t I r  orkmen's 
c  e  for it. I ent right ac  t  ork. 
. r  r lt r  ill  i  f r  
orkers' co p? 
.   t r ember. 
. RKE: kay. ell, you ill be 
a  t   t at, I t i k, I  fi is e  at 
i  ti e. 
THE ITNESS: Good because mv head is 
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Attorneys for Plaintiff Billie Jo Major
IN THE DISTRICTCOURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OFADA
BILLIE JO MAJOR and individual
Plaintiff






ANSWERS AND RESPONSES TO
DEFENDANT FIRST SET OF
INTERROGATORIES AND REQUESTS
FORPRODUCTION OF DOCUMENTS
COMES NOW the Plaintiff by and through her counsel of record Jones Swartz PIIC
and supplements her answers and responses to Defendants First Set of Interrogatories and
Requests for Production of Documents served by email and US Mail on June 25 2010 on
Defendantscounsel as follows
PRELIMINARY STATEMENT
The following Answers and Responses are based upon a reasonable inquiry and diligent
search by the Plaintiff but reflect only the current state of Plaintiffs understanding and belief
respecting the matters about which inquiry was made It is anticipated that further discovery
PLAINTIFFSSUPPLEMENTAL ANSWERS ANDRESPONSES TO DEFENDANTSFIRST SET OF
INTERROGATORIES ANDREQUESTS FOR PRODUCTION OF DOCUMENTS I
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 ,  #5887 
ric . artz, I  #6396 
J  & TZ,  
 . r line ri , it   
t i    
s ,   
l : (2 ) -898  
acsi ile: (208) 489-8988 
ttorne s f r l intiff, illie  j r 
       I I    
   ,        
I I  J  J ,  i i i l, 
i tif , 
. 
I  I  I , 
 iss ri r r ti , 
ant. 
 .  I  
I TIFF'S  
S     
ENDANT'S    
I E IES   
    
  t e laintiff,  a  t r  er c sel f rec r , J es & artz PLLC, 
and supple ents her ans ers and responses to efendants' First Set of Interrogatories and 
equests for roduction f ocu ents, served by e ail and .S. ail on June 25, 2010 on 
efe dant's c sel, as f ll s: 
I   
e f ll i  s ers a  es ses are ase   a reas a le i ir  a  ili e t 
search by the Plaintiff, but reflect only the current state of Plaintiffs understanding and belief 
respecting the matters about which inquiry was made. It is anticipated that further discovery, 
I TIFF'S  S   S S  ENDANT'S    
I IES  ES S  I    _. 1 
independent investigation and consultation with experts may supply additional facts add
meaning to known facts and establish entirely new factual conclusions and legal contentions all
of which may lead to substantial additions to modifications of and variations from the Answers
and Responses herein The following Answers and Responses are therefore made without
prejudice to the Plaintiffs right to produce evidence of subsequently discovered facts which the
Plaintiffmay then have available
CONTINUING OBJECTIONS
Nothing herein contained is intended to be nor should be construed as a waiver of any
attorneyclient privilege work product protection trade secrets proprietary information or the
right of privacy and to the extent the Interrogatories and Requests for Production may be
construed as calling for the disclosure of information protected by such privileges andor
doctrines a continuing objection to each and every Interrogatory and Request for Production is
hereby imposed
INTERROGATORIES
INTERROGATORY NO 1 Please identify the names addresses and phone
numbers of each person having knowledge about the subject matter of this Lawsuit and state the
general knowledge about which You understand each such person to have
ANSWER TO INTERROGATORYNO 1 Plaintiff answers Interrogatory No 1
by stating the following individuals have knowledge concerning the incident that caused
Plaintiffsinjuries andor knowledge of the Plaintiffs injuries
1 Plaintiff As to her employment medical history injury damages medical expenses
and all other factual basis for her injuries and damages
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TODEFENDANT FIRST SET OF
INTERROGATORIES AND REQUESTS FOR PRODUCTIONOF DOCUMENTS 2
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i e e e t i esti ati , a  c s ltati  it  e erts a  s ppl  a iti al facts, a  
i  t   ts,  t li  ti l   t l l i   l l t nti s, ll 
     t nti l i  , ic i s f,      
 s  r in.  ll i      t   it t 
r j ice t  t  l i tiffs ri t t  r  i  f s s ntl  is r  f ts i  t  
l i ti   t   il l . 
 S 
othing herein contained is intended to be nor should be construed as a aiver of any 
attomey/client privilege, ork-product protection, trade secrets, proprietalY infor ation, or the 
ri t f ri y,  t  t  t t t  I t rr t ries  sts f r r ti    
construed as calling for the disclosure of infor ation protected by such privileges andlor 
tri s,  ti i  j ti  t    r  I t rr t r   st f r r ti  is 
 i . 
 
 . : lease i e tif  t e a es, a resses a  e 
rs f  rs  i  ledge t t  s j t tt r f t is s it,  st t  t  
general kno ledge about hich ou understand each such person to have. 
   .1: l i tiff rs I t rr t r  .  
by stating the follo ing individuals have kno ledge concerning the incident that caused 
laintiffs injuries andlor kno ledge f the laintiffs injuries: 
. l i tiff -As t  r l t, i l i t r , i j r , , i l e ses 
and all other factual basis for her injuries and da ages; 
I TIFF'S  S E S    ENDANT'S    
I TE IES    I    -  
2 Those individuals and entities listed or otherwise identified in documents produced
herewith on the accompanying compact diskette
3 The following physicians
William Loveland
Danny J Hendrix





















Dr Reese A Verner





South West Idaho Ear Nose Throat
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. Those individuals and entities listed or other ise identified in docu ents produced 
here ith on the acco panying co pact diskette. 
.  f ll i  si i s: 
lia   
 J. ri  
  ss iates - is  
 s  
ise   
- -003  
 . oldenha   
ir ractic e ter 
228 olly 
i , I   
- -575  
-46 -451   
r. e  .  , S  
   
   
   
3- -446  
-42 -889  
 'Do ne  
 t    
  
is    
8- -00  
r.  .  
 e     
  
ise, I  -010  
8- -283  
r. t   
      
 rt  i rt  t. 
te  
ise   
- -332  
I TIFF'S      FENDANT'S    





Plaintiffsroommate has knowledge of Plaintiffsphysical state the day of the OC Spray
training at IDOC knowledge of her life style activity levels sleep difficulties and social
interactions before and after injury knowledge of the measures Plaintiff takes on a daily basis
just to function knowledge of Plaintiffsresponse to being around anyone with the slightest
amount of OC Spray
Mr Schaeffer should be contacted through Plaintiffs counsel in order to avoid direct
contact with the Plaintiff by IDOCscounsel since they are roommates
5 Bob Long PhD
Healthwise VP Research Technical Development
7475 Hidden Valley Drive
Boise ID 83709
2084841602 cell
has knowledge of Plaintiffsphysical state the day of the OC Spray training at IDOC
knowledge of her life style activity levels and social interactions before and after injury
knowledge of the measures Plaintiff takes on a daily basis just to function knowledge of
Plaintiffsresponse to being around anyone with the slightest amount of OC Spray Plaintiffs
prior life style activities including Horseback Riding Mountain biking 4 wheeling ATV
hiking snow shoeing landscaping any outdoor activities
Annette Phillipp PHD
2311 N 22 St
Boise ID 83702
208 8664315
has knowledge of Plaintiffseveryday life and prior lifestyle activities including Horseback
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TO DEFENDANTSFIRST SET OF
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. r  eff  
   
,   
- -24  cell 
- laintiffs r t ;  l  f laintiffs i l st t  t  y f t   r  
  ;     tyl , ti i  ls, l  i l , n  i l 
i t r ti s f r   ft r i j ry; l  f t  s r s l i tiff t s   il  sis 
s   tion; e   l intif s        l  
   ray. 
r. ff r l   t t  t r  l i tiff  l i  r r t  i  ir t 
   l i t   C's l    . 
5.  , h.D., 
lt i e,   & i l l t 
 i  ll  i e 
,   
-48 -160  ll 
---has kno ledge f laintiffs physical state the day f the  pray training at I ; 
kno ledge of her life style, activity levels, and social interactions before and after injury; 
kno ledge of the easures Plaintiff takes on a daily basis just to function; kno ledge of 
Plaintiffs response to being around anyone with the slightest amount of OC Spray. Plaintiffs 
prior life style activities including Horseback Riding, ountain biking, 4 wheeling ATV, 
i ,  i , a    e . 
nnette illipp , 
 . 211<1  
,   
- -431  
--has kno ledge of Plaintiffs everyday life, and prior lifestyle activities including orseback 
P lFF'S L NS ERS    NDANT'S IRS   F 
INTERROGATORIES  ES S  I  F  -  
Riding 4 wheeling ATV Mountain biking hiking snow shoeing landscaping any outdoor
activities
Becky Coles
Occupational Health and Safety Manager
5282 S Williamette PL
Boise ID 83716
208841 9069
has known Plaintiff over 20 years lifestyle activities prior to the injury including camping
white water rafting activities
Roger Barnheardt




has knowledge of Plaintiffsprior lifestyle activities including Mountain Biking hiking






Known Plaintiff for 10 years
Angie Schaeffer
16508 N Alcatraz Ave
Kuna ID 83634
208631 1352
Known Plaintiff for 10 years
Jeff Champaign
ChampagneJeff@principalcom
has knowledge of Plaintiffscondition shortly after she was injured
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TO DEFENDANTSFIRST SET OF
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iding. 4 heeling , ountain biking, hiking, sno  shoeing, landscaping any outdoor 
activities. 
ck   
ti l lt   f t   
5282 . illia ette L. 
i e,   
-841-9  
--- has kno n laintiff over 20 years, lifestyle activities prior to the injury including camping, 
  ft  ctiviti s. 
  
   @  
 it   
a,   
-461-75  
--has knowledge of Plaintiffs prior lifestyle activities including ountain Biking, hiking, 
alks, level of activity. Started at prison the sa e ti e Plaintiff did and ent through training 
t r. 
ia  r  
 . c ire 
,   
-631-135  
n  l i ti  or + ears 
n ie er 
8 . lcatraz . 
u , I  4 
- 31-135  
no n l i ti f fo  1  + years 
J f ha paign 
.J ff@principal.com 
--has knowledge of Plaintiffs condition shortly after she as injured. 
P IFF'S S P E TAL ANSWERS ND S S S O NDANT'S FIRST S  F 
INTERROGATORIES ND RE UESTS  P ION OF E TS - 5 
INTERROGATORYNO 2 Identify all witnesses whom You expect or intend to
testify at a trial of this matter and state the facts and opinions about which You expect each
witness to testify
ANSWER TO INTERROGATORY NO 2 Plaintiff answers Interrogatory No 2 by
referring Defendant to her Answer to Interrogatory No I above
INTERROGATORY NO 3 Identify each person whom You expect or intend to
testify as an expert at a trial of this matter and with respect to each such person state the
following
A The substance and summary of all facts and opinions about which each expert
is expected to testify
B Identify each fact Document and all data pursuant to Rule 705IREupon
which each expert intends to rely in rendering any opinions at a trial of this matter and
C Identify all information and Documents required to be disclosed by expert
witnesses pursuant to Rule26aIdaho Rules ofCivil Procedure
ANSWER TO INTERROGATORY NO 3 Plaintiff at this point have not
determined who their expert may be at trail but reserve the right to identify them at a later date
INTERROGATORY NO 4 Identify each exhibit which You intend to offer into
evidence at a trial ofthis matter
ANSWER TO INTERROGATORY NO 4 Plaintiff answers Interrogatory No 4 by
referring Defendants to the documents produced herewith on the accompanying compact
diskette
INTERROGATORY NO 5 Please state Majors full name date of birth and social
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TO DEFENDANTSFIRST SET OF
INTERROGATORIES AND REQUESTS FOR PRODUCTIONOF DOCUMENTS 6
001620
 . : ti  ll it e    t  i t  t  
testify at a trial of this atter, and state the facts and opinions about hich ou expect each 
itness t  t stif . 
   . : i ti  s  .   
r f rri  efe a t t  r s r t  I t rr t r  . I ve. 
 . :          
t stif  s  rt t  trial f t is tt r,  it  r s t t   s  rson, st t  t  
f ll i : 
. e s sta ce a  s ar  f all facts a  i i s a t ic  eac  e ert 
is t  t  t tif ; 
.   t,    t ,    , .R.E.,  
hich each expert intends to rely in rendering any opinions at a trial of this atter; and 
. I e tif  all i f r ati  a  c e ts re ire  t  e iscl se   e e11 
itnesses pursuant to ule 26(a)(2), Idaho ules of ivil Procedure. 
   . : laintiff, t  point,   
eter ined  t eir e ert a  e at trail t reser e t e ri t t  i e tif  t e  at a later ate. 
 . : Identify each exhibit hich ou intend to offer into 
   l  s t r. 
   . : laintiff ans ers Interrogatory o. 4 by 
referring efendants to the docu ents produced here ith on the acco panying co pact 
tte. 
 . : l s  st t  jor's f ll , t  f irt   s i l 
I TIFF'S      ENDANT'S    
I TERR TORIES  RE ESTS F R PR CTI  F C E TS - 6 
security number
ANSWER TO INTERROGATORY NO 5 Billie Jo Major DOB SS
INTERROGATORY NO 6 Please identify each employer for whom or which
Major has worked during the Iast ten 10 years and for each employer please state
A Name last address and telephone number of each employer
B Inclusive dates ofMajorsemployment with each employer
C Reasons for termination ofemployment
D Majorsjob title and a description of her duties for each employer and
E Her rate ofpay wage or other salary for each employer
ANSWER TO INTERROGATORY NO 6 Plaintiff answers Interrogatory No 6 by
reference to the document entitled Employment History bates stamped Employment History
000001 03180 through 000003 03180 contained on the compact diskette provided
herewith
INTERROGATORY NO 7 With respect to each Health Care Provider who has
examined Major or provided her with any treatment diagnosis prognosis or health care for any
symptom complaint injury aggravation or adverse reaction to any injury which You allege she
suffered as a result of the Incident please state
A The name address and telephone number of each
B The dates of inclusive care treatment diagnosis or examination
C The names and addresses of each hospital the dates of admission and dates of
discharge for each hospitalization and
D The nature of any treatment or therapy received tests performed andor
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TODEFENDANTFIRST SET OF
INTERROGATORIES ANDREQUESTS FOR PRODUCTION OF DOCUMENTS 7
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s rit  r. 
S E   TE  . : llie  r,   S# 
 
TE  . : lease identify each e ployer for ho  or hich 
ajor has orked during the last ten (10) years, and for each e ployer please state: 
. , last r ss  t le  r f  l r; 
. Inclusive dates of ajor's e ploy ent ith each e ployer; 
. eas s f r ter i ati  f e l ent; 
. ajor's job title and a description f her duties for each e ployer; and 
E. er rate of pay, age or other salary for each e ployer. 
S   TE  . : l i ti   n'  .   
reference to the docu ent entitled ploy ent istory, bates sta ped ploy ent istory 
000001 03/18/10 through 000003 0311811 0, contained on the co pact diskette provided 
it . 
E  . : it  r s t t   lt  r  r i r  s 
exa ined ajor, or provided her ith any treat ent, diagnosis, prognosis or health care for any 
sy pto , co plaint, injury, aggravation or adverse reaction to any injury, hich ou allege she 
suffered as a result of the Incident, please state: 
.  ,   t l    ch; 
. e ates f i cl si e care, treat ent, ia sis r e a ination; 
.    r  f  spital, t  t  f i i   t  f 
discharge for each hospitalization; and 
. The nature of any treat ent or therapy received, tests perfor ed and/or 
I TIFF'S      FENDANT'S    
INTERROGATORIES AND REQUESTS FOR PRODUCTION OF DOCU ENTS -- 7 
surgeries performed
ANSWER TO INTERROGATORY NO 7 Plaintiff answers Interrogatory No 7 by
referring Defendant to the medical records and bills contained on the compact diskette provided
herewith
INTERROGATORY NO 8 With respect to each Health Care Provider who has
examined Major or provided her with any treatment therapy diagnosis prognosis or health care
for any medical physical mental or health related symptom complaint injury or condition
within ten years prior to the Incident please state
A The name address and telephone number of each Health Care Provider
providing such treatment diagnosis prognosis or health care
B The dates of inclusive care treatment diagnosis or examination
C The symptom complaint injury or condition treated and the nature of any
treatment or therapy received tests performed andor surgeries performed
ANSWER TO INTERROGATORY NO 8 Plaintiff answers Interrogatory No 8 by
referring Defendant to document entitled DisabilityWorkers Comp 000051 0510 contained
on the compact diskette provided herewith along with the other medical records and bills
contained thereon
INTERROGATORY NO 9 As a result of the injuries which Major sustained in the
Incident did she lose or do You claim any wage or earning loss or loss of earning capacity If
so please state
A How much time if any was lost from work or employment listing dates
involved and the name and addresses of each employer
B State the gross and net salaries or wages which Major received from any
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surgeries perfor ed. 
S    . : l i ti   n'  .   
referring efendant to the edical records and bills contained on the co pact diskette provided 
it . 
 . : t          
ine  j r, r r ide  r ith  tr t t, t r py, i sis, r sis r lt  r  
  i al, i l, t l  lt  l t  to , plaint, i j ry,  iti  
ithin te  ears ri r t  t e I ci e t, lease state: 
. he na e, address and telephone nu ber f each ealth are rovider 
providing such treat ent, diagnosis, prognosis or health care; 
. e ates f i cl si e care, treat ent, ia sis, r e a i ation; 
. he sy pto , co plaint, injury or condition treated and the nature of any 
tre t e t r t r  r i , t sts rf r  /or s r ries rf r d. 
   . : laintiff ans ers Interrogatory .  by 
r f rring f t t  t title  is ilit /Workers   5/0 110 t i  
on the co pact diskette provided here ith, along ith the other edical records and bills 
e  n. 
 . : s a result of the injuries hich ajor sustained in the 
I ci e t, i  s e l se, r   clai , a  a e r ear i  l ss r l ss f ear i  capacity? If 
so, please state: 
. o  uch ti e, if any, as lost fro  ork, or e ploy ent, listing dates 
i l e   t    s    l r; 
B. State the gross and net salaries or wages which ajor received fro  any 
I TIFF'S      ENDANT'S    
I TER TORIES  S S F  P I  F S -  
employer for whom or which she contends she lost time
C State the amount of income salary or wages actually lost as a result of her
injuries and
D State the value of any lost earning capacity You contend she suffered or will
suffer as a result of her injuries and describe in detail the manner and method of computing lost
earning capacity
ANSWER TO INTERROGATORY NO 9 Plaintiff answers Interrogatory No 11 by
stating that she has been unable to work in any capacity since March 2008 Plaintiff further
answers this interrogatory by referring Defendant to her 2003 through 2009 tax returns Plaintiff
is claiming she is unable to work in any capacity and is in the process of determining the value of
that injury
INTERROGATORY NO 10 Do You or Your attorneys have possession of any
recorded transcribed written or typed statements or affidavits of any person who has knowledge
about facts related to the subject of this action If so as to each such statement or affidavit
please state
A The name address and telephone number of each person giving each such
statement or affidavit and
B The dates on which each such statement or affidavit were given
ANSWER TO INTERROGATORYNO 10 Plaintiff and her attorney have had many
communications by writing and electronic transmissions that are protected by the attorney client
privilege and that privilege is asserted herein Plaintiffscounsel may have consulted with
experts in their relevant field and those communications are protected by the attorney work
product privilege which is herein asserted Without waiving any objections or privileges
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l r f r  r i  s  t s s  l st ti e; 
. t t  t  t  i , l    t ll  l t   ult  r 
;  
.       r  i       ill 
s ff r s  r s lt f r i j ries  s ri  i  tail t  r  t  f ti  l st 
i  pacity. 
  I  . : l i tif   t t  .   
stati  t at s e as ee  a le t  r  i  a  ca acit  si ce arc  8. lai tiff f rt er 
r  t i  i t rr t r   r f rri  f t t  r  t r   t  r t r s. l i tiff 
is clai ing she is unable to ork in any capacity and is in the process f deter ining the value f 
 ry. 
 . 0: o ou or our attorneys have possession f any 
recorded. transcribed, ritten or typed state ents, or affidavits of any person ho has kno ledge 
t fa ts r l t  t  t  s j t f t is ti n? If s , s t   s  st t t r ffi vit, 
leas  t t : 
. he na e, address and telephone nu ber f each person giving each such 
  it;  
. The dates on hich each such state ent or affidavit ere given. 
S E  T  I TE T  . 10: Plaintiff and her attorney have had any 
co unications by riting and electronic trans issions that are protected by the attorney client 
ilege  t  ivilege s  r i . laintiff's counsel ay have consulted ith 
experts in their relevant field and those co unications are protected by the attorney ork 
 le ,  s  rt d. it t ai i  a  jecti s r ri ile es, 
I TIFF'S  S ERS    FENDANT'S    
I TERR TORIES  S S  I    --- 9 
Plaintiff answers Interrogatory No 10 by referring the Defendant to the documents produced on
the accompanying compact diskette
INTERROGATORY NO 11 Please identify the following persons
A Majorsimmediate supervisor at IDC at the time of her employment
B All persons managing supervising andorconducting any OC Spray training
alleged by You in Paragraphs 5 8 and 11 of the Complaint in the Lawsuit
C All persons present during any training session involving the use of OC Spray
as alleged in Paragraphs 5 8 and 11 on the Complaint in the Lawsuit and
D All persons knowledgeable of IDCspurchase and use of OC Spray for or at
any IDC facility at which You allege exposure to OC Spray in Paragraphs 5 8 and 11 of the
Complaint in the Lawsuit
ANSWER TO INTERROGATORYNO 11 Plaintiff answers Interrogatory No 1 I by
referring Defendant to documents contained on the accompanying compact diskette entitled
Employment History 000001 03180and to IDCRecords 000001 03172010 to 000086
03172010
FIRST SUPPLEMENTAL ANSWER TO INTERROGATORY NO 11 Plaintiff
supplements her answer to Interrogatory No 11 by stating
A Sgt Link was the Plaintiffs supervisor at IDC during her employment at IDC
from approximately September or October 2007 to May 2008 Sgt Link is a
female whose first name is unknown to the Plaintiff With the exceptions of
Sgt Link the Plaintiff recalls none of her other supervisors While working
at IDC her supervisors would change frequently Those records are available
through IDC to the Defendant pursuant to the authorization for release of
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Plaintiff ans ers Interrogatory o. 10 by referring the efendant to the docu ents produced on 
   tt . 
I  . 1: l s  i tif  t  f ll i  rsons: 
. ajor's i ediate supervisor at I  at the ti e of her e ploy ent; 
. ll rs s gi g, s r isi  nd/or ti    r  tr i i  
alleged by ou in Paragraphs 5, 8 and 11 of the o plaint in the a suit; 
. ll rs s r s t ri   tr i i  s ssi  i l i  t  s  f  r  
as alleged in Paragraphs 5, 8 and lio  the o plaint in the a suit; and 
. ll persons kno ledgeable f I C's purchase and use f  pray for or at 
 I  f ilit  t i   ll  s r  t   r  i  r r s ,    f t  
l i t i  t  uit. 
   . : l i ti    . 1  
r f rri  f t t  ts t i   t  i  t is tt  titl  
e t   311 110  t  .D.C.   3/17/2010 t   
3117/2010. 
     . : l i tif  
supple ents her ans er to Interrogatory o. 11 by stating: 
. Sgt. Link as the Plaintiffs supervisor at I  during her e ploy ent at I  
fro  approxi ately Septe ber or ctober 2007 to ay 2008. Sgt. ink is a 
fe ale hose first a e is  t  t e lai tiff. it  t e e ce ti s f 
Sgt. Link, the Plaintiff recalls none of her other supervisors. hile orking 
at I , her supervisors ould change frequently. hose records are available 
through I  to the efendant pursuant to the authorization tor release of 
I TIFF'S L NS ERS  S S  FENDANT'S    
I E T IES  ESTS  I   S -  
information signed by the Plaintiff and attached hereto
B As to the July 2004 OC Spray Training the Plaintiff does not know who the
person was who conducted the training Plaintiff recalls a 2006 OC Spray
training while she was working at the Womens Prison and the person
conducting the training was Sgt Schaffer Plaintiff is without further
knowledge as to who else may have been involved in managing supervising
andor conducting the 2006 training The March 2008 Training was
conducted by Corrections Officer Doan who was the person who asked
questions of the trainees during the training Sgt Overgaard supervised the
training
C In July 2004 Plaintiff was present along with three other officers who were
from max Correctional Officer Bunn another person who Plaintiff does not
retail his name Present for the 2006 training were Plaintiff Correctional
Officer Spackman Sgt Schaffer Correctional Officer Haynes Correctional
Officer Kelm Correctional Officer Crowl There were others present who the
Plaintiff either has never known their names or she cannot recall their names
D Sgt Overgaard has knowledge of IDCs purchase and use of OC Spray and
all officers who worked at IDC had knowledge of how and where to purchase
OC Spray To name all officer employed at IDC who have knowledge of the
purchase and use of OC Spray is unduly burdensome and therefore the
Plaintiff objects to the interrogatory on that basis Additionally the request
now understood by the Plaintiff to be a very broad request is for information
that is not reasonably calculated to discovery of admissible evidence and
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    l i ti   e  r to. 
. s t  t  l    r  r i i , t  l i tiff  t   t  
ers  as  c cte  t e trai i . lai tiff recalls a   ra  
t i i  ile   i  t t  en's ri n,  t   
ti  t  tr i i  s t. haffer. l i ti     
kno ledge as to ho else ay have been involved in anaging, supervising 
and/or c cti  t e  trai i . e arc   rai in  as 
t   rr ti s ffic r    t  r    
questions of the trainees during the training. Sgt. vergaard supervised the 
trai i g. 
.  l  , l i ti   t l  it  t  t  i    
 x.   n,    l i ti    
c l  s . r t f r t   tr i i  r  laintiff, rr ti l 
fficer Spack an, Sgt. Schaffer, Correctional fficer aynes, Correctional 
fficer eIrn, orrectional fficer ro l. There ere others present ho the 
i ti  t e     i      l  i  . 
. t. ergaar  as le e f I C's rc ase a  se f  ray, a  
ll fficers  r e  t I   le  f   r  t  rchas  
 Spray. o na e all officer e ployed at I  ho have kno ledge of the 
purchase and use of OC Spray is unduly burdenso e, and therefore the 
l i tiff j t  t  t  i t rr t r   t t is. iti ally, t  r st, 
 erst   t e lai tiff t  e a er  r a  re est, is f r i f r ati  
that is not reasonably calculated to discovery of ad issible evidence, and 
I TIFF'S L      FENDANT'S    
I IES    I    -  
therefore Plaintiff objects to the interrogatory on that basis
INTERROGATORYNO 12 Please identify all IDC facilities at which Major
worked as a prison guard or other employee and at which You allege Major received any
exposure to OC Spray products including but not limited to the Product and give the dates at
which Major worked at each such facility
ANSWER TO INTERROGATORY NO 12 Plaintiff answers Interrogatory No 12 by
referring Defendant to the documents contained on the accompanying compact diskette which are
identified as Disability Benefits and Workers Compensation 00001 00051 Employment
History Idaho Dept ofCorrections Records and Material Safety Sheet
SUPPLEMENTAL ANSWER TO INTERROGATORY NO 12 Plaintiff
supplements her answer to Interrogatory No 12 by stating that Idaho Maximum Security
Institution and Southwest Boise Women Correction Institute were the only two IDC facilities in
which she worked OC Spray training was conducted at both facilities Plaintiff worked at the
maximum facility from 2004 to approximately 2006 when she moved to the womans prison
She continued to work at the womans facility until September or August 2007 when she
returned to maximum
INTERROGATORY NO 13 For each occasion on which Major was exposed to OC
Spray in her lifetime please state
A The date and place of each such exposure
B The brand name model name manufacturer and model number of each OC
Spray product to which Major was allegedly exposed on each such occasion and
C Describe in detail the manner and circumstances of each such exposure
ANSWER TO INTERROGATORY NO 13 Plaintiffanswers Interrogatory No 13 by
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therefore laintiff objects to the interrogatory on that basis. 
 . : l s  i tif  ll I  f ilities t i  j r 
orked as a prison guard or other e ployee, and at hich ou allege ajor received any 
 t    t , i l i , t t li ite  t , t  r uct,  i  t  t  t 
hich ajor orked at each such facility. 
   . : l i ti    .   
r f rri  fe t t  t  ts t ine   t  i  t is tt  i  r  
i tified  is ility fits  r ers ti   - 51; l t 
r ;  t.  re tions r ;    et. 
L  S    . 2: l i ti  
supple ents her ans er to Interrogatory o. 12 by stating that Idaho axi u  ecurity 
Institution and South est oise o en's orrection Institute ere the only t o I  facilities in 
hich she orked.  pray training as conducted at both facilities. laintiff orked at the 
i  f ilit  fr   t  r i t l    s   t  t  an's ris n. 
he continued to ork at the o an's facility until epte ber or ugust 2007 hen she 
  . 
 . : For each occasion, on hich ajor as exposed to  
ra  i  r lifeti e, lease state: 
.  t   la     re; 
. he brand na e, odel na e, anufacturer and odel nu ber f each  
Spray product to hich ajor as allegedly exposed on each such occasion; and 
. escri e i  etail t e a er a  circ sta ces f eac  s c  e s re. 
   . : l i tif   t t  .   
I TIFF'S L  S E     FENDANT'S    
I IES  S S  I    -  
stating that each instance of OC Spray exposure is recorded in her employment records with
IDOC contained in the document entitled Idaho Dept of Corrections Records contained on the
compact diskette accompanying this answer
SUPPLEMENTAL ANSWER TO INTERROGATORY NO 13 Plaintiff
supplements her Answer to Interrogatory No 13 by stating as follows
A In addition to the OC Spray exposures identified in PlaintiffsSupplemental
Answer to Interrogatory No 12 above Plaintiff was exposed nearly every day
to some lower levels of OC Spray while she was employed at IDC Items
within the facility were contaminated with OC Spray at all times including
uniforms and equipment Slight exposure to OC Spray also occurred in
October 2008 when an Ada County Sheriff came to Plaintiffs home to
investigate a DUI that the Plaintiff reported The officer had OC Spray on his
person and the Plaintiff had a physical response to his OC Spray
B All Plaintiffsstraining and exposures to OC Spray at IDC prior to the May 3
2008 training with Sabre Red OC Spray were with a product manufactured by
Security Equipment Corporation that had lower heat intensity than Sabre Red
The First DefenseRproduct shown in Bates Stamped No MK4 1
03182010 looks identical to the product Plaintiff recalls using prior to May
3 2008
Plaintiff further answers by stating that the documents that Plaintiff identified in her
initial answer are responsive to the request as they reference her training transcripts and
exposure incident reports
INTERROGATORY NO 14 Please identify all facts persons and Documents who
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stating that each instance f  pray exposure is recorded in her e ploy ent records ith 
I oe t i  i  t  t ntitl  I  pt. f n' ti s r s t i   t  
t is tt  i  t is s er. 
PL     O. 3: laintiff 
l t  r r t  I t rr t r  .   t ti   f ll s: 
. I  a iti  t  t e  ra  e s res i e tifie  i  laintiffs le e tal 
ns er to Interrogatory o. 12 above, Plaintiff as exposed nearly every day 
t  s e l er le els f  ra  ile s e as e l e  at I . Ite s 
ithin the facility ere conta inated ith  pray at all ti es, including 
unifor s and equip ent. Slight exposure to  Spray also occurred in 
ct er  e  a  a t  eriff ca e t  lai tiffs e t  
investigate a I that the Plaintiff reported. he officer had  Spray on his 
person and the Plaintiff had a physical response to his C Spray. 
. ll Plaintiffs's training and exposures to  Spray at I  prior to the ay 3, 
 tr i i  it  r    r  r  it   r t f t r   
Security Equip ent orporation that had lo er heat intensity than Sabre ed. 
The First Defense(R) product shown in Bates Stamped No. K-4 1 
03/18/2010 looks identical to the product Plaintiff recalls using plior to ay 
, . 
laintiff further ans ers by stating that the docu ents that laintiff identified in her 
i itial er re re sive t  t e r t,  t  reference r tr i ing tra ri ts  
e posure incident . 
INTERR  . : Please identify all facts, persons and ocu ents ho 
I IFF'S L S E S  SP SES  NDANT'S S    
INTERRO TORIES  E UESTS F   F E TS --  
or which support Your contention that Major was exposed to any OC Spray product designed
manufactured distributed andor sold bySEC
ANSWER TO INTERROGATORY NO 14 Plaintiff answers Interrogatory No 14 by
referring Defendants to her employment records with IDOC contained in the document entitled
Idaho Dept of Corrections Records contained on the compact diskette accompanying this
answer
SUPPLEMENTAL ANSWER TO INTERROGATORY NO 14 Plaintiff
supplements her Answer To Interrogatory No 14 by stating that a public records request was
served on the IDC requesting all information identifying the OC Spray product that was used
during PlaintiffsMay 3 2008 training and the IDC responded by providing the Materials Safety
Sheet identified in Plaintiffsproduction by Bates No 13
The Plaintiffs prior exposure to OC Spray was to lower intensity products produced by
SEC until the May 3 2008 OC Spray training at IDC At that point in time Plaintiff was
suffering a sinus infection and Bronchitis Plaintiff had never been warned of the risks
associated with being exposed to Sabre Red in closed confinement while being ill with sinus and
bronchitis Almost immediately upon being exposed to OC Spray on May 3 2008 Plaintiff
started experiencing a chronic cough that has worsened ever since After months of medical
screening Plaintiffs medical providers have concluded that the Plaintiffs injuries were the
result of occupational expose to OC Spray For persons who support Plaintiffsclaims please see
Plaintiffs Answer to Interrogatory No 1 For documents that support Plaintiffs claims please
see the documents produced previously Plaintiff is not in possession of any additional
documentation other than what has thus far been produced to the Defendant
INTERROGATORY NO 15 With respect to the allegations in the First Cause of
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or hich s rt our c te tion that ajor as exposed to a   ray r duct desi , 
anufactured, distributed and/or sold by S . 
S E   INTERR T  . 1 : l i tiff ers Interrogat ry . 4  
referring efendants to her e ploy ent records ith I  contained in the docu ent entitled 
Idaho Dept. of Corrections Records contained on the co pact diskette acco panying this 
a . 
 S E    . 14: laintiff 
supple ents her ns er To Interrogatory o. 14 by stating that a public records request as 
served on the I  requesting all infonnation identifying the  pray product that as used 
during Plaintiffs May 3, 2008 training and the IDC responded by providing the Materials Safety 
Sheet identified in Plaintiffs production by ates o. 1-3. 
The Plaintiffs prior exposure to OC Spray was to lower intensity products produced by 
S  until the ay 3, 2008  Spray training at I . t t t i t i  ti , l i ti   
suffering a sinus infection and Bronchitis. l i ti         
associated ith being exposed to Sabre ed in closed confine ent hile being ill ith sinus and 
bronchitis. l ost i ediately upon being exposed to  pray on ay 3, 2008, laintiff 
started experiencing a chronic cough that has worsened ever since.     
screening, Plaintiffs edical providers have concluded that the Plaintiff's injuries ere the 
result of occupational expose to OC Spray. For persons who support Plaintiff's claims please see 
Plaintiff's ns er to Interrogatory o.1. For docu ents that support Plaintiffs clai s, please 
see the documents produced previously. laintiff i  t i  ssi   ny dditi l 
c entati  t er t a  at as t s far ee  r ce  t  t e efe dant. 
 . 5: it  r t t  t  ll ti  i  t  i t  f 
LAINTIF 'S PLE      EFENDANT'S FI T   
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Action in Your Complaint that the Product was defective and unreasonably dangerous please
state
A Describe in detail how You contend the Product was defective and
unreasonably dangerous
B Describe in detail how You contend the Product should have been designed or
manufactured in order to make it reasonably safe for its intended use
C Identify all Documents on which You rely to support this contention and
D Identify all persons on whom You rely to support this contention
ANSWER TO INTERROGATORY NO 15 Plaintiffobjects to Interrogatory No 15
to the extent that it requires the disclosure of experts with whom Plaintiffscounsel may have
consulted with in forming trial strategy who are not required by the IRCP 26 to be disclosed
unless and until it is determined that those experts will provide expert testimony at trial Until
such time Plaintiffobjects on attorney work product grounds
SUPPLEMENTAL ANSWER TO INTERROGATORY NO 15 Plaintiff
supplements her Answer to Interrogatory No 15 by stating
Plaintiff maintains that at all times mentioned in her complaint the Defendant was
negligent in failing to provide adequate warnings and instructions to the consumer including
Ms Major such that Sabre Red OC Spray was unreasonably dangerous and hazardous with
respect to its foreseeable and intended use within prison facilities such as IDC Said warnings
should have consisted of a warning that Sabre Red OC Spray should only be used for training
officers who do not have a history of respiratory illness such as chronic asthma or bronchitis or
other health problems that may make the officer more susceptible to injury by Sabre Red OC
Spray Said warnings should have consisted of a warning expressing what types of symptoms
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ction in our o plaint that the roduct as defective and unreasonably dangerous, please 
s : 
. es ribe     te  the t  e  
unreasonably dangerous; 
. be      the    e    
anufactured in order to ake it reasonably safe for its intended use; 
. I tif  ll ocu ents  ich  r l  t  s rt t is t ti ;  
. Identify all persons on ho  ou rely to support this contention. 
   . : l i ti  e   t  .  
t  t e e te t t at it re ires t e iscl s re f e erts ith  laintiffs c sel a  a e 
consulted ith in for ing trial strategy ho are not required by the I P 26 to be disclosed 
less  til it is t r i  t t t s  rts ill r ide rt t sti  t tri l. til 
such ti e, Plaintiff objects on attomey ork product grounds. 
PL     . 5: l i tiff 
supplements her Answer to Interrogatory No. 15 by stating: 
laintiff aintains that at all ti es entioned in her co plaint, the efendant as 
negligent in failing to provide adequate wamings and instructions to the consumer, including 
s. ajor, such that Sabre Red OC Spray was unreasonably dangerous and hazardous with 
respect to its foreseeable and intended use within prison facilities such as IDC. Said wamings 
should have consisted of a aming that Sabre ed  Spray should only be used for training 
officers ho do not have a history f respiratory illness, such as chronic asth a or bronchitis, or 
other health proble s that ay ake the officer ore susceptible to injury by Sabre Red DC 
Spray. Said wamings should have consisted of a waming expressing what types of symptoms 
LAINTIF 'S L      EFENDANT'S I    
I I     I    - 1  
officers should be cognizant of as requiring medical attention Said warnings should have
consisted of a warning that the use of a strong irritant such as Sabre Red OC Spray may cause
respiratory illness such as RADS chronic cough syndrome vocal cord dysfunction esophageal
dysmotility and reflux and that it may act as an aggravating factor for those who may already
have one or more of those medical conditions Instructions should have been included clearly
defining the safe use of the product and further warning against use within confined areas
chronic exposure and prolonged periods of exposure
Plaintiff maintains that the Sabre Red OC Spray manufactured by Defendant was
unreasonably dangerous and defective in that it utilized a concentration of major capsaicinoids in
its product that was far in excess of what is reasonably safe for either acute or chronic human
exposure Defendant knew or should have known that the excessively high potency of Sabre Red
OC Spray was grossly in excess of what is reasonably safe for use within closed environments
such as within the IDC Such a potent concentration of capsaicinoids posed a risk of serious
harm to prison guards such as Ms Major Defendant knew or should have known that its
product posed a serious risk of harm to prison guards like Ms Major because it expressly
marketed its product to prison facilities such as IDC The Defendantsproduct is marketed and
sold with no warnings or cautions as to the dangers posed by long term exposure to it product or
to the dangers posed by direct exposure during training in closed environments such as within a
prison building In fact few warnings or cautions are provided with the product There is a
general warning to keep the product out of the hands of children a warning that the product is
only to be used for selfdefense purposes and another general warning stating The contents are
dangeroususe with caution The following statements are also made on the side of the canister
Caution Avoid discharge into headwinds or shield face to prevent
PLAINTIFFSSUPPLEMENTAL ANSWERS AND RESPONSES TO DEFENDANTSFIRST SET OF
INTERROGATORIES AND REQUESTS FOR PRODUCTION OF DOCUMENTS 16
001630
officers should be cognizant of as requiring edical attention. i  ar ings l  e 
consisted f a arning that the use f a strong irritant such as abre ed  pray ay cause 
respiratory illness such as RADS, chronic cough syndrome, vocal cord dysfunction, esophageal 
dys otility and reflux, and that it ay act as an aggravating factor for those ho ay already 
   r   se  . s tions    lude   
defining the safe use of the product, and further arning against use ithin confined areas, 
r i  r ,  r longed ri s f r . 
laintiff aintains that the abre ed  pray anufactured by efendant as 
unreasonably dangerous and defective in that it utilized a concentration f ajor capsaicinoids in 
its product that as far in excess of hat is reasonably safe for either acute or chronic hu an 
exposure. Defendant knew or should have known that the excessively high potency of Sabre Red 
 Spray as grossly in excess of hat is reasonably safe for use ithin closed environ ents 
such as ithin the I . uch a potent concentration of capsaicinoids posed a risk of serious 
harm to prison guards such as Ms. Major.         
product posed a serious risk of har  to prison guards like s. ajor because it expressly 
arketed its product to prison facilities such as I C. The efendant's product is arketed and 
sold ith no amings or cautions as to the dangers posed by long ter  exposure to it product, or 
to the dangers posed by direct exposure during training in closed environments such as within a 
prison bUilding. I  t t f  r i s r ti s r  r i  it  t  r duct. r  is  
general waming to keep the product out of the hands of children, a warning that the product is 
only to be used for self-defense purposes, and another general arning stating "The contents are 
dangerous-use ith caution." he follo ing state ents are also ade on the side of the canister: 
Caution:  void discharge into head inds or shield face to prevent 
LAINTIF 'S UPPLE      FENDANT'S I    
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blowback exposure Do not discharge at distances less than three
feetmay cause injuries to soft body tissue Test fire
periodically to assure performance and familiarity of spray pattern
DO NOT puncture or incinerate can DO NOT expose to heat or
store above 120 degrees F DO NOT uses after canisters
expiration date It is the user responsibility to keep the canister
from accidently firing
There is also a warning on the front of the canister stating CAUTION SEVERE SKIN
AND EYE IRRITANT CONTENTS UNDER PRESSURE SEE OTHER WARNINGS ON
BLACK LABEL The warnings are inadequate See Complaint
The instructions on how to use the product are inadequate as they only describe how to
spray the product into the face of an attacker and when to deploy the next appropriate force
option Defendant knew its product was being used within prisons for purposes of training but
provided no instruction on the use of its product under those circumstances Additional
instructions are provided for decontamination after deploying the Defendants product but
there are no instructions as to how to avoid chronic exposure within the confines of a working
prison facility
Plaintiff relies on the medical records and opinions of her medical healthcare providers
which have previously been produced to the Defendants in discovery
Plaintiff relies on the medical providers identified in her Answer to Interrogatory No 1
and specifically Dr Hendrickson Dr Loveless DrODonnell and Dr Moldenhauer Plaintiff
may also rely on experts who Plaintiff is at this time not required under the Idaho Rules of Civil
Procedure 26 to disclose at this time
INTERROGATORY NO 15 sic 161 With respect to the allegations in the Second
Cause of Action in Your Complaint that SEC failed to provide adequate warnings and
instructions for the Product please state
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blo -back e p s re. o not discharge at istances less than three 
feet-may cause injuries to soft body tissue. est fire 
periodically to assure performance and fa iliarity of spray pattern. 
 OT puncture or incinerate can. O  expose to heat or 
store a e 120 degrees .   uses after c i ter's 
expiration date. It is the user's responsibility to keep the canister 
ro  a ide tly firi . 
here is also a arning on the front f the canister stating "CAUTION  I  
 E I . TS E    ER INGS  
C  EL." he arnings are inadequate. ee o plaint. 
he instructions n  t  s  t  r t r  inadequate s t  l  s ri   t  
spray the product into the face of an attacker and hen to deploy the next appropriate force 
option. Defendant knew its product was being used within prisons for purposes of training but 
provided no instruction on the use of its product under those circumstances. iti l 
instructions are provided for "deconta ination" after deploying the efendant's product but 
t r  r   i tr tions  t   t  i  r i  re it i  t  fi e    r i  
prison facility. 
i t  ies         i l  rs, 
which have previously been produced to the Defendants in discovery. 
l i tiff r lies  t  i l r i rs i tifi  i  r s r t  I t rr t r  .1, 
and specifically Dr. Hendrickson, Dr. Loveless, Dr. O'Donnell, and Dr. oldenhauer. Plaintiff 
ay also rely on experts ho Plaintiff is at this ti e not required under the Idaho Rules of Civil 
r r   t  i l  t t i  ti . 
I  . 15 (sic; 161: ith respect to the allegations in the econd 
ause of ction in our o plaint that S  failed to provide adequate arnings and 
instructions for the Product, please state: 
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A Describe in detail how You contend any instructions or warnings of SEC for
the Product were inadequate
B Describe in detail what warnings and instructions should have been given but
were not in order to make the Product reasonably safe for its intended use
C Identify all Documents on which You rely to support this contention and
D Identify all persons on whom You rely to support this contention
ANSWER TO INTERROGATORY NO 16 Plaintiff objects to Interrogatory No
16 to the extent that it requires the disclosure of experts with whom Plaintiffs counsel may have
consulted with in forming trial strategy who are not required by the IRCP 26 to be disclosed
unless and until it is determined that those experts will provide expert testimony at trial Until
such time Plaintiff objects on attorney work product grounds Without waiving any privileges or
objections Plaintiff maintains that at all times mentioned in her complaint the Defendant was
negligent in failing to provide adequate warnings and instructions to the consumer including
Ms Major such that Sabre Red OC Spray was unreasonably dangerous and hazardous with
respect to its foreseeable and intended use within prison facilities such as IDC Said warnings
should have consisted of a warning that Sabre Red OC Spray should only be used for training
officers who do not have a history of respiratory illness such as chronic asthma or bronchitis or
other health problems that may make the officer more susceptible to injury by Sabre Red OC
Spray Said warnings should have consisted of a warning expressing what types of symptoms
officers should be cognizant of as requiring medical attention Said warnings should have
consisted of a warning that the use of a strong irritant such as Sabre Red OC Spray may cause
respiratory illness such as RADS chronic cough syndrome vocal cord dysfunction esophageal
dysmotility and reflux and that it may act as an aggravating factor for those who may already
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. es ribe in  h  ou contend a  instructions r arnings of  for 
the Product ere inadequate; 
. es ribe in  hat arnings a  instructions s ld a e ee  , t 
ere not, in order to ake the Product reasonably safe for its intended use; 
. I tif  ll ocu e ts  ic   rel  t  s rt t is t ti ;  
. Identify all persons on ho  ou rely to support this contention. 
  INTER  . :  e ts  t  . 
16 to the extent that it requires the disclosure of experts ith ho  Plaintiffs counsel ay have 
consulted ith in for ing trial strategy ho are not required by the I  26 to be disclosed 
unless and until it is deter ined that those experts ill provide expert testi ony at trial. ntil 
s c  ti e, lai tiff jects  att r e  r  r ct r s. ith t ai i  a  ri ileges r 
objections, Plaintiff aintains that at all ti es entioned in her co plaint, the efendant as 
negligent in failing to provide adequate warnings and instructions to the consumer, including 
s. ajor, such that Sabre ed  Spray as unreasonably dangerous and hazardous ith 
respect to its foreseeable and intended use ithin prison facilities such as I C. Said arnings 
should have consisted of a arning that Sabre ed  Spray should only be used for training 
officers ho do not have a history of respiratory illness, such as chronic asth a or bronchitis, or 
other health proble s that ay ake the officer ore susceptible to injury by Sabre Red OC 
Spray. Said arnings should have consisted of a arning expressing hat types of sy pto s 
officers should be cognizant of as requiring edical attention. i   l   
consisted of a arning that the use of a strong irritant such as Sabre Red C Spray ay cause 
respiratory illness such as S, chronic cough syndro e, vocal cord dysfunction, esophageal 
dys otility and reflux, and that it ay act as an aggravating factor for those who ay already 
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have one or more of those medical conditions Instructions should have been included clearly
defining the safe use of the product and further warning against use within confined areas
chronic exposure and prolonged periods of exposure
SUPPLEMENTAL ANSWER TO INTERROGATORY NO lbsic15 Plaintiff
supplements her Answer To Interrogatory No 16sie5by stating
A Plaintiff maintains that the Sabre Red OC Spray manufactured by Defendant was
unreasonably dangerous and defective in that it utilized a concentration of major capsaicinoids in
its product that was far in excess of what is reasonably safe for either acute or chronic human
exposure Defendant knew or should have known that the excessively high potency of Sabre Red
OC Spray was grossly in excess of what is reasonably safe for use within closed environments
such as within the IDC Such a potent concentration of capsaicinoids posed a risk of serious
harm to prison guards such as Ms Major Defendant knew or should have known that its
product posed a serious risk of harm to prison guards like Ms Major because it expressly
marketed its product to prison facilities such as IDC The Defendantsproduct is marketed and
sold with no warnings or cautions as to the dangers posed by long term exposure to it product or
to the dangers posed by direct exposure during training in closed environments such as within a
prison building In fact few warnings or cautions are provided with the product There is a
general warning to keep the product out of the hands of children a warning that the product is
only to be used for self defense purposes and another general warning stating The contents are
dangeroususe with caution The following statements are also made on the side of the canister
Caution Avoid discharge into headwinds or shield face to prevent
blowback exposure Do not discharge at distances less than three
feetmay cause injuries to soft body tissue Test fire
periodically to assure performance and familiarity of spray pattern
DO NOT puncture or incinerate can DO NOT expose to heat or
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ha e e r ore  those e ical iti . nstructions s l  a e  i lude  l l  
defining the safe use of the product, and further waming against use within confined areas, 
chronic exposure, and prolonged periods of exposure. 
L S E   TE  . 6(sic;15): lai tiff 
supple ents her ns er To Interrogatory o. 16(sic; is) by stating: 
. l i ti  aintains t at t e re    a t re   t a  
unreasonably dangerous and defective in that it utilized a concentration of ajor capsaicinoids in 
its product that as far in excess of hat is reasonably safe for either acute or chronic hu an 
exposure. Defendant knew or should have known that the excessively high potency of Sabre Red 
OC Spray was grossly in excess of what is reasonably safe for use within closed environ ents 
such as ithin the I . Such a potent concentration of capsaicinoids posed a risk of serious 
al  t  ris  ar s s c  as s. aj r.         
product posed a serious risk of harm to prison guards like s. ajor because it expressly 
r t  its r t t  ris  f ilities s  s I .  f ndant's r t is r t   
sold ith no arnings or cautions as to the dangers posed by long ter  exposure to it product, or 
to the dangers posed by direct exposure during training in closed environ ents such as ithin a 
prison building. I  fact fe  ami s r ca ti s are r i e  it  t e r uct. ere is a 
general aming to keep the product out of the hands of children, a aming that the product is 
only to be used for self-defense purposes, and another general aming stating "The contents are 
dangerous-use with caution." The following state ents are also ade on the side of the canister: 
aution:  void discharge into head inds or shield face to prevent 
blo -back exposure. o not discharge at distances less than three 
feet-ma  ca se i j ries t  s ft  tiss e. t fi  
periodically to assure perfor ance and fa iliarity of spray pattern. 
 T puncture or incinerate can.  T expose to heat or 
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store above 120 degrees F DO NOT uses after canisters
expiration date It is the user responsibility to keep the canister
from accidently firing
There is also a warning on the front of the canister stating CAUTION SEVERE SKIN
AND EYE IRRITANT CONTENTS UNDER PRESSURE SEE OTHER WARNINGS ON
BLACK LABEL The warnings are inadequate See Complaint
The instructions on how to use the product are inadequate as they only describe how to
spray the product into the face of an attacker and when to deploy the next appropriate force
option Defendant knew its product was being used within prisons for purposes of training but
provided no instruction on the use of its product under those circumstances Additional
instructions are provided for decontamination after deploying the Defendantsproduct but
there are no instructions as to how to avoid chronic exposure within the confines of a working
prison facility
Plaintiff relies on the medical records and opinions of her medical healthcare providers
which have previously been produced to the Defendants in discovery
Plaintiff relies on the medical providers identified in her Answer to Interrogatory No 1
and specifically Dr Hendrickson Dr Loveless DrODonnell and Dr Moldenhauer Plaintiff
may also rely on experts who Plaintiff is at this time not required under the Idaho Rules of Civil
Procedure 26 to disclose at this time
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st re a e 0 e rees .   s  t r ister's 
expiration date. It is the user's responsibility to keep the canister 
fro  i tl  i i . 
here is als  a arning  t e fr t f t e ca ister stati  "CAUTIO   I  
 E I .      R INGS  
 EL." he arnings are i a e ate. ee lai t. 
he instructions on ho  to use the product are inadequate as they only describe ho  to 
s ra  t e r ct i t  t e face f a  attac er a  e  t  e l  t e e t a r riate f rce 
option. efendant kne  its product as being used ithin prisons for purposes of training but 
provided no instruction on the use of its product under those circu stances. itio l 
instructions are provided for "deconta ination" after deploying the efendant's product but 
Ulere are no instructions as to ho  to avoid chronic exposure ithin the confines of a orking 
prison facility. 
Plaintiff relies on the edical records and opinions of her edical healthcare providers, 
which have previously been produced to the Defendants in discovery. 
Plaintiff relies on the edical providers identified in her ns er to Interrogatory o.1, 
and specifically r. endrickson, r. Loveless, r. 'Donnell, and r. oldenhauer. Plaintiff 
ay also rely on expelts ho laintiff is at this ti e not required under the Idaho ules f ivil 
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DATED this day of 2010
OBJECTIONS IF ANY BY
JONES SWARTZ PLLC
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I BILLIE JO MAJOR being first duly sworn depose and state that I am the Plaintiff in the
above entitled action that I have read the above and foregoing First Supplemental Answers to
DefendantsFirst Set of Interrogatories and that I believe the facts therein stated to be true and
correct to the best ofmy knowledge information and belief
BILLIE JO MAJOR
SUBSCRIBED AND SWORN TO before me this 24 day of June 2010
y F 5a Notary Public for Idaho
My Commission expires I S 12
9T rip
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VE IFICATION 
S TE F ID . ) 
: s . 
County of Ada ) 
I, BILLIE 10 AJOR, being first duly sworn, depose and state that I am the Plaintiff in the 
above-entitled action, that I have read the above and foregoing First Supple ental ns ers to 
efendant's First Set of Interrogatories, and that I believe the facts therein stated to be true and 
correct to the best of y kno ledge, infor ation and belief. 
I IE J  J  
I     ef re e t is 4th a  f J e, . 
k'.1/~ ,4 LJt ~c.4wu~ j 
t  li    
y o ission expires: --,-1_. 9=--....!.·/.::!..?~ __ _ 
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CERTIFICATE OFSERVICE
I HEREBY CERTIFY that on this 7z day o 2010 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
GREENER BURKE SHOEMAKER PA
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CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that on this ZS= day ~o, a true and co rect copy of 
the foregoing document was served on the following individual(s) by the method indicated: 
Christopher C. Burke 
GREENER BURKE SHOE AKER P  
950 . Bannock Street, Suite 900 
Boise, ID 83702 
N- .S. il 
[ ] Fa : 319-2601 
[ ] Overnight Delivery 
[ ] Me senger elivery 
}><i E : cburke re nerlaw.com 
<Zm ~~ h -- I  . ERS  
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Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
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CHRISTOPHER D RICH Clerk
By CARLY LATIMORE
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA




CORPORATION a Missouri corporation
Defendant
CaseNo CVPI 1003515
MEMORANDUM IN SUPPORT OF
DEFENDANTSMOTION FOR
CLARIFICATION
Defendant Security Equipment Corporation SEC by and through its counsel of
record Greener Burke Shoemaker PA pursuant to Idaho Rule of Civil Procedure 7b
respectfully submits this Memorandum in Support of its Motion asking this Court to clarify its
ruling at the September 15 2011 hearing on SECsSecond Motion for Summary Judgment and
PlaintiffsMotion to Reconsider For the reasons set forth herein SEC believes and seeks
confirmation that this case ought to be now adjudicated in its entirety with no remaining issues
left for trial
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hristopher C. urke, IS  #2098 
Thomas J. Lloyd III, IS  #7772 
GREENER RKE ER P  
950 . annock treet, Suite 900 
oise, Idaho 83702 
el: (208) 319-2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
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I  . I , l r  
 e  L I  
D!!1"UTY 
I   IS I       IS    
  I , I        
I LIE J  J , an individual, 
laintiff, 
v. 
SECURITY EQUIP ENT 
CORPORATION, a issouri corporation, 
ant. 
 .: - I-  
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Defendant Security Equip ent Corporation ("SEC"),       
record, Greener Burke Shoemaker P.A., pursuant to Idaho Rule of Civil Procedure 7(b), 
respectfully submits this emorandum in Support of its otion asking this Court to clarify its 
ruling at the Septe ber 15,2011 hearing on SEC's Second otion for Su ary Judg ent and 
laintif s ti  t  consider. r t   t t  rein,  li  a   
confir ation that this case ought to be no  adjudicated in its entirety, ith no re aining issues 
f   trial. 
III 
III 
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I PROCEDURAL BACKGROUND
As the Court is well aware this action arises out of Plaintiffslimited exposure to
products manufactured by SEC specifically oleoresin capsicum OC products also known as
pepper spray Through the course of her employment and training with Idaho Department of
Corrections IDOC Plaintiff was exposed to SECs OC products in addition to OC products
manufactured by other manufacturers
Following disciplinary action by IDOC that resulted in her termination Plaintiff
instituted the present action against SEC She has a parallel action pending before the Idaho
Industrial Commission against her former employer IDOC In her Complaint in this action
Plaintiff asserted causes of action for strict liability and for failure to provide an adequate
warning on its OC products Throughout the life ofthis litigation Plaintiff has alleged that her
exposure to OC resulted in longterm andor chronic respiratory illnesses manifested by a
chronic cough and a number of other chronic health problems Plaintiff has never based her
claims against SEC on injuries that were temporary or acute reactions to her exposure to OC
Following motion practice by SEC asserting that SEC as a matter of law did not have a
duty to warn against unknown or unforeseeable longterm andor chronic health effects of
exposure to OC summary judgment was granted in favor ofSEC on all causes of action asserted
by Plaintiff At the conclusion ofthe most recent hearing held on September 15 2011 after this
Courtsruling on the record that Plaintiff had failed to establish that SEC owed Plaintiff any duty
to warn against those injuries actually alleged by Plaintiff in a lastditch effort to keep the case
alive Plaintiff reversed direction and suddenly began claiming that her case was based on the
acute temporary reaction to SECsOC products Because Plaintiff had never based any claims
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I. P  GROUND 
s the ourt is e l , this  arises t f intif  s limited s re t  
products anufactured by SEC, specifically oleoresin capsicu  ("OC") , s    
"pepper s ray." r  the c rse f er e l e t a  trai in  ith I a  e art e t f 
o rections ("IDOC"), Plaintiff as exposed to S C's  products, in addition to  products 
anufactured by other anufacturers. 
Following disciplinary action by IDOC that resulted in her ter ination, Plaintiff 
instituted the present action against S . She has a parallel action pending before the Idaho 
Industrial o ission against her for er e ployer, I .     s ti , 
l i tiff ss rt  s s f ti  f r stri t li ilit   f r f il r  t  r i   t  
warning on its OC products. Throughout the life of this litigation, Plaintiff has alleged that her 
exposure to DC resulted in long-ter  and/or chronic respiratory illnesses, anifested by a 
chronic cough and a number of other chronic health problems. l i tif      
claims against SEC on injuries that were temporary or acute reactions to her exposure to ~C. 
Following otion practice by SEC, asserting that SEC as a atter of law did not have a 
duty to warn against unknown or unforeseeable long-term and/or chronic health effects of 
exposure to ~C, summary judgment was granted in favor of SEC on all causes of action asserted 
by Plaintiff. At the conclusion of the most recent hearing, held on September 15,2011, after this 
Court's ruling on the record that Plaintiff had failed to establish that SEC owed Plaintiff any duty 
to arn against those injuries actually alleged by Plaintiff, in a last-ditch effort to keep the case 
alive, Plaintiff reversed direction and suddenly began clai ing that her case as based on the 
acute, temporary reaction to SEC's OC products. Because Plaintiff had never based any claims 
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in this action on alleged acute or temporary reactions to exposure to OC spray but has instead
repeatedly taken the position that her Complaint was based on alleged longterm chronic
injuries and that she was well informed of the acute health risks of exposure to OC spray
Plaintiff should be judicially estopped from altering her position so significantly at this stage in
order to keep her case alive Accordingly SEC respectfully requests that this Court clarify that
Plaintiffscase has in fact been resolved in its entirety
II STATEMENT OF PERTINENT FACTS
Throughout this litigation Plaintiff has based her claims against SEC on alleged chronic
andor longterm injuries which Plaintiff asserts are the result of her limited exposure to SECs
OC products Originally in her Complaint Plaintiff pled
11 After the approximately twoandahalfhour Sabre Red OC
Spray training on March 3 2008 Ms Major experienced a
worsening of her cough that did not resolve She was taken off
work by her doctor on March 4 2008 and has been unable to
return ever since Over time her cough became even more
continuous and debilitating She is unable to sleep her lungs
continuously feel as though they are on fire she has coughing
spells so intense that she damaged her ribs and has become
permanently disabled and unable to work Ms Major cannot
exercise or exert herself in any way and has suffered severe
weight gain as a result Severe coughing is triggered merely by
talking The excessive coughing causes Ms Major nausea leading
to vomiting headaches and dizziness and great anxiety and
depression At times the coughing is so violent that Ms Major
passes out
Complaint and Demand for Jury Trial filed in this action on February 4 2010 Complaint
11 emphasis added
Plaintiff proceeds to allege in Paragraph 13 ofher Complaint that nine 9 days after her
March 3 2008 exposure on March 12 2008 she was referred to Dr Hendrickson a pulmonary
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i  t is ti   lle e  t   t  tions t   t   r y, t  i t  
r t l  t  t e iti  t at r l i t    ll  l -ter , r i  
i j ri s,  t t s  as ll-i f r  f t  t  lt  ris s f s r  t   s r y, 
lai tiff s l  e j iciall  est e  fr  alteri  er siti  s  si ifica tl  at t is sta e i  
     . i l ,  ctf l  ests  s  ri  t 
Plaintiffs case has, in fact, been resolved in its entirety. 
.    S 
hroughout this litigation, laintiff has based her clai s against  on alleged chronic 
and/or long-ter  injuries, hich Plaintiff asserts are the result of her li ited exposure to S C's 
 r ts. ri i ally, i  r l i t, l i tiff l d: 
. fter t e a r i atel  t -an -a-half r a re e   
ra  trai i ,  arc  , 8, s. aj r e erie ce  a 
orsening f her cough that did not resolve. he as taken off 
ork by her doctor on arch 4, 2008, and has been unable to 
  . ver ti e her cough beca e even ore 
continuous and debilitating. She is unable to sleep, her lungs 
continuously feel as though they are on fire, she has coughing 
s ells s  i te se t t s e e  er ri s  s ec e 
er e tly is le   le to rk. s. aj r ca t 
exercise or exert herself in any ay, and has suffered severe 
eight gain as a result. Severe coughing is triggered erely by 
talking. The excessive coughing causes s. ajor nausea leading 
to vo iting, headaches and dizziness, and great anxiety and 
e ression. t ti es, t e c i  is s  i le t t at s. aj r 
passes out. 
(Co plaint and e and for Jury Trial, filed in this action on February 4,2010 ("Co plaint"), ~ 
11 (e phasis added).) 
lai tiff r cee s t  alle e, i  ara ra  13 f er laint, t at i e (9) a s after er 
arch 3, 2008 exposure, on arch 12,2008, she as referred "to r. endrickson, a pul onary 
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physician to evaluate her chronic severe cough Complaint 13 emphasis added
Paragraph 13 further describes a litany of tests that were performed over the course of the
following year ultimately resulting in a suspected diagnosis of Reactive Airway Dysfunction
Syndrome RADS a longterm andorchronic illness Id The Complaint alleges further
that Dr Hendrickson referred Ms Major to the National Jewish Health Hospital for further
evaluation ofher chronic cough Id 14 emphasis added These injuries chronic and long
term in nature are the injuries for which Plaintiff seeks damages in Paragraphs 17 and 20 of her
Complaint
Indeed in setting forth the Second Cause of Action those warnings that Plaintiff alleges
ought to have been included in the labeling of the OC spray Plaintiff focuses entirely on
warnings against longterm andor chronic respiratory injuries Said warnings should have
consisted of a warning that the use of a strong irritant such as Sabre Red OC spray may cause
respiratory illness such as RADS chronic cough syndrome vocal cord dysfunction esophageal
dysmotility and reflux and that it may act as an aggravating factor for those who may already
have one or more of those medical conditions Complaint 19 In contrast at no point
throughout her Complaint does Plaintiff describe or otherwise emphasize alleged injuries
resulting from the known acute health effects associated with exposure to OC See generally
Complaint
Plaintiff continues to assert her allegations of longterm chronic adverse health effects as
a result of her exposure to SECsOC products through discovery As Plaintiff self describes her
own injuries and claims they are chronic and longterm in nature Almost immediately upon
being exposed to OC spray on May 3 2008 Plaintiff started experiencing a chronic cough that
MEMORANDUM IN SUPPORT OF DEFENDANTSMOTION FOR CLARIFICATION Page 4
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i i n,      ough." (Co plaint, ~ 13 (e phasis added).) 
  t  i   "litan   t sts" t t  r   t    t  
f ll i  r, lti t l  r sulti  i   s s t  i sis f cti  ir  sf ti  
r e ("RADS"), a l -ter  and/or c r ic ill ess. (I ) e lai t alle es f rt er 
t t "D . i s   . j  t  t  ti l i  lt  it l r f t  
l ti    i  h. (Id, ~ 14 (e phasis added).) hese injuries, chronic and long-
t r  i  t r , r  t  i j rie  f r i  l i tiff   i  r r     f r 
o plaint. 
I ed, i  s tti  f rt  t   s  f ti , t s  r i s t t l i tiff ll s 
t t  a e ee  i cl e  i  t e la eli  f t e  s ray, lai tiff f c ses e tirel   
ar i s a ai st l -ter  and/or c r ic res irat r  i j ries: "Sai  ar ings s l  a e 
i t    i  t t t     t  i ita t         
r ir t r  illness   , r i   r , l r  f nction, l 
s tilit  a  refl , a  t at it a  act as a  a ra ati  fact r f r t se  a  alrea  
   re  t  i l nditions." (Co l i t, ~ 19.) In contrast, at no point 
throughout her o plaint does Plaintiff describe or other ise e phasize alleged injuries 
r s lti  fr  t  , t  lt  ffe ts ss i t  it  s r  t  . (See e erally, 
plaint. ) 
Plaintiff continues to assert her allegations of long-ter , chronic adverse health effects as 
 r s lt f r s r  t  C's  r ts t r  is ry. s l i tiff s lf- s ri es r 
 i juries a  clai s, t e  are c r ic a  l -ter  i  at re: "Almost i e iatel   
being exposed to  spray on ay 3, 2008, Plaintiff started experiencing a chronic cough that 
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has worsened ever since After months of medical screening Plaintiffsmedical providers have
concluded that the Plaintiffsinjuries were the result of occupational exposed to OC spray
PlaintiffsSupplemental Answer to Interrogatory No 14 Plaintiffs Supp Ans a true and
correct copy of which is attached as Ex C to the Affidavit of Counsel filed herewith emphasis
added
Also telling about the reality of Plaintiffsclaims is the Complaint she has filed with the
Industrial Commission in connection with her workerscompensation claim against her former
employer for the same injuries According to that Complaint when asked to describe how her
injury or occupational disease occurred Plaintiff claims chronic exposure and acute exposure to
pepper spray caused a severe chronic coughing condition Deposition ofBillie Jo Major taken
in these proceedings on January 6 2011 Major Dep Ex 20 thereto WorkersCompensation
Complaint a true and correct copy of which is attached as Ex A to Affidavit of Counsel
Moreover when asked to describe the nature of the medical problems alleged as a result of the
accident or occupational disease Plaintiff alleges severe chronic coughing condition Coughing
to the extent of passing out Coughing continuously Id Plaintiff describes the issues
involved in her workerscompensation case as
1 Whether claimantschronic cough condition qualifies as
permanent disability
2 Whether claimantschronic cough condition qualifies as an
occupational disease
3 Whether claimantschronic cough condition was a work
place injury
Id While each of these allegations was made in Plaintiffsparallel WorkersCompensation
Complaint she confirmed during her deposition that the aforementioned statements accurately
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has orsened ever since. fter onths f edical screening, laintiffs edical providers have 
concluded that the laintiffs injuries ere the result of occupational exposed to  spray." 
(Plaintiffs Supple ental ns er to Interrogatory o. 14 ("Plaintiffs Supp. ns."),    
rr t  f i  is tt  s x.  t  t  ffid it f s l file  r it  (e phasis 
added).) 
lso telling about the reality f laintiff s clai s is the o plaint she has filed ith the 
I tri l i i , i  ti  it  r rker's ti  l i  i t r f r r 
e ployer for the sa e injuries. ccording to that o plaint, hen asked to describe ho  her 
injury or occupational disease occurred, Plaintiff clai s "chronic exposure and acute exposure to 
pepper spray caused a severe chronic coughing condition." (Deposition of Billie Jo ajor, taken 
in these proceedings on January 6, 2011 ("Major ep."); Ex. 20 thereto (Worker's o pensation 
plaint),  tr   rr t  f i  is tt  s x.  t  ffi it f nsel.) 
re er, e  as e  t  escri e t e at re f t e e ical r le s alle e  as a res lt f t e 
accident or occupational disease, laintiff alleges "severe chronic coughing condition. oughing 
to the extent of passing out. i  ntinuously." (I .) l i ti     
involved in her orker's co pensation case as: 
. hether clai ant's chronic cough condition qualifies as 
per anent disability 
. hether clai ant's chronic cough condition qualifies as an 
occupational disease 
. hether clai ant's chronic cough condition as a ork 
place injury 
(Id.) hile each of these allegations as ade in Plaintiff s parallel orker's o pensation 
Co plaint, she confir ed during her deposition that the afore entioned state ents accurately 
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described her claims in this action as well Major Dep at 25212537 Ex B to Affidavit of
Counsel
Most significantly Plaintiff has confirmed in her recent filings opposing SECsMotions
for Summary Judgment and in support of her own Motion for Reconsideration that her claimed
injuries in this action are specifically limited to longterm chronic adverse health effects andor
illnesses Plaintiff own very first statement of undisputed facts in her Opposition to SECs
first Motion for Summary Judgment and in support of her own Cross Motion for Partial
Summary Judgment states the following
1 Plaintiff Billie Jo Major Ms Major or Plaintiff was
at the time of the filing of this action a resident of Ada County
Idaho Ms Major claims that she suffered injuries following
exposure to oleoresin capsicum OC spray also referred to as
pepper spray during the training sessions she was attending as an
employee of the IDOC She specifically claims that she suffers
from a longterm or chronic respiratory illness such as chronic
cough syndrome R4DS vocal cord dysfunction esophageal
dysmotility andor gastrointestinal reflux andor a longterm
chronic aggravation or exacerbation of an existing health
condition as a result of her exposure to OC spray
PlaintiffsOpposition to DefendantsMotion for Summary Judgment p 2 emphasis added
By Plaintiff and her counselsown assertions this case is and always has been specifically
about a longterm or chronic respiratory illness alleged by Plaintiff By Plaintiffsown
statement this is an undisputedfact
Finally and most recently Plaintiff herself has submitted an affidavit that explains well
why she brought her claims alleging longterm andorchronic injuries See generally Affidavit
of Plaintiff in Support of Motion to Reconsider Major Aff In that affidavit Plaintiff
explains thatwhile working at IDOC she developed a chronic cough Major Aff at 13
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s ri  r l i s i  t is ti , s ll. (Major . t 52:21- 53:7, x.  t  ffida it f 
nsel.) 
ost significantly, laintiff has confir ed in her recent filings opposing EC's otions 
f r ar  J e t a  i  s rt f er  ti  f r ec si erati  t at er clai e  
injuries in this action are specifically li ited to long-ter , chronic adverse health effects and/or 
illnesses. Plaintiffs o n very first state ent of undisputed facts, in her pposition to SEC's 
first ti  f r ar  J e t a  i  s rt f er  r ss- ti  f r artial 
Su ary Judg ent, states the follo ing: 
. Plaintiff Billie Jo ajor ("Ms. ajor" or "Plaintiff') as, 
at t e ti e f t e filin  f t is acti n, a resi e t f a nty, 
I . s. j r l i s t t s  s ff r  i j ri s f ll i  
e s re t  le resi  ca sic  ("O ") s ray, als  referre  t  as 
pepper spray, during the training sessions she was attending as an 
e ployee of the I . She specifically clai s that she suffers 
fro  a long-term or chronic respiratory illness, such as chronic 
cough syndro e, ADS, vocal cord dysfunction, esophageal 
dys otility and/or gastrointestinal reflux, and/or a long-ter  
chronic aggravation or exacerbation of an existing health 
condition, as a result of her exposure to  spray. 
(Plaintiffs pposition to efendant's otion for u ary Judg ent, p. 2 (emphasis added).) 
y Plaintiff and her counsel's o n assertions, this case is and al ays has been "specifically" 
about a long-ter  or chronic respiratory illness alleged by Plaintiff. By Plaintiffs o n 
state ent, this is an undisputed fact. 
Finally, and ost recently, Plaintiff herself has sub itted an affidavit that explains ell 
 s  r t r l i s ll i  l -ter  nd/or r i  i j ri s. (S  nerally, ffi it 
of Plaintiff in Support of otion to Reconsider ("Major ff.").)   ff vit, l i ti  
explains that "[w]hile working at IDOC, [she] developed a chronic cough." (Major Aff. at ~ 3.) 
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As Plaintiff describes it then she developed that chronic cough prior to the March 3 2008
exposure to OC spray but was nevertheless able to continue caring for herself and participate in
recreational activities as she had done before Id Then Plaintiff testifies that she participated
in an OC spray training session on March 3 2008 during which she experienced a strong
burning sensation in her lungs and could not stop coughing Id Plaintiff does not go on to
describe the damages or injuries she suffered as a result of that immediate reaction but rather
only mentions her immediate reaction to set the scene for her allegations of a longterm chronic
condition The coughing continued even after the training When the coughing continued into
the next day I went to my doctor and was placed on medical leave Id Thereafter Plaintiff
made perhaps the most telling admission relevant to this present Motion
Had I known that the kind of exposure I was going to receive
posed a risk of the kind of chronic respiratory injuries I suffered I
would have refused to participate but I was assured by all the
training materials I had prior to and during the training that any
affects of OC spray were purely temporary and did not pose a
health risk
Id Plaintiff was clearly informed of knew about and appreciated the acute and temporary
adverse health effects of exposure to OC but nevertheless chose to proceed with the training
The remainder of Plaintiffsaffidavit focuses entirely on her alleged chronic or longterm
adverse health reactions and illnesses
In paragraph 7 of her affidavit keeping in mind that she has already testified that she was
and had been well informed of the acute and temporary health effects of exposure to OC
Plaintiff asserts that had she been informed of the health risks associated with OC spray in the
MK9 Fogger in particular she would have insisted that she be permitted to opt out of the
March 3 2008 training and would have taken steps to protect herself Id 7 Logically as
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 l i tif  i  it, t   l  t t r i   i  t  t   ,  
r  t   r y, t  rt eles  l  t  ti  ri  f r r lf  rti i t  i  
r r ti l ti itie      f re. (/ ) , l i tiff t tifi  t t  rti i t  
i    s r  tr i i  s ssi   r  , 8, ri  i  s  "experienc   str  
r i  se sati  i  [her] l s a  c l  t st  c ughing." (/ ) lai tiff es t   t  
describe the da ages or injuries she suffered as a result f that i ediate reaction, but rather 
l  ti  r i i t  r ti  t  t t   f r r ll ti  f  l -ter , r i  
c diti : "The c i  c ti e  e e  after t e trai i . e  t e c i  c ti e  i t  
t  t y,  t t   t    l   i l l ave." (I ) after, l i ti  
 r s t  t t lli  i i  r l t t  t i  r t ti : 
 I  t t t  i  f s r  I s i  t  r i  
se  a ris  f t e i  f c r ic res irat r  i j ries I s ffered, I 
ould have refused to participate, but I as assured by all the 
trai i  aterials I a  ri r t  a  ri  t e trai i  t at a  
affects f  s ra  ere rel  te rar  a  i  t se a 
ealt  ris . 
(Id) l i tiff as l rl  i for e  f,  ut,  r i t d, t  t   t r r  
adverse health effects f exposure to , but nevertheless chose to proceed ith the training. 
 r i r f l intiffs ffi it f s s tir l   r lle  r i  r l -ter  
 lt  ti   illne s. 
In paragraph 7 of her affidavit, keeping in ind that she has already testified that she as 
   ll-infor ed  t  t   t r r  lt  ff t   r  t  , 
lai tiff asserts t at, "had [ she] ee  i for e  f t e ealt  ris s ass ciate  it   s ra  i  t e 
-9 ogger, in particular, [she] ould have insisted that [she] be per itted to opt out of the 
arch 3, 2008 training and ould have taken steps to protect [herself]." (/d, ~ 7.) ogically, as 
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she knew well the acute effects ofOC spray the health risks that she discusses in her affidavit
are those same chronic andorlongterm health effects and only those chronic andorlongterm
health effects that Plaintiff has claimed since the inception of this case
Plaintiff concludes her affidavit again acknowledging that OC spray would cause
irritation and inflammation of the respiratory tract and confirms that she was always told and
in everything she read that those effects were purely temporary Id 7 Following
confirmation that she had been informed of those temporary health risks Plaintiff makes the
following statement
I was not informed in any manner during my employment at IDOC
that exposure to OC spray could put me at risk for the kinds of
respiratory illnesses that I have sustained Had I been informed of
those risks and exposure could not be avoided while still doingmy
job I would have found a different job rather than risk aggravating
my respiratory problems any further
Id emphasis added Thus as Plaintiff claims that she was informed of the temporary effects
ofOC and simultaneously asserts that she was not informed of the kinds of respiratory illnesses
that she claims to have sustained it is evident that the kinds of respiratory illnesses that this
case was about had nothing to do with acute or temporary reactions to OC
Notably the parties have now been through two separate rounds of summary judgment
motions filed by SEC both ofwhich sought explicitly to resolve all of the issues in this litigation
and to obtain judgment as a matter of law in SECsfavor At no point until the final disposition
of those motions for summary judgment did Plaintiff ever claim that full summary judgment was
not appropriate based on some acute injuries upon which SEC had not properly moved for
summary judgment Even the commentary from both Plaintiffscounsel and the Court during
the hearing on SECsfirst Motion for Summary Judgment evidences that all parties have been
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  ll t  t  ff t  f  r y, t  "healt  ri ks" t t  i s  i  r ffi it 
r  t s  s  r i  nd/or l -ter  lt  ff ts,  l  t s  r i  nd/or l -ter  
ealt  effects, t at lai tiff as clai e  si ce t e i ce tion f t is case. 
Plaintiff concludes her affidavit again ackno ledging "that  spray ould cause 
irritatio   i fla ti   t  r ir t r  tract,"  fir  t t   "always t l ,  
in everything [she] read, that those effects ere purely te porary." (I ., 1 .) ll i  
c fir ati  t at s e a  ee  i for e  f t se te rar  ealt  ris s, lai tiff a es t e 
follo ing state ent: 
I as not infor ed in any anner during y e ploy ent at I  
that exposure to  spray could put e at risk for the kinds f 
respiratory illnesses that I have sustained. ad I been infor ed of 
those risks, and exposure could not be avoided hile still doing y 
job, I ould have found a different job rather than risk aggravating 
y respiratory proble s any further. 
(Id. (emphasis added).) Thus, as Plaintiff clai s that she as infor ed of the te porary effects 
f  a  si lta e sl  asserts t at s e as not infor ed f t e kinds f respiratory illnesses 
that she clai s to have sustained, it is evident that "the kinds of respiratory illnesses" that this 
case as about had nothing to do ith acute or te porary reactions to ~C. 
otably, the parties have no  been through t o separate rounds of su ary judg ent 
otions filed by S , both of hich sought explicitly to resolve all of the issues in this litigation 
 t  t i  j e t s  tt r fl  i  EC's f or. t  i t til t  fi l is siti  
f those otions for su ary judg ent did laintiff ever clai  that full su ary judg ent as 
not appropriate based on so e acute injuries upon hich S  had not properly oved for 
su ary judg ent. Even the co entary fro  both Plaintiff s counsel and the ourt during 
the hearing on SEC's first otion for Su ary Judg ent evidences that all parties have been 
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litigating and the Court has been deciding a case about alleged longterm chronic respiratory
injuries Plaintiff counsel spent a considerable amount of time during the hearing on SECs
first Motion for Summary Judgment trying to distance his expert affidavit from the idea that
the injuries sustained by his client were in fact merely acute The majority of the debate during
the hearing on SECsfirst Motion for Summary Judgment revolved around whether Plaintiffs
expert Dr Yost had sufficiently distinguished within his affidavit between the known acute
effects of exposure to OC and the alleged chronic effects of exposure to OC The Court
concluded at the hearing on SECsfirst Motion for Summary Judgment
The fact in this case is whether at the time Ms Majors
Ms Major was exposed to the capsacin sic or pepper spray
was there an unreasonable risk of the foreseeable injury that she
suffered in this case the chronic illness that she suffered as a
result And the emphasis really is on the chronic nature of her
illness
Thats the real issue at the time in 2008 would the
Defendant have known that there was this foreseeable danger to
people using that product
Mr Yost in response to the questions in the deposition
which I have read does not really address the real issue here
which was whether they would have known in 2008 when this
this product was marketed that there was this danger a foreseeable
risk of developing a chronic illness such as the Plaintiff developed
Hedoes not say chronic He says acute Thats what he
says
Transcript of hearing on SECs first Motion for Summary Judgment held July 14 2011
Transcript pp 7722821attached as Ex A to Affidavit of Thomas J Lloyd III in Support
of SECsMotion to Strike Portions of the Second Affidavit of Garold S Yost PhD Lloyd Aff
re Mot to Strike At the end of the hearing on SECsfirst Motion for Summary Judgment
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liti ti ,  t  rt s  ci i g,  s  t ll  l -ter , r i  r s ir t r  
i j ries. laintiffs c sel s e t a c si era le a t f ti e ri  t e eari   EC's 
first otion for u ary Judg ent trying to distance his expert's affidavit fro  the idea that 
t  i j ie  t i e   i  lie t , i  t, l  te.  j rit   t  t  i  
t  ri   EC's first ti  f r r  J t r l  r  t r laintiffs 
e ert, r. st, a  s fficie tl  istinguishe  it i  is affi a it et ee  t e  ac te 
effects of exposure to  and the alleged chronic effects of exposure to .   
concluded at the hearing on SEC's first otion for Su ary Judg ent: 
e fact i  t is case is et er at t e ti e s. aj rs --
s. ajor as exposed to the capsacin [sic] or pepper spray ... 
as there an unreasonable risk of the foreseeable injury that she 
f , i  t i  , t  i  illnes  t t     
sult. nd the e phasis really is on the chronic nature of her 
ln . 
at's t  r l i ; t t  ti  i   l  t  
f t   t t t r  s t is f r s l  r t  
e le si  t at r ct. 
r. ost in response to the questions in the deposition, 
i  I  r , ... does not really address the real issue here, 
hich as hether they ould have kno n in 2008 hen this --
this product as arketed that there as this danger, a foreseeable 
ris  f e el i  a c r ic illness s c  as t e lai tiff e el ed. 
[H]e does not say chronic. e says acute. hat's hat he 
says. 
(Transcript of hearing on SEC's first otion for Su ary Judg ent held July 14, 2011 
("Transcript"), . 7:22-82:1, attac e  as x.  t  ffida it f as J. l  III i  rt 
of C's otion to trike ortions f the econd ffidavit of arold  . ost h.D. ("Lloyd ff. 
: t.  e").) t the end of the hearing on SEC's first otion for Su ary Judg ent, 
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despite there having been much discussion about the known acute adverse health effects of
exposure to OC this Court ruled that the only remaining question left for trial or further motion
practice was whether Plaintiff had a cause of action under the Federal Hazardous Substances
Act Id at pp 8687 Plaintiffs counsel did not assert even at that point that there were any
allegations of acute injuries that were germane to Plaintiffsclaimed damages or for that matter
this case in general All of this goes to show that until September 15 2011 Plaintiff had pled
the parties had litigated and the Court had presided over a case about an alleged longterm
chronic respiratory illness
III ARGUMENT
The above litany of Plaintiffs own statements and admissions as well as those by her
counsel throughout the course of this litigation in large part make Defendantspresent argument
without the need for much additional analysis The simple truth of this case is that Plaintiff has
alleged damages and injuries based on her long lasting andor permanent condition that she
claims arises from her exposure to OC spray Nevertheless in the interest of being thorough
SEC presents the following more technical arguments as to why Plaintiffscase ought now to be
deemed adjudicated in full
A Plaintiff is Judicially Estopped from Proceeding on a Claim forAcute Injuries
As has been briefed previously in this action there are wellestablished principles of
Idaho law the prohibit a party from reversing position as Plaintiff has done here with her sudden
reversion to allegations of acute injuries
This Court adopted the doctrine of judicial estoppel in Loomis v
Church 76 Idaho 87 277 P2d 561 1954 In Loomis this Court
held that a litigant who obtains a judgment advantage or
consideration from one party through means of sworn statements is
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despite there having been uch discussion about the kno n, acute adverse health effects of 
exposure to , this ourt ruled that the only re aining question left for trial or further otion 
practice as hether Plaintiff had a cause of action under the Federal azardous Substances 
Act. (Id. at pp. 86-87.) Plaintiffs counsel did not assert even at that point that there were any 
allegations of acute injuries that ere ger ane to laintiffs clai ed da ages or, for that atter, 
this case in general. ll of this goes to sho  that until Septe ber 15, 2011, Plaintiff had pled, 
the parties had litigated, and the ourt had presided over a case about an alleged long-ter , 
chronic respiratory illness. 
II.  
  lita  f l i tiff s  st t ts  issi s, s ll s t s   r 
c sel, t r t t e c rse f t is litigati  i  lar e art a e efendant's rese t ar e t 
it t t   f r  iti l l sis.  si le tr t  f t is case is t at lai tiff as 
alleged da ages and injuries based on her long-lasting and/or per anent condition that she 
clai s arises fro  her exposure to  spray. evertheless, in the interest of being thorough, 
SEC presents the follo ing ore technical argu ents as to hy Plaintiff s case ought no  to be 
dee ed adjudicated in full. 
. Plaintiff is Judicially stopped fro  Proceeding on a lai  for cute Injuries 
s s  ri f  r i sl  i  t is ti , t r  r  ell- st lis  ri i les f 
Idaho law the prohibit a party from reversing position, as Plaintiff has done here with her sudden 
reversion to allegations of acute injuries: 
his ourt adopted the doctrine of judicial estoppel in Loo is v. 
Church, 76 Idaho 87, 277 P.2d 561 (1954). In Loo is, this Court 
held that a litigant ho obtains a judg ent, advantage, or 
consideration fro  one party through eans of s orn state ents is 
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judicially estopped from adopting inconsistent and contrary
allegations or testimony to obtain a recovery or a right against
another party arising out of the same transaction or subject matter
Judicial estoppel precludes a party from gaining an advantage by
taking one position and then seeking a second advantage by taking
an incompatible position The policies underlying judicial
estoppel are general considerations of the orderly administration of
justice and regard for the dignity of judicial proceedings Judicial
estoppel is intended to prevent a litigant from playing fast and
loose with the courts
Heine v Bauer 145 Idaho 232 235 178 P3d 597 600 2008 internal citations omitted
Plaintiff has previously taken the position in this litigation that the injuries about which
she complained are long term chronic injuries and not the wellknown and foreseeable acute
injuries that she has testified she was aware of during her employment with IDOC The purpose
ofPlaintiff previously taking that position arises from her need under her now dismissed theories
to distinguish the information that she was provided about the effects of OC as between acute
and chronic The context of Plaintiffs affidavit is that it was filed in support of her Motion for
Reconsideration which motion followed SECs first Motion for Summary Judgment As the
Court will recall in SECs first Motion for Summary Judgment SEC moved in part on the
concept that Plaintiffsknowledge ofthe adverse health effects ofexposure to OC including the
adverse respiratory health effects of exposure to OC resulted in an overall inability of Plaintiff
to meet the proximate cause element of her causes of action As SEC had argued because
Plaintiff was well aware of the adverse respiratory health effects of exposure to OC and because
she had not personally seen the canister of OC that was sprayed during the March 3 2008
training the alleged lack of an appropriate label on the OC product could not possibility be
determined by a reasonable juror to constitute a proximate cause ofPlaintiffsalleged injuries
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judicially estopped fro  adopting inconsistent and contrary 
allegations or testi ony, to obtain a recovery or a right against 
a t er part , arisin  t f the sa e transaction or s ject atter. 
Judicial estoppel "precludes a party fro  gaining an advantage by 
taking one position, and then seeking a second advantage by taking 
an inco patible position." he licies l i  ju icial 
estoppel are general considerations of the orderly ad inistration of 
justice and regard for the dignity of judicial proceedings. Judicial 
estoppel is intended to prevent a litigant fro  playing fast and 
ose ith the . 
einze v. Bauer, 145 Idaho 232, 235, 178 P.3d 597, 600 (2008) (internal citations o itted). 
Plaintiff has previously taken the position in this litigation that the injuries about hich 
she complained are long-term, chronic injuries, and not the well-known and foreseeable acute 
injuries that she has testified she as a are of during her e ploy ent ith I C. The purpose 
of Plaintiff previously taking that position arises fro  her need under her now-dis issed theories 
to distinguish the infor ation that she was provided about the effects of OC as between acute 
and chronic. he context f laintiffs affidavit is that it as filed in support f her otion for 
econsideration, hich otion follo ed SEC's first otion for Su ary Judg ent. s the 
ourt ill recall, in EC's first otion for u ary Judg ent,  oved, in part, on the 
concept that Plaintiffs knowledge of the adverse health effects of exposure to OC, including the 
adverse respiratory health effects of exposure to C, resulted in an overall inability of Plaintiff 
to eet the "proximate cause" ele ent of her causes of action. As SEC had argued, because 
Plaintiff as ell a are of the adverse respiratory health effects of exposure to , and because 
she had not personally seen the canister of OC that was sprayed during the March 3, 2008 
training, the alleged lack of an appropriate label on the OC product could not possibility be 
determined by a reasonable juror to constitute a proximate cause of Plaintiffs alleged injuries. 
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With that context in mind Plaintiff filed her affidavit to demonstrate that SECs
argument on proximate cause could not apply to her chronic longterm injuries because as her
argument reads she would have opted not to go through with the training if she had been
informed of those longterm andor chronic adverse health effects Implicit in her argument
then is an acknowledgement that SECsargument regarding proximate cause could only apply
to the adverse health effects ofwhich she was informed the acute and temporary health effects
of exposure to OC With that in mind SEC incorporates and restates the entire argument on
proximate cause as set forth in its first Motion for Summary Judgment with the additional
evidence presented by Plaintiff as described herein
The end result of the convergence of thesemultiple filings arguments and admissions is
that Plaintiffsnewfound assertion that she has made any claims whatsoever for acute andor
temporary injuries as a result of exposure to OC is the epitome of playing fast and loose with
the Court Plaintiff should be judicially estopped from now reversing position to claim the very
injuries that she knew would result from exposure to OC assumed the risk by allowing herself to
be exposed to OC and willfully and voluntarily subjected herself to the March 3 2008 training
with the IDOC
B Plaintiffs Final Effort at Salvaging Some Case for Trial will Result in More than a
Waste ofJudicial Resources and Time
In light of all of the evidence presented herein and the fact that as set forth in SECs
forthcoming filed Motion in Limine given that Plaintiff should not be permitted to present
evidence of damages outside of a maximum of three 3 days following her March 3 2008
exposure to SECs Sabre Red OC spray there is no case worthy to be tried in this Court
Clearly had Plaintiff made allegations of acute injuries at any time prior to September 15 2011
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ith t at c te t i  i , lai tiff file  er affi a it t  e strate t at EC's 
ar e t  r i ate ca se c ld t a l  t  er c r ic, l -ter  i j ries eca se, as er 
ar e t rea s, s e l  a e te  t t   t r  it  t e trai i  if s e a  ee  
infor ed of those long-ter  and/or chronic adverse health effects. li it i   nt, 
t , i   le e t t at EC's r t r r i  r i ate  l  l  l  
  s       as for e  - t e c te  te r ry e lt  effects 
f exposure to . ith that in ind,  incorporates and restates the entire argu ent on 
proxi ate cause, as set forth in its first otion for Su ary Judg ent, ith the additional 
evidence presented by laintiff as described herein. 
  lt  t    t  lti le ili , r ents,  i i  i  
t t l intiffs f  ss rti  t t s  s   l i s ts r f r t  nd/or 
t r r  i j rie    r lt f r  t   i  t  it  f "playin  f t  l e" it  
t  urt. l i tiff s l   j i i ll  st  fr   r rsi  siti  t  l i  t  r  
injuries that she kne  ould result fro  exposure to , assu ed the risk by allo ing herself to 
 s  t  ,  illf ll   l t ril  s j t  rs lf t  t  r  ,  tr i i  
t   . 
. laintiff's inal ffort at alvaging o e ase for rial ill esult in ore than a 
  i i l    
In light f all f the evidence presented herein, and the fact that, as set forth in EC's 
forthco ing filed otion in i ine, given that laintiff should not be per itted to present 
evidence of da ages outside of a axi u  of three (3) days follo ing her arch 3, 2008 
exposure to SEC's Sabre Red C spray, there is no case orthy to be tried in this Court. 
Clearly, had Plaintiff ade allegations of acute injuries at any ti e prior to Septe ber 15, 2011, 
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SEC would have moved for summary judgment on those claims More clearly as is evident by
Plaintiffsown testimony in her Affidavit in Support of Motion for Reconsideration SEC would
have been successful on such a motion in that Plaintiff would have been unable to prove that
SECs alleged failure to provide an adequate label on its product was a proximate cause ie
substantial factor of her alleged injuries As the case currently sits Plaintiff cannot even
allege damages sufficient to bring her outside of small claims court
As has been discussed ad nauseum herein SEC has prevailed against the Plaintiffs
causes of action in all respects as pled and litigated up until September 15 2011 There is
nothing left to be tried and deadlines for amending pleadings and for moving for summary
judgment have all expired SEC is sensitive to this Court burdened schedule and submits that
Plaintiffs lastditch effort to keep this litigation alive should be rejected as both improper and
futile
IV CONCLUSION
Based on the foregoing Defendant SEC respectfully requests that this Court issue an
order clarifying its incourt ruling on September 15 2011 and issue a judgment as a matter of
law in favor of SEC determining unequivocally that all issues in this litigation have been
resolved
Y
DATED this day of September 2011
GREENER BURKE SHOEMAKERPA
Christopher C Burk
Thomas J Lloyd III
Attorneys for Defendant
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing MEMORANDUM IN SUPPORT
OF DEFENDANTSMOTION FOR CLARIFICATION on the following named personson the
date indicated below in the manner indicated below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220




x Via Facsimile 2084898988
ViaOvernight Delivery
DATED thisOF1 day of September 2011
Christopher C Bur e
Thomas J Lloyd III
MEMORANDUM IN SUPPORT OF DEFENDANTSMOTION FOR CLARIFICATION Page 14
14542 011 414577doc 001651
CE IFICATE F S ICE 
I hereby certify that I caused to be served the foregoing EMORANDUM IN SUPPORT 
OF DANT'S OTION F R IFICATION on the follo in  na ed p rson(s) on the 
date indicated belo , in the anner indicated belo : 
Darwin Overson, Esq. 
Eric B. Swartz, Esq. 
J ES & S RTZ, PLLC 
1673 . Shoreline rive, Suite 220 
. .  08 
Boise, Idaho 83707 
E  isifday of Septe ber, 2011. 
[ ] ia .S. ail 
[ ] ia and elivery 
[  ] ia ile (208/489-89 ) 
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165 ener Burke 1208319261
Christopher C Burke ISB 2098
Thomas 1 Lloyd III ISB 47772
GREENER BURKE SHOEMAKER PA









CHRISTOPHER D RICH Clerk
By RIC W21SON
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR ITIE COUNTY Or ADA




CORPORATION a Missouri corporation
Defendant
Casc No CVPI 1003515
DEFENDANTSMOTION
INLIMINE NO 1
TO EXCLUDE EVIDENCE OF
DAMAGES OUTSIDE OF THREE DAY
PERIOD FOLLOWING MARCH 3 2008
EXPOSURE
Defendant Security Equipment Corp SEC pursuant to Idaho Rules ofEvidence 401
403 this Court July 14 2011 ruling and subsequent written Order and this Court September
15 2011 ruling hereby moves this Court for an Order to exclude evidence of alleged damages
andor injuries outside of the three days immediately following Plaintiffs alleged exposure to
SECs pepper spray product on March 3 2008 Pursuant to this Court July 14 2011 and
September 15 2011 rulings Plaintiffs claims for damages from alleged chronic or longterm
injuries have been dismissed Plaintiffscounsel suggested at the September 15 2011 hearing
all that remains are alleged claims for damages associated with Plaintiffs acute symptoms
MOTION IN LIMINE 1 TO EXCLUDE EVIDENCE OF DAMAGES OUTSIDE THREEDAYPERIOD
FOLLOWING 038 EXPOSURE Page 1 14542 414850doc
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Thomas 1. Lloyd Ill, 1SB #7772 
GREENER BURKE SHOE AKER PA 
950 W. Bannock Street, Suite 900 
Boise, Idaho 83702 
Tel: (208) 319·2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
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Defendant Security Equipment Corp. ("SEC'), pursuant to Idaho ules of Evidence 401-
403~ this Court's July 14, 2011 ruling and subsequent written Order and this Court's September 
15, 2011 ruling, hereby moves this Court for an Order to exclude evidence of alleged damages 
and/or injuries outside of the three days immediately following Plaintiff's alleged exposure to 
SEC's pepper spray product on March 3, 2008. ur uant to t i  ourt's July 14, 2011 and 
September) 5, 20 It rulings, Plaintiffs claims for damages from alleged chronic or long-term 
injuries have been dismissed. Plaintiffs counsel suggested at the September 15, 2011 hearing, 
all that remains are alleged clai s for damages associated with Plaintiffs acute sympto s 
MOTION IN LIMINE #1· TO EXCL e EVIDENCE OF DA  OUTSIDE "HREE.DAY PERIOD 
FOLLOWING 03/03/08 EXPOSURE - Page I 14542·011 (~14HSO.dIIC) 
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following her alleged exposure on March 3 2008 Defendant disputes that such claims are or
ever were a part of this litigation however if these new claims do proceed to trial any attempt
by Plaintiff to introduce evidence of injuries andor damages outside of the threeday period
following her exposure on March 3 2008 would be nothing more than an impermissible attempt
to circumvent this Court orders on summary judgment holding that SEC cannot be held liable
for unknown or unforeseeable risks of longterm andor chronic adverse health effects Evidence
of alleged damages outside of the time period attributable to acute symptoms is no longer
relevant to this litigation Additionally even if the evidence is deemed relevant the probative
value of the evidence does not outweigh the prejudice the evidence would create against SEC if
it were allowed
This Motion is supported by the pleadings and other documents on file with the Court
and the Memorandum in Support of DefendantsMotion in Limine No 1 to exclude evidence
outside the three day period following Plaintiffs the March 3 2008 exposure
Oral argument is requested
DATED thisZEday of September 2011
GREENER 13URKESIIOCMAKER PA
Christopher C Burke
Thomas J Lloyd III
Attorneys for Defendant
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following hcr alleged exposure on March 3, 2008. Defendant disputes that such claims are or 
cver were a part of this litigation. However, if these new clai s do proceed to trial, any atte pt 
by Plaintiff to introduce evidence of injuries and/or damages outside of the three-day period 
following hcr exposure on March 3, 2008 would be nothing morc than an impem,issiblc attcmpt 
to irc vent t is rt's rders on s r  judg ent l ing t t  t e cl  lia le 
f r u n n r foreseea le ris s f l -term a /or c r ic a erse ealt  effects. i e ce 
of alleged damages outside of thc time period attributable to acute symptoms is no longer 
relevant to this litigation. dditionally, even if the evidence is dee ed relevant, the probativc 
al e f t e e i e cc cs t t ei  the rej ice t e e i e ce l  create a ai st  if 
it er  ll . 
This otion is supported by the pleadings and other documents on tile with the Court 
and the e orandu  in Support of efendant's otion in Li ine o.1 to exclude evidence 
outside the three day period follo ing laintiffs the arch 3, 2008 exposure. 
Oral argument is requested. 
  Zfday of Septe ber, 2011. 
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing document on the following
named persons on the date indicated below in the manner indicated below
Darwin Overson Esq I I Via USMail
Eric B Swartz Esq Via1land Delivery
JONES WARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 r Via Overnight Delivery
P 0 Box 7808
Boise Idaho 83707
DATED this ZZ day of September 2011
Christopher C Burke
Thomas I Lloyd III
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IN THE DISTRICT COURTOF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THECOUNTYOF ADA
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FOLLOWING MARCH 3 2008
EXPOSURE
Defendant Security Equipment Corporation SEC by and through its counsel of
record Greener Burke Shoemaker PA submits this Memorandum in Support of its Motion in
Limine No 1 by which it seeks to exclude evidence of damages falling outside of the threeday
timeframe immediately following Plaintiffs alleged exposure to SEC pepper spray on March 3
2008
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efendant ecurity quip ent orporation ("SEC'), by and through its counsel of 
record, reener Burke Shoe aker P.A., sub its this e orandu  in Support of its otion in 
i ine o.1, by hich it seeks to exclude evidence of da ages falling outside of the three-day 
ti efra e i ediately follo ing Plaintiff's alleged exposure to SEC pepper spray on arch 3, 
08. 
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INTRODUCTION
Plaintiff filed this lawsuit against SEC seeking damages for alleged longterm andor
chronic injuries as a result of exposure to SECslaw enforcement branded oleoresin capsicum
OC or pepper spray products Following motion practice on SECs first and second
motions for summary judgment this Court ruled as a matter of law that SEC cannot be held
liable for Plaintiffs alleged long term andorchronic injuries as any longterm injuries were
unknown andor unforeseeable to SEC at the time that SEC sold its products to Plaintiffs
employer Idaho Department of Corrections IDOC At the conclusion of the hearing on
SECssecond motion for summary judgment held on September 15 2011 Plaintiff made a final
attempt to keep some aspect of her case alive by asserting that she still had causes of action to be
tried that pertained to alleged acute injuries sustained as a result of Plaintiffs exposure to
SECsOC products Accordingly by this motion SEC seeks to exclude from evidence as
prejudicial irrelevant confusing and misleading evidence of any claimed injuries symptoms
damages or other allegations of adverse effects outside of a three 3 day window of time
following Plaintiffs exposure to SECsOC products on March 3 2008
ARGUMENT
Idaho Rule of Evidence 401 defines relevant evidence as evidence having any
tendency to make the existence of any fact that is of consequence to the determination of the
action more probable or less probable than it would be without the evidence IRE401
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l i tiff fil  t i  l s it i t  s i  s f r ll  l -ter  nd/or 
r i  i j ri s s  r s lt f s r  t  EC's l - f r t r  l r si  si  
(''~C''), or pepper spray, products. ollo ing otion practice on EC's first and second 
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unkno n and/or wtforeseeable to SE  at the ti e that S  sold its products to Plaintiffs 
l r, I  rt t f rr ti s ("IDO "). t t  l si  f t e ri   
EC's s  ti  f r s r  j nt, l   t r , 1, l i tiff   fi l 
tt t t    t    li   rti  t t  till    ti  t   
t i  t t t i  t  ll  "ac t " i j ries t i    lt  laintiff's r  t  
C's  r ts. r i gly,  t is ti ,  s s t  l  fr  i e, s 
prejudicial, irrelevant, confusing and isleading, evidence of any clai ed injuries, sy pto s, 
a a es, ot' t er alle ati s f a erse effects tsi e f a t ree (3) a  i  f ti e 
f ll i  l i tiffs r  t  C's D  r t   r  , 8. 
 
Idaho ule of Evidence 40 I defines "relevant evidence" as evidence having "any 
tendency to ake the existence of any fact that is of consequence to the deter ination of the 
ti  r  r l  r l ss r l  t  it l  e it t t  i ence." I.R.E.401. 
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Pursuant to Rule 402cvddence which is not relevant is not admissible IRE402 Finally
IRE403 provides
Although relevant evidence may be excluded if its probative value
is substantially outweighed by the danger of unfair prejudice
confusion of the issues or misleading the jury or by
considerations of undue delay waste of time or needless
presentation of cumulative evidence
IRE403
Under the present circumstances any evidence of injuries or symptoms outside of a
maximum three 3 day period of time following Plaintiffs March 3 2008 exposure is plainly
irrelevant Any attempt by Plaintiff to argue that symptoms andor injuries outside of that three
3 day period of time can only be considered a veiled attempt to circumvent this Court
decision on summary judgment and to nevertheless present and litigate a case about longterm
andorchronic injuries and the damages attendant thereto
If Plaintiff is permitted to present evidence outside of the three 3 day period of time
established herein SEC will suffer substantial prejudice at the time of trial A jury will be
unable to distinguish between the acute injuries that are at issue in this case and the chronic
issues that are not there will be no meaningful difference between a temporary vs a long term
adverse health effect In other words the Parties efforts and this Court rulings on summary
judgment will be rendered moot
SEC acknowledges that to some extent the three 3 period identified herein is somewhat arbitrary The evidence
in this case submitted to date by both Plaintiffs and Defendantsexperts indicates that acute and temporary effects
ofOC exposure typically wear off within minutes or hours of exposure but in no event longer than one or two days
Accordingly for purposes of this motion SEC is giving Plaintiff the benefit of the doubt on the meaning of the
words acute and temporary
DEFENDANTSMEMORANDUM IN SUPPORT OF ITS MOTION INLIMINENO 1page 3
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Conversely the issues in this case have apparently now been narrowed to questions
surrounding PIaintiffsclaims for alleged acute injuries Accordingly there is no probative
value to any allegations of injuries symptoms andor damages outside of the immediate three 3
day period of time following PlaintiffsMarch 3 2008 exposure No allegations or evidence
about injuries symptoms andordamages later than the immediate three 3 day period of time
will have any tendency to make PIaintiffsremaining allegations more probable or less
probable than they would be without that evidence IM 401
The facts and procedural posture of this case arc such that SEC cannot be held liable for
any injuries or damages that were unforeseeable at the time of Plaintiffs exposure on March 3
2008 The Court must recognize that any attempt by Plaintiff to introduce evidence outside of
the limited zone of inquiry three days that can logically and realistically be deemed
temporary is merely an attempt by Plaintiff to call her chronic case acute As recognized
by William Shakespeare that which we call a rose By any other name would smell as sweet
Romeo andJuliet Act 2 Scene 2
It is imperative that this Court protect SEC from the imposition of a duty that it otherwise
did not owe simply because Plaintiff is creative with her word choice
2 In making this argument SEC does not acknowledge that acute injuries or damages resulting from any acute
injuries have ever been a part ofPlaintiffs case See SECsMotion for Clarification fled in this case on
September 20 2011 Nonetheless this motion is made under the assumption that this Court still plans on a trial in
this case
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Attorneys for Defendant
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MOTION TO VACATE TRIAL
Plaintiff respectfully moves to vacate trial on the grounds that the Defendant has filed a
motion for clarification of this Court ruling granting summary judgment as to the Plaintiffs
claim for chronic injury and denying summary judgment on the claim for acute injury The case
is therefore set for trial on the issue of whether the Defendant is liable for damages arising from
the Plaintiffsacute injury This Court ruling significantly alters the nature of the case The
Plaintiff seeks to vacate the trial in order to reevaluate the remaining claim the chances of
settlement the procedural posture of the case and whether it makes sense to go to trial at all
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The economics of proceeding to trial on just the acute injury may not make sense and in
the interest ofjudicial economy the trial should be vacated
DATED this 21 st day ofSeptember 2011
ERIC B SWARTZ
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 21st day of September 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA




CORPORATION a Missouri corporation
Case No CVPI 1003515
DEFENDANTSOPPOSITION TO
PLAINTIFF MOTION TO VACATE
TRIAL
Defendant
Defendant Security Equipment Corporation SEC by and through its counsel of
record Greener Burke Shoemaker PA hereby submits this Opposition to PlaintiffsMotion to
Vacate Trial of even date
As is more thoroughly evident from SECs Motion for Clarification filed on September
20 2011 the basis for SECsrequest for clarification is not that SEC seeks clarification of this
Courts ruling granting summary judgment as to the Plaintiffs claim for chronic injury and
denying summary judgment on the claim for acute injury Plaintiffs Motion to Vacate p 1
Rather SECs position is that there is no and never has been any claim for acute injury involved
in this litigation See generally SECs Motion for Clarification With that correction SEC
DEFENDANTSOPPOSITION TOPLAINTIFFSMOTION TO VACATE TRIAL Page 1
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By ELYS IA L ES J 
 
           
  ,        
I IE J  J , an individual, 
l intif , 
v. 
I  I  
RATI , a iss ri c r rati n, 
ant. 
 o.: - I-  
FENDANT'S I   
LAINTIF 'S    
 
efe a t ec rit  i e t r rati  ("SE "),  a  t r  its c sel f 
record, reener urke Shoe aker P.A., hereby sub its this pposition to Plaintiffs otion to 
t  ri l f  te. 
As is ore thoroughly evident fro  SEC's otion for Clarification, filed on Septe ber 
20,2011, the basis for SEC's request for clarification is not that S  seeks "clarification of this 
ourt's ruling granting su ary judg ent as to the Plaintiff s clai  for chronic injury and 
denying su ary jUdg ent on the clai  for acute injury." (Plaintiffs otion to acate, p. 1) 
Rather, SEC's position is that there is no and never has been any clai  for acute injury involved 
in this litigation. (See generally SEC's otion for Clarification.) ith that correction, SEC 
FENDANT'S OSITI   LAINTIF 'S I    I  - Page 1 
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agrees that the current posture ofthe case is significantly alteredas the Plaintiff is seemingly
attempting to amend her claims and in fact assert brand new claims on the eve of trial On that
basis SEC contends that Plaintiffsrequest to reevaluate her recentlyasserted claim is nothing
more than a veiled attempt to obtain more time to prepare a brand new case for trial which case
is based on claims injuries andor damages that have never previously been asserted in this
litigation
If this Court is inclined to allow Plaintiff to proceed on these new allegations SEC
contends that Plaintiff must do so according to the long established trial schedule in this case
After all if Plaintiffs claim for damages from alleged acute injuries has been apart of this case
all along then Plaintiff should be prepared for trial on that issue
Oral argument is hereby requested on an expedited basis preferably to be heard during
the pretrial conference presently set for September 22 2011
yf
DATED this day of September 2011
GREENER BURKE SHOEMAKERPA
Christopher C Burke
Thomas J Lloyd III
Attorneys for Defendant
DEFENDANTSOPPOSITION TO PLAINTIFFSMOTION TO VACATE TRIAL Page 2
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing DEFENDANTSOPPOSITION
TO PLAINTIFFSMOTION TO VACATE TRIAL on the following named personson the date
indicated below in the manner indicated below
Darwin Overson Esq ViaUSMail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC x Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O Box 7808
Boise Idaho 83707
DATED this2day of September 2011
S
Christopher C Burke
Thomas J Lloyd III
DEFENDANTSOPPOSITION TO PLAINTIFFSMOTION TO VACATE TRIAL Page 3
14542 011415432 001664
ICATE   
I hereby certify that I caused to be served the foregoing DEFENDANT'S OPPOSITION 
O I TIFF'S OTION    n the follo in  e  rson(s) n t e t  
indicated belo , in the anner indicated belo : 
ar in verson, sq. 
ric . artz, sq. 
J ES & ,  
 . line i , ite  
. .   
ise, I a   
  ~  of Septe ber, 2011. 
[ ] ia .S. ail 
[ ] ia  liver  
[  ] ia i il  (208/489-89 ) 
[ ] ia i t li e  
~ j . «z:L .,.~;::::= 
hristopher . urke 
as . lo   
EFENDANT'S PPOSITI  T  PLAINTIFF'S TI  T  TE T I L - Page 3 
14542-011 (415432) 
0922011 0937 FAX 208 8988 Jones Swartz
IL
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZPLLC
1673 W Shoreline Drive Suite 200 83702










SEP 2 2 2011
CHRZrCHER D RICH Clerk
By KATHY BIEHL
Deputy
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICTOF
THE STATE OF IDAHO IN AND FOR THE COUNTY OFADA






Case No CV PI 1003515
PLAINTIFFSOBJECTION TO
DEFENDANT PROPOSED ORDER
Plaintiff hereby files her objection to the DefendantsProposed Order Granting Motion
for Summary Judgment Striking Affidavit ofGerold sic Yost and Denying Plaintiffs Motion
for Reconsideration
The Defendantsproposed order paragraph three includes language to the effect that this
Courtgranted its summary judgment in all respects when this Court was clear in its ruling that
the motion for summary judgment was being granted only as to Ms Major chronic injury
PLAINMTS OBJECTION TO DEFENDANTSPROPOSED ORDER1
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 22 day of September 2011 a true and correct copy
of the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA





PLAINT ffFSOBJECTION TO DEFENDANTSPROPOSED ORDER 3
ERicB SWARTL
001667
09/22/2011 09:38 FAX 208 8988 Jones S artz ~0 4/  
I   E I  
I HEREBY CERTIFY that on this 2200 day of September, 2011, a true and correct copy 
 t  i  t    t  ll i  i dividual( s)  t  t  i i ted: 
ri t r . r  
a  .  ill 
    
 .  tr et,   
,   
[ ] .S. il 
[ l ax: -2  
[ ] essenger elivery 
[ ] Email: cb~D@green~ 
oyd(Q}..2I~' 
INTIF 'S J   NDANT'S   -  
0922011 1402 FAX 208 489 8 Jones Swartz IM 00125
M h2
SEP 2 2 2011
Darwin Overson ISB 5887
Eric BSwartz ISB 6396
JONES SWARTZPLLC
1673 W Shoreline Drive Suite 200 83702






Attorneys for Plaintiff Billie Jo Major
CBF3iSTOPfIE R Cl Clerk
By Ric
DZPU1 V
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA






Case No CV PI 1003515
REPLY IN SUPPORT OFPLAINTIFFS
MOTION TOVACATE THE TRIAL
Plaintiff respectfully submits her reply in support of her Motion to Vacate Trial
Submitted herewith is the Affidavit ofCounsel in Support of PlaintiffsMotion to Vacate and In
Response to DefendantsObjection to Motion to Vacate
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Defendantsobjection is a complete hundred and eighty degree change from the position that was
taken just two days ago when counsel was told by opposing counsel that vacating the trial made
sense for both parties Despite the Defendants threatening correspondence the Plaintiff was
willing to vacate trial stipulate to a Rule 54b certification for appeal and explore settlement in
light of this Court most recent ruling All three issues were raised by opposing counsel4
Plaintiffscounsel spent a considerable amount of time working toward putting together the
necessary elements of in place to obtain settlement authority the appropriate waiver of claims
from the Idaho State Insurance Fund and determining a fair value of the case within the
parameters of the procedural posture the case is now in After all that effort it is clear that
Defense counsel had no intention of vacating the trial agreeing to Rule 54b certification or
engaging in any kind of serious settlement negotiations
The Plaintiff will be taking this case up on appeal and it makes no sense to try the case
irrespective of the outcome of that appeal If the Plaintiff prevails the case will have to be tried
as to both acute and chronic injuries If the Plaintiff does not prevail the case is highly likely to
settle since the damages are severely limited
The Defendant has filed a motion to reconsider styled as a motion for clarification It
makes no sense for the parties to prepare for trial while that motion is pending The Defendants
objection has no rational basis and is transparently filed for tactical purposes The economics are
a consideration under the rules of civil procedure and the economics of this case weigh heavily
in favor of granting the Plaintiffsmotion to vacate trial
Aff of Counsel in Support of Motion to Vacate 1129
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The Plaintiff ill be taking this case up on appeal and it akes no sense to try the case 
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It should also be noted that the trial in this case has never been continued and this is
thefirst request by eitherparty to vacate a trial setting
As such this Court should vacate the trial
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of the foregoing document was served on the following individualsby the method indicated
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Thomas J Lloyd III
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA





Case No CV PI 1003515
AFFIDAVIT OFCOUNSEL IN
SUPPORT OF PLAINTIFFSMOTION
TOVACATE TRIAL AND IN
RESPONSE TO DEFENDANT






I Darwin L OVerson being first duly sworn upon oath depose and state upon my own
personal knowledge as follows
1 I am an attorney with the law firm of Jones Swartz PLLC and am authorized to
practice law before this and all courts of the State of Idaho
AFFIDAVIT OF COUNSEL IN SUPPORT OF PLAINTIFFSMOTION TO VACATE TRIAL AND IN RESPONSE TO
DEFENDANTSOBJECTION TO TIM MOTION TO VACATE1
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2 I was caught off guard and surprised at the Defendantsopposition to the
Plaintiff s motion to vacate I was contacted by Mr Lloyd by telephone on September 16 2011
during which he expressed some concern about the posture of the case moving forward as we are
now very close to trial and this Court partial grant of the Defendantssummary judgment
motion presents a significant change in the nature of the case I indicated that I was still thinking
through some of the issues presented by this Court ruling
3 Later that same day I received a letter from Mr Lloyd that I have attached a true
and correct copy of as Exhibit A My reading of the letter was that it was a threat that if the
Plaintiff proceeded to trial the Defendant would seek attorney fees and costs irrespective of the
outcome and indicated that the Defendant would be seeking a large amount of money from my
client That amount was not indicated in the letter The letter clearly threatened to attach my
clients property and place a lien on any recovery from Workers Compensation that she may
receive in the future The letter ended by inviting an offer to settle the case The letter set a
deadline ofTuesday September 20 2011 for making such an offer and indicated that any such
offer would promptly communicate to the Defendant
4 On that same day I received an email from Mr Lloyd a true and correct copy of
which I have attached as Exhibit B In that email Mr Lloyd raised the potential for a stipulation
to a Rule 54b certification in order to avoid additional litigation costs if the Plaintiff was
planning to take any of the issues in the case up on appeal In response to Mr Lloydsletter I
called him and spoke to him about where I felt the case was going procedurally
5 In that conversation I was led by Mr Lloyd to believe he would seek permission
from his client to stipulate to vacate the trial in order to 1 have the Defendantsmotion for
clarification heard 2 explore settlement possibilities and 3 stipulate to a Rule 54b
AFFIDAVIT OF COUNSEL IN SUPPORT OF PLAINTIFFSMOTION TO VACATE TRIAL AND IN RESPONSE TO
DEFENDANTSOBJECTION TO THE MOTION TO VACATE 2
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2. I was caught off guard and surprised at the Defendant's opposition to the 
Plaintiff's motion to vacate. I was contacted by Mr. Lloyd by telephone on September 16, 2011 
during which he expressed so e concern about the posture of the case moving forward as we are 
now very close to trial and this Court's partial grant of the Defendant's summary judgment 
motion presents a significant change in the nature of the case. I indicated that I was still thinking 
through so e f the issues presented by this ourt's ruling. 
3. Later that sa e day, I received a letter fro  r. Lloyd that I have attached a true 
a  c rrect c  f as i it .  rea i  f t e letter as t at it as a t reat t at if t e 
Plaintiff proceeded to trial, the Defendant would seek attorney fees and costs irrespective of the 
outcome, and indicated that the Defendant would be seeking a large amount of money from my 
client. That amount was not indicated in the letter. The letter clearly threatened to attach my 
client's property and place a lien on any recovery from Workers Compensation that she may 
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deadline of Tuesday, September 20, 2011 for making such an offer, and indicated that any such 
e   "prompt  te"   e t. 
4. On that same day, I received an email from Mr. Lloyd, a true and correct copy of 
which I have attached as Exhibit B. In that email Mr. Lloyd raised the potential for a stipulation 
to a Rule 54(b) certification in order to avoid additional litigation costs if the Plaintiff was 
planning to take any of the issues in the case up on appeal. In response to Mr. Lloyd's letter, I 
called him and spoke to him about where I felt the case was going procedurally. 
5. In that conversation, I was led by Mr. Lloyd to believe he would seek permission 
from his client to stipulate to vacate the trial in order to (1) have the ef nt's otion for 
"clarification" heard, (2) explore settlement possibilities, and (3) stipulate to a Rule 54(b) 
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certification At the end of the telephone call Mr Lloyd indicated that he would be contacting
his client to discuss these matters and that he or Mr Burke would get back to me I asked him
whether the Tuesday deadline for making an offer to settle set in stone or if additional time
could be given for me to evaluate the posture of the case and discuss it with my client along with
the potential for settlement Mr Lloyd indicated that his clients wanted to settle the case and the
deadline was flexibile but an earlier rather than later offer of settlement would be more likely to
succeed
6 As a result of my conversation with Mr Lloyd I shifted my efforts away from
preparing for trial and worked toward evaluating a settlement offer the risks of trial versus
proceeding with a Rule 54bcertification and research the issue of whether a lien against any
potential workers compensation pay out was a true risk for my client
7 In determining whether settlement would be a possibility and if so at what
range I contacted counsel for the Idaho State Insurance Fund to inquire as to whether the fund
would be willing to waive any claim to settlement proceeds if a settlement could be reached
After several conversations it was determined that there would be some likelihood but a final
figure would have to be obtained before they could make a decision
8 On Tuesday I had not heard back from Mr Lloyd regarding whether there would
be a stipulation to vacate or a stipulation to a Rule 54bcertification I called Mr Lloydsoffice
and he returned my call I spoke with him at length regarding these two stipulations and was led
to believe by Mr Lloyd that that he and Mr Burke had discussed it and that Mr Burke was the
one who was in contact with their client regarding these issues I contacted Mr Burke and was
surprised to learn that Mr Burke had not talked to his client about these issues According to
Mr Burke his client was not even available until the end ofthe week I mentioned that we were
AFFIDAVIT OF COUNSEL IN SUPPORT OF PLAINTIFFSMOTION TOVACATE TRIAL AND IN RESPONSE TO
DEFENDANTSOBJECTION TO THE MOTION TO VACATE 3
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certification. At the end of the telephone call, Mr. Lloyd indicated that he would be contacting 
his client to discuss these matters and that he or Mr. Burke would get back to me. I asked him 
whether the Tuesday deadline for aking an offer to settle set in stone, or if additional ti e 
could be given for me to evaluate the posture of the case and discuss it with my client, along with 
the potential for settlement. r. Lloyd indicated that his clients anted to settle the case and the 
deadline was flexibile but an earlier rather than later offer of settlement would be more likely to 
succeed. 
6. As a result of my conversation with Mr. Lloyd, I shifted my efforts away from 
preparing for trial and orked to ard evaluating a settle ent offer, the risks of trial versus 
proceeding with a Rule S4(b) certification, and research the issue of whether a lien against any 
potential orkers co pensation payout as a true risk for y client. 
7. In determining whether settlement would be a possibility, and if so, at what 
range, I contacted counsel for the Idaho State Insurance Fund to inquire as to whether the fund 
l   illing t  ive  l i  t  s ttl t rocee s if  s ttl t l   r d. 
fter several conversations, it as deter ined that there ould be so e likelihood but a final 
figure ould a e t  e tained ef re the  c ld ake a ecisi . 
8. On Tuesday, I had not heard back from r. Lloyd regarding whether there would 
be a stipulation to vacate or a stipulation to a Rule 54(b) certification. I called Mr. Lloyd's office 
and he returned y call. I spoke with him at length regarding these two stipulations and was led 
to believe by r. Lloyd that that he and r. Burke had discussed it, and that r .. Burke as the 
one who was in contact with their client regarding these issues. I contacted r. Burke and was 
surprised to learn that Mr. Burke had not talked to his client about these issues. According to 
Mr. Burke, his client was not even available until the end of the week. I mentioned that we were 
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putting together an offer of settlement and Mr Burke indicated that there was little or no
inclination on the part ofhis clients to settle since they had won the case I toldMr Burke that I
was in agreement with the idea of stipulating to a Rule 54b certification I was told that that
was not an option and would not be recommended to his client I told Mr Burke that since he
could not reach his client I would file a motion to vacate the trial in order to put this Court on
notice that the issue would come up at the pretrial He agreed that that would be a good idea but
he could not stipulate because he had not talked to his client
9 Based on Mr Lloyds and Mr Burkes representations I am very surprised that
the Defendant objected to the Plaintiffs motion to vacate trial I have expended a great deal of
time and effort working with opposing counsel in order to try to work through some of these
issues to see if the matter could be resolved without either party expending more resources by
preparing for and conducting a trial on the acute injury only I undertook those efforts at Mr
Lloyds suggestion I worked on these issues over a period of days and shifted my focus away
from trial preparation I believe I have been misled for no other purpose than to distract me from
preparing for trial
FURTHER YOUR AFFIANT SAYETH NAUGHT
DARwnv L OVERSON
SUBSCRIBED AND SWORN TO before me this 22 day ofSeptember 2011
Notary Public for Idaho
My Commission expires
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putting together an off r of settlement and r. Burke indicated that there was little or no 
incli ati  on the part of his clients to settle since they had won the case. I told r. Burke that I 
as in agreement ith the idea of stipulating to a Rule S4(b) certification. I as told that that 
s n t an opti  and uld not be reco  to his client. I told r. Burke that since he 
could not reach his client, I would file a otion to vacate the trial in order to put this Court on 
notice that the issue would come up at the pretrial. He agreed that that would be a good idea but 
 l  ot sti l t    d t t l  t  i  client. 
9. Based on r. Lloyd's and r. Burke's representations, I am very surprised that 
the Defendant objected to the Plaintiff's motion to vacate trial. I have expended a great deal of 
time and effort working with opposing counsel in order to try to work through some of these 
issues to see if the matter could be resolved without either party expending more resources by 
preparing for and conducting a trial on the acute injury only. I undertook those efforts at r. 
Lloyd's suggestion. I worked on these issues over a period of days and shifted my focus away 
from trial preparation. I believe I have been misled for no other purpose than to distract me from 
re a ing  t i l. 
    E  . 
WIN . ERS  
SUBSCRIBED AND S ORN TO before me this 22nd day of September, 2011. 
Notary Public for Idaho 
My Commission expires ______ _ 
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I HEREBY CERTIFY that on this 22 day of September 2011 a true and correct copy
ofthe foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENERBURKE SHOEMAKER PA
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TI I   SERVI  
I HEREBY CERTIFY that on this 22nd. day of September, 2011, a true and correct copy 
f t  f r i  t s ser   t  f ll i  i dividual(s)  t  t  i i ted: 
r .  
 .  m 
    
 .  tr et,   
,   
[ J .S. il 
[ J ax: -  
[ ] Messenger Delivery 
[ ] Email: cburke@gree .• n.IO"~ 
t lGyd@8i;eem~W(, 
Ic . Z 
AFFIDAVIT OF COUNSEL TIll SUPPORT OF PLAINTIFF'S MOTION TO VACATE 1 .IAL AND IN RESPONSE TO 
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September 16 201 I
VIAFACSIMILE ONLY 208 4898988
Mr Darwin Overson Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200
Boise ID 83702
ALFAS INTERNATIONAL
The Global Legal Network
C12NFIly1C U AJSETTIICMNTNF022ATION
privileged Protectedpursuant To R 408
Re Blllle Jo Major Y SecurityEquipment Corporation
GBS File No 14542011
Deal Darwin
Q000815
from our telephone conversation moments ago I understand that you intend to proceedto trial with Ms Major remaining claims now limited to the acute health effects of OC with
which site was very familiar prior to her exposure to our clientsproducts I feel compelled to
follow up This case unlike our last together which included very little cost to the parties due to
a lack of experts has been extraordinarily expensive for both sides thus far Without even
considering the potential for attorney fees you should be advised that if we arc pushed to trial
and we succeed our client will insist that we pursue recovery ofall expert costs and fees In our
collective judgment given that your client has gone so far as to sign affidavits In this case
acknowledging that she was fully informed of the acute health effects of OC you have some
substantial hurdles to overcome with respect to contributory negligence and proximate cause
Comparing the problems of your clients case with the fact that you will likely be
prevented from presenting evidence of alleged injuries more than two or three days following
the March 08 exposure any benefit that your client could hope to achieve is extraordinarily
offset by the risk she faces I understand that you acknowledged at yesterday hearing that the
damages will be very small even on your best day If our client prevails at trial we will be
attaching that judgment to her property if any and placing a lien on any recovery that she mayhope to get out of her WorkersCompensation case Thus proceeding to trial at this stage means
more than simply taking the gamble in this case it means risking her ability to recover anythingat all across the board and a risk of losing even more
Moreover as the case now sits we have a strong argument that we are already the
prevailing party in this litigation no matter what happens at trial Your client set out to obtain
950w bannock 111001 sultp 900 1 bolse Idaho 837021 2083192601104319260
20110916 14 34 Greener Burke 12083192601 208 484 8488 P 23
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Thomas J. Lloyd II  
IlIo~dGgr.enarlaw.com 
(208) 318.2fOO ®B+S 
September 16~ 201  
VIA FACSIMIL  ONLY «(2 8) 489- 8 ) 
r. Darwin OV!il'son, sq. 
JONES &, SWARTZ. PLL  
1673 . Shoreli e rive, Suite 200 
Boise,1O 83702 
ALFA® INTERNATIONAL 
The Q(obal Logal Network 
CONFIDENTIAL SETTLlCMENT Nll'§OTIATIQN 
P,l le '"  P   lR.E.  
Rc: IIII, Jf) ajor v. Security qlllp ent orporatIon 
D   . 4542·011 
Dear Darwin: 
From our telephone conversation moments agol I understand that you intend to proceed 
t  tri l it  . jort s re i i  l i s - now limited to the acute health effects of OC with 
which sIte was vcry familiar prior to her exposure to our client's products. I feel compelled to 
follow up. This case, unlike our last together which included very little cost to the parties duo to 
a lac  f e orts, has ee  e tra r i aril  e pe sive f r both sides t s far. ithout even 
considering the potential for attorney fees, you should be advised that if we arc pushed to trial 
and we"succeed, our client will insist that we pursue recovery of all expert costs and fees. In our 
collective judgment, given that your cHent has gone so Car as to sign affidavits in this case 
acknowledging that she was fully infonned of the acute health effects of ~C, you have some 
substantial hurdles to overcome with respect to contributory negli;ence and proximate cause. 
Comparing the problems of your client's case with the fact that you will likely be 
prevented from presenting evidenoe of alleged "injuries" more than two or three days followinG 
the March '08 exposure, any benefit that your client could hope to achieve is extraordinarily 
offset by the risk she faces. I understand that you acknowledged at yesterday's hearing that the 
damages will bo very small even on your best day. If our client prevails at trial, we will be 
attaching that judgment to her property, if any, and placing a lien on any recovery that she may 
hope to get out other Worker's Compensation case. Thus, proceeding to trial at this stage means 
more than simply taking the gamble in this case~ it means risking her ability to recover anything 
at all across the board (and a risk of losing even more). 
Moreover, as the case now sits, we have a strong argument that we are already the 
prevailing party in this litigation no matter what happens at trial. Your client set out to obtain 
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substantial damages based on an allegedly longterm debilitating injury and she is now limited
to at best a very small recovery Thus even if your client manages to obtain some nominal
amount of damages from a sympathetic jury she may nevertheless end up paying our costs
including expert costs That nominal recovery would be entirely offset and the difference
again would be attached to her other assets andor potential recovery through WorkersCompensation
In light ofthe foregoing our client is not inclined to produce a settlement offer Frankly
I was surprised to hear that any aspect of the case survived given that your clientsclaims have
never been about acute effects of OC as evidenced by your acknowledgement today that your
Trial Brief now needs revision because the issues have changed Nevertheless you have
salvaged an opportunity for your client to avoid the aforementioned attachments liens andor
garnishments that may otherwise be suffered upon your client following the final resolution of
this case but only if your client settles this matter in the very near term You may want to
consider making an offer which we will promptly communicate to our client
As you can appreciate trial preparation is well underway Thus if you are hoping to
convince our client that settlement is worthwhile any such offer must be communicated to my
office no later than close of business next Tuesday September 20 2011 After that date our
client will have spent more than what the case is now worth if it is indeed worth anything and
it will turn its attention entirely towards recovering its litigation costs from your client





Thomas J Lloyd III
I 1
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Mr. Darwin Overson, Esq. 
September 16, 2011 
Page 2 
gr00ncr J burke t slioemaker [ p.O. 
substantial damages based on an allegedly long-tenn, debilitating il\iury, and she is now limited 
to, at best, a vcl')' small recovery. Thus, even if your client manages to obtain SOme nominal 
amount of damages from a sympathetic jury. she may nevertheless end up paying our costs 
(including expert costs). That nominal recovery would be entirely offset and the difference, 
again, would be attached to her other assets and/or potential recovery through Worker's 
Co pensation. 
In light of the foregoing. our client is not inclined to produce a settlement offer. Frankly, 
I was swprised to hear that any aspect of the case survived, given that your client's claims have 
never been about acute effects of OC (as evidenced by your acknowledgement today that your 
Trial Brief now needs revision because ''the issues have changecl'~. Nevertheless. you have 
salvaged an opportunity for your client to avoid the aforementioned attachments, liens and/or 
garnishments that may otherwise be suffered upon your client following the final resolution of 
this case, but only if your client settles this matter in the very ncar term. You may want to 
   f r,   i   icat    t. 
As you can appreciate, trial preparation is well undet'Way. Thus, if you are hoping to 
convince our client that settlement is worthwhile, any such offer must be communicated to my 
office no later than close of business next Tuesday, September 20, 2011. After that date, oUt' 
client will have spent marc than what the case is now worth (if it is indeed worth anything), and 
it will tum its attention entirely towards recovering its litigation costs &om your client. 
We iIl  for ar  to o r re . 
ery truly yours, 
REE ER B KE SHOEMAKER. P.A. 
t;~:f~~ 
(414176) 
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Darwin Overson
From Thomas J Lloyd III tlloyd@GreenerLawcom
Sent Friday September 16 2011330 PM
To Darwin Overson
Cc Eric Swartz Chris Burke Jamie Miller Christina Morrow
Subject Major v SEC
Darwin
As an addendum to my letter of todaysdate faxed not long ago I submit the following
It occurs to us that you and your client may be intending to seek an appeal on some or all of the rulings made thus
far by Judge Copsey If it is your intention to proceed to trial rather than to attempt settlement for the sole purpose of
concluding the case so that you can seek that appeal please be advised that we would consider not objecting to a motion
by your client for issuance of a Rule 54b Certificate if you already plan to appeal then it makes little sense foranyone
to proceed to trial now and assuming for the sake of argument that you have any success on appeal then end up with a
total of two trials in this matter As I suspect you have this case on contingency then I needntpoint out to you that It
makes the least amount of sense for Plaintiff to take that route I cannot guarantee that my client will not contest a Rule
54battempt but it would at least be a conversation worth having
Thanks
Tom
Thomas J Lloyd III I attorney
GBS greener Burke shoemaker pa
950 wbaock street suite 9001 boise I idaho 83702
o2083196001 f2083196 11 e t11oyd0enedawcom
CONFIDENTIALITY NOTICE This amall communication and any attachments may contain confidential and privileged Information for the use of the designated recipients named If you
are not the Intended recipient you are hereby notified that you have received this communication In error and that any review disclosure dissemination distribution or copying of it or
Its contents Is prohibited If you have received this communication in error please destroy all copies of this communication and any attachments Thank you
001681
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riday,  16, 2011 3:30  
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ri  artz; ri  urke; ie iller; ristina  
j  .  
   t   l tt  f t day's te, f  t long go, I it t  f llowing: 
~0011/0015 
It occurs to us that you and your client ay be intending to seek an appeal on so e or all of the rulings ade thus 
far by Judge opsey. If it is your Intention to proceed to trial, rather than to atte pt settle ent, for the sole purpose of 
concluding the case so that you can seek that appeal, please be advised that e ould consider not objecting to a otion 
y y r cli t f r Iss c  f  ule 54(b) rtific te. If you lr y plan to appeal, then It akes little sense f r anyone 
to proceed to trial now and, assuming for the sake of argument that you have any success on appeal, then end up with a 
total of two trials In this atter. As I suspect you have this case on contingency, then I needn't point out to you that it 
akes the least a ount of sense for laintiff to take that route. I cannot guarantee that y client ill not contest a ule 
4{b) t pt,          ing. 
s. 
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are not the Intended recipient, you are hereby notified that YDU have received this co unication In error and that any revie . disclosure. disse ination. distribution Dr copying of it or 
Its contents Is prohibited. If you have received this communication In error. pllue destroy all cDples ofthls communlcdon and any attachments. Thank you. 
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Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKERPA








SEP 2 9 2011
CHRISTOPHER D RICH Clerk
By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURTOF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
Defendant
The parties by and through their respective counsel of record Darwin Overson and Eric







CORPORATION a Missouri corporation
B Swartz of the firm JONES SWARTZ PLLC for the Plaintiff and Christopher C Burke and
Thomas J Lloyd III of the firm GREENER BURKE SHOEMAKER PA for Defendant hereby
stipulate to the following schedule for filing briefs and affidavits on Defendantspending Motion
for Clarification set for hearing on October 17 2011 at900am
1 Plaintiffs Opposition briefing andor affidavits if any must be filed and served
by hand delivery on Defendantscounsel no later than October 4 2011 and
2 DefendantsReply briefing if any must be filed and served by hand delivery on
Plaintiff s counsel no later than October 11 2011
E
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By STEPHANIE VIDAK 
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The parties, by and through their respective counsel of record, ar in verson and Eric 
.      & S ARTZ PLLC for the Plaintiff, and Christopher C. Burke and 
Tho as J. Lloyd III of the fir  REE ER B R E S E ER P.A. for efendant, hereby 
stipulate to the follo ing schedule for filing briefs and affidavits on efendant's pending otion 
f r l rification t f r ri   t r ,  t : 0a : 
. Plaintiffs pposition briefing and/or affidavits, if any, ust be filed and served 
by hand-delivery on efendant's counsel no later than ctober 4, 2011; and 
. efendant's eply briefing, if any, ust be filed and served by hand-delivery on 
l i tiff s c sel  later t a  ct er , 1. 
 n     - Page 1 
(416302.doc) 
-0  
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The parties have submitted herewith a proposed Order consistent with this Stipulation
The parties agree that this Stipulation does not affect the ability of either party to file any other
Motions or other documents with the Court as necessary and appropriate
DATED this 1 day of September 2011
DATED this day of September 2011
r
URKE x KER
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing Stipulation for Briefing
Schedule on the following named persons on the date indicated below in the manner indicated
below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220






DATED thisA day of September 2011
Christopher C Burke
Thomas J Lloyd III
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ric . artz, s . 
J S & S TZ, PLL  
1673 . horeline rive, uite 220 
. .   
, da  07 
 is ~ day of Septe ber, 2011. 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA












Plaintiff respectfully moves pursuant to Idaho Rule of Civil Procedure 11a2bfor
reconsideration of this Court orders granting DefendantsMotion for Summary Judgment as to
the foreseeability of injury element of Plaintiffsfirst and second causes of action and granting
DefendantsSecond Motion for Summary Judgment
Plaintiff seeks reconsideration for the following reason If a material issue of fact exists
as to the foreseeability of an acute injury when the product was sold to IDOC then the Plaintiff
has made a threshold case for liability and is entitled to a full measure of damages caused by
PLAINTIFFSMOTION FORRECONSIDERATION OF THE COURTSORDER GRANTING
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I I   J ,  i i i l, 
laintiff, 
vs. 
I  I  RATI , 
a issouri corporation, 
nt. 
 .    
I TIFF'S I   
I    
URT'S   
FENDANT'S   
  
Plaintiff respectfully oves, pursuant to Idaho ule of ivil Procedure 11(a)(2)(b), for 
reconsideration of this ourt's orders granting efendant's otion for Su ary Judg ent as to 
t e f reseeabilit  f i j r  ele e t f laintiffs first a  sec  ca ses f acti , a  ra ti  
efe dant's ec  ti  f r ar  J ent. 
lai tiff see s rec si erati  f r t e f ll i  reason: If a aterial iss e f fact e ists 
as to the foreseeability of an acute injury hen the product as sold to I , then the Plaintiff 
has ade a threshold case for liability and is entitled to a full easure of da ages caused by 
I TIFF'S   I    URT'S  I  
FENDANT'S     -  
SECswrongful conduct A full measure of damages would include consequential damages that
SEC may not have known were a risk of its product So long as the consequential damages were
proximately caused bySECsconduct they are recoverable
In short if the Plaintiff can prove liability by showing SEC knew or should have known
of the risk of acute injury SEC is also liable for the chronic injury even if it was unforeseeable at
the time
This Motion is supported by the pleadings papers affidavits and depositions on file as
well as the Memorandum and Affidavits filed concurrently herewith
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 4th day of October 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke USMail
Thomas J Lloyd III Fax 3192601
GREENER BURKE SHOEMAKER PA X Messenger Delivery
950 W Bannock Street Suite 900 Email cburke@greenerlawcom
Boise ID 83702 tl rlawcom
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA









Case No CV PI 1003515
AFFIDAVIT OF BILLIE JO MAJOR IN
OPPOSITION TO DEFENDANTS
THIRD MOTION FOR SUMMARY
JUDGMENT AND IN SUPPORT OF
PLAINTIFFSSECOND MOTION FOR
RECONSIDERATION
I Billie Jo Major being first duly sworn upon oath depose and state upon my own
personal knowledge as follows
1 I am the Plaintiff in the above captioned lawsuit
2 During the March 3 2008 training at IDOC I was exposed in a prison cell to OC
in the form of a fog It appeared as a mist in the air While I was in the cell I experienced
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JUDGMENTAND IN SUPPORT OF PLAINTIFFSSECOND MOTION FOR RECONSIDERATION 1
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
Q JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702







 rson,  #588  
 . artz,  #639  
 &   
 . li  i , ite  [8 2] 
ost ffice ox 7808 
,   
ele ne: (2 ) -89  
si ile: (2 ) -89  
ail: dar in jonesandswartzlaw.com 
ric jonesandswartzlaw.com 
tt r e s f r laintiff, illie J  aj r 
 4 zon 
( ;iFliS I GPHER D. RICH. GlIde 
  BIEHL 
Deputy 
       I I    
   I , I        
  J ,  i al, 
l intif , 
s. 
  RATI , 
 is ri r r ti , 
f nt. 
   ) 
: . 
t    ) 
 .  I  
I   I   J   
SI I   FENDANT'S 
    
     
LAINTIF 'S    
I  
I, illie Jo ajor, being first duly s orn upon oath, depose and state upon y o n 
personal kno ledge as follo s: 
. I a  the laintiff in the above-captioned la suit. 
. uring the arch 3, 2008 training at I , I as exposed in a prison cell to  
in the for  of a fog. It appeared as a ist in the air. hile I as in the cell, I experienced 
  IE J  J   I   ENDANT'S I     
  I    I TIFF'S  IO   I I  -  
almost immediately a strong burning in my lungs that was much worse than any of my prior
experiences with OC exposure I completed the training but could not stop coughing The
coughing continued into the next day so I went to the doctor My doctor took me off work and
put me on sick leave because of my respiratory condition I had bronchitis when I went through
the training Bymy next doctorsappointment in April 2008 my bronchitis had resolved but the
coughing continued and continues to this day Prior to March 2008 I had had bronchitis on
several occasions and none of those occasions were like the bronchitis I had after the March 3
2008 training It was more painful and lasted longer than any of the other times I had had
bronchitis
3 While I had several trainings on OC products and generally understood that OC
causes respiratory irritation and inflammation nothing in my training experience or observations
at IDOC regarding OC informed me that there was a serious health risk from any of the OC
products I was not made aware that an existing respiratory illness could be made worse by OC
exposure I was not made aware that an existing respiratory illness meant that a person would be
more sensitive to the effects of OC We were trained that if a serious medical condition
existed to call EMS We were never told that OC would make the condition worse that such
persons were more sensitive to OC or even what medical conditions would be considered
serious I simply was not aware that people with a respiratory illness such as chronic cough or
bronchitis would be more sensitive to OC and would experience an aggravation of their
respiratory illness I was particularly not made aware of the dangers of overexposure to OC
which in hindsight I believe I experienced an overexposure to OC during the March 3 2008
training As presented in the trainings and on the label of the SABRE Red products all the
effects from OC were temporary and the product was generally safe There were never
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respiratory illness. I was particularly not ade aware of the dangers of overexposure to OC 
hich, in hindsight, I believe I experienced an overexposure to  during the arch 3, 2008 
training. s presented in the trainings and on the label of the S E ed products, all the 
effects fro  OC were te porary and the product was generally safe.    
  I   J   I   FENDANT'S     
     INTIF 'S    I  -  
discussions regarding the dangers of overexposure I was repeatedly instructed that the effects
were all temporary I understood the effects ofOC exposure to be temporary and safe based on
how I had been trained and what I had been told By temporary I understood that relief from
exposure would occur within 20 to 30 minutes
4 I was never provided a copy of SECsor any other OC product manufacturers
MSDS for OC products prior to the training on March 3 2008 During my employment at
IDOC I read the label of one of SECs SABRE Red OC Spray canistersan OC Spray stream
product Nothing on the label indicated a risk of respiratory injury Nothing warned against
overexposure Nothing on the label said anything about ventilation in the area other than saying
that the sprayed subject should be moved to fresh air after being exposed Nothing on the label
said that OC exposure presented a risk to persons with respiratory illness in the form of
aggravating the illness andormaking it harder to recover from the illness Nothing on the label
said anything about people with respiratory illness being more sensitive to OC or that they
would have more extreme effects from OC exposure At the time of the training I had been
diagnosed with bronchitis
5 Most of my experience at IDOC with OC products was with sprays While
working at IDOC I developed a chronic cough Other employees and some of the prisoners
would make comments about my coughing thinking I was a smoker I was not and I am not a
smoker Even though I had a chronic cough I was able to perform the work continue to care for
myself and participate in recreational activities much as I had always done before I was an avid
cyclist rode horses and generally was physically fit and active during most all of the period that
I worked at IDOC In late February early March 2008 I developed bronchitis and was placed on
light duty by my doctor On March 3 2008 I participated in an OC training where I was exposed
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I worked at IDOC. In late February, early arch 2008, I developed bronchitis and was placed on 
light duty by y doctor. n arch 3,2008, I participated in an  training here I as exposed 
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to SECs MK9 Fogger The MK9 Fogger produces an aerosol of widely disbursed micro
droplets Other of SECsOC products used at IDOC were streams and foams that in my
experience mostly caused eye and skin irritation although there would be some coughing too
By comparison the MK9 Fogger had less effect on my eyes and skin and more effect on my
respiratory system During the training I experienced a strong burning sensation in my lungs and
could not stop coughing The coughing continued even after the training I had never had any
experience like that during my prior experiences with OC When the coughing continued into
the next day I went to my doctor and was placed on medical leave The burning in my chest
continued into the next day and was more severe than anything I had experienced during prior
OC exposures
6 Before starting that training session I asked to be excused but was told that I
would not be excused from the training I participated in the training because I feared that if I
refused I would either lose myjob or be written up Had I known that the kind of exposure I was
going to receive posed a risk of the kind of acute respiratory injuries I suffered I would have
refused to participate but I was assured by all the training I had had prior to and during that
training that any effects of OC Spray were purely temporary 20 to 30 minutes and it did not
pose a serious health risk I have previously said that I would have refused to participate in the
training had I known of the risk of chronic respiratory injury posed bythe MK9 Fogger and that
is true I want it clear that I would have refused the training had I known even just the harmful
acute effects I was going to experience from being exposed to OC under those circumstances
7 Had I been informed of the health risks associated with OC Spray and the MK9
Fogger in particular I would have insisted that I be permitted to opt out of the March 3 2008
training and would have taken steps to protect myself I believe that if the negative health effects
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  IE  J   I   ENDANT'S     
J   I    I TIFF'S  I    -  
of the MK9 Fogger were made known to IDOC employees it is likely the trainers I had would
have designed the training on March 3 2008 differently in order to provide ventilation in the
area in order to avoid spraying so much of the MK9 Fogger in the cell and that they would
have been more open to excusing me from the training due to the fact that I had bronchitis at the
time During none of those trainings did I see or hear anything that would have informed me of
the risks of acute and chronic respiratory illness such as I have experienced during and after the
March 3 2008 training at IDOC I was informed during trainings that OC Spray would cause
irritation and inflammation of the respiratory tract but was always told and in everything I read
that those effects were purely temporary By temporary I mean that it was understood that the
effects of the OC would dissipate after 20 to 30 minutes
FURTHERYOUR AFFIANT SAYETH NAUGHT
fW410
BIL IE JO MAJOR
SUBSCRIBED AND SWORN TO before me this day ofOctober 2011
Notary Public for Idaho
My Commission expires Lo
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 4th day of October 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
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IN THE DISTRICT COURT OF THE FOURTH JUDICIALDISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA









Case No CV PI 1003515
AFFIDAVIT OF COUNSEL IN
OPPOSITION TO DEFENDANT
THIRD MOTION FOR SUMMARY
JUDGMENT
I Darwin L Overson being first duly sworn upon oath depose and state upon my own
personal knowledge as follows
1 I am an attorney with the law firm of Jones Swartz PLLC and am authorized to
practice law before this and all courts of the State of Idaho
2 I am counsel of record for Plaintiff Billie Jo Major in the above action and have
AFFIDAVIT OF COUNSEL IN OPPOSITION TO DEFENDANTS
THIRD MOTION FOR SUMMARY JUDGMENT I
1
001694
.......J -« z -(!J -a:: 
o 
in , IS  #5 87 
ic . r , S  #6396 
S &  C 
~ 
A.M=_=-______ "'ijtFie6".'"':!.3~: -S-iT-
 . reline ri , ite 0 [837 ] 
t ice   
is , I   
Telephone: (208) 489-8989 
Facsi ile: (208) 489-8988 
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  S      I I    
   ,        
I I  J  J , a  i i i al, 
laintiff, 
vs. 
SE IT  E IP E T PORATI N, 
a issouri corporation, 
ant. 
   ) 
: ss. 
County of da ) 
 .    
I     
I   ENDANT'S 
    
 
I, ar in . verson, being first duly s orn upon oath, depose and state upon y o n 
personal kno ledge as follo s: 
. I a  an attorney with the law fir  of Jones &  LLC,   t r   
practice law before this and all courts of the State ofIdaho. 
. I a  c sel f rec r  f r laintiff illie J  aj r i  t e above action, an  a e 
I I    I  POSITI   EFENDANT'S 
I  I   U  J T - 1 
---
firsthand knowledge ofthe documents materials and all other discovery that has been produced
by either party in this case
3 Attached hereto as Exhibit 1 is a true and correct copy of the First Amended
Complaint filed in Ms Major workerscompensation action I prepared and filed the same on
her behalf
FURTHER YOURAFFIANT SAYETH
SUBSCRIBED AND SWORN TO before me this 4th day ofOctober 2011
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firsthand knowledge f the docu ents, aterials, and all other discovery that has been produced 
by either party in this case. 
. tached hereto  hibit  is  true  rrect   the irst ende  
Complaint filed in s. ajor's worker's compensation action. I prepared and filed the same on 
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 4th day of October 2011 a true and correct copy of
the foregoing document was served on the following individualsbythe method indicated
Christopher C Burke
Thomas J Lloyd III
GREENERBURKE SHOEMAKER PA
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TELEPHONE NUMBER POBox 7808
Boise ID 83707 7808
EMPLOYERSNAMEAND ADDRESS attinle Of injury WORKERS COMPENSATION INSURANCE CARRIERS
Idaho State 1299 N Orchard Ste 110 NOrADJUSTOWS NAMEAND ADDRESS
Department ofCorrections PO Box 83720 Idaho State Insurance Fund
Boise ID 83720 1215 West State Street
PO Box 83720 Boise Idaho 837200044
CLAIMANTSSOCIALSECURITY NO
DATE OF INJURY OR MANIFESTATION OF OCCUPATIONAL DISEASE
332008 Injury either happenod on308or took placeover a period offmlr years
The 308date is a date of thdhuv aggravation
STATEAND COUNTYIN WHICH INJURY OCCURRED WHENINJURED CLAIMANT WAS EARNING AN AVERAGE WEEKLY WAGE
State of Idaho Ada County 61740OF PURSUANT TO IDA110 CODE 72419
DESCRIBE HOWINJURY OR OCCUPATIONAL DISEASE OCCURRED WHAT HAPPENED
Chronic Exposure Acute Exposure to Oleoresin Capsicum OCSpray caused asevere chronic coughing condition and damage to the respiratorypubn ona system She experienced Iowa level chronic exposure on nearly a doi y
basis while working in the maximum facil ity along with pmiodie higher levels ofchronic exposure during trainings and whileeoetroling prisoners On Match 3 2008 whilewffering a respiratory illness she underwent training that
required exposure to an OC Spray product specifically designed to targel Ilia respiratory Incl She had a severe scale reaction to the exposure and her physician directed she not return to work until receverod Themakc ilia was
unable to return to workdue to severe chronic cough vocal cord dysfunction and other related complicaliansthat resulted ion her being exposed to OC spnv
NATURE OF MEDICAL PROBLEMS ALLEGED AS ARESULT OFACCIDENT OR OCCUPATIONAL DISEASE
I Iurinrtttriggcrcd vocal Cod dysfunclion and accondary cough
to olcoresiin cnlnaieunn weight due to lackofczcrcisc aM nnedir
consuitationtvrtln Ur Garold Yost oflluc University oEUtal1 Dc
Depression enuscd by tfie nature ofWe and the Inebail
exposure at work as a prison guard for Idaho
I old Neurotin 3Chronic severe cough all
WISy 110 is aTanis in the area of the rIrticipate in norms life activity Severe Dew
itity and reflexaggravated by otxuppmional expowro
1110causerelationshipwa Nit r confirmed by
related oonsatuous on human tissues Severe
WIIArWORKERSCOMPENSATION BENEFITS ARE YOU CLAIMING AT THIS TIME
Permanent Disability Permanent Impairment Temporary Disability Medical Care Lost Wages Lost Earning Capacity Rehabilitation p ha
HOW NOTICE WAS GIVEN ORAL WRITTEN OTHER PLEASE SPECIFY C
w
Observation by supervisors and during ilia process ofapplying fordisability insurance She had to listgo on IiSlu duty rot two weds and at the end of that period she was unableto continue and nvenioyCthedknt lciJc She provided written Bolesfrom berdoetordue tohermcvlical condition though she was unaware ofthecausal fink at nhar fne wanrn s
ISSUE OR ISSUES INVOLVED
I Whether exposure to OC Spray caused the Claimantsmedical condition r
2 Whether claimantsmedical condition qualifies as all occupational disease
3 Whether claimant medical condition was a work place injury
4 If an occupational disease exists was the manifestation of such disease due to the nature of employment in which the hazards of such
disease actually exist are characteristic of and peculiar to the trade occupation process or employment
5 Whether Claimant provided timely notice of her injuryoccupational disease
6 The extent if any to which the Claimantslimitation werefare due to pre existing injury or condition
DO YOU BELIEVTsHIs CLAIM PRESENTSANEW QUESTION Or LAW ORA COMPLICATED SET OF PAC D YES NO IPSO PLEASE STATE WHY
fhc employer ami solely dispute camarion It took until H 1708 for Claimantspulmonary specialist to suspect a nasal relationship between her occupational exposure toOC Spray and her medical oondilion She obuin a diagnos that
accurately described her coalition only aaerbeing referred to the nationally recognized leading medical facility in pulmonary illnesswhich related11conditinn to occupational exposure toOC Spray of April 2 2010 Shc was then diagnosed
as follows I laitam IrilIScred vocal cod dysfunction and secondary cough aurilxrabic to oleoresin capsicum exposure at workas a prison guard for Idaho Corrections 2 Esophygeal dysmodliry and renuxaggravated by occupational
exposure to oleoresin capsicum weight due to lack ofexeroise and medications including Klonopin Restoil and Nnnmin 3 Chronic severe cough nudtiCnetoriai 4 restless legsyndroma The causal relationship was furthcromufirmed byconsultation with Dr Garold Yost of the University ofUlah Depanmcut ofToxicology and Pharmacology who is a specialist in the are ofthe effects 01oleoesin capsicum and its related constituents on human tissues
NOTICE COMPLAINTS AGAINST THE INDUSTRIAL SPECIAL INDEMmryFUND MUST BE IN ACCORDANCE WITH
IDAHO CODE 72334 AND PILED ON DORMIC 1002
DATE ONWHICH NOTICEOF INJURY WAS GIVEN TOEMPLOYER TOWHOM NOTICE WASGIVENty Warden Yonly SgtWor the Sr maduty ht writing
2182008 332008 342008 I 1609 along with other times Lear Van Mamen with the aisIrlfylsrgtOvofggsrd arid otharlDOCemplowho were Involved in Claimsllll ilig applilgtion for disability benelita




SEND ORIGINAL TO: INDUSTRIAL COMMISSION, JUDICIAL DIVISION, P.O. BOX 83720, BOISE, IDAHO 83720- 041 
FI T  
RKERS' COMPENSATI  
OMPLAI T 
CLAIMANT'S (I JURED WORKER) NAME AND ADDRESS CLAIMANT'S AITORNllY'S NAME, ADDRESS, AND TELEPHONE NUMBER 
Darwin Overson 
ill  aj r Jones & Swartz 208-489-  
TELEPHONE NUMBER! 
MPLOYER'S NA E  A S ( t time of injury) 
Idaho State 1299 N. Orchard Ste 110 
rt t f rr cti  PO Box 83720 
oise, I  83720 
POBox 7808 
Boise, ID 83707- 8 
S' COMPENSATI  INSURANCE CAR IER'S 
( OT ADJUSTOR'S) NAME AND A J) S 
I  Stat  I   
 t t t  Str t 
   is  I  8 -00  
CLAIMAN'I'S SOCIAL SECURITY NO, DA  OF I J Y O  II' T H N OF OCCUPATIONAL I  
3-3-2008 I.jury .lIher h<ppc: .. cd on 3·3·08 or .. ok place over a p .. iod orr"'IT )'<: .... 
The 3·3·08 dale is 8 date offurthct aggravation. 
STATE AND COUNTY IN WHICH INJUR.Y OCCURRED 
t t  fIdaho,  t  
HEN I J RE , CL I T AS eARNI  AN eR E EEKLY E 
f': $ 617.40 I'URSUA TTO IDAHO C E 72419 
B I     PATI  se  (  ENED) 
Clm:mic Exposure & Acwe Sxposllrc to Oleorclin Capsicum (OC) Spray eauw1 a ~ve,c chronic coughing coodifiofl and <iAn13g(: to tM rupl'&tory/pulmonaTY ".ystcnl. She expcritllced lower le"el chronic exposure on neatly a dl1lily 
bASis while working in the maltimunl f.1Ci! ily ttlong with periodic hither levels or chronic cxposprc during trainings and wllilc conttotlng prisoners. On Mardi 3,2008, wbilo sulThring a reSpirAtory iUIWSIIi, she u»dcnvcnt training that 
reQ1fired exposure to;m OC Spray product specifically dcsi&11cd 10 tlU"G~ the respiratory tract She had II severe;ellte rencdo., to 1hc exposure Iud her physician dircelCd she not return 10 work until rccovcrod.. 'rhcrcr.ftct, sho was 
le t  Tenlr  10 rk  10 cYcro chrOlliC cough,   y.$ .li lJ B  Ol  l  on'pJieMioll  Ihnt r sult  from r i  c r ed t   spray. 
  I  l'ROB  F.      B   I  S  
I. Irritauf.trigs:crcd vocal eord dysfuncliol1 nnd seeondary couch anriblilablo 10 oleoresin cap;icum   r  lUi  ri  r    Corrcctiol1$. 2. EsoI)hY8C41 dysmotility and reflux. aggravated by occupational c~-posur-o 
10 e c: ll ps c tll, eic t   :.e1c.ofclCcrcis , nd Hl eatit)J)$ including Klonopin, RcsIMiI, anel ul'olin. . i , ItVt c gh, ll1ulti·factoriBI. 4. rCSIlcu leg: syndrotn", 'n1C e.usn1 rolaljOll$hip WM (unbel' tonf'lnncd by 
COfIsuh"ti  Wllh Dr. r l  VOlt C l~ ! ,crsily f t h, ~partmcnt ".fToxicology 81H1 PhannllC<?'l~sy ~ho is I. ~ialist .ill.the MCl oflhe ofTcct5 ofolcoresin tapsh:l.un and its rclaledconstlluclM$ on hunlan lissu~. Se"CfC 
c tcs iOI1 ca e   Ih - ature (lh  COluiltlon li  .b  a ibty to excrc(Sc. work, or oli1crwJse p.rtlC! 4  I  mud o acUVJty.  p ession, 
HAT ORKERS' CO PENSA:nON BENEFITS ARE YOU CLAI ING AT TH1S TI E? 
Cl1uanent isability, er anent I pninnent, e porary isability, edical are, ost ages, ost arning apacity, ehabilitation, 
TE     J  S      I   IVmfti>"IY w.ns.. V rd ; CI F :: ~r.~h.SrQj:",~dU1Y in riti ; 
2-18-2008, 3-3-2008, 3-4-2008, 1-16-09 along ith other ti es. toih v ••  .... n  lh'di~7,Srgt Ov~tClIJ d .lI  lher IDOC eml'lnyees who wcrc in\<OJved in Cfa'manpia~fj~ app1iQ!i9n {(lr disabilhy benefits. 
HO  NOTICE AS GIVEN: [XJ ORAL I!l I  IXl , P S  SP lF  g ~.::: 
Observation by Sl.lpcrvisOtS Qlld d'iring the proccss or applying for disability in$ur:u\Ce. She hud to {inl go on IiCht duly for lwo weeks and at the end of th!t period, she was unable 10 continue :md \~I.Df·JWcdicftlTclL~e, She provided wrinen ~cs 
from her doctor due to her medical condittOl1 thousl' she was unawa.re oflhc c;wullillk lit tllat time. When she was diagnosed with au occupalional iniu!)'!diseasc, she provided written notice by filii! first n.cp;t~rJfliuty on January 1(> 20009. 
ISSUE OR ISSUES INVOLVED 
rn 
1. ether s re t  C  s   i ant's e  tion 
2. hether clai ant's edical condition qualifies as an occupational disease 
3. hether clai ant's edical condition as a ork place injury 
4. If an occupational disease exists, was the anifestation of such disease due to the nature of e ploy ent in which tile hazards of such. 
disease actually exist, are characteristic of and peculiar to the trade, occupation, process or employment 
5. 
6. 
hether laimant rovided timely notice f er injury/occupational isease 
The extent, if any, to which the Claimant's limitation were/are due to pre-existing injury or condition 
DO YOU BELIINE THIS CLAIM P Ese S A NEW QUIlS ION OF LAW ORA P IC TED SET 0[> FACTS1 Iii! YDS 0 NO IF S , PLEASIl STATE HY, 
'fhe employer and Stitely dispute causation. It took unlilll~ 17·08 forClail113nC's pulmonary .specialist to suspeer a causal relationship bct,vcen herotcupslional exposure to OC Spmy and ber nlCdic:d condilion. Sho abhlinll diagnosis that 
accurately described her cOIKlition only ilO~rbeing rc:(errcd to jhe nationally recognized lcadina medical £'1Cility in )mln'OUlf)' iIIncss which relBted hcrconditian to occupatioJ1al oxpo$\lre to OC Sp.-.y ou April 2, 2020. She WIIS ellen dillsnOS«l 
ItS follows: I. Irritant-triggered voc.."l cord dysfunction ;lnd secol1dltl')' couSh luributablc 10 oleoresin capsicum exposure a.t wMk as" prison guard {or Idaho COMclions. 2. Bsoph)'SCfll dysll\Otility and reflux. 8ggrawWd by occtlp1lional 
exposure to oleoresin cnpsieulll, wejght due to lack ofexcrcioKt and luc:dicatio(l$ including Klonopin, Re.slotil, a.Dd NetlrOlin. 3. CJ}ronic. severe COtI&h, 111\1lti-fBetoriot. 4. tC$llesslegsyndrome. The caurol rctalionshlp \VA$ fllnhcr COIllilmcd by 
consuhncion with Dr. Oarold Yost oftbe Univcr"ily ",rUhdl, Dcp311rncnl orToxicolo.BY and PhAnnltcoloRY who is .. Jt,eciali51 in the area ofthc arrecis ofolcorcsln CIlI)&ieum and its rehnedc<matituc:ms on human tissucs. 
NOTICE: CO PLAINTS AGAINST THE INDUSTRIAL SPECIAL INDE NITY FUND UST BE IN ACCORDANCE ITH 
IDAHO CODE § 72- 34 AND FILED ON F  I.C. 1002 
ICIOOI (Rev. 110112004) (COMPLETE OTHER SI ) Complaillt - Page 1 or 3 
APllClldix 1 
See Attached List ofPhysicians
PHYSICIANS WHOTREA EDCLAIMANTNAMEANDADDRESS
r
RE OFCLAIMA O TTORNEY
Altgust 18 2011
WilliamIoWand MD Glenn H Moldenhauer DC Jewish
Karen A Pacheco MD MBPEI
National Health
Janat0011 Chiropractic Cantor
RELATION TO DECEASED CLAIMANT
Dmaty1IlcndricksonM 228 Holly
1400 Jackson Street
Idaho PulmonaryAssoctloisc Nampa ID 83666
Co 5020b





WHAT MEDICAL COSTS HAVE YOU INCURRED TO DATE Prescriptions Approximately 231300 Medical CareApproximately6632200
WHAT MEDICALCOSTS HAS YOUR EMPLOYER PAID IfANY S 0 WHATMEDICAL COSTS HAVE YOU PAID IFANY 3496 00 proximate
IAM INTERESTED IN MEDIATINGTHIS CLAIM IF THE OTHERPARTIES AGREE YES NO
DATE LSNATU
PLEASE ANSWER THE SET OF QUESTIONS IMMEDIATELY BELOW
ONLY IF CLAIM IS MADEFOR DEATH BENEFITS
NAME AND SOCIAL SECURITY NUMBER OFPARTY DATEOF DEATH
FILING COMPLAINT
WAS FILING PARTY DEPENDENTON DECEASED DID FILING PARTY LIVE WITH DECEASED AT17ME OF ACCIDENT
YES NO 1 YES NO
CLAIMANT MUST COMPLETE SIGN AND DATE THE ATTACHED MEDICALRELEASE FORM
CERTIFICATEOFSERVICE









via 0 personal service ofprocess
A regularUSMail
SURETYNAMEAND ADDRESS
Idaho State Insurance Fund
CO Gardner W Skinner




via 0 personal service ofprocess
regul S Mail
Signatur
NOTICE An Employer or Insurance Company served with a Complaint must file an Answer on DormIC 1003 with
the Industrial Commission within 21 days of the date of service as specified on the certificate ofmailing to avoid
default If no answer filed a Default Award may be entered
Further information may be obtained from Industaial Commission Judicial DivisionPO Box 83720 Boise Idaho
83720 00412 83346000
COMPLETEMEDICAL RELEASE FORM ONPAGE3
Complaint Page 2of 3
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.. 
   of i  
I I   IlATH  CLAIMANT (NAMH AN  ADDRIlS ) 
illia  l...o\leland, D 
lanat QiOonncll 
.""y 1. H,ndric!<sol1. M.D. 
Idaho Pulmonary ss-oc.·Boisc 
100S North C.~i, Rood 
noi.o, ID 83706 
208·323·0031 
l nn W. l auer I DC 
hiropraceic ent(!Jl: 
220 ll  
Nampa. 10 8  
208-< 1-57 9/ 4 1-451  f  
Or. aran .. Pacheco, MO, MS U 
ti l Je i  Health 
1"00 Jackson Street 
Donver, CO. 80 6 
30 - -1 1 
8 -4 -8 1 
WHAT MEDICAL COSTS HAVE YOU INCURRED TO DATE? Prescriptions pproxi ately 2313.00 edical Care Approxi ately $66,322.00 
T E I L STS S  !l PL E  PAID, II' Y'I $   I   li  PAID, I ' ANY? $ 3 .  - ap r  
  E     LAI ,     E. rn  0  ----- ;X .",- "'\ DATE ~~EOI'CLAIMA.btTTOI~'i u  8,  
~ ---
        
        
  I l. I   01' I'  DATE OF DEATH   E  L I  
P  I.  
 I I     ED? I  I      1   CIDENT? 
Dy  DNO DYE  DN  
  ,     I     
  ti    e ..!L..    
PL YER'S   RESS 
Idaho State 
 f  
/o G lilnc  W. Skm  
tril , , livan & i  LP 
  c 
   
Ois ,1   
i : [.l  ice  ces  
I    
, 20.!.!.., I caused to be served a true and correct copy ofthe foregoing Co plaint upon: 
URETY'S    
    
/O er . nne  
C tri J 1 j Dn  nJ J jyan &- Ki n9 r.LP 
 ll ane 
00-1:100( J  
9 ,   
ia: IJ ers a) scr ice f rocess 
:lll re l r .S. il 
~iI 
i t r 
I : n ployer 01' Insurance o pany served ith a o plaint ust file an ns er on For  I.C. 1003 ith 
the Industrial Commission within 21 days of the date of service as specified 011 the certificate of mailing to avoid 
f lt. f  (lllSWer is file ,  ef lt rd y e e tere ! 
rther infonnation  e taine  fr : Industrial issi , J i ial i isi , .O.  , is , I  
3720- 041 (208) 334-60 . 
(COMPLET  ICA  EASE    ) 
o plaint - Page :1 of 3 
Cr
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZPLLC
1673 W Shoreline Drive Suite 200 83702











IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA













Plaintiff submits the following Memorandum in Opposition to DefendantsMotion for
Clarification which in substance is the Defendantsthird Motion For Summary Judgment and
in Support ofPlaintiff s Motion for Reconsideration
I STATEMENT OF FACTS
The facts of this case have been extensively briefed by both parties This Court is
familiar with the general history of Ms Major employment with IDOC her training with OC
products and the effects that she suffered as a result Rather than burden the Court with an entire
MEMORANDUM IN OPPOSITON TO DEFENDANTSMOTION FOR CLARIFICATION
THIRD MOTION FOR SUMMARY JUDGMENT AND IN SUPPORT OF PLAINTIFFS




ar in verson, IS  #5887 
Eric . S rt , IS  #6396 
J ES &  P LC 
1673 . reline ri , ite  [837 ] 
Post ffice ox 7808 
Boise, I  83707 
Telephone: (208) 489-8989 
si il : (20 ) -8988 
E ail: dar in jonesandswartzlaw.com 
eric jonesandswartzlaw.com 
Attorneys for Plaintiff, Billie Jo ajor 
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 E I    E     
E   , I        
I IE J  J , and individual,  .    
laintiff, 
  I  
vs. 
I  I  RATI , 
a issouri corporation, 
 ENDANT'S   
I  (THIR   
  MENT)   
  I TIFF'S  
 I I  
nt. 
Plaintiff sub its the follo ing e orandu  in pposition to efendant's otion for 
larification hich, in substance, is the efendant's third otion For Su ary Judg ent, and 
in Support of Plaintiffs otion for econsideration. 
I.    
The facts of this case have been extensively briefed by both parties.   i  
fa iliar ith the general history of s. ajor's e ploy ent ith I , her training ith  
products, and the effects that she suffered as a result. Rather than burden the Court with an entire 
 I  POSI   EFENDANT'S I  F  I I I  
(THIRD OTION FOR SU ARY JUDGMENT) AND IN SUPPORT OF PLAINTIFF'S 
  I  - 1 
recitation of the factual history just the most salient factual points will be presented in this
Memorandum and cited within the argument All other factual background is set forth in the
Statement of Undisputed Facts and Statement of Disputed Facts set forth in Plaintiffs
Memorandum in Opposition to DefendantsMotion for Summary Judgment and Memorandum
in Support of PlaintiffsCross Motion for Partial Summary Judgment and Memorandum in
Support of Plaintiffs Motion for Reconsideration and in Opposition to DefendantsSecond
Motion for Summary Judgment Those documents are hereby incorporated as though fully set
forth herein
II ARGUMENT
A Motion for Summary Judgment Standard
Summary judgment is proper when there are no genuine issues of material fact and the
moving party is entitled to judgment as a matter oflaw All controverted facts are to be liberally
construed in favor ofthe non moving party
B Acute Injury Has Always Been Part ofThis Case and There Are Genuine Material
Issues of Fact For a Jury to Decide
1 The Complaint put SEC on Notice of Acute Injury
Defendant claims the Plaintiff has not brought an acute injury claim
The Defendant is wrong
The Complaint describes Ms Major prior respiratory illness
The Complaint describes Ms Major on light duty due to bronchitis in February and
March 2008
IRCP56c
2 Heath v HonkersMiniMart Inc 134 Idaho 711 712 Ct App 2000
3
Complaint 6
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r it ti  f t e fa t l ist r , just t e st s li t f t l i ts ill e r s t  i  t is 
e ora   ite  ithin the r t. ll t r fa t l r  is s t f rt  in t  
t t t f ndisputed ts  t t e t f is te  ts s t f rt  i  laintiff's 
e ora  in siti  t  efe dant's tion f r ar  J e t a  e ra  
in rt f laintiff's ross tio  f r rtial r  ent;  r  i  
rt  l i tiff's tio  f r i r ti   i  iti  t  f ndant's  
otion for Su ary Judg ent. hose docu ents are hereby incorporated as though fully set 
 i . 
.  
. otion for Su ary Judg ent Standard 
r  judg e t i  r r  t r  r   i  i  f t ri l f t  t  
i  rt  is titl  t  judg e t s  tt r fl w.! ll tr rte  f ts r  t   li r ll  
c str e  i  fa r f t e - i  arty.2 
. t  j  s l a   t  i      i  t i l 
Issues of Fact For a Jury to ecide 
. e o plaint t  on otice f cute I j r  
efendant clai s the Plaintiffhas not brought an acute injury clai . 
The efendant is rong. 
The o plaint describes s. ajor's prior respiratory illness. 3 
 l i t s ri es s. j r  li t t   t  r itis i  r r   
 08.4 
1 I.R.C.P. 6(c). 
2 e t  v. nker's i i- rt I c.,  I a  1,  (Ct. p. 000). 
3 Complaint, ~ . 
  I   FENDANT'S    
(THIR  TI  F  S  J MENT)  I  S PP T F PL INTIFF'S 
  I I  -  
The Complaint describes the exposure to OC during the March 3 2008 training
The Complaint describes the immediate effects of the March 3 2008 OC exposure
The Complaint describes Ms Major as continuing to cough after the training and having
to go to the doctor
The multiple summary judgment documents discuss the events that include acute injury
The Complaint and summary judgment documents fully put SEC on notice that
Ms Major was claiming both an acute and a chronic injury
Idaho adopted notice pleading All that is required is a short and plain statement of the
claim showing that the pleader is entitled to relief
Idaho abandoned the old more rigid pleading requirement that a complaint allege a
statement ofthe facts constituting the cause of action in ordinary and concise language
Cases should be decided on their merits and not on pleading technicalities
There is no requirement that Ms Major separately plead acute and chronic injury
It is sufficient that a complaint include a claim for physical injury










8 Memo in Opp to Def s MSJ Memo in Supp of PlfsCross Mot for Partial Summary Judgment
Memo in Supp of Mot for Reconsideration and in Opposition to Defendant Second MSJ
9 Seiniger Law Office v North Pacific Insurance 145 Idaho 241 24648 2008IRCP8a1
to
Seiniger Law Office 145 Idaho at 24648
IdIRCP1a
12 Memo in Opp to Def s MSJ Memo in Supp of Plf s Cross Mot for Partial Summary Judgment
Memo in Supp ofMot for Reconsideration and in Opposition to Defendant Second MSJ
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The o plaint describes the exposure to  during the arch 3, 2008 training.5 
he o plaint describes the i ediate effects of the arch 3, 2008  exposure.6 
The o plaint describes s. ajor as continuing to cough after the training and having 
to go to the doctor.7 
The multiple summary judgment documents discuss the events that include acute injury.8 
he o plaint and su ary judg ent docu ents fully put  on notice that 
s. ajor as clai ing both an acute and a chronic injury. 
Idaho adopted notice pleading. ll that is required is a "short and plain state ent f the 
claim showing that the pleader is entitled to relief.9 
I  ed t  l , re ri i  l i  r ir t t t  l i t ll  "a 
state ent of the facts constituting the cause of action, in ordinary and concise language."IO 
ases should be decided on their erits and not on pleading technicalities. I I 
here is no require ent that s. ajor separately plead acute and chronic injury. 
It is sufficient that a co plaint include a clai  for physical injury. 
It i  tr  t t t  f r t  f s  i l    . jor's r i  nditi n.  
4 Co plaint, ~ . 
5 Complaint, ~ . 
6 Complaint, ~~ , . 
7 Complaint, ~~ 11, 13. 
8 e o. in pp. to efs SJ & e o. in SUpp. of Plfs ross ot. for Partial Su ary Judg ent; 
Memo. in SUpp. of ot. for Reconsideration and in Opposition to Defendant's Second SJ. 
9 Seiniger Law Office v. North Pacific Insurance, 145 Idaho 241, 246-48 (2008); LR.C.P. 8(a)(1). 
10 Seiniger Law ffice, 145 Idaho at 246-48. 
11 Id.; I.R.C.P. l(a). 
12 e o. in Opp. to efs SJ & e o. i  upp. f ifs r ss ot. f r artial ar  J dg ent; 
Memo. in SUpp. of Mot. for Reconsideration and in Opposition to Defendant's Second MSJ. 
 I  SI   FENDANT'S    
(THIRD MOTION FOR SUMMARY JUDGMENT) AND IN SUPPORT OF PLAINTIFF'S 
  I  -  
SEC placed the focus on chronic injury by successfully moving to dismiss chronic injury
damages from the case which is an odd result considering that there is evidence of the
foreseeable acute injury causing the chronic injury
All that has changed since this Court ruling dismissing Ms Major chronic injury
damages is that SECs third motion for summary judgment is now targeting Ms Major
damages for the acute injuries
The focus of the motions until now has been on the foreseeability of the chronic injury
14
The focus is now on the foreseeability ofMs Major acute injury
Just because the Complaint includes chronic injury does not mean it is not also for acute
injury
SEC pretends that there must be a cause of action for acute injury and a cause of action
for chronic injury That is a manipulation of the pleading requirements
The Complaint states a strict liability and a negligence cause of action
Both claims seek damages for acute and chronic injuries
13 See Gallick v Baltimore O R Co 372US 108 121 1963 once a threshold case is established
showing some foreseeable injury all damages that flow from the defendantsnegligence are recoverable
irrespective of whether all the injuries were foreseeable citing Boal v Electric Battery Co 98 F2d
815 819CA3dCir cancer caused by inhalation of acidic gas Koehler v Waukesha Milk Co 208
NW 901 903905 1926 collecting authorities wrongful death resulting from a finger cut by broken
milk bottle Restatement Torts 435 2 Harper and James Torts 11391140 Prosser Torts 260 2d
ed Seavey Mr Justice Cardozo and the Law of Torts 48 Yale LJ390 402403 Aff of Major 2
47 Aff of Counsel in Opp to Def s MSJ and in Supp ofPltf s CrossMPSJ 3 Ex 1 Pacheco Dep
2822 341 3811 471 641 731 751 8811 9025 12022112102425 1275
142917 and Exs 69 72 73 Bates Nos NJH 48 63 8087 9 Ex 7 Schaffer Dep 764 771
9016 9116 10 Ex 8 Nance Dep 214 4311 4412 486 501 6016 6322 643
654 904 942 12425 12721 1307 13725 1390 1402 1574 1635 and Exs B D E
J LO 11 Ex 9 Link Dep 571 5825 605 6215 Second Yost Affidavit 913 Aff of
Counsel in Supp of Plaintiffs Motion for Reconsideration and in Opposition to DefendantsSecond
Motion for Summary Judgment 3 Ex 1 Aff of Major in Opp To Defs 3d MSJ 210
14 Memo in Opp to Def s MSJ Memo in Supp of Plfs Cross Mot for Partial Summary Judgment
Memo in Supp ofMot for Reconsideration and in Opposition to Defendant SecondMSJ
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SEC placed the focus on chronic injury by successfully oving to dis iss chronic injury 
da ages fro  the case, hich is an odd result considering that there is evidence f the 
foreseeable acute injury causing the chronic injury. 13 
All that has changed since this Court's ruling dis issing s. ajor's chronic injury 
da ages is that SEC's third otion for su ary judg ent is no  targeting s. ajor's 
da ages for the acute injuries. 
he focus f the otions until no  has been on the foreseeability ofthe chronic injury. 14 
he focus is no  on the foreseeability f s. ajor's acute injury. 
Just because the o plaint includes chronic injury does not ean it is not also for acute 
InJury. 
S  pretends that there ust be a cause of action for acute injury and a cause of action 
for chronic injury. That is a anipulation of the pleading require ents. 
he o plaint states a strict liability and a negligence cause of action. 
oth clai s seek da ages for acute and chronic injuries. 
\    .  & 0. R. Co., 372 U.S. 108, 121 (1963) (once a threshold case is established 
sho ing so e foreseeable injury, all da ages that flo  fro  the defendant's negligence are recoverable 
irrespective of hether all the injuries ere foreseeable) (citing Baal v. Electric Battery Co., 98 F.2d 
815, 819 (C.A.3d Cir.) (cancer caused by inhalation of acidic gas); Koehler v. aukesha ilk Co., 208 
N.W. 901, 903-905 (1926) (collecting authorities) (wrongful death resulting fro  a finger cut by broken 
ilk bottle); Restate ent Torts § 435; 2 arper and Ja es, Torts, 1139-1140; Prosser, Torts, 260 (2d 
ed.); Seavey, r. Justice ardozo and the La  f Torts, 48 ale .J. 390, 402-403); ff. of ajor, ,-r,-r , 
4-7; ff. of ounsel in pp. to efs SJ and in Supp. of ltfs ross- PSJ,,-r , x.  (Pa  ep., 
28:2-22,34:1 - 38:11,47:1 - 64:14, 73:13 -75:1,8 : 1 - 0:25, 20:2-2 , 21:10-2 , 122:25 - 127:15, 
142:9-17 and Exs. 69, 72, & 73 (Bates os. J  48,63, 80-87), ,-r 9, Ex. 7 (Schaffer ep., 76:4 - 7:1, 
0:16 - 91:16), , ,-r 10, Ex. 8 (Nance ep., 21:24 - 43:11,44:12 - 8:6,50:10 - 0:16, 3:6-22, :3-
65:4,90:4 - 94:24, 124:25 - 127:21, 130:7 - 37:25, 39:10 - 40:12, 57:14 - 163:5  xs. , , , 
J, & -O), ,-r 11, x. 9 (Link ep., 57:1 - 8:25; 0:5 - 62:15); Second ost ffidavit, ,-r,-r -1 ; f . f 
ounsel in SUpp. f laintiffs otion for econsideration, and in pposition to efendant's econd 
otion for Summary Judgment,,-r 3, x. 1; ff. of ajor in pp. o efs 3d SJ,,-r,-r -1 . 
14 e o. in pp. to efs SJ & e o. in Supp. of Plfs Cross ot. for Partial Su ary Judg ent; 
emo. in SUpp. of ot. for Reconsideration and in Opposition to Defendant's Second SJ. 
  SI   FENDANT'S   L I I I  
(THIRD OTION FOR SU ARY JUDG ENT) AND IN SUPPORT OF PLAINTIFF'S 
  I  -  
The plain reading of the Complaint and summary judgment documents is that the acute
injury occurred and led to the chronic injuries
Even if the chronic injuries were unforeseeable since the acute injuries were foreseeable
Ms Major should be able to recover for both under well established case law
Nonetheless this Court has cut away the chronic injury damages that flowed from
Ms Major acute injury
In the current procedural posture of this case the focus is on whether the Defendant knew
or should have known that SABRE Red Law Enforcement Unit 10 OC MK9 Fogger posed a
danger of acute respiratory injury
An acute injury is generally an immediate injury brought about suddenly
16
ie extreme
burning ofthe lungs upon being overexposed to OC aerosol
17
An acute injury can be an injury that continues several days weeks or up to three
months
In this case the Plaintiff was exposed to a high concentration of highly aerosolized 10
OC and immediately experienced a strong burning in her lungs that was much worse than any of
her prior experiences with OC exposure and lasted far longer than the 20 to 30 minutes that the
effects normally took to stop
19
15 See CSXTransp Inc v McBridel31 S Ct 2630 2639 2011 Gallick 372US at 121 Boal 98F2d
at 819 Koehler 208 NW at 903905 Restatement Third Torts 435 2 Harper and James Torts
11391140 Prosser Torts 260 2d ed Seavey Mr Justice Cardozo and the Law ofTorts 48 YaleLJ
390 402403
16 StedmansMedical Dictionary p 22 27 Ed 1999
17 See Aff of Major in Opp To Defs3d MSJ 2 Plaintiff experienced a strong burning sensation in
her lungs
18 StedmansMedical Dictionary p 348 27 Ed 1999
19 Aff ofMajor in Opp to Defs3d MSJ 2
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The plain reading of the Co plaint (and su ary judg ent docu ents) is that the acute 
i jur  rre   le  t  the r i  i j ri s. 
en if t e r i  i juries ere f res l , si ce t  t  i j ries r  f r s bl , 
s. j r s l   le t  r r f r t  r ll- st lis  s  l w. 15 
et eless, t is rt as c t a a  t e c r ic i j r  a a es t at fl e  fr  
s. jor's t  i j r . 
I  t  rre t r r l st r  f t is s , t  f s is  t r t  f t  
r s l    t at  , a  f rce e t it, 0% ~C, -9 r s   
danger of acute respiratory injury. 
n acute injury is generally an i ediate injury brought about suddenly,16 .e., t  
burning f the lungs upon being overexposed to  aerosol.1  
 acute injury can be an injury that continues several days, eeks, or up to three 
nths. 18 
I  t is case, t e lai tiff as e se  t  a i  c ce trati n f i l  aer s lize  0% 
  i i t l  ri   str  r i  i  r l s t t s  rs  t   f 
her prior experiences with OC exposure and lasted far longer than the 20 to 30 minutes that the 
effects normally took to stop.19 
15 See S Transp., Inc. v. c ride131 S. t. 2630, 2639 (2011); allick, 372 .S. at 121; aal, 98 .2d 
at 819; Koehler, 208 N.W. at 903-905; Restate ent (Third) Torts § 5;  ar er a  Ja es, rts, 
-11 ; r sser, rts,  (2  d.); avey, r. sti  r z   t   f rts,  l  J. 
, -4 3). 
16 Sted an's edical ictionary, p. 22 (2ih Ed. 1999). 
17 ee ff. f j r i  .  ef's  J, ~  (Plai tiff ri   str  r i  s s ti  i  
her lungs). 
18 Sted an's edical Dictionary, p. 348 (27th Ed. 1999). 
19 Aff. of ajor in Opp. to Def's 3d SJ, ~ . 
  I   FENDANT'S    
(THIR  TI  F  S  J ENT)  I  S PP T F PLAINTIFF'S 
  I  -  
The coughing was much worse than any of her prior experiences with OC exposure
20
The next day she went to the doctor because the coughing would not stop
Her doctor took her off work because she could not work in her condition
22
Her bronchitis took until almost April to resolve
Her bronchitis was worse than it had been in the past
SEC has known of Ms Major acute injuries since being served with the Complaint
SEC has done extensive discovery
SEC has copies ofMs Major medical records
SEC tookMs Major deposition
There is absolutely no way SEC can be surprised by MsMajor acute injury claim
2 Ms Major Did Not Know the Health Risks of SABRE Red Law
Enforcement Unit 10 OCMK9 Fogger
Ms Major knowledge training observations and experience were that the effects ofOC
last approximately 20 to30 minutes and that the product was safe
What she did not know was that the MK9 Fogger was different in terms of the health
risks that it posed
While she understood that unlike the sprays the fogger was specifically designed to
irritate the respiratory tract she did not know the adverse health effects of being exposed to
aerosolized OC while a person has chronic cough bronchitis or other respiratory illness
27
20 Aff of Major in Opp to Defs3d MSJ 2
21 Aff ofMajor in Opp to Defs3d MSJ 2
22 Aff ofMajor in Opp to Def s 3d MSJ 2
23 Aff ofMajor in Opp to Defs3d MSJ 2
24 Aff ofMajor in Opp to Defs3d MSJ 2
25 Aff ofMajor in Opp to Defs3d MSJ 37
26 Aff ofMajor in Opp to Defs3d MSJ 37
27 Aff ofMajor in Opp to Defs3d MSJ 37
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he coughing was uch orse than a y f her prior e periences ith  e p s re.20 
The next day she went to the doctor because the coughing would not stop.21 
er t r took er ff or  ecause s e ld t ork in r i .22 
er r c itis to  til al ost pril t  resolve.23 
er r c itis as orse tha  it a  ee  in the ast.24 
 as no n f . j r's te injuries ince i  r e  it  t e l i t. 
S  has done extensive discovery. 
 as ies f s. jor's i l r r s. 
SEC took s. ajor's deposition. 
There is absolutely no way SEC can be surprised by s. ajor's acute injury clai . 
. . j  i  t  t e lt  i  f  ,  
nforce ent nit, 10% , -9 ogger 
s. ajor's kno ledge, training, observations and experience ere that the effects of  
last approximately 20 t030 minutes and that the product was safe?S 
t s  i  t  s t t t  -9 r s iffer t i  t r s f t  lt  
risks that it posed. 26 
ile s  rst  t t, li  t  s r s, t  f r s s ecifi ll  si  t  
irritate the respiratory tract, she did not know the adverse health effects of being exposed to 
aerosolized C hile a person has chronic cough, bronchitis or other respiratory illness?7 
20 Aff. of ajor in Opp. to Defs 3d SJ, ~ . 
21 Aff. of ajor in Opp. to Defs 3d SJ, ~ . 
22 Aff. of ajor in Opp. to efs 3d SJ, ~ . 
23 Aff. of ajor in Opp. to efs 3d SJ, ~ . 
24 Aff. of ajor in Opp. to efs 3d SJ, ~ 2. 
25 Aff. of ajor in Opp. to efs 3d SJ, ~~ -7. 
26 Aff. of ajor in Opp. to Defs 3d SJ, ~~ -7. 
27 Aff. of ajor in Opp. to efs 3d SJ, ~~ 3-7. 
 I  SI   EFENDANT'S I   I I I  
(THIRD MOTION FOR SUMMARY JUDGMENT) AND IN SUPPORT OF PLAINTIFF'S 
I   ECONSIDERATI  - 6 
She was not aware that persons with respiratory illness are more sensitive to OC
She was not aware that OC complicates respiratory illnesses
29
She was not aware that OC exposure while she had bronchitis would make the bronchitis
worse and make it harder to get well
She was not aware ofthe safety concerns ofrespiratory overexposure to OC
Had she known the true danger involved in being exposed to aerosolized OC while she
was suffering from a respiratory illness she would have refused the training
32
3 SEC Knew orShould Have Known the Acute Health Risks of SABRE Red
Law Enforcement Unit 10 OC MK9 Fogger
Did the Defendant know that its product would specifically target the respiratory tract
Yes it was designed for that purpose
33
Did the Defendant know that exposing persons with respiratory illness to OC would
aggravate the illness and make it harder to recover Yes SEC knew a safety concern existed
with OC when used on people with respiratory illness
Q Okay Particularly there are concerns with the safety of OC
products when used on individuals with pulmonary issues
generally
Q Respiratory issues
A The effects may be greater
34
28 Aff of Major in Opp to Def s 3d MSJ 37
29 Aff of Major in Opp to Defs 3d MSJ 37
30 Aff of Major in Opp to Defs 3d MSJ 37
31 Aff of Major in Opp to Defs 3d MSJ 37
32 Aff of Major in Opp to Def s 3d MSJ 37
33 Aff of Counsel in Opp to Defs MSJ and in Supp of Pltfs CrossMPSJ 10 Ex 8 Nance Dep
501 5617 7519 811 125 1273 and Exs B D E J LO
34 Aff of Counsel in Opp to Defs MSJ and in Supp of Pltfs CrossMPSJ 10 Ex 8 Nance Dep
441216
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 as t r  t t rs s it  r s ir t r  illness r  r  s siti  t  C.28 
e as t a are t at  c licates res irat r  illnesses.  
 s t r  t t  s r  ile s   r itis l   t  r itis 
rse a  a e it ar er t  et ell.3o 
  t r  f t  f t  r  f r ir t r  r r  t  C.3 ! 
   t  tr  r i l e  i  i  s  t  r li   il   
as suffering fro  a respiratory illness, she ould have refused the training.  
.  ne   l    t  t  lt  is    d, 
 f rce t it, 0% , -9 r 
id the efendant kno  that its product ould specifically target the respiratory tract? 
es, it as designed for that purpose. 33 
Did the Defendant know that exposing persons with respiratory illness to OC would 
a ra ate t e illness a  a e it ar er t  recover? es,  e  a safet  c cer  e iste  
it   e  se   e le it  res irat r  illness: 
. kay. Particularly there are concerns with the safety of OC 
r cts e  se   i i iduals it  l ar  iss es, 
generally? 
* * * 
. espiratory issues. 
. The effects ay be greater. 34 
28 ff. of ajor in pp. to efs 3d SJ, ~~ -7. 
29 ff. of ajor in pp. to efs 3d SJ, ~~ -7. 
30 ff. of ajor in pp. to efs 3d SJ, ~~ -7. 
31 ff. of ajor in pp. to efs 3d SJ, ~~ -7. 
32 ff. of ajor in pp. to efs 3d SJ, ~~ -7. 
33 ff. f ounsel in pp. to efs J and in SUpp. f ltfs ross- P J, ~ 10, Ex. 8 (Nance Dep., 
0:10 - 56:17, 75:19 - 81 :1; 125:1 - 127:13 and xs. , , , J, & -O). 
34 ff. of ounsel in pp. to efs J and in upp. of ltfs ross- P J, ~ 10, Ex. 8 (Nance Dep., 
44:12-16). 
    ENDANT'S    
(THIR  I    J NT)  I    LAINTIF 'S 
  I ERATION-  
The MK9 Fogger MSDS included a statement that the product may cause more severe
temporary effects on those persons who are asthmatics or suffer from emphysema
Did SEC know that there was a health risk associated with overexposure to OC Yes
SECsVice President considered other manufacturers selling 145 20and maybe even30
capsaicinoids OC products as irresponsible because they are dangerous 36 The risks of those
products according to SECs Vice President were that they Cause could cause some could
possibly cause longterm damage or extremely long recovery periods
Was there sufficient literature at the time that the Defendant sold its product to IDOC that
the SEC knew or should have known that persons who have chronic respiratory illness will be
more sensitive to the effects of OC Yes Dr Yost has provided extensive literature and his
expert opinion on that fact
38
Was there sufficient literature at the time that the Defendant sold its product to IDOC that
SEC knew or should have known that persons suffering from a respiratory illness would be at
risk of an aggravation of that illness Yes Dr Yost has provided extensive literature and his
expert opinion on that fact
39
As this Court stated in its ruling whether an injury is foreseeable is normally an issue of
fact for the jury When viewed in a light most favorable to the Plaintiff a genuine issue of
material fact exists to preclude summary judgment as to Ms Major acute injuries
35 Aff of Counsel in Opp to Def s MSJ and in Supp of Pltf s CrossMPSJ 10 Ex 8 Nance Dep
125 1273 Ex J Ms Major never saw SEC MSDS for the SABRE Red Law Enforcement Unit
10 OC MK9 Fogger Aff ofMajor in Opp To Def s 3d MSJ 4
36 Aff of Counsel in Opp to Defs MSJ 10 Ex 8 Nance Dep 64321
37 Aff of Counsel in Opp to Def s MSJ 10 Ex 8 Nance Dep 64321 emphasis added
38 Aff of Yost 1 14 Ex 1 2 d Aff of Yost 1 14 ExsAB
39 Aff of Yost 1 14 Ex 1 2 d Aff of Yost 1 14 Exs AB
ao See Sliman v Aluminum Co of America 112 Idaho 277 283 1986 The factual question of
foreseeability is for the jury to determine 1 Products Liability supra 8031 This being an area
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he -9 ogger S S included a state ent that the product "may cause ore severe, 
te porary, effects on those persons ho are asth atics or suffer fro  e physe a. ,,35 
i    t at t ere as  lt  is  iate  it  os re t  ? , 
S C's ice President considered other anufacturers selling 1.45%, .0%  e  .0% 
capsaicinoids  products as irresponsible because they are dangerous.36  is s   
products, according to SEC's Vice President, were that they "Cause -- l    -- l  
possibly cause long-term da age or extre ely long recovery periods.,,37 
as t ere ie  itera   e  t at         
the  kne  or should have kno n that persons ho have chronic respiratory illness ill be 
re i   e e ts  C? , .     itera    
expert opinion on that fact. 38 
as t ere s fficie t literat re at t e ti e t at t e efe a t s l  its r ct t  I  t at 
 kne  or should have kno n that persons suffering fro  a respiratory illness ould be at 
risk f an aggravation f that illness? es, r. ost has provided extensive literature and his 
expert opinion on that fact. 39 
As this Court stated in its ruling, whether an injury is foreseeable is nor ally an issue of 
fact for the jury.40 hen viewed in a light ost favorable to the Plaintiff, a genuine issue of 
aterial fact e ists t  recl e s ar  j e t as t  s. ajor's ac te i j ries. 
35 ff. of Counsel in pp. to efs SJ and in Supp. of Pltfs Cross-MPSJ, ~ 0, x.  (Nan  ep., 
5:1- 27:13 & Ex. J). s. ajor never sa  SE  S S for the S E ed, La  Enforce ent nit, 
10% , -9 Fogger. ff. of ajor in pp. o efs 3d SJ, ~ . 
36 ff. of ounsel in pp. to efs SJ, ~ 10, x. 8 ( ance ep., 64:3-21). 
37 ff. of ounsel in pp. to efs SJ, ~ 10, x. 8 ( ance ep., 64:3-21) (e phasis added). 
38 ff. of ost, ~~ -1  & Ex. 1; 2nd ff. of ost, ~~ -1  & xs. - . 
39 ff. of ost, ~~ -1  & x. 1; 2nd f .  st, ~~ -1  & xs. - . 
40 See Sli an v. Alu inu  o. of A erica, 112 Idaho 277, 283 (1986) ("The factual question of 
foreseeability is for the jury to determine); 1A Products Liability, supra, § 8.03[1] ("This being an area 
  I   FENDANT'S   I I  
(THIRD OTION FOR SU ARY JUDG ENT) AND IN SUPPORT OF PLAINTIFF'S 
  I  -  
C SEC Failed to Warn of the Known Danger ofAcute Respiratory Injury
SEC knew the risks of acute respiratory injury associated with the MK9 Fogger
The label says absolutely nothing about any risk to the respiratory system
The label says absolutely nothing about people with respiratory illness being more
sensitive to OC
The label says absolutely nothing about OC aggravating existing respiratory illness
The label says absolutely nothing about the dangers ofOC overexposure
44
D This Court Should Reinstate Ms Major Chronic Injury Damages
This Court should reconsider its prior ruling granting SECsfirst and second motions for
summary judgment
This Court prior rulings relating to chronic injury are contrary to wellestablished law
That an acute injury was foreseeable is enough to hold SEC responsible for unforeseeable
injuries that follow
It is fundamental to tort law that once a threshold tort has been proven the defendant
will be liable for all damages resulting from the tort Liability extends to both foreseeable
and unforeseeable consequences 49
in which judges find it difficult to agree the issue should ordinarily be left to the common sense of the
jury
41 Aff of Counsel in Opp to Def s MSJ 10 Ex 8 Nance Dep Ex O Mk9 Fogger Label
42 Aff of Counsel in Opp to Deft s MSJ 10 Ex 8 Nance Dep Ex O Mk9 Fogger Label
43 Aff of Counsel in Opp to Def s MSJ 10 Ex 8 Nance Dep Ex O Mk9 Fogger Label
44 Aff of Counsel in Opp to Defs MSJ 10 Ex 8 Nance Dep Ex O Mk9 Fogger Label
45 Reconsideration of any interlocutory order is provided for under IRCP 11a2BPlaintiff s Second
Motion for Reconsideration is timely as no final judgment has been entered
46 See Gallick v Baltimore D R Co 372 US 108 121 1963 once a threshold tort is proven
whatever damages flow therefrom are recoverable CSX Transp Inc v McBride 131 S Ct 2630 2639
2011 same USv Sutro 235F2d 499 500 9thCir 1956 same
47 Gallick 372USat 121 CSXTransp Inc 131 S Cta 2639 Sutro 235 F2d at 500
48 Gallick 372US at 121 citing Boal v Electric Battery Co 98F2d 815 819CA3dCir cancer
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.  ailed to arn of the no n anger of cute espiratory I j r  
 ne  the ris s f te r s ir t r  injury ss i t  ith t e -9 r. 
The label says absolutely nothing about any risk to the respiratory system.41 
he label says absolutely nothing about people ith respiratory illness being ore 
i e  c.42 
he label says absolutely nothing about  aggravating existing respiratory illness.43 
he label says absolutely nothing about the dangers f  overexposure.  
. is rt l  i st t  s. ajor's r i  I j r  es 
his ourt should reconsider its prior ruling granting SEC's first and second otions for 
su ary judgment. 45 
his ourt's prior rulings relating to chronic injury are contrary to ell-established law.46 
hat an acute injury as foreseeable is enough to hold S  responsible for unforeseeable 
injuries that follow. 47 
  f        e     n.   
  i le  l es l    ort. 48 t  s   e  
 es  .  
in which judges find it difficult to agree, the issue should ordinarily be left to the common sense of the 
jury"). 
41 ff. of ounsel in pp. to efs SJ, ~ 10, x. 8 (Nance ep., x. 0 ( k-9 Fogger abel). 
42 ff. of ounsel in pp. to efs SJ, ~ 10, x. 8 (Nance ep., x. 0 ( k-9 Fogger abel). 
43 ff. of ounsel in pp. to efs SJ, ~ 10, x. 8 (Nance ep., x. 0 ( k-9 Fogger abel). 
44 ff. f ounsel in pp. to efs J, ~ 10, x. 8 (Nance ep., x. 0 ( k-9 ogger abel). 
45 econsideration of any interlocutory order is provided for under I  11(a)(2)(B). laintiffs econd 
tio  f r ec si erati  is ti el  as  fi al j e t as ee  e tered. 
  l  .  & 0. R. o., 372 .S. 108, 121 (1963) (once a threshold tort is proven 
hatever da ages flo  therefro  are recoverable); S  ransp., Inc. v. c ride.131 . t. 2630, 2639 
(2011) (sa e); .S. v. Sutro, 235 .2d 499,500 (9th ir. 1956) (sa e). 
47 allick, 372 .S. at 121; SXTransp., Inc.,.131 S. t.at 2639; Sutro, 235 F.2d at 500. 
48 Gallick, 372 U.S. at 121 (citing Baal v. Electric Battery Co., 98 F.2d 815, 819 (C.A.3d Cir.) (cancer 
  I   FENDANT'S    
(THI  I    J ENT)  I    LAINTIF 'S 
  I I  -  
In 1963 the United States Supreme Court in Gallick v Baltimore recognized this
fundamental principle
It is widely held thatfor a defendant to be liablefor consequential
damages he need not foresee the particular consequences of his
negligent acts assuming the existence of a threshold tort against
the person then whatever damages flow from it are recoverable
And we have no doubt that under a statute where the tortfeasor is
liable for death or injuries in producing which his negligence
played any part even the slightest such a tortfeasor must
compensate his victim for even the improbable or unexpectedly
severe consequences of his wrongful act
50
The Court went on to note that If the actorsconduct is a substantialfactor in bringing about
harm to another thefact that the actor neither foresaw nor should haveforeseen the extent of
the harm or the manner in which it occurred does notprevent him from being liable
Instructive is the Boal v Electric Battery C0 case cited by the Court Boal involved a
set of facts similar to those in this case There an employee sued his employer seeking recovery
in tort for cancer allegedly caused by inhalation of fumes in a battery plant where he worked 53
The defendant argued that experts could not recall a single instance of inhalation of sulfuric acid
caused by inhalation of acidic gas Koehler v Waukesha Milk Co 208NW901 903905 Wisc 1926
collecting authorities wrongful death resulting from a finger cut by broken milk bottle
RESTATEMENT FIRST TORTS 435 2 HARPER AND JAMES TORTS 11391140 PROSSER TORTS 260
2d ed Seavey Mr Justice Cardozo and the Law of Torts 48 Yale LJ 390 402403 emphasis
added
49 CSX Transp Inc v McBride 131 S Ct 2630 2639 2011 Gallick 372 US at 121 Koehler 208
NW at 903 905 Restatement Third Torts 435 2 Harper and James Torts 11391140 Prosser
Torts 260 2d ed Seavey Mr Justice Cardozo and the Law of Torts 48 Yale LJ 390 402403
so
Gallick 372USat 12021 emphasis added quoting Rogers v Missouri Pac R Co 352 US500
506 1957
51 Id at 121 n 8 emphasis added citing Restatement Torts 435
52
Boal 98F2d at 819
53 Id at 81618 At the time the Pennsylvania WorkmensCompensation Act was in effect but did not
cover occupational disease Id Thus the employees claim was not barred by an exclusive remedies
provision normally found n workers compensation acts Id at 81920
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In 1963, the nited tates upre e ourt m allick v. alti ore recognized this 
funda ental principle: 
It is i ely el  t t f r  efe t to e li le f r c se enti l 
da ages he need not foresee the particular consequences f his 
e li e t cts: ss i  t e existe ce f  t res l  t rt i st 
t  n, t  t  e  fl  f  it  r ble. 
And e have no doubt that under a statute here the tortfeasor is 
li l  f r t  r i j ries i  r i  i  is "negligence 
played any part, even the slightest" such a tortfeasor ust 
c e s te is victi  f r eve  t e i r le r ex ecte ly 
severe consequences f his rongful act. 50 
The ourt ent on to note that: "If the actor's conduct is a substantial factor in bringing about 
har  to another, the fact that the actor neither foresa  nor should have foreseen the extent of 
t e r  r t e er i  ic  it cc rre  es t reve t i  fro  ei  li le. ,,51 
I str ctive is t e a l v. lectric ttery o. 52 case cite   t e urt. l i l e  a 
t f f ts i ilar t  t s  i  t i  . r ,  l e   is l r eki  r r  
i  t rt f r r ll l  s   i l ti  f f s i   tt r  l t r   r d. 53 
The defendant argued that experts could not recall a single instance of inhalation of sulfuric acid 
caused by inhalation of acidic gas); oehler v. aukesha ilk o., 208 .W. 901, 903-905 ( isc. 1926) 
(collecting authorities) (wrongful death resulting fro  a finger cut by broken ilk bottle); 
 (FI )  § ;  P   , , -11 ; , ,  
(2d ed.); Seavey, r. Justice ardozo and the La  f Torts, 48 ale J. 390, 402-403) (e phasis 
ed). 
49  r nsp., I . . ri ,  . t. ,  (2 1); lli k,  .S. t ; hler,  
.W.  -9 ;  (Th ) ts § 435; 2 arper and Ja es, orts, 1139-1140; rosser, 
orts, 260 (2d ed.); Seavey, r. Justice ardozo and the a  of orts, 48 ale .J. 390,402-403. 
50 allick, 372 .S. at 120-21 (emphasis added) (quoting ogers v. issouri ac. . o., 352 .S. 500, 
506 (1957)). 
51 Id. at 121, n. 8 (e phasis added) (citing estate ent, Torts, § 5). 
52 l,  .2d at . 
53/d. at 816-18. t the ti e, the ennsylvania ork en's o pensation ct as in effect but did not 
cover occupational disease. Id. hus, the e ployee's clai  as not barred by an exclusive re edies 
provision nor ally found n orkers co pensation acts. Id. at 819-20. 
    FENDANT'S    
(THIR  I    J MENT)  I    I TIFF'S 
I   I I  -  
fumes or mist actually resulting in cancer
54
The court rejected the argument that the defendant
could only be held liable for the plaintiffs foreseeable injuries and not for cancer because that
was not a foreseeable injury The court explained that evidence that the acid had never caused
cancer was not conclusive to the plaintiff s claims
This however is not conclusive for the effect of this mist upon
different persons would vary according to their physical resistance
Furthermore where a danger is known to exist or the
employer is presumed to know of its existence it is not
necessary that the employer should have contemplated or
should have been able to anticipate the particular
consequences the form of the accident or the nature of the
injury and where the act or omission of the master threatened
danger the fact that the accident itself was unusual
extraordinary or even unheard of does not relieve him from
liability
The holding is instructive because it clarifies that if Ms Major can prove that her acute injuries
were foreseeable when SEC sold its MK9 Fogger to IDOC she is entitled to damages for the
acute injury as well as for the chronic injury
Evidence that the chronic injuries were foreseeable is not necessary to Plaintiff s prima
facie case
All that is required for a plaintiff to be entitled to unforeseeable consequential damages is
to make out a threshold tort including proof of some foreseeable injury no matter how small or
relatively inconsequential and a causal link to the unforeseeable consequential damages
Whether she can recover damages for her chronic injury becomes a causation issue rather than a
liability issue This principle is extremely well established
so Id at 81619
55 Id
56 Id italic emphasis in original bold emphasis added citing 39 CJ 290 Dulligan v Barber Asphalt
Paving Co 87 NE567 Mass 1909 Fletcher v Ludington LumberCo 155 76 So 592 La 1917
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fu es or ist actually resulting in cancer. 54 he court rejected the argu ent that the defendant 
l  l   l  lia l  f r t  l i tiff s f res l  i j rie   t f r r  t t 
as t  f res l  i jury. 55  rt l ine  t t i e ce t t t  i   r s  
cancer as not conclusive to the plaintiff s clai s: 
i , r, i  t l i   t  t  t i  i t  
different persons ould vary, according to their physical resistance. 
,          
      ts , t   
necessary that the e ployer "should have conte plated r 
l   been able t  a ticipate t   
,           
,           
er,   t t t   ts   ual, 
t r i r ,    f,  t li  i   
liability. ,,56 
he holding is instructive because it clarifies that if s. ajor can prove that her acute injuries 
ere foreseeable hen SE  sold its -9 Fogger to I , she is entitled to da ages for the 
acute injury as ell as for the chronic injury. 
vidence that the chronic injuries ere foreseeable is not necessary to Plaintiff s pri a 
facie case. 
ll that is required for a plaintiff to be entitled to unforeseeable consequential da ages is 
to ake out a threshold tort including proof of so e foreseeable injury, no atter ho  s all or 
relatively inconsequential, and a causal link to the unforeseeable consequential da ages. 
hether she can recover da ages for her chronic injury beco es a causation issue rather than a 
liability issue. This principle is extre ely ell established. 
54/ . t -1 . 
55/d. 
6I . (italic e asis i  ri i al, l  e asis a ded) (citing  .J. 0; lliga  v. r er s lt 
Paving Co., 87 .E. 567 (Mass. 1909); Fletcher v. Ludington Lu ber Co., 155, 76 So. 592 (La. 1917». 
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This year the United States Supreme Court reaffirmed this principle in CSX Transport
Inc v McBride
57
The McBride case is consistent with the Restatement Third of Torts 435
which provides that
If the actorsconduct is a substantial factor in bringing about
harm to another the fact that the actor neither foresaw nor
should have foreseen the extent of the harm or the manner in
which it occurred does not prevent him from being liable
58
Idaho law is consistent with the majority view expressed in McBride and other sources
In Burklund v Oregon Shoreline R Co the Idaho Supreme Court held that an instruction
limiting the plaintiffsrecovery to foreseeable damages was error
The true rule as we understand it does not require that the
defendant must have been able to foresee the precise injury which
in fact resulted from the accident or the particular injurious result
which might be inflicted upon person or property as the result
thereof on the other hand the law only requires that he shall be
able to understand and appreciate that results of some kind of
injurious nature may be reasonably anticipated from the negligent
act ofomission or commission 60
In this case since Ms Major suffered an acute respiratory injury from exposure to SECs
MK9 Fogger and SEC knew when it sold the product to IDOC that the MK9 Fogger posed a
health risk to people who have a respiratory illness MsMajor should be able to recover damages
for her acute and chronic injuries
57 131 S Ct 2630 2639 2011
58 Id and cases cited therein emphasis added
59 56 Idaho 703 777 1936
60 Id citing De Mott v Knowlton 100NJLaw 296 126 A 327 328 Washington Georgetown R Co
v Hickey 166 US 521 17 SCt 661 41 LEd 1101 Baltimore O R Co v McBrideCA36
F2d 841 Soda v Marriott 118 Ca1App 635 5P2d 675 677 Carroll v Central Counties Gas Co
74 Ca1App 303 240 P 53 Lashley v Dawson 162 Md 549 160 A 738 742 Siskv Chicago B Q
R CoMoApp67 SW 2d 830 834 2 Restatement of the Law of Torts p 1173 435 12RCL
53 p 913
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his year, the nited tates upre e ourt reaffir ed this principle in S  ransport, 
. . ri .  he c ride case is consistent ith the estate ent (Third) of orts § , 
hich provides that: 
If t e actor's co ct is a s sta tial factor i  ri gi g a o t 
  t er,      i    
  ese           
ic  it occ rre  oes ot reve t i  fro  ei g lia le.58 
 l  is i t t it  t  j it  ie   i  i   t  r s. 
I  r l  v. re  r line . O.,59 t  I  r  rt l  t t  i str ti  
li iting the plaintiff s recovery to foreseeable da ages as error: 
 tr  r l ,   r t  it,  t r ir  t t t  
defendant ust have been able to foresee the precise injury hich 
i  f t r s lte  fr  t  i nt, r t  rti l r, i j rious r s lt 
i  i t  i flicte   rs  r r rt  s t  r s lt 
thereof; on the other hand, the la  only requires that he shall be 
l  t  rst   r i t  t t r s lts f s  i  f 
i j ri s t r    r s l  ti i t  fr  t  li t 
  ission  i .6o 
I  t is , i  . j r ff r   t  r ir t r  i j r  fr  r  t  EC's 
-9 Fogger, and SE  kne  hen it sold the product to I  that the -9 Fogger posed a 
health risk to people ho have a respiratory illness, s. ajor should be able to recover da ages 
for her acute and chronic injuries. 
57  . t. 0,  (2 1). 
58Id. and cases cited therein (emphasis added). 
59  I a  ,  (19 6). 
60 I . (citing  tt . lt ,  .J.Law, ,  . , ; i t  & t  . . 
. i ,  u.s. ,  .Ct. ,  .Ed. ; lti e & 0. R. Co. v. cBride (C.C.A.) 36 
F.(2d) 841; Soda v. arriott, 118 Cal.App. 635, 5 P.(2d) 675, 677; Carroll v. Central Counties as Co., 
74 al.App. 303, 240 P. 53; Lashley v. a son, 162 d. 549, 160 . 738, 742; Sisk v. hicago, B. & . 
R. Co. (Mo.App.) 67 S.W. (2d) 830, 834; 2 Restate ent of the La  of Torts, p. 1173, § 435; 12 R.C.L. 
§ 53, p. 913). 
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  I  -  
This Court should therefore reconsider its prior ruling and deny SECsfirst second and
third motions for summary judgment
E How Ms Major Framed the Issues Involved In HerWorkers Compensation
Complaint Has No Relevance to Her Claims In This Case
SEC makes much of the language ofMs Major workers compensation complaint
That argument is empty
The legal and factual standards of proof are very different in aworkers compensation case
than they are in a product liability case
In workers compensation cases the Issue or Issues Involved section of the form
complaint is for identifying those factual and legal issues the parties anticipate will be most in
dispute
What injuries Ms Major is claiming in the workers compensation case do not create any
kind of limitation on what injuries she is claiming in this case
They are different cases
The information SEC relies on is outdated since the workers compensation complaint has
been amended
The issues involved are now identified as follows
Whether exposure to OC Spray caused the claimantsmedical condition
Whether claimantsmedical condition qualifies as an occupational disease
Whether claimant medical condition was a workplace injury
If an occupational disease exists was the manifestation of such disease due to the
nature of employment in which the hazards of such disease actually exist are
characteristic of and peculiar to the trade occupation process or employment
61 See generally Title 72 of the Idaho Code for the workers compensation statutes Workers
compensation is a no fault system Liability arises purely as a function of the injury occurring on the job
See Fowble v Snoline Exp 146 Idaho 70 7475 2008 The provisions ofworkers compensation laws
are to be liberally construed in favor of the claimant as the humane purposes they seek to serve leave no
room for narrow technical construction
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is rt s l  t erefore rec si er its ri r r lin  a  e  EC's first, sec  a  
third otions for su ary judg ent. 
.  s. j r ra e  t e "Issues I l d" I  r r ers s ti  
o plaint as o elevance to er lai s In This ase 
 a es c  f t e la a e f s. ajor's r ers c e sati  c lai t. 
at ar e t is e t . 
e le al a  fact al sta ards f r f are er  iffere t i  a r ers c e sati  case 
t  t  r  i   r t li ilit  ase.61 
I  rkers s ti  s s, t  "Issue r Iss s I l d" s ti  f t  f r  
c laint is f r i e tif i  t se fact al a  le al iss es t e arties a ticipate ill e st i  
is te. 
at i j ries s. aj r is clai i  i  t e r ers c e sati  case  t create a  
i  f li itatio   at i j rie   i  l i i  i  t i  e. 
They are different cases. 
 i f r ti   r lies  is t t  si  t  r rs s ti  l i t s 
 d. 
  e    t   ll s: 
• hether exposure to  pray caused the clai ant's edical condition. 
• et er clai ant's e ical c iti  alifies as a  cc ati al isease. 
• hether clai ant's edical condition as a orkplace injury. 
• If  ti l is s  ists, s t  if st ti  f s  is s   t  t  
t r  f l t i  i  t  r s f s  is s  t ll  xist, r  
characteristic of and peculiar to the trade, occupation, process or e ploy ent. 
61 See generally Title 72 of the Idaho Code for the workers co pensation statutes. r r  
co pensation is a no fault syste . Liability arises purely as a function of the injury occurring on the job. 
 le . li  xp.,  I  , -75 (2 8) ("The r isi s f r rs' s ti  l s 
are to be liberally construed in favor of the clai ant, as the hu ane purposes they seek to serve leave no 
r  f r rr , t i l str cti ."). 
  I   FENDANT'S    
(THIR  TI  F  S  J MENT)  I  S PP T F PLAINTIFF'S 
  I  -  
Whether claimant provided timely notice ofher injuryoccupational disease
The extent if any to which the claimantslimitations wereare due to preexisting
injury or condition
62
F Ms Major Very Own First Statement ofUndisputed Facts Clearly Stated That
There was An Injury Following Exposure to Oleoresin Capsicum OC Spray
SEC selectively reads the record cherry picking what is useful while ignoring everything
else Paragraph 1 of MsMajor undisputed facts in her Cross Motion for Partial Summary
Judgment includes the following sentence that clearly states that she was injured DURING THE
TRAININNG AND FOLLOWING EXPOSURE TO OC
Ms Major claims that she suffered injuries following exposure to
oleoresin capsicum OC spray also referred to as pepper spray
during the training sessions she was attending as an employee of
IDOC
Breaking the sentence down it says 1 Ms Major 2 suffered injuries 3 following
exposure to OC 4 during training 5 at IDOC What follows that sentence is a list of
chronic effects stemming from that acute injury
The focus at that time in the litigation was on chronic injury Specifying acute injuries in
the statement of fact would not present facts material to the motion for summary judgment
It should be noted that if there is anything confusing about the way the paragraph was
worded it is the fault of SECs counsel The paragraph is identical to the Defendants
Statement of Undisputed Facts in its memorandum in support of summary judgment
62 Aff of Counsel in Opp to Defs 3MSJ 3 Ex 1
63 Memo In Supp OfDefsMSJ 1 ofthe statement offacts
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injury or condition.  
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 l ti l  rea s t  r r , rr  i i  t i  f l ile i rin  r t i  
. aragraph 1 of s. ajor's undisputed facts in her ross- otion for artial u ary 
Judg ent includes the follo ing sentence that clearly states that she as injured I   
I      : 
s. ajor clai s that she suffered injuries follo ing exposure to 
oleoresin capsicu  ("OC") spray, also referred to as pepper spray, 
during the training sessions she as attending as an e ployee of 
. 
Breaking the sentence down, it says (1) s. ajor (2) "suffered injuries" (3) "following 
exposure" to  (4) "during training" (5) at I .         
chronic effects ste ing fro  that acute injury. 
he focus at that ti e in the litigation as on chronic injury. Specifying acute injuries in 
t  t t t  t l  t t t  t i l t  t  ti    j t. 
It should be noted that if there is anything confusing about the ay the paragraph as 
r , it is t  f lt f EC's sel. The paragraph is identical to the efendant's 
State ent of ndisputed Facts in its e orandu  in support of su ary judgment. 63 
62 ff. of ounsel in pp. to ef's 3rd SJ, ~ 3, Ex. 1. 
63 e o. In Supp. f ef's SJ, ~   t  t t t f cts. 
  I   FENDANT'S    
(T I  I    J ENT)  I    LAINTIF 'S 
  I  -  
G SECsArgument Highlights Why Plaintiff Should Be Able To Recover For Both
Her Acute And Chronic Injuries
SEC states the following on page 7 of its memorandum in support of its third motion for
summary judgment
Plaintiff testifies that she participated in an OC spray training
session on March 3 2008 during which she experienced a strong
burning sensation in her lungs and could not stop coughing
Plaintiff does not go on to describe the damages or injuries she
suffered as a result of that immediate reaction but rather only
mentions her immediate reaction to set the scene for her allegations
of a longterm chronic condition
SEC acknowledges that Ms Major was complaining of an immediate impact of OC exposure
SECs argument however is that because Ms Major did not provide a detailed description about
the acute injury there must be no intent to pursue recovery for those injuries Again SEC
overlooks the fact that the affidavit was filed in response to SECsmotion for summary judgment
that focused solely on chronic injury
The most telling part of SECsargument however is that it acknowledges that it knew
Ms Major claimed an acute injury that led to a chronic condition The extreme reaction
Ms Major had to the aerosolized OC was something SEC knew would happen in people with
bronchitis or chronic cough SEC knew that it was dangerous to expose those people to OC
and that complications were likely But SEC did not include anything on its label to warn of
those complications There is nothing on their label to warn of any kind of respiratory injury
64 See footnotes 33 37 of this Memorandum
65 See footnotes 33 37 of this Memorandum
66 See footnotes 41 44 of this Memorandum
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bronchitis or chronic cough.64 SEC knew that it was dangerous to expose those people to OC 
and that co plications ere likely.65 But, SEC did not include anything on its label to arn of 
those co plications.66 There is nothing on their label to arn of any kind of respiratory injury 
  t te  -37   u . 
  t tes -37  s . 
66  f t tes -44 f t is r . 
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whether such injury is characterized as acute or chronic
67
SEC knew the danger and did not
warn It should be held liable for the injury it caused
SEC should actually be held responsible for all the injury it caused because it knew of the
risk of the acute injury Just because it may or may not have known of the longterm health
effects that were caused by the immediate injury does not mean they should only pay for the
immediate injury It makes no sense to carve the injury in two Unforeseen complications of a
foreseeable acute injury are recoverable
68
H Ms Major is Not Judicially Estopped Because Her Position Is Not Contrary
And She Clearly Has Gained No Advantage In This Litigation
SEC claims that Ms Major is estopped from recovering damages for acute injury because
she has argued for recovery of damages for chronic injury SECsargument succeeds only if the
evidence is ignored that SEC knew that the effects of OC exposure for people who suffer a
respiratory illness is going to be more extreme and may cause an aggravation of the injury
Concededly there are acute effects of OC that are generally the ones people experience They
are normally shortterm and of a certain intensity For most people the normal effects last 20 to
30 minutes They include feelings of burning of the skin coughing excessive mucus the eyes
burn and involuntarily shut Those are the typical effects However Ms Major experience was
not within the general experience category Hers was different because she suffered from a
respiratory illness She was more sensitive to OC than the general population She was exposed
to more of MK9 OC fog than what was directed in the instruction SEC knew people in her
situation would experience more extreme effects SEC knew that overexposure was dangerous to
67 See footnotes 41 44 of this Memorandum
68 See HDsupra
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situation ould experience ore extre e effects. SE  kne  that overexposure as dangerous to 
  t te  -44   r ndum. 
  § II(D), supra. 
  I   FENDANT'S    
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  I  -  
peopleshealth SEC knew people in Ms Major situation would suffer complications of their
respiratory illness SEC knew of these dangers because those dangers were identified on SECs
MSDS sheet and SECsvice president testified that he knew these dangers
SECsestoppel argument is without merit
III CONCLUSION
For the reasons set forth herein SECs third motion for summary judgment should be
denied and this Court should reconsider its prior interlocutory rulings on SECsfirst and second
motions for summary judgment and deny the same
DATED this 4th day ofOctober 2011
JONES SWAR
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AND IN REPLY TO PLAINTIFF
OPPOSITION TO DEFENDANT
MOTION FOR CLARIFICATION
Defendant Security Equipment Corporation SEC or Defendant by and through its
counsel of record Greener Burke Shoemaker PA hereby submits this memorandum in
opposition to Plaintiff Billie Jo Majors Plaintiff Second Motion for Reconsideration and in
reply to Plaintiffsopposition to SECspreviouslyfiled Motion for Clarification In addition to
this Memorandum SEC relies on the documents and pleadings previously filed in this case
INTRODUCTION
Following the submission of SECs pending Motion for Clarification Plaintiff filed a
Motion to Vacate Trial which motion was heard and granted on the date previouslyset for the
pre trial conference in this matter September 22 2011 This Court vacated the trial to allow
DEFENDANTS MEMORANDUM IN OPPOSITION TO PLAINTIFFS SECOND MOTION FOR
RECONSIDERATION AND IN REPLY TO PLAINTIFF OPPOSITION TO DEFENDANT MOTION
FOR CLARIFICATION Page 1 14542 011 419045
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   2011 
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 TEPHANIE I K 
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IE J  J ,  in i i l, 
l i tiff, 
v. 
SEC RIT  E IP E T 
CORPORATION, a issouri corporation, 
nt. 
s  o.: -PI- 5 
FENDANT'S   
I   I TIFF'S  
  I  
    LAINTIFF'S 
I   FENDANT'S 
  I  
efendant Security Equip ent orporation ("SE " or "Defendant"),   t r  it  
s l f r r , r r r  r .A., r  s its t is. r  i  
opposition to Plaintiff Billie Jo ajor's ("Plaintiff') Second otion for Reconsideration, and in 
reply to Plaintiffs opposition to SEC's previously-filed otion for Clarification. In addition to 
t is r u ,  r li s  t  ts  l i s r i sl  fil  i  t is se. 
I  
Follo ing the sub ission of SEC's pending otion for larification, Plaintiff filed a 
otion to acate Trial, hich otion as heard and granted on the date previously-set for the 
pre-trial conference in this matter, September 22, 2011. This Court vacated the trial to allow 
EFENDANT'S  I  PP SI I  T  PLAINTIFF'S SECO  I  F  
ONSI A I   I  L   LAINTIF 'S PPOSITI  T  EFENDANT'S I  
 L I I I  - Page 1 14542-  ( 045) 
SECsMotion for Clarification to be heard and to otherwise allow Plaintiff to seek a certificate
of final judgment pursuant toIRCP54b At the hearing on September 22 2011 the Court
indicated that it would treat SECsMotion for Clarification as a motion for summary judgment
underIRCP 56 and directed the parties to brief the issue presented by the Motion for
Clarification prior to a hearing set for October 17 2011
The only remaining issue in this case which is the subject of SECs Motion for
Clarification is whether Plaintiff has any cause of action for acute injuries that she allegedly
sustained following her exposure to SECsSabre Red 10 OC Spray on March 3 2008 Had
SEC known that its Motion for Clarification would be treated as a motion for summary
judgment it would have briefed the issue differently than it did That said by SECs
incorporation of its prior arguments on the causation element of Plaintiffsclaims which have
gone unaddressed by Plaintiff in her response see Memorandum in Support of SECsMotion for
Clarification pp 11 12 SEC contends that entry of summary and final judgment against
Plaintiff is now appropriate Not only have Plaintiffsclaims for alleged acute injuries never
been a part of Plaintiffscase SEC has gone one step further and demonstrated why no
reasonable juror could find for Plaintiff on such claims
Additionally PlaintiffsSecond Motion for Reconsideration should be denied as Plaintiff
has simply altered her theory in this case a third time in order to circumvent both this Court
decisions and the relevant case law that she has been thus far unable to overcome The new
theory presented by Plaintiff is that despite having no duty to warn against unforeseeable risks of
chronic injury SEC should nevertheless be held liable for the damages arising from Plaintiffs
alleged chronic injuries Plaintiff bases this theory on irrelevant andor antiquated case law that
is wholly inconsistent with established Idaho law on products liability See eg Sidwell v
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's otion for larification to be , a d to ther ise  f t  s  a ficate 
of final judgment pursuant to LR.C.P. 54(b). t the hearing on Septe ber 22, 2011, the Court 
indicated that it ould treat S 's otion for larification as  tion for s ary judg ent 
nder LR.C.P. , a  irected the arties t  rief t e issue rese te   t e otion f r 
larification prior to a eari  set f r ctober , . 
The only remaining issue in this case, which is the subject of SEC's otion for 
l i i ti , is het e  l i ti    ause  ti n  t  i juries t at  ll l  
sustained follo ing her exposure to SEC's Sabre Red 10% C Spray on arch 3, 2008. ad 
  t it's otion  ica i    treat       
judgment, it would have briefed the issue differently than it did. t i ,  EC's 
incorporation of its prior arguments on the causation element of Plaintiff s claims, which have 
gone unaddressed by Plaintiff in her response (see e orandu  in Support of SEC's otion for 
larification, pp. 11-12),  contends that entry of su ary (and final) judg ent against 
Plaintiff is now appropriate. Not only have Plaintiffs claims for alleged acute injuries never 
been a part of Plaintiff s case, SEC has gone one step further and demonstrated why no 
reasonable juror could find for Plaintiff on such clai s. 
dditionally, Plaintiffs Second otion for econsideration should be denied, as Plaintiff 
has simply altered her theory in this case a third time in order to circumvent both this Court's 
decisions and the relevant case la  that she has been thus far unable to overco e. he ne  
theory presented by Plaintiff is that despite having no duty to warn against unforeseeable risks of 
chronic injury, SEC should nevertheless be held liable for the damages arising from Plaintiffs 
alleged chronic injuries. Plaintiff bases this theory on irrelevant and/or antiquated case law that 
is wholly inconsistent with established Idaho law on products liability. ee, .g., id ell v. 
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William Prym Inc 112 Idaho 76 730 P2d 996 1986 Because Idaho requires knowledge
andor foreseeability of the risk for liability to attach in failure towarn cases SEC simply cannot
be held liable for the damages attributable to the unforeseen risk of longterm chronic injuries
112 Idaho at 7879
For all of these reasons as well as those set forth in SECs two prior motions for
summary judgment SEC respectfully asks this Court to enter an Order granting SECsMotion
for ClarificationSummary Judgment and to issue a final judgment to SEC on all issues and
causes of action in this litigation
ARGUMENT
A SEC Cannot Be Held Liable For Damages Associated With MajorsAlleged
Chronic Injuries
As SEC understands Plaintiff newest argument Plaintiff claims that SEC ought to be
held liable for all of the damages that she claims arise from her exposure to SECs OC product
on March 3 2008 Even if the chronic injuries were unforeseeable since the acute injuries
were foreseeable Ms Major should be able to recover for both under well established case
law PlaintiffsMemorandum in Opposition to DefendantsMotion for Clarification Third
Motion for Summary Judgment and in Support ofPlaintiffsMotion for Reconsideration filed
in this action on October 4 2011 PlaintiffsMemo p 5 In other words Plaintiff has tried
to change the debate from the issues of duty and liability to the issue of damages She has tried
to blur the distinction between foreseeability of risk legal duty and foreseeability of damages
She is asking this Court to hold SEC liable for the unforeseeable damages allegedly associated
with unforeseeable risks of injury something the law does not permit This veiled attempt to
DEFENDANTS MEMORANDUM IN OPPOSITION TO PLAINTIFFS SECOND MOTION FOR
RECONSIDERATION AND IN REPLY TO PLAINTIFF OPPOSITION TO DEFENDANT MOTION
FORCLARIFICATION Page 3 14542011 419045
001720
illiam Pry , Inc., 112 Idaho 76, 730 P.2d 996 (1986). ecause Idaho re ires no ledge 
and/or fores ilit  oft e risk for liability to tta  in failure-to-warn cas s,  si l  t 
be held liable for the da ages attributable to the unforeseen risk of long-ter , chronic injuries. 
12 da  t -79. 
or ll f these re ,  ll  those t forth in C's t  i r tions f  
su ary judg ent, SE  respectfully asks this ourt to enter an rder granting SEC's otion 
for Clarification/Summary Judg ent and to issue a final judg ent to SEC on all issues and 
causes of action in this litigation. 
 
.  t   a   a ages  th jor's lege  
Chronic Injuries. 
s  rsta s l intiff s e t r ent, l i tiff l i  t t  t t   
held liable for all of the da ages that she clai s arise fro  her exposure to SEC's  product 
on arch 3, 2008: "Eve  if t e c r ic i j ries ere f reseeable, si ce t e c te i j ries 
were foreseeable, s. ajor should be able to recover for both under well-established case 
law." (Plaintiffs emorandum in Opposition to Defendant's otion for Clarification (Third 
otion for Su ary Judg ent) and in Support of Plaintiffs otion for Reconsideration, filed 
in this action on ctober 4,2011 ("Plaintiffs e o."), . .)  t  s, l i ti   t i  
to change the debate from the issues of duty and liability to the issue of damages. She has tried 
t  l r t  isti ti  t  f r s eabilit  f ris  (le l uty)  f r seeability f ges. 
She is asking this Court to hold SEC liable for the unforeseeable damages allegedly associated 
ith unforeseeable risks of injury, so ething the la  does not permit. his veiled atte pt to 
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end around the established Idaho case law that this Court has relied upon in its prior decisions in
this case should be rejected and prior Idaho precedent upheld
1 The authority relied upon by Plaintiff fails to provide any reason for this Court
to reconsider its prior decisions
The Court should note that the well established case law relied upon by Plaintiff is
nothing but a mixture of irrelevant antiquated andorsignificantly distinguishable law from the
last century and across the country Plaintiff primarily relies on a concoction of six 6 cases
only one 1 of which is an Idaho case and only one 1 of which is dated later than 1965 the
year that the Restatement Second of Torts was drafted In all events all of the authority
presented by Plaintiff is inapposite
First three of the cases relied upon by Plaintiff are cases deciding the extent of liability
under the Federal Employers Liability Act FELA See generally CSX Transportation Inc v
McBride 131 SCt 2630 2011 Gallick v Baltimore OhioR Co 372 US 108 1963
Burklund v Oregon Short Line R Co 56 Idaho 703 58 P2d 773 1936 The standard of care
and the extent of liability under FELA as explained very clearly by the Supreme Court in
McBride was designed in the statutory scheme to be a deviation from the general principals of
negligence andorstrict liability that are relevant in the instant case Before FELA was enacted
the harsh and technical rules of state common law had made recovery difficult or even
impossible for injured railroad workersDissatisfied with the railroadscommonlaw duty
Congress sought to supplan that duty with FELAs far more drastic duty of paying damages
for injury or death at work due in whole or in part to the employersnegligence McBride 131
S Ct at 2638 internal citations omitted alterations in original FELA like most state workers
compensation laws rejected commonlaw formulations of proximate cause and instead sought
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- r  t  t lishe  Ida  ase la  t t t is rt as r li   i  its ri r isions i  
this case should be rejected and prior Idaho precedent upheld. 
. he a t rity relie  on  lai tiff fails t  r ide a  reas  f r t is rt 
to re sider its ior i i . 
 rt ld te t t t  "well- t lis e  s  l " r lie    l i tiff i  
nothing but a ixture of irrelevant, antiquated, and/or significantly distinguishable la  fro  the 
last ce t r  a  across t e c tr . lai tiff ri aril  relies  a c c cti  f si  (6) cases, 
only one (1) of which is an Idaho case, and only one (1) of which is dated later than 1965 (the 
e r t t t  st t t (Se ) f rts s r fted). I  ll ts, ll f t  t rit  
presented by laintiff is inapposite. 
irst, three f the cases relied upon by laintiff are cases deciding the extent f liability 
r t  r l l r ' i ilit  t (F LA).  erally,  ortati n, I . . 
cBride, 131 S.Ct. 2630 (2011); allick v. Balti ore & i  .R. o.,  .S.  (1 63); 
Burklund v. regon Short Line R. Co., 56 Idaho 703, 58 P.2d 773 (1936). The standard of care 
a  t e e te t f lia ilit  er , as e lai e  er  clearl   t e re e rt i  
cBride, was designed in the statutory scheme to be a deviation from the general principals of 
negligence and/or strict liability that are relevant in the instant case: "Before FEL  as enacted, 
t e 'hars  a  tec nical' r les f state c  la  a  ' a e rec er  iffic lt r e e  
impossible' for injured railroad workers. '[D]issatisfied with the [railroad's] common-law duty,' 
Congress sought to 'supplan[t] that duty ith [FELA's] far ore drastic duty of paying da ages 
for injury or death at work due in whole or in part to the e ployer's negligence.'" ri e,  
. t. at  (internal citati s itted, alterati s i  riginal). LA, li e st state r ers 
compensation laws, "rejected common-law formulations of proximate cause," and instead sought 
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to fix liability in language that was simple and direct Id at 26392640 Notably however
even the principals articulated by FELA hinge on an element of foreseeability ifaperson has
no reasonable ground to anticipate that a particular condition would or might result in a
mishap and injury then the party is not required to do anything to correct the condition Id at
2643 internal citations omitted alterations and omissions in original Where FELA deviates
from common law principals of tort liability then is in rejecting stock proximate cause
terminology and applying a standard whereby a railroad carrier is liable for the entirety of the
injured workers injuries no matter how insignificant the carriers negligence and no matter how
remote the workersinjuries Id at 2644 This standard as made clear by each of the FELA
cases cited by Plaintiff is unique to FELA and a great deviation from the common law principals
that govern this case
The remaining cases cited by Plaintiff are equally distinguishable and similarly lack any
authoritative weight over the issues relevant to this case US v Sutro 235 F2d 499 9th Cir
1956 for example sets forth a guideline for determining damages in a contract case governed
by the Federal Tort Claims Act 235 F2d at 500 The 9th Circuit determined that damages in
such a case must be decided in the same way as would be done between private parties under the
applicable state common law Id Thus evaluating the then relevant law of California circa
1956 as it pertained to contract cases the court affirmed the award of damages against the
defendant for all damages proximately arising from her delay in performing under the subject
contract Id at 501 Thus not only does Sutro utilize the law of another state it does so with
This analysis not only distinguishes the only one of Plaintiffs cases that was decided after the drafting of the
Restatement SecondMcBride but also the only one ofPlaintiffscases that is an Idaho case Burklund
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to "'fix liability' in language that as 'simple and direct. '" I . t -26 . t l , r, 
e en t e principals articulated   inge  a  ele e t f f reseeability: "[i]f a ers  as 
 reas a le r  t  a ticipate that a artic lar c ition ... ld  t  n  
ishap and injury, then the party is not required to do anything to correct [the] condition." Id. at 
2643 (internal citations o itted, alterations and o issions in original). here F  deviates 
fro  co on la  principals of tort liability, then, is in rejecting "stock proxi ate cause 
ter inology" and applying a standard hereby a railroad carrier is liable for the entirety of the 
i jure  rker's i j ries,  tt r  i si ifica t t  rrier's li e    tt r  
re ote the orker's injuries. Id. at 2644. his standard, as ade clear by each of the F  
cases cited by Plaintiff, is unique to FEL  and a great deviation fro  the co on la  principals 
that govern this case. 1 
The remaining cases cited by Plaintiff are equally distinguishable and similarly lack any 
authoritative eight over the issues relevant to this case. s. v. Sutro, 235 .2d 499 (9th ir. 
1956), for exa ple, sets forth a guideline for deter ining da ages in a contract case governed 
by the Federal Tort lai s ct. 235 F.2d at 500. The 9th ircuit deter ined that da ages in 
such a case ust be decided in the sa e ay as ould be done bet een private parties under the 
applicable state common law. Id. Thus, evaluating the then-relevant law of California (circa 
1956) as it pertained to contract cases, the court affir ed the a ard of da ages against the 
defendant for "all da ages proxi ately arising" fro  her delay in perfor ing under the subject 
contract. Id. at 501. hus, not only does Sutro utilize the la  of another state, it does so ith 
1 This analysis not only distinguishes the only one of Plaintiffs cases that was decided after the drafting of the 
Restatement (Second) (McBride), but also the only one of Plaintiffs cases that is an Idaho case (Burklund). 
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respect to an issue not sounding in tort There simply is no rule of law that can be gleaned from
Sutro that would be remotely applicable to these present circumstances
Koehler v Waukesha Milk Co 190 Wis 52 208NW 901 Wis 1926 which is the
Wisconsin case cited by Plaintiff that precedes any draft of the Restatement of Torts involved a
woman who sliced her finger on a cracked bottle of milk The woman thereafter became septic
and died less than one month later 208NW at 902 There was no dispute in the case about
whether the defendant owed the plaintiff a legal duty or whether that duty was breached The
court found that Defendant failed to exercise ordinary care in providing a glass bottle that was
broken Id at 904 In doing so it recognized the distinction between duty on the one hand and
damages on the other The measure of the defendantsduty in determining whether a wrong
has been committed is one thing the measure of liability when a wrong has been committed is
another Id at 904 This pre Restatement Wisconsin decision is therefore premised on the
assumption that a legal duty and some liability for a breach of that duty existed In contrast in
the instant case Plaintiff is unable to prove a fundamental element of her liability claim a legal
duty to warn and as such the question of damages discussed in Koehler is not even reached
Finally Boal v Electric Storage Battery Co 98 F2d 815 3d Cir 1938 also cited by
Plaintiff in support of her new theory to gain access to damages associated with her alleged long
term chronic illness is a 1938 case evaluating an employersliability for injuries to his
employee under Pennsylvania law 98 F2dat 817 In Boal which is the closest case that
Plaintiff cites to an actual products liability case and the only case to addresses a duty to warn an
employee developed cancer following his exposure to mist of sulphuric acid in a battery making
process Id In ruling that the defendant employer could be held liable for the employees
cancerous injuries the Third Circuit made two findings that substantially distinguish Boal from
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respect to an issue not sounding in tort. here si ply is no rule f la  that can be gleaned fro  
S t o that o ld e re t l  lica le t  t e  res t ircu st . 
oe l r v. s  ilk .,  is. ,  .W.  (Wis. 26), i  is t  
isconsin case cited by Plaintiff that precedes any draft of the Restate ent of Torts, involved a 
a   slice  er finger  a crac e  ttle f il . e a  t ereafter eca e se tic, 
 i  less t   th lat r.  .W. t . ere a   i t  i  t   t 
hether t  t  t e l i ti   l l t   t  t t t   d.  
rt f  t t fe t f ile  t  r i  r i r  r  i  r i i   l  ttl  t t  
broken. Id. at 904. In doing so, it recognized the distinction bet een duty on the one hand, and 
da ages on the other: "The easure of the defendant's duty in deter ining hether a rong 
as ee  c itte  is e t i g; t e eas re f lia ilit  e  a r  as ee  c itte  is 
other." .  . This pre-Restate ent isconsin decision is therefore pre ised on the 
ass ti  t at a le al ty, a  s e lia ilit  f r a reac  f t at ty, e iste . I  c trast, i  
the instant case, Plaintiff is unable to prove a funda ental ele ent of her liability clai  -  l l 
duty to arn -    t  ti  f  i  i  l r i  t  r ed. 
inally, aal v. lectric Storage attery o., 98 .2d 815 (3d. ir. 1938), also cited by 
Plaintiff in support of her new theory to gain access to damages associated with her alleged long-
t r , r i  illn ss, is   s  l ti   ployer's li ilit  f r i j ri s t  is 
employee under Pennsylvania law.  .2d  17.  aal, i  i  t  l t  t t 
Plaintiff cites to an actual products liability case and the only case to addresses a duty to arn, an 
e ployee developed cancer follo ing his exposure to ist of sulphuric acid in a battery- aking 
process. . In ruling that the defendant e ployer could be held liable for the e ployee's 
cancerous injuries, the Third Circuit made two findings that substantially distinguish Baal from 
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the present case First the court found that the precautions taken by defendant for the safety of
its employees while working in its plant did not come up to the standards prevailing in the
industry generally Id at 818 Moreover the court found
The evidence shows that the existence and danger of this spray
could have been known by the defendant if it had exercised due
and proper diligence which the law required of a reasonable
prudent person There existed on this subject general scientific
knowledge which the defendant could have ascertained from
various publications and persons acquainted with the art if proper
inquiry had been made
Id emphasis added In contrast despite multiple affidavits from Plaintiffsexpert Dr Yost no
evidence has been produced that would suggest that SEC could have ascertained the risk of
longterm chronic injuries claimed by Plaintiff Thus if Boal is instructive on anything it is that
this Court decisions to date have been proper in determining that there is no liability for
unknown andor unforeseeable risks
Plaintiffs reliance on 435 of the Restatement Second of Torts is also misplaced
The Restatement Second contains a specific Chapter dedicated to the law of products liability
Chapter 14 The Restatement sections included in Chapter 14 run from 388 to 408 and are
referred to and relied upon throughout Idaho jurisprudence governing products liability See
eg Sidwell v William Prym Inc 112 Idaho 76 730 P2d 996 1986 Toner v Lederle
Laboratories 112 Idaho 328 732P2d 297 1987 It is with reliance on the sections contained
in Chapter 14 that Idaho courts have determined that liability in a products liability action will
only attach when the risks of harm are actually foreseeable to the manufacturer of the product
2 Throughout her memorandum Plaintiff repeatedly makes reference to 435 of the Restatement Third of Torts
SeeegPlaintiffs Memo p 5 n 15 In addition to the fact that the Restatement Third has notyet been
adopted or embraced by the Idaho Supreme Court and therefore does not have any controlling weight in this action
it appears that Plaintiffscitation is incorrect The Restatement Third was a substantial reorganization from the
prior two Restatements and does not have a 435 Accordingly Defendant is assuming that Plaintiffs citations are
intended to refer to the Restatement Second ofTorts
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the present case. First, the court found that "the precautions taken by defendant for the safety of 
its e ployees hile orking in its plant did not co e up to the standards prevailing in the 
industry generally." Id. at 818. oreover, the court found: 
[T]he evidence sho s that the existence and danger of this spray 
c ld a e ee    t e efe a t if it a  e ercise  e 
a  roper iligence ic  t e la  re ire  f a reas a le 
prudent person.  i t   t i  j t l i ti ic 
kno ledge hich the defendant could have ascertained fro  
various publications and persons acquainted ith the art if proper 
inquiry had been ade. 
Id. (emphasis added). In contrast, despite ultiple affidavits fro  Plaintiff s expert, r. ost, no 
evidence has been produced that ould suggest that S  "could have ascertained" the risk of 
long-ter , chronic injuries clai ed by Plaintiff. Thus, if Boal is instructive on anything, it is that 
t is urt's ecisi s t  ate a e ee  r er i  eter i i  t at t ere is  lia ilit  f r 
 nd/or res  . 
l intif s ia ce  § 435 of the estate ent (Second) of orts is also isplaced? 
he estate ent (Second) contains a specific hapter dedicated to the la  of products liability -
hapter 14. The estate ent sections included in hapter 14 run fro  §§   8,   
referred to and relied upon throughout Idaho jurisprudence governing products liability. See, 
e.g., Sid ell v. illia  Pry , Inc., 112 Idaho 76, 730 P.2d 996 (1986); Toner v. Lederle 
r t ri s,  I  ,  .2d  (1 7). It i  it  r li   t  cti  t i  
in Chapter 14 that Idaho courts have determined that liability in a products liability action will 
only attach when the risks of harm are actually foreseeable to the manufacturer of the product. 
2 Throughout her memorandum, Plaintiff repeatedly makes reference to § 435 of the Restatement (Third) of Torts. 
(See, e.g., Plaintiff's emo., p. 5 n. 15.) In addition to the fact that the Restatement (Third) has not yet been 
adopted or embraced by the Idaho Supreme Court, and therefore does not have any controlling weight in this action, 
it appears that Plaintiffs citation is incorrect. The Restatement (Third) was a substantial reorganization from the 
prior two Restatements, and does not have a § 435. Accordingly, Defendant is assuming that Plaintiffs citations are 
intended to refer to the Restate ent (Second) of Torts. 
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Id Section 435 cannot be read as Plaintiff has attempted to do in a vacuum Rather as set
forth in the Restatement Second the person whose conduct is in question is liable if but only
if there also exist the other conditions necessary to liability Restatement Second of Torts
388 cmt f As Plaintiff has repeatedly failed to establish the foreseeability condition necessary
to liability in this products liability action her Second Motion for Reconsideration must fail
2 Plaintiffs newest theory ought to be rejected as inconsistent with established
and relevant Idaho case law
As this Court has recognized there is an Idaho Supreme Court case that is directly on
point with the facts of this case Sidwell v William Prym Inc 112 Idaho 76 1986 SEC
contends that it is impossible to read Sidwell which remains to be good law in Idaho and the
cases cited by Plaintiff without an insurmountable contradiction In Sidwell as here the product
in question was dangerous by nature it is clear that the manufacturer could anticipate the
danger of a pin pricking puncturing or piercing dressmaking or other materials or the bodily
surface ofa user 112 Idaho at 79 Also as here the Plaintiff asserted a claim for damages from
a greater injury that was rooted in that foreseeable danger the pin puncturing a user body
the manufacturer is asked to anticipate not only that pins will pierce but they will be driven into
the body with such force as to strike a bone and thus shatter Id Affirming the trial courts
decision granting the manufacturersmotion for a directed verdict on the grounds that the
plaintiff had not produced more than a mere scintilla of evidence that the manufacturer had
reason to anticipate that danger the Idaho Supreme Court determined that the manufacturer
could not be held to a duty to warn ofunforeseeable dangers and thus could not be held liable in
the case See generally Id citing Restatement Second of Torts 402A cmt h
Of greatest import here the Sidwell court did not remand the case for a determination by
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I .   t  ,   as t   ,   . t r,   
f rt  i  t  st t e t (Se nd), "the rs  s  t is i  sti  is li l  if, t l  
if, t ere als  e ist t e t er c itions ecessar  t  lia ility." estate e t (Sec d) f rts § 
, . . s i ti      s   abilit    
t  lia ilit  i  t i  cts lia ilit  ti ,   tio   i ti  t il. 
2. laintiff's ne est theory ought to be rejected as inconsistent ith established 
 re e a  a   . 
s t is rt as rec ize , t ere is a  I a  re e rt case t at is irectl   
point ith the facts of this case: Sid ell v. illia  ry , Inc., 112 Idaho 76 (1986).  
t s t t it is i ssi l  t  r  i ll (whic  r ins t    l  i  I o)  t  
cases cite   lai tiff it t a  i s r ta le c tra icti . I  i ell, as ere, t e r ct 
i  esti  as a er s  at re: " ... it is clear t at t e a fact rer c l  a tici ate t e 
danger f a pin pricking, puncturing, or piercing dress aking or other aterials or the bodily 
   er."   t . ls   , t  l i ti  t   l i     
a greater injury that as rooted in that foreseeable danger (the pin puncturing a user's body): " .. 
. t e a fact rer is as e  t  a ticipate t l  t at i s ill ierce, t t e  ill e ri e  i t  
the body ith such force as to strike a bone and thus shatter." Id. ffir ing the trial court's 
decision granting the anufacturer's otion for a directed verdict on the grounds that the 
lai tiff a  t r ce  re t a  a ere sci tilla f e i e ce t at t e "manufact rer [had] 
'reason to anticipate that danger,'" the Idaho Supre e ourt deter ined that the anufacturer 
could not be held to a duty to arn of unforeseeable dangers, and thus could not be held liable in 
the case. See generally Id. (citing estate ent (Second) of Torts § 402A, c t. h). 
f r t st i rt r , t  i ll rt i  t r  t  s  f r  t r i ti   
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a jury as to what damages are attendant to or otherwise arise from the known and obvious
dangers of the pins akin to that which Plaintiff is now suggesting should occur in this case Id
Indeed once the Idaho Supreme Court decided that the manufacturer in Sidwell could not be held
to a duty to warn of a danger which could not be foreseen the manufacturer was absolved of
all liability for those unforeseeable injuries Id at p 79 81 The issue of damages was never
reached The posture of the present case is indistinguishable and SEC must not be held liable
for unforeseeable dangers and injuries
B Plaintiff Cannot Prevail On A Claim For Acute Injuries
1 The alleged violation was not the proximate cause ofPlaintiffs injury
To adequately address the Plaintiffsclaims relative to alleged acute injuries sustained as
a result of exposure to SECs OC product on March 3 2008 as noted in SECs Motion for
Clarification this Court must review a number of the undisputed facts that have been previously
put in the record in this litigation Relevant to this issue SEC restates the following Statements
ofFact SOF
1 While employed at IDOC Major was required to attend different training courses
which were taught by other IDOC personnel Affidavit of Christopher C Burke in Support of
Opposition to Plaintiffs Cross Motion for Summary Judgment filed June 30 2011 Burke
Aff 112 3 and 5 Ex A Major Dep 92109317 Ex B Kimmel Dep 9059213 and Ex
3 In her briefing Plaintiff refers to the StedmansMedical Dictionary definition of either acute or acute injury
apparently in an effort to expand the relevant time period for which SEC could potentially be held liable under her
remaining theory PlaintiffsMemo p 5 SEC notes that relevant Idaho case law discussing the foreseeability
of harm standard in products liability cases including but not limited to Sidwell focuses the attention on what is
actually known or foreseeable about the particular product at issue in the litigation It does not permit a party to use
a semantic characterization of aword concept or injury to expand that which is actually known or foreseeable about
that product There is simply no evidence in the record to suggest that the acute and temporary adverse health
effects of exposure to OC are known to last weeks or up to three months Neither does the case law permit a
party to rely on the manufacturersknowledge or suspicions about the dangers associated with entirely different
products as Plaintiff has attempted to do throughout this litigation in focusing on Mr Nances deposition testimony
about other manufacturers and their more potent OC products Plaintiff Memo p 8
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a jury as to hat da ages are attendant to or other ise arise fro  the kno n and obvious 
dangers of the pins, akin to that hich Plaintiff is no  suggesting should occur in this case. Id. 
I ,  t e Ida  r  rt i  t t t  f t r r i  i ll l  t  l  
to a duty ''to arn f a danger hich could not be foreseen," the anufacturer as absolved f 
ll li ility  t s  ores l  i j i . . t . , .  is      
reached. he posture of the present case is indistinguishable, and  ust not be held liable 
for unforeseeable dangers and injuries? 
. laintiff annot revail n  lai  or cute Injuries. 
. he alleged violation as not the proxi ate cause of laintiff's injury. 
 t l  ress t  l intiffs l i s r l ti  t  ll  t  i j ri  t i   
a result of exposure to SEC's C product on arch 3, 2008, as noted in SEC's otion for 
larificati , t is rt st re ie  a er f t e is te  facts t at a e ee  re i sl  
put in the record in this litigation. Relevant to this issue, SEC restates the following State ents 
  ("S "): 
. ile l  t I , j r s r ir  t  tt  iffer t tr i i  rs s 
hich ere taught by other I  personnel. (Affidavit of hristopher . urke in upport of 
Opposition to Plaintiffs Cross- otion for Summary Judgment filed June 30, 2011 ("Bur  
ff.") ~~ 2,3 and 5, Ex.  (Major ep. 92:10-93:17), Ex. B (Kim el ep. 90:5-92:13), and Ex. 
3 In her briefmg, Plaintiff refers to the "Sted an's edical ictionary" defmition of either "acute" or "acute injury," 
a are tl  i  a  eff rt t  e a  t e rele a t ti e eri  f r ic   c l  tentiall  e el  lia le er er 
re aining theory. (Plaintiff's e o., p. 5.) SE  notes that relevant Idaho case la  discussing the "foreseeability 
of harm" standard in products liability cases, including but not limited to Sidwell, focuses the attention on what is 
actually kno n or foreseeable about the particular product at issue in the litigation. It does not per it a party to use 
a se antic characterization of a ord, concept or injury to expand that hich is actually kno n or foreseeable about 
that product. There is simply no evidence in the record to suggest that the acute and temporary adverse health 
effects of exposure to C are kno n to last "weeks, or up to three onths." either does the case la  per it a 
party to rely on the anufacturer's knowledge (or suspicions) about the dangers associated with entirely different 
products, as Plaintiff has attempted to do throughout this litigation in focusing on Mr. Nance's deposition testimony 
about "other anufacturers" and their ore potent  products. (Plaintiff's emo., p. 8.) 
FENDANT'S   SI I   LAINTIFF'S    
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D The training courses included among other training courses annual training regarding the
use of OC Spray Id
2 The effects of OC exposure are acute temporary transient reversible and
recoverable Burke Aff 3 and 68 Ex B Kimmel Dep 36133725 Ex E Schaffer Dep
35376 Ex F Overgaard Dep 5113 564 Ex G Doan Dep 2517266 Affidavit of
Christopher A Reilly PhD in Support of DefendantsMotion for Summary Judgment filed
April 22 2011 Reilly Aff 7 Affidavit of Robert Nance in Support of DefendantsMotion
for Summary Judgment filed April 22 2011 Nance Aff 2 The effects include mucous
production redness of the eyes watery eyes or crying involuntary closing of the eyes burning
sensation of the skin such as a sunburn inflammation of the skin sneezing and coughing and
slightly restricted airways Id
3 Major attended IDOC OC training sessions wherein she received minor acute
exposures to OC spray on only five 5 occasions in almost five 5 years 0820402147
022170713 1807 and 038 Burke Aff IT 28 and 10 Exs D C J Ex B Kimmel
Dep 1824195 119251218 Ex E Schaffer Dep 43174425 63126612 6726812
70137223 Ex G Doan Dep 214 2214 2392413 27162915 4022 411 4517
508 Ex F Overgaard Dep 4117 4517 7858216 and Ex A Major Dep 921010125
1075 1089 11091128 11291194 119525 1231340 Major was exposed
to SECspepper spray products at only three 3 of these five 5 trainings on 021470713
1807 and 038 Id 3 4 and 68 Ex B Kimmel Dep 119251218 1344 1385
Ex C Ex E Schaffer Dep 43174425 6312 6612 672 6812 70137223 Ex G Doan
Dep 214 2214 239 2413 27162915 4022 411 4517508 and Ex F Overgaard
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.)  t i i   i l d,  t  t i i  s, l t i i  i  t  
 f  ray. (I .) 
. e effects f  e s re are ac te, te rary, tra sient, re ersi le a  
r l . (Burke . ~~  a  -8, x.  (Kimmel e . 6:13- 7:25), x.  (Schaffer ep. 
35:3-37:6), x.  (Overgaard ep. 51:13-56:4), x.  (Do an ep. 25:17-26:6); ffidavit of 
hristopher A. eilly, Ph.D. in Support of efendant's otion for Su ary Judg ent filed 
ril ,  ("Reill  ff.") ~ ; ffid it f rt  i  rt f f ndant's ti  
f r r  J t file  ril ,  ("Nanc  ff.") ~ .)  ffe ts i l  s 
production, redness of the eyes, atery eyes or crying, involuntary closing of the eyes, burning 
se sati  f t e s i  (suc  as a s nburn), i fla ati  f t e s i , s eezi  a  c i , a  
slightly restricted air ays. (ld.) 
. ajor attended I   training sessions herein she received inor, acute 
exposures to  spray on only five (5) occasions in al ost five (5) years: 08/20/04, 02/14/07, 
02/21/07, 07/13-18/07, and 03/03/08. (Burke ff. ~~ 2-8 and 10, Exs. , , J, Ex.  (Kim el 
e . 8:24- 9:15; 19:25- 21:18), .  (Schaffer e . 3:17- 4:25; 3:12- 6:12; 7:2- 8:12; 
70:13-72:23), Ex.  (Doan ep. 21:24-22:14; 23:9-24:13; 27:16-29:15; 40:22-41:11; 45:17-
50:8), Ex. F (Overgaard Dep. 41:17-45:17; 78:5-82:16) and Ex. A (Major Dep. 92:10-101:25; 
107:15-108:9; 110:19-112:18; 112:19-119:14; 119:15-25; 123:12-134:10).) ajor as exposed 
to SEC's pepper spray products at only three (3) of these five (5) trainings, on 02/14/07, 07/13-
18/07, and 03/03/08. (ld. ~~ 3, 4 and 6-8, Ex. B (Kimmel ep. 119:25-121 :18; 134:14-138:5), 
Ex. C, Ex. E (Schaffer Dep. 43:17-44:25; 63:12-66:12; 67:2-68:12; 70:13-72:23), Ex. G (Doan 
Dep. 21 :24-22:14; 23:9-24:13; 27:16-29:15; 40:22-41 :11; 45:17-50:8) and Ex. F (Overgaard 
ENDANT'S   I   LAINTIF 'S    
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Dep 41174517 7858216 On the other two 2 trainings Major was exposed to pepper
spray products manufactured by Defense Technologies Id
4 Major received her first exposure to OC during her August 20 2004 training
Burke Aff 12 Ex A Major Dep 931894497623 98251012 She entered a six foot
by eight foot 6x 8 room which had been previously sprayed by her trainer with a white
canister of MK9 fog Id at 98251012 She stayed in the room about 20 seconds until she
started to cough and then walked outside Id She stopped coughing after the training session
ended Id She does not know what brand of OC was sprayed in the room Id She did not
see the writing on the OC canister Id
5 Majors next OC training took place on February 14 2007 Her instructor was
Sgt Brett Kimmel Burke Aff IT 2 and 3 Ex B Kimmel Dep 13441385 and Ex A
Major Dep 10751089Major does not recall anything about this training or whether or not
she was exposed to OC Id Ex A Major Dep 1075 1089
6 Major received OC training from Sgt Dan Schaffer on February 21 2007
Burke Aff 2 and 6 Ex E Schaffer Dep 63126612 and Ex A Major Dep 1109
1128 Major recalls the training which was a classroom training during which she was not
exposed to OC Id Ex A Major Dep 11091128
7 Major received OC training from Sgt Dan Schaffer on July 13 andor 18 2007
Burke Aff 112 and 6 Ex A Major Dep 1129 1194 and Ex E Schaffer Dep 6726812
70137223 Major received a 15second exposure to OC during this training where she was
required to pick up and move an object that had been sprayed with OC spray Id Ex A Major
Dep 1129 1194 Major started coughing when the OC was sprayed on the object but the
cough was temporary Id Following her own exposure she watched and laughed as other
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ep. 41:17-45:17; 78:5-82:16).) n the other t o (2) trainings ajor as exposed to pepper 
spray products anufactured by efense Technologies. (Id.) 
. ajor re i e  r first os re t   ri  r u st ,  tr i i . 
(Burke ff. ~ , .  (Major . 3:18-94:4; 7:6-2 ; 8:25- 01 :12).)  t r   si  f t 
by eight foot (6'x 8') roo  which had been previously sprayed by her trainer with a white 
canister of -9 fog. (Id. at 98:25-101:12.) he stayed in the roo  about 20 seconds until she 
t rt  t    t  l e  t i . (I . )  t  i  fter t  tr i i  i  
ended. (Id.) She does not kno  hat brand of  as sprayed in the roo . (Id.) She did not 
see the riting on the  canister. (Id.) 
. ajor's next  training took place on February 14, 2007. er instructor as 
Sgt. rett i el. (Burke ff. ~~   , x.  (Kimm l . 34:14- 38:5)  x.  
(Major ep. 107:5-108:9).) ajor does not recall anything about this training or hether or not 
she as exposed to . (Id., x.  (Major ep. 107:5-108:9).) 
. ajor received  training fro  gt. an chaffer on ebruary 21, 2007. 
(Burke ff. ~~   , x.  (Sch  . 3:12- 6:12)  x.  (Maj  p. 10:19-
112:18).) ajor recalls the training, hich as a classroo  training, during hich she as not 
exposed to OC. (Id., Ex. A (Major Dep. 110:19-112:18).) 
. ajor received  training fro  Sgt. an Schaffer on July 13 and/or 18, 2007. 
(Burke Aff. ~~ 2 and 6, Ex. A (Major Dep. 112:19-119:14) and Ex. E (Schaffer Dep. 67:2-68:12; 
70:13-72:23).) ajor received a 15-second exposure to OC during this training, where she was 
required to pick up and move an object that had been sprayed with OC spray. (Id., Ex. A ( ajor 
Dep. 112:19-119:14).) ajor started coughing when the OC was sprayed on the object, but the 
cough was temporary. (Id.) ll i  er  ex sure, s e atc e  a  la e  as t er 
FENDANT'S  I  OSITI   LAINTIF 'S E  I   
ONSIDERATI    L   LAINTIF 'S SITI   EFENDANT'S  
F  L IFI TI  - Page 11 14542-  ( 045) 
correctional officer trainees came out of the building coughing after they received their
exposures to OC Id She does not know the brand name or color of the OC spray canister that
was used in the training Id
8 Major had her last OC training with Sgts Nick Doan and Joshua Overgaard on
March 3 2008 Burke Aff IT 2 7 and 8 Ex A Major Dep 119525 12321340 Ex G
Doan Dep 2392413 27162915 4022411 4517508 and Ex F Overgaard Dep
41174517 7858216 This was an exposure where Major entered a room which had
previously been sprayed with an MK9 OC fog Id Major did not see the canister of MK9
OC fog used in this training and doesntknow its color shape size or brand Id Ex A Major
Dep133240
9 In providing annual OC training to IDOC correctional officers including Major
the IDOC instructors including Sgts Kimmel Schaffer Overgaard and Doan used a
PowerPoint presentation that was prepared and provided to them by SEC Burke Aff 3 68
and 12 Ex B Kimmel Dep 13271342 1613 1633 Ex E Schaffer Dep 7421756
7727820 Ex G Doan Dep 5210 5422 Ex F Overgaard Dep 2542917 6686723
and Ex K The SEC PowerPoint was shown to Major and other correctional officers during
their annual OC trainings Id The PowerPoint presentation provides in part
PHYSIOLOGICAL EFFECTS
Eyes tear up and close involuntarily
OC causes inflammation of the respiratory tract
Inflammation causes coughing gagging and a loss of breath
sensation
The skin exposed to OC may also become inflamed and will burn
Swelling may occur around the eyes nose and mouth
The nose will run and produce excessive mucous
Id at ExK
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c rre tional fficer trainees  t  t e ildin  ing t  t  re i e  t i  
exposures to ~C. (Id.) She does not kno  the brand na e or color of the C spray canister that 
as se  in t e trai i . (Id.) 
. ajor had her last OC training with Sgts. Nick Doan and Joshua Overgaard on 
arch 3, 2008. (Burke ff. ~~ 2, 7 and 8, x.  (Major ep. 119:15-25; 123:12-134:10), x.  
(Doan ep. 23:9-24:13; 27:16-29:15; 40:22-41:11; 45:17-50:8) and x. F (  . 
1: 7- 5:17; 8:5- 2:16).) is s  s re r  j r t r   r  i   
previously been sprayed ith an -9 C fog. (Id.) ajor did not see the canister of -9 
OC fog used in this training and doesn't know its color, shape, size or brand. (Id., Ex. A (Major 
Dep. 133:12-134:10).) 
. In providing annual C training to I C correctional officers, including ajor, 
the I  instructors, including gts. i el, chaffer, vergaard and oan, used a 
Po erPoint presentation that as prepared and provided to the  by S C. (Burke ff. ~~ , -8 
and 12, x.  (Kimmel ep. 132:7-134:2; 161:13-163:3), x.  (Schaffer ep. 74:21-75:6; 
77:2-78:20), Ex.  (Doan ep. 52:10-54:22), Ex. F ( vergaard ep. 25:4-29:17; 66:8-67:23) 
and x. .) he S  Po erPoint as sho n to ajor and other correctional officers during 
their annual C trainings. (Id.) The Po erPoint presentation provides, in part: 
I I   
• Eyes tear up and close involuntarily 
•      i t   
• Infla ation causes coughing, gagging and a loss of breath 
ati  
• e s i  e se  t   a  als  ec e i fla e  a  ill r  
• elli  a  cc r ar  t e e es, se a  t  
• he nose ill run and produce excessive ucous 
(Id. at Ex. "K".) 
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10 As part of their annual OC training IDOC correctional officers including Major
were administered written tests Burke Aff 3 7 and 13 15 Ex B Kimmel Dep 197211
2132217Ex F Overgaard Dep 1141153Dep Ex 28 Ex L Ex M and ExN
11 Majorstest results for the 08204 OC training are reflected in Exhibit L
Burke Aff 3 and 13 Ex B Kimmel Dep 197211and Ex L Question 14 of that test
and Majorscorrect answer state
14 What are the 3 distinct physical effects when contaminated with
OC
A Facial burning eye closure respiratory
Id
12 Majorstest results for the 02147 OC training are reflected in Exhibit M
Burke Aff It 3 and 14 Ex B Kimmel Dep19721213and Ex M Question 12
of that test and Majorscorrect answer state
12 What are the physiological effects ofOC
A Redness ofthe eyes running nose shortness of breath
Id
13 Majorstest results for the 038 OC training are reflected in Exhibit N
Burke Aff T 3 7 and 15 Ex B Kimmel Dep 2112217 Ex F Overgaard Dep 114
1153andExN Question 9 of that test and Majors correct answer state
9 The physiological effects ofbeing sprayed with OC spray are
A Running nose with mucus discharge
B Eyes tear and involuntarily close
C Respiration ofOC causes of inflammation of the respiratory tract
D All ofthe above
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. s art f t eir a al  trai i , I  c rrecti al fficers, i cl i  aj r, 
ere ad inistered ritten tests. (Burke ff. ~~ 3, 7 and 13-15, x.  (Kim el ep. 19:17-21:1; 
1 :3- 2:17), x.  (Overga r  . 14:1- 15:3; . x. 8), x. , x.   x. .) 
1. jor's t st r s lts f r t  8/2 /04  tr i i  r  r fl t  i  i it . 
(Bur  ff. ~~   , x.  (Kim l . 9:17-21:1)   .) sti   f t t t st, 
 jor's rr t swer, st te: 
(/ .) 
. t r  t   i ti t i l ff t   t i t  it  
? 
. acial burning, eye closure, respiratory 
. jor's t st r s lts f r t  2/1 /07  tr i i  r  r fle t  i  i it . 
(Burke ff. ~~  a  , .  (Kim el ep. 9:17-21:1 21:3-22:17) a  x. .) esti   
ofthat test, and ajor's correct ans er, state: 
. t r  t  i l i l ff t  f C? 
. ess f t  s, r i  se, s rt ess f r t . 
(/ .) 
. ajor's test results for the 03/03/08  training are reflected in xhibit . 
(Burke ff. ~~ ,   , x.  (Kim l . 1:1- 2:17), x.  (Overgaar  . 14:1-
15:3)  . .) ti    t t t t,  jor's t r, t te: 
. he physiological effects of being sprayed ith  spray are: 
. unning nose ith ucus discharge 
. Eyes tear and involuntarily close 
. espiration of  causes of infla ation of the respiratory tract 
.   e  
ENDANT'S   I   I TIFF'S    
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The bold of D indicates Major correct answer Id
14 Major was aware of the acute temporary reversible and recoverable effects of
OC exposure having experienced them at least four 4 times in OC trainings between 2004 and
2007 all prior to her March 3 2008 OC training that is the subject of PlaintiffsComplaint
Burke Aff 2 Ex A Major Dep 921010125 1129 1194
Under the facts stated above no reasonable juror will be able to find that SECsalleged
failure to warn Plaintiff of the acute temporary reversible and recoverable effects of exposure to
OC proximately caused Plaintiffsalleged acute injuries In Idaho proximate cause is split
into two components
First there is actual cause and second there is true proximate
cause sometimes known as legal cause Munson v State Dept
of Highways 96 Idaho 529 531 531 P2d 1174 1176 1975
Sisters of the Holy Cross 126 Idaho at 103940 n 1 895 P2d at
123233 n 1 Actual cause is the factual question of whether a
particular event produced a particular consequence Sisters of the
Holy Cross 126 Idaho at 103940 n 1 895 P2d at 123233 n 1
True proximate cause focuses upon legal policy in terms of
whether responsibility will be extended to the consequences of
conduct which has occurred
Newberry v Martens 142 Idaho 284 288 127P3d 187 191 2005 When there are multiple
possible causes of an injury the defendantsconduct or omission amounts to proximate cause if
it was a substantial factor in bringing about the damage Id emphasis added Based on the
evidence of record SEC contends that no reasonable juror could determine that SECsalleged
conduct in not warning against the wellknown effects ofOC on the labeling of its OC products
was a substantial factor leading to Plaintiffsalleged acute injuries Therefore this is a legal
cause issue which the Court can decide on summary judgment
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[The bold of  indicates ajor's correct answer.] (Id.) 
. aj r as a are f t e ac te, te rary, re ersi le a  rec era le effects f 
 exposure, having experienced the  at least four (4) ti es in  trainings bet een 2004 and 
2007, all prior to her arch 3, 2008  training that is the subject of Plaintiffs o plaint. 
(Burke ff. ~ , .  (Maj r . 2:10- 01:25; 12:19- 19:14).) 
* * * 
nder the facts stated above, no reasonable juror ill be able to find that EC's alleged 
il  t   l i ti   t  te, t rary, i l   l  ts   t  
OC proxi ately caused Plaintiffs alleged acute injuries. In Idaho, "proximate cause" is split 
into t o co ponents: 
First there is actual cause, and second there is true proxi ate 
cause, so eti es kno n as "legal cause." unson v. State, ept. 
of igh ays, 96 Idaho 529, 531, 531 P.2d 1174, 1176 (1975); 
Sisters of the oly Cross, 126 Idaho at 1039-40 n. 1, 895 P.2d at 
-33 . . t l s  is t  f t l sti  f t r  
particular event produced a particular consequence. Sisters of the 
ly r ss,  I a  at -4  . 1,  .2d at -33 . . 
r e r i ate ca se "focuses  le al lic  i  ter s f 
hether responsibility ill be extended to the consequences f 
   cur ed." 
e berry v. artens, 142 Idaho 284, 288, 127 P.3d 187, 191 (2005). hen there are ultiple 
possible causes of an injury, the defendant's conduct or o ission a ounts to proxi ate cause if 
"it as a s sta tial fact r i  ri i  a t t e a age." Id. (emphasis added). ase   t e 
evidence of record, S  contends that no reasonable juror could deter ine that SEC's alleged 
conduct in not arning against the ell-kno n effects of  on the labeling of its  products 
as  s st ti l f t r l i  t  l intiff s lle  t  i j ri s. r f re, t is is  l l 
cause issue hich the Court can decide on su ary judg ent. 
ENDANT'S   I   I TIFF'S    
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The statement of relevant facts at the beginning of this section of the memorandum
SOF provides an accounting ofPlaintiffsknowledge of and experience with how OC affects
the human body Much of Plaintiffsknowledge and experience was obtained prior to Plaintiff
having any exposure to OC manufactured by SEC SOF 38 Throughout the course of her
employment with various Idaho correctional institutions Plaintiff received a number of trainings
regarding the use and effects ofOC Id As a part of the training Plaintiff was educated on the
use and effects ofOC from Idaho Department of Corrections IDOC instructors SOF 913
The IDOC instructors that trained Plaintiff used both a training manual and a PowerPoint
presentation provided by SEC each of which identified the known acute adverse respiratory
effects of exposure to OC Id As a part of her training through IDOL Plaintiff was
administered written tests on the use and effects ofOC and through those tests Plaintiff was able
to correctly identify the known acute adverse respiratory effects of exposure to OC Id Also
as a part of her training Plaintiff was exposed to OC and witnessed firsthand the acute
respiratory effects ofOC exposure SOF 38
Despite having obviously known well the acute adverse respiratory effects of OC
Plaintiff cannot now reasonably argue that her conduct would have changed had the OC
container contained any different label4 Importantly Plaintiff cannot recall having ever had the
opportunity to review the OC canisters used in any of her training exposures SOF 4 5 7 and
8 In short she never saw the labels on SEC canisters from which she alleges OC exposure
Despite having known of and been trained in the adverse acute respiratory effects of exposure to
OC and despite having previously experienced the acute respiratory effects of OC exposure
4 To the extent that Plaintiff has attempted to testify as to how the conduct of the IDOC training instructors may
have changed such testimony ought to be stricken as lacking foundation and being based on pure speculation
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 t t t  l t t  t t  gi i   t i  secti  f t  r  
("S F") r i s  ti  f laintiffs l  f  ri  it    ff ts 
t e a  y. c  f laintiffs le e a  e erie ce as tai e  ri r t  laintiff 
having any exposure to  anufactured by EC. (S  3-8.) hroughout the course f her 
e ploy ent ith various Idaho correctional institutions, laintiff received a nu ber of trainings 
regarding the use and effects of ~C. (Id.) s a part of the training, Plaintiff as educated on the 
          ("IDO ") instructors. (S F 9-13.) 
 I  i str t rs t t tr i  l i tiff s  t   tr i i  l   r i t 
presentation provided by S , each of hich identified the kno n acute adverse respiratory 
ts    D . (/ .)   rt f r tr i i  t r  I C, l i tiff  
ad inistered ritten tests on the use and effects of C, and through those tests Plaintiff as able 
to correctly identify the kno n, acute adverse respiratory effects f exposure to ~C. (/ .) lso 
  t   t i i , l i ti    t    it ed, i t-h , t  t  
r ir t r  ffects  r . (SOF -8.) 
espite having obviously kno n ell the acute adverse respiratory effects of , 
Plaintiff cannot now reasonably argue that her conduct would have changed had the OC 
container contained any different labe1.4 I portantly, Plaintiff cannot recall having ever had the 
opportunity to revie  the C canisters used in any of her training exposures. (S F 4, 5, 7 and 
.) In short, she never saw the labels on SEC canisters from which she alleges DC exposure. 
espite having kno n of and been trained in the adverse acute respiratory effects of exposure to 
D , and despite having previously experienced the acute respiratory effects of C exposure 
4 To the extent that Plaintiff has atte pted to testify as to how the conduct of the IDOC training instructors ay 
have changed, such testi ony ought to be stricken as lacking foundation and being based on pure speculation. 
NDANT'S E  IN   P IFF'S  I   
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from earlier trainings using OC pepper spray manufactured by manufacturers other than SEC
Plaintiff nonetheless voluntarily participated in the trainings without regard for warnings or lack
of warnings on the canister of SEC OC product Regardless ofwhether SEC had warned of the
acute temporary recoverable and reversible adverse respiratory effects on the label of the OC
Plaintiff subjected herself to the OC product and assumed the risk of the same known and
obvious risks ofwhich she is now complaining no reasonable juror will be able to determine that
a lack ofwarning on the product was the proximate cause of or a substantial factor contributing
to Plaintiffs alleged acute injuries Clearly it was not SEC is therefore entitled to entry of
summary judgment in its favor on all remaining claims ofPlaintiff
Z The acute adverse health effects of OC were open and obvious and therefore
SEC had no duty to warn against them and Plaintiff cannot attribute her alleged
damages from her chronic injury to those acute effects
Finally in addition to and as a corollary to the foregoing SEC submits that the Court
need not address the issue of causation in light of Plaintiffs continued inability to establish a
fundamental element of her claims the existence of a legal duty to warn Because the nature
and purpose of pepper spray makes the risks of acute temporary and reversible injuries so
apparent and obvious and because effects of pepper spray are widely known to have temporary
adverse affects on the eyes skin and respiratory functions there can be no genuine issue of
material fact that SEC had no legal duty to warn against the risks of acute temporary and
reversible injuries associated with exposure to its pepper spray product
While a plaintiffsconduct affecting his comparative responsibility is generally a
question for the jury where the undisputed facts lead to only one reasonable conclusion the
5
Notably even Plaintiffsnewest Affidavit filed in conjunction withher latest Motion for Reconsideration again
verifies her familiarity with the temporary adverse effects of OC Iwas repeatedly instructed that the effects
were all temporary I understood the effects of OC exposure to be temporary and safe based on how I had been
trained and what I had been told PlaintiffsMemo 3
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l i ti  t les  l t ril  rti i t  i  t  t i i  it t r   r i s,  l  
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te, t orary, r r l   r r i l  r  r pir t r  ff t   t  l l f t  , 
l i tiff s j t  rs lf t  t   r t  ss  t  ris  f t  s e,   
i s ris s f ic  s e is  c plaining;  reas a le j r r ill e a le t  eter i e t at 
           f,   t nti l  t  
to, laintiffs alleged acute injuries.5 learly, it as not.  is therefore entitled to entry of 
s ar  j e t i  its fa r  all re ai i  clai s f laintiff. 
2. e   l        i s,   
 had no duty to ar  against the  and laintiff cannot attribute er alleged 
da ages fro  her chronic injury to those acute effects. 
i ll , i  iti  t     r ll r  t  t  f r i g,  it  t t t  rt 
 t ress t  iss  f s ti  i  li t f l i tiff s ti  i ilit  t  st lis   
     - the existence f a legal duty to arn. ecause the nature 
 r s  f r r   t  ri  f t , t r r   r r i l  i j rie   
apparent and obvious, and because effects of pepper spray are widely known to have te porary 
adverse affects on the eyes, skin and respiratory functions, there can be no genuine issue f 
t ri l f t t t    l l t  t  r  i t t  ris  f t , t r r   
re ersi le i j ries ass ciate  it  e s re t  its e er s ra  r ct. 
"[W]hile a plaintiffs conduct affecting his co parative responsibility is generally a 
ti  f r t  j r , 'where t  is t  f t  l  t  l   r l  l i  t  
5 Notably, even Plaintiffs newest Affidavit filed in conjunction with her latest Motion for Reconsideration again 
verifies her fa iliarity ith the te porary adverse effects of : "I as repeatedly instructed that the 'effects 
ere all te porary.' I understood the effects of  exposure to be te porary and safe based on ho  1 had been 
traine   hat 1  een t ld." (Plaintiffs o., ~ .) 
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court may rule as a matter of law Puckett v Oakfabco Inc 132 Idaho 816 824 979P2d
1174 1182 1999 citing Corbridge v ClarkEquip Co 112 Idaho 85 87 730P2d 1005 1007
1986 see also Tuttle v Sudenga Indus Inc 125 Idaho 145 149 868 P2d 473 477 1994
The question becomes whether the danger involved is so obvious that it is unreasonable to
impose on the manufacturer a duty to warn Id citing Watson v Navistar IntlTrans Corp
121 Idaho 643 660 827 P2d 656 673 1992 Rephrased when the risks involved here
are so undisputedly obvious failure to warn of those risks does not render the product
defective Id The Restatement Second of Torts 496C further supports this notion
1 Except as stated in Subsection 2 a plaintiff who fully
understands a risk of harm to himself or his things caused by the
defendantsconduct or by the condition of the defendant land or
chattels and who nevertheless voluntarily chooses to enter or
remain or to permit his things to enter or remain within the area of
that risk under circumstances that manifest his willingness to
accept it is not entitled to recover for harm within that risk
See alsoIC 61405b
In a case with facts strikingly similar to those before this Court the Idaho Supreme Court
determined that the obviousness of an acute injury barred a plaintiff from seeking damages
attendant to that acute injury See Sidwell v William Prym Inc supra Though the product in
question in Sidwell was inherently dangerous on some level that danger did not open the door
for plaintiff to obtain a windfall judgment in her favor
In the instant case it is clear that the manufacturer could anticipate
the danger of a pin pricking puncturing or piercing dressmaking
or other materials or the bodily surface of a user However it is
equally clear that such danger is as obvious to the user as it is to
the manufacturer Hence there was no requirement that the
manufacturer give notice of such a danger and a jury could only
have found that such danger was obvious
112 Idaho at 79 emphasis added
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4,  (19 ) (citin  r  . l  uip. o.,   , ,  .2d ,  
(1986); see also uttle v. Sudenga Indus., Inc., 125 Idaho 145, 149, 868 .2d 473,477 (1994).) 
"Th  ti   ' het  t   i l e  i   i  t t it i  l  t  
i   t  t   t  t  arn.'" . (citin  t  . i t r t'l r ns., orp., 
 I  , ,  .2d 6,  (1 92).) "Rephr d, [wh ] t  ri  i l  r  
[are] so undisputedly obvious, failure to arn f those risks [does] not render the product 
fective." / .  t t t (S nd)  ts §  t  t  t i  ti : 
(1) ce t as state  i  secti  (2), a lai tiff  f ll  
ersta s a ris  f ar  t  i self r is t i s ca se   t e 
efendant's c ct r  t e c iti  f t e efendant's la  r 
chattels, and ho nevertheless voluntarily chooses to enter or 
re ain, or to per it his things to enter or re ain ithin the area of 
t t ri , r ir sta  t t if t i  illingnes  t  
t it, i  t titl  t  r r f r r  it i  t t ri . 
 l  I.C. § - 405(b). 
In a case ith facts strikingly si ilar to those before this ourt, the Idaho upre e ourt 
deter ined that the obviousness f an acute injury barred a plaintiff fro  seeking da ages 
tt t t  t t t  i j r .  i ll v. illi  r , I c., s ra.  t  r t i  
question in Sid ell as inherently dangerous on so e level, that danger did not open the door 
 l i ti  t  t i   i ll judg e t i   r: 
In the instant case it is clear that the anufacturer could anticipate 
t e a er f a i  ric i , ct ri , r ierci  ress a i  
or other aterials or the bodily surface f a user. o ever, it is 
equally clear that such danger is as obvious to the user as it is to 
t e r. ence, there as no require ent that the 
anufacturer give notice of such a danger, and a jury could only 
have found that such danger as obvious. 
 Ida  t  (emphasis ded). 
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It should further noted that the plaintiff in Sidwell sought damages for an unforeseen risk
as here but was unable to establish that that the defendant had a legal duty to warn of said risk
As the only foreseeable risks of that product were obvious to a reasonably prudent person the
plaintiff could not establish a duty to warn of those risks either and was therefore not allowed to
seek any damages against the defendant The same result is appropriate here
There is no dispute in this action over the purpose of OC spray Pepper spray is
intended to cause acute adverse health affects in humans its purpose is to demobilize subjects
for a temporary period of time allowing the individual using the product to safely escape or in
the case of law enforcement gain control of an offender Affidavit of Robert Nance in Support
of DefendantsFirst Motion for Summary Judgment filed in this action on April 22 2011 Is
Nance Aff 2 The product is classified as a nonlethal weapon used worldwide by
military law enforcement and private citizens Id at 112 9 14 All known affects sic of
exposure to pepper spray are acute temporary reversible and recoverable Id at 2 Even
within this litigation this Court has recognized the widespread use of pepper sprays for
innumerable aspects of law enforcement and personal protection including within the very walls
of the Courthouse housing this case This product is not perfume it is not a food seasoning
Based on the foregoing and the very nature of SECsproduct the acute temporary
reversible and recoverable effects of exposure to OC are so obvious that as in Sidwell no
reasonable juror could determine that SEC had a duty to warn Plaintiff of the risks of the alleged
acute and temporary respiratory injuries on which Plaintiff now hinges her case Judgment as a
matter of law is therefore appropriate in SECs favor on each and every claim asserted by
Plaintiff
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plaintiff could not establish a duty to arn of those risks either and as therefore not allo ed to 
seek any da ages against the defendant. The sa e result is appropriate here. 
There is no dispute in this action over the purpose of  spray: "Pepper s r  is 
i te e  t  ca se ac te a erse ealt  affects i  a s; its r se is t  e ilize s jects 
for a te porary period of ti e, allo ing the individual using the product to safely escape or, in 
t e case f la  e f rce ent, ai  c tr l f a  ffender." (Affida it f ert a ce i  rt 
of Defendant's [First] otion for Summary Judgment, filed in this action on April 22, 2011 ("1 st 
 ff."), ~ 2.) he product is classified as a "non-lethal eapon," used orld ide by 
ilitary, la  enforce ent, and private citizens. (Id. at ~~ 2, 9, 14.) "All kno n affects [sic] of 
exposure to pepper spray are acute, te porary, reversible and recoverable." (ld. at ~ .)  
ithin this litigation, this ourt has recognized the idespread use of pepper sprays for 
innu erable aspects of la  enforce ent and personal protection, including ithin the very alls 
of the ourthouse housing this case. his product is not perfu e; it is not a food seasoning. 
ased on the foregoing and the very nature of SEC's product, the acute, te porary, 
r rsi l   r r l  ff ts f s r  t   r  s  i s t at, s i  idwell,  
reasonable juror could determine that SEC had a duty to warn Plaintiff of the risks of the alleged 
acute and te porary respiratory injuries on hich Plaintiff no  hinges her case. Judg ent as a 
atter of la  is therefore appropriate in SEC's favor on each and every clai  asserted by 
laintif . 
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CONCLUSION
Based on the foregoing arguments as well as the prior motion practice throughout this
case and this Court previous decisions SEC is entitled to judgment as a matter of law on all
issues and controversies in this litigation PlaintiffsMotion for Reconsideration ought to be
denied as the only authority presented in support of her motion is significantly distinguishable
and in all events in dire conflict with wellreasoned and established Idaho case law
Additionally given the nature of the product SEC is entitled to a ruling that the risks of
temporary adverse health effects from exposure to the pepper spray were apparent and obvious
and that SEC therefore had no duty to warn of such acute effects Moreover as Plaintiff was
well trained in the acute temporary recoverable and reversible effects of exposure to OC but
nevertheless voluntarily allowed herself to be exposed to the same the contents of SECs
warning label cannot reasonably be considered a substantial factor giving rise to Plaintiffs acute
injuries To complete this litigation SEC respectfully requests entry of judgment as a matter of
lawon all remaining claims by Plaintiff arising from her exposure to SECsOC products
DATED this 11 day of October 2011 GREENER BURKE SHOEMAKERPA
Christopher C Burke Thomas J Lloyd III
Attorneys for Defendant
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ased  t e fore i  r t ,  ll  t e rior tion r ti  t r t t i  
ase  t is urt's re ious isi s,  is title  t  judg ent s  tt r f l   ll 
iss es a  c tr ersies in t is litigati . laintiff s tio  f r ec si erati  t t  e 
denied, as the only authority presented in support f her otion is significantly distinguishable 
, i  ll t , i  i  lict it  ll-   t lis   s  l . 
dditionally, given the nature of the product, S  is entitled to a ruling that the risks of 
te porary adverse health effects fro  exposure to the pepper spray ere apparent and obvious, 
and that  therefore had no duty to arn of such acute effects. oreover, as laintiff as 
ll-t i  i  t  t , t rary, le  i l  e ts   t  , t 
nevertheless voluntarily allo ed herself to be exposed to the sa e, the contents of SEC's 
arning label cannot reasonably be considered a substantial factor giving rise to Plaintiffs acute 
injuries. To co plete this litigation, SEC respectfully requests entry of judg ent as a atter of 
la  on all re aining clai s by laintiff arising fro  her exposure to EC's  products. 
DATED this 11 th day of October, 2011.    .A. 
-Lr.~-= 
rist er . rke / as J. l  III 
tt r e s f r efe a t 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OFTt6PUTY
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff Case No CVPI1003515
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OF GAROLD YOST AND DENYING
PLAINTIFFSMOTIONS FOR
RECONSIDERATION
On July 19 2011 the Court entered its Order Re Pending Motions for Summary
Judgment and to Strike Affidavit of Garold Yost Order granting Defendant Security
Equipment Corporations SEC Motion for Summary Judgment in all respects and denying
Plaintiff Billie Jo Majors Major Cross Motion for Summary Judgment In its Order the
Court reserved but did not decide the issue of whether or not Major had any viable claim arising
out of the Federal Hazardous Substances Act FHSA but invited the parties to file further
motions on this last issue
On July 22 2011 SEC filed its Second Motion for Summary Judgment focusing on the
FHSA issues On July 26 2011 Major filed a Motion for Reconsideration of the CourtsOrder
granting SECsfirst Motion for Summary Judgment First Motion for Reconsideration In
support of that Motion Major filed a second affidavit of her expert Garold Yost Second Yost
Affidavit On August 18 2011 SEC filed a Motion to Strike portions of the Second Yost
Affidavit Each party filed briefs and affidavits in support of and in opposition to these three 3
new motions
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On July 19,2011, the Court entered its Order Re Pending Motions for Summary 
Judgment and to Strike Affidavit of Garold Yost ("Order"), granting efendant ecurity 
Equipment Corporation's ("SEC") ti    t i  ll ts  i  
Plaintiff Billie Jo ajor's ("Major") - ti    ent.  it  r, t  
Court reserved, but did not decide, the issue of whether or not Major had any viable claim arising 
out of the Federal Hazardous Substances Act ("FHSA"), t i  t    f  f r 
otions on this last issue. 
On July 22, 2011, SEC filed its Second Motion for Summary Judgment focusing on the 
FHSA issues. On July 26, 2011, ajor filed a otion for Reconsideration of the Court's Order 
granting SEC's first Motion for Summary Judgment ("First t  for econsiderati "). In 
support of that Motion, Major filed a second affidavit of her expert, Garold Yost ("Second Yost 
ffidavit"). On August 18,2011, SEC filed a Motion to Strike portions of the Second Yost 
Affidavit. Each party filed briefs and affidavits in support of and in opposition to these three (3) 
new motions. 
ORDER GRANTING DEFENDANT'S MOTIONS FOR SUMMARY JUDGMENT, STRIKING AFFIDAVIT OF 
GAROLD YOST AND DENYING PLAINTIFF'S MOTI NS FOR RECONSIDERA nON - Page I 
14542-011 (420572.doc) 
After considering the written submissions of the parties and hearing oral argument by
counsel on these three 3motions on September 15 2011 and good cause appearing the Court
HEREBY ORDERS as follows
1 SECsMotion to Strike the Second Yost Affidavit is GRANTED on the grounds
and for the reasons stated by the Court on the record during the September 15 2011 hearing on
the Motion The Court denied Plaintiffsrequest for permission to file a third affidavit of Garold
Yost
2 Majors First Motion for Reconsideration is DENIED on the grounds and for the
reasons stated by the Court on the record during the September 15 2011 hearing on the Motion
and
3 SECsSecond Motion for Summary Judgment is GRANTED on the grounds and
for the reasons stated by the Court on the record during the September 15 2011 hearing on the
Motion
Thereafter on September 20 2011 SEC filed a Motion for Clarification of the Courts
incourt order to clarify whether or not Plaintiff has any remaining claims associated with her
acute reactions to exposure to SECs pepper spray product on March 3 2008 On September 21
2011 Plaintiff filed a Motion to Vacate the Trial of this matter to give the parties additional time
to address SEC Motion to Clarify On September 22 2011 after hearing arguments by
counsel the Court vacated the trial previously set to begin on October 17 2011 and ordered the
parties to treat SECsMotion for Clarification as a Motion for Partial Summary Judgment and to
submit briefs and other supporting and opposing pleadings as if the Motion was a Motion for
Summary Judgment
ORDER GRANTING DEFENDANTSMOTIONS FOR SUMMARY JUDGMENT STRIKING AFFIDAVIT OF
GAROLD YOST AND DENYING PLAINTIFFSMOTIONS FOR RECONSIDERATION Page 2
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After considering the written sub issions of the parties and hearing oral argu ent by 
counsel on these three (3) motions on September 15, 2011, and good cause appearing, the Court 
E  ORDERS as follo s: 
. S 's otion to trike the Second ost ffida it is TED on the rounds 
and for the reasons stated by the Court on the record during the Septe ber 15,2011 hearing on 
the otion. he ourt denied laintiff s request for per ission to file a third affidavit f arold 
Yost; 
2. ajor's First otion for Reconsideration is DENIED on the grounds and for the 
reasons stated by the Court on the record during the September 15,2011 hearing on the otion; 
 
3. S C's Second otion for Su ary Judg ent is  on the grounds and 
for the reasons stated by the Court on the record during the September 15,2011 hearing on the 
ti . 
Thereafter, on September 20, 2011, SEC filed a otion for Clarification of the Court's 
in-court order to clarify whether or not Plaintiff has any remaining claims associated with her 
acute reactions to exposure to SEC's pepper spray product on arch 3, 2008. On Septe ber 21, 
2011, Plaintiff filed a Motion to Vacate the Trial ofthis matter to give the parties additional time 
t  r ss EC's ti  t  larify.  ept r 2,2011, aft r ri  arg ts  
counsel, the Court vacated the trial, previously set to begin on October 17, 2011, and ordered the 
parties to treat SEC's Motion for Clarification as a Motion for Partial Summary Judgment, and to 
submit briefs and other supporting and opposing pleadings as if the Motion was a Motion for 
Summary Judgment. 
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On October 4 2011 Plaintiff filed a Motion for Reconsideration of the CourtsOrder
Granting DefendantsMotion for Summary Judgment Second Motion for Reconsideration
Each party submitted briefs and affidavits in support of and in opposition to SECsMotion for
Clarification Third Motion for Summary Judgment and PlaintiffsSecond Motion for
Reconsideration After considering the written submissions of the parties and hearing oral
argument by counsel on these two 2motions October 17 2011 and good cause appearing the
Court HEREBY ORDERS as follows
PlaintiffsSecond Motion for Reconsideration is DENIED on the grounds and for
the reasons stated by the Court on the record during the October 17 2011 hearing on the Motion
2 SECsMotion for Clarify which was treated by the Court and the parties as
SECs Third Motion for Summary Judgment is GRANTED in all respects on the grounds that
there are no disputes of material fact on the issues raised by SECsMotion that SEC is entitled
to judgment against Plaintiff on all of Plaintiffs claims as a matter of law and for the other
grounds and reasons stated by the Court on the record during the October 17 2011 hearing on
the Motion and
The Court having disposed of all of Plaintiff s claims by this and its prior orders
and there being no remaining issues for trial SEC is entitled to entry of judgment dismissing
Plaintiffs Complaint and all ofPlaintiffs claims against SEC with prejudice SEC is ordered to
submit a proposed Judgment for the Courtsreview and approval
IT IS SO ORDERED
dam
DATED this day of October 2011
Honorable Cheri C Copsey istrict Judge
Fourth Judicial District Ada County
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n tober , , l i ti  filed  otion  e i tion  t  urt's r er 
Granting Defendant's otion for Summary Judgment ("Second otion for Reconsideration"). 
a  rt  s itted riefs d ffidavits i  s rt f  i  siti  t  C's tio  f r 
larification ("Third otion for u ary Judg ent")  l intif  s  otion  
econsideration. fter considering the ritten sub issions of the parties, and hearing oral 
argu ent by counsel on these t o (2) otions ctober 17, 2011, and good cause appearing, the 
t  S  s: 
1. laintiffs ec  ti  f r ec si erati  is I   t e r s a  f r 
the reasons stated by the Court on the record during the October 17, 2011 hearing on the otion; 
. S C's otion for larify, hich as treated by the ourt and the parties as 
SEC's Third otion for Su ary Judg ent, is R TE  in all respects on the grounds that 
t ere are  is tes f aterial fact  t e iss es raise   EC's ti , t at  is e title  
to judgment against Plaintiff on all of Plaintiff s claims as a matter of law, and for the other 
grounds and reasons stated by the ourt on the record during the ctober 17, 2011 hearing on 
the otion; and 
3. The ourt having disposed of all of Plaintiff s clai s by this and it's prior orders, 
 t r  i   r i i  iss s f r trial,  is titl  t  tr  f j t is issi  
Plaintiffs Complaint and all of Plaintiffs claims against SEC with prejudice. SEC is ordered to 
sub it a proposed Judg ent for the ourt's revie  and approval. 
   RED. 
I-" 
  ~day of October, 2011. 
ra le eri . sey, Istnct Judge 
rt  udi i l i trict,  t  
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
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CORPORATION a Missouri corporation
Defendant
Pursuant to Rule 54aof Idaho Rules of Civil Procedure and this Court Orders entered
July 19 2011 and October jb 2011 judgment is hereby entered in favor of Defendant
Security Equipment Corporation SEC against Plaintiff Billie Jo Major dismissing Plaintiffs
Complaint against SEC and each and every claim asserted therein with prejudice and awarding
SEC its costs in an amount to be determined under the procedures set forth in Rule 54 of Idaho
Rules ofCivil Procedure
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Pursuant to Rule 54( a) of Idaho Rules of Civil Procedure, and this Court's Orders entered 
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Security Equip ent Corporation ("SEC") against Plaintiff Billie Jo ajor, dis issing Plaintiffs 
Co plaint against SEC, and each and every clai  asserted therein, with prejudice, and awarding 
SE  its costs in an a ount to be deter ined under the procedures set forth in ule 54 of Idaho 
  i  r cedure. 
~ 
 this 90> day of ctober, 2011. 
JUDGMENT - Page 1 
14542-011 (420627.doc) 
r l  ri . s  ,Di t t J  
rt  Judicial istrict, a t  
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing JUDGMENT on the following
named personson the date indicated below in the manner indicated below
Darwin Overson Esq ViaUSMail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 ViaOvernight Delivery
P O Box 7808
Boise Idaho 83707
Christopher C Burke Esq ViaUSMail
Thomas J Lloyd III Esq ViaHand Delivery
GREENER BURKE SHOEMAKERPA Via Facsimile 2083192601
950W Bannock Street Suite 900 Via Overnight Delivery
Boise Idaho 83702






   
I hereby certify that I caused to be served the foregoing J  on the follo ing 
na ed person(s) on the date indicated belo , in the anner indicated belo : 
ar in ers , s . 
ric . artz, sq. 
 & , C 
 . line i , it   
. .   
i , Idaho  
hristopher . urke, sq. 
ho as 1. lo  III, s . 
   .A. 
 .  t t,   
oise, Idaho 83702 
 s ~ day of ctober, 2011. 
JUDG ENT - Page 2 
14542-011 (420627.doc) 
~ ia .S. ail 
[ ] ia  li e  
[ ] i  i ile (20 /4 9-8 ) 
[ ] ia vernight elivery 
I ~Via .S. ail 
[ ] Via Hand Delivery 
[ ] ia acsi ile (208/319-2 ) 





OCT 2 k 2011
CHRISTOPHER D RICH ClerkBy JAMIE RANDALL
DEPUTY
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STRIKE THE AFFIDAVIT OF
DR YOST AND 2 MOTIONS FOR
SUMMARY JUDGMENT
Plaintiff Billie Jo Major by and through her counsel of record Jones Swartz PLLC
respectfully moves pursuant to Idaho Rule ofCivil Procedure I Ia2Bfor reconsideration of
this Court rulings and orders granting Defendantsmotion to strike Dr Yostssecond affidavit
and Defendantsvarious motions for summary judgment
This Motion is supported by the pleadings papers affidavits and depositions on file as
well as the supporting Memorandum and third Affidavit of Dr Yost both filed concurrently
herewith This Motion is further supported by the first and second Affidavits ofDr Yost and the
PLAINTIFFSMOTION FOR RECONSIDERATION OF THE COURTSORDERS GRANTING DEFENDANTS
1 MOTION TO STRIKE THE AFFIDAVIT OF DRYOST AND 2 MOTIONS FOR SUMMARY JUDGMENT 1
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
Boise ID 83707




Attorneys for Plaintiff Billie Jo Major
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Plaintiff illie Jo ajor, by and through her counsel of record, Jones & S artz PLLC, 
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Affidavit of Counsel in Support of PlaintiffsMotion for Reconsideration and in Opposition to
DefendantsSecond Motion for Summary Judgment






I HEREBY CERTIFY that on this 24th day of October 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
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County of Salt Lake
ss
Case No CV PI 1003515
AFFIDAVIT OF GAROLD S YOST
PHDIN SUPPORT OF PLAINTIFF
MOTION FOR RECONSIDERATION
OF THIS COURTORDER STRIKING
THE SECOND AFFIDAVIT OF
DR YOST
I GAROLD S YOST PHDbeing first duly sworn upon oath depose and state of my
own personal knowledge that if called upon to testify I would competently testify to the
following
1 I am a professor of Pharmacology and Toxicology and an adjunct professor of
Medical Chemistry at the University of Utah Department of Pharmacology and Toxicology My
credentials as an expert have previously been submitted in myprior affidavits
AFFIDAVIT OF GAROLD S YOST PHDIN SUPPORT OF PLAINTIFFSMOTION FOR
RECONSIDERATION OF THIS COURT ORDER STRIKING THE SECOND AFFIDAVIT OF DR YOST I
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I, GAROLD S. YOST, PH.D., being first duly sworn upon oath, depose and state of my 
own personal knowledge that, if called upon to testify, I would competently testify to the 
following: 
. I a  a professor of Phar acology and Toxicology and an adjunct professor of 
edical he istry at the niversity of tah, epart ent of Phar acology and oxicology. y 
credentials as an expert have previously been sub itted in y prior affidavits. 
FFI IT F R L  S. ST, PH.D., I  S PP RT F PLAINTIFF'S TI  F R 
I I   I  OURT'S  STRIKI   SECOND FI A I  O  R.  - 1 
2 I submit the information in this affidavit for the purpose of clarifying and
explaining any perceived conflicts between my deposition testimony and my affidavit testimony
in this case
3 First the following scientific literature cited in my first affidavit was researched
and located after my deposition
a JE Mitchel AP Campbell NE New LR Sadofsky JA Kastelik
SA Mulrennan SJ Compton and AHMorice EXPRESSION AND CHARACTERIZATION OF THE
INTRACELLULAR VANILLOID RECEPTOR TRPV1 IN BRONCHI FROM PATIENTS WITH CHRONIC
COUGH Experimental Lung Research 31295306 2005
b T Higenbottam CHRONIC COUGH AND COUGH REFLEX IN COMMON LUNG
DISEASES Pulmonary Pharmacology Therapeutics 15241247 2002
c P Geppetti S Materazzi P Nicoletti THE TRANSIENT RECEPTOR POTENTIAL
VANILLOID 1 ROLE IN AIRWAY INFLAMMATION AND DISEASE European Journal of
Pharmacology 533207214 2006
d WJ Meggs NEUROGENIC INFLAMMATION AND SENSITIVITY TO
ENVIRONMENTAL CHEMICALS Environ Health Prospect 101234238 1993
e LuYuan Lee and Qihai Gu ROLE OF TRPV1 IN INFLAMMATION INDUCED
AIRWAY HYPERSENSITIVITY Current Opinion in Pharmacology 9243 249 2009
f J Adcock TRPV 1 RECEPTORS IN SENSITIZATION OF COUGH AND PAIN
REFLEXES Pulmonary Pharmacology Therapeutics 22 6570 2009
4 As Exhibit A I have attached hereto copies of additional research publications
and literature that further support my opinion that the scientific literature and studies in existence
prior to 2008 was such that when viewed as a body of literature and human and animal studies it
was known that a product such as SEC MK9 Fogger posed a risk of both acute and chronic
respiratory injury such as that described in Ms Major medical records These are articles and
literature that I did not have at the time of my deposition and which were located after my
second affidavit in this case
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RECONSIDERATION OF THIS COURT ORDER STRIKING THE SECOND AFFIDAVIT OF DR YOST 2001748
.  t the information in is ida t for the rpose  a fying  
explaining any perceived conflicts between y deposition testi ony and y affidavit testi ony 
i  t is c . 
. First, the follo ing scientific literature cited in y first affidavit as researched 
and located after y deposition: 
. lE. it l, .P. bell, .E. , .R. dofsky, 1.A. telik, 
S.A. ulrennan, S.l. o pton, and .H. orice, E P ESSI   C R CTERIZ TI  F T E 
I  I I   (TR ) I  I  I  I  I  
, xperi ental Lung esearch, 31 :295-306 (2005). 
b. T. igenbotta , C R IC C  AND C  REFLE  I  C  L  
ISE SES, Pul onary Phar acology & ti s, 5:241-247 (2 2). 
. P. eppetti, S. aterazzi, P. icoletti, T E TR SIE T RECEPT R P TE TI L 
I I  :  I  I  I I   I ,  l  
Pharmacology, 533:207-214 (2006). 
d. .l. eggs,    I I   
I  I S, nviron. ealth rospect, 101:234-238 (1993). 
. -Yua     ,   1 I  -I  
I  P S NSITIVI , urrent pinion in har acology, 9:243-249 (2009). 
. 1. c ck, 1  I  SITI I     I  
REFLEXES, Pul onary Phar acology & Therapeutics 22, 65-70 (2009). 
. s i it , I a e attac e  eret  c ies f a diti al researc  licati s 
and literature that further support y opinion that the scientific literature and studies in existence 
prior to 2008 as such that hen vie ed as a body of literature and hu an and ani al studies, it 
was known that a product such as SEC's K-9 Fogger posed a risk of both acute and chronic 
respiratory injury such as that described in Ms. Major's medical records. These are articles and 
literat r  t t I i  t  t t  ti  f  siti   i  r  l t  ft r  
 ffi it i  t i  e. 
I I    . ST, H.D., I    LAINTIF 'S I   
I I   Ill  OURT'S  STRI I   SECON  FI I   R.  - 2 
5 I would like to draw attention to the MSDS ofSIGMA ALDRICH for Capsaicin
CAS 404864 part of Exhibit A which is the same capsaicinoid as is used in SABRE Red
Law Enforcement Unit 10 OC MK9 Fogger I have attached a copy of the MSDS for the
MK9 Fogger should the Court wish to compare the CAS list on the two MSDS documents I
have attached the MK9 Fogger MSDS hereto as Exhibit B I draw attention to the SIGMA
ALDRICH MSDS because it states May cause sensitization by inhalation and skin contact
identifies the target organ as nerves and identifies the compound as being Highly Toxic
This MSDS has a print date ofOctober 27 2004
6 Second my testimony in my deposition was not in conflict with what I said in my
affidavits
7 On pages 100 to 101 I was asked the following question and provided the
following answer
22 All right Do you recall having in your
23 review of the scientific and medical literature
24 seeing any peer reviewed publications that
25 specifically address the association between OC
1 exposure on the one hand and long term chronic
2 adverse health effects on the other
3 A Well thatswhat I was referring to
4 before that I dontthink the studies have been done
S or published that definitively well that provide
6 robust data about that scenario that OC exposure
7 now Im talking about OC exposure in a chronic
s sense multiple cases of exposure
My affidavit does not conflict with my answer to this particular question I was being
very specific in my answer as that was what the question called for The use of the term
AFFIDAVIT OF GAROLD S YOST PHDIN SUPPORT OF PLAINTIFFSMOTION FOR
RECONSIDERATION OF THIS COURT ORDER STRIKING THE SECOND AFFIDAVIT OF DRYOST 3001749
5. I would like to dra  atte tion to the S S  - LDRICH for a i i , 
S #404-86-4 (part of Exhibit ), hich is the sa e capsaicinoid as is used in E ed, 
a  nforce ent it, 0% , -9 r. I  attached    the S S f r t e 
-9 Fogger should the ourt ish to co pare the S# list on the t o S S docu ents. I 
have attached the -9 ogger S S hereto as xhibit . I dra  attention to the I -
LDRIC  S S because it states "May cause sensitization by inhalation and skin contact," 
identifies the target organ as "nerves" and identifies the co pound as being "Highly oxic." 
his S S as a ri t ate f ctober , . 
. econd, y testi ony in y deposition as not in conflict ith hat I said in y 
i . 
. n pages 100 to 101, I as asked the follo ing question and provided the 
following answer: 
 Q. ll ri t. o  r ll i  i  r 
 e    i ti   i  terat re 
 seeing any peer-revie ed publications that 
 specifically address the association bet een OC 
 exposure on the one hand and long-ter  chronic 
  l     t er? 
 . el , at's      
 f re,   on't       
5 or published that efi iti el  -- ell, t t r i  
     enario,    
 ow, I'm tal i  about OC exposure in a chronic 
8 sense, Ultiple cases of exposure. 
y affidavit does not conflict ith y ans er to this particular question. I as being 
very specific in my answer as that was what the question called for.  e of t  ter  
FFI A IT F L  S. ST, PH.D., I  S PP T F PLAINTIFF'S TI  F R 
NSI I  F I  OURT'S  STRIKI   SECON  FI I   DR.  - 3 
specifically coupled with the phrase the association between OC exposure on the one hand
and the longterm adverse health effects on the other was interpreted by me as asking whether
there was a study that I was aware of where humans purposely received chronic exposure to OC
for the purpose of determining whether they would or would not suffer long term adverse health





A And no I dontthink that I havent
seen studies that make that that come to that
conclusion that there are adverse effects because I
dont think people have done the studies
My answers were truthful as I am not aware of such a definitive study
My answers were also very clear that I was referring to an absence of definitive or even
robust data about that scenario As I explained in my deposition and in my affidavits the weight
of evidence is that longterm chronic adverse health effects can occur from exposure to OC for a
certain population under certain circumstances As I have repeatedly said there is an entire body
of research relating to the physiological biological toxicological and pharmaceutical effects of
capsaicinoids on human tissues The weight of that evidence strongly suggests that exposure to
capsaicinoids can cause longterm adverse health effects in persons who are already sensitized to
capsaicinoids whether it be because of preexisting respiratory injury or because of prior
exposures that up regulated the TRPV 1 receptor The fact that there was not any definitive
studies showing long term adverse health effects does not detract from the reality that prior to
2008 enough was understood about the toxicology of capsaicinoids that it was understood that
capsaicinoids are irritants that are toxic to sensory neurons under certain circumstances It was
understood that respiratory tissues are particularly sensitive to the effects of capsaicinoids It
AFFIDAVIT OF GAROLD S YOSTPHDIN SUPPORT OF PLAINTIFFSMOTION FOR
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"specifically" coupled ith the phrase "the association bet een  exposure on the one hand 
and the long-term adverse health effects on the other" as interpreted by e as asking hether 
there as a study that I as a are of here hu ans purposely received chronic exposure to  
for t e rpose f eter i in  het er t e  ld r o ld t s ffer l -ter  a erse ealt  
c se e ces. I elie e t is is clear   a s er t at a ears  a e , lines  t  : 
 . , ,  n't n   --  ven't 
  ies at e t -- t    
    e rse t ,   
 don't think people have done the studies. 
y ans ers ere truthful as I a  not a are of such a defmitive study. 
y ans ers ere also very clear that I as referring to an absence of defmitive or even 
robust data about that scenario. s I explained in y deposition and in y affidavits, the eight 
of evidence is that long-ter  chronic adverse health effects can occur fro  exposure to  for a 
certain population under certain circu stances. s I have repeatedly said, there is an entire body 
of research relating to the physiological, biological, toxicological and phar aceutical effects of 
capsaicinoids on human tissues. The weight of that evidence strongly suggests that exposure to 
capsaicinoids can cause long-ter  adverse health effects in persons who are already sensitized to 
capsaicinoids, whether it be because of pre-existing respiratory injury or because of prior 
exposures that up-regulated the TRPVl receptor.  t t t t   t  efi iti  
studies sho ing long-ter  adverse health effects does not detract fro  the reality that, prior to 
2008, enough as understood about the toxicology of capsaicinoids that it as understood that 
capsaicinoids are irritants that are toxic to sensory neurons under certain circumstances. It was 
understood that respiratory tissues are particularly sensitive to the effects of capsaicinoids. It 
FFI I  F  S. ST, PH.D., I  S PP  F PLAINTIFF'S I  F  
NSI RA I  F IS OURT'S  STRI I   S  FFI I  F R. S  - 4 
was also understood that exposure to capsaicinoids can result in either hypersensitivity or
hyposensitivity to capsaicinoids and other more common irritants Finally it was understood
that biological changes occurring within human and animal tissues can be of a short duration
long duration or even permanent
On page 101 lines 21 to 25 I was asked the following question and provided the
following answer which appears on page 102 lines 1 to 8
21 Q Have you in your review of peer reviewed
22 publications seen any articles that focus on the
23 duration of time after exposure to OC that adverse
24 health effects are customarily deemed persistent in
25 humans
1 A I would say my general opinion is that
2 general conclusion from literature is that they are
3 transitory and that would generally mean you know
4 more than a minute and probably less than a day or
5 two So I think theressubstantial evidence that
6 the pain irritation lacrimation et cetera that we
7 talked about before is not long it doesn persist
8 for weeks and months
8 I understood the question as asking about studies of the customarily expected
health effects of OC exposure in humans I think it is clear from my answer that what I am
referring to is that it is understood that the effects of OC exposure are generally transitory
However Ms Major situation does not fall within the common experience people normally
have to OC exposure As I have said while most people have transitory effects from OC
exposure there is a population of persons with respiratory illness who are going to have effects
AFFIDAVIT OF GAROLD S YOSTPHDIN SUPPORT OF PLAINTIFFSMOTION FOR
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as ls  understood t t posure t  s i i oids  r s lt i  it r rs siti it  r 
hyposensitivity to capsaicinoids and other ore co on irritants. i ll , it as t  
that biological changes occurring ithin hu an and ani al tissues can be of a short duration, 
long duration, or even per anent. 
n page 101, lines 21 to 25, I as asked the follo ing question and provided the 
f ll i  a s er, ich a ears  a e , lines  t  8: 
 . ave you,   e   er-r  
 li ti ,   ti le  t t f s  t  
 duration of ti e after exposure to OC that adverse 
 ealt  effects are c st aril  dee ed ersiste t i  
 ns? 
 . I l  sa  y e eral i i  is t t --
 e eral c cl si  fr  literat r  is t t t e  are 
 tra sit r  and t at ould e erall  ean, you kno , 
 ore than a inute and probably less than a day or 
 .    ere's t  e e  
 the pain, irritati , lacri ation, et cetera, that e 
7 talked about before is not long -- it oesn't r i t 
    t s. 
. I erst  t e esti  as as i  a t st ies f t e "cust arily" e ecte  
health effects of  exposure in hu ans. I think it is clear fro  y ans er that hat I a  
referring to is that it is understood that the effects of OC exposure are generally transitory. 
However, s. ajor's situation does not fall within the common experience people normally 
a e t   e sure. s I a e said, ile st e le a e tra sit r  effects fr   
exposure, there is a population of persons with respiratory illness who are going to have effects 
I I    . ST, H.D., I  S P   LAINTIF 'S I   
I    OURT'S  TRI I    FFIDAVIT  R.  - 5 
that are different from those experienced by most individuals Prior to 2008 it was understood
that OC exposure under certain circumstances could result in either an upregulation or a down
regulation in TRPV 1 population in respiratory tissues It was understood that people with
respiratory illness were more sensitive to OC than most It was also understood that for those
with respiratory illness OC exposure in sufficient concentration and duration posed a risk of
adverse health changes that could be chronic However I was not asked about that information
in my deposition and so I did not talk about that information in my deposition
I was asked about the effects that are customarily observed in humans when they are
exposed to OC This is clear from the followup question I was asked on page 102 lines 9 to 12
and my answer relating to the effects that would generally be expected from acute exposure to
OC
9 Q Okay So its basically your
10 understanding that the adverse health effects to
11 acute exposures to OC are generally deemed to be
12 temporary reversible and recoverable
13 A In general I think thats true It does
14 not mean that they cant exacerbate an underlying
15 condition for someone who is highly sensitized and
16 thats what I opine in my statement But certainly
17 in a majority of cases a large majority of cases
18 the effects are temporary and reversible yes from
19 acute exposure
Nothing in this testimony is inconsistent with my statements made in my affidavits I
was not asked any questions about what was understood in the scientific community about the
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that are different fro  those experienced by ost individuals. Prior to 2008, it as understood 
that  exposure under certain circu stances could result in either an up-regulation or a do n-
regulation in T P 1 population in respiratory tissues. It as rst  t t le it  
respiratory illness were more sensitive to OC than most. It was also understood that for those 
ith respiratory illness,  exposure in sufficient concentration and duration posed a risk of 
a erse ealt  c a es t at c l  e c r ic. e er, I as t as e  a t t at i f r ati  
in my deposition and so I did not talk about that information in my deposition. 
    t e fects   ri    a s    
exposed to ~C. This is clear fro  the follo -up question I as asked on page 102, lines 9 to 12, 
and my answer relating to the effects that would generally be expected from acute exposure to 
: 
 . ay. o it's si ll  r 
 understanding that the adverse health effects to 
 acute exposures to OC are generally dee ed to be 
 te rary, r rsi le a  r overable? 
 . In general, I think t at's true.   
 not ean t at they can't exacerbate an underlying 
 c itio  f r so eone ho is i l  sensitized, and 
 that's hat I opine in my state ent. t rt i l  
 i  a aj rit  f cases, a lar e aj rit  f cases, 
 t  ff t  r  t r r   r rsi l , s,  
 acute exposure. 
Nothing in this testi ony is inconsistent with y state ents ade in y affidavits. I 
as not asked any questions about hat as understood in the scientific co unity about the 
I I    S. T, H.D., I    LAINTIF 'S I  F  
I I   Ill  OURT'S  STRI I   EC  FI I   R.  -  
effects of OC at certain concentrations and duration on populations of humans who have a
respiratory illness
9 I have reviewed my deposition testimony on pages 153 line 16 to 155 line 25
which appears in the transcript as follows
16 Q In your opinion as of March of 2008 was
17 there anything definitively published in the
18 peer reviewed scientific and medical literature that
19 would have put a manufacturer of pepper spray
20 products such as SEC on notice that exposure to their
21 products by somebody with the chronic health
22 conditions of Ms Major would have caused her an
23 exacerbated response which would have included an
24 ongoing chronic cough for the subsequent period of
25 time
1 A I dontthink its possible for me to
2 place a nefarious intent You know the
3 responsibility of whether or not there was sufficient
4 evidence there to say you know if you do if you
5 expose somebody to this they are going to have
6 life altering changes I don think that existed
7 then In the literature today I don think it
8 exists except through the preponderance of evidence
9 and it may very well be that other people dont
LO believe that thats the case but I do And so you
L1 know blame is for the jury to decide
L2 Q Well do you think people that were
L3 trained in toxicology such as yourself would have
L4 been able to review the medical literature and the
L5 scientific literature that existed on or prior to
L6 March of 2008 and have been able to determine that
L7 there would have been a lifealtering condition that
LS resulted from pepper spray exposure
L9 A I dontsee evidence that the normal ways
20 for industrial hygiene officers and personnel to
21 evaluate such kinds of exposures may or may not have
22 existed at that time I haventseen it I mean I
23 donthave evidence that would say heres an
24 MSVS sheet that says this bad thing is going to
25 happen if you expose it It does say you know this
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respiratory illness. 
. I have revie ed y deposition testi ony on pages 153, line 16, to 155, line 25, 
hich appears in the transcript as follo s: 
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 l t   i  f  ay   t  
    ti e.  aven't  t. I an, I 
 on't   t t l  ay, ere's  
 S S s t t t sa s t is a  t i  i  i  t  
25 happen if you expose it. t  ay,  ow, i  
I I    . ST, H.D., I  S P   LAINTIF 'S I   
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1 is an irritant This is an acute thing It is going
2 to cause this this and this so you better be aware
3 of But Imnot aware of anything that the normal
4 layperson in the industry would say or would see that
5 would necessarily show that
6 Conversely maybe there is something in
7 the not in the maybe in the product information
8 or whatever which I haventseen just the MSVS So
9 again I really cant place blame necessarily on
10 whomever All I can say is I think theresan
11 association between the condition she now has and
12 that exposure
13 Q And thatsbased upon your many years of
14 experience as a toxicologist
15 A Yes
16 Q Itsbased on your extrapolation of a
17 number of scientific papers and your weighing of the
is evidence is that right
19 A Yes
20 Q But you cantcite me to one specific
21 paper out there that existed prior to March of 2008
22 that specifically would have put laypersons without
23 your background on notice that exposure to their
24 product could have caused these longterm health
25 conditions
As to the question on page 153 I answered it from my perspective on what a
manufacturer might actually have known prior to March 2008 regarding whether chronic adverse
health effects were a risk for persons with respiratory illness That is I understood the question
as asking me if there was a study that I was aware of that would definitively state such health
risks existed in terms that a typical manufacturer would understand That is the reason I
answered in terms of whether I thought there was nefarious intent on the part of the
manufacturer I also went on to state that there was not and is not a definitive piece of literature
that says that OC exposure would cause life altering adverse health changes I was however
clear in my answer that the preponderance of the evidence was that such adverse effects were a
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As to the question on page 153, I answered it fro  y perspective on what a 
anufacturer ight actually have known prior to arch 2008 regarding whether chronic adverse 
health effects ere a risk for persons ith respiratory illness. That is, I understood the question 
as asking e if there as a study that I as a are of that ould "definitively" state such health 
ris s e iste  i  ter s t at a t ical a fact rer l  erstand.  i     
ans ered in ter s of hether I thought there as nefarious intent on the part of the 
a facturer. I als  e t  t  state t at t ere as t, a  is t, a efi iti e iece f literat re 
that says that C exposure would cause life altering adverse health changes. I as, ho ever, 
clear in y ans er that the preponderance of the evidence as that such adverse effects ere a 
FFI I  F  S. ST, PH.D., I  S PP  F PLAINTIFF'S I  F  
NSI I  F IS OURT'S  STRI I   S  FFI I  F R. S  - 8 
risk associated with OC exposure for certain populations of people I was not entirely clear in
my answer that I also meant that such evidence existed prior to March 2008 but I can say that it
did exist at that time
In answering that question I also understood from the use of the word would that the
question was referring to some level of certainty which I have already explained does not exist
except through a preponderance of the evidence Had I been asked whether the preponderance
of the evidence prior to March 2008 was that longterm adverse health effects was a risk of OC
exposure for certain populations I would have provided a yes answer That was not however
the question as I understood it It would be untrue to say that the evidence was that OC exposure
would cause adverse health effects The term is one of near certainty and that type of certainty
is very rare in good science Probabilities weight of the evidence and risks of are the
verbiage that would be most accurate in describing the conclusions drawn from most scientific
investigations
The question that appears on page 154 lines 12 to 17 was similarly asked in terms of
certainty as to the outcome of OC exposure which is the reason I answered as I did Had the
question been asked in terms of probability or risks I would have answered the question in the
manner in which I have described those risks in my prior affidavits In reviewing the question I
also notice that I may have misinterpreted part of the question I see that it was stated as a
question of what a toxicologist such as I am would have known during the relevant time I
misinterpreted the question as again asking what a manufacturer would know which is why I
spoke of lay persons and of placing blame
10 I would also like to point out that during my deposition I was recovering from a
back surgery The deposition took place in my home because I was not able to travel because of
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risk associated ith  exposure for certain populations of people. I as not entirely clear in 
y ans er that I also eant that such evidence existed prior to arch 2008, but I can say that it 
id ist  at ti . 
In ans ering that question, I also understood fro  the use of the ord "would" that the 
question as referring to so e level of certainty hich I have already explained does not exist 
except through a preponderance of the evidence. ad I been asked hether the preponderance 
of the evidence prior to arch 2008 as that long-term adverse health effects as a risk of  
exposure for certain populations, I would have provided a ''yes'' answer. That was not, however, 
the question as I understood it. It ould be untrue to say that the evidence as that  exposure 
"wo ld"  rse lt  ff t .  t r  is e  r rt i t   t t t   rt i t  
is very rare in good science. "Pro bilities," "weight  t  i nce"  "risks '  t  
verbiage that would be most accurate in describing the conclusions drawn from most scientific 
investigations. 
he question that appears on page 154, lines 12 to 17, as si ilarly asked in ter s f 
certainty as to the outco e of OC exposure, which is the reason I answered as I did. Had the 
question been asked in terms of probability or risks, I would have answered the question in the 
 i  i    i  t  i  i   i  ffi vits.  i i  t  stion,  
also notice that I ay have isinterpreted part f the question.      st t    
question of what a toxicologist such as I am would have known during the relevant time. I 
misinterpreted the question as again asking what a manufacturer would know, which is why I 
spoke of lay persons and of placing blame. 
0. I would also like to point out that during y deposition I was recovering fro  a 
back surgery. The deposition took place in my home because I was not able to travel because of 
FFI I  F  S. ST, PH.D., I  S PP  F PLAINTIFF'S onO  F  
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my health condition My mobility was impaired When I was asked to identify articles that
supported my opinion regarding chronic effects of exposure to OC I explained to the attorney
that I did not have all the articles there I asked for them from SECsattorney several times
which is evidenced on pages 133 line 19 to 142 line 18 but they were not available for
whatever reason Ms Major attorney was not physically present to assist me in locating the
articles because he attended the deposition by telephone
11 Since my deposition and last affidavit I have reviewed additional literature
attached as Exhibit A that suggests that there have been reports by law enforcement officers
who were exposed to OC during training and experienced long lasting adverse effects
Specifically THE HUMAN HEALTH EFFECTS OF PEPPERSPRAYA REVIEW OF THE LITERATURE
AND COMMENTARY Michael D Cohen which was published in 1997 in the Journal of
Correctional Health Care Dr Cohen writes in the article thatstudies of the effects of
capsaicin on human physiology anecdotal experience with field use of pepperspray and
controlled exposure of correctional officers in training have shown adverse effects on the lungs
larynx middle airway protective reflexes and skin In the article it notes Dr Stopfords 1996
publication that analyzed records from the North Carolina Department of Corrections
Stopford 1996 analyzed these records and found symptoms
requiring medical attention occurred in five percent of those
sprayed Of greatest concern were incidents in which officers
developed shortness of breath high blood pressure chest pain
headache and loss of consciousness For some symptoms
persisted for weeks or more
Dr Cohen continued his review
There have been several reviews of animal and human studies of
the toxicology of oleoresin capsicum and capsaicin
DiBartolomeis et al 1993 Both concluded that there are
insufficient data currently available to fully define the health risks
of pepperspray but they cited animal studies showing that
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supported y opinion regarding chronic effects of exposure to , I explained to the attorney 
t at I i  t  ll the ti le  t . I   t  r  C's tt  l ti , 
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ho ere exposed to  during training and experienced long-lasting adverse effects. 
Specifically, THE HUMAN HEALTH EFFECTS OF PEPPERSPRAY-A REVIEW OF THE LITERATURE 
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capsaicin on hu an physiology, anecdotal experience ith field use of pepperspray, and 
controlled exposure of correctional officers in training have sho n adverse effects on the lungs, 
larynx, iddle air ay, protective reflexes, and skin." In the article, it notes r. Stopford's 1996 
publication that analyzed records fro  the orth arolina epart ent of orrections: 
Stopford (1996) analyzed these records and found sy pto s 
requiring edical attention occurred in five percent of those 
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(DiBartolo eis, et aI., 1993).   t  t r  r  
insufficient data currently available to fully defme the health risks 
of pepperspray, but they cited ani al studies showing that 
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capsaicin can be mutagenic or carcinogenic alters immune
responses and has substantial effects on nerves heart blood
vessels lungs and kidneys
In another portion of the review Dr Cohen states These studies provide firth evidence
for a toxic effect of capsaicin on lung function of certain asthmatics Dr Cohen noted that
many of the studies of the effects of capsaicin use dosages much lower than those that result
from exposure to OC by hand held devices used in law enforcement Dr Cohen concludes his
article with the following warning Use of pepperspray should be restricted in order to prevent
serious injuries which are most likely to occur in people with asthma or chronic lung disease
12 Groneberg published MODELS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE in
2004 and made clear that it was understood that depending on the duration and intensity of
exposure to noxious inhalants there could be induced signs of chronic inflammation and airway
remodeling Capsaicinoids would be classified as a noxious inhalant and in many ways would
be understood as one of the primary noxious inhalants Groneberg work supports the notion
that longterm changes to the respiratory tract may take place due to exposure to capsaicinoids
depending on the concentration and duration of exposure
13 I would also like to point out that my own work with Dr Reilly in 2005
recognizes that
lung epithelium is the initial barrier that xenobiotics encounter
upon inhalation and is a frequent target for toxicants Burgel
Nadel 2004 Damage to the respiratory epithelium compromises
respiratory function by increasing the susceptibility of individuals
to subsequent lung injury and infections and ultimately
contributes to hypersensitivity disorders such as asthma and COPD
Kasper Haroske 1996 Kuwano et al 2001 Selman et al
2001 Witschi 1991 Activation of TRPV 1 capsaicin receptor
VRl in lung epithelial cells by certain types of airborne
particulate pollutants and prototypical agonists initiates
inflammatory responses and promotes cell death Agopynan et al
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. I ould also like to point out that y o n ork ith r. eilly in 2005 
recognizes that 
lung epitheliu  is the initial barrier that xenobiotics encounter 
upon inhalation and is a frequent target for toxicants (Burgel & 
adel,2004). a age to the respiratory epitheliu  co pro ises 
respiratory function by increasing the susceptibility f individuals 
 subsequent lung injury  ,  l  
contributes to hypersensitivity disorders such as asth a and  
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2003a b 2004 Oortgiesen et al 2000 Reilly et al 2003
Veronesi et al 1999b
Since capsaicin is the primary agonist of TRPVI it is clear that OC exposure can cause
longterm adverse health effects involving the respiratory system I bring this up because this
article was cited in my first affidavit filed with this Court
14 My own work in accompaniment with Dr Reilly makes it clear that TRPV1
agonists such as capsaicinoids cause cell death in human lung cells under certain circumstances
These findings are significant within the context of lung
inflammatory diseases where elevated concentrations of
endogenous TRPV1 agonists are probably produced in sufficient
quantities to cause TRPV1 activation and lung cell death
Thomas Sabnis Johansen Lanza MOOS Yost and Reilly TRANSIENT RECEPTOR POTENTIAL
VANILLOID 1 AGONISTS CAUSE Endoplasmic RETICULUM STRESS AND CELL DEATH IN HUMAN
LUNG CELLS J ofPharm Exper Therap 321 No 3 2007
15 Again in METABOLISM OF CAPSAICINOIDS BY P450 ENZYMES published in
2006 Dr Reilly and I recognized that Capsaicinoids are also toxic to many cells via TRPV1
dependant and independent mechanisms This conclusion is further supported by CAPSAICIN
INDUCED NEUROTOXICITY IN CULTURED DORSEL ROOT GANGLION NEURONS 1995 where it was
concluded that capsaicin kills a subpopulation of sensory neurons by activating a receptor
operated channel
FURTHER YOUR AFFIANT SAYETH NOT
GAROLD S YOST
SUBSCRIBED AND SWORN TO before me thiscday ofOctober 2011
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A MOTION FORRECONSIDERATION STANDARD
Motions for reconsideration are matters for the trial courtsdiscretion A party making
a motion for reconsideration is permitted to present new evidence but is not required to do so
Jordan v Beeks 135 Idaho 586 592 21 P3d 908 914 2001
2 Johnson v Lambros 143 Idaho 468 147P3d 100 Ct App 2006
MEMORANDUM IN SUPPORT OF PLAINTIFFSMOTION FORRECONSIDERATION OF THE COURTS
ORDERS GRANTING DEFENDANT 1 MOTION TO STRIKE THE AFFIDAVITOF DR YOST AND
2 MOTIONS FOR SUMMARY JUDGMENT 1
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
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otions for reconsideration are atters for the trial court's discretion.! "A party aking 
a otion for reconsideration is per itted to present ne  evidence, but is not required to do SO.,,2 
1 Jorda  v. eeks,  I a  6, , 21 .3d ,  (2 1). 
2 Johnson v. a bros, 143 Idaho 468, 147 P.3d 100 (Ct. pp. 2006). 
    I TIFF'S   I    OURT'S 
 I  ENDANT'S (1) I   I   I I   . T,  
(2) OTIONS FOR SU ARY JUDG ENT -  
A motion for reconsideration is timely if it is filed any time prior to a final judgment or within 14
days thereafter
B MOTION FOR SUMMARY JUDGMENT STANDARD
Summary judgment is proper when there are no genuine issues of material fact and the
moving party is entitled to judgment as a matter of law All controverted facts are to be liberally
construed in favor of the nonmoving party
C THIS COURT SHOULD RECONSIDER ITS ORDER GRANTING DEFENDANTSMOTION TO
STRIKE THE SECOND AFFIDAVIT OF DRYOST BECAUSE HE HAS NOW SUBMITTED A
THIRD AFFIDAVIT FURTHER SUPPORTING HIS OPINIONS AND EXPLAINING ANY
CONFLICTS THATWERE PERCEIVED TO EXIST BETWEEN HIS DEPOSITION TESTIMONY
AND HIS AFFIDAVITS
This Court granted Defendantsmotion to strike Dr Yosts second affidavit on the
grounds that it conflicted with his deposition testimony as to his opinion regarding the state of
knowledge at the time SEC sold its product to IDOC regarding longterm health risks posed by
its OC Spray This Court should reconsider its prior ruling on the following bases
Dr Yoststhird affidavit explains that the literature he identified in his first affidavit
was researched and located after his deposition
Dr Yost has provided additional articles that were in existence prior to 2008 which
support his contention that it was known that products such as SEC OC Spray products posed
longterm health risks to the respiratory system such as those indicated in the medical records of
3IRCP11a2B
4IRCP56c
5 Heath v HonkersMiniMart Inc 134 Idaho 711 712 Ct App 2000
6 3raAff of Yost 3
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ORDERS GRANTING DEFENDANT 1 MOTION TO STRIKE THE AFFIDAVIT OF DR YOST AND
2 MOTIONS FOR SUMMARY JUDGMENT 2
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grounds that it conflicted with his deposition testimony as to his opinion regarding the state of 
kno ledge at the ti e S  sold its product to I  regarding long-ter  health risks posed by 
its  Spray. his ourt should reconsider its prior ruling on the follo ing bases: 
• r. ost's third affidavit explains that the literature he identified in his first affidavit 
as researched and located after his deposition.6 
• r. ost has provided additional articles that ere in existence prior to 2008 hich 
support his contention that it as kno n that products such as S   Spray products posed 
long-ter  health risks to the respiratory syste  such as those indicated in the edical records of 
3 LR.C.P. 11(a)(2)(B). 
41.R.C.P.56(c). 
5 eath v. onker's ini-Mart Inc., 134 Idaho 711, 712 (Ct. pp. 2000). 
6 
rd ff. f st, ~ . 
    I TIFF'S   I    OURT'S 
S I  FENDANT'S (1) I   S I   FFI I  F . ST,  
(2) TI S F  S  J E T -  
Ms Major Those articles were researched and located after Dr Yost submitted his second
affidavit and after his deposition
Along with the scientific articles Dr Yost identifies a manufacturer MSDS sheet
that includes the information regarding sensitization by inhalation of capsaicin and identifies the
target organ as the nerves which is consistent with Dr Yosts expressed opinions The MSDS
is dated 2004 and identifies capsaicin as highly toxic
Dr Yost explains in his third affidavit that his deposition testimony did not conflict
with his second affidavit
10
Dr Yost has included a number of articles published by him and Dr Reilly prior to
2008 that expressly recognized long term negative health effects of exposure to capsaicinoids
Damage to the respiratory epithelium compromises respiratory
function by increasing the susceptibility of individuals to
subsequent lung injury and infections and ultimately contributes to
hypersensitivity disorders such as asthma and COPD
Activation of TRPV1 capsaicin receptor VRl in lung epithelial
cells by certain types of airborne particulate pollutants and
prototypical agonists initiates inflammatory responses and
promotes cell death
Dr Yost explains that because capsaicin is the primary agonist of TRPV1 it is clear
that OC exposure can cause long term adverse health effects involving the respiratory system
He also points to the statement in his and Dr Reillys 2007 work that hese findings are
significant within the context of lung inflammatory diseases where elevated concentrations of
Id at 4 and Ex A
a Id at 4 11 12
9 Id at 5 and Ex B
old at 610
11 Id at 1315
121d at 13
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s. ajor.7 hos  icles er    located t  . ost i ted is  
ffid it a  fter is osition.8 
• long it  the s i tific rti l s, r. ost i tifies  facturer's S  s t 
t t i ludes t e i for ation r r i  s siti ti   i l ti  f s i i   i tifies t  
target organ as the "nerves," which is consistent with Dr. Yost's expressed opinions. The SDS 
is ate   a  i e tifies ca saici  as "highl  t ic". 9 
• r. ost lains i  is t ir  ffi it t t is siti  t sti  i  t fli t 
t  is  i . 0 
• r. ost as· include  a er f articles lis e   i  a  r. eill  ri r t  
2008 that expressly recognized long-term negative health effects of exposure to capsaicinoids: 11 
a age to the respiratory epitheliu  co pro ises respiratory 
function by increasing the epti ilit  f i i iduals t  
subsequent lung injury and infections, and ulti ately contributes to 
hypersensitivity      . . .. 
ti ti  f l (ca s i i  r tor, l) i  l  it li l 
lls  rt i  t es f ir r e rti l t  ll t ts  
prototypical agonists tiate  i fla at r  res ses  
promotes cell death .... ,,12 
Dr. Yost explains that because capsaicin is the pri ary agonist of TRPVl, it is clear 
that OC exposure can cause long-term adverse health effects involving the respiratory system. 
e also points to the state ent in his and r. eilly's 2007 ork that "[t]hese findings are 
significant ithin the context of lung infla atory diseases here elevated concentrations of 
7 . t ~   x. . 
8 . t ~~ 4, 11-12. 
.  ~   x. . 
10Id. t ~~ -1 . 
 . ~~ -1 . 
Id. t ~ 3. 
    LAINTIF 'S   SI I    OURT'S 
E S TI  EFENDANT'S (1) TI  T  ST I E T E FFI IT F R. ST,  
(2) TI S F R S R  J E T -  
endogenous TRPV1 agonists are probably produced in sufficient quantities to cause TRPV1
activation and lung cell death
i 3
This Court should reconsider its ruling striking Dr Yostssecond affidavit and should
further reconsider its granting ofDefendantsmotions for summary judgment since the scientific
evidence existed prior to 2008 when SEC sold its product to IDOC to put manufacturers on
notice that the product posed a risk of adverse longterm respiratory injury
D THIS COURT SHOULD RECONSIDER ITS GRANT OF SUMMARY JUDGMENT BECAUSE ITS
RULINGS WERE GROUNDED ON ITS RULING STRIKING THE SECOND AFFIDAVIT OF
DR YOST
This Court was clear that the reason it was granting Defendantsmotions for summary
judgment was because it was granting SECs motion striking Dr Yosts second affidavit Now
that Dr Yost has clarified any perceived conflicts between his deposition testimony and his
affidavits and has provided additional support for his opinions a material issue of fact exists that
would prevent summary judgment Accordingly it is respectfully requested that this Court
reconsider its granting Defendantsmotions for summary judgment and reverse the same so that
this matter can proceed to trial
II
CONCLUSION
For the reasons set forth herein Plaintiffsmotion for reconsideration should be granted
and DefendantsMotion to Strike the Affidavit ofDr Yost and Motions for Summary Judgment
should be denied
13 Id at 14
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endogenous TRPVl agonists are probably produced in sufficient quantities to cause TRPVl 
activation and lung cell death.,,13 
is t l  re i e  its li  t i ing . st's  i vit,  l  
further reconsider its granting of efendant's otions for su ary judg ent since the scientific 
evidence existed prior to 2008 hen  sold its product to I  to put anufacturers on 
notice that the product posed a risk of adverse long-ter  respiratory injury. 
. IS   SIDER S     USE S 
INGS    S I G I  E  I   
.  
is rt as clear t at t e reas  it as ra ti  efendant's ti s f r s ar  
judg ent was because it was granting SEC's otion striking Dr. Yost's second affidavit. Now 
that r. ost has clarified any perceived conflicts bet een his deposition testi ony and his 
affidavits, and has provided additional support for his opinions, a aterial issue of fact exists that 
ould prevent su ary judg ent. cc r i ly, it is res ectf ll  re este  t at t is rt 
reconsider its granting Defendant's otions for su ary judg ent and reverse the sa e so that 
this matter can proceed to trial. 
I. 
 
For the reasons set forth herein, Plaintiffs otion for reconsideration should be granted, 
 f ndant's   t   i   r.     r  t 
l   i . 
 .  ~ 4. 
    LAINTIF 'S   I    OURT'S 
R ERS R TI  EFENDANT'S (1) TI  T  STRI E T E FFI IT F R. ST,  
(2) MOTIONS FOR SUMMARY JUDGMENT - 4 
DATED this 24th day of October 2011
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ERRATA RE AFFIDAVIT OF
GAROLD S YOSTPHDIN SUPPORT
OFPLAINTIFFSMOTION FOR
RECONSIDERATION OF THIS COURT
ORDER STRIKING THE SECOND
AFFIDAVIT OF DR YOST
I Darwin L Overson being first duly sworn upon oath depose and state upon my own
personal knowledge as follows
1 I am an attorney with the law firm of Jones Swartz PLLC and am authorized to
practice law before this and all courts of the State of Idaho
2 I am counsel of record for Plaintiff Billie Jo Major in the above action and have
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Post Office Box 7808 
Boise, ID 83707 
Telephone: (208) 489-8989 
Facsimile: (208) 489-8988 
Email: darwin@jonesandswartzlaw.com 
eric@jonesandswartzlaw.com 
Attorneys for Plaintiff, Billie Jo ajor 
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CHRJSTOPHER D. RI , Cieri< 
By JERI HEATON 
DEPUTY 
IN E IS I    E  J I I  IS I   
E TE  I , I    E    
BILLIE JO MAJOR, and individual, 
Plaintiff, 
vs. 
SECURITY EQUIPMENT CORPORATION, 
a Missouri corporation, 
dant. 
ST TE FI  ) 
: s. 
County of Ada ) 
 .   5 
E: I I   
 . T, H.D.,   
 I TIFF'S   
I    URT'S 
llU G SE  
I   .  
I, Darwin L. Overson, being first duly sworn upon oath, depose and state upon my own 
personal knowledge as follows: 
1. I am an attorney with the law firm of Jones & Swartz PLLC, and am authori d to 
practice law before this and all courts of the State ofIdaho. 
2. I am counsel of record for Plaintiff Billi  Jo ajor in the above action, and have 
J ERRATA RE: AFFIDAVIT OF GAROLD S. YOST, PH.D., IN SUPPORT OF PLAINTIFF'S MOTION FOR 
~ RECONSIDERA nON OF THIS COURT'S ORDER STRIKING THE SECOND AFFIDAVIT OF DR. YOST - 1 
firsthand knowledge of the documents materials and all other discovery that has been produced
by either party in this case
3 Please take notice that the Affidavit of Garold S Yost PhDIn Support of
PlaintiffsMotion for Reconsideration of this Court Order Striking The Second Affidavit ofDr
Yost was inadvertently filed without Exhibit A and Exhibit B referenced in the affidavit at
paragraphs 45 and 11 12 I have attached hereto as Exhibit 1 is a true and correct copy of the
Affidavit of Garold S Yost PhD In Support ofPlaintiffsMotion for Reconsideration of this
CourtsOrder Striking The Second Affidavit ofDr Yost with Exhibit A and Exhibit B attached
thereto and request that it the full affidavit replace the affidavit that was filed in error without the
exhibits
FURTHER YOURAFFIANT SAYETH NAUGHT
r
DARWIN L OVERSON
SUBSCRIBED AND SWORN TO before me this Z5 day of October 2011
OTA
tiTH E l
p G t Public for IdahoUBLZ
My Commission expiresr9n FTnP
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firsthand knowledge of the docu ents, aterials, and all other discovery that has been produced 
by either party in this case. 
3. Please take notice that the A fidavit of arold . os , h.D., In rt of 
Plaintiff's otion for econsideration f this ourt's rder Striking he econd ffidavit f r. 
ost as inadvertently filed ithout xhibit  and xhibit  referenced in the affidavit at 
paragraphs 4-5, and 11-12. I have attached hereto as Exhibit 1 is a true and correct copy of the 
ffidavit of arold S. ost, Ph.D., In Support of Plaintiff's otion for econsideration of this 
ourt's rder Striking he Second ffidavit of r. ost ith xhibit  and xhibit  attached 
thereto and request that it the full affidavit replace the affidavit that was filed in error without the 
i i . 
FURTHER YOUR AFFIANT AYE HNA~,/ 
I  .  
,2 d-da   t er, . 
-"Notary ubli  f  I  
 issi  ir s 11. I.L 
ERRATA RE: FFI IT F R L  S. ST, PH.D., I  SUPPORT OF PLAINTIFF'S TI  F R 
RECONSIDERATION OF THIS COURT'S ORDER STRIKING THE SECOND AFFIDAVIT OF DR. YOST - 2 
CERTIFICATE OFSERVICE
I HEREBY CERTIFY that on this 25th day of October 2011 a true and correct copy of
the foregoing document was served on the following individualsbythe method indicated
Christopher C Burke USMail
Thomas J Lloyd III Fax 3192601
GREENER BURKE SHOEMAKER PA X Messenger Delivery
950 W Bannock Street Suite 900 Email cburke@greenerlawcom
Boise ID 83702 filo com
DARWIN L OVERSON
ERIC B SwARTz
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IFICATE  S ICE 
I HEREBY IFY that on this 25th day f cto r, 2 , a true a d correct c  of 
the foregoing document was served on the following individual(s) by the ethod indicated: 
Christopher C. Burke 
Tho as J. Lloyd ill 
EE ER R E S KER   
950 . annock Street, uite 900 
Boise, ID 83702 
[ ] .S. ail 
[ ] F : -2601 
[X] essenger eliver  
[ ] il: c urke gre nerlaw.com 
. t .com 
I  . ERS  
I  . W Z 
A  E: FI A I   A L  S. Y ST, PH.D., I  SUPPORT  PLAINTIF 'S TI  FOR 
RECONSIDERATI  OF T IS OURT'S ORDE  STRIKI  T E SECOND AFFIDAVIT OF DR. Y ST - 3 
EXHIBIT 1
EXHIBIT 1
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County of Salt Lake
I GAROLD S YOST PHDbeing first duly sworn upon oath depose and state ofmy
own personal knowledge that if called upon to testify I would competently testify to the
following
I I am a professor of Pharmacology and Toxicology and an adjunct professor of
Medical Chemistry at the University ofUtah Department of Pharmacology and Toxicology My
credentials as an expert have previously been submitted in my prior affidavits
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o 
ar in verson, IS  #5887 
ric . ar ~ IS  #6396 
J ES & Z  
 . reline i , ite  [837 ] 
ost fice  8 
Boise, I  83707 
Telephone: (208) 489-8989 
Facsi ile: (208) 489-8988 
ail: dar in jonesandswartzlaw.com 
eric jonesandswaltzlaw.com 
Attorneys for Plaintiff, Billie Jo Major 
NO.~ 
AM.--., 1'11.('1/) -"--_ 
--_P.M ... ---
OCT 2 4 2011 
CHRISTOPHf:Fl D 
By JAMiF. RAN~fH. ler  
E TY ' L 
 E IS         
   ,        
I I   J ,  i i i l, 
l intiff, 
vs. 
SEC RIT  E IP E T C RPORATION, 
a issouri corporation, 
ant. 
   ) 
: s. 
County of Salt Lake ) 
 .    
I    . T, 
H.D., I    LAINTIF 'S 
I   I  
 IS URT'S  I  
  I   
.  
I,  S. ST, PH.D., being first duly s orn upon oath, depose and state of y 
own personal knowledge that, if called upon to testify, I would competently testify to the 
following: 
1. I a  a professor of Phat acology and Toxicology and an adjunct professor of 
edical he istry at the niversity of tah, epart ent of Ph anna co logy and Toxicology. y 
credentials as an expert have previously been submitted in my prior affidavits. 
I A I    . T, H.D., I    LAINTIF 'S I  F  
I I   I  OURT'S  T I I    FIDAVI   R. T - 1 
2 I submit the information in this affidavit for the purpose of clarifying and
explaining any perceived conflicts between my deposition testimony and my affidavit testimony
in this case
3 First the following scientific literature cited in my first affidavit was researched
and located after my deposition
a JE Mitchel AF Campbell NE New LR Sadofsky JA Kastelik
SAMulrennan SJ Compton andAH Morice EXPRESSION AND CIIARACii IATION OF TIII
INTRACELLULAR VANILLOID RECI ProR TRPV1 IN BRONCHI FROM PAIFNS WITH CHRONIC
CoUGi1 Experimental Lung Research 31295306 2005
b T Higenbottam CHRONIC COUGH AND COUGH RiU tIX IN COMMON LUNG
DISEASES Pulmonary Pharmacology Therapeutics 15241247 2002
c P Geppetti S Materazzi P Nicoletti THE TRANSIENT RECEPTOR POTENTIAL
VANILLOID 1 Rohl IN AIRWAY INFLAMMATION AND DISEASE European Journal of
Pharmacology 5332072142006
d WJ Meggs NEURoGIaNIC INFLAMMATION AND SENSITIVITY TO
ENVIRONMENTAI CHIMICAISEnviron Health Prospect 101234238 1993
e LuYuan Lee and Qihai Gu RoIF of TRPVI IN INFLAMMATION INDUCI31
AIRWAY HYPERSENSrrlvrry Current Opinion in Pharmacology9243249 2009
f J Adcock TRPVI RECEiPTORS IN SlNSIrIAION OF COUGH AND PAIN
REFLEXES Pulmonary Pharmacology Therapeutics 22 65 70 2009
4 As Exhibit A I have attached hereto copies of additional research publications
and literature that further support my opinion that the scientific literature and studies in existence
prior to 2008 was such that when viewed as a body of literature and human and animal studies it
was known that a product such as SEC MK9 Fogger posed a risk of both acute and chronic
respiratory injury such as that described in Ms Majorsmedical records These are articles and
literature that I did not have at the time of my deposition and which were located after my
second affidavit in this case
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. I sub it the infor ation in this affidavit for the purpose of clarifying and 
l i i   r i  flicts t   siti  t sti    ffi it t sti  
i  t i  e. 
. First, the follo ing scientific literature cited in y first affidavit as researched 
    siti n: 
. .E. it l, .P. ell, .E. , .R. f k , lA. telik, 
.A ulrennan, .l o pton, and H. orice, E P ESSI   UARACTERIZATIO  F THE 
I   NI L I  EPTOR (TR  1) I  IlI F  PATIENTS IT  I  
O H, ri t l  s ar , 1 :295-306 (2 5). 
b. . igenbotta , C R IC C  AND C  REFLE  IN CO ON L  
IS AS S, l ry r c l y & er eutics, 5:241-24  (2 2). 
. . etti, . t r zzi, . i letti,  I   I  
I  : OLE   I   ,    
har acology, 533:207-214 (2006). 
. .J. , O E I  I I   ITI I   
I NTAL HE ICALS, i . lt  ct, 01:234-23  (1 3). 
. -Yua    i i , OLE OF l I  I I -I ED 
IR    HYPERSENSITIVITY, urrent pinion in Phar acology, 9:243-249 (2009). 
. J. c ck, I lYf  I  ENSITIZATION F  )) I  
, l ry r c l y & er e tics , -7  (2 9). 
.  i it , I  tt  r t  i   iti l r r  li ti  
and literature that further support my opinion that the scientific literature and studies in existence 
prior to 2008 as such that hen vie ed as a body of literature and hu an and ani al studies, it 
as kno n that a product such as S C's -9 Fogger posed a risk of both acute and chronic 
r s ir t r  i j r  s  s t t s ri  i  s. ajor's i l r r s. s  r  rti l s  
lit t  t t I i  t  t t  ti    iti   i   l t  t   
    e. 
F IDA VIT   . T, H.D., I  PP   I TIFF'S OTION  
 F 1'1-118 T'S   HE E ND l    .  - 2 
5 I would like to draw attention to the MSDS of SIGMA ALDRICH for Capsaicin
CAS 404864 part of Exhibit A which is the same capsaicinoid as is used in SABRE Red
Law Enforcement Unit 10 OC MK9 Fogger I have attached a copy of the MSDS for the
MK9 Fogger should the Court wish to compare the CAS list on the two MSDS documents I
have attached the MK9 Fogger MSDS hereto as Exhibit B I draw attention to the S1GMA
ALDRICH MSDS because it states May cause sensitization by inhalation and skin contact
identifies the target organ as nerves and identifies the compound as being Highly Toxic
This MSDS has a print date of October 27 2004
6 Second my testimony in my deposition was not in conflict with what I said in my
affidavits
7 On pages 100 to 101 I was asked the following question and provided the
following answer
t2 J All righ Do you recall having in
review of the scientific and literature
24 seein anv peerrvi w publications rhat
specificalvaddress rassociation be D
exposure on the one had and lon1terra chronic
2 adverse health fects on the other
3 A wellhawtls2c3t 1 was referring o
4 before that I dontthink the studies have beien done
CrT171isIZ2C tfit Ck2fZktlrri 47e11 that hrC
rbut data a ijut that scenar that OC eosurc
7 now Im talking abou 0C exposure in a chronic
1 sense multiple cases of exposure
My affidavit does not conflict with my answer to this particular question I was being
very specific in my answer as that was what the question called for The use of the term
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5. I ould like t  ra  tt tion t  t e S S  I - I  f r i i , 
S #404-86-4 (part f xhibit ), hich is the sa e capsaicinoid as is used in  ed, 
a  force ent it, 0% , -9 r.  e ttached    t e S S  t e 
-9 Fogger should the Court ish to co pare the C S# list on the t o S S docu ents. I 
have attached the -9 Fogger S S hereto as xhibit . I dra  attention to the SIGMA-
RIC   e a se it st tes "May se s siti tion  i l ti   s i  ntact," 
identifies the target organ as "nerves" and identifies the co pound as being "Highly Toxic." 
is S S as  rint t  f t er , . 
. Second, y testi ony in y deposition as not in conflict ith hat I said in y 
f vits. 
.  s  t  , I s s  t  f llo in  sti   r ide  t  
follo ing ans er: 
22 Q. ll ri t. o ycm recall having i  your 
23 e    i ti   medical iterat re 
 seeing any peer-reviewed publications that 
~~ specifically address the association between C 
expOSlu'e on the one hand and 10r:'9-tenn chrC>l1ic 
  l  effects   t er? 
 P> •• W ll, ha~'s what I   co 
 f re, t t I on't t i  t  st i s a e n e 
5 or published that definitively -- well, t at provide 
(i 1.'ob';.12.t  bout : .s.c nar-io, ha  oe xposure 
7 o,,>,. I'm talking about DC exposure in a chronic 
::) se se, lti le cases f e sure. 
y affidavit does not conflict ith y ans er to this particular question. I as being 
very specific in y ans er as that as hat the question called for.   f  t r  
I  I    S. ST, H.D., I   F LAINTIF 'S MO I  F R 
E ONSIDERATION  I  OURT'S E  TRIKI   SECO  FI A I   R.  -  
specifically coupled with the phrase the association between OC exposure on the one hand
and the longterm adverse health effects on the other was interpreted by me as asking whether
there was a study that I was aware ofwhere humans purposely received chronic exposure to OC
for the purpose of determining whether they would or would not suffer longterm adverse health
consequences I believe this is clear by my answer that appears on page 101 lines 12 to 15
12 A And no I dontthink that I havent
13 seen studies that make that that come to that
14 conclusion that there are adverse effects because I
15 dontthink people have done the studies
My answers were truthful as I am not aware of such a definitive study
My answers were also very clear that I was referring to an absence of definitive or even
robust data about that scenario As I explained in my deposition and in my affidavits the weight
of evidence is that longterm chronic adverse health effects can occur from exposure to OC for a
certain population under certain circumstances As I have repeatedly said there is an entire body
of research relating to the physiological biological toxicological and pharmaceutical effects of
capsaicinoids on human tissues The weight of that evidence strongly suggests that exposure to
capsaicinoids can cause longterm adverse health effects in persons who are already sensitized to
capsaicinoids whether it be because of pre existing respiratory injury or because of prior
exposures that upregulated the TRPV 1 receptor The fact that there was not any definitive
studies showing longterm adverse health effects does not detract from the reality that prior to
2008 enough was understood about the toxicology of capsaicinoids that it was understood that
capsaicinoids are irritants that are toxic to sensory neurons under certain circumstances It was
understood that respiratory tissues are particularly sensitive to the effects of capsaicinoids It
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"specifically" coupled ith the phrase "the association bet een  exposure on the one hand 
and the long-ter  adverse health effects on the other" as interpreted by e as asking hether 
                 
for the purpose of deter ining hether they ould or ould not suffer long-ter  adverse health 
s s. I li  t is is l r   s r t t rs   1, li s  t  : 
 . , , I on't t i  t t --  ven't 
  es    --     
     se f ts, s   
 on't t i  le   t  t i s. 
 s rs r  tr t f l s I  t r  f s   fi iti  st dy. 
  e  l   l  t t r  i  t     fi iti e   
r st t  t t t s nario. s I l i  i   siti   i   ffi vits, t  i t 
 e    -ter     ts         
certain population under certain circu stances. s I have repeatedly said, there is an entire body 
f research relating to the physiological, biological, toxicological and phar aceutical effects f 
capsaicinoids on hu an tissues. The weight of that evidence strongly suggests that exposure to 
capsaicinoids can cause long-ter  adverse health effects in persons ho are already sensitized to 
capsaicinoids, whether it he because of pre-existing respiratory injury or because of prior 
exposures that up-regulated the l receptor. he fact that there as not any definitive 
studies sho ing long-ter  adverse health effects does not detract fro  the reality that, prior to 
2008, enough as understood about the toxicology of capsaicinoids that it as understood that 
capsaicinoids are irritants that are toxic to sensory neurons under certain circumstances. It was 
understood that respiratory tissues are particularly sensitive to the effects of capsaicinoids. It 
I     . , H.D.,    LAINTIF 'S   
I   HTS URT'S   TI-IE  I  l   .  -  
was also understood that exposure to capsaicinoids can result in either hypersensitivity or
hyposensitivity to capsaicinoids and other more common irritants Finally it was understood
that biological changes occurring within human and animal tissues can be of a short duration
long duration or even permanent
On page 101 lines 21 to 25 I was asked the following question and provided the
following answer which appears on page 102 lines I to 8
21 Q Have you in your review of peer reviewed
22 publications seen any articles that focus on the
23 duration of time after exposure to OC that adverse
24 health effects are customarily deemed persistent in
25 humans
1 A I would say my general opinion is that
2 general conclusion from literature is that they are
3 transitory and that would generally mean you know
4 more than a minute and probably less than a day or
5 two So I think theres substantial evidence that
6 the pain irritation lacrimation et cetera that we
7 talked about before is not long it doesn persist
8 for weeks and months
8 1 understood the question as asking about studies of the customarily expected
health effects of OC exposure in humans I think it is clear from my answer that what I am
referring to is that it is understood that the effects of OC exposure are generally transitory
However Ms Major situation does not fall within the common experience people normally
have to OC exposure As I have said while most people have transitory effects from OC
exposure there is a population of persons with respiratory illness who are going to have effects
AFFIDAVIT OF GAROI D S YOSTPHDIN SUPPORT OIPLAINTIFFSMOTION FOR
RDCONSIDERATION OF TIIISCOURT ORDER STRIKING TIILSFCOND AFFIDAVIT OF DR YOST 5
001774
as also understood that exposure to capsaicinoids can result in either hypersensitivity or 
hyposensitivity to capsaicinoids and other ore co on irritants. Finally, it as understood 
t at i lo ical c a es cc rring ithin a  a  a i al tissues ca  be f a s rt rati , 
long duration, or even per anent. 
 a e , lines 21 t  , I as as e  t e f ll i  esti  a  r ided t e 
follo ing ans er, hich appears on page 102, lines I to 8: 
 . ave you, i  your revie  f peer-revie ed 
 publications, seen any articles that focus on the 
23   ti e ter e    s  
 lt  ffe ts r  st ril  ee e  r i t t i  
 ans? 
 . I ould say y e eral i i  is t at --
 general conclusion fro  literat r  is t at they are 
 tra sit r  and that ould generally ean, you know, 
 re t a  a i te a  r a l  l ss t a  a a  r 
S .    ere's t ti    
 the pain, irritati , lacri ation, et cetera, that e 
 talked about before is not long -- it doesnlt persist 
S    t s. 
. I erst  t e esti  as as i  a t st ies f t e "c stomarily" e ecte  
health effects of OC exposure in hu ans. I think it is clear fro  y answer that what I a  
referring to is that it is understood that the effects of  exposure are generally transitory. 
e er, s. ajor's sit ati  es t fall it i  t e c  e erie ce e le r all  
have to  exposure. s I have said, hile ost people have transitory effects fro   
exposure, there is a population of persons ith respiratory illness ho are going to have effects 
FFI  IT F L  S. ST, PH.D., I  SOPP T F PLAINTIFF'S TI  F R 
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that are different from those experienced by most individuals Prior to 2008 it was understood
that OC exposure under certain circumstances could result in either an upregulation or a down
regulation in TRPV 1 population in respiratory tissues It was understood that people with
respiratory illness were more sensitive to OC than most It was also understood that for those
with respiratory illness OC exposure in sufficient concentration and duration posed a risk of
adverse health changes that could be chronic However I was not asked about that information
in my deposition and so I did not talk about that information in my deposition
I was asked about the effects that are customarily observed in humans when they are
exposed to OC This is clear from the followup question I was asked on page 102 lines 9 to 12
and my answer relating to the effects that would generally be expected from acute exposure to
OC
9 Q Okay So its basically your
10 understanding that the adverse health effects to
11 acute exposures to OC are generally deemed to be
12 temporary reversible and recoverable
13 A In general I think thats true It does
14 not mean that they cant exacerbate an underlying
15 condition for someone who is highly sensitized and
16 thats what I opine in my statement But certainly
17 in a majority of cases a large majority of cases
18 the effects are temporary and reversible yes from
19 acute exposure
Nothing in this testimony is inconsistent with my statements made in my affidavits I
was not asked any questions about what was understood in the scientific community about the
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that are different from those experienced by most individuals. Prior to 2008, it as understood 
that OC exposure under certain circumstances could result in either an up-regulation or a down-
regulation in TRPVl population in respiratory tissues. It as understood that people ith 
respiratory illness were more sensitive to OC than most. It was also understood that for those 
with respiratory illness, OC exposure in sufficient concentration and duration posed a risk of 
adverse health changes that could be chronic. o ever, I as not asked about that infor ation 
in my deposition and so I did not talk about that information in my deposition. 
I as  t t e ffects that re t ril  r  i  a s  t e  r  
exposed to OC. This is clear from the follow-up question I was asked on page 102, lines 9 to 12, 
and y ans er relating to the effects that ould generally be expected fro  acute exposure to 
: 
 . kay. o itls si ll  your 
 rst i  t t t  rse lt  ff t  t  
 t  e s res t   r  r ll  ee e  t  e 
 te orary, r rsi l  a  rec verable? 
 . In general, I think thatls true.   
 t  t t t  an't r te  rl i  
 iti  f r s e e ho i  i l  s nsiti ed, a  
 thatls hat I opine in my state ent. t rt i l  
 in a majority of cases, a large majority of cases, 
 the effects are te porary and reversible, yes, fro  
 acute exposure. 
othing in this testi ony is inconsistent ith y state ents ade in y affidavits. I 
as not asked any questions about hat as understood in the scientific com unity about the 
FI A I  F AROLD S. ST, PH.D., IN SUPPORT  PLAINTI F'S M TI  F R 
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effects of OC at certain concentrations and duration on populations of humans who have a
respiratory illness
9 X have reviewed my deposition testimony on pages 153 line 16 to 155 line 25
which appears in the transcript as follows
16 Q in your opinion as of March of 2008 was
17 there anything definitively published in the
16 peer reviewed scientific and medical literature that
19 would have put a manufacturer of pepper spray
20 products such as SEC on notice that exposure to their
21 products by somebody with the chronic health
22 conditions of Ms Major would have caused her an
23 exacerbated response which would have included an
24 ongoing chronic cough for the subsequent period of
25 time
1 r I dontthink its possible for m to
p ea 4sfarious int You now the
responseYility of whether or Wert there was sufficient
4 evidence there to say you knoc if you do if you
5 expose somelpo3y to this tiey are going to have
lifealrinc hangas I don think that xisted
7 then Tltle literatLx c today IrZon tlin it
8 ts except throcth ele repozlQ rrci2lC c vidence
anl it Play very w 11 be that other people don
LCD b4ieve thaC that I s tiie Cease nut I do Pild so you
L1 now 3lati far the jury to I ide
L2 C c3o you think people thFit wer
L3 traineet in toxiclcysuc11 as yourself woulci have
L4 bea able to cviw the neiical1iteratu2e and the
LS SCiter3tuataat isted o or
Ls March of 2008 and have been able to determine t11nt
L there woldhave been a life alteringcndition that
L5 resilt4d rom pepper spray
L9 A Civt c ieicllC tl CSY nor WAV
C for industrla1 hygiene of tiers an3personnal t
21 esluate such kinds ofcnrur MAY or nay Cthave
teeat that time I haentseem it I mean I
doll t have evietence that WUa say 1Prt g as
4 Ireet that says this 1ping is goinfto
CS liapLn fyou expose it It does say you know tlli
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fects f  t tain tr tions  ration n lations  a s    
respiratory illness. 
. I e re ie ed  iti  t ti   a  , line , t  , line , 
which appears in the transcript as follows: 
 - In  i i n,   a c   8,  
 t ere ng f  ished n  
8 r-r i ed i ti i   i l literature t t 
 ould e t a t rer    
 cts     tice t t r  t  i  
 r cts  s e  ith t e r i  lt  
 itions  s_ ajor l      
 te  e s  c  d  lude   
 i  i    t  t i   
S e? 
 A.  n't  t's e  ~  
lace a nefa s ntent_ 
 i  ~h  t  y.  ow, ~    
  ebody  is. he      
-altering chan es.  on't   eXisted 
 en_ In he terature oday  dcn'~ hink  
B exists  hrough th  p eponderance of e iden . 
9 d  m   ell  t r  'c 
lO el  t at'  h  case. b   o_ F..J"ld SO,  
l kno , blame is o   u~   dec . 
 Q. Well. d   ~  l  t at ere 
l  ined i  toxicology ch  u~self ld  
 een   re iew  med cal li tur    
l5 scientific literature h t existed en  prior to 
lG jvla      ee~"l l   .;- Z:I:,ine hc..  
l7  ould    -alt ri  ondition  
 P •. I don't see evidence hat the ormal ways 
20 fo~- i strial hY':.ciene ::,ffic-e,,:s and erso el tc: 
,  v.?lUate  J-:inds f ,2Xp,:,su e:3 may  m  not  
exist d   ti e_  aven't n t_ I n1." n.  
!3 n'   d  t would ay, he e's n 
!4 MSVS sheet t t sa s t is bad thin  is oing t  
!  ~  ay,  ow. h~s 
I  l    S. T, H.D., I  SU PORT  LAINTIF 'S I   
NSIDERA I   Tr-n  OURT'S  TRI I  HE  Fl  vrr  R. OST -  
1 is all irritarit 111s1S an a0ute t11 i 1t 1S Ct131C
to cause th s this a1ci this s you L ttei is awa
fcf BLit Imnot awaie of anythi2l9 that the normal
4 layperson n the Industry would ay would sw that
S Would how that
Convwrs ly may there is molehill in
the nor in the maybe in the prcduet inforillatio2
e orwlatcv which I havent5iEz 1Llsr the r1SVS So
n again 1 really ztplace ialame necessarily on
1C1 whomvE All 1 can aay is I think there an
11 asstciati Detwae thW condirion se ncw 1as a
12 that
1 thar ti 1aSPC1 L12U11 your many y car8 of
14 expeince as a taxicoIogisr
iS A Ymss
i6 G Its used n yc titrapo1arion of a
1 zu17 er rfscientifi paers and your wiThing c tier
19 ev i diEce s that right
19 A
2 r Q But you rantcitz tips to one slriic
21 naIDe out tlere that existed prior Marc of 208
2 that specifically would have put laypersons without
2 3 your 1acicd on notice that 1ts5tlr totheir
24 could hav caLisr6 t3 longterwt healtl
S Condit ios
As to the question on page 153 I answered it from my perspective on what a
manufacturer might actually have known prior to March 2008 regarding whether chronic adverse
health effects were a risk for persons with respiratory illness That is I understood the question
as asking me if there was a study that I was aware of that would definitively state such health
risks existed in terms that a typical manufacturer would understand That is the reason I
answered in terms of whether I thought there was nefarious intent on the part of the
manufacturer I also went on to state that there was not and is not a definitive piece of literature
that says that OC exposure would cause life altering adverse health changes I was however
clear in any answer that the preponderance of the evidence was that such adverse effects were a
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1  n .n . This .  c  h~ng. 
2   i ,  nd , e  be t r be re 
of. u  'm  r   ing   l 
 s  in  i   sa  or  ee  
5 w l  necessarily s  t. 
(5 versely, aybe   something  
8  hatever   ven't s •• n, ju t  M . 
9 in, I l  can't a e bla e, ssarily,  
0 homever.  I  s     r 's  
 ociation between e t  he ow has nd 
  exposure. 
3 Q. 





Q . t's ba  on our extra l t    
c' .... _,t,.;.I, 
7 !-"umber of cient ifi,:- apers  OU!: ".'ei·::"1hing of ,e 
8 enc ; i  ha  ht? 
0 . t. )/'c>u carll t ite- HiE- tel Oli€> poi-cific 
 p per  here    to rch  0 8 
2 l"l·?t.t eci fic.Etlly \" ~llci e Llt: ~ Y1-"H?r.sC)ns "~i t l"'lci\''1.t: 
 product l  ve u .d h.sa g- erm alth 
25 conditic~ns? 
s t  t  sti    , I s r  it fr   rs ti   t  
t  i t t ll    i  t  a   i  t  i   
ealt  effects ere a ris  f r ers s it  res irat r  illness. at is, I erst  t e esti  
 i   if t r    t  t t I  r  f t t l  "defi iti ely" t t   lt  
risks existed in ter s that a typical anufacturer ould understand.      
s r  i  t r s f t r I t t t r  s f ri s i t t  t  rt f t  
f t rer.  l  t  t  t t  t t t   t,  i  t,  fi iti  i   lit t  
that says that C exposure would cause life altering adverse health changes. I as, ho ever, 
clear in my ans er that the preponderance of the evidence as that such adverse effects ere a 
I  I    . T, H.D., I    LAINTI F'S I   
  I-II  URT'S  I  T     . ST -  
risk associated with OC exposure for certain populations of people I was not entirely clear in
my answer that I also meant that such evidence existed prior to March 2008 but I can say that it
did exist at that time
In answering that question I also understood from the use of the word would that the
question was referring to some level of certainty which I have already explained does not exist
except through a preponderance of the evidence Had I been asked whether the preponderance
of the evidence prior to March 2008 was that longterm adverse health effects was a risk of OC
exposure for certain populations I would have provided a yes answer That was not however
the question as I understood it It would be untrue to say that the evidence was that OC exposure
would cause adverse health effects The term is one of near certainty and that type of certainty
is very rare in good science Probabilities weight of the evidence and risks of are the
verbiage that would be most accurate in describing the conclusions drawn from most scientific
investigations
The question that appears on page 154 lines 12 to 17 was similarly asked in terms of
certainty as to the outcome of OC exposure which is the reason I answered as I did Had the
question been asked in terms of probability or risks I would have answered the question in the
manner in which I have described those risks in my prior affidavits In reviewing the question I
also notice that I may have misinterpreted part of the question I see that it was stated as a
question of what a toxicologist such as I am would have known during the relevant time I
misinterpreted the question as again asking what a manufacturer would know which is why I
spoke of lay persons and of placing blame
10 1 would also like to point out that during my deposition I was recovering from a
back surgery The deposition took place in my home because I was not able to travel because of
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ris  ass ciated ith  e posure for certain populations f pe le. I as not e tirely clear in 
y ans er that I also eant that such evidence existed prior to arch 2008, but I can say that it 
 e ist at that ti . 
  that ti , I s  erst d fro  the s  f the  "wo l " that the 
question as referring to so e level of certainty hich I have already explained does not exist 
except through a preponderance of the evidence. Had I been asked whether the preponderance 
of the evidence prior to arch 2008 as that long-ter  adverse health effects as a risk of  
exposure for certain populations, I ould have provided a "yes" ans er. That as not, ho ever, 
the question as I understood it. It ould be untrue to say that the evidence as that C exposure 
"wo "    t .       i       
is very rare in good science. "Probabilities," "weight of the evidence" and "risks of" are the 
verbiage that would be ost accurate in describing the conclusions drawn fro  ost scientific 
investigations. 
The question that appears on page 154, lines 12 to 17, was similarly asked in terms of 
certainty as to the outco e of C exposure, hich is the reason I ans ered as I did. ad the 
question been asked in terms of probability or risks, I would have answered the question in the 
anner in hich I have described those risks in y prior affidavits. In revie ing the question, I 
l  ti  t t I   i i t r r t  rt f t  stion. I  t t it  t t    
question of what a toxicologist such as I am would have known during the relevant time. I 
isinterpreted the question as again asking hat a anufacturer ould know, hich is hy] 
spoke of lay persons and of placing blame. 
0. J would also like to point out that during y deposition I was recovering fro  a 
back surgery. The deposition took place in y ho e because I as not able to travel because of 
FFI IT F L  S. ST, PH.D., I  SUPPORT F PLAIN'rIFF'S TION F R 
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my health condition My mobility was impaired When I was asked to identify articles that
supported my opinion regarding chronic effects of exposure to OC I explained to the attorney
that I did not have all the articles there I asked for them from SECs attorney several times
which is evidenced on pages 133 line 19 to 142 line 18 but they were not available for
whatever reason Ms Major attorney was not physically present to assist me in locating the
articles because he attended the deposition by telephone
11 Since my deposition and last affidavit I have reviewed additional literature
attached as Exhibit A that suggests that there have been reports by law enforcement officers
who were exposed to OC during training and experienced long lasting adverse effects
Specifically THu HUMAN HEAirHEFFECTS OF PEPPERSIRAYA REV1Ew OF THE LITERATURE
AND COMMliNTARY Michael D Cohen which was published in 1997 in the Journal of
Correctional Health Care Dr Cohen writes in the article thatstudies of the effects of
capsaicin on human physiology anecdotal experience with field use of pepperspray and
controlled exposure of correctional officers in training have shown adverse effects on the lungs
larynx middle airway protective reflexes and skin In the article it notes Dr Stopfords 1996
publication that analyzed records from the North Carolina Department of Corrections
Stopford 1996 analyzed these records and found symptoms
requiring medical attention occurred in five percent of those
sprayed Of greatest concern were incidents in which officers
developed shortness of breath high blood pressure chest pain
headache and loss of consciousness For some symptoms
persisted for weeks or more
Dr Cohen continued his review
There have been several reviews of animal and human studies of
the toxicology of oleoresin capsicum and capsaicin
DiBartolomeis et al 1993 Both concluded that there are
insufficient data currently available to fully define the health risks
of pepperspray but they cited animal studies showing that
AFFIDAVIT OP GAROLD S YOST PILD IN SUPPORT OF PLAINTIFFSMOTION FOR
RECONSIDI RATION OF THIS COURT ORDER STRIKING THE SECOND AFFIDAVIT OF DR YOST
IO
001779
y health condition. y obility was i paired. hen I was asked to identify articles that 
supported my opinion regarding chronic effects of exposure to OC, I explained to the attorney 
t at  d  have l the ticles t .  e    r  C's r e   ti , 
hich  idence   a es , line , t  , line ,   e  t a e  
t r r s . s. jor's tt r  as t si ll  res t t  ssist  i  l ti  t e 
cles a se      . 
. Since y deposition and last affidavit I have revie ed additional literature, 
  it ,  s        rce e t icers 
who were exposed to OC during training and experienced long-lasting adverse effects. 
Specifically, THE HU AN HEALTH EFFECTS OF PEPPERSI~RAY-A REVIEW OF THE LITERATURE 
 E , icha  . ,   s        
  . r.  rite  i  t  rti l  t t "[s]tudies  t  ff t   
capsaicin on human physiology, anecdotal experience with field use of pepperspray, and 
controlled exposure of con'ectional officers in training have sho n adverse effects on the lungs, 
larynx, middle airway, protective reflexes, and skin." In the article, it notes Dr. Stopford's 1996 
publication that analyzed records from the North Carolina Department ofCon'ections: 
Stopford (1996) analyzed these records and found sy pto s 
requiring edical attention occurred in five percent f those 
sprayed. f reatest c cer  ere i ci e ts i  ic  fficers 
developed shortness of breath, high blood pressure, chest pain, 
headache, and loss of consciousness. or so e, sy pto s 
ersiste  f r ee s r re. 
r.  ti  is r view: 
   l i   ni l   st i   
 toxicology f i  capsicu   capsaIcm. 
( iBartolo eis, et al., 1993).  l  t t t  r  
i suffi i t t  rr ntl  il l  t  f ll  efi  t  lt  ris s 
of pepperspray, but they cited ani al studies sho ing that 
FFI  IT F L  S. ST, PH. ., I  S PP T F PLAINTIFF'S TI  F  
I E I    OURT'S  TRI I   E  FI A I   . ST-
10 
capsaicin can be mutagenic
responses and has substantial
vessels lungs and kidneys
r carcinogenic alters immune
effects on nerves heart blood
In another portion of the review Dr Cohen states These studies provide firm evidence
for a toxic effect of capsaicin on lung function of certain asthmatics Dr Cohen noted that
many of the studies of the effects of capsaicin use dosages much lower than those that result
from exposure to OC by hand held devices used in law enforcement Dr Cohen concludes his
article with the following warning Use of pepperspray should be restricted in order to prevent
serious injuries which are most likely to occur in people with asthma or chronic lung disease
12 Groneberg published Moixiu S OF CHRONIC OBSTRUCIVPPULMONARY DISEASI in
2004 and made clear that it was understood that depending on the duration and intensity of
exposure to noxious inhalants there could be induced signs of chronic inflammation and airway
remodeling Capsaicinoids would be classified as a noxious inhalant and in many ways would
be understood as one of the primary noxious inhalants Groneberg work supports the notion
that longterm changes to the respiratory tract may take place due to exposure to capsaicinoids
depending on the concentration and duration of exposure
13 I would also like to point out that my own work with Dr Reilly in 2005
recognizes that
lung epithelium is the initial barrier that xenobiotics encounter
upon inhalation and is a frequent target for toxicants Burgel
Nadel 2004 Damage to the respiratory epithelium compromises
respiratory function by increasing the susceptibility of individuals
to subsequent lung injury and infections and ultimately
contributes to hypersensitivity disorders such as asthma and COPD
Kasper Haroske 1996 Kuwano et al 2001 Selman et al
2001 Witschi 1991 Activation of TRPV1 capsaicin receptor
VRt in lung epithelial cells by certain types of airborne
particulate pollutants and prototypical agonists initiates
inflammatory responses and promotes cell death Agopynan et al
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capsaicin can be utagenic or carcinogenic, alters i une 
responses, and has substantial   , art,  
ss ls, l s  i s. 
I  t r rti  f t  r i , r.  t t s: "These t i  r i  fir  i  
f r a t ic effect f ca saici   l  f cti  f certai  asthmatics." r. e  te  t at 
  t  t ies  t  t   i i     l  t  t  t t lt 
 s re          nt. r.  es  
article ith the follo ing arning: "Use of pepperspray should be restricted in order to prevent 
serious injuries, hich are ost likely to occur in people ith asth a or chronic lung disease." 
. roneberg published ODl:':LS OF CHRONIC OBSTRUCTIVE PUL ONARY DISEASE in 
 a  a e clear t at it as erst  t at e e i   t e rati  a  i te sit  f 
exposure to noxious inhalants, there could be induced signs of chronic infla ation and air ay 
r deling. s i i i s l   l ssifie  s  i s i l t d, i   s, l  
 t     t  i  i  i l t . eberg's  t  t  ti  
t t l -ter  es t  t  r s ir t r  tr t  t  l   t  s r  t  s i i i s 
i   t  t ti   ti   . 
. I ould also like to point out that y o n ork ith r. eilly in 2005 
ize  t t 
lung epithelium is the initial barrier that xenobiotics encounter 
upon inhalation and is a frequent target for toxicants (Burgel & 
adel, 2004). a age to the respiratory epitheliu  co pro ises 
respiratory function by increasing the susceptibility of individuals 
 subsequent lung injury  infections,  lti t l  
contributes to hypersensitivity disorders such as asth a and  
(Kasper & aroske, 1996; u ano et aI., 2001; el an et ai., 
2001; itschi, 1991). ctivation of TRP l (capsaicin receptor, 
1) in lung epithelial cells by certain types of airborne 
particulate pollutants  prototypical agonists tiate  
inflammatory responses and promotes cell death (Agopynan et aI., 
I  I    S. , H.D., IN   LAINTIF 'S I  FOR 
I    T'S  IU      . T-
11 
2003x b 2004 Oortgiesen et al 2000 Reilly et al 2003
Veronesi et al 1999b
Since capsaicin is the primary agonist of TRPVI it is clear that OC exposure can cause
longterm adverse health effects involving the respiratory system I bring this up because this
article was cited in my first affidavit filed with this Court
14 My own work in accompaniment with Dr Reilly makes it clear that TRPV 1
agonists such as capsaicinoids cause cell death in human lung cells under certain circumstances
These findings are significant within the context of lung
inflammatory diseases where elevated concentrations of
endogenous TRPV 1 agonists are probably produced in sufficient
quantities to cause TRPV 1 activation and lung cell death
Thomas Sabnis Johansen Lanza Moos Yost and Reilly TRANSIENT RECEPTORPOTBNTIAL
VANIL LOID 1 AGONISTSCAUSI Endoplasmic Ri RCULUMSTRESS AND CELL DEATH IN HUMAN
LUNG CELLS J of Pharm Exper Therap 321 No 3 2007
15 Again in METABOLISM Or CAPSAICINOIDS BY P450 ENLYMIiS published in
2006 Dr Reilly and I recognized that Capsaicinoids are also toxic to many cells via TRPVI
dependant and independent mechanisms This conclusion is further supported by CAPSAICIN
INDUCEDNIUROTOXICTTY IN CULUR1DDORSEL ROOT GANGLION LURoNS 1995 where it was
concluded that capsaicin kills a subpopulation of sensory neurons by activating a receptor
operated channel
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Street Address 3050 Spruce Street
City State Zip Country SAINT LOUIS MO 63103 US
Technical Phone 314 771 5765
Emergency Phone 414 273 3850 Ext 5996
Fax 800 325 5052
Section 2 CompositionInformation on Ingredient
Substance Name CAS SARA 313









NCI C56564 6Nonenamide 8methylNvanillyl
E 8CI
RTECS Number RA8530000
Section 3 Hazards Identification
EMERGENCY OVERVIEW
Highly Toxic USA Toxic EU
Toxic if swallowed Irritating to respiratory system and skin
Risk of serious damage to eyes May cause sensitization by
inhalation and skin contact









For additional information on toxicity please refer to Section 11
Section 4 First Aid Measures
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r diti l i f r ti   t xicity, l   t  cti  1. 
ecti   - i t   
ORAL EXPOSURE
If swallowed wash out mouth with water provided person is
conscious Call a physician immediately
INHALATION EXPOSURE
If inhaled remove to fresh air If not breathing give
artificial respiration If breathing is difficult give oxygen
DERMAL EXPOSURE
In case of skin contact flush with copious amounts of water for
at least 15 minutes Remove contaminated clothing and shoes
Call a physician
EYE EXPOSURE
In case of contact with eyes flush with copious amounts of
water for at least 15 minutes Assure adequate flushing by
separating the eyelids with fingers Call a physician
Section 5 Fire Fighting Measures
FLASH POINT






Suitable Water spray Carbon dioxide dry chemical powder or
appropriate foam
FIREFIGHTING
Protective Equipment Wear self contained breathing apparatus
and protective clothing to prevent contact with skin and eyes
Specific HazardsEmits toxic fumes under fire conditions
Section 6 Accidental Release Measures
PROCEDURE TO BE FOLLOWED IN CASE OF LEAK OR SPILL
Evacuate area
PROCEDURESOF PERSONAL PRECAUTIONS
Wear self contained breathing apparatus rubber boots and heavy
rubber gloves
METHODS FOR CLEANING UP
Sweep up place in a bag and hold for waste disposal Avoid
raising dust Ventilate area and wash spill site after material
pickup is complete
Section 7 Handling and Storage
HANDLING
User Exposure Do not breathe dust Do not get in eyes on skin
on clothing Avoid prolonged or repeated exposure
STORAGE
Suitable Keep tightly closed
Store at 2 8C
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Section 8 Exposu Controls PPE
ENGINEERING CONTROLS
Safety shower and eye bath Use only in a chemical fume hood
PERSONAL PROTECTIVE EQUIPMENT
Respiratory Government approved respirator
Hand Compatible chemical resistant gloves
Eye Chemical safety goggles
GENERAL HYGIENE MEASURES
Wash contaminated clothing before reuse Wash thoroughly after
handling































































At Temperature or Pressure
Method closed cup
Solvent 50 mgml CHC13 Clear
Section 10 Stability and Reactivity
STABILITY
Stable Stable
Materials to Avoid Strong oxidizing agents
HAZARDOUS DECOMPOSITION PRODUCTS
Hazardous Decomposition Products Carbon monoxide Carbon dioxide
Nitrogen oxides
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HAZARDOUS POLYMERIZATION
Hazardous Polymerization Will not occur
Section 11 Toxicological Information
ROUTE OF EXPOSURE
Skin Contact Causes skin irritation
Skin Absorption May be harmful if absorbed through the skin
Eye Contact Lachrymator Causes severe eye irritation
Inhalation May be harmful if inhaled Material is irritating to
mucous membranes and upper respiratory tract
Ingestion Toxic if swallowed
SENSITIZATION
Sensitization May cause allergic reaction
TARGET ORGANS OR SYSTEM
Nerves
SIGNS AND SYMPTOMS OF EXPOSURE
Symptoms of exposure may include burning sensation coughing
wheezing laryngitis shortness of breath headache nausea and
vomiting To the best of our knowledge the chemical physical
and toxicological properties have not been thoroughly
investigated
CONDITIONS AGGRAVATED BY EXPOSURE
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Dose 7500 UG KG
Mutation test Micronucleus test
Species Mouse
Route Intraperitoneal
Dose 1800 UG KG
Mutation test DNA inhibition
Species Mouse
Route Intraperitoneal
Dose 93120 UG KG
Exposure Time 32D
Mutation test Sister chromatid exchange
Species Hamster
Dose 5 MGL S9
Cell Type lung
Mutation test Mutation in microorganisms
Section 12 Ecological Information
No data available
Section 13 Disposal Considerations
APPROPRIATE METHOD OF DISPOSAL OF SUBSTANCE OR PREPARATION
Contact a licensed professional waste disposal service to dispose
of this material Dissolve or mix the material with a combustible
solvent and burn in a chemical incinerator equipped with an
afterburner and scrubber Observe all federal state and local
environmental regulations
Section 14 Transport Information
DOT
Proper Shipping Name Toxic solids organic nos
UN 2811
Class 61
Packing Group Packing Group II
Hazard Label Toxic substances
PIH Not PIH
IATA
Proper Shipping Name Toxic solid organic nos
IATA UN Number 2811
Hazard Class 61
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Packing Group
Section 15 Regulatory Information
EU ADDITIONAL CLASSIFICATION
Symbol of Danger T
Indication of Danger Toxic
R 25 378 41 423
Risk Statements Toxic if swallowed Irritating to respiratory
system and skin Risk of serious damage to eyes May cause
sensitization by inhalation and skin contact
S 22 26 28 369 45
Safety Statements Do not breathe dust In case of contact with
eyes rinse immediately with plenty of water and seek medical
advice After contact with skin wash immediately with plenty of
soap suds Wear suitable protective clothing and eye face
protection In case of accident or if you feel unwell seek
medical advice immediately show the label where possible
US CLASSIFICATION AND LABEL TEXT
Indication of Danger Highly Toxic USA Toxic EU
Risk Statements Toxic if swallowed Irritating to respiratory
system and skin Risk of serious damage to eyes May cause
sensitization by inhalation and skin contact
Safety Statements Do not breathe dust In case of contact with
eyes rinse immediately with plenty of water and seek medical
advice After contact with skin wash immediately with plenty of
soap suds Wear suitable protective clothing gloves and
eye face protection In case of accident or if you feel unwell
seek medical advice immediately show the label where possible
US Statements Sternutator Lachrymator Target organsNerves
UNITED STATES REGULATORY INFORMATION
SARA LISTED No
TSCA INVENTORY ITEM Yes
CANADA REGULATORY INFORMATION
WHMIS Classification This product has been classified in
accordance with the hazard criteria of the CPR and the MSDS
contains all the information required by the CPR
DSL Yes
NDSL No
Section 16 Other Information
DISCLAIMER
For RD use only Not for drug household or other uses
WARRANTY
The above information is believed to be correct but does not
purport to be all inclusive and shall be used only as a guide The
information in this document is based on the present state of our
knowledge and is applicable to the product with regard to
appropriate safety precautions It does not represent any
guarantee of the properties of the product SigmaAldrich Inc
shall not be held liable for any damage resulting from handling or
from contact with the above product See reverse side of invoice
or packing slip for additional terms and conditions of sale
Copyright 2004 Sigma Aldrich Co License granted to make unlimited
paper copies for internal use only
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The Human Health Effects of Pepperspray A Review of the
Literature and Commentary
Michael D Cohen MD FAAP
Abstract With widespread use of pepperspray by public safety and
corrections agencies injuries have occurred and questions have been
raised about the safety and toxicity of oleoresin capsicum and the active
ingredient capsaicin There are no published studies of the human health
effects of pepperspray used for aerosol restraint This article reviews
current knowledge and experience concerning the health effects of
pepperspray and capsaicin Studies of the effects of capsaicin on human
physiology anecdotal experience with field use of pepperspray and
controlled exposure of correctional officers in training have shown
adverse effects on the lungs larynx middle airway protective reflexes
and skin Behavioral and mental health effects also may occur if
pepperspray is used abusively
Pepperspray for Aerosol Restraint
More than 2000 public safety agencies now use a form of tear
gas called pepperspray With widespread use of a new police
weapon injuries have occurred and questions have been raised
about the safety and toxicity of pepperspray This article reviews
what is known about the human health effects of pepperspray and its
active ingredients
The active agent in pepperspray is the crude biological extract
of hot peppers oleoresin capsicum Oleoresin capsicum contains
Michael D Cohen MD FAAP is a consultant in correctional health services
For correspondence copntact Michael D Cohen MD FAAP RD 2 Box 2016
Argyle NY 12809 Phone 518 6388592
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several different compounds that cause pain when applied to mucus
membranes One of these active ingredients is capsaicin
The effects of pepperspray are rapid and intense Like other
tear gases it disables people by causing pain blindness gagging
and intense coughing Police and other agencies have promoted the
use of chemical weapons for aerosol restraint because they are
believed to be safer than alternative physical restraint techniques
CapStun 1990 Staff 1994
Although pepperspray and other tear gases are marketed
explicitly because of their pharmacological effect they are tested
and regulated in the United States as weapons not drugs The use
of potentially toxic substances as drugs is regulated by the Food and
Drug Administration which requires testing to determine product
safety prior to permitting widespread use As weapons tear gases
are subject to less stringent standards Safety testing generally has
not been required prior to marketing toxins as weapons Rather
after injuries occur and evidence of harm accumulates dangerous
health effects may be recognized later
Experience with Pepperspray
There have been no published clinical studies of the human
health effects of pepperspray marketed for police use
The North Carolina Department of Corrections uses
pepperspray for aerosol restraint and requires correctional officers
to be exposed to pepperspray during their training An officer who
opposes the full exposure policy has obtained agency records
concerning adverse health effects among officers sprayed
intentionally during training Stopford 1996 analyzed these
records and found that symptoms requiring medical attention
occurred in five percent of those sprayed Of greatest concern were
incidents in which officers developed shortness of breath high
blood pressure chest pain headache and loss of consciousness
For some symptoms persisted for a week or more
Sudden unexpected incustody deaths following exposure to
pepperspray have occurred in several jurisdictions Man 31 dies
74
Downloadedfrom jcx sag5pub com by guest on September 13 2011
001794
     
several different co pounds that cause pain hen applied to ucus 
.   t  ti  i i t  i  aicin. 
he effects of pepperspray are rapid and intense. ike other 
t r s s, it is l s l   si  in, li ss, gi g, 
  i g.        
  i l s  l traint,  t   
lie  t    t  lt ti  i l t i t t i  
(Cap-Stun, 1990; Staff, 1994). 
lthough pepperspray and other tear gases are arketed 
explicitly because of their phar acological effect, they are tested 
       ,  s.   
f t ti ll  t i  t   r  i  r l t   t    
r  i istrati n, ic  re ires testi  to eter i e r ct 
t  i  t  nnitti  ides  .  , t   
r  s j t t  less stri t st r s. f t  t sti  r ll  s 
        . t er, 
after injuries occur and evidence of har  accu ulates, dangerous 
health effects ay be recognized later. 
erie ce it  e ers ray 
r     lis  li i l t i  f t   
lt  t    t   li  e. 
   epart ent  rr ti   
pepperspray for aerosol restraint and requires correctional officers 
t  be e se  t  e ers ra  ri  t eir training.  fficer  
opposes the "full exposure" policy has obtained agency records 
r i   l   a ong  r  
intentionally during training. Stopford (1996) analyzed these 
r r s a  f  t t s t s r iri  e ical tt ti  
occurred in five percent of those sprayed. f greatest concern ere 
incidents in hich officers developed shortness of breath, high 
l  ressure, c est ai , ea ac e, a  l ss f c sci s ess. 
For so e, sy pto s persisted for a eek or ore. 
udden, unexpected in-custody deaths follo ing exposure to 
pepperspray have occurred in several jurisdictions ("Man, 31, dies," 
 
Downloaded from JCx sag0Pl,b CO;il by guest on Septe ber 13. 2011 
Health Effects of Pepperspray
1995 Steffee Lantz Flannagan Thompson Jason 1995 In
California where the state environmental protection agency
regulates the marketing and use of all toxic substances such deaths
have been monitored closely statewide The American Civil
Liberties Union of Southern California ACLU 1995 published a
summary of information regarding twentysixCalifornia incustody
deaths following the use of pepperspray that occurred between 1993
and 1995
In these California deaths police action often was related to
bizarre or aggressive behavior and most individuals were under the
influence of street drugs alcohol or prescribed psychotropic
medications Some had underlying chronic medical conditions such
as coronary artery disease None of the California deaths was
directly attributed to pepperspray Coroners reports thus far have
found the causes of death to be drugrelated or due to underlying
disease In North Carolina on the other hand an incustody death
was attributed to the effects of pepperspray in a person with chronic
lung disease Flannagan 1993
The FBI firearms training unit produced a report concerning
the effectiveness of pepperspray as a weapon CapStun 1990
This report attested to the effectiveness and safety of pepperspray
for aerosol restraint and was very influential in the rapid and
widespread adoption of pepperspray by police and correctional
agencies Later disclosures of conflict of interest have raised
serious questions regarding the objectivity of the FBI report In
January 1996 Thomas W W Ward the reportsprincipal author
pled guilty to federal charges that he had a financial relationship
with the manufacturer of CapStun brand pepperspray at the same
time that he was evaluating it and promoting its use on behalf of the
FBI
The FBI report described the disabling effects of pepperspray
rather than investigating possible health effects The research
design was inadequate to assess safety since only healthy volunteers
were used Adverse effects on people with chronic lung disease
such as asthma were not studied at all No objective measures of
lung function or protective reflexes were used Without such
75
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measures subclinical responses cannot be identified Followup
was limited to a few hours following pepperspray exposure
Without more prolonged followup subacute effects occurring 12
to 24 hours after exposure cannot be identified
Although it is well known that many serious toxins occur in
nature FBI consultants suggested that pepperspray is safe because
it is a natural product As further evidence of safety they pointed
out that hot peppers have been consumed widely as food without
significant adverse effects However stomach and intestinal
exposure that occurs when eating spicy foods is qualitatively
different from lung and eye exposure to concentrated oleoresin
capsicum in pepperspray Also epidemiological studies have in
fact shown that populations that consume larger amounts of hot
peppers experience higher rates of stomach cancer and peptic ulcer
disease Lopez Carillo Hernandez Dubrow 1994
Toxicology Reviews of Oleoresin Capsicum
There have been several reviews of animal and human studies
of the toxicology of oleoresin capsicum and capsaicin
DiBartolomeis et al 1993 Both concluded that there are
insufficient data currently available to fully define the health risks
of pepperspray but they cited animal studies showing that capsaicin
can be mutagenic or carcinogenic alters immune responses and has
substantial effects on nerves heart blood vessels lungs liver and
kidneys
Physiology of Capsaicin
Although there are no clinical studies of the health effects of
pepperspray there is a growing literature on capsaicin owing to
interest in its unique physiological properties Capsaicin has been
used in research on cough and other respiratory reflexes and is
beginning to emerge as a drug for treatment of specific types of
pain Capsaicin causes pain by selectively stimulating receptors on
skin and mucus membranes which are associated with thin
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Health Effects of Pepperspray
unmyelinated sensory nerves called Cfibers Barnes 1984
proposed that these particular nerves play a sensory role with the
autonomic nervous system in control of lung functions
Classical studies of human physiology found that the autonomic
nervous system regulates vital body functions via two systems of
nerves the adrenergic or sympathetic system and the cholinergic
or parasympathetic system Functions such as blood flow to organs
heart rate blood pressure and airway size are regulated by the
balance of adrenergic and cholinergic impulses to smooth muscles
that open or close blood vessels airways and ducts The
unmyelinated sensory nerves stimulated by capsaicin are a newly
recognized participant in this system of control Barnes 1984
There is intense interest among physiologists and drug
companies in compounds that stimulate or block sensory Cfiber
receptors Research in this area will likely lead to a new class of
drugs with potential to treat asthma hypertension pain syndromes
and more Capsaicin skin creams are already available for treatment
of pain from diabetic neuropathy osteoarthritis and after
mastectomy
The participation of sensory Cfibers in the autonomic nervous
system suggests that massive exposure to capsaicin in pepperspray
risks altering or disrupting the most vital functions of the body and
provides a mechanism for sudden deaths associated with
pepperspray exposure Many prescribed drugs and drugs of abuse
have autonomic side effects When pepperspray is used on someone
who is already taking antipsychotic medication or cocaine drug
interactions may give rise to clinically significant autonomic
dysfunction Unexpected incustody deaths have been attributed to
other drugs that are present especially cocaine and to underlying
heart disease It may be that pepperspray was the precipitating
agent in combination with other drugs and underlying disease that
caused a lethal event
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Harmful Effects of Capsaicin on Humans
Direct harmful effects of capsaicin and hot peppers have been
shown in studies of human physiology and case reports Although
there have been many animal studies utilizing capsaicin this
discussion is focussed principally on research that used human
subjects
Exacerbation of Asthma
Hudgel 1994 described asthma as a chronic lung disease
characterized by excessive narrowing of small airways in response
to specific triggers such as allergens irritants infection cold air
exercise and stress Any irritant may precipitate an asthma attack
in a susceptible individual Asthmatics are more vulnerable to
serious reactions when they already are partially compromised by
active disease
The Occupational Safety and Health Administration requires
employers to inform employees about toxic substances used in their
workplace This information is communicated via Material Safety
Data Sheets which are made available by manufacturers The
Material Safety Data Sheet for First Defense brand pepperspray
states May cause severe temporary effects on those persons who
are asthmatics or suffer from emphysema Defense Technology
Corporation 1992
The basic physiology of airway control in asthma is under
intense study as researchers attempt to understand better the airway
inflammatory response There have been several studies of the
effects of capsaicin on asthmatics These studies were done to
investigate human physiology not to test the toxicity of capsaicin in
pepperspray They used cough threshold doses of capsaicin that is
the minimum dose needed to cause coughing All asthmatic subjects
were asymptomatic at the time of testing
Hathaway Higenbottam Morrison Clelland and Wallwork
1993 studied the response to inhaled capsaicin in normal subjects
asymptomatic asthmatics and heartlung transplant recipients In
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the transplant operation all nerves to and from the lungs are
severed Those patients would be unable to show any lung effects
resulting from reflex arcs mediated by the central nervous system
Seven of seventeen asthmatics showed decreases in airflow
characteristic of active asthma including one whose airflow
decreased forty percent see Figure 1 This is clear evidence that
certain asthmatics experience significant airway narrowing when
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Fujimura and colleagues 1993 studied the response to inhaled
capsaicin in normal subjects asthmatics and people with chronic
bronchitis Their object was to study the effects of the drug
procaterol on the cough threshold and the interaction of procaterol
and capsaicin on airway size They showed that cough threshold
doses of capsaicin caused narrowing of the small airways in people
with asthma and chronic bronchitis but not in normal subjects
Fuller Dixon and Barnes 1985 studied airway narrowing in
response to two concentrations of inhaled capsaicin in normal
subjects smokers and asymptomatic asthmatics They found that
a rapid airway narrowing of brief duration occurred in all three
groups The asthmatics in this study did have greater airway
constriction than normal subjects and it was greater still at the
higher dose of capsaicin studied however the mean asthmatic
response was not significantly greater than that of normal subjects
Lundberg Martling and Saria 1983 studied the effect of
capsaicin on pieces of human bronchus They found that direct
application of capsaicin causes human bronchial smooth muscle to
contract The effect was similar in intensity to that of histamine a
potent agent used to induce airway narrowing similar to asthma
Lammers Minette McCusker Chung and Barnes 1989
studied the effect of capsaicin on respiratory resistance in nine
asymptomatic mild asthmatics When asthma is active there is
increased resistance to airflow Following exposure to capsaicin
four asthmatics showed increased resistance while five showed a
decrease in resistance The increases were blocked by pre treatment
with ipratropium an anti cholinergic drug used to treat asthma
The authors concluded that airway narrowing in response to
capsaicin in these asthmatics was mediated via a cholinergic reflex
Lundberg Alving Karlsson Matran and Nilsson 1991
reviewed the role of small protein molecules including capsaicin
in the airway response in irritant and allergeninvoked asthma
They suggested that sensory Cfiber stimulation with capsaicin
primes the airways to react more strongly when subsequently
exposed to allergens or irritants resulting in more severe airway
narrowing
80
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These studies provide firm evidence for a toxic effect of
capsaicin on lung function of certain asthmatics Though some
studies purport to show no difference between the mean responses
of asthmatics and normal subjects the calculation of a mean
conceals individuals with more extreme reactions It is precisely
this variability in the severity of adverse reactions that must be
studied before a drug is allowed to be marketed for human use and
which has not been studied adequately for pepperspray or other tear
gases
The studies described here used cough threshold doses of
capsaicin Pepperspray is not marketed in cough threshold doses
but in doses that induce severe coughing Pepperspray is commonly
used without reference to the presence or absence of asthma asthma
activity or severity Since even low cough threshold doses have
been shown to cause bronchospasm in some individuals whose
asthma was inactive more severe reactions may occur at higher
doses or when used on persons whose asthma is in an active phase
Laryngeal spasm and croupe
The FBI report indicated that some people were unable to
speak immediately after being sprayed with pepperspray CapStun
International 1990 This is the result of spasm of the muscles that
control the vocal cords in the larynx Rubin Wu and Tunis 1991
described a patient with severe laryngeal spasm after accidental
inhalation of Tabasco R brand hot sauce
Croupe that is obstruction of the middle airway in the neck
is caused by edema or swelling in the lining of the airway
Winograd 1977 reported an 11 year old boy with severe subglottic
narrowing due to edema following intentional exposure to a personal
defense aerosol containing oleoresin capsicum and freon
In the extreme laryngospasm or airway swelling can cause
suffocation by completely obstructing the upper airway This is
another possible mechanism for sudden unexpected death following
pepperspray exposure
81
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Chemical pneumonitis
Inhalation of certain chemical substances can cause
inflammation in the peripheral air sacs of the lung where gas
exchange between blood and air occurs In the case reported by
Winograd 1977 chemical pneumonitis was observed six to twelve
hours following pepperspray exposure Billmire and colleagues
1996 reported an infant who was sprayed accidently with a
pepperspray personal defense product and experienced severe
chemical pneumonitis with respiratory failure Extreme measures
were required to support this child until her lungs recovered from
the acute chemical injury
Loss of protective reflexes
The corneal blink reflex protects the eyes from trauma by
forcefully closing the eyelids when the cornea is touched The
airway and lungs are protected by the gag reflex which closes the
epiglottis over the airway and by the cough reflex which forcefully
ejects foreign bodies and irritants from the airway These reflexes
are initiated by sensory nerves responding to a stimulus
Stopford 1996 described North Carolina correctional officers
who experienced loss of corneal sensitivity for up to a week
following a single exposure to pepperspray Levy Abraham and
Tomlinson 1991 reported animal studies that showed damage to
corneal nerves with frequent or prolonged exposure to capsaicin
This appeared to be a dose sensitive effect
Blanc Liu Juarez and Boushey 1991 studied cough
threshold in spice grinders who are chronically exposed to hot
pepper dust and compared their responses to others not exposed to
such dust They found an increased cough threshold among spice
grinders suggesting a diminished protective reflex response This
finding was more pronounced in males and smokers
These research studies suggest that prolonged or repeated
exposure to capsaicin can damage sensory nerves that initiate
protective reflexes The experience of the North Carolina
82
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correctional officers demonstrated temporary loss of protective
reflexes in the eye after a single exposure Loss of these reflexes
puts a person at risk for eye injury or airway problems
Chemical burns
Greer Rosen and Tschen 1993 reported a woman who
developed severe second degree burns on the hands two days after
pickling hot peppers Several of the North Carolina correctional
officers developed blisters around the eyes after being exposed to
pepperspray Stopford 1996
Physical and emotional abuse
In jails prisons and delinquency programs there is a tension
between legitimate control and physical punishment When
correctional officers are permitted to use techniques that inflict pain
such as pepperspray aerosol restraint there is a risk that it may be
used abusively
Parental use of hot peppers to punish a child was reported by
Tominack and Spyker 1987 as a special example of child abuse
I have reviewed aerosol restraint practices in secure juvenile
facilities in two states In these facilities when defiant youth
disobeyed correctional officers escalating cycles ofprovocation and
reaction occurred This resulted in repeated use of tear gas or
pepperspray especially in confrontations over movement in and out
of isolation cells on segregation units The punitive use of
pepperspray to force compliance through fear of reprisals is within
the scope of common definitions of both child abuse and torture
Physical punishment imposed by state authorities to compel
obedience and break the spirit of prisoners is compatible with the
United Nations definition of torture Doerr Zegars Hartmann Lira
Weinstein 1992
Both child abuse and torture have been shown to have profound
effects on the mental health of the victims including increases in
violent behavior toward others posttraumatic stress disorder and
83
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suicidal behavior Lewis 1992 MalinoskyRummel Hansen
1993 Ramsay Gorst Unsworth Turner 1993 Shaunesy
Cohen Plummer Berman 1993
Conclusion
Following widespread use of tear gas in Northern Ireland in
1968 a British Home Office investigation of the health effects of
tear gas concluded that adequate safety studies were lacking and
recommended that such agents not be deployed without thorough
toxicity studies Sanford 1976 Twentyfive years later
pepperspray has been marketed and widely adopted in the United
States without adequate safety studies Anecdotal and clinical
research evidence of serious adverse effects have been presented
Additional risks have been suggested by animal studies Use of
pepperspray should be restricted in order to prevent serious injuries
which are most likely to occur in people with asthma or chronic
lung disease
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Abstract othersections
Chronic obstructive pulmonary disease COPD is a major global health problem and is predicted to become the
third most common cause of death by 2020 Apart from the important preventive steps of smoking cessation
there are no other specific treatments for COPD that are as effective in reversing the condition and therefore
there is a need to understand the pathophysiological mechanisms that could lead to new therapeutic strategies
The development of experimental models will help to dissect these mechanisms at the cellular and molecular
level COPD is a disease characterized by progressive airflow obstruction of the peripheral airways associated
with lung inflammation emphysema and mucus hypersecretion Different approaches to mimic COPD have
been developed but are limited in comparison to models of allergic asthma COPD models usually do not mimic
the major features of human COPD and are commonly based on the induction of COPDlike lesions in the lungs
and airways using noxious inhalants such as tobacco smoke nitrogen dioxide or sulfur dioxide Depending on
the duration and intensity of exposure these noxious stimuli induce signs of chronic inflammation and airway
remodelling Emphysema can be achieved by combining such exposure with instillation of tissuedegrading
enzymes Other approaches are based on geneticallytargeted mice which develop COPDlike lesionswith
emphysema and such mice provide deep insights into pathophysiological mechanisms Future approaches
should aim to mimic irreversible airflow obstruction associated with cough and sputum production with the
possibility of inducing exacerbations
Keywords Chronic obstructive pulmonary disease COPD asthma animal mice rat guinea pig tobacco smoke nitrogen dioxide
sulfur dioxide
Introduction othersections
The global burden of disease studies point to an alarming increase in the prevalence of chronic obstructive
pulmonary disease COPD 1 which is predicted to be one of the major global causes of disability and death in
the next decade 2 COPD is characterized by a range of pathologies from chronic inflammation to tissue
proteolysis and there are no drugs specifically developed for COPD so far Cessation of cigarette smoking is
accompanied by a reduction in decline in lung function 3 and is a most important aspect of COPD
management The mainstay medication consists of betaadrenergic and anticholinergic bronchodilators addition
of topical corticosteroid therapy in patients with more severe COPD provides may enhance bronchodilator
responses and reduce exacerbations 4
In contrast to the large amount of experimental studies on allergic asthmaand the detailed knowledge that
exists on mediators of allergic airway inflammation 56 much less has been conducted for COPD More effort
and resources have been directed into asthma research in comparison to COPD The available insights into the
pathogenesis and pathophysiology of asthma may help to improve research in COPD 7 Many research centres
that previously focused on asthma now also investigate mechanisms of COPD Using molecular and genetic
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approaches an increasing range ofmolecules has been identified that could underlie the pathogenic
inflammation ofchronic allergic airway inflammation 8Based on these findings and on new ways of
administering drugs to the lungs2a new image ofoverwhelming complexity of the underlying
pathophysiology of COPD has emerged Figure 1 The current challenge in COPD research is to identify the role
of the various mediators and molecular mechanisms that may be involved in its pathophysiology and obtain
new treatments In addition it is incumbent to understand the effect ofsmoking cessation on the pathogenetic
process
Figure 1
Potential pathogenetic mechanisms involved inCOPD Exogenous inhaled noxious stimuli such
as tobacco smoke noxious gases or indoor air pollution and genetic factors are proposed to be
the major factors related to the pathogenesis of COPD These factors may influence protease
activity and may also lead to an imbalance between pro inflammatory and anti inflammatory
mediators
Studying the molecular pathways in human subjects is restricted to the use ofmorphological and molecular
assessment of lung tissues obtained at surgery or performing limited in vitro studies at one single point in time
10 There is a need for in vivo animal models to examine more closely pathogenesis functional changes and
the effects of new compounds or treatments However animal models have limitations since there is no
spontaneous model and models do not necessarily mimic the entire COPD phenotype The best model remains
chronic exposure to cigarette smoke since this is the environmental toxic substance that cause COPD in
man However other substances are also implicated such as environmental pollution due to car exhaust fumes
The present review draws attention to specific aspects of functional and structural features of COPD that need to
be realized when interpreting molecular mechanisms identified in animal models ofCOPD It identifies
important issues related to the ongoing experimental COPD research which may in the future provide optimized
COPD diagnosis and treatment
COPD
Clinical features
Before characterizing and discussing the different animal models ofCOPD which have been established so far it
is crucial to reflect that within COPD different disease stages exist and that only some of them may be
mimicked in animal models The diagnosis of COPD largely relies on a history of exposure to noxious stimuli
mainly tobacco smoke and abnormal lung function tests Since COPD has a variable pathology and the
molecular mechanisms are only understood to a minor extent a simple disease definition has been difficult to
establish However the diagnosis of COPD relies on the presence of persistent airflow obstruction in a cigarette
smoker 4
A classification ofdisease severity into four stages has been proposed by the GOLD guidelines based primarily
on FEV1 4The staging on the basis of FEV1 alone as an index of severity for COPD has been criticised A
composite measure essentially based on clinical parameters BODE has been shown to be better at predicting
mortality than FEV1 11The natural history of COPD in terms of evolution of FEV1 remains unclear and the
temptation is to regard the stages as evolving from Stage 0 to Stage 4 Just as many smokers do not develop
COPD it is possible that the disease may not progress from one stage to the next Some patients with severe
COPD are relatively young and it is not clear if early stages of their disease are similar to those found in
patients with mild COPD COPD is a heterogeneous disease and different possible outcomes may occur at each
of the stages Experimental modeling ofeach stage ofseverity may be a way of providing an answer to this
issue Animal models may also help to provide a better classification of severity by correlating biochemical
molecular and structural changes with lung function and exercise tolerance
Pathophysiology
The presence of airflow obstruction which has a small reversible component but which is largely irreversible is
a major feature ofCOPD as indicated by the Global Initiative for Chronic Obstructive Lung Disease GOLD
guidelines4It is proposed to be the result of a combination ofsmall airways narrowing airway wall
inflammation 12 and emphysema related loss of lung elastic recoil 1314 These features differ to a large
extent to findings observed in bronchial asthma Table 1 where airflow obstruction is usually central while
involvement of the small airways occurs in more severe disease The degree ofairflow obstruction in COPD can
be variable but loss of lung function over time is a characteristic feature Ideally the development of airflow
obstruction which is largely irreversible but has a small reversible component should be a feature of animal
models ofCOPD but this has not been reproduced so far One of the important limitations of animal models of
COPD is the difficulty in reproducing small airways pathology particularly when working in small animals
particularly the mouse and rat where there are few levels of airway branching This is a problem inherent to
small laboratory animal models but provides an advantage for developing models in larger animals such as the
pig or sheep Part of the problem of analyzing small airways is also due to the lack of sophistication of lung
function measurements particularly in mice but there has been recent development in the methodology of
lung function measurement 15 A new exvivo method of analyzing the airway periphery is by the technique
of precision cut lung slices combined to videomorphometry 167
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Table 1
Currently known phenotype differences between COPD and asthma
In addition to pulmonary alterations other organ systems may be affected in COPD 18 Systemic effects of
COPD include weight loss nutritional abnormalities and musculoskeletal dysfunction These systemic
manifestations will gain further socioeconomic importance with an increasing prevalence of COPD in the next
years 19 Therefore these systemic effects should be present in animal models of COPD and further analysis
of mechanisms underlying these systemic effects in experimental models may help to optimize disease
management
Inflammatory cells
An important feature of COPD is the ongoing chronic inflammatory process in the airways as indicated by the
current GOLD definition of COPD 4 There are differences between COPD and asthma while mast cells and
eosinophils are the prominent cell types in allergic asthma the major inflammatory cell types in COPD are
different Table 2 2022
Table 2
Differences in inflammatory cells between COPD and asthma Ranked in relative order of
importance
Neutrophils play a prominent role in the pathophysiology of COPD as they release a multitude of mediators and
tissue degrading enzymes such as elastases which can orchestrate tissue destruction and chronic inflammation
823 Neutrophils and macrophages are increased in bronchoalveolar lavage fluid from cigarette smokers
24Patients with a high degree of airflow limitation have a greater induced sputum neutrophilia than subjects
without airflow limitation Increased sputum neutrophilia is also related to an accelerated decrease in FEV and
sputum neutrophilia is more prevalent in subjects with chronic cough and sputum production 25
The second major cell type involved in cellular mechanisms are macrophages 26 They can release numerous
tissue degrading enzymes such as matrix metalloproteinases MMPs In an animal model of tobacco smoke
induced tissue matrix degradation not only neutrophil enzymes but also macrophagederived enzymes such as
MMP12 are important for the development of emphysema like lesions 27A further key enzyme is the
macrophage metalloelastase which was reported to mediate acute cigarette smoke induced inflammation via
tumor necrosis factor TNFalpha release 28 Neutrophils and macrophages can communicate with other cells
such as airway smooth muscle cells endothelial cells or sensory neurons and release inflammatory mediators
that induce bronchoconstriction 29airway remodelling 30 and mucin gene induction and mucus
hypersecretion involving the induction of mucin genes 3133
Lymphocytes are also involved in cellular mechanisms underlying COPD 345Increased numbers of
CD8 positive Tlymphocytes are found in the airways of COPD patients 212and the degree of airflow
obstruction is correlated with their numbers 36 However the Tcell associated inflammatory processes
largely differ from those in allergic asthma which is characterized by increased numbers of CD4 positive
Tlymphocytes 737Table 2 Although eosinophils may only play a major role in acute exacerbations of
COPD 38 their presence in stable disease is an indicator of steroid responsiveness 3941
Different inflammatory cell types have also been characterized in airway tissues Epithelial neutrophilia has
been seen in proximal and distal airways of patients with COPD 423The airway wall beneath the epithelium
shows a mononuclear inflammation with increased macrophages and Tcells bearing activation markers 2036
Di Stefano 1996 An excess od CD8 T cells are particularly observed in central airways peripheral airways
and parenchyma 2043In the small airways from patients with stage 0 to at risk stage 4 very severe
COPD the progression of the disease is strongly associated with the accumulation of inflammatory exudates in
the small airway lumen and with an increase in the volume of tissue in the airway wall 10 Also the
percentage of airways containing macrophages neutrophils CD4 cells CD8 cells B cells and lymphoid follicle
aggregates and the absolute volume of CD8 Tcells and B cells increased with the progression of COPD 10
The changes are also most likely associated with an induction of mucin gene expression 44 The presence of
increased numbers of B cells begs the question regarding the role of these cells in the pathophysiology of COPD
In the airway smooth muscle bundles in smokers with COPD increased localisation of T cells and neutrophils
has been reported indicating a possible role for these cells interacting with airway smooth muscle in the
pathogenesis of airflow limitation 45
Mechanisms of COPD
On the basis of the different pathophysiological mechanisms illustrated in Fig different animal models have
been developed in past years
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Protease antiprotease imbalance
An imbalance between protease and antiprotease enzymes has been hypothesized with respect to the
pathogenesis of emphysema 46This concept derives from early clinical observations that alphalntitrypsin
deficient subjects develop severe emphysema and the role of protease antiprotease imbalance was later
demonstrated in animal models of COPD 478Although alphalantitrypsindeficiency is a very rare cause of
emphysema 4950it points to a role of proteases and proteolysis512Neutrophil elastase deficient mice
were significantly protected from emphysema development induced by chronic cigarette smoke 48 Depletion
of the macrophage elastase gene also led to a complete protection from emphysema induced by cigarette
smoke 47 Each of these elastases inactivated the endogenous inhibitor of the other with macrophage
elastase degrading alphalantitrypsin and neutrophil elastase degrading tissue inhibitor of metal loproteinase 1
48 In tobacco smoke exposureinduced recruitment of neutrophils and monocytes was impaired in elastase
gene depleted animals and there was less macrophage elastase activity due to a decreased macrophage influx
in these animals Thus a major role for neutrophil elastase and macrophage elastase in the mediation of
alveolar destruction in response to cigarette smoke has been shown 478This experimental evidence
derived from animal models points to an important pathogenetic role for proteases that correlates well with the
imbalance ofproteases present in human COPD However many pathways of tissue destruction can be found in
animal models that lead to a picture similar to human disease and it is important to examine whether these
mechanisms are operative in the human disease itself
Oxidative stress
Oxidative stress arising from inhaled noxious stimuli such as tobacco smoke or nitrogen dioxide may be
important cause of the inflammation and tissue damage in COPD This potential mechanism is supported by
clinical reports of increased levels of oxidative stress indicators in exhaled breath condensates ofCOPD patients
5355Apart from elevated levels of 8 isoprostane 55 nitrosothiol levels were increased in COPD patients
5658 Studies in a mouse model of tobacco smoke induced COPD also demonstrated the presence of tissue
damage due to oxidative stress 59These changes could be blocked by superoxide dismutase 60 Oxidative
stress has also been implicated in the development of corticosteroid resistance in COPD
Mediators
Many mediators have been identified which may contribute to COPD pathogenesis 8 As in bronchial asthma
pro and anti inflammatory mediators of inflammation such as tachykinins 61vasoactive intestinal
polypeptide VIP 62 histamine 63 nitric oxide 645 leukotrienes 66 opioids 67 or intracellular
mediators such as SMADs 689have been implicated The balance of histone acetylases and deacetylases
70 is a key regulator of gene transcription and expression by controlling the access of the transcriptional
machinery to bind to regulatory sites on DNA Acetylation of core histories lead to modification of chromatin
structure that affect transcription and the acetylartion status depends on a balance of histone deacetylase and
histone acetyltransferase This is also likely to play a role in the regulation of cytokine production in COPD
Cigarette smoke exposure led to altered chromatin remodelling with reduced histone deacetylase activity with a
resultant increase in transcription of pro inflammatory genes in lungs of rats exposed to smoke linked to an
increase in phosphorylated p38 MAPK in the lung concomitant with an increased histone 3 phospho acetylation
histone 4 acetylation and elevated DNA binding of NFkappaB and activator protein 1 AP170 In addition
oxidative stress has also been shown to enhance acetylation of histone proteins and decrease histone
deacetylase activity leading to modulation of NFKB activation 71similar to the effect of cigarette smoke
A Th2 cytokine that has been proposed to be implicated in the pathophysiology of COPD is IL13 It is also
overexpressed and related to the pathogenesis of the asthmatic Th2 inflammation and airway remodelling
process 72The effects of IL13 in asthma have been elucidated in a series of experiments that demonstrated
the an airway specific constitutive overexpression of IL13 leads to a process of airway remodelling with
subepithelial fibrosis and mucus metaplasia combined with an eosinophil lymphocyte and macrophagerich
inflammation and increased hyperresponsiveness 73 Since asthma and COPD pathogenesis may be linked
similar mechanisms may contribute to the development and progression of both diseases 74 In this respect
IL13 may also play a role in COPD since the inducible overexpression of IL13 in adult murine lungs leads to
alveolar enlargement lung enlargement and an enhanced compliance and mucus cell metaplasia 75 with
activation of MMP2 9 12 13 and 14 and cathepsins B S L H and K in this model
Parallel to proteasebased and extracellular mediatorbased concepts altered intracellular pathways may also
play a role in COPD MAPK signalling pathways ie p38 and cJun N terminal kinase INK 7677 seem to be
important signal transducers in the airways and airway innervating neurons 7880 and may therefore display
an interesting target for COPD research For some cells the activation of p38 or INK pathways may promote
apoptosis rather than proliferation 82
Viral infections
Previous studies showed an association between latent adenoviral infection with expression of the adenoviral
ElA gene and chronic obstructive pulmonary disease COPD 8384 It may therefore be assumed that latent
adenoviral infection can be one of the factors that might amplify airway inflammation Human data 35
demonstrating the presence of the viral ElA gene and its expression in the lungs from smokers 856animals
87 and cell cultures 88 support this hypothesis A small population of lung epithelial cells may carry the
adenoviral ESA gene which may then amplify cigarette smoke induced airway inflammation to generate
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parenchymal lesions leading to COPD Inflammatory changes lead to collagen deposition elastin degradation
and induction of abnormal elastin in COPD 8990Also latent adenovirus ElA infection of epithelial cells could
contribute to airway remodelling in COPD by the viral ElA gene inducing TGF beta 1 and CTGF expression and
shifting cells towards a more mesenchymal phenotype84
Genetics
Since only a minority of smokers approximately 15 to 20 develop symptoms and COPD is known to cluster
in families a genetic predisposition has been hypothesized Many candidate genes have been assessed but the
data are often unclear and systematic studies are currently performed to identify disease associated genes
Next to alphal antitrypsin deficiency several candidate genes have been suggested to be linked to COPD
induction Genetic polymorphisms in matrix metalloproteinase genes MMP1 MMP9 and MMP12 may be
important in the development of COPD In this respect polymorphisms in the MMP1 and MMP12 genes but not
MMP9 have been suggested to be related to smoking related lung injury or are in a linkage disequilibrium with
other causative polymorphisms 9193 An association between an MMP9 polymorphism and the development
of smoking induced pulmonary emphysema was also reported in a population of Japanese smokers 94 Also
polymorphisms in the genes encoding for IL1195 TGFbetal 96 and the group specific component of
serum globulin 97 have been shown to be related to a genetic predisposition for COPD Since it was difficult to
replicate some of these findingsamong different populations future studies are needed Also whole genome
screening in patients and unaffected siblings displays a promising genetic approach to identify genes associated
with COPD
Experimental models of COPD
There are three major experimental approaches to mimic COPD encompassing inhalation of noxious stimuli
tracheal instillation of tissue degrading enzymes to induce emphysemalike lesions and gene modifying
techniques leading to a COPD like phenotype Figure 2 These approaches may also be combined Ideally a
number of potential indicators for COPD which have been proposed by the GOLD guidelines should be present in
animal models of COPD Table 3 Since COPD definition still rests heavily on lung function measures airflow
limitation and transfer factor it would be ideal to have lung function measurements in experimental models
15The challenge is in the measurement of lung function in very small mammals such as mice and since the
use of the enhanced pause Penh in conscious mice as an indicator of airflow obstruction is not ideal 98
invasive methods remain the gold standard and these should be correlated with inflammatory markers and
cellular remodelling
Figure 2
Experimental approaches to mimic COPD There are three major experimental approaches to
mimic COPD or emphysema consisting of inhalation of noxious stimuli such as tobacco smoke
tracheal instillation of tissue degrading enzymes to induce emphysema like lesions and
gene modifying techniques leading to COPD like murine phenotypes
Table 3
Indicators forCOPD These indicators are related to the presence of COPD and should ideally be
present in animal models and available for analysis
Inhalation models tobacco smoke
A variety of animal species has been exposed to tobacco smoke Next to guinea pigs rabbits and dogs and
also rats and mice have been used Guinea pigs have been reported to be a very susceptible species They
develop COPDlike lesions and emphysema like airspace enlargementwithin a few months ofactive tobacco
smoke exposure 99 By contrast rat strains seem to be more resistant to the induction ofemphysema like
lesions Susceptibility in mice varies from strain to strain The mode of exposure to tobacco smoke may be
either active via noseonly exposure systems or passive via large wholebody chambers
The first species tobe examined in detail for COPD like lesions due to tobacco smoke exposure was the guinea
pig 99 Different exposure protocols were screened and exposure to the smoke of 10 cigarettes each day 5
days per week for a period of either 1 3 6 or 12 months resulted in progressive pulmonary function
abnormalities and emphysema like lesions The cessation of smoke exposure did not reverse but stabilized
emphysema like airspace enlargement On the cellular level long term exposure lead to neutrophilia and
accumulation of macrophages and CD4 Tcells 83100 Latent adenoviral infection amplifies the
emphysematous lung destruction and increases the inflammatory response produced by cigarette smoke
exposure Interestingly it was shown that the increase in CD4 Tcells is associated with cigarette smoke and
the increase in CD8 Tcells with latent adenoviral infection 83
Mice represent the most favoured laboratory animal species with regard to immune mechanisms since they
offer the opportunity to manipulate gene expression However it is more difficult to assess lung function and
mice tolerate at least two cigarettes daily for a year with minimal effects on body weight and
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carboxyhemoglobin levels Mice differ considerably in respiratory tract functions and anatomy if compared to
humans they are obligate nose breathers they have lower numbers of cilia fewer Clara cells and a restriction
of submucosal glands to the trachea Next to a lower filter function for tobacco smoke mice also do not have a
cough reflex and many mediators such as histamine or tachykinins have different pharmacological effects The
development of emphysemalike lesions is strain dependent enlarged alveolar spaces and increased alveolar
duct area are found after 3 6 months of tobacco smoke exposure in susceptible strains such as B6C3F1 mice
101 At these later time points tissue destruction seems to be mediated via macrophages At the cellular
level neutrophil recruitment has been reported to occur immediately after the beginning of tobacco smoke
exposure and is followed by accumulation of macrophages The early influx of neutrophils is paralleled by a
connective tissue breakdown The early stage alterations of neutrophil influx and increase in elastin and
collagen degradation can be prevented by pretreatment with a neutrophil antibody or alphaantitrypsin 102
Rats are also often used for models of COPD However they appear to be relatively resistant to the induction of
emphysema like lesions Using morphometry and histopathology to assess and compare emphysema
development in mice and rats significant differences were demonstrated 101 Animals were exposed via
wholebody exposure to tobacco smoke at a concentration of 250 mg total particulate matterm3 for 6 hday 5
daysweek for either 7 or 13 months Morphometry included measurements of tissue loss volume density of
alveolar septa and parenchymal air space enlargement alveolar septa mean linear intercept volume density
of alveolar air space Also centroacinar intra alveolar inflammatory cells were assessed to investigate
differences in the type of inflammatory responses associated with tobacco smoke exposure In B6C3F1 mice
many of the morphometric parameters used to assess emphysemalike lesions differed significantly between
exposed and nonexposed animals By contrast in exposed Fischer344 rats only some parameters differed
significantly from non exposed values The alveolar septa mean linear intercept in both exposed mice and rats
was increased at 7 and 13 months indicating an enlargement of parenchymal air spaces In contrast the
volume density of alveolar air space was significantly increased only in exposed mice The volume density of
alveolar septa was decreased in mice at both time points indicating damage to the structural integrity of
parenchyma There was no alteration in Fischer344 rats Morphologic evidence of tissue destruction in the mice
included irregularlysized and shaped alveoli and multiple foci of septa discontinuities and isolated septa
fragments The morphometric differences in mice were greater at 13 months than at 7 months suggesting a
progression of the disease Inflammatory influx within the lungs of exposed mice contained significantly more
neutrophils than in rats These results indicated that B6C3F1 mice are more susceptible than F344rats to the
induction of COPD like lesions in response to tobacco smoke exposure 101
Recent work on cigarette exposure in rats indicate that this model also achieves a degree of corticosteroid
resistance that has been observed in patients with COPD 1034 Thus the inflammatory response observed
after exposure of rats to cigarette smoke for 3 days is noty inhibited by pre treatment with corticosteroids 70
This may be due to the reduction in histone deacetylase activity which could result from a defect in recruitment
of this activity by corticosteroid receptors Corticosteroids recruit hitone deacetylase 2 protein to the
transcriptional complex to suppress proinflammatory gene transcription 105 Modifications in histone
deacetylase 2 by oxidative stress or by cigarette smoke may make corticosteroids ineffective 106 Therefore
models of COPD that show corticosteroid resistance may be necessary and could be used to dissect out the
mechanisms of this resistance
Generally tobacco smoke exposure may be used to generate COPD features such as emphysema and airway
remodelling and chronic inflammation Although the alterations still differ from the human situation and many
involved mediators may have different functional effects especially in the murine respiratory tract these
models represent useful approaches to investigate cellular and molecular mechanisms underlying the
development and progression of COPD As a considerable strain tostrain and species tospecies variation can
be found in the models used so far the selection of a strain needs to be done with great caution Animal models
of COPD still need to be precisely evaluated as to whether they mimic features of human COPD and their
limitations must be appreciated Findings obtained from these models may provide significant advances in
terms of understanding novel mechanisms involved in COPD
Inhalation models sulfur dioxide
Sulfur dioxide S02 is a gaseous irritant which can be used to induce COPDlike lesions in animal models With
daily exposure to high concentrations of S02 chronic injury and repair of epithelial cells can be observed in
species such as rat or guinea pig The exposure to high levels of this gas ranging from 200 to 700 ppm for 4 to 8
weeks has been demonstrated to lead to neutrophilic inflammation morphological signs of mucus production
and mucus cell metaplasia and damage of ciliated epithelial cells in rats 1078 These changes are directly
dependent on the exposure to the gas signs of mucus production and neutrophilic inflammation are almost
entirely reversed within a week after termination of exposure 108 Acute exposure to S02 also leads to loss of
cilia and exfoliation of ciliated cells as demonstrated in S02exposed dogs using transmission electron
microscopy 109 After a longer period of exposure the epithelial layer regenerates and airway wall thickening
and change in cilia structure can be observed 110 Long term exposure also increases in mucosal permeability
both in vivo and in vitro 111
Mucus hypersecretion is an important indicator for COPD and experimental models should encompass features
of hypersecretion After chronic exposure to S02 in rats visible mucus layers and mucus plugs may sometimes
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be observed in the large airways 107 and an elevation of mucus content may be found in bronchoalveolar
lavage fluids 112 Parallel to these findings there is an increase of PAS and Alcian Bluestaining epithelial
cells in chronically S02 exposed rats 113 but there is substantial variation present as with human COPD 114
Tracheal mucus glands are also increased in size after S02exposure 115 and increased levels of mucin RNA
can be found in lung extracts 112 The mechanisms underlying mucus hypersecretion have not been
elucidated so far and also functional studies assessing basal and metacholine induced secretion have not been
conducted so far
Airway inflammation with cellular infiltration is an important feature of COPD After exposure to S02 increases
in mononuclear and polymorphonuclear inflammatory cells are present in rat airways However the influx is
confined to large but not small airways which are important in human COPD 107 Even after one day of
exposure polymorphonuclear inflammatory cells are found and their influx can be inhibited with steroid
treatment 116
S02 based models of COPD have also been shown to be associated with an increase in pulmonary resistance
and airway hyperresponsiveness 107 and it was hypothesized that elevated levels of mucus may account for
the increased responsiveness 117 Since sensory nerve fibres may function as potent regulators of chronic
inflammation in COPD by changes in the activation threshold and the release of pro inflammatory mediators
such as tachykinins 118 or CGRP 6 119 this class of nerve fibres was examined in a number of studies
1201 The results of these studies supported the hypothesis that rather than contributing to the
pathophysiological manifestations of bronchitis sensory nerve fibres limit the development of airway
obstruction and airway hyperresponsiveness during induction of chronic bronchitis by S02exposure In this
respect the enhanced contractile responses of airways from neonatally S02exposed capsaicin treated rats
may result from increased airway smooth muscle mass and contribute to the increased airway responsiveness
observed in these animals 1211
To obtain coexisting expression ofemphysema and inflammatory changes as seen in COPD neutrophil elastase
instillation and S02exposure were performed simultaneously 108 The pre treatment with elastase aimed to
render the animals more susceptible to the inflammation induced by S02 However neither allergy phenotype
Brown Norway nor emphysematous SpragueDawley rats displayed an increased sensitivity to S02exposure
With regard to the observed histopathological changes it can be concluded that S02 exposure leads to a more
diffuse alveolar damage with a more extensive damage with destruction of lung tissue after longer exposure
Therefore the outcome is more or less a picture of tissue destruction with close resemblance to end stages of
emphysema but not a complete picture of COPD
Inhalation models nitrogen dioxide
Nitrogen dioxide NO2 is a another gas that may lead to COPD like lesions depending on concentration
duration of exposure and species genetic susceptibility 122 Concentrations ranging from 50150 ppm
94282 mgm3 can lead to death in laboratory animals due to extensive pulmonary injury including
pulmonary oedema haemorrhage and pleural effusion
Short term exposure to NO2 leads to a biphasic response with an initial injury phase followed by a repair phase
Both increased cellular proliferation and enzymatic activity occur during the repair phase Exposure of rats to 15
ppm NO2 for 7 days leads to an increased oxygen consumption in airway tissues The increase in oxidative
capacity reflects an increase in mitochondrial activity consistent with observations of increased DNA synthesis
123 Exposure to 10 ppm NO2 for more than 24 h causes damage to cilia and hypertrophy of the bronchiolar
epithelium 124 Also exposure to 1520 ppm NO2 leads to a type II pneumocyte hyperplasia 1256
As with the exposure to other noxious stimuli there is also a significant inter species variability In comparison
to mice and rats guinea pigs exhibit changes in lung morphology at much lower NO2 concentrations It was
shown that a 2 ppm NO2 3day exposure causes increased thickening of the alveolar wall damage to cilia and
pulmonary oedema 127 Other changes are an influx of inflammatory cells and increases in connective tissue
formation 128
There is also a significant mode of inheritance of susceptibility to NO2induced lung injury in inbred mice
Susceptible C57BL61B6 and resistant C3H HeJ C3 mice as well as Fl F2 and backcross BX populations
derived from them were acutely exposed to 15 parts per million NO2 for 3 h to determine differences 122
Significant differences in numbers of lavageable macrophages epithelial cells and dead cells were found
between inbred strains distributions of cellular responses in F1 progeny overlapped both progenitors and mean
responses were intermediate It was shown that inC3BX progeny ranges of responses to NO2 closely
resembled C3 mice Ranges of cellular responses to NO2 in B6X and intercross progeny were reported to
overlap both progenitor and mean responses of both populations were intermediate to progenitors Therefore
there were likely two major unlinked genes that account for differential susceptibility to acute NO2 exposure
122 Based on the genetic background of C57BL6mice a model of long term NO2 exposure was recently
established leading to signs of pulmonary inflammation and progressive development of airflow obstruction
129
Inhalation models oxidant stimuli and particulates
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The administration ofoxidants such as ozone also causes significant lung injury with some features related to
inflammatory changes occurring in human COPD 130 and this causes numerous effects in airway cells
131 135 As a gaseous pollutant ozone targets airway tissues and breathing slightly elevated concentrations
of this gas leads to a range of respiratory symptoms including decreased lung function and increased airway
hyper reactivity In conditions such as COPD and asthma ozone may lead to exacerbations of symptoms
Ozone is highly reactive the reaction with other substrates in the airway lining fluid such as proteins or lipids
leads to secondary oxidation products which transmit the toxic signals to the underlying pulmonary epithelium
These signals include cytokine generation adhesion molecule expression and tight junction modification leading
to inflammatory cell influx and increase of lung permeability with oedema formation 130 However the
nature and extent of these responses are often variable and not related within an individual The large amount
ofdata obtained from animal models of ozone exposure indicates that both ozone and endotoxin induced
animal models are dependent on neutrophilic inflammation It was shown that each toxin enhances reactions
induced by the other toxin The synergistic effects elicited by coexposure to ozone and endotoxin are also
mediated in part by neutrophils 1367
Further animal models focus on the exposure to ultrafine particles silica and coal dust 1389Ultrafine
particles are a common component of air pollution derived mainly from primary combustion sources that cause
significant levels of oxidative stress in airway cells 1401 Theanimal models are predominantly
characterized by focal emphysema and it was suggested that dust induced emphysema and smoke induced
emphysema occur through similar mechanisms 142
Exposure to diesel exhaust particles DEP may also lead to chronic airway inflammation in laboratory animals
as it was shown to have affect various respiratory conditions including exacerbations ofCOPD asthma and
respiratory tract infections 143 Both the organic and the particulate components of DEP cause significant
oxidant injury and especially the particulate component of DEP is reported to induce alveolar epithelial damage
alter thiol levels in alveolar macrophages AM and lymphocytes and induce the generation of reactive oxygen
species ROS and pro inflammatory cytokines 144 The organic component has also been shown to generate
intracellular ROS leading to a variety of cellular responses including apoptosis Longterm exposure to various
particles including DEP carbon black CB and washed DEP devoid of the organic content have been shown to
produce chronic inflammatory changes and tumorigenic responses 144 The organic component of DEP also
suppresses the production of pro inflammatory cytokines by macrophages and the development of Thl
cellmediated mechanisms thereby enhancing allergic sensitization The underlying mechanisms have not been
fully investigated so far but may involve the induction of haeme oxygenases which are mediators of airway
inflammation 145 Whereas the organic component that induces IL4and IL10 production may skew the
immunity toward Th2 response the particulate component may stimulate both the Thl and Th2 responses
146 In conclusion exposure to particulate and organic components of DEP may be a helpful approach to
simulate certain conditions such as exacerbations Also the development of lung tumours after long term
exposure may be useful when studying interactions between COPD like lesions and tumorigenesis
A further toxin is cadmium chloride a constituent of cigarette smoke Administration of this substance also
leads to alterations in pulmonary integrity with primarily interstitial fibrosis with tethering open of airspaces
147 A combination of cadmium and lathyrogen beta aminopropionile enhances emphysematous changes
148
Tissue degrading approaches
Emphysema like lesions can also be achieved by intrapulmonary challenge with tissuedegrading enzymes and
other compounds 149 Figure 2 Proteinases such as human neutrophil elastase porcine pancreatic elastase
or papain produce an efficient enzymatic induction of panacinar emphysema after a single intrapulmonary
challenge 1501 Since bacterial collagenases do not lead to the formation of emphysema the effectiveness
of the proteinases is related to their elastolytic activity While these models may not be as useful as smoke
exposure studies to achieve COPD like lesions they can lead to a dramatic picture of emphysema and may be
used to study mechanisms related specifically to emphysema and to the repair of damaged lung However the
method of inducing emphysema like lesions by intratracheal instillation of these enzymes may not very closely
relate to mechanisms found in the human situation
Among the different emphysema models elastaseinduced emphysema has also been characterized to be
accompanied by pulmonary function abnormalities hypoxemia and secretory cell metaplasia which represent
characteristic features of human COPD Recent studies suggested that exogenous retinoic acid can induce
alveolar regeneration in models of elastase induced experimental emphysema 152 and that retinoic acid may
have a role for alveolar development and regeneration after injury 1534 However the role of retinoic acid
in relation to alveolar development has only been analysed in a rat model and models in other animals did not
show similar effects 155 Also the ability of alveolar regeneration which is present in rats does not occur to a
similar extent in humans a recent clinical trial using retinoic acid in COPD did not show positive results 156
The mechanisms of emphysema induction by intratracheal administration of elastase encompass an initial loss
of collagen and elastin Later glycosaminoglycan and elastin levels normalize again but collagen levels are
enhanced The extracellular matrix remains distorted in structure and diminished with resulting abnormal
airway architecture 157 The enlargement of the airspaces immediately develops after the induction of
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The administration of oxidants such as ozone also causes significant lung injury with some features related to 
inflammatory changes occurring in human COPD [130] and this causes nu erous effects in airway cells 
[ill- 5]. As a gaseous pollutant, ozone targets airway tissues and breathing slightly elevated concentrations 
of this gas leads to a range of respiratory symptoms including decreased lung function and increased airway 
hyper-reacti it . In conditions such as COPO and asth , ozone may lead to exacerbations of sy t . 
Ozone is highly reactive: the reaction with other substrates in the airway lining fluid such as proteins or lipids 
leads to secondary oxidation products which transmit the toxic signals to the underlying pulmonary epitheliu . 
These signals include cytokine generation, adhesion olecule expression and tight junction modification leading 
to inflammatory cell influx and increase of lung per eability with oede a formation [130]. Ho ever, the 
nature and extent of these responses are often v ri le and not related ithin an in i i . The large t 
of data obtained from ani al odels of ozone exposure indic t s that t  oz -  e i - ced 
ani al odels are dependent on tro ilic infl ti . It as shown t t each toxin enhances r actions 
induced by the other toxin. The synergistic effects elicited by coexposure to ozone and endotoxin are also 
e i , in p , y n t il . [136,137]. 
Further ani al odels focus on the exposure t  ltrafine p rti l , ili  a  coal dust [138,139]. ltr fine 
particles are a co on co ponent of air pollution, derived ainly fro  primary co bustion sources that cause 
significant levels of oxidative stress in airway cells [140,141]. The animal models are predominantly 
characterized y f l  and it as sted t t st-i ced e physema and -i ced 
e physema ccur t rough si ilar ec is s [1 ]. 
Exposure to diesel exhaust particles (OEP) may also lead to chronic airway inflammation in laboratory animals 
as it s sho n to ve a fect ri  r iratory iti  i l i  r tions  O, a,  
respiratory tr t i f ctions [1 ]. th t  rganic  t e rti l t  t  f OEP  i ific nt 
OXidant injury and especially the particulate component of OEP is reported to induce alveolar epithelial damage, 
alter thiol levels i  lveolar r ages (A )  l t ,  i uce t  ration f r ti  ygen 
species (ROS) and prO-inflammatory cytokines [144]. The organic co ponent has also been shown to generate 
intracellular R S, leading to a variety of cellular responses including apoptosis. Long-term exposure to various 
particles including DEP, carbon black (CB), and washed OEP devoid of the organic content, have been shown to 
produce chronic inflammatory changes and tumorigenic responses [144]. The organic component of OEP also 
suppresses the production of prO-infla atory cytokines by acrophages and the develop ent ofTh1 
ll- i t  i  t r  i g ll r ic iti ti .  rl i  i   t  
fully investigated so far but ay involve the induction of hae e oxygenases, which are ediators of airway 
i fl ti  [1 ].  t  r i  t t t i  I -4  I -10 ti    t  
i unity to ard h2 response, the particulate co ponent ay sti ulate both the Th1 and h2 responses 
[146]. In conclusion, exposure to particulate and organic co ponents of OEP ay be a helpful approach to 
Si ulate c rt i  c iti s such as x c r ti s. lso, t  v l nt f l  t rs ft r l  t r  
x s r  y  s f l  st yi  i t r cti s t  PO-like l si s  t ri sis. 
 f rt r t i  is i  l ri ,  tit t f i r tt  . i i tr ti  f t i  t  l  
l  t  lt r ti  i  l r  i t rit  it  ri ril  i t r titi l fi r i  it  t t ri   f ir  
[147]. A co bination of cad iu  and lathyrogen beta-a inopropionile enhances e physe atous changes 
[148]. 
Tissue-<iegrading approaches 
Emphysema-like lesions can also be achieved by intrapulmonary challenge with tissue-degrading enzymes and 
other compounds [149] (Figure ~). Proteinases such as human neutrophil elastase, porcine pancreatic elastase, 
or papain produce an effiCient enzymatic induction of panacinar emphysema after a single intrapulmonary 
challenge [150,151]. Since bacterial collagenases do not lead to the for ation of e physe a, the effectiveness 
of the proteinases is related to their elastolytic activity. hile these odels ay not be as useful as s oke 
exposure studies to achieve C PO-like lesions, they can lead to a dra atiC picture of e physe a and ay be 
used to study mechanisms related speCifically to emphysema and to the repair of damaged lung. However, the 
method of inducing emphysema-like lesions by intratracheal instillation of these enzymes may not very closely 
 t   f  i  t e  it ation. 
Among the different emphysema models, elastase-induced emphysema has also been characterized to be 
accompanied by pulmonary function abnormalities, hypoxemia, and secretory cell metaplasia which represent 
 t r    PO.  t i  suggested t   tinOiC aci  an i  
alveolar regeneration in odels of elastase-induced experi ental e physe a [152] and that retinoic acid ay 
have a role for alveolar develop ent and regeneration after injury [153,154]. owever, the role of retinoic acid 
in relation to alveolar develop ent has only been analysed in a rat odel and odels in other ani als did not 
s  si il r ff cts [1 5]. lso, the ability f lv l r r r ti  hich is pr s t i  rats does not occur to a 
si ilar extent in hu ans; a recent clinical trial using retinoic acid in COPO did not show positive results [156]. 
The mechanisms of emphysema induction by intratracheal administration of elastase encompass an initial loss 
of collagen and elastin. Later, glycosaminoglycan and elastin levels normalize again but collagen levels are 
enhanced. The xtr c ll l r atrix re ains ist rt  in str ct r  and di inished ith r s lti  abnor l 
airway architecture [157]. The enlargement of the airspaces immediately develops after the induction of 
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elastolytic injuries and is followed by inflammatory processes which lead to a transformation of airspace
enlargement to emphysema like lesions This progression most likely occurs due to destructive effects exerted
by host inflammatory proteinases Addition of lathyrogen beta aminopropionile leads to an impairment of
collagen and elastin crosslinking and therefore further increases the extent of emphysemalike lesions 158
Effects seem to be mediated via IL10 and TNFa receptors since mice deficient in IL13Typel receptor and in
TNFalpha type 1 and 2 receptors are protected from developing emphysema following intratracheal challenge
with porcine pancreatic elastase This was associated with reduced inflammation and increased apoptosis 159
In general intrapulmonary administration of tissue degrading enzymes represents a useful tool especially when
focusing on mechanisms to repair emphysematic features However the lack of proximity to the human
situation needs tobe realized since the mechanisms ofemphysema induction are clearly not related to the
human situation An advantage of proteinasebased models is the simple exposure protocol with a single
intratracheal administration leading to significant and rapid changes However extrapolating these findings to
slowly developing features of smoking induced human COPD is very difficult since a large number of mediators
may not be involved in the rapid proteinase approach Therefore these models may not encompass important
features of human COPD which may be more closely mimicked by inhalation exposures and it is clear that
tissue degrading enzyme models always represent the picture of an induced pathogenesis
Genetargeting approaches
The genetic predisposition to environmental disease is an important area of research and a number of animal
strains prone to develop COPD like lesions have been characterized 160162 Figure 2 Also genetically
altered monogenic and polygenic models to mimic COPD have been developed in recent years using modern
techniques of molecular biology 1634
Gene depletion and overexpression in mice provide a powerful technique to identify the function and role of
distinct genes in the regulation of pulmonary homeostasis in vivo There are two major concepts consisting of
gainoffunction and lossoffunction models Gainoffunction is achieved by gene overexpression in transgenic
mice either organ specific or non specific while loss of function is achieved by targeted mutagenesis techniques
1656 These models can be of significant help for the identification of both physiological functions of distinct
genes as well as mechanisms of diseases such as COPD
A large number of genetically altered mice strains have been associated to features of COPD and a primary
focus was the assessment of matrix related genes As destruction of alveolar elastic fibres is implicated in the
pathogenic mechanism of emphysema and elastin is a major component of the extracellular matrix mice
lacking elastin were generated It was shown that these animals have a developmental arrest development of
terminal airway branches accompanied by fewer distal air sacs that are dilated with attenuated tissue septae
These emphysemalike alterations suggest that in addition to its role in the structure and function of the mature
lung elastin is essential for pulmonary development and is important for terminal airway branching 167 Also
deficiency of the microfibrillar component fibulin5and platelet derived growth factor A PDGFA leads to
airspace enlargement 1689 PDGF A mice lack lung alveolar smooth muscle cells exhibit reduced
deposition of elastin fibres in the lung parenchyma and develop lung emphysema due to a complete failure of
alveogenesis 170 The postnatal alveogenesis failure in PDGFA mice is most likely due to a prenatal
block in the distal spreading of PDGFR alpha cells along the tubular lung epithelium during the canalicular
stage of lung development 170
The importance of integrins in causing emphysema has been demonstrated in mouse Epithelial restricted
integrin a vi6null mice develop age related emphysema through the loss of activation of latent TGFbeta
which leads to an increase in macrophage MMP 12 expression 171
Fibroblast growth factors are known to be essential for lung development Mice simultaneously lacking receptors
for FGFR3 and FGFR 4have an impaired alveogenesis with increased collagen synthesis 172 It is crucial to
distinguish developmental airspace enlargement from adult emphysema which is defined as the destruction of
mature alveoli However the identification ofnumerous factors influencing lung development is an important
step towards identifying potential mechanisms underlying the development and progression of emphysema in
human COPD
Next to developmental airspace enlargement also spontaneous emphysema may occur in genetically modified
mice strains and a gradual appearance of emphysema like lesions has been found in mice lacking the surfactant
protein D SPDgene 173 and in mice lacking the tissue inhibitor ofmeta lloproteinase 3 TIMP3 gene
174 In these strains matrix meta lloproteinases were suggested to be the primary mediators of tissue
destruction
A further mechanism to induce emphysemalike lesions is to expose developmentally normal genetically
modified animals to exogenous noxious stimuli such as tobacco smoke This also allows identifying potential
molecular mechanisms involved in the pathogenesis ofCOPD Using macrophage elastase MMP12
gene depletion studies it was shown that in contrast to wild type mice the lung structure of MMP 12
gene depleted animals remains normal after long term exposure to cigarette smoke 47 These animals also
fail to develop macrophage accumulation in response to cigarette smoke an effect that could be related to
MMP12 induced generation of elastin fragments that are chemotactic for monocytes 1756
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elastolytic injuries and is follo ed by infla atory processes hich lead to a transformation of airspace 
enlarge ent to e physema-like lesions. This progression ost likely occurs due to destructive effects exerted 
by ost inflam atory r t i s s. iti  of lathyrogen eta-a inopropionile l ads to an i ir ent f 
collagen and elastin cr sslinking and therefore further i creases the exte t f a-like l i  [1 ]. 
Effects see  t  be i ted via I -1j3 a  T Fo r ptors since ice defiCient in I -1j3 1 r t r  in 
TNFalpha type 1 and 2 receptors are protected fro  developing e physe a following intratracheal challenge 
ith porcine pancreatic elastase. This as associated ith reduced infla ation and increased apoptosis [159]. 
In general, intrapul onary ad inistration of tissue-degrading enzy es represents a useful tool especially hen 
focusing  i  to repair yse atic f . ,  l  f r i ity t  t   
situation needs to be realized since the echanis s of e physe a induction are clearly not related to the 
hu an situation. n advantage f proteinase-based odels is the si ple exposure protocol ith a single 
i tr tracheal i i tr tion l i  t  i ific t  r i  . r, tr l ti  t s  fi i  t  
slowly developing features of s oking induced hu an COPD is very difficult since a large nu ber of ediators 
ay not be involved in the rapid proteinase approach. Therefore, these odels ay not enco pass i portant 
f t res f an  i  y  ore l l  i i   i l ti  xposures   i  l r t at 
tissue-degrading enzy e odels al ays represent the picture of an "induced pathogenesis". 
ene-targeting approaches 
The genetiC predisposition to environ ental disease is an i portant area of research and a nu ber of ani al 
strains prone to develop COPD-like lesions have been characterized [160-162] (Figure ~). Also, genetically-
altered onogenic and polygenic odels to i ic P  have been developed in recent years using odern 
t c i s f l c l r i l y [163,164]. 
ene-depletion and -overexpression in ice provide a po erful technique to identify the function and role of 
distinct genes in the regulation of pul onary ho eostasis in vivo. There are t o ajor concepts consisting of 
gain-of-function and loss-of-function odels. ain-of-function is achieved by gene overexpression in transgenic 
ice either organ specific or non-specific hile loss of function is achieved by targeted utagenesis techniques 
[165,166]. These models can be of significant help for the identification of both physiological functions of distinct 
genes as well as mechanisms of diseases such as COPD. 
A large nu ber of genetically-altered ice strains have been aSSOCiated to features of COPD and a pri ary 
f   t  t f trix-r l t  .  tr ti  f l l r l tiC fi r  i  i li t  i  t  
pathogenic echanis  of e physe a and elastin is a ajor co ponent of the extracellular atrix, ice 
lacking elastin ere generated. It as sho n that these ani als have a develop ental arrest develop ent of 
t r i l ir y r c s cc i  y f r ist l ir s cs t t r  il t  it  tt ted tiss  s t . 
These emphysema-like alterations suggest that in addition to its role in the structure and function of the mature 
lung, elastin is essential for pulmonary development and is important for terminal airway branching [167]. Also, 
fi i  f t  i fi ill  t fi li -5  l t l t i  t  f t   (PDGF-A) l s t  
airspace enlarge ent [168,169]. P F-A(-/-) i  l  l  l l  t  l  ll , i i   
siti  f l sti  fi r s in t  l  r c y ,  v l  l  ys   t   c l t  f il r  f 
lv sis [1 0].  st t l lv sis f il r  i  - (-/-)  i     t    
l  i  t  i t l r i  f -R l ha+ ll  l  t  t l r l  it li  ri  t  li l r 
t  f l  l t [1 0]. 
 i rt c  f i t ri s i  c si  ys  s  str t  i  se. it li l r strict  
integrin a vj3 6-null mice develop age-related emphysema through the loss of activation of latent TGF-beta 
which leads to an increase in acrophage P-12 expression [171]. 
Fibroblast growth factors are known to be essential for lung develop ent. ice si ultaneously lacking receptors 
for F F -3 and F F -4 have an i paired alveogenesis ith increased collagen synthesis [172]. It is crucial to 
distinguish developmental airspace enlargement from adult emphysema which is defined as the destruction of 
mature alveoli. However, the identification of numerous factors influencing lung development is an important 
t  t r  i tif i  t ti l i  rl i  t  l t  r r i  f  i  
 D. 
t t  l t l ir  l r t l  t    r i  ti ll - ifi  
i  tr i    r l r  f -li  l i s   f  in i  l i  t e rf t t 
protein D (SP-D) gene [173] and in ice lacking the tissue inhibitor of etalloproteinase-3 (TI P-3) gene 
[174]. In these strains, matrix metalloproteinases were suggested to be the primary mediators of tissue 
destruction. 
 further echanis  to induce e physe a-like lesions is to expose develop entally nor al genetically-
ifi  i ls t  ex s xi s sti li suc  s t cc  s oke. is ls  allo s identifyi  t ti l 
olecular echanis s involved in the pathogenesis of PD. sing acrophage elastase ( -12) 
gene-depletion studies it was shown that in contrast to wild type mice, the lung structure of MMP-12 
gene-depleted animals remains normal after long term exposure to Cigarette smoke [47]. These animals also 
fail to develop macrophage accumulation in response to cigarette smoke, an effect that could be related to 
MMP-12 induced generation of elastin fragments that are chemotactiC for monocytes [175, 176]. 
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In summary genetargeting techniques display very useful tools to examine potential molecular mechanisms
underlying human COPD In combination with inhalation protocols they may identify important protective or
pro inflammatory mediators of the disease
Other models
Various other agents have also been characterized to induce airway inflammation injury In this respect
administration of toxins such as endotoxin leads to a recruitment of neutrophils and macrophage activation with
concomitant airspace enlargement 1778
Non inflammatory emphysemalike lesions may also be accomplished by intravascular administration ofa
vascular endothelial cell growth factor receptor2 VEGFR2 blocker 179 VEGF is required for blood vessel
development and endothelial cell survival and its absence leads to endothelial cell apoptosis 180 An increased
septal cell death in human emphysematous lungs and a reduced expression of VEGF and VEGFR2 is found in
emphysema lungs 181 Also chronic blockage of VEGFR2 causes alveolar septal cell apoptosis and airspace
enlargement 179 These findings of airspace enlargement point to a role of the vascular system in the
development and progression of emphysema
Conclusions OtherSections
In contrast to the variable pathology and different stages of severity in human COPD currently available animal
models are restricted to mimicking a limited amount of characteristic features of COPD Animal models need to
be precisely evaluated based on whether they agree with features ofhuman COPD in order to advance the
understanding of mechanisms in human COPD
Based on inhalative exposure to noxious stimuli such as cigarette smoke the administration of tissue degrading
enzymes or gene targeting techniques a number of experimental approaches to mimic acute and chronic
features of COPD have been established in the past years Due to the complexity of the disease and species
specific differences they are all limited concerning their clinical significance
While the induction of the COPD lesions by tissue degrading enzymes may appear artificial in many cases it
does not mean that these models are not valuable because they can be used to study many aspects of
pulmonary pathophysiology of end stage emphysema Cellular mechanisms can be studied efficiently and
underlying molecular mechanisms and potential therapeutic approaches can be revealed if the data is
extrapolated cautiously
Combined models of inhalative exposure proteinasebased tissue degradation to produce emphysema and
genetargeting techniques may provide models of COPD which encompass more features of the disease
However one cannot assume that reproducing COPD with a high degree of fidelity in the animal necessarily
means that the model simulates the human condition In fact a model that only produces a single pathologic
COPD feature may be more useful as long as it produces this feature via a relevant mechanism that allows
exploratory research By contrast a model producing all kinds of COPD features via irrelevant mechanisms
may be less useful In this respect validation of models as being relevant is an extremely important issue in
the early steps of model development Anima models should not only assess histopathological features but also
attempt to focus on functional features of human COPD such as airflow limitation mucus hypersecretion
chronic cough and exacerbations and also on pharmacological features such as corticosteroid resistance or
diminished iadrenergic bronchodilator responses In conclusion there are many benefits that can accrue from
the development of animal models of COPD most important of which is understanding of mechanisms and
development of specific drugs for COPD
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The inhalation of reactive gases and vapors can lead to severe damage of the airways and lung compromising the
function of the respiratory system Exposures to oxidizing electrophilic acidic or basic gases frequently occur in
occupational and ambient environments Corrosive gases and vapors such as chlorine phosgene and chloropicrin
were used as warfare agents and in terrorist acts Chemical airway exposures are detected by the olfactory
gustatory and nociceptive sensory systems that initiate protective physiological and behavioral responses This
review focuses on the role of airway nociceptive sensory neurons in chemical sensing and discusses the recent
discovery of neuronal receptors for reactive chemicals Using physiological imaging and genetic approaches
Transient Receptor Potential TRP ion channels in sensory neurons were shown to respond to a wide range of
noxious chemical stimuli initiating pain respiratory depression cough glandular secretions and other protective
3 responses TRPA1 a TRP ion channel expressed in chemosensory Cfibers is activated by almost all oxidizing and
electrophilic chemicals including chlorine acrolein tear gas agents and methyl isocyanate the highly noxious
chemical released in the Bhopal disaster Chemicals likely activate TRPA1 through covalent protein modification
Animal studies using TRPA1 antagonists or TRPA1deficient mice confirmed the role of TRPA1 in chemically induced
respiratory reflexes pain and inflammation in vivo New research shows that sensory neurons are not merely
passive sensors of chemical exposures Sensory channels such as TRPA1 are essential for maintenance of airway
inflammation in asthma and may contribute to the progression of airway injury following high level chemical
exposures
Keywords chemosensation TRPA1 channel irritants airway obstruction chemical injury
Toxic inhalation hazards TIHs are noxious gases and vapors that are harmful and often deadly when inhaled
Specific sensory receptors in the airways sense the presence of these chemicals and initiate conscious involuntary
autonomic inflammatory and other responses to them 1 Some inhaled toxicants have their primary actions in
3 tissues outside of the lungs or hinder oxygen from reaching the alveolar sacs Usually the only noticeable sensations
1 by these toxicants are their smell and taste or they are not detected at all and are only recognizable by the signs
a
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and symptoms of their toxicity 2 Most TIHs are reactive chemical gases and vapors that can severely change the
structures of the proteins lipids DNA and other biomolecules resulting in a loss of protein function DNA mutations
and necrosis of airway epithelial cells 3 4 The body defends itself against these reactiveTIHs with the tissue
barriers presented by hair skin and mucous membranes as well as by extracellular fibers fluids membrane
cytosolic components and glandular secretions containing high concentrations of antioxidants buffers and other
compounds that sequester and neutralize reactive chemicals These include uric acid glutathione ascorbic acid
carotenes lipoic acid tocopherol ubiquinol ammonia carbonic acid phosphate and enzymes In certain incidences
these enzymes produce more toxic metabolites 57In severe exposures these protective chemicals are saturated
and the reactive chemicals react with lung tissues damaging lung and its delicate alveolar sacs 8 The airways
3 have specialized mechanisms to protect alveoli from damage The peripheral sensory neurons of the airways
express specific acid sensitive ion channel ASIC and TRIP cation channels that are directly activated by reactive
chemicals The activation of these ion channels triggers signaling to the brain to perceive pain and to initiate
involuntary autonomic and motor reflexes of the glands and muscles of the airways and lungs 914 The activated
channels also induce the sensory neuronal peripheral endings to release proinflammatory factors near the site of
contact with the reactive TI 15
At trace levels the reactive TIHs are perceived as pungent and irritating and induce sneezing coughing mucus
secretion upper airway inflammation and tearing At higher levels these sensory neuron mediated sensations and
responses progress to incapacitating pain uncontrollable coughing profuse lacrimation and resistance to airflow by
bronchospasm mucus hypersecretion and upper and lower airway inflammation pneumonitis 10 1621 These
responses neutralize hinder and expel toxic materials limiting damage to the delicate alveolar sacs However
continued exposures can lead to exaggerated responses that compromise respiratory function 20 22 Reactive
TIHs can compound pre existing conditions For example they are notorious for triggering attacks in individuals with
asthma irritantinduced asthma 23 The continual respiratory responses might be involved in the development of
chronic airway diseases including bronchitis and occupational asthma and reactive airway dysfunction syndrome
2022 2429 Exaggerated sensory neuronal responses may contribute to the pulmonary edema and adult
respiratory distress syndrome ARDS seen with high concentration exposure of TIHs 30 31 Therefore not only
fr must the airways be able to immediately detect the presence of reactive TIHs and initiate the appropriate responses
to prevent exposure to the alveolar sacs they must also deactivate this in a controlled manner to allow for normal
breathing and blood flow to occur once the threat has disappeared
Injury and inflammation alter sensory neurons to become hyperactive or hypersensitive to noxious stimuli This
phenomenon has been thoroughly characterized in pain conditions such as migraine and chronic inflammatory or
neuropathic pain It would seem likely that similar mechanisms occur in the airway sensory innervation 3234 The
necrotic and damaged cells of the airway epithelium release signaling molecules such as DNA ATP adenosine uric
acid other small molecules peptides peptidase products lipids and lipid oxidation products These molecules act
as warning signals to the nearby tissues and initiate and modulate inflammatory responses by the surrounding cells
especially the front line immune cells 4 These signaling molecules cytokines and other inflammatory mediators
released during an airway injury modulate the sensitivity and expression of sensory neuronal TIH receptors 35 36
see Table 2 for TRPA1 modulators This could result in chronic or hypersensitive neurogenic inflammatory
3
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TOXIC INHALATION HAZARDS ACTIVATING THE SENSORY NEURONAL ION
CHANNEL TRPA1
Currently the therapy for acute exposures to reactive TIHs is their removal by dilution washing and chemical
neutralization the treatment of pain and inflammation with anti inflammatory medications and analgesics and
stabilization of the airways with bronchodilators 38 Morbidity from highlevel exposures to reactive TIHs can occur
after the initial structural damage Sensory neuron mediated inflammation may have role in pulmonary edema
pneumonitis and other complications of ARDS implicated in fatalities from highlevel exposures 30 Occupational
asthma can develop from reactive TIH exposure in workplace settings and this is usually treated by counteracting
the symptoms of airway inflammation and smooth muscle constriction Antagonists blocking TIH receptors and or
modulators of these receptors may provide novel therapeutics to alleviate the irritation and inflammation resulting
from acute exposures This may in turn abate the inflammation and pulmonary edema caused by highlevel
exposures and treat the chronic lung and airway diseases associated with reactive chemical inhalation
Noxious gases and other inhalation toxins are widely used and produced in the modern industrial world The ease
and low cost of manufacturing of these chemicals plus their high toxicity and relatively short half life make them very
beneficial as fumigants nematicides fungicides disinfectants and sanitizers in agriculture pest control disinfection
E cleaning and water purification industries Many TIHs are important reactants in metallurgy and in the organic
synthesis of plastics pharmaceuticals semiconductors and other materials Copious amounts of chlorine gas and
other TIHs are used for bleaching and chemical synthesis and large quantities of ammonia and nitric acid are used
2 for fertilizer production 2 39 TIHs are created as byproducts of water purification metal smelting and
combustion as well as by the interaction of combustion byproducts with ultraviolet light and oxygen in the air or
water 40 This includes oxides and other towns produced in welding and numerous other air pollutants from
industry automobiles smelters forest fires cigarette smoke and volcanoes2Workers in industrial custodial
agricultural and other occupations with low but frequent exposures to reactive TIHs as well as welders smokers
and people in areas of frequent air pollution often suffer from the chronic airway and lung diseases 4143
To maintain a supply for their use large volumes of TIHs are transported and stored sometimes near large
population centers Unfortunately accidental leaks from industrial facilities and transportation vehicles do occur The
resulting high concentration exposures to TIH have caused immediate largescale evacuations fatalities and severe
injuries of the lungs and other tissues in the survivors 44 The most infamous accident involving TIHs was the
3 tragedy of Bhopal India where thousands of residents died from exposure to methyl isocyanate 45 High
exposures of TIHs were used in chemical warfare especially in World War I and have since been outlawed by
international treaties Unfortunately rogue military regimes and terrorists have used gaseous warfare agents to
attack and indiscriminately kill and injure civilian populations 46 47
U7
Expectantly state federal and international law and agencies tightly regulate the use storage transportation
emissions and disposal of TIHs and the exposure levels allowed in the environment and the workplace The
executive agencies of the United States concerned with these regulations have classified and described the various
TIHs This information is accessible through the Material Safety Data Sheets the websites of the individual agencies
and the National Library of Medicine Toxicological Data Network ToxNet website http toxnetnlmihgov
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The occupational health database HazMap http hazmapnlihgovwithin ToxNet has classified about 220
chemicals as Toxic Gases and Vapors this group is not all the TIH for instance the database has 450 chemicals
that can induce pneumonitis In Table 1 these Toxic Gases and Vapors are loosely categorized by their chemistry






acetylcholine antagonists and acetylcholine esterase inhibitors Category 2 includes chemicals that deplete or
hinder oxygen from reaching the alveoli and thereby asphyxiate simple asphyxiates Category 3 included chemicals
that target metal ions in vital enzymes cytochrome c oxidase hemoglobin and other metalloproteins cyanides
aliphatic nitriles metalloid hydrides and carbon monoxide The cyanide anion is a nucleophile that readily forms
nitriles This reaction is readily reversible in biological systems for most aliphatic nitriles thereby producing cyanide
3 but less reversible for aromatic nitriles 48 49 Category 4 includes chemicals that induce severe blistering
including blistering and damage to the airways arsines and mustard gases Some of these vesicants are only
detectable by their odor and the blistering effects do not occur until hours after exposure Category 5 includes
co
chemicals that react indiscriminately with most biological molecules These can be further categorized by the type of
chemical reactant acids corrosive gases oxidants reducers electrophiles and nucleophiles and the type of
chemical isocyanate halogen Some chemicals belong to multiple subcategories and members of a category may
differ in their chemical properties but react in a manner similar to other members of the category For example often
acid halides will produce an alkylation of a protein and a strong acid both contributing to the toxicity Members of the
reactive chemical subcategories usually induce similar symptoms irritation pneumonitis and pulmonary edema
Only a few sensory neuron ion channels are responsible for detecting most of the TIHs and initiating many of their
symptoms TIHs activate these channels by forming chemical reactions with them Therefore TIHs that form similar
















Olfactory and Gustatory Chemoreceptors
The major sensations induced by exogenous chemicals are smell detected by olfactory neurons taste detected by
the taste receptor cells in the taste buds and pungency irritationp n that are mediated by peripheral sensory
neurons 50 Most TIHs are associated with an odor and many elicit a taste sensation such as the sour taste of
acids and the bitter taste of cyanide In addition to being an important aspect of consciously identifying TIHs odors
and tastes may have a role in initiating peripheral physiological responses This is probably a more important
mechanism in animals with more sophisticated olfactory systems than humans such as rodents and certain insects
51 The odors of the volatile organic sulfur compounds and some other TIHs are innately repulsive and nauseating
52 However this repulsive sensation can desensitize with continued exposure and toxic exposures have occurred
without victims becoming aware of the presence of the sulfide compound 53 Certain TIHs have an agreeable smell
and elicit no acute noxious sensations so their avoidance behavior has to be learned For example the faint and
agreeable odor of certain nerve gases is the only physiological mechanism to recognize them until the
hypercholinergic effects occur 54 Carbon monoxide some simple asphyxiates and the chemical weapon
quinuclidinyl benzilate BZ are odorless and can go undetected until victims show effects from their toxicity 2
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The chemoreceptors for odors are specific ligandgated G protein coupled receptors GPCRs on olfactory neurons
that stimulate adenylate cyclase to synthesize cAMP via a G protein called Golf Insects also express ion channel
odorant receptors 55 The receptor for bittertasting chemicals is the GPCR TAS2Rn which is coupled with the G
protein gustducin Interestingly these receptors are also expressed in the motile cilia of the airway epithelium The
asubunit of gustducin facilitates the activity of cAMP phosphodiesterase by binding inhibitory subunits and thereby
decreasing intracellular cAMP levels while the R subunit activates PLC R2 and subsequently increases intracellular
Ca The rise in Ca gates the monovalent TRP ion channel TRPMS This produces a bitter taste sensation
mediated by the taste buds and increases the activity of cilia to expel mucous bound toxin up and out of the lung
5658
3
J The acidity invoked sour sensation is not completely understood at the receptor level It is likely due to H and H3O
cations activating specific ion channels Different acid receptor proteins have been proposed including members of
co the ASICs a sub family of the amiloridesensitive Na channels hyperpolarizationactivated cyclic nucleotidegated
r K channels HCNs 2pore domain K leak conductance channels and the TRP ion channel TRPP3 and its partner
PKD1 L3 59 It is possible that ASIC channels are directly activated by low pH while TRPP3 and PKD1 L3 are
primed by acidity and subsequently activated by return to physiological pH 60 61
Sensory Neuron Chemoreceptors
Most TIHs 8090 of theTIHs in HazMap are reactive chemicals and produce similar sensations of a pungent
burning irritation and pain by activating chemoreceptor sensory neurons The airway mucosal epithelium is densely
innervated with projections from the peripheral nerves of the somatic sensory system including two nerve fiber types
involved in chemical nociception 62 These fibers are anatomically distinguishable from each other by their diameter
and degree of myelination A6 fibers have a slightly larger diameter and are encased in thin myelin sheaths while
the Cfiber neurons are unmyelinated with smaller diameters Activation of Ab fibers nerves produces a fast sharp
3 pain sensation while the slow velocity Cfiber activation induces a slow burning pain In the respiratory system
i these fibers correspond through the trigeminal or vagus nerve with brainstem nuclei to coordinate sensations This
results in reflexes and responses to deter further inhalation expel toxicants by coughing and sneezing dilute and
j neutralize reactive toxins by parasympathetic glandular secretions and alter breathing patterns and other brain
mediated airway responses to reactive TIHs 10 1621 In rodents TIHs activation of sensory neurons induces a
decrease in respiratory rate by increasing the pause between individual breaths This is used as a common model to
measure and determine respiratory irritation by TIHs 16 18 63
Reactive TIHs also induce peripheral endings of Cfiber neurons to secrete peptides and other molecules at and near
the site of contact such as Substance P SP and calcitonin gene related peptide CGRP SP preferentially binds to
the tachykinin receptor NK1 receptors while CGRP binds to calcitonin receptorlike receptor CRLR coupled with
the receptor activity modifying protein RAMP1 or 3 NK1 receptors are GPCRs coupled to the Gq subunit which
actives PLC and increases intracellular Ca CGRP receptors CRLRRAMP are coupled to the Gs subunit which
activates adenylate cyclase increasing intracellular CAMP These peptide receptors show partially overlapping
expression patterns In certain instances their actions are synergistic while in other instances they counteract each
other 34 64 65 Extensive studies on SP and CGRP have shown that they are predominantly proinflammatory
factors that increase bronchoconstriction immune cell infiltration vasodilation mast cell degranulation plasma
extravasation and other local inflammatory responses 34 The acute pneumonitis from certain reactive TIHs most
likely has a neurogenic inflammatory component Possibly the pulmonary edema resulting from reactive TI H
co
a exposure also has a sensory neuronal component Substance P and CGRP have been proposed to be involved in the
pathology of allergic asthma 66 67 Occupational asthma and reactive airway dysfunction syndrome may also
have a neurogenic inflammatory component 68
Acid Sensing ASICs
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he che oreceptors for rs re s ecific li and-gated  r t i -- upled r t r  (GP ) n lf ctory r  
that sti ulate adenylate cyclase to synthesize cA P via a  protein called olf. Insects also express ion channel 
odorant receptors (55). The receptor for bitter-tasting che icals is the  2 n, hich is coupled ith the  
protein gustducin. Interestingly, these receptors are also expressed in the motile cilia of the airway epithelium. The 
a-subunit of gustducin facilitates the activity of cA P phosphodiesterase by binding inhibitory subunits and thereby 
decreasing intracellular cA P levels, while the l3-subunit activates PLC 132 and subsequently increases intracellular 
2+.  ri  in a2+ t  t  l t  i  l 5. i  r uces  itt r t t  ti  




;! The acidity-invoked sour sensation is not co pletely understood at the receptor level. It is likely due to H+ and 30 + 
~ c ti s ctivating s cific i  c ls. iff r t ci  r c t r r teins v   r s , i cl i  rs f 
" g: the ASICs (a sub-family of the amiloride-sensitive Na + channels), hyperpolarization-activated cyclic nucleotide-gated 
" K+ channels (H s), 2-pore do ain K+ leak conductance channels, and the T P ion channel T PP3 and its partner 
1 L3 (59). It is possible that I  channels are directly activated by lo  p , hile T 3 and 1 L3 are 
ri   i it , d tly ti t   r t r  t  i l i l  (60, 1). 
Sensory euron he oreceptors 
ost TI s (80-90% of theTI s in az-Map) are reactive che icals and produce si ilar sensations of a pungent 
"burning" irritation and pain by activating chemoreceptor sensory neurons. The airway mucosal epithelium is densely 
innervated with prOjections fro  the peripheral nerves of the so atic sensory syste , including two nerve fiber types 
i l  i  i l i ti  (6 ).  fi r  r  t i ll  i ti i l  fr   t r  t ir i t r 
and degree of myelination. A-5 fibers have a slightly larger diameter and are encased in thin myelin sheaths, while 
"3 t  -fiber r s r  y li t  it  s ll r i t rs. ctiv ti  f -5 fi rs rv s r c s  f st, s r  
,-, 
§' pain sensation, while the slow velocity C-fiber activation induces a slow "burning" pain. In the respiratory system, 
;! these fibers correspond through the trige inal or vagus nerve with brainste  nuclei to coordinate sensations. This 
~ r lt  i  r fl   r  t  t r f rt r i lation, l t i t   i   i g, il t   
~ neutralize reactive toxins by parasy pathetic glandular secretions, and alter breathing patterns and other brain-
>:) 
<"> ediated air ay responses to reactive I s (10, 16-21). In rodents, I s activation of sensory neurons induces a 
cr s  i  r s ir t ry r t  y i cr si  t  s  t  i ivi l r t s. is is s  s  c  l t  
easure and deter ine respiratory irritation by TIHs (16, 18,63). 
Reactive TIHs also induce peripheral endings of C-fiber neurons to secrete peptides and other molecules at and near 
t  sit  f c t ct, s c  s st c   (S )  c lcit i  -r l t  ti  ( P).  r f r ti lly i s t  
the tachykinin receptor NK1 receptors, while CGRP binds to calcitonin receptor-like receptor (CRLR) coupled with 
the receptor activity odifying protein (RA P1 or 3). NK1 receptors are PCRs coupled to the q subunit, which 
   i  i  a2+.  r t r  (C +RA ) r  l  t  t   nit, i  
activates adenylate cyclase, increasing intracellular cAMP. These peptide receptors show partially overlapping 
2? expression patterns. In certain instances their actions are synergistic, while in other instances they counteract each 
; other (34,64,65). Extensive studies on SP and CGRP have shown that they are predominantly proinflammatory 
~ factors that increase bronchoconstriction, i une cell infiltration, vasodilation, ast cell degranulation, plas a 
~ extravasation, and other local infla atory responses (34). The acute pneu onitis fro  certain reactive TIHs ost 
:'=: likely has a neurogenic infla atory co ponent. Possibly, the pul onary ede a resulting fro  reactive TI  
CJ) 
g exposure also has a sensory neuronal component. Substance P and CGRP have been proposed to be involved in the 
pathology of allergic asthma (66,67). Occupational asthma and reactive airway dysfunction syndrome may also 
have a neurogenic inflammatory component (68). 
cid ensing: I s 
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Acidic TIHs stimulate both A6 and Cfiber sensory neurons This results in acidic TIH induction of a sharp immediate
pungent pain and reflexlike breath withdrawal as well as burning pain pneumonitis coughing mucus secretion and
other responses 6971 Cfibers appear to have at least two distinct electrophysiological currents sensitive to
acidic pH suggesting at least two distinct ion channel populations responding to acidic stimuli An influx of Na occurs
at pH levels slightly below the homeostatic level that rapidly inactivates and a mixed Ca Na influx occurs at more
acidic conditions Various combinations of splice variants of the three members of the ASIC ASIC1a ASIC1 b
ASIC2a ASIC2b and ASIC3 family of ion channels appear to be responsible for the first currents These channels
are expressed in both A6 and Cfiber sensory neurons and show similar electrophysiological properties in
heterologous expression systems with conducting Na currents induced between pH 6 and 7 that rapidly inactivate
3 Different combinations of subunits and splice variants of the three ASIC genes may explain the observed differences
in kinetics and pH sensitivity in native neurons 59
co AcidSensing Ion Channels TRPV1
At lower pH 5 the nonspecific cation channel TRPV1 is activated in sensory neurons 72 While the various
heteromeric combinations of ASICmediated acid sensitive channels are ubiquitous in both chemosensory fiber
types the splice variant and subtype distribution of ASICs have some specificity TRPV1 like acidsensitive currents
are primarily observed in unmyelinated Cfiber neurons 59 These currents correlate with TRPV1 expression and
the currents are not observed in the sensory neurons of mice devoid of TRPV1 While TRPV1 is activated at
relatively low pH inflammatory mediators and injury signals can augment the sensitivity of TRPV1 to acidity and
acidity can in turn hypersensitize TRPV1 73 While it is unlikely that the pH in the lung would drop low enough to
activate TRPV1 during inhalation of a TIH repeated inhalation or underlying inflammation may facilitate TRPV1 to
become hypersensitive and therefore triggered by an exposure to a gaseous acid 7380 For instance TRPV1 is
0 sensitized by the potent proinflammatory signal bradykinin 81
0
TRPV1 is well established to have a crucial role in the nociception of heat It is the site of action for the active
iingredient in chili peppers capsaicin There are symptom similarities between highlevel exposures to capsaicin as
C
pepper spray OC tear gas and exposures to reactive chemical TIHs However studies of TRPV1 gene deleted
mice still show normal irritant responses to TIHs mediated by sensory neurons 82
Most C fibers express either TRPV1 8090 or the cold activated ion channel TRPM8 8 TRPM8 is sensitive
to cool temperatures and is at least partially responsible for the sensation elicited by cool temperatures and by
menthol and related compounds Similar to TRPP3 and TRPM5 these proteins belong to the Transient Receptor
Potential TRP superfamily of cation channels TRP proteins are believed to form tetrameric cation channels in a
manner similar to the voltagegated K channels with six transmembrane spans and an ion selectivity filterpore
between the fifth and the sixth span Both the amino and carboxyl terminal spans are cytosolic Most TRP channels
conduct and are regulated by calcium ions Predictably their physiological functions often correlate with the dynamic
roles that calcium performs in cells organisms and disease especially in sensing and signaling 83
Oxidant and Electrophile Sensing TRPA1
TRPA1 a nonspecific cation channel expressed in 304 of the TRPV1 expressing Cfiber neurons is directly
activated by volatile reactive organic electrophiles or oxidative agents 40 TIHs on HazMap site shown in Table 1
84 This has been demonstrated in vitro and in vivo in numerous publications using TRPA1 gene deleted mice or
treatments with TRPA1 antagonists Table 2 provides a relatively inclusive list of all the TIHs and related chemicals
cn
found thus far to activate TRPA1 However TRPA1srole in the airway responses to many of these reactive
chemical TIHs has yet to be characterized The most potent and specific TRPA1 agonists characterized so far are
the CS CR and CNtear gases riot control agents 85 86 These agents appear to target TRPA1 to induce
their intended effects of incapacitating pain glandular secretions coughing acute neurogenic inflammation and other
symptoms associated with exposures to reactive chemical TIHs
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~ TRPA 1, a nonspecific cation channel expressed in 30-40% of the TRPV1-expressing C-fiber neurons, is directly 
~ activated by volatile reactive organic electrophiles or oxidative agents (-40% TI s on az-Map site sho n in Table 1 
g- ) (84). This has been de onstrated in vitro and in vivo in nu erous publications using T 1-gene deleted ice or 
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che ical TI s has yet to be characterized. The ost potent and specific T PA 1 agonists characterized so far are 
the S-, -, and -tear gases (riot control agents) (85, 86). These agents appear to target T PA1 to induce 
their intended effects of incapacitating pain, glandular secretions, coughing, acute neurogenic infla ation, and other 
sy pto s associated ith exposures to reactive che ical I s. 
1211201  7:32  
Sensory Detection and Responses to Toxic Gase http wncbilntinihgovpmcarticlesPMC3136963
Just before the first putative transmembrane span of TRPA1 a short protein moiety is located containing three





TIHs It is believed that covalent modification of these residues leads to activation of the channel although additional
residues have been shown to also be involved 8789 Figure 1 shows the likely modification of cysteine residues by
certain types of TIH molecules that are electrophiles or oxidants As mentioned some of these reactive organic
molecules have yet to be examined for activity on TRPA1 9092 Most likely if the molecule can form covalent
bonds with the cysteine residues of glutathione then it will also react with the cysteines in the covalent modification
binding site and thereby activate TRPA1 and the C type sensory neuron Interestingly ammonia also activates
TRPA1 probably through alkalinization of the cytosolic spans 93
Figure 1
Chemical structure drawings representing the possible interaction of a cysteine at the TRPA1
covalent modification binding site and a toxic inhalation hazard chemical Each of the reactions
shown is with a chemical known to activate more
Similar to many TRP channels TRPA1 conducts both divalent and monovalent cations TRPA1carried cations
depolarize the membrane thereby activating voltagegated Na and Ca2 channels to propagate action potentials
and consequentially signal the spinal and brainstem nerves to initiate reflexes and autonomic and other protective
responses of the airways and the lungs 94 In TRPA1 deficient Trpa1 I mice or mice treated with a TRPA1
3 antagonist pain neurogenic inflammation bronchial constriction and respiratory depression in response to reactive
chemicals are absent or abated see Table 2 second to last row Activation of TRPA1 also results in the secretion
of proinflammatory factors such as Substance P and CGRP 95 Neuronal peptide release is thought to be triggered
v by the influx of Ca into the airway nerve ending either directly through TRPA1 or by TRPA1triggered
voltagegated Ca channels However other mechanisms may be involved About half of TRPA1s amino acid
sequence is dedicated to a span of about 17 ankyrin repeat domains on the amino terminal span that may interact
with signaling complexes and the vesicle release machinery
Some of the necrotic cellderived factors and mediators released as a consequence of chemical injury and
inflammation modulate the sensitivity and activity of TRPA1 see Table 2 Hyperactive or hypersensitive TRPA1
channels may contribute to chronic bronchitis occupational asthma and other inflammatory lung diseases associated
with exposures to reactive TIHs 96 TRPA1 is crucially involved in allergenic respiratory sensitivity to ovalbumin an
inducer of allergic asthma in animal models 97 These findings show that airway sensory neurons actively modulate
the local immune response to allergens
Z Phosgene Ozone and Nitrogen Dioxide
The relatively hydrophobic reactive chemicals phosgene ozone and nitrogen dioxide do not readily diffuse through
the mucus and epithelium to reach underlying sensory nerve endings 2 Therefore they are usually not detected by
8 sensory neurons and do not trigger defensive responses thereby permitting the toxicants to penetrate more deeply
t
into the lungs to the delicate alveolar sacs The inability of the chemosensory system to detect these hydrophobic
TIHs may compound the damage these chemicals inflict in the respiratory system An additional factor to their
toxicity is that hydrophobic TIHs do not readily interact with the aqueous compounds in the airway fluids that
sequester and neutralize reactive chemicals
HLAL I M tFPEG US UP TIMS AND GUUNTERMEASURES
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The TIHs can be loosely grouped into those that are reactive chemicals and those that are not The major sensations
to nonreactive TIHs are smell and taste or a lack of any sensation The sense of smell is important to recognize the
danger so the appropriate protective measures can be made In addition to having an odortaste associated with
them most of the reactive TIHs activate specific receptors on the somatosensory peripheral nerves of the airways
The receptors for the reactive TIHs may become hyperactive hypersensitive or overexpressed As summarized
above these receptors are cation channels that stimulate the sensory nerves to initiate a variety of physiological
responses including local neurogenic inflammation and reflexmediated responses such as bronchospasms mucus
hypersection coughing and central sensations such as pain Therefore hyperactive or hypersensitive channels may
cause continuous or hypersensitive inflammation airway resistance coughing and pain and possibly contribute to
3 chronic inflammatory lung diseases Targeting these ion channels may not only alleviate the acute effects from




The sensory neuronal receptors for the reactive TIHs have been identified Slight acidity activates ASIC Na
channels while stronger acidity activates TRPV1 Ca Na conducting channels The ASIC channel antagonist
amiloride might be effective in treating people exposed to acidic TIHs and more specific antagonists have been
developed 98 In the last few years the pharmaceutical industry has produced several potent TRPV1 antagonists
with hopes of treating aliments such as chronic cough chronic pain and arthritis However the role of TRPV1 in heat
sensitivity and its apparent function in the regulation of body core temperature caused potentially detrimental side
effects 99 100 Topical and acute applications such as an aerosol spray of TRPV1 antagonists may minimize
these side effects while being efficacious in treating airway irritation and inflammation TIHs that are electrophils and
oxidants activate the Ca Na channel TRPA1 Antagonists to TRPA1 have been discovered but are in the early
phases of research and development and are currently not ready for clinical use 101 103 Rodents treated with
these antagonists have shown reduced nociception and inflammatory peptide release in response to reactive TIHs
see Table 2
Inflammatory mediators resulting from tissue injury immune challenge or other sources can modulate TRPA1
TRPV1 and other sensory neuron ion channels Current therapies for reactive TIH induced airway irritation and
inflammation target these mediators and include methyl xanthines as well as steroidal and nonsteroidal
antiinflammatory drugs Perhaps part of these medications therapeutic effect is to diminish the modulation and
facilitation of reactive TIH receptors
Activation of TRPA1 TRPV1 AISCs and other C fiber ion channels can induce the release of proinflammatory
peptides such as SP and CGRP These peptides mediate many of the sensory neuron inflammatory effects and
may have a role in the asthmatic like symptoms seenwith frequent lowlevel exposures to TIHs CGRP antagonists
are used in treating migraine headeaches and may also prove beneficial to decrease neurogenic inflammation in the
airways
T
In summary most toxic gases and vapors are detected by olfactory neurons and taste receptor cells Those that are
reactive chemicals are detected by the peripheral sensory neurons by activating TRPV1 TRPA1 or ASIC ion
channels TIH receptors The activation of these channels induces neurogenic inflammatory and brain mediated
J responses of the airways These responses compromise breathing and can lead to disease states if they persist
0
i The TIH receptors and the sensory neurons may be hypersensitized leading to disorders of hypersensitive or
g chronic airway inflammation and cough The channels may have a role in the pulmonary edema and other aspects of
ARDS seen with highlevel exposures to reactive TIHs Therefore targeting these channels may provide novel
treatments to alleviate TIH induced irritation airway inflammation disorders of chronic airway inflammation cough
and perhaps even the ARDS seen with highlevel exposure
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'"' i!] chronic air ay infla ation and cough. The channels ay have a role in the pul onary ede a and other aspects of 
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Hyperinnervation of the Airways in Transgenic Mice Overexpressing
Nerve Growth Factor
GaryW Hoyle Regina M Graham Jeffrey B Finkelstein Kim Phuong Thi Nguyen David Gozal
andMitchell Friedman
Section of Pulmonary Diseases Critical Care andEnvironmental Medicine Department of Medicine and Pediatrics Tulane
University Medical Center TulaneXavier Center for Bioenvironmental Research New Orleans and Graduate Program in
Molecular and Cellular Biology Tulane University New Orleans Louisiana
Neuropeptides released from sensory nerve endings are potential mediators of airway inflammation in
asthma and lung injury induced by inhalation of respiratory irritants To develop an in vivo model for as
sessing the contribution of neurogenic inflammation in these processes we have generated transgenic mice
with altered innervation of the lung To generate mice with an increased innervation of the airways we
placed the gene that encodes nerve growth factor NGF under control of the lung specific Clara cell
secretory protein CCSP promoter Two lineages of CCSPNGF transgenic mice overexpressed NGF in
the lung and developed a hyperinnervation of the airways Immunohistochemistry for substance P a sub
stance P enzyme immunoassay and catecholamine histofluorescence indicated that both tachykinincon
taining sensory fibers and sympathetic fibers were increased around the airways of CCSPNGF mice
Treatment of CCSPNGF mice with the sympathetic specific neurotoxin 6hydroxydopamine 6OHDA
eliminated the sympathetic component of the airway innervation leaving a specific hyperinnervation by
tachykinincontaining sensory fibers CCSPNGF mice were more sensitive than normal mice to capsai
cininduced increases in respiratory system resistance demonstrating that the increased sensory innerva
tion led to a change in airway function We conclude that NGF overexpression from a lungspecific promoter
produces anatomic and functional changes in lung innervation and that CCSPNGF mice will be useful for
studying the role of neurogenic inflammation in airway disease Hoyle G W R M Graham J B
Finkelstein KPT Nguyen D Gozal and M Friedman 1998 Hyperinnervation of the airways in
transgenic mice overexpressingnervegrowth factor Am J Respir Cell Mol Biol 1849157
Asthma is characterized by reversible airway obstruction
airway inflammation and increased sensitivity to bron
choconstricting stimuli Inhalation of respiratory irritants
can produce persistent asthmalike symptoms or exacer
bate existing asthma 1 2 Through its ability to release
inflammatory mediators and modulate smooth muscle
tone the nervous system is likelyto play an important role
in the pathogenesis of asthma and irritant induced lung in
jury One potentially important mechanism in these pro
cesses is the release of tachykinin neuropeptides from air
Received in original form October 8 1996 and in revised form April 29
1992
Address correspondence to Gary W Hoyle PhD Section ofPulmonary
Diseases Critical Care and Environmental Medicine Department of
Medicine SL9 Tulane University Medical Center 1430 Tulane Avenue
New Orleans LA 70112 Email ghoyle@tmctulanedu
Abbreviations Claracell secretory protein CCSP glyceraldehyde 3 phos
phate dehydrogenase GAPDH nerve growth factor NGF 6hydroxy
dopamine 6 OHDA respiratory system resistance R
Mn J Respir Cell Mol Biol Vol 18 pp 14957998
way sensory nerves 3 Tachykinins including substance
P neurokinin A and neurokinin B are released from sen
sory nerve fibers known as Cfiber afferents by stimuli
such as volatile organic compounds 4 ozone 5 and al
lergens 6 Tachykinins bind to neurokinin receptors pres
ent on a variety of cell types in the lung and mediate ef
fects such as bronchoconstriction 7 mucus secretion 8
microvascular leakage 9 chemotaxis and activation of
inflammatory cells 1012 and stimulation of cytokine
production 13 Paradoxically tachykinins have also been
reported to mediate bronchodilation and to limit irritant
induced airway inflammation 1416
Tachykinin levels may be altered in inflammatory states
in human lung and tachykinins have been implicated as me
diators of inflammation in animal models In humans in
creased airway or serum levels of substance P have been de
tected in asthmatic individuals challenged with allergen 6
or hypertonic saline 17 in asthmatic individuals during
spontaneous asthma attacks 18 and in normal individu
als after ozone inhalation 5 In animal studies tachyki
nins have been implicated in allergen and ozone induced
001872
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Asthma is characterized by reversible airway obstruction, 
airway inflammation, and increased sensitivity to bron-
choconstricting stimuli. Inhalation of respiratory irritants 
can produce persistent asthma like symptoms or exacer-
bate existing asthma (1, 2). Through its ability to release 
inflammatory mediators and modulate smooth-muscle 
tone, the nervous system is likely to play an important role 
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ay sensory nerves (3). achykinins, including substance 
, r i  ,  r ki  ,    en-
sory nerve fibers kno n as C-fiber afferents by sti uli 
such as volatile organic compounds (4), ozone (5). and al-
lergens (6). achykinins bind to neurokinin receptors pres-
t   ri t  f cell t s i  t  l   i t  ef-
f t    constri ti  (7),  secreti  (8). 
icr asc lar lea a e (9), c e ta is a  acti ati  f 
infla atory cells (10-12). and sti ulation of cytokine 
production (13). ParadOXically, tachykinins have also been 
reported to ediate bronchodilation and to li it irritant-
i  i  i l ti  (14-1 ). 
achykinin levels ay be altered in infla atory states 
in hu an lung, and tachykinins have been i plicated as e-
i  f i ti  i  i l odels.  u ans, i -
creased air ay or seru  levels of substance  have been de-
tecte  i  asthmatic i i i als challe ed it  aller e  (6) 
or hypertonic saline (17), in asth atic individuals during 
spontaneous asth a attacks (18), and in nor al individu-
l  ft   i l ti  (5).  ni l studies, tachyki-
i s   i li t  i  ll rgen-  -i  
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plasma extravasation as well as airway reactivity to aller
gen and nonspecific bronchoconstrictors such as histamine
1924 In other studies however depletion of sensory
neuropeptides by chronic capsaicin treatment has been re
ported to either be without effect on these processes or to
exacerbate inflammatory effects suggesting a protective
role for tachykinins 1416 2527
Because of the controversy about the function of tachy
kinins during periods of lung injury and inflammation a
method for manipulating the amount of Cfiber afferent
innervation that the lung receives would be valuable As a
novel approach to examining the role of tachykinins in air
way inflammation and hyperreactivity we have manipu
lated the innervation of the airways in transgenic mice by
overexpressing nerve growth factor NGF NGF is se
creted by neuronal target tissues and affects the develop
ment of a subset of peripheral nervous system neurons
including tachykinin containing sensory neurons 28 Dur
ing development NGF has multiple effects on responsive
neurons including promotion of survival induction of ax
onal outgrowth and branching and chemoattraction of grow
ing axons 28 29 Transgenic mice overexpressing NGF
from tissue specific promoters exhibit localized hyperinner
vation around the sites of NGF expression 29 30 Here
we report that lung specific expression of NGF in trans
genic mice driven by the Claracell secretory protein CCSP
promoter results in a hyperinnervation of the airways
These transgenic mice represent a novel model for study




Mice were housed in an AAALAC Association for As
sessment and Accreditation of Laboratory Animal Care
accredited facility according to National Institutes of
Health NIH guidelines and were specific pathogenfree
Mice were maintained on a 14 h light10 h dark schedule
and given food and water ad libitum Transgenic mice
were generated and maintained on a mixed genetic back
ground derived from the C57BL6 and SJL inbred strains
Generation of CCSPNGF Transgenic Mice
A 24kb DNA fragment from the 5 flanking region of the
rat CCSP gene was isolated with the polymerase chain reac
tion PCRThe upstream PCRprimer of sequence 5 CGC
GGATCCTCTGTGCAGCAGAGGGTGCACAC3con
tained bases 2301 to 2278 of the CCSP gene numbered
as in 311 and a flanking BamHI site The downstream
PCR primer of sequence5GGATCGTCGACGATG
TGGGCTGATGTTGTAATGTGAGG3contained CCSP
bases 15 to 41 and a flanking Sall site These primers were
used to amplify from rat DNA a 24kb fragment that was
cloned into the BamHI and Sall sites of Bluescript II KS
Stratagene La Jolla CA The NGF coding sequence is
derived from the human NGF gene and consists of bases
9084 Genbank numbering to the EcoRI site at the 3 end
of clone XhRN8 32 Insulin sequences were derived from
the rat insulin II gene and consisted of bases 6 to 177
33 The CCSPNGF DNA construct was assembled in
the Bluescript vector and then linearized and cut free
from vectorsequences for microinjection
Transgenic mice were generated by microinjection of
the linear CCSPNGFDNA fragment into fertilized mouse
eggs derived from matings between B6SJLF hybrids as
described 34 Mice that developed from injected eggs
were screened for the presence of the transgene byhybrid
ization of tailbiopsy DNAwith a transgene specific probe
consisting of sequences from the human NGF gene Five
transgenic foundermice carrying the CCSPNGF gene were
identified in this manner and were bred to B6SJLF hy
brids to generate transgenic offspring for analysis
RNA Analysis
RNA was prepared from tissue samples by acid phenol ex
traction or by ultracentrifugation through cesium chloride
35 RNA was subjected to Northern blot analysis 36
with a probe derived from the human NGF gene that does
not hybridize with mouse NGF sequences under the con
ditions used or from the rat glyceraldehyde 3phosphate
dehydrogenase GAPDH gene which does hybridize with
mouse sequences and serves as a loading control
Histologic Histochemical and
Immunohistochemical Analysis
For histologic analysis lungs were fixed by intratracheal
instillation of 10neutral buffered formalin at a pressure
of 25 cmH for 30 min at room temperature followed by
fixation by immersion overnight at 4C Lungs were em
bedded in paraffin and sectioned at 5 m Immunohisto
chemistry was done with an immunoperoxidase technique
similar to that recently described 37 Rabbit polyclonal
antibody to synaptophysin Dako Carpinteria CA was
used at a dilution of100 and rat monoclonal antibody to
substance P clone YMC1021 Accurate Westbury NY
was used at a dilution of150 Bound antibodies were de
tected with biotinylated goat antirabbit or antirat IgG Jack
son ImmunoResearch West Grove PA diluted 14000
followed by streptavidin conjugated horseradish peroxi
dase Jackson ImmunoResearch diluted 12000 500 ngml
After incubation with diaminobenzidine DAB as a chro
mogen slides were counterstained with hematoxylin Cat
echolamine histofluorescence was produced by reacting fro
zen tissue sections with glyoxylic acid as described 29 38
SubstanceP Assays
Substance P was measured in lung homogenates of CCSP
NGF and normal micewith an enzyme immunoassay Lungs
were collected weighed minced and boiled for 10 min in
2 ml of4acetic acid After boiling lung tissue was homo
genized and the homogenate was centrifuged at 1900 x g
for 20 min Supernatants were applied to Sep Pak C18 re
versed phase columns Waters Associates Milford MA
and washed with 6 ml 4acetic acid Substance P was
eluted from the columns with 3 mlethanolwateraceticacid
366404The eluates were evaporated to dryness under
vacuum and redissolved in 04ml water Substance P was
measured in aliquots of the samples using a commercially
available enzyme immunoassay Cayman Chemical Ann
Arbor MI according to the manufacturer instructions
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plasma extravasation as ell as air ay reactivity to aller-
gen and nonspecific bronchoconstrictors such as histamine 
(19-24). In other studies, ho ever, depletion of sensory 
neuropeptides by chronic capsaicin treat ent has been re-
ported to either be ithout effect on these processes or to 
exacerbate infla atory effects, suggesting a protective 
role for tachykinins (14-16, 25-27). 
ecause of the controversy about the function of tachy-
kinins during periods of lung injury and infla ation, a 
ethod for anipulating the a ount of -fiber afferent 
innervation that the lung receives would be valuable. As a 
novel approach to examining the role of tachykinins in air-
way infla ation and hyperreactivity, we have anipu-
lated the innervation of the air ays in transgenic ice by 
overexpressing nerve growth factor (NGF). NGF is se-
creted by neuronal target tissues and affects the develop-
ent of a subset of peripheral nervous syste  neurons, 
i l in  t inin-c t i ing s s r  r s (2 ). r-
ing develop ent, F has ultiple effects on responsive 
neurons, including promotion of survival, induction of ax-
onal outgrowth and branching, and chemoattraction of grow-
ing axons (28, 29). Transgenic mice overexpressing NGF 
from tissue-specific promoters exhibit localized hyperinner-
vation around the sites of NGF expression (29, 30). Here 
we report that lung-specific expression of NGF in trans-
geniC mice, driven by the Clara-cell secretory protein (CCSP) 
promoter, results in a hyperinnervation of the airways. 
These transgenic ice represent a novel odel for study-
ing the role of neurogenic inflammation in irritant-and al-
lergen-induced airway disease. 
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available enzy e i unoassay ( ay an hemical, nn 
Arbor, I) according to the manufacturer's instructions. 
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6Hydroxydopamine Treatment
Mice were treated with 6 hydroxydopamine 6OHDA
as described previously for rats 39 6OHDA was dis
solved in normal saline containing 1 mgml ascorbic acid
and was injected subcutaneously at 100 mgk The drug
was injected on the day of birth postnatal day 1 and on
postnatal days 3 5 8 and 13 Parallel sets of animals re
ceived injections of saline containing 1 mgml ascorbic acid
vehicletreated controls After the treatment mice were
allowed to grow to adulthood before killing and analysis of
lung innervation
Respiratory Measurements
Total respiratory system resistance RJ was measured in
conscious spontaneously breathing mice placed in a cali
brated dual chamber plethysmographic system Buxco
Electronics Troy NY in which an airtight seal was ap
plied at the level of the neck of the animal Ventilatory
measurements corresponding to the thoracic and nasal com
partments were acquired separately using the methods
described by Bartlett and Tenney 40 and Pappenheimer
41 At least 15 min prior to the start of each protocol an
imals were allowed to acclimate to the chamber through
which room air was passed at a rate of 1 litermin using a
precisionflow pumpreservoir system Pressure changes
in each chamber caused by inspiratory and expiratory tem
perature changes were measured with a highgain differ
ential pressure transducer Model MP451 Validyne Inc
Northridge CA Analog signals were continuously digi
tized and analyzed online by a microcomputer software
program Buxco Electronics A rejection algorithm in
cluded in the breathbybreath analysis routine allowed
for accurate rejection of motion induced artifacts The
phase shift between the thoracic and nasal displacement
flows was measured from the Lissajous loop presentation
and R was computed in a breathbybreath mode using a
modification of the method described by Pennock and col
leagues 42 Computed Rr5 values were stored for subse
quent offline analysis After stable R baseline measure
ments were obtained for each animal increasing doses of
aerosolized capsaicin 0 10 33 100 330 and 1000 gml
were delivered for 2 min using a Devilbiss 646 nebulizer
Devilbiss Somerset PA at a constant airflow of 5 liters
min and R was measured over a 5 min period after each
dose Capsaicin dose response curves for CCSPNGF n
7 and control n 5 micewere significantly different P
01 analysis of variance ANOVA and were used to
determine the concentration of capsaicin inducing a 50
increase in Rrs PC50
Results
Generation of CCSPNGF TransgenicMice
The DNA construct used to generate CCSPNGF trans
genic mice contained a 24kb fragment from the 5 flank
ing region of the rat CCSP gene fused to the human NGF
coding region Figure 1 The rat CCSP promoter frag
ment has been previously shown to direct expression of
transgenes specifically to airway epithelial cells in mice
31 43 The coding sequence of NGF contains the entire
translated sequence and 1 kb of 3 untranslated sequence
151
Figure 1 CCSPNGF DNA construct CCSP sequences solid
are derived from the rat CCSP gene 31 and consist of bases
2301 to 41 relative to the transcription initiation site Insulin
sequences shaded are derived from the rat insulin II gene and
consist ofbases 6to 177 33 Thin line indicates intronic se
quences that are removed during splicing NGF sequences
striped are derived from the human NGF gene and consist of
bases 9084 Genbank numbering to the EcoRI site at the 3 end
of cloneXh3N8 32
but lacks most of the 5 untranslated sequence 29 The
CCSP NGF construct also has an introncontaining 5 un
translated sequence from the rat insulin II gene upstream
from the NGF fragment The insulin sequence was in
cluded because the presence of introns increases the effi
ciency with which DNA constructs are expressed in trans
A 1 2 3 4 5
NGF
GAPDH
B S U I KTLuH BM S U I KTLuH B M
NGF
GAPDH
Figure2 Analysis of transgene message A Northern blot anal
ysis of lung RNA for transgene message RNA was prepared from
the lungs of transgenic mice from the four CCSPNGF lineages
and from an agematched nontransgenic mouse by acid phenol
extraction 35 Poly A RNA was selected with oligodT latex
beads Qiagen Chatsworth CA according to the supplier in
structions The messenger RNA mRNA prepared from each
lung was subjected to Northern blot analysis with a probe derived
from the human NGF gene The same blot was hybridized with a
rat glyceraldehyde 3 phosphate dehydrogenase GAPDH probe
to serve as a loading control Lane 1 nontransgenic control Lane
2 lineage 82 Lane 3 lineage 204 Lane 4 lineage 143 Lane5
lineage 206 Arrow indicates band at the expected size of2 kb
in Lane 5 Note from the loading control that this sample is un
derloaded relative to the samples from the other expressing lin
eages B Organ distribution of transgene message expression
RNA from theorgans indicated was prepared from a mouse of the
206 lineage and from a nontransgenic littermate by centrifuga
tion through cesium chloride 35 Total RNA from each organ
was subjected to Northern blot analysis with the NGF andGAPDH
probes Arrow indicates expected size of the 2kb transgene
message S spleen Li liver I small intestine K kidney
T testis Lu lung H heart B brain M skeletal muscle
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Figure 2. Analysis of transgene message. (A) Northern blot anal-
i   l    t  ge.   re   
t e l s f tra s e ic ice fr  t e f r -NG  li ea es 
and fro  an age- atched nontransgenic ouse by acid phenol 
extraction (35). Poly A + RNA was selected with oligo-dT latex 
beads (Qiagen. hatsworth. l according to the supplier's in-
ti s.    (m A)    
l  as s jecte  t  rt er  l t a al sis it  a r e eri e  
fro  the hu an F gene. he sa e blot as hybridized ith a 
rat glyceraldehyde 3-phosphate dehydrogenase (G P ) probe 
to serve as a loading control. ane 1. nontransgenic control; ane 
. line  -2;  . li  -4;  . li e  -3;  . 
linea e -6. rro  i icates a  at t e e ecte  size f .2  
in ane 5. ote fro  the loading control that this sa ple is un-
rloa e  r l ti  t  t  l  fr  t  t r r i  li -
eages. (B) Organ distribution of transgene message expression. 
   a s      s    
-6 linea e a  fr  a  tra s e ic Iitter ate  centrif ga-
tion through cesiu  chloride (35). Total R  fro  each organ 
as s jecte  t  rt er  l t a al sis it  t e  a   
probes. rro  indicates expected size of the 2.2-kb transgene 
ss .  = s l n. i = r.  = l  t .  = i y. 
 = ti .  = lung.  = art.  = in.  = l t l cle. 
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genic mice 33 44 Microinjection of the CCSPNGF
DNA construct yielded five founder transgenic mice four
ofwhich produced progeny carrying the transgene which
were used to establish transgenic mouse lineages
Analysis ofTransgene Expression
Mice from the four CCSPNGF lineages were screened
with Northern blot analysis to determine those in which
the transgene was expressed Three lineages designated
82 143 and 206 exhibited a transgene specific band by
Northern blot analysis of lung RNA with a human NGF
probe Figure 2A No transgene message could be de
tected in lungs from the fourth CCSPNGF lineage Mice
from the 20 6 lineage displayed the expected 2 kb band
for the CCSP NGF message Mice from lineages 82 and
143 displayed a message of smaller size 14 kb suggest
ing that the transgene was truncated or that the message
was not processed properly in mice from these lineages
Mice of the 206 lineage had the expected tissue distribu
tion of CCSPNGF message since the transgene was ex
pressed in the lung but not in spleen liver small intestine
kidney testis heart brain or skeletal muscle Figure 213
To examine expression of the NGF polypeptide we an
alyzed homogenates of CCSPNGF mouse lungs with an
enzyme linked immunosorbent assay ELISA An initial
screening of one mouse from each lineage revealed that
two of the lineages in which transgene message was de
tected 143 and 20 6 exhibited high levels of NGF pro
duction in the lung whereas the remaining two lineages
82 and 20 4 produced the same amount of NGF as non
transgenic mice not shown The transgene message in
lineage 82 is apparently not translated efficiently since
no overexpression of NGF was detected by ELISA Al
though lineage 143 produces a transcript that is smaller
than expected it could still generate functional NGF if the
missing sequence was derived from the 3 untranslated re
gion These results indicated that the 14 3 and 206 lin
eages expressed high levels of NGF polypeptide in the
lung and these lineages were studied in more detail To
obtain a more accurate determination of the extent of NGF
overexpression in CCSPNGF mice NGF levels in lung
homogenates were measured in three mice from each of
the expressing lineages and in three nontransgenic mice
Figure 3 These results indicated that NGF was overex
pressed 28 fold and 31 fold in the 143 and 20 6 lineages
respectively over the levels found in nontransgenic mice
of similar genetic background Mice from these two lin
eages displayed the histologic changes described subse
quently whereas mice from the two lineages in which
NGF overexpression was not detected with ELISA dis















Figure 3 NGF levels in lung homogenates from CCSPNGF and
normal mice Lungs were homogenized and NGF was measured
in the homogenates with an ELISA as described 33 Lungs from
three mice each in the 143 and 206 CCSPNGF lineages and
from three nontransgenic mice were analyzed Data are ex





Figure 4 Lung histology in CCSPNGF and normal mice Lungs
were fixed sectioned and stained with HE a Lung section
from a CCSPNGF mouse from the 143 lineage showing subepi
thelial thickening around the airways Arrow indicates a large





2 E I  J   I     I  .  1  
i  ice (3 . ). icroinjection f t e SP-NGF 
 str t ielded five founder tra s i  i . fo r 
of hich produced progeny carrying the transgene. hich 
ere used to establish transgenic ouse lineages. 
nal si   ransgene re i  
ice fr  t e f r SP-NGF lineages ere scree e  
ith orthern blot analysis to deter ine those in hich 
the transgene as expressed. Three lineages, designated 
-2, -3.  -6. i ite   tra s - i i    
orthern blot analysis of lung  ith a hu an F 
probe (Figure 2 ). o transgene essage could be de-
tected in lungs fro  the fourth SP-NGF lineage. ice 
fro  t e -6 lineage isplayed t e e ecte  .2-kb a  
for the SP-NGF essage. ice fro  lineages 8-2 and 
14-3 displayed a essage of s aller size (1.4 kb). suggest-
ing that the transgene as truncated or that the essage 
as t ces  rl  i  i  r  t  line . 
ice f the 20-6 lineage had the expected tissue distribu-
tion of SP-NGF essage. since the transgene as ex-
pressed in the lung but not in spleen, liver, s all intestine. 
kidney, testis, heart. brain, or skeletal uscle (Figure 2B), 
o exa ine expression f the  polypeptide, e an-
alyzed ho ogenates of SP-NGF ouse lungs ith an 
enzyme-linked immunosorbent assay (ELISA). An initial 
i   e ouse ro   line  e le  t at 
t  f t  linea e  i  i  tra s    -
tected (14-3 and 20-6) exhibited high levels of F pro-


















Figure 3. NGF levels in lung homogenates from CCSP-NGF and 
nor al ice. Lungs ere ho ogenized and F as easured 
in the homogenates with an ELISA as described (33). Lungs from 
three ice each in the 14-3 and 20-6 SP-N F lineages and 
from three non transgenic mice were analyzed. Data are ex-
pressed as sa ple eans ::<:: . *  < . 0 I  l  
tudent's  t. 
(8-2  0-4) roduce  t e e t f   -
transgenic ice (not shown). he transgene essage in 
lineage 8-2 is apparently not translated efficiently. since 
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Figure 4. Lung histology in SP-N F and nor al ice. Lungs 
ere fixed, sectioned. and stained ith &E (a) ung section 
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Histologic and Immunohistochemical Analysis of
CCSPNGFMouse Lungs
CCSPNGF transgenic mice were analyzed with histologic
and immunohistochemical techniques to determine the
effects of NGF overexpression on the innervation of the
airways Hematoxylin and eosin HEstained sections
revealed clear histologic abnormalities that were confined
to the airways of CCSPNGF mice Mice from both the
143 and 20 6 lineages displayed a subepithelial thickening
around the airways that was not seen in nontransgenic lit
termates Figures 4ab 5 ab CCSPNGF mice also con
tained abundant large nerves adjacent to larger airways
The thickening around the airways was observed in bron
chi as well as in large and small bronchioles but was mini
mal in the trachea Alveolar structure in CCSPNGF mice
was normal and no evidence of inflammation was ob
served On the basis of the known functions of NGF we
hypothesized that the airway thickening in CCSP NGF
micewas a result of ingrowth of excessive peripheral nerve
fibers To ascertain the neuronal origin of the material sur
153
rounding the airways immunohistochemistry with antibod
ies against the neuronal marker synaptophysin was per
formed on lung sections from CCSPNGF transgenic mice
Staining with this antibody was observed throughout the
subepithelial material around the airways in the transgenic
mice Figures 5c and 5e In nontransgenic mice synapto
physin staining was absent from small airways Figure 5d
or was present in larger airways in isolated nerve fibers at
much lower density than in the transgenic mice Figure
50 This result confirms the postulate that the CCSPNGF
gene results in a hyperinnervation of the airways Similar
results were obtained with neurofilament immunohisto
chemistry not shown To examine alterations in tachyki
nincontaining sensory fibers lung sections from CCSP
NGF and nontransgenic mice were stained with antibodies
to substance P Substance P is stored in varicosities ofex
tremely fine sensory nerve endings The varicosities con





Figure 5 Histologic and immunohistochemical analysis of lungs from CCSPNGF and normal mice Lungs of mice from the 20 6 trans
genic lineage or from normal mice were fixed sectioned and subjected to standard histologic analysis or immunohistochemical analysis
as described in MATERIALS AND METHODS a HE staining of a section showing a small airway from a CCSPNGF mouse Arrow
head indicates subepithelial thickening around the airway b HE staining of a similar section from a normal mouse c Synapto
physin immunostaining of a small airway from a CCSPNGF mouse Arrowhead indicates staining fibers surrounding the airway d
Synaptophysin immunostaining of a small airway from a normal mouse No staining fibers are present e Synaptophysin immunostain
ing of a large airway from a CCSP NGF mouse Arrowhead indicates staining fibers beneath the airway epithelium f Synaptophysin
immunostaining of a large airway from a normal mouse Arrowheads indicate staining in isolated varicosities that are difficult to see at
this magnification g SubstanceP immunostaining in a large airway from a CCSPNGFmouse Arrowheads indicate clusters of stain
ing fibers beneath the airway epithelium h SubstanceP immunostaining in a large airway from a normal mouse Arrowhead indicates
staining in isolated varicosities that is typical of the airways in normal mice Bar 25 m in a through fand 125min g and h
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Figure 5. Histologic and immunohistochemical analysis of lungs from CCSP-NGF and normal mice. Lungs of mice from the 20-6 trans-
genic lineage or from normal mice were fixed, sectioned, and subjected to standard histologic analysis or immunohistochemical analysis 
as es ribed in ATERIALS  ETHO S. (a) &E st i ing f  s ti . s ing a s ll ir  fro  a SP-NGF s . rr -
head indicates subepithelial thickening around the airway. (b) H&E staining of a similar section from a normal mouse, (c) Synapto-
physin immunostaining of a small airway from a CCSP-NGF mouse. Arrowhead indicates staining fibers surrounding the airway. (cI) 
Synaptophysin immunostaining of a small airway from a normal mouse. No staining fibers are present. (e) Synaptophysin immunostain-
ing of a large airway from a CCSP-NGF mouse. Arrowhead indicates staining fibers beneath the airway epithelium. (I) Synaptophysin 
immunostaining of a large airway from a n r al ouse. rrowheads indicate staining in isolated aric sities that are difficult to see at 
this agnification. (g) Substance-P immunostaining in a large air ay fro  a SP-NGF ouse. Arrowheads indicate clusters of stain-
ing fibers beneath the air ay epitheliu , (h) Substance-P i unostaining in a large air ay fro  a nor al ouse. rrowhead indicates 
staining in isolated varicosities that is typical of the airways in nor al ice. Bar = 25 fLm in (a) through (f), and 12.5 fLm in (g) and (h), 














Figure 6 Substance P levels in lung homogenates ofCCSPNGF
and normal mice Lungs from CCSPNGF 206 lineage and nor
mal mice were homogenized and the homogenates were assayed
for substance P with an enzyme immunoassay as described in
MATERIALS AND METHODS Data are expressed as sample
means SEM P 02versus normal withStudent t test
as a series of beadlike structures Clusters of varicosities
that contained substance P immunoreactivity and ap
peared to be derived from multiple nerve fibers were ob
served adjacent to the airways in CCSPNGF transgenic
mice Figure 5g In nontransgenic mice immunoreactive
varicosities could be seen but always appeared to be de
rived from single fibers Typically only a few varicosities
could be seen before the fiber turned out of the plane of
section Figure 5h Clusters of immunoreactive varicosi
ties like those in CCSPNGF mice were not observed in
nontransgenic mice The results of the staining for sub
stance P indicated that innervation of the airways by ta
chykinincontaining sensory fibers is increased in CCSP
NGFmice
SubstanceP Content of CCSPNGF Mouse Lungs
To quantitate the increase in tachykinincontaining sen
sory innervation in CCSPNGF mouse lung substance P
was measured in lung homogenates with an enzyme immu
noassay Figure 6 Lungs from CCSPNGF transgenic
mice contained approximately 5fold more substance P than
did lungs from nontransgenic mice Since the immunohis
tochemical results indicated that substance P in the lungs
of CCSPNGF mice was confined to nerve fibers the in
crease in substance P in CCSPNGFmice resulted from an
increase in tachykinincontaining nerve fibers
Figure 7 Histologic and histochemical analysis of lungs from mice treated with 6OHDA CCSP NGF 206 lineage and normal mice
were treated with 6OHDA as described in MATERIALS AND METHODS Control groups of transgenic and normal mice were treated
identically with the vehicleused to dissolve 6OHDA Catecholamine histofluorescence was produced by reacting frozen tissue sections
with glyoxylic acid as described 29 38 a HE staining of an airway section from a 6OHDAtreated CCSPNGF mouse b Cate
cholamine staining of an airway from a vehicle treated CCSPNGFmouse Arrowindicates staining fibers surrounding the airway epi
thelium c Catecholamine staining of an airway from a vehicle treated normal mouse Arrows indicate isolated staining fibers innervat
ing the airway a Catecholamine staining of an airway from a 6OHDAtreated CCSP NGF mouse Arrows indicate isolated staining
Normal CCSPNGF
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Figure 7. Histologic and histochemical analysis of lungs from mice treated with 6-0HDA. CCSP-NGF (20-6 lineage) and normal mice 
ere treate  ith -0  as escri e  i  TE I LS  ETHO . tr l rou s f tra s e ic a  r al ice ere treate  
identically with the vehicle used to dissolve 6-0HDA. Catecholamine histofluorescence was produced by reacting frozen tissue sections 
ith glyoxylic acid as described (29. 38). (a) &E staining of an air ay section fro  a 6-0 A-treated SP-NGF ouse. (b) ate-
chola ine staining of an air ay fro  a vehicle-treated CCSP-NGF ouse. Arrow indicates staining fibers surrounding the air ay epi -
thelium. (e) Catecholamine staining of an airway from a vehicle-treated normal mouse. Arrows indicate isolated staining fibers innervat-
ing the air ay. (d) atechola ine staining of an air ay fro  a 6-0 A-treated SP-NGF ouse. Arrows indicate isolated staining 
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Treatment with 6OHDA
The airways in CCSPNGF transgenic mice contained abun
dant nerve fibers that did not stain with antibodies to sub
stance P Since NGF promotes the growth of sympathetic
axons we hypothesized that many of the nerve fibers ob
served in the airways of CCSPNGFmice were of sympa
thetic origin To test this hypothesis CCSP NGF and non
transgenic mice were treated with the sympathetic specific
neurotoxin 6OHDA Treatment ofCCSPNGFmice with
6OHDA resulted in a dramatic loss of nerve fibers from
the airways as judged by staining with HE Figure 7a
compare with Figure 5a To demonstrate directly the loss
of sympathetic fibers lung sections were stained with a
catecholamine histofluorescence technique that detects
sympathetic nerve fibers 29 38 Vehicletreated CCSP
NGF transgenic mice contained abundant sympathetic fi
bers innervating the airways Figure 7b The airways of
vehicletreated nontransgenic mice contained very few
staining fibers indicating a sparse innervation by sympa
thetic nerve endings in normal mice Figure 7c Treat
ment of CCSPNGF mice with 6OHDA eliminated the
majority of staining fibers around the airways Figure 7d
The sections showing this appeared similar to those from
untreated nontransgenic mice Sections from nontrans
genic mice treated with 6 OHDA showed no detectable
sympathetic fibers around the airways Figure 7e It is
not clear why there are residual sympathetic fibers after
6 OHDA treatment in CCSP NGF mice This may relate
to the large number of fibers initially present in these
mice or may result from some protective effect of high
levels of NGF Immunohistochemistry with antibodies to
substance P revealed that 6OHDA treatment did not alter
the increased level of substance Pimmunoreactive fibers
characteristic of CCSP NGF mice Figure 70 These re
sults indicated that the majority of the neuronal fibers in
nervating the airways in CCSP NGFmice were of sympa
thetic origin and that 6 OHDA treatment could be used
to generate CCSP NGF mice that had increased tachyki
nin innervation but normal levels of sympathetic innerva
tion of the airways
Sensitivity to Inhaled Capsaicin
To determine whether altered airway innervation in
CCSPNGFmicehad functional consequences we measured
the effect of inhaled capsaicin on R Capsaicin stimulates
sensory C fiber afferents and triggers tachykinin release
An exaggerated response to capsaicin in CCSPNGF mice
would indicate that these mice have an increased ability to
respond to irritant stimuli via sensorynerve pathways Base
line Rrs was not different in CCSPNGF and normal mice
Inhaled capsaicin induced a dose dependent increase in
Rrs in both CCSP NGF and normal mice CCSP NGF
mice were more sensitive to the constrictive effect of cap
















Figure8 Sensitivity to inhaled capsaicin in CCSP NGF and nor
mal mice R15 was measured in CCSPNGF mice ofthe 206 lineage
and in normal mice after increasing doses of inhaled capsaicin as
described in MATERIALS AND METHODS The concentration of
capsaicin resulting in a 50 increase over baseline R PC was
determined for each group ofmice n 7 CCSPNGF mice n
5 normal mice
induce a 50 increase in R Figure 8 This result indi
cated that the altered innervation in CCSPNGF mice ren
dered them more susceptible to an irritant stimulus of the
respiratory tract
Discussion
Neurogenic inflammation is a potentially important mech
anism by which lung injury induced by irritants and aller
gens may be initiated and maintained Enhanced accumu
lation of tachykinins in asthmatic and in normal subjects
exposed to respiratory irritants highlights the need for fur
ther research into the neuronal control of airway inflam
mation 5 6 17 18 A significant value of the mouse in
airwaysdisease research lies in the ability to use it for per
forming genetic manipulations to test the role of specific
mediators in disease processes We have developed a
novel approach to manipulating tachykinin levels by alter
ing the growth of nerve fibers that contain these neu
ropeptides In the transgenic mouse model presented here
lung specific expression of NGF was used to alter the in
nervation of the airways The advantages of this approach
are that tachykinins will be released by stimuli that nor
mally cause neuropeptide release and that multiple pep
tides will be concurrently released as happens in normal
animals In addition since the alteration is confined to the
fibers innervating the airway e Catecholamine staining of an airway from a 6 OHDAtreated normal mouse No staining fibers are
present 7 SubstanceP immunostaining of an airway from a 6OHDA treated CCSPNGF mouse Arrows indicate clusters of staining
varicosities beneath the airway epithelium Bars 25m in a 50 Rm in b through e and 125min t
Normal CCSPNGF
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airways there is a specific increase in tachykinin levels at
the anatomic site of interest
The present model depends on the action of NGF on
specific populations ofperipheral neurons and on its mul
tiple effects on these responsive neurons The actions of
NGF on neuronal cells are mediated primarily by the high
affinity NGF receptor encoded by the trk protooncogene
45 Expression of trk in the peripheral nervous system
has been detected exclusively in sympathetic neurons and
in a subset of neural crest derived sensory neurons 46
Tachykinincontaining sensory C fibers appear to be among
the neural crest derived sensory neurons most responsive
to the effects of NGF 47 Other types of peripheral neu
rons such as parasympathetic neurons and placodederived
sensory neurons lack NGF receptors and cannot respond
to NGF 48 These neurons rely on other neurotrophic
factors for survival growth and differentiation during de
velopment
NGF exerts multiple effects on developing neurons that
possess the trk receptor NGF is required for the survival
of responsive neurons and controls neuronal gene expres
sion 28 These effects are produced by binding and inter
nalization of NGF followed by retrograde axonal trans
port to the cell body 49 50 NGF also promotes axonal
branching and the directional growth of NGFresponsive
axons to sites ofNGF production 29 51These effects of
NGF appear to be direct local effects that do not require
transport of NGF to the soma 51
We have previously shown that overexpression ofNGF
in transgenic mice resulted in local hyperinnervation in tis
sues that expressed the transgene 29 In the present
study we used DNA regulatory sequences from the CCSP
gene to direct expression specifically to the lung This tis
suespecific expression resulted in anatomic alterations
that were confined to the lung and resembled the changes
in innervation that were observed previously in other tis
sues Because NGF is expressed in many organs and in ep
ithelial cells 52 53 it is likely that Clara cells normally
synthesize and have the abililty to process the NGF
polypeptide However the levels at which NGF is pro
duced in the lungs of CCSPNGF mice are much higher
than would normally be the case thereby accounting for
the change in innervation In the present study we identi
fied significant changes in both tachykinincontaining sen
sory fibers and sympathetic fibers in the airways ofCCSP
NGFmice Substance P was used as a marker for tachyki
nincontaining sensory nerve fibers CCSPNGF mice
were found to have an increased density of innervation by
substance Pcontaining fibers which was demonstrated
both by immunostaining and by enzyme immunoassay As
discussed earlier these changes in innervation are consis
tent with what is known about the action of NGF during
development and the distribution of NGF receptors in the
peripheral nervous system
Tachykinins including substance P have been docu
mented to mediate inflammation and bronchoconstriction
in the lung 3 Although the lungs of CCSPNGF trans
genic mice in the present study had a 5 fold increase in the
amount of substance P over those of normal mice the
transgenic mice had a normal baseline Rrs and did not ex
hibit any evidence of inflammation The lack of inflamma
tion was not due to the presence of excess sympathetic
nerve fibers since no inflammation was observed in CCSP
NGF mice treated with 6OHDA Rather the lack of in
flammation was most likely due to sequestering of the
tachykinins in sensory nerve endings and their lack of re
lease in appreciable amounts until an irritant stimulus is
encountered In accordance with this concept we have
found that the level of substance P in lung lavage fluid
from both CCSPNGF and normal mice is below the limits
of detection as measured with an enzyme immunoassay
7 pgml not shown
CCSPNGF mice were more sensitive than normal mice
to airway constriction induced by inhaled capsaicin Cap
saicin acts on sensory C fibers to stimulate both central re
flex pathways and peripheral tachykinin release Stimula
tion of central reflex pathways leads to airway constriction
54 whereas tachykinins act on mouse and rat airways to
produce bronchodilation 16 55 Our experiments showed
that capsaicin inhalation produced an increase in Rrs in
conscious mice suggesting that the effects of the central
pathway predominate in the intact mouse CCSPNGFmice
required a lower dose of capsaicin than normal mice to
produce the same increase in R This observation is con
sistent with the histologic and biochemical observations of
an increase in tachykinin containing nerve fibers in the
lungs ofCCSP NGFmice The capsaicin inhalation exper
iments showed that the additional tachykinincontaining
sensory fibers in CCSPNGF mice are functional since
they mediate a process in which C fiber afferents are known
to be involved ie capsaicininduced airway constriction
CCSPNGF mice may be used to test the hypothesis that
increased innervation by tachykinincontaining sensory
neurons results in increased sensitivity to irritant induced
airway inflammation and hyperreactivity CCSPNGF mice
therefore represent a novel model for examining neuronal
mechanisms of irritant induced lung injury
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l ti . ver, t e le els t i   is ro-
   s  -NG     e  
than ould nor ally be the case, thereby accounting for 
the change in innervation. In the present study, we identi-
i  i i i t e  in t  t yki i - t i i  en-
sory fibers and sy pathetic fibers in the air ays f -
F ice. Substance P as used as a arker for tachyki-
i -c tai i  se s r  erve fi ers. -N  ice 
  t  ve  i  it   i tion  
s st  - t i i  fi rs, i  s str t  
both by i unostaining and by enzy e i unoassay. s 
is s  rli r, t es  es i  i r ti  r  is-
tent ith hat is kno n about the action of F during 
l t  t e i tri tio  f  r t rs i  t  
eri eral erv s s ste . 
Tachykinins, including substance P, have been docu-
  te la a io   t  
in the lung (3). lthough the lungs of SP-NGF trans-
genic mice in the present study had a 5-fold increase in the 
t  t    t se  l i , t  
transgenic ice had a nor al baseline rs and did not ex-
hibit any evidence of infla ation. The lack of infla a-
tion as not due to the presence of excess sy pathetic 
 ,       P-
    -0 . t r,    -
fla ation as ost likely due to sequestering of the 
tac i ins i  se s r  er e e i s a  t eir lac  f re-
l s  i  Ci l  ts til  i ita t ti l s i  
t r d. I  r  it  t i  pt.   
f  t at t e le el f s sta ce  i  l  la a e fl i  
  -NG         
    t     
«  /ml;  own). 
-NG     i   l  
to air ay constriction induced by inhaled capsaicin. ap-
saicin acts on sensory  fibers to sti ulate both central re-
     . ti ula-
tion of central reflex path ays leads to air ay constriction 
(54), hereas tachykinins act on ouse and rat air ays to 
  (1 , 5).    
t t i i  i l ti  r   i reas  i  rs i  
conscious ice, suggesting that the effects f the central 
path ay predo inate in the intact ouse. CCSP-N F ice 
required a lo er dose of capsaicin than nor al ice to 
r  t   i r  i  rs. i  r ti  i  n-
 t      s  
an increase in tachykinin-containing nerve fibers in the 
lungs of CCSP-NGF mice. The capsaicin inhalation exper-
ts     chykinin- t i i  
s s r  fi rs i  -NG  i  r  f ti nal, si  
t e  e iate a r cess in ic  -fiber affere ts are  
to be involved (Le., capsaicin-induced air ay constriction). 
CCSP-NGF ice ay be used to test the hypothesis that 
rea    chykinin- t i   
r s r s lts i  i r s  s siti it  t  irrita t-i  
air a  i fla ati  a  erreactivity. -N  ice 
t r f r  r r t  l l f r i i  r l 
is s f irrit t-i  l  i j ry. 
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CN chlorobenzylidene malononitrile CS dibenzfoxazepine CR capsaicin sensory irritation ocular effects
pulmonary effects repeated dose toxicity genotoxicity carcinogenicity developmental toxicity mechanism of action
The desired effect of all riot control agents is the temporary disablement of individuals by way of intense
irritation of the mucous membranes and skin Generally riot control agents can produce acute site
specific toxicity where sensory irritation occurs Early riot control agents namely chloroacetophenone CN
and chlorodihydrophenarsazine DM have been replaced with safer agents such as ochlorobenzylidene
malononitrile CS and oleoresin of capsicum OC Riot control agents are safe when used as intended
however the widespread use of riot control agents raises questions and concerns regarding their health
effects and safety A large margin exists between dosages that produce harassment and dosages likely to
cause adverse health effects for modern riot control agents such as CS and dibenzbJ14oxazepine CR
Yet despite the low toxicity of modern riot control agents these compounds are not entirely without risk The
risk of toxicity increases with higher exposure levels and prolonged exposure durations Ocular pulmonary
and dermal injury may occur on exposure to high levels of these substances and exposure to riot control
agents in enclosed spaces may produce significant toxic effects Reported deaths are few involving riot control
agents and then only under conditions of prolonged exposure and high concentrations Recently concern
has focused on the deaths resulting from law enforcement use ofOC a riot control agent generally regarded
as safe because it is a natural product As with other xenobiotics not enough is known concerning the
longtermchronic effects of riot control agents Clearly there is considerable need for additional research to
define and delineate the biological and toxicological actions of riot control agents and to illuminate the full
health consequences of these compounds as riot control agents Published in 2001 by John Wiley Sons
Ltd
INTRODUCTION
Riot control agents are highly potent sensory irritantsf rel
atively low toxicity that produce dose and time dependent
acute site specific toxicity Collectively these compounds
have been referred to as harassing agents or as lacrima
tors and in common parlance they are known as tear
gases These chemicals interact pharmacologically with
sensory nerve receptors associated with mucosal surfaces
and the skin at the site of contamination resulting in
localized discomfort or pain with associated reflexes
This biological response eg ocular irritation results in
pain in the eye warning and excess reflex lacrima
tion and blepharospasm protection The response is
concentration dependent and ceases on removal of the
sensory irritant stimulus Although intense lacrimation is
a common reaction on exposure to riot control agents
it must be recognized that these compounds can elicit a
diverse array of physiological effects Thus lacrimatooy
Correspondence to E J Olajos US Army Edgewood Chemical and
Biological Center Attn AMSSBRRT 5183 Blackhawk Rd Aberdeen
Proving Ground MD 210105424 USA
This is a US government work and is in the public domain in the
USA
compounds also may produce respiratory tract irritation
andor gastrointestinal irritationie nausea and vomiting
Riot control agents have both civil and military applica
tions and have been classified as either military chemicals
or chemical warfare agents The common classification
of military chemicals and chemical agents is based on a
predominant physiological action although classification
also may be based on use physical state or persistency
Physiologically riot control agents may be classified
according to type lacrimators which primarily cause eye
irritation and lacrimation vomiting agents which addi
tionally cause vomiting and sternutators which mainly
cause uncontrolled sneezing and coughing Riot control
agents also have been referred to as irritants or irritating
agents harassing agents and incapacitating agents
or short term incapacitants The aforementioned cate
gories are general classifications or have special meaning
in terms of military usage and may not represent useful
equivalents Thus vomiting agents may be described erro
neously as riot control agents and should be considered
as a separate category of military chemicals as they are
in various military chemical classifications Moreover
it must be recognized that a physiologically based clas
sification of chemical agents and compounds of military
interest is by no means a rigid one ie the classifying
of a military compound as a lung irritant does not mean
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l itrile (CS) d leoresin f i  (D ). i t tr l ts r  f     i t d: 
ho ever, the idespread use of riot control agents raises questions and concerns regarding their health 
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Riot control agents are highly potent sensory irritantsf rel-
atively low toxicity that produce dose and ti e-dependent 
acute site-specific toxicity. Collectively, these co pounds 
a e ee  referre  t  as ' arassi  a ents' r as lacri a-
tors, and in co on parlance they are known as 'tear 
gases'. These chemicals interact pharmacologically with 
sensory nerve receptors associated with mucosal surfaces 
and the skin at the site of contamination, resulting in 
localized disco fort or pain with associated rd1exes. 
This biological response, e.g. ocular irritation, results in 
pain in the eye (warning) and excess reflex lacri a-
tion and blepharospas  (protection). The response is 
concentration-dependent and ceases on removal of the 
sensory irritant sti ulus. Although intense lacri ation is 
a co on reaction on exposure to riot control agents, 
it must be recognized that these compounds can elicit a 
diverse array of physiological effects. Thus, lacri atory 
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co pounds also ay produce respiratory tract lITltation 
and/or gastrointestinal irritation (i,e. nausea and vo iting). 
Riot control agents have both civil and ilitary applica-
ti s    l ssifi  s it r ilit r  i ls 
r i l rf r  gents.   l ifi ti  
f ilit r  i l   i l t  i     
predo inant physiological action, although classification 
als  a  e ase   se, sical state r ersistency. 1-4 
Physiologically, riot control agents ay be classified 
according to type: lacri ators, hich pri arily cause eye 
i it ti   l ri tion; iti  nts, i  ddi-
ti ll   iting;  t r ut tors, i  i l  
cause uncontrolled sneezing and coughing. Riot control 
agents also have been referred to as irritants or irritating 
agents,5.6 harassing agents 7 -10 and incapacitating agents 
or short-ter  incapacitants.9 - 11 The afore entioned cate-
gories are general classifications or have special eaning 
i  t r  f ilit r   a   t r r t ef l 
equivalents. Thus, vo iting agents ay be described erro-
neously as riot control agents and should be considered 
as a separate category of ilitary che icals-as they are 
i  ri s ilit r  che i l lassifications. 12 r ver, 
it must be recognized that a physiologically based clas-
sifi ti  f i l ag ts an  co s f ilit r  
interest is by no eans a rigid one, i.e. the classifying 
f a ilitar  c  as a l  irrita t es not ea  
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that it cannot be considered as a lacrimogenic compound
The classification issue may never be fully resolved yet
a system of classification serves to provide a basis for
comparisons among chemical warfare agents and between
chemical warfare agents and other chemicals Verwey
has provided an excellent overview on the subject of
classification criteria to distinguish riot control agents
from chemical warfare agents and concepts pertaining
to harassing irritating and incapacitating Character
istics common to riot control agents include rapid onset
of effect relatively short duration of action following
cessation of exposure and relatively high safety margins
Ideally in riot control situations these substances should
produce harassing effects that are relatively benign with
a low incidence of casualties Riot control agents should
possess low acute toxicity and have toxicological and
chemical properties that ensure minimal risks The physic
ochemical and biological properties of the common riot
control agents are highlighted in Table 1
In the chemical warfare literature and in military Field
and Technical Manuals a distinction is made between
military chemicals and chemical warfare agents Of addi
tional note is that the term military chemical compound
excludes chemical warfare agent Chemical warfare agents
include the following categories nerve agents eg sarin
GB soman GD and VX blister agents eg mus
tard HD and lewisite L incapacitating agents ie
adamsite DM lung irritantschoking agents ie phos
gene CG and blood agents eg hydrogen cyanide
AC and cyanogen chloride CK Military chemical
compounds include the following categories riot control
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agents eg chloroacetophenone CN dibenz f 1 4
oxazepine CR and ochlorobenzylidene malononitrile
CS training agents eg CN smoke materials eg fog
oil SGF and white phosphorus WP and herbicides eg
245trichlorophenoxy acetic acid 245T and arsenic
trioxide Riot control agents are not considered by the
USA as chemical weapons however some other coun
tries do not draw a distinction Military Field and Tech
nical Manuals ie Army FM 8285 give definitions for
chemical agent military chemical and riot control agent
Sidell writing on the subject of riot control agents stated
the following The United States does not recognize riot
control agents as chemical warfare agents as defined in the
Geneva Convention of 1925 Despite considerable atten
tion and much debate on the definition and classification
of riot control agents recently published literature on the
subject matter has not provided clear distinctions on the
classification of chemical warfare agents and riot control
compounds 121 Currently the official policy on riot con
trol agents by the USA is that riot control agents are not
chemical warfare agents22
HISTORICAL PERSPECTIVES
Lacrimatory and irritant compounds many of which are
listed in Table 2 have a history dating from World War I
They have been used in riot control and civil disturbances
military exercises and training and as chemical warfare







mg m3 mg m3 mg m3
CN Solid Insoluble in Stable in closed Slow Instantaneous 1 5 850
water containers
CR Solid Limited Stable in Very Instantaneous 002 1 10000










DM Solid Insoluble in Stable in pure Very Rapid 1 5 650










a Physicochemical data Refs 1418 S Katz personal communication 2000
b Threshold values for eye irritationCNRSfrom Ref 19 minimum lethal concentration for 10min exposure
Capsaicin is the major ingredient ofoleoresin capsicum OC
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that it t  sidered as  la i o  . 
he classification issue ay never be fully resolved, yet 
a syste  of classification serves to provide a basis for 
co parisons a ong che ical arfare agents and bet een 
che ical arfare agents and other che icals. er eyl3 
as r ide   ll t r i   t  s j t f 
l ifi ti ; riteria t  istin is  riot tr l ts 
fro  i l arfare t ;  e ts rt i ing 
to 'harassing', 'irritating' and 'incapacitating'. haracter-
istics  t  riot trol ents i l : r i  t 
 f ect(s); re a e      llo ing 
cessation of exposure; and relatively high safety argins. 
I eall , i  riot c tr l sit ati s these s sta ces s ld 
produce 'harassing effects' that are relatively benign ith 
 l  incidence f s lti s. i t tr l ts s l  
ossess l  t  t i it   a e t i l i l  
i l r rties t t r  i i l ris . e sic-
ical  i l i l r rties  t   ri t 
control agents are highlighted in Table I. 
 t e  arfare iterature   ita   
  a ,  s tion is e  
ilitary che icals and che ical arfare agents. f addi-
tional note is that the ter  'military che ical co pound' 
excludes che ical arfare agent. he ical arfare agents 
include t e f ll i  cate ries: er e a e ts, e.g. sari  
(G ), so an (GO) and ; blister agents, e.g. us-
tar  (H )  l isite (L); i it ti  ts, i.e. 
adamsite (O ); lung irritants/choking agents, i.e. phos-
 (C );  l  t , .g. r  i e 
(A )   l ride (C ). ilit r  i l 
co pounds include the follo ing categories: riot control 
, .g. roacet he e (C ), i enz[b, ]1 : 4-
oxazepine (C ) and o-chlorobenzylidene alononitrile 
(C );  , .g. ;  t ri ls, .g.  
 (S )  t  s (W );  , .g. 
2,4,5-trichlorophenoxy acetic acid (2,4,5-T) and arsenic 
tri i . i t tr l ts r  t sidere   t  
  i l ; r,  t r n-
tries  t r   i ti ti n. ilitar  i l   ch-
i l anuals (i.e.   -2 ) i  i itions  
i l t, ilita  i l  i t t l gent. 20 
idell 17 riting       ts  
 : "The te     ize  
l       e    
   ". e te e -
      fi   i  
  r l t ,  ishe  literature   
s ject atter as t r i e  clear isti ctions  t e 
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c unds. 1 1.21 UlTe tl , t e fficial lic   ri t c n-
t l ts  t   i  t t i t t l ts  t 
i l rfare t . 22 
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RIOT CONTROL AGENTS
Table 2Riot control and lacrimatory tear gas compounds
































































































a Militarycode or identifier usually one legitimate code designation
b Active component capsaicin 8methyl6transnonenoylvanillylamide
Chemical intermediate for various industrial chemicals and pharmaceuticals
Chemical intermediate for certain industrial chemicals
Chemical intermediate for pharmaceuticals
f Military designation Green Cross I
included acrolein papite bromoacetone BA Bstoff
bromobenzyl cyanideCABBCchloroacetone Astoff
xylyl bromide Tstoff and diphenylaminochloroarsine
DMChloropicrin trichloronitromethane a wellknown
chemical substance prior to World War I was used both as
a harassing agent and a lethal chemical during World War
I In fact Chloropicrin was one of a group of lethal agents
the others being chlorine phosgene and trichlorethylchlo
roformate Bromoacetone a highly potent lacrimator was
the most widely used lacrimatory agent in World War I
and xylyl bromide also was an early war gas
Diphenylaminochloroarsine adamsite an arsenic
based compound having the military designation DM was
developed for use during World War I Classified militarily
as a vomiting agent and as a sternutator DM was used as
a riot control agent after the war Chloroacetophenone was
discovered over a century ago however it was not utilized
in World War L Incontemporary terminology it is referred
to as mace Mace liquid mixture containing CN
active ingredient hydrocarbons and freon propellant in
1trichloroethane It is of interest to note that prior
to the development of Chloroacetophenone the potent
lacrimatory compound ethyl bromoacetatewas the
first riot control agent based on its use in Paris in 1912
According to Royer and Gainet ethyl bromoacetate was
purported to have been used in the 1970s in riot control
situations
Military experience with harassing agents had prompted
the utilization of these compounds in law enforcement
operations however many of the military harassing
agents were not suitable for law enforcement use due
to concerns related to their likelihood to produce fatal
ities andor total incapacitation Thus the development
ofmodern riot control agents has been driven by require
ments to develop safe and effective compounds that can be
disseminated readily Riot control agents are intended for
temporary disablementthe intense irritant effects lead
to a more orless pronounced incapacitation The reader
is referred to several sources that provide a more detailed
discussion on the incapacitating effects of riot control
agents 1225 27 A systematic search of compounds suitable
for temporary incapacitation and riot control was in place
by the end of the World War I Despite considerable
research effects on a substantial number of candidate com
pounds interest centered on CN and DM and subsequently
CR and CS Both CN and DM had become the harassing
agents of choice despite the early use of bromobenzyl
cyanide CA as a riot control agent and considerable
stockpiles of CN and DM existed at the time of World
War II Although adamsite DM has been used as a riot
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 Chemical r iate r i  i l   ceuticals. 
d i l i t r iate  t i  i trial i ls. 
" i al i t r diate f r r aceuticals. 
f ilit ry i ti  = r  r ss . 
included acrolein (papite), bro oacetone (B , -stoff), 
bro obenzyl cyanide (CA,BBC), chloroacetone (A-stoff), 
xylyl bro ide (T-stoff) and diphenyla inochloroarsine 
(D ). hloropicrin (trichloronitro ethane), a ell-kno n 
c e ical s sta ce ri r t  rl  ar I, as se  t  as 
a arassi  a e t a  a let al c e ical ti  rl  ar 
1. I  f t, c l r i ri  as  f  r  f l t l ts, 
the others being chlorine, phosgene and trichlorethylchlo-
rofor ate. ro oacetone, a highly potent lacri ator, as 
the ost idely used lacri atory agent in orld ar I 
and xylyl bro ide also as an early ar gas. 
iphenyla inochloroarsine (ada site), an arsenic-
based co pound having the ilitary designation , as 
developed for use during orld ar I. lassified ilitarily 
as a vo iting agent and as a sternutator,  as used as 
a ri t c tr l a e t after t e ar. loroacetophenone as 
is r  r  t r  ; r, it s t tiliz  
in orld ar I. In conte porary ter inology, it is referred 
to as 'mace' (Mace®)-a liquid ixture containing C  
(active ingredient), hydrocarbons and freon propellant in 
I, I, I-trichloroethane). It is of interest to note that prior 
to the develop ent of chloroacetophenone the potent 
lacri atory co pound-ethyl bro oacetate-was the 
i t i t t l t   its  i  i  i  912.23 
ccording to oyer and ainet,24 ethyl bro oacetate as 
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of odem riot control agents has been driven by require-
ents to develop safe and effective co pounds that can be 
disse inated readily. iot control agents are intended for 
te porary disablement-the intense irritant effects lead 
to a ore-or-less pronounced incapacitation. he reader 
is referred to several sources that provide a ore detailed 
isc ssi   t e 'inca acitati ' effects f ri t c tr l 
agents.12.25-27  syste atic search of co pounds suitable 
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cyanide (C ) as a riot control agent, and considerable 
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ar II. lthough ada site (D ) has been used as a riot 
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control agent chloroacetophenone CN had become the
lacrimator of choice by law enforcement personnel Ini
tially synthesized by Corson and Stoughton in the late
1920s chlorobenzylidene malononitrile CS was not
developed as a riot control agent until the 1950s CS
has largely replaced CN for riot control use and is the
most widely utilized tear gas lacrimator in riot con
trol situations Dibenz fI 4oxazepine CR a riot
control agent of recent origin has seen limited appli
cation but this may increase owing to the compounds
greater potency and lower toxicity than some of the
other riot control agents including CS The compound
1methoxy135cycloheptatriene CHT tropilidene has
been demonstrated to be a potent irritant with physiologi
cal effects characteristic of riot control agents Tropilidene
toxicity is generally similar to that of CR The naturally
occurring substance oleoresin capsicum pepper spray
a mixture with capsaicin as the major pungent component
may find increased utilization in law enforcement and riot
control situations Pepper spray is currently available
over the counter for personal protection and is used by
postal carriers for repelling animals and by campers as a
bear repellent
CHEMISTRY OF SELECTED RIOT CONTROL
AGENTS
A considerable number ofchemicals have been developed
for riot control and law enforcement use The most com
monly available riot control agent is chlorobenzylidene
malononitrile CS which replaced chloroacetophenone
CN the latter agent having replaced adamsite DM
Oleoresin capsicum OC in various formulations has




















Figure 1 Structures of CN CR CS OM and capsaicin
The structures of riot control agents CS CR CN DM
and capsaicin are depicted in Fig 1 Table 1 highlights
selected physical data on the common riot control agents
Table 3 summarizes physicochemical data of riot control
agents including adamsite and bromobenzylcyanide In
pure form the common riot control agents are solids
although lacrimatory agents such as acrolein chloroace
tone and tropilidene are liquids Of the modern riot con
trol agents CS hydrolyzes rather rapidly however other
compounds such as dibenz f 1 4 oxazepine CR are
particularly stable and persist for prolonged periods The
common riot control agents are alkylating agents that react
with nucleophilic sites of macromolecular moieties A
brief description of the chemicophysical properties of the
common riot control agents is presented
Oleoresin capsicum OC
Oleoresin capsicum a mixture of many compounds is
obtained by extracting dried ripe fruit of chilli peppers
usually Capsicum annuurn or Capsicum frutescenes Its
composition is variable and depends on factors such as
maturity of the fruit the environment in which the plants
are grown and the conditions of the extraction More
than 100 compounds have been identified in oleoresin
capsicum Among the branched and straightchain alkyl
vanillylamides isolated from oleoresin capsicum cap
saicin 8methyl6 transnonenoyl vanillylamide is the
principal constituent Capsaicin particularly noted for its
irritant properties is the major pungent component in
many peppers Depending on the variety of chilli pep
per oleoresin capsicum contains 0110 capsaicinoids
on a dry mass basis Some of the capsaicinoids vanil
lylamides found in oleoresin capsicum are capsaicin
70 dihydrocapsaicin 20 norhydrocapsaicin
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control agent, chloroacetophenone (CN) had become the 
lacrimator of choice by law enforcement personnel. Ini-
tially synthesized by Corson and Stoughton in the late 
1920s,28 ch10robenzylidene malononitrile (CS) was not 
developed as a riot control agent until the 1950s; CS 
has largely replaced CN for riot control use and is the 
ost idely utilized tear gas (lacrimator) in riot con-
trol situations. ibenz[b, fll : 4-oxazepine (CR), a riot 
control agent of recent origin, has seen limited appli-
cation but this ay, increase o ing to the co pound's 
greater potency and lower toxicity than some of the 
other riot control agents, including CS. The compound 
l-methoxy-l,3,5-cycloheptatriene (CHT, tropilidene) has 
been de onstrated to be a potent irritant with physiologi-
cal effects characteristic of riot control agents. Tropilidene 
toxicity is generally si ilar to that of CR. The naturally 
occurring substance oleoresin capsicum ('pepper spray'), 
a ixture ith capsaicin as the ajor pungent co ponent, 
ay find increased utilization in la  enforce ent and riot 
tr l s t . 'Pepper s ' is curre tly la le 
over the counter for personal protection and is used by 
postal carriers for repelling animals and by campers as a 
bear repellent. 
     
S 
 i l    icals   l  
f r ri t tr l  l  f r t . e t -
monly available riot control agent is chlorobenzylidene 
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p ic la ly sta le a d ersist  prolonged . he 
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(~70%), dihydrocapsaicin (~20%), i  





 O- l ro- , 1 O- i yl rs zi  (O ) 
Oibenz[b, f ]1 :4-oxazepine (CR) -(4- ydroxy-3- ethoxybenzyl)-8- ethyl-6-nonena ide 
(c icin) 
A-~ 7 QCTcl 
1-Chloroacetophenone (CN) 
Figure 1. Structures of CN, CR, CS, OM and capsaicin. 
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Table 3Riot control agents comparative physicochemical data
359
Compound CS CR CN Capsaicin DM CA
Molecular wt 188 195 154 305 277 196
Melting point 93C 72C 54C 64C 195 25C
Vapor pressure at 20Cmm Hg 00034 00059 0054 2 x 103 011
Volatility mgm per C or mgm C 07125 6325 3420 27130
Solubility IOC IOC IOC IOC 0 10
Persistence Varies Persistent Short Fairly persistent Persistent
Odor Pepperlike Odorless Apple blossoms Odorless Bitter almond Decaying fruit
2 Capsaicin is the major pungent component of oleoresin capsicum OC pepper spray
b Solubility I limited inwater 0 soluble in organics C soluble in chlorinated organics
1 Other components eg phenolic compounds
acids and esters of oleoresin capsicum also may possess
irritant properties
the environment because as a class of compounds ben
zodiazepines are very stable in aqueous media
Chlorobenzylidene malononitrile CS
Chlorobenzylidene malononitrile is a variant of the
riot control agent bromobenzylcyanide CA which
dates from about 1920 Chemically CS is 2
chlorophenylmethylenepropan di itrile or dicyano
ochlorostyrene Of note is that riot control agent
CS exists as a family of three forms CS CS 1 and
CS2 The agent symbol CS identifies the compound
in pure form and the symbols CS 1 and CS2
identify mixtures of crystalline agent and an aerogel
CS is prepared as the condensation product of o
chlorobenzaldehyde and malononitrile or the condensation
product of ochlorobenzaldehyde with cyanoacetamide
and subsequent dehydration It is a white crystalline
powder with a molecular weight of 188 corresponding
to a molecular formula ofCThe melting and
boiling points are 93C and 310Crespectively It has a
pungent pepper like odor and is immediately detectable
The vapor is several times heavier than air and the
vapor pressure of the solid is 00034 mmHg at 20
It is sparingly soluble in water and readily soluble in
methylene chloride The molar solubility in water at
20C is 20x 10 mol 1 4mg 100 ml and CS
hydolyzes somewhat slowly the hydrolysis products are
ochlorobenzaldehyde and malononitrile Chemically CS
is the most persistent of lacrimatory agents and will absorb
into most porous surfaces
Dibenzf14oxazepine CR
Dibenz fI 4oxazepine having the military designa
tion CR is synthesized by the reaction of oacylamino
diphenyl ether and polyphosphoric acid and other methods
can be used to obtain the product It is a pale yellow
solid that is chemically stable in organic solvents It has a
molecular weight of 195 corresponding to a molecular for
mula ofCHThe molar solubility in water at 20C
is 35 x 10 mol 1 7 mg 100 ml The melting
and boiling points are 72Cand 335Crespectively The
vapor is 67 times heavier than air The vapor pressure of
the solid is00059 mmHg at 20CIt is soluble in water
and in organic solvents eg ethanol propylene glycol
Riot control agent CR solution consists of01CR dis
solved in a solution of 80 parts of propylene glycol and
20 parts of water It may persist for prolonged periods in
Chloroacetophenone CN
Chloroacetophenone was specifically developed as a riot
control agent and is referred to also as cu chloroaceto
phenone achloroacetophenone phenacyl chloride 2
chlorophenylethanone and phenyl chloromethyl ketone
It is prepared by the chlorination of acetophenone with
selenium oxychloride and has the military designation
CN This lacrimator was developed shortly after World
War I and was used extensively as a training agent Both
CN and its variants eg CNB CNC and CNS replaced
DM and Dseries riot control agents At present CN
is considered obsolete by the US military however it
is still common in police agency mixtures It survives
as the principal component in a liquid mixture under
the tradename Mace It is a crystalline solid having a
molecular weight of 1545 corresponding to a molecu
lar formula ofCThe molar solubility at 20C
is 4 x 10 molI68 mg 100 ml Melting and
boiling points are 54C and 247C respectively The
density of the solid is 131 g cm at 0C and the den
sity of the liquid is 187 g m at 58C The vapor is
53 times heavier than air The vapor pressure of the solid
is 26 x 10 Torr at 0C41 x 10 Torr at 20Cand
152x 10 Torr at 50C
Adamsite DM
Diphenylaminochloroarsine was developed as a chemical
variant of diphenylchloroarsine and is commonly known
as adamsite with the military designation DM It was pro
duced worldwide until it was superseded by the CNseries
of lacrimatory compounds In the past DM has found use
also as an effective pesticide It has a molecular weight of
277 with a molecular formula ofCIt
is a yellowish and odorless solid that is very stable in pure
form The melting point is 195C and the vapor pressure
is negligible 2 x 10 mmHg at 20C As a solid the
rate of hydrolysis is not significant owing to the forma
tion of an oxide coating however the rate of hydrolysis is
rapid when it is in the form of an aerosol Hydrolysis prod
ucts are hydrochloric acid and diphenylarsenious acid The
nauseacausing effect and toxic byproducts ie arsine
based compounds has led to its discontinued useban on
civilian populations
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Table -Riot control agents: co parative physicoche ical data'"~17 
Compound  R CN i i '  A 
olecular t  195  305 277 196 
elting int 93°C 2°C 54°C 4°C 195'C 5'C 
Vapor pressure at 20°C (mm g) 0.0 034 .0 059 .0054   0-'3 0.011 
l tility (mg/m 3 r °c or g/m 3 t ) 0.71125 0.63/25 34120 71/30 
Solubilityb  I  I  10  0  
ersistence aries ersistent hort i l  r istent i t t 
dor r-like dorle s pple blossoms rless itter l ond ying fruit 
, psaicin is the j r pungent c nt f l resin c sicu  (O , r s ray). 
b l ilit : I = li ited i  t r;  = soluble i  i ;  = l le i  l rinated . 
(~l%). ther co ponents (e.g. phenolic co pounds, 
acids and esters) of oleoresin capsicu  also ay possess 
irrita t r erties. 
l r lidene l itrile (C ) 
hlorobenzylidene alononitrile is a variant of the 
riot control agent bro obenzyl cyanide (CA), which 
 r  t . Che ically,   -
chlorophenyl-methylenepropanedinitrile or {3, ,B-dicyano-
o-chlorostyrene. f note is that riot control agent 
CS exists as a family of three forms: CS, CS 1 and 
S2. he agent sy bol 'CS' identifies the co pound 
in pure form and the symbols 'CS 1 ' and 'CS2' 
identify ixtures of crystalline agent and an aerogel. 
CS is prepared as the condensation product of 0-
chlorobenzaldehyde and malononitrile or the condensation 
product of o-chlorobenzaldehyde with cyanoacetamide 
 s s t y ration. It is  ite r st lli  
powder with a olecular weight of 188 corresponding 
to a olecular for ula of CLOH,N2Cl. The elting and 
boiling points are 93DC and 3IODC, respectively. It has a 
pungent pepper-like odor and is immediately detectable. 
The vapor is several times heavier than air, and the 
vapor pressure of the solid is 0.00034 g at 20DC. 
It is sparingly soluble in water and readily soluble in 
ethylene chloride. The olar solubility in ater at 
0DC i  .0 X --1 l I-I (= ~4 g 100 l- I)   
hydolyzes somewhat slowly-the hydrolysis products are 
o-chlorobenzaldehyde and malononitrile. Chemically, CS 
is the most persistent of lacrimatory agents and will absorb 
into ost porous surfaces. 
ibenz[b,{]l: 4-oxazepine (C ) 
Oibenz[b,f]I : 4-oxazepine, having the ilitary designa-
tion CR, is synthesized by the reaction of o-acylamino-
diphenyl ether and polyphosphoric acid and other methods 
can be used to obtain the product. It is a pale yellow 
solid that is chemically stable in organic solvents. It has a 
molecular weight of 195 corresponding to a molecular for-
ula of C 13Hg ON. The olar solubility in water at 20 DC 
i  .5 X 10--1 l - 1(= ~7 mg 100 ml- I). The melting 
and boiling points are 72 DC and 335°C, respectively. The 
vapor is 6.7 ti es heavier than air. he vapor pressure of 
the solid is 0.00059 g at 20 DC. It is soluble in ater 
and in organic solvents (e.g. ethanol, propylene glycol). 
Riot control agent CR solution consists of 0.1 % CR dis-
solved in a solution of 80 parts of propylene glycol and 
20 parts of water. It may persist for prolonged periods in 
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 r e t ,   ass  , -
ia ne   e  e  s i . 
loroacetophenone (C ) 
oroacetophe ne as i   s   
 t   e re     w- to-
, -chl r t enone,  l ri , -
hloro-I- l t   l l r t l t . 
It is r r   t  l ri tio  f t  it  
l i  l ri    t  ilitar  i ti  
. is la i at r  l  tl  t  l  
a    as  i l     nt.  
  s a ts (e.g.    S)  
O -  O-s ri s ri t tr l ts. t r sent,  
i  i e  l t   t   ilit ry; r, it 
i  till  i  li   i t .  r i  
as the principal co ponent in a liquid ixture under 
  ' e'.    ine l    
l l r i t f 54.5 rr i  t   lecu-
l r f r l  f gH70Cl.  l r solubilit  t 0 DC 
 .4 X -3 l 1- 1(=    l- I). lti   
ili  i ts  4 DC  47 DC, spectively.  
density of the solid is 1.31 g cm-3 at 0 DC and the den-
sity f the liquid is 1.187 g -3 at 58 Dc. he vapor is 
.3   t  ir.     t  oli  
 .6  0-3  t O°C, .1 X 0-3  t 0°C  
5.2  0-3 rr t 0 DC. 
 ( ) 
Oiphenyla inochloroarsine as developed as a che ical 
    i    
as ada site, ith the ilitary designation O . It as pro-
 l i  ntil it    t  N- ri  
of lacri atory co pounds. In the past, O  has found use 
ls  s  ff ti  sticide. It s  l l r i t of 
 it   l l r f r l  f 6H.(AsCl)(NH)C6H •. It 
is a yello ish and odorless solid that is very stable in pure 
for . he elting point is 195 DC and the vapor pressure 
is negligible (2 x 10- 13 g at 20 DC). s a solid the 
rate of hydrolysis is not significant o ing to the for a-
ti n f n i  oating; o ever, t  r te of r l sis is 
rapid when it is in the for  of an aerosol. Hydrolysis prod-
ucts ar  r l ri  i   i l r i  acid.  
nausea-causing effect and toxic by-products (i.e. arsine-
based co pounds) has led to its discontinued use/ban on 
civilian popUlations. 
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360 E J OLAJOS AND H SALEM
ACUTE SENSORY IRRITATION OF RIOT
CONTROL AGENTS
Ocular Effects
Many chemicals possess more or less lacrimatory prop
erties varying in irritancy from mild to very severe Irri
tancy data ocular and human toxicity estimates for the
common riot control agents are highlighted in Table 1
and the comparative ocular irritancy for humans of vari
ous lacrimatory compounds is presented in Table 4 The
most characteristic property of riot control agents is their
ability to cause an intense and immediate stinging sen
sation in the eyes with tearing at low concentrations
resulting in a temporary disabling Low levels of riot con
trol agents produce reversible and non injurious effects
however with some of these compounds high concentra
tions can produce ocular injury Excessive exposure to riot
control agents can produce ocular injury such as corneal
edema which is reversible More serious consequences
involving the eye following exposure to riot control agents
include corneal ulceration and scaring corneal opacifica
tion and corneal vascularization Tearing agents that have
been associated with ocular injury include chloroacetophe
none CN chloracetone and bromobenzyl cyanide Con
cerning ocular injury and desemination techniques it may
be stated that ocular injuries are more prevalent following
use of explosive thermal type tear gas devices as con
trasted to solvent spray type tear gas devices MacLeod
has provided a description of the differences between ther
mal and solvent spray devices The reader is referred to
a number of publications which include reviews regard
ing riot control agent induced ocular injuty 39 Ocular
effects are described in greater detail for each of the main
riot control agents
Oleoresin capsicum OC capsaicin and capsaicinoids
Typical ocular signs and symptoms associated with expo
sure to aerosols of oleoresin capsicum consist of lacrima
tion conjunctival inflammation redness severe burning
pain swelling and blepharospasm In humans exposure to
OC can cause loss of the blink reflex Capsaicin applied to
the eye leads to neurogenic inflammation vasodilatation
and extravasation and unresponsiveness to chemical and
mechanical stimuli It has been reported that the topical
application of capsaicin eliminates the blink reflex for up
to 5 days following dosing Systemic administration of
capsaicin is associated with trigeminal nerve fiber degen
eration in the cornea
Chlorobenzylidene malononitrile CS The ocular
effects of CS aqueous and non aqueous solutions have
been studied in both animals and humans The effects
on the rabbit eye have been examined following topical
application of CS Conjunctivitis was a common find
ing which had completely subsided within a few hours
Moderate injury involving the cornea was not observed
Application of more concentrated solutions of CS also
had no effect on the cornea Animal studies have demon
strated that the potential for eye damage with CS is signif
icantly less than with CNd7 39 Studies by Ballantyne and
Swanston indicate that the human eye is more sensitive
to CS aerosol than to CS in solution
Dibenzf14oxazepine Higginbottom and Sus
chitzky had reported the occurrence of intense
lacrimation and skin irritation on exposure to CR
Studies on the irritancy of CR and that of the riot
control agents CN and CS have been conducted in
various animal species41155 Owens et al evaluated
the ocular effects of 1 CR solutions in rabbits and
monkeys after single or multipledose application Mild
and transitory eye effects namely slight redness and
mild chemosis were observed in rabbits and monkeys
after a single application of 1 CR solution Multiple
applications over a 5 day period of CR solution to the
eye resulted in only minimal ocular effects Rengstorff
et al reported moderate conjunctivitis following the
application of CR 5 solution to the eyes of rabbits
and histological examination revealed normal corneal
and eyelid tissues Biskup et al also reported the
absence of ocular irritation in animals following single or
repeateddose applications of I CR solution The ocular
irritant potential of CR in several species was studied
also by Ballantyne and Swanston who formulated
estimates of the median threshold concentration TC50
for blepharospasm By utilizing procedures developed
for CS they conducted a comparative study including
human subjects to assess the irritant potency of CR
Dilute solutions of CR in saline were applied to the
eyes to ascertain the threshold concentration for producing
uncontrollable closure of the eyelids blepharospasm
Comparative TC50 values computed for several animal
















Acrolein High Rapid 27 50 350
Benzyl bromide High Rapid 4 50 4500
Bromobenzyl cyanide Profound Rapid 015 08 350
Chloroacetone High Rapid 18 100 2300
Chloropicrin High Rapid 29 50 2000
DM High Rapid 1 5 650
Xylyl bromide High Rapid 5 15 5600
When more than one value has been reported a range is given
Estimate for minimal lethal concentration for 10min exposure
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 iot tr l ts  i lighte  i  le , 
and the co parative ocular irritancy for hu ans of vari-
ous lacri atory co pounds is presented in able 4. he 
st istic t  f riot  ts  t r 
ability to cause an intense and i ediate stinging sen-
sati  in the e es, ith teari  at l  c ce trati s, 
r lting i   te rar  is li .  le els f ri t n-
tr l ts r  r r i le  -i j rious ff ts; 
r, ith s e f t es  s i  tr -
tions   l  i j r . ces i e s e t  i t 
tr l ts  roduce l r injur    r l 
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i l ing t   llo ing s re t  iot t l ts 
i lude r e l l r ti   ring, r l cifi -
tion and corneal vascularization. Tearing agents that have 
 i te  it  l  i j r  i l  l t phe-
 (C ), ra    i . -
cerning ocular injury and dese ination techniques, it ay 
be stated that ocular injuries are ore prevalent follo ing 
use of explosive (thermal type) tear gas devices as con-
trasted to solvent spray-type tear gas devices. ac eod30 
as r ide  a escri ti  f t e ifferences et ee  t er-
al a  s l e t s ra  e ices. e rea er is referre  t  
 er f lications (which i lude r i s) r r -
i  ri t c tr l a e t-i ce  c lar i jury.30-  c lar 
ffe ts r  ri  i  r t r t il f r  f t  i  
riot control agents. 
Oleoresin capsicum (OC), capsaicin and capsaicinoids. 
ical c lar si s a  s t s ass ciate  it  e o-
s r  t  r s ls f l r si  si  sist f l ri a-
ti , c j cti al i lla ati , re ess, se ere r i  
ai , s elli  a  le ar s as . I  ans, e s re t  
OC can cause loss of the blink reflex. Capsaicin applied to 
the eye leads to neurogenic infla ation (vasodilatation 
 tr sation)  r i  t  i l  
echanical sti uli. It has been reported that the topical 
application of capsaicin eli inates the blink reflex for up 
t   a s follo ing osing. 40 ste ic a i istration f 
s i i  is ss iatcd it  tri i l cr c fi r n-
  t  rnea.41 
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applications over a 5-day period of  solution to the 
eye resulted in only ini al ocular effects. engstorff 
et al. 55 reported oderate conjunctivitis follo ing the 
application of  (5% l ti n)     i , 
and histological exa ination revealed nor al corneal 
a  e eli  tiss es. is  et l.54 als  re rte  t e 
a se ce f c lar irritati  i  a i als f ll i  si le- r 
r t -dose li ti s f 1 %  s l ti .  l r 
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for blepharospasm. By utilizing procedures developed 
f r , t  t   r ti  t  i l i  
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il t  s l ti s f  i  s li  r  li  t  t  
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Table 4-0cular irritancy thresholds and toxicity esti ates for hu an responses to various lacri ogenic 
compounds! 2.-1..6 H1.L2 17 ]<}.2l) 
Irritancy' 
    
 i it   (m  -3 ) 
i  i  i  -7 
l i  i  i   
Bro obenzyl cyanide  i  .15 
 i  i   
hloropicrin igh apid -9 
O  i  i  ~1 
ylyl bro ide igh apid ~5 
'  r  t   v l  s  r orted,  r  is iv . 
b ti t  f r i i l l t l tr ti  f r -mi  osure. 
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RIOT CONTROL AGENTS
species are TC5o 79 x 105 M for rabbit TC5o 35 x
105 for guinea pig The TC5o to produce sensation
on the human eye is 49 x 10 M 91 x 10 mg 1
solution It was determined that the TC50 to produce
blepharospasm for man is 86 x 10 M It was suggested
that CR at a concentration of 3 x 10 M would be
incapacitating based on extrapolation from human eye
data on sensation In general their findings suggest that
the molar concentration required to elicit threshold effects
on the human eye is less for CR than for CS They
further postulated that a CR concentration of 025 M
5 solution would not produce structural damage to
the eye when applied to the conjunctiva Ballantyne and
Swanston also cited data by Hogg on the threshold
irritant response burning sensation of the human eye
to CR aerosol A TC50 for burning sensation of 40 x
10 mg m 40 x 106 mg 1 was calculated for CR
aerosol Thus the human eye is much more sensitive
to CR aerosol TC50 40 x 106 mg 1 than to CR
in solution TCSO 91 x 10 mg 1 Other studies
reported by Ballantyne et al included an investigation to
ascertain the effect of CR solution 1CR splashed on
the face and a study on the effects of very dilute solutions
0025 001 of CR on volunteer subjects subjected
to wholebody exposures After a 15 s individual drench
with CR subjects experienced intense stinging of the
eyes profuse lachrimation injection of the conjunctivae
and blepharospasm The stinging of the eyes was very
rapid in onset occurring within seconds Additionally
there was a rapid onset of stinging of the skin around
the eyes which rapidly intensified to a strong burning
sensation Group drenches of I min in duration also were
conducted The ocular effects noted were similar to those
observed in the individual 15s drenches Compared with
CR responses elicited by CS were of shorter duration
less severe and more variable It should be noted also that
following CS exposure stinging of the eyes was the first
biological effect seen From the data it was concluded
that even very dilute solutions of CR0025 001
produced sensory ocular effects Ballantyne et ali also
conducted extensive studies on the ocular effects of
CR as an aerosol 360571 mg m 30min exposure
as a solid 015 mg and as a solution 110
in polyethylene glycol Measurements of intraocular
tension and corneal thickness were conducted as well
as histological examination of the eyes The CR in
solution resulted in mild to moderate concentration related
ocular effects that persisted for several days transient
at the higher concentrations Solid CR resulted in
lacrimation and minor irritation of the conjunctivae and
eyelids Exposure to CR aerosol Ct of 10800 and
17 130 mginm resulted in mild lacrimation and
conjunctival injection with clearing in 1 h Solutions of
CR produced reversible dose related increases in corneal
thickness Ballantyne et al concluded that CR produced
considerably less damage to the eye than CNand that there
was a much greater degree of safety for CR than CN
Chloroacetophenone CN Chloroacetophenone is a
highly potent irritant that is more likely to cause
serious eye effects than either CR or CS The ocular
irritation caused by CN signals avoidance and the
intense lacrimation and blepharospasm initiate a defense
mechanism High concentrations of CN may result in
361
chemical injury to the eye with corneal and conjunctival
edema corneal edema erosion or ulceration chemosis
and focal hemorrhages The CNinduced ocular
effects on the rabbit eye following treatment with various
CN formulations have been investigated by Gaskins
et al and Ballantyne et a1 Ocular effects included
lacrimation chemosis iritis blepharitis and keratitis the
severity depending on the formulation of CN
Adamsite DM Immediate effects such as eye irrita
tion and lacrimation on exposure to DM are similar to
those associated with tear gas compounds 60 Local appli
cation of DM to rabbit eyes resulted in conjunctivitis
blepharitis and corneal opacity Ballantyne2 described
the ocular effects of human inhalation exposure to DM
consisting of lacrimation blepharospasm and eye pain
Additionally DM has been noted to produce necrosis of
the corneal epithelium in humans 12
Dermal effects
Although the eyes and respiratory tract are the primary
organs affected by riot control agents the skin also is often
involved Riot control agents are primary irritants that in
low concentrations produce a tingling or burning sensation
and transient erythema At higher concentrations agents
such as CN CS and DM can cause edema and blistering
In addition riot control agents can produce allergic contact
dermatitis after an initial exposure The effects of riot
control agents on the skin are successfully treated with
topical steroid preparations and oral antihistamines for
itching Appropriate antibiotics are administered to treat
secondary infection
Capsaicincapsaicinoids Dermal exposure to aero
solized OC produces an intense burning pain tingling
edema erythema and occasionally blistering Carpen
ter and Lynn studied the dermal sensory and vascular
response in humans following topical application of cap
saicin Topical application of capsaicin has been reported
to deplete the skin of a variety of biochemical constituents
including substance P somatostatin prostaglandin and
acetylcholine Studies by Wallengren et al demon
strated that topical pretreatment with capsaicin enhances
different experimental inflammations including allergic
dermatitis Multiple exposures of the skin over a period of
minutes exaggerate the response It is postulated that cap
saicin amplifies inflammation via the release of substance
P from the skin
Chlorobenzylidene malononitrile CS Chloroben
zylidene malononitrile is a primary irritant that elicits
injurious action on the skin when applied topically either
as a powder or as a solution or on exposure to CS
aerosol61 At areas of clothing contact excessive per
spiration may contribute to the development of dermal
lesions Gutentag et al 15 and Bowers et al reported the
occurrence of erythema and vesiculation in human sub
jects topically exposed to CS powder or CS solution
Exposure to CS aerosols at a concentration of 300 mg m3
for 45 min produced erythema and vesiculation however
skin lesions were not evident at an exposure duration of
Published in 2001 by John Wiley Sons Ltd J Appl Tocic l 21 355 391 2001
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species are: TC50 = 7.9 X IO-s  for rab it; T 50 = 3.5 X 
10-5 for guinea pig. The TCso to produce sensation 
on the human eye is 4.9 x 10-7  (9.1 X 10-2 g I-I 
solution). It was deter ined that the TCso to produce 
blepharospasm for man is 8.6 x 10-7 . It as suggested 
that CR at a concentration of 3.3 x 1 .-6  ould be 
incapacitating, based on extrapolation fro  human eye 
data on sensation. s2 In general, their findings suggest that 
the olar concentration required to elicit threshold effects 
on the hu an eye is less for  than for S. They 
further postulated that a R concentration of < 0.25  
(5% solution) ould not produce structural da age to 
the eye when applied to the conjunctiva. Ballantyne and 
anston also cited data by oggS6 on the threshold 
irritant response (burning sensation) of the hu an eye 
to CR aerosol. A TCso for burning sensation of 4.0 x 
10-3 mg m-3 (4.0 x 10-6 g I-I) as lated for  
a r l. , the a   i  uc  re iti e 
to  aer s l (T 50 = 4.0 X 10-6 mg I-I) tha    
i  s l tion (T 50 = .1 X 0-2  I-I). ther ies 
reported by Ballantyne et al. 57 included an investigation to 
ascertain the effect of CR solution (I % CR) splashed on 
the face, and a study on the effects of very dilute solutions 
(0.0025-0.00 1%) of CR on volunteer subjects subjected 
to whole-body exposures. After a 15-s individual drench 
with CR, subjects experienced intense stinging of the 
eyes, profuse lachrimation, injection of the conjunctivae 
and blepharospasm. The stinging of the eyes was very 
rapid in onset, occurring within seconds. Additionally 
there was a rapid onset of stinging of the skin around 
the eyes, which rapidly intensified to a strong burning 
sensation. Group drenches of 1 min in duration also were 
. he lar e ts ted   t  se 
observed in the individual 15-s drenches. Co pared with 
CR, responses elicited by CS ere of shorter duration, 
less    l .       
following CS exposure stinging of the eyes was the first 
biological effect seen. From the data, it was concluded 
that even very dilute solutions of CR (0.0025-0.001 %) 
produced sensory ocular effects. Ballantyne et al.53 also 
te   es      
 as an aerosol (360-571 g -3 , 30-min exposure), 
as a solid (0.1-5 mg) and as a solution (1-10% 
in polyethylene glycol). Measurements of intraocular 
   e   t ,   
as histological examination of the eyes. The CR in 
s l ti  res lte  i  il  t  erate c ce trati -relate  
ocular effects that persisted for several days-transient 
at the higher concentrations. Solid CR resulted in 
lacri ation and inor irritation of the conjunctivae and 
eyelids. Exposure to CR aerosol (et of 10800 and 
17130 g·min -3 ) l  i  i    
conjunctival injection, with clearing in 1 h. Solutions of 
CR produced reversible dose-related increases in corneal 
thickness. Ballantyne et al.s3 concluded that CR produced 
considerably less damage to the eye than CN and that there 
was a much greater degree of safety for CR than CN. 
hloroacetophenone ( N). hloroacetophenone is a 
highly potent irritant that is more likely to cause 
serious eye effects than either CR or CS. The ocular 
irritation caused by CN signals avoidance, and the 
intense lacrimation and blepharospasm initiate a defense 
mechanism. High concentrations of CN may result in 
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30 min Workers in a CS manufacturing and process
ing plant developed rashes pruritis vesicles and wheals
which may have been representative of sensitization and
reaction to reexposure Rothberg continued that both
CS and CNcould produce skin sensitization in guinea pigs
when administered topically and intradermally Fuchs and
in der Wiesche conducted patch testing of individuals
who had been exposed to CS or CN during civil distur
bances Skin symptoms were reported in over 50 of the
individuals exposed and positive test reactions to CS and
CN were observed
Dibenzf14oxazepine CR The effects of CR
on the skin are generally limited to the production of
transient erythema and contact with CR does not induce
vesication or contact sensitization or delay the healing of
skin injuries 972 The burning sensation on exposure to
CR persists for 1530 min and erythema may last for
1 2 h Considerable interest in the cutaneous effects of
sensory irritant compounds has led to several studies on
the dermal effects of CR in humans 7213 Weigand and
Mershon studied the dermal effects of dilute CR and
CS solutions Test subjects were patch tested on various
anatomical sites with concentrations of test article rang
ing between 01 to 10 exposure duration was for 5
or 30 min A stinging sensation was evident on expo
sure to both compounds with CR eliciting a response of
greater intensity The onset of stinging was more prompt
at higher ambient temperatures Transient erythema of
varying degree was evident which subsided within 4 h
Holland evaluated skin reactions to CR in humans after
application of varying amounts of CR as a powder or as
dry material moistened with saline Erythema was noted
in 10 min which faded on removal of test article when
moistened CR produced marked irritation No swelling
or vesication was evident even under adverse conditions
It was concluded that CR is capable of producing acute
cutaneous discomfort In comparing the results with sim
ilar studies on CS and CN Holland12 concluded that all
reactions to CR were mild and transient compared with
that of CS which resulted in an erythema of greater dura
tion and with that of CN which produced blistering
Ballantyne and coworkers drenched volunteer subjects
with very dilute solutions of CR and CS for durations
of 15 and 60 s In the studies comprising subjects that
were exposed individually stinging of the skin around
the eyes was rapid in onset which spread to other parts
of the face The burning sensation involving facial skin
was the next pronounced feature for approximately the
first minute Scalp and ears usually were not affected
During the second minute stinging was associated with
the back of the neck and irritation of the genital area
Stinging of the shoulder and back followed at 34min
and the burning sensation was intense by 5 min Other
anatomical sites egchest abdomen thighs and buttocks
were affected at 5 min The burning sensation of the
skin was intense primarily affecting the trunk and back at
10 min Approximately 15 min from the onset of expo
sure the skin sensation had subsided By 20 min the skin
sensations were reduced to mild tingling or had disap
peared Erythema of the skin was produced within several
minutes and persisted for 1 2 h no other skin effects were
noted Many areas of the skin were rather resistant to irri
tation which included such sites as the ears nose scalp
palms of the hands knees and the lower legs In general a
more intense response was elicited by CR at higher con
centrations however it should be noted that individual
variations were more marked than the differences between
CR concentrations In the group drenching studies burn
ing of the skin was the most prominent symptom As
with the individual drenches considerable variation in the
severity of the symptoms was manifested Compared with
CR the effects elicited by CS were less severe of shorter
duration and more variable Stinging of the skin followed
a similar progression face neck genital areas shoulders
and back chest abdomen and thighs to that seen with the
CR drenches The studies by Ballantyne and coworkers
demonstrated that very dilute solutions of CR and CS pro
duce a strong stimulation of sensory receptors in the skin
and mucous membranes The burning sensation was more
intense and of longer duration on exposure to CR than
with CS Skin irritation and erythema were evident fol
lowing exposure to either CR or CS and the signs were
more pronounced with CS than with CR No individual
drenched with CR or CS manifested edema vesication or
desquamation
Chloroacetophenone CN Exposure to CN has been
associated with primary irritation and allergic contact
dermatitis It is a potent skin irritant and is more
likely to cause serious effects of the skin compared with
that induced by CS or CR Severe exposure to CN results
in skin injury that may consist of severe generalized
itching a diffuse and intense erythema severe edema and
vesication In addition to being a more potent skin irritant
than CS CN is considered a more potent skin sensitizer
Adamsite DM Skin effects include erythema and
local application can produce skin necrosis Adamsite is
not a skin sensitizer based on studies by Rothberg
TOXICOLOGY OF RIOT CONTROL AGENTS
Riot control agents generally regarded as having low
toxicity are potent sensory irritants that elicit acute site
specific toxicity see Fig 2 and Tables 3 and 4 These
agents have been described as non lethal Exposure to riot
control agents may occur via inhalation dermal and oral
routes of exposure These compounds primarily act on
the eye which is the most sensitive target organ how
ever the majority of these compounds also will affect the
pulmonary system and the skin Riot control agents can
cause some or all of the effects on these target organs to
a greater or lesser extent Effects immediately produced
on exposure to riot control agents are intense irritation
of the eyes marked irritation of the nose throat and
lungs and irritation of the skin The margin of safety
between the amount causing an intolerable effect and
that which may cause serious adverse responses is large
For instance the lethal quantity for the tear agent CS is
estimated to be 2600 times as great as the dosage nec
essary to cause temporary disabling Permanent adverse
effects usually do not accompany riot control agents how
ever the risks for deleterious effects long term effects
or even lethality increase with higher exposure levels
andor greater exposure times The acute and shortterm
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RIOT CONTROL AGENTS












Figure 2 Acute site specific toxicity of riot control agents
repeateddose toxicity of riot control agents have been
studied adequately however the extent of our knowl
edge concerning the long term and chronic toxicity of
these compounds is somewhat limited The animal and
human toxicology of modern riot control agents CS CR
CN DM and OC is presented Topics covered include
comparative toxicology dose effect relationships target
organ effects lowdose toxicity biochemistry and mech
anismsinteractions
Mammalian toxicology acute toxicity
Oleoresin capsicum OC and capsaicin Oleoresin
capsicum OC is obtained from pepper plants and is
a mixture containing capsaicinoids including the active
ingredient capsaicin 8methylNvanillyl6 nonenamide
and other compounds A highly effective irritant OC has
received much attention as a less than lethal agent within
civilian governmental and military sectors The OC spray
pepper spray has gained popularity as a police weapon
in recent years Oleoresin capsicum is a natural product
and is generally considered safe which is a viewpoint
that is not necessarily accurate It has been incorporated
into various formulations and marketed as pepper spray
pepper gas and pepper mace for law enforcement
civil disturbance control purposes criminal incapacita
tion and self defense As a spray OC quickly produces




elicits respiratory related responses such as nasal irrita
tion bronchoconstriction severe coughing and sneezing
and shortness of breath Oleoresin capsicum addition
ally causes burning sensation of the skin and neuromotor
dysfunction ie loss of motor control Consequently
exposed individuals in most cases can be subdued easily
Acute effects of capsaicin and capsaicinoids are associated
chiefly with the pulmonary system eg bronchospasm
respiratory arrest pulmonary edema but also may encom
pass hypertensive crisis and hypothermia Suprathreshold
levels of capsaicin can result in serious respiratory and
cardiovascular effects as well as permanent damage to
the sensory nervous system There have been a consid
erable number of deaths related to OC use Although
a causal relationship has not been established most of
the reported deaths have occurred within an hour after
exposure Additional information on the chemistry phar
macology toxicology and physiology of OC capsaicin
and capsaicinoids can be found in numerous articles and
reviews14407993
As early as the 1920s capsaicin was prepared for eval
uating the physiological and pharmacological effects in
humans Interest in the development of capsaicin as a
riot control agent waned as research efforts were directed
to understanding the biological actions of the newly
synthesized agent CS Unlike other lacrimatory agents
such as CN CR and CS which have definite chemical
compositions OC is a mixture of compounds containing
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capsaicin and its structural analogs various acids and
esters alcohols aldehydes ketones and carotenoid pig
ments 99 Numerous compounds in OC have been iden
tified via gas chromatographymass spectrometry GC
NIS by Keller et a1 The capsaicinoid content of the
dried fruit has been reported to range from 01 to 1
The capsaicinoid content of the oleoresin is as follows
capsaicin 70 dihydrocapsaicin 20 norhydro
capsaicin 7 homocapsaicin 1 and homodihy
drocapsaicin 1 Because capsaicin is the principal
active ingredient of OC little consideration has been given
to the other capsaicinoids with regard to their biologi
cal effects and mechanism of action Generally these
analogs have effects similar to capsaicin although with
different potencies
Toxicological studies have been conducted on both cap
saicin and OC however despite extensive field applica
tion few formal evaluative studies of OC have been con
ducted Because OC is a much utilized food component it
is widely regarded as safe with a low degree of toxicity
Overall data on the toxicology of OC is extant partic
ularly regarding effects following exposure to OC via
inhalation Recent inhalation studies on OC have indicated
that the toxicity of OC may be minimal following inhala
tion exposure R Mioduszewski 1997 unpublished data
Ref 102 Debarre andcoworkers conducted nose only
inhalation exposures in rats to ascertain the effects of
aerosolized OC and various solvents Pulmonary physi
ology parameters were evaluated to determine alterations
in respiratory function as well as histopathological evalu
ation of pulmonary tissues The salient finding follow
ing exposure to OC was a decreased minute volume
Histopathological changes included interstitial edema of
the lungs and epithelial lesions of the trachea Debarre
et al suggested that additional studies are needed using
an animal model of bronchial hyperresponsiveness ie
rat see Ref 103 to assess better the risk of individu
als with compromised pulmonary function to riot control
agents and irritant chemicals
The pharmacological and toxicological effects of cap
saicin are far better characterized than that ofOC In vivo
the severity of toxic effects depends on factors such as
route of administration the dose of capsaicin and the age
of the animal Pertaining to capsaicin toxicity Glinsukon
etal have derived LD50 values for capsicum extracts
and capsaicinoids Representative values for capsaicin are
056mg kg iv 76 mg kg ip 78 mg kg jm
90mg kg sc 190 mg kg intragastric 512 mg kg
dermal and 16 mg kg intratracheal It was noted that
the toxicity of capsaicin in the capsicum extract was about
four fold greater than that of pure capsaicin administered
intraperitoneally Findings indicated that guineapigs were
more susceptible than mice or rats whereas hamsters and
rabbits were less vulnerable to the toxic actions of cap
saicin The most likely cause of death was respiratory
paralysis
Pharmacological and toxicological studies to include
inhalation exposureshave contributed to a better under
standing of capsaicininduced effects and actions on the
living organism The multivaried pharmacological actions
of capsaicin and capsaicinoids were characterized in the
19500 and further elucidated in the 1980s for
reviews see Refs 40 and 110112 Capsaicin has a spec
trum of effects on sensory neurons ranging from excita
tion to cell death and as stated previously suprathreshold
amounts of capsaicin can cause irreversible damage to
the sensory nervous system The functions of
capsaicin sensitive sensory neurons representative ther
apeutic applications of capsaicin and pathophysiological
implications following treatmentexposure to suprathresh
old doses are highlighted in Table 5 It has been assumed
generally that capsaicinsneurotoxic effects are limited to
sensory neurons with smalldiameter unmyelinated affer
ent processesd011I 11245 150 however findings reported by
Ritter and coworkers1515 suggest that capsaicin induced
neurotoxicity is more widespread in the nervous system
than previously assumed Systemic administration of cap
saicin produces degeneration of cell bodies axons and
nerve terminals at specific sites throughout the entire neu
roaxis Capsaicin has been used as a selective probe to
study the role of neurogenic inflammation a phenomenon
resulting from stimulation of certain types of sensory
nerves producing vasodilatation and extravasation Ref
erence to this condition as neurogenic inflammation is
attributed to Jancso and has been the object of exten
sive researchthe reader is referred to Refs 112114
147 150 157 162 Capsaicin also has been used to elu
cidate the role of nociceptors and has gained the status of
an invaluable tool in sensory neuron research
In addition to capsaicin induced effects on thin sen
sory neurons capsaicin exerts action on non sensory
neurons and non neural excitable cells The cell non
selective effects of capsaicin include inhibition of cardiac
muscle excitability 1631 inhibition of visceral smooth
muscle activity16566 and contraction of vascular smooth
muscle 1611 In addition capsaicin has been reported to
Table 5Functions of capsaicin sensitive sensory neurons
pathological implications of capsaicin exposure and clinical
applications
Functions of capsaicinsensitive sensory neurons
Visceral afferents Somatic afferents
Afferent function Afferent function
Nociception and reflex Nociception and reflex
homeostasis homeostasis
Cardiovascular regulation Cardiovascular regulation
Efferent function Efferent function
Neurogenic plasma Neurogenic plasma
extravasation extravasation
Vascular control Modulation of inflammatory
Mucous secretion reactions
Smooth musclecontraction Antidromic vasodilatation
Pathological implications of Representative clinical
capsaicin damage applications of capsaicin
Reduced response in Ablation of skin
detecting noxious stimuli inflammatory responsesie
and loss of homeostasis whealing
Weakened resistance of Treatment of urogenital
tissueiegastric to dysfunction iebladder
injurious stimuli altered hyperreflexia
gastric mucosal defense
mechanisms
Skin pathophysiology as a
result of altered blood flow
and vascular permeability
Corneal opacities
Pathological implications from Refs 134142 clinical applica
tions from Refs 142 144
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0.56 mg kg-I i.v., 7.6 g kg-I i.p., 7.8 g kg-I i.m., 
9.0 mg kg-I s.c., 190 mg kg-I intragastric, 512 g kg-I 
der al and 1.6 g kg-I intratracheal. It was noted that 
the toxicity of capsaicin in the capsicu  extract as about 
four fold greater than that of pure capsaicin ad inistered 
intraperitoneally. Findings indicated that guinea-pigs ere 
ore susceptible than ice or rats, hereas ha sters and 
rabbits ere less vulnerable to the toxic actions of cap-
saicin. he ost likely cause of death as respiratory 
paralysis. 
Phar acological and toxicological studies-to include 
inhalation exposures-have contributed to a better under-
standing of capsaicin-induced effects and actions on the 
living organis . he ulti-varied phar acological actions 
of capsaicin and capsaicinoids were characterized in the 
1950s 105- J09 and further elucidated in the 1980s (for 
revie s, see efs 40 and 110-112). apsaicin has a spec-
tru  of effects on sensory neurons, ranging fro  excita-
tion to cell death, and as stated previously suprathreshold 
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RIOT CONTROL AGENTS
influence various metabolic processes Importantly the
cell non selective effects of capsaicin are usually produced
by concentrations of capsaicin that are far in excess of
those needed to stimulate sensory neurons
The airway mucosa is highly sensitive to capsaicin
and exposure to this substance leads to intense irrita
tion which in severe cases is highly painful to the nasal
passages In the nasal passages activation of capsaicin
sensitive sensory nerves results in profound vasodilation
secretion and increased nasal mucosal volume Capsaicin
markedly influences pulmonary function and mechanics
and the pulmonary toxicology of capsaicin has been stud
ied in some detail Capsaicin activates protective reflexes
such as avoidance4014871 or bronchoconstriction sneez
ing coughing and apnea and rapid shallow breathing
in response to airway irritation 12 175 Apnea followed
by rapid shallow breathing is the classical chemoreflex
response on stimulation of sensory neurons in the lung
All of the aforementioned reflexes function to restrict
access of irritant material to lower airways Furthermore
activation of sensory neurons of the upper and lower res
piratory tract is associated with increased vascular perme
ability to plasma proteins in the airway mucosa 176 Other
reflexes involve cardiovascular 177 neuroendocrinelso
and thermoregulatory control mechanisms Cap
saicin may induce the Kratschmer reflex which on inhala
tion of an irritant causes cardiorespiratory dysfunction
which is characterized as consisting ofapnea bradycardia
and a biphasic fall and rise in aortic blood pressure
The bronchoconstriction and airway mucosal edema
manifested in laboratory animals and humans exposed
to capsaicin are phenomena associated with the release
of the neuropeptide substance P from sensory nerve
terminals The involvement of substance P in
capsaicin induced physiological effects is discussed in
a subsequent section on mechanisms of action and
interactions In addition to the depletion of substance
P there is also depletion of other neuropeptides
from primary sensory neurons namely neurokinin
A NKA calcitonin gene related peptide CGRP
somatostatin SOM and kassinin as revealed by
immunohistochemistry and radioimmunoassay 199
The pulmonary system effects of capsaicin are
species related In the guineapig intravenous and
intra arterial dosing causes bronchoconstriction 211 In
the dog and cat intravenous dosing of capsaicin
results in bronchoconstriction that is dependent on a
vagal cholinergic reflex Aerosol exposure of cats to
capsaicin also evokes a vagatmediated cholinergic reflex
bronchoconstriction 211 Studies designed to elucidate
the mechanism by which aerosolized capsaicin causes
bronchoconstriction in guineapigs suggest that a
vagal cholinergic and non cholinergic local axon reflex
contribute to this effect
Capsaicin induces complex effects on the cardiovascu
lar system tachypnea hypotension seen in the Bezold
Jarrish reflex bradycardia and apnea The cardiores
piratory effects of capsaicin have been studied follow
ing intravenous dosing Capsaicin treatment resulted in
a triphasic effect on blood pressure and altered cardiac
parameters203 204
Perturbations in thermoregulation can result after
exposure to capsaicin and capsaicinoids10 1062 523for
an authoritative review see Ref 120 Capsaicin has
been used for the last 25 years as the tool of
fc1T7
choice in elucidation of the physiological processes
underlying the control of body pain and temperature
It has been demonstrated that pretreatmenttr atme
of animals with capsaicin results in severely impaired
heat escape behavior and induces an irreversible
impairment in thermoregulation2056123In elevated
environments body temperature rose concomitant with an
inability to discriminate and seek cooler environments 212
Additionally capsaicin treated animals consumed less
water and became dehydrated Dermal blood vessels
failed to dilate and the animals did not take appropriate
behavior to prevent heat stroke Szolesanyi also
noted that sc administration of capsaicin reduced body
temperatures and that the dosing regimen resulted
in a tolerance to thermal regulation Studies by
Frens demonstrated that sc injections of capsaicin
decreased body temperature in goats On the subject of
nociceptors Konietzny and Hensel demonstrated that
topical treatment of human skin with 1 capsaicin and
capsaicinoids lowered the threshold to thermal pain The
collective data regarding capsaicininduced perturbations
of theimoregulation support the notion that capsaicin
and capsaicinoids have potentially adverse physiological
consequences to individuals exposed to these substances
at elevated temperatures as well as under conditions
involving repeateddose scenarios
The effects of capsaicin and capsaicinoids on the gas
trointestinal tract and nutritional impacts also have been
examined 211 2222 The duodenal mucosal response to cap
saicinoids and altered fat uptake by damaged duodenal
epithelium as reported by Nopanitaya and Nopani
taya and Nye has led to subsequent studies on the
alteration of nutrient absorption and metabolism by cap
saicinoids Studies by Sambaiah et al 21922 and Kawada
et al 121 indicated that capsaicinoids had no adverse effect
on fat intake or absorption The lipotropic and hypoli
demic effects of capsaicinoids also have been examined in
some detai12201 Sambaiah and Satayanarayana had
postulated that capsaicinoids counteract the accumulation
of fat in the liver by the reduction of hepatic lipogenesis
andor increased oxidation of lipids
Repeated administration of capsaicin produces systemic
desensitization to chemogenic and thermal nociceptive
stimulation 83225230 Desensitization may be considered
as the initial manifestation of the longterm neurotoxic
action of capsaicin on sensory neurons It implies a read
ily reversible functional refractoriness in the absence of
morphological changes Alterations in neurophysiology
concomitant with morphological changes are generally
viewed as implying neurotoxicity Experimental data sug
gest that exposure to high doses of capsaicin and its
analogs results in long lasting insensitivity to stimuli such
as irritants pain and temperature Capsaicininduced
desensitization which may be manifested for weeks is
associated with reversible structural changes Longterm
effects involving the pulmonary system are characterized
by desensitization of the airways to chemical irritants
and the marked inhibition of vagal bronchoconstriction
effects 116 It is postulated that capsaicin induced desen
sitization is caused by acute and excessive depletion of
the neurotansmitter substance P which is expressed as a
lack of normal physiogical response to stimuli such as
heat and cold High doses of systemic capsaicin produce
a permanent or long lasting desensitization of capsaicin
sensitive afferent nerves in newborn rats In adult rats
Published in 2001 by John Wiley Sons Ltd J Appl Toxicol 21 35539I 2001
001891
I  R L GE TS 365 
influence various etabolic processes. 169 I portantly, the 
ll non-s lective ffects of caps icin re us ll  roduced 
by concentrations of capsaicin that are far in excess of 
those needed t  sti ulate se s ry e r s. 
he ir a  ucosa is i l  s siti e t  s i in 
 e pos re t  t is s stance leads t  intense irrit -
ti , hich in ere cases is ig l  i f l t  t  l 
passages. 170 In the nasal passages, activation of capsaicin-
sensitive sensory nerves results in profound vasodilation, 
r ti , and increas  nasal ucosal vol . a s i in 
arkedly influences pul onary function and echanics, 
and the pulmonary toxicology of capsaicin has been stud-
ied in so e detail. apsaicin activates protective reflexes 
s  s a idance40.148. 71 r r stri ti , s z-
ing, coughing and apnea and rapid shallow breathing 
in response to air ay irritation. 172 - 175 pnea follo ed 
by rapid shallo  breathing is the classical che oreflex 
response on sti ulation f sensory neurons in the lung. 
 f   lexes u   t  
access of irritant aterial to lo er air ays. urther ore, 
activation f sensory neurons f the upper and lo er res-
piratory tract is associated ith increased vascular per e-
ability to plas a proteins in the air ay ucosa. 176 ther 
r flexes i lve r i vascular,I77-1 9 r rine l80 
and thermoregulatoryI2o.181,182 control mechanisms. Cap-
saicin ay inducc the ratsch cr reflex. hich on inhala-
tion f an irritant causes cardiorespiratory dysfunction, 
ic  is c aracterized as c sisti  f a ea, ra car ia 
and a biphasic fall and rise in aortic blood pressure. 
he bronchoconstriction and air ay ucosal ede a 
manifested in laboratory animals and humans exposed 
t  ca saici  are e e a ass ciate  it  t e release 
of the neuropeptide substance P fro  sensory nerve 
t i l . 183-189  in olve e t f t   i  
ca saici -i ce  si l ical effects is isc sse  i  
 s s t s cti   is s f ti   
interactions. In addition to the depletion of substance 
, t r  i  l  l ti  f t r r ti e  
fro  pri ary sensory neurons, na ely, neurokinin 
A (NKA), calcitonin gene-related peptide (CGRP), 
so atostatin (S ), and kassinin, as revealed by 
immunohistochemistry and radioimmunoassay. 175.190-199 
 pulmonary syste  effects of capsaicin are 
species-related. In the guinea-pig, intravenous and 
intra-arterial dosing causes bronchoconstriction.20o In 
the dog and cat, intravenous dosing of capsaicin 
results in bronchoconstriction that is dependent on a 
vagal cholinergic reflex. erosol exposure of cats to 
capsaicin also cvokcs a vagal-mediated cholinergic reflex 
bronchoconstriction.201 Studies designed to elucidate 
the echanis  by hich aerosolized capsaicin causes 
bronchoconstriction in guinea-pigs suggest that a 
vagal/cholinergic and non-cholinergic local axon renex 
tri t  t  t i  ffect. 202 
Capsaicin induces complex effects on the cardiovascu-
lar system: tachypnea, hypotension (seen in the Bezold-
larrish reflex), bradycardia, and apnea. The cardiores-
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the same doses elicit a long lasting but temporaneous
block of the nerves In both instances transmission of
pain in response to various noxious stimuli was inhib
ited or abolished in animals dosed with capsaicin The
effect is postulated to be capsaicin induced and the result
ing neurodegeneration of Cfiber receptors More recent
findings suggest that this effect can be dissociated by using
lower doses 211
Chlorohenzylidene malononitrile CS The com
pound ochlorobenzylidene malononitrile first synthe
sized in 1928 is an extensively used tear gas It is com
monly know as CS and is named after the initials of the
two British chemists who synthesized a number of ben
zylidene malononitriles including CS2 The riot control
agent CS was developed in the 1950s as a potent and
safe riot control agent and the US Army adopted CS as
their standard riot control agent in 1959 It is regarded
as a potent and generally safe riot control agent yet
as with this class of compounds high air concentrations
can lead to toxic reactions in experimental animals and
humans 642232 It has been studied extensively in animals
and humans and has been widely used around the world
with no verified deaths in humans following its use Like
CN and DM CS is a crystalline solid substance that is
soluble in organic solvents but poorly soluble in water
These compounds can be disseminated as dry powders
by thermal or explosive methods via spraying of the
molten materials or in solution with organic solvents A
micronized formulation of CS is CS2 which consist of
95 CS 5 CaboSiV Cabot Corp and 1 hexam
ethyldisilazane The additives prevent agglomeration and
produce a free lowing powder that can be dispersed from
powder formulation devices
Chlorobenzylidene malononitrile a peripheral sensory
irritant is highly irritating to mucous membranes that
cover or line tissues of the eyes nose throat and stomach
Ocular effects of CS include intense irritation excessive
tearing conjunctivitis discomfort and pain and uncon
trolled blinking blepharospasm The nose and mouth
may perceive a stinging or burning sensation concomitant
with excessive rhinorrhea or discharge of nasal mucous
Irritation of the respiratory tract prevalent following CS
exposure is also associated with sneezing and coughing
increased tracheobronchial secretions and tightness of the
chest Severe lung injury and consequent respiratory and
circulatory failure characterize death in experimental ani
mals after inhalation of CS Irritation of the gastrointesti
nal tract may cause vomiting andor diarrhea Exposure of
the skin to CS results in a burning sensation which may be
followed by inflammation and erythema The skin effects
may be more severe and result in blistering particularly
when exposure occurs in hot and humid conditions Within
30 s of exposure some or all of the aforementioned effects
may occur and subside andor disappear within minutes on
cessation of exposure The irritation during exposure is so
great that it causes an exposed individual to seek escape
from the exposure The lethal effect of CS by inhalation is
due to lung damage which leads to asphyxia and circula
tory failure Bronchopneumonia secondary to respiratory
tract injury also may be a cause of death Pathological
changes involving extrapulmonary tissues eg liver and
kidneys following exposure to high concentrations of CS
are secondary to respiratory and circulatory failure The
reader is referred to numerous publications concerning the
animal and human toxicity ofCS294274102j 239
The pharmacology of CS has been studied by Bis
coe and Shephard and Brimblecombe et al Brimble
combe and coworkers investigated the pharmacological
actions of CS pure or pyrotechnically generated admin
istered by various routes to animals and when applied to
isolated organs and tissues Following iv administration
a typical response to CS was a rise in arterial blood pres
sure Qualitative and quantitative species differences were
noted following CS treatment for example dogs appeared
less sensitive than cats to the cardiovascular effects of CS
Animals exposed via inhalation to pyrotechnically gener
ated CS manifested changes in respiratory parameters A
number of studies have been conducted to characterize
the acute toxic effects of CS which included incapac
itating studies by aerosol or vapor exposure as well as
skin and eye irritation studies The inhalation toxicity
of chemical warfare agents military chemicals and riot
control agents is by convention expressed by the nota
tion Ct It is defined as the product of the concentration
in mg m3 multiplied by the exposure time t in min
utes mginm The terms LCt and ict describe the
airborne dosages that are lethal L or incapacitating I
to 50 of the exposed population A number of animal
studies on CS have been reviewed and summarized in a
report by McNamara et al Various animal species were
exposed for 590 min to CS aerosols that were gener
ated using various dissemination techniques Toxic signs
observed in mice rats guineapigs rabbits dogs and
monkeys on acute exposure to CS were immediate and
included hyperactivity followed by copious lacrimation
and salivation within 30 s in nearly all species Goats pigs
and sheep did not manifest hyperactivity on exposure to
the test article The heightened activity that was observed
initially subsided rather quickly and by 5 15 min from
the start of exposure the animals exhibited lethargy and
pulmonary stress These latter effects continued for 1
h on cessation of exposure All other signs had abated
within 5 min on removal from the exposure atmosphere
When toxic signs were noted these occurred following
exposure via all dispersion methods Lethality estimates
expressed as Lct from acute exposures to CS dispersed
from 10n CS in methylene dichloride are as follows rats
1004000 mgmin m mice 627000 mgmin m and
guineapigs 46000 mgmin m3 No deaths occurred in
rabbits exposed to CS dosages of up to 47 000 mgmin
m Dosages up to 30000 mgmin m3 were not lethal to
monkeys including those that had associated pulmonary
dysfunction ie pulmonary tularemia The combined
LCt for CS dispersed from methylene dichloride for
rats mice guineapigs and rabbits was calculated to be
1230000 mgmin M3 The order of sensitivity of vari
ous animal species to molten CS is guineapig rabbit
rat dog mouse monkey The results from acute
exposures to CS sprayed as molten agent are presented
in Table 6 Because of their resistance to the lethal effects
of CS LQ values could not be calculated for swine
sheep and goats However the combined LCt for mice
rats guinea pigs rabbits dogs monkeys swine sheep
and goats was estimated to be 300000 mgmin m
The results LU from acute exposures to CS dispersed
from M18 thermal grenades are 164000 mgmin m3 for
rats and 36000 mgmin M3 for guinea pigs The order
of sensitivity to thermally generated CS is swine dog
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eys, i cl i  t se t at a  associate  l ar  
sf cti  (i.e. l ar  t laremia). e c i e  
LCtso for  dispersed fro  ethylene dichloride for 
rats, ice, i ea-pigs a  ra its as calc late  t  e 
1230000 g· in m-3. he order of sensitivity of vari-
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The LCt50 values have been rounded
off
rabbit goat guineapig rat monkey Results
from acute exposure to CS dispersed from M7A3 thermal
grenades are summarized in Table 7
Combining the results from all of the acute exposures
the LCt50 values are as follows all non rodents combined
36000 mgin m all rodents combined 79000 mgin
m and all species combined 61000 mgin m The
inhalation toxicity of CS2 which comprises 95 CS
5 CaloSil and 1 hexamethyldisilazane also has
been evaluated The results LCt from acute exposure
to CS2 are as follows rats 68000 mgin m3 guinea
pigs 49000 mgin m3 dos 70000 mgin m and
monkeys 74000 mginm
Cucinell et al reported the physiological and tox
icological effects of CS in rats and dogs exposed to
CS aerosol Because lungs of animals exposed to riot
control agents manifest edema hemorrhage and atelec
tasis studies in rats were conducted to assess the sur
factant and lysosome activity from lung washings of
CSexposed rats In these studies rats were exposed to
CS aerosols at Ct values that ranged from 40000 to
80000mgin m3 The findings indicated an increase
in the surface tension of the saline washouts of lungs
from CS exposed animals Analysis of lung lavage fluid
from CSexposed animals indicated an increase in B
glucuronidase suggestive of lysosomal activity follow
ing injury to the pulmonary tract Dogs were exposed
to CS aerosol at either a low or a very high concen
tration of test article In the low dose segment the face
of the animal was exposed to an airborne concentra
tion of 25 g I of CS for 30 s In the highdose study
the animals were exposed to an aerosol concentration of
2300 g l for 23 min which was equivalent to a Ct of
57000mgin m3 Physiological effects noted on expo
sure to the low level of CS aerosol consisted of alterations
Table 7Acute toxicity estimates
for CS grenade








The LCt50 values have been rounded
off
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in respiratory patterns and an increase in blood pres
sure The pattern of response observed was suggestive
of the Sherrington pseudoaffective response Exposure
to very high levels of CS aerosol resulted in respiratory
stress and mortalities however details were not given
Debarre and colleagues 102 conducted noseonly inhalation
studies on CS Results indicated altered lung physiol
ogy ie decreased minute ventilation and histopathlog
ical of changes eg cytoplasmic vacuoles and areas of
emphysema
Dibenzf14oxazepine CR Amore recent addi
tion to the riot control family of compounds is CR first
synthesized in 1962 It is a potent sensory irritant of low
toxicity The irritating effects on the eye and skin irrita
tion are more transitory than those of other riot control
agents such as CS Vesication or contact sensitization are
not associated with CR exposure
It has low acute toxicity as demonstrated in various
animal species exposed to CR via different routes the
data are summarized by Ballantyne The LD and
LCt50 values for CR and other commonly used riot
control agents are summarized in Table 8 Ballantyne
demonstrated that CR by all routes of exposure is less
toxic than CN or CS Animals dosed with CR mani
fest rapid breathing ataxia incoordination spasms and
convulsions Generally these effects gradually subside
over a 15 60 min period after which time the ani
mals appear normal or there is marked respiratory dis
tress and death Pathological changes noted in iv and
orally dosed animals consisted of congestion of alveo
lar capillaries and liver sinusoids No histological abnor
malities were noted in CR treated animals following
intraperitoneal administration of CR Compound related
effects included muscle weakness and heightened sen
sitivity to handling Toxic effects persisted through the
first day after exposure and some animals exhibited CNS
effects Animals surviving the postexposure period exhib
ited no gross or histological abnormalities at necropsy
Ballantyne also studied the effects of CR in various ani
mal species following inhalation exposure Animals were
acutely exposed to CR aerosol or CR smoke for vary
ing exposure times and at different concentrations of test
article Rats exposed to CR aerosol at Ct values rang
ing from 13050 to 428400mgin m3 manifested nasal
secretions and blepharospasm uncontrollable closure of
the eyelids which subsided within 1 h on cessation of
exposure Mortalities had not occurred among the CR
exposed rats In rabbits guineapigs and mice exposed
to CR aerosol no deaths occurred at Ct values up to
68400 mginm Exposure to pyrotechnically gener
ated CR resulted in alveolar capillary congestion and
intra alveolar hemorrhage as well as congestion of the
liver and kidneys
The potential of CR aerosol to produce physiologi
cal and ultrastructural changes of the lung was stud
ied by Pattle and coworkers In these studies rats
were exposed to high dosages of CR aerosol Ct
115 000mginM3 Electron microscopy examination
revealed that organellesie lamellated osmiophilic bod
ies were not altered as a result of exposure to CR In
studies by Colgrave et al 211 the effects of high CR aerosol
dosages 78200 140900 and 161 300 mgin M3 on
the pulmonary system were evaluated The lungs appeared
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It has lo  acute toxicity, as de onstrated in various 
ani al species exposed to  via different routes-the 
data are su arized by allantyne.29.71 he LDso and 
L tso values for  and other co only used riot 
control agents are su arized in able 8. allantyne71 
de onstrated that , by all routes of exposure, is less 
    . i als    ni-
f st r i  r t i , t i  (inco r i ation), s s s  
l i . erally, t  ff t  r all  i  
r  5-60 i  ri d, ft r i  ti  t  ni-
als appear nor al or there is arked respiratory dis-
t   t . t l i l  t  i  i.v.  
  s     l o-
lar capillaries and liver sinusoids. o histological abnor-
alities ere noted in -treated ani als follo ing 
intraperitoneal ad inistration of . o pound-related 
effects included uscle eakness and heightened sen-
siti it  t  a li . ic effects ersiste  t r  t e 
first a  after e s re a  s e a i als e i ite   
ff ts. i als s r i i  t  st- s r  ri  xhib-
ited no gross or histological abnor alities at necropsy. 
allantyne71 also studied the effects of  in various ani-
al species follo ing inhalation exposure. ni als ere 
acutely exposed to  aerosol or  s oke for vary-
ing exposure ti es and at different concentrations of test 
article. ats exposed to  aerosol at t values rang-
ing fro  13050 to 428400 g·min -3 anifested nasal 
secretions and blepharospas  (uncontrollable closure of 
the eyelids), hich subsided ithin I h on cessation of 
exposure. ortalities had not occurred a ong the CR-
e se  rats. I  ra bits, i ea-pigs a  ice e se  
to  aerosol, no deaths occurred at t values up to 
 g·min -3 • Exposure to pyrotechnically gener-
t   r lt  i  l l r ill r  ti   
i tra- l lar rr , s ll s sti  f t  
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The potential of  aerosol to produce physiologi-
cal and ultrastructural changes of the lung as stud-
ied by Pattie and co- orkers.244 In these studies, rats 
ere exposed to high dosages of  aerosol (C t = 
115000 g·min m-3 ). lectron icroscopy exa ination 
revealed that organelles (i.e. la ellated os iophilic bod-
ies) ere not altered as a result of exposure to . In 
studies by olgrave et al.,245 the effects of high  aerosol 
dosages (78200, 140900 and 161300 g· min m-3) on 
the pulmonary system were evaluated. The lungs appeared 
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Table 8Comparative toxicity of CR CS and CN LD50 a and LCt b
Route Species CR CS CN
a LD50 mg kgc
iv Mouse 112 48 81
Rat 68 28 40
Rabbit 47 27 29
ip Rat 766 48 38
Guinea pig 463 73 17
Oral Mouse 4000
Rat 5900 1284 52
Rabbit 1760 142 118
Guinea pig 629 212 157
b Lct mg min m
Inhalation Mouse 203600 76000
pyrotechni Rat 139000 68000 23000
cally Rabbit 160000 63000 15800
generated
Inhalation aerosol Mouse 169500 67200 1820073500
Rat 428400 88460 3700 18800
Rabbit 169000 54100 5840 11480d
Guineapig 169500 50010 3500 13140
3 Data from several sources as reported by Ballantyne
b Data from several sources as documented in a report by the National Academy of
Sciences
Lowest value reported
d Range of values from several sources
normal on gross examination however microscopic ex
amination revealed mild congestion hemorrhage and
emphysema Electron microscopy identified isolated swel
ling and thickening of the epithelium and early capil
lary damage as evidenced by ballooning of the endothe
lium Colgrave and coworkers concluded that very high
doses of CR aerosol produced only minimal pulmonary
damage
The effects of intravenously administered CR on
the cardiovascular system were studied by Lundy and
McKay and Lundy A dose dependent increase in
blood pressure of short duration was observed Stimulation
of the heart rate and increased arterial catecholamine
content also were noted following treatment with CR
The authors postulated that the CR induced cardiovascular
response was associated with sympathetic nervous
system effects as evidenced by abolition of the
CRinduced pressor effect by phentolamine and 6
hydroxydopamine
Chloroacetophenone CN Chloroacetophenone a
white crystalline solid with an apple blossom odor is
commonly known as tear gas or Mace and has the
military designation CN First synthesized in 1871
chloroacetophenone was studied for its use as a tear gas
shortly after World War I It acts directly on the mucous
membranes to produce intense ocular and respiratory
irritation and associated burning and pain sensation of
the eyes nose throat and lungs Ocular effects consist of
lacrimation blepharospasm and conjunctivitis Irritation
of the respiratory tract produces sneezing coughing
secretions nasal congestion and a sense of suffocation
The onset of some or all of these symptoms is immediate
and persists from up to 20 min after removal from the
contaminated atmosphere
Acute and repeateddose inhalation studies have been
conducted in various animals to ascertain the compar
ative toxicity of CN The toxicology of CN has been
reviewed and summarized by McNamara et al National
Academy of Sciences in a report and by Hu et al249 Early
toxicity studies on CN were highly variable and studies
subsequently conducted in the mid1960s in various ani
mal species were designed to provide more quantitative
data In these studies CN was dispersed in acetone or
from commercially available thermal grenades Sublethal
effects noted on exposure to CN consisted of lacrimation
conjunctivitis copious nasal secretions salivation hyper
activity dyspnea and lethargy Cutaneous effects seen in
the exposed animals consisted mainly of erythema The
salient biological finding exhibited by all exposed ani
mals on post exposure was dyspnea Ocular effectsie
conjunctivitis and dermal effectsieerythema persisted
for 3 7 days after exposure The primary cause of death
following CN inhalation was from the injurious action of
CN on the pulmonary system The LCtso estimates for CN
in various species are as follows rat 8878 mgin m
guineapig 7984mgin m and dog 7033 mgin
M Pathological findings in animals that died after CN
aerosol exposures consisted of pulmonary congestion
edema emphysema tracheitis bronchitis and bronchop
neumonia in dogs and pulmonary congestion edema and
bronchopneumonia in rats mice and guineapigs The
pathology reported by Ballantyne and Swanson 231 in ani
mals that died after CN inhalation included congestion of
the alveolar capillaries alveolar hemorrhage and exces
sive secretion in the bronchi and bronchioles There were
also areas of acute inflammatory cell infiltration of the
trachea bronchi and bronchioles
Diphenylaminochloroarsine adamsite DM As
discussed previously riot control agents may be classified
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RIOT CONTROL AGENTS
according to type eg lacrimators vomiting agents
sternutators based on a salient physiological effect
Diphenylaminochlorarsine DM is one of several com
pounds classified militarily as vomiting agents including
diphenylchloroarsine DA diphenylcyanoarsine DC
and chloropicrin It has been categorized as both a vom
iting agent and sternutator and was known as adamsite
during the World War I It has been used also as a riot con
trol agent and according to Cookson and Nottingham
only by the USA It is more toxic than other riot con
trol compounds and is considered a potentially dangerous
agent As reported by Sidell the estimated human LCt
is 11 000 mgin m3 It produces symptoms of slightly
delayed onset and a relatively long recovery period The
DMrelated effects do not appear immediately as in the
case of riot control agents CN CS and CR The DM
induced responses occur in 3 min after the start of
exposure and depending on the severity of the expo
sure the effects may last for up to several hours2110
Unlike other lacrimatory compounds DM is more likely
to cause prolonged systemic effects Signs and symptoms
of DM exposure include eye irritation upper respira
tory tract irritation uncontrolled sneezing and coughing
choking headache acute pain tightness in the chest nau
sea and vomiting In addition to these effects DM can
cause unsteady gait weakness in the limbs and trembling
Ballantyne has drawn attention to mental depression as a
prominent symptom following exposure to DM Exposure
to high concentrations of this material can result in seri
ous illness as a result of pulmonary damage and edema
or death210
A number of investigations on the physiological effects
of DM in various species of animals including primates
have been conducted and the findings are summarized
in reviews by McNamara et al and Owens et al251
as well as in a National Academy of Sciences report
Acute exposure to DM results in hyperactivity ocular
and nasal irritation salivation labored breathing ataxia
and convulsions Punte and coworkers have reported
the acute inhalation effects of high aerosol concentra
tions of various irritant compounds which included DM
Toxic signs observed in animals were hyperactivity ocu
lar and nasal irritation lacrimation salivation respira
tory distress and lethargy Histopathological examination
revealed no abnormalities below an inhaled dosage of
500 mgin m of DM The LCt50 estimates were as fol
lows rat 3700 mgin m3 mouse 22400 mgin m3
and guineapig 7900 mginm The authors also com
puted the theoretical dose inhaled L received which
was calculated from the respiratory volume the LCtso and
the estimated percentage retention The computed inhaled
LD values for DM are as follows rat 14 mg kg
mouse 179 mg kg and guineapig 24 mg kg Ani
mals exposed to DM at a dosage of 500 mgin m3 did
not exhibit pathological changes Animals sacrificed or
dying after exposure to DM manifested hyperemia of the
trachea pulmonary congestion and edema and pneumonia
The clinical and pathological findings are in concordance
with those observed on exposure to other pulmonary irri
tants Striker and coworkers studied the effects of DM
in monkeys exposed to test article at varying concen
trations and exposure periods 855 mg M3 for 3 min
1708 mg m3 for 5 min and 2615 mg M3 for 11 min
At the lowest exposure toxic effects were limited to a
369
single animal that exhibited a diminished response to stim
uli and oral and nasal discharge Exposure to a Ct of
8540 mgin In produced ocular and nasal irritation
conjunctival congestion facial erythma and decreased
responsesall signs had abated by 24 h Exposure to
a Ct of 28765 mgin m3 resulted in hyperactivity
conjunctival congestion copious nasal discharge marked
respiratory distress gasping and gagging in all animals
exposed In the high exposure group eight deaths had
occurred within 24 h Necropsy of the high dose group
revealed congested and extremely edematous lungs and
microscopic examination revealed ulceration of the tra
cheobronchial tree and pulmonary edema Additional stud
ies in monkeys also were conducted by Striker et al In
these studies the effects of low concentrations of DM
were evaluated Animals were exposed to DM at target
concentrations of 100 and 300 mg m3 for exposure peri
ods of 260 and 240 min respectively A progression of
toxic signs characteristic of irritant gases were seen as
the exposure times were increased At the maximum Ct of
13200 mgmin m3 animals exhibited conjunctival con
gestion oral and nasal discharge and nausea and vomiting
At Ct values of 1296 mgin m3 responses were lim
ited to blinking Serious effects involving the eyes have
been characterized as necrosis of the corneal epithelium
on exposure to DM
Repeateddose toxicity
Capsaicin and capsaicinoids The bulk of available
toxicological data on the effects of repeated dosing
of capsaicin and capsicum was reported by Lee 55
Nopanitaya and Monsereenusorn Multiple dosing of
capsaicin and capsicum in the rabbit resulted in patholog
ical alterations in several organ systems In the study
reported by Lee capsaicin resulted in hepatic necrosis
following multipledose administration Mice fed a diet
containing capsicum extract for 4 weeks did not exhibit
signs of toxicity21 Intragastric administration of cap
saicin 50 mg kg day or crude extract of capsicum
05 mg kg day for 60 days was conducted in rats
by Monsereenusorn2 The findings of Monsereenusorn
are in concordance with those reported by Nopanitaya
Biochemical parameters altered by capsaicin and crude
extract included significant reductions in plasma urea
nitrogen glucose phospholipids triglyceride transami
nase and alkaline phosphatase
Chlorobenzylidene malononitrile CS Repeated
dose studies with CS have been conducted in several
species by inhalation and oral routes and the findings are
reported 211 Inhalation studies conducted on rats and dogs
are highlighted In these studies animals were exposed for
4 5 min daily for 5 daysa week for 5 weeks to thermally
dispersed CS The daily dosage of CS to the dogs was
680 mgin m3 with a total accumulated dosage of
17000 mginM3 For rats the daily dosage of CS
was 3640 mgin m3 with a total accumulated dosage
of 91000 mgin M3 During the exposure rats mani
fested a heightened degree of hyperactivity and aggres
sive behavior In CSexposed rats accumulated dosages
of 25 000 and 68 000 mgin m3 resulted in mortali
ties Gross pathological changes were not evident in any
of the rats that died or the surviving animals that were
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according to type (e.g. lacri ators, vo ltmg agents, 
ster tat rs) ase   a salie t p si lo ical effect. 
Diphenylaminochlorarsine (D ) is one of several com-
pounds classified ilitarily as vo iting agents, including 
diphenylchloroarsine (D ), diphenylcyanoarsine (DC), 
and chloropicrin. It has been categorized as both a vom-
iting agent and sternutator and was known as adamsite 
during the orld ar I. It has been used also as a riot con-
trol agent and, according to Cookson and Nottingham, 12 
only by the S . It is ore toxic than other riot con-
trol co pounds and is considered a potentially dangerous 
agent. As reported by Sidell,17 the estimated human LCt50 
is 11000 mg·min -3 • It produces symptoms of slightly 
delayed onset and a relatively long recovery period. The 
-related effects do not appear i ediately as in the 
case f riot c tr l a ents , , a d . he -
induced responses occur in ~ 3 in after the start of 
exposure and, depending on the severity of the expo-
sure, the effects ay last for up to several hours.29,250 
Unlike other lacrimatory compounds, D  is more likely 
to cause prolonged systemic effects. Signs and symptoms 
of D  exposure include eye irritation, uppcr respira-
tory tract irritation, uncontrolled sneezing and coughing, 
choking, headache, acute pain, tightness in the chest, nau-
sea and vo iting. In addition to these effects,  can 
cause unsteady gait, weakness in the limbs and trembling. 
Ballantyne29 has drawn attention to mental depression as a 
pro inent sy pto  follo ing exposure to . Exposure 
to high concentrations of this material can result in seri-
s illness as a res lt f l ar  a a e a  e e a 
r eath.25  
 nu ber of investigations on the physiological effects 
of  in various species of ani als, including pri ates, 
have been conducted and the findings are su arized 
in reviews by cNamara et al. 61 and Owens et al.,251 
as ell as in a ational cade y of Sciences report.6 
Acute exposure to DM results in hyperactivity, ocular 
and nasal irritation, salivation, labored breathing, ataxia 
and convulsions. unte and co- orkers60 have reported 
the acute inhalation effects of high aerosol concentra-
tions of various irritant compounds, which included DM. 
Toxic signs observed in animals were hyperactivity, ocu-
lar and nasal irritation, lacrimation, salivation, respira-
tory distress and lethargy. Histopathological examination 
revealed no abnor alities belo  an inhaled dosage of 
500 mg·min m-3 of DM. The LCtso estimates were as 101-
lo s: rat, 3700 g·min -3 ; ouse, 22400 g·min -3 ; 
and guinea-pig, 7900 mg·min m-3 • The authors also com-
puted the theoretical dose (inhaled LD50) received, which 
was calculated fro  the respiratory volu e, the LCt50 and 
the estimated percentage retention. The computed inhaled 
LD50 values for  are as follo s: rat, 14.1 g kg-I; 
mouse, 17.9 mg kg-I; and guinea-pig, 2.4 mg kg-I. ni-
als exposed to  at a dosage of 500 g· min -3 did 
not exhibit pathological changes. Ani als sacrificed or 
dying after exposure to DM manifested hyperemia of the 
trachea, pulmonary congestion and edema and pneumonia. 
he clinical and pathological findings are in concordance 
with those observed on exposure to other pul onary irri-
ts. tri   o- orkers252   f    
in monkeys exposed to test article at varying concen-
trations and exposure periods: 855 mg m-3 for 3 min; 
1708 mg m-3 for 5 min; and 2615 mg m-3 for II min. 
At the lowest exposure, toxic effects were limited to a 
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sacrificed following completion of the exposures Body
weight losses in the CSexposed animals were minimal
and no significant difference was noted in organ tobody
weight ratios following the 5week exposure Marrs and
coworkers studied the effects of neat CS aerosol in
rats mice and guineapigs subjected to repeated inhalation
doses I h day 5 days a week for 120 days of test arti
cle High concentrations of CS were fatal to the animals
after several exposures Mortality in the low and mid
dose animals was not significantly different from controls
It was concluded that CS concentrations 30 mg m
were without deleterious effects These concentrations of
CS are about ten times the intolerable level 3 mg m for
1 min estimated for humans
Dibenzf14oxazepine CR Acute toxicity stud
ies on CR have established the low toxicity of this
substance and the absence of untoward effects involv
ing altered morphology ie respiratory tract lesions and
altered biochemical parameters ie altered lung surfac
tant Nevertheless concerns over the health effects aris
ing from multiple exposures to this class of chemicals
have prompted a number of repeateddose studies to eval
uate clinicobiochemical physiological and morphological
parameters Marrs and coworkers reported findings on
the repeateddose inhalation toxicity of aerosolized CR
technical grade in mice and hamsters Animals were
exposed to CR for up to 10 min at test article con
centrations of 204 236 and 267 mg m for 5 days a
week for 18 weeks Follow up observations on animals
retained for up to I year after the start of the exposure
were conducted to detect recovery from or persistence
of toxic effects High concentrations mean daily Ct of
4222minm of CR affected the survival of both
species and no single cause of death could be ascer
tained although pneumonitis was evident in many cases
The CR exposure produced minimal organ toxicity how
ever chronic inflammation of the larynx was noted in
mice findings consistent with repeated dose exposure
to irritants No significant pulmonary lesions were mani
fest In contrast to the aforementioned findings no lung
tumors were noted in hamsters exposed to CR Like
wise no lesions were present in the larynx of hamsters
exposed to CR aerosol Histopathological evaluation of
the liver revealed hepatic lesions in mice however these
were of infective origin and not test article related Based
on their findings Marrs et al 21 concluded that expo
sure to high concentrations of CR reduced survivability
and that CR produced minimal organ specific toxicity at
levels many times 200x the intolerable human dose
00 07mg m within I min IC50 015 mg M3
within I min Kumar eta1212 performed a toxicologi
cal evaluation of CR after repeated inhalation exposure
in mice Mice were subjected to 15min daily inhala
tion exposures of CR at a concentration of 1008 mg m
for 5 and 10 days a level equivalent to the 05 LC50
dose Biochemical parameters evaluated were hepatic lipid
peroxidation malondialdehyde MDA formation glu
tathione GSH levels liver acid phosphatase ACP
liver alkaline phosphatase ALP glutamic oxaloacetic
transaminase SGOT and glutamic pyruvic transaminase
SGPT The liver lungs and kidneys were evaluated
for histopathological changes Significant decreases in
body weight gain were noted in animals exposed to CR
Hepatic biochemical parameters were not altered signif
icantly by exposure to CR Histopathological changes
were noted in CRexposed animals mild congestion and
intraalveolar hemorrhages focal in nature of pulmonary
tissue The severity of these lesions increased with the
number of exposures Overall these findings were con
sistent with results reported by Ballantyne who exam
ined the cumulative 5 day oral toxicity of CR in various
animals
A number of studies have been reported on the
repeateddose toxicity of CR following dermal administra
tion563 Owens and coworkers studied the effects
of CR in rabbits and monkeys following cutaneous
application of test article applied daily for 5 days
however assessment was limited to dermal effects only
In the study by Marrs and coworkers261 CR in acetone
was applied to the skin of mice C3H and Porton strains
for 5 days a week for up to 12 weeks Two control groups
consisted of the solvent group and untreated controls
Animals were kept for an additional 80 weeks following
the end of the application period In general a greater
degree of histological abnormalities was noted in the
Porton strain of mice than that observed in the C3H
strain of mice No abnormalities were noted that could be
attributed to CR but a high incidence of fatty infiltration
of the liver was noted in one strain of mice most likely
due to acetone It was concluded that the repeated dermal
application of CR had little effect on the skin The authors
further postulated that in view of the absence of any
specific organ toxicity the absorption of even substantial
amounts of CR would have little effect
Chloroacetophenone CN McNamara et al sum
marized the findings of a repeateddose inhalation study
on the effects of thermally generated CN on monkeys
dogs and guinea pigs In one set of experiments mon
keys and guinea pigs were exposed for ten consecutive
days to CN at Cts between 2300 4000 mgin m3 for a
total exposure dosage of 31445 mginm This dosage
is considered lethal to 75of the guinea pigs and 100
lethal to monkeys if given in a single exposure Exposure
to CN for 10 days resulted in the death of five guinea pigs
however no deaths occurred in monkeys subjected to mul
tiple exposures of CN The data suggest that the toxicity
of CN is considerably less when administered in divided
dosages In another multiple inhalation exposure study
involving CN also summarized by McNamara et al
dogs were exposed on ten consecutive days to CN at
Cts ranging between 3000 7000 tngmin m for a total
dosage of 60000 mginm A subsequent repeated
dose inhalation study also was conducted in guineapigs
dogs and monkeys exposed daily for 10 days to Cts
between 4200 13 000 mgin M3 for a total exposure
of 88000 mginm This dosage was determined to
be lethal in the majority of animals for all species tested
Collectively these studies demonstrated the lack of cumu
lative toxicity of CN when administered as repeat doses
In a recent study Kumar and coworkers reported find
ings on the effects of multiple exposure to CN and CR in
mice Animals were exposed to test article at concentra
tions equivalent to the 05 LC50 87 mgM3 of CN for
15 min a day for 5 and 10 days Biochemical endpoints
measured included blood glucose plasma urea liver alka
line phosphatase ALP liver acid phosphatase ACP
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fesl. In contrast to the aforementioned findings, no lung 
tumors were noted in hamsters exposed to CR. Like-
wise, no lesions were present in the larynx of hamsters 
exposed to CR aerosol. Histopathological evaluation of 
the liver revealed hepatic lesions in ice; however, these 
ere of infective origin and not test article related. ased 
on their findings, Marrs et al. 260 concluded that expo-
sure to high concentrations of CR reduced survivability, 
and that CR produced minimal organ-specific toxicity at 
levels many times (~200x) the intolerable human dose 
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i i   i . 261 Kumar et al. 262 performed a toxicologi-
cal evaluation of CR after repeated inhalation exposure 
in mice. ice were subjected to 15-min daily inhala-
tion exposures of CR at a concentration of 1008 mg m-3 
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transaminase enzymes SGOT SGPT liver glutathione
GSH levels and hepatic lipid peroxidation malondi
aldehyde MDA formation Histological evaluation of
pulmonary hepatic and renal tissues also was performed
Clinical parameters affected following repeated exposure
to CN were characterized as hepatic glutathione deple
tion increased lipid peroxidation and increased hepatic
acid phosphatase activity The CNinduced elevation in
acid phosphatase levels reflected the release of lysosomal
enzyme from the liver indicative of tissue injury Addi
tionally hyperglycemia was observed after exposure to
CN an effect previously reported by Husain et al It was
postulated that hyperglycemia may have been induced by
stressmediated release of epinephrine which is known
to elevate glucose levels Significant decreases in body
weight gain also were noted on exposure to these com
pounds with CN having a more prominent effect on
body weight Histopathological changes of the lung fol
lowing CN exposure included hemorrhage perivascular
edema congestion of the alveolar capillaries occluded
bronchioles and alveolitis Renal histopathology demon
strated congestion and coagulative necrosis in the cortical
renal tubules in CNexposed mice Hepatic histopathology
consisted of cloudy swelling and lobular and centrolob
ular necrosis of hepatocytes following CN exposure The
National Institutes of Health cited a subchronic study on
CN that was conducted under the National Toxicology
Program 261 Mice and rats were exposed to CN aerosol
for 13 weeks and the findings indicated no gross clinical
signs in rats or mice except irritation of the eyes includ
ing opacity No microscopic lesions were noted compared
with controls
Reproductivedevelopmental toxicity
Upsha11 studied the developmental toxicity of CS in
rats and rabbits exposed via inhalation to test article at a
concentration of 10 mg m which represents the level
most likely to exist in riot control situations Fetuses were
examined for abnormalities and no increase of significance
was noted in the numbers of abnormal fetuses or resorp
tions But it should be acknowledged that the exposure
conditions low dosages and short exposure duration of
5 min may not have been adequate to assess the feto
toxic and teratogenic potential of CS Teratology studies
are conducted routinely at dosages that produce mater
nal toxicity No data were presented regarding the degree
of maternal toxicity or mortality Based on the findings of
the Upshall study it is impossible to conclude definitively
that CS would not be fettoxic andor teratogenic under
other exposure conditions
The effects of CR on rabbit and rat embryonic develop
ment were studied by Upshall 267 Animals were exposed to
aerosolized CR at concentrations of 2 20 and 200 mg m
for 5 to 7min exposures The highest concentration rep
resents a level about 200 times the intolerable concen
tration of CR to humans Additionally some rats were
dosed intragastrically at 2 20 and 100 mg kg on days
6 8 102 and 14 of pregnancy and others were dosed
intragastrically with 400 mg kg on days 7 10 and 13 of
pregnancy Rabbits were dosed intragastrically with CR
022 and 20 mg kg on days 6 8 10 12 14 16 and
18 of pregnancy Recorded data included the number of
litters litter size and weight number of abnormal litters
number of live fetuses and placental weight Although
371
the concentration of CR aerosol represented a level much
higher than the concentrations expected under riot control
situationsie 10 mg m pregnant female rats exposed
to CR aerosol did not manifest toxic effects There were
no dose related effects of CR on the parameters measured
or the number or type of fetal malformations Predomi
nant abnormalities observed in all groups were skeletal in
natureegpoorly ossified sternebrae extra ribs Fetuses
from female rats dosed intragastrically with CR exhibited
skeletal anomalies in all groups Pregnant rabbits exposed
to CR aerosol did not manifest overt signs of toxicity
There were no dose related effects of CR on any of the
parameters measured and the numbers or types of mal
formation Based on the overall observations the authors
concluded that CR was neither teratogenic nor embry
otoxic to rats and rabbits
Genotoxicity and carcinogenicity
Capsaicin and capsaicinoids There is widespread
concern regarding the mutagenic and carcinogenic poten
tial of capsaicinoids because these substances are metab
olized to derivatives with the capability of alkylating
genetic material Thus the mutagenic potential of capsai
cinoids has been studied in both microbial and mammalian
genotoxicity assays The mutagenicity of capsaicinoids
has been tested extensively in the Ames S typhimurium
assay212 Buchanan and coworkers evaluated the
mutagenicity of chilli pepper oleoresins and capsaicinoids
and neither the oleoresin nor the purified capsaicin pro
duced mutations in S typhimurium In studies by Toth
and coworkers purified capsaicinoids exhibited muta
genic activity in the presence of liver activating enzymes
Damhoeri and coworkers studied the mutagenic poten
tial of capsicum pepper oleoresins using S typhimurium
in the absence of metabolic activation Under the condi
tions of the assay the oleoresins were found to be muta
genic Nagabhushan and Bhide in assessing the muta
genicity of capsaicin in S typhimurium strains reported
that capsaicin was mutagenic with metabolic activation
In genotoxicity studies by Gannett et al capsicum and
the ethanol extract of red pepper were evaluated using
the TA 98 and TA 1535 strains of S typhimurium in
the absence and presence of metabolic activation The
findings of Gannett and coworkers suggest that cap
saicin and the pepper extract were not genotoxic In the
rec rec assay capsaicinoids were non mutagenic for B
subtilis2 The mutagenic potential of capsaicinoids also
has been evaluated in bioassays using mammalian cells
ie V79 cell line to ascertain the mutagenic potential
for capsaicinoids271724 In the V79 mammalian test sys
tem Nagabhushan and Bhide reported that capsaicin
was non mutagenic However studies by Gannett et al
and Lawson and Gannett using the V79 cell line sug
gested that capsaicin and capsaicinoids were genotoxic
Using the Micronucleus Mutation Assay Naghabhusahan
and Bhide evaluated the mutagenic potential of cap
saicin Results from these studies indicated that capsaicin
was positive for mutagenicity The mutagenic potential of
capsaicin was assessed also in the Dominant Lethal Assay
by Narasimhamurthy and Narasimhamurthy Capsaicin
was found not to be mutagenic in this bioassay In spite
of equivocal findings regarding the mutagenic potential of
capsaicin and capsaicinoids the prudent approach from
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i  ti it  i  t  r s  f li r- cti ti  s. 
a hoeri and co- orkers270 studied the utagenic poten-
ti l  i   (oleor i ) i  . t i i  
i  t  s  f t li  ti ti . r t  ndi-
tions of the assay, the oleoresins ere found to be uta-
genic. agabhushan and hide,271 in assessing the uta-
e icit  f ca saici  i  . ty i ri  strains, re rte  
t t s i i  as t i  it  t li  ti ti . 
I  e t icit  st ies  a ett et al.,272 ca sic  a  
t e et a l e tract f re  e er ere e al ate  si  
t       str i s f . t i riu  i  
the absence and presence of etabolic activation. The 
findings of annett and co- orkers suggest that cap-
saicin and the pepper extract ere not genotoxic. In the 
rec+ /rec- assay, capsaicinoids ere non- utagenic for B. 
subti/is.273 e ta e ic te tial f ca saici i s als  
s  l t  i  i ass s si  lia  lls 
(i.e. V79 cell line) to ascertain the utagenic potential 
f r ca saici ids.271 .272.274 I  t e  a alian test s s-
tem, Nagabhushan and Bhide27I reported that capsaicin 
as non- utagenic. o ever, studies by annett et al.272 
and La son and annett2J.I using the 79 cell line sug-
gested that capsaicin and capsaicinoids ere genotoxic. 
sing the icronucleus utation ssay, aghabhusahan 
and hide271 evaluated the utagenic potential of cap-
saicin. es lts fr  t ese st ies i icate  t at ca saici  
s siti  f r t enicity.  t i  t ti l f 
capsaicin was assessed also in the Do inant Lethal Assay 
by Narasimhamurthy and Narasimhamurthy.275 Capsaicin 
as found not to be utagenic in this bioassay. In spite 
of equivocal findings regarding the utagenic potential of 
capsaicin and capsaicinoids, the prudent approach fro  
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the health hazard perspective is that these compounds
should be regarded as having genotoxic potential
In human populations who routinely use peppers in
their diet an increased incidence of gastric cancer is
noted1712 Capsaicin has been reported to induce mucous
fibrosis in the oral cavity and could be relevant in the
development of esophageal cancer 261 When adminis
tered in the diet capsaicin induced cancer in the mouse
duodenum269 Studies by Kim et al 2 suggest that cap
saicinoids may act as cocarcinogens A rodent carcino
genesis bioassay to assess the carcinogenic potential of
capsaicin was conducted by Toth and Gannet Increases
were noted in the incidence of benign tumors poly
ploid adenomas in the cecum of treated animals An
increased rate of malignant tumors however was not evi
dent Chronic treatment with capsaicin appeared not to
alter the general health of the animals influence growth
rate or alter body weight The effect of capsaicin on
120tetradecanoylphorboll3acetate TPA widely used
in tumor promotion studies was studied by LaHann
and Sasajima et al LaHann concluded that capsaicin
appeared to facilitate the onset of TPA induced tumor for
mation and that capsaicin could enhance the risk of skin
cancer Studies by Sasajima and coworkers demon
strated that capsaicin induced ornithine decarboxylase
ODC activity an enzyme used as an index of tumor
promoting capability Based on the collective data there
appears to be sufficient evidence that capsaicin may pose
a tumorigenic threat
Chlorobenzylidene malonoritile CS The mutagenic
potentials of CS and CS2 a formulation containing CS
in a mixture of 5 CaboSil and 1 methyldisilizane
have been studied in microbial and mammalian bioassays
As reported by von Daniken et al 215 CS was positive
for mutagenicity in the Ames assay however subsequent
findings by Zeiger et al indicated questionable geno
toxicity for S typhimurium Findings by Rietveld et al
and Wild etal288 indicated that CS was non mutagenic for
S typhimuriurn Mutagenicity studies by Meshram et al289
using the Ames assay also demonstrated that CS did not
induce a mutagenic response in the presence or absence
of S9 mix CS2 a mixture of micropulverized CS and
an aerogel was negative when tested in S ryphimurium
strains TA98 TA 1535 and TA 1537 with or without
metabolic activation The genotoxic potentials of CS
and CS2 were evaluated using various mammalian geno
toxicity assays which included the Chinese hamster ovary
CHO assay for induction of sister chromatid exchange
SCE and chromosomal aberration CA and the mouse
lymphoma L5178Y assay for induction of trifluorothymi
dine Tft resistance 290 The results of these assays
indicated that CS2 induced sister chromatid exchanges
resulted in chromosomal abberations and caused induction
of Tft resistance
Carcinogenicity studies of CS2 were conducted in
rats F2344Nand mice B6C3F1 Animals were
exposed via inhalation over their lifetime to CS2 aerosol
Compound related nonneoplastic lesions characterized as
hyperplasia and squamous metaplasia of the respiratory
epithelium and degenerative changes of the olfactory
epithelium were evident in CS2exposed rats Pathological
changes observed in CS2exposed rats included squamous
metaplasia of the olfactory epithelium as well as hyperpla
sia and metaplasia of the respiratory epithelium Hyperpla
sia and squamous metaplasia of the respiratory epithelium
were noted also in mice exposed to CS2 These findings
are not unexpected because the epithelium of transitional
areas of the respiratory tract is reported to be the most
sensitive areas for cellular alterations such as epithelial
degeneration hyperplasia and squamous metaplasia fol
lowing exposure to irritants 291294 Neoplastic effects were
not observed in either rats or mice exposed to test article
Conclusions drawn from these findings suggest that CS2
is non carcinogenic for rats and mice
Dibenzf14oxazepine CR There is a paucity of
data addressing the subject of genotoxic potential of CR
A review of the database has identified a single study
in the mainstream medical literature Colgrave et al
evaluated the mutagenic potential of CR and its precur
sor 2aminodiphenyl ether in microbial and mammalian
genotoxicity bioassays The S typhimurium assay served
as the microbial test for predicting mutagenic response
Mammalian assay systems for the detection of muta
tions consisted of the following Chinese hamster cell
mutagenesisV79HGPRT system mouse lymphoma cell
mutagenesis L5178YTKTK and the micronucleus
test erythrocytes Both CR and its precursor were neg
ative in all assays The results from such varied bioas
says would suggest that CR does not pose a mutagenic
threat however additional genotoxicity testing would
establish CR as a non mutagen The carcinogenic poten
tial of CR is unknown because very little research has
been conducted to ascertain the ability of CR to pro
duce neoplasia or longterm effects However Marrs and
coworkers in a repeated dose 18 week study have
reported the occurrence of alveologenic carcinoma in a
single lowdose group mouse and in a single high dose
group mouse This tumor type was observed also in a
control mouse The validity of these findings as well
as interpretationsconclusions may be questioned because
the spontaneous frequency of alveologenic carcinoma is
high in many mouse strains297 Further this tumor type
is dissimilar in many respects from human types of lung
tumors
Chloroacetophenone CN Carcinogenicity bioassays
have been conducted in rats and mice to ascertain the
carcinogenic potential of 2chloroacetophenone There
was no indication of carcinogenic activity of CN in male
rats exposed to test article Equivocal evidence of car
cinogenicity of CN was based on findings in female rats
indicating an increase in fibroadenomas of the mammary
Aland The findings of a 2year inhalation bioassay in mice
suggested no carcinogenic activity in male or female mice
exposed to CN
Uptake distribution metabolism and excretion
Capsaicin and capsaicinoids Saria et al studied the
distribution of capsaicin in tissues of rats following sys
temic administration Uptake in the CNS was rapid and
high levels of capsaicin were detected following iv dos
ing Slow diffusion from the site of application was noted
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the health hazard perspective is that these co pounds 
should be regarded as having genotoxic potential. 
In human populations who routinely use peppers in 
t eir iet, an increase  incidence f gastric ca cer is 
noted.276- 278 Capsaicin has been reported to induce ucous 
fibrosis in the oral cavity and could be relevant in the 
develop ent of esophageal cancer.279.280 hen ad inis-
tered in the i t, caps icin induced cer i  the use 
duodenu .269 Studies by Ki  et al.281 suggest that cap-
i inoids a  a t s - r ino e .  r t r i -
genesis bioassay to assess the carcinogenic potential of 
capsaicin was conducted by Toth and Gannet. 282 Increases 
ere noted in the incidence of benign tu ors (poly-
ploid adenomas) in the cecum of treated animals. An 
increase  rate f aligna t tu rs, r, as t i-
dent. hronic treat ent ith capsaicin appeared not to 
alter the general health of the ani als. influence gro th 
rate or alter body eight. he effect f capsaicin on 
- O-t tr l r l-13- tate (TP ), i l  s  
in t r r tion t i , as t ied  an 283 
and Sasaji a et al.28+ La ann283 concluded that capsaicin 
appeared to facilitate the onset of TP -induced tu or for-
ation and that capsaicin could enhance the risk of skin 
cancer. Studies by Sasaji a and co- orkers284 de on-
strated that capsaicin induced ornithine decarboxylase 
(ODC) activity, an enzyme used as an index of tumor-
promoting capability. Based on the collective data, there 
appears to he sufficient evidence that capsaicin ay pose 
a tu origenic threat. 
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potentials of CS and CS2, a for ulation containing CS 
in a ixture of 5% Cab-o-Sil'~ and 1% ethyldisilizane, 
have been studied in icrobial and a alian bioassays. 
As reported by von Daniken et al.,m CS was positive 
for mutagenicity in the Ames assay; however, subsequent 
findings by Zeiger et al. 286 indicated questionable geno-
toxicity for S. typhi uriu . Findings by ietveld et al.287 
and ild et al.288 indicated that S as non- utagenic for 
S. typhi urium. utagenicity studies by eshra  et af.289 
using the Ames assay also demonstrated that CS did not 
induce a utagenic response in the presence or absence 
of S9 ix. CS2, a ixture of icropulverized CS and 
an aerogel, as negative hen tested in S. typhi uriu  
strains 98,  1535 and  1537 ith or ithout 
metabolic activation. 29O The genotoxic potentials of CS 
and CS2 were evaluated using various mammalian geno-
toxicity assays, hich included the Chinese ha ster ovary 
(CHO) assay for induction of sister chromatid exchange 
(S E) and chro oso al aberration (C ) and the ouse 
lymphoma L5178Y assay for induction of trifluorothymi-
dine (Tft) resistance.29O-292 The results of these assays 
indicated that CS2 induced sister chro atid exchanges, 
l    r ti     
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Carcinogenicity studies of CS2 were conducted in 
rats (F2344/N) and ice (B6C3FI).290 ni als ere 
exposed via inhalation over their lifeti e to CS2 aerosol. 
Compound-related non-neoplastic lesions characterized as 
hyperplasia and squa ous etaplasia of the respiratory 
epithelium and degenerative changes of the olfactory 
epithelium were evident in CS2-exposed rats. Pathological 
changes observed in CS2-exposed rats included squamous 
Published in 200 I by John Wiley & ons, td. 
eta lasia f the lfactory iu  as ell as r l -
sia d etaplasia f the res irat ry e it li . yper l -
a and s a ous eta lasia  the re  e the iu  
c c noted lso in ice posed t  . hese in i  
r  t e pected ecause the it li   tr iti l 
areas of the respiratory tract is reported to be the ost 
ve   lular terations   al 
degeneration, hyperplasia and squa ous etaplasia fol-
in  posure t  irritants. 293 .294 e lastic e ts  
t s ed i  ther ts  ice ose  t  te  . 
s s   es  in in  est that  
is n- r i i  f r r ts  i . 
ibenz[b/ 1: - a ne (C ).    t   
 g the t  c t ial  . 
 re ie   t e ta ase  ie     
i  t  i strea  i l liter t r . l ra e t al.295 
l t  t e t i  t ti l    its r-
 (2- i iphe l t er) i  icr ial  lia  
t i  .  . iu    
 t  icr ial t t  i ti  t i  se. 
lia   t   t e t ti   t -
    : ines    
ta  (V79IHGPRT stem); se   
t  (L 178Y ITK +ITK -); a  t e icronucleus 
test (erythrocytes). oth  and its precursor ere neg-
ti  i  ll ss ys.  r s lts fr  s  ri  i s-
says ould suggest that  does not pose a utagenic 
at; ver,  t xi i  ti   
t l     - n.   n-
     s   ttle   
     bili     ro-
 l si  r l -term tTe ts. r, arrs  
- orkers263 i   t -dos  (1  ek) t   
t  t    l l i  r i  i   
single lo -dose group ouse and in a single high-dose 
 e.         
t  .  li i    i s,  ll 
s i t r r t ti s/con l si s,   sti  s  
t  s t s fr  f l l i  r i  is 
high in any ouse strains.296.297 Further, this tu or type 
i  i i il r i   r t  fr   t  f l  
rs. 
l r acet e e (C ). arci enicit  i assa s 
  t  i  t   i  t  scert i  t  
arci ni  t ti l f - l r acetophenone.265 r  
  i i ti  f rci ni  cti it  f  i  l  
t   t  t t rticle. i l i   car-
cinogenicity of  as based on findings in fe ale rats, 
i icati  a  i crease i  fi r a e as f t e a ar  
gland. e fi i s f a 2-year i alati  i assa  i  ice 
s st d  rci ni  activit  i  l  r f l  i  
exposed to CN. 
ptake, distribution, etabolis  and excretion 
a saici  an  capsaicinoi s. Sari  t al. 298 studi d t  
distribution of capsaicin in tissues of rats following sys-
te ic administration. ptake in the  as rapid and 
high levels of capsaicin were detected following i.v. dos-
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on sc administration however detectable levels of cap
saicin were found in various tissues Kim and Park211 sug
gested that capsaicin and its analogs were poorly absorbed
in the gut which led Kawada et al30 to investigate fur
ther the gastrointestinal uptake of capsaicin and associ
ated analogs conducted in vivo and in situ absorption
studies in rats Their findings indicated that absorption
of capsaicin and dihydrocapsaicin occurred rapidly from
the stomach and small intestine85of the dose was
absorbed from the gastrointestinal tract Regional capac
ities for uptake also were investigated Results indicated
regional differences in the absorption of capsaicin from
the gastrointestinal tract The findings reported by Kawada
et al are in agreement with the in vitro results reported
by Monsereenusorn regarding the in vitro intestinal
absorption of capsaicin The degree and processes of
absorption of capsaicin and capsaicinoids in the respira
tory tract have not been elucidated Capsaicin and capsai
cinoids undergo bioconversion which involves oxidative
and non oxidative pathways The highest enzymatic activ
ity is found in the liver followed by extrahepatic tissues
egkidney lung and small intestine Kawada and Iwai
studied the in vivo and in vitro metabolism of the capsaicin
analog dihydrocapsaicin in rats The parent compound was
metabolized to metabolic products that were excreted in
the urine mostly as glucuronides The metabolic processes
involved in the bioconversion of capsaicin and analogs
were studied initially by Lee and Kumar They demon
strated the conversion to catechol metabolites via hydrox
ylation on the vanillyl ring moiety findings later con
firmed by Miller et al The conversion of capsaicin by
373
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the liver mixed function oxidase system to an electrophilic
epoxide is one example of metabolism to an electrophilic
metabolite Other pathways leading to highly reactive
intermediates involve the formation of a phenoxy radical
as well as the formation of a quinonetype product The
generation of a quinone derivative is believed to proceed
via O demethylation at the aromatic ring with concomi
tant oxidation to the semiquinone and quinone derivatives
or via demethylation of the phenoxy radical intermediate
of capsaicin see Fig 3 It should be noted also that the
quinone pathway involving the phenoxy radical leads to
the formation of an extremely reactive methyl radical In
addition to the above oxidative pathways the alkyl side
chain of capsaicin is susceptible to enzymatic oxidation
oxidative deamination Capsaicin may also undergo
non oxidative metabolism via hydrolysis of the acid amide
bond to yield vanillylamine and fatty acyl moieties see
Fig30205
Chlorobenzylidene malonoritite CS Leadbeater
reported findings regarding the uptake of CS by
the respiratory tract of animals and humans the
gastrointestinal absorption of CS in rats and its metabolic
conversion The absorption of CS from the respiratory
tract is very rapid and the halflives of CS and its principal
bioconversion products are reported to be extremely
short 306 The elimination of CS follows first order
kinetics over the dose range examined It spontaneously
hydrolyzes to malononitrile which is transformed to
cyanide in animal tissues 301119 It undergoes metabolic
Published in 2001 by John Wiley Sons Ltd J Appl Toxicol 21 355391 200 1
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saicin ere found in various tissues. i  and Park299 sug-
gested that capsaicin and its analogs were poorly absorbed 
in the gut, hich led a ada et al.3("I.) to investigate fur-
ther the gastrointestinal uptake of capsaicin and associ-
ated analogs conducted in vivo and in situ absorption 
studies in rats. heir findings indicated that absorption 
of capsaicin and dihydrocapsaicin occurred rapidly from 
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absorbed fro  the gastrointestinal tract. Regional capac-
ities for uptake also were investigated. Results indicated 
regional differences in the absorption of capsaicin from 
the gastrointestinal tract. The findings reported by Kawada 
et l.3OO are i  a ree e t it  t e i  vitr  res lts re rte  
by onsereenusorn301 regarding the in vitro intestinal 
absorption of capsaicin. The degree and processes of 
absorption of capsaicin and capsaicinoids in the respira-
tory tract have not been elucidated. apsaicin and capsai-
cinoids undergo bioconversion, which involves oxidative 
and non-oxidative pathways. The highest enzymatic activ-
ity is found in the liver, followed by extrahepatic tissues 
(e.g. kidney, lung and small intestine). Kawada and Iwapo2 
studied the in vivo and ill vitro etabolis  of the capsaicin 
analog dihydrocapsaicin in rats. The parent compound was 
metabolized to metabolic products that were excreted in 
the urine, ostly as glucuronides. The etabolic processes 
involved in the bioconversion of capsaicin and analogs 
ere studied initially by Lee and Kumar.303 They demon-
strated the conversion to catechol etabolites via hydrox-
ylation on the vanillyl ring moiety-findings later con-
firmed by iller et al. 169 The conversion of capsaicin by 
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epoxide is one exa ple of etabolis  to an electrophilic 
etabolite. ther path ays leading to highly reactive 
t e iates        
as ell as the for ation of a quinone-type product.93 he 
generation of a quinone derivative is believed to proceed 
i  - t l ti  t t  r ti  ri  it  comi-
t t i ti  t  t  i i   i  ri ti  
or via de ethylation of the phenoxy radical inter ediate 
of capsaicin (see Fig. 3). It should be noted also that the 
quinone path ay involving the phenoxy radical leads to 
the for ation f an extre ely reactive ethyl radical. In 
iti  t  t   i ti  athways, t  l l si  
chain of capsaicin is susceptible to enzy atic oxidation 
(oxidative deamination).304 Capsaicin ay also undergo 
non-oxidative etabolis  via hydrolysis of the acid a ide 
 t   il    cyl i  (s  
Fig. 3).300.302.305 
l  l norit  (C ). eadbeater306 
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t  r spir t r  tr t f ni ls  hu ans, t  
gastrointestinal absorption of CS in rats and its etabolic 
onversion.  sor ti  f  fr  t  r spiratory 
tract is very rapid, and the half-lives of S and its principal 
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hydrolyzes to alononitrile,307 hich is transfor ed to 
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conversion to 2 chlorobenzyl malononitrile CSH 2
chlorobenzaldehyde oCB 2chlorohippuric acid and
thiocyanate312 Both CS and its metabolites
can be detected in the blood following inhalation
exposure but only after large inhalation doses Both
CS and two of its metabolites 2chlorobenzaldehyde
and 2chlorobenzyl malononitrile were detected in the
blood following inhalation exposure of rodent and non
rodent species to CS aerosol Brewster and co
workers 13 studied the fate of CS in rats following
intravenous and intragastric doses Findings from these
studies indicated that in most cases the majority of
the administered dose was eliminated in the urine
A metabolic conversion that leads to a decrease in
the lethal potency and peripheral sensory irritancy is
the NADPHdependent reduction of the benzylidene
double bond in CS to yield 2chlorobenzaldehyde o
chlorobenzaldehyde The in vivo conversion of CS to 2
chlorobenzaldehyde is followed by further bioconversion
to the 2chlorobenzoic acid intermediate which undergoes
subsequent glycine conjugation or reduction to 2
chlorobenzyl alcohol with ultimate excretion as 2
chlorobenzyl acetyl cysteine or 1 O2chlorobenzyl
glucuronic acid see Fig 4 The principal urinary
metabolites of CS are 2chlorohippuric acid 102
chlorobenzyl glucuronic acid 2chlorobenzyl cysteine
and 2chlorobenzoic acid Lesser amounts of 2
chlorophenyl acetyl glycine 2chlorobenzyl alcohol and
2chlorophenyl 2 cyanopropionate also were identified
Leadbeater also studied the uptake of CS by the
human respiratory tract and found trace amounts of 2
chlorobenzyl malononitrile in the blood however CS and
2chlorobenzaldehyde were not detected after exposure to
a very high dose of CS Ct 90 mginmThese
results are in concordance with CS uptake studies in
animals and with the maximum tolerable concentration
in humans which is I0 mg m3 Leadbeater theorized
that significant amounts of CS would not be absorbed via
inhalation at or near the tolerable concentration
The formation of cyanide from CS has been the sub
ject of several studies in laboratory animals and in
humans21106311 Free cyanide has been detected fol
lowing iv administration of CS in dogs exposed to lethal
doses of CS but little experimental data were presented
It is of interest to note that CS and malononitrile pos
sess two nitrile residues and in theory may give rise
to two cyanide ions per molecule of the parent com
pound Experiments were conducted to test this postulate
and data suggest that under in vivo conditions only one
cyanide radical is converted to cyanide thus the total
amount of cyanide generated may be minimal2 Studies
to ascertain cyanide production measured as plasma thio
cyanate levels in human subjects exposed to CS have
been conducted106 Findings from these studies have
indicated negligible levels of plasma thiocyanate
Dibenzf14oxazepine CR As part of the tox
icological assessment of CR the biotransformation and
metabolic fate of CR have been studied in a number
of animals 316 32 Human metabolic studies on CR have
not been conducted owing to the very high sensitivity
of humans to the irritant properties of CR which has
precluded metabolic studies because the maximal tol
erated dosage is too low to prevent metabolic detec






















2chlorobenzyl alcohol 2chlorobenzoic acid
Figure 4 CS metabolic pathways
respiratory tract and the plasma halflife T of CR
after inhalation exposure to CR aerosol is 5 min The
plasma halflife of CR following iv administration is
also 5 min The uptake and metabolic fate of CR in
intact cornea and corneal homogenates was studied by
Balfour The data indicated that these tissues readily
took up CR and metabolized CR to a lactam derivative
French and coworkers 19320 and Furnival et al 1 have
studied the metabolism and fate of CR in a series of
in vivo and in vitro studies French etal studied the
in vivo metabolism and metabolic fate of CR in rats
guinea pigs and monkeys after intragastric dosing of CR
and iv administration of CR to rats and mice It was
effectively absorbed from the gastrointestinal tract and
the fate of absorbed CR was in general similar to that
following iv administration Similar excretory patterns
and metabolites were noted among the species with uri
nary excretion as the major route of elimination In the
rat CR is converted to the lactam derivative followed
by subsequent hydroxylation to monohydroxylated deriva
tives ie 47 and 9hydroxylactams and the eventual
formation of sulfate conjugates see Fig 5 In the rat
the major conjugation pathway for CR metabolic prod
ucts involves sulfate conjugation which is irrespective of
dose and the route of administration The bile contained
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conversion to 2-chlorobenzyl alononitrile (CSH2), 2-
chlorobenzaldehyde (oCB), 2-chlorohippuric acid and 
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and 2-chlorobenzyl alononitrile ere detected in the 
blood follo ing inhalation exposure of rodent and non-
rodent species to CS aerosoI.31l6. 311 re ste   -
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results are in concordance with CS uptake studies in 
  t      
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Figure 5 Bioconversion pathways for CR
only small levels of sulfate conjugates In his review
on the metabolism of CR Upshall had also discussed
glucuronide conjugate formation involving CR metabolic
intermediates as an additional conjugationpathway which
are eventually excreted in the urine as sulfate conjugates
French and coworkers point out that similar metabolic
products and excretory pathways exist however only
free hydroxylactams were isolated from monkey urine
In the same study wholebody autoradiography stud
ies were performed in ivdosed mice and the results
suggested the rapid uptake of CR from the blood into
other compartments such as the liver kidney and small
intestine These findings are consistent with rat studies
indicating rapid absorption hepatic metabolism biliary
secretion interohepatic recirculation and renal excretion
In vitro metabolic studies that utilized rat liver prepa
rations were conducted by Furnival and coworkers
The findings demonstrated that CR metabolic conversion
involved ring opening and reduction and oxidation to lac
tams Additional in vitro and in vivo metabolic studies
were conducted by French et al Results from these
studies supported previous conclusions that the major
metabolic fate of CR in the rat is oxidation to the lac
tam subsequent ring hydroxylation sulfate conjugation
and urinary excretion With the exception of CRlactam
phase I metabolites of CR are acutely less toxic than the
parent compound
Chloroacetophenone CN The metabolism and full
metabolic fate of CN have not been studied in great
detail and are poorly characterized What is known con
cerning the metabolism of CN is that it is converted
to an electrophilic metabolite It is an SN alkylating
agent that reacts with SH groups and nucleophilic sites
of macromolecules Alkylation of SHcontaining enzymes
leads to enzyme inactivation with subsequent disrup
tion of cellular processes Based on the potential to
disrupt enzyme function Castro examined the effects
of various alkylating agents including CN on human
plasma cholinesterase Chloroacetophenone inhibited ChE
activity but not as a consequence of interaction with
SH moieties It is postulated that some of the toxic
actions ofCN may be due to alkylation of SHcontaining
enzymes
Mechanisms interactions and cytotoxicity
The mechanism underlying the pharmacological phys
iological effects and the mechanismsresponsible for
the toxic effects of riot control agents are reviewed
The underlying mechanism of action of some of the
riot control agents such as capsaicin is better under
stood and more fully delineated than it is for other riot
control agents such as CR A great portion of the dis
cussion related to mechanisms of action focuses on the
adverse effects whose etiology stems from the inter
action of toxic electrophilic metabolites of riot control
agents that alkylate critical molecular targets such as DNA
and proteins Interactions of electrophilic metabolites with
nucleophilic moieties of biological material with potential
consequences are highlighted in Fig 6 Discussion also
includes the generation of other toxic metabolic products
of riot control agents such as reactive oxygen species
ROS and cytotoxic metabolites such as cyanide and their
interactions with biochemical and physiological processes
which lead to deleterious effects Adverse effects that
may result from such toxic metabolites include mutagene
sis carcinogenesis immunotoxicity perturbations involv
ing bioenergetic pathways oxidation of macromolecules
ie DNA proteins and lipids alteration of detoxication
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Figure 6 Biological interactions of toxic metabolites with nucleophilic moieties and there consequences
processes capabilities cytotoxicity and the activation of
signaling pathways involved in pathological processes and
carcinogenesis The mechanisms by which some of these
toxic intermediates eg phenoxy radicals quinones TH
and ROS can produce adverse effects may be straightfor
ward or rather complex as in the case of toxic interme
diates such as quinones
Capsaicin and capsaicinoids It is important to
determine whether a single mechanism of neurotoxicity
accounts for capsaicin induced degeneration in the diverse
population of capsaicinsensitive neurons in the peripheral
and central nervous system326 It is now well accepted
that the specific action of capsaicin on a subpopulation
of neuropeptidecontaining afferent neurons involves the
activation of a specific receptor that recognizes capsaicin
capsaicinlike compounds the vanilloid receptor121330
This leads to the opening of a peculiar type of receptor
operated cation channel3253 The consequent influx of
Ca and Na leads to depolarization triggering the local
release of neuropeptides central protective reflexes and
autonomic motor responses1913323 A transient excitation
of primary afferents is followed by a more prolonged
condition of refractoriness whereby the primary afferents
become unresponsive to further application of capsaicin
capsaicin like agents densensitization of the primary
afferent neuron The excitotoxic actions of capsaicin
is the result of calcium and sodium influxes via a
capsaicinactivated channel 3213 The influx of Ca and
Na may cause rapid damage and eventual cell death
by osmosis and calciumdependent proteases The
ionic mechanisms underlying the actions of capsaicin
on primary afferent neurons have been established 3245
When capsaicin is administered sc at 50 mg kg to
neonatal rats 50 of the dorsal root ganglion DRG
neurons are rapidly destroyed
The acute biological effects of capsaicin are due to the
release of bioactive compounds eg substance P neu
rokinin A and calcitonin gene related peptide CGRP
from sensory nerves by capsaicin resulting in altered neu
rophysiology of sensory neurons in the airway mucosa
and neuromediated inflammation of the epithelium air
way blood vessels glands and smooth muscle which
leads to bronchoconstriction mucous secretion edema of
the tracheobronchial mucosa enhanced vascular perme
ability and neutrophil chemotaxis344 Biochem
ical and histochemical markers associated with primary
afferent neurons include a number of peptides such as
substance P somatostatin neurotensin and calcitonin
gene related peptide These bioactive materials play a
role in the communication of primary sensory neurons
with other neural and non neural cells3450 The mech
anismsegthe release of neuropeptides substance P
neurokinin A involvement of CGRP and the induction
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ward, or rather complex as in the case of toxic interme-
diates such as quinones. 
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This leads to the opening of a peculiar type of receptor-
operated cation channel.325 •331 Thc conscqucnt influx of 
Ca and Na leads to depolarization, triggering the local 
release of neuropeptides, central protective reflexes and 
autonomic motor responses. 197.J32.m A transient excitation 
of primary afferents is followed by a more prolonged 
condition of refractoriness hereby the pri ary afferents 
become unresponsive to further application of capsaicin 
/capsaicin-like agents-densensitization of the primary 
afferent neuron. The excitotoxic actions of capsaicin 
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RIOTCONTROL AGENTS
of ion fluxes in neuronsthat underlie the pharmaco
logical actions of capsaicin have been elucidated in part
in the 1970s and 1980S Itt1232509347357 Some of
these effects such as bronchoconstriction vasodilatation
and protein extravasation are mediated by substance P
which belongs to a group of biologically active pep
tides referred to as tachykininsthe reader is referred to
papers on substance P by Stern 311 Leeman and Mroz
Hokfelt et al360 and Lembeck and Gamse Substance
P is one of the more thoroughly studied of these puta
tive neurotransmitters It was originally discovered by
von Euler and Gaddum and has been researched since
the 1930s The isolation and biochemical character
ization of substance P was reported by Chang and
Leeman and subsequently sequenced by Chang and
colleagues 365 Substance P is thought to have a neuro
transmitter role in primary sensory neurons for central
transmission of afferent information 366 368 and as a periph
eral mediator of neurogenic inflammation and smooth
muscle contraction 159361 The aforementioned effects
bronchoconstriction vasodilatation and plasma extrava
sation are mimicked by substance P andor inhibited by
SP antagonists however other biological actions of cap
saicin eg the chronotropic and isotropic effect on the
heart are not mediated via substance P As mentioned
capsaicin has been shown to release substance P which
can cause bronchoconstriction directly by activation of
specific receptors or by release of histamine and other
mediators Capsaicin also may cause reflex bronchocon
striction by stimulating C fibers in both the pulmonary
and bronchial circulation Therefore bronchoconstriction
could be secondary to substance P release or to a vagal
reflex
In the previous section discussion focused on the mech
anisms that formed the basis for the neurotoxic action
of capsaicin Subsequent discussion on the mechanisms
continues with a focus on the toxic metabolic products
of capsaicin and their effects on the biological system
Surh and Lee13 in their review on the metabolism and
toxicity of capsaicin have discussed the role of metabolic
activation in capsaicin induced toxicity and the metabolic
pathways involved in the bioconversion of capsaicin to
electrophilic metabolites and other reactive moieties eg
ring epoxide phenoxy radical and quinone However the
interactions of these toxic metabolites with critical molec
ular targets and the consequences of such interactions
were minimally addressed In general these moieties can
interact with nucleophilic sites of macromolecules such as
proteins DNA and RNA that are thought to be critical in
the etiology of capsaicin induced cytotoxicity mutagenic
ity and carcinogenicity The formation of a quinonetype
intermediate following metabolism of capsaicin is of great
interest owing to the multiplicity of quinonemediated
effects including alkylation of DNA and proteins GSH
depletion reactive oxygen species ROS formation and
ROSrelated effects such as DNA oxidation and lipid per
oxidation
Quinones activated metabolites of polycyctic aro
matic hydrocarbonsrepresent a class of reactive inter
mediates that produce a number of deleterious effects
including cytotoxicity immunotoxicity and carcinogene
sis The mechanisms by which quinones produce these
effects can be via alkylation of proteins andor DNA or
by the formation of reactive oxygen species ROS that
are generated by the redox cycling of quinones Quinones
377
can react with nucleophilic amino groups of DNA and
proteins Additionally quinones react with sulfur nucle
ophilesie GSH and cysteine residues of proteins lead
ing to protein alkylation andor GSH depletion The gener
ation of ROS leads to severe oxidative stress in cells via
the formation of oxidized cellular macromolecules eg
DNA proteins and lipids as well as activation of sig
naling pathways involved in the initiation promotion and
progression of carcinogenesis For more indepth discus
sion on the subject of quinone chemistry and toxicology
the reader is referred to Monks etal and Bolton et al 71
The hepatic cytochrome P450catalyzed conversion of
capsaicin to reactive species includes the conversion to
semiquinone and quinone derivatives Quinones is a gen
eral term for a class of compounds that are endogenous
biochemicals are found in natural products or are gener
ated via metabolism of xenobiotics The quinone interme
diate of capsaicin also represents an ultimate electrophilic
metabolite This intermediate can be formed by one of the
following metabolic pathways initial O demethylation of
the 3methoxy group on the vanillyl ring with concomitant
oxidation to the semiquinone or oquinone derivatives
or O demethylation of the phenoxy radical intermediate
of capsaicin The latter pathway generates the extremely
reactive methyl radical which is wellknown to alkylate
nucleic acids and proteins Quinone derivatives of xeno
biotics elicit toxic effects in vivo including cytotoxicity
carcinogenicity and immunotoxicity Cellular damage can
occur via alkylation of critical cellular proteins andor
DNA In addition it should be recognized that redox
cycling of quinones generates adducts and the formation
of reactive oxygen species ROS Production of reactive
oxygen moieties can lead to severe oxidative stress in cells
via the formation of oxidized cellular macromolecules
The alkylation of proteins andor GSH by electrophilic
metabolites of capsaicin has consequences affecting cel
lular energetics detoxication processes etc The potential
of covalent binding with microsomal protein for example
may account for the impact of capsaicin on xenobiotic
metabolizing enzymes and liver toxicity In addition to
the potential adverse reactions resulting from the interac
tions of cellular constituents with the metabolic products
of capsaicin deleterious effects result as a direct action
of capsaicin on cellular processes namely cell bioen
ergetics Concerning mitochondria energy metabolism
Yagi postulated that capsaicin and dihydrocapsaicin pro
duce repression of NADH quinone oxidoreductase activ
ity which confirms findings suggesting capsaicin induced
inhibitory effects on hepatic mitochondrial bioenergetics
Chlorobenzylidene malononitrile CS The cyano
genic properties of CS have been investigated since Patai
and Rappoport demonstrated the hydrolysis of CS to
malononitrile the latter being converted to cyanide in ani
mal tissues The conversion of CS to cyanide with
malononitrile as an intermediate led Jones and Israe1
to postulate that some of the toxic effects attributed
to CS may arise from the conversion of CS in vivo
to cyanide It is understandable that considerable inter
est has evolved regarding the cyanogenic properties of
CS because cyanide is an extremely toxic poison The
mechanism of action of cyanide is generally accepted as
impairment of cellular respiration via the inhibition of
cytochrome oxidase leading to altered cellular electron
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Alkylation of GSH depletion GSH Hydroperoxide buildup leading to oxidative
glutathione GSH peroxidase damage and metabolic dysfunction eglipid
peroxidation resulting in functional impairment
of mitochondria nucleic acid oxidation leading
to mutations hemoglobin oxidation resulting
in diminished oxygen transport
GSH Decreased detoxification and excretion of
S transferase harmful electrophilic metabolites via
mercapturic acid pathway
Cysteine Altered protein synthesis
transporta




Lipoic acid Pyruvate Decreased acetyl CoA resulting in perturbed
depletion decarboxylase cell bioenergetics and decreased lipogenesis
system
Alkylation of Inactivation Various targets Modified protein structure non specific
proteins cytotoxicity cell death
Alkylation of Inactivation Nucleic acids Mutations alteration of genetic integrity
nucleic acids
I Glutathione serves as a transport form of cysteine
b Alkylation of dihydrolipoic acid which is the disulfhydryl form of lipoic acid is a coenzyme in the pyruvate
decarboxylase system
transport and resulting in cytotoxic hypoxia Addition
ally Way has suggested that our understanding of the
mechanistic aspects of cyanide induced toxicity proceed
beyond cytochrome oxidase inhibition to include also the
following biochemical lesions cyanide release of endoge
nous opioids which may cause respiratory paralysis 3756
lipid peroxidation 378 altered calcium levels379 and
phospholipid hydrolysis Involvement of the aforemen
tioned biochemical lesions in cyanide toxicity helps to
explain the diverse biological effects of cyanide
Maehly and Swensson had conducted studies to
ascertain urinary and blood levels of cyanide and thio
cyanate in workers exposed to low levels of cyanide With
regard to the cyanogenic properties of CS Frankenberg
and Sorbo conducted studies in animals to determine
blood cyanide levels and thiocyanate excretion as well
as defining the relationship between cyanide levels and
symptomatology They determined blood cyanide levels
and thiocyanate excretion in mice after intraperitoneal
administration and inhalation exposure to CS Mice were
exposed to a CS aerosol dosage of 20000 mgin m3
which corresponded to about onehalf of the LD50 for CS
This dosage resulted in high levels of blood cyanide that
were reached rapidly with peak levels 4 t6 min after
injection Equitoxic doses of malononitrile and cyanide
also were evaluated for generating blood cyanide
Based in part on xenobiotic interactions with sulfhydryl
groups and the findings of Mackworth and Dixon
on the inhibitory effect of various lacrimatory compounds
on thiol enzymes Lovre and Cucinell and Cucinell
et cal studied the effects of the riot control agents CN
and CR on SHdependent enzyme systems Lovre and
Cucinel1 postulated that sulfhydrylcontaining enzymes
eg lactic dehydrogenase glutamic dehydrogenase and
pyruvic decarboxylase are alkylated by CS Ballantyne
and Swanston also have reported that both CS and
CN are SN alkylatiog agents indicating that they react
directly with nucleophilic sites Findings by Cucinell
et a1 suggest that lactic dehydrogenase LDH is inhib
ited by CS and enzyme inhibition via CS was partially
reversed by the addition of excess glutathione GSH indi
cating the involvement of thiol groups These findings led
Cucinell et al 212 to suggest that alkylation of nucleophilic
sites including SH containing enzymes is the underlying
biochemical lesion responsible for CS induced toxicity
Chlorobenzylidene malononitrile is known to react with
the SH groups of dihydrolipoic acidthe disulfhydryl
form of lipoic acidwhich is a coenzyme in the pyru
vate decarboxylase system Alteration of dihydrolipoic
acid biochemistry can lead to decreased acetyl CoA levels
resulting in perturbation of cellular bioenergetics The bio
chemical interactions and potential mechanisms of cellular
injury involving CS are summarized in Table 9 Lastly
regarding the mechanism s of action of CS it is theo
rized that the irritant and painful effect of CS may be due
to bradykinin release1242
Clinical chemistry
Husain et al 21 studied the effects of CR and CN aerosols
on clinical chemistry parameters eg plasma glutamic
oxaloacetic transaminase GOT plasma glutamic
pyruvic transaminase GPT acid phosphatase and alka
line phosphatase Rats were exposed via inhalation to
aerosols of CR or CN Animals exposed to CR aerosol
exhibited no significant changes in plasma GOT and GPT
Published in 2001 by John Wiley Sons Ltd J Appl Toxicol 21 355 391 2001
001904
78 E. 1. OLAJOS N  . S E  
Table -Bioch i al intera tions  potential e a is s  cellular injury involving S 
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transport and resulting in cytotoxic hypoxia. Addition-
ally, aym has suggested that our understanding of the 
mechanistic aspects of cyanide-induced toxicity proceed 
beyond cytochro e oxidase inhibition to include also the 
following bioche ical lesions: cyanide release of endoge-
nous opioids, which may cause respiratory paralysis;m,J76 
lipid peroxidation;377,378 altered calcium leve\s;J79 and 
phospholipid hydrolysis. J80 Involve ent of the afore en-
tioned bioche ical lesions in cyanide toxicity helps to 
explain the diverse biological effects of cyanide. 
Maehly and SwenssonJ81 had conducted studies to 
ascertain urinary and blood levels of cyanide and thio-
cyanate in workers exposed to low levels of cyanide. ith 
regard to the cyanogenic properties of CS, Frankenberg 
 orboJ'5  es     
blood cyanide levels and thiocyanate excretion, as ell 
as defining the relationship between cyanide levels and 
symptomatology. They determined blood cyanide levels 
and thiocyanate excretion in ice after intraperitoneal 
ad inistration and inhalation exposure to S. ice ere 
exposed to a CS aerosol dosage of 20000 mg·min m--', 
which corresponded to about one-half of the LD50 for CS. 
his dosage resulted in high levels of blood cyanide that 
ere reached rapidly, ith peak levels -16 in after 
injection. Equitoxic doses of malononitrile and cyanide 
also were evaluated for generating blood cyanide. 
Based in part on xenobiotic interactions with sulfhydryl 
groupS.182 and the findings or aekworth38.1 and OixonJ84 
on the inhibitory effect of various lacri atory co pounds 
on thiol enzy es, Lovre and Cucinell J85 and Cucinell 
et aiY2 studied the effects of the riot control agents C  
and CR on SH-dependent enzy e systems. Lovre and 
Cucinell385 postulated that sulfhydryl-containing enzymes 
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RIOT CONTROL AGENTS
Table 10Comparative toxicity of lacrimatory compounds human estimates1246279
Minimal irritant lct5o mg ict mg
Compound cone mg min min m3 min m3
m3
CN 031 85002 000 2050
CR 002 100000 1
CS 004 25 00015 000 5
DM 1 5 1100035000 20 150
Acrolein 2 7 3500 7000
Bromobenzyl cyanide 03 800011000 30
Chloroacetone 18 3000
Chloropicrin 29 2000
Xylyl bromide 5 5600
Capsaicin
a Lct50 the concentration x time Ct that is lethal to 50 ofan exposed population
b ict the concentration x time Ct that incapacitates 50 of an exposed population
activities or in acid and alkaline phosphatase activities
In contrast CNexposed animals manifested significant
increases in GOT GPT acid phosphatase and alkaline
phosphatase activities Conclusions drawn from the study
was that exposure to CN aerosol could lead to tissue
damage
Human pharmacology and toxicology clinical
considerations related to riot control agent exposure
Riot control agents exert their effects on eyes lungs and
skin and can enter the body via the inhalation dermal and
oral routes of exposure The clinical symptoms which are
felt within 1030 s on exposure to riot control agents are
the consequence of these agents ability to cause intense
sensory irritation at various body sites Almost immedi
ately the eyes are affected with copious lacrimation ble
pharospasm conjunctivitis and pain Nasal effects consist
of rhinorrhea itching and pain also a stinging or burning
sensation of the mucosal surfaces is experienced Symp
toms such as sneezing coughing and increased respiratory
tract secretions are accompanied by a burning sensation
and chest tightness The more severe effects identified as
marked coughing retching and vomiting may occur if an
individual remains in a riot control agent atmosphere Psy
chological effects such as anxiety and panic are reactions
that are commonly noted on exposure to these compounds
The intense physical discomfort and anxiety also can lead
to cardiovascular changes such as increased blood pres
sure Effects on the skin consist mainly of an intense
burning sensation followed by erythema After cessation
of exposure most symptoms persist for a brief period
and by 30 min most symptoms have abated completely
however conjunctivitis can remain for up to 30 min On
exposure to massive doses which can be achieved with
aggressive use of certain riot control agents such as CN
severe effects involving the eyes ie corneal damage
and lungs eg hemorrhaging edema and congestion can
result These agents also may complicate and exacerbate
existing conditions such as bronchitis and asthma The
comparative toxicity human of various lacrimatory com
pounds is summarized in Table 10
Oleoresin capsicum OC and capsaicin Oleoresin
capsicum OC pepper spray purportedly safe and effec
tive has seen increased adoption and utilization by law
379
enforcement agencies Recently Smith and Stopford
have reviewed the effects of exposure to OC sprays and
have discussed the occupational health risks Onnen
on the subject of oleoresin capsicum as related to law
enforcement cited findings by Weaver and Jett who
reported the lack of adverse effects in humans exposed
to OC Recently a number of reports have appeared per
taining to incustody deaths and pepper spray use
Granfield and colleagues have published the findings
of their review of aggregated data related to incustody
deaths where pepper spray was used Thirty incustody
cases were reviewed to ascertain the role of pepper spray
as being unrelated contributory or causative They con
cluded that OC had not contributed to or was the cause of
death in 22 cases where sufficient information permitted
a thorough review Granfield et al also discussed fac
torsconditions eg positional asphyxia cocaine intoxica
tion excited delirium cocaine induced and neuroleptic
malignant syndrome NNIS Incustody deaths follow
ing OC pepper spray use also was the subject of a
paper by Steffee et al They described two cases of
incustody death both associated with the use of pep
per spray A detailed autopsy and toxicological analysis
was performed coupled with pre mortem chain of events
symptomatology and degree of natural disease processes
Findings in the first case indicated that pepper spray
neither caused nor contributed to the death whereas in
the second case the findings suggested a direct contribu
tion of pepper spray to the death The reader is referred
to an excellent paper by Lifschultz and Donaghue on
the broader issues related to in custody deaths Of con
siderable interest concerning the potential life threating
and ill effects of OC is a report by Billmire et al 392
which describes the adverse health consequences of OC
spray in an infant In that incident a 4 weekold healthy
infant was exposed to 5 pepper gas when a self defense
device was accidentally discharged The subject experi
enced respiratory failure and hypoxemia The treatment
regimen included extracorporeal membrane oxygenation
The patient was discharged and a subsequent 12month
followup was conducted that revealed several episodes
of viral respiratory infections
Studies have been published concerning the human
response to inhaled capsaicin 3 The human phar
macology of capsaicin has been reviewed by Fuller and
Watson etaldescribed the clinical effects in individuals
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u an phar acology and toxicology: clinical 
considerations related to riot control agent exposure 
Riot control agents exert their effects on eyes, lungs and 
skin and can enter the body via the inhalation, der al and 
oral routes of exposure. he clinical sy pto s, hich are 
felt ithin 10-30 s on exposure to riot control agents, are 
the consequence of these agents' ability to cause intense 
sensory irritation at various body sites. l ost i edi-
ately the eyes are affected, with copious lacrimation, b~e­
pharospas , conjunctivitis and pain. Na~al ~ffects con~lst 
of rhinorrhea, itching and pain; also, a stmgmg or burnmg 
sensation of the ucosal surfaces is experienced. Sy p-
toms such as sneezing, coughing and increased respiratory 
tract secretions are acco panied by a burning sensation 
and chest tiohtness. The more severe effects identified as 
marked cou~hing, retching, and vomiting may occur if an 
individual re ains in a riot control agent at osphere. Psy-
chological effects such as anxiety and panic are reactions 
that are co only noted on exposure to these co pounds. 
The intense physical discomfort and anxiety also can lead 
to cardiovascular changes such as increased blood pres-
sure. Effects on the skin consist mainly of an intense 
burning sensation followed by erythema. After cessation 
of exposure, most symptoms persist for a brief period 
and by 30 in ost sy pto s have abated co pletely; 
however, conjunctivitis can remain for up to 3.0 min. C?n 
exposure to massive doses, which can be achIeved With 
aggressive use of certain riot control agents such as CN, 
severe effects involving the eyes (i.e. corneal da age) 
and lungs (e.g. hemorrhaging, edema and congestion) can 
result. hese agents also ay co plicate and exacerbate 
existing conditions such as bronchitis and asthma. The 
comparative toxicity (human) of various lacrimatory com-
pounds is summarized in Table 10. 
Oleoresin capsicum (Oe) and capsaicin. l si  
capsicu  ( C, pepper spray), purportedly safe and effec-
tive, has seen increased adoption and utilization by la  
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exposed to OC The probable lethal oral dose of cap
saicin for humans is considered to be 0550 g kg 401
The upper respiratory tract effects on exposure to cap
saicin have been described311102 Healthy young human
adult subjects that were challenged intranasally with cap
saicin manifested rhinorrhea sneezing nasal burning and
congestion 197 Capsaicin application to the nasal mucosa
produced a painful sensation and copious secretion of
nasal fluid and these effects undergo desensitization
after repeated application Studies by Geppetti et a140
support the hypothesis that the therapeutic effectiveness
of capsaicin treatments in painful diseases might not be
linked to nerve fiber degeneration due to the neurotoxic
effect of capsaicin but might rely on desensitization of the
mechanism activated by capsaicin on the nerve terminal
The larynx may represent the primary site of stimulation
of inhaled capsaicin Because respiratory impairment is
one of the most obvious effects observed in capsaicin
exposed animals bronchoconstriction has been the subject
of a number of human studies on capsaicin1978 35t3 8
Fuller and coworkers117 demonstrated that when inhaled
in humans capsaicin produced a dose dependent bron
choconstriction that was the same as in asthmatics and
smokers The majority of subjects manifested coughing
and all reported retrosternal discomfort The studies by
Fuller and colleagues 117391 confirmed that the bronchocon
strictor reflex following capsaicin stimulation in animals
is present also in humans The capsaicininduced bron
choconstriction and the release of substance Pthe puta
tive neurotransmitterneurogenic mediator found in sen
sory neurons is caused by stimulation of the Cfibers
of the non myelinated afferent fibers These studies and
those using isolated human airway preparations showed
that repeated dosing causes tachyphylaxis In humans the
mechanism of bronchoconstriction following inhalation of
capsaicin is uncertain but possible mechanisms can be
inferred from animal studies
Chlorobenzylidene malononitrile CS On exposure
to CS humans manifest immediate signs and symp
toms that disappear in minutes on cessation of expo
sure Chlorobenzylidene malononitrile causes only tran
sient effects on the eye and irritation and blistering of the
skin at high concentrations Healthy individuals repeat
edly exposed to CS do not manifest ill effects Human
volunteers have been exposed to CS under varying con
ditions and concentrations to determine the ict50 value
defined as the concentration that will incapacitate 50 of
the exposed population in I min The incapacitating signs
and symptoms included intense burning of the eyes pro
fuse lacrimation blepharospasm burning sensation of the
nose and respiratory tract excessive salivation tightness
in the chest and a feeling of suffocation The time to
incapacitation did not appear to differ among the test sub
jects exposed to CS via the different dispersion techniques
reduced ambient temperatures and subjects with medical
histories suggestive of respiratory cardiovascular or hep
atic dysfunction However at wholebody exposures at
elevated temperatures ie 95T and 3597 relative
humidity the time to incapacitation was shortened McNa
mara et al reported that people may work without any
signs of discomfort in an atmosphere where CS gradually
accumulates whereas these concentrations were intoler
able to individuals entering the contaminated area from
unexposed areas Thus it appears that adaptation devel
ops gradually as the CS concentration increases When the
tolerant individual left the contaminated area for short
periods of 1030 min the tolerance was lost and reentry
into the contaminated areas resulted in intolerable irrita
tion Moreover additional studies on human volunteers
have documented the development of tolerance to CS
Except for skin effects workers in a CS manufacturing
facility had not manifested untoward illness Further the
mortality rate among these workers was less compared to
other groups of men of the same age range104
As the standard riot control agent of the US Army
since 1959 CS has largely replaced CN as the riot con
trol agent of choice worldwide The selection of CS as
the riot agent of choice was based on its low mammalian
toxicity and high sensory irritant potency It was used
in the United Kingdom in 1969 to quell riots in North
ern Ireland Rose and Smith 26 have reported alleged toxic
reactions in human beings exposed to agent CS and reac
tive airway dysfunction RADS following exposure to
CS was reported by Hu and Christiani The Himsworth
Report parts I and II40406 was the focus of an indepth
inquiry into the adverse health and toxicological effects
of CS following the use of CS in Londonderry Northern
Ireland in 1969 There was no evidence of incapacita
tion that prevented an individual egress from a CS
contaminated environment even among the most heavily
exposed individuals Additionally no evidence was found
that previously healthy persons exposed 3 weeks before
had developed any illness Attention focused on suscepti
ble subpopulations namely the very young the elderly
pregnant women and those with preexisting cardiopul
monary dysfunction Infants exposed to CS promptly
recovered from the irritating effects of CS when removed
to fresh air There was no indication that CS exposure
markedly altered the pre existing pulmonary function of
individuals with cardiopulmonary compromise Regard
ing adverse effects on reproductive function and preg
nancy the Himsworth Committee concluded that CS
exposure had not significantly affected reproductive physi
ology however meaningful epidemiological studies were
not conducted to address more fully the issue of repro
ductive risks The potential adverse effects in the very
young following exposure to CS was addressed also by
Park and Giammona who have described the effects of
CS in a 4month old infant after prolonged exposure The
infant manifested severe respiratory distress and symp
toms included copious nasal and oral secretions sneez
ing and coughing and obstruction of the upper airways
The patient was released from hospital yet within 24 h
was rehospitalized with a diagnosis of pneumonitis The
patient was treated and released following a 28day hos
pitalization Additional documentation pertaining to the
health effects of CS following its application in riot con
trol and law enforcement situations is that of Anderson
et al They described the findings of a review of case
studies of detainees presented for medical treatment fol
lowing exposure to CS in a riot control situation During
this civil disturbance large quantities of CS were utilized
in a confined space and under humid conditions Two
months after the incident when the patients were asymp
totic the case notes of all patients who had presented to
the clinic within 21 days following exposure with possible
CSrelated symptoms were reviewed Findings indicated
that the most common complaint was coughing Although
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edly exposed to S do not anifest ill effects. u an 
volunteers have been exposed to S under varying con-
ditions and concentrations to deter ine the [Ctso value, 
defined as the concentration that will incapacitate 50% of 
the exposed population in I min. The incapacitating signs 
and sy pto s included intense burning of the eyes, pro-
fuse lacri ation, blepharospas , burning sensation of the 
nose and respiratory tract, excessive salivation, tightness 
in the chest and a feeling of sutTocation. 61 The ti e to 
incapacitation did not appear to differ among the test sub-
jects exposed to CS via the different dispersion techniques, 
reduced ambient temperatures and subjects with medical 
histories suggestive of respiratory, cardiovascular or hep-
atic dysfunction. However, at whole-body exposures at 
elevated te peratures (i.e. 95 OF) and 35-97% relative 
hu idity, the ti e to incapacitation was shortened. cNa-
mara et al.61 reported that people may work without any 
signs of discomfort in an atmosphere where CS gradually 
accu ulates, whereas these concentrations were intoler-
able to individuals entering the contaminated area from 
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the majority of patients had recovered completely within
2 weeks of exposure one asthmatic child had sore throat
and shortness of breath This condition persisted for 38
days following exposure to CS Additionally a 3month
old infant with confirmed hematemesis was admitted to
the hospital for observation Because there was a 68
h delay from exposure to presentation at the clinic the
immediate and transient effects of lacrimation and rhin
orrhea were not reported A high incidence of skin burns
was noted among the CS exposed individuals many of
which healed with scarring and disfigurement There was
no clinical evidence of serious sequelae to CS exposure
in the patients examined however the high incidence of
burns due to the large amounts of CS generated in a con
fined area under conditions of high humidity was a cause
for concern Anderson et al confirmed the findings of
the Himsworth Committee at least with respect to
the transient nature of riot control agent induced effects
involving the eye and upper respiratory tract
In spite of its extensive use there have been no verified
causes of death in humans following CS application116
There have been several alleged reports of death follow
ing CS exposure but these were non verifiable andor
incorrect Hu reported that a middle aged adult suf
fered heart failure and hepatic damage on exposure to CS
and had eventually succumbed A review of the original
report of the incidence by Krapf and Thalmann indi
cated that the subject did indeed suffer heart failure and
hepatic insult This individual was hospitalized treated
and discharged 3 months after the exposure in a condi
tion capable of work Another report on the subject of
CS related fatality was a GAO document that focused on
allegations that the Israeli Defense Forces had mis used
USmanufactured CS The alleged misuse was reported
to have caused numerous deaths principally among the
sick and elderly The majority of casualities were pur
ported to be 1 year old or over 55 years of age The
Physicians for Human Rights reported in 1988 that they
could not confirm that deaths were linked to tear gas
exposure In addition the US Department of State did
not have any medical evidence to support a direct cau
sation between CS inhalation and the number of deaths
reported It was concluded that only four deaths might
have been attributable to CS use by the Israeli Defense
Forces Furthermore Israel was utilizing two types of tear
gas but generally employed CN Hence it is believed
that the allegations of death following the use of CS in
the West Bank and Gaza were unsubstantiated Accord
ing to Ballantyne there are no authorized reports ofdeath
from CS smokes Published estimates of the human acute
lethal inhalation dosage of CS vary between 25 000 and
150000 mginm A widely quoted estimate of the
human LCt for CS is 61000 mgin m3 which is from
US sources For humans lethal dosage estimates can be
derived only by extrapolation from animal data because
humans can withstand only minute dosages of riot control
agent Furthermore in light of the variance in the lethal
dose response noted in various animal species conser
vative values should be adopted In addition it must be
recognized that estimates of lethal amounts on the basis
of deaths occurring in law enforcement operations can
be quite imprecise The Himsworth Report concluded
that the physical properties of CS smoke and the unpleas
ant nature of the symptoms produced exposures that were
self limiting and short For irritants such as CS a person
RRE
is considered incapacitated when the exposed individual
will no longer remain in the contaminated atmosphere
Motivated persons may remain in a cloud of irritant for
longer periods of time because a condition of adapta
tion occurs and the irritant effects are diminished The
irritant n5o for CS that is considered intolerable for
1 min is 0110 mg m However the exact concentra
tion depends on the individualsdegree of motivation
Dibenzf14oxazepine CR A number of investi
gators19515772744123 have reported on the effects of
CR on human subjects following aerosol exposures
drenches with dilute solutions and local application The
estimated human LCt of CR is 100000 mginm
Human studies have been conducted to determine the
effects of CR after aerosol or cutaneous exposures and
the findings are summarized in a National Academy of
Sciences report Human subjects manifested mostly ocu
lar and respiratory effects after acute exposure to CR
aerosol Ocular effects included lacrimation irritation and
conjunctivitis and respiratory effects included upper res
piratory tract irritation and associated choking and dys
pnea Ballantyne et al described the effects of dilute
CR solutions following splash contamination on the
face In addition to the classical effects on the eye CR
facial drenches also produced an immediate increase in
blood pressure concomitant with decreases in heart rate
Subsequent studies to ascertain the effects of CR after
wholebody drenches also were conducted by Ballantyne
and coworkers Immediate increases in blood pressure
were noted as in the previous study however Ballantyne
etal concluded that the cardiovascular effects described
in both studies were not due to CR They theorized
that there was insufficient CR uptake to cause the sys
temic effects on the heart and the cardiovascular effects
were due to the sensory irritant induced stress However
Lundy and McKay2167 suggested that the cardiovascu
lar effects described by Ballantyne and coworkers were
the result of CRinduced effects on the heart via the sym
pathetic nervous system Ashton et al also had studied
the effects of CR aerosol on the respiratory physiology of
humans Test subjects were exposed to CR aerosol of par
ticle size 1 2 gm at a mean concentration of025 mgm
for 1 h Expiratory Now rate was decreased 20 min
after onset of exposure The authors postulated that CR
stimulated the pulmonary irritant receptors to produce
bronchoconstriction and increased the pulmonary blood
volume by augmenting sympathetic tone
Chloroacetophenone CN Initially the LCt estimate
of CN for humans was set at 7000 mgin m3 and sub
sequently was revised and established as 14000mgin
m In human volunteer studies the immediate effect on
exposure to CN was a burning sensation or stinging in
the eyes nose throat and exposed skin Immediate symp
toms were followed by lacrimation salivation rhinorrhea
and dyspnea Lacrimation persisted for 20 min post
exposure whereas conjunctivitis and blepharospasm per
sisted for up to 24 h High levels of CN can produce chem
ical injury to the eye which is characterized as corneal
and conjunctival edema chemosis and loss of corneal
epithelium Physical injuries also may occur following
dispersion via grenadetype teat gas devices Punte
and coworkers studied the effects of CN on human
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subjects Individuals were exposed to CN aerosol at a
Ct of 350 mgin m which is considered the maxi
mum safe inhaled dosage for humans Common symptoms
included rhinorrhea lacrimation blurred vision conjunc
tivitis and burning of the throat Less frequent but more
severe symptoms included difficulty in breathing nausea
and burning in the chest Persistence of effects was neg
ligible with no overt clinical signs noted 10 min from
cessation of exposure
The incapacitating dosage tet50 of CN has ranged
from 20 to 50 mginM3 The tct50 of CN is com
parable to DM an early riot control agent that CN
replaced However the 1et0 value for CN is considerably
greater than the 1et50 of CS which replaced CN in turn
The estimate for the human LCt of CN dispersed from
grenades is 7000 mgin m3 other reported estimates
are in the range 85002 00 mgin m3 According
to Punte etal the maximum safe inhaled dose of CN
for man is estimated at 500 mgin m3 As reported by
Thorbum pulmonary lesions may occur at the inhala
tion dosages and the effects of CN exposure in confined
spaces can be severe Exposed individuals manifested
lacrimation conjunctivitis conjunctival edema upper res
piratory tract irritation cough dyspnea and skin burns
Death from high concentrations of CN may occur and the
postmortem examination may reveal edema and conges
tion of the lungs alveolar hemorrhage necrosis of the
mucosal lining of the lungs and bronchopneumonia 1611
Lethal exposures to CN have been reported15417
Adamsite DM The human toxicology of DM has
been reviewed by Owens et al 251 McNamara et al and
Ballantyne The earliest human study on the effects of
DM was that of Lawson and Temple which described
the DM induced effects following inhalation exposure
The human toxicology of DM was revisited in studies by
Gongwer et al 19 and Punte et al who investigated the
effects of varying concentrations of DM on human sub
jects Punte and coworkers investigated the onset and per
sistency of effects following exposure to aerosolized DM
and other irritant compounds in a small group of human
subjects The dosage had not exceeded 100 mgin m3
which was considered the maximum safe inhaled dose
for man and many of the experiments were terminated
so as not to exceed the safe dosage Subjects reported
experiencing a burning sensation of the nose throat and
chest coughing and sneezing and salivation Several of
the symptoms persisted for up to 2 h upon termination
of exposure Based on their findings Punte et al esti
mated that the ECt for irritation 3min exposure was
19 mginmThe dosage Ct required to elicit vomit
ing and nausea however could not be established Addi
tional human toxicological data were reviewed by McNa
mara et cit McNamara cited a dosage of 49 mgin m3
as necessary to cause vomiting and nausea based on
human studies where individuals were exposed to DM at
Ct 7 236 mgin m3 High confidence in the above
estimate however is lacking because the estimate was
based on a highly variable dataset Ballantyne had esti
mated a dosage of 370 mgin M3 to elicit nausea and
vomiting Inhalation of high concentrations of DM has
resulted in severe pulmonary damage and death 250
GENERAL SUMMARY
The desired effect of all riot control agents is the tem
porary incapacitation of individuals via irritation of the
mucous membranes and skin Generally riot control
agents can produce acute sitespecific toxicity where sen
sory irritation occurs eg eyes respiratory tract and skin
The early riot control compounds such as CN and DM
have been replaced with safer compounds such as CS
and OC As much is known of the toxicity of riot con
trol agents such as CS as for many regulated chemicals
such as pesticides Substantial evidence suggests that riot
control agents are safe when used as intended However
the widespread use of riot control agents raises questions
and concerns regarding their health effects and safety For
modern riot control agents eg CS and CR there is a
large margin between dosages that produce harassment
and dosages likely to cause adverse health effects Yet
despite the low toxicity of modern riot control agents
these compounds are not entirely without risk The risk
of toxicity increases with higher exposure doses and pro
longed exposure durations Pulmonary dermal and ocular
damage may occur on exposure to high concentrations of
these substances particularly on exposure to DM or CN
Furthermore it is best recognized that exposure to riot
control agents in enclosed spaces may produce simifi
cant toxic effects irrespective of the riot control agent in
question Also misuse of riot control agents has resulted
in varying degrees of eye andor skin damage Addi
tionally it is important to note that the intense physical
discomfort and anxiety associated with riot control chem
icals may elicit cardiovascular changes that may have
significant implications for individuals with pre existing
disease Reported lethalities are few involving riot con
trol agents and then only under conditions of prolonged
exposure and high concentrations Recently concern has
focused on the deaths resulting from law enforcement use
of OC a riot control agent generally regarded as safe
because it is a natural product As with other xenobiotics
not enough is known concerning the longterm chronic
effects of riot control agents Repeated dose studies have
been conducted for some of the riot control agents but
additional studies are needed to address concerns magni
fied by the potential of multiple exposures during situa
tions of civil unrest Clearly there is considerable need
for additional research to define and delineate the bio
logical and toxicological actions of riot control agents
and to illuminate the full health consequences of these
compounds
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I Foreword ABriefHistoryof aReallyHot Aspect of
Pharmacology
Natural products afford a window of opportunity to study important biology If the
natural product is used or abused by human beings finding its biological
targets is all the more significant Hot pepper is eaten on a daily basis by an
estimated one quarter of the worldspopulation and represents an aspect of
pharmacology intimately familiar to most readers of this review Recall your
culinary experiences in let us say a Mexican restaurant Food flavored with
jalapeno pepper bites it induces profuse perspiration and a subsequent diarrhea
is not uncommon when pepper bites again However these symptoms become
less intense in regular patrons of the restaurant In more scientific terms hot
pepper is pungent affects thermoregulation activates autonomic reflexes and is
poorly absorbed However all these acute effects undergo tachyphylaxis upon
repeated applications
Hot pepper is a native of the Americas cf Andrews 1984 Naj 1992 Aztecs
called it chili this is how hot pepper is mentioned in the pre Columbian Aztec
manuscripts known as tlacuilos a name that has stuck in Latin America
information from the Internet EncycloPepredia http thepeppershopcom
indexhtml and Chili Gazette http mexicanfood tqncommsubhishtml But
the Old World adopted a different name red pepper instead erroneously linking
chili pepper Capsicum annuum to a similarly hot tasting plant black pepper
Piper nigrum Garrison 1929 Following the discovery of the New World the
habit of the natives to eat their food hot was first noted by Diego Alvarez Chanca
a physician to the fleet of Columbus cf De Ybarra 1906 In Europe a depiction
of the chili pepper plant appeared for the first time in the magnificent book of
Fuchs 11542 Hot pepper was cultivated in monastery gardens in Moravia as early
as 1 566 cf Kohler 1883 The Latin name of the plant Capsicum was given by
the French botanist de Tournefort for unclear reasons cf Naj 1992 A popular
theory holds that the name Capsicum was derived from the Greek kapto meaning
to bite cf Maga 1975 which appropriately describes the main characteristic of
the fruit Others argue that the name Capsicum is derived from capsa the Latin
word for box referring to the fact that the pepper pod is hollow divided into
compartments containing the seeds cf Naj 1992
The active ingredient in hot pepper was first isolated by Thresh 1846 more than
a century ago Thresh named this compound capsaicin and predicted that the
structures of capsaicin and vanillin were closely related Despite this early
discovery it was not until 1919 that the exact chemical structure of capsaicin
Figlwas determined Nelson 1919 The complete synthesis of capsaicin took
another decade Spath and Darling 1930 In 1912 Wilbur Scoville Scoville 1912
introduced his Organoleptic Test to quantitate the pungency of hot peppers that
is their capsaicin content and although HPLC has long supplanted the use of the
human tongue cf Suzuki and Iwai 1984 for quantitation the Scoville Unit
remains the measure of hotness If a pepper has 50000 Scoville Heat Units this
means that its alcoholic extract needs to be diluted 150000 for it to cease to be
hot tasting on the human tongue The hottest pepper is the Mexican habanero
which boasts 35000 Scoville Units cf Naj 1992 The oral test of Scoville
abandoned by the food industry survives in laboratories where it is still used to
detect capsaicin like compounds in plant extracts
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Typical vanilloid structures
RTX capsaicin isovelleral and scutigeral representing the four known
chemical classes of naturally occurring vanilloids resiniferanoids
capsaicinoids unsaturated dialdehydes and triprenyl phenols
respectively
With regard to the varied nonculinary uses of hot pepper there is apparently
little new under the sun For example Incas burned dried chili peppers to combat
the invading Spaniards by temporarily blinding them cf Naj 1992 Four
centuries later the first US patent was issued for the use of capsaicin for martial
tear gas purposes US patent 16598 1928 Nowadays capsaicin
containing sprays fondly called Sergeant Pepper are used by lawenforcement
officials in the United States to subdue violent criminals and in California are
marketed as a cop inacan for self defense Hyder 1996
The analgesic use of capsaicin is not novel either cf Whittet 1968 Lembeck
1987 Dasgupta and Fowler 1997 Native Americans rubbed their gums with
pepper pods to relieve toothache cf Naj 1992 This practice later also gained
popularity in European folk medicine as was noted by the Hungarian botanist
turnedcle gymanHa gay 1887 As early as 1850 the Dublin Free Press
recommended the use of alcoholic hot pepper extract on sore teeth for instant
relief recognizing for the first time the therapeutic potential of capsaicin
Turnbull 1850 A fascinating aspect of the rich history of the analgesic use of
capsaicin is that eunuchs serving the Chinese Emperors were castrated after their
scrotums had been repeatedly rubbed with hot pepper extracts cf Anderson
1990 As a curiosity it is also notable that Native Americans used hot pepper
extracts topically as an aphrodisiac a practice adopted by early settlers to the
dismay of their priests Chili Gazette httpmexicanfoodtgcommsubhishtmp
In 1640 Sir John Parkinson noted in his famous Theatricum Botanica that dogs
detest hot peppers cf Naj 1992 Chickens by contrast can be fed dried pepper
powder to turn the yolks of their eggs orange red These observations anticipate
the modern use of capsaicin to make bird food squirrel free cf Rouhi 1996 It
remains a mystery why is it that the same hot taste which repels a variety of
mammals from rats to squirrels to dogs is found pleasurable by so many
humans Psychologists speculated that eating hot peppers may be a form of
masochism Rozin and Schiller 1980 This theory however is at variance with
the well known geographic pattern of hot pepper consumption namely people
living in tropical climates prefer their food hotter than those residing in
temperate climates Moore 1970Rozin 1978 This pattern gave rise to the
theory that eating hot spicy food helps combat the warm climate via gustatory
sweating Haxton 1948 Lee 1954 This model has gained recent reinforcement
by the cloning of a capsaicin receptor which seems to be operated by both heat
and capsaicin Catering et al 1997 Nonetheless the human liking of or
aversion toward the taste of hot pepper is probably far more complex than this
relatively simple physiological model implies For instance Russians like their
vodka hot vodka peperovka whereas efforts by the Pabst Brewing Company to
introduce a pepper flavored beer were unsuccessful cf Naj 1992
II Introduction
A Overview
If one compares the two previous capsaicin reviews in this Journal Buck and
Burks 1986 Holzer in 1991 one can notice the steady evolution of ideas for
instance the identification of ultrapotent capsaicin analogs cf Szallasi and
Blumberg 1990a or the development of the first competitive capsaicin
antagonist capsazepine Bevan et al 1991 The past years however have
witnessed unprecedented advances that have revolutionized this field Holzer
1991 described the vanilloid receptor VRZ as a capsaicinoperated
conductance the expression of which is virtually restricted to a distinct
subpopulation of primary sensory neurons This is apparently no longer true In
1997 a VR termed VRI was cloned Catering et al 1997 The emerging concept
is that this VRI functions as a molecular integrator of painful chemical and
physical stimuli including noxious heat 48C and low pH Tominaga et al
1998 Apparently it is not capsaicin but heat that has the capability of opening
the channel pore ofVRI whereas capsaicin and protons only serve to lower the
heat threshold of the receptor Consequently even room temperature is able to
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gate VR1 in the presence of mildly acidic conditions and or capsaicin Tominaga
et al 1998 Moreover the expression of VRs is not restricted to sensory
neurons In addition to several brain nuclei Acs et al 1996a Sasamura et al
1998 nonneuronal tissues such as mast cells B1r6 et al 1998a and glial cells
Bird et al 1998b may express VRs There is mounting evidence both biological
and electrophysiological to suggest heterogeneity within VRs cf Szallasi and
Blumberg 1996 Szallasi 1997 As yet it is not known whether or not all VR
subtypes recognize capsaicin Therefore we chose to use in this review the
broader term vanilloidsensitive neuron over the traditional term capsaicin
sensitive neuron
It has also been found that ligands with little resemblance to the vanillyl group in
capsaicin can also act as vanilloids Szallasi et al 1996a 1998a 1999a
implying that the term VR is somewhat of a misnomer Terpenoid unsaturated
dialdehydes Szallasi et al 1996a8 and triprenyl phenols Szallasi et al
1999a Fig 1 are two chemical classes of such newly discovered vanilloids At
present resiniferatoxin RTX see Fig 1 for structure an ultrapotent capsacin
analog Szallasi and Blumberg 1989a 1990a is undergoing clinical trials where
it proves clearly superior to capsaicin Chancellor 1997 Cruz et al 1997a
Lazzeri et al 1997 Cruz 1998 At a recent meeting on urinary incontinence 1 st
International Consultation on Incontinence Monaco 1998 a proposal was
accepted that a Vanilloid Club should be formed From cloning to clinic the
vanilloid field is now vibrating with a frenzy of activity which makes the life of
review writers most complicated For instance rumor has it that additional VR
isoforms have been cloned and an endogenous vanilloid has been isolated
In this review we are deliberately focusing on recent developments in the field
The reader can refer to either the above review by Holzer 1991 or the
subsequently published book on capsaicin edited by John N Wood 1993 for
detailed background information Excellent short reviews are also available from
several authors eg Andy Dray 1992 Gabor Jancs6 and colleagues 1994
Carlo A Maggi 1991 or Janos Szolcsanyi 1996 among others In any case we
have tried to provide limited background information to the degree that it is
necessary to provide the context for understanding recent developments
The literature on vanilloids is vast Using the subject word capsaicin a Medline
search yielded 2892 publications that have appeared since 1991 the year when
the comprehensive capsaicin review by Holzer was published On average one
paper dealing with capsaicin actions has thus been published every day over the
past 7 years Approximately one tenth of these papers 245 publications since
1991 deal with some aspect of the therapeutic application of capsaicin in
humans Because a complete overview of this vanilloid literature would be
overwhelming this review tries to provide a selective coverage of the literature
with the focus on breakthrough discoveries emerging concepts and provocative
new ideas
B Capsaicin Targets and Actions
Capsaicin excites a subset of primary sensory neurons with somata in dorsal root
ganglion DRG or trigeminal ganglion Tablel As a general rule these vanilloid
sensitive neurons are peptidergic small diameter 50 pm neurons giving rise
to thin unmyelinated C fibers cf Holzer 1991 Among sensory neuropeptides
the tachykinin Substance P SP shows the best correlation with vanilloid
sensitivity cf Buck and Burks 1986 Holzer 1991 However on the one hand
not all small diameter DRG neurons respond to capsaicin and on the other hand
large diameter vanilloidsensitive neurons predominantly of the Abtype are
also known to exist Table 1 Indeed in certain tissues such as the tooth pulp
ASfibers predominate among the vanilloidsensitive nerve population Ikeda et
al 1997 Some small diameter sensory neurons are polymodal nociceptors
whereas neurons with Abfibers may function as mechanoheatsensitive
nociceptors cf Meyer et al 1994 In other words vanilloidsensitive neurons
are heterogeneous morphologically neurochemically and functionally and they
encompass several subclasses of DRG neurons fable 1 cf Holzer 1988
1991 Szolcsanyi 1996 Holzer and Maggi 1998 Because sensitivity to vanilloids
is the only known trait that all of these neurons seem to share they are best
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sensitive primary sensory neurons
According to a recent exciting finding by Seybold and colleagues Stucky et al
1998 vanilloid sensitivity is a plastic property of DRG neurons For instance the
algogenic substance bradykinin is able to recruit intermediate size neurons
240320 pM normally unresponsive to capsaicin to respond to vanilloids
Stucky et al 1998 Consequently the number of nociceptors that innervate
inflamed tissues increases As we will see later this novel mechanism may play
an important role in the development of inflammatory hyperalgesia via spatial
summation on spinal neurons
Central fibers of vanilloidsensitive neurons enter the central nervous system
CNS where they synapse on secondorder neurons of the dorsal horn of the
spinal cord for DRG neurons or the spinal nucleus of the trigeminal tract for
trigeminal ganglion neurons respectively cf Yaksh and Malmberg 1994
Generally speaking vanilloidsensitive neurons transmit noxious information
usually perceived as itching or pain to the CNS afferent function whereas
peripherial terminals of these neurons are sites of release for a variety of
proinflammatory neuropeptides efferent function these neuropeptides are
summarized in Table 1 These neuropeptides are believed to play an important
role in initiating the cascade of neurogenic inflammation Fig2 cf Foreman
1987 Geppetti and Holzer 1996 In most experimental paradigms capsaicin was
found to activate both afferent and efferent functions leading to the adaptation
of the axon reflex model cf Bayliss 1901 Bruce 1910 Lewis 1927 Celander
and Folkow 1953 Lisney and Bharali 1989 by capsaicin researchers cf Holzer
1988 Maggi and Meli 1988Burnstock 1990 Lynn and Cotsell 1991 However it
has recently been shown that capsaicin is capable of releasing sensory
neuropeptides such as SP somatostatin and calcitonin gene related peptide
CGRP from the peripheral endings of sensitive nerves in the presence of
lignocaine tetrodotoxin wconotoxin or agatoxin suggesting a direct
mechanism for peptide release not mediated by axon reflex Szolcsanyi et al
1998a
Figure 2
f Schematic illustration ofthe
role of peripheral
0 vanilloidsensitive nerve






from Szallasi and Blumberg
In this page Ina new window 1993b Vanilloidsensitive
nerves may be stimulated to
release prestored proinflammatory neuropeptides by both exogenous
and endogenous stimuli Some of these agents like bradykinin have
their own receptors others may act on VRs Protons are unique in that
they have their own receptors called acid sensitive ion channels or
ASICs but they act also on VRs The competitive VR antagonist
capsazepine ameliorates carrageenan induced inflammation in vivo
implying a role for an endogenous vanilloid in initiating the
inflammatory cascade Generally speaking the tachykinin SP released
from vanilloidsensitive nerves causes smooth muscle cells to contract
egbronchospasm and opens endothelial gaps plasma
extravasation by interacting at NK1 Rs Also SP can stimulate mucus
secretion and activate various inflammatory cells The predominant
effect of CGRP is vasodilation There are several important positive
feedback mechanisms involved in neurogenic inflammation For
example SP released from vanilloidsensitive nerves activates mast
cells Mast cells liberate histamine which in turn stimulates vanilloid
sensitive nerves to release more SP It is easy to visualize how the
defunctionalization of sensory nerves by vanilloids may prevent or at
least ameliorate neurogenic inflammatory symptoms For further
details see text
In addition to capsaicin vanilloidsensitive neurons are also activated by a variety
of chemical and physical both heat and pressure stimuli cf Maggi 1991
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Lundberg 1993 Some of these compounds like histamine and bradykinin have
their own receptors Others for example xylene and mustard oil are believed to
work in a non receptor mediated fashion N Jancs6 et al 1968 possibly by
perturbing membranes Protons low pH are unique in that they have their own
receptors known as acid sensitive ion channels or ASICs Waldmann et al
1997 but at the same time they also act on VRs capsaicin Bevan and Yeats
1991 Petersen and LaMotte 1993 Liu and Simon 1994 Martenson et al 1994
Kress et al 1996a Caterina et al 1997 Tominaga et al 1998 Finally there are
compounds eg sesquiterpene unsaturated dialdehydes Szallasi et al 1996a
and more surprisingly physical stimuli eg noxious heat Caterina et al 1997
that appear to stimulate sensory neurons in a VRmediated fashion Again it
needs to be emphasized that VR is a target but not the target for noxious heat
because the overlap between heat and capsaicinsensitive DRG neurons is only
partial Cesare and McNaughton 1996 Kirschstein et al 1997 Reichling and
Levine 1997
Among irritant compounds acting on primary sensory neurons capsaicin and
related vanilloids are unique in that the initial stimulation by vanilloids is
followed by a lasting refractory state traditionally termed desensitization N
Jancs6 and A Jancs6 1949NJancs6 1955 1968 cf Szolcsanyi 1984 G Jancs6
1994 As discussed later this desensitization is a complex process and has a
clear therapeutic potential
Although capsaicin was regarded as a remarkably selective tool for primary
sensory neurons Holzer 1991 it was clear from the beginning that not all
capsaicin actions can be attributed to the activation of primary sensory neurons
The lack of probes to detect VRs has led to considerable confusion as to what
constitutes vanilloidsensitive targets This confusion persists to the present
There was little debate that there are vanilloid sensitive neurons in nodose
ganglia Szolcsanyi and Barth6 1978 1982 Marsh et al 1987 Raybould and
Tache 1989 Waddell and Lawson 1989Sharkey et al 1991 Carobi 1996 The
actual existence of these neurons was recently confirmed by both binding
Fig 3 Szallasi et al 1995a and VRl mRNA in situ hybridization studies
Helliwell et al 1998a It was also generally accepted that intrinsic sensitive
neurons located in the hypothalamus can mediate the well known effects of
vanilloid administration on temperature regulation aancs6 Gabor et al 1970
Szolcsanyi et al 1971 Recent experiments with both RTX binding Fig 4Acs et
al 1996a and reverse transcription polymerase chain reaction using primers
based on the VRl sequence Sasamura et al 1998 have confirmed the existence
of these VRexpressing hypothalamic neurons Other capsaicin actions turned out
to be mediated by targets unrelated to VRs cf Holzer 1991 Szallasi 1994
Nonetheless the recognition that nonneuronal tissues may express VRs Bir6 et
al 1998abimplies that capsaicin effects previously considered to be nonspecific





the rat Note the intense
labeling in dorsal root b upper
five samples trigeminal b
lower two samples and
nodose c ganglia containing
cell bodies of vanilloid
View larger version sensitive neurons Central
In this page Ina new window fibers of DRG trigeminal
ganglion and nodose ganglion
neurons terminate in the dorsal
horn of the spinal cord a small arrowheads the spinal trigeminal
nucleus of the medulla oblongata a big arrowhead and the area
postremanucleus of the solitary tract a open arrow respectively
Peripheral axons of DRG and nodose ganglion neurons traverse in the
sciatic d and vagus c nerves respectively Following ligation there is
a marked accumulation of specific binding sites proximal to the
ligature in the vagus c or sciatic d nerves suggesting that VRs are
transported intraaxonaily to the periphery in a form capable of ligand
binding Reprinted with permission from Szallasi 1995
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In this page In a new window Figure 4
VRs in the human brain as
detected by specific binding For comparison in the first
column we show the density of specific RTX binding sites in the dorsal
horn of the human spinal cord SCthe central termination site for
vanilloid sensitive neurons In three nuclei PA preoptic area LC locus
ceruleus MH medial hypothalamus the density of RTX binding sites
approaches one third of that in the dorsal horn The presence of VRs in
these nuclei is expected as they were reported to respond to capsaicin
in vivo A low density or affinity but reproducible RTX binding was
detected in additional two areas the reticular formation RF and the
ventral nucleus of the thalamus VT A very low level of binding was
found in the midbrain central gray matter CG Finally no specific
binding could be detected in the somatosensory cortex SSC
Reproduced with permission from Acs et al 1996a
C Early Indirect Evidence for and against a VanilloidCapsaicin Receptor VR
From the beginning three lines of strong evidence pointed to the existence of a
specific capsaicin recognition site First capsaicin like activity required fairly
strict structure activity relations Szolcsanyi and JancsoGabor 1975
1976Szolcsanyi 1982 Hayes et al 1984 Walpole and Wrigglesworth 1993
Second capsaicin sensitivity seemed to be restricted to welldefined neuronal
tissues cf Buck and Burks 1986 Holzer 1991 Third susceptibility to capsaicin
showed striking species related differences Most authorities agreed that
capsaicin sensitivity occurred only in mammals and even mammalian species
differed considerably in their responsiveness to capsaicin cf Buck and Burks
1986 Holzer 1991 Furthermore corroborative evidence for the existence of a
capsaicin receptor was the finding that the inorganic dye ruthenium red was able
to block the capsaicin induced responses cf Amann and Maggi 1991
If sufficiently high capsaicin doses are used the above tissue and species
specificities of capsaicin actions are however lost For example Ritter and Dinh
1993 demonstrated capsaicinevoked silver staining along almost the entire
neural axis of the rat including the retina In keeping with this Szikszay and
London 0988described enhanced glucose use by capsaicin in a wide variety of
CNS structures in the rat Capsaicin was found to inhibit various enzymes
Shimomura et al 1989 Yagi 1990 Teel 1991 Wolvetang et al 1996 induce
pseudochannel formation in lipid bilayers Feigin et al 1995 alter membrane
fluidity Aranda et al 1995 and block K channels Dubois 1982 Petersen et
alI987Bleakman et al 1990 Castle 1992 Baker and Ritchie 1994 Kuenzi and
Dale 1996 just to name a few characteristic non VRmediated capsaicin
actions
Early efforts to demonstrate specific binding sites for
Szebeni et al 1978 or photoaffinity labeled capsaicin like molecules James et
al 1988 failed due to a combination of the high lipophilicity and relatively low
affinity of these molecules
III DirectEvidence for a Vanilloid Capsaicin Receptor
A Specific Binding of resiniferatoxin RTX a Naturally Occurring Ultrapotent
Agonist
It has been known since the dawn of recorded history that the latex of the
Moroccan cactuslike plant Euphorbia resinifera contains an extremely irritant
component FigS cfAppendino and Szallasi 1997 But it was not until 1975
that the compound responsible for this irritancy was isolated and named RTX
Hergenhahn et al 1975 RTX see structure in Fig 1 combines the structural
features of two classes of natural irritants phorbol esters and capsaicinoids
Although RTX did bind to the phorbol ester receptor protein kinase C PKC see
in Section XIIIB this low affinity interaction could not explain its extreme
pungency In a series of experiments beginning in 1989 and continuing to date
we have identified RTX as an ultrapotent capsaicin analog with a unique spectrum
of biological activities Table 2 Because capsaicin and RTX analogs share a
homovanillyl group as a structural motif essential for bioactivity but differ
dramatically in the rest of the molecule Fig 1 they are collectively termed
vanilloids Consequently the primary target for these compounds appears to be
best described as the VR
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The collection of the latex of an
euphorbia plant as depicted in Codex Ayasofia 3103 f 136 Freer
Gallery of Art Smithsonian Institution Washington DCan Arabic
version ofDe Materia Medica by Dioscorides During antiquity the dried
latex called euphorbium was used as a vesicant skin irritation and
sternutative nose irritation agent It was also given as a general
remedy for various snakebites and poisons
View this table
Table 2
In this window Ina new window
Potency of RTX relative to
capsaicin in selected assays in
the rat
In several assays RTX is several thousandfold more potent than capsaicin Table
2 cf Szallasi and Blumberg 1990a 1993b 1996 This ultrapotency predicted
the existence of highaffinity specific RTX binding sites VRs Despite multiple
obstacles in 1990 we finally managed to demonstrate specific binding by
rat DRG membranes Szallasi and Blumberg 1990b providing the first
unequivocal evidence for the existence of VRs Fig6This initial binding assay
was however plagued by a very high nonspecific binding which prevented the
detection of VRs in the spinal cord or peripheral tissues
srter Prot Rat DRGuwr Figure 6
z
Scatchard plots of specific
E binding to rat DRG
membranes This binding is of
z
da high affinity Kd is 20 pM and
follows positive cooperative
behavior as reflected in the
convex Scatchard plot The
o ro w
tNIRTX 8d Omolmgi
cooperativlty index Is 2
view larger version indicating the existence of at
In this page In a new window least two interacting binding
sites Capsaicin and
capsazepine both at a
concentration of 3 wM reduce the apparent affinity of RTX binding
having little or no effects on cooperativity or maximal receptor density
This behavior is consistent with a competitive binding mechanism
The methodological means to overcome the problems created by the high
nonspecific RTX binding was furnished by an accidental observation of ours In
search of endogenous ligands for VRs we assayed a variety of body fluids and
tissue extracts and found that the acute phase serum protein alacid
glycoprotein also known as orosomucoid binds RTX Szallasi et al 1992
al Acid glycoprotein is an important drug binding protein Paxton 1983 Kremer
et al 1988 Maruyama et al 1990 We showed that RTX binds to the well known
drug recognition domain on alacid glycoprotein that it shares with warfarin
Szallasi et al 1992 Plasma binding of RTX to at acid glycoprotein may have
clear consequences on pharmacokinetics upon systemic administration that we
will discuss later RTX binding to al acid glycoprotein however differs in two
very important aspects from VR binding First it is not markedly influenced by
temperature and second it is of an at least 1000fold lower affinity Szallasi et
al 1992 At 0C the dissociation of receptor bound RTX is unmeasurably slow
Szallasi and Blumberg 1993a By contrast alacid glycoprotein readily binds
unbound RTX in the aqueous phase Szallasi et al 1992 Because nonspecifically
bound RTX in the membrane lipids is in equilibrium with the unbound RTX in the
aqueous phase alacid glycoprotein is able to extract nonspecifically bound RTX
from the membranes without compromising specific binding Szallasi et al
1992 By centrifuging the membranes it is then easy to separate the membrane
mostly receptor bound RTX from the al acid glycoprotein bound form that
remains in the supernatant
The introduction of at acid glycoprotein to the VR binding assay resulted in a
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dramatic improvement in the ratio of specific binding from 50 of the total at
concentrations close to theKd to 90 of the total binding or even higher Using
this improved assay we are now able to detect specific RTX binding sites in the
dorsal horn of the spinal cord Szallasi et al 1993abAcs and Blumberg 1994
Acs et al 1994abSzallasi and Goso 1994 in various peripheral tissueseg
urinary bladder Szallasi et al 1993c Acs et al 1994a urethra Parlani et al
1993 nasal mucosa Rinder et al 1996 airways Szallasi et al 1993b 1995b
colon Goso et al 1993a as well as in several brain nuclei Fig 4 and Table3
Acs et al 1996a Furthermore we developed an autoradiographic approach to




In this window In a new window
Parameters of binding
to VRs in the rat
Figure 7
Autoradiographic visualization
by binding of VRs in
porcine A small arrowheads
and human B dorsal horn of
the spinal cord the central
termination site for vanilloid
sensitive neurons The labeling
is highly specific because it is
completely missing in the
View larger version presence of nonradioactive RTX
In this page Ina new window CReprinted with permission
from Szallasi et al 1994a
B Development of Capsazepine a Competitive VanilloidAntagonist
Capsazepine Fig 8 the first and as yet only commercially available competitive
VR antagonist comes from an extensive program at the former Sandoz now
Novartis Institute for Medical Research London to explore structureactivity
requirements for vanilloid like activity cf Walpole and Wrigglesworth 1993
Capsazepine inhibits vanilloid responses in vitro with Schild plots consistent with
a competitive mechanism Bevan et al 1991 1992 Moreover capsazepine
competes for specific RTX binding sites in a competitive manner Szallasi et al
1993b In rat trigeminal ganglion neurons capsazepine inhibits vanilloidevoked
currents Liu and Simon 1994 In a variety of bioassays capsazepine is effective
against both capsaicin Dickenson and Dray 1991Urban and Dray 1991 Belvisi
et al 1992 Perkins and Campbell 1992 Maggi et al 1993 Santicioli et al
1993 Seno and Dray I993Ueda et al 1993 Lee and Lundberg 1994 Lalloo et
al 1995 Fox et al 1995 and RTX Ellis and Undem 1994 Walpole et al
1994Acs et al 1996b 1997 Wardle et al 1996 1997 but surprisingly not
against olvanil Davey et al 1994 The utility of capsazepine is however limited
by its moderate potency At micromolar concentrations which are necessary to
inhibit capsaicinevoked responses in most tissues capsazepine also blocks
voltagegated calcium channels Docherty et al 1997 as well as nicotinic
acetylcholine receptors Liu and Simon 1997 Furthermore recent evidence
suggests that capsazepine insensitive VRs also exist Liu et al 1998 Therefore
one should be very careful when interpreting results obtained with capsazepine
because positive effects are not necessarily mediated by VRs nor do negative
data rule out the involvement of VRs One more reason for being cautious when
working with capsazepine was furnished by the observation that at least in the
rabbit it may act as a weak vanilloid agonist Wang and Hakanson 1993
Figure 8
Selected vanilloid structures
Capsazepine is a competitive
VR antagonist Eugenol in an
analgesic used in dental
practice Olvanil is a
nonpungent orally active
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View larger version capsaicin analog Compound
In this page In a new window
57 is the most potent
capsaicinoid for inducing
Cat uptake by DRG neurons
in culture PPAHV binds to VRs in a noncooperative fashion Also it
gates two pharmacologically distinct conductances in rat DRG neurons
one that is inhibited by capsazepine and another that does not
recognize this antagonist PDDHV induces Cat uptake by DRG
neurons with a potency of 15 nM however it fails to inhibit
binding to these cells up to a concentration of 10 pM This finding
implies that the RTX binding domain on VRs is distinct from the site
mediating calcium influx
C Cloning ofthe First VR TermedVRt
Repeated efforts to clone a VR using RTX like photoaffinity probes resulted in the
identification of several relatively lowaffinity RTXbinding proteins none of
which showed the expected tissue distribution for VRs nor did they show a
VRlike activity in functional assays Ninkina et al 1994 Davies et al 1997
David Julius group at the University of California in San Francisco chose
therefore a different approach They transfected eukaryotic cells with pools of a
rat cDNA library and used calcium imaging to identify those cells that responded
to capsaicin Caterina et al 1997 Once a positive pool was found it was divided
into smaller pools a procedure known as sib selection until they had isolated a
single cDNA encoding the capsaicin gated channel They named this receptor
VRI
The rat VRI cDNA contains an open reading frame of 2514 nucleotides This cDNA
encodes a protein of 838 amino acids with a molecular mass of 95 kDa At the N
terminus VRI has three ankyrin repeat domains Fig9A The carboxy terminus
has no recognizable motifs Predicted membrane topology of VRl features six
transmembrane domains and a possible pore loop between the fifth and sixth
membrane spanning regions Fig 9A There are three possible protein kinase A
phophorylation sites on the VRI that might play a role in receptor desensitization
Figure 9
A predicted membrane
topology and domain structure
Al
of the first cloned VR called
VRI VRI has six complete
transmembrane segments and
a
a partial one which is believed
to be associated with the
channel pore As indicate
ankyrin repeat domains Outer
View larger version oand inner i plasma
In this page In a new window membrane leaflets are also
indicated B rat VRI shows
homology to the Drosophila
TRP channel and a related protein in the nematode C elegans Several
human ESTs such as T12251 in heart are also similar to VRI Identical
residues are in black boxes and conservative substitutions are in gray
Reprinted by permission from Nature Caterina et al 1997 Copyright
1997 Macmillan Magazines Ltd
VRI is a distant relative of the transient release potential TRP family of store
operated calcium channels Monteli and Rubin 1989Hardie and Minke 1993 Wes
et al 1995 Clapham 1996 Colbert et al 1997 Roayaie et al 1998 There is
considerable homology between VRI and the drosophila TRP protein in retina
Fig 9B This sequence similarity seems to be restricted to the pore loop and the
adjacent sixth transmembrane segment in VRI Interestingly VRI also shows
similarity to a Scares human retina cDNA L Hillier N Clark T Dubuque K
Elliston M Hawkins M Holman M Hultman T Kucaba M Le G Lennon M
Marra J Parsons L Rifkin T Rohlfing F Tan E Trevaskis R Waterston A
Williamson P Wohldman and R Wilson unpublished observations Washington
UniversityMerck expressed sequence tags EST Project Accession AA047763
Because capsaicin causes a marked calcium accumulation in rat retina Ritter and
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Dinh 1993 it might be speculated that the retina has a site related to VRI that
recognizes vanilloids OSM9 a novel protein with similarity to rat VRI plays a
role in olfaction mechanosensation and olfactory adaptation in Caenorhabditis
elegans Colbert et al 1997 OSM9 however does not recognize capsaicin
Cornelia Bargmann personal communication These findings imply that 1 in
contrast to previous beliefs VR isoforms did occur early during evolution but 2
the capsaicin recognition site is a recent addition to VRI
It should be noted that a human EST in heart IT 2251 displays striking similarity
68 amino acid identity to the pore loop and the adjacent sixth transmembrane
segment in rat VRI Fig 9B Additional human EST clones are similar to other
regions of the VRI and could represent fragments of the human transcript The
presence of a VRI like EST clone in heart is surprising but it is entirely in accord
with the recent recognition of nonneuronal VRs Biro et al I998abCapsaicin
has long been known to influence cardiac functions Fukuda and Fujiwara 1969
Molnar et al 1969 Some capsaicin actions on heart were attributed to an
interaction at Kchannels Castle 1992 whereas others were explained by the
liberation of neuropeptides most notably CGRP from the vanilloidsensitive
innervation of the heart Franco Cereceda et al 1988 1991 Ono et al 1989 It
is not impossible that capsaicin can also act directly on the heart via a cardiac VR
When expressed in Xenopus oocytes VRI is similar in its electrophysiological
properties to native vanilloidoperated channels in sensory ganglia Caterina et
al 1997 As observed in cultured DRG neurons Baccaglini and Hogan 1983
Heyman and Rang 1985 Forbes and Bevan 1988 Winter et al 1990 Vlachovs
and Vyklicky I993Liu and Simon 1994 Petersen et al 1996 capsaicin evoked
currents readily disappear after agonist removal whereas RTX induced currents
are much longer in duration and often persist even in the absence of the agonist
Hill coefficients approximately 2 derived from the analysis of capsaicin induced
currents in oocytes injected with mRNAs encoding VRI indicate the existence of
more than one agonist binding site Caterina et al 1997 Again this is in accord
with the properties of native VRs in sensory neurons Szallasi et al 1993a Oh et
al 1996 The implications of this finding are discussed inSection VIJ
RTX is however only 20 fold more potent than capsaicin to activate the cloned
VRl Caterina et al 1997 which is at variance with the several thousandfold
higher affinity of RTX in the binding assay cf Szallasi and Blumberg 1990a
1996 Szallasi 1994 This apparent contradiction was first explained by
postulating the existence of two distinct classes of VRs the channel which
represents a low affinity site for RTX and a yet to be cloned high affinity site
seen in the binding assay We referred to these receptors as C type and Rtype
VRs respectively cf Acs et al 19978ir6 et al 1997 Szallasi 1997 However
preliminary binding experiments with human embryonic kidney HEK293 cells
stably transfected with VRl cDNA suggests that this is not the case the same
receptor protein seems to mediate both the high affinity RTX binding and the
lower affinity calcium uptake response A Szallasi D N Cortright P M
Blumberg and J E Krause manuscript in preparation
IV Anatomical Localization and TissueSpecificity ofVRs
A VRs in Primary Sensory Neurons Colocalization with Other Receptors
Neuropeptides and the Isolectin B4
As first shown by RTX autoradiography cf Szallasi 1995 VRs are expressed
along the entire length of vanilloidsensitive sensory neurons from the
peripheral terminals to the axons to the somata to the central endings Fig 3 and
Table 3 In corresponding areas compare Figs 3 and 10 the presence of
VRI like immunoreactivity has also been demonstrated Guo et al 1999
Tominaga et al 1998 Nerve ligation studies suggest that VRs are transported
from the cell bodies to the periphery in a form capable of ligand binding Fig 3
Szallasi et al 1995a Peripheral tissues in which VRs were demonstrated by RTX
binding to be present are listed in Section IIIA and in Table 3 In the urinary
bladder VRs seem to be expressed exclusively on nerve endings rather than in
bladder epithelium or the muscle layer for denervation of the bladder leads to a
complete depletion of specific RTX binding sites Szallasi et al 1993d The
majority approximately 90 of the RTX sites appear to be present on the
pudendal nerve with a relatively minor fraction on the hypogastric nerve Szallasi
et al 1993d
Figure 10
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View larger version
In this page Ina new window Visualization by
immunohistochemistry of VRI
receptor like immunoreactivity
in central A and C and peripheral E and G terminals of vanilloid
sensitive neurons in the rat Compare this figure to Fig 3 and notice
the colocalization of specific RTX binding sites and VRI in the nucleus
of the solitary tract A arrows the spinal trigeminal nucleus A arrow
heads and the superficial dorsal horn of the spinal cord C VRI like
immunoreactivity is also present in the sciatic nerve Fthe paw skin
E and the cornea G The specificity of the immunostaining is
demonstrated by peptide blocking B and by the absence of labeling
following unilateral dorsal rhizotomy D Reprinted with permission
from the European Journal of Neuroscience Guo et al 1999
Northern blot analysis confirmed the presence of VRI transcripts in dorsal root
and trigeminal ganglia Caterina et al 1997 Helliwell et al 1998a VRI like
immunoreactivity was detected in more than 50 of DRG neurons Fig 11 with
the expression being most prevalent in small to medium sized neurons Guo et
al 1999 VRI like immunoreactivity was also observed in both the central eg
dorsal horn of the spinal cord and the caudal nucleus of the spinal trigeminal
complex and peripheral eg skin and cornea processes of primary afferent
neurons Fig 10 Guo et al 1998 In DRG neurons VRI like immunoreactivity
was associated with the Golgi complex and the plasma membrane Guo et al
1999 In the dorsal horn of the spinal cord the VRI protein was associated with
small clear vesicles in preterminal axons and with the plasma membrane of
nerve terminals Guo et al 1999 The latter finding is in line with an earlier
observation of Szolcsanyi Szolcsanyi et al 1975 according to which capsaicin
depletes small clear vesicles from nerve endings
Figure 11
MEN Colocalization of VRI like
immunoreactivity in the spinal
dorsal horn A B D E G
and K and in DRG neuronss C
MEN
F 1 and Lwith the lectin A
aB nd C the P2X3 receptor D
E and F and the
MEE andCGeptides SP H and 1GRP Q K and LThis
View larger version figure suggests that vanilloid
In this page In a new window sensitivity encompasses several
subpopulations of DRG
neurons both peptidergic and
nonpeptidergic However none of the markers tested 194 P2X3 SP
and CGRP is present exclusively in VRI expressing neurons Note that
the intensity of VRI receptor like immunostaining is strongest in the
substantia gelatinosa lamina 1 and the inner layer of Rexed lamina II
Reproduced with permission from the European Journal of
NeuroscienceGuoet al 1999
The distribution of VRI like immunoreactivity in the spinal dorsal horn deserves
particular attention The labeling is strongest in the Lissauer zone lamina I Fig
IOC VRI protein is also abundant in the inner but not in the outer layer of
lamina II Fig 1OC Guo et al 1999 There is an apparent discrepancy between
this finding and the even distribution of VRIlike immunoreactivity in the
substantia gelatinosa reported by Julius and colleagues Tominaga et al 1998
the reason for which is not clear It should be noted that several important
proteins involved in pain transmission are also enriched in the inner layer of
lamina II ie in close proximity to VRI Notable examples include PKC isozyme y
PKCy Malmberg et al 1997a as well as ATP sensitive P2X3 receptors
Vulchanova et al 1998 P2X3 receptors colocalize with VRI both in DRGs where
75 of the P2X3 positive neurons also express VRI FigIIF and in the inner
layer of lamina II Fig 11 D and E Guo et al 1999 By contrast PKCy is confined
to a population of interneurons that reside in lamina 11 of the dorsal horn
Malmberg et al 1997a The possible role of PKCy and P2X3receptors in
nociception is discussed in Section VIII
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Surprisingly the colocalization of VRI with SP in DRG neurons is limited for
example only 33 of L5 DRG neurons positive for VRI contain SP like
immunoreactivity as well Fig 111 Guo et al 1999 Moreover much of the VRI
staining in the dorsal horn is concentrated in the inner layer of lamina II where
both SP Fig 11 G and H and CGRP like immunoreactivities are sparse Fig 11 J
and K Guo et al 1999 This limited colocalization between VRI and SP is at
variance with the profound effects that vanilloids have on SP expression see
inSection VIIIB5
The colocalization of VRl with the lectin 164 Fig 11 AC Guo et al 1999
Tominaga et al 1998 may shed new light on the regulation of VR expression by
trophic factors Vanilloid sensitive neurons require nerve growth factor NGF for
survival during embryogenesis Ruit et al 1992 as evidenced by a severe deficit
in nociception and thermoreception in mice with a null mutation in the gene
encoding trkA the signal transduction receptor for NGF Smeyne et al 1994
Mature DRG neurons however are able to survive in the absence of NGF Yip et
al 1984 Lindsay 1988 There is evidence that those neurons that bind 164 also
express receptors for glial cell derived neurotrophic factor abbreviated GDNF
Bennett et al 1998 In 1997 Snider and coworkers Molliver et al 1997
showed in elegant experiments that 164 positive DRG neurons switch from
dependence on NGF to dependence upon GDNF during development
Subsequently McMahon and colleagues Bennett et al 1998 demonstrated that
164 positive neurons may be rescued by exogenous GDNF following nerve injury
Clearly it would be interesting to explore the effects of GDNF on VR expression
B VRs in Vagal Nodose Ganglion Neurons
In addition to DRG Figs 3 and 7 and trigeminal ganglion Fig 3 neurons
Szallasi and Blumberg 1990b Szallasi et al I993ab1994a Acs et al 1994a
a subset of nodose ganglion neurons also expresses VRs Fig 3 and Table 3 Acs
et al 1994a Szallasi et al 1995a A strong autoradiographic signal is present in
the area postremanucleus of the solitary tract region Fig3 representing the
central termination area for sensory neurons of the vagus nerve Szallasi et al
1995a This area is also stained by an anti VRI antibody Fig 10A Guo et al
1999
An unexpected result in the VRI cloning article by Julius and colleagues Catering
et al 1997 is the failure of Northern blot hybridization to detect mRNAs
encoding VRl in nodose ganglia However using a probe corresponding to
nucleotides 1513 2482 of the rat VRl sequence a strong in situ hybridization
signal was detected in nodose ganglion neurons Helliwell et al 1998 To
resolve the apparent contradiction between these studies it should be noted that
whereas Julius and coworkers Caterina et al 1997 used the entire VRI sequence
for Northern blot hybridization Bevan and colleagues Helliwell et al 1998
generated by polymerase chain reaction a partial VRI sequence only Therefore it
is entirely possible that nodose ganglion neurons express a VR isoform that
differs from VR1 in nucleotides not included in the probe used for in situ
hybridization histochemistry The existence of distinct VR isoforms in DRGs and
nodose ganglia would be consistent with the different embryonic origin of these
tissues cf Vogel 1992 It would also be in accord with the observations that
different neurotrophic factors regulate capsaicin sensitivity in DRG NGF and
possibly also GDNF and nodose ganglion neurons brainderived neurotrophic
factor respectivelyWinter et al 1988Winter 1998
C VRs inBrain
A low to moderate level of specific RTX binding can be detected in various CNS
areas not associated with primary sensory neurons Acs et al 1996a suggesting
the existence of intrinsic brain neurons with VRs Fig 4 Among these brain
areas the presence of VRs in the hypothalamus was expected based on the
proposed role of this structure in the hypothermic action of vanilloids
gancsdGabor et al 1970 Szolcsanyi et al 1971 The presence of VR1 mRNA in
the hypothalamus has recently been confirmed by reverse transcription
polymerase chain reaction Sasamura et al 1998 These vanilloidsensitive
terminals in the hypothalamus are probably glutaminergic because capsaicin
evokes glutamate release from slices of hypothalamus Sasamura et al 1998 It
is also easy to visualize how VRs in the reticular formation Acs et al 1996a may
mediate some vanilloid actions on autonomic regulation Uancsd and Such 1985
Koulchitsky et al 1994 Seller et al 1997 The biological role of specific RTX
binding sites in other brain areas is unclear
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A link between the SP content of sensory neurons and their sensitivity to capsaicin
was postulated as early as the mid 1960s Gasparovic et al 1964 In 1976 the
high concentration of SP in the substantia nigra was first reported Brownstein et
al 1976 and the search for capsaicinsensitive neurons in the basal ganglia
began Five years later an enhanced locomotor activity in rats following bilateral
intranigral capsaicin injection and a concomittant decrease in the cataleptic
action of fluphenazine was described Dawbarn et al 1981 In 1988 capsaicin
microinjected into the substantia nigra or caudatus putamen was reported to
induce peripheral vasodilatation and a subsequent hypothermic response Hajds
et al 1988 These biological actions suggested the existence of intrinsic
vanilloid sensitive cells in the basal ganglia The recent detection of VRl mRNA in
the striatum now firmly establishes the existence of such neurons Sasamura et
al 1998 As yet it is not known which subpopulation of nigral neurons express
VRs Neonatal capsaicin treatment does not deplete SP from the striatum nor
does it alter the expression of the opioid peptides dynorphin and
metenkephalin Sivam and Krause 1992 Repeated attempts to elucidate the
effects of capsaicin treatment on monoaminergic systems in the brain have
yielded controversial results For example increased Holzer et al 1981 or
decreased Dawbarn et al 1981 5hydroxytryptamine levels or no change at all
GJancs6 et al 1981 were reported in the very same year With the recent
availability of VRl detecting antibodies as well as probes for in situ hybridization
histochemistry the identity of the VR1expressing subpopulation of basal
ganglion neurons will be revealed shortly
VRl mRNA seems to be widely present in the brain Relative levels are as follows
hypothalamus and cerebellum cortex striatum and midbrain olfactory bulb
pons hippocampus and thalamus Sasamura et al 1998 Although Northern
blot analysis failed to show VR1 mRNA in the brain Caterina et al 1997 this
discrepancy may be due to the difference in sensitivity between polymerase chain
reaction and Northern blot hybridization In support of this explanation is the
detection of VRl mRNA in the rat cortex in solution hybridization nuclease
protection experiments D N Cortright and J E Krause personal
communication VRl positive cells may also be visualized in the brain by both in
situ hybridization and immunostaining experiments E Mezey A Guo D N
Cortright R Elde J E Krause P M Blumberg and A Szallasi manuscript in
preparation
D Possible Presence of VRs inNonneuronal Tissues Such as Mast Cells and
Glia
It has been long noted that capsaicin exerts a variety of effects on nonneuronal
tissues cf Buck and Burks 1986 Holzer 1991 These actions were considered
nonspecific because they were at variance with the prevailing concept of
capsaicin being selective for sensory neurons In 1998 we showed that vanilloids
induce calcium uptake by mast cells 1346 et al 1998a and in a glioma cell line
Biro et al 1998b The pharmacological characteristics of this calcium influx
response by mast cells and glioma cells were very similar to those described in
DRG neurons Table4 with the exception of the magnitude of the uptake which
was much smaller implying a VR density lower than in sensory neurons In
keeping with this no specific binding by mast cells or glioma cells could
be detected Table 4 We will return to the biological relevance of such
nonneuronal vanilloid interactions later The novel concept of nonneuronal VRs
has received support from the presence of EST clones homologous to VRl in the
heart and other nonneuronal tissues Caterina et al 1997
View this table
Table 4
In this window In a new window
Comparison of VR binding and
vanilloid induced
45Ca2uptake in sensory DRG neurons mast cells and glioma cells
Capsaicin stimulates the migration of human polymorphonuclear cells Partsch
and Matucci Cerinic 1993 blocks melanotroph cells in rat pituitary Kehl 1994
and inhibits the activation of pheochromocytoma cells by acetylcholine
Nakazawa et al 1994 just to name a few nonneuronal actions The biological
relevance of these findings is unclear On isolated human bronchi capsaicin may
exert a contractile Lundberg et al 1983 relaxant Chicano et al 1994 or
biphasic bronchoconstriction at low and relaxation at high capsaicin
concentrations action Ellis et al 1997 Unlike in the mouse Manzini 1992 the
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relaxant effect of 2capsaicin on human bronchi does not appear to be mediated
by nitric oxide but may reflect a direct action on airway smooth muscle instead
Ellis et al 1997 Indeed capsaicin was shown to evoke an outward current in
human airway smooth muscle cells in culture via charybdotoxinsensitive
Cat activated K channels Ellis et al 1997 At present the possibility cannot
be ruled out that capsaicin activates these channels directly however we prefer
the alternative explanation that capsaicin increases intracellular calcium levels in
smooth muscle cells by opening a VR1 like conductance which in turn activates
the charybdotoxinsensitive channels With the availability of sensitive molecular
probes for VR1 message a systemic evaluation of RNA samples obtained from
various tissues might identify further nonneuronal cells expressing VRs
The most recent addition to the list of candidate tissues to express VRs is human
lymphocytes Lai et al 1998 Human lymphocytes like sensory neurons cf
Hokfelt et al 1975 Pernow 1983Nakanishi 1987 apparently store preformed
SP Lai et al 1998 As we already discussed capsaicin releases SP from sensory
neuronsGaparovic et al 1964 Jessell et al 1978 Yaksh et al 1979 Gamse et
al 1980 1981 Capsaicin also seems to release SP from human lymphocytes Lai
et al 1998 Unfortunately it is not known whether the release of SP by capsaicin
from human lymphocytes is blocked by VR antagonists Nevertheless the
similarity between capsaicin actions in sensory neurons and lymphocytes is
striking
VEvidence forMultiple VRs
The spectrum of biological activities of vanilloid compounds show marked
differences which are difficult if not impossible to reconcile with the concept of
a single VR but which are entirely consistent with the existence of multiple VRs
Szolcsanyi and coworkers Szolcsanyi et al 1990 1991 compared the effects of
capsaicin and RTX on the pulmonary chemoreflex in the rat This reflex response
involves three components namely bradycardia a slowing of respiration and a
drop in the systemic blood pressure and is also known as the BezoldJarisch
reflex cf Coleridge and Coleridge 1986 Capsaicin evokes this reflex Pdrszasz
et al 1955 Toh et al 1955 Makara et al 1967 which unlike other capsaicin
induced responses shows little or no desensitization upon repeated challenge
Szolcsanyi et al 1990 Interestingly RTX shows the opposite behavior it
desensitizes the pulmonary chemoreflex with no prior activation Szolcsanyi et
al 1990 A likely explanation is that two receptors are involved a receptor that
is selective for capsaicin and mediates excitation and another one that is
selective for RTX and causes desensitization
Another interesting observation was made by Appendino and coworkers 1996
when exploring the biological activities of a phorbol base vanilloid phorbol
12phenylacetate 13acetate 20homovanillate PPAHV Fig 8 PPAHV mimics
most characteristic vanilloid actions in the rat such as the induction of protective
eyewiping movements upon intraocular challenge or the down regulation of
specific RTX binding sites following systemic administration however it fails to
induce hypothermia Appendino et al 1996 It was speculated that VRs
expressed by neurons mediating vanilloid effects on temperature regulation are
pharmacologically distinct and do not recognize PPAHV As we will see below
PPAHV is also interesting in that 1 it distinguishes pharmacologically distinct
vanilloid activated conductances in trigeminal ganglion neurons Fig12 Liu et
al 1998 and 2 it binds to VRs in a noncooperative manner Fig13 Szallasi et
al 1996b
Figure 12
Typical capsaicin and PPAHV
induced currents in the absence




PPAHV however elicits both
capsazepine sensitive and
insensitive currents implying
View larger version the existence of
in this page Ina new window pharmacologically distinct VR
subclasses A modification of
Fig 4 in Liu et al 1998
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Figure 13
F PPAHV not only binds to VRs in
a noncooperative manner but
X
F also abolishes positive
fit b cooperativity ofLL
w 0 y 665 i binding compare the convex
Scatchard plot in the absence of
PPAHV and the linear plot in the
IArx 8 dC111maPam presence of PPAHV
View larger version respectively implying that
In this page In a new window
positive cooperativity is a
ligand induced property of VRs
Reprinted with permission from Szallasi et al 1996b
Colquhoun and colleagues Colquhoun et al 1995 Griffiths et al 1996
measured oxygen uptake and vasoconstriction in the isolated rat hindpaw and
came to the conclusion that these responses were mediated by distinct peripheral
VR subtypes which they termed VNt and VNZ respectively Activation of VNl
receptors stimulates oxygen uptake this response is selectively inhibited by
capsazepine Griffiths et al 1996 If agonist concentrations are further
increased VNZ receptors are also occupied Colquhoun et al 1995 It leads to
vasoconstriction and an inhibition of the initial oxygen uptake response These
responses are blocked by ruthenium red Griffiths et al 1996
As yet the strongest evidence for VR heterogeneity is furnished by
electrophysiology which gives a complicated picture of multiple targets activated
selectively by different vanilloids Liu and Simon 1996abLiu et al 1996 1997
1998 Petersen et al 1996 Under voltageclamp conditions capsaicin and RTX
evoke a number of currents that differ both in peak amplitude and duration
Fig14 A and B At present it is unclear how these conductances translate into
VR subtypes Nonetheless the tendency of RTX to provoke slow sustained
currents Fig 14B as opposed to the rapidly activating and dissipating capsaicin
induced fluxes Fig 14A may give a rationale to explain why RTX in general is
more potent for desensitization than activation of biological responses Table 2
Figure 14
Typical capsaicin A and
RTX induced B currents in rat
trigeminal ganglion neurons in
culture Bars represent the
duration of vanilloid
View larger version
In this page In a new window application A observe that
capsaicin may elicit a rapidly
activating current A a slowly
activating current B or a combination of rapidly and slowly activating
currents C B a 25 nMconcentration of RTX evokes a sustained
currentA An increase inthe concentration of RTX to 100 nM
enhances the amplitude of the current BD but it remains persistent
with a very slow return to baseline Reprinted with permission from Liu
and Simon 1996a
PPAHV see Fig 8 for structure operates two kinetically distinct conductances in
cultured trigeminal ganglion neurons Fig 12 Liu et al 1998 The rapidly
activating inward current disappears completely upon repeated PPAHV
application leaving a reduced slowly activating current Fig 12 Liu et al 1998
Interestingly scutigeral a novel VR agonist belonging to the triprenyl phenol
class of vanilloids see below likewise abolishes the rapidly activating
component of the capsaicin evoked response lending further support to the
concept that rapidly and slowly activating conductances are pharmacologically
different Szallasi et al 1999a The rapidly and slowly activating channels also
differ in reversal potentials 58 mV and 104 mV and have ED50s for PPAHV of
27 pM and 09 pM respectively Even more interesting capsazepine fails to
inhibit a subset of PPAHVevoked inward currents especially of the slowly
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activating type Fig 12 Liu et al 1998 This latter finding may be interpreted as
an indication of the existence of capsazepinesensitiv and insensitive VRs
The cloned VRI when expressed in Xenopus oocytes has a reversal potential of
4 mV and is inhibited by capsazepine Caterina et al 1997 The similarity
between VRI and the PPAHV gated rapidly activating current is obvious It is
tempting to speculate that the slowly activating current evoked by PPAHV
represents another yet tobe cloned VRI isoform
Whether these pharmacologically distinct vanilloidactivated conductances
represent real isoforms or alternatively reflect interaction with putative
regulatory factors remains to be seen For instance the DRGspecific form of
proton gated channels called DRASICs has been shown to form oligomers with
other members of the degenerin epithelial Na channel superfamily most
notably with the mdegenerins MDEG1 and MDEG2 Lingueglia et al 1997 These
DRASICMDEG1MDEG2 heteropolymers display different kinetics pH
dependences and ion selectivities Lingueglia et al 1997 As opposed to VRI
heterogeneity a similar association of VRl with other members of the TRP family
of store operated calcium channels or other regulatory proteins might provide
an attractive alternative model to explain the diversity of vanilloidevoked
currents Also the existence of such oligomeric VRs would entirely be in accord
with the radiation inactivation size approximately 300 kDa of VRs Szallasi and
Blumberg 1991 At the time when this review was written several groups were
searching for VRI isoforms thus a satisfactory answer to the above question is
anticipated in the foreseeable future Finally it has to be emphasized that VRI
homologs do not necessarily mediate heat sensitivity pungent chemogenic
activation or acid sensitivity The recognition domains for these types of
activation are not well understood and they may not be at all conserved There
may be an extended gene family but there may be a very diverse biology
associated
V1 Biochemical Pharmacology ofVRs
VRs show a variety of unusual features Tables that should be taken into account
when interpreting the differences among vanilloid actions Some of these
properties may even be of relevance for future drug development
View this table
Table 5
In this window Ina new window
Biochemical pharmacology of
VRs
A The Cloned VR Is a Nonselective Cation Channel with a Limited Selectivity
for Calcium
The cloned Vill does not discriminate among monovalent cations however it
exhibits a notable preference for divalent cations Caterina et al 1997 The
reported permeability sequence is as follows Cat M Na K Cs
This finding is in agreement with previous observations in cultured DRG neurons
Wood et al 1988 and thus lends further support to the longheld concept of the
capsaicin receptor being a nonselective cation channel with a preference for
calcium cf Bevan and Szolcsanyi 1990 The relative permeability of VRI to
calcium is high the PCa PNa ratio is approaching 10 for a nonselective cation
channel Caterina et al 1997 This calcium permeability is very similar to the
value reported PCaPNa 106 forNmethyloaspartate NMDAtype glutamate
receptors Mayer and Westbrook 1987
B Role of Calcium inModulating VR Functions
For capsaicin desensitization has been shown to depend on a variety of factors
including concentration the duration of application and the presence or absence
of extracellular calcium cfHolzer 1991 Szolcsanyi 1993 Mechanisms
underlying desensitization will be discussed later here we concentrate on the
role of calcium only Numerous studies have shown that the removal of
extracellular calcium diminished desensitization to capsaicin Santicioli et al
1987 Amann 1990 Craft and Porreca 1992Cholewinski et al 1993 Garcia
Hirschfeld et al 1995 Liu and Simon 1996a It was speculated that a rise in
intracellular calcium served as an inital step only to activate biochemical
pathways ultimately leading to VR desensitization This model was reinforced by
the findings that 1 specific inhibitors of protein phosphatase 29 also known as
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calcineurin reduced desensitization Docherty et al 1996 and 2 removal of ATP
or GTP from the internal solution resulted in a nearly complete tachyphylaxis
even in the presence of calcium Koplas et al 1997 Recent evidence implies an
even more complex situation In addition to the above calciumactivated indirect
pathways of tachyphylaxis a direct action of calcium on VRs leading to
desensitization is also likely to exist For example the electrophysiological
desensitization of VRl expressed inXenopus oocytes requires the presence of
extracellular calcium Catering et al 1997 In the absence of extracellular
calcium VR1 shows little or no tachyphylaxis in response to repeated capsaicin
challenges In the presence of calcium capsaicin evoked currents via VR1 have
two distinct components one desensitizing and one relatively constant upon
repeated agonist applications Caterina et al 1997 Thus the calcium
dependence of vanilloid desensitization can be reproduced without a neuronal
context
To complicate matters even further the role of calcium in modulating
desensitization to vanilloids is also dependent on the agonist used In contrast to
observations by capsaicin Fig15A desensitization to olvanil see Fig 8 for
structure is apparently not influenced by the removal of extracellular calcium
Fig 5B Liu and Simon 1998 Under resting conditions the channel pore of
C type receptors is closed Agonist binding is likely to induce a conformational
change in receptor protein leading to an opening of the conductance According
to a recent model by Sidney A Simon vanilloid gated conductances cycle
between open and closed states via various transitional states reflecting
desensitization Liu and Simon 1996a Tachyphylaxis can be viewed as the time
required for the receptors to recover from these transitional states to the closed
state in which the receptor is capable of ligand binding again For capsaicin
Simon argues that calcium may increase the probability of a transition from the
open state into a transitional desensitized state Alternatively calcium may
inhibit the recovery of the receptor from the desensitized states to the closed
state Either mechanism may explain how the removal of extracellular calcium
can reduce desensitization to capsaicin Fig 15A Simon speculates Liu and
Simon 1998 that olvanil utilizes a different mechanism maybe receptor
internalization to achieve desensitization hence the indifference of
desensitization to olvanil for calcium Fig 5B
Figure 15
Tachyphylaxis of capsaicin
and olvanil induced currents in
Y rat trigeminal ganglion neurons
in culture Tachyphylaxis to
olvanil is rapid the second
application evokes less than
20 of the control current and
does not require the presence
of extracellular Caz By
View larger version contrast tachyphylaxis to
In this page Ina new window capsaicin develops gradually
the 4th challenge still elicits a
half maximal response and
occurs in the presence of extracellular Cat only A possible
interpretation of these findings is that capsaicin and olvanil employ
different biochemical mechanisms to achieve tachyphylaxis
Recordings are from Figs 1 3 and 4 in Liu and Simon 1998
Reproduced with permission
C Where Is the Vanilloid Binding Site on VRs
At present the ligand recognition domain of VRs is not known although
site directed mutagenesis studies with the VR1 clone will no doubt soon identify
structures involved in agonist binding Humphrey H Rang suggested Spring Pain
Conference Grand Cayman BWI 1998 that the capsaicin binding site is in fact
intracellular They added capsaicin to the bathing solution of voltage clamped
sensory neurons and to the buffer in the intracellular electrode respectively and
found that lower capsaicin concentrations are required to activate the cells from
the inside Surprisingly Julius and coworkers Caterina et al 1997 reported
identical capsaicin responses from either side of a patch excised from a cell
expressing VR1 Julius speculates that either capsaicin permeates the lipid bilayer
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freely or that there are functionally equivalent capsaicin binding sites on both
sides of the plasma membrane Caterina et al 1997 The reason for the apparent
contradiction between these two studies is unclear
D VR1 Is Activated by Noxious Heat and Low pH Protons the VR as an
Integratorof Painful Chemical and Physical Stimuli
Protons have long been regarded as small stimulants of capsaicin sensitive
sensory nerves Bevan and Geppetti 1994 The similarity between heat induced
and capsaicinevoked inward currents in isolated DRG neurons was also noted
before Baumann and Martenson 1994 Cesare and McNaughton 1996
Kirschstein et al 1997 As discussed in Section IIIC an exciting aspect of the
cloning of VRI is the finding that both noxious heat a rapid increase in
temperature from 22 to 48Cand low pH are able to activate the capsaicingated
channel Caterina et al 1997 Tominaga et al 1998 In fact this may be the very
reason why capsaicin is hottasting to humans Thus VRI can be viewed as an
integrator of painful chemical and physical stimuli Probably it is heat only that
has the power to open VRI capsaicin and low pH merely serve to reduce the heat
threshold of the receptor Tominaga et al 1998 Consequently even room
temperature is able to open VRI under mildly acidic conditions
Protons however exert a complex action on the cloned VRI For instance a
reduction from 76 to 63 in the pH of the bath solution does not open VRl
expressed in oocytes nonetheless it results in a 5 fold increase in the amplitude
of the current evoked by 300 nM of capsaicin Caterina et al 1997 This is
consistent with the earlier observations that 1 low pH potentiated responses to
low concentrations of capsaicin in rat Petersen and LaMotte 1993 Kress et al
1996a rabbit Martenson et al 1994 or human Baumann et al 1996 sensory
neurons in culture Fig 16 and 2 low pH evoked a current in cultured trigeminal
neurons that could be prevented by the VR antagonist capsazepine Liu and
Simon 1994 A further reduction in the pH to 50however evokes a current
through VRI Tominaga et al 1998 Moreover hydrogen ions can increase the
response of VRI to noxious heat Caterina et al 1997 Protons also inhibit RTX
binding to DRG neuron or spinal cord membranes Szallasi et al 1995c It is
important to remember however that VRI represents only one targetand not
the targetfor noxious heat or acids in sensory neurons
Y Figure 16
Low pH faciliates the capsaicin
evoked inward current in rat
DRG neurons in culture A
dose response curves for
L X11 n proton activated currents in
1 t ti c i i f s
a
the absence or presence e
View larger version of 3 pM capsaicin Note that at
In this page Ina new window pH 73capsaicin 3pM evokes
a current with a mean
amplitude of 365 pA B Mild
acidification of the buffer to pH 6 induces a current of 46 pA which
is enhanced to 1700 pA in the presence of capsaicin Increasing the
proton concentration together with 3 pM capsaicin results in a
potentiation of the inward current that is more than additive for each
PH value examined B C an original recording observe that the
inward current in the presence of pH 56 and capsaicin greatly exceeds
the sum of the currents evoked by pH 56 and capsaicin at pH 73
alone D capsaicin 3 pM evokes a negligible smaller than 10 pA
current in large DRG neurons this current is not facilitated by protons
Reproduced with permission from Kress et al 1996a
E Ruthenium Red Blocks VRs by an Unknown Mechanism
Ruthenium red is an inorganic dye that was introduced into sensory
pharmacology in the late 1980s as a functional capsaicin antagonist cf Amann
and Maggi 1991 The molecular mechanism by which ruthenium red blocks
vanilloid actions isare unknown LorisChahl 1989 postulated two sites for
ruthenium red a reversible site inhibiting excitation by vanilloids and a second
site that binds ruthenium red irreversibly and is involved in desensitization By
the mid 1990s ruthenium red had largely been replaced by capsazepine a
competitive antagonist see above The interest in ruthenium red has been
19 of 82 92011238PM
001936
Y.mill i  (Cap i i ) t rs  ec isr 
0  
fr l   t t r   i lly i l t i i      
 f    (Caterin  t I., 97).   r   
tr i tion      l r. 
. l  ivate   ious  d o   (P t ns): e    
Inte  f i      
     s "sm  i l nts  icin- i  
s s ry s" (Beva   eeppet i, 94).  l it   t-i  
d psaicin-  i  r ts i  i l ted O e   l  t  
fore (Bauman   , ; r   ughton, 96; 
ir t i  t I., 97). s i  i  tion III.C,  iti  t f t  
loning    t   t at th i   (a    
t r t re    8'C)     l  t   t  icin-gated 
l (Cateri  t I., ; i ga t I., 98). I  f t, t i    t   
r s   i   "h t- ting"  s. ,  1      
i tegrator f i f l i l d i l ti uli. r l  it i  t ly t t 
 t  r t   R I-capsai i   l   rely r  t  r  t  t 
t r l  f  tor (Tomina  t I., 98). uently,   
t r t re is l  t   I r il ly i i  iti . 
, r,    i   t   I.  i t ,  
r i   .6  .3    f       I 
r ssed i  t s; t l s, it r lt  i   S-fold i r  i  t  litude 
f t  t      i i  (Cateri  t I., 97). i  i  
i t t ith t  rli r r tions that ) l   t ti t  r  t  
lo  tr tions f icin i  r t (Petersen  otte, 3; r  t I., 
96a), it ( rtenson  I., 94),   (Baumann  I., )  
rons  lture (Fi . 6),  )       lt red i i l 
rons t t l   r t   t   t i t i  (Li   
, 94).    i  t   to .0, ver,    
t r  I (Tominaga et aI., 1998). oreover, hydrogen ions can increase the 
r s s       (Cateri  t I., 97).  l  it  
i i  t  O e r   i l r  r  (Szalla i t I., 5c). It i  
i rtant t  r r, ver, t t  1 r r s ts ly  t rget-and t 
"the "-for  t   i  sory r s . 
o.:-·U4J(lOWft.rKDoI'I~oKA I>H _~>I'-__ 
"~:MIIlS0't\4 .. ~,_~~ 
I:. ~ 
ie  lar er versi : 
In t is a e In a e  indow 
. igure 16 
    icin-
.      
O e   r . , 
, -r   f  
r t n-activ t  c rr ts i  
t   (0) r  (e) 
f  iJ  saicin. t  t t t 
 .3 i i  (3 iJ )  
     
a plitude of 365 p  (B). ild 
i ifi ti  f t  ff r (to  .6) i   rr t f  , i  
is enhanced t  1700  in the presence f capsaicin. Increasing t  
proton concentration together ith 3 iJ  capsaicin results in a 
t ti tion f t  i r  rr t t at i  r  t  iti  f   
p  l  i  (B). ,  ri i l r r i : r  t t t  
i r  rr t i  t  r s c  f  .6  c s ici  r tly xc s 
the su  of the currents evoked by p  5.6 and capsaicin (at p  7.3) 
alone. 0, capsaicin (3 J.lM) evokes a negligible (smaller than 10 pAl 
rr t i  l rge O e r ; t i  rr t i  t f ilit t   r t . 
eproduced it  r ission fro  ress t aI., 1996a. 
. t i   l s    n is  
uthenium red is an inorganic dye that as introduced into sensory 
l  i   l  s   "function l i i  onist" (c . nn 
 i, 91).  lecular chanism(s)  i  r t i  r  l cks 
vanilloid actions is(are) unkno n. Loris hahl (1989) postulated t o sites for 
rutheniu  red, a reversible site inhibiting excitation by vanilloids and a second 
site that binds rutheniu  red irreversibly and is involved in desensitization. By 
the id-1990s, rutheniu  red had largely been replaced by capsazepine, a 
i i  t nist (see ove).  i t r t i  t iu     
 . spetj r l . l ontentl511 1159.full 
/912011 2:38  
Vanilloid Capsaicin Receptors and Mechanisr h harnrev aspetjournals orgcontent512159full
rekindled by a recent report Acs et al 1997 that this compound may be fairly
selective for the RTX site on VRs In addition ruthenium red seems to inhibit VN2
receptors preferentially mediating an increase in perfusion pressure in the
isolated rat hindpaw model Griffiths et al 1996
F VRs Are Sensitized by Inflammatory Mediators and Proinflammatory
Cytoldnes
According to an emerging concept hydrogen ions heat and capsaicin or
putative endogenous capsaicinoids may act synergistically to activate VRl
Caterina et al 1997 Tominaga et al 1998 Thus a combination of otherwise
harmless heat and tissue acidosis may become very painful Steen et al 1995
1996 In addition to protons other ingredients in inflammatory exudates may
also target VRs Reeh and coworkers Kress et al 1997 Vyklicky et al 1998
demonstrated that a combination of at least four inflammatory mediators
namely bradykinin histamine serotonin and prostaglandin E2 act together to
activate a conductance also operated by capsaicin This action is prevented by
capsazepine Vyklicky et al 1998 Peter W Reeh speculates that these
inflammatory mediators do not interact directly at VRs but rather converge on a
secondary messenger pathway which in turn sensitizes VR1 to heat or protons
Some of these inflammatory mediators like bradykinin can activate vanilloid
sensitive sensory neurons on their own cf Dray and Perkins 1993 however
their action is more powerful in the presence of other mediators with which they
act synergistically
It has long been known that proinflammatory Prostaglandins enhance the
sensitivity of primary sensory neurons to noxious stimuli Higgs et al 1984
Salmon and Higgs 1987 Prostaglandin E2 increases the intracellular levels of
cAMP in sensory neurons Hingtgen et al 1995 Moreover sensitizing effects of
prostaglandin E2 on sensory neurons are mimicked by membrane permeant cAMP
analogs Cui and Nicol 1995 These observations imply a major role for the cAMP
transduction cascade in the sensitization of vanilloidsensitive neurons In
keeping with thisLopshire and Nicol 1997 1998 recently demonstrated the
enhancement by prostaglandin E2 of the capsaicin elicited current in rat DRG
neurons in culture Fig 7A which was mimicked by forskolin Fig 17B
A Foeo mmn
Figure 17
V Prostaglandin E2 PGE2 1 PM
enhances the amplitude of
wow capsaicin induced control
i0s
100 nM capsaicin currents in
B end tooAFU rat embryonal DRG neurons in
V culture A The effect of PGE2 is
mimicked by forskolin FSK
Isom implying a central role for the
0 cAMP transduction cascade in
View larger version sensitization A modification of
In this page In a new window
Fig 1 in Lopshire and Nicol
1998 Reprinted with the
permission of the Society for Neuroscience
Proinflammatory cytokines like tumor necrosis factor TNFa and interleukin
can also enhance the capsaicin sensitivity of rat DRG neurons in culture Nicol et
al 1997 Following pretreatment with 10 ng ml TNFa a greater than 2 fold
increase in the peak amplitude of the inward current evoked by 100 nM capsaicin
was described Nicol et al 1997 This increase was prevented by either
indomethacin or the specific cyclooxygenase2 inhibitor SC 236 implying a
central role for neuronal prostaglandin production in sensitization to capsaicin
Nicol et al 1997 Of relevance is the finding that intradermal injection of TNFoc
or interleukin 1 5 lowers the response threshold to noxious stimulation Ferreira
et al 1988 Scheizer et al 1988Follenfant et al 1989 The exact mechanisms
by which cyclooxygenase 2 products potentiate capsaicin responses via VRs
isare unknown
A direct interaction at VRs has been suggested for a variety of irritant compounds
ranging from environmental pollutants to chemicals causing occupational asthma
cf Maggi 1991 Lundberg 1993 1995 These xenobiotics may induce
conformational changes in VRs similar to those proposed for hydrogen ions and
heat Other compounds probably act on separate targets on sensory nerves but
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then sensitize VRs in a way similar to that suggested for inflammatory mediators
G Aspirin and Related Drugs May in Part Exert Their Analgesic Actions by
BlockingVRs
Reeh Kress et al 1996b had another intriguing observation according to which
aspirin and diclofenac along with other commonly used nonsteroid
anti inflammatory drugs can block VRs This observation raises the possibility
that the well known analgesic anti inflammatory actions of nonsteroid
anti inflammatory drugs are at least in part mediated by VRs In human
volunteers topically applied acetylsalicylic acid was shown to attenuate
capsaicin induced pain and allodynia probably by blocking cutaneous
nociceptors Schmelz and Kress 1996
H Proposed Role of Phosphorylation Sites in Modulating VR1Activity
Removal of ATP and GTP from the intracellular solution resulted in a state of
nearly complete insensitivity to capsaicin even with intracellular calcium buffered
to low levels Koplas et al 1997 One might argue therefore that sustained
capsaicin sensitivity requires VRl to be phosphorylated via an ATP dependent
mechanism please recall that VRl has three predicted phosphorylation sites for
protein kinase A As a matter of fact it has recently been demonstrated that the
activity of VRs is reduced by dephosphorylation Oh et al 1998 By contrast
dephosphorylation by Cat dependent phosphatases such as calcineurin might
be an important mechanism of receptor tachyphylaxis once VRs are opened and
intracellular calcium begins to rise Docherty et al 1996
As mentioned above PKCy is abundant in the inner layer of lamina II of the spinal
dorsal horn an area also rich in VR1 like immunoreactivity Guo et al 1999 As
demonstrated by Basbaum and coworkers Malmberg et al 1997a PKCy
knockout mice show an elevated threshold for chronic neuropathic pain
Consequently it was suggested that PKCy mediated phosphorylation of proteins
in lamina 11 played a central role in the development of neuropathic pain
Although PKCy is predominantly present in interneurons it is not impossible that
VR1 expressing nerve terminals also express PKCy If this assumption holds true
VRl may be an attractive target to explore for phosphorylation by PKCy
1 Regulation of VR Expression
NGF is produced in the periphery from where it is transported intra axonally to
the cell bodies of DRG neurons cf Lewin and Mendell 1993 In DRG neurons
NGF plays a central role in the regulation of gene expression DRG neurons
obtained from neonatal rats and cultured in the absence of NGF lose their
sensitivity to capsaicin Winter et al 1988 In keeping with this NGF has recently
been shown to regulate the expression of VRl mRNA in adult rat DRG neurons in
culture Helliwell et al 1998 Interestingly capsaicin sensitivity of nodose
ganglion neurons is regulated by brain derived neurotrophic factor and not by
NGF Winter 1998 NGF production is enhanced during inflammation cf Lewin
and Mendell 1993 Neurons isolated from DRGs of rats with inflammation
however do not show increased sensitivity to capsaicin HuTsai et al 1996 Nor
did we observe an increase in autoradiographic labeling of VRs with in
lumbar DRGs of the rat with hindpaw skin inflammation A Szallasi T Farkas
Szallasi and T Hokfelt unpublished observation Taken together these findings
imply the existence of a NGF response element in the genes encoding VRs VR
expression however appears to be maximal in the presence of physiological NGF
concentrations and cannot be enchanced by extra NGF
J VRs Are Thiol Proteins Displaying Positive Cooperativity
RTX binding to rat DRG neurons follows sigmoidal saturation kinetics Szallasi et
al 1993a resulting in convex Scatchard plots Fig 6 This binding behavior is
consistent with the existence of multiple binding sites that cooperate ie
occupation of one site by a given ligand helps one or more additional molecules
bind to additional site positive cooperativity Dose response relations for
capsaicinevoked calcium uptake by cultured sensory neurons Acs et al 1996b
or capsaicin evoked currents detected under voltageclamp conditions Oh et al
1996 Koplas et al 1997 can also be fitted to the Hill equation with a
cooperativity index of approximately 2 In keeping with this capsaicin and RTX
gate VR1 when expressed in Xenopus oocytes with Hill numbers of 208and 195
respectively Catering et al 1997 implying that the full activation of VRl
involves the binding of more than one agonist molecule As mentioned above
PPAHV acts on two kinetically distinct conductances in sensory neurons under
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voltage clamp conditions Liu et al 1998 PPAHV however activates both
conductances in a noncooperative manner Liu et al 1998 Moreover PPAHV not
only binds to DRG membranes noncooperatively but also abolishes the positive
cooperativity of RTX binding Fig 13 Szallasi et al 1996b These latter findings
imply that positive cooperativity or the lack of it may be a ligand induced
property of VRs
VRs appear to be thiolproteins inasmuch as heavy metals and other sulfhydryl
reactive agents inhibit RTX binding Szallasi and Blumberg 1993a Szallasi et al
1993a and block capsaicinevoked ion fluxes Wood et al 1988 An
unexplained finding is that cadmium like vanilloids produces a concentration
dependent contraction of the rat isolated urinary bladder which is in cross
tachyphylaxis with the contractile response to capsaicin Patacchini et al 1988
Both reducing and oxidizing agents reduce the affinity as well as the positive
cooperativity of RTX binding to DRG and spinal cord membranes Szallasi et al
1993a This observation implies that maximal ligand binding is dependent on an
optimal redox state of VRs
VII Requirements for Ligand Recognition byVRs Typical and
Novel Vanilloids
A StructureActivity Relations for Capsaicinoids
In the mid1970s Szolcsanyi and JancsoGabor 1975 1976 attempted a
systematic exploration of structure activity relations for capsaicin like activity
Based on the fairly strict structure activity relations they came to the astute and
to date valid conclusion that capsaicin effects are most likely mediated by a
receptor Fig 18 upper panel The authors used a test in which the protective
wiping movements upon intraocular instillation provided a biological measure of
capsaicin like activity This assay is easy to perform but according to our
present knowledge is difficult to interpret because pain is not a direct
consequence of capsaicin binding to its receptor Ion flux through the capsaicin
operated conductance needs to cause membrane depolarization sufficient to
result in impulse action potential generation cf Bevan and Szolcsanyi 1990
Now we know that capsaicinoids differ not only in affinity for receptor binding
cfSzallasi 1994 but also in channel gating kinetics Figs 12 and 14 Winter et
al 1990 Liu and Simon 1996a Caterina et al 1997 Liu et al 1998 Current
kinetics in turn has a marked effect on membrane depolarization and thus on
pain perception Therefore there is no direct relationship between the affinity of
a given capsaicinoid for VRs and the resulting pungency A well known example
of this phenomenon is olvanil Fig 8 Brand et al 1987 which induces calcium
uptake by DRG neurons with a potency similar to that of capsaicin Winter et al
1993 but is nonpungent Dray et al 1990
Figure 18
VR models The first model
upper drawing is based on
structure activity relationships
for the pungency of capsaicin
congeners as determined in
the eyewiping assay
rt Szolcsanyi and JancsoGabor
1975 The second model
middle drawing was
View larger version constructed based on
In this page In a new window structure activity relationships
for capsaicinoid induced
Cat uptake by rat DRG
neurons in culture Walpole and Wrigglesworth 1993 The three
dimensional model of the capsaicinoid pharmacophore was worked out
by Klopman and Li 1995 using the measured Cat uptake values of
Walpole and Wrigglesworth Reproduced with permission
Important natural capsaicin congeners include piperine zingerone eugenol Fig
8 and guaiacol Piperine and zingerone were identified as vanilloids decades ago
cf Szolcsanyi 1982 Both piperine and zingerone show important dissimilarities
in action to capsaicin see below and therefore they are frequently used tools to
study the biology of VRs Eugenol and guaiacol are obtained from oil of cloves
have a pungent taste and are used as dental analgesics Recently Ohkubo and
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colleagues Ohkubo and Kitamura 1997 Ohkubo and Shibata 1997
demonstrated the existence of two separate targets for eugenol in DRG neurons
One receptor is a Cat permeable channel blocked by capsazepine that is
probably a VR whereas the other one seems to be a chloride channel Ohkubo
and Kitamura 1997 When given intrathecally both eugenol and guaiacol exert
antinociceptive activity as demonstrated by the inhibition of acetic acid induced
writhings in the mouse Ohkubo and Shibata 1997 This antinociceptive effect
does not occur in the presence of capsazepine These results suggest that
eugenol and guaiacol are analgesic by desensitizing sensory nerve endings in the
tooth pulp in a VRmediated fashion
Olvanil Fig 8 and nuvanil are synthetic vanilloids coming from a program at
Procter Gamble discontinued in the late 1980s aimed at exploring structural
requirements for capsaicin like activity Brand et al 1987 Another major effort
to understand capsaicin mechanisms and to synthesize novel capsaicinoids
devoid of the irritancy of capsaicin was launched at the Sandoz now Novartis
Institute for Medical Research London Christopher Walpole Roger
Wrigglesworth and coworkers established comprehensive structure activity
relationships for capsaicin analogs cf Walpole and Wrigglesworth 1993 As a
biological assay they used calcium uptake by cultured DRG neurons which is
thought to be a direct consequence of VR activation They analyzed capsaicin
structure activity requirements in terms of three functional regions an aromatic
A region Walpole et al 1993a an aliphatic C region Walpole et al 1993c and
the ester or amide linker referred to as the B region Walpole et al 1993b
between the A and C regions Fig 19 Their most important findings may be
summarized as follows 1 a parent homovanillyl 3methoxy 4hydroxybenzyl
group is optimal in the A region 2 a dipolar amide or thiourea in the B region is
beneficial but an ester is also adequately tolerated and 3 a lipophilic octanyl or
p chlorophenethyl moiety in the C region is associated with the highest potency
A two dimensional model was proposed to rationalize the profile of compounds
that differ in the B region based on consideration of multiple hydrogen bonding
interactions Fig 19 middle panel Walpole and Wrigglesworth 1993
ca
Figure 19
Functional regions of the
capsaicin pharmacophore an
aromatic A region an aliphatic
C region and the ester or
amide linker referred to as the
B region between A and C
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In 1995 Klopman and Li 1995 used a MULTICASE Multiple Computer Automated
Structure Evaluation method to delineate structural features essential for the
activation of VRs using a database of 123 capsaicin analogs compiled from the
publications of Walpole and coworkers Walpole et al I993abcWalpole and
Wrigglesworth 1993 After the cluster analysis MULTICASE identified three
structural motifs biophores 1III with high probability of relevance Fig 19
Biophore I present in the A region see Fig 19 seems to be the most significant
fragment which alone could account for 76 of the active compounds in the
database Compounds with a 3 alkoxy4substituted benzyl ring have the
highest probability of being active Although biophore I does not specify the
substituent requirement at the 4 position it was noted that 66 of the 70 ligands
containing this biophore have a hydroxyl group at this position This is entirely
consistent with the observation that the removal of the phenolic OH group at the
4 position of the benzene ring leads to a loss of capsaicin like activity
Substitution of the hydrogens at positions 2 5 or 6 also results in an abolition of
agonist activity Biophore II Fig 19 is similar to biophore I because it contains a
hydroxyl group at the 3 position and a NH group next to the phenyl ring Biophore
III Fig 19 constitutes anacatechol moiety in the A region In this case A and
B regions are constrained by a fusion ring Based on the MULTICASE analysis the
authors have worked out a threedimensional model of capsaicin receptor
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interactions Fig 18 lower panel For further details interested readers are
referred to the article
Capsaicin induces 45Ca2uptake by cultured DRG neurons with an EC50 value in
the range of 200 to 300 nM Wood et al 1988 Acs et al 1996b Although
several synthetic capsaicin analogs approach the potency of capsaicin only a few
are more active cf Walpole and Wrigglesworth 1993 The improvement in the
potency of capsaicinoids in the calcium uptake assay is very moderate at best
5 fold see compound 57 in Fig 8
A systematic comparison of the activities of capsaicin analogs in the calcium
assay versus their potencies for inhibiting RTX binding is yet to be performed
Winter and coworkers Winter et al 1993 examined five capsaicin analogs and
found them from 13 to 60 fold less potent for inhibiting binding than for
inducing calcium uptake Table6 The finding that capsaicin is at least 10fold
less potent in the RTX binding assay than in the calcium uptake measurements
Winter et al 1993 has been confirmed repeatedly Acs et al 1996b 1997
View this table
Table 6
In this window Ina new window
Distinct structure activity
relations for VR binding and
subsequent calcium uptake
B Structure Activity Relations for Resiniferanoids for Inducing Calcium
Uptake by Sensory Neurons
For comparison with capsaicinoids RTX Fig 1 may likewise be dissected into
three regions Walpole et al 1996 Regions a and i are similar to the
corresponding regions A and B in capsaicin nevertheless structure activity
relations for these two regions in capsaicinoids and resiniferanoids show
important differences The diterpene skeleton X region in resiniferanoids is
much more complex than the relatively simple aliphatic C region of capsaicin and
appears to play a far more important role in receptor recognition as well
As we saw above all of the three biophores identified by the MULTICASE analysis
in capsaicinoids represent the A region the B region modifies the activity set by
the A region biophore and the importance of the C region seems to lie mostly in
determining lipophilicity Klopman and Li 1995 Generally speaking
resiniferanoids tolerate substitutions in the phenolic ring a region better than
capsaicinoids but are very sensitive to modifications of the diterpene
pharmacophore X region The phenolic OH group which is critical for the activity
of capsaicin analogs A region cf Walpole and Wrigglesworth 1993 is of little
importance in RTX analogs a region for Cat uptake Walpole et al 1996
Changing the ester link to amide which is adequately tolerated in capsaicin B
region results in a 30 to 100 fold drop in activity in RTX analogs implying the
importance of the 6 region Acs et al I996bWalpole et al 1996 With regard to
the diterpene moiety X region reduction of the 3 keto group in RTX leads to a
significant loss of activity Walpole et al 1996 The inactivity of the simplified
RTX analog described by Bloomfield and coworkers Bloomfield et al 1992
which contains the phenylacetyl ortho ester moiety but not the fused 5 and
7member rings is consistent with the notion that the diterpene moiety in
resiniferanoids plays a far more important role than being a simple hydrophobic
anchor
C Differences in Structure Activity Relationships of Vanilloids for Receptor
Binding and Calcium Uptake
Whereas capsaicinoids seem to be consistently less potent for inhibiting RTX
binding than for inducing Winter et al 1993 Acs et al 1996b RTX
structural analogs differ greatly in relative potency for these responses Table 6
One extreme is RTX Fig 1 which is approximately 25 fold more potent for
binding than in the calcium uptake assay Acs et al 1996b The other extreme is
phorbol 123 didecanoate 20homovanillate PDDHV Fig 8 which evokes
calcium uptake by adult rat DRG neurons in culture with an affinity of 15 nM that
is it is 20fold more active in this assay than capsaicin but fails to inhibit
binding by these cells up to the concentration of 10000 nM Table 6
Szallasi et al 1998a In the middle we have RTX amide Acs et al 1995
RTX thiourea Lee et al 1995 and PPAHV Fig 18 Appending et al 1996
these compounds display similar potencies in the binding and calcium uptake
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assays Table 6 Acs et al 1996b Szallasi et al 1996b These findings were
originally interpreted in terms of separate VR subtypes mediating binding and
calcium uptake cf Szallasi and Blumberg 1996 Biro et al 1998 Recent
evidence however suggests that it is not the case HEK293 cells transfected with
VR1 cDNA bind vanilloids with parameters similar to those described in native rat
DRG neurons A Szallasi D N Cortright P M Blumberg and J E Krause
manuscript in preparation One explanation is that VR1 has two separate
although overlapping binding domains for resiniferanoids and capsaicinoids
respectively PDDHV is unique in that it binds exclusively to the portion of the
capsaicin site that does not overlap with the RTX recognition domain In a much
simplified manner the capsaicin domain is more efficient in opening the channel
pore whereas activation of the RTX site predominantly leads to tachyphylaxis
Alternatively the distinct pharmacology for binding and calcium uptake could
reflect different receptor conformations
D Why Is RTX Ultrapotent as a Vanilloid
RTX has a relatively rigid diterpene skeleton to which two flexible aromatic
moieties are bound Although the presence of the aryl ring is essential in RTX
but as we will see later not in novel vanilloid classes of terpenoid unsaturated
dialdehydes and triprenyl phenols for vanilloid like activity it tolerates chemical
substitutions unexpectedly well Recent evidence suggests an equally important
role for the orthoester functionality in RTX PPAHV is very similar to RTX cf Figs
1 and 8 but possesses a phenylacetate group at the 12 position In its
pharmacological properties PPAHV differs from RTX in four important aspects 1
PPAHV is 60000fold less potent than RTX for binding 2 PPAHV binds to
cultured DRG neurons and induces calcium uptake by them with similar affinities
3 PPAHV binds in a noncooperative manner Fig 13 and 4 PPAHV is devoid of
the characteristic hypothermic action of RTX Appendino et al 1996Szallasi et
al 1996b At the electrophysiological level RTX and PPAHVevoked currents in
DRG neurons in culture differ both in onset and duration cf Figs 12 and 14 Liu
et al 1998 Furthermore unlike RTX PPAHV elicits both capsazepinesensitive
and insensitive currents Fig 12 Liu et al 1998
In polar solution the aromatic moieties of RTX show a pronounced clustering
Victory et al 1998 This phenomenon is known as hydrophobic collapse Vander
Velde Victory et al 1998 and colleagues reasoned that the clustering of the
orthophenyl acetate group may facilitate the attainment of an optimal aligment
between the vanillyl moiety and the diterpene core necessary for high affinity
receptor binding On the other hand the necessarily different alignment of the
orthoester phenyl ring in resiniferonol9134orthobenzoate 20homovanillate
which retains binding affinity and shows only modest loss of potency for
Catuptake argues against this model
E Novel Vanilloids Lacking 3Hydroxy 4methoxyphenyl vanillyl
Functionality 1 Sesquiterpene Unsaturated 14Dialdehydes and Related Bioacdve
Terpenoids
To date approximately 80 terpenoids containing an aiunsaturated
14dialdehyde 3formyl 3butenal functionality have been isolated from natural
sources cf jonassohn and Sterner 1997 The majority of these compounds are
present in terrestrial plants and fungi However algae liverworts arthropods
sponges and molluscs are included among the natural sources of unsaturated
14dialdehydes In general these compounds are believed to form a multifaceted
chemical defense system that protects the producing organism from parasites
and predators Kubo and Nakanishi 1979 Kubo and Ganjian 1981 Camazine et
al 1983 Cimino et al 1983 Caprioli et al 1987 Vidari et al 1997 Because
these attacking organisms may range from bacteria to mammals it is hardly
surprising that most of these unsaturated dialdehydes exert a very broad
spectrum of bioactivities cfJonassohn and Sterner 1997
A prominent representative of unsaturated dialdehydes is warburganal isolated
from the bark of Warburgia ugandensis and W stuhlmannii two tropical trees
growing in East Africa Kubo and Nakanishi 1979 Warburganal has antifungal
antibacterial and phytotoxic activities cf Anke and Sterner 1991 Jonassohn
1996 Moreover it is antifeedant to nematodes Kubo et al 1976 and is
hot tasting to humans Kubo and Ganjian 1981 Native tribes use the bark of
warburgia trees as a spice to flavor food Watt and Breyer Brandwijk 1962 Along
with warburganal another unsaturated dialdehyde polygodial is also present in
water pepper Polygonum hydropiper Fukuyama et al 1982 At one time water
pepper was used as a pepper substitute in Europe and its sprout called mejiso
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or benitade in Japanese is still a popular relish for sashimi raw fish
Fukuyama et al 1982 The extract of Cinnamosma fragrans a native plant of
Madagascar which contains several sesquiterpenes eg cinnamolide
cinnamodial and cinnamosmolide was described as having a distinct
pepperlike taste Canonica et al 1969 The similarity between the pungent
sensation evoked in the human tongue by capsaicin and isovelleral compare
structures in Fig 1isolated from the hot mushroom Lactarius vellereus was also
noted List and Hackenberger 1973 Despite these telling observations it was
not until 1996 that the possibility that unsaturated dialdehydes may be pungent
by activating VRs was investigated
Like capsaicin the fungal terpenoid isovelleral causes protective eyewiping
movements in the rat upon intraocular instillation Szallasi et al 1996a There is
cross tachyphylaxis between capsaicin and isovelleral actions both in the rat eye
and the human tongue Szallasi et al 1996a Isovelleral induces calcium uptake
by rat DRG neurons in culture Table 6 which is fully inhibited by the competitive
VR antagonist capsazepine Szallasi et al 1996a Furthermore isovelleral
inhibits binding by rat trigeminal ganglion or spinal cord membranes
Table 6 consistent with a competitive mechanism Szallasi et al 1996a Taken
together these findings strongly suggest that isovelleral is pungent by activating
VRs on sensory neurons For a series of 14 terpenoids with an unsaturated
14dialdehyde moiety a good correlation was found between pungency on the
human tongue and affinity for VRs in the rat spinal cord Szallasi et al 1996a
However as expected from their reactive nature dialdehyde sesquiterpenes and
other terpenoids possess additional sites of action as reflected in the complex
behavior of the calcium uptake responses induced by cinnamodial and
cinnamosmolide Szallasi et al 1998a At low concentrations cinnamodial and
cinnamosmolide evoke calcium uptake in a dose dependent manner which is
superceded by a blockade of the response at higher concentrations The
separation between cinnamodial concentrations causing stimulation and block of
the calcium influx respectively is incomplete which makes cinnamodial only a
partial agonist Szallasi et al 1998a This observation may also explain the
unexpectedly weak membrane depolarization by cinnamodial compared with
capsaicin under currentclamp conditions Szallasi et al 1998a
At the whole animal level polygodial inhibits the pain response evoked by
intradermal formalin or capsaicin injection in the mouse and it also blocks acetic
acid induced writhings Mendes et al 1998 Moreover polygodial has
antiallergic and anti inflammatory activities Tratsk et al 1997 At present the
role played by vanilloid sensitive neurons in these beneficial effects of polygodial
is unclear Polygodial has a supraspinal antinociceptive action mediated by opioid
and or serotoninergic mechanisms Q B Calixto personal communication
Furthermore polygodial blocks tachykinin NK2 receptors El Sayah et al 1998
which might play a role in its antiallergic and anti inflammatory actions
Polygodial appears to be an interesting new lead for drug development inasmuch
as it targets a variety of pathways involved in pain perception and inflammation
2Tripreny Phenols as Vanilloids
The archetypal triprenyl phenol is scutigeral Fig 1 isolated from Albatrellus
ovinus Dekermendjian et al 1997 Unlike terpenoid unsaturated dialdehydes
scutigeral is not pungent Szallasi et al 1998b As a matter of fact A ovinus is a
delicious mushroom often used by the food industry as a substitute for truffles
Scutigeral and related compounds were first isolated based on their affinity for
dopamine D1 receptors Dekermendjian et al 1997 Scutigeral induces calcium
uptake by rat DRG neurons in culture and blocks RTX binding to rat spinal cord
membranes Table 6 Calcium uptake by scutigeral is prevented by both
capsazepine and ruthenium red Szallasi et al 1999a Taken together these
observations are consistent with scutigeral being a vanilloid The finding that
scutigeral is nonpungent is surprising but hardly unprecedented Olvanilis also
considered nonpungent Brand et al 1987 Dray et al 1990 although it mimics
most capsaicin responses Brand et al 1987Drayet al 1990 Wrigglesworth et
al 1996 Interestingly pretreatment with scutigeral abolishes the first rapidly
activating current elicited by a subsequent capsaicin challenge leaving the
second slowly activating current relatively intact Szallasi et al 1999a This
latter finding implies that scutigeral should be able to selectively block capsaicin
responses mediated by the rapidly activating conductance This hypothesis is
currently being investigated
3Implications oftee DiscoveryofNovel Vanilloids Lacking a VanillylLike Functionality
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st icin r  (Brand t I., 987;Dray t I., ; ri l rt  t 
I., 96). I t r sti ly, r tr t ent it  sc ti ral lis s t  first, r i ly 
activating current elicited by a subsequent capsaicin challenge, leaving the 
second, slowly activating current relatively intact (Szallasi et aI., 1999a). This 
l tt r fi i  i li  t t ti r l l   l  t  l ti l  l  icin 
responses ediated by the rapidly activating conductance. This hypothesis is 
currently being investigated. 
3. Implications f the iscovery f ovel anil/oids acking a anil/yl-Like unctionality. 
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Terpenoid unsaturated dialdehydes and triprenyl phenols are not real vanilloids
from a chemical point of view compare structures in Fig 1 implying that the
term VR is somewhat of a misnomer Receptors are preferentially named after
their endogenous activators Identification of such endogenous activator of
vanilloid receptors will ultimately give these receptors a rational name From the
perspective of drug discovery the demonstration that the presence of a vanillyl
functionality is not essential for vanilloidlike activity opens up new possibilities
In collections of natural products and or compound libraries of pharmaceutical
companies many interesting vanilloids may be hidden
VIII VanilloidMechanisms
Binding of vanilloids to their receptors initiates a complex and as yet poorly
understood cascade of intracellular events which for practical purposes can be
divided into three separate but not independent phenomena namely 1
excitation 2 desensitization and 3 neurotoxicity cf Nagy 1982 Buck and
Burks 1986 Holzer 1991Wood 1993
A Excitation by Vanilloids 1 Sdmaladon of VanilloidSensidve Neurons and Its
Consequences
Agonist binding to the vani lloid operated nonspecific cation channel opens the
channel pore and leads to cation predominantly calcium influx Marsh et al
1987 Wood et al 1988 This cation influx may cause membrane depolarization
cf Bevan and Szolcsinyi 1990 When membrane depolarization reaches the
threshold level an action potential is generated cf Bevan and Docherty 1993
The action potential is propagated along the entire length of the vanilloid
sensitive neuron and may be perceived as itch or pain in the CNS cf Holzer
1991 It is not known exactly how the painful information is transmitted from the
central terminals of the vanilloid sensitive neurons to secondorder neurons of
the dorsal horn Vanilloid sensitive neurons use glutamate ATP and a variety of
neuropeptides as transmitters cf Holzer 1991 Yaksh and Malmberg 1994
Lundberg 1996 It is likely that not a single transmitter but rather a combination
of them play roles in pain transduction because none of the tested receptor
antagonists alone could achieve complete analgesia cf Dray and Urban 1996
It should be noted however that the selective and competitive NMDA receptor
antagonists D 2amino5phosphono valeric acid and W32
carboxypiperazine4yl propyl phosphoric acid are very effective at inhibiting
the acute nociceptive response to intraplantar injection of capsaicin in the mouse
Sakurada et al 1998 The noncompetitive NMDA receptor antagonist MK 801 is
likewise effective Sakurada et al 1998 Even more important injection of NMDA
into the cerebrospinal fluid of the rat mimics both acute pain and the subsequent
hyperalgesia and allodynia that develop following intradermal capsaicin injection
also see below Aanonsen and Wilcox 1987 It is known that both capsaicin and
RTX can release glutamate from the rat spinal dorsal horn Kangrga and Randic
1991 which in turn may excite about 85 of spinal dorsal horn neurons those
that possess NMDA receptors Murase et al 1989 Tolle et al 1993 These
findings present a strong case for presynaptic NMDA receptors Liu et al 1994
on central vanilloidsensitive nerve terminals being centrally involved in the
facilitation of pain transmission
Initial reports described a single vanilloid evoked current in sensory neurons
Heyman and Rang 1985 Forbes and Bevan 1988 Recent studies however have
found multiple currents Liu and Simon 1994Liu et al 1996 Petersen et al
1996 that seem to differ not only in kinetics Figs 12 and 14 but also in affinity
for agonists and in sensitivity to the antagonist capsazepine Fig 12 Liu et al
1998 A likely explanation for this phenomenon is the existence of VRl isoforms
andor VR subtypes
Agonist binding to VRs however does not necessarily lead to neuronal
excitation Several vanilloids for example olvanil Dray et al 1990 and
scutigeral Szallasi et al 1999a have been noted for their nonpungent nature It
is thought that pungent and nonpungent vanilloids differ in their channel gating
properties Liu et al 1997 Pungent vanilloids like capsaicin open the
conductance promptly Figs 12 and 14 and cause a massive cation influx
Nonpungent vanilloids by contrast open the channel pore slowly Figs12 and 14
and the resulting subdued cation influx is not sufficient to generate action
potentials
The mechanisms by which vanilloids liberate neurotransmitters are not
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completely clear either Originally it was postulated by Maggi and colleagues
Maggi et al 1988 that capsaicin releases neuropeptides via two independent
mechanisms one of which is sensitive to both tetrodotoxin TTX and
wconotoxin CTX and another that is resistant to these toxins TTX and CTX
block voltage sensitive Na channels and voltagedependent N type Cat
channels respectively The observation that both TTX and CTX inhibit sensory
neuropeptide release by capsaicin implies a central role for action potential
generation and is in accord with the classical axon reflex theory see above
Furthermore the finding that TTX and CTX achieve only a partial blockade of the
neuropeptide release implies a direct role for VRs in this response The TTX and
CTX resistant neuropeptide release by capsaicin requires the presence of
extracellular calcium Gamse et al 1981 It is easy to visualize how rising
intracellular calcium concentrations may lead to a fusion of vesicles in which
neuropeptides are stored with the plasma membrane resulting in exocytosis
In 1996 Lundberg 1996 reevaluated this model and came to the conclusion that
these mechanisms are not really independent but are related to the capsaicin
concentration used At low 108 M concentration capsaicin occupies only a
fraction of VRs and thus the resulting calcium influx is moderate The increase in
intracellular calcium is sufficient to generate action potential formation but not
massive exocytosis Neuropeptide release occurs via TTX and CTXsensitive
mechanisms Kroll et al 1990Lou et al 1991 1992 At high 106 M
concentration capsaicin occupies most the receptors and causes a massive
calcium influx via the channel pore At this stage the axon reflex mechanism is
of minor importance because N type Cat channels are already blocked by the
high intracellular calcium levels and the calciummediated exocytosis plays the
major role in neuropeptide release Lou et al 1992
Most recently Szolcsanyi Szolcsanyi et al 1998a questioned the role of the
axon reflex in capsaicinevoked neuropeptide release His colleagues examined
in parallel the release of three neuropeptides SP CGRP and somatostatin from
rat trachea induced by capsaicin in the concentration range of 108 to 10 5 M
They found that none of the channel blockers TTX CTX agatoxin and lidocaine
inhibited release at any of the capsaicin concentrations tested Consequently
Szolcsanyi postulated that the release sites of sensory neuropeptides serve also
as sensory receptors This hypothesis has gained recent support by the
demonstration in the laboratory of Robert Elde Guo et al 1999 that VRl is
associated with small clear vesicles in nerve endings The cause of the
contradiction between studies by the groups of Maggi Maggi et al 1988 and
Lundberg Kroll et al 1990 Lou et al 1991 1992 on the one hand and
Szolcsanyi and coworkers 1998a on the other hand is unknown
Vanilloids release a variety of proinflammatory neuropeptides from sensitive
nerve endings Table 1 cf Holzer 1988 These neuropeptides initiate the
cascade of neurogenic inflammation Fig 2 cf Geppetti and Holzer 1996
Among these neuropeptides SP and CGRP are the best studied SP preferentially
interacts at NK 1 receptors NK1 Rcf Regoli et al 1994 Stimulation of NK1 Rs
in endothelial cells leads to plasma extravasation edema formation by opening
gaps at postcapillary venules Fig 2 McDonald et al 1988 Rogers et al 1988
In the airways NK 1 Rs can mediate both bronchoconstriction and bronchodilation
Devillier et al 1988 Maggi et al 1991Manzini 1992 depending on their
localization smooth muscle versus epithelium Fig 2 Bronchodilation is
believed to be mediated by cyclooxygenase products Manzini 1992 In addition
to the bronchomotor and vasoregulatory actions SP can stimulate myoepithelial
cells in submucosal glands to produce mucus and activate alvelolar macrophages
Coles et al 1984 Barnes et al 1991 Finally SP was shown to stimulate human
neutrophils and T lymphocytes although these actions are probably not mediated
by tachykinin receptors Repke and Bienert 1987
Interestingly not all sensory neuropeptides are proinflammatory For instance
somatostatin seems to block neurogenic plasma extravasation by mustard oil
Szolcsanyi et al 1998b If mustard oil is applied to the rat hindpaw skin
repeatedly the inflammatory response for the latter applications is diminished
This preventive action is abolished by pretreatment with a somatostatin
antiserum Szolcsanyi et al 1998c It is concluded that somatostatin might play
an important role in the beneficial effects of counterirritation
An exciting new advance in the field is the concept that vanilloids may activate
mast cells directly in a VR mediated fashion fable 4 Biro et al 1998a Mast
cells are known to exist in close proximity to sensory nerves in several tissues
such as the dura Dimitriadou et al 1987 airways Kiernan 1990 Alving et al
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1991 and small intestines Bienenstock et al 1991 Furthermore there appears
to be important cross talk between sensory nerves and mast cells inasmuch as SP
released from the nerve endings can activate mast cells Repke and Bienert 1987
and histamine liberated from mast cells can stimulate sensory nerves cf
Lembeck 1983 The finding that vanilloids activate sensory neurons and mast
cells at similar concentrations Biro et al 1998a raises the interesting possibility
that neuronmast cell interactions may greatly facilitate the actions of low
vanilloid concentrations Moreover it forms another bridge between vanilloid
sensitive sensory nerves and neuroimmune regulation Interestingly nociceptin a
novel neuropeptide related to opioids cf Darland et al 1998 blocks capsaicin
evoked release of sensory neuropeptides from sensory nerves and at the same
time prevents the actions of mast cell degranulating peptide Helyes et al 1997
Nemeth et al1998
2Hyperalgesia and AHodynia Following Vanilloid Administration
Intradermal injection of capsaicin in humans results in primary hyperalgesia to
heat and mechanical stimuli in the vicinity of the injection site Simone et al
1987 1989 LaMotte et al 1991 This is followed by the development of
secondary mechanical hyperalgesia and allodynia in an area surrounding the site
of primary hyperalgesia Simone et al 1991 Torebjork et al 1992 In the rat
surgical removal of the sympathetic postganglionic neurons innervating the paw
skin or treatment with the aadrenoreceptor blocker phentolamine or with
prazosin a selective al receptor antagonist prevents the development of
secondary hyperalgesia by capsaicin Kinnman and Levine 1995 implying a role
for the autonomic nervous system Subcutaneous injection of phentolamine is
also effective in humans in the prevention of hyperlagesia that develops after
intradermal capsaicin injection Kinnman et al 1997
Mounting evidence suggests a central role for nitric oxide in nociceptive
processing in the spinal cord cf Meller and Gebhart 1993 Intradermal injection
of capsaicin in the hindpaw of the rat induces a marked increase in nitric oxide
production in the spinal cord Wu et al 1998 Nitric oxide synthase inhibitors
block the behavioral responses scratching biting and licking evoked by
capsaicin in the mouse Sakurada et al 1996 It is now believed that capsaicin
stimulates nitric oxide production via illdefined mechanisms which in turn
initiates the release of glutamate from central terminals of vanilloidsensitive
neurons Sakurada et al 1996 Glutamate activates NMDA receptors both
presynaptically on central terminals of vanilloidsensitive neurons and
postsynaptically on second order neurons of the dorsal horn of the spinal cord
cf Yaksh and Malmberg 1994 Dorsal horn neurons including spinothalamic
tract cells show enhanced responses sensitization to excitatory amino acids
during capsaicin induced hyperalgesia in the monkey Dougherty and Willis
1992 This sensitization is predominantly mediated by NMDA receptors
Dougherty et al 1992 The development of NMDA receptor mediated
hyperalgesia can be prevented by both NMDA receptor antagonists Dougherty et
al 1992 and nitric oxide inhibitors Kitto et al 1992 Meller et al 1992 It is
notable that spinal glutamate receptors of the nonNMDAtype 01amino
3hydroxy5methyl4 isoxazolepropionic acid receptors are upregulated in
chronic pain Harris et al 1996 In addition to the effects of glutamate released
from vanilloidsensitive nerve terminals on NMDA and nonNMDAtype
glutamate receptors on dorsal horn neurons the positive feedback by glutamate
on vanilloid sensitive nerve endings is also very important in that it facilitates the
release of SP Liu et al 1997 Spinal cord neurons involved in pain transmission
express receptors NK1 Rs for SP whose expression is remarkably upregulated
during inflammatory hyperalgesia Schafer et al 1993 McCarson and Krause
1994 SP binding initiates the internalization of NK 1 Rs into dorsal horn neurons
and causes structural changes in their dendrites Mantyh et al 1995
Furthermore ablation of dorsal horn neurons by a cytotoxic conjugate of SP and
saporin attenuates the mechanical and thermal hyperalgesia following capsaicin
administration Mantyh et al 1997 NK 1 R antagonists prevent the sensitization
of spinothalamic tract neurons after intradermal capsaicin injection Dougherty et
al 1994 Finally tachykinins given intrathecally like capsaicin evoke
scratching biting and licking responses Hylden and Wilcox 1981 followed by
hyperalgesia Yashpal et al 1982 These observations suggest a major role for
SP in the development of hyperalgesia However unlike capsaicin induced pain
behavior nociceptive responses to tachykinins are not antagonized by nitric
oxide synthase inhibitors Sakurada et al 1996 Therefore it may be concluded
that although SP is important it is NMDA that plays the pivotal role in the
development of capsaicin induced hyperalgesia
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Zinc is concentrated in the dorsal horn of the spinal cord Donaldson et al 1973
and has been proposed to alter the excitability of afferent Cfibers Larson and
Kitto 1997 Recently zinc injected intrathecally has been shown to block the
behavioral responses biting scratching etc induced by capsaicin given via the
same route in the mouse Larson and Kitto 1997 Zinc is known to inhibit a
variety of ion channels including NMDA receptors Westbrook and Mayer 1987
Furthermore zinc inhibits RTX binding to spinal cord membranes A Szallasi
unpublished observation suggesting a possible interaction at VRs as well Thus
endogenous zinc may exert an important inhibitory control over spinal pain
transmission possibly by blocking several receptors simultaneously
Another important player in capsaicinevoked hyperalgesia is the cAMP
transduction cascade The adenylate cyclase inhibitor tetrahydrofuryl adenine
reduces mechanical hyperalgesia and allodynia produced by capsaicin injection in
a dose dependent manner Sluka 1997a Furthermore targeted disruption of the
gene encoding the neuronalspecific isoform of the type I regulatory subunit RIP
of the cAMPdependent protein kinase A significantly reduces pain behavior and
hyperalgesia by intradermal capsaicin Malmberg et al 1997b As we already
discussed cAMP is believed to mediate the facilitatory action of prostaglandin E2
on capsaicin evoked neuropeptide release Lopshire and Nicol 1998 It is easy to
visualize how rising intracellular cAMP levels can prolong the transmission of
nociceptive information by facilitating SP release from central terminals of
vanilloidsensitive neurons
As discussed in Section IVA the majority approximately 75 of VRl expressing
DRG neurons also possess ATP sensitive P2X3 receptors Fig 11 Guo et al
1999 To date six ATP P2X receptors have been cloned all of which are
expressed in sensory neurons in dorsal root trigeminal and nodose ganglia cf
Wood and Docherty 1997 P2X3receptors are however unique in that their
expression is confined to small nociceptive neurons Chen et al 1995 Lewis et
al 1995 ATP is painful when injected on to human blister base 8leehen and
Keele 1977 suggesting a pain transmitter role for ATP released from injured
tissues Moreover spinal P2X3 receptors are believed to play a role in the
processing of nociceptive information Kennedy and Leff 1995 Interestingly VRs
Docherty et al 1996 and P2X3 receptors King et al 1997 share a biochemical
mechanism of desensitization ie dephosphorylation by Ca dependent
calcineurin implying a coregulation of these two receptor classes
The ASIC also has a DRG specific isoform called DRASIC Lingueglia et al 1997
Moreover DRG neurons express at least three types of voltagegated
Na channels that differ in sensitivity to TTX cf Nowycky 1992 Rang et al
1994 In the context of persistent pain the slowly activating TTX resistant
voltage gated Na channel Akopian et al 1996 seems to be of particular
importance for the following reasons 1 persistent activation of nociceptors is
associated with development of chronic pain 2 increased Na channel activity
may underlie such persistent activation and 3 TTX is frequently ineffective in
blocking this enhanced channel activity cf Rang et al 1994 Akopian et al
1996 Dray and Urban 1996
We also mentioned in Section IVA that VRl is abundant in the inner layer of
lamina II of the spinal dorsal horn an area rich in PKCy Guo et al 1999 Mice
with a disrupted PKCy gene respond normally to acute painful stimuli but show an
elevated threshold for chronic neuropathic pain Malmberg et al 1997a
Changes in gene expression induced by persistent pain are virtually absent in
these mutant mice Malmberg et al 1997a These findings suggest that a
PKCy mediated phosphorylation of proteins in lamina II is involved in the
development of neuropathic pain Although PKCy is predominantly present in
interneurons it is not unlikely that VRl possessing nerve terminals in lamina II
also express PKCy VRl has predicted phosphorylation sites and its
dephosphorylation by calcineurin is thought to represent a biochemical
mechanism for receptor desensitization If dephosphorylation of VRl causes
desensitization phosphorylation by contrast might lead to sensitization
Therefore it might be speculated that phosphorylation of VR1 by PKCy can play a
role in the development of persistent pain states
Finally a blockade of voltage gated Ca channels can also prevent the onset of
secondary hyperalgesia and allodynia that may follow intradermal capsaicin
injection in the rat Sluka 1997b
In conclusion mechanisms of capsaicininduced hyperalgesia and allodynia are
very complex and are only beginning to be understoodcfMeyer et al 1994 An
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added complication is the finding that bradykinin and maybe also other
algogenicproinflammatory mediators recruit normally vanilloid insensitive
sensory neurons to respond to capsaicin and or low pH Stucky et al 1998 As a
consequence inflamed tissues may contain an increased number of nociceptors
that could contribute to hyperalgesia via spatial summation on spinal neurons
During inflammation socalled silent nociceptorscfMcMahon and Koltzenburg
1990 may also be activated It is not known whether or not such silent
nociceptors may respond to vanilloids
B Desensitizationto Vanilloids
Excitation of sensory neurons by vanilloids is followed by a refractory state in
which 1 neurons do not respond to a subsequent vanilloid challenge or 2
neurons are resistant to various stimuli ranging from noxious heat to mechanical
pressure to endogenous eg histamine and bradykinin or exogenous eg
xylene and mustard oil algesic proinflammatory agents The late Nicholas
Jancs6 who was the first to describe this phenomenon in 1949 did not
distinguish between these two forms of neuronal insensitivity he termed them
collectively desensitization Note In 1949 Jancs6 originally described
desensitization of sensory nerves by capsaicin in Hungarian Therefore as a
reference for desensitization to capsaicin most authors cite a later review of his
in English However this review was written not by Jancso himself but by his wife
and coworker Aurelia Aranka Jancs6 Gabor and his student Janos Szolcsanyi To
make the first literature on capsaicin desensitization broadly available as an to
this review we provide its English translation For this historical reason the
refractory state that follows vanilloid treatment is still generally called
desensitization despite several efforts to introduce a more accurate terminology
cf Szolcsanyi 198991 Holzer 1991 Wood 1993 Szolcsanyi et al 1994
Now it is clear that desensitization to vanilloids is not a single welldefined
biochemical process but rather a cascade of events the relative contributions of
which vary depending on the vanilloid dose used for the challenge and the time
elapsed since then For didactic reasons we will distinguish below receptor
desensitization and tachyphylaxis from impairment of neuronal functions
Both desensitization and tachyphylaxis occur at the receptor level By
desensitization we mean a rapid loss of activity of the receptor occupied by an
agonist For example in the continuous presence of capsaicin capsaicin elicited
currents quickly fade Tachyphylaxis represents gradually diminishing response
to repeated agonist administrations
As follows from the above definition tachyphylaxis is selective to a subsequent
vanilloid challenge and does not prevent neurons from responding to other
stimuli Impaired neurons do not respond to various stimuli regardless of whether
or not those stimuli target VRs Impairment of neuronal functions by vanilloids is
often referred to as defunctionalization of vanilloidsensitive neurons cf Holzer
1991 It is imperative to understand that both tachyphylaxis and impairment are
reversible and thus should be clearly distinguished from gross neurotoxicity an
irreversible process
1 Desensitization
Desensitization of VRs probably reflects an agonist induced conformational
change in receptor protein which ultimately leads to the closing of the channel
pore It is notable however that capsaicin may elicit not one but multiple
currents that differ in desensitization kinetics Liu and Simon 1996a 1998 It
might also be relevant to desensitization that binding shows an unusual
dissociation kinetics that depends on fractional receptor occupancy Szallasi and
Blumberg 1993a If only a small percentage 10 or less of specific RTX binding
sites are occupied dissociation follows first order kinetics Szallasi and
Blumberg 1993a With increasing receptor occupancy the release becomes
multiphasic and progressively more receptors bind RTX in an irreversible manner
Szallasi and Blumberg 1993a
2 Taehyphylaxic
According to a current electrophysiological model VRs cycle between closed
resting and open active states via numerous nonconducting intermediate states
Liu and Simon 1996a Consequently tachyphylaxis can be viewed as the rate of
recovery of VRs from the intermediate states to the resting state when receptors
can be activated again by agonist binding This cycle probably occurs via
conformational changes in the receptor protein As we saw above extracellular
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calcium may play a crucial role in regulating such conformational changes
leading to tachyphylaxis or the lack of it Koplas et al 1997 Liu and Simon
1998
Piperine the active principle in black pepper and zingerone the pyrolytic product
of ginger oleoresin evoke similar rapidly activating currents Both piperine and
zingerone are pungentcfSzolcsanyi 1982 Piperine and zingerone differ
however in tachyphylaxis Piperineevoked currents show little tachyphylaxis
upon repeated applications Liu and Simon 1996b By contrast zingerone
induced ion fluxes dissipate rapidly Liu and Simon 1996b Thus vanilloids
differ not only in their relative activation of rapid versus slow currents but also in
their ability to shift the activated conductances into a state of tachyphylaxis
3 Is Lasting Tachyphylaxis Possible WithoutPrior Excitation
Of great importance is the question whether it is possible to synthesize
nonirritant vanilloids capable of lasting desensitization in the sense originally
used by Nicholas Jancso Generally speaking to find such a vanilloid that is a
ligand that does not evoke action potentials but desensitizes VRs one requires a
compound that will slowly activate VRs while relatively rapidly inactivating via
increasing intracellular calcium levels voltagedependent Na and Cat
channels Olvanil Brand et al 1987 Dray et al 1990 SDZ 249482 Bevan et al
1995 Wrigglesworth et al 1996 and lowdose RTX Szallasi and Blumberg
1989 Cruz et al 1997a represent prototypes
4 Impairment ojNeuronal Functions after VanilloidTreatment
Vanilloidsensitive nerves include polymodal nociceptors detecting noxious heat
and pressure cf Szolcsinyi 1989 Meyer et al 1994 and express receptors for
algesic and proinflammatory agents such as hydrogen ions bradykinin
histamine and serotonin just to name a few cf Maggi 1991 Lundberg 1993
Rang et al 1994 It is easy to visualize how the well known depletion by vanilloid
treatment of neurotransmitters cf Buck and Burks 1986 Holzer 1991 prevents
the actions of agents stimulating sensory nerves
As we saw in the section dealing with excitation vanilloids release sensory
neuropeptides via exocytosis and maybe also via the axon reflex cf Lundberg
1996 What is the mechanism by which vanilloids prevent the restoration of
neuropeptides Capsaicin was shown to block the intra axonal transport of
macromolecules including NGFGamse et al 1982 Miller et al 1982 Taylor et
al 1984 There is an NGFresponsive element in the preprotachykinin gene
encoding SP and neurokinin A NKA Gilchrist et al 1991 Thus it is easy to
visualize how capsaicin treatment can down regulate SP and NKA expression by
depleting NGF from the perykarya of sensory neurons Less clear is the
mechanism by which vanilloid treatment depletes neuropeptides whose
expression does not depend on the presence of NGF
4DownRegulation ofVRs as a Mechanism oJLongTerm Desensitization to Vanilloids
There is a complete dose dependent loss of specific RTX binding sites in
trigeminal and dorsal root ganglia spinal cord as well as urinary bladder of the
rat following systemic RTX treatment Szallasi and Blumberg 1992b Goso et al
1993b Szallasi et al 1995a This receptor loss occurred later 24 h than the
loss of the biological responses protective eyewiping and xyleneinduced
neurogenic inflammation responses disappeared by 6 h after treatment and
required higher RTX doses Szallasi and Blumberg 1992b The receptor loss in
the spinal cord was entirely due to a reduction in the Bmax In the bladder of rats
pretreated with 30 ug kg RTX approximately at a concentration of the EC50 for
the loss of binding sites in the spinal cord both receptor binding and the
neurogenic inflammatory responses recovered almost completely within 2 months
after treatment Fig 20 Goso et al 1993b By contrast no recovery of specific
binding to spinal cord membranes was observed Goso et al 1993b
These finding suggest that VR loss after RTX treatment can be either reversible
reflecting desensitization or irreversible indicating neurotoxicity and that
peripheral and central terminals of vanilloid sensitive neurons have a differential
sensitivity to these long term vanilloid actions
Figure 20
Loss and recovery of the
xyleneinduced Evans blue
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6 Messenger Plasticity by Vanillolds as a Novel Mechanism ofAnalgesia
Early reports indicated a nondiscriminative depletion of sensory neuropeptides in
the rat following systemic capsaicin treatment cf Buck and Burks 1986 Most
authorities agreed that this loss might play a central role in desensitization to
capsaicin cfBuck and Burks 1986 Holzer 1991 Nevertheless there has always
been a lingering doubt as to what degree this depletion of neuropeptides reflects
desensitization as opposed to possible neurotoxicity Capsaicin activates a variety
of autonomic reflexescfMonsereenusorn et al 1982 Buck and Burks 1986
Consequences include but are not limited to a severe depression of respiration
Fig 21 which was first noted by Toh and coworkers in 1955 Toh et al 1955
These acute responses severely limit the initial dose of capsaicin that can be
given for desensitization For instance Gamse and coworkers noted in 1980 that
rats given 50 mgkg capsaicin sc needed manually assisted respiration for up to
5 min to survive the severe impairment in respiration To circumvent this problem
and to achieve lasting desensitization capsaicin needs to be given repeatedly in
increasing doses taking advantage of the tachyphylaxis as it develops Although
N Jancs6and colleagues showed as early as 1961 that 4 8 and finally 15 mg of
capsaicin administered to adult rats approximately 80 mg kg sc over a period
of 1 to 3 days is sufficient to render the animals fully insensitive to chemically
evoked pain for I to 3 months later studies adopted a more aggressive treatment
protocol which included 950 mg kg capsaicin given sc over a period of 5 days
G Jancso and Khinyar 1975 Jessell et al 1978 Such high doses of course
enhance the possibility for toxicity In fact using this protocol a loss of DRG
neurons in adult rats was demonstrated GJancso et al 1985
Severing the peripheral fibers for example by axotomy leads to dramatic
changes in the expression of neuropeptides and their receptors in primary
sensory neurons including those sensitive to vanilloids cf G Jancso 1992
Hokfelt et al 1994 Certain neuropeptides are upregulated whereas other
peptides by contrast are down regulated It was suggested that those
neuropeptides that are upregulated promote the survival and or regeneration of
neurons cfH6kfelt et al 1994 These neuropeptides have been called injury
peptides G Jancso 1992 The best studied of these injury peptides is galanin
Galanin administered intrathecally has a clear analgesic effect in mice in both the
tail flick and hot plate tests Post et al 1988 As first noted by Hokfelt and
coworkers in 1987 galanin is upregulated in DRG neurons after their peripheral
axons have been severed In these axotomized animals the galanin receptor
antagonist M35 potentiates the facilitation of the flexor reflex a
neurophysiological equivalent of pain sensation WiesenfeldHallin et al 1992
Taken together these findings suggest that galanin acts as an endogenous
analgesic compound to counteract neuropathic pain evoked by nerve injury
Contrasting to this model galanin was found to induce membrane
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extravasationwithout causing
View larger version
In this page In a new window any respiratory depression
This is not possible with
capsaicin only a partial
densitization can be achieved before a rapidly developing respiratory
depression kills the injected animals Reproduced with permission
from Szallasi and Blumberg 1993b
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depolarizations in DRG neurons in culture Puttick et al 1994 DRG neurons
express both known classes of galanin receptors referred to as GAL R1 Burgevin
et al 1995 Xu et al 1996 and GALR2 Ahmad et al 1996 Shi et al 1997
respectively However the expression of both GALRI and GAL R2 is
down regulated following axotomy Xu et al 1996 Shi et al 1997 which might
protect DRG neurons from an exaggerated feedback response
Most neuropeptides known to disappear from neurons with axotomy are thought
to be involved in chemical neurotransmission These changes in peptides and
receptors are collectively referred to as messenger plasticity cf Hdkfelt et al
1994 Messenger plasticity has attracted much publicity lately as a likely
mechanism underlying the poor efficacy of opiates to relieve neuropathic pain
cholecystokinin CCK upregulated by nerve injury is believed to act as an
endogenous antiopiate cf Stanfa et al 1994 Messenger plasticity also explains
why SP antagonists are ineffective in axotomized animals SP is down regulated
whereas vasointestinal polypeptide VIP antagonists gain therapeutic value VIP is
upregulated Wiesenfeld Hallin et al 1990
Mechanisms underlying the upregulation of injury peptides are poorly
understood however there is a striking parallel between the induction of c Jun
and the upregulation of galanin in rat DRG neurons following axotomy
Herdegen et al 1993 implying a role for immediate early genes Jenkins and
Hunt 1991 Leah et al 1991 Herdegen et al 1992
By means of a single well tolerated injection of RTX a complete long lasting
desensitization against chemogenic pain Szallasi and Blumberg 1989a Szallasi
et al 1989a noxious heat Xu et al 1997 and neurogenic inflammation
Szallasi et al 1989a Goso et al 1993b can be achieved Fig 21 Using this
treatment protocol RTX treated rats show changes in neuropeptide in
neuropeptide receptor and in nitric oxide synthase NOS expression very similar
to those described in rats with axotomy Table7 cf Szallasi 1996 Szallasi and
Blumberg 1996 For example the expression of the neuropeptides galanin and
VIP Farkas Szallasi et al 1995 Xu et al 1997 the neuropeptide receptor
CCKBR C Broberger T Farkas Szallasi A Szallasi J M Lundberg T HBkfelt Z
Wiesenfeld Hallin and X J Xu submitted for publication as well as the enzyme
NOS Farkas Szallasi et al 1995 are markedly enhanced These changes are fully
reversible Other neuropeptides for instance SP are depleted Szallasi 1996
This change in SP expression is also reversible and is due to a decrease in the
steady state levels of total mRNAs encoding SP Szallasi et al 1999b
Importantly the number of DRG neurons showing an in situ hybrid ization signal
for mRNAs encoding SP is not reduced Szallasi et al 1999b Finally there are
neuropeptides that do not show changes in expression following RTX treatment
CGRP and somatostatin are notable examples of this phenomenon Szallasi
1996 However the regulation of neuropeptide expression by RTX seems to be
very complex For example RTX dramatically upregulates CGRP expression in
DRG neurons obtained from mouse embryos Qakab et al 1994
View this table
Table 7
In this window Ina new window
Changes in selected markers
neuropeptides enzymes
receptors of rat primary sensory neurons following RTX single sc
dose or capsaicin cumulative sc dose treatment as well as axotomy
However RTX when given repeatedly in a capsaicin like treatment protocol
depletes CGRPlike immunoreactivity from DRG neurons Szolcssnyi et al 1990
The finding that single moderate doses of RTX have a differential effect on
neuropeptide expression compared with high cumulative RTX doses represents a
powerful argument that depletion of neuropeptides by high vanilloid doses
reflects neurotoxicity rather than desensitization
Despite the striking similarities between vanilloid and axotomyinduced
changes in the expression of neuropeptides there is an essential difference in
the behavior of animals whereas mechanical nerve injury usually results in the
development of neuropathic pain as most dramatically demonstrated by
autotomy behavior vanilloids by sharp contrast have a clear analgesic action
cf Szallasi and Blumberg 1996 Spinal cord injury leads to allodynia like
behavior to cold stimuli Xu et al 1992 RTX treatment abolishes this behavior
Hao et al 1996 Moreover RTX induces a longlasting analgesic action on the
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hot plate test as well as a transient hypoalgesia to mechanical stimuli Fig 22A
Xu et al 1997 This is surprising because capsaicin when given to adult rats
fails to achieve similar changes Obal et al 1979 Hayes and Tyers 1980 G
Jancso and jancsoGabor 1980
Figure 22
A in rats systemic RTX 500
l 1 pg kg sc causes a profound
long lasting analgesia
response in the hotplate test
1 I Also it evokes a transient
increase in paw withdrawal
threshold to pressure B
prepeatedtrains of conditioning
stimuli applied to the sural
View larger version nerve of the rat evoke
In this page In a new window contractions in hamstring
muscles of increasing
amplitude open columns This
phenomenon is often referred to as windup or facilitation of the
flexor reflex and is thought to reflect sensitization of spinal cord
neurons The facilitation of the flexorreflex is diminished in
RTX treated rats closed columns This effect is probably mediated by
galanin which is known to be upregulated following RTX treatment
since the galanin receptor antagonist M35 is able to restore the
windup phenomenon in RTX treated animals crossedhatched
columns Data are from Xu et al 1997
It has long been known that trains of equal stimuli to the sural nerve evoke
contractions of increasing strength in the hamstring muscles cfH6kfelt et al
1994 This phenomenon is called facilitation of the flexor reflex also known as
the wind up phenomenon and is believed to reflect spinal hyperexcitability as a
consequence of Cfiber activation Wall and Woolf 1984 A causal relationship
between spinal hyperexcitability and neuropathic pain has been postulated cf
Hokfelt et al 1994 The windup phenomenon is greatly reduced in RTX treated
rats Fig 22B Xu et al 1997 These RTX treated animals show enhanced
galanin expression both at the mRNA and the peptide levels Farkas Szallasi et
al 1995 The galanin receptor antagonist M35 restored the Cfiber mediated
hyperexcitability in the RTX treated rats Fig 22B Xu et al 1997 Furthermore
the decrease in galanin expression with increasing time after RTX administration
was accompanied by a gradual restoration of heat sensitivity Xu et al 1997
Taken together these observations imply that upregulation of the inhibitory
neuropeptide galanin plays a central role in the prolonged analgesic action of
RTX
As already mentioned CCKB receptor expression is markedly upregulated in
RTX treated animals The level of mRNAs encoding CCKA receptors is moderately
increased This is surprising for two reasons First enhanced CCKB receptor
expression in rats with nerve injury is believed to contribute to the persistent
morphineresistant pain that develops in such animals cf Stanfa et al 1994
RTX treated animals however show marked analgesia and not chronic pain
Szallasi and Blumberg 1989a Xu et al 1997 Second capsaicin treatment
results in a marked loss of CCK binding sites suggesting the down regulation of
CCK receptors Ghilardi et al 1992 A potentially important difference between
the effects of mechanical nerve injury and RTX treatment is that CCK is elevated in
axotomized Verge et al 1 993 but not in RTX treated rats Xu et al 1998 Thus
probably there is no agonist to occupy the extra CCKBreceptors following RTX
treatment Another vanilloid effect not mimicked by axotomy is the loss of VRs
Farkas Szallasi et al 1996
The differential regulation of CCKB receptor expression in capsaicin and
RTX treated animals is not unprecedented Table 7 lists several additional
interesting examples of this phenomenon The most likely explanation is a
dominating nonspecific neurotoxicity by capsaicin
C Neurotoxicity by Vanilloids
In 1977 it was reported that capsaicin given to newborn rats sacrificed the
majority of small to medium seized DRG neuronsGjancso et al 1977 Since
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then neonatal capsaicin treatment has been used routinely to identify capsaicin
sensitive neuronal pathways and to explore their contributions to physiological
and pathological regulatory processes cf Buck and Burks 1986 Holzer 1991 It
is known that NGF is required for the survival of immature DRG neurons Ruit et
al 1992 It is also known that capsaicin treatment stops the intraaxonal
transport of NGF from the periphery where it is produced to the cell bodies of
DRG neurons Taylor et al 1985 Based on these observations it was postulated
that neonatal capsaicin administration kills neurons by depriving them of NGF
cfWood 1993 Experimental support for this explanation was provided by Otten
and colleagues in 1983 Otten et al 1983 who showed that DRG neurons
doomed to perish following neonatal capsaicin treatment may be rescued by
exogenous NGF
There can be little doubt that capsaicin is able to kill adult sensory neurons in
culture in a VRmediated fashion Winter 1987 Wood et al 1988 This action is
mimicked by RTX geftinija et al 1992 and is most likely mediated by calcium
because removal of extracellular calcium or block of the calcium influx by
ruthenium red prevents capsaicin induced cell death Wood et al 1988 Winter
et al 1990Chard et al 1995 Inhibiting calciumactivated proteases such as
calpain by E64 or MDL 28170 also minimizes capsaicin mediated cell death
Chard et al 1995 There are however important differences between
capsaicin induced neurodegeneration in animals and in culture In vitro
capsaicin kills DRG neurons rapidly regardless of the presence of NGF Wood et
al 1988 Jeftinija et al 1992 In sharp contrast capsaicin given to neonatal rats
induces no early cell death Szolcsanyi et al 1998 and even the delayed
neuronal loss can be prevented by NGF Otten et al 1983 Szolcsanyi et al
1998d
Although calcium seems to be an important orchestrator of capsaicin induced
neuronal degeneration in vitro the question remains open whether or not the rise
in intracellular calcium by capsaicin can achieve sufficiently high levels in adult
sensory neurons in vivo to cause irreversible neuronal damage In humans
intradermal injection of high capsaicin doses produces degeneration and
subsequent reinnervation of cutaneous nerve endings Simone et al 1998 It is
not known however whether any DRG neurons innervating the capsaicin treated
skin area perish In adult rats a significant loss of DRG neurons was reported
following systemic sc capsaicin administration G Jancs6 et al 1985 The
interpretation of this findings is however complicated by subsequent studies by
Ritter and Dihn 1993 who demonstrated that capsaicin given at similarly high
doses may induce argyrophylia believed to reflect neurotoxicity along the entire
neuroaxis of the rat including the retina RTX ablates DRG neurons in newborn
Szallasi et al 1990 but not in adult Szallasi and Blumberg 1992b rats
Therefore toxicity by capsaicin in adult rats may reflect a nonspecific toxic action
via an RTX insensitive site see Section IX for details Alternatively respiratory
depression by capsaicin see above may lead to tissue hypoxia which in turn
may damage neurons regardless of whether or not they possess VRs Finally
novel VRs may exist that recognize capsaicin but not RTX As already mentioned
several ESTs show a high degree of similarity to VRI Caterina et al 1997
including an EST in the retina Washington University St Louis MOMerck EST
Project unpublished data accession no AA047763 a tissue particularly
susceptible to toxicity by capsaicin Ritter and Dihn 1993
IX Diverse Biological Actions ofVanilloids VRMediated and
Independent Mechanism
Vanilloid ligands show striking differences in biological actions Some of these
differences can be explained at the level of a single receptor For instance the
archetypal vanilloid capsaicin is both pungent and desensitizing Piperine is
pungent Szolcsanyi 1982 but does not desensitize Liu and Simon 1996b In
the case of olvanil the pattern is the opposite it is nonpungent Brand et al
1987 Dray et al 1990 but desensitizing Dray et al 1990 Liu L et al 1997 As
we saw above these differences in biology are likely to reflect kinetic differences
in channel gating properties
Other differences are better explained by postulating VR heterogeneity For
example vanilloids evoke multiple currents that seem to differ in affinity
kinetics and sensitivity to antagonists Figs 12 and 14 Liu and Simon 1996a
Liu et al 1996 1998
Capsaicin actions have traditionally been divided into specific ie
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VRmediated and nonspecific effects cf Holzer 1991 Specific action was
defined as that occurring via interaction of capsaicin at primary sensory neurons
With the discovery of VRs on cells other than primary sensory neurons such as
mast cells and glial cells Biro et al I998abit needs to be reevaluated whether
certain biological actions of capsaicin previously considered nonspecific may
be specific after all
Capsaicin interacts at several targets other than neuronal and nonneuronal VRs
We already commented briefly on some of these targets including a block of K
channels Dubois 1982Petersen et al 1987 Kehl 1994 Kuenzi and Dale 1996
inhibition of NADHoxidoreductase and other enzymes Shimomura et al 1989
altered membrane fluidity Meddings et al 1991 Aranda et al 1995 and
formation of so called pseudochannels Feigin et al 1995 For instance changes
in membrane fluidity may underlie the inhibitory effect of capsaicin on
thrombocyte aggregation Hogaboam and Wallace 1991 whereas ligand
induced pseudochannel formation may contribute to the nondiscriminative
neurotoxic action of capsaicin at high doses Ritter and Dinh 1993 What we
have not mentioned yet but may be important is the finding that capsaicin acts
as a competitive inhibitor of tyrosyl tRNA synthetase Cochereau et al 1996
Capsaicin inhibits tyrosyl tRNA synthetase in hippocampal astrocytes with a Ki
value of 42 pM and then kills these cells Astrocytes may be rescued by adding
tyrosine to the culture medium Cochereau et al 1997 As mentioned above
capsaicin induces degeneration of neurons not supposed to express VRs Ritter
and Dinh 1993 It is not unlikely that some of the unexpected neurotoxic actions
of capsaicin are due to an inhibition of tRNA aminoacylation
RTX differs from capsaicin in its spectrum of non VRmediated actions For
example RTX does not inhibit K channels Castle 1992 However RTX has its
own independent targets RTX binds to Szallasi et al 1989b Acs et al 1995
and activates PKC Acs et al 1995 Harvey et al 1995 inhibits nuclear
transcription factor KB NFKB Singh et al 1996 and induces apoptosis in
human Bcells via Bcl 2 and calcineurin Wolvetang et al 1996 It should be
noted however that whereas capsaicin acts on VRs and other targets in
overlapping concentration ranges RTX shows from a hundred to several
thousandfold separation in favor of VRs Because of its side effects capsaicin is
often referred to as a double edged sword cf Surh and Lee 1995 In light of the
above findings it is not surprising that RTX at doses relevant for VRs seems to be
devoid of most undesirable capsaicin like side effects cf Szallasi and Blumberg
1996
Previously we discussed vanilloid binding by al acid glycoprotein in serum as a
methodological means to reduce nonspecific RTX binding Szallasi et al 1992 In
the context of this section it should be noted that serum binding of vanilloids
may be a major pharmacodynamic pharmacokinetic factor influencing vanilloid
actions in vivo If the concentration of a drug binding plasma protein and its
affinity for the drug are known the fraction of the drug that remains unbound in
the plasma and thus is available for specific receptor binding can be estimated
By using the reported plasma alacid glycoprotein level in the rat 4 pM and the
affinities of al acid glycoprotein for RTX 05 pM and capsaicin 105 pM
respectively it can be calculated that a much higher 72 fraction of capsaicin
remains free than that of RTX 13 upon systemic administration cf Szallasi et
al 1992 This is in accord with the observation that RTX actions are
characteristically subdued and often occur after a delay Szallasi and Blumberg
1989a Maggi et al 1990 Furthermore this serum binding may provide a
rationale to explain the observation that chloral hydrate that also binds to
al acid glycoprotein facilitates acute vanilloid actions in the rat Szallasi et al
1998d al Acid glycoprotein is a well known drug binding protein in serum cf
Paxton 1983 Kremer et al 1988 In clinical practice the possible competition
between vanilloids and nonvanilloid drugs eg chlorpromazine and warfarin for
sites on plasma proteins needs to be carefully evaluated
X Species Related Differences in Vanilloid Actions
It has long been known that vanilloids show striking species related differences
in biological actions Glinsukon et al 1980 Buck and Burks 1986 Holzer 1991
According to a frequently cited example the dose of capsaicin that can kill the
guinea pig almost instantaneously is well tolerated by the hamster Glinsukon et
al 1980 In principle these differences may reflect 1 species related
differences in VR expression Table8 2 species related differences in
neurotransmitter expression in vanilloidsensitive neurons and 3 species
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related differences in the expression of receptors for these neurotransmitters
There are several examples for the relevance of all these three mechanisms in the
markedly dissimilar vanilloid actions in different species An important
consequence of these differences is that great attention must be paid to the
choice of animal models in preclinical studies to evaluate vanilloid toxicity
View this table
Table 8
In this window Ina new window
Parameters of binding
to VR in spinal cord of several
species including humans
A Species Related Differences inVR Expression
Birds do not respond to capsaicin Oancs6 1968 As expected no specific RTX
binding was found in chicken DRGs Szallasi and Blumberg 1990b Among
mammalian species rabbits are distinguished by their marginal sensitivity to
capsaicin Glinsukon et al 1980 Tervo 1981 In keeping with this the density
and or affinity of RTX binding sites in rabbit trigeminal ganglion membranes
isare under the detection limit of the binding methodology Szallasi and
Blumberg 1993a Hamsters are interesting in that their DRGs are comparable
with those of the rat in terms of RTX binding Szallasi and Blumberg 1993a
however in hamster urinary bladder Szallasi et al 1993d or trachea Szallasi et
al 1995b no specific RTX binding can be detected Apparently hamster sensory
neurons are capable of the synthesis of VRs but the receptor protein is not
transported to the periphery at a measurable level Hamsters are noted for their
resistance to capsaicin Glinsukon et al 1980 Maggi et al 1987a which is in
accord with the lack of detectable RTX binding sites in their peripheral tissues In
general insensitivity to vanilloids seems to be associated with the absence or
expression at undetectably low levels of specific RTX binding sites However the
reverse statement is not true a hypersensitivity to vanilloid actions does not
necessarily mean the existence of unusually high affinity or density of VRs For
instance although guinea pigs are very sensitive to vanilloids cf Buck and Burks
1986 Holzer 1991 neither the affinity nor the density of RTX binding sites in
this species exceeds the parameters determined in the rat Szallasi and Goso
1994 Szallasi et al 1995b
B Species Related Differences in Expression of Sensory Neuropeptides and
Their Receptors
Interested readers may find several excellent reviews on this topic Here we wish
to mention one intriguing example only Vanilloids induce equally powerful
edema responses in airways of the guinea pig Lundberg et al 1984 mouse A
Szallasi unpublished observation and rat Saria et al 1983 However with
regard to bronchomotor responses these three species show markedly dissimilar
reactions to capsaicin treatment Guinea pig airways are contracted Szolcsanyi
and Barth6 1982 Lundberg and Saria 1987 whereas mouse airways are dilated
Manzini 1992 by capsaicin administration Rat airways show no changes in
bronchial tone loos et al 1986 Interestingly the very same neuropeptide SP
mediates bronchoconstriction in the guinea pig and bronchodilation in the mouse
cf Manzini et al 1994 The difference in biological responses seems to stem
from the cellular localization of SP receptors NK1Rs which are present on
bronchial smooth muscle in the guinea pig Devillier et al 1988 Maggi et al
1991 and on airway epithelium in the mouse Manzini 1992 SP binding to
NK 1Rs leads to a direct contraction of bronchial smooth muscle in the guinea
pig Maggi et al 1991 In the mouse bronchodilation is an indirect effect
mediated by cylcooxgenase products generated in the epithelium upon NK 1R
activation Manzini 1992 Interestingly equine airways are also relaxed by
capsaicin Zhu et al 1997 This effect however is not mimicked by
neuropeptides or prostanoids but is prevented by charybdotoxin a blocker of
Cat activated K channels Zhu et al 1997 As we will see below human
airways behave in a unique manner in response to vanilloids
CHuman VRs
The presence of vanilloidsensitive nerves in humans is well established cf
Fuller 1990 Lynn 1990 Winter et al 1995 For obvious reasons it is very
difficult to study VRs in freshly obtained human sensory ganglia or spinal cord
Nevertheless Baumann and colleagues 1996 characterized Capsaicinevoked
responses in adult human DRG neurons in culture For cell culture they used
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DRGs removed surgically for chronic intractable pain a fortunately uncommon
procedure In neuronal tissues obtained post mortem a high density of specific
RTX binding sites can be demonstrated using membranes Tables Acs et al
1994b Szallasi and Goso 1994 or an autoradiographic approach Fig 7 Szallasi
et al 1994a There are conflicting reports about the cooperativity of RTX binding
by human spinal cord membranes Acs and colleagues 1994b reported positive
cooperative binding to spinal cords removed within 4 h after death from victims
of traffic accidents in Hungary Szallasi and Goso 1994 by contrast found
noncooperative binding to spinal cord samples removed from elderly Italians 24
to 48 In after death This change in cooperativity may reflect differences in the
time elapsed after death 4 h versus 24 h and may also be influenced by other
factors such as age gender and or ethnicity of the tissue donors
Surgically obtained human airway specimens and guinea pig airways bind RTX
with similar parameters Szallasi etal1995b Airways removed from cadavers
show marked differences in RTX binding ranging from no binding at all to
binding similar to surgical samples Szallasi et al 1995b Whether this variation
reflects post mortem autolysis or is due to the underlying disease remains to be
seen Interestingly a similar variability was noted in bronchomotor responses to
capsaicin in humans Lundberg et al 1983 Honda et al 1991 Chitano et al
1994 Molimard et al 1994 Ellis et al 1997
Actually the high density of specific RTX binding sites in human bronchi is
surprising Vanilloids contract isolated human bronchi only to a minimal degree
Lundberg et al 1983 Honda et al 1991 or not at all Molimard et al 1994
and the neurogenic plasma extravasation response also seems to be missing in
human airways Bascom et al 1991 Greiff et al 1995 However capsaicin may
provoke severe bronchoconstriction in asthmatic patients Marciniak et al 1995
The reason why asthmatics are more susceptible to capsaicin inhalation than
healthy individuals is not known cf Lundberg 1995 In animals the
bronchocontractile action of capsaicin is mediated by SP acting on NKl Rs and
the expression of both SP 011erenshaw et al 1991 and its receptor Adcock et
al 1993 were reported to be increased in patients with asthma However unlike
in guinea pigs in humans the bronchoconstrictor action of capsaicin is
apparently not mediated by tachykinins Ellis et al 1997 The only known
response that capsaicin reproducibly provokes in healthy human airways is cough
cfKarlsson 1996
The affinity of specific RTX binding sites and their density seem to be fairly
similar in human Acs et al 1994b Szallasi and Goso 1994 monkey T Biro and
P M Blumberg unpublished results and porcine spinal cord Acs and Blumberg
1994 Szallasi et al 1994b Table 8 As regards human VRs a cell line stably
transfected with a human VRl like receptor c DNA is probably already in the
pipeline
XI EndogenousVanilloids Do They Exist
The high affinity of VRs strongly argues for the existence of endogenous
vanilloids VRs show positive cooperativity in ligand binding and it has been
speculated that this behavior might serve as a relay mechanism to amplify the
actions of an endogenous activator produced in low quantity or affinity
Maderspach and Fajszi 1982
Endogenous VR activators are yet to be identified As we saw VRs are expressed
along the entire length of sensory neurons in several brain nuclei and also in
nonneuronal tissues This broad expression of VRs hinders the isolation of
endogenous ligands especially if they are produced on demand only For VRI
noxious heat and or low pH Catering et al 1997 Tominaga et al 1998 or a
combination of inflammatory mediators Kress et al 1997 Vyklicky et al 1998
have been suggested to act as natural activators Whereas it is easy to visualize
how peripheral VRs may be activated by such agents the relevance of heat or
hydrogen ions in stimulating central VRs is rather doubtful Consequently it may
be postulated that VRs depending on the tissue in which they are expressed
have distinct endogenous activators
Capsazepine given to control rats has no perceptible actions Perkins and
Campbell 1992 which led to the conclusion that endogenous vanilloids either
do not exist or are produced on demand only In accord with the latter model are
the findings that capsazepine is beneficial in animal models of pain and
inflammation Santos and Calixto 1995 Campbell et al 1996 Kwak et al 1998
For example capsazepine can antagonize carrageenan or formalin induced
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hyperalgesia in the rat as well as the corresponding increase in the number of
dorsal horn neurons positive for Fos like immunoreactivity Kwak et al 1998
These observations imply that hyperalgesia is mediated at least in part by a
substance that is released from inflamed tissues and that acts on VRs This
concept is however weakened by a recent report by Reeh and coworkers
Vyklicky et al 1998 Carrageenan is known to promote the release of
inflammatory mediators such as histamine 5hydroxytryptamine prostaglandins
and cytokinins Watkins et al 1995 Reeh and colleagues showed that a
combination of such inflammatory mediators can activate vanilloidsensitive
neurons in a capsazepine sensitive manner Vyklicky et al 1998 Therefore now
it is unclear whether capsazepine inhibition of carrageenan inflammation
induced hyperalgesic responses really implies the release of a novel specific
endogenous VR activator or rather reflects the interaction of well known
mediators at sensory nerves
There is indirect evidence to imply a role for an endogenous vanilloid in
maintaining physiological functions A well known long term sequel of vanilloid
treatment is a loss of hair which may be followed by skin exulcerations Maggi et
al 1987b Carrillo et al 1998 This skin damage might be due to the depletion
of SP from dermal sensory nerve endings Gamse et al 1980 because SP has
been shown to exert trophic actions on fibroblasts and keratinocytes Sporn and
Roberts 1988 Consequently a link has been postulated between alopecia areata
and malfunctioning of vanilloidsensitive nerves Rossi et al 1997 In fact SP
was shown to facilitate hair growth in mice Paus et al 1994 It was also
speculated that a sustained release of SP from sensory nerves is important in
keeping the skin and its appendices healthy Sporn and Roberts 1988 An
endogenously produced VR activator might subserve this role Furthermore an
accelerated release of SP form cutaneous terminals may explain how topical
capsaicin can accelerate wound healing in the pig Watcher and Wheeland 1989
XII Vanilloids in Clinical Practice Current Uses and Future
Perspectives
In principle all the three characteristic actions of vanilloids excitation
desensitization and neurotoxicity may have therapeutic value cf Szolcsanyi
1991 Szallasi and Blumberg 1993b Stimulation counterirritation and
desensitization are already in use in clinical practice Ablation of Cfibers by
perineural capsaicin injection cf G jancsd and Ambrus 1994 may be attempted
in cancer patients with otherwise untractable pain
A CounterirritationwithCapsaicin
Capsaicin is a standard ingredient in a variety of over the counter drugs eg
Stimurub Heat Capsoderma used worldwide to relieve muscle ache In the case
of sore muscles after rigorous exercise beneficial capsaicin effects may be
attributed to an increase in microcirculation in the treated area A likely mediator
of this action is CGRP cf Holzer 1988 When muscle ache is due to bruises such
capsaicin ointments probably act as counterirritants The mechanism of
counterirritation is poorly understood Previously it was believed to occur at the
level of the spinal cord and it was also referred to as hyperstimulation analgesia
Melzack 1975 or nocigenic inhibition Ness and Gebhart 1991 Recent
findings however imply a predominantly peripheral mechanism mediated by
somatostatin released from vanilloidsensitive nerve endings Szolcsanyi et al
1998c It is not unlikely that desensitization by creams containing low
concentrations of capsaicin such as Axsain 075 capsaicin GenDerm Canada
Inc Montreal Canada Euroderma Ltd and Zostrix025 capsaicin GenDerm
Canada Inc reflects counterirritation instead
B Desensitization to Capsaicin
Vanilloid sensitive nerves participate in various reflex responses such as the
micturition reflex cf Maggi and Meli 1988 The existence of vanilloidsensitive
nerves in the human urinary bladder is well established and these nerves were
shown to play a pivotal role in the reflex control of micturition in humans Maggi
et al 1989 The micturition reflex is under the inhibitory control of descending
supraspinal pathways cf Blaivas 1982 When these inhibitory pathways are
disrupted for example by trauma or multiple sclerosis the urinary bladder
becomes autonomous and the urge to void occurs at low bladder volumes cf
Blaivas 1982 De Groat 1997 This condition is called detrusor hyperreflexia of
spinal origin Capsaicin injected via a catheter into the urinary bladder is
beneficial in this condition by decreasing the sensitivity of C fibers subserving
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the micturition reflex cf De Groat 1997 Cruz 1998 Capsaicin is also beneficial
in bladder hypersensitivity a condition caused by an abnormal perception of
bladder filling Detrusor hyperreflexia is a motor form whereas bladder
hypersensitivity is a sensory form of urge incontinence Stephenson and Mundy
1994 Heritz and Blaivas 1996 which next to stress incontinence only is the
second most common type of incontinence in women Diakno 1996 Hampel et
al 1997 A complication of capsaicin instillation into the urinary bladder is the
initial hyperreflexic contractions that may cause urethral leakage cfCruz 1998
Also most patients report suprapubic pain cf Fowler et al 1994 Cruz 1998
Both pain and hyperreflexic contractions may be minimized in selected patients
by electromotive lidocaine administration Dasgupta et al 1998a However
many patients report intense pain by capsaicin even after lidocaine anesthesia
Das et al 1996 Cruz et al 1997b
A traditional indication for capsaicinoids is toothache Turnbull 1850 As
discussed above both eugenol and guaiacol appear to exert their analgesic
activity via VRs Ohkubo and Kitamura 1997 Ohkubo and Shibata 1997 Topical
capsaicin seems to have a therapeutic value in atypical odontalgia an unusual
chronic orofacial pain condition with no other known effective pharmacological
therapy Vickers et al 1998 and also in the so called burning mouth
syndrome another disease of unknown etiology Huang et al 1996
Topical capsaicin can ameliorate the symptoms rhinorrhea nasal obstruction
pruritus etc of vasomotor rhinitis LaCroix et al 1991 Marabini et al 1991
Stjarne et al 1991 Filiaci et al 1994 Wolf et al 1995 Blom et al 1997 a
common disorder that as Philip and Togias I99S succintly put it is difficult to
define difficult to treat and difficult to understand A recent report from the
Karolinska Institute Stjarne et al 1998 also describes a lasting amelioration of
nasal congestion in patients with birch pollen allergic rhinitis following a single
intranasal application of a 30 uM capsaicin solution As an added benefit
capsaicin treatment once a week for 5 weeks seems to reduce the size of nasal
polyps as well Filiaci et al 1996 Interestingly intranasal capsaicin is also
effective in cluster headache Sicuteri et al 1989 Fusco et al 1991 Marks et al
1993
Notalgia paresthetica is a condition characterized by intense pruritus usually
accompanied by macular pigmentation over the scapular area Weber and Poullos
1988 It is thought to be due to entrapment of the posterior rami of the T2 to T6
spinal nerves Itching improves in most notalgia paresthetica patients undergoing
topical capsaicin therapy Wallengren 1991 Leibsohn 1992 Wallengren and
Klinker 1995 Capsaicin also reduces the severity of pruritus in psoriasis
Bernstein 1988 Ellis et al 1993 and in hemodialysis patients with uremia
Breneman et al 1992 Tarng et al 1996
Topical capsaicin has been also tried as an adjuvant analgesic in a variety of
neuropathic pain conditions Table9 such as postherpetic neuralgia Bernstein et
al 1987 Bucci et al 1988 Hawk and Millikan 1988Watson et al 1988 painful
diabetic neuropathy Ross and Varipapa 1989 Chad et al 1990 Basha and
Whitehouse 1991 Capsaicin Study Group 1991 Schefflar et al 1991 Low et al
1995 and postmastectomy pain syndrome Watson et al 1989 Watson and
Evans 1992 Dini et al 1993 as well as in osteo and rheumatoid arthritis Deal
et al 1991 McCarthy and McCarthy 1992 Matucci Cerinic et al 1995 A critical
overview of these clinical trials at least 50 of them is out of the scope of this
review Briefly the therapeutic value of capsaicin in neuropathic pain conditions
is difficult to judge because of three reasons First controlled capsaicin trials
versus placebo are impossible to blind due to the characteristic burning sensation
induced by capsaicin Second a high placebo response rate was reported in the
controlled trials which may account for some salutary capsaicin effects in the
uncontrolled studies In extreme cases placebo gives an even better response
rate than capsaicin For example four of seven lichen simplex chronicus patients
reported an improvement of the pruritus following capsaicin treatment Kantor
and Resnick 1996 However three of the four patients who reported beneficial
effects actually preferred placebo over capsaicin And third many patients decide
to quit treatment because they find the irritancy of available capsaicin
preparations intolerable Reported withdrawal rates are 30 or higher cf Carter
1991 Rumsfield and West 1991 Watson 1994 Rains and Bryson 1995 C P N
Watson 1994 who has conducted the most postmastectomy pain studies and
thus has firsthand experience in using capsaicin as an analgesic concludes
topical capsaicin is generally not satisfactory as a sole therapy for chronic
painful conditions although it may serve as an adjuvant to other approaches
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Table 9
Current clinical indications for use of topical capsaicin
Those who favor the use of capsaicin creams in clinical practice frequently cite
the finding that topical capsaicin effectively desensitizes the rat skin to
neurogenic inflammatory agents McMahon et al 1991 Human skin is however
less permeable by a factor of 48 than rat skin to capsaicin Kasting et al 1997
In rat skin capsaicin analogs are extensively metabolized during passage the
primary route of degradation being the hydrolysis of the amide bond Kasting et
al 1997 This is probably also the case in human skin Due to a combination of
low potency and poor bioavailability capsaicin applied topically on the skin is not
likely to effectively desensitize nerve endings in human skin This conclusion is
supported by the lack of effect of topical capsaicin on the SP immunoreactivity in
human skin biopsy samples Munn et al 1997 This is in dramatic contrast to
the marked degeneration of SPcontaining cutaneous nerve fibers following
intradermal injections of high capsaicin doses Simone et al 1998
Finally there are reports that capsaicin may be beneficial in the treatment of the
following disease states GuillainBarresyndrome Morgenlander et al 1990
reflex sympathetic dystrophy Cheshire and Snyder 1990 meralgia paresthetica
Puig et al 1995 stump pain Rayner et al 1989 apocrine chromhidrosis
Marks 1989 burning mouth syndrome Huang et al 1996 and vulvar
vestibulitis Friedrich 1988 Table 9 As yet these reports should be considered
anecdotal due to the very small number of patients at best five cases involved
A new approach to enhance the clinical effectiveness of capsaicin is to use large
doses a 10 solution instead of the commercially available025 and075
creams under regional anesthesia Robbins et al 1998 Of 10 patients with
intractable pain due to bilateral peripheral neuropathy 9 obtained significant
analgesia by this treatment protocol that lasted 1 to 18 weeks The authors
concluded that intermittent use of largedose capsaicin may decrease chronic
analgesic dependence Another as yet clinically untested possibility is epidural
vanilloid administration In the rat epidural capsaicin caused prolonged
segmental thermal analgesia Eimer and Papir Kricheli 1987
We think that the unsatisfactory clinical results with capsaicin are predominantly
due to the unfavorable ratio of irritation to desensitization of this drug which is
also apparent in animal studies Consequently a drug with improved
desensitization to irritation ratio ideally causing lasting desensitization with no
prior pungency promises to be of great clinical value Ongoing clinical trials with
RTX indicate see below that such vanilloids may in fact be synthesized
C Adverse Effects ofTopical Capsaicin
The most important adverse effect of capsaicin is the initial burning sensation
that it produces cf Carter 1991 Watson 1994 Cruz 1998 According to both
animal experiments Craft and Porreca 1994b Avelino et al 1998a and clinical
observations Fowler et al 1994 Chandiramani et al 1996 Dasgupta et al
1998a the pain response to capsaicin can be minimized by lidocaine
administration without compromising the desired effect desensitization
However as we saw above the real problem with topical capsaicin is not its
pungency but rather its poor efficiency to achieve clinically useful desensitization
which of course cannot be improved with lidocaine
Capsaicin is usually regarded as a remarkably safe drug and other than
pungency very few adverse effects have been reported Initial studies indicated a
relatively high frequency affecting 5 12 of the patients of respiratory problems
cough and sneezing Capsaicin Study Group 1991 Scheffler et al 1991 Ellis et
al 1993 Watson et al 1993 but it may effectively be eliminated by bathing the
skin 30 to 40 min after treatment to prevent aerosolization of the unabsorbed
dried capsaicin Marciniak et al 1995 It should be noted however that one
nurse with a history of asthma experienced severe enough congestion coughing
and shortness of breath when applying capsaicin cream on a patient to require
use of her albuterol inhaler Marciniak et al 1995 It is recommended therefore
that all health care workers especially those who are asthmatic wear masks
during application of capsaicin creams
DNovel InnovativeClinical Uses
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Aspiration pneumonia is among the most common causes of death in the elderly
Both swallowing and cough reflexes are mediated by SP released from vagal
sensory nerve endings subserving the pharynx and the upper airways cf
Lundberg 1993 Karlsson 1996 It has been suggested that supplementation of
food with capsaicin which stimulates SP release may help prevent aspiration
pneumonia Sasaki et al 1997 An added benefit of this diet is the improved
clearance of the esophagus Gonzalez et al 1998
A particularly attractive and as yet largely unexplored area for the therapeutic
use of vanilloids is weight control It was concluded in 1986 that those who eat
plenty of hot spicy food have a high metabolic rate and stay lean Henry and
Emery 1986 In 1990 Cameron Smith and colleagues indicated the need to
evaluate capsaicin as an antiobesity or slimming agent in humans More
recently two independent groups have shown that dietary hot pepper increases
energy expenditure and diminishes long term excess energy intake in humans at
the same time Doucet and Tremblay 1997 Lim et al 1997 This is entirely in
accord with the animal experiments which have repeatedly shown enhanced
oxygen uptake following capsaicin administration Kawada et al 1986 Watanabe
et al 1987 Cameron Smith et al 1990 The area postrema nucleus of the
solitary tract area is believed to play an important role in satiety cf South and
Ritter 1983 The presence of VRs inthis area is firmly established Szallasi et al
1995a It is more likely than not that VRs in the area postrema mediate the
antiemetic actions of vanilloids too Andrews and Bhandari 1993Matsuki et al
1996 Shirosita et al 1997
Last it is noteworthy that capsaicin is bacteriocidal toHelicobacter pylori Qones et
al 1997 In animal experiments topical capsaicin protects against gastric ulcer
formation cf Abdel Salam et al 1994 Thus ingestion of chili peppers or
supplemetation of the diet with capsaicin could have a protective effect against
gastroduodenal diseases In the rat orally administered RTX at a dose as low as
06 pgkg was reported to protect against ethanol or aspirininduced gastric
mucosal damage Abdel Salam et al 1995
E RTX an Improved VanilloidDrug Undergoing Clinical Trials
RTX was first isolated in 1975 by Hecker and coworkers Hergenhahn et al 1975
but it was not until 1989 that it was identified as an ultrapotent vanilloid De Vries
and Blumberg 1989 Szallasi and Blumberg 1989a Nonetheless euphorbium
the dried latex of E resinifera has been in medicinal use as an analgesic for two
millennia Fig 5 cf Appendino and Szallasi 1997 As we saw above in animal
experiments RTX shows a far more favorable ratio of desensitization to irritation
than does capsaicin Table 3cfSzallasi and Blumberg 1990a 1993b Blumberg
et al 1993 RTX is also more potent than capsaicin for desensitization Fig 21
cfSzallasi and Blumberg 1990a 1996
As discussed above the overactive bladder is one of the few clinical conditions in
which capsaicin has fulfilled expectationscfChancellor 1997 De Ridder et al
1997 Intravesical capsaicin is as effective as the oral anticholinergic drugs
traditionally used to treat bladder hyperreflexia however capsaicin bypasses the
very unpleasant atropine like side effects of these drugs cf Andersson 1997
Better yet capsaicin has no effects on the detrusor muscle and therefore it does
not increase residual urine cf Cruz 1998 Finally no premalignant or malignant
changes were found in the urinary bladders of patients who had received
repeated capsaicin instillations for up to 5 years Dasgupta et al 1998b No
wonder that 16 posters featured capsaicin treatment at the last two annual
American Urological Association meetings Intravesical capsaicin however has its
own side effects cf Cruz 1998 prompting clinicians and pharmacologists to
search for better vanilloid drugs First as mentioned above capsaicin induces
intense suprapubic pain during intravesical instillation that may be made
tolerable by lidocaine in some but not all patients Second capsaicin frequently
causes a transient worsening of the urinary conditions before improvement of
symptoms due to desensitization of bladder afferents becomes evident Fowler et
al 1994 Das et al 1996 Cruz et al 1997b De Ridder et al 1997 And third in
patients with high spinal cord lesions capsaicin might provoke lifethreatening
autonomic dysreflexia Geirsson et al 1995
Porreca and colleagues Craft et al 1993 Craft and Porreca 1994abfound RTX
to be approximately 1000 times more potent than capsaicin for desensitizing
urinary bladder afferents in the rat RTX treatment depletes SP from sensory
nerves supplying the rat urinary bladder Fig20 Avelino et al 1998b and
down regulates specific RTX binding sites Fig 20 Goso et al 1993b These
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RTX induced changes are long lasting in the bladder but completely reversible
Fig 20 Inspired by these findings in 1997 two groups working independently
initiated the intravesical use of RTX in humans Turini and colleagues Lazzeri et
al 1997 compared the action of RTX 30 ml of 10 nM RTX for 30 min in controls
eight individuals and detrusor hyperreflexia six cases patients Intravesical RTX
in subjects with a normal filling cystometrogram did not produce significant
functional changes RTX however did increase the mean bladder capacity in
patients with hyperactive bladder from 175 to 280 ml This improvement
persisted up to 4 weeks Even more important none of the subjects involved in
this study reported any discomfort after RTX treatment Cruz and coworkers Cruz
et al 1997a chose to pursue a more aggressive treatment protocol 100 ml of 50
to 100 nM RTX solutions for 30 min Again discomfort evoked by RTX was
minimal Fig23upper panel and the improvement was even longer lasting up to
3 months following a single treatment Fig 23 lower panel Based on these
reports a recent editorial in The journal of Urology Chancellor 1997 concluded
that Perhaps we should go directly to RTX as the preferred intravesical drug to
inhibit the sensory cfiber RTX appears to have efficacy similar to capsaicin but
with much less acute side effects Clearly intravesical RTX results in a lasting
improvement in the life of patients with urge urinary incontinence Fig 23 lower
panel Cruz et al 1998 Patients who previously had to rely on adult diapers
became dry continent again following a single intravesical treatment with RTX




pane ispain experienced by ti nts
following intravesical RTX
treatment Of the 14 patients 9
received intravesical capsaicin
previously They were asked to
tratethe pain evoked by RTX on
a subjective scale of 0 to 10
where 10 represents the
View larger version intensity of pain response to
In this page Ina new window intravesical capsaicin All the
patients reported no pain at all
or minimal discomfort only in
response to 50 nM RTX Lower panel Average of incontinent episodes
in 8 patients who have received a single intravesical RTX treatment
note the remarkable and long lasting improvement in the condition of
the patients Figure is a courtesy of Dr Francisco Cruz University of
Porto Porto Portugal
XIII Vanilloids Carcinogens Anticarcinogens or Neither
1
A Capsaicin
Given the broad human exposure to capsaicin both dietary and medicinal
reports that capsaicin may be mutagenic may promote tumor formation or may
act as a complete carcinogen deserve serious and critical consideration Before
going into details it is important to emphasize that there is a concensus in the
literature that it is not capsaicin itself but its liver metabolites that may be
hazardous cfSurh and Lee 1995 1996 Consequently topical capsaicin
solutions and creams are most likely safe to use Fowler and colleagues
Dasgupta et al 1998b followed 20 patients for 5 years who had received an
average of six intravesical treatments with capsaicin None of the bladder
biopsies showed any premalignant metaplasia or dysplasia or malignant in situ
papillary or invasive cancer changes
1 Mutagenesis byCapsaicin
There are several reports both for Toth et al 1984 Nagabhushan and Bhide
1985 1986 Lawson and Gannett 1989 Azizan and Blevins 1995 and against
Buchanan et al 1981 Gannett et al 1988 Kim et al 1991 Vinitketkumnuen et
al 1991 capsaicin induced mutagenesis inSalmonellatyphimurium Based on
these conflicting findings three major conclusions may be drawn 1 capsaicin is
not mutagenic unless metabolized by activated liver microsomes S9 fractions 2
capsaicin metabolites are weak mutagens maximal mutagenicity is 3 fold higher
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than the background value and 3 to detect mutagenicity extremely high
capsaicin concentrations are needed up to 7 mM which are most unlikely to
occur in the liver of human beings
As is the case with bacteria capsaicin does not cause mutations in mammalian
cells V79 cell line in culture unless metabolized by 59 hepatic microsomes
Nagabhushan and Bhide 1985 Lawson and Gannett 1989 At a concentration of
200 uM capsaicin only 14 mutants per one million survivors can be observed
Lawson and Gannett 1989 By comparison an approximately 50 fold lower
concentration of benzopyrene induces at least 60 times more mutations
Nagabhushan and Bhide 1985
When injected ip capsaicin inhibits DNA synthesis in the mouse testis
Nagabhushan and Bhide 1985 This action however was detected using 75
mg kg capsaicin which is the approximate LD50 value of capsaicin given ip to
the mouse Glinsukon et al 1980 Thus the relevance of this study is highly
questionable
2 Carcinogenesis by CapsaicinAnimal Experiments
Since the initial report by Hoch Ligeti 1951 that chili pepper consumption may
induce liver carcinoma formation in the rat a number of studies have investigated
the possibility that capsaicin may be carcinogenic or at least cocarcinogenic in
animal experiments To mimic natural exposure and to save cost most studies
employed chili pepper powders instead of pure capsaicin in the diet of animals
Hoch Ligeti 1951 Kim et al 1985 Agrawal et al 1986 Most of these studies
reported a promoter effect by chili pepper on gastrointestinal tumor formation
However even if one ignores the relevancy of a diet containing 10ww chili
pepper powder Kawada et al 1984 the question arises whether the observed
carcinogenic effect was in fact due to capsaicin or rather some other constituent
in the chili pepper powder
Inclusion of pure capsaicin into mouse chow was also reported to increase the
incidence of gastrointestinal tumors Toth et al 1984 Moreover a capsaicin
containing diet promoted the formation of di ethylnitrosamine induced
hepatomas in the rat fang and Kim 1988 Again the interpretation of these
findings is complicated by the extremely high capsaicin doses used For example
in a frequently cited study Toth et al 1984 mice were fed as much as 150
mg kg capsaicin per diem which exceeds the usual human capsaicin
consumption 0510mg kg in tropical countries and probably much less than in
the United States or Europe by a factor of 100 Of special importance are the
findings that repeated application of capsaicin on shaved mouse skin neither
leads to carcinoma formation nor enhances papilloma formation following
initiation of the skin by the complete carcinogen 712 dimethylbenzanthracene
Park and Surh 1997 Quite the contrary capsaicin seems to inhibit papilloma
formation when given before each topical phorbol ester a typical tumor
promoter application to the initiated skin Park and Surh 1997
In the liver three major metabolic pathways are believed to generate hazardous
potentially mutagenic and or carcinogenic capsaicin metabolites cf Surh and
Lee 1995 1996 First epoxidation of the vanillyl moiety by hepatic cytochrome
P 450 particularly CYP2El can produce an arene oxide Second demethylation
and subsequent oxidation of the vanillyl group can yield semiquinone
derivatives And third oxidation of the phenolic OH group on the vanillyl moiety
can form a reactive phenoxy radical However liver cells possess very effective
self protective mechanisms such as reduced glutathione as well as conjugation
reactions thus unless capsaicin is given in high abusive doses or these
self protective mechanisms are malfunctioning mutagenic capsaicin metabolites
are very unlikely to escape the hepatic detoxification process
3May Culinary Hot Pepper Consumption Be a Risk Factor forStomach Cancer inHumans
The laboratory studies indicating that chili peppers may induce tumor formation
in the gastrointestinal tract of rodents Toth et al 1984 Kim et al 1985 Agrawal
et al 1986 have prompted to date three epidemiological studies Notani and
jayant 1987 Buiatti et al 1989 Lopez Carillo et al 1994 to compare the
incidence of stomach cancer between hot pepper consumers and nonconsumers
Whereas studies carried out in Mexico Lopez Carillo et al 1994 and India
Notani and jayant 1987 found a significant correlation between chili pepper
consumption and risk of having gastric cancer the Italian study Buiatti et al
1989 reached the opposite conclusion eating hot pepper on a regular basis
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protected against carcinoma of the stomach Further studies are needed to
confirm or rule out the hazards of hot pepper consumption
4CapsaicinA Potential Antitumor Agent
The potential carcinogenic activity of capsaicin has been a focus of attention
however the reports that capsaicin might be anticarcinogenic Miller et al 1993
Teel 1993 Zhang et al 1993 1997 have received less publicity Various
chemical carcinogens must undergo metabolic activation Important examples
include tobaccospecific nitrosamines benzopyrene and aflatoxin These
carcinogens and capsaicin are processed at least in part via the same metabolic
pathways in the liver cf Surh and Lee 1995 1996 Consequently capsaicin may
be chemoprotective by retarding the metabolic activation of carcinogens A recent
interesting observation is that capsaicin can inhibit the growth of a number of
transformed cell lines Morre et al 1995 For example HL60 human
promyelocytic leukemia cells are unable to divide in the presence of 100 pM
capsaicin however these cells become resistant to the growth inhibitory action
of capsaicin after they have been induced to differentiate with dimethyl sulfoxide
It is believed that the transformed cells express an unusual NADH oxidase
isoform that is absent in the normal cells Morre et al 1995 This putative
enzyme is the suggested target for capsaicin
BRTX
Although human contact with Euphorbium the dried latex of E resinifera from
which RTX is isolated has occurred over 2000 years cf Appendino and Szallasi
1997 some concern still surrounds the medicinal use of RTX This concern stems
from the structural similarity between RTX and tumor promoting phorbol esters
cf Blumberg et al 1993 Phorbol esters enhance papilloma formation in mouse
skin pretreated initiated with a subeffective dose of a complete carcinogen cf
Hecker 1968 A receptor for phorbol esters was identified as the enzyme PKC cf
Blumberg 1988 The structure activity relations for phorbol ester binding to PKC
have been explored in depth PKC binding requires the presence of a free OH
group at the C20 position Hecker 1978 However RTX is esterified with a
homovanillic acid substituent at this position Hergenhahn et al 1975 Therefore
it is hardly surprising that RTX shows only marginal affinity toward PKC For
example RTX inhibits the specific binding of 123dibutyrate to PKC
in rat DRG membranes with a K value of 10 pM Szallasi and Blumberg 1990b
Furthermore binds to partially purified PKC with an affinity of 404 nM
Szallasi et al 1989b Evans and coworkers Dimitrijevic et al 1995 determined
the affinity of RTX for seven recombinant PKC isotypes and reported values of 9
NM and 45 pM for isotypes p1 and 02 respectively The other PKC isoforms did not
bind RTX In 1995 the isolation of a RTX stimulated Cat inhibited but
phosphatidylserinedependent kinase from human neutrophils and murine
macrophages was reported Sharma et al 1995 this socalled Rx kinase
bound RTX with an affinity of 4 pM These affinities should be compared with the
affinity of RTX for VRs which is approximately 20 pM in rat Szallasi et al 1992
1993abAcs et al 1994a and 500 pM in human spinal cord Acs et al 1994b
respectively At concentrations at which it saturates VRs RTX is unlikely to
activate PKC In keeping with this RTX is inactive in the cellular assays used to
detect phorbol esterlike activity Driedger and Blumberg 1980
In theory RTX applied to the skin and bladder or nasal mucosa might be
deesterified at C20 position to yield its parent diterpene resiniferonol9134
orthophenyl acetate ROPA ROPA is approximately 10fold more potent than RTX
for PKC binding Szallasi et al 1989b Also ROPA is a weak tumor promoter
Hergenhahn et al 1982 Direct experimentation shows however that RTX does
not induce hyperplasia in mice Szallasi and Blumberg 1989b nor does it
promote the formation of tumors in initiated that is pretreated with a
subthreshold dose of carcinogen mouse skin Zur Hausen et al 1979
XIVConcluding Remarks Emerging Principles and Future
Perspectives
Over the past 6 years vanilloid research has experienced an unprecedented rate
of advances The simple model of a single receptor recognizing a chemically
well defined pharmacophore can no longer be maintained anymore In 1997 a
VR termed VRI was cloned This VRI is a distinct relative of the TRP family of
store operated calcium channels Sequences ESTs similar to VR1 are also found
in nonneuronal tissues This is entirely in accord with the demonstration of
VRmediated calcium uptake by mast cells and glia Taken together these
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findings imply that capsaicin is much less specific for primary sensory neurons
than was thought before and thus nonspecific capsaicin actions need to be
carefully reevaluated VRl is activated not only by vanilloids but also noxious heat
and acids thus it can now be viewed as a molecular integrator of chemical and
physical stimuli that elicit pain The emerging concept is that it is heat that gates
VR1 whereas capsaicin and low pH only serve to reduce the heat activation
threshold of the receptor An important implication of this model is that even
innocuous for example room temperatures are able to stimulate VRl in the
presence of mildly acidic conditions
In contrast to early reports capsaicin activates not a single conductance but
multiple inward currents that differ in kinetics affinity for agonists and
sensitivity for antagonists These both kinetically and pharmacologically distinct
currents seem to represent VR1 isoforms and or related receptor subtypes and
thus imply heterogeneity of VRs
VR1 homologs however may not necessarily mediate heat acid and or
vanilloidsensitivity The recognition domains for these types of activation are not
well understood and they may not be at all conserved If there is an extended VR
gene family it may be associated with a very diverse biology The presence of VRs
in several of brain nuclei as well as in nonneuronal tissues lends support to this
prediction
Inflammatory mediators like bradykinin and prostanoids have been shown to
activate VRs in sensory neurons in an indirect fashion The intracellular
mediators of this actions isare unknown The competitive VR antagonist
capsazepine prevents the activation of VRs by inflammatory mediators which
implies the involvement of an endogenous vanilloid Moreover capsazepine is
also effective in animal models of chronic pain and inflammation Thus VRs
appear to have a complex regulation in which exogenous vanilloid drugs
endogenous VR activators low pH and heat may facilitate each others effects
Another breakthrough discovery in the field was the demonstration that
compounds structurally unrelated to typical vanilloids namely sesquiterpene
unsaturated dialdehydes and other bioactive terpenoids as well as triprenyl
phenols may activate sensory neurons via stimulation of VRs These novel
vanilloids represent new chemical leads for drug development Also their very
existence implies that the term VRs is somewhat of a misnomer The
identification of endogenous vanilloids will give these receptors a rational
name
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Mr and Mrs Miklos Jancs6 1949Desensitization of sensory nerve endings in
Hungarian Kiserletes Orvostudomany Experimental Medicine2Suppl15
There are compounds that can selectively desensitize sensory nerve endings to
noxious chemical stimuli without causing local anesthesia In the state of
desensitization reflex responses egcorneal reflex mediated by sensory
nerves may be evoked by physical stimuli However the same sensory nerves are
unresponsive to noxious chemical stimuli
Capsaicin is the paradigm of such desensitizing agents Capsaicin effects last for
days and protect against various chemicals Repeated instillation of capsaicin into
the eye of rats or guinea pigs results in gradually increasing desensitization
which finally becomes complete Following capsaicin treatment eyes do not
respond to other pungent or tear inducing agents either the sensitivity of eyes
to such agents may diminish by a thousand fold Repeated capsaicin treatments
lead to desensitization of skin and airways as well
Nicotine is nonpungent in the guinea pig eye pretreated with nicotine lobeline
coniine or sparteine This desensitization by nicotine is however short in
duration 20 min to 2 h and specific to the stimulus it does not protect against
capsaicin Our experiments show that the nicotine family of toxins act on sensory
nerves and parasympathetic neurons in a similar fashion The fact that atropine
desensitizes to nicotine highlights the importance of the piperine structure
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Most recently the cloning of two vanilloid receptor homologs has been reported
One homolog was cloned from rat brain and termed VRLI for vanilloid
receptor like protein 1 Catering et al 1999 This terminology is however
confusing as VRLI does not respond to vanilloids The other homolog is present
in rat kidney where it is believed to sense stretch Suzuki et al 1999 This
receptor is called stretch inhibitable nonselective cation channel or briefly SIC
SIC is not sensitive to vanilloids either
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Abbreviations
ASIC acid sensitive ion channel
CGRP calcitonin gene related peptide
CNS central nervous system
DRASIC dorsal root ganglionspecific acid sensitive ion channel
DRG dorsal root ganglion
GDNF gliaderived neurotrophic factor
NGF nerve growth factor
NK1 neurokinin 1
NK1 R neurokinin 1 receptor
NKA neurokinin A
NMDA NmethylD aspartate
NOS nitric oxide synthase
PKC protein kinase C
PDDHV phorbol 123 didecanoate 20homovaniI late
PPAHV phorbol 12phenylacetate 13acetate 20homovanillate
RTX resiniferatoxin
SP Substance P
TRP transient release potential
TTX tetrodotoxin
VR vanilloid receptor
VR1 vanilloid receptor type 1
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TCJCSJUVENILE JUSTICE INITIATIVE
Executive Summary
On August 1 2007 and again on November 7 2007
the Texas Youth Commission TYC sought to increase
the number of situations in which juvenile correctional
officers could use pepper spray on confined youth The
agencysgoal was to reduce restraint related injuries to
staff and youth
The Texas Criminal Justice Coalition TCJC in our
efforts to advocate for effective juvenile justice
solutions wanted to better understand the physical and
psychological effectsof pepper spray use on youth held in
state custody aswell asthe ramifications of its expanded
use Although pepper spray is widely accepted by the
law enforcement and adult correctional communities as
an important tool in aiding in subject control we find
that it poses significant risks to both youth and staff
which makes it inappropriate as a permanent first
response policy to youth non compliance
Below are some key findings from our research
Not one single study examined recommended
pepper spray as safe for use on children
The pepper spray formulas used by TYC staff are
typicallyused bylaw enforcement The manufacturer
does not specifically claim that the products have
been formulated or safety tested for use against
children in a detention setting
The confined environment of a juvenile correctional
facility allows for increased risks of harm to both
youth and staff as pepper spray may produce
significant toxic effects in enclosed spaces
Pepper spray has been found to increase youths
violent behavior toward others posttraumatic
stress disorder and suicidal behavior
If juvenile corrections personnel are not proficient in
primary control and deescalation techniques they
may increasingly rely on pepper spray as an option
of force
Pepper spray is regulated as a weapon as such it
avoids the more rigorous testing required of drugs
and depends largely on reports of its use in the field
to support claims of safety and effectiveness
At least one federal court has determined that the
harm resulting from pepper spray use is so severe
that it satisfied the definition of a dangerous
weapon
Although most effects of pepper spray are reported
to last for less than a few hours one investigation
into the health risks of pepper spray exposure found
adverse effects severe enough to require medical
attention including eye burns and abrasions
asthma attacks acute high blood pressure chest
pains and loss of consciousness
Preliminary research on the longterm risks
associated with pepper spray points to the following
potential harmful effects a degeneration of nerve
terminals which results in desensitization to pain
and thermal regulation lasting nerve damage in
corneal tissue acute pulmonary inflammation and
respiratory cell injury a mutagenic effect on organs
changes in the body leading to various types of
cancer including gastric esophageal and skin
cancers and tumors
Youth at increased risk from pepper spray exposure
include those with impaired eye conditions skin
conditions such as allergic dermatitis asthma
or respiratory complications underlying cardiac or
pulmonary diseases and those taking prescribed
antipsychotic drugs
Dangers and deaths associated with pepper spray
may be underestimated as a result of medical
examiners failure to adequately consider pepper
spray role in the factors causing death
Given the many flaws and limitations pervasive in
effectiveness studies it is difficult to conclude with
any certainty whether pepper spray is effective in
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achieving control of subjects and increasing safety take the following three critical actions
Due to the lack of wellconstructed data driven
research policy makers seeking guidance on safe
and effective ways to utilize pepper spray receive
limited and biased information
The State of Texas has a moral and statutory obligation to
provide a safe humane and rehabilitative environment
for children in its custody The potential for abusive
use of pepper spray especially in facilities already
sufferingfrom shortages in staff and inadequate training
suggest that the expanded use of pepper spray may
actually decrease safety in TYC facilities and is likely to
pose additional problems for the agency
Convene a collaborative working group including
representatives with critical perspectives from the
juvenile justice health care advocacy and legisla
tive arenas that will consider whether the use of
pepper spray is the best course of action to reduce
violence in TYC facilities as well as provide input on
any policies or procedures regarding limitations on
pepper spray use training decontamination and
other accountability measures
Require that an external review panel be established
for all situations involving pepper spray against
youth
Ultimately the real solutions to TYCsproblems are not
found in a 3ounce can of pepper spray but rather in the
wellfunctioning policies programs and practices of the
agency We recommend that TYC focus on the following
to create an effective juvenile corrections system that
will successfully rehabilitate the youth in its care
The agency should continue implementing the 80th
Legislaturesmandates outlined in SB 103 and
heed the recommendations of its own Blue Ribbon
Task Force in addressing the pervasive underlying
issues driving the increased levels of violence in
TYC facilities
It should develop effective behavioral and mental
health treatment including intensive evidence
based programs aimed at reducing aggression and
defiance without resorting to use of force
It should conduct an independent and comprehen
sive evaluation of the use of force in its facilities to
identify and best address the root problems of en
demic violence in the facilities
It should provide staff with the tools to deescalate
crisis situations without resorting to use of force
Conduct regular audits on the use of pepper spray in
TYC facilities to alert administrators of any problems
before they become liabilities
Should TYC decide to continue its push to expand
pepper spray use TCJC recommends that the agency
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Introduction
As the recent scandals of sexual abuse in Texas Youth
Commission TYC facilities became fodder for national
headlines the 80 Texas Legislature took it upon itself
to ensure the protection and rehabilitation of children
in State custody Lawmakers unanimously passed SB
103 omnibus reform legislation aimed at increasing
the system accountability and structural integrity Act
ing TYC administration drawn primarily from the adult
prison system has been tasked with the implementa
tion of the ambitious reform initiatives begun this spring
and the daunting goal of turning Texas sinkingjuvenile
corrections ship around
On July 25 2007 in a memo to TYC leaders TYC Om
budsman Will Harrell expressed concerns over the new
administration consideration of pepper spray escala
tion as a means to control children in TYC facilities In
the memo Harrell warned that the implications of an ex
panded pepper spray policywarranted broad input from
TYC staff medical and juvenile justice experts and leg
islative and community representatives to consider the
legal and practical ramifications of such a policy
On August 2 2007 Acting Executive Director of TYC
Dimitria D Pope issued a directive requiring the ex
panded use of oleoresin capsicum OC or pepper
spray in the use of force continuum to preempt physi
cal restraint The stated goal of the directive was a
reduction in injuries to staff and children which were
largely the result of the application of physical restraint
techniques5 The directive reaffirms TYCsoverall phi
losophy that force should only be used as a last resort
but suggests that in order to avoid further injuries it
is necessary to change the way in which staff applies
force6 The prior TYC administrationsproblematic his
tory and the closed nature of the new administrations
decision making process in implementing this pepper
spray directive triggered skepticism and concern from
juvenile justice advocates who feared the new directive
was an inappropriate strategy modeled after practices
used in the adult corrections system
forfailingto abide bythe rules of the state Administrative
Procedures Act in issuingthe pepper spray directive By
September 28 2007 the State had quickly settled the
lawsuit and agreed that it had overstepped its bounds
by increasing the use of pepper spray on TYC youth via
administrative directive rather than the formal policy
making process which provides for public input On
November 7 2007 TYC officially proposed a new use of
force policy by posting it to the Texas Register a weekly
periodical that provides information to the public about
proposed administrative rule changes However by
November 192007 TYC found itself in court again with
Texas Appleseed and Advocacy Inc alleging that the
agency was failing to abide by the settlement agreement
and inappropriately using pepper spray on youth who
did not pose any threat of imminent danger
In the context of the ongoing reform effort some
experts in the field suggest that this recent directive
to use pepper spray as an alternative to handson
restraint does not adequately address the underlying
problems at TYC as outlined by the Legislature and in
fact may actually function to undermine the agencys
statutorily mandated goal of rehabilitation Patricia
Arthur of the National Center for Youth Law warns that
an expanded pepper spray policy would only compound
the problems However officials at TYC argue that
using pepper spray as a restraint alternative will reduce
related injuries and ultimately improve conditions for
children and staff at TYC facilities In this report the
Texas Criminal Justice Coalition TCJC takes a look at
the research to see if increased dependence on pepper
spray really is the best solution to address the safety
issues at TYC
On September 12 2007 two Austinbased advocacy
groups Texas Appleseed and Advocacy Inc sued TYC
1
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Pepper Spray
General Background on Pepper Spray
Pepper spray formulas include concentrated oils
extracted from hot peppers which are referred to as
oleoresin capsicum or OC The bioactive chemicals
contained in oleoresin capsicum are known as
capsaicinoids The capsaicinoid content is the most
important factor in determining product efficacy and
safety The most prominent and best understood of the
capsaicinoids is called capsaicin
Products Authorized by TYC
The primary sprays authorized for carryon use by TYC
staff include First Defense MK3 and MK4 Stream
Aerosol Projectors and the MK9 Vertical Aerosol
Projector both manufactured by Defense Technology
The First Defense formulas selected by TYC are a
standard 10 percent oleoresin capsicum solution
typically used by law enforcement According to
manufacturer specifications the First Defense formula
has a capsaicinoid concentration of 020 percent and
includes carrier ingredients of distilled water ethanol
and propylene glycol These products are designated
for use by law enforcement and corrections personnel
and are tested for quality control however the
manufacturer does not specifically claim that any of
these products have been formulated or safety tested
for use by juvenile corrections staff against children in
a detention setting
Summary of Research on Effectiveness
The bulk of research discussing pepper spray is in the
context of its use by law enforcement Pepper spray
gained popularity among law enforcement in the mid
1990sfollowing an FBI study which reported favorably
on its use however that report has since become
suspect following the conviction of its author for
accepting 57000 in kickbacks from the pepper spray
manufacturer15 Subsequent reports often focus on
the effectiveness of pepper spray as a lessthan lethal
option intended to reduce officer and suspect injuries
claims of excessive force and civil liability arising from
lasting or overt visible signs of injury 1116 Pepper spray
does not require safety testing and regulation as a drug
despite its pharmacological effects on the human body
instead it is regulated as a weapon subvertingthe more
rigorous testing required of drugs and depending largely
on its use in the field to support claims of safety and
effectiveness In reviewing literature on the subject
claims of pepper spray effectiveness and safety often
appear to reach broad conclusions based on limited or
subjective information no studies exist that definitively
demonstrate a reliable effectiveness measure nor
the safety of pepper spray For a detailed discussion
of studies done on pepper spray effectiveness see
Appendix A
Immediate Effects
The capsaicin contained in pepper spray induces the
immediate release of substance P a neurotransmitter
which assists in cell communication between primary
sensory neurons and other cells The flood ofsubstance
P stimulates other cell activities which results in an
almost instant onset of physical responses 18 Effects
of pepper spray exposure to the eyes include tearing
redness and swelling of mucous membranes stinging
pain and involuntary closure of the eyelid One study
noted reduced visual acuity lasting at least one week
Corneal damage may also occur through the use of high
velocity sprays at close distances The immediate
effects of pepper spray on skin include intense burning
pain swelling reddening and occasional blistering
Respiratory effects include nasal irritation and a
tightening of airways severe coughing and sneezing
and shortness of breath 22 Additionally laryngospasm
or closing of the vocal cords may result in a blocked
airway for up to 45 seconds Researchers also note
a marked increase in heart rate and blood pressure
even in controlled settings More systemic effects
of pepper spray exposure may include disorientation
panic and loss of motor control Although most
symptoms are reported to last for less than a few
hours one investigation into the health risks of pepper
spray exposure to officers found adverse effects severe
enough to require medical attention including eye
burns and abrasions asthma attacks acute high blood
pressure chest pains and loss of consciousness 26 The
effects of pepper spray may easily become exacerbated
and cause greater injury when subjects do not receive
2
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Potential LongTermEffects
Often reports describe only the visible effects of
exposure noting that they are relatively short lived
and thus claim that pepper spray is a safe option when
compared to potentially lethal force However in a
thorough study of the toxicology of oleoresin capsicum
and capsaicin researchers Olajos and Salem of the
US Army Edgewood Chemical and Biological Center
noted additional and potentially longterm risks from
capsaicin exposure Capsaicin has been the subject of
research for its effects on nerve tissue and is known to
facilitate the degeneration of nerve terminals a problem
which results in desensitization to pain and thermal
regulation Decreasingthe bodysabilityto sense pain
and temperature changes may affect the longterm
health and safetyof individuals exposed to pepperspray
Similarly researchers note that repeated pepper spray
exposure may cause lasting nerve damage in corneal
tissue thus reducing sensitivity Studies also note a
marked decrease in physical responses to subsequent
exposures 30 meaning that as the use of pepper spray
increases it will likely become less effective against
those previously exposed
The toxicity study by Olajos and Salem cites several
experiments which indicate capsaicin and capsaicinoids
as having a mutagenic effect on organs they warn the
prudent approach from the health hazard perspective
is that these compounds should be regarded as having
genotoxic potential
31 The researchers further cite
studies in which capsaicin was reported to induce or
facilitate changes in the body leading to various types of
cancer including gastric esophageal and skin cancers
and conclude that enough evidence exists to suggest
that capsaicin may cause tumors32 A recent study by
Reilly and colleagues demonstrated that capsaicinoids
produced acute pulmonary inflammation and respiratory
cell injury in experimental animals and in human lung
epithelial cells This information suggests that the
full health ramifications of the capsaicinoids in pepper
spray have not yet been fully identified
Determining Safety
Discussions about the overall safety of pepper spray
TCJCSJUVENILE JUSTICE INITIATIVE
indicate a dearth of empiricallybased research and
differing expectations for determining its safety
Arguments suggesting that pepper spray is safe point to
the widespread use of pepper spray by law enforcement
the temporary nature of many of the effects and the lack
of definitive evidence showing that pepper spray is not
safe Arguments disputing pepper spray overall safety
cite numerous reported injuries and deaths related
to pepper spray exposure clinical studies indicating
potential adverse effects and the need for additional
research prior to its expanded use Due to the lack of
wellconstructed data driven research policy makers
seeking guidance on safe and effective ways to utilize
pepper spray receive limited and biased information
Since pepper spray is not regulated and tested for safety
under pharmacological standards researchers policy
makers and the public only learn of its health risks
after the discovery of accumulated injuries or deaths
Researchers for the National Institute of Justice NIJ
noted the widespread acceptance of pepper spray by
law enforcement agencies based on the premise that
it was a safe and effective method of incapacitating
violent or threatening subjects but they warned
tjhere is however a lack of objective data on OC its
risks and its benefits 1135 Over a decade later reports
discussing the safety of pepper spray continue to rely
heavily on anecdotal or disputable evidence and vary
widely in their conclusions about safety
In a recent report commissioned by the New Zealand
Ministry of Health researcher Broadstock conducted a
detailed analysis of seven relevant studies to determine
the safety of pepper spray In each study Broadstock
noted significant limitations including small sample
sizes no data on possible confounders subjective
information from officers missing information and
potential for bias lack of control groups and no long
term study analyzing effects of pepper spray beyond a
few hours Nevertheless Broadstock noted that the
adverse health effects described in several studies
appear reasonably likely to have resulted from pepper
spray and suggested that a careful approach would
be to oppose the deployment or usage of pepper spray
until more thorough independent research evaluates
the health risks 37
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PEPPER SPRAY IN THE TEXAS YOUTH COMMISSION
Certain Populations at Risk of Adverse Reactions
Although the immediate effects of pepper spray may
dissipate relatively quickly medical experts note some
populations are at increased risk of harm including
death resulting from pepper spray exposure Those
with impaired eye conditions are at increased risk of
corneal abrasions Similarly exposure to pepper spray
worsens skin conditions such as allergic dermatitis and
increases allergic sensitization
More significantly however several studies implicate
pepper spray exposure as a related or contributing
factor in numerous deaths often involving individuals
with asthma or respiratory complicationS39 Specifically
individuals with asthma and other respiratory
compromising conditions are particularly vulnerable
to the bronchial constriction effects of pepper spray
Capsaicin exposure may result in a 40 percent
decrease in airflow a significant risk for those already
predisposed to asthmatic attacks or suffering from
diminished breathing capability At least one well
documented death has occurred where the individual
died as a direct result of severe bronchial constriction
precipitated by pepper spray exposure 41 Positional
restraint which increases strain on respiration has
also been associated with deaths where individuals
were sprayed with pepper spray
Individuals with underlying cardiac or pulmonary
diseases are equally vulnerable to the effects of pepper
spray One researcher in examining the effects of
restraint in unexpected deaths noted an increased
risk for those exhibiting signs of excited delirium
a term used to describe acute psychiatric agitation
and warned that individuals with heart disease are
particularly vulnerable when exposed to pepper spray
Researchers Olajos and Salem report that the chemical
properties of capsaicin induce cardiorespiratory
dysfunction as characterized by changes in blood
pressure44 and additionally note that the pain and
anxiety resulting from pepper spray exposure may also
elicit cardiovascular changes that may have significant
implications for individuals with preexisting disease 1145
Individuals taking prescribed antipsychotic drugs or
using cocaine also may be more susceptible to the
dangerous effects of pepper spray Some prescription
and non prescription drugs affect the bodysautonomic
system which includes blood flow heart rate and
airflow Pepper spray may have the effect of altering or
disrupting the autonomic functions of the body which
may result in death when used against individuals
already under the influence of drugs As one researcher
noted about unexpected in custody deaths attributed to
other drugs It may be that pepperspray sic was the
precipitating agent in combination with other drugs
and underlying disease that caused a lethal event
Thus there may be increased risk of death when pepper
spray is used against individuals under the influence of
psychotropic drugs prescription or otherwise
Finally some researchers suspect that dangers
and deaths associated with pepper spray may be
underestimated because medical examiners may not
adequately consider pepper spray as linked to other
factors causing death One researcher reexamining
21 reported deaths in police custody noted that these
types of high profile cases often pose a dilemma
for medical examiners the autopsy findings are
frequently non specific detailed witness descriptions of
the circumstances of the terminal event are often not
initially obtained and accurate accounts are difficult to
collect later because of potential litigation Similarly
Broadstock criticized previous safety studies notingthat
the autopsy reports used are notoriously non specific
with little pathological evidence making conclusions
open to interpretation and bias
Risk to Staff
In an effort to demonstrate the effectiveness and
safety of pepper spray some agencies have required
staff to submit to being sprayed with pepper spray
during training suggesting that the exposure will help
staff better understand the effects with the goal of
increasing compassion for victims and preparedness
in the event of their own exposure Due to growing
concerns over potential health risks to police officers
researchers recommend the discontinuation of such
practices 50 Such policy readjustments suggest that
some administrators recognize that not enough is
4
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known about the hazards of pepper spray exposure to
warrant its routine use in training thus lendingsupport
to the theory that pepper spray indeed poses health
risks to those who are exposed
Impact on Children
Children may face the same if not greater risks of
harm as adults exposed to pepper spray and no
studies or reports suggest that pepper spray is safe for
use on children Many juvenile justice medical and
mental health experts note that there are differences
in childrens psychological and physical development
which contra indicate the use of pepper spray as an
appropriate method of control The airway of a small
child is more fragile than an adults and children have
not yet fully developed the muscles which normally aid
in breathing Children with asthma are at especially
significant risk for severe respiratory compromise
during restraint a situation which is only exacerbated
by exposure to irritants such as pepper spray
schizophrenia and other psychotic disorders 56 Pepper
spray is often cited as ineffective against individuals
with mental illness and likely has an exacerbating effect
on increasing childrens anger and trauma Mental
Health America MHA formerly known as the National
Mental Health Association cites sanctions like pepper
spray as detrimental to young people with emotional
and behavioral disorders or those with histories of
maltreatment1157 MHA further states in its policy
position that incarcerated youth have tjhe right to be
free from corporal punishment chemical restraints and
sexual abuse or coercion1151
Several studies cite the serious adverse effects of an
accidental pepper spray on a four weekold healthy
infant The infant experienced a multitude of adverse
symptoms including respiratory failure which required
oxygen therapy and mechanical ventilation altogether
the infant remained hospitalized for 13 days In the
following 12month period the child experienced several
episodes of viral respiratory infections 54 indicating the
effects of pepper spray may be more severe and longer
lasting on children than on adults
Impact on Children with Disabilities
Many children entering juvenile justice facilities suffer
from emotional and mental health disorders which
may go undiagnosed and untreated resulting in
symptomatic behavioral problems In fact children
with mental disorders in juvenile justice facilities may
comprise up to 5075 percent of the population and
many have more than one cooccurring mental health
or substance abuse problem Specifically children
who enter the juvenile system often suffer from anxiety
and mood disorders including Post Traumatic Stress
Disorder PTSD disruptive behavior disorders including
Attention Deficit Hyperactivity Disorder ADHD or
5
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PEPPER SPRAY IN THE TEXAS YOUTH COMMISSION
Use in the Juvenile Justice System
Children in a juvenile correctional setting present
special circumstances that for many reasons warrant
greater consideration and caution in the use of pepper
spray First the confined environment of a juvenile cor
rectional facility allows for increased risks of harm to
both youth and staff as pepper spraymay produce sig
nificant toxic effects in enclosed spaces Secondly
under current legal standards juveniles held in state
custody are entitled to a reasonable expectation of safe
ty medical and mental health care and rehabilitative
treatment The State is under special legal and moral
obligation to address the needs of children in its custody
in ways which nurture their development and prepare
them for reintegration into their communities Dana
Schoenberg and Mark Soler of the Center for Children
Law and Policy note that youth in correctional settings
also have a right to protection from unnecessary and
wanton infliction of pain the unwarranted or excessive
use of restraints and excessive uses of force1161 Final
ly as juvenile justice expert Barry Krisberg President of
the National Council on Crime and Delinquency warns
pepper spray use in secure juvenile facilities usually
creates more problems than it solves as taff come
to rely on chemical agents in lieu of communicating with
youngsters to defuse confrontational situations 1161 Sev
eral national juvenile justice organizations have recom
mended the prohibition of chemical restraints against
children in juvenile facilities either completely or lim
ited to extreme circumstances and only under stringent
controls Many juvenile facilities have chosen not to
use pepper spray against youth in detention facilities 64
either in response to settlement agreements or based
on a set of core values promoting the wellbeing of the
children in their custody
Legal Standards
The federal courts have weighed in on this issue as well
In 1974 a Texas federal district court concluded in the
landmark case ofMorales v Turman that theStatesuse
of chemical agents in situations not posingan imminent
threat to human life or an imminent and substantial
threat to property violated the Eighth Amendment
More recently in Alexander S v Boyd 1995 a federal
district court in South Carolina found that conditions
in the state juvenile corrections facilities violated the
youths substantive due process rights to reasonably
safe conditions of confinement citing staff regular
use of a chemical agent against youth among other
serious problems Some legal experts contend that
expanded use of pepper spray by TYC would violate
the Morales v Turman settlement agreement which
explicitly prohibits the use of chemical agents except
when necessary to control a riot More recently US
Department of Justice DOJ investigations into juvenile
facilities have found inappropriate use of pepper spray
by staff against youth for minor infractions in response
to symptoms of mental illness or in tandem with severe
physical abuse Additional abusive practices include
delayed decontamination or medical attention leaving
youth to suffer extended painful effects of pepper
spray Such abusive practices have profound effects
on the mental health of the victims including increases
in violent behavior toward others posttraumatic stress
disorder and suicidal behavior
Schoenberg and Soler of the Center for Childrens
Law and Policy warn that DOJ findings in other states
specifically California should serve as a cautionary
tale to TYC in regards to the use of pepper spray In a
recent findings letter on conditions ofconfinement in Los
Angeles County Juvenile Halls DOJ investigators noted
multiple occasions in which staff utilized pepper spray
againstyouth in minor situations that escalated because
staff lacked the skills to deescalate incidents in which
youth failed to comply with orders thus causing minor
problemsto become major confrontationsthat otherwise
would not have required spray 1172 Staff were also found
to have used pepper spray against youth specifically
exempted including children with respiratory problems
pregnant girls youth on psychotropic medications and
suicidal youth 73
Possible Unintended Consequences
In their analysis of a working draft of TYCsproposed
change to the use of force policy Schoenberg and
Soler suggested that the changes in wording could be
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interpreted to encourage the use of pepper spray for
behavioral issues of non compliance or in situations
where youth are merely disruptive since the draft
removes specific safeguards which would protect
youth from the abusive use of pepper spray In other
words changes in TYC policy which in effect increase
the use of pepper spray may not achieve the safety
goals sought by TYC as effectively as other measures
and instead risk violating youths established rights to
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PEPPER SPRAY IN THE TEXAS YOUTH COMMISSION
Placement in the Use of Force Continuum
The location of pepper spray in the use offorce continuum
varies amongagencies Some consider pepper spray as
a relatively benign method of control placing it low on
the continuum In 1994 the NIJ suggested that pepper
spray belonged after physical pain compliance and
before impact weapons on the use of force continuum
based largely on the stated belief that there appears to
be no verified longterm physical effects or health risks
associated with the use of OC 1175
Some law enforcement representatives note that as
pepper sprays continue to increase in strength and
hotness agencies might consider moving pepper
spray above other methods of restraint to near or above
the level of an intermediate weapon 76 At least one
federal court has determined that the harm resulting
from pepper spray use is so severe that it satisfied
the definition of a dangerous weapon 1117 Researchers
Smith and Stopford point to another federal case in
which the court ruled that pepper spray should not
be used except in situations of absolute necessity to
incapacitate dangerous youth 711 The Ella Baker Center
for Human Rights declares that the potential adverse
health effects of pepper spray include death therefore
the deployment of pepper spray risks the application of
extreme and excessive force and thus violates rights
afforded by the US Constitution and international
human rights laws79
Juvenile corrections staff must thoroughly understand
the range of options that exist along the use of force
continuum if not proficient in primary control and de
escalation techniques personnel may increasingly
rely on pepper spray as an option of force One expert
drawingfrom personal experience in reviewing chemical
restraints in juvenile facilities noted the repeated
problems of pepper spray use in situations where staff
interactions with defiant youth often led to escalating
cycles of provocation and reaction rather than the de
escalation necessary to restore controlS Such reports
reinforce concerns that pepper spray while perhaps an
important tool as an alternative to lethal or potentially
lethal force should not be used as a substitute for lower
level alternatives to force in juvenile facilities84
Information from effectiveness studies indicates
that implementation of pepper spray does not lead
to a reduction in overall use of force Researchers
hypothesize that this is because officers carrying
pepper spray may feel more confident and such over
assurance may increase the projection of assertive
aggressive behaviors or increase the willingness of
officers to enter into more facetoface situations1181
In fact officers armed with pepper spray may actually
increase occasions for risk to themselves and their
suspects Thus a directive to expand pepper spray
usage may actually exacerbate problem situations by
encouraging the preemption of verbal de escalation or
other non violent methods of contro1
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Best Practices for Improving Safety
The TYC administrationsemphasis on increasing
control through an upward adjustment in the use of
force continuum appears to be inconsistent with the
agencys goal of rehabilitating children Evidencebased
research suggests that the application of deterrent
sanctions such as pepper spray may actually result in
a counterproductive deteriorating cycle of defiance
whereas intensive treatment models hold greater
promise to reduce violence and rates of recidivism
Several studies show that treatment programs with
a therapeutic emphasis that are developed and
implemented in consultation with child and adolescent
psychologists are more effective at reducing aggression
and defiance in youth offenders particularly those with
mental health needS86
A solid understanding of the psychological development
stages of children is essential in developing tools for
effective behavior management in juvenile corrections
facilities In a speech delivered to the National Juvenile
Corrections and Detention Forum Steven Rosenbaum
warned against the increasing wholesale adoption of
adult system modeled tactics including pepper spray
use without adequate consideration of the relevant
differences between adolescents and adults 81 He
advised that such tactics are especially prone to abuse
when staff are not adequately trained 1188 Rosenbaum
further stated
independent evaluation of the use of force are most
effective to ensure that appropriate control tactics are
being used Too often restraint techniques originally
intended for use as a last resort or to prevent imminent
danger are inappropriately employed as a behavioral
intervention
National juvenile justice experts convened in May 2007
as a Blue Ribbon Task Force to evaluate Texas juvenile
justice system and recommend solutions In the final
report the Task Force expressed concern about the use
of pepper spray to address safety in juvenile facilities
particularly in an institution which has not yet seen
a shift in culture away from punishment and towards
treatment The Task Force also recommended that
TYC find ways to decrease all uses of force through
alternative methods emphasizing greater priority and
resource allocation toward training in skillsbased
techniques which promote deescalation in crisis
situations Echoing the recommendations of the Blue
Ribbon Task Force one expert in adolescent care states
that the most effective means of reducing risks
associated with restraints is prevention of their use
through effective deescalation and crisis intervention
strategies 1193
We have seen that officers trained in
adult prison practices or who come from a
background of adult corrections are often
bewildered by the reactions of juveniles by the
failure of traditional correctional responses to
achieve desired results When staff are trained
or allowed to resort too quickly to threats and
force in the face of non compliant adolescent
behavior minor incidents get escalated and the
risk of harm increases for both the juvenile and
the officer
When confronted with problems in institutional control
some experts suggest that a comprehensive review and
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Policy Recommendations
While TCJC strongly supports the goal of improving
safety for both youth and staff in TYC institutions based
on the results of our research we cannot recommend
the escalation of pepper spray use against youth as
a reasonable solution to address problems in TYC
facilities Pepper spray poses significant risks which
make it inappropriate as a permanent first response
policy to youth non compliance
Conduct regular audits on the use of pepperspray in
TYC facilities to alert administrators of any problems
before they become liabilities
Instead we urge the TYC leadership to focus its efforts
on implementing the 80t Legislaturesmandates out
lined in SB103 and the recommendations of its own
Blue Ribbon Task Force in addressing the pervasive un
derlying issues driving the increased levels of violence
in TYC facilities See Appendix 8 for a listof key legisla
tive mandates and expert recommendations that would
positively impact safety We also suggest that TYC
commission an independent and comprehensive evalu
ation of the use of force in TYC facilities which would
help the agency identify and develop specific solutions
to address the root problems of endemic violence in TYC
facilities Lastly it is critical that TYC provide its direct
care staff with the training needed to deescalate crisis
situations without resorting to pepper spray or physical
restraint 94
However should TYC decide to continue its push toward
expanded pepper spray use TCJC recommends that the
agency take the following three critical actions
Convene a collaborative working group including
representatives with critical perspectives from the
juvenile justice health care advocacy and legisla
tive arenas that will consider whether the use of
pepper spray is the best course of action to reduce
violence in TYC facilities as well as provide input on
any policies or procedures regarding limitations on
pepper spray use training decontamination and
other accountability measures
Require that an external review panel be established
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Conclusion
While pepper spray is widely accepted by the law
enforcement and adult correctional communities as an
importanttool in aiding in subject control the significant
differences that exist in the States relationship to
incarcerated children should give TYC pause in its
decision to expand use of pepper spray in its juvenile
facilities Pepper spray gained its popularity as an
alternative to lethal or near lethal force situations
which should never apply to children confined in a well
run juvenile facility Further as it undertakes badly
needed reform efforts TYC should not strive to emulate
the adult correctional system as it has a different
statutory obligation to the still developing population in
its care
Although we understand that the children sent to
TYC pose a significant challenge in terms of behavior
management we nonetheless recognize them as
children who often suffer from a history of abuse
mental illness or emotional disturbance Children in
TYC facilities are perceived as the worst of the worst
yet fewer than 40 percent enter TYC for violent crimes96
Lacking better alternatives in their own communities too
many children sent to TYC facilities do not receive the
treatment they need and are legally entitled to instead
often facing dangerous and neglectful conditions
Particularly in TYC where the system has failed to
demonstrate trustworthiness and compliance with
minimum standards of child care and transparency the
anticipated positive effects of expanding pepper spray
use against children coupled with a relative lack of
treatment and programming appear more likely to
aggravate problems in an already struggling system
Notes
1 SB 103 authored by Senator Juan Chuy Hinojosa
includes the following reforms enhanced communitybased
programs as an alternative to incarceration a parents Bill
of Rights a special prison prosecution unit and an Office
of Inspector General for the independent investigation
and prosecution of crimes occurring in youth correctional
facilities an independent Ombudsman to act as an advocate
for incarcerated youth public reporting of cases of abuse and
neglect a prohibition on the incarceration of misdemeanants
in TYC improved procedures governing the length of a childs
placement in TYC a mandate to improve youth re integration
back into his or her home community
2 Will Harrell Proliferation of OC Spray memo to Billy
Humphrey cc Dimitria Pope and Ed Owens 25 July 2007
TYCs stated goal of reducing injuries to staff and
children is highly commendable however expanding
use of pepper spray to facilitate safety appears
shortsighted Ultimately the real solutions are not
found in a 3ounce can of pepper spray but rather in the
wellfunctioning policies programs and practices of the
agency The use of pepper spray cannot substitute for
or facilitate a healthy institutional culture particularly
where the explicit goal of the State and expectation of
the community is treatment and rehabilitation
In order to gain and keep control of its institutions
TYC must address the underlying issues at the crux of
its problems specifically understaffing inadequate
staff training and poorly established behavioral and
mental health assessment and treatment programs
3 The current TYC policy specified in the Texas Administrative
Code General Administrative Policy GAP 9723 clearly
delineates the use of force continuum in TYC institutions to
the following order 1 non verbal and verbal interventions
including team interventions and problem solving groups
2 physical interventions including manual and mechanical
restraints and 3 OC spray
Dimitria D Pope Executive Directive 2 FY07 memo to
Institution Superintendents 2 August 2007
5 Ibid Pope states in the Directive we must change the
way force is applied to reduce the number and severity
of injuries to youth and staff According to the agencys
Workers Compensation report we have had 447 workers
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of Texas Medical Branch UTMB injury report indicates 913
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Review of Research on Pepper Spray Effectiveness
Effectiveness Measures
Pepper spray studies commonly attempt to determine
a rate of effectiveness for pepper spray use through
various measures including a noted ease in suspect
apprehension a decline in injuries to officers and a
decline in injuries to suspects or a reduction in excessive
use of force complaints Researchers examining pepper
spray as a safe tool for restraint often note significant
study limitations These includethe lack of comparable
data and the opportunity for bias since studies are
often dependent on selfreport surveys from officers
in the field 3 Researchers lacking empirical evidence
of effectiveness must interpret officers descriptions of
human responses to pepper spray possibly allowingfor
skewed data limitations which may be exacerbated in
studies utilizing dichotomous measures ie effective
or ineffective 114 In a study of the implementation of
pepper spray into Marylands Baltimore County Police
Department researchers noted There may well be
wide differences in the use of terms depending on the
individual officersunderstanding and expectation of
what OC is supposed to do to a suspect 5 Given the
many flaws and limitations pervasive in these studies
it would be difficult to conclude with any certainty
whether pepper spray is effective in achieving control
and increasing safety
Inconsistent Findings
Law enforcement agencies often argue the positive
effects of pepper spray as a non lethal use of force to
reduce physical harm to officers and assailants while
enabling them to successfully apprehend a suspect
In a twoyear study by the University of North Carolina
Injury Prevention Research Center funded by the
National Institute of Justice NIJ researchers were
able to confirm with statistical significance that pepper
spray reduced officer injuries in only one of the three
jurisdictions studied In the two remaining jurisdictions
researchers could not confirm pepper spray as an
associated or contributing factor in reducing officer
injury The analysis of suspect injury data from two
of the North Carolina jurisdictions resulted in similarly
divergent results Although one jurisdiction noted a
statistically significant decline in injuries the second
jurisdiction indicated that the introduction of pepper
spray had no effect in reducing an already downward
trend in suspect injuries
Other study findings vary drastically in how effective
pepper spray is ranging from zero percent in some
studiestofrequentlyreported claims of 90100 percent
in others depending on the population in the study
and researchers methodology A study by Morabito
and Doerner analyzed data from the Tallahassee
Police Department and reported an overall 73 percent
effectiveness rate In a newly expanded study of
Baltimore County Police Department data by Kaminski
Edwards and Johnson the researchers analyzed
officer reported suspect behavior following pepper
spray and found it was effective in only 70 percent
of the cases substantially lower than the suggested
90 percent effectiveness previously reported in a study
of Baltimore data by the International Association of
Chiefs of Police IACP
Particularly in cases where individuals exhibit symptoms
of drug use or mental illness pepper spray is repeatedly
cited as ineffective and mounting evidence indicates
that these individuals may be highly resistant to
its effects12 Researchers for the IACP warned that
individuals who are heavily intoxicated drugged and
or mentally ill are in such a state that OC will have little
or no effect and may make the individual more difficult
to control 1113 Thus use of pepper spray against those
exhibiting signs of mental illness or under the influence
of drugs or alcohol may instead increase risk of harm to
officers and suspects
In one study examining suspect deaths while in police
custody the researcher noted an effectiveness rate of
only 20 percent when the suspects were violent or on
drugs Similarly in an analysis of 26 reported deaths
following pepper spray exposure the American Civil
Liberties Union ACLU of Southern California reported
the use of pepper spray as completely ineffective finding
that in some cases the subject became more combative
17
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with officers Researchers note a wide variation in
human responses which introduces additional ambiguity
in pepper spray use and they admonish that pepper
spray is not a panacea 1116
Notes
1 US Department of Justice National Institute of Justice
The Effectiveness and Safety of Pepper Spray April 2003
7 12 httpwwwojpusdojgovnij 9 September 2007
Report presented information from several studies One
study examining suspect and officer injuries noted limitations
including variations in reporting and availability of data among
agencies and inconsistency in injury data collection Another
study examining the effects of pepper spray and positional
restraint noted the impossibility to replicate field conditions
in laboratory and further limitations including the testing of
only healthy cadet volunteers limited exposure to pepper
spray through the use of goggles and subject restraint on
examination tables rather than hard surfaces
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study of suspect injuries included two jurisdictions Charlotte
Mecklenburg Police Department and Winston Salem Police
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TCJCSJUVENILE JUSTICE INITIATIVE
APPENDIX B
Key Expert Recommendations and Legislative Mandates
Expert Recommendations from the Blue Ribbon Task
Force Report Transforming Juvenile Justice in Texas
A Framework forAction
Funding and Governance
Recommendation 21 Allocate adequate funding
for facilities rehabilitation and treatment programs
appropriate staffing ratios education and the training
of employees
Security
Recommendation 25 Maintain a safe place for
youth that embraces a non violent approach The
classification system needs to address the security and
safety of the juveniles while confined in TYC To this aim
decisions for housing juveniles need to include among
other things the age and vulnerability of the juvenile
The Task Force recommends monitoring of assaults
identifying trouble areas and taking action to separate
aggressive youth from targeted youth with the intention
of preventing continued violence in TYC facilities
Recommendation 26 Develop goals to carefully
ration supervise and document the use of seclusion
restraints chemical control agents and the use of force
generally There is convincing evidence that lowering
the size of living units and enriching staff resources at
facilities likeTYC can reduceviolence within thefacilities
and promote better rehabilitative outcomes Lowering
the size of living units to no more than 50 wards has
been shown to substantially improve correctional
management and advance treatment goals
concern about TYCs new policy allowing the use of
chemical control agents such as pepper spray We
understand that the new policy regarding pepper spray
was implemented in an effort to decrease injuries to
staff and juveniles however the ease with which pepper
spray can be employed is exceptionally troubling This is
especially true in an environment that has not yet seen
a shift in culture away from punishment and towards
a treatment approach While there could potentially
be scenarios in which the use of pepper spray is the
best alternative in dealing with a crisis situation it is
all too easy to employ this technique in dealing with
recalcitrant youth who refuse to obey an order or in an
effort to extract a juvenile from his or her cell In neither
situation would the use of pepper spray be appropriate
Although public debates so far have framed this as a
choice between the use of pepper spray and the use of
restraints or physical force we think that such a debate
creates a false choice The challenge is for TYC to find
ways to decrease all uses of force through an emphasis
on other methods Specifically greater priority should
be given and resources allocated toward skillsbased
training using standardized approaches for workers on
how to verbally deescalate crisis situations This will
require a shift in culture that iscongruent with treatment
over punishment
Management
Recommendation28 Ensure that the staff are an
appropriately educated workforce whoare youthfocused
and strengthbased in their approach Properly equip all
TYC employees with sufficient education training and
credentials
At rootthe newTYC executive leadership at Central
Office in Austin should foster a new organizational
culture that does not accept ward violence or staff use
of force Organizational culture change is aided by a
new clarity of policy and procedure but this must be
strongly reinforced by ongoing training as well as daily
reaffirmation of the values of the new culture
Recommendation 230 Establish and maintain
an adequate youth tostaff ratio using national best
practice standards aiming for a 10ratio
Legislative Mandates from Senate Bill 103
33 Subchapter B Chapter 61 Sections 61023
This Task Force unequivocally expresses its Human Resources Code This section requires TYC
M
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to begin the process for gaining accreditation by the
American Correctional Association ACA for correctional
facilities operated directly or through contract with TYC
National accreditation with the ACA would improve
facility standards and may thus help address many of
the issues at the rootof TYC facility violence
youth development behavior management and safety
facilitates increased professionalism and confidence
among staff so that they are better equipped to
appropriately recognize and respond to situations which
might otherwise escalate into violence
34 Section 6103 5 Human Resources Code
This section requires TYC to establish and implement
necessary rehabilitative programming and services as
recommended by the court committing the child to TYC
custody The establishment of rehabilitative treatment
transitions the focus of TYC from one that emphasizes
punitive adultmodel corrections to one that prioritizes
the moral and legal obligations for rehabilitating youth
in a safe structured environment
35 Subchapter C Chapter 61 Sections 610331
610332 and 610345 Human Resources Code
These sections require TYC to conduct internal audits of
all TYC correctional facilities including those managed
directly by TYC employees and those under contract and
report their findings to the joint selection committee
Furthermore TYC shall adopt a mission statement
These steps should facilitate increased accountability
and transparency thus lead to opportunities to address
issues of pervasive violence in TYC facilities
40 Subchapter C Chapter 61 Sections 610356
610357 and 610386 Human Resources Code
Section610356 specifies an increase in training hours
forjuvenile corrections officers and requires instruction
in the recognition of signs of abuse assault neglect
and risk of suicide the identification of mental health
issues an understanding of the neurological physical
and psychological development of youth and youth
specific social and cultural differences The training
specified by SB 103 also requires staff development
in the use of interpersonal relationship skills behavior
management conflict resolution techniques and
dispute mediation Finally TYC must provide juvenile
correction officers with training in the applicable use of
force appropriate restraint techniques emergency first
aid and the rights and responsibilities of children in
TYC custody The increase in training and emphasis on
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EXPERIENCE AND REASON Briefly Recorded
In Medicine one must payattention not to plausible theorizing but to experience and reason together I
agree that theorizing is to be approved provided that it is based on facts and systematically makes its
deductions from what isobserved But conclusions drawn from unaided reason can hardly be serviceable
only those drawn from observed fact Hippocrates Precepts Short communications of factual material are
published here Comments and criticisms appear as fetters to the Editor
Pepper Spray induced Respiratory
Failure Treated With Extracorporeal
Membrane Oxygenation
ABBREVIATIONS ECMO extracorporeal membrane oxygen
ation MAP mean airway pressure F1o fraction of inspired ox
ygen Paco partial pressure of carbon dioxide arterial Pao
partial pressure of arterial oxygen CN chloroacetophenone CS
chlorbenzylmalononitrile AaDO difference in partial pressures
of oxygen in mixed alveolar gas and mixed arterial blood
Selfdefense sprays have been available to the
general public since the 1970s They are easily
obtained and over 6 million spray units were sold in
the United States in 1993 alone The intent of these
sprays is to cause skin and mucosal irritation without
producing serious injury We describe the accidental
exposure to peppergas spray of an infant who
experienced immediate lifethreatening respiratory
distress followed by progressive deterioration
Ultimately he required extracorporeal membrane
oxygenation ECMO for survival The decision to
place the infant on ECMO was made more difficult
by the lack of information about potential reversibil
ity with this rare toxic cause of respiratory failure
CASE REPORT
A 4weekold healthy male infant was exposed to 5 pepper
gaswhen a selfdefense spray accidentally discharged in his face
The spray device was attached to a key chain and discharged in
hismother handwhile she was attempting toplace him in his car
seat He had the rapid onset of gasping respirations and epistaxis
followed by apnea and cyanosis
His parents began mouth tomouth breathing and he was
transferred by ambulance to a nearby hospital within 20 minutes
He was incubated and supported by mechanical ventilation for
respiratory failure shortly after arrival He required high peak
inflating pressures 45 cm Hand peak end expiratory pressure
8 cm H to achieve adequate chest wall movement His initial
chest radiograph showed bilateral diffuse parenchymal infiltrates
During the first 24 hours he continued to require mean airway
pressure MAP of approximately 1520cm H and greater than
45 inspired oxygen concentration MO
At 30 hours postinjury he had marked worsening of the hypox
emia despiteF1o and increased ventilator support The next 60
hours of his course were complicated by hypotension requiring
dopamine bilateral tension pneumothoraces and copious thick
tracheal secretions Frequent suctioning was required to maintain
endotracheal tube patency but was associated with prolonged
periods of oxyhemoglobin desaturation and hypotension that
Received for publication Oct 25 1995 accepted Jan 23 19
Reprints will not be available
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were difficult to correct By postinjury day 2 the sputum was
grossly purulent with many polymorphonuclear cells and Gram
negative diplococci on gram stainCulture of these tracheal secre
tions grew Moraxella catarrhalis for which he received cefuroxime
therapy His condition continued todeteriorate as evidencedby an
average alveolararterial gradient Patin47Pac08Pao of470
mm Hg an oxygenation index MAP x F1o x 100Pao of 30
and a MAP requirement of 21 cm H He was placed on veno
arterial ECMO hours postinjury Fig 1ECMO flow was main
tained at 120 mLkgmin Dopamine was discontinued and the
ventilator was placed at rest settings of F1o ventilator rate of
10 and pressure 205cm H Herequired 138 hours of ECMO for
lung recovery Within 24 hours of discontinuation from ECMO he
required only minimal ventilator support with F10 21 He was
extubated the following day The infant was discharged home 9
daysafter his ECMO course oncromolyn Fisons Pharmaceuticals
Rochester NY and albuterol Rugby Laboratories Inc Norcross
GA aerosols Fig 2In the subsequent 12 months of followuphe
has had three admissions for viral respiratory infections with
fever wheezing and tachypnea Viral culture for respiratory syn
cytial viruswas positive onone occasion Growth parameters have
been maintained at the 10th to25th percentile and his neurologic
examination remains normal
DISCUSSION
Mace is a general term for aerosolized lacrimators
There are twocategories of agents available classic tear
gas and peppergasspraysClassic tear gas contains the
alkylating agent chloroacetophenoneCN orchlorben
zylmalononitrile CSThe usual effects of these chem
icals include irritation of eyes mucous membranes
and skin Interaction of the alkylating agents with sulf
hydryl groups and nucleophilic sites may inhibit im
portant enzyme systems leading to tissue injury and
necrosis When used in high concentrations or for pro
longed periods in closed spaces more serious effects
can occur These include bronchospasm noncardio
genic pulmonary edema acute tracheobronchitis with
necrosis of respiratory mucosa and pseudomembrane
formation infraalveolar hemorrhage and broncho
pneumonia Several deaths from respiratory failure
with pseudomembrane formation and bronchopneu
monia have been reported after exposure to CN and
CS4
The lacrimator contained in the present selfde
fense spray was 5 oleoresin capsaicin or pepper
gas a volatile oil derived from red chili peppers
Like the above mentioned compounds it is an alky
lating agent that also causes severe irritation to skin
and mucous membranes Additional compounds in
this selfdefense spray included the propellants
isobutanepropane and two organic solvents meth
ylisobutyl ketone which has been reported to cause
upper respiratory tract irritation and tetrachloroeth
ylene which may produce pulmonary edema 6
Peppergas induces its effects primarily through
the release of substance P from sensory neurons
Downloaded from pediatricsaappublicat onsb001i Mbkr9N6November 1996 961
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cytial virus was positive on one occasion. Growth para eters have 
been aintained at the 10th to 25th percentile and his neurologic 
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ace is a e eral ter  f r aer s lize  lacri at rs. 
There are t o categories of agents available: classic tear 
as a  e er-gas s rays. lassic tear as c tai s t e 
alkylating agent chIoroacetophenone (C ) or chIorben-
zyl alononitrile (CS).l he usual effects of these che -
icals include irritation of eyes, ucous e branes, 
and skin. Interaction of the alkylating agents ith sulf-
hydryl groups and nucleophilic sites ay inhibit i -
portant enzy e syste s leading to tissue injury and 
necrosis. hen used in high concentrations or for pro-
longed periods in closed spaces, more serious effects 
can occur. These include bronchospas , noncardio-
genic pul onary ede a, acute tracheobronchitis ith 
necrosis of respiratory ucosa and pseudo e brane 
for ation, intra-alveolar he orrhage, and broncho-
pneu onia. Several deaths fro  respiratory failure 
with pseudomembrane formation and bronchopneu-
onia have been reported after exposure to CN and 
S.2- 4 
The lacri ator contained in the present self-de-
fense spray was 5% oleoresin capsaicin or pepper-
s,  l til  il ri  fr  r  ili ppers.s 
ike the above- entioned co pounds, it is an alky-
lati  a e t t at als  ca ses se ere irritati  t  s i  
and mucous membranes. Additional compounds in 
t is s lf- fe s  s r  i l  t  r lla ts 
isobutane/propane and two organic solvents; eth-
l-isobut l et e, ich as ee  re rte  t  ca se 
upper respiratory tract irritation, and tetrachloroeth-
ylene, hich ay produce pul onary ede a.6 
Pepper-gas induces its effects pri arily through 
the release of substance P fro  sensory neurons.7 
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Effects of this neuropeptide include vasodilatation
increased vascular permeability and altered neutro
phil chemotaxis Acute bronchospasm and reversible
pulmonary edema have been reported from pepper
gas exposure but there have been no reported cases
of necrotizing tracheobronchitis pneumonitis or
death An 11yearold boy developed noncardio
genic pulmonary edema and severe croup requiring
intubation 4 hours after deliberate inhalation of an
oleoresin capsaicin spray No difficulty with tra
cheal secretions was described and he improved rap
idly permitting extubation by 48 hours The appear
ance of copious thick tracheal exudate in our infant
on the second postinjury day is similar to the clinical
course of adult patients with fatal necrotizing tra
cheobronchitis after exposure to CN and CS Al
though the secretions may have been a response to
infection it is possible that extensive injury to the
respiratory epithelium produced exudative slough
ing and necrosis that may have facilitated secondary
infection with M catarrhalis
ECMO was instituted when this infant condition
deteriorated despite aggressive conventional therapy
Although the potential reversibility of this particular
toxic pneumonitis was unknown the success of ECMO
for severe hydrocarbon aspiration pneumonia encour
aged us to consider this form of therapy
The use of ECMO outside of the neonatal period is
relatively new and the appropriate selection of patients
is a difficult task Because of the potential morbidity
and the extensive resources required to provide
ECMO only those patients with a high riskof mortality
and a potentially reversible disease process should be
considered In neonates the contribution of reversible
pulmonary hypertension to most cases of respiratory
failure contributes to the high success rate in this well
defined patient group In contrast older children and
adults are more likely to have primary lung parenchy
mal damage and quickly develop irreversible pulmo
nary fibrosis This permanent damage results in a pa
tient who is stable while on ECMO but who can never
be weaned from support
In addition although fibrosis may be part of the
primary process the usual ventilator therapy re
quired for management results in barotrauma and
oxygen toxicity that contribute to ongoing lung in
jury Duration of ventilator therapy before ECMO
has been demonstrated to correlate with mortality A
history of high inspired oxygen concentration and
inspiratory pressure requirements for greater than 7
to 10 days results in few survivors and is considered
a relative contraindication to pediatric ECMO Be
cause of this dilemma attention has recently been
focused on parameters that will allow early identifi
cation of the patient at high riskof mortality before
overt failure of gas exchange has occurred
Several investigators have examined the relation
ship of early respiratory support requirements and
blood gas values to eventual outcome Debruin et al
noted a mortality rate of 72 in children with acute
hypoxemic respiratory failure defined as an arterial
Pa0 of 75 Torr while receiving Fio 5 Tamburro
et al found a mortality of 42 in a group of pedi
atric patients with Pao 60 Torr while receiving
Flo 5 They also measured the alveolar arterial
oxygen gradient AaDO and noted 100 mortality
when the A aD0 was 450 Torr for 16 hours A
third study by Timmons et a1 of children with adult
respiratory distress syndrome found single values of
several parameters to be predictive of high mortality
including AaD0 470 Torr 81 mortality a MAP
23 cm H 90 mortality and intrapulmonary
shunt QspQt of 5 93 mortality
This patient not only shared these parameters of
severe lung injury but also had progressive clinical
deterioration and episodes of instability that were
increasingly difficult to control despite aggressive
conventional therapy We feel that the use of ECMO
was lifesaving
This report emphasizes the potential for severe pul
monary injury from commonly available selfdefense
products Parents should be cautioned to keep self
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Fig 1 Chest radiograph just before ECMO
Fig 2 Chest radiograph five days after completion of ECMO
course
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cause of this dile a, attention has recently been 
focused on para eters that ill allo  early identifi-
cation of the patient at high-risk of ortality before 
overt failure of gas exchange has occurred. 
Several investigators have exa ined the relation-
ship of early respiratory support require ents and 
blood gas values to eventual outcome. Debruin et aPD 
noted a ortality rate of 72% in children ith acute 
hypoxe ic respiratory failure defined as an arterial 
Pao2 of < 75 Torr while receiving FI02 >.5. Ta burro 
et alII found a mortality of 42% in a group of pedi-
atric patients with Pao2 <60 Torr while receiving 
FI02 > .5. hey also easured the alveolar-arterial 
oxygen gradient (A-aD02) and noted 100% mortality 
hen the -a 02 as >450 orr for 16 hours.  
third study by i ons et aP2 of children ith adult 
respiratory distress syndrome found single values of 
several para eters to be predictive of high ortality 
including -a 02 > 470 orr (81 % ortality), a  
> 23 cm H20 (90% mortality) and intrapulmonary 
shunt (Qsp/Qt) of > .5 (93% ortality). 
This patient not only shared these parameters of 
severe lung injury, but also had progressive clinical 
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increasingly difficult to control despite aggressive 
conventional therapy. e feel that the use of EC O 
as life-saving. 
his report e phasizes the potential for severe pul-
monary injury from commonly available self-defense 
products. Parents should be cautioned to keep self-
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defense sprays out of the reach of children Despite
severe toxic pneumonitis this injury is potentially re
versible with the aid of ECMO support and lung rest
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occur most frequently in young children Each year
tap water burns result in approximately 2600 visits to
emergency rooms in the United States and cause
approximately 200 deaths but these burns are rare
in the hospital setting We describe a case of scald
injury in a newborn during routine postnatal bathing
that occurred shortly after an increase in the temper
ature of the hospital water supply due to a Legionella
outbreak and discuss precautions that should be
used by hospitals to avoid scald injuries
CASE REPORT
The infant was the fullterm product of an uncomplicated preg
nancy with normal spontaneous vaginal delivery She had normal
Apgar scores and her initial newborn examination including
skin was unremarkable Several hours later immediately after
being bathed by an experienced neonatal nurse she was noted to
have multiple areas of erythema and blistering A dermatologic
consultation was requested
The infantsphysical examination was remarkable for irritabil
ity and diffuse erythema limited to the lower half of her body Fig
1 The erythema was clearly demarcated and spared the flexural
area behind the knees Fig2Within thebackground of erythema
clear tense bullae were evident There was no family history of
blisters skin defects or other ectodermal abnormalities The
mothersserologies were negative for syphilis rubella and human
immunodeficiency virus and she denied perinatal rash fever or
drug ingestion A diagnosis of a water immersion scald burn was
made The infant was treated with sterile lancing of the tense
blisters application of Vaseline gauze to the denuded areas and
monitoring of temperature fluid and electrolyte status She de
veloped no further skin lesions and rapidly improved within 48
hours She recovered fully except for a small hypopigmented scar
on the left thigh
The nurse who bathed her hadworked in the nursery for many
years She was healthy onnomedications and denied any history
of diabetes Raynaud disease or neuropathy She reported that
she had checked the temperature of the bath water with her bare
elbow and she was gloved during the bath No thermometer was
used to measure the temperature of the water Further investiga
tion revealed that the hot water temperature in the hospital had
recently been increased from 50C to 60C shortly before this
incident because of a nosocomial outbreak of Legionella On the
day of this incident the source temperature was 66C Because
there is a drop of about 7 to 10 degrees from the source to
distribution on the floor we estimate that the temperature from
the nursery hot water faucet was most likely between 56Cand
59C Mixing this with cold water as the nurse reported she did
further decreased the temperature but the actual temperature of
the water used is not known
DISCUSSION
Iatrogenic Scald Burn A
Consequence of Institutional
Infection Control Measures
ABBREVIATION UCSF University of CaliforniaSan Francisco
Accidental burns are common causing significant
morbidity and mortality in all age groups but they
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A large number of conditions can result in ery
thema and blistering in the newborn period includ
ing bullous impetigo staphylococcal scalded skin
syndrome and epidermolysis bullosa 3 but this pa
tient had all of the characteristics of an immersion
injury there was a distinct and welldemarcated wa
ter line the perineum external genitalia lower ab
domen and upper thighs were most affected and
the flexures were spared due to the apposition of
skin surfaces
Tap water burns are a common cause of accidental
injury and children 5 years old account for 46 of
tap water scald injuries Although some of these
burns are intentionally inflicted most are not4 In
fants are unable to physically remove themselves
from inappropriately hot water In retrospect this
infants cries were misinterpreted as the normal fuss
iness that some young infants exhibit during baths
Downloaded from pediatricsaappublicat ons by guest on Sept NER AND REASON 963
002029
  t  t    il n. ite 
  iti ,    ti ll  -
versible ith the aid of  support and lung rest. 
 .  ,  
RLES I ,  
UREEN G ,  
Depart ent of Surgery 
St hristopher's ospital for hildren 
e le niversity chool f edicine 
Philadelphia, P  19134 
C  . ,  
 ,  
 S,  
 I ,  
ES . ,  
rt t f i trics 
t hristopher's ospital for hildren 
Te ple niversity School of edicine 
Philadelphia, P  19134 
 
. e rn I.  C. irborne . : lenh rn I, re-
 C. s. e ial  l y. iIlgnosis   ... t nrt  un"," 
oisoning. e  ork. : lsevier cience ublishing; 1988:881-887 
. a  I. it  . t  r ltin  fr  l ri t r  t . , 
 i. 978;2 :527-530 
3. horburn KM. Injuries after use of the lacri atory agent chloroaceto-
e e i  a c fine  s . rc  vir   ... lt . 982;37:182-186 
4. ark . ia ona . oxic effects of tear as on a  infant follo ing 
r l e  r .  I is il . 972;123: 45-246 
5. Ellenhorn I, 8arceloux C. P1ants- ycotoxins- ushroo s. In: Ellen-
m I, a  C, s. l l y. iIlgnos s   ... t  
f  i i . e  r . : ls i r i  lis i ; : 
9-1241 
. t l , I ir ,  O. l onary a e t  t tr chlo-
ro .   mpect. 977;2 :247-249 
. r ll . raujo . i i : i tifi ti . cl t re.  
phar acotherapy. nn Phar acother. 1993;27:330-336 
8. inograd HL. Acute croup in an older child: an unusual toxin origin. 
eli  tdilltr. 977;16:884- 8  
9. calzo I. eber . Iaeger . et aI. xtracorporeal e brane oxy-
e ati  f r rocar  as irati .  I is il . 990;144:867-871 
10. e ruin , otter an O , agid . et aI. cute hypoxe ic respira-
tory failure in infants and children: clinical and pathologic characteris-
. e t Ol  td. 99 ;2 :1 23-123  
. rro , itz . ti  . lve lar- rt ri l gen ra-
dient as a predictor of outcome in patients with non-neonatal respira-
t r  il . I tdilltr. 991;11 :935-938 
12. Timmons 00. Dean 1 , Vernon OP. ortality rates and prognostic 
iables i  il  ith lt i t  istres  . , t illt . 
991;119:896-899 
I troge ic c l  rn:  
o se e ce of I stit tio al 
fe   e e  
ABBREVIATION. UCSF, University of California, San Francisco. 
Accidental burns are common, causing significant 
morbidity and mortality in all age groups, but they 
eceived for publication ug 29, 1995; accepted Jan 9, 1996. 
Reprint requests to (G.W.M.l Depart ent of Der atology. 550 North Uni-
versity Blvd, Suite 3240, Indiana University. Indianapolis. IN 46202. 
I I  (ISS   (5). right 01996 by the American Acad-
e y of Pediatrics. 
 t tl  i   il r n.  r, 
tap ater burns result in approxi ately 2600 visits to 
e ergency roo s in the nited States! and cause 
a r i atel  200 eaths,2 t t ese r s are rare 
   tti .       
i j r  i  a e r  ri  r ti e st atal at i  
t t rr  rtl  ft r  i re  i  t  t r-
at re f t e s ital ater s l  e t  a egionella 
t r   is ss r ti s t t s l   
used by hospitals to avoid scald injuries_ 
  
The infant as the full-term product of an unco plicated preg-
  al,   li ry. e   
pgar scores, and her initial ne born exa ination, including 
skin, as unre arkable. everal hours later, i ediately after 
    ienced t l ,  as   
e lti le   t e a  li t i .  r t l i  
l  s sted. 
e i f nt's i l i ti   le  i it bil-
t     te    e  l     (F  
1). he erythe a as clearly de arcated and spared the flexural 
area behind the knees (Fig 2). ithin the background of erythe a, 
  lae  i nt.  as  i    
s ,  f ts,   t r l nor alities.  
other's serologies were negative for syphilis, rubella, and hu an 
i unodeficiency virus, and she denied perinatal rash, fever, or 
 ti .     -   m  
ade. The infant was treated with sterile lancing of the tense 
blisters, application f aseline gauze to the denuded areas, and 
onitoring of te perature, fluid, and electrolyte status. She de-
ope   rthe     i l     
hours. he recovered fully except for a s all hypopig ented scar 
 t  l ft t i . 
 rse     e       
years. She was healthy, on no edications, and denied any history 
of diabetes, aynaud's disease, r neuropathy. he reported that 
  e  t  t r t r  f t  t  ter it  r r  
elbo , and she as gloved during the bath. o ther o eter as 
s  t  r  t  t r t r  f t  t r. rt r i sti a-
ti  re eale  t at t e t ater te erat re i  t e s ital a  
tl   rea   sooC  °C rtl    
incident because of a nosoco ial outbreak of Legionella. n the 
a  f this incident, the source te perature as 66°C. ecause 
     t         
   r,  ate     
the nursery hot ater faucet as ost likely bet een 56"<: and 
°C. i ing t is it  c l  ater (as t e rse re rte  s e i ) 
further decreased the te perature, but the actual te perature of 
     . 
 
A large number of conditions can result in ery-
t e a a  listeri  i  t e e r  eri  i clud-
ing bullous impetigo, staphylococcal scalded skin 
syndro e, and epidennolysis bullosa, 3 but this pa-
   f      
i j r : t ere as a isti ct a  ell- e arcate  a-
ter line; the perineu , external genitalia, lo er ab-
do en, and upper thighs ere ost affected; and 
the flexures ere spared due to the apposition of 
 s. 
ap ater burns are a co on cause of accidental 
injury, and children <5 years old account for 46% of 
ta  ater scal  i j ries. ltho  s e f t ese 
burns are intentionally inflicted, ost are not.4 In-
fants are unable to physically re ove the selves 
fr  i a r riatel  t ater. I  retr s ect, t is 
infant's cries ere isinterpreted as the nonnal fuss-
iness that some young infants exhibit during baths. 
nloade  ro  ediatrics.aappublicat ons.org  t  ptmERt~CE AND REASON 963 
PepperSpray induced Respiratory Failure Treated With Extracorporeal Membrane
Oxygenation
Deborah F Billmire Charles Vinocur Maureen Ginda Nancy B Robinson Howard
Panitch Helena Friss David Rubenstein and James F Wiley
Updated Information including high resolution figures can be found at
Services httppediatrics aappublicationsorglcontent985961
Citations This article has beencited by 4 HighWirehosted articles
httplfpediatricsaappubIicat onsorgcontent 98151961 relatedurls
Permissions Licensing Information about reproducing this article in parts figures tables
or in its entirety can be found online at
http pediatricsaappublicationsorglsitelmiscLPermissionsxht l
Reprints Information about ordering reprints can be found online
http peeliatricsaappublicationsorgsi tomi sereprintsxhtmI
PEDIATRICS is the official journal ofthe American Academy ofPediatrics A monthly publication it
has been published continuously since 1948 PEDIATRICS is owned published and trademarked by the
American Academy ofPediatrics 141 Northwest Point Boulevard Elk Grove Village Illinois 60007
Copyright 1996 by the American Academy ofPediatrics All rights reserved Print ISSN 0031 4005
Online ISSN 10984275
American Academy of Pediatrics
DEDICATED TO THE HEALTH OF ALL CHILDREN
Downloaded from pediatricsaappublicat onsorgby guest on September 12 2011
002030
r- r y-i e  ir t r  il r  r t  it  tra rporeal ra e 
e ati  
r  . ill ir , rles i r, r  i a,  . i , r  
Panitch, elena Friss, avid ubenstein and Ja es F. iley 
t   & 
ices 
ta ions 
r  & ice  
e ri ts 
D."/; ',,, lQQf\.QR·Qf\l 
i l in  i  l ti  i ,    t: 
http://ped iatrics.aappu b Ii cations. org/con tent/98/ /96 I 
is rti le s  ite    i ire- ste  rti l s: 
ttp://pediatrics.aappub licati ns.orgicontent!98!5/ I #relatc -urls 
  ng s    (figure , l s) 
r i  its tir t    f  li e t: 
ttp://pc i t i . bli ti . /sitc/misc/Permissions.xhtml 
I for ation a t r eri  re ri ts ca  e f  li e: 
tt :// d iatri cs.aappu b I i a t ions.orgl s i tel m i c/rep i ts.xhtml 
I ICS is t e fficial journal f t e erica  ca e  f e iatrics.  t l  licati , it 
has been published continuously since 1948. PE I TRICS is o ned, published, and trade arked by the 
erican cade y f Pediatrics, 141 orth est Point oulevard, lk rove illage, Illinois, 60007. 
ri t ©   t e erica  ca e  f e iatrics. ll ri ts reser e . ri t I N:  1-40 . 
ine : -42 . 
American Academy of Pediatrics 
      ILDREN'· 
o nloaded fro  pediatrics.aappublications.org by guest on epte ber 12.2011 
2003 SPECIFICATION MANUAL
AERODYNAMIC PARTICLE SIZE ANALYSIS
OF FIRST DEFENSE PEPPER SPRAY
David K DuBay Director of Research Defense Technology Corporation of America Casper Wyoming
Rusty E Rush Associate Director of Toxicology Springborn Laboratories Spencerville Ohio
INTRODUCTION
In an effort to further evaluate the safety of First Defense aerosol products an aerodynamic particle size
analysis was conducted on the MK4 Based upon the aerodynamic size of the particles a theoretical
respiratory deposition can be determined It should be noted that the mechanism of delivery utilized produces
a stream of ballistic droplets It is not dispensed in the form of a mist or fog which generally produces
significantly smaller particles
BACKGROUND
Pepper sprays have been used in various capacities throughout the United States over the past fifteen years
In that time numerous products have been produced and sold in a variety of shapes and sizes Unfortunately
very few manufacturers have conducted adequate safety evaluations of their products Recently however
increased concern from legitimate manufacturers and regulatory agencies have forced a review of the
products on the market The initial focus has centered around formulations and potentially harmful
ingredients with additional concerns on flammability and environmentally safe propellants The latest issue is
the deliver s stem and the resultin aerod namicY Y g Y
particle size of the aerosol produced
Particle size is generally considered the critical factor
that determines the region of deposition within the
respiratory tract 3 For the purpose of understanding the
mechanism of deposition the respiratory tract will
be compartmentalized into three regions the
nasopharyngeal tracheobronchial and the pulmonary
Figure 1 As air is inhaled it travels through these
regions following a complex pathway that includes nasal
hair and mucous lined surfaces This combination along
with the changing velocities in the branching pathways
help to filter inhaled particles
The nasopharyngeal region consists of the oral and nasal cavity down to the larynx This region removes the
larger inhaled particles 5 to 30p microns by impaction and filtration The tracheobronchial region as the
name implies includes the trachea and extends to the terminal bronchioles Particles ranging from 1 to 5p
generally are deposited in this region by sedimentation due to the lower airflow and gravitational forces
The remaining particles 1 p and smaller settle in the pulmonary region by diffusion This region consists of the
respiratory bronchioles and alveoli where gas exchange takes place
The aerodynamic particle size is crucial to minimizing the possibility of undesirable and even harmful effects
from an exposure to pepper spray The active ingredient in pepper sprays is oleoresin capsicum OC an oily
resin plant extract The spray is intended to cause a burning sensation in the eyes nose and mouth Contact
with OC particles incapacitates subjects by causing an almost immediate burning of the skin and a burning
tearing and swelling of the eyes This exposure to the OC can cause severe blepharospasm twitching or
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regions following a complex pathway that includes nasal 
hair and ucous-lined surfaces. This co bination, along 
with the changing velocities in the branching pathways, 
help to filter inhaled particles. 
r.xhcobrOfl llliII 
i r  . AL~pT:WJr; rw 
The nasopharyngeal region consists of the oral and nasal cavity down to the larynx. This region re oves the 
larger inhaled particles, S to 30fJ (microns), by i paction and filtration. The tracheobronchial region, as the 
na e i plies, includes the trachea and extends to the ter inal bronchioles. Particles ranging fro  1 to SfJ 
generally are deposited in this region by sedimentation due to the lower airflow and gravitational forces. 
The remaining particles, 1 fJ and smaller, settle in the pulmonary region by diffusion. This region consists of the 
respiratory bronchioles and alveoli, where gas exchange takes place. 
The aerodynamic particle size is crucial to ini izing the possibility of undesirable and even harmful effects 
fro  an exposure to pepper spray. The active ingredient in pepper sprays is oleoresin capsicu  (O ), an oily 
resin plant extract. The spray is intended to cause a burning sensation in the eyes, nose and mouth. Contact 
with OC particles incapacitates subjects by causing an almost immediate burning of the skin, and a burning, 
tearing and swelling of the eyes. This exposure to the OC can cause severe blepharospas  (twitching or 
spasmodic contraction) of the eyes and even involuntary closing of the eyes (1). 
fE   
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When the agent is inhaled the respiratory tract is inflamed resulting in a swelling of the mucous membranes
lining the breathing passages and temporarily restricting breathing to short shallow breaths 6 Inhalation
causes coughing and shortness of breath This in turn causes a gagging reflex and gasping for breath This has
been reported to be a response to bronchoconstriction a constriction of the airway 2 5 Repeated exposure
can cause tachyphylaxis a decreasing response following consecutive administration 2 Furthermore if a
significant amount of the aerosolized product reaches the pulmonary or alveolar region where air exchange
takes place it may greatly interfere with essential respiration This is a primary concern for aerosols generating
a mist or a fog where the aerodynamic particle size is much smaller thus potentially allowing an excess
amount of active ingredient to travel to the alveolar region
STUDY DESIGN
This study was performed to assess the aerodynamic particle size when aerosolized under exaggerated clinical
use conditions The test article was discharged into a 22 liter collection chamber maintained under slightly
negative pressure A total of 14 live MK 4 units were consecutively discharged into a collection chamber
The total discharge time was 5 minutes and 25 seconds The stream impacted the end cap of the chamber at a
distance of 18 inches The aerosol was drawn from the chamber through an exhaust system consisting of a
pre filter a HEPA filter a charcoal filter and a water scrubbing tower The chamber was equilibriated prior to
the initiation of the sampling by completely discharging one MK4 into the chamber
The aerosol was sampled using a cascade impactor which was attached to a dry gas meter and a vacuum
pump The filters within the cascade impactor were weighed prior to initiation of the sampling and upon
completion A controlled amount of aerosol was drawn from the chamber at a rate of 7 liters per minute for
5 minutes to ensure an adequate sample
RESULTS
A total of182 grams of the test article was discharged into the 22 liter collection chamber This produces an
aerosol concentration of057 mgL resulting in an estimated aerosolization rate of0001 Of the percent
aerosolized the mass median aerodynamic particle size and geometric standard deviation was calculated
to be 6Op 42p microns The aerodynamic particle size range would theoretically result in a 70 nasopha
ryngeal deposition a 20 tracheobronchial deposition and a 10 alveolar deposition 3 4
Based upon the experimental results for the MK4 values were calculated for recommended one
Milligrams per burst were calculated by dividing the content weight by the average number of bursts for each
container This number was multiplied by the aerosolization rate of0001 determined in the analysis
in order to calculate the milligrams aerosolized in each one second burst Based upon a particle size of




MK3 MK4 MK5 MK6
Net Weight 417 grams 850grams 417 grams 193 grams
Avg 1 Second Burst 8 19 8 4
mgBurst 5213 4474 5213 4825
mg Aerosolized 05213 04474 05213 04825
Naso har n eal 03649 mg 03132 mg 03649 mg 03378 m
Tracheobronchial 01043 mg 0895 mg 01043 mg 0965 m
Pulmonary 0521 mg 0442 mg 0521 mg 0482 mg
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hen the agent is inhaled, the respiratory tract is infla ed, resulting in a s elling of the ucous e branes 
lining the breathing passages, and te porarily restricting breathing to short, shallo  breaths (6). Inhalation 
causes coughing  s rt  f r t . i , i  t r ,   ging r fl   i g f r r t . i  s 
been reported to be a response to bronchoconstriction, a constriction of the airway (2, 5). Repeated exposure 
can cause tachyphylaxis, a decreasing response follo ing consecutive ad inistration (2). Further ore, if a 
significant amount of the aerosolized product reaches the pulmonary or alveolar region, where air exchange 
takes place, it ay greatly interfere with essential respiration. This is a pri ary concern for aerosols generating 
a ist or a fog here the aerodyna ic particle size is uch s aller, thus potentially allo ing an excess 
amount of active ingredient to travel to the alveolar region. 
  
This study as perfor ed to assess the aerodyna ic particle size hen aerosolized under exaggerated clinical 
use conditions. The test article as discharged into a 22-liter collection cha ber aintained under slightly 
negative pressure. A total of 14 live MK-4 units were consecutively discharged into a collection chamber. 
The total discharge ti e was 5 inutes and 25 seconds. The strea  i pacted the end cap of the cha ber at a 
i t  f  i .  r l  r  fr  t  r t r   t t  i ti  f  
pre-filter, a EPA filter, a charcoal filter and a ater scrubbing to er. The cha ber as equilibriated prior to 
the initiation of the sampling by completely discharging one MK-4 into the chamber. 
The aerosol as sa pled using a cascade i pactor hich as attached to a dry gas eter and a vacuu  
pump. The filters within the cascade impactor were weighed prior to initiation of the sampling and upon 
completion. A controlled amount of aerosol was drawn from the chamber at a rate of 7 liters per minute for 
5 inutes to ensure an adequate sa ple. 
 
A total of 1,182 grams of the test article was discharged into the 22-liter collection chamber. This produces an 
aerosol concentration of 0.057 glL resulting in an esti ated aerosolization rate of 0.0001 %. f t  r t 
aerosolized, the ass edian aerodyna ic particle size and geo etric standard deviation as calculated 
to be 6.0fJ ± 4.2fJ (microns). The aerodyna ic particle size range would theoretically result in a 70% nasopha-
ryngeal deposition, a 20% tracheobronchial deposition, and a 10% alveolar deposition (3, 4). 
Based upon the experi ental results for the K-4, values were calculated for reco ended one. 
-3 -4 -5 -6 
Net Weight: 41.7 grams 85.0 gra s 41.7 gra s 9.3  
Avg. 1-Second Burst:     
glBurs :     
mg Aerosolized: .5213 . 47  .521  .482  
p y g l: 0.3649 g 0.3132 g 0.3649 g . 37  g 
i l: 0.1043 g 0.0895 g 0.1043 g .096  g 
Pul onary: 0.0521 g .044   .052   0.0482 g 
Milligrams per burst were calculated by dividing the content weight by the average number of bursts for each 
container. This number was multiplied by the aerosolization rate of 0.0001 % determined in the analysis, 
in order to calculate the milligrams aerosolized in each one-second burst. Based upon a particle size of 
6.0fJ ± 4.2fJ, the theoretical deposition for each region of the respiratory tract as calculated. 
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DISCUSSION
This study was designed under exaggerated clinical conditions in order to provide valuable information on the
safety of these products For example the material was impacted from a minimal distance of 18 inches onto a
flat surface This close distance and flat surface produces an elevated aerosolization rate compared to what
would be expected in true field exposures In addition the aerosol generated was maintained in an enclosed
container allowing the aerosol concentration to remain unaffected by movement or natural influences such as
a breeze Other considerations and factors that would influence the exposure would be impaction in the close
proximity of the nasal andor oral cavities and respiration at the time of impact
CONCLUSION
Based upon an average 70 kg human the MK3 and MK5 produce a00074 mgk pulmonary dose while
the MK4 and MK6 produce00064 mgk and00069 mgk pulmonary dose respectively All three
values would be considered low under ideal clinical exposures However it should be noted that individuals
with respiratory conditions such as emphysema asthma or bronchitis may be more sensitive to any
foreign agent
The delivery systems used in the products mentioned above produces a stream of ballistic droplets
This mechanism proves to be very advantageous from both a tactical ie accuracy and distance and a
safety viewpoint Because the agent is dispensed in this form very little of the product becomes aerosolized
minimizing the potential for pulmonary exposure This is the distinct advantage over aerosols generating
similar particles in a mist or fog
REFERENCES
Chemical Agent Research Oleoresin Capsicum US Department of Justice Federal Bureau of
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J Appl Physiol 58 10801084 1985
3 Gordon T and Amdur MO Responses of the Respiratory System to Toxic Agents In Amdur MODoull
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Ch 12 pp 391 392
4 Kennedy GLJr INhalation Toxicology In HaycsAEed Principles and Methods of Toxicology Vol 2
Raven Press New York 189 Ch 12 pp 361 366
5 Lammers JwJ P Minette MT McCusker KF Chung and RJ Barnes Capsaicin induced
bronchodilation in mild asthmatic subjects possible role of nonadrenergic inhibitory system The American
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I  
This study was designed under exaggerated clinical conditions in order to provide valuable information on the 
safety of these products. For example, the material was impacted from a minimal distance of 18 inches onto a 
flat surface. This close distance and flat surface produces an elevated aerosolization rate co pared to what 
ould be expected in true field exposures. In addition, the aerosol generated as aintained in an enclosed 
container, allo ing the aerosol concentration to re ain unaffected by ove ent or natural influences such as 
 r . t r i r ti   f t r  t t l  i fl  t  r  l   i ti  i  t  l  
r i it  f t  l /or r l iti ,  r ir ti  t t  ti  f i ct. 
 
Based upon an average 70 kg hu an, the K-3 and K-5 produce a 0.00074 glkg pul onary dose, hile 
t  -4  -6  . 06  glkg  . 06  glkg l  se, ctively. ll t  
values ould be considered lo  under ideal clinical exposures. o ever, it should be noted that individuals 
it  r ir t r  iti   as a, t a, r r iti    r  iti  t   
f i  t. 
 liv ry syst s s  i  t  r cts ti  v  r c s  str  f llistic r l ts. 
i  is  r  t   r  t  fr  t   t ti l, i.e., r   i t ,   
safety viewpoint. Because the agent is dispensed in this form, very little of the product becomes aerosolized, 
minimizing the potential for pulmonary exposure. This is the distinct advantage over aerosols generating 
i il r rti l  i   i t r f g. 
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Material Safety Data Sheet
May be used to comply with OSHAsHazard Communication Standard





SECTION 1 CHEMICAL PRODUCT COMPANY IDENTIFICATION
Mentdoclurets
CF171 PITV MAI HDACAITrD0r0A WotracEmergency Phone Number
Address










SABRERDPCone 5200BTC 5200BTRC 520001 C 521010C 721010C 520010C
520010CSW 520020C 5200201520030C 5200301920050C 920060 C
ISECTION 2 HAZARDOUS INGREDIENTS IDENTITY
Hazardous Components chemical common names contents OSHA PEL ACGIH TLV Carcinigen Yes r No
Oleoresin Capsicum 10 NA NA No
Scoville Heat Units 2000 NA NIA No




HFC 134a is the exclusive propellant
Major Capsaicinoids are determined viaAOCMethod 99503 Other ingredients are trade secrets as
defined In Hazard Communications ACT 29 CFR 191020 Para 1 1 end Appendix D to CFR 191020
SECTION 3 HAZARD IDENTIFICATION I
SEVERE SKIN AND EYE IRRITANT CONTENTS UNDER PRESSURE KEEP OUT OF THE REACH OF
CHILDREN DO NOT PUNCTURE OR INCINERATE CAN DO NOT EXPOSE TO HEAT OR STORE ABOVE
120 F DO NOT USE AFTER CANISTERSEXPIRATION DATE
HMIS Ratings Health 2 Fire 1 Reactivity 0
Signs Symptoms Of Exposure Ingredients cause irritation through all routes of entry
EYE Liquid or vapors may cause redness burning tearing swelling andor pain
SKIN Frequent or repeated contact with skin may cause skin irritation and dermatitis
INGESTION Ingestion may cause nausea vomiting andor diarrhea
INHALATION May cause irritation of the respiratory tract
MEDICAL CONDITIONS AGRAVATED May cause more severe temporary effects on those persons
who are asthmatics or suffer from emphysema
CARCINOGEN DATA None of the Ingredients in this product are listed with OSHA IARC or NTP
as cacinogenic
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t i l f t  t  t 
 be us  to co ply ith SHA's z r  o unication Standard, 
29 eF  1910. 1200. t r    reviewed f r s ifi  requirements. 
SECTION 1 ~   &  I I I I  
NFIDENTIA  
  one 
Quick Identifi  
1/1/201  
SECURITY EQUIPMENT CORPORATION 
Infotrae r cy Pho e Number: 
800-535-5053 
Address: 
   RIVE Ot o Ca"s: 636-343-0  
City. St."', Zip T N,   F •• Number: -3 -  
Chemlc., Name: 
Oleoresin i  (  Pepper) 
ll's: 
·e. . 2·FL· e· , 
TTSdeNamo: 
 ed PS  ·e. ·e. 5 · . ·e. - , ·  
·C·S .52002 - , . . · . 52 · . · .920 ·  
ISECTI N 2 -  I  I  
li_zardous Component{s) (chemical & eOJlVnon name(s) C lant(s)  L I TLV Careinigen (Yes I No) 
l i  i : 0% /A /A  
Scoville Heat Units ,000,000 /A /   
j  i i i  .3 % /A /A  
Capsaicin CAS #404·86-4 
r i r i   #1940 ·8 ·5 
i r i i   #28789·3  
    i  l ant. 
ajor apsaicinoids are deter ined via .OAC. ethod 995.03. ther ingredients are trade secrets as 
defined in azard o unications A T 29 F  1910.1200 Para 1 (1) end Appendix  to F  1910.1200. 
I I  ·  I I I  
 I    I I . TS  .       
.      .         
0 . 00    ISTER'S  . 
I  : lt :  ir :  tivity:  
igns & y pto s f xposure: Ingredients cause irritation through all routes of entry. 
EYE: Liquid or vapors ay cause redness, burning. tearing, s elling and/or pain. 
I : r t r r eated c tact it  i   se i  irrit tion d r titi . 
I : I tion y use , , nd/or i . 
I I : ay c se irritation f t  r s ir t ry tr ct. 
MEDICAL CONDITIONS AGRAVATED: May cause more severe, temporary, effects on those persons 
ho are asth atics or suffer fro  e physe a. 
CARCINOGEN : one f t  Ingredients i  this r uct re listed ith , I  r  
as c i . 
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SECTION 4 FIRST AID MEASURES
Remove victim from contaminated area and remove contaminated clothing
emer FirstAidPWeres Provide fresh air irrigate with copious amounts of cool water Obtain medical
advice is symptoms persist
innaiaron provide fresh air
Rz
Eyes Only exposed subject or EMS should remove subject contact lenses
Ouw Rb Irri ate with cool water at least 15 minutes or until relieved
s skin Flush with cool water Wash with mild soap and water
4 rngesUon Rinse mouth with water Ingest milkor water Obtain medical
advice Immediately
SECTION 5 FIREFIGHTING MEASURES
Flammability Classification iB CFR 150045 Non Flammable Electronic Immobilization Device Compatible
Flash Point 106 C 228 F
Tempe
Extinguishing
e Halon Carbon Dioxide D Chemical or Waterempeatur 228 C 442 F Media ry
Special Fire
Fighting Wear respirator or self contained breathing apparatusProcedures
Unusual Flea and
Explosion Smoke would be irritating to eyes and mucous membranes
Hazards
S ACCIDENTAL RELEASE MEASURES
Slaps fo toaowilmatenal isspitted or Wipe up small spills with absorbent material With large spills uset
respiratory equipment to avoid irritation and collect absorbent materials
Ifinside Ventilate area and after absorbent process wash area with soap and cold water
Itoutside Stay upwind
SECTION 7 HANDLING AND STORAGE I
pose
Store upright in a cool dry area Avoid direct light and heat
storage pPrecautions to be taken in handoGng DO NOT ex to tem eratures over 120 degrees F
DO NOT puncture or incinerate container
Other Precautions Assure can is in a secure place to prevent accidental rupture
ISECTION 8 EXPOSURE CONTROLS AND PERSONAL PROTECTION
ResphatoryProtection Not required under normal conditions of use
Ventilation Yes
ProtectiveGloves Suggested not required
Eye Protection Yes Exposure without protection in training environment is acceptable
Other Protoctive Clothing or
NotrqEquipment
workMygienic Practices Normal
SECTION 9 PHYSICAL CHEMICAL PROPERTIES I





230 C 446 F
Specirrc Gravity iH2O
1 095 @ 20 C
solubo
Soluble VVorPressure 100 Psi
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002036
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I S I  4 • FIRST I  EA  
Remove victim from contaminated area and remove contaminated clothing. 
Emetgency&FirsIAldPfOl: •• dureo: Provide fresh air, irrigate with copious a ounts of cool water. Obtain medical 
advic  is sy pto s persist. 
1. Inhale/ion: Pr ide fresh air. 
2. Eyes: 
nly expos  subject or E  should remove subject's contact lenses. 
Ro tes Of Enby Irri ate with cool water at least 1  inutes, or until relieved. 
3. Skin: Flush ith cool water. ash ith il  soap and ater. 
4. Ingestion; 
i  o t  it  ater. Ing t ilk  ater. btain edical 
i  I ediately. 
ISECTION 5 - IRE-FI I   







Unu.UB' Firs and 
Explosion 
Ho%anls: 
> 06°  (2 8° ) 
80  (4 ° ) 
'J li i i g 
edia: alon,  i xide, ry l  t r 
r i   l - t i  i  ratus. 
        ranes. 
SECTION 6 -    
S1epstofoUowifma18riali •• piHad()T ipe up small spills with absorbent material. With large spills, use 
rotea.ad: r ir t r  i t, t  i  irrit ti ,  ll t r t t ri l . 
II inSide: entilate area and after absorbent process, ash area ith soap and cold ater 
/I outside:  i  
ISECTI   - I    
PreCBlJlionsto be take" in h.ndoUng 
'storags: 
OlhOf Precautions: 
tore upright in a cool, dry area. void direct light and heat. 
  x  t  t r t r  r  r  . 
  t r  r i i  i r. 
ssure can is in a secure place to prevent accidental rupture. 
SECTION 8 -  S   I  
Respiratory ProlacliOt1: ot r quired nder r l i  f . 
Ventilallon: Yes 
pror9ctiv9 Gloves: sted (not r ) 
Eye Proleclion: Yes. Exposure without protection in training environ ent is acceptable. 





ISECTION 9 - PHYSICAL & I L P PERTIES 
Appesfanco & 
Odor: ed/Orange in col . Odor is pungent 
Bouing /"oint: 
230° C (446° F) 
Solubility in Water. Soluble Vapor Pre sure: 1 0 PSI 





SECTION 10 STABILITY AND REACTIVITY
stability
Unstable





May Occur Hazardous Decomposition Products NAPo mariza
tail Not Occur X
Conditions To
Awld
SECTION 11 TOXICOLOGICAL INFORMATION
Standard Dralze Test Severity Mildly Irritating
Skin rabbit 500 m
Standard Draize Test Severity Mildly Irritating
Eye rabbit 100 mg
ACUTE INHALATION LC50 rat 1005mglL
SECTION 12 ECOLOGICAL INFORMATION
This product has not been tested for environmental effects
I SECTION 13 DISPOSAL CONSIDERATIONS I
WasteDisposal Methods Consult Federal State and Local Regulations
Evacuate contents in a safe area dispose of container
SECTION 14 TRANSPORT INFORMATION I
SECTION 15 REGULATORY INFORMATION I
TOXIC SUBSTANCES CONTROL ACT This product is incompliance with the USToxic Substances
Control Act TSCA inventory requirements
SARA TITLE IIi SECTION 313 Not Listed
CLEAN AIR ACT CAA Not Listed
CLEAN WATER ACT CWA Not Listed
CALIFORNIA PROPOSITION 65 Not Listed
CANADIAN WORKPLACE HAZARDOUS MATERIALS INFORMATIONS SYSTEMS WHMIS Not Listed
SECTION 16 OTHER INFORMATION
Supercedes any prior versions
DISCLAIMER The information contained herein is based upon data provided to us by our suppliers and reflects our best Judgement
However no warranty of merchantability fitness for any use or any other warranty is expressed or Immplied regarding the accuracy of such
data or the results to be obtained from the use thereof Since the information contained herein may be applied under conditions beyond
our controland with which we may be unfamiliar we do not assume any responsibility for the results of such application The information is
furnished upon the condition that the persons receiving it shall make their own determination of the suitability of the material for anv
particular purpose
Page 3 of 3 SECO00024
GROUND AIR
Proper Shipping Name Consumer Commodity Consumer Commodity
Hazzard Class or Division ORMD Class 9
Identification Number none ID 8000
Packaging Group none none
Labels Required none Class 9 Miscellaneous
INTERNATIONAL TRANSPORTATION REGULATIONS
GROUND AiR OCEAN
Proper Shipping Name Consumer Commodity Consumer Commodity Aerosols NonFlammable
Hazzard Class or Division ORMD Class 9 2
Identification Number none ID8000 UN1950
Packaging Group none none none
LabelsRequired none Class 9 Miscellaneous Class 2
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I SECTI  10 • STABILITY AND REACTIVITY 






Hazardous Decomposit on Product.: NI A 
Will Not Occur X 
Condffl"". To 
Avoid 
I  11 • TOXI  INF I  
Standard Draize Test: Severity: Mildly Ir itating 
Skin, rabbit. 500 mg 
Standard Dralze Test: everity: ildly Ir itating 
Eye, rabbit, 100 g 
T  I L TI  L 50 (rat): > 10 .5 /  
I SECTION 12·  I  
i  r     t  f r ir t l ef ects. 
 I  · I  I I  
Waste Disposal Methods: 
onsult Federal, tate, and Local egulations 
t  t t  i   f  , & i  f tainer. 
I I  ·  I I  
DOT HM·181 INFORMATION 
GROUND 
 i i  : onsu er o odity onsu er o odity 
azzard lass or ivision: -O   
Identification u ber:  10-800  
ing :   
l{ ) ired:  l   i ll  
I I L I  I  
R UND I   
roper ipping : r it  Consu er Co odity Aerosols, Non-Fla able 
azzard l ss r ivisi : -O l   .2 
Identification Number: ne 10-8 00  
k ging : 
bel(s) i : 
e 
ne 
I TI  15 • LATORY I ATION 
  
l ss 9 i ll  lass  
T XI  TANCES TR L : is r ct i  in compliance ith the .S. xic tances 
ontrol Act (TSC ) inventory reqUirements. 
SARA I L  III, SECTION 3 : ot Listed 
CLEAN AI  ACT (CM): ot Listed 
CLEAN ATE  ACT (C ): ot Listed 
CALIFORNIA PR POSITI N 6 : ot Listed 
I 
CANADIAN WORKPLACE HAZARDOUS ATERIALS INFORMATIONS SYSTEMS (WH IS): ot Listed 
I SECTION 16· OTHER INFORMATION 
Format and Preparation Complies with ANSI Z400.1-1993 
Supercedes any prior versio . 
DISCLAIMER: The information contained herein is based upon data provided to us by our suppliers. and renects our best Judgement. 
However, no warranty of merchantability, fitness for any use, or any oth<lr warranty Is expressed or Immplled regarding the accuracy of such 
data. or the results to be obtained from the use thereof. Since the information contained herein may be applied under conditions beyond 
our controland with which we may be unfamiliar. we do not assume any responsibility for the results of such application. The information is 
furnished upon the condition that the persons receiving it shall make their own determination of the suitability of the materiAl for anv 
particular purpose, 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA













I Christopher C Burke being first duly sworn upon oath state as follows
1 I am one of the attorneys of record for Defendant Security Equipment Corporation
SEC or Defendant and submit this Memorandum of Costs Memorandum on behalf of
SEC pursuant to Idaho Rules of Civil Procedure Rule 54d1 and this Courts Judgment
entered October 20 2011 Judgment
2 To the best of my knowledge all of the cost items claimed in this Memorandum are
costs as a matter of right pursuant toIRCPRule 54d1Cwere necessarily incurred by
SEC and are correctly computed and in compliance with Rule 54d1
SECURITY EQUIPMENT CORPORATIONSMEMORANDUM OF COSTS Page 1
14542011 421801doc
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Christopher C. Burke, ISB #2098 
homas J. loyd III, ISB #7772 
REE ER BURKE S KER  
950 . annoc  tr t, ite 9  
oise, Idaho 83702 
Tel: (208) 319-2600 
Fax: (208) 319-2601 
ttorneys for efendant 
KJV ~  2011 
IS .... ".c D, i , lerk 
y L Y~'>lIA HOUJ1ES 
DEPUTY 
 E IS    E   IS    
S  F I , I   F    F  
I IE J  J , a  i i i al, 
Plaintiff, 
v. 
I  I  
CORPORATION, a issouri corporation, 
ant. 
   ) 
)ss. 
County of da ) 
as  o.: -PI-  
  
PORATION'S   
 
I, Christopher C. Burke, being first duly s orn upon oath, state as follo s: 
1. I a  one f the attorneys f record for efendant ecurity quip ent orporation 
("S "  "Defen t"),  i     t  ("Memora ")  l  f 
SEC, pursuant to Idaho Rules of Civil Procedure Rule 54(d)(1) and this Court's Judg ent 
entered October 20,2011 ("Judgment"). 
2. o the best of y kno ledge, all of the cost ite s clai ed in this e orandu  are 
costs as a atter of right, pursuant to I.R.C.P. Rule 54(d)(1)(C), ere necessarily incurred by 
SEC and are correctly computed and in compliance with Rule 54(d)(1). 
SECURITY EQUIP ENT CORPORATION'S E ORANDU  OF COSTS - Page 1 
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3 The following are costs due SEC as a matter of right pursuant to IRCP Rule
54d1C
a Filing Fees Rule54d1C
04210 Ada County Court Filing Fee Answer 5800
b Service Fees Rule54d1C2
0610TriCounty Process Service Service to 4900
IDOC with subpoena on06710
0610Tri County Process Service Service to 4900
IDOC with amended subpoena on06910
Total for Service Fees 9800
c Witness Fees Mileage for Depositions Rule54d1C3 4
Dr JanetODonnell 2500
Dr Daniel Hendrickson 2600
Total forWitness Fees for Depositions 5100
d Depositions Reporting Transcribing and a coveRule54d1C9 10
03171 Deposition of Robert Nance 60745
0151 Deposition ofBillie Jo Major Vol I 83456
0161 Deposition of Billie Jo Major Vol II 42322
02141Deposition of Brett Kimmell IDOL 147882
02151Deposition of Nicholas Doan Sara Link and 41056
Joshua Overgaard all of IDOC
0311 Deposition ofDr Daniel Hendrickson 82591
03811 Deposition of Dr William Loveland 4582
03911 Deposition ofDr JanetODonnell 3525
04191 Deposition of Dr Garold Yost 102355
04211 Deposition ofDr Karen Pacheco Vol I 58165
042211 Deposition ofDr Karen Pacheco Vol II 27593
06311 Deposition of Gary R Couillard CPA 54226
06911Deposition ofDr Roberto Negron 55570
062311Deposition ofDr Mary BarrosBailey 73245
063011 Deposition of J P Purswell 155568
Total for Depositions 1165837
SECURITY EQUIPMENT CORPORATIONSMEMORANDUM OF COSTS Page 2
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. he follo in  r  sts   s  atter f ri t, rs t t  LR.C.P. l  
54( d)(1 )(C): 
. iling es - le 4(d)(1)(C)(1) 
04/02/10 da County Court Filing Fee -  
. ice ees - le 4(d)(1)(C)(2) 
0611611 0 Tri-County Process Service (Service to 
I  it  s ena  6/0 /10) 
06/16/10 ri- ounty rocess ervice (Service to 
I  ith a ended subpoena on 06/0911 0) 




. itnes   & ileage  iti - e 4(d)(1)(C)(3) & (4) 
.  'Do nell 
.  ickson 




. ions (Re ,    opy)- ule 54(d)(1)(C)(9) & (1 ) 
03/17/11 eposition of Robert ance 
01105/11 Deposition of Billie Jo ajor (Vol. I) 
01106111 eposition of illie Jo ajor (Vol. II) 
02/14111 eposition of rett i ell (ID C) 
02115/11 Deposition of Nicholas Doan, Sara Link and 
Joshua Overgaard, all of IDOC 
03/03111 eposition of r. aniel endrickson 
03/08/11 Deposition of Dr. illiam Loveland 
03/09111 eposition of r. Janet 'Donnell 
04/19/11 eposition of r. arold ost 
04121111 eposition of r. aren Pacheco (Vol. I) 
04/22/11 Deposition of Dr. Karen Pacheco (Vol. II) 
06/03/11 Deposition of Gary R. Couillard, CPA 
06/09111 Deposition of Dr. Roberto Negron 
06/23111 Deposition of Dr. ary Barros-Bailey 
06/30/11 eposition of J. P. Purs ell 
otal for epositions 
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m
e Expert Fees to Testify at Deposition Rule54d1C8
Dr JanetODonnell 14000
Dr Mary BarrosBailey 7600
J P Purswell actual43927 2000
Dr Roberto Negron actual23500 000
Dr Karen Pacheco actual 8800 2000
Gary R Couillard CPA 82500
Dr Garold Yost 18000
Total for Expert Fees for Depositions 107850
f TOTAL OF COSTS AS A MATTER OF RIGHT
4 Attached to this Memorandum as Exhibit A is a true and accurate copy of excerpts
from my firmsTransactions Cost Listing printout This printout is taken from the firms
bookkeeping database It accurately reflects costs incurred and paid by my firm on behalf of
SEC during the course of this litigation This printout supports the costs claimed in this
Memorandum under the categories of filing fees service fees witness fees and some but not all
of the expert witness fees and deposition fees and costs Other expert witness fees and
deposition fees and costs were paid directly to the vendor by SECsliability insurance carrier
Admiral Insurance Company on behalf of SEC rather than being advanced by my firm
5 Attached hereto as Exhibit B are true and correct copies of the invoices or other
documentation supporting and documenting the costs claimed in this Memorandum under the
categories of filing fees service fees witness fees one of the deposition transcript costs and
some but not all of the expert witness fees Other expert witness fees and deposition transcript
costs were paid directly to the vendor by SECs liability insurance carrier Admiral Insurance
Company on behalf ofSEC rather than being advanced by my firm
6 Attached to this Memorandum as Exhibit Care true and accurate copies of invoices
reflecting the amounts actually paid by Admiral Insurance Company on behalf of SEC for
SECURITY EQUIPMENT CORPORATIONSMEMORANDUM OF COSTS Page 3
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. t ees t  e ti  t itio  - le 4(d)(1)(C)(8) 
.  'Do ne  
r. ary arros- ailey 
J. P. Purs ell (actual $4,439.27) 
r. erto e r n (actual $2,350. 0) 
r. aren  (actual $2, 80.00) 
ary R. ouillard, P  
. a ld ost 
Total for Expert Fees for epositions 
f.   S      
$1,400.00 
60. 0 
,0 0. 0 
2,0 0. 0 





. tached  t s   t "A"         
fro  y fir 's "Transactions Cost Listing" printout. s      's 
bookkeeping database. It accurately reflects costs incurred and paid by my firm on behalf of 
SE  during the course of this litigation. This printout supports the costs clai ed in this 
e ra  r t  t ri s f fili  f s, s r i  f s, itness f s  s , t t ll, 
of the expert itness fees and deposition fees and costs.      
deposition fees and costs were paid directly to the vendor by SEC's liability insurance carrier, 
d iral Insurance Co pany, on behalf of SEC, rather than being advanced by y fir . 
5. ttached hereto as xhibit "B" are true and correct copies f the invoices or other 
docu entation supporting and docu enting the costs clai ed in this e orandu  under the 
categories of filing fees, service fees, witness fees, one of the deposition transcript costs and 
some, but not all, of the expert witness fees. Other expert witness fees and deposition transcript 
costs ere paid directly to the vendor by SEC's liability insurance carrier, d iral Insurance 
o pany, on behalf of S C, rather than being advanced by y fir . 
6. ttached to this e orandu  as xhibit "C" are true and accurate copies f invoices 
reflecting the amounts actually paid by Admiral Insurance Company, on behalf of SEC, for 
SEC RIT  E IP E T C RPORATION'S E R  F C STS -   
1454 -  ( 21801.doc) 
deposition reporting transcribing of each deposition and one copy of each deposition all of
which are costs as a matter of right and are being sought in this Memorandum
7 Attached hereto as Exhibit D are true and accurate copies of invoices actually paid
by Admiral Insurance Company on behalf of SEC for expert fees in connection with each
expert testifying at his or her depositions in this matter
DATED thiseday ofNovember 21
IA
SUBSCRIBED AND SWORN TO before me this day ofOctober 2011
SECURITY EQUIPMENT CORPORATIONSMEMORANDUM OF COSTS Page 4
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@y otary Public for Idaho
T Aw o Ak c Residing at Star Idaho







e siti  re orti , tra scri i  f eac  e siti  a  e c  f eac  eposition, all f 
          i     r ndum. 
7. Attached hereto as Exhibit "D" are true and accurate copies of invoices actually paid 
   ny,  l  f ,    i  t   c  
rt t tif i  t i  r r siti  i  t i  tt r. 
 t i  '~   er, 011. 
By __ ~~ ________ ~ ____ ~~ ______ _ 
Christopher C. Burke 
      his~y of ctober, 2011. 
ifot r  lic f r I a  
esi i  at .:=;S=tar=,......,I=d=ah=o"--_________ _ 
o ission xpires: .!<..06~/.!:::22:::!/-==2~0=12"'__ ____ _ 
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CERTIFICATE OFSERVICE
I hereby certify that I caused to be served the foregoing Security Equipment
CorporationsMemorandum of Costs to be served on the following named personson the
date indicated below in the manner indicated below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC





P O Box 7808
Boise Idaho 83707
DATED thisd day ofNovember 2011
CBurke
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Matter 1D Matter Description
14542011 Billie Jo Major v Security Equipment Corporation
Date Description Units Price Value
Component COPY
452010 COPY Photocopies 400 015 600
4210 0 COPY Photocopies 600 015 090
525010 COPY Photocopies 1200 015 180
572010 COPY Photocopies 600 015 090
528010 COPY Photocopies 1900 015 285
642010 COPY Photocopies 600 015 090
682010 COPY Photocopies 700 015 105
6102010 COPY Photocopies 1300 015 195
720010 COPY Photocopies 36400 015 5460
7162010 COPY Photocopies 200 015 030
720010 COPY Photocopies 400 015 060
720010 COPY Photocopies 100 015 150
722010 COPY Photocopies 8500 015 1275
92010 COPY Photocopies 61500 015 9225
9210 0 COPY Photocopies 500 015 750
83120 0 COPY Photocopies 200 015 030
92010 COPY Photocopies 400 015 060
9152010 COPY Photocopies 35100 015 5265
1025010 COPY Photocopies October 2010 30900 015 4635
11250 0 COPY Photocopies November 2010 7600 015 1140
1225010 COPY Photocopies December 2010 63500 015 952
125011 COPY Photocopies January 2011 22500 015 3375
25011 COPY Photocopies February 2011 8200 015 12300
325011 COPY Photocopies March 2011 copied additional documents 144200 015 21630
to send to each ofour three experts in this case as well
as additional documents to produce during the
deposition
425011 COPY Photocopies April 2011 163100 015 24465
525011 COPY Photocopies May 2011 22900 015 345
625011 COPY Photocopies June 2011 95600 015 14340
1120 1 102756AM Page 1
002044
~ 
ransactions ost isting 
atte  I  atter escription 
4542-011 Billie Jo ajor v. Security Equip ent Corporation 
ate escription its ice Value 
Component: COpy 
/5/2010  Photocopies 0. 0 0.15 6.00 
/2112010  Photocopies . 0 .15 0.90 
/25/2010  Photocopies 12.00 0.15 1.80 
/7/2010 py Photocopies . 0 .15 0.90 
/28/2010  Photocopies 9. 0 .15 2.85 
/4/2010  hotocopies 6.00 .15 .90 
/8/2010  t c pies . 0 0.15 1.05 
/10/2010  t c ies 13.00 .15 1.95 
/2012010 py Photocopies 64.00 0.15 4.60 
116/2010 py Photocopies . 0 .15 0.30 
/2012010  Photocopies .00 .15 0.60 
/20/2010 py Photocopies 10.00 .15 .50 
/22/2010  Photocopies 5. 0 0.15 2.75 
1212010  Photocopies 15.00 .15 92.25 
/2112010  hotocopies 0. 0 .15 .50 
/31/2010 py Photocopies . 0 .15 .30 
/212010  Photocopies . 0 .15 0.60 
115/2010  Photocopies 51.00 .15 52.65 
0/25/2010  hotocopies; ctober 2010 09.00 .15 6.35 
1125 2010  Photocopies; November 201 0 6. 0 .15 1.40 
2/25/ 010  t c ies; ece er  35.00 .1  5.25 
125/20 1  Photocopies; January 2011 25.00 0.15 3.75 
/25/20 1  Photocopies; February 2011 20. 0 .15 123.00 
/25/20 1 py Photocopies; arch 2011 - copied additional docu ents ,4 2.00 .15 216.30 
t  s  t   f r t r  rts i  t is s  s ll 
as a iti al c e ts t  r ce ri  t e 
deposition 
/25/20 1  Photocopies; April 2011 ,6 1.00 0.15 24 .65 
/25/20 1  Photocopies; ay 2011 29. 0 .15 34.35 
/25/20 1  Photocopies; June 2011 56. 0 .15 43.40 
111/20 1 0:27:56  Page: 1 
Transactions Cost Listing
Matter ID Matter Description






























92010 EXPC United Parcel Service Express Courier 100 3174 3174
92010 EXPC United Parcel Service Express Courier 100 5519 5519
1032010 EXPC United Parcel Service Express Courier 100 471 471


















Ada County Clerk of the Court Filing Fee Answer
District Court of the Fourth Judicial District Copy of
Summary Judgment Transcript 7141
Kim Madsen Additional costs for 7141 MSJ Hearing
Transcript







M M Court Reporting Service Inc Witness Bob 100 60745
Nance 3172011
Component CTRP 100
Dan J Hendrickson MD Witness Fee
WilliamLoveland MD W fitness Fee
JanatODonnell MD Witness Fee
William Loveland MD Witness Fee
National Jewish Medical and Research Center First hour
ofdeposition ofDr Karin Pacheco
1120 1 102756AM Page 2
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s ti s st isti  
atter ID  cri  
14542-011 illie 10 ajor v. ecurity quip ent orporation 
Date ri tio   ri   
7/25/2011 P  t c ies; July 201 1 ,1 4.00 .15 315.60 
8/25/2011 py t i ;   208. 0 .1  1.20 
9/25/2011 P  t i ;    81. 0 .15 2.15 
10/25/2011  t i ; t r  105. 0 .15 5.75 
onent:  0,617.00 1,5 2.55 
onent:  
4/2/2010   t  l r  ft  urt; ili   - r .00 8. 0 8. 0 
/1/2011  istrict ourt of the Fourth Judicial istrict; opy of .00 04.50 04.50 
r  t r ri t - 114 11 
115/20 1  Ki  adsen; dditional costs for 7114/11 SJ earing .00 4.25 4.25 
ra ri t 
111120 1  i  ; ra ripts  rings  115 11  .00 14.00 14.00 
011 /11 
nt:  .00 20.75 
nt:  
6116/2011   &  rt e rti  ervice, I c.; it ss:  .00 07.45 07.45 
a ce - 117/20 1 
nt:  .00 07.45 
t:  
2118/2011 F  an 1. endrickson, ; itness ee . 0 0. 0 0. 0 
2118/2011 F  llia  o e , ; it   .00 0. 0 0. 0 
118/2011  t 'Do nell, ; itness  .00 0. 0 0. 0 
411/2011 F  i lia  o e a , ; itness  . 0 -20.00 -20.00 
4114/2011  ational s  e ical   r; rst r . 0 80. 0 80. 0 
 i   .  eco 
o ponent: F  5.0  20. 0 
e t: PC 
9/9/2010 P  nited r l r i ; press rier . 0 1.74 1.74 
/9/2010 P  nited l i ; press rier . 0 5.19 5.19 
0/13/2010 P  nited l i ; xpress rier . 0 7.41 7.41 
10113/2 10 P  nited  ; press rier . 0 8.95 8.95 
1111201 I 0:2 :56  Page: 2 
r
Transactions Cost Listing
Matter ID Matter Description
Fax 300 025




Description Units Price Value
1032010 EXPC United Parcel Service Express Courier 100 804 804
1032010 EXPC United Parcel Service Express Courier 100 455 455
122010 EXPC United Parcel Service Express Courier 100 6512 6512
29011 EXPC United Parcel Service Express Courier 100 1083 1083
29011 EXPC United Parcel Service Express Courier 100 1569 1569
23011 EXPC United Parcel Service Express Courier 100 1647 1647
42011 EXPC United Parcel Service Express Courier 100 2385 2385
42011 EXPC United Parcel Service Express Courier 100 1846 1846
42011 EXPC United Parcel Service Express Courier 100 1173 1173
462011 EXPC United Parcel Service Express Courier 100 1723 1723
462011 EXPC United Parcel Service Express Courier 100 3270 3270
462011 EXPC United Parcel Service Express Courier 100 4864 4864
4132011 EXPC United Parcel Service Express Courier 100 1581 1581
420011 EXPC United Parcel Service Express Courier 100 1609 1609
420011 EXPC United Parcel Service Express Courier 100 1966 1966
420011 EXPC United Parcel Service Express Courier 100 2748 2748
420011 EXPC United Parcel Service Express Courier 100 2749 2749
52011 EXPC United Parcel Service Express Courier 100 1966 1966
51512011 EXPC American Express FedEx charge for MSJ Briefing 100 1293 1293
72011 EXPC United Parcel Service Express Courier 100 1651 1651




720010 FAX Fax 500 025 125
720010 FAX Fax 500 025 125
720010 FAX Fax 500 025 125
720010 FAX Fax 500 025 125
720010 FAX Fax 500 025 125
720010 FAX Fax 500 025 125
1120 1 10275 AM Page 3
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,. 
s ti s st isti  
atter I  t r scri  
14542-011 illie J  j r . c rit  i t r r ti  
ate scri i  i  r  l  
10113/2010   r l rvice;  ri r .00 8.0  .0  
10/13/2010 E P  it  r l rvi e; r ss ri r .00 .5  4.5  
12/1/2010 E P  it  r l rvi ; r  ri r .00 5.12 5.12 
2/9/2011  it  r l rvice;  i  .00 0.83 0.83 
2/9/2011  t  r l ervice;   .0  5.69 5.69 
2/23/2011  ite  arcel ervice; ress rier .00 6.47 6.47 
4/412011  ite  r l r i ; r ss ri r . 0 3.85 3.85 
4/4/2011  t   r i ;   .00 8.46 8.46 
/4/20 1  it  l r i ; res  i  . 0 1.73 1.73 
/6/20 1  nited arcel ervice; xpress ourier .00 7.23 7.23 
4/6/2011    r i ; re   .00 2.70 2.70 
4/6/2011 E P  ite  r l r i ; ress ri r .00 8.64 8.64 
4/13/2011  ite   r i ; re   . 0 5.81 5.81 
4/20/2011 P  ite   r i ; re   .00 6.09 6.09 
4/20/2011 E P  ite   r i ; re   .00 9. 6 9. 6 
4/20/2011  nited Parcel Service; Express ourier . 0 7.48 7.48 
4/2012011 P  ite   r i ; re   .00 7.49 7.49 
5/212011 P  ite  arcel er ice; ress rier .00 9. 6 9. 6 
5/   eric  r ss; c x r  f r J ri fin  . 0 2.93 2.93 
171201\  nited Parcel Service; Express ourier .00 6.51 6.51 
t:  4. 0 92. 3 
t:  
7115/2010  a  .00 .25 .75 
/20/2010  ax .00 .25 .25 
712012010  a  .00 .25 .25 
712012010  a  . 0 .25 .25 
7/20/2010  ax . 0 .25 .25 
7/20/2010  ax .00 .25 .25 
7/20/2010 F  Fax . 0 .25 .25 
7/20/2010 F  a  . 0 .25 .25 
111112011 0:2 :57  Page: 3 
r
Transactions Cost Listing
Matter ID Matter Description
14542011 Billie Jo Majorv Security Equipment Corporation
Date Description Units Price Value
8182010 FAX Fax 600 025 150
83120 0 FAX Fax 300 025 075
1052010 FAX Fax 600 025 150
1052010 FAX Fax 600 025 150
1052010 FAX Fax 600 025 150
1052010 FAX Fax 600 025 150
1022010 FAX Fax 600 025 150
27011 FAX Fax 100 025 025
217011 FAX Fax 800 025 200
217011 FAX Fax 800 025 200
3172011 FAX Fax 400 025 100
3182011 FAX Fax 1200 025 300
4142011 FAX Fax 300 025 075
4142011 FAX Fax 300 025 075
4210 1 FAX Fax 1700 025 425
524011 FAX Fax 500 025 125
525011 FAX Fax 400 025 100
612011 FAX Fax 500 025 125
62011 FAX Fax 200 025 050
620011 FAX Fax 900 025 25
83120 1 FAX Fax 800 025 200
920011 FAX Fax 1900 025 475
920011 FAX Fax 3600 025 900
920011 FAX Fax 1800 025 450
9210 1 FAX Fax 400 025 100
1052011 FAX Fax 500 025 125
Component FAX 24800 6200
Component LD
425010 LD Long Distance323010 3500 045 157
625010 LD Long Distance5172010 1400 045 630
11l2011 10275 AM Page 4
002047
fA 
s ti s st isti  
atter I  r scri  
14542-011 illi  10 j r . curit  i t r r ti  
ate cr   r  l  
8/18/2010 F  Fax .00 .25 1.5  
8/3112010 F   .00 .25 0.7  
10/512010   .00 .2  .50 
10/5/2010  ax .00 .2  .50 
10/5/2010 F   .00 .25 .50 
10/5/2010   .00 .2  .50 
10/2212010  a  .00 .2  .50 
21712011 F  Fax \.00 .2  .25 
2/17/2011 F  Fax .00 .2  .00 
2/17/2011 F   .00 .25 .00 
3/17/2011  a  .00 .25 .00 
3/18/2011  a  2. 0 .25 .00 
4/14/2011  Fax .00 .25 .75 
4/1412011   .00 .25 .75 
/21120 1   7. 0 .25 .25 
5/2412011  a  . 0 .25 .25 
5/25/2011   .00 .25 .00 
6/112011   .00 .25 .25 
6/2120 1   .00 .25 .50 
612012011  a  .00 .25 .25 
8/31/201 1  a  .00 .25 . 0 
9/20/2011   9. 0 .25 .75 
/20/20 1  ax 6. 0 .25 . 0 
120/20  1  a  8. 0 .25 .50 
/21120  1  ax . 0 .25 .00 
10/5/2011  Fax .00 .25 .25 
o ponent: F  48.00 2. 0 
t:  
4/2512010  ong istan ; 3/23/2010 5. 0 .45 5.75 
6/25/2010  ong is ta ; 5/17/2010 4.00 .45 .30 
111112011 0:2 :57  Page: 4 
Transactions Cost Listing
Matter ID Matter Description
14542011 Billie Jo Major v Security Equipment Corporation
Date Description Units Price Value
925010 LD Long Distance720010 2600 045 1170
925010 LD Long Distance842010 800 045 360
925010 LD Long Distance892010 800 045 360
1025010 LD Long Distance9152010 11500 045 5175
1025010 LD Long Distance923010 12300 045 553
11250 0 LD Long Distance 1027010 20300 045 9135
11250 0 LD Long Distance 1027010 20100 045 9045
11250 0 LD Long Distance 1027010 600 045 270
1225010 LD Long Distance 11220 0 3800 045 170
1225010 LD Long Distance 113020 0 16100 045 7245
1225010 LD Long Distance 11820 0 1400 045 630
125011 LD Long Distance 1262010 11600 045 5220
25011 LD Long Distance126011 700 045 315
25011 LD Long Distance152011 2500 045 1125
25011 LD Long Distance142011 5600 045 250
25011 LD Long Distance125011 1500 045 675
325011 LD Long Distance216011 2400 045 108
325011 LD Long Distance217011 500 045 25
425011 LD Long Distance342011 1300 045 580
425011 LD Long Distance32011 10800 045 4860
425011 LD Long Distance32011 600 045 270
425011 LD Long Distance31120 1 12600 045 5670
525011 LD Long Distance422011 500 045 25
525011 LD Long Distance42011 900 045 405
525011 LD Long Distance42011 900 045 405
525011 LD Long Distance4122011 1800 045 810
525011 LD Long Distance4142011 10500 045 4725
525011 LD Long Distance420011 4600 045 207
525011 LD Long Distance420011 4700 045 2115
525011 LD Long Distance423011 2200 045 90
1120 1 10275 AM Page 5
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,-
   
atter ID r scri t  
14542-011 illi  J  j r . ecurit  i t r r ti  
Date scri  i   l  
9/25/2010 LD  e; /2 /2 10 6. 0 0.4  11.70 
9/25/2010   e; /4/2010 .0  0.4  .6  
9/25/2010 L   e; /9/2010 .00 .45 .60 
10/25/2010   s ; 115/2010 115. 0 .45 1.75 
10/25/2010 L   s ; 123/2010 23.00 .45 5.35 
11125/2010   ist e; 0/27/2010 03. 0 .45 1.35 
11125/2010   ; 0/27/2010 01. 0 .45 0.45 
11125/2010   ; 0/27/2010 .00 .4  .70 
12125/2010 L   i t ; 111212010 8. 0 .45 7.10 
12125/2010   i t ; 1130/2010 61.00 .45 2.45 
12125/2010   ; 118/2010 4. 0 .45 .30 
1125/2011 L   ; 2116/ 010 16.00 .45 2. 0 
2/25/2011   ; 126/20 1 .00 .45 .15 
2/25/2011  ong ; 15/20 1 5. 0 .45 1.25 
2/25/2011  ong ista ; 114/20 1 6. 0 .45 5.20 
2/25/2011  ong ist ; 125120 1 5. 0 .45 .75 
/25/20 1  ong ista ; /16/20 1 4. 0 .45 0.80 
/25/20 1  ong ista ; 117120 1 . 0 .45 .25 
/25/20 1  ong ista ; /4/20 1 30. 0 .45 8.50 
4/25/2011  ong ista ; /3/20 1 08.00 .45 8.60 
4/25/2011 L   ista ; 13120 1 .00 .45 .70 
/25/20 1  ong ist ; /11120 1 26.00 .45 6.70 
/25/20 1  ong ista ; 4/22/ 0 1 . 0 .45 .25 
/25/20 1  ong ist ; 4/4/20 1 . 0 .45 .05 
5/25/2011  ong s ; /4120 1 . 0 .45 .05 
5/25/2011  ong ista ce; 411212011 8.00 .45 .10 
5/25/2011  ong ista ; 4114/20 1 05.00 .45 7.25 
/25/20 1  ong ista ; 4/20/20 1 6. 0 .45 0.70 
/25/20 1  ong ista ; 4/20/20 1 7. 0 .45 1. 5 
5/25/2011  ong ista ; 4/23/20 1 2. 0 .45 .90 
111112011 10:27:57  Page: 5 
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Transactions Cost Listing
Matter ID Matter Description
St Lukes Film Library FilmCDcopy ofmedical records 100 3500
14542011 Billie Jo Major v Security Equipment Corporation
Boise Surgical Group PACopy fee for medical records 100 3500
Date
832010
Description Units Price Value
525011 LD Long Distance423011 3200 045 1440
525011 LD Long Distance425011 4800 045 2160
525011 LD Long Distance425011 1300 045 585
525011 LD Long Distance426011 4900 045 2205
525011 LD Long Distance426011 4600 045 207
525011 LD Long Distance427011 1600 045 720
525011 LD Long Distance428011 1100 045 495
525011 LD Long Distance428011 5100 045 2295
525011 LD Long Distance4172011 2500 045 1125
525011 LD Long Distance4210 1 600 045 270
525011 LD Long Distance4132011 1200 045 5400
525011 LD Long Distance4152011 1200 045 540
525011 LD Long Distance4192011 2500 045 1125
525011 LD Long Distance462011 4100 045 1845
525011 LD Long Distance420011 1400 045 630
625011 LD Long Distance5102011 800 045 360
725011 LD Long Distance624011 600 045 270
725011 LD Long Distance622011 1500 045 675
725011 LD Long Distance627011 600 045 270
825011 LD Long Distance7152011 2400 045 108
825011 LD Long Distance7182011 1700 045 765
925011 LD Long Distance83120 1 700 045 315




OB Southwest Idaho Ear Nose and Throat Billie Jo Majors 100 300 300
Medical Records Fee
832010 OB Glenn W Moldenhauer DC Billie Jo Majors Medical 100 7500 7500
Records Fee
842010 OB HealthPort Copy ofMedical Records Billie Jo Major 100 10146 10146
112011 102758AM Page 6
002049
s  t  
atter I  tt r scri  
14542-011 ill    . ecurit  i t r t  
Date cri i  i  ri  l  
5/25/2011   ; /23/2011 2. 0 0.4  4. 0 
5/25/2011   ; /25/20 1 8. 0 0.4  1.60 
5/25/2011 L   ; /25/20 1 3. 0 .4  5.8  
5/25/2011   ; /26/20 1 9. 0 0.4  2.05 
5/25/2011   ; /26/2011 6. 0 0.4  0.70 
5/25/2011 L   ; /27/20 1 6. 0 .4  .20 
5/25/2011   ; /28/2011 1. 0 .4  .95 
5/25/2011   i t ; /28/2011 1. 0 .45 2.95 
5/25/2011 L   i t ; 117120 1 5. 0 .45 1.25 
/25/20 1  on  i t ; /21120 1 .00 .45 .70 
5/25/2011 L   ; /13/20 1 20. 0 .45 4. 0 
5/25/2011   st ; 115/20 1 2. 0 .45 .40 
5/25/2011   ist ; 119/20 1 5. 0 .45 1.25 
5/25/2011   ist ; /6/20 1 1. 0 .45 8.45 
5/25/2011  ong istance; 4/20/2011 4. 0 .45 .30 
6/25/2011   s ; 110/20 1 .00 .45 .60 
/25/20 1   ist ; /24/20 1 .00 .45 .70 
/25/20 1   ist ; /22/ 0 1 5. 0 .45 .75 
7/25/2011  ong ist ; /27/20 1 .00 .45 .70 
8/25/2011  ong istance; 7115/2011 4. 0 .45 0.80 
8/25/2011  ong s ; 118/20 1 7. 0 .45 .65 
9/25/2011  ong ista ce; /31120 1 .00 .45 .15 
t:  ,4 3.00 ,0 0.35 
t:  
7/29/2010  t. e's il  ibrar ; ilm/CD c  f e ical rec rds . 0 5. 0 5. 0 
7/29/2010  oise r ical r , .A.;  fee f r i l r r s . 0 5. 0 5. 0 
8/3/2010  Southwest Idaho Ear, ose and Throat; illie 10 ajors - . 0 0. 0 0. 0 
e ic l e rds ee 
/3/2010  lenn . oldenh , ; illie J  ajors - edical . 0 5. 0 5. 0 
ecords Fee 
8/4/2010  HealthPort; Copy of edical Records - Billie Jo ajor . 0 01.46 01.46 
111112011 0:2 :58  Page: 6 
r1
Transactions Cost Listing
Matter ID Matter Description
14542011 Billie Jo Majorv Security Equipment Corporation
Date
PRINT
Description Units Price Value
842010 OB St LukesRegional Medical Center Copy ofMedical 100 7261 7261
525010 PRINT
Records Billie Jo Major
152300 05 7615




8172010 OB Ascensio Duplicates ofCDscontaining radiology films 100 12720 12720
from experts production
9102010 OB HealthPort Copy ofMedical Records Billie Jo Major 100 27194 27194
1022010 OB St Lukes Family Health Billie Jo Major Copy of 100 3200 3200
MedicalRecords
1082010 OB Neurological Associates CTD Medical Records 100 2800 2800
Request Billie Jo Major
1120 0 OB Digestive Health Clinic The Billie Jo Major Medical 100 4850 4850
Records Request
132011 OB Ascensio Scanning litigation and scanning color create 100 6890 6890
CD for database electronic annotations
214011 OB AndysDeli Lunch for deposition of IDOC witnesses 100 2553 2553
215011 OB AndysDeli Lunch for deposition of IDOC witnesses 100 2739 2739
218011 OB Ascensio Duplicate DVD for production to plaintiffs 100 1590 1590
4122011 OB St Alphonsus Physicians Services Deposition 100 14000 14000
attendance fee Dr JanatODonnell
4210 1 OB Ascensio Scan bates additional IDDL production per 100 26563 26563
subpoena
712011 OB Intermountain Vocational Services Inc Testimony 100 7600 7600
623011 Mary BarrosBailey will be donating this fee
to charity
823011 OB Roberto NegronMDTravel time and deposition ofDr 100 23500 23500
Negron
Component OB 200 581140
Component PRINT
325010 Print Copies March 2010 5300 05 265
425010 PRINT Print Copies April 2010 20100 05 1005
Print Copies May 2010
625010 PRINT Print Copies June 2010 16900 05 845
Print Copies July 2010
112011 102758AM Page 7
002050
,J 
ransactions ost isting 
a ter  atter escription 
14542-0 1 Billie Jo ajor v. Security Equip ent Corporation 
ate escription its ice alue 
8/4/2010  t. e's e i al e ical e ter;  f e ical 1.00 72.61 72.61 
e r s - illie J  ajor 
110/2010  fide tial i r , I .; pies f e ical ecords - 1.00 41.34 41.34 
illie 10 ajor 
117/2010  scensio; uplicates of C 's containing radiology fil s . 0 127.20 127.20 
fro  erts & r tion 
110/2010  ealthPort; Copy of edical Records - Billie 10 ajor . 0 271.94 271.94 
0112/2 10  st. e's  lt ; i lie   -   1.00 2. 0 32.00 
e i l ec rds 
0118/2010  eurological ssociates, T ; edical ecords . 0 8. 0 28.00 
equest - illie Jo ajor 
11112010  igestive ealth Clinic, The; Billie 10 ajor - edical . 0 8.50 48.50 
Records Request 
113 2011  scensio; canning litigation and scanning color; create 1.00 8.90 8.90 
 for database; electronic annotations 
114/20  I  Andy's Deli; Lunch for deposition ofIDOC witnesses 1.00 5. 3 5. 3 
/15/20 1  Andy's Deli; Lunch for deposition ofIDOC witnesses 1.00 27.39 27.39 
/18/20 1  scensio; uplicate DVD for production to plaintiffs . 0 15.90 15.90 
1121 0 1  St. Alphonsus Physicians Services; Deposition 1.00 ,4 0. 0 ,4 0. 0 
  - r.  'Do ne  
/21120 1  scensio; can, ates a iti al I  r cti  er .00 265.63 265.63 
subpoena 
11/20 1  I ter tai  cati al er ices, Irk.; esti  - .00 60. 0 60. 0 
6/23/201 1 (Mary Barros-Bailey will be donating this fee 
to charity) 
/23/20  I  Roberto Negron, .D.; Travel time and deposition of Dr. .0  ,3 0. 0 ,3 0. 0 
Negron 
Component: OB 0. 0 ,8 1.40 
Co ponent: PRINT 
/25/2010 I  Print Copies; March 2010 53. 0 .0  .6  
/25/2010  rint opies; pril 2010 01. 0 .0  0. 5 
/25/2010  Print Copies; ay 2010 1,523.00 .0  6.15 
/25/2010  Print Copies; June 2010 69. 0 .05 8.45 
/25/2010  Print Copies; July 2010 97. 0 .0  14.85 
1 11201 I 0:27:58  age: 7 
fI
Transactions Cost Listing
Matter ID Matter Description
14542011 Billie Jo Major v Security Equipment Corporation
Date Description Units Price Value
825010 PRINT Print Copies August 2010 31100 05 155
925010 PRINT Print Copies September 2010 39600 05 1980
1025010 PRINT Print Copies October 2010 17100 05 855
11250 0 PRINT Print Copies November2010 18700 05 5935
1225010 PRINT Print Copies December 2010 50700 05 253
125011 PRINT Print Copies January 2011 24400 05 11220
25011 PRINT Print Copies February 2011 283400 05 14170
325011 PRINT Print Copies March 2011 printed additional documents 425300 05 21265
to send to each of our three experts in this case as well
as additional documents to produce during the
deposition
425011 PRINT Print Copies April 2011 616300 05 30815
525011 PRINT Print Copies May 2011 25200 05 1260
625011 PRINT Print Copies June 2011 19900 05 5995
725011 PRINT Print Copies July 2011 84900 05 425
825011 PRINT Print Copies August 2011 38700 05 1935
925011 PRINT Print Copies September 2011 419500 05 20975
1025011 PRINT Print Copies October 2011 211800 05 10590
Component PRINT 2930900 1465
Component SERV
6162010 SERV TriCounty Process Service upon IDOCJohnMcKinney 100 4900 4900
672010
6162010 SERV Tri County Process Serving Service upon IDOCBill 100 4900 4900
Looms 692010
Component SERV 200 9800
Component TRVL
218011 TRVL Dan J Hendrickson MD Mileage 100 600 600
218011 TRVL William Loveland MD Mileage 100 750 750
218011 TRVL JanatODonnell MD Mileage 100 500 500
412011 TRVL William Loveland MD Mileage 100 750 750
482011 TRVL Cardmember Service Airfare Boise to Salt Lake 100 35740 35740
4182011 C Burke
1120 1 102758AM Page 8
002051
, . 
ans tio s st isti  
atte  I  atter escri tio  
-011 illie J  ajor . rit  quipment r r tion 
te escri tion its rice l e 
/25/2010 T  ; u   311.00 0.05 15.55 
/25/2010 T Print Copies; Septe ber 2010 96.00 .05 19.80 
0/25 2010 T Print Copies; ctober 2010 71.00 .05 .55 
1125/2010 T Print opies; ove ber 2010 ,1 7.00 .05 59.35 
2125/2010 T rint i s; e r  07.00 .05 5.35 
125/20 1 I  ri t i ; r   ,2 4.00 .05 12. 0 
/25120 1  t ;   ,8 4.00 .05 41.70 
/25/20 1  rint opies; arch 2011- printed additional docu ents ,2 3.00 0.05 212.65 
to send to each of our three experts in this case as ell 
s itional ts t   ing t  
deposition 
/25/20 1  Print opies; pril 2011 ,1 3.00 .05 08.15 
/25/20 1 T rint opies; ay 2011 52.00 .05 12.60 
/25/20 1  ri t i s;   ,1 9.00 .05 9. 5 
/25/20 1  Print opies; July 2011 49.00 .05 2.45 
/25/20 1  Print opies; ugust 2011 87.00 .05 9.35 
/25/20 1  ri t ies; e te er  ,1 5.00 .05 209.75 
0/25/20 1  ri t i s; t r  ,1 8.00 .05 05.90 
nt: I  9,30 .00 ,4 5.45 
o ponent: S  
116/2010  Tri-County Process Service upon: !DOC/John cKinney .00 9. 0 9. 0 
- 617 2010 
116/2010  ri- t  r cess ervi ; er ice on: ! IBill .00 9. 0 9. 0 
is - /912010 
nent:  . 0 98.00 
Co ponent: TRVL 
118/20 1  an 1. endrickson, ; ileage .00 .00 .00 
118/20 1  illia  l , ; ileage .00 .5  .50 
118/20 1  Janat 'Donnell, ; ileage .00 .0  .00 
/1120 1  illia  ela , ; ileage .00 -7.50 -7.50 
/8/20 1  ard e ber Service; irfare - oise to Salt ake- .00 57.40 57.40 
118120 1 - .  
111/20 1 0:2 :58  age: 8 
Transactions Cost Listing
Matter 1D Matter Description
14542011 Billie Jo Major v Security Equipment Corporation
Date Description Units Price Value
482011 TRVL Cardmember Service Airfare Boise to Denver 100 5701 5701
420011 C Burke
4210 1 TRVL Christopher C Burke Gas for rental car in SLC Depo of 100 1041 1041
Dr Yost
4210 1 TRVL Christopher C Burke Meals in SLC Depo ofDr Yost 100 1183 1183
4210 1 TRVL Christopher C Burke Parking in SLC Depo ofDr Yost 100 600 600
52011 TRVL Christopher C Burke Gas for rental car in Denver Depo 100 76 76
of Dr Pacheco
52011 TRVL Christopher C Burke Parking for rental car in Denver 100 2675 2675
Depo ofDr Pacheco
52011 TRVL Hertz Corporation The CarRental Denver420 100 19530 19530
42211 deposition ofDr Pacheco
52011 TRVL Hertz Corporation The Car Rental Denver418 100 1275 1275
4191 deposition ofDr Yost
52011 TRVL American Express Lodging in SLC depo ofDr Yost 100 19703 19703
418 4191
52011 TRVL American Express Meals in Denver depo ofDr 100 141 141
Pacheco
51512011 TRVL American Express Lodging in Denver depo ofDr 100 42701 42701
Pacheco 420 42211
525011 TRVL Cardmember Service Airfare Refund Boise to Salt Lake 100 35740 35740
4182011 C Burke
525011 TRVL Cardmember Service Airfare Refund Boise to Denver 100 5701 5701
420011 C Burke
525011 TRVL Cardmember Service Airfare Boise to Salt Lake 100 26740 26740
4182011 C Burke
525011 TRVL Cardmember Service Airfare Boise to Denver 100 3604 3604
420011 C Burke
929011 TRVL Purswell Purswell Engineering Ergonomics Inc 100 43927 43927
Travel expenses for Deposition ofJPPurswell
Component TRVL 2100 610184
Component WEST
29011 WEST West Group Payment Center Westlaw Legal Research 100 382 382
January 2011
4132011 WEST West Group Payment Center Approved Westlaw Legal 100 31897 31897
Research March 2011
1120 1 102758AM Page 9
002052
" 
a s i   i i  
atter ID r scri  
4542-011    . ecurit    
ate cr  i  ri  l  
4/8/2011   rvice; rfa  - se  - .00 70.10 70.10 
120/20 1 - . r e 
4/21/2011   . rke;       -   1.00 10.41 0.41 
r. st 
4/2112011   . rke;    -   r.  .00 1.83 1.83 
4/21/2011   . rke; r    -   r.  .00 .00 .00 
5/5/2011  i t  . rke;   t l  i   -  .00 7.76 .76 
of Dr. Pacheco 
5/5/2011  hristopher . urke; Parking for rental car in enver- .00 6.75 6.75 
e o  r.  
5/5/2011  ertz r oration, e;  tal-  120 - .00 95.30 195.30 
/22 11 - siti   r.  
/5/20 1 TRVL e tz r oration, e;  tal-  118- .00 27.57 127.57 
119 11 - iti   r. t 
/5/20 1  erican Express; Lodging in SL  depo of r. ost- .00 97.03 97.03 
118 - 119 11 
/5/20 1  ic  ss; e ls i   -   . .00 4. 1 4. 1 
o 
5/512011  c  ss; ng     r. .00 27.01 27.01 
ac eco - 4120 - 4/22111 
5/25/2011   r i ; irfare  - ise    .00 - 57.40 - 57.40 
- 4/1812011- C. urke 
5/25/2011   r ; irfare  - ise   - . 0 - 70.10 - 70.10 
4/2012011 - . urke 
5/25/2011   rvi e; irfare - ise   a  - . 0 67.40 67.40 
118/20 1 - . rke 
5/25/2011   r i ; irfare - ise  er- . 0 60.40 60.40 
4/20/2011 - . urke 
9/29/2011   & urs ell ngineering & rgono ics, Inc.; .00 ,4 9.27 ,4 9.27 
ravel expenses for eposition f J.P. urs ell 
e t:  1. 0 ,1 1.84 
nt:  
2/912011  est ro  a e t e ter;  estla  e al esearch - . 0 8.28 8.28 
Ja ar   
4113/2011  est ro  a e t e ter; roved estla  e al .00 18.97 18.97 
es  - arc   
111112011 0:2 :58  Page: 9 
Transactions Cost Listing
Matter 1D Matter Description
14542011 Billie Jo Major v Security Equipment Corporation
Date Description Units Price Value
5102011 WEST West Group Payment Center Westlaw Legal Research 100 6653 6653
April 2011
6102011 WEST West Group Payment Center Westlaw Legal Research 100 1120 1120
May 2011
7122011 WEST West Group Payment Center Westlaw Legal Research 100 36653 36653
June 2011
8102011 WEST West Group Payment Center Westlaw Legal Research 100 21991 21991
July 2011
9132011 WEST West Group Payment Center Westlaw Legal Research 100 8660 8660
August 2011
1082011 WEST West Group Payment Center Westlaw Legal Research 100 45308 45308
September 2011
Component WEST 800 15610
Grand Total 4268200 2032312
1120 1 102758AM Page 10
002053
ra sactio s ost isti g 
atter ID r cri  
14542-011 illi   j  . curi   r ti  
ate scri t  
5/10/2011 EST t  ay t nter;  tl    -
ril  
6/101201 I S  t   t r;     -
  
711212011 S  t r  t ter; tl  l r  -
  
8/10/201 I  t r  t t r; tl  l r  -
l   
9/13/2011     r;   r  -
  




I 11112011 0:2 :58  
i  r  
.00 6.53 
.00 1.20 
.00 6 .53 
.00 19. 1 

















Date452010 Fourth Judicial District Court Ada County NO 0042800
Time 0335 PM Receipt Page 1 of 1
Received of Burke Christopher C attorney for Security Equipm 5800
Fifty Eight and 00100 Dollars
Case CVPI201003515 Defendant Billie Jo Major vs Security Equipment Corporation Amount
11 Initial Appearance by persons other than the plaintiff or petitioner 5800












i e: 3: 5  
FOllrth Judicial istrict ourt - da ounty 
eceipt 
i  f: urke, i t   (att r  f r rit  i  
-Ei   0/1 0 ll r  
se: -PI- -03  f ndant: illi   j  s.   r r ti  
11 - I iti l r   r  t r t  t  l i tiff r titi r 
r:  t  (d ant) 
tal: 
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t t :  
unt T : 
l :  
8. 0 
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June 2014 C69VEDRi EiVE APPTRICOUNTYPROCESS SERVINGLC U 01
POBox 1224 By
Boise ID 83701 GriserR14t9Cs s nwP6W 0208 3444132 Business
2083381530 Fax
Federal Tax ID 820348092 File
f
Invoice96160
Attn Christopher C Burke
GREENER BURKE SHOEMAKER PA




Reference Job96160 when remitting
Billie Jo Major vs Security Equipment Corporation
Case Number CVPI1003615
Documents Subpoena Duces Tecum and Notice of Taking Deposition
Service Upon Idaho Department ofCorrections
Personal Service to John McKinney Deputy Attorney General on tune 7 2010 at230PM
at Idaho Department of Corrections 700 W Jefferson Street Boise ID 83702




Job Notations Subpoena Duces Tecum and Notice of Taking Deposition 2copies of each
DUE ON RECEIPT 4900
Thank You for Choosing
TRCOUNTY PROCESS SERVING LRC
002056
" •  7. 0 
I I ED PPROVED 
J N - 8 ?OtD eb I-   I  .L.C. 
P.o. Box 1224 ' " , • 
, f 1 
(2 ) -413  i  
(2 ) -153  x 
n_ .......... ", 0:>.-.... ". P e::'-iJ--r'-''1...Jr-, --
Qt .. ",,,erc!.'n\:;;;~.""""""" Date ~~J; -
 a  10: ,..0348092 
tt : i t r . r e 
 :   
 .  ., .  
 10  
08-319-2600  
- -26   
f r   #9616   r itting. 
illi      
 H er:, - I- 5  
en1s:  s   ti   i  iti  
ervice pon: Idaho epart ent of orrections 
E!rso l fn ice t  J  i y, E!pUty tt r  r l,  J  ,  at :30 , 
t I  rt t f rr cti s,  , J ff rs  tr et" is , 10  
ac  . eesc  
FHa # 11/S1{;C-11 
I i  #9616  
--< 
ileage  $9. 0 
  $40.00 
l: $49.00 
Job otations: ubpoena uces ecu  and otice f aking epoSition (2 copies f each) 
hank ou for hoosing 
RI-    L ! 




JUN 10 2010 APPROVED
POBox 1224
Boise ID 83701 Greener Burke Shoemaker F Akay200 3444132 Business
208 3381530 Fax 0ate IV
Federal Tak ID 820348092
File
Invoice 96161
Attn Christopher C Burke
GREENER BURKE SHOEMAKER PA HECK F
950 W BANNOCK ST STE 900 ADOBOISE ID 8370
2083192600 Business
2083192601 Fax
Reference lob 66161 when remitting
Billie Jo Major vs Security Equipment Corporation
Case NumberCVP14003615
Documents Subpoena Guess Tecum and Notice of Taking Deposition
Service Upon Idaho Department ofCorrections
Personal Service to Bill Loomis Deputy Attorney General on June 9 2010at328PM
at Idaho Department of Corrections 1299 N Orchard St Suite 110 Boise ID 83706









June 9. 2010 
: D 
JUN t  2010 'I~ PROV  . TRI-CQl1NTY PRQCES  SERVIN  L.l.C. 
P.O. Box 1224 
Boise, 10. 83701 
( 6) 34  Business 
( 8) 338·  Fax 
Greener 6urkeShoemaker p.ABy-----:~(:::.-. -I-r~­
Oate --U~t.:.-\)-
Federal Tax 10: 82"()348092 
t n: ri t  .Burk  
    
9  . BA  T., TE.  
BOISE 1083702 
08-319-  i  
208-319-2601 Fax 
f r c  J  #961   r itti . 
      i  
 er:CV-PI-1003515 
ts: l18 D ce    ti  f i  iti  
r  O :  o.part   s 
rs l rvic  t  iJlloo is, ty tt r y r l,  J  ,  at :28 , 
 I  OE!part t ¢ ti ,  .  t, s it  , i e, 10  
  O.  
 ou f r OOSing 
-  ROCESS I  ! , ' 
--< 
Mileage Fee $9.00 
Service Fee $40.00 
Total: $49.00 
DUE ON RECEIPT: $49.00 
Page 1 of 1
Catherine Houts
From Christina Morrow
Sent Wednesday February 16 2011 356 PM
To Bookkeeping
Cc Kimberly E Aulenbacher Chris Burke
Subject 14542011
I need several checks cut in this case for witness appearance fees and mileage
Check No 1 Dan J Hendrickson MD 2600 witness fee200 and600 mileage
Check No 2 William Loveland MD 2750witness fee 200 and750 mileage
Check No 3 JanatODonnell MD 2500witness fee 200 and500mileage
Please give checks to Kimberly when they are done Need Checks 1 and 2 by 100 am
tomorrow please Thanks
Christina Morrow I paralegal
GIBS greener burkc shoemaker pa
950 w bannock suite 900 1boise I idaho 83702
o208319600if2083196 11c208514897
e cmorrowa2reenerlam
v sn a t atzs id a x sicr3 J w




i e  
: i  rro  
t: , r ry ,  :56  
: ookkeeping 
: i rl  . l r; ri  r  
j t: -011 
I  s r l s t i  t is as  f r itness r  f s  il . 
 .  -----  . ,  - $26.00 (witness  $20.00  $6.00 ) 
 .  ------ illia  l d,  - $27.50 (witness fe  $20.00  $7.50 il e) 
 .  ------- Ja at 'Donnell,  - $25.00 (witness fee $20.00 a  $5.00 ilea e) 
leas  i e s t  i rl  he  t  r  .       0: 0 .m. 
to orro  please. hanks. 
Christina -':lormw I paralegal 
IJ+S greener burke shoe aker p.a. 
950 . bannock, suite 900 1 boise 1 idaho 83702 
0: 08.3 9.2600If: 08.3 9.2601Ic: 08.514.5897 
: morrow(a;greene law.com 
116120 1 
a e  f  
Page 1 of 1
Catherine Houts
From Christina Morrow
Sent Wednesday February 16 2011 356 PM
To Bookkeeping
Cc Kimberly E Aulenbacher Chris Burke
Subject 14542011
I need several checks cut in this case for witness appearance fees and mileage
Check No 1 Dan J Hendrickson MD 2600 witness fee 200 and600 mileage
Check No 2 William Loveland MD 2750 witness fee 200 and750mileage
Check No 3 JanatODonnell MD 2500witness fee 200 and500mileage
Please give checks to Kimberly when they are done Need Checks 1 and 2 by 100 am
tomorrow please Thanks
Christina Moriow paralegal
GtrS greener burke shoemaker pa
950 w bannock suite 900 1Boise I idaho 83702
o2083196 01f2083196 11c208514897
e crnorrowdreenerlawcoin
araIIGre u iedNm tt i ri
iLit 1 U1 J 7iG fFi tG ftstiD L7t3 1 03








t i  t  
r : ri ti  rr  
ent: ay,  ,  :56  
: i  
: rl  . er; i   
j t: -0  
I  s r l s t i  t is s  f r it ss r  f s  il ge. 
 .1 -----  . dri son,  - $26.00 (witness f  $20.00  $6. 0 il ge) 
 .  ------ ia  l nd,  - $27.50 (witness fee $20.00 a  $7.50 ileage) 
 .  -------  'Donn l ,  - $25.00 (witness fee $20.00 a  $5. 0 ilea e) 
lease i e c ec s t  i erl  e  t e  are e. ee  ec s  a    0: 0 a.m. 
 e. ks. 
i ti  "vl no  I l l 
B+S greener lmrk", shoe aker p.a. 
 . ,    b  1 da   
0: 08.3 9.2600If: 08.3 9.2601Ic: 08.514.5897 
e: cmorrow(aigreenerlaw.com 
:;, its rf:'lii.;iHS !,..: pr(ll!lbitl.'d. it h;1\{>, 
y,HL 
118/20 1 






I M COURT REPORTING SERVICE I
FED ID NO 820298125
Excellence in Court Reporting Since 1970
Thomas J Lloyd III
Greener Burke Shoemaker
950 W Bannock Ste 900
Boise ID 83702
EEBilledW
Greener Buke Shoemaker P AA
JUN 16 2011
DOCKffM
Job 26864134 Invoice 3764465 Claim












Return this section with check
SOUTHERN OFFICE
421 WFranklin Street
POBox 2636 Boise ID 83701 2636
208 345 9611 208 345 8800 fax
1800 2349611

















JUNE 15 2011 REBILLING





816 E Sherman Ave Ste 7
CoeurdAlene ID 838144921







Date f !, Ii,/! I 
File # \~~-\ \ 
I &   TI  , I 
ED I . . - 98125 
"Excellence i  ourt rti g i  " 
ill  t : 
Tho as J. Lloyd III 
r ner  r 
 . , t .  
i , I   
~[g@[gDW[g@)Billed: 
ree er UTke r, P .A. 
  6  
,,/ SCANNED /' ROUllID ' --r __ IMPORTED __ DOCKETED 




ajor v. Security Equip ent 
ob ance-30(b)(6) 
/17/20 1 :13:00  
Charges: 
opy of eposition - lectronic nly 
ough raft Provided 
i it  - i   
6/15/2011 finance charge 
1n <e/2~~~ 
CH  # ~AS~E # 11/542- /1 
 $ W2. "5 
l i  # 
$1.95  





8 l   
J  15, 2011 ILLI  
(Return this section with check)  : 
I i  # 
ill : 
 e: 














   I  
 . kl  t  
.O.   is , ill -26  
- -  - -8  (fax) 
- - -96  
email courtreporters m-mservice.com 
emit Pay ent [ ] 
 E. nn  e, te.  
oeur 'Ale , ill 83814-  
2 - -1  -7 -  (f x) 
- - -1  
e ail cs it mrncourt.com 









































































































































































































































































































1"_._ === ===F= keL ==~- sac .~===== NP.. 
PAY 
GREENER BURKE SHOEMAKER P.A. 
950 W. BANNOCK ST. STE. 900 . 
BOISE, 10 83702 
(208) 319-2600 
TO THE St. Alphonsus Physicians Services 
OADEROF 
** One Thousand, Four Hundred & No/10  
10AHOTRUST NAT ONAL BANK 
. 888 W. Broad st. 
. Boise, 1083702 
92·384·124  








St. Alphonsus Physicians Services 
P.O. Box 3930 
OPERATING ACCOUNT 
~ 
Portland, OR 97208-3930 
MEMO 
11·0 It *80711· I: * 21t *038 It *1: *0 *0 *0 *8? 1111· 
GREENER BURKE SHOEMAKER P.A. 
41807 
St. Alphonsus Physicians Services 04/12/11 




















RE MAJOR Billie Jo Date 62311
Date Activity Billing TravelMait Mileage
62311 Testimon 38
Subtotal 38@ 200hr 0 @ 6750hr 0 @ 51mi
TOTAL 76000 0 0
TOTAL DUE7600
Terms Billed monthly and payable within 30 days from date of statement








Bilingual Rehabilitation Counselor PH208298484
Vocational Expert Lite Care Planner POBox 7511 Boise Idaho 837071511 FX208796830
xre R Y o u xix




























E: JOR, illi   
Date 
6/23/11 Testi ony 
Sub-total 
TOTAL 
TIN: 2-049527  
te: /23/11 
cti it  illi a ravel W  ileaae 
3.8 
.8  $20 / r. o  $67.50/hr. O  .51/ i. 
$76 .  $0 $0 
i!'  E: $7 0. 0 
 
By &J3 ~ 
Terms: 0 ill  t ly  le it i    fr  t  f t t t 
o t   f  % per onth (12% per year) ill be charged on delinquent accounts 
TE7)~!D 
HECK # WO? ~F E #Jl-/S qt.-II 
 $ 7~(!) '00 
n:c. , " .. -:;:r.~.==========-,,---,.....-,_. '_ 
Bilingual Rehab litation Counselor. 
Vocational Expert & Life Care Planner .O. ox , Boi , Idaho 83707-15 1 
P  .............. 208.229.8484 
F  .............. 208.279.6630 
b rr sm20 2@gmail.com 
Date P -70-1/ 
il  # 11/7"071 
I N TEA .. 0 U N 1 1 I N 




Colorado Springs CO 80920 1603
719 5921773












Case Re Major v SEC
Date Description Quantity Rate Amount
629011 Travel from COS to BOI i 5 2500 137500
302011 deposition 65 2500 62500
6302011 Travel in Excess of 8 Hours 575 8500 48875
627011 Airfare 60800 60800
29011 Hotel 11701 11701
6302011 Meals 105897679 837378 4028 4028
302011 Car Rental 13723 13723















Terms 99 Due on receipt
002063
ill to: 
 &  
NGINEE I  & NOMICS, I C. 
 ll  ri  
l  prings,  -  
(7 9) -  
  10 ber: 4-14  
ar in verson 
Jones & artz pllc 
PO Box 7808 
ise, 10 -78  
"-
Case  j    
Date i i  
6/29/2011 r v l fr   t  I 
6/3 120 1 i  
6/30/2011 r v l i  xc ss f  rs 
6/27/2011 irf r  
6/29/2011 Hotel 
6/30/2011 ls 0.58+ .76+7.79 + .3 + .78 
6/30/2011 r t l 
6/30/2011 ! i  +6 
I 
Pa ts : 
-
R E (~E 
1~ .l 
I Nv61 E 
Inv i  # 2 8 
Date 7/1/201  
Ter s Due on receipt 
, 
i  t  t J 
! .5 50. 0 ,3 5.00 





5. 0 8 .75 I 
I 
I 08.00 08.00 
i 17.01 17.01 l 
I ! 0.28 0.28 , I 37.23 37.23 ! , 
I I 8. 0 48.00 









I i I 1 , 
I 
I 




t l I $4,439.27 i 
r= 
l ay ents/C red its $0.00 ! 
t---~~~ I ; 
l e  $4,439.27 I I ! ~ 
I
ROBERTO NEGRONMD




To Greener Burke Shoemaker
Christopher Burke Atty
950 W Bannock 900
Boise ID 83702
Phone 208 3502174















692011 Travel time for deposition I hr @ 3500 per hr 3500
692011 Deposition 4 hr @ 5000 per hr 20000
Total Due 235000
002064
 N, .D. 
 .   ET,  101 
ISE, I   (208)323-1 1 25 
lori.clay n@ age-healthcare.co  
t , 01  
: r r r  ak r 
 r ,  
950 w. annock #900 
,   
e: (2 ) 50-2174 







35 . 0 
Page 1 of 1
Catherine Houts
From Kimberly E Aulenbacher
Sent Thursday April 14 2011 834 AM
To Bookkeeping
Subject Check request for TODAY Thursday 0411
Importance High
Please prepare a check as follows and give to me today for faxing with a letter to the deponent
thanks
Payee National Jewish Hospital
Amount 4800
ClientMatter 14542011
Purpose First hour of deposition ofDr Karin Pacheco
Kimberly E Aulenbacher
Legal Secretary to Christopher C Burke
Thomas J Lloyd III William C Tharp
G S greener Burke shoemaker pa













i  . l  
ursday,  ,2  :34  
 
 r t f r  (Thur  4/14/11 ) 
rt :  
Page 1 of 1 
l s  r r    s f ll s  i  t   t  f r f i  it   l tt r t  t  t ~ 
t ks: 
: ti l J is  s it l 
nt: $4 0. 0 
lient/ atter: -01  
e: irst r f siti  f r. ri   
 .  
l    . rke, 
 .   & i  .  
8+S  b   .a. 
  ck, s it  lbois li  83702 
0: 08.350.21741 f: 08.319.2601 








Amount Due OnBefore 0410212011 83456
Amount Due After0422011 91802
Please detach and return this bottom portion with your payment














Thank you for your businessl
076 0000235659 02162011 6 000083456 3 03182011 04022011 8 000091802 50
fi9z00




2700 Centennial Tower PO Box 934157
101 Marietta Street AtlantaGA 311934157





Toll Free 888 4864044
950WEST BANNOCK STREET




ROBERTSTEERE Date of Loss
ADMIRAL INSURANCE COMPANY
1255 CALDWELL ROAD Name of Inaur d WR BERKLEYARMIRALI GREENER
CHERRY HILL NJ 08034 Adjustor C L Fri PENDING
Claim Number C141670
Assignment Case I Assignment Shipped Shipped Via
01105201 1 MAJOR BILLIE JO vs SECURITY EQUIPMENT 196898 01280 1 UPS
Description Amount
Services Provided on01512011 BILLIE MAJOR BOISE ID M i1 r 5
ORIGINAL 8ONEWORD INDEX 210 Pages
a
87150
EXHIBITS U l 1850
APPEARANCE FEE6 Units 00
ASCII DISK e c 00










@ES I  
ir  r r t  l ti  
 t i l r 
101 ri tt  tr t 
l ta,   
  (8 ) -40  
 (8 ) -3  
T T  
@ 
SQ!l..IB.& 
I i  #  
I il:  t  
nn. 
hymen . 
t  f  
e it to: 
ir  l ti  
   
tl t   -415  
ww.esquires lutions.com 
2116/ 0 1 
  
3118 2011 
A I AL I S A E PA Y 
1255 CALD ELL R AD 
  I s re   - l U  
 I ,    .  ,;4!-", I  
l i  r  
 •• i e t al. Auignment #  i   
---;---------------------------+----------r-----------+-------------~ 
01/0512011 ,   .  I   1fl8fl0 1  
:rl ti  
i  i   1/05/20 , I   (B ,I ) 
I I  & NElWORD I  (21  s) 
EX IBITS 
  (6 its) 
II I  
   
  
- I  
V L E IS T % 
G a- I I  
_ED : UfIK , I T PHER o ~ . 
SUITEtIH/ 
fSO S  a  I  
I ,I  U Z 
/\ ~;·)~~r· :' 




)":'~-. ;. . ,., 
r- F..Jy'.> b 




  /Befor  /02  










$- 2. 4 
$ .00 
$ -57.44 




J~~~~~~_~~ ______________________________________________________ _ 
@ 
I ; 
T T E 
AD IRAL   
255   
 , J  
l ase t   m i      t 
r y onnne t ww.esquireco nectnet 
/ _L~. I i  #: 
t : 
  nlBefore 4102/ 011 
   4102 2011 
it t : 
i  l i S 
   
tl t   -415  
ww.esqulreso tions.com 














































MAJOR BILLIE JO vs SECURITY EQUIPMENT
Name of Insured WR BERKLEYARMIRAU GREENER
Adjustor PENDING
Claim Number C141670
Assignment I Case Assignment Shipped Shipped Via
01620 1 200871 012912011 UPS
Description Amount
Services Provided on01612011 BILLIE MAJOR BOISE ID







DISCOUNT VOLUME a1 3148
a 2648
SHIPPED TOSURKE CHRISTOPHERCESQ Tax 00
SUITE 900
950WESTaANNOCK STREET Paid 00
BOISE ID 83702
Amount Due OnBefore03172011 42322
Amount Due After03172011 46554
Tax Number
Please detach and return this bottom portion with your payment




Payment Due 0310201 1
ES DIRE Amount DueOnBefore03172011 42322
Amount Due After 0311720 1 46554
ROBERTSTEERE Remit to
ADMIRAL INSURANCE COMPANY
1255 CALDWELL ROAD Esquire Solutions
CHERRY HILL NJ 08034
PO Box 1
Atlanta GA 311934 57
wwwesquiresolutionscom
Thank you for your businessl
076 0000231564 01312011 6 000042322 1 03022011 03172011 6 000046554 02
002068
QESQUH  
i   l i  
 t i l r 
 ri tt  tr t 
l ta,   
  (8 ) -40  




 #  
I i  t  
r s 
  
t  lloa& 
it : 
i  l i  
ID. x  
t   3-  
ww.esquires lutions.com 
1/31 20  
  
 
I  I   
  I   LEY- I   1255 AL ELL A  
 ILL, J 08034 j t r I  
l i  r 7D 
i t I  signment #  I i d i  
0110612011 I J , I I  J  vs. I  I   112912011 I  
i ti  I t 
   1/06120 , I   (B I , ) 
 &   (108 s) $448.20 
I IT  $1.50 
  $0.00 
 I  $ .00 
E-TRANSCRIPT $ .00 
$449.70 
SO-S IPPI  
<r ((J;2. ~.~._ 
$ .00 
.' J. 'i .2~/L._ I -  $- 1.48 
/ ... 
;;... ; . .2 01/ r .''' ~ , . $ -26.48 ~,~ :.'; - . .. , 
. -.---"~ . ~ .... , 
/1,¢t,/ - - , ., i-rt"'-=: .. 
. *,-", .. ' ~ .. ~ .... -
SHlPP£O TO: etJRKE, CHRISTOPHER c. ESQ. : $ .00 
tJl f!9DO 
  B   i : $0.00 
,  3102 
  /Bef  3/17/20 1 $ 23.22 
t  tt r 3117 2011 $465.54 
ax r: U.-vl ,,,go .. -----------------------------------------------------------------
 E 
I  I   
   
 I .   
l se t ch  r t r  t i  tt  rti  it  r t 
r  li   ww. squireco n ct.net 
v,sAIII~1! #: 
t : 
  n/Before 3/17/20 1 
t  ll  311712011 
a it : 
i  l ti  
  934 57 
tl t   1 93-4157 
ww.esquires lutions.com 













































Name ofInsured WR BERKLEYARMIRAL GREENER
Adjustor PENDING
Claim Number 0141670
Assignment I Case Assignment Shipped Shipped Via
0211420 1 MAJOR BILLIE JO vs SECURITY EQUIPMENT 0352011 UPS
Description Amount
Services Provided on02142011BRET KIMMEL BOISE ID






Services Provided on02142011DANIEL SCHAFFER BOISE ID








Please detach and return this bottom portion with your payment
or pay online atwwesquireconnect
MOWER
VISA d IF Invoice CSD242037
Payment Due 0410920 1
E5 tIRE Amount Due OnBefore042011 147882
Amount Due After042011 162670





CHERRY HILL NJ 08034
Atlanta GA 311934157
wwwesquiresolutionscom
Thank you for your business
076 0000242037 03102011 8 000147882 2 04092011 04242011 3 000162670 71
002069
OESQL:mE 
i   l i  
 t i l r 
 ri tt  tr t 
tl t ,   
ll  (88 ) -4044 





I i  #  
I i  t  
III1Il$ 
  
O t.  I. $ 
it t : 
  
   




4/ 9 2011 
age 1 01  
I L I E  
5   
  r   · I U  
 I , J  j t r  
  C  
i t I s   iI   Ia 
----------------~r_--~----+_----~----1_----~------~ 
211412011 I J , I I  J  VS. I  I   3/ 5 2011  
==============================~========~ 
ion 
i  i   2114/ 0 1, T I MEl (B , ) 
 & lW   (251 ) 
I I  
APPEA A E FEE (7.25 nits) 
II I  
  
ervices r i   2114/ 0 1, I   (B I , I ) 
I I L & NElWORD  (119 ) 
I  
II I  
  












$ 1 .60 
$ · 10.93 
   AGE ... 




I  I   
55   
 I ,   
l  t   r t r  t i  tt  rti  it  r t 
or pay online at ww.esquirec nnect.net 
" l>OSCr ...... I' "'''''wn .... .:.::....I1iilii i  #: 
Pay ent ue: 
  /Bef  4124 20 1 
t   4124/2011 
 : 
ir  l ti  
   
 3 -415  
www.esquiresolutions.com 




$ ,6 6.70 



























Atlanta GA 311934 57
wwwesquiresolutionscom






Name of Insured WR BERKLEYARMIRAU GREENER
Adjustor PENDING
Claim Number C141670
Assignment Case Assignment Shipped Shipped Via





SNIPPED TO BURKE CHRISTOPHER CESQ Tax 00
SUITE 400
450 WEST BANNOCK STREET Paid 00
BOISE ID 87702
Amount Due OnBefore042011 147882
Amount Due After042011 162670
Please detach and return this bottom portion with your payment
or pay online atwwesquireconnectt
VISA e6C Invoice CSD242037
Payment Due 0492011
ESQ Amount Due OnBefore 0424011 147882
Amount Due After 0412412011 162670




CHERRY HILL NJ 08034 PO Box 934157
Atlanta GA 311934 57
wwwesquiresolutionscom
Thank you for your business
076 0000242037 03102011 8 000147882 2 04092011 04242011 3 000162670 71
002070
o E l"IHE 
  l ti  
2700 entennial o er 
101 ri tt  tr t 
tlanta.  30303 
l   (8 )486-  
ax (8 6)590-3205 
BE T STEE E 
I L I   
1255 AL ELL A  
 I L.   





 Box 93415  
tlanta  1 93-4157 
ww.esquire lutions.com 
I i  #  
I i  t  3110/20 1 
renn    
8 41091201  
t    
    -   
j  I  
l i  r  
 i t # i e  i  i  
P 8 r2 
0211412011 I J R. I I  J  s. I  I  
~====== 
 3105 2011  
i tion 
- I I  
.,' 
'. 
":', it: r {, 7'7f:f;J 
:··.··· .. ..,·r.t .. - •• .-.. ...... ;.~;Jo" ........ .., •• :.~...-..-...~ 
, :. \ :'>' 7" / S- . .2-,!J . 
) .... b;i~i~E. ;;·7JJ~I7-
b' { ______ ..:..j/YJ._"_.'ttV..,;. __ 
HI  : .  . O. 
I  9 D 
950 EST BANN CK STREET 
BOISE. 10 BJ7D2 
x: 
: 
  /Bef r  4/24 2011 












ADMIRAL I CE PANY 
1255 L LL R A  
ERRY I . J  
l se t   t r  i   rti  i   ent 
r pay li  t ww.esquirec nnect.net 
-~ .. ~ ISA~ ... ...:..;..,j_  #: 
y t : 
  /Befor  /24/20 1 
t   / /20  
it : 
Esquire Solulions 
PO   
tl t   1 93-4157 
ww.esquires lutions.com 
k y  f r y r b si ss! 
 
4/ 9 2011 
$1,478.82 
$ .6 6.70 
.-. ' ...... ~-~, . 
f : __ 
.:, ~. 
\. ".' 
:- ~ .. t;:: 
L;.;' ~ ~ 



























Please detach and returnthis bottom portion with your payment
0423011
Date of Loss
or pay online atwwesquireconnectt
Name of Insured








Amount Due After0582011 155162




1255 CALDWELL ROAD Esquire Solutions
Services Provided on021512011 SARA LINK BOISE ID






wwwesqu iresolution s corn
00
Thank you for your business
Services Provided on02152011JOSHUA OVERGAARD BOISE ID
076 0000246288 03242011 9 000141056 6 04232011 05082011 2 000155162 23
ESQUIRE
an Alrtondar Gann COrvnnr
Invoice CSD246288
Remit to











Assignment Case Assignment Shipped Shipped Via
021512011 MAJOR BILLIE JO vs SECURITY EQUIPMENT 0392011 UPS
Description Amount
Services Provided on02152011 NICHOLAS DOAN BOISE ID















o ESQ 'IHE Remit to: 
Esquire orporate Solutions 
2700 Centennial Tower 
~ 
 !lIrBJ;~ 
sq ir  Solutions 
P  ox 934157 
101 arieHa Street 
AUanta. GA 30303 
Atlant   31193-  
www.esquiresolutions.com 
T ll  (8 ) -  
ax (866) 590-  
ROBERT STEERE 
I i  #  
I i  t  
 
  
t   lD . 
 
  
4123 20 1 
ADMiRAl INSURANCE COMPANY 
1255 CAlD ELL ROAD 
 f I r   - U  
 ILL.   j  
l i  r 
i v t I Case  # 
0211512011 1 . I I   s. I  I   
ription 
   2115 20 1.   (B . 10) 
I I L & lW  I  (97 s) 
EXHIBITS 
  (7 its) 
ASCII DISK 
 I  
E-TRANSCRIPT 
i  i   21 5/ 01 .   (BOI . 10) 
 & NE/WORD  (8  s) 
ASCII DISK 
CONDENSED TRANSCRIPT 
·T I T 
r i  r i   2115 20 1.   (BOI . 10) 
 & NEIWORD  (165 ) 
i  









$ . 0 
$ . 0 








I    GE ... 
J~~~~~~3~E~~~ ___________________________________________________ _ 
o 
SQUIRE 
'H ....... ' • ...•• 
ROBERT STEERE 
ADMIRAL INSURANCE COMPANY 
1255 CALD ELL ROAD 
CHERRY I . J 08034 
l  detach  t  this tt  ti  it   pay ent 
or pay li  t ww.esquireco nect.net 
IS  ._~::/ iM::;~1 I volce#: 
Payment Due: 
t ue n/Before 08/  
t ue  5108 2011 
e it t : 
squire olutions 
 ox 157 
Atlanta GA 31193-4157 
w .esquiresolutions.com 






























Atlanta GA 31193 4157
wwwesquireSDiubonscom





MAJOR BILLIE JO vs SECURITY EQUIPMENT
Name of Insured WR BERKLEYADMIRAU GREENER
Adjustor PENDING
Cbim Number C141670
Assignment Case Assignment Shipped Shipped Via
02152011 209382 0310920 1 UPS
Description Amount







VOLUME DISCOUNT 7 10579
CSDSHIPPING st
7L h tie u 100791 x
SHIPPED TO BURKECHRISTOPHER CESQ Tax QDO
5W900
950 WEST BANNOCK STREET Paid 00
800SE ID 93702
Amount Due OnBefore0582011 141056
Amount Due After0510820 1 155162
Please detach and return this bottom portion with your payment
















06 0000246288 03242011 9 000141056 6 04232011 05082011 2 000155162 23
002072
Page2of2 
o ES()l'IHE to: 
s ir  Corporate Solutions 










1 01 Marietta Street  311 -  
AUanta. GA 30303 uiresolutions.com 
Toll r  (8 ) 86-40 4 
 ( )590-3205 
R BERT STEERE 
I i  #  
I v ic  at  
nn  
ay ent·  
te fl05S 
o 3124/20 1 
N   
o 41231201  
AD IRAL INSURANCE CO PANY 
1255 CALD ELL R AD 
 f I r   KLEY - I   






i t I Case t # i  
----------------r---~----1_----~----
0211512011 I , I   VS.    3/ 9/2 1 
============================ 
ription 
i  i ed  2/151 0 1.   (B . 10) 
EXHIBITS 




V LU E DISC UNT - 7% 
CSD·SHIPPING 
I  : . HRISTOPHER . O. 
SU/TE!IIH1 
950 In"ST BANNOCK STREET 
BOISE. ID 83102 
I 
.... 
:' .. ; . ~'. 
: 
i : 
 e n/Before 5/08/2 011 
t   510812 011 
." .... 











$ - 05.79 
." .;:; S 5.00 
~ 




$ ,4 0.56 
$1,551.62 




R BERT STEERE 
AD IRAL INSURANCE COMPANY 
1255 CALD ELL ROAD 
E Y HIL . J 08034 
l ase t ch a  r tum t i  tt  rti  ith yo r pay ent 
r  li  t ww.esquireco nect.net 
.". IXSCeVfI: j·"'iJff·t 
'SA~_ . .:..:.;.., ",. In voice #: 
nt ue: ay e 
unt  /Befor  5/08 /2011 
0812011 ount Due fter 051 
Remit 10: 
squire Solutions 
 Box  
Atlanta GA 31193-4157 
www.esquiresolulions.com 











































CHERRY HILL NJ 08034
Tax Number
Please detach and return this bottom portion with your payment
OVA
or pay online atwwuvesquireconnectt
VISA Invoice CSD251190
Payment Due 0522011















Name of insured WR BERKLEYADMIRAUGREENER
Adjustor PENDING
Claim Number C141670
Assignment Case Assignment ill Shipped Shipped Via
032011 MAJOR BILLIE JO vs SECURITY EQUIPMENT 0325011 UPS
Description Amount
Services Provided on032011 DAN HENDRICKSON BOISEIDy
ORIGINAL ONENVORD INDEX 193 Pages 80095
EXHIBITS




MEDICAL TECHNICAL SURCHARGE 193 Pages 00
88270





SHIPPED TOBURKE CHRISTOPHER C ESQ Tax 00
SIATE 900
950WESTaANNOCK STREET Paid 00
BOISE ID 83702
Amount Due OnBefore 051222011 82591





CHERRY HILL NJ 08034






Thank you for yourbusinessl
076 0000251190 04072011 8 000082591 6 05222011 05222011 6 000090850 44
002073
@ESQt.:IHE 
s ir  orp r t  Solutions 
2700 CenlelVlial Tower 
101 arietta treet 





 Box 9341  
tl t   31193-  
ww.esquiresolutions.com 
Toll Free (888) 486-4044 
 (8 ) -  
ROBERT STEERE 
ADMIRAL INSURANCE COMPANY 
1255 CAlDWELL ROAD 
P.O. BOX 5725 
 ILL, J 08034 
ssi ent, s  
0310312011 AJ , BILLIE J  VS. SE ITY E IP E T 
Invoice #  
InVoic;:  P t  4/07/20  
~~------~----------renn   45 
~~~--~~+------------
ayin~nt u,_,' 51221201  
~~~~~~---------­
Dat.·~fl  
  I ni   L -  
rAdj~'u-'s"-tor-, -, --~-t------------PENDING 
--------------~ 
   ~ ________ J-________ __ 
", t# 
 
' i  ' 1 i  ia 
~--------------~ 
3125/2011 I  
ri ti  =:,=== 'Amc,==u=n=t===: 
~~~~--~~--~~~------~----------~------~---
Services Provided on 03/0312011, DAN HENDRICKSON (BOISE, 10) b.;~;~t~!j::nD tj'~~ 
I I  & lW   (19  s) 
EXHIBITS 
  (4 it ) 
AS II ISK 
CONDENSED TRANSCRIPT 
E-TRANSCRIPT 
I L   (19  s) 
V LU E DISCOUNT - 7 % 
CSD-SHIPPIN  
I  : , I  . . 
SVITE'OO 
950 T BANNOCK T T 
BOISE, ID B3702 
Tax u ber: 
" 




nt  n/Befor  5122 011 
t  ft r 5122 2011 

















 Jl. BJ;; 
ROBERT STEERE 
ADMIRAL INSURANCE COMPANY 
1255 CALD ELL ROAD 
P.O. BOX 5725 
CHERRY HI , NJ  
lease tach  r t m t i  tt  rti  it  r t 
r y online t ww.esquireco nect.net 
lSA"I""5~i!  #: 
ay ent : 
unt  /Befor  512 12011 
t ue ft r 5122 2011 
e it to: 
Esquire olutions 
PO Box 934157 
tlanta A 31193-4157 
ww.esquiresolutions.com 































Nanaof Insured WR BERKLEYARMIRAL GREENER
Adjustor PENDING
Claim Number C141670
Assignment Case Assignment 0 Shipped ShippedVIa
0310820 1 MAJOR BILLIE JO vs SECURITY EQUIPMENT 0410120 1 UPS
Description Amount
Services Provided on 031082011WILLIAM LOVELAND BOISE ID








ETRANSCRIPT IYr r 00
MEDICAL TECHNICAL SURCHARGE 101 Pages 00
4870
CSDSHIPPING t i i
YS
3 rte 5003




7 s 9 Tax 00
Paid 00
Amount Due OnBefore05210 1 4582
Amount Due After05210 1 50411
Tax Number
Please detach and return this bottom portion with your payment
or pay online atwwesquireconnectt
VISA Invoice CSD250702
Payment Due 0562011
ESQUIRE Amount DueOrtBefore05210 1 4582
Amount Due After05210 1 50411
ROBERTSTEERE Remit to
ADMIRAL INSURANCE COMPANY
1255 CALDWELL ROAD Esquire Solutions




Thank you for your businessl
076 0000250702 04062011 4 000045828 2 05062011 05212011 5 000050411 06
002074
9 ESQlJlRE e it to: 
 r t  l ti  




   
101 ri tt  tr t 
tl ta,   
l t   -4  
ww.esquirBsolulions.com 
ll  (8 ) -  
ax (866)590-  
  
I i  #  
in i  a 
ar . 
  
t   llS 
41061201  
  
51 6 2011 
I  I   
me    LEY- U  1255 AL ELL A  
 I L,   Ulit   
l i  r  
 I  nl ent'  I hipped ia 
3/08/2011 I , I   .    410 /2  I  
 I t 
r i    3108 20 1,   (B , 10) 
 & NElWORD  (10  s) 
APPRO"e,D 
$419.15 
I I  $ 8.25 
  
~fl.'{ 19 2U\\ 
$0.00 
AS II ISK $0.00 
 I  
OM? 
$0.00 
· I  $0.00 
I  I   (101 ) $ .00 
$ 87.40 
• ·c .•• ,... "'y. ,~,w ct' '(S-? 2? 
e O- I I  j!~!~1~ l ~~~lU ~-;: .. __ .~_~ ___ "JI~;~~"'- $5. 0 
  % "~. " .. ~ (.I, ''T .. ,~. .). ,2 J . ;< t) i/ $ -34.12 (";,V ~ "1-,, r . -'pif" "","i t t ,., ,,----~.' , IJ 
$ -29.12 
i; .... Nur~v- ~ ... 'l.!}r~ F·IP·.2.:>b 
~>' ' ~ i~·_ c ""' .. '\ -~ hJ;-;' : $ .00 
BY,,',', i : $ .00 . .. , 
  /Bef  5121/20 1 $458.28 
t  ft r 5121 2011 $ 04.11 
r: 1.1.~llltgCl't 




I  I   
55   
 ,   
l  t ch  r t r  t i  tt  rti  it  r ent 
  li   ww.esquireco nect.net 
I  1II!1lISS;;j1i  #: 
 : 
  n/Before 5/21120 1 
   512112011 
ll : 
 l  
   
tl t   -41  
ww.esquires lutions.com 




$ 04. 1 

























CHERRY HILL NJ 08034
Assignment I Case
0392011 MAJOR BILLIE JOvs SECURITY EQUIPMENT
Description
iervices Provided on03912011 JANATODONNELL BOISE ID
ORIGINAL ONEWORD INDEX 90 Pages











Payment Due 0512720 1
Date of loss













VOLUME DISCOUNT70 Z7 2615
y 1
2115
SHIPPED ToBURKE CHRISTOPHER C ESO Tax
00
SUITE 900 Paid 00
950WEST BANNOCK STREET
BOISE ID 83702 Amount Due OnBefore0527011 3525
Amount Due After0527011 38759
Tax Number
Please detach and return this bottom portion with your payment
or pay online atwwesquireconnectt
VISAL Invoice CSD252870
Payment Due 0527011
ESQUIRE Amount Due OnBefore0527011 3525
Amount Due After0527011 38759
ROBERT STEERE Remit to
ADMIRAL INSURANCE COMPANYfrd Esquire Solutions
1255 CALDWELL ROAD PO Box 934157
POBOX 5725 Atlanta GA 311934157
CHERRY HILL NJ 08034 SEG 14 all wwwesquiresolutionscom
Thank you for your business
076 0000252870 04122011 9 000035235 05272011 05272011 4 000 038759 03
002075
o ESQUIRE Remit to: 
Esquire Corporate Solutions 




PO Box 934157 
101 MarIetta Str et 
AUanta, GA 30303 
Atlanta GA 3 193-4157 
www.esqulresolutions.com 
Toll Free (888) 486-4044 
Fax(866)5~3205 
R BERT STEERE 








ADMIRAL INSURANCE PANY 
12 5 CAL  ROAD 
Nanie of Insured R L -ARMIRAU  
P.O. BOX 5725 
CHERRY HILL, NJ 08034 
ssign ent I ase J 
03J09l2011 I MAJ . BILLIE J  vs. SECURITY E UIPMENT I 
Description 
Services Provided on 03/0912011, JA AT _DO NELL (BOISE, 10) 
I I L & NEiWORD I EX (90 ) 
E  (2 nits) 
AS II ISK 
CONDENSED TRANSCRIPT 
- I I  
V LU E DISC UNT 7.0% 
SHIPPEO TO; BURKE, CHRISTOPHER C. ESQ. 
'TEPOO 
P50    
BOISE, 10 13702 
djustor PENDING 
laim Nu i)er C141670 
, ,AsSigrinient II I Shipped I 
216624  0410112011 , 
. -- .' ,I 
ax: 
Paid: 
  /  5127 20 1 
















3~~~~~~~~~~~~ ___________________________________________________ _ 
ROBERT STEERE 
ADMIRAL INSURANCE COMPANY 
1255 CALDWELL ROAD 
P.O. BOX 5725 
CHE Y HILL. NJ 08034 
l  t   ret r  t i  tt  rti  it  r pay e t 
or pay onli  t ww.esquirec nnect-net 
VISA ~IPISS:;j1il In i #: 
Pay ent Due: 
t ue / f r  5127120 1 
"'CD ., Lt ') fl 11 0\....ll " 1.1I .. 
ount Due After 05127120 1 
Remit to: 
Esquire Solutions 
PO Box 934157 
AU ta G  31193- 57 
www.esquire olutions.com 
r"~ ~~~ ;:~ . 


















CHERRY HILL NJ 08034
ESQUIREasAlexander Cal la Coo pan
Invoice CSD264409











Ntnof kisprod WR BERKLEYARMIRAU GREENER
Adluttto PENDING
Ckkyli timixtr C141670
Assl9nnatlt Case x yAsslgrlment gMpped Shippact
MAJOR BILLIE JO vs SECURITY EQUIPMENT 228372 051012011 UPS
Services Provided on 041192011 GEROLD YOST SANDY UT
ORIGINAL ONEANORD INDEX 199 Pages 69650
EXHIBITS S y 3025




COLOR COPY DOCUMENTS 26 Units 5200
CONDENSEDTRANSCRIPT 00
TRANSCRIPT 00
MEDICAL TECHNICAL SURCHARGE 199 Pages 00
ROUGH ASCII DISK O 027 S 174
01855




CONTINUED ON NEXT PAGE
Tax Number 223778684
Please detach and return this bottom portion with your payment




Q Amount Due OnBefore0625011
Amount Due After 06252011
ROBERT STEERE Remit to
ADMIRAL INSURANCE COMPANY
Esquire Solutions1255 CALDWELL ROAD
PO Box 934157
CHERRY HILL NJ 08034
POBOX
Atlanta GA 311934 57
wwwesoTesolutonscom





076 0000264409 05112011 4 000102355 9 06102011 06252011 4 000112591 83
002076
@ESQUI  
i  r orate l ti  
2700 entennial To er 
101 MarieHa Street 
Atlanta. GA 30303 
  ( 8)  
 (8 ) ()'  
ROBERT STEERE 
I L I   
1255 L LL  
.O.   
 ILL. J 08034 
~ 
SQ1!..!Ii~ 
I i  #  
it to: 
s ir  l tio  
   





 · I   
ING 
age 1 012 
0411912011 J . I I  J  s. I  I  
rvices   1191 .   (S . T) 
 & IW   (19  s) 
I I  
APPEARANCE FEE 
II I  
   (26 t ) 




$ 5. 0 
$0.00 





$ 1.0 8.55 
$ .00 
$ .00 
   GE ... 




AD I AL I   
1255 L LL  
P.O.  5725 
ERRY I . J 08  
l  tach  r t r  1his tt  rti  it  r t 
r  l  t ww.esquireconnect.net 
VISA ill voice': 
y t : 
  lBefor  6/25/2011 
ount   12 1201  
rnitt : 
ir  olutions 
O  93415  
tl t  A 1 934157 
ww.esquiresoiutions.com 
 y  f r r buslnessl 
D2  
611 12  
$1.023.55 
$ .1 5.91 


























Atlanta GA 311934 57
wwwesquiresolutionscom
Page 2 of 2








AdJustor 1 1 PENDING
ClaknNumti C141670
Asslgnment ftv ShipPd i
04192011 MAJOR BILUE JO vs SECURITY EQUIPMENT 228372 05102011 UPS
Tax S00
Paid 00
Amount Due OnBefore0625011 102355
Amount Due After05252011 12591
Tax
Please detach and return this bottom portion with your payment
or pay online atwwesquireconnectt




Amount Due After06252011 12591
ROBERTSTEERE Remit to
ADMIRAL INSURANCE COMPANY
1255 CALDWELLROAD Esquire Solutions
POBOX5725 PO Box 934157
CHERRY HILL NJ 08034 AtlantaGA 311934157
wwwesquiresolutionscom
Thank you for your businessl
076 0000264409 05112011 4 000102355 9 06102011 06252011 4 000112591 83
002077
@ESQUI  
squire Corporate olutions 
2700 Centennial Tower 
101 Marietta Street 
AUanta, GA 30303 
Toll Free (888) 486-40« 
 ( 6) 90-32 5 
ROBERT STEERE 
ADMIRAL INSURANCE COMPANY 
1255 CALDWEll ROAD 
P.O. BOX 5725 
 ILL, J  
Re it to: 
Esquire Solutions 
PO Box 934157 
Pave 2 ot2 
~ 
SQ!2!B.~ 
Atfanla  31193-4157 
www.esquiresolutions.com 









unt  /Befor  6/25/2011 
A ount   51 5120 1 
':~~~:::.~.*: 
' }~; 











ADMIRAL INSURANCE COMPANY 
1255 CALD ELL ROAD 
P.O. BOX 5725 
CHERRY HILL, NJ 08034 
Please etadl a d r t r  fils t  rti n it  your t 
r pay online t ww.esquireco nect.net 
I  I voice#: 
t u : 
unt  nlBefore 6125 2011 
09 S 2644 
06/10 12011 
S 1,02 3.55 
A ount ue After 061 5120 1 $ 1,1 25.91 
Remit to: 
Esquire Solutions 
PO Box 934157 
M ta GA 3119 -4157 
www.esquiresolutioos.com 
Thank you for your busine sl 











































CHERRY HILL NJ 08034
Assigmnent rT Casa lgnAssrtierhaR Shlpp9dn ShlppedVia
04210 1 MAJOR BILLIE JO vs SECURITY EQUIPMENT 230495 05102011 UPS
DBSCrIplloQk t ttxAmoun
Services Provided on04212011 KARIN PACHECO DENVER CO
ORIGINAL ONEIWORD INDEX 188 Pages
t








CSDSHIPPING 1 3ti F 500
76VOLUME DISCOUNT 2 430
v 3840
SMPPEQ TO BURKECHMSTOPHER CESQ
Tax ODD
SUITE goo
950WESTBANROCK STREET Paid 00
BOISE ro 83702
Amount Due OnBefore 061252011 58165
Amount Due After0625011 63982
Tax Number 77
Please detach and return this bottom portion with your payment




Q E Amount Due OnBefore 061252011 58165
Amount Due After0625011 63982
ADMIRAL INSURANCE COMPANY Remit to
1255 CALDWELL ROAD
POBOX5725 Esquire Solutions
CHERRY HILL NJ 08034 PO Box 934157
Atlanta GA 311934157
wwwesquiresoludonscom
Thank you for your businessl




Esquire Corporate Solutions 
2700 Centennial Tower 
101 Marietta Street 
Atlanta. GA 30303 
~ 
 !l.IS);; 
Re it to: 
Esquire Solutions 
PO Box 934157 
Atlanta GA 311 - 7 
www.esquire olutions.com 
Ton Free (888) 486-4044 
 ( 6) 590-  I i  # 264287 
ADMIRAL INSURANCE COMPANY 
1255 CALDWELL ROAD 
P.O. BOX 5725 




WR BERKLEY-ARMIRAU GREENER 
KRISTENE lEAP 
C141670 
· .. ~.,::~19:iJJ1w,~;'f?:;;lt~*~~}~:;~i'*~\~~)'fi:;·;i·:,P#~;5~",/::1;;;2;;.;.· . '. ·-:.I·;:·~silin~'!t~~:h·i'~;~'i;~~~Ip.~Iit{t~*:t.~:*~hipj:lecJVI ':~ ....... ;:: 
0412112011 I J . I I  J  s. I  I  I 5 I 5110 2011 I  
   4 211201 .   ( . ) 
 &   (1  ges) 
EXHIBITS 





7% VOLUME DISCOUNT 
SHIPPED TO: BURKE. CHRISTOPHE'R C. ESQ. 
SU/TE8DO 
850 weST BANN CK STREET 
BOISE, ID 137112 
\ N 23 G'\~ 
'~J ~\Jl Y 
x: 
i : 
t  n/Befor  6/25/ 0 1 















J~~~~~~3~£~~ ___________________________________________________ _ 
~ 
ESQl!..!B~ 
ADMIRAL INSURANCE COMPANY 
1255 CALDWEll ROAD 
P.O. BOX 5725 
CHERRY HilL, NJ 08034 
Please detach and return this botto  portion ith your pay ent 
or pay li  at www.esquireconnect.net 
v SA"~1I Invoice ,: 
Payment Due: 
ount ue n/Before 6125/ 011 
A ount Due After 0612512011 
emit to: 
Esquire Solutions 
PO Box 934157 
Atlanta GA 31193-4157 
www.esquiresoluUons.com 




















CHERRY HILL NJ 08034
Tax Number 2
Please detach and return this bottom portion with your payment





























MAJOR BILLIE JO vs SECURITY EQUIPMENT
N ri of linurod WR BERKLEYARMIRAL GREENER
AdJuite tt KRISTENE LEAP
Clak C141670
Asslpnerotrt asy3 er Casst Z r StM YMY f hlppe 14Tta t
0412220 1 230498 0592011 UPS
Services Provided on 041222011 KARIN PACHECODENVER CO sa
3
ORIGINAL ONEWORDINDEX 63 Pages j1 26145
EXHIBITS 3025




EXPERT WITNESS 63 Units 00
G








Amount Due OnBefore 061252011 27593







076 0000264157 05112011 9 000027593 9 06102011 06252011 4 000030352 21
002079
@ESQUI  
squire r r t  Solutions 
2700 Cenlemlal Tower 
Remit to: 
Esquire l tions 
PO Box 934157 
101 ri ll  Street 
tlanta.  30303 
~ 
QQ. R~ 
tlanta  31193-  
ww.esquiresolutions.com 
Toll Free (888)486-4044 
 ( 88) 90k3205 
ROBERT STEERE 
I i  #  
05 11120  
N  5 
6110/20 1 
I L I   
1255 CALDWELl ROAD  KLEY- I AU  
P.O. B X 5725 
CHERRY HILL. NJ 08034 
   /2 r.! . I   (D . ) 
I I  & NElWORD I  (6  s) 
EX IBITS 
  (2 its) 
II I  
CONDENSED TRANSCRIPT 
E-TRANSCRIPT 
 I  (63 its) 
.. ,~~r CtUE_ .. ~d.z~~:9.~h' 
CSO-SHIPPING ..• :,j:{ DAJ1L._... ~;1 1<.J ... 1 J . 
CSD-7% VOLUME DISCOU~." \",:\.-~,.,f r}~~fF' ?.) ;'7l<JJ) 
~t .. f~ ~ 'f r;" 1 ..,.w"~'\'i ~ Il'.,''''·'' riP 
SHIPPED TO: BURKE. C:HIIISTOI'HER .Eb:V __________ -"t2_ .. A/' .. ·o.-.. ' -
SUl~_ 
,so WES T NII  STR  
I  LEAP 
 
t; .. I:t.:t"ll1 ." 
\\}~. '20 7.\}\\ 
.,...r,f .. P 
\ $ 0\." 
: 
: 
I . 10 1 D  
t  /Befor  6/25 011 
ount ue ll  12  
$ 61.45 
S 0.25 













J~~~~~~_! _______________________________________________________ _ 
Q 
 Y B  
ROBERT STEERE 
ADMIRAL INSURANCE COMPANY 
1255 CALD ELL ROAD 
P.O. BOX 5725 
CHERRY HILL, NJ 08034 
I i  II: 
y t ue: 
ount  n/Before 6/25/2011 
A ount Due ller 061 5120 1 
e it to: 
squire SolutiOns 
PO Box 934157 
Allanta A -4157 
www.esquiresolulions.com 




























CHERRY HILL NJ 08034
0632011 I MAJOR BILLIE JOVs SECURITY EQUIPMENT
s WR BERKLEYARMIRAL GREENER
KRISTENE LEAP
C141670
242246 1 062312011 I UPS
Services Provided on 0632011GARYCOUILLARD BOISE ID





READ SIGN 0 00
ax


















CHERRY HILL NJ 08034
Atlanta GA 311934 57
Amount Due OnBefore0892011 54226
Thank you for your business
Amount Due After 08109201 1 59649
Number




Jil S Amount Due After0892011U
ATTN KRISTENE LEAPADJ 49 Remit to
1255 CALDWELLROAD
POBOX 5725 PO Box 934157
wwwesquiresolutionscom
076 0000279638 06252011 0 000054226 4 08092011 08092011 4 000059649 76
002080
o I  
i  orporate l ti  
2700 Centennial Tower 
it to: 
ir  l tions 
  934  
101 arietta Street 
tlanta.   
@ 
Q!21 J;; l t   193--4  ww.esquiresolutions.com 
l  (8 ) -404  
 (8 ) 590-  
nN: K ISTE E lEA - J 
AD iRAl INSURANCE CO PANY 
1255 CAlDWELL ROAD 
P.O. BOX 5725 
 ilL,   
lVi  i   61 3120 1.  I  ( I . 10) 
I INAl & l   (12  es) 
I I  
  (2.50 its) 
ASCII DISK 
 I  
READ & SI N 
- L  IS T 7% 
-5 I I  
 : 8 KE,  . . 
IT 1II/fI 
!150 '  BA K £Fr 
801S£.10 .J7rJZ 
I i  #  
: 
: 
 ue n/Befor  8109/2011 






$ .  
$ 7 .70 
$-40.44 
$5. 0 
$ -35. 4 
$0.00 
$0.00 
$ 42. 6 
$ 96.49 
J~~~~~~ _________________________________________________________ _ 
~ 
SQ!lIB._~ 
 I : I E  -AD  
DMiRAl I A CE  
12 5  AD 
P.O. BOX 5725 
 I ,  080  
lease detach and return thill bollo  portion ith your pay ent 
r  li  t ww.esquireco nect.net 
ISA"~. I voice#: 
/'~;. ~:=;~ r::· :.~~.; ;J; ~:f;~:J t : 
nt  /Befor  8/09/2011 
ount  ll  810912011 
e it t : 
uire l ti  
 ox  
Atlant   31193-4157 
ww.ellquiresolutlons.com 











Toil Free 888 4864044













CHERRY HILL NJ 08034
ESQUIRE





rites Provided on0692011ROBERTO NEGRON BOISE ID






























076 0000281104 06292011 8 000055570 4 08132011 08132011 4 000061127 97






Amount Due OnBefore 081132011
Amount Due After08132011
ax Number
Please detach and return this bottom portion with your payment






YAfu 11 Amount Due After08132011
ROBERTSTEERE
pi Remit toADMIRAL INSURANCE COMPANY
1255 CALDWELL ROAD Esquire Solutions
POBOX 5725 PO Box934157
CHERRY HILL NJ 08034 Atlanta GA 311934157
wwwesquiresolutionscom
Thank you for your business
002081
~ESQlJIHE 
Esquire Corporate olutions 
2700 Centennial Tower 
Re it to: 
Esquire Solutions 
PO Box 934157 
101 Marietta Street 
tl nta,  30303 
~ 
llIBJ;; tlanta GA 31193- 7 ww.esqulresolutions.com 
Toll Free (888) 486-4044 
Fax (866) 590-3205 
ROBERT STEERE 
ADMIRAL INSURANCE COMPANY 
1255 CALDWELL ROAD 
P.O. BOX 5725 
 ILL, J 08034 
I i  #  
Servic  i   6109/20",   ( , 10) 
 & lW   (1  es) 
EXHIBITS 




JI!', ~ :".~:'~' ~-:"'.' r. ;~ 
I  I   (14  ges)F';: \,: :. ':;·'/i.':. 
.. ',~ .. '~.~,.. -';", "~"""'~~ ~ ., ... )
CSD-VOLUME DISCOUNT - 7% 
S -SHIPPI  
SHIPP  : BURK , I E  C. E . 
SlllTEfIIO 
;7. ;2a·2 .. /./ 





: gSQ WEST BANNOCK STREET 
BOISE, /0 13701 
nt  /Before 8/13 2011 




















ADMIRAL INSURANCE COMPANY 
12 5 CALDWELL ROAD 
P.O. BOX 5725 
CHERRY HILL. NJ 08034 
Please detach and retum this botto  portion ith your pay ent 
r y online t ww.esqulreco nect.net 
IS  i i  #: 
't.~~:] ri:7l r; l!/~:'.r.) Payment Due: 
- ount  n/Before 8113 2011 
Jl\ L 2. 0 LG 11 ount ue M r 0811312011 
DNiP e it to: 
Esquire Solutions 
PO  934157 
Atlanta GA 3 193-4157 
www.esquiresol tions.com 























N4fInsured WR BERKLEYARMIRAU GREENER
Adjustor KRISTENE LEAP
ClaimNumber C141670
Assignment Case Assignment Shipped Shipped A
MAJOR BILLIE JO vs SECURITY EQUIPMENT 248269 072011 UPS 9
Description Amount
Services Provided on 0612312011 MARY BARROS BAILEY BOISE ID
ORIGINAL ONEWORDINDEX 183 Pages 75945
EXHIBITS 2275
CE FEE350 Units
IEASCII ISK 1PIpIRnV Y 00
CONDENSED TRANSCRIPT 00
TRANSCRIPT 2 2011 00
78220
3 s
CSDVOLUME DISCOUNT 7 a rM a 5475
CSD SHIPPING t 1 500
V
4975
SHIPPED TO BURKE CHRISTOPHER CESQ Tax 00
SUITE 900
950WEST RMNOCKSTREET Paid 00
BOISE ID 97702
Amount Due OnBefore082712011 73245















Please detach and return this bottom portion with your payment
or pay online atwwesquireconnectt
VISA1 Invoice CSD284623
Payment Due 0827011
Amount Due OnBefore0827011 73245






Thank you for your businessl
076 0000284623 07132011 2 000073245 9 08272011 08272011 0 000080570 86
002082
(J SQL"IHE 
squire t  l tions 
700 entennial er 
 i tta treet 
n t ,   
ll r e (88 ) 86-4044 
x (86 ) -3205 
 E 
I L I  Y 
55 l  AD 
.O.  725 
 I L.   
~ 
Q!.B~ 
I i  #  
e it to: 
i   
   
  -415  
ww.esquires lutions.com 
l!:8 t ' 7/13 2011 
r-~--------~----------
 T 45 
~~--~~~----------ni t ile . 8127/2011 
~~------~r----------­
ilteof~" 
ari!eofln   lEY- I AU  
~Ad~-~j~~'Uw~-~'--~~----------K--RISTENELEAP 
lili . ni.be  .  
~~~~__ J-________ __ 
ss gn e t ase i Pe  1 Vla • 
12  , I IE  V6. I    07/07flO11 I  
I· 
.. 
nl  ;.' 
' .. ri ti  
r ices r i   ,  S- l  (B I , 10) 








-  I  % 
-  
I  : . I ER . . 
 JOO 
,~u S  lMNNO  li  
I . I  ~7  
rt.pPRO"e.O $0.00 
,.. $ . 0 
~llG 2.2. lU'\ __ -:-:-$.,.-0. __ 00 




  /Bef  8/27/201  












   
   
.O.   
 ILL.   
l  t   r t r  t i  tt  rti  it  r t 
r y li  t ww.esqulrec nnect.net 
v,sA.I~. #: 
t ue: 
t  /B f  8/27/20 1 
t  ft r 812712011 
a t : 
 ir  l ti  
   
U t   193-  
ww.esquiresolutions.com 
  f r r i l 
 
8/27 20 1 
$ 32.45 
$ 805.70 





















Atlanta GA 30303 ESQUIRE
Adjustor
A1dcnoc
Toll Free 888 4864044
C141670

















Name of Insured WR BERKLEYARMIRAL GREENER
KRISTENE LEAP
Claim Number
Assignment Case Assignment Shipped Shipped Via
06302011 MAJOR BILLIE JO vs SECURITY EQUIPMENT 07152011 UPS
Description Amount
Services Provided on 06302011JPPURSWELL BOISE ID
ORIGINAL ONEIWORD INDEX 326 Pages 135290
AP FEE7 Units ItP qq 0
ASCII DISK 2U
CONDENSED TRANSCRIPT NZ 00
TRANSCRIPT 00
MEDICAL TECHNICAL SURCHARGE 326 Pages 00
ROUGH ASCII DISK 26600
r
166740
li FcVOLUME DISCOUNT 7 hr11672
1
CSDSHIPPING J 1 7
roa0








ES UIRE Amount DueOnBefore 0962011 15568
Amount Due After0962011 171125
ROBERT STEERE Remit to
ADMIRAL INSURANCE COMPANY
1255 CALDWELL ROAD Esquire Solutions
POBOX5725 PO Box 934157
CHERRY HILL NJ 08034 Atlanta GA 311934157
wwwesquiresoluUonscom
Thank you for your business
076 0000288535 07232011 4 000155568 3 09062011 09062011 6 000171125 59
002083
@ES I  
ir  orporate l ti  
2700 CentennialTower 
101 arietta treet 
U ta,   
l  r  (6 ) 6 -40  
 (6 ) -  
BE T STEE E 
ADMIRAL INSURANCE COMPANY 
   
.O.  5725 




Invoice #  
it to: 
ir  olutions 
 ox 934157 
tl nta  31193-41  
ww.esquire lutions.com 
Involc~ ate 7123 2011 
r---~~--~----------
ll  
age 1 of2 
~P~aY-~~'~'=D~ue---;------------0-9-m-~~01-1-----------; 
ate,  Oll  
a f I s r   LEY- I ALI  
~--------~----------
j t r   
~~------4-----------
l  r  
~----~--~------------
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CHERRY HILL NJ 08034
Assignment Case
0630M1 1 MAJOR BILLIE JO vs SECURITY EQUIPMENT
Description










CHERRY HILL NJ OBD34











Please detach and return this bottom portion with your payment
or pay online atwwesquireconnectt
VISA I Invoice
Payment Due 0962011
Amount Due OnBefore0962011 155568






Thank you for yourbusiness
076 0000288535 07232011 4 000155568 3 09062011 09062011 6 000171125 59
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{)ESQl7IH  
Esquire Corporate Solutions 
2700 Centennial Tower 
101 Marietta S1reet 
Allanta, GA 30303 
Toll Free (Ba8) 486- 044 
Fax (866) 590-3205 
ROBERT STEERE 
ADMiRAl INSURANCE COMPANY 
1255 CAlDWELL ROAD 
P.O. BOX 5725 
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ADMIRAL INSURANCE COMPANY 
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CHERRY HilL, NJ 08034 
Please detach and r t r  this bottom portion with your payment 
or pay online at ww.esquireco nect.net 
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Payment Due: 
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Amount Due After 091 6 2011 
Remi  to: 
Esquire Solutions 
PO Box 934157 
Atlanta GA 3 193-4157 
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Invoice National Jewish Health
POBox 17379 Denver CO 802170379
Phone 303 398 1314
Fax 303 270 2152
Federal Tax ID 74 2044647
GREENERBURKESHOEMAK
CHRISTOPHER BURKE













Patient Date ChargeCPT Charge Description Amount
GREENERBURKESHOEMA 04211 203016699 75 PACHECOMAJOR DEPOS 216000
GREENERBURKESHOEMA 042211 203016699 75 PACHECOMAJOR DEPOS 7200
Patient Total 288000
TOTAL CURRENT CHARGES 288000
Payment and Adjustment Activity
Posting Transaction
Date Description Amount
05611 CLIENT ACCOUNT PAYMENT 4800
TOTAL CURRENT PAYMENTS AND ADJUSTMENTS 4800
TOTAL CURRENT AMOUNT DUE 24000
PLEASE REMIT IN US CURRENCY
TERMS NET 30
002086
Invoice National Je ish ealth 
P.O. Box 17379 De , . 0217-0379 
P : (30 ) 98-1314 
F : (30 ) 270-2152 
e  Tax ID#: 7 -  
I ED 
JUN -  2011 
ree;;er 8ur:<e S::oemaker A 
06/02/2APPROVED 
By CC6 




50 . O  , #9 0 
B IS , ID 83702 
INVOICE #: 1001454336 
: 4/0 /11 








ar e t il 
ar e/CP  c  r  
030166/99075 CHECO-MAJO  P  
030166/99075 ECO-MAJO   
 t l: 
  : 
  ust  t  
p  r ti n 
  
5/0 /11    
    : 
   : 
(P    .S. ENCY) 







- 80. 0 
- 80. 0 







GREENERBURKESHO MAKE GREENERBURKESHO MAKE ACCT 1001454336
CHRISTOPHER BURKE Admit Date 0411 Discharge Date 043011




Date Code Qnt Description Amount
04211 2030166 9 PACHECOMAJOR DEPOSITION 216000
04211 Service Date Total 216000
042211 2030166 3 PACHECOMAJOR DEPOSITION
7200
042211 Service Date Total 7200
Charge Summary
Code
960 PRO FEE 288000
TOTAL CHARGES 288000
Payment and Adjustment Activity
Posting Transaction
Date Description
0562011 CLIENT ACCOUNT PAYMENT 4800
TOTAL PAYMENTS AND ADJUSTMENTS 4800
TOTAL AMOUNT DUE 24000
002087
I, 
Ite ized tate e t 
t r: 
 s  e th 
400 s  t. 
e r, . 206 
ti t: 
6/02/2011 
GREENER, BURKE, SHOEMAKER 
IS  R E 
REENER, BURKE, SHOEMAKER  #: 1001454336 
950 . O  S , #900 
BOISE, I  2 
d it : 4/01/11 ischarge : 4/3 /11 
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ce  t l: 
 EC -MAJO  I  
ce  t l: 
harge Su ary 
Pay ent and djust ent cti it  
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s ri tion 
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Christopher C Burke Esq
GREENER BURKE SHOEMAKER





CPA 71131 1 t Ave uite 706 tttllYlii
SLCUT 84103
801245566






Major vs Security Equipment Corp
Date Service Fee
632011 Travel Time No Charge
632011 Transportation SLC to Airport 2300
312011 Southwest Ticket SLC toBoise 31740
632011 Deposition Standard Fee 82500
2011 Transportation SLC to Airport 2300









t :  ,  
: hristopher . urke, sq. 
   
~!lIlm~meJ~ it   
 R. illard,  
   , t   
,   
01.824.5566 
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J TheUniversity ofUtahhanriacclog Toxicology 30 S 2000 E RM 201 Salt Lake City Utah 84112
October 24 2011
Greener Burke and Shoemaker
950w Bannock Street ste 950
Boise Idaho 83702
Dear Persons
581 6287 FAX 801 5855111
This letter is my billing for six hours ofdeposition on4172011 concerning the Major v Security
Equipment Corporation case I am submitting this invoice for my time as of 10032011 for a
total of1800 Please send the check to me at my office in the Department of Pharmacology
and Toxicology at the address shown above Thank you for your prompt attention to this matter
Sincerely
A
Garold S Yost PhD
Professor of Pharmacology and Toxicology




o  i i  f  
C Ph rrnaccioqy' & Toxic l  30 S 2000 E RM 201 Salt Lake City. Utah 841 2 (801) 581-5 87 FAX ( 01) 585-5111 
t r 4, 2011 
ner,   h  
950w. annock Street ste 950 
i e,   
ear ersons 
This letter is my billing for six hours of deposition on 4/17/2011 concerning the Major v Security 
quip ent orporation case. I a  sub itting this invoice for y ti e as f 10103/20 II for a 
t t l  $1,8 0. Please send the check to e at y office in the Depart ent of Phar acology 
and oxicology at the address sho n above. hank you for your pro pt attention to this atter. 
l , 
PcWYYj4 
 . t, h.D. 
fess r     
: (80 ) 1-7956 
fax: (80 ) -3945 
-ma l: ost pharm.uta .edu 
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZPLLC
1673 W Shoreline Drive Suite 200 83702












CHRISTOPHER D RICH Clerk
By JAMIB RANDALL
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA






Case No CV PI 1003515





STRIKE THE AFFIDAVIT OF
DR YOST AND 2 MOTIONS FOR
SUMMARY JUDGMENT
PLEASE TAKE NOTICE that on Thursday December 15 2011 at 400pm or as
soon thereafter as counsel can be heard PLAINTIFFSMOTION FOR RECONSIDERATION OF THE
COURTSORDERS GRANTING DEFENDANTS1MOTION TO STRIKE THE AFFIDAVIT OF DR
YOST AND 2 MOTIONS FOR SUMMARY JUDGMENT will be called for hearing before The
Honorable Cheri C Copsey at the Ada County Courthouse in Boise Idaho
NOTICE OF HEARING ON PLAINTIFFSMOTION FOR RECONSIDERATION OF THE COURTSORDERS
GRANTING DEFENDANTS1MOTION TO STRIKE THE AFFIDAVIT OF DR YOST AND2MOTIONS
FORSUMMARY JUDGMENT 1
002090
 r on,  #5887 
 . artz,  #639  
 &   
 . r l  ri e, i   [8 02] 
Post ffice ox 7808 
,   
ne: (2 ) -89  
csi il : (2 ) -898  
ail: r i jonesandswartzlaw.com 
ri jonesandswartzlaw.com 
tt rne s  l intif , illie  j  
r~o·=-----':ii"i:n_4.q,....,...._ 
A.M. ______ FIL,~.M. ~ = 
V f   
CHRISTOPHER D. RICH, Clerk 
By JA IE RANDALL 
epUT  
       I I    
   ,        
IE  ,  i al, 
l intif , 
vs. 
  A I , 
a issouri corporation, 
nt. 
 .  I  
    
LAINTIF 'S   
I    
URT'S   
ENDANT'S (1) I   
  I   
. ,  (2) I   
  
  I  that on hursday, ece ber 15, 2011, at 4:00 p.m., or as 
 t e t   nsel   r , IFF'S      
RT'S  I  NDANT'S (1) I   I   I I   . 
S ,  (2) I S F  S  J E T ill be called for hearing before he 
onorable heri . opsey, at the da ounty ourthouse in oise, Idaho. 
ICE  I   I TIFF'S IO   I   E URT'S  
GRANTING DEFENDANT'S (1) OTION TO STRIKE THE AFFIDAVIT OF DR. YOST, AND (2) OTIONS 
 S  J DGMENT-  






I HEREBY CERTIFY that on this 10th day ofNovember 2011 a true and correct copy
of the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA









NOTICE OF HEARING ONPLAINTIFFSMOTION FORRECONSIDERATION OF THE COURTSORDERS
GRANTING DEFENDANTS1MOTION TO STRIKE THE AFFIDAVIT OF DR YOST AND2MOTIONS
FOR SUMMARY JUDGMENT 2
002091
ED this 10th day of ove ber, 2011. 
 
I  .  
  I  
I  I  t at  t is t  a  f e er, 1, a tr e a  c rrect c  
ft e foregoing docu ent as served on the follo ing individual(s) by the ethod indicated: 
hristopher . urke 
Tho as J. Lloyd III 
    
 . a c  treet, ite  
oise, I  83702 
[ ] .S. i  
[X] x: -2  
[ ] ess r li r  
[ ] ail: c r e greenerlaw.com 
11oyd@gre n_eII~ .co 
 .  
 .  
    LAINTIF 'S   I I    OURT'S  
GRANTING DEFENDANT'S (1) MOTION TO STRIKE THE AFFIDAVIT OF DR. YOST, AND (2) MOTIONS 
   -  
ORIGINAL
Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKERPA
950 West Bannock Street Suite 900
Boise Idaho 83702







CHRISTORHc D RICH ClarkBY JAMIE rRANDALL
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA




CORPORATION a Missouri corporation
Defendant
Case No CVPI1003515
NOTICE OF HEARING RE SEC
MEMORANDUM OF COSTS
PLEASE TAKE NOTICE that Defendant Security Equipment Corporation SEC by
and through its attorney of record Greener Burke ShoemakerPAshall call up for hearing its
Memorandum of Costs which was filed with this Court on November 3 2011 Said hearing
shall be held on December 15 2011 at 400pmor as soon thereafter as counsel can be heard
before the Honorable Cheri C Copsey at the Ada County Courthouse located at 200 West Front
Avenue Boise Idaho
DATED this 10 day of November 2011 GREENER BURKE SHOEMAKERPA
IJ4
Christopher C Burke Thomas J Lloyd III
Attorneys for Defendant




Christopher C. Burke, ISB #2098 
Thomas J. Lloyd III, ISB #7772 
GREENER BURKE S AKER P.A. 
950 est annock treet, Suite 900 
Boise, Idaho 83702 
Tel: (208) 319-2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
NO·-=--F.U:n--+L,/.u.~ 
AM· ___ ~~ .= Lftti.= 
N V f  011 
ISTOPHER 0 R ' 
By JAMIE R.4ND1~H, Clark 
DEPUTY 
I   IS    E     E 
TE  I , I    E  F  
ILLIE J  J , an individual, 
Plaintiff, 
v. 
SECURITY EQUIP ENT 
CORPORATION, a issouri corporation, 
nt. 
 o.: -PI-  
ICE    EC'S 
  S 
  I  that efendant ecurity quip ent orporation ("SE "),  
and through its attorney of record, Greener Burke Shoemaker P.A., shall call up for hearing its 
e orandu  of Costs, hich as filed ith this Court on ove ber 3, 2011. Said hearing 
shall be held on ece ber 15, 2011, at 4:00 p.m., or as soon thereafter as counsel can be heard, 
before the onorable heri . opsey at the da ounty ourthouse, located at 200 est Front 
Avenue, Boise, Idaho. 
DATED this 10th day of November, 2011.   SHOE  P.A. 
hri  . r  / oma  J. Ll  III 
ttorneys for efendant 
TI E  A I  E SEC'S TI  - PA  1 14542-011 ( 25257.doc) 
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing NOTICE OF HEARING RE
SEC MEMORANDUM OF COSTS on the following named persons on the date indicated
below in the manner indicated below
Darwin Overson Esq Via US Mail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC X Via Facsimile 2084898988
1673 W Shoreline Dr Suite 220 Via Overnight Delivery
POBOX 7808
Boise ID 83707
DATED this 10 day of November 2011
Christopher C Burke
Thomas J Lloyd III
NOTICE OF HEARING RESEC MOTIONS PAGE 2 14542011 425257doc
002093
C IFICATE F S  
I hereby certify that I caused to be served the foregoing NOTICE OF HEARING RE 
S C'S E OR ND  F OSTS on the fo lowing a e  p rson(s) n the ate indicated 
belo , in the anner indicated belo : 
ar in verson, Esq. 
Eric . S artz, Esq. 
J ES & ,  
3 . reline r., ite  
.O. ox  
Boise, ID 83707 
DATED this 10th day of November, 2011. 
[ ] ia .S. a  
[ ] ia a d iver  
[X] ia acsi ile (20 - -89 ) 
[ ] ia er i t elivery 
hristopher . urke 
as . l   
TI  F EA I  RE SEC'S M TI S - PAGE 2 14542- 1 ( 252 7.doc) 
Attorneys for Plaintiff Appellant Billie Jo Major
N0
AM
NOV 2 3 2011
CHRISTOPHEl D RICH Clerk
By JAMIE RANDALL
DEPUTy
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA





Case No CV PI 1003515
NOTICE OF APPEAL
TO The abovenamed Defendant SECURITY EQUIPMENT CORPORATION and its
Attorneys of Record CHRISTOPHER C BURKE and THOMAS J LLOYD III GREENER
BURKE SHOEMAKER PA 950 W Bannock Street Suite 900 Boise ID 83702 and the
CLERK of the above entitled Court
NOTICE IS HEREBYGIVEN THAT
1 The abovenamed Plaintiff Appellant BILLIE JO MAJOR appeals against the
abovenamed Defendant Appellee to the Idaho Supreme Court from the October 20 2011
Judgment and the following orders July 19 2011 ORDER RE PENDING MOTIONS FOR SUMMARY
JUDGMENT AND TO STRIKE AFFIDAVIT OF GERALD YOST October 20 2011 ORDER GRANTING
NOTICE OF APPEAL 1
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 837021







r  rson, I  #588  
 . wartz, I  #639  
J  &  PL  
 . r l  ri e, ui   [ ] 
Post ffice ox 7808 
i e, I   
l ne: (2 ) -89  
csimile: (2 8) -898  
ail: r i jonesandswartzlaw.com 
ri jonesandswartzlaw.com 
ttorne   l intif - ll nt, illie  j  
~.~=:Jlll FilED - - P.M. ___ _ 
 3 20  
CHRISTOPHEFl D. RICH, Clerk 
By JAMIE RANDALL 
DEPUTY 
       I I    
   ,        
I   ,  i l, 
l i tiff- ll t, 
vs. 
  RATI , 
 is  ti , 
Defendant-Appellee. 
 .    
   
: he e-named t, SECURITY EQUIP ENT CORPORATION,  ts 
ttorneys of Record, CHRISTOPHER C. BURKE and THO AS J. LLOYD III, GREENER 
BURKE SHOE AKER PA, 950 . Bannock Street, Suite 900, Boise, ID 83702, and the 
  the - tle  rt. 
IC  S   : 
1. The above-named Plaintiff- ppellant, BILLIE J  J R, appeals against the 
above-named efendant- ppellee to the Idaho upre e ourt fro  the ctober 20, 2011 
Judg ent and the follo ing orders: July 19, 2011 E  E PE I  TIO S F R S R  
J E T  TO S I E FFI IT   ; ctober ,   I  
OTICE OF PP  - 1 
DEFENDANTSMOTIONS FOR SUMMARY JUDGMENT STRIKING AFFIDAVIT OF GAROLD YOST AND
DENYING PLAINTIFFSMOTIONS FOR RECONSIDERATION and October 20 2011 JUDGMENT the
Honorable Cheri C Copsey presiding
2 Appellant has a right to appeal to the Idaho Supreme Court and the Judgment and
Orders described in paragraph 1 above are appealable under and pursuant to Idaho Appellate
Rule 11a
3 Appellant requests a review of the following issues
a In granting the Defendantsfirst motion for summary judgment did the
district court err in its finding that there were no genuine material issues of fact as to the
foreseeability of injury element of each of the Plaintiffsproduct liability claims
b In granting the Defendantssecond motion for summary judgment and
denying the Plaintiffsmotion for reconsideration did the district court err in its finding that
there were no genuine material issues of fact as to the foreseeability of injury element of the
Plaintiffsproduct liability case
c In granting the Defendantsthird motion for summary judgment and denying
the Plaintiffsmotion for reconsideration did the district court err in its finding that the Plaintiff
could not proceed to trial on her acute injury claims because the risk of those injuries were
known to her and were disclosed on the product label
d In granting the Defendantsthird motion for summary judgment did the
district court err in finding that the Plaintiff could only establish the foreseeability of injury
element of her claims by proof that it was known at the time the product was sold to Plaintiffs
employer that there was a risk of chronic injury when there was ample evidence in the record of
the then known acute injury risks
NOTICE OF APPEAL 2
002095
ENDANT'S    ENT, T I I  I      
I  I TIFF'S I   NSIDERATION;  t r ,2  T, t  
r l  ri .  r siding. 
2. ella t as a ri t t  a eal t  t e I a  re e urt, a  t e J e t a  
r ers escri e  i  ara ra   a e are a eala le er a  rs a t t  I a  ellate 
  1 (a)(1). 
. ll t t   i   t  ll i  i s: 
(a) In granting the efendant's first otion for su ary judg ent, did the 
    ts              
foreseeability of injury ele ent of each of the Plaintiff s product liability clai s? 
(b) In granting the efendant's second otion for su ary judg ent, and 
i  t  laintif  s ti   si eration, i  t  i t i t t  i  it  i i  t t 
there ere no genuine aterial issues of fact as to the foreseeability of injury ele ent of the 
laintif  s  a t  e? 
(c) In granting the efendant's third otion for su ary judg ent, and denying 
the Plaintiffs otion for reconsideration, did the district court err in its finding that the Plaintiff 
l  t r  t  tri l  r t  i j r  lai s s  t  ris  f t s  i j ries r  
 t  r  ere is l s   t  r t l el? 
(d) In granting the Defendant's third motion for summary judgment, did the 
district court err in finding that the Plaintiff could only establish the foreseeability of injury 
ele ent of her clai s by proof that it as kno n at the ti e the product as sold to Plaintiffs 
e ployer that there as a risk f chronic injury, hen there as a ple evidence in the record f 
the then kno n acute injury risks? 
I    -  
e In granting the Defendantsmotion to strike and denying the Plaintiffs
motion for reconsideration did the district court err in finding that the second affidavit of
Plaintiffsexpert was in direct conflict with his prior deposition testimony and it was therefore a
sham affidavit
f Did the district court apply the correct standard for admissibility of expert
testimony
g In denying the Plaintiffsmotion for partial summary judgment and granting
the Defendantsfirst motion for summary judgment did the district court err in its finding that
the Federal Hazardous Substance Act preempted Occupational Safety and Health Act regulations
governing labeling requirements for products used in the workplace
4 On January 25 2011 the district court entered its Confidentiality Order relating to
certain documents produced by the Defendant in discovery Documents filed under seal include
the following
a Affidavit of Christopher A Reilly PhDin Support ofDefendantsMotion
for Summary Judgment filed April 22 2011
b Affidavit of Robert Nance in Support of DefendantsMotion for Summary
Judgment filed April 22 2011
c Affidavit of Counsel in Support of DefendantsMotion for Summary
Judgment filed April 22 2011
d Affidavit of Counsel in Support of PlaintiffsOpposition to Defendants
Motion for Summary Judgment and in Support of Plaintiff Cross Motion
for Partial Summary Judgment filed June 10 2011
5 The following reporterstranscripts are requested
a The July 14 2011 hearing on DefendantsMotion for Summary Judgment
PlaintiffsCross Motion for Partial Summary Judgment and Defendants
Motion to Strike Portions of the Affidavit of Garold Yost Reporter
estimated page length is less than 100 pages
NOTICE OF APPEAL 3
002096
(e) I  ti  t  fendant's ti  t  trike,  i  t  laintif s 
otion for reconsideration, did the district court err in finding that the second affidavit f 
l intif  s t  i  i t fli t it  i  i  siti  t ti   it  t   
s a  affi avit? 
(f) id the district court apply the correct standard for ad issibility of expert 
ti ony? 
(g) I  denying the laintiff s otion for partial su ary judg ent, and granting 
t  f ndant's ir t ti    j t, i  t  i t i t t  i  its i i  t t 
t  r l r s st  t r t  ti l f t   lt  t r l ti s 
governing labeling require ents for products used in the orkplace? 
. n January 25,2011, the district court entered its onfidentiality rder relating to 
certain docu ents produced by the efendant in discovery. ocu ents filed under seal include 
t  f ll i g: 
(a) ffida it f ri t r . illy, h.D. i  rt f f ndant's tio  
f r r  J t file  ril , . 
(b) ffida it f rt  i  rt f f ndant's ti  f r r  
Judg ent filed pril 22, 2011. 
(c) ffidavit of ounsel in Support of efendant's otion for Su ary 
Judg ent filed pril 22, 2011. 
(d) ffidavit of ounsel in Support of Plaintiffs pposition to efendant's 
tio  f r r  J t  i  rt f l intiffs r ss tio  
for artial u ary Judg ent filed June 10,2011. 
. The follo ing reporter's transcripts are requested: 
(a) The July 14, 2011 hearing on efendant's otion for Su ary Judg ent, 
l intiffs ross ti  f r rti l r  J nt,  f ndant's 
tion t  ike s   id    t. Reporter's 
esti ated page length is less than 100 pages. 
I    -  
b The September 15 2011 hearing on DefendantsSecond Motion for
Summary Judgment Plaintiffs Motion for Reconsideration and
DefendantsMotion to Strike Portions of the Second Affidavit of Garold
Yost Reporter estimated page length is less than 100 pages
c The September 22 2011 Pretrial Hearing Conference Reportersestimated
page length is less than 100 pages
d The October 17 2011 hearing on DefendantsMotion for Clarification third
motion for summary judgment and Plaintiffs Second Motion for
Reconsideration Reportersestimated page length is less than 100 pages
6 Appellant requests the following documents to be included in the clerksrecord in
addition to the standard clerks record
a Register ofAction
b Table ofContents of each volume
c Complaint2410
d Answer to the Complaint4510
e SECsMotion for Summary Judgment42211
f Memorandum in Support of SECs Motion for Summary Judgment
42211
g Affidavit of Christopher A Reilly PhDin Support of DefendantsMotion
for Summary Judgment42211
h Affidavit of Robert Nance in Support of DefendantsMotion for Summary
Judgment42211
i Affidavit of Counsel in Support of DefendantsMotion for Summary
Judgment42211
j Affidavit of Counsel in Support of PlaintiffsOpposition to Defendants
Motion for Summary Judgment and in Support of Plaintiff Cross Motion
for Partial Summary Judgment42211
k Affidavit of Counsel in Support ofMotion for Summary Judgment52611
1 Plaintiffs Cross Motion for Partial Summary Judgment6101
NOTICE OF APPEAL 4
002097
(b)  t  5,  ari   fendant's  ti  f r 
r  udg ent, laintiffs   econsideration,  
fendant's  t  tri  rt  f t  c  i  f r l  
ost. eporter's esti ated page length is less than 100 pages. 
(c) he Septe ber 22, 2011 Pretrial earing onference. eporter's esti ated 
a e le t  is less t a  100 ages. 
(d) he ctober 17,2011 hearing on efendant's otion for larification (third 
ti  r  j ent),  laintiffs c    
econsideration. eporter's esti ated page length is less than 100 pages. 
. ll t t  t  ll i  t  t   i l  i  t  lerk's  i  
    lerk's ord: 
(a)    
(b)       
( c)  (2/24/10) 
(d) ns er to the o plaint (4/5110) 
(e) SEC's otion for Su ary Judg ent (4122/11) 
(f) e orandu  in Support of SEC's otion for Su ary Judg ent 
(412 /11 ) 
(g) ffida it f rist er . eill , h.D. i  rt f efendant's ti  
for u ary Judg ent (4/22111) 
(h) Affidavit of Robert Nance in Support of Defendant's otion for Su ary 
Judg ent (4122111) 
(i) ffidavit of ounsel III Support of efendant's otion for Su ary 
J t (4122111) 
(j) ffidavit f ounsel in upport f laintiffs pposition to efendant's 
otion for u ary Judg ent and in upport f laintiffs ross otion 
for artial u ary Judg ent (4122/11) 
(k) Affidavit of Counsel in Support of Motion for Summary Judgment (5126111) 
(1) Plaintiffs Cross otion for Partial Su ary Judg ent (6/10/11) 
I  F PP  - 4 
m PlaintiffsOpposition to Motion for Summary Judgment and Memorandum
in Support of Cross Motion for Partial Summary Judgment6101
n Affidavit of Counsel in Opposition to SECsMotion for Summary Judgment
and In Support of Plaintiffs Cross Motion for Partial Summary Judgment
6101
o Affidavit of Garold S Yost PhD in Opposition to SECsMotion for
Summary Judgment6101
p Affidavit of JP Purswell PhD in Opposition to SECs Motion for
Summary Judgment and in Support of Plaintiffs Cross Motion for Partial
Summary Judgment6101
q SECsMotion to Strike Portions of the Affidavit of Garold S Yost PhD
62411
r Affidavit of Thomas J Lloyd in Support of SECsMotion to Strike Portions
of the Affidavit of Garold S Yost PhD62411
s SECsMemorandum in Support of Motion to Strike Portions of Affidavit of
Garold S Yost PhD62411
t SECsReply Memorandum in Support of DefendantsMotion for Summary
Judgment62411
u SECs Memorandum in Opposition to Cross Motion for Partial Summary
Judgment63011
v Affidavit of Chris Burke in Support of Opposition to Plaintiffs Cross
Motion for Partial Summary Judgment63011
w Affidavit of Nicholas Roberts in Support of Opposition to Plaintiffs Cross
Motion for Partial Summary Judgment63011
x Affidavit of Robert Nance in Support of Opposition to Plaintiffs Cross
Motion for Partial Summary Judgment63011
y Second Affidavit of Robert Nance in Support of Opposition to Plaintiffs
Cross Motion for Partial Summary Judgment63011
z Affidavit of Thomas J Lloyd III in Support of Opposition to Plaintiffs
Cross Motion for Partial Summary Judgment711
aa Plaintiff s Opposition to SECsMotion to Strike Portions of the Affidavit of
Garold S Yost PhD711
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(m) laintiffs siti  t  ti  f r u r  J t  r  
in upport f ross otion for artial u ary Judg ent (6/10/11) 
(n) ffidavit of ounsel in pposition to SEC's otion for Su ary Judg ent 
and In Support of Plaintiffs ross otion for Partial Su ary Judg ent 
(6/1 0/11) 
(0) ffidavit f arold . ost, h.D. in pposition to EC's otion for 
u ary Judg ent (6/10/11) 
(p) i it  .P. rswell, h.D., i  siti  t  EC's ti  r 
r  t  i  rt  l i tiff  r  ti  f r rti l 
r  t (6/10/11) 
(q) EC's ti  t  tri  rti s f t  ffid it f r l  . st, h.D. 
(6/24/11) 
(r) ffida it f as J. l  i  rt f EC's ti  t  tri e rti s 
of the ffidavit of arold S. ost, Ph.D. (6/24/11) 
(s) SEC's e orandu  in Support of otion to Strike Portions of ffidavit of 
arold S. ost, Ph.D. (6/24/11) 
(t) EC's e l  e ra  i  rt f efendant's ti  f r ar  
J e t (6/24/11) 
(u) SEC's e orandu  in Opposition to Cross otion for Partial Su ary 
J e t (6/30/11) 
(v) ffida it f ris r e i  rt f siti  t  lai tiffs r ss 
otion for Partial Su ary Judg ent (6/30/11) 
(w) ffidavit of icholas oberts in Support of pposition to Plaintiffs ross 
otion for Partial Su ary Judg ent (6/30/11) 
(x) ffidavit f obert ance in upport f pposition to laintiffs ross 
otion f r artial ary J e t (6/30/11) 
(y) Second ffidavit of obert ance in Support of pposition to Plaintiffs 
ross otion for Partial Su ary Judg ent (6/30/11) 
(z) ffidavit f as J. loyd III in rt f siti  t  l i tiffs 
ross otion for artial u ary Judg ent (7/1/11) 
(aa) l i tiff  ition t  C's otion t  tri e rtions  t  ffida it f 
arold S. ost, Ph.D. (7/1/11) 
I  F PP  -  
bb Plaintiffs Reply to Opposition to Cross Motion for Summary Judgment
711
cc Amended Affidavit ofJP Purswell Filed in Opposition to SECsMotion
for Summary Judgment711
dd Ex Parte Motion to Strike Amended Affidavit of JP Purswell Filed in
Opposition to Motion for Summary Judgment711
ee PlaintiffsMotion for Order Shortening Time for Filing Amended Affidavit
ofDr Purswell7121
ff Affidavit ofCounsel in Opposition to DefendantsEx Parte Motion to Strike
Dr PurswellsAmended Affidavit and in Support of PlaintiffsMotion to
Shorten Time for Filing Amended Affidavit ofDr Purswell 7121
gg Order re Pending Motions for Summary Judgment and Motion to Strike
Affidavit of Garold S Yost 7191
hh SECsSecond Motion for Summary Judgment72211
ii Second Affidavit ofChristopher Burke72211
Oj SECs Memorandum in Support of Defendants Second Motion for
Summary Judgment72211
kk PlaintiffsMotion for Reconsideration72611
11 Affidavit of Counsel in Support of PlaintiffsMotion for Reconsideration
72611
mm Affidavit of Billie Major in Support of Plaintiffs Motion for
Reconsideration72611
nn Affidavit of Garold S Yost PhD in Support of Plaintiffs Motion for
Reconsideration72611
oo Plaintiffs Memorandum in Support of Plaintiffs Motion for
Reconsideration and in Opposition to DefendantsSecond Motion for
Summary Judgment72611
pp SECsMotion to Strike Portions of Second Affidavit of Garold S Yost
PhD8181
qq Affidavit of Thomas J Lloyd III in Support of SECsMotion to Strike
Portions of Second Affidavit ofGarold S Yost PhD8181
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(b ) laintiffs pl  t  siti  t  r ss ti  f r u ary J t 
( 17 11) 
(c )  ffi it f J.P. rs ll il  i  siti  t  EC's ti  
f r ar  J e t ( 17/11) 
(d )  r   t  t     J.P. urs el  i  i  
pposition to otion for Su ary Judg ent (7/11111) 
(e ) laintiffs ti  f r r r rt i  i  f r ili   ffi it 
f r. rs ll (7/12/11) 
(ff) ffi it f s l i  siti  t  f ndant's  rt  ti  t  tri  
r. urswell's  ffi it  i  rt f laintiffs ti  t  
Shorten Ti e for Filing ended ffidavit of r. Purs ell (7/12111) 
(g ) r er re e i  ti s f r ar  J e t a  ti  t  tri e 
ffidavit f arold . ost (7/19/11) 
(hh) SEC's Second otion for Su ary Judg ent (7/22/11) 
(ii)  ffida it f rist r r  (7/22 11) 
(jj) EC's e ra  i  rt f f ndant's  tion f r 
r  J t (7/22/11) 
(kk) laintiffs otion for econsideration (7/26111) 
(1 ) fida it  l i  t  laintif s tion  i ti  
(7/2 /11) 
(m ) ffida t  illie a r III rt  laintif s ion  
on (7/26/11) 
(nn) Affidavit of Garold S. Yost, Ph.D. in Support of Plaintiffs otion for 
econsideration (7/26/11) 
(00) l intiffs e ra  in rt  laintif s ion  
econsideration and in pposition to efendant's Second otion for 
Su ary Judg ent (7/26/11) 
(Pp) S C's otion to Strike Portions of Second ffidavit of arold S. ost, 
Ph.D. (8/18/11) 
(qq) ffidavit of Tho as J. Lloyd III in Support of SEC's otion to Strike 
Portions of Second ffidavit of arold S. ost, Ph.D. (8118/11) 
I  F PP L -  
rr SECsMemorandum in Support of DefendantsMotion to Strike Portions of
Second Affidavit ofGarold S Yost PhD8181
ss SECs Reply Memorandum in Support of Defendants Second Motion for
Summary Judgment and in Opposition to Plaintiffs Motion for
Reconsideration82611
tt DefendantsMotion for Clarification treated as a third motion for summary
judgment92011
uu Affidavit of Counsel in Support ofSECsMotion for Clarification92011
vv Memorandum in Support of SECsMotion for Clarification92611
ww Plaintiffs Motion for Reconsideration of Courts Order Granting
Defendant Motion for Summary Judgment 1041
xx Affidavit of Billie Jo Major in Support of PlaintiffsMotion for
Reconsideration and in Opposition to Defendants Third Motion for
Summary Judgment1041
yy Affidavit of Counsel in Support ofPlaintiffsMotion for Reconsideration of
Courts Order Granting DefendantsMotions for Summary Judgment
1041
zz Memorandum in Support of Plaintiffs Motion for Reconsideration of
Courts Order Granting DefendantsMotions for Summary Judgment
1041
aaa DefendantsMemorandum in Opposition to PlaintiffsSecond Motion for
Reconsideration and in Reply to Plaintiff Opposition to Defendants
Motion for Clarification 101111
bbb Order Granting DefendantsMotions for Summary Judgment Striking




a That a copy of this Notice of Appeal has been served on each reporter of
whom a transcript has been requested as named and at the address set out below
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(r ) EC's e ra  i  rt f efendant's ti  t  tri e rti s f 
ec  ffi a it f ar l  . st, h.D. (8118 11) 
(s ) EC's l   i  t  fendant's  ti  r 
 Judg ent   pposition  laintif s   
i r ti  (8126111) 
(tt) fendant's ti  f r l rifi ti  (treate    t ir  ti  f r u r  
j nt) (912 /11) 
(u ) ffi it f l i  rt f EC's ti  f r l rifi ti  (9/20/11) 
(v ) r  i  rt f EC's ti  f r l rifi ti  (9/26 11) 
(w ) laintif s ti   i r ti   ourt's  Granting 
efendant's ti  f r ar  J e t (10/4 11) 
(x ) ida it  illi   j  i  t  laintif s ti  r 
si r ti   i  siti  t  f ndant's ir  ti  f r 
r  J t (10/4/11) 
(y ) ffida it f sel i  rt f laintiffs tio  f r ec si erati  f 
ourt's r er ra ti  efendant's tions f r ar  J e t 
(10/4111) 
(z )  i  t  laintif s ti   i ti   
ourt's rder ranting efendant's otions for Su ary Judg ent 
(10/4 11) 
(a ) f ndant's r  i  iti  t  laintiffs  ti  f r 
ec si erati  a  i  e l  t  laintiffs siti  t  efendant's 
otion for larification (10111/11) 
(bbb) rder ranting efendant's otions for u ary Judg ent, triking 
fida t   t,  enying laintif  s ions  
i r ti  (1012 111) 
(ccc) J e t (1012 111) 
.  rtify: 
(a) That a copy of this otice of ppeal has been served on each reporter of 
  tra s ri t s  re est  s   t t  r ss s t t l : 




200 West Front Street
Boise ID 83702
b That the reporter has been paid the estimated fee for preparation of the
reporterstranscript
c That the estimated fee for preparation of the clerksrecord has been paid
d That the appellate filing fee has been paid
e That service has been made upon all parties required to be served pursuant to
Idaho Appellate Rule 20
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i  a se  
rt  istrict rt 
 t  rt s  
 t t t t 
,   
(b) at t e re rter as ee  ai  t e esti ate  fee f r re arati  f t e 
porter's script. 
(c) t t  ti t  f  f r r r ti   t  lerk's r r    id. 
(d) at t e a ellate fili  fee as ee  aid. 
(e) hat service has been ade upon all parties required to be served pursuant to 
 ll t  l  . 
     r, . 
 &   
~ 
 .  
Ie .  
I  F P  -  
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 23rd day of November 2011 a true and correct copy
of the foregoing document was served on the following individualsbythe method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
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I EREB  CERTIF  that on this 23rd day of ove ber, 2011, a true and correct copy 
f t e f r i  t s s r   t  f ll i  i dividual(s)  t  t  i i t : 
hristopher . urke 
as . l   
     
 .  tr t, it   
i , I   
 a s  
rth i tri t rt 
da  thouse 
    
i ,   
   -  
[X] .S. il 
[ ] x: -260  
[ ]  e  
[ ] ail: c r e greenerlaw.com 
tlloyd greenerlaw.com 
[~ .S. il 
[ ] x: 
LX] ess r li r  
[ ] il: 
~-
 .  
 . W Z 
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AM PM
DEC 0 12011
Christopher C Burke ISB 2098
Thomas J Lloyd 1II ISB 7772
GREENER BURKE SHOEMAKER PA





CHRISTOPHER D RICH Clerk
By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA




CORPORATION a Missouri corporation
Case No CVPI 1003515
SEC MOTION TO STRIKE THIRD
AFFIDAVIT OF GAROLD S YOST




Defendant Security Equipment Corporation SEC by and through its counsel of
record Greener Burke Shoemaker PA pursuant to Idaho Rules of Civil Procedure 7 and 56c
objects to and hereby moves this Court to strike the Third Affidavit of Garold S Yost PhD
Third Yost Affidavit which was filed by Plaintiff Billie Jo Major Plaintiff on October
24 2011 in support of PlaintiffsThird Motion for Reconsideration
This Motion to Strike is made on the following grounds
1 The Third Yost Affidavit was not permitted per the Court during oral argument on
the parties motions heard September 15 2011
SEC MOTION TO STRIKE THIRD AFFIDAVITOF GAROLD S YOSTPHDFILED IN SUPPORT OF
PLAINTIFF MOTION FOR RECONSIDERATION Page 1 14542 011 427149doc
002103
hristopher . urke, IS  #2098 
Tho as J. Lloyd III, IS  #7772 
  ER  
 .  t,   
is , I   
el: (20 ) -2600 
x: (2 ) -2601 
ttorneys for efendant 
NO.-___ ~~~.....,~i'_ 
.M. ____ r:J_LI~~. Cf ::zr 
   201  
I  . I , l  
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  ,        




P ATI , a issouri corporation, 
nt. 
 o.: - I-  
EC'S   I   
I I    . T, 
H.D     
I TIFF'S   
I  
efendant Security Equip ent Corporation ("SEC"), by and through its counsel of 
record, reener urke Shoe aker P.A., pursuant to Idaho ules of ivil Procedure 7 and 56(c), 
objects to and hereby oves this ourt to strike the Third ffidavit of arold S. ost, Ph.D. 
("Third st id "), which was filed by Plaintiff Billie Jo ajor ("Plaintiff') on October 
24, 2011 in support f laintiff s hird otion for econsideration. 
This otion to Strike is ade on the follo ing grounds: 
. he hird ost ffidavit as not per itted per the ourt during oral argu ent on 
t  rties ti s r  t r , 1; 
C'S I   I  I  I I    . T, H.D I  I    
I TIFF'S I   I I  -   14542-011 (427149 doc) 
2 Plaintiffs Third Motion for Reconsideration made after entry of final judgment
is not a proper procedure for addressing an order entered prior to entry of final
affidavit
The Third Yost Affidavit discloses facts and opinions which were in existence
prior to entry of final judgment and which could have with the exercise of due
diligence been incorporated into prior Yost Affidavits before entry of final
judgment and
4 The Third Yost Affidavit suffers from many of the same defects that led the Court
to strike the Second Yost Affidavit it contains inadmissible conclusory
statements it lacks foundation it confuses medical causation for foreseeability of
risk and its attached articles do not support the breadth of opinions offered by Dr
Yost
This Motion is further supported by the Idaho Rules of Civil Procedure the transcript of
this Court hearings held September 15 and October 17 2011 this CourtOrder Granting
DefendantsMotions for Summary Judgment Striking Affidavit of G Yost and Denying
Plaintiffs Motions for Reconsideration the Judgment entered in this case and the other orders
pleadings and documents on file with the Court and made a part of the record during the
summary judgment proceedings
Oral argument is scheduled to be heldDeccmtwr 15 2011
DATED this day of December 2011 RE N By K I
Christopher C Burke Momas J Lloyd III
Attorneys for Defendant
SEC MOTION TO STRIKE THIRD AFFIDAVIT OF GAROLD S YOST PHDFILED IN SUPPORT OF
PLAINTIFF MOTION FOR RECONSIDERATION Page 2 14542011 427149doc
002104
. lai tiff s ir  tion f r ec si eration, a e after e tr  f fi al j e t, 
is t a r er r ce re f r a ressi  a  r er e tere  ri r t  e tr  f fi al 
vit; 
3.  ir  st ffida it is loses f ts  i i s i  r  i  iste e 
ri r t  e tr  f fi al j e t, a  ic  c l  ave, it  t e e ercise f e 
diligence, been incorporated into prior ost ffidavits before entry of final 
j t;  
. he hird ost ffidavit suffers fro  any of the sa e defects that led the ourt 
 e    fida t - it contains inad issible conclusory 
state ents; it lacks foundation; it confuses edical causation for foreseeability of 
risk; and its attached articles do not support the breadth of opinions offered by r. 
t. 
his otion is further supported by the Idaho ules f ivil rocedure, the transcript f 
this ourt hearings held Septe ber 15 and ctober 17,2011, this ourt's rder ranting 
Defendant's otions for Summary Judgment, Striking Affidavit ofG. Yost and Denying 
Plaintiffs otions for econsideration, the Judg ent entered in this case, and the other orders, 
pleadings and docu ents on file ith the ourt, and ade a part of the record during the 
su ary judg ent proceedings. 
l e  i  l    l  ec m  , . 
  U a  f ece er, 1. 
EC'S        . , H.D     
I TIF 'S I   I I  -   14542-011 (427149.doc) 
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing SECMOTION TO STRIKE
THIRD AFFIDAVIT OF GAROLD S YOSTPHD FILED IN SUPPORT OF PLAINTIFFS
MOTION FORRECONSIDERATION on the following named personson the date indicated
below in themanner indicated below
Darwin Overson Esq
Eric B Swartz Esq
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 220






DATED this 4 day ofNovember 2011
Christopher C Burke
Thomas J Lloyd III
SEC MOTION TO STRIKE THIRD AFFIDAVIT OF GAROLD S YOST PHDFILED IN SUPPORT OF
PLAINTIFF MOTION FOR RECONSIDERATION Page 3 14542011 427149doc
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I hereby certify that I caused to be served the foregoing SEC'S I   S I  
    . , H.D.     I TIFF'S 
I   I I   t e f ll i  a e  erson(s)  t e ate i icated 
l ,    indicated l : 
ar in verson, sq. 
ric . artz, sq. 
 & ,  
 . reline ri e, ite  
. .   
oise, Idaho 83707 
TE  s \f a  f e er, . 
[ ] ia .S. il 
[ ] ia and elivery 
[ v1 Via i ile (20 /489-89 ) 
[ ] Via Overnight Delivery 
Christopher C. Burke 
as 1. l  III 
EC'S   I   I    . T, H.D I  I    
LAINTIF 'S I   I  n  -   145 -  (427149.doc) 
n F I C7Ii lA L Igo FILE
AM PM
DEC 0 12011
Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKER PA





CHRISTOPHER D RICH Clerk
By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FORTHE COUNTY OF ADA








56cAWARD OF ATTORNEYS FEES
AND COSTS
Defendant
Defendant Security Equipment Corporation Defendant or SEC by and through its
attorneys of record Greener Burke ShoemakerPA moves the Court for an order pursuant to
Rule 56c of the Idaho Rules of Civil Procedure awarding it reasonable attorneys fees and
costs in the form of sanctions imposed against Plaintiff and her attorneys for disregarding the
Courts order on Plaintiffsrequest to file a third affidavit of Garold Yost for filing an improper
motion for reconsideration of orders entered before final judgment was entered and for failing to
timely and efficiently respond to Defendantssummary judgment motions This Motion is based
upon the Affidavit of Counsel in Support of DefendantsMotion for Rule 56c Award of
Attorneys Fees and Costs SECs Memorandum in Support of Motion to Strike Third Affidavit
SECURITY EQUIPMENT CORPORATIONSMOTION FOR RULE 56c AWARD OF ATTORNEYS FEES
AND COSTS Page 1 14542011 424312doc
6
002106
hristopher C. urke, IS  #2098 
Thomas J. Lloyd III, ISB #7772 
EE ER RKE S KER P  
950 . annock treet, uite 900 
oise, Idaho 83702 
Tel: (208) 319-2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
~-._ -_ -_ -_ -_ -_-_ -:~_L~~,.6:r-M.--'q"""r"j""·J""'qa..,r-
   2011 
I  . I , l r  
y STEPHANIE IDAK 
DEPUTY 
I  E IS ICT      IS I    
E  I , I    E    
I IE J  J , an individual, 
laintiff, 
v. 
SE IT  E IP E T 
C RP RATI , a issouri corporation, 
nt. 
se o.: -PI-  
  
PORATION'S    
6(c)   '  
  
efendant Security Equip ent Corporation ("Defendant" or "SEC"),   t r  its 
attorneys of record, Greener Burke Shoemaker P.A., moves the Court for an order, pursuant to 
ule 56(c) of the Idaho ules of ivil Procedure, a arding it reasonable attorneys' fees and 
costs in the for  of sanctions i posed against Plaintiff and her attorneys for disregarding the 
ourt's order on Plaintiffs request to file a third affidavit of arold ost, for filing an i proper 
ti  f r r si r ti  f r rs t r  f r  fi l j t s ntered,  f r f ili  t  
timely and efficiently respond to Defendant's summary judgment motions. This otion is based 
upon the ffidavit of Counsel in Support of efendant's otion for Rule 56(c) ard of 
ttorneys' Fees and osts, SEC's e orandu  in Support of otion to Strike Third ffidavit 
SECURITY EQUIP ENT CORPORATION'S OTION FOR RULE 56(c) A ARD OF ATTORNEYS' FEES 
  - Page I 14542-  ( 24312.doc) 
of Garold Yost and for Rule 56cAward of Attorneys Fees and Costs and the pleadings and
documents on file with the Court








I hereby certify that I caused to be served the foregoing Security Equipment
CorporationsMotion for Rule 56cAward of Attorneys Fees and Costs on the following
named personson the date indicated below in the manner indicated below
Darwin Overson Esq Via USMail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O BOX 7808
Boise Idaho 83707
DATED this day of 2011
Christopher C Burke
Thomas J Lloyd III
SECURITY EQUIPMENT CORPORATIONSMOTION FOR RULE 56cAWARD OF ATTORNEYS FEES
AND COSTS Page 2 14542011 424312doc
002107
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Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKER PA






CHRISTOPHER D RICH Clerk
By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
BILLIE JO MAJOR an individual
Plaintiff Case No CVPI 1003515
V
SECURITY EQUIPMENT





AFFIDAVIT OF COUNSEL IN
SUPPORT OF SECURITY EQUIPMENT
CORPORATION MOTION FOR RULE
56c AWARD OF ATTORNEYS FEES
AND COSTS
IChristopher C Burke being first duly sworn upon oath state as follows
1 I am one of the attorneys ofrecord for Defendant Security Equipment Corporation
SEC or Defendant I make this Affidavit based upon personal knowledge in support of
SECsMotion for Rule 56c Award of Attorneys Fees and Costs
2 The first round of cross motions for summary judgment in this case during which
Plaintiff Billie Jo Major Plaintiff or Major filed the first affidavit of her expert witness Dr
Garold Yost ended on July 15 2011 with the Courtsruling granting SECsMotion for
AFFIDAVIT OF COUNSEL IN SUPPORT OF SECURITY EQUIPMENT CORPORATIONSMOTION FOR
RULE 56c AWARD OF ATTORNEYS FEES AND COSTS Page 1 14542 011 424317doc
002108
, 
Christopher C. Burke, ISB #2098 
Thomas 1. Lloyd III, ISB #7772 
GREENER BURKE SHOE AKER P A 
950 W. Bannock Street, Suite 900 
Boise, Idaho 83702 
Tel: (208) 319-2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
NO.----~~_r_r__......;J,_,( 
AJA.= ~l~~. q ( 3'{ 
DEC 0 1 2011 
CHRISTOPHER D. RI , Clerk 
By STEPHANIE VIDAK 
DEPUTY 
I  E IS I    E  I I  IS I   E 
ST TE F I , I   F  T E T  F  




CORPORATION, a Missouri corporation, 
ant. 
STATE OF IDAHO ) 
)ss. 
County of Ada ) 
s  o.: - I-I  
    
  I   
PORATION'S    
6(c)   '  
  
I, Christopher C. Burke, being first duly sworn upon oath, state as follows: 
. I a  one of the attorneys of record for efendant Security Equip ent orporation 
("S C" or "Defendant"). I ake this ffidavit based upon personal kno ledge in support of 
SEC's Motion for Rule 56(c) Award of Attorneys' Fees and Costs. 
2. T  fi t round of cr s- oti  for sum ary j t in this case, duri  whi  
Plaintiff Billie Jo Major ("Plaintiff' or "Major") fil d the first af idavit of her expert witnes , Dr. 
Garold Yost, ended on July 15,2011, with the Court's ruling granting SEC's Motion for 
AFFIDA VIT OF COUNSEL IN SUPPORT OF SECURITY EQUIPMENT CORPORATION'S MOTION FOR 
RULE 56(c) AWARD OF ATTORNEYS' FEES AND COSTS - Page 1 14542-01  (424317.doc) 
Summary Judgment and denying PlaintiffsMotion for Summary Judgment Attached to this
Affidavit as Exhibit 1 is a true and accurate summary of the attorneys fees and costs actually
incurred by SEC in prosecuting and defending the first round motions through July 15 2011
The total amount incurred by SEC for that first round of motions was 2685550
The second round of motions which included SECsSecond Motion for
Summary Judgment on the FHSA claim left open by the Court and Plaintiffsfirst Motion for
Reconsideration covered the time period between July 16 2011 and September 15 2011
During that second round Plaintiff filed a second Affidavit of Dr Garold Yost and the first
Affidavit of Billie Jo Major in support of her Motion for Reconsideration and in opposition to
Defendantssummary judgment motion Attached to this Affidavit as Exhibit 2 is a true and
accurate summary of attorneys fees and costs actually incurred by SEC in prosecuting and
defending this second round of motions through September 15 2011 The total amount of fees
and costs incurred by SEC for the second round ofmotions was 190680
4 The third round of motions which included a third Motion for Summary
Judgment on the acute injury issued raised by Plaintiff during oral argument on September 15
2011 and Plaintiff s second Motion for Reconsideration took place between September 16
2011 and October 19 2011 During that third round Plaintiff filed a second Affidavit of Billie
Jo Major in support of her Motion for Reconsideration and in opposition to SECssummary
judgment motion and asserted a new legal theory based on damages Attached to this Affidavit
as Exhibit 3 is a true and accurate summary of attorneys fees and costs actually incurred by
SEC in prosecuting and defending this third round of motions through October 19 2011 The
total amount of fees and costs incurred by SEC for the third round of motions was912300
AFFIDAVIT OF COUNSEL IN SUPPORT OF SECURITY EQUIPMENT CORPORATIONSMOTION FOR
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" 
Su ary Judg ent and denying Plaintiff s otion for Su ary Judg ent. Attached to this 
fidavit as x ibit  is a true and accurate s ary of the attorne s' fees  costs t ll  
incurred by SEC in prosecuting and defending the first round motions through July 15,2011. 
The total a ount incurred by SE  for that first round of otions as $26,855.50 
3. he se nd round  , ich included C's  tio   
Summary Judgment on the FHSA claim left open by the Court and Plaintiff s first otion for 
econsideration, covered the ti e period bet een July 16,2011 and Septe ber 15,2011. 
During that second round, Plaintiff filed a second Affidavit of Dr. Garold Yost, and the first 
ffidavit of illie Jo ajor in support of her otion for econsideration and in opposition to 
Defendant's su ary judg ent otion. Attached to this Affidavit as Exhibit 2 is a true and 
accurate summary of attorneys' fees and costs actually incurred by SEC in prosecuting and 
defending this second round of motions through September 15,2011. The total amount of fees 
and costs incurred by SEC for the second round of motions was $19,068.00 
.  t i    ti s, i  i l   t i  ti  r  
Judgment on the acute injury issued raised by Plaintiff during oral argument on September 15, 
2011, and Plaintiff s second otion for econsideration, took place bet een Septe ber 16, 
2011 and ctober 19,2011. uring that third round, Plaintiff filed a second ffidavit of illie 
Jo Major in support of her Motion for Reconsideration and in opposition to SEC's summary 
judgment motion, and asserted a new legal theory based on damages. Attached to this Affidavit 
as x i it 3 is a true and accurate su ary of attorneys' fees and costs actually incurred by 
SEC in prosecuting and defending this third round of motions through October 19, 2011. The 
total a ount of fees and costs incurred by  for the third round of otions as $9,123.00 
FI I  OF COU EL I  SUPPORT OF SECURITY EQUI  CORPORATION'S TI  F R 
RULE 56(c) AWARD OF ATTORNEYS' FEES AND COSTS -Page 2 14542- 11 ( 24317.doc) 
On October 24 2011 after this Court entered its final order and judgment
granting SEC summary judgment on all issues in the case Plaintiff initiated the fourth round of
motions by filing a third Motion for Reconsideration along with a third affidavit of Dr Garold
Yost Since October 24 2011 SEC has incurred additional attorneys fees and costs in
defending this fourth round ofmotions Attached to this Affidavit as Exhibit 4 is a true and
accurate summary of attorneys fees and costs incurred by SEC in defending this fourth round of
motions from October 24 2011 to present The total amount of fees and costs incurred by SEC
to date for this fourth round of motions is937450 SEC will continue to incur fees and costs
in defending this fourth round of motions and reserves the right to supplement this Affidavit
with an updated summary of fees and costs
6 The following timekeepers of Greener Burke Shoemaker billed services to SEC at





These billing rates are equal to or less than the billing rates customarily charged by other
attorneys and paralegals in the Boise area with the same or similar experience performing the
same or similar services The services for which these timekeepers billed SEC as reflected in
the attached Exhibits 1 through 4 were reasonably and necessarily incurred in the prosecution
and defense of the Cross Motions for Summary Judgment PlaintiffsMotions for
Reconsideration and SECsMotions to Strike variations of the Yost Affidavits
AFFIDAVIT OF COUNSEL IN SUPPORT OF SECURITY EQUIPMENT CORPORATIONSMOTION FOR
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5. n ctober , , a ter t is ourt e tered its fina  rder a d judgment 
granting SEC su ary judgment on all issues in the case, Plaintiff initiated the fourth round of 
otions by filing a third otion for econsideration, along ith a third affidavit of r. arold 
ost. ince ctober , ,  as incurred itio l tt r s' fees  sts in 
defending this fourth round of otions. Attached to this Affidavit as Exhibit 4 is a true and 
accurate su ary of attorneys' fees and costs incurred by S  in defending this fourth round of 
otions fro  ctober 24, 2011 to present. The total a ount of fees and costs incurred by SE  
t  te f r t is fo rth round  tions i  $9,374.50.  ill ti  t  i r f   ts 
in defending this fourth round of otions, and reserves the right to supple ent this ffidavit 
with an updated summary of fees and costs. 
. he follo ing ti ekeepers of reener urke Shoe aker billed services to S  at 
the follo ing billing rates: 
Christopher Burke 
Thomas Lloyd 






These billing rates are equal to or less than the billing rates custo arily charged by other 
attorneys and paralegals in the Boise area with the same or similar experience performing the 
s  r si il r servi s.  s r i s f r i  t s  ti rs ill  C, s r fl t  i  
the attached xhibits 1 through 4, ere reasonably and necessarily incurred in the prosecution 
and defense of the ross- otions for Su ary Judg ent, Plaintiffs otions for 
econsideration, and EC's otions to trike variations f the ost ffidavits. 
FFI  I  F S L I  S PP  F SECURI  IP  ORPORATION'S I  F  
RULE 56(c) A ARD OF ATTORNEYS' FEES AND COSTS - Page 3 14542- 1 ( 24317.doc) 
7 Attached to this Affidavit as Exhibit 5 is a true and accurate copy of a Transcript
of Proceedings of the Courtshearings on motions held on September 15 2011 and October 17
2011
DATED this day of December 11
WAND SWORN TO before me this day ofr2011
AR
G e Notary Public for Idaho
PU p Residing at Star Idaho
lOQ Commission Expires0622012
oTc OF160
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. ttached to this ffidavit as xhibit 5 is a true and accurate copy of a Transcript 
f r cee i s f t e urt's eari s  tions el   e te er ,  a  ct er , 
. 
 s 11 day of ece ber, 201 L 
otary Public for Idaho 
esiding at ~S.!:!:ta!!.r,-" I~d~a:!..!h~o _________ _ 
issi  ires: .;::..0=6/'-'=2=2"-.:/2"-'0"--'1'-'=2'----_____ _ 
I  I    I    I  I  PORA nON'S I   
 6(c)    '    -   14542-011 (424317.doc) 
S
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing Affidavit of Counsel in Support
of Security Equipment CorporationsMotion for Rule 56cAward of Attorneys Fees and
Costs to be served on the following named personson the date indicated below in the manner
indicated below
Darwin Overson Esq ViaUS Mail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O Box 7808
Boise Idaho 837007
DATED this 4 day of December 2011
C Burke
AFFIDAVIT OF COUNSEL IN SUPPORT OF SECURITY EQUIPMENT CORPORATIONSMOTION FOR
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I r  rtif  t t I s  t   s r  t  f r i  ffida it f s l i  rt 
of Security Equip ent orporation's otion for ule 56(c) ard of ttorneys' Fees and 
sts to be served on the follo ing na ed person(s) on the date indicated belo , in the anner 
icate  low: 
ar in verson, sq. 
ri  . rt , s . 
 & ,  
 . ine ,   
. .   
i , I  7  
  \1' day of ece ber, 2011. 
[ ] ia .S. i  
[ 1 ia and elivery 
[ I] ia Facsi ile (208/489-8988) 
[ ] ia er i t eli er  
         PORATION'S   
 6(c)   '    -   14542-011 (424317.doc) 
EXHIBIT 1
002113
I   
Transactions Fee Listing
14542011 Admiral Insurance Company Major v Security Equipment
Date Prof Description Units Price Extended Amt
382011 TJL Research possible summary judgment 130 1400 18200
options A102 L240
392011 TJL Office conference with Christina Morrow 030 1400 4200
re possible motion for summary judgment
on inadequate warning A105 L120
392011 CLM Office conference Thomas Lloyd re 030 8500 2550
motion for summary judgment deadlines
and arguments to be made re express
warranty and warnings review case law
re same A105 L120
392011 CCB Office conference with Tom Lloyd re 040 16500 6600
strategy and legal and factual issues
involved with a summary judgment motion
A105 L120
31120 1 TJL Additional review of case file in 150 1400 2100
preparation for drafting summary
judgment motion and defending
deposition of Bob Nance A104 L210
3172011 CLM Research re strict liability and Federal 140 8500 11900
Hazardous Substance Act summary of
same to Thomas Lloyd A102 L110
3172011 TJL Review research pulled by Christina 050 1400 700
Morrow re federal hazardous substances
act and whether it impacts strict liability
standards A104 L120
3182011 TJL Review research prepared by Dari 260 1400 36400
Huskey restrict liability standards
additional research re summary judgment
on express and implied warranties A102
L120
3182011 DMH Research and analysis re strict liability 200 1400 2800
and unreasonably dangerous A104
L120
302011 CLM Review letters with client and consumer 170 8500 14450
protection re FHSA requirements for
motion for summary judgment internet
research re FHSA requirements over
pepper spray A104 L320
302011 TJL Research on inadequate warnings and 090 1400 12600
FHSA A102 L120
3120 1 TJL Review research on various sections of 170 1400 23800
CFR for labeling requirements and
required tests A104 L120
002114
ti   i ti  
-01     j  . it  i t 
 r f ri tion i  i    
/8/20 1  l r  i l  r  j t .30 40.00 82.00 
ti s (A 1 ; l240) 
/9/20 1  l i   i  i i   .30 40.00 2. 0 
 i l  i    j t 
 i t  r i  (A 1 ; l120) 
/9/20 1 l  i    l   .30 5. 0 5. 0 
ti  f r r  j t li  
 r t  t    r  r  
r t   i s, i   l  
  (A ; l120) 
/9/20 1  ffi  f  it   l   .40 65.00 6. 0 
tr t   l l  f t l i  
i l  it   r  j t ti  
(A105; l120) 
/11/20 1  l i i l i      .50 40. 0 10. 0 
preparation for drafting su ary 
j t ti   f i  
iti  f   (A ; l210) 
/17/20 1 l  esearch re strict liability and Federal .40 5. 0 19.00 
azardous ubstance ct, su ary of 
 t   l  (A 1 ; l ) 
/17/20 1 Jl evie  research pulled by hristina .50 40. 0 0. 0 
     
t  t r it i ts tri t li ilit  
st r s (A 10 ; l120) 
/18/20 1  l i  r r  r r   ri .60 40. 0 64.00 
y  strict li ilit  t ards; 
iti l r r  r  r  j t 
   i li  ti  (A 10 ; 
l120) 
/18/20 1  s rc   lysis r  strict li ility .00 40. 0 80.00 
and unreasonably dangerous (A 104; 
l120) 
/30/20 1 l   l tt rs     .70 5. 0 4 .50 
protection re F  require ents for 
ti  f r r  j t, i t r t 
research re F SA require ents over 
pepper spray (A 104; l320) 
/30/20 1  l r   i t  r i   .90 40. 0 26.00 
F  (A102; l120) 
/31/20 1  l       .70 40. 0 38.00 
 f r l li  r ir t   
r ir  t t  (A 1 ; l120) 
PL
42011 TJL Draft affidavit of Bob Nance 90 A103 140 1400 19600
L210 compile necessary elements for
expert testimony on summary judgment
50 A102 L210
42011 CLM Office conference with Thomas Lloyd re 030 8500 2550
instruction for affidavits of Chris Reilly
expert and Bob Nance to support motion
for summary judgment A105 L210
462011 CLM Revise and edit draft affidavit of Bob 070 8500 590
Nance A103 L210
462011 CLM Email communications with Bob Nance re 090 8500 7650
call today 20 A106 L210 attend
conference call with R Nance and
Thomas Lloyd re Nance affidavit in
support of motion for summary judgment
and related filings 70 A106 L210
462011 TJL Telephone conference with Bob Nance 070 1400 9800
and Christina Morrow re edits to affidavit
A106 L210
472011 CLM Additional revisions and edits to affidavit 130 8500 1105
of Bob Nance to incorporate information
re affiliations publications training
companies discussed with him04611
re resources for industry information
research and pull information from
internet re some companies to explain
same within affidavit of Bob Nance A102
L1102
41120 1 TJL Office conference with David Goicochea 030 1400 4200
re motion for summary judgment
research performed to date and theories
to be advanced 10 A105 L120 office
conference with Chris Burke re affidavit of
Chris Reilly for motion for summary
judgment 20 A105 L210
4122011 CCB Review and revise draft affidavit of Bob 030 16500 4950
Nance in support of summary judgment
motion A103 L210
4122011 CCB Office conference with Tom Lloyd re 050 16500 8250
strategy and issues for summary
judgment motion A105 L120
4122011 TJL Office conference with Chris Burke re 050 1400 700
motion for summary judgment documents
to be filed by end of week A105 L210
002115
/4/20 1  l ft it    (.90) (A ; .40 40. 0 96.00 
l210); l     
t ti    j t 
(.50) (A1 ; l210) 
/4/20 1 l  ffic  c f r c  it  s l y  r  .30 5. 0 25.50 
i tr ction f r ffi it  f ri  illy, 
rt,    t  t ti  
f r r  j t (A1 ; l210) 
/6/20 1 l  i   it r ft ffi it f  .70 5. 0 9.50 
 (A 1 ; l21 ) 
/6/20 1 l  il i ti  it    r  .90 5. 0 6.50 
ll t  (.20) (A ; l210); tt  
f r  ll it  .   
    i it  
rt f ti  f r r  j t 
   (.7 ) (A1 ; l21 ) 
/6/20 1   Telephone conference ith Bob ance .70 40. 0 8. 0 
       
(A1 ; l210) 
/7/20 1 l        .30 5. 0 10.50 
f   t  i r r t  i f r ti  
r  ffili ti , li ti ns, tr i i  
co panies discussed ith hi  04/06/11 
r  r r  f r i tr  i f r ti ; 
r r   ll i f r ti  fr  
i t r t r  s  c i s t  x l i  
 it i  ffi it f   (A 1 ; 
l110/l210) 
/11/20 1  ffi e f  it  i  i  .30 40.00 2. 0 
r  ti  f r s ry j t, 
r r  rf r  t  t   t ri  
to be advanced (.10) (A 105; l120); office 
 i     it  
ri  ill  f r ti  f r r  
judg ent (.20) (A105; l210) 
/12/20 1     ft it   .30 65.00 9.50 
 i  rt f r  j t 
 (A ; l210) 
/12/20 1  ffi  f r  it   l  r  .50 65.00 2.50 
strategy and issues for su ary 
j t ti  (A 1 ; l120) 
/12/ 0 1  ffi e   i    .50 40. 0 0. 0 
otion for su ary judg ent docu ents 
t   fil  y  f k (A 1 ; l210) 
t
4132011 TJL Office conference with Christina Morrow 050 1400 700
re edits to Bob Nance affidavit and
proposed telephone conference with
expert Chris Reilly A105 L210130
4132011 TJL Telephone conference with Dr Reilly re 130 1400 18200
affidavit for motion for summary judgment
A108 L210
4142011 TJL Revise affidavit of Dr Reilly in support of 240 1400 33600
motion for summary judgment 10
A103 L210 office conference with Dave
Goicochea re law on strict liability and
inadequate warnings to be included in
affidavit of Dr Reilly 80 A105 L210
revise affidavit of Bob Nance 60 A103
L210
4142011 CCB Review and revise draft summary 150 16500 24750
judgment affidavits of Dr Reilly and Bob
Nance A103 L210
4142011 CLM Review and revise draft affidavit of Chris 500 8500 42500
Reilly 12review and revise draft
affidavit of Bob Nance 3 begin drafting
statement of undisputed facts to
accompany motion for summary
judgment 34 all A103 L210
4152011 CCB Office conference with Tom Lloyd re 030 16500 4950
summary judgment motion briefing and
affidavit and changes A105 L210
4152011 CCB Continue review and revisions of Bob 080 16500 13200
Nance summary judgment affidavit
A103 L210
4172011 TJL Telephone conference with Chris Reilly re 050 1400 700
edits to his affidavit in support of motion
for summary judgment A108 L210
4172011 CLM Review and revise affidavit of Chris Reilly 040 8500 3400
A103 L210
4172011 CCB Telephone conference with Tom Lloyd re 150 16500 24750
changes to Reilly affidavit and status of
summary judgment briefing and argument
50 A105 1210 revise Dr Reilly
affidavit 10 A103 L210
4182011 TJL Telephone conference with C Burke re 010 1400 1400
Affidavit of Chris Reilly alterations A105
L210
4182011 CCB Continue review and revise draft 20 16500 36300
summary judgment motion brief and
affidavit of Dr Reilly A103 L210
002116
/13/20 1   ffi  f r  it  ri ti  rr  .50 40. 0 0. 0 
       
 t l  f  it  
rt ri  ill  (A 1 ;  OIL 130) 
/13/20 1  elephone conference ith r. eilly re .30 40. 0 82.00 
ffi vit f r ti  f r r  j t 
(A ; 0) 
/14/20 1   i  ffi it f r. ill  i  rt f .40 40.00 36.00 
i    j t (.1 ) 
(A1 ; 10);     
i  r  l   tri t li ilit   
i t  i  t   i l  i  
ffi it f r. ill  (.8 ) (A ; 10); 
r i  ffi it f   (.60) (A1 ; 
) 
/14/20 1  i   r i  r ft r  .50 65.00 47.50 
judg ent affidavits of r. eilly and ob 
c  (A ; ) 
/14/20 1      i it   .00 5. 0 25.00 
eilly (1.2); revie  and revise draft 
affidavit f ob ance (.3); begin drafting 
t t t f i t  f t  t  
acco pany otion for su ary 
j t (3.4) (all ; ) 
/15/20 1  ffi  f r  it   l  r  .30 65.00 9.50 
s ry j t ti  ri fi   
ffi it   (A 1 ; ) 
/15/20 1  ti  r i   r i i  f  .80 65.00 32.00 
c  s ry j t ffi vit 
(A1 ; ) 
/17/20 1  l  c f r c  it  ris illy r  .50 40. 0 0. 0 
its t  i  ffi it i  rt f ti  
for su ary judg ent (A108; L210) 
/17/20 1  i   r i  ffi it f ri  ill  .40 5. 0 4. 0 
(A103; L210) 
/17/20 1  l  f r  it   l  r  .50 65.00 47.50 
s t  ill  ffi it  t t  f 
su ary judg ent briefing and argu ent 
(.50) (A ; L21 ); r i  r. ill  
ffi it (1.0) (A ; ) 
/18/20 1  l  f r  it  . r  r  .10 40. 0 4. 0 
ffidavit of hris eilly alterations (A 105; 
) 
/18/20 1  ti  i   i   .20 65.00 63.00 
s ry j t ti  ri f  
ffi it f r. ill  (A1 ; ) 
4192011 TJL Review and revise B Nance affidavit 40 280 1400 39200
A103 L210 draft summary judgment
briefing 14 A103 L210 review
discovery received from opposing
counsel especially re motion for
summary judgment 60 A104 L310
telephone conference with Dr Reilly re
additional items in affidavit based on
discovery received 40 A108 L130
4192011 CLM Research forThomas Lloyd re motion for 080 8500 6800
summary judgment arguments re Federal
Hazardous Substance Act and state law
claims re warnings and labels A102
L210
420011 CCB Telephone conference with Dr Reilly re 100 16500 16500
Dr Yost deposition and changes in
summary judgment affidavit A108 L130
420011 TJL Edits to Reilly affidavit draft brief 20 270 1400 37800
A103 L210 review rough Yost
transcript 70 A104 L330
420011 CCB Draft further revisions to Dr Reilly 030 16500 4950
summary judgment motion affidavit
A103 L210
420011 CCB Begin review rough draft of deposition 050 16500 8250
transcript of Dr Yost for potential use in
summary judgment motion A104 L330
4210 1 CLM Review and revise statement of 620 8500 52700
undisputed facts for motion for summary
judgment including review of deposition
transcripts etc for citations supporting
same 53 prepare affidavit of counsel in
support of motion for summary judgment
and pull all exhibits to same 9 all A103
L210
4210 1 KEA Compile exhibits to affidavits of Bob 030 6500 1950
Nance and Chris Reilly in support of
motion for summary judgment and
prepare same for filing under seal A101
L210
4210 1 CLM Telephone conference with Bob Nance re 030 8500 2550
revisions to his affidavit finalizing same
A106 L210
4210 1 CCB Follow up telephone conference with Tom 030 16500 4950
Lloyd re issues with summary judgment
motion A105 L210
4210 1 CCB Begin review draft summary judgment 10 16500 18150




/19/20 1 Jl i   i  .  ffi it (.40) .80 140.00 392.00 
(A 10 ; l210); ft r  j ent 
ri fi g (1.4) (A1 ; l210); r i  
i ry i  f  sing 
l, i ll  r  ti  f r 
 j t (.60) (A ; l310); 
t l  f r  it  r. ill  r  
i i l it s  it   
discovery received (.40) (A1 08; l130) 
/19/20 1 l  r  f   l  r  ti  f  .80 5. 0 8. 0 
r  j t r t  r  r l 
 t  t  t  l  
l i  r  r i   l l  (A 10 ; 
l2 ) 
/20/20 1  l  f r  it  r. ill  r  1.00 65.00 65.00 
r. t iti n   i  
r  j nt ffi it (A 1 ; l130) 
/20/20 1  l it  t  ill  ffi it; ft i f (2.0) .70 40. 0 78.00 
(A1 ; l210); r i  r  t 
transcript (.70) (A 104; l330) 
/20/20 1  r ft f rt er r visi s t  r. illy .30 65.00 9.50 
r  j t ti  ffi it 
(A103; l210) 
/20/20 1  i  r i  r  r ft f iti  .50 65.00 2.50 
tr ri t f r. t f r t ti l  i  
su ary judg ent otion (A 104; l330) 
/21/20 1 l  i   r i  t t t f .20 5. 0 27.00 
i t  f t  f r ti  f r r  
j t i l i  r i  f iti  
tr scri ts, tc. f r cit ti s s rti  
 (5.3); r r  ffi it f l i  
support of otion for su ary judg ent 
 ll ll x i its t  s  (.9) (all ; 
l210) 
/21/20 1  o pile exhibits to affidavits of ob .30 5. 0 9.50 
  ri  ill  i  rt f 
otion for su ary judg ent and 
prepare sa e for filing under seal (A 101 ; 
l210) 
/21/20 1 l  Telephone conference ith Bob ance re .30 5. 0 5. 0 
revisions to his affidavit, finalizing sa e 
(A ; l210) 
/21/20 1  Follo  up telephone conference ith To  .30 65.00 9.50 
l y  r  iss s it  s ry j t 
ti  (A ; l210) 
/21/20 1  Begin revie  draft su ary judg ent .10 65.00 81.50 
state ent of undisputed facts and brief 
(A104; l210) 
ar
422011 CLM Edits and revisions to statement of 300 8500 25500
undisputed facts in support of motion for
summary judgment with citations to same
as as necessary review and revise
memorandum in support of motion
finalize everything for filing A103 L210
422011 TJL Draft and edit memorandum in support of 690 1400 96600
motion for summary judgment A103
L210
422011 CCB Continue review and revise draft 100 16500 16500
summary judgment statement of
undisputed facts and telephone
conference with paralegal re same A103
L210
422011 CCB Follow up telephone conference with with 040 16500 6600
paralegal re changes to summary
judgment statement of undisputed facts
and expert disclosures A105 L210
525011 CCB Review excerpts from Dr Pacheco 170 16500 2805
deposition for supplemental summary
judgment affidavit A104 L330
525011 CCB Conference with Tom Lloyd re disclosure 030 16500 4950
of Pacheco deposition testimony in
supplemental summary judgment affidavit
A105 L210
525011 CCB Review and revise draft supplemental 030 16500 4950
affidavit of counsel in support of summary
judgment motion to include Dr Pacheco
deposition excerpts A103 L210
526011 CCB Conference with paralegal re revisions of 030 16500 4950
supplemental summary judgment affidavit
and attached exhibits A105 L210
526011 CCB Finalize supplemental summary judgment 010 16500 1650
affidavit to add Dr Pacheco deposition
excerpts A103 L210
692011 TJL Draft reply memorandum in support of 080 1400 11200
Motion for Summary Judgment A103
L210
6102011 CCB Conference with Tom Lloyd re strategy 040 16500 6600
and research for summary judgment reply
memorandum A105 L120
6132011 TJL Conference with C Burke re reply brief 030 1400 4200
A105120
6132011 CCB Conference with Tom Lloyd on strategy 030 16500 4950




/22/ 0 1  its and r i i  to t t ent f . 0 5. 0 55.00 
isputed f cts i  pport f tion  
summary judgment with citations to same 
as as necessary; revie  and revise 
e orandu  in support of otion, 
fi li  r t i  f r fili  (A 10 ; ) 
/22/ 0 1   raft nd it r  i  rt f .90 40. 0 6 .00 
otion f r r  j ent (A 10 ; 
) 
/22/ 0 1  tinue i    ft . 0 65.00 65.00 
su ary judg ent state ent of 
is t  f cts  t l  
f rence it  r l l r   (A 10 ; 
L210) 
/22/ 0 1  Follow up telephone conference with with .40 65.00 6. 0 
paralegal re changes to su ary 
j t st t t f is t  f cts 
and expert disclosures (A 105; L210) 
/25/20 1  vi  xc r ts fr  r. c c  .70 65.00 80.50 
deposition for supple ental su ary 
judg ent affidavit (A 104; L330) 
/25/20 1  f r  it   l  r  i l r  .30 65.00 9.50 
f co ition t ti  i  
supple ental su ary judg ent affidavit 
(A1 ; ) 
/25/20 1  i   r i  r ft l t l .30 65.00 9.50 
ffi vit f c s l i  s rt f s ry 
j t ti  t  i l  r.  
deposition excerpts (A 103; L210) 
/26/20 1  f  it  l l  i i  f .30 65.00 9.50 
supple ental su ary judg ent affidavit 
and attached exhibits (A105; L210) 
/26/20 1  i liz  s l t l s ry j t .10 65.00 6.50 
affidavit to add Dr. Pacheco deposition 
excerpts (A 103; L210) 
/9/2011   Draft reply e orandu  in support of .80 40.00 12. 0 
otion for Su ary Judg ent (A103; 
10) 
/10/20 1  f r c  it   l y  r  str t y .40 65.00 6. 0 
 r r  f r r  j t r l  
e orandu  (A105; L 120) 
/13/20 1   f r c  it  . rk  r  r ly ri f .30 40.00 2. 0 
(A105; L 120) 
/13/20 1  onference ith To  Lloyd on strategy .30 65.00 9.50 
f r r lyi  t  s ry j t ti  
(A105; L 120) 
6132011 TJL Review opposition briefing and motion for 230 1400 32200
partial summary judgment A104 L210
6142011 TJL Conference with C Morrow re strategy 040 1400 5600
responding to Plaintiffs Cross Motion for
Summary Judgment and drafting reply
brief on our motion for summary judgment
2conference with C Burke re reply
and opposition briefing 2 all A105
L120
6142011 TJL Draft Reply Brief on Motion for Summary 50 1400 7700
Judgment A103 L210
6142011 CCB Conference with Tom Lloyd re strategy for 040 16500 6600
replying on summary judgment motion
and responding to Majorssummary
judgment motion A105 L120
6142011 CCB Review and analyze plaintiffs summary 170 16500 2805
judgment response brief and affidavits
rebuttal expert disclosures and cross
summary judgment motion A104 L210
6152011 CCB Strategy conferences with paralegal and 200 16500 3300
Tin Lloyd re summary judgment reply and
response to motion for summary
judgment by plaintiff A105 L120
6152011 CLM Review and strategy discussion re 160 8500 13600
comparison of deposition of Dr Yost and
affidavit ofYost and motion to strike
affidavit based upon inconsistent opinions
in each A105 L120
6152011 TJL Continue drafting reply memorandum and 540 1400 75600
opposition to cross motion for summary
judgment A103 L210
6152011 CCB Review Idaho case on implied warranty in 030 16500 4950
re summary judgment reply A104 L120
6152011 CLM Strategy and legal analysis and 060 8500 5100
discussion with C Burke re outline of
reply brief arguments to raise in same
and which to save for opposition to cross
motion for summary judgment A105
L210
6152011 CLM Research re F HSA A102 L210 050 8500 4250
162011 TJL Continue drafting reply brief on our Motion 400 1400 5600
for Summary Judgment A103 L210
6162011 CLM Continue review of Yost deposition re 040 8500 3400
motion to strike A104 L330
002119
6/13/20 1 TJl Review opposition briefing and otion for 2.30 140.00 322.00 
partial summary judgment (A10 ; l ) 
6/14/20 1 T Jl onference with . orro  re tr tegy 0.40 140.00 56.00 
responding to Plaintiffs Cross- otion for 
u ary Judg ent and drafting reply 
brief on our otion for su ry judgment 
(.2); conference with C. Burke re reply 
and opposition briefing (.2) (all 105; 
l ) 
/14/20 1  l r ft ply ri f  tion f r u ary .50 40. 0 770.00 
Judg ent (A103; l210) 
/14/20 1  onference it   l y  r  tr t  f r .40 65.00 6. 0 
replying on su ary judg ent otion 
nd r ing t  jor's r  
j ent ti  (A 10 ; l1 ) 
/14/20 1  i   lyze l i tiffs r  1.70 165.00 280.50 
j g ent r  ri f  ffi its, 
rebuttal expert disclosures and cross 
su ary judg ent otion (A104; l210) 
/15/20 1  trategy conferences ith paralegal and . 0 65.00 30. 0 
Tin Lloyd re su ary judg ent reply and 
response to otion for su ary 
judg ent by plaintiff (A 105; l120) 
/15/20 1 l  vi   str t y isc ssi  r  .60 5. 0 36.00 
ri  f iti  f r. t  
fi it  t     
ffi vit s   i c sist t i i s 
in each (A105; l120) 
/15/20 1 l ti  fti  l    .40 40.00 756.00 
opposition to cross- otion for su ary 
judg ent (A103; l210) 
/15/20 1  evie  Idaho case on i plied arranty in .30 65.00 9.50 
re su ary judg ent reply (A 104; l120) 
/15/20 1 l  Strategy and legal analysis and .60 5. 0 1. 0 
  .   li   
reply brief, argu ents to raise in sa e 
and hich to save for opposition to cross-
ti  f r r  j t (A 1 ; 
l210) 
/15/2011 l  s rc  r   ( 2; l210) 0.5  5. 0 2.50 
6/16/2011 l ti  r fti  r l  ri f  r ti  .00 140.00 560.00 
for Su ary Judg ent (A103; l210) 
/16/20 1 l  ti  r i  of t iti  r  0.4  85. 0 34.00 
otion to strike (A 104; l330) 
6172011 CCB Conference with Tom Lloyd re strategy for 070 16500 11550
responding to plaintiffs summary
judgment motion and replying to SEC
summary judgment motion A105 L120
6172011 CCB Review Bret Kimmel deposition and 240 16500 39600
exhibits for excerpts and documents to
respond to plaintiffs summary judgment
motion A104 L330
6172011 TJL Continue researching and drafting reply 450 1400 6300
and opposition memoranda A103 L210
620011 CLM Continued review of Yostsdeposition and 260 8500 22100
prepare motion to strike re same A104
L33021
620011 TJL Continue drafting memoranda for pending 070 1400 9800
motions for summary judgment A103
L210
6210 1 TJL Conference with C Morrow re Motion to 040 1400 5600
Strike and scope of affidavit testimony
that we are focused on 2 conference
with C Burke re status of statement of
facts for opposition to plaintiffs motion for
summary judgment 2 all A105 L120
6210 1 TJL Continue drafting reply memorandum and 350 1400 4900
opposition memorandum for pending
Motions for Summary Judgment A103
L210
6210 1 CCB Review depositions of Schaeffer Major 420 16500 69300
Doan and Overgaard to identify facts for
response to Major summary judgment
motion A104 L330
6210 1 CLM Finalize draft motion to strike affidavit of 370 8500 31450
Yost memorandum in support of same
and affidavit of Thomas Lloyd in support
of same A103 L310
6210 1 TJL Conference with Christina Morrow for 010 1400 1400
status update on motion to strike A106
L120
6210 1 CCB Begin outline and draft statement of facts 130 16500 21450
for response to plaintiffs summary
judgment motion and conference with
Tom Lloyd re strategy for same A105
L120
6210 1 CLM Additional legal research for motion to 060 8500 5100
strike and strategy meeting with Thomas
Lloyd re same A105 L120




/17/20 1  f r  it   l  r  tr t  f r 0.70 65.00 15. 0 
i   l i ti fs ry 
judg ent otion and replying to SE  
r  j t ti n (A10 ; l12 ) 
/17/20 1  i  r t i l iti n  .40 65.00 96.00 
exhibits for excerpts and docu ents to 
r  t  l i tiffs r  j t 
ti  (A 1 ; l330) 
/17/20 1 l ti ue r r i   r fting r l  .50 40. 0 30. 0 
 sition r nda (A1 ; l210) 
/20/20 1 l  ti ued r vi  f st's siti   .60 5. 0 21.00 
r r  ti  t  tri  r   (A 1 ; 
l330/l210) 
/20/20 1  l ti ue r fting r  f r i  0.70 40. 0 8. 0 
ti  f r  t (A 10 ; 
l210) 
/21/20 1  l f r c  i  .   i   .40 40. 0 6. 0 
trike and scope of affidavit testi ony 
t t  r  f c s   (.2); c f r c  
 .     t f 
facts for opposition to plaintiffs otion for 
su ary judg ent (.2) (all 105; l12 ) 
/21/20 1  l ontinue drafting reply e orandu  and .50 40. 0 490.00 
sition r  f r i  
ti  f r r  t (A 1 ; 
l210) 
/21/20 1  i  iti  f ffer, j r, .20 65.00 93.00 
   t  i tif  f t  f  
r  t  j r r  j t 
ti  (A 1 ; l33 ) 
/21/20 1 l  i  ft i      .70 5. 0 14.50 
t, r  i  rt f e, 
and affidavit of Tho as Lloyd in support 
of same (A103; l310) 
/21/20 1 l      .10 40. 0 4. 0 
status update on otion to strike (A 106; 
l120) 
/21/20 1  egin outline and draft state ent of facts .30 65.00 14.50 
for response to plaintiffs su ary 
j t ti   f r  it  
 l  r  tr t  f r  (A ; 
l120) 
/21/20 1 l  iti l l l r s rc  f r ti  t  .60 5. 0 1. 0 
tri   tr t  ti  it   
Lloyd re sa e (A105; l120) 
/21/20 1  l        .10 40. 0 4. 0 
ffi it (A ; l210) 
622011 CCB Continue drafting statement of facts for 600 16500 9900
summary judgment response brief A103
L210
622011 TJL Review of and edits to Christina Morrow 490 1400 68600
draft of Motion to Strike Yost testimony
10 continue drafting summary
judgment documents39all A103
L210
622011 CLM Update Affidavit of Counsel in Support of 100 8500 8500
Motion to Strike to incorporate information
re Yost no having completed change
sheet 3update and revise draft
memorandum in support of motion to
strike affidavit of Yost per instructions
from T Lloyd with additional caselaw re
addressing arguments under IRCP 30e
7 all A103 L210
622011 CLM Telephone conference with Nick Roberts 030 8500 2550
re affidavit from him in support opposition
to cross motion for summary judgment
notes re same A108 L210
622011 CLM Strategy discussion with T Lloyd re N 040 8500 3400
Roberts affidavit outline of same A105
L120
622011 TJL Research on law relevant to motions to 150 1400 2100
strike A102 L120
622011 TJL Conference with C Morrow re obtaining 030 1400 4200
additional affidavit testimony from Bob
Nance and Nick Roberts re foreseeable
use of Oleoresin Capsicum products in
household A105 L120
623011 CLM Revise memorandum in support of motion 390 8500 33150
to strike10 draft affidavit of Nick
Roberts and affidavit of Bob Nance in
support of opposition to cross motion for
summary judgment 29all A103 L210
623011 TJL Finish drafting summary judgment reply 230 1400 32200
memorandum A103 L210
623011 TJL Telephone conference with B Nance re 020 1400 2800
possible affidavit to oppose cross Motion
for Summary Judgment A106 L210
002121
• 
6/22/ 0 1  Continue drafting statement f facts for . 0 165.00 990.00 
su mary judgment response brief (A 103; 
l ) 
/22/ 0 1  l Review of  edits to ri ti  rr  4.90 140.00 686.00 
draft f otion to trike ost testi ony 
(1.0); continue drafting su r  
judgment documents (3.9) (all A103; 
l210) 
/22/ 0 1 l  pdate ffidavit of ounsel in upport of . 0 5. 0 5.00 
otion to trike to incorporate infor ation 
re ost o aving co pleted c ange 
sheet (.3); update and revise draft 
randu  i  pport f otion t  
tri  ffi vit f ost er i tructions 
fro  . Lloyd ith additional case la  re 
ressing r t  der I  0(e) 
(.7) (all 103; l210) 
/22/ 0 1 l  l  f r  it  i  rts .30 85.00 25.50 
r  ffi vit   i  rt sition 
t  r - ti  f r r  j t, 
notes re sa e (A108; l210) 
/22/ 0 1 l  Strategy discussion ith T. Lloyd re N. .40 5. 0 4. 0 
rts ffi vit, tli  f  (A 1 ; 
l120) 
/22/ 0 1  l      i   .50 40. 0 210.00 
tri  (A 1 ; l120) 
/22/ 0 1  l f r  it  . rr  r  t i i  .30 40. 0 42.00 
l it    
      
 f l i  i  t  i  
s l  (A 1 ; l120) 
/23/20 1 l  i  r  i  rt f ti  .90 5. 0 331.50 
to strike (1.0); draft affidavit of ick 
  it    i  
rt f iti  t  r - ti  f r 
summary judgment (2.9) (all A103; l210) 
/23/20 1  l Finish drafting su ary judg ent reply .30 40.00 2 . 0 
r  ( ; l210) 
/23/20 1  l Telephone conference ith B. ance re .20 40.00 8. 0 
possible affidavit to oppose cross otion 
f r r  t (A ; l210) 
623011 CCB Review and revise draft statement of 280 16500 46200
facts in response to Major summary
judgment motion120 identify exhibits
for affidavit of counsel in opposition to
plaintiffs motion for summary judgment
80 review and revise draft affidavits of
counsel Bob Nance and Nick Roberts in
support of summary judgment motions
80 all A103 L210
623011 TJL Review and edit next draft of motion to 120 1400 16800
strike Dr Yost affidavit and supporting
documents A103 L210
623011 CLM Assist pulling materials for affidavit of 120 8500 10200
counsel in opposition to cross motion for
summary judgment A110 L210
624011 CCB Review and revise draft summary 290 16500 47850
judgment reply brief12review and
revise draft memorandum in support of
motion to strike Yost affidavit based on
deposition excerpts 10 review and
revise draft affidavit of counsel and
statement of facts for response to
plaintiffs summary judgment motion 7
all A103 L210
624011 BWE Prepare exhibits to affidavits 28edit 540 8500 45900
affidavit of Tom Lloyd in support of motion
to strike12 review and edit
memorandum in support of motion to
strike6 review and edit citations in
memorandum in opposition to plaintiffs
cross motion for summary judgment 8
all A103 L210
624011 CCB Conference with T Lloyd re edits to draft 040 16500 6600
reply brief in support of summary
judgment A105 L210
624011 TJL Draft all documents for filing on cross 50 1400 7700
summary judgment motions A103 L210
627011 BWE Review and edit statement of facts in 290 8500 24650
memorandum in opposition to plaintiffs
cross motion for partial summary
judgment14edit affidavit of Chris
Burke and memorandum citations A
prepare additional exhibits and deposition
excerpts 1 all A103 L210
627011 TJL Draft opposition to PlaintiffsCross Motion 450 1400 6300
for Summary Judgment A103 L210
002122
.. 
6/23/20 1 CCB Review and revise draft statement of 2.80 165.00 462.00 
facts in response to ajor summary 
judgment otion (1.20); identify exhibits 
for affidavit of counsel in opposition to 
plaintiff's otion for su ary judgment 
(.80); revie  and revise draft affidavits f 
co l, Bob ance nd Nick rts in 
support of summary judg ent otions 
(.80) (all A1 ; ) 
/23/20 1  JL eview nd edit next draft of otion to .20 140.00 168.00 
tri  r. ost ffidavit  supporting 
cu ents (A10 ; L ) 
/23/20 1 L  Assist pulling t ri l  f r ffi vit of .20 85.00 102.00 
counsel in opposition to cross- otion for 
s ary judg t (A11 ; ) 
/24/20 1  i  nd r i  r ft r  .90 65.00 478.50 
judg ent reply brief (1.2); revie  and 
r vis  raft r  in s rt f 
ti   t i  st fi it   
deposition excerpts( 1.0); review and 
i  ft i i   l  
t t t f f t  f r r  t  
plaintiff's su ary judg ent otion (.7) 
(all ; 0) 
/24/20 1  Prepare exhibits to affidavits (2.8); edit .40 5. 0 459.00 
affidavit of o  Lloyd in support of otion 
t  tri  (1.2); r i   it 
r  i  rt f ti  t  
strike (.6); review and edit citations in 
r  i  iti  t  l i tiff'  
cr ss- ti  f r s ry j t (.8) 
(all A103; L210) 
/24/20 1  f r  it  . l  r  it  t  r ft .40 65.00 66.00 
reply brief in support of summary 
judgment (A105; L210) 
/24/20 1   raft all docu ents for filing on cross .50 40.00 770.00 
summary judgment motions (A103; L210) 
/27/20 1  i   it  f f cts i  .90 85. 0 246.50 
memorandum in opposition to plaintiff's 
cross- otion for partial su ary 
judg ent (1.4); edit affidavit of Chris 
urke and e orandu  citations (.4); 
prepare additional exhibits and deposition 
excerpts (1.1) (all A103; L210) 
6/27/2011  JL raft opposition to Plaintiff's Cross- otion 4.5  140.00 630.00 
for r  Jud t ( 3; L210) 
627011 CCB Begin review and revision of first draft of 240 16500 39600
brief in response to plaintiffs cross motion
for summary judgment A103 L210
627011 CLM Telephone conference with expert N 020 8500 1700
Roberts re his finalized affidavit in support
of opposition to cross motion A108
L130
628011 CCB Continue revisions of draft memorandum 200 16500 3300
in opposition to plaintiffs summary
judgment motion A103 L210
628011 CCB Finalize my affidavit and exhibits for 030 16500 4950
opposition to plaintiffs summary judgment
motion A103 L210
628011 CCB Conference with paralegal re strategy and 020 16500 3300
support for oral argument on summary
judgment motions A105 L120
629011 CCB Review and analyze summary judgment 150 16500 24750
motion briefs to develop oral argument
approach A104 L210
762011 CCB Continue to analyze summary judgment 150 16500 24750
pleadings for oral argument approach
A104L210
72011 TJL Review of documents filed by opposing 030 1400 4200
counsel including amended affidavit of
Purswell A104 L210
72011 TJL Conference with Christina Morrow re 010 1400 1400
motion to strike the same A105 L210
782011 CCB Review and analyze plaintiffs amended 170 16500 2805
affidavit of JP Purswell in opposition to
SECsmotion for summary judgment 8
review and analyze plaintiffs reply brief in
support of plaintiffs motion for summary
judgment 9 all A104 L210
782011 CCB Conference with Tom Lloyd re strategy for 070 16500 11550
striking amended Purswell affidavit A
conference with T Lloyd re strategy for
responding to issues raised by it 3 all
A105 L120
782011 CCB Continue analysis of summary judgment 20 16500 36300
issues for oral argument A104 L120
782011 TJL Research FHSA identification of principal 100 1400 1400
hazard A102 L120
71120 1 TJL Draft motion to strike amended affidavit of 450 1400 6300
JP Purswell A103 L210
7122011 CCB Review SECsmotion to strikeJP 020 16500 3300
Purswell affidavit A104 L210
7122011 TJL Prepare for oral argument A101 L240 130 1400 18200
002123
.. 
/27/20 1  gin i   i ion f fi t ft f 2.40 65.00 96.00 
rief i  r  t  l i tiff  r  tion 
f r  j t (A 10 ; ) 
/27/20 1  Telephone conference ith expert N. .20 5. 0 17.00 
rts  i   it  t 
f osition t  cr ss- ti  (A 10 ; 
 ) 
/28/20 1  tinue i i  f ft  .00 65.00 30. 0 
i  iti  t  l i tiffs r  
j t ti  (A 1 ; 0) 
/28/20 1  i li   ffi vit  i it  f r .30 65.00 9.50 
ition t  l i tiff  r  j t 
ti  (A ; ) 
/28/20 1  f r  it  r l l r  tr t   .20 65.00 3. 0 
s rt f r r l r t  s ry 
j nt ti  (A 1 ;  ) 
/29/20 1  i   l  r  j t 1.50 65.00 47.50 
ti    lop   
r  (A ; ) 
/6/20 1  ontinue to analyze su ary judg ent .50 65.00 47.50 
l i  f r r l r t r  
(A104; L210) 
/7/20 1   i  f ts fil   i  .30 40. 0 2. 0 
l, i l i   ffi it f 
urs ell (A104; L210) 
/7/20 1      : .10 40. 0 4. 0 
ti  t  tri  t   (A ; ) 
/8/20 1  evie  and analyze plaintiffs a ended .70 165.00 80.50 
ffi vit f J.P. rs ll i  siti  t  
C's ti  f r r  j t (.8); 
revie  and analyze plaintiffs reply brief in 
s rt f l i tiffs ti  f r s ry 
j t (.9) (all ; ) 
/8/20 1  f r  it   l  r  tr t  f r .70 65.00 15.50 
striki   rs ll ffi vit (.4); 
f r  it  . l  r  tr t  f r 
responding to issues raised by it (.3) (all 
105; L 120) 
/8/20 1  ti  l i  f r  j t .20 65.00 63.00 
issues for oral argu ent (A 104; L 120) 
/8/2011   r   i tifi ti  f ' ri i l .00 40.00 40. 0 
r ' (A 2;  0) 
/11/20 1     i    f .50 40. 0 30. 0 
.P. r ll (A ; 10) 
/12/20 1   EC's    .P. .20 65.00 3. 0 
Purs ell affidavit (A104; L210) 
/12/20 1  r r  f r r l r t (A 1 ; 0) .30 40.00 82.00 
7132011 CCB Review and analyze plaintiffs brief and 040 16500 6600
affidavit in opposition to SEC motion to
strike supplemental affidavit of Dr
Purswell A104 L210
7132011 CCB Conference with T Lloyd re strategy for 040 16500 6600
responding to motion to strike JP
Purswell affidavit and themes for oral
argument on summary judgment A105
L120
7142011 CCB Review transcripts of Yost and Pacheco 130 16500 21450
for inclusion in summary judgment oral
argument A104 L120
7142011 CCB Final preparation for motion for summary 100 16500 16500
judgment argument A101 L240
7142011 CCB Attend oral argument on motion for 300 16500 49500
summary judgment A109 L240
7142011 TJL Prepare for argument on motions for 510 1400 71400
summary judgment A101 L240
7152011 CCB Draft order on summary judgment 100 16500 16500
motions 50 review and revise draft
order re summary judgment motions 50
all A103 L210
Grand Total 19990 2685550
002124
7/13/2011 CCB Review and analyze plaintiffs brief and 0.40 165.00 66.00 
affidavit in opposition to SEC otion to 
strike supplemental affidavit of Dr. 
Purswell (A104; L210) 
7/13/20 1 B Conference with T. Lloyd re strategy for 0.40 165.00 66.00 
responding to otion to strike J.P. 
Purswell a fidavit and themes for oral 
argument on su ary judgment (A 105; 
L ) 
7/14/20 1 B eview transcripts of Yost and acheco .30 165.00 214.50 
for inclusion i  s ary judgment ral 
argu ent (A 104; L 120) 
7/14/20 1 CB Final preparation for motion for summary . 0 165.00 165.00 
judg ent argu ent (A101; L240) 
/14/20 1  Attend oral argu ent on otion for . 0 65.00 495.00 
su ary judg ent (A109; L240) 
/14/20 1   Prepare for argument on motions for .10 140.00 714.00 
summary judgment (A 101; L240) 
/15/20 1  Draft order on su ary judg ent . 0 65.00 165.00 
otions (.50); revie  and revise draft 
order re su ary judg ent otions (.50) 
(all A103; L210) 





14542 011 Admiral Insurance Company Major v Security Equipment
Date Prof Description Units Price Extended Amt
7152011 CCB Conference with T Lloyd re strategy for 050 16500 8250
motion for summary judgment on Federal
Hazardous Substances Act negligence
per se claim A105 L120
7182011 CCB Conference with T Lloyd on issues for 030 16500 4950
follow up summary judgment motion
A1062 0
7182011 TJL Research for FHSA summary judgment 380 1400 53200
motion A102 L210
7192011 CCB Conference with T Lloyd re issues and 030 16500 4950
strategy on second summary judgment
motion A105 L120
7192011 CCB Work on drafting statement of undisputed 320 16500 52800
facts for second summary judgment
motion A103 L210
7192011 TJL Additional research on FHSA issues 40 1400 61600
relative to labeling and chronic health
effects A102 L210
720011 CCB Conference with T Lloyd re summary 030 16500 4950
judgment issues of proximate cause
A105 L120
720011 TJL Continue researching drafting and editing 670 1400 93800
memorandum in support of Motion for
Summary Judgment on FHSA claim
A1023 L210
7210 1 CCB Review and revise draft of second 250 16500 41250
summary judgment motion A103 L210
7210 1 TJL Continue drafting and editing motion for 590 1400 82600
summary judgment on FHSA issues
A1032 0
722011 CCB Continue review and revisions of draft 230 16500 37950
second motion for summary judgment
brief A103 L240
722011 CCB Conference with T Lloyd re negligence 040 16500 6600
per se arguments in second summary
judgment motion A105 L240
722011 CCB Research deposition testimony and 070 16500 11550
exhibit for inclusion in affidavit for second
summary judgment motion and draft
affidavit adding such transcript and exhibit
A102240
722011 KEA Pull exhibits to affidavit of Chris Burke in 020 6500 1300
support of SECs second motion for
summary judgment A103 L210
722011 CCB Review and revise draft second motion 010 16500
for summary judgment
002126
Transactions Fee Listing 
14542-011 Admiral Insurance Company ajor v. Security quip ent 
Date Prof Description nits Price Extended A t 
7/15/2011 CCB onference with T. Lloyd re strategy for 0.50 65.00 82.50 
otion for summary judgment on ederal 
Hazardous Substances Act negligence 
per se claim (A 105; L 120) 
/18/20 1 B onference ith . l  on iss s for 0.30 65.00 49.50 
follow up su ary judg ent otion 
(A106; L210) 
/18/20 1 JL rc  f r FHSA s r  judgment .80 40. 0 532.00 
otion (A102; L210) 
/19/20 1 B f rence ith . l  re i sues  .30 65.00 49.50 
strategy on second su ary judg ent 
otion (A105; L 120) 
7/19/20 1  rk  drafting t t t f i t  .20 65.00 528.00 
f t  f r cond r  j t 
otion (A103; L210) 
/19/20 1  iti l r rch    AO 40. 0 616.00 
relative to labeling and chronic health 
effects (A102; L210) 
/20/20 1  onference ith T. Lloyd re su ary .30 65.00 9.50 
judgment issues of proximate cause 
(A105; L 120) 
/20/20 1   ontinue researching, drafting and editing .70 40. 0 38.00 
e orandu  in support of otion for 
Summary Judgment on FHSA claim 
(A1 02/A1 03; L210) 
/21/20 1        .50 65.00 412.50 
su ary judg ent otion (A103; L210) 
/21/20 1   Continue drafting and editing otion for .90 140.00 826.00 
summary judgment on FHSA issues 
(A103; L210) 
7/22/2011        .30 65.00 79.50 
second otion for su ary judg ent 
brief (A103; L240) 
/22/20 1  Conference with T. Lloyd re negligence OAO 65. 0 6. 0 
per se argu ents in second su ary 
judgment motion (A 105; L240) 
/22/20 1  esearch deposition testi ony and .70 65. 0 115.50 
i it f r i l i  i  ffi it f r s  
summary judgment motion and draft 
affidavit adding such transcript and exhibit 
( 102; L240) 
/22/2011  ll i it  to affi vit of hris rk  in .20 65. 0 13.00 
support of SEC's second otion for 
summary judgment (A103; L210) 
7/22/2011  evi  and r i  r ft seco  ti  0.10 165. 0 
for summary judgment 
722011 TJL Finish drafting and editing motion for 420 1400 58800
summary judgment re FHSA claim A103
L240
727011 CCB Summary review of Yost affidavit in 20 16500 36300
support of motion for reconsideration 7
summary review of affidavits of Major and
counsel in support of motion for
reconsideration A summary review of
plaintiffs brief in support of motion for
reconsideration and in response to SECs
second motion for summary judgment
1 all A104 L210
727011 CCB Strategy conferences with T Loyd re 090 16500 14850
same motion for reconsideration and
opposition to motion for second summary
judgment A105 L120
727011 CCB Begin review of new medical articles 180 16500 29700
relied on by Dr Yost in new affidavit
A104L320
727011 TJL Full review of documents filed by 500 1400 7000
opposing counsel 23A104 L210
research on timing of filing affidavits after
discovery deadlines case law research
on cases cited by opposing counsel read
various articles newly attached to Second
Yost Affidavit 18 A102 L120
conference with C Burke re strategy to
respond to motion for reconsideration 9
A105 L120
728011 CCB Continue review of new medical articles 200 16500 3300
produced by Major as part of motion for
reconsideration A104 L320
728011 CCB Detailed analysis of Dr Yost affidavit for 040 16500 6600
motion to strike A104 L210
728011 CLM Email to C BurkeT Lloyd and 090 8500 7650
memorandum to file re costs for obtaining
transcripts timeline it will be received
directions for making payment including
information re obtaining audio copies of
hearing from court and internet research
re procedures for same 7draft letter to
court reporter with formal request for
transcript to go out Monday 2 all A103
L110
812011 TJL Draft renewed and supplemental motion 130 1400 18200
to strike Yost affidavit A103 L210
002127
7/22/ 0 1 T JL Finish drafting and editing motion for 4.20 140.00 588.00 
summary judgment re FHSA claim (A 103; 
L240) 
7/27/20 1 CCB Summary review of Yost affidavit in 2.20 165.00 363.00 
support of otion for reconsideration (.7); 
summary review of affidavits of ajor and 
counsel in support of otion for 
reconsideration (.4); su ary review of 
plaintiffs brief in support of otion for 
reconsideration nd in r sponse to C's 
second otion for s r  judgment 
(1.1) (all A104; L210) 
/27/20 1 B Strategy conferences with T. Loyd re .90 65.00 148.50 
sa e tion f r i ti   
opposition to otion for second su ary 
judg ent (A105; L 120) 
/27/20 1 B in r vi  f  ic l rticles .80 165.00 297.00 
relied on by Dr. Yost in new affidavit 
(A 104; L320) 
/27/20 1  J  ull revie  of docu ents filed by .00 40. 0 700.00 
opposing counsel (2.3) (A 104; L210); 
research on ti ing of filing affidavits after 
discovery deadlines; case law research 
on cases cited by opposing counsel; read 
various articles ne ly attached to econd 
t ffi it (1.8) (A ;  20); 
f r  it  . r  r  tr t  t  
respond to motion for reconsideration (.9) 
(A105; L 120) 
/28/20 1  i     l  .00 65.00 330.00 
produced by ajor as part of otion for 
reconsideration (A 104; L320) 
/28/20 1  Detailed analysis of Dr. Yost affidavit for .40 65.00 66.00 
otion to strike (A104; L210) 
/28/20 1  ail to . urkelT. Lloyd and .90 5. 0 76.50 
r  t  fil  r  t  f r t i i  
transcripts, ti eline it will be received, 
directions for aking pay ent including 
infor ation re obtaining audio copies of 
hearing from court and internet research 
re procedures for sa e (.7); draft letter to 
court reporter with for al request for 
transcript to go out Monday (.2) (all A103; 
L 110) 
/1/201   raft rene ed and supple ental otion 1.30 140.00 182.00 
t  strik  st affi vit ( 3; L210) 
812011 CLM Finalize letter to court reporter requesting 020 8500 1700
transcript from 07141 hearing on
motions for summary judgment A103
L110
832011 CCB Conference with T Lloyd re strategy re 030 16500 4950
responding and replying to motions to
reconsider and for second summary
judgment and motion to strike Yost
affidavit A105 L120
832011 TJL Conference with C Burke re timing of 030 1400 4200
filing various briefs and content of briefs
A105 L120
832011 CLM Research re standard for review re courts 060 8500 5100
rulings on evidentiary issues for motion to
strike affidavit of Yost write same and
email to Thomas Lloyd for insertion into
memorandum A102 L110
832011 TJL Research and draft motion to strike Yost 340 1400 47600
affidavit A103 L210
892011 TJL Continue drafting Motion to Strike Yost 210 1400 29400
Affidavit A103 L210
8102011 TJL Continue drafting memorandum for 250 1400 3500
Motion to Strike Yost Affidavit A103
L210
81120 1 TJL Research re motion to strike portions of 180 1400 25200
Yost affidavit A102 L210
81120 1 TJL Draft memorandum in support of motion 290 1400 40600
to strike Yost affidavit A103 L210
8152011 CCB Review and revise draft memorandum in 320 16500 52800
support of second motion to strike Yost
affidavit A103 L210
8152011 CCB Conference with T Lloyd re changes to 040 16500 6600
brief on motion to strike Yost affidavit and
summary judgment reply strategy A106
L120
8152011 CCB Review transcript of hearing on first 460 16500 75900
summary judgment motions for
admissions and arguments to use in
memoranda in support of second
summary judgment motion reply and
motion to strike second Yost affidavit
2detailed review and analysis of
plaintiffs brief in opposition to SECs
motion of summary judgment for
development of reply arguments 24 all
A104 L210
8152011 TJL Edits to motion to strike Yost affidavit 050 1400 700
A103 L210
002128
8/1/20 1 CLM Finalize le ter to court reporter requesting .20 85.00 17.00 
transcript from 07/14/11 aring on 
otions for su r  jUdgment (A10 ; 
L 110) 
8/3/20 1  onference ith T. Lloyd re strategy r  0.30 165.00 49.50 
responding and replying to otions to 
r consider and for second s ry 
judg ent and otion to strike ost 
affidavit (A 105;  ) 
/3/20 1   f rence ith . rke re ti i g f .30 40. 0 42.00 
filing various ri fs and content f riefs 
(A10 ;  ) 
/3/20 1  rch  t rd f r i  r  c urt's .60 5. 0 51.00 
r li s  i ti r  issues f r tion t  
tri  ffidavit f t, it   d 
il t   l  f r i rtion i t  
r  (A 1 ;  ) 
/3/20 1   rch  ft i   tri  st .40 40. 0 476.00 
affidavit (A 103; L210) 
/9/20 1   ontinue drafting otion to trike ost .10 40. 0 294.00 
Affidavit (A 103; L210) 
/10/20 1  ontinue drafting e orandu  for .50 40. 0 50. 0 
otion to trike ost ffidavit (A103; 
L210) 
/11/20 1    i   i  ti s f .80 40. 0 252.00 
st ffi it (A1 ; 0) 
/11/20 1  r ft r  i  rt f ti  .90 40. 0 06.00 
t  strik  st ffi vit (A1 ; 0) 
/15/20 1  i    t   .20 165.00 528.00 
s rt f s c  ti  t  strik  st 
affidavit (A103; L210) 
/15/20 1  f r c  it  . l y  r  c s t  .40 65.00 66.00 
i   i   i   i i   
su ary judg ent reply strategy (A106; 
L 120) 
/15/20 1  evie  transcript of hearing on first .60 65.00 59.00 
summary judgment motions for 
i i   r t  t   i  
r  i  rt f  
su ary judg ent otion reply and 
i  t  t i    ffi it 
(2.2); detailed review and analysis of 
plaintiffs brief in opposition to EC's 
otion of su ary judg ent for 
v l t f r ly r ts (2.4) (all 
A104; L210) 
/15/20 1   it  t  ti  to tri   ffi it 0.5  140.00 70.00 
(A103; L210) 
8162011 TJL Conference with C Burke re strategy and 260 1400 36400
content of Opposition to Motion to
Reconsider FHSA issues and possible
Affidavit of Nance conference with C
Burke re opposing counsels
memorandum and strategy in responding
conference with C Burke re citations to
Nance Affidavit in opposing counsels
memorandum and how to respond A
A105 L120 edits to Motion to Strike
Second Yost Affidavit to include transcript
received today additions to Motion to
Strike Second Yost Affidavit to include
legal conclusions issue 2A103 L210
8162011 CCB Continue review medical articles identified 320 16500 52800
by Dr Yost for summary judgment reply
A detailed review of Nance deposition
citations in plaintiffs brief for verification
of accuracy and reply brief 28 all A104
L330
8162011 CLM Prepare Affidavit of Counsel in Support of 10 8500 9350
motion to strike and compile exhibits to
same A103 L210
8172011 TJL Additions to Motion to Strike Second Yost 100 1400 1400
Affidavit based on transcript and courts
comments A103 L210
8172011 CLM Final revisions and edits to memorandum 8500
in support of motion to strike Yost affidavit
two and affidavit of Thomas Lloyd with al
exhibits in support of same A103 L210
8172011 CCB Finalize memorandum in support of 060 16500 9900
second motion to strike Yost affidavit
A103 L210
8182011 TJL Outline for reply memorandum and 120 1400 16800
memorandum in opposition to motion for
reconsideration all A103 L210
8192011 TJL Review affidavit of Major and 050 1400 700
memorandum on reconsideration A104
L210
8192011 TJL Research negligence per se standard 40 1400 61600
throughout country additional research
for and drafting of reply memorandum
and memorandum in opposition to
reconsideration all Al02L1 3 L120
822011 TJL Continue drafting opposition to reconsider 430 1400 60200
and reply for second motion for summary
judgment A103 L210
824011 TJL Review and revise reply brief A103 10 1400 15400
L210
002129
/16/20 1 JL f rence it  . r  r  strategy  .60 140.00 364.00 
tent f ition t  ti  to 
i r, A i ,  sible 
ffi i  f ; f r  it  . 
rke r  i  sel's 
randu   tr t y i  r i ; 
f r  i  . rke  it ti  t  
ance ffidavit i  ing nsel's 
r u    t  r s ond (.4) 
(A 10 ;  0); it  t  ti  t  trike 
nd st ffi it t  i l  tr ript 
r ceived t y; iti s t  ti  t  
tri   t i i  t  i l  
legal conclusions issue (2.2) (A 103; L210) 
/16/20 1  tinue i  i l ti l  i i i  .20 65.00 528.00 
by Dr. Yost for summary judgment reply 
(.4); detailed revie  of ance deposition 
citations in plaintiffs brief for verification 
f cc r cy  r ly ri f (2.8) (all  ; 
L330) 
/16/20 1  repare ffidavit of ounsel in upport of .10 5. 0 3.50 
ti  t  tri   il  i it  t  
sa e (A103; L210) 
/17/20 1  i       t .00 40. 0 140.00 
ffi vit s   tr scri t  c urt's 
co ents (A 103; L210) 
/17/20 1  i l      5. 0 
i  rt f ti  t  tri  t ffi it 
t   ffi it f  l  it  l 
x i its i  s rt f s  (A ; 0) 
/17/20 1  i li   i  t f .60 65.00 9. 0 
 i      
(A103; L210) 
/18/20 1   utline for reply e orandu  and .20 40.00 68.00 
e orandu  in opposition to otion for 
reconsideration (all A103; L210) 
/19/20 1  evie  affidavit of ajor and .50 40.00 0. 0 
r   r i r ti  (A ; 
L210) 
/19/20 1   esearch negligence per se standard .40 40.00 16.00 
t r t c ntry; iti l r s rc  
for and drafting of reply e orandu  
and e orandu  in opposition to 
r i r ti  (all  1 02/L 103;  ) 
/22/20 1   ontinue drafting opposition to reconsider .30 40.00 02. 0 
and reply for second otion for su ary 
j t (  ; 210) 
/24/2011   Review and revise reply brief (A 103; .10 40.00 154.00 
L210) 
825011 TJL Continue drafting and editing 390 1400 54600
reply opposition memorandum on motion
for summary judgment A103 L210
825011 CCB Review and revise draft brief in reply to 390 16500 64350
SEC summary judgment motion and in
response to plaintiffs motion for
reconsideration A103 L210
826011 CCB Review revise and finalize draft 290 16500 47850
memorandum in reply to SECsmotion for
summary judgment and in opposition to
plaintiffs motion for reconsideration
A1032 0
826011 CCB Conference with Tom Lloyd re treatment 040 16500 6600
of cases cited by plaintiff in summary
judgment response brief A105 L210
826011 TJL Conference with C Burke re second 050 1400 700
motion for summary judgment and final
edits thereto A105 L210
92011 CCB Conference with T Lloyd re strategy for 030 16500 4950
arguing motions for reconsideration
second summary judgment motion and
motion to strike Yost affidavit A105
L120
92011 CCB Begin review pleadings on motions for 20 16500 36300
summary judgment reconsideration and
to strike Yost affidavit and transcripts in
preparation for hearing on motions A104
L120
92011 CLM Review opposition to motion to strike 030 8500 2550
Yost discussion with T Lloyd re same as
to whether we file a reply brief or not
A104O5 L210
92011 TJL Review Plaintiffs reply memorandum on 050 1400 700
reconsideration and opposition to motion
to strike portions of Second Yost Affidavit
2 A104 L210 conference with C
Burke re briefing schedule for reply
memorandum on motion to strike 3
A105120
9122011 CCB Continue review and analysis of 630 16500 103950
pleadings briefs transcripts and cases in
preparation for oral argument on pending
motions for summary judgment
reconsideration and to strike affidavit
A1042 0
9122011 CCB Begin draft outline of argument on 20 16500 36300
pending motions for summary judgment
reconsideration and to strike A103 L120
002130
/25/20 1   tinue drafting nd editing .90 40. 0 546.00 
replylopposition r u   tion 
for s ary jUdg ent (A1 ; ) 
/25120 1  i   r ise r ft rief i  r ply t  .90 65.00 643.50 
 s r  judg ent ti n  i  
response to plaintiffs otion for 
reconsideration (A 103; L210) 
/26/20 1  i , r ise  fi liz  raft .90 65.00 78.50 
 i  l   C's ti n f r 
s ry judg ent  i  sition t  
l i tiffs ti  f r r i r ti  
(A103; L210) 
/26/20 1  f r c  ith  l y  r  tr t t .40 65.00 6. 0 
f  it   l i tiff i  r  
j t r s s  ri f (A 1 ; ) 
/26/20 1   f r ce it  . r  r   .50 40. 0 0. 0 
motion for summary judgment and final 
edits thereto (A105; L210) 
/9/20 1  onference ith T. Lloyd re strategy for .30 65.00 9.50 
arguing motions for reconsideration, 
second su ary judg ent otion and 
otion to strike ost affidavit (A 105; 
 ) 
/9/2011  Begin review pleadings on otions for .20 165.00 63.00 
su ary judg ent, reconsideration and 
t  strik  st ffi vit  tr scripts, i  
r r tion f r ri   ti  (A 1 ; 
 ) 
/9/2011  i  ition t  ti  t  tri  .30 5. 0 5. 0 
ost, discussion ith T. Lloyd re sa e as 
t  t r  fil   r l  ri f r t 
(A104/A105; L210) 
/9/2011   evie  laintiffs reply e orandu  on .50 40.00 0. 0 
reconsideration and opposition to otion 
to strike portions of econd ost ffidavit 
(.2) (A104; L210); conference ith . 
Burke re: briefing schedule for reply 
e orandu  on otion to strike (.3) 
(A105; L 120) 
/12/20 1  Continue review and analysis of .30 65.00 ,0 9.50 
pleadings, briefs, transcripts and cases in 
r r ti  f r r l r t  i  
otions for su ary judg ent, 
i ti      
(A104; L210) 
/12/20 1  Begin draft outline of argu ent on .20 65.00 63.00 
pending otions for su ary judg ent, 
reconsideration and to strike (  103; L 120) 
9132011 CCB Continue draft outline of argument for 430 16500 70950
motions for summary judgment
reconsideration and to strike23 review
and revise outline of argument for
motions for summary judgment
reconsideration and to strike and review
exhibits relating to same 20 all A103
L120
9132011 CLM Compile and organize additional 040 8500 3400
documents for C Burkes use tomorrow
at hearing on second motion for summary
judgment and motion for reconsideration
A101L210
9152011 CCB Prepare for oral argument on motions for 360 16500 59400
summary judgment reconsideration and
to strike Gerald Yost affidavit A101
L240
9152011 CCB Attend hearing on motions for summary 250 16500 41250
judgment reconsideration and to strike
A109 L240
Grand Total 12730 190680
002131
/13/20 1  ntinue draft tli  f r ent  .30 65.00 709.50 
otions for s r  j t, 
reconsideration  t  tri  (2.3); i  
nd r vise tli  f r nt f r 
otions for r  j t, 
r i ti ,  t  t i   ie  
x i its r l ti  t  s e (2.0) (all ; 
l120) 
/13/20 1 l  o pile and organize additional OAO 5. 0 34.00 
cu ents f r . rke's   
t ri   nd ti n f r r  
judg ent and otion for reconsideration 
(A101; l2 0) 
/15/20 1  repare for oral argu ent on otions for .60 65.00 94.00 
r  j t, r i r ti   
t  tri  r l  t ffi it (A 1 ; 
l240) 
/15/20 1  ttend ri   ti  f r r  .50 65.00 412.50 
j t, r i r ti   t  tri  
(A 1 ; l240) 





14542011 Admiral Insurance Company Major v Security Equipment
Date Prof Description Units Price Extended Amt
9192011 TJL Review all pleadings depositions and 690 1400 96600
discovery responses by plaintiff for
confirmation that she has never made a
claim for acute injuries23 A104
L120 draft Motion for Clarification 46
A103 L210
9192011 CCB Telephone conference with T Lloyd re 030 16500 4950
motions for clarification and in limine
strategy and issues A10512021
9192011 CLM Prepare affidavit of counsel in support of 050 8500 4250
motion for reconsideration re allowing trial
to proceed and compile enclosures to
same A103 L210
9192011 CLM Review transcript of hearing for original 130 8500 1105
Motion for Summary Judgment additional
discovery other pleadings filed and
affidavits to obtain any additional
statements to include in motion for
reconsideration supporting fact that
Plaintiff only ever moved on chronic
conditions never on acute conditions
A104 L240
920011 CCB Draft review and revise draft order on 120 16500 19800
second motion for summary judgment
motion for clarification and motion to
strike Yost affidavit A103 L210
920011 TJL Continue drafting motion for clarification 510 1400 71400
draft motion in limine 1 48 revise
motion for clarification reconsideration
3 all A103 L210
920011 CLM Revise and finalize motion for clarification 120 8500 10200
and help to file same 9 finalize affidavit
of counsel in support of motion for
clarification and all exhibits to same 3
all A103 L210
927011 CCB Review and revise draft order re summary 030 16500 4950
judgment motions motion to vacate trial
and other motions A103 L210
928011 CCB Exchange emails on dispute with 030 16500 4950
plaintiffs attorneys on language of
summary judgment order A107 L210
9302011 CCB Review and analyze SECsmotion 090 16500 14850
memorandum and affidavit in support of
motion for clarification and other
pleadings relating to same A104 L210
002133
Transactions Fee Listing 
14542-011 Ad iral Insurance Co pany ajor v. ecurity ip ent 
ate r f Description nits ri  Extended A t 
9/19/2011 T Jl eview all pleadings, depositions, and .90 140.00 966.00 
discovery responses by plaintiff for 
confir ti  t t s  as ever de  
cl i  f r acute i j ri  (2.3) (A 10 ; 
l120); draft otion for larification (4.6) 
(A103; l ) 
/19/20 1  elephone c f r c  ith . l y  re .30 65.00 49.50 
tions f r clarification  i   
strategy  i s (A 10 ; l 120/l21 0) 
/19/20 1 l  Prepare affidavit of counsel in support of .50 85.00 42.50 
tion f r r i r ti   ll i  tri l 
t  r   il  l r s t  
sa e (A103; l210) 
/19/20 1 l  i  tr ri t f ri g f r ri i l .30 5. 0 10.50 
otion for Su ary Judg ent, additional 
discovery, other pleadings filed and 
affidavits to obtain any additional 
t ts t  l   ti   
reconsideration supporting fact that 
l i tiff l  r   r i  
iti , r  t  iti  
(A 104; l240) 
/20/20 1  r ft, r i   r i  r ft r r  .20 165.00 198.00 
 ti  f   j t, 
  i i ti     
tri  t ffi it (A / l210) 
/20/20 1  l  i    ti ; .10 40.00 14.00 
r ft ti  i  li i  #1 (4.8) ; r i  
  ifi ti n/reco i  
(.3) (all ; l210) 
/20/20 1 l       l i  .20 5. 0 02.00 
 l  t  fil   (.9); fi li  ffi it 
of counsel in support of otion for 
clarification and all exhibits to sa e (.3) 
(all A103; l210) 
/27/20 1  i   r i  r ft r r r  r  .30 165. 0 9.50 
judg ent otions, otion to vacate trial 
 t r ti s (A ; l210) 
/28/20 1  Exchange emails on dispute with .30 165. 0 9.50 
l i tiffs tt r ys  l  f 
r  j t r r ( 7; l210) 
/3 /20 1  evie  and analyze SEC's otion, .90 165. 0 48.50 
e orandu  and affidavit in support of 
ti  f  l i  nd t er 
pleadings relating to sa e (A 104; l210) 
1042011 CCB Summary review of plaintiffs motion and 080 16500 13200
brief in support of second motion for
reconsideration A104 L210
1042011 TJL Review newest motion for reconsideration 040 1400 5600
received from opposing counsel today
A104L210
1042011 TJL Conference with C Burke re plaintiffs 060 1400 8400
motion for reconsideration A105 L210
1052011 CCB Review third affidavit of plaintiff on 040 16500 6600
pending motions for clarification and
reconsideration A104 L210
1052011 CCB Strategy conferences with T Lloyd re 080 16500 13200
arguments to respond to plaintiffs second
motion for reconsideration and motion for
clarification A105 L120
1052011 CCB Review and revise draft order re motion to 040 16500 6600
vacate trial and second motion for
summary judgment and first motion for
reconsideration A103 L210
1052011 CLM Review and strategy of various issues in 060 8500 5100
plaintiffs recent motion for
reconsideration assignments for
research and pulling from record for T
Lloyds use in opposition to same A104
L120
1052011 TJL Conferences with C Burke re strategy in 080 1400 11200
responding to latest motion for
reconsideration A105 L120
1062011 CLM Detailed review of all materials in record 320 8500 27200
and make note and quotes of all
references to exposure to OC spray
being acute andor temporary and
testimony re duration of temporary or
acute A104 L110L120
1062011 CCB Begin review of cases cited by plaintiff in 120 16500 19800
second motion for reconsideration A104
L210
1062011 TJL Review case law cited by plaintiff A102 170 1400 23800
L210
1072011 CCB Continue analysis of cases on damages 090 16500 14850
and proximate cause proof cited in
plaintiffs motion for reconsideration
A104L210
1072011 CCB Conferences with T Lloyd re arguments 070 16500 11550
and strategy for responding replying to
second motion for reconsideration and




10/4/2011  JL 
0/4/20 1  JL 
0/5/20 1 B 
0/5/20 1  
0/5/20 1  
0/5/20 1  
0/5/20 1   
0/6/20 1  
0/6/20 1  
0/6/20 1   
0/7/20 1  
0/7/20 1  
Summary revie  of plaintiffs otion and 
brief in support f second otion for 
reconsideration (A 104; L210) 
eview ne est otion for reconsideration 
received from opposing counsel today 
(A104; L210) 
nference ith . urke re l intiffs 
otion for r i r tion (A10 ; L ) 
eview third affidavit f laintiff  
pending otions for clarification and 
r c sid ration (A10 ; ) 
Strategy conferences ith T. Lloyd re 
argu ents to respond to plaintiffs second 
ti  f r r c i r ti   tion f r 
l rification (A 10 ;  ) 
i  nd r i  r ft r  ti  t  
t  tri l  nd tion f r 
su ary judg ent and first otion for 
r c si r ti  (A 10 ; ) 
Review and strategy of various issues in 
plaintiffs recent otion for 
reconsideration, assign ents for 
r rc   lli  fr  r r  f r . 
Lloyd's use in opposition to sa e (A 104; 
 0) 
f r  it  . r  r  tr t  i  
responding to latest otion for 
r i r ti  (A 1 ;  ) 
   l    
  t   t  f ll 
f  t   t  .C.  
being acute and/or te porary and 
t ti  r  r ti  f 'te r r ' r 
'acute' (A 104; L 11 OIL 120) 
Begin review of cases cited by plaintiff in 
 ti  f r r i r ti  (A 1 ; 
L210) 
i   l  it   l i tiff (A ; 
L210) 
ontinue analysis of cases on da ages 
and proxi ate cause proof cited in 
plaintiffs otion for reconsideration 
(A104; L210) 
f r  it  . l  r  r t  
and strategy for respondinglreplying to 
 ti   i r ti   
ti  f r l rifi ti  (  ;  20) 
0.80 165.00 132.00 
OAO 140.00 56.00 
.60 40. 0 84.00 
OAO 65.00 6.00 
.80 65.00 32.00 
OAO 165.00 66.00 
.60 5. 0 51.00 
.80 140.00 112.00 
.20 5. 0 272.00 
.20 65.00 98.00 
.70 40.00 38.00 
.90 65.00 48.50 
.70 165. 0 15.50 
1072011 CCB Review and assess memorandum on 040 16500 6600
deposition and affidavit cites in record on
acute temporary exposures to pepper
spray in preparation for response to
motions A102 L210
1072011 TJL Conference with C Burke re case law 070 1400 9800
cited by plaintiff and our strategy
responding to plaintiffs briefing A105
L120
102011 TJL Draft reply memorandum on motion for 430 1400 60200
clarification and response to second
motion for reconsideration A103 L210
10120 1 CLM Review and revise opposition to plaintiffs 130 8500 1105
motion for reconsideration A103 L210
10120 1 TJL Draft and revise reply memorandum in 750 1400 1050
support of motion for clarification and
opposing motion for reconsideration
A1032 0
10120 1 CCB Review and revise draft response brief on 260 16500 42900
plaintiffs second motion for
reconsideration during conference with T
Lloyd A103 L210
1022011 CCB Analyze arguments of parties on pending 180 16500 29700
motions in preparation for oral argument
A104220
1022011 CCB Conferences with T Lloyd re strategy and 090 16500 14850
issues for oral argument on pending
motions A105 L120
1032011 CCB Begin preparing for oral argument on 350 16500 5770
pending motions for clarification and
reconsideration A101 L220
1072011 CCB Review and revise add to draft outline of 200 16500 3300
oral argument on pending motions A103
L210
1072011 CCB Final preparation for oral argument on 380 16500 62700
pending summary judgment
motionsreconsideration A101 L240
1072011 CLM Pull materials for C Burkesuse during 070 8500 590
oral argument today and make copies of
same for handouts to court and opposing
counsel Al01L330
1072011 CCB Attend hearing and oral argument on 140 16500 23100
pending motions for summary judgment
and to reconsider A109 L240
1082011 CCB Draft order on all pending motions and 190 16500 31350
judgment A103 L210
1092011 CCB Further review and revisions of draft order 050 16500 8250
and judgment on all pending motions
A103 L210
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0/7/20 1  i    r   0.40 65.00 6. 0 
ition  i it     
t , t r ry r  t  r 
 i  ti  f   t  
ti  (A1 ; ) 
0/7/20 1   r c  i  .    l  .70 40. 0 8. 0 
cited by plaintiff and our strategy 
r s i  t  l i tiff's ri fi  (A 10 ; 
 ) 
0/10/20 1  ft l    i   .30 40. 0 02.00 
l rifi ti   r  t  nd 
ti n f  i ti  (A 1 ; ) 
0/11/20 1  i   i  iti  t  l i tiff'  .30 5. 0 10.50 
ti n f r r c si r ti  (A 1 ; ) 
0/11/20 1  ft  i  l   i  .50 40. 0 ,0 0.00 
rt f ti  f r l rifi ti   
i  ti  f r r i r ti  
(A103; L210) 
0/11/20 1  evie  and revise draft response brief on .60 65.00 29.00 
l i tiff's d ti  f r 
reconsideration during conference ith . 
l  (A1 ; ) 
0/12/ 0 1  l    i   i  .80 65.00 97.00 
ti s i  r r ti  f r r l r t 
(A 104; L220) 
0/12/ 0 1  f  it  . l   t t   .90 65.00 48.50 
i  f r r l r t  i  
ti  (A 1 ;  ) 
0/13/20 1  i  r ri  f r r l r t  .50 65.00 7 .50 
i  ti  f r l rifi ti   
r c si r ti  (A 10 ; ) 
0/17/20 1  i   r i ,  t  r ft tli  f .00 65.00 30. 0 
oral argu ent on pending otions (A 103; 
0) 
0/17/20 1  Final preparation for oral argu ent on .80 65.00 27.00 
pending su ary judg ent 
ti slreconsid r ti  (A 1 ; 0) 
0/17/20 1  Pull aterials for . Burke's use during .70 5. 0 9.50 
r l r t t y  k  c i s f 
  -out      
l (A 1 1; L 3 ) 
0/17 2011  ttend hearing and oral argu ent on .40 65.00 31.00 
i  ti  f r r  j t 
and to reconsider (A 109; L240) 
0/18/20 1  r ft r r  ll i  ti   .90 65.00 13.50 
judg ent (A 103; L210) 
0/19/20 1       ft r .50 65.00 2.50 
and judg ent on all pending otions 
(A103; L210) 
Grand Total 6380 912300
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  3.80 ,1 3.00 
EXHIBIT 4
002137
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1h
Transactions Fee Listing
14542011 Admiral Insurance Company Major v Security Equipment
Date Prof Description Units Price Extended Amt
1025011 CCB Review and analyze plaintiffs third motion 300 16500 49500
for reconsideration and third affidavit of
Dr Yost A104 L210
1025011 CCB Email to clients re plaintiffs third motion 040 16500 6600
for reconsideration and third affidavit of
Dr Yost A106 L210
1025011 CCB Conference with T Lloyd re strategy for 030 16500 4950
responding to plaintiffs third motion for
reconsideration A105 L120
1025011 CCB Email to plaintiffs attorney re needing 010 16500 1650
exhibits to Yost affidavit and whether
hearing has been set A107 L210
1025011 CCB Review Idaho rules and cases on motions 100 16500 16500
for reconsideration A104 L120
1025011 CCB Telephone conference with B Nance re 040 16500 6600
capsaicin MSDS sheet and Dr Yosts
third affidavit A106 L110
1025011 TJL Conference with C Burke re newest 020 1400 2800
motion to reconsider and supporting
documents from opposing counsel A105
L210
1026011 TJL Research on courtsdiscretion to deny 030 1400 4200
motions without hearing A102 L120
1026011 CCB Conference with T Lloyd re strategy for 030 16500 4950
responding to plaintiffs third motion for
reconsideration A105 L120
1026011 CCB Begin review of medical and scientific 130 16500 21450
articles attached to third affidavit of
Gerald Yost A104 L210
1027011 CCB Continue reviewing new scientific articles 040 16500 6600
relied on by Dr Yost A104 L210
1120 1 CCB Review new articles attached to third Yost 100 16500 16500
affidavit A103 L210
11320 1 CCB Conference with T Lloyd re strategy for 020 16500 3300
responding to plaintiffs third motion for
reconsideration A105 L120
11320 1 CCB Review transcripts of prior summary 210 16500 34650
judgment hearings to find excerpts to
support response to third motion for
reconsideration A104 L210
11420 1 CCB Continue reviewing new articles attached 090 16500 14850
to third Yost affidavit A104 L210
11420 1 CCB Analyze facts and issues for response to 10 16500 18150
plaintiffs third motion for reconsideration
A1041 0
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r ti s  i ti  
-011 ir l I r    .  i t 
t   ri tion it  ri    
0/25/20 1  i   l ze l i tiff  t i  ti  . 0 165.00 95.00 
f r    i it  
. t (A1 ; ) 
0/25/20 1  il t  cli ts r  l i tiffs t ir  ti  .40 65.00 6. 0 
f r    i it  
r. ost (A106; L210) 
0/25/20 1  onference ith . Lloyd re strategy for .30 65.00 9.50 
r i  t  l i tiffs t ir  ti  f r 
i r ti  (A 1 ;  ) 
0/25/20 1  il t  l i tiff  tt r  r  i  .10 65.00 6.50 
i it  t  t ffi it  t  
ri g   t (A1 ; ) 
0/25/20 1  i   l     i  . 0 65.00 65.00 
  (A 10 ;  ) 
0/25/20 1  l  f r  it  .  r  .40 65.00 6. 0 
capsaicin  sheet and r. ost's 
 ffi it (A 1 ;  0) 
0/25/20 1  f r nce  .    .20 40. 0 8. 0 
ti  t  r c si r  s rti  
t  fr  i  l (A1 ; 
L210) 
0/26/20 1   r   urt's i r ti  t   .30 40.00 2. 0 
ti  it t i  (A 1 ;  ) 
0/26/20 1  onference ith . Lloyd re strategy for .30 65.00 9.50 
r i  t  l i tiff  t ir  ti  f r 
i i  (A 1 ;  0) 
0/26/20 1  i  r vi  f ic l  sci tific .30 65.00 14.50 
i l    i  i i   
erald ost (A104; L210) 
0/27/20 1  ti  r vi i   sci tific rticl s .40 65.00 6. 0 
r li    r. t (A ; 0) 
1/2/20 1         .00 65.00 65.00 
affidavit (A103; L210) 
1/3/20 1  f r  it  . l  r  tr t  f r .20 65.00 3. 0 
responding to plaintiffs third otion for 
reconsideration (A 105; L 120) 
1/3/20 1  i  tr ri t  f ri r r  .10 65.00 46.50 
judg ent hearings to find excerpts to 
rt r  t  t ir  ti  f r 
r i r ti  (A ; ) 
1/4/20 1  ontinue revie ing ne  articles attached .90 65.00 148.50 
to third ost affidavit (A104; L210) 
1/4/20 1  Analyze facts and issues for response to .10 65.00 81.50 
plaintiffs third otion for reconsideration 
(A104; L 110) 
11420 1 CCB Strategy conference with T Lloyd re 080 16500 13200
issues research and themes for
responding to plaintiffs third motion for
reconsideration A105 L120
11420 1 CCB Review billing statements and rules for 160 16500 26400
support for motion for attorney fees in
connection with plaintiffs latest motion for
reconsideration A104 L110
11720 1 CCB Draft motion affidavit and brief insert for 340 16500 56100
attorney fee sanctions
11720 1 CCB Review and revise draft motion and 090 16500 14850
affidavit for attorney fees and costs
sactions
11720 1 TJL Conference with C Burke re additional 020 1400 2800
thoughts on strategy for opposing latest
motion for reconsideration
11720 1 CCB Conference with Tom Lloyd re motion for 020 16500 3300
attorney fees supplemental Nance
affidavit and strategy for response to 3rd
motion for reconsideration
11820 1 CCB Review and revise draft brief excerpt on 100 16500 16500
motion for sanctions against plaintiff
11920 1 CCB Further revisions to draft brief on motion 040 16500 6600
for sanctions
11920 1 CCB Further revisions to draft brief on motion 050 16500 8250
for sanctions A103 L210
1120 1 TJL Conference with C Burke re status of 060 1400 8400
opposition to latest motion to reconsider
2 A105 L120 research for opposition
based on motion to strike newest affidavit
of Yost A A102 L120
11420 1 TJL Review transcript of last hearing for use in 060 1400 8400
opposition to latest motion for
reconsideration and in motion to strike
latest Yost affidavit A104 L110
11620 1 CCB Review and edit billing entries for support 080 16500 13200
in affidavit for attorney fee sanctions due
to plaintiffs third motion for
reconsideration A104 L110
11720 1 CCB Review and analyze Idaho cases on legal 230 16500 37950
requirements for attacking judgment v
motion for reconsideration 20 A104
120 conference with T Lloyd re same
and strategy for opposing plaintiffs third
motion for reconsideration 03 A105
L120
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1/4/20 1  trategy conference ith T. Lloyd re 0.80 65.00 132.00 
i , r rch  t es  
responding to plaintiff's third otion for 
r i r ti  (A 10 ;  ) 
1/4/20 1  ie  illi  t t t   r l  f r .60 65.00 64.00 
rt f  ti  f  tt r y f  i  
c cti  it  l i tiffs' l t st ti  f r 
r i r ti  (A 10 ;  ) 
1/7/20 1  t tion,. i it  i f i rt f r .40 65.00 61.00 
tt r  f  ti  
1/7/20 1  i   i  r ft ti   .90 65.00 48.50 
ffi avit f r tt r  f   ts 
ti  
1/7/20 1   f rence it  . r  r : iti l .20 40. 0 8. 0 
t t   tr t  f r i  l t t 
ti  f r r i r tion. 
1/7/20 1   it     i   .20 65.00 3. 0 
tt r  f , l t l  
ffi avit  t t  f   t   
i    
1/8/20 1  i   r i  r ft ri f r t  .00 65.00 65.00 
otion for sanctions against plaintiff 
1/9/20 1   i i  t  t i   i  .40 65.00 6. 0 
f r  
1/9/20 1   i i    i   i  .50 65.00 2.50 
for sanctions (A103; L210) 
1/11/2011    .     .60 40. 0 4. 0 
iti  t  l t t ti  t  r i r 
(.2) (A1 ;  0);   iti  
     t  
f t. (.4) (A1 ; ) 
1/14/20 1  i  tr ri t f l t ri  f r  i  .60 40. 0 4. 0 
sition t  l t st ti  f r 
      
latest Yost affidavit (A 104; L 110) 
1/16/20 1  evie  and edit billing entries for support .80 65.00 32.00 
in affidavit for attorney fee sanctions due 
to plaintiff's third otion for 
reconsideration (A 104; L 110) 
1/17/20 1  Review and analyze Idaho cases on legal .30 65.00 79.50 
require ents for attacking judg ent v. 
otion for reconsideration (2.0) (A 104; 
L 12 ); c f r c  it  . l y  r  s  
 tr t  f r i  l i tiff'  t ir  
otion for reconsideration (0.3) (A 105; 
 ) 
11720 1 TJL Research alternative responses to latest 470 1400 65800
motions including that opposing party has
filed under wrong rule 4hrs A102
L110 Conference with C Burke re
improper filing by opposing counsel and
thus new avenue to attack filings
Conference with C Burke re interplay
between rules 11 59 and 60 3 hr
A105120
11820 1 CCB Revise draft motion for attorney fees to 080 16500 13200
add new grounds for filing improper
motion for reconsideration and to cite
additional supporting facts A103 L210
1120 1 CCB Review and revise draft motion to strike 120 16500 19800
third affidavit of Garold Yost 7 further
revisions to draft brief in support of
motion for attorney fees 5 all A103
L210
1120 1TJL Draft and research briefing relative to 520 1400 72800
most recent motions filed by plaintiff
A103102 L210
11220 1 TJL Research and draft opposition to motion 40 1400 61600
to reconsider A102 L210
11230 1 TJL Continuing to research and draft 120 1400 16800
opposition to motion to reconsider A102
L210
11280 1 CCB Conference with T LLoyd re notice of 030 16500 4950
appeal and how that may effect pending
motion for reconsideration
11280 1 TJL Continue researching and drafting 170 1400 23800
opposition to motion for reconsideration
11290 1 CLM Review record and pull citations and 140 8500 11900
documents for T Lloyd as necessary in
preparation of opposition of third motion
for reconsideration
11290 1 TJL Continue researching and drafting 760 1400 10640
opposition to motion for reconsideration
converted Rule 60b motion
Conferences with C Burke re best ways
to respond to new affidavit of Yost
113020 1 CLM Research re cases supporting standard 210 8500 17850
on summary judgmentand discussion of
same with T Lloyd19pull docket
information for review relating to appeal
2
002140
11/17/2011 T JL Research alternative responses to l test .70 40. 0 658.00 
ti s, including that opposing party has 
filed under wrong rule (4.4 hrs.) (A10 ; 
L ); onference with C. Burke re 
i proper fili  by pposing counsel and 
thus e  avenue t  ttack fili ; 
onference ith . rke  i terplay 
between r l  1 , 59 d 0 (.3 h ) 
(A105; L 120) 
11/18/2011  is  r ft ti  for tt r  fees t  .80 65.00 32.00 
add ne  grounds for filing i proper 
tion f r r i ti   t  it  
iti l porting facts (A 10 ; ) 
11/21/2011  vie   i  ft ti   i  .20 65.00 198.00 
t ir  ffi vit f r ld st (.7); f t r 
r i i s t  r ft ri f i  ort f 
ti  f r tt  f  (.5) (all ; 
L210) 
1/21/20 1  r ft  r rch ri fi  r l ti  t  .20 40. 0 28.00 
t t ti  fil   l i tiff 
(A1 3/L 102; ) 
1/22/ 0 1   r   r ft iti n t  ti  .40 40. 0 16.00 
to reconsider (A102; L210) 
1/23/2011   ontinuing to research and draft .20 40. 0 68.00 
opposition to otion to reconsider (A 102; 
L210) 
1/28/2011  onference ith . LLoyd re notice of .30 65.00 49.50 
appeal and how that ay effect pending 
i    
1/28/20 1   ti  r r i   r fti  .70 40.00 38.00 
opposition to otion for reconsideration. 
1/29/20 1  i  r r   ll it ti   .40 85.00 119.00 
t  f  . l    i  
preparation of opposition of third motion 
  
1/29/20 1   ontinue researching and drafting .60 40.00 ,0 4.00 
opposition to motion for reconsideration 
(converted ule 60(b) otion). 
onferences ith . urke re: best ays 
t  r  t   ffi it f st. 
1/30/20 1  esearch re cases supporting standard .10 5. 0 78.50 
on su ary judg entand discussion of 
sa e ith T. Lloyd; (1.9); pull docket 
i i  f r r i  r l i  t  l 
(.2) 
113020 1 CCB Review and revise draft memorandum in
opposition to plaintiffs 3d motion for
reconsideration and in support of SECs
motion to strike Yost 3d affidavit and for
attorney fees










11/30/2011 CCB Review and revise draft memorandum in 1.50 165.00 247.50 
o position to plaintiff's 3d motion for 
reconsideration and in support of S 's 
otion to strike Yost 3d a fidavit and for 
attorney fees 
11/30/2011  JL Finalize and edit opposition to ule .90 140. 0 686.00 
11/60(b) otion. 
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MR OVERSON Your Honor if I might
THE COURT Yes
MR OVERSON In order to avoid the obvious
difficulty with proceeding with my client inthe
roomIdask that she be excused Iveasked her
to be here today becausewe anticipated
THE COURT She doesntneed to be here
MR OVERSON Thankyou Your Honor
THE COURT All right Wev got a couple
of things as I understand it We have a motion
for reconsideration a motion to strike and I
suspectwe need to talk about the motion to strike
because thatsgoing to be integral to just about
everything else And then a motion a second
motion for summary judgment Have Igot
everything right
MR BURKE Yes
THE COURT Whydontwe deal with the
motion to strike This is a sort ofa renewal
of an earlier motion that I actually denied on the
firstDr Yost affidavit This is now on the
motion to strike the second one
And for the recordIve read all of the
5
So letslook at Dr Yostssecond
affidavit Just like the first affidavit the
second affidavit reliesupon inadmissible
conclusory statements and legal conclusions And
I point out the main statement which I think is
the subject of our motion occurs in paragraph
nine of the second affidavit And what it says is
the scientific literature and studies in existence
prior to 20o8were such that when viewed as a body
of literature in human and animal studies it was
knownthat a product such as SECMK9 Fogger
produceda riskof both acute and chronic
respiratory injury such as that described in Ms
Majors medical records
Our contention Your Honor is that
this is a conclusory statement Its very
similar by the way to the one that was contained
in Dr Yostsfirst affidavit which was at
paragraph six which that this court has
previously deemed to be conclusory and
constituting a legal conclusion
The statement at paragraph six said
Based on my review of the abovecited articles
andmy education training research and knowledge




















































material I even have read the studies so I
didorganic them at the University of Utah in
fact so I have a science background Imnot
your typical lawyer But I have actually read the
studies soIve read more than just the title I
kind of wish Dr Yost were here
MR OVERSON I can do that
THE COURT No its okay All right Ill
go ahead and hear the motion to strike
MR BURKE Thankyou Your Honor I will
address the motion to strike I think I can also
probably go over all of it pretty quickly even in
addition to that
This is the same song its just the
second verse The plaintiff has simply wrapped
her old arguments up intoa new package but once
the package is unwrapped the arguments are the
same Theresno new material facts which
preclude summary judgment
The second affidavit ofDr Yost
suffers from the same deficiencies that the first
one did and the plaintiff still has failed to
submit any evidence that SEC knew or should have
known prior to 2008 that exposure to OC spray
could cause chronic irreversible disease
6
that the risk to the respiratory tract posedby
exposure to SECsMK9 Fogger were a known and
foreseeable risk at the time SEC sold its product
to IDOC
The only material difference between
the old affidavitstatement and the new one is the
addition ofthe words acute and chronic to
modify the word respiratory Other than that
theyr both equally conclusory
THE COURT But isn the real problem the
whenyou take lets assume that thesearent
conclusory just for a second
MR BURKE All right
THE COURT The real concern in here is that
these statements seem to be directly at odds with
the deposition testimony
MR BURKE Well they are Imean
THE COURT And that to me is the crux of
the motion to strike
MR BURKE Well actually I think its two
I think theres two ways Last time Your Honor
you were able to avoid dealing with the sham
affidavit argument because you were able to look
at the affidavit and say you know its not
enough Its conclusory It doesn have
KIM Maasen Umaai ourc Kepvrwr ovisc ivanv
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1 BOIS , IDA , S.EPTEMBER 15, 2011 1 a . I even have read the studies, so -- I 
2 2 did organic chern at the University of Uta , in 
3 R O ERS : Your Honor, if I ight? 3 fa , so I have a science ba ro . I'm not 
4 THE C : Yes. 4 your typical la r. ut I ave actually read the 
5 R O ERS : In order to a id the obvious 5 st ie , s  I've read ore than just the title. I 
6 difficulty with proceeding with my client in the 6 kind of ish . ost ere he . 
7 roo , I'd ask that she be excused. I've asked her 7 R E : I can do th t. 
8 to be here today because we anticipated -- 8 E : , i 's o . l rig . I'll 
9 E C : he d n't need to be her . 9 go ead a d ear the tion to st i . 
10 R OVERSON: Thank you, Your Honor. 10 R : hank y , our r. I l 
11 THE COURT: All right. e've got a couple 11 ress the otion to . I think I an s  
12 of things as I understand it. e have a motion 1  proba ly  er a l f it retty ic ly e e  n 
13 for reconsideration, a motion to strike, and I  tion t  t t. 
14 suspect we need to talk about the motion to strike 14 his is e e ; i 's just the 
15 because that's going to be integral to just about   ve . he    rapped 
 everything else. And then a otion --   16 er ld argu e ts  i t  a e  ac a e, t nce 
 motion for summary judgment. Have I got 7  a a e  , the e ts   
 everything right? 8 . re's   al ts ich 
19  : e .  preclude su ary judg ent. 
20 THE COURT: hy don't we deal with the   d id t  r. ost 
 tion t  tri . his is  --    al  fers fro   e ie cies  e rs  
 of an earlier otion that I actually denied on the      i ti  ti   e   
 first r. st ffi it. is is   t e  s it a  e i e ce t t  e  r s l  a e 
24 ion t  ike e  .   i  t   t t  t  .C.  
25   e  've    e   se   . 
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 conclusory statements and legal conclusions. And  t  I C." 
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foundation in it It confuses foreseeability of
risk knowledge of that and medical causation
THE COURT Well and I also said it really
wasntinconsistent because he really
MR BURKE Right
THE COURT because he never he
avoided the use of the
MRBURKE Right
THE COURT word chronic
MRBURKE But what Imsaying Your Honor
is if you chose not to get into the issue of sham
affidavit this affidavit suffers from the same
defects as the other one even if you dontaddress
the issue of sham affidavit but it has the added
consideration that now the sham affidavit rule
comes into play
And so I thinkthat there is more to
this than just meets the eye This is more than
just a sham affidavit because there is a complete
lack of foundational basis and that was one of the
problems we had with the last one right
In this particular case in paragraph 12
of the new affidavit Dr Yost has cited the same
eight articles that he previously cited but we
already know how the court disposed of those
9
which a significant number at least a number of
them were after 2008 And my comment was how do
I know which ones are the ones that hesrelying
on Well hes attempted to fix that but I think
it still has a problem because he now is in my
opinion in direct contradiction with his
deposition testimony and thatsthe real problem
Now given that I can tell you I went
back and its interesting that in his affidavit
he has picked up I guess because he thinks
people dontread hes picked up those things
that have the word chronic in them
MR BURKE Yes
THE COURT significantly But if you
actually go back and look at the studies they
arentdealing with a
MR BURKE No
THE COURT tie between the exposure to
capsaicin and the creation of a chronic condition
What theyr doing is theyr looking
at the effect of capsacin as well as other
irritants on people who have a chronic cough And
whats whatsalso significant is they dontgo
beyond a period of time of about 48 hours
MRBURKE Yeah
U
1 They were not sufficient to put ES SEC on
2 notice of the chronic disease
3 So now hescited an additional seven
4 articles Well three of those I think suffer
5 from defect because they are articles that were
6 published in 2009
7 Now he explains that these are reviews
8 and what they do is they look at other articles
9 thatwere published prior to 20o8
10 THE COURT Well
11 MR BURKE The point is that hes still
12 he still Your Honor draws conclusions in those
13 articles
14 THE COURT Well Im not so much concerned
15 about that Let me kind of clarify a couple of
16 things
17 In his previous affidavit first it
18 was conclusory and it really didntaddress
19 whether these studies at the time in the
20 studies had demonstrated that as of 20o8 a company
21 would be on notice that the use of capsaicin would
22 cause chronic effects from from its exposure
23 The problem I a couple of problems
24 One the affidavit when it when he made that
25 statement he listed a whole series of studies of
10
1 THE COURT They are not studies that are
2 addressing the issue of whether capsaicin exposure
3 causes a chronic condition And thatsreally the
4 crux of this whole issue And if in his
5 affidavit hes not identifying what existed that
6 he didntknow about when he was being deposed
7 And if you look at the case law on a
8 sham affidavit and I I dontactually like the
9 term shamaffidavit because it sounds like a
1 o making some moral judgment But really what a
11 sham affidavit is is an attempt to create an issue
12 of fact by coming out and saying something thats
13 dimetrically opposed to what you said earlier
14 And the Supreme Court and the 9th Circuit have
15 made it clear that if at the time you made the
16 original statement you either said I donthave a
17 clear memory of this and then the new statement is
18 because you now have a memory of it thatsnot a
19 sham thatsnot a sham affidavit Or ifits I
20 got new studies that Ive now looked at that I
21 didntknow about at the time or facts that I
22 didntknow those arentsham
23 But here his affidavit and obviously
24 Im going to be asking Mr Overson this question
25 where in his affidavit does he explain away his
103120 102247PM KIM mausen Unitow w Pu
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1 foundation in it. It confuses foreseeability of 1 They were not su ficient to put ES -- SEC on 
2 risk, knowledge of that, and medical causation. 2 notice of the chronic disease. 
3 THE COURT: Well, and I also said it really 3 So now h 's cited an additional seven 
4 wasn't inconsistent because he really -- 4 articles. We l, thr e of those I think su fer 
5 MR. BURKE: Right. 5 from defect because they are articles that were 
6 THE C : -- because he never -- he 6 published in 200 . 
7 avoided the use of the -- 7 No , he explains that these are reviews 
8 R. BURKE: Right. 8 and what they do is they look at other articles 
9 THE C RT: -- word chronic. 9 that were published prior to 200 . 
10 . BUR : But what I'm saying, our Honor, 10 HE C : ell--
11 is if you chose not to get into the issue of sham 1 . BU : The point is that h 's s l --
12 affidavit, this affidavit suffers from the same 12 he s , our Ho , ra s conclusions in those 
13 defects as the other one even if you don't address 3 a icle . 
14 the issue of sha  affidavit, but it has the added  HE : ll, I'm not s  uch concerned 
15 consideration that no  the sha  affidavit rule 5 a t th . Let e ind  cla fy a couple f 
16 comes into play.  t i . 
17 nd so I think that there is ore to 7 n is re ious it, firs , it 
18 this than just meets the eye. This is more than 8 as c lus ry  it l  i n't ress 
19 just a sham affidavit because there is a complete  hether these ies  e i e  -- the 
20 lack of foundational basis and that as one of the  s ies ad ate  t   08   
21 problems we had with the last one; right?  ld e  ice   se    
22 In this particular case in paragraph 12     ro  --  ts . 
23 of the ne  affidavit, r. ost has cited the sa e   l   --    l s. 
24 eight articles that he previously cited, but we  , e t  t -- e  e a e t at 
25 already know how the court disposed of those.  t ent,  iste   le es  es  
 10 
1 which a significant number, at least a number of   T:    t    
2 them, were after 2008. And my comment was how do 2 a ressi  t e iss e f et er capsaici  e s re 
3 I kno  hich ones are the ones that he's relying     nditi .  at's r al  t  
4 on. Well, he's attempted to fix that, but I think    t i  l  i ue.  i  -- in his 
5 it still has a problem because he now is in my  f  e's t i ntif    t t 
6 opinion in direct contradiction with his   idn't      i  sed. 
7 deposition testimony and that's the real problem.    y  l k  t   l   a 
8 Now, given that, I can tell you I went  s  ffi avit,  I -- I on't actual  li  t  
9 back -- and it's interesting that in his affidavit 9 t r , "sh  f idavit," b c  it s  li  a 
10 he has picked up -- I guess because he thinks 10 aking so e oral judg ent. But really hat a 
11 people don't read -- he's picked up those things 1   ff i  i  i  a  att  t  cr at  a  i  
12 that have the word "chronic" in them -- 12 f f ct by c i  o t an  sayi  something that's 
13 R. RKE: es. 13 di etrically opposed to what you said earlier. 
14 T  OURT: -- significantly. But if you 14 nd the upre e Court and the 9th Circuit have 
15 actually go back and look at the studies, they 15 ade it clear that if at t  ti  y u d  the 
16 aren't dealing with a -- 16 origi l state ent you eit er said I don't have a 
17 R. BURKE: No. 17 cl ar memory of thi  and then the new statement is 
18 T E COURT: -- tie bet een the exposure to 1B because you now have a memory of it, that's not a 
19 capsaicin and the creation of a chronic condition. 19 sha  -- that's not a sham af idavit. Or if it's I 
20 What they're doing is they're looking 20 got new studies that I've now looked at that I 
21 at the effect of capsacin as well as other 21 didn't know about at the ti  or facts that I 
22 irritants on people who have a chronic cough. And 2  didn't know, those aren't sham. 
23 what's -- what's also significant is they don't go 23 But here his af idavit -- and obviously 
24 beyond a period of time of about 48 hours. 24 I'  going to be asking Mr. Overson this question, 
25 MR. BURKE: Yeah. 25 where in his affidavit does he explain away his 
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very clear and uncontradicted testimony And I
looked at it andhe pretty clearly says no there
were no studies that showed this And he even
says Im not so sure there are studies today
MRBURKE I agree
THE COURT He goes one step farther So
Im trying to figure out what made himchange from
no there really arentany to yes there really
are And the ones hes identifying I Imnot
a scientist andIm not an expert but if I read
it and it doesn say anything about it causing a
chronic condition what youredoing is taking
people with a chronic cough chronic cough caused
by smoking caused by GERD caused by all of these
various things and then comparing them to people
who donthave a chronic cough and seeing what
this TrpV1what those receptors do
MR BURKE What they do
THE COURT What they do
MR BURKE Right
THE COURT Andthey actually genetically
modify the receptors in a couple of these things
to see what can happen So its
MR BURKE YourHonor youreright on
point And those articles really the focus of
13
patients already having chronic disease from
various reasons none ofwhich were exposure to
OC
THE COURT Andthe studies dontgo beyond
that to determine whether the exposure to the
capsacin made their condition more chronic
MR BURKE Right
THE COURT which
MR BURKE They dontdo that
THE COURT As I understand the plaintiffs
position she comes in to the workplace she
already got some compromised lung capacity
probably asthma and her claim is that the
exposures that she endured to capsacin and they
are interesting exposures They go from touching
which is dermal to actual inhalation And the
claim is that that because she was already
compromised triggered a chronic condition
Thatsmy understanding
MR BURKE It is the claim
So lets look at the sham affidavit
issue to use that pejorative term and I agree
that you have really described what it is And
one of the things that it is is you cantallow
somebody to come in after the fact and contradict
12
1 them is all of the TprVi receptors
2 THE COURT Right
3 MR BURKE In fact the only way that the
4 capsacin comes into play is they actually sue that
5 as an experimental agent because they already know
6 that that causes that receptor to be sensitive
7 So they take these people who are patients they
8 study their own chronic disease for the purpose of
9 developing a therapeutic agent that could help
1 o them
11 And so what do we do wellpurposely
12 expose them to capsacin and that will allow an
13 enhanced cough response and therefore we can
14 study the TrpVi Thatsall that does And a
15 right those are not studies of longterm chronic
16 disease
17 THE COURT Well creation of longterm
18 chronic disease
19 MR BURKE Imsorry
20 THE COURT Its not these arentstudies
21 designed to determine whether capsacin
22 MR BURKE Right
23 THE COURT causes chronic longterm
24 disease
25 MR BURKE All of these people came in as
14
1 specific testimony given before unless you explain
2 it
3 And the point is the affidavit the
4 second affidavit does nothing to explain the
5 deposition testimony All it does is attempt to
6 explain the first affidavit In other words
7 counsel and Ms Major went back and reviewed what
8 the court said in the last hearing of what was
9 defective about the first affidavit and theytried
10 to fix it and so the second affidavit tries to
11 explain whythe first affidavit meant to say more
12 But what it doesn do is explain what
13 happened in the deposition so let me focus on the
14 deposition I will point to you what I think are
15 the clear contradictions
16 And just for ease of reference I have
17 a copy here of a very small part of the deposition
18 that has these in it
19 THE COURT Id love it I tore apart
2o and I have to admit I tore apart all of the files
21 and Ididntwant to try to put them back together
22 because my clerk gets mad at me because Im always
23 losing things So this is mucheasier Thank
24 you
25 MR BURKE Let me trade and give you this
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1 very clear and uncontradicted testimony? And I 
2 l oked at it and he pretty clearly sa s, no, there 
3 were no studies that showed this. And he even 
4 says I'm not so sure there are studies today. 
5 R. BURKE: I agree. 
6 THE C RT: He goes one step farther. So 
7 I'm trying to figure out what ~ade him change from 
8 no, there really aren't any, to yes, there really 
9 are. And the ones he's identifying, I -- I'm not 
10 a scientist and I'm not an expert, but if! read 
11 it and it doesn't say anything about it causing a 
12 chronic condition, what you're doing is taking 
13 people with a chronic cough, chronic cough caused 
14 by smoking, caused by GERD, caused by all of these 
15 various things and then co paring the  to people 
16 ho don't have a chronic cough and seeing hat 
17 this TrpVl, what those receptors do. 
18 . : hat they do. 
19 THE COURT: hat they do. 
20 R. B R E: Right. 
21 E :  t e  act all  e eticall  
22 modify the receptors in a couple of these things 
23 to see what can happen. So it's --
24 R. BURKE: Your Honor, you're right on 
 point. And those articles, really the focus of 
 
1 patients already having chronic disease from 
2 various reasons, none of hich ere exposure to 
3 .C. 
 T E T: nd the studies don't go beyond 
5 that to determine whether the exposure to the 
6 capsacin made their condition more chronic --
7 MR. BURKE: Right. 
8  URT: --  --
9 MR. BURKE: They don't do that. 
10 T E C RT: s I understand the plaintiffs 
11 position, she comes in to the workplace, she's 
12 already got some compromised lung capacity, 
13 probably asthma, and her claim is that the 
14 exposures that she endured to capsacin -- and they 
15 are interesting exposures. They go from touching, 
16 which is dermal, to actual inhalation. And the 
17 claim is that that, because she was already 
18 compromised, triggered a chronic condition. 
19 That's my understanding. 
20 R. BURKE: It is the claim. 
21 So let's look at the sha  affi avit 
22 issue, to use that pejorative term, and I agree 
23 that you have really described what it is. And 
24 one of the things that it is is you can't allow 
25 somebody to come in after the fact and contradict 
CVPI1003515 
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1 them is all of the Tpr l rece t s. 
2 THE C : Right. 
3 MR. BUR E: In fact, the only way that the 
4 capsacin comes into play is they actua ly sue that 
5 as an experimental agent because they already kno  
6 that that causes that receptor to be se . 
7 So they take these people who are patie , they 
8 study their o n chronic disease for the purpose f 
9 de eloping a therape tic agent that c uld help 
10 th . 
1 nd s  hat o e , 'll rpos y 
12 expose the  to capsacin a d that ll a lo  an 
13 a ced  re , , th , e can 
14 t  the r l. t's ll that . nd a 
15 , those re ot ies of ng-term r ic 
16 disease. 
 E : ll, ti  l g-term 
  . 
 . : I'm rry. 
 E T: t's t -- t ese aren't st ies 
   ne hether  --
 . : t. 
  T: --   -ter  
 is se. 
 . :     e   
14 
 cif   e      
 it. 
   i    f i avit,  
  ff vit,      
 siti  t sti ony. ll it  i  tt t t  
 l i  t  first ffi avit. I  t r r s, 
 l  . j r t   r i  t 
  rt i  i  t   r  f   
9  b t t  f  af i vit an  t y t  
10   i   s  t  sec  af i i  t  t  
11 explain hy the first affidavit eant to say ore. 
12   i  oesn't  i  x l i   
13 h p  i  t  deposition, so l t  f  on t  
14 eposition. I ill point t  y  t I t i  are 
15 t  l r contradictions. 
16  j st for ease of reference, I have 
17 a copy her  of a very small part of th  depositi  
18 t t has these in it. 
19 T  COURT: I'd l  it. I tor  apart--
20 and I have to admit I tore apart al  of the fil s 
21 and I didn't want to try to put the  back together 
22 because y clerk gets mad at me because I'm always 
23 losing things. So this is much easier. Thank 
24 you. 
25 MR. BURKE: Let me trade and give you this 
Kim Madsen, OffiCial Court Reporter, BOise, Idaho 10/31/2011 02:24:27 PM 
VIAJOR VS SECURITY EQUIPMENT CORPORATION Uvri iuvaaio
1615
1 one Ivegot some pen markings on thatone 1 page It starts at line 21 page lol The
2 THE COURT Okay 2 question there is Haveyou in your reviewof
3 MR BURKE All right So the first quote 3 peer reviewed publications seen anyarticles that
4 that we rely upon is on page loo And it starts 4 focus on the duration oftime after exposure to
5 at line 22 andwill just read here the pertinent 5 OC that adverse health effects are customarily
6 parts Question All right Do you recall 6 deemed persistent in humans
7 having in your review of the scientific and 7 Going on to the next page 102
8 medical literature seeing any peer reviewed 8 Answer I would say my general opinion is that
9 publications that specifically address the 9 general conclusion from the literature is that
1 o association betweenOC exposure on the onehand 1o theyr transitory and that would generally mean
11 and longterm chronic adverse health effects on 11 you know more than a minute and probably less
12 the other Answer Well thatswhat I was 12 than a day or two So I think theressubstantial
13 referring to before that I dontthink the 13 evidence that the pain irritation lacrimation
14 studies have been done or published that 14 et cetera that we talked about before is not long
15 definitively well that provide robust data 15 it doesn persist for weeks andmonths
16 about that scenario that exposure NowIm 16 Quote numberthree is the one that
17 talking about exposure in a chronic sense 17 starts at page 153 And I am going to start
18 multiple cases of exposure 18 reading here at line 16 where the questions
19 And you drop down to line 12 And no 19 asked In your opinion as of March of 2oo8 was
20 I dontthinkthat I haventseen studies that 20 there anything definitivelypublished in the
21 made that that come to that conclusion that there 21 peer reviewed scientific and medical literature
22 are adverse effects because I dontthink people 22 that would have put a manufacturer of pepper spray
23 have done the studies Okay Thatsquote 23 products such as SEC on notice that exposure to
24 number one 24 their products by somebody with chronic health
25 Quote No 2 is actually on the same 25 conditions ofMs Major would have caused her an
17 18
1 exacerbated response which would have included 1 three But I am not aware of anything that the
2 ongoing chronic cough for a subsequent period of 2 normal lay person in the industry would say or
3 time 3 would see thatwould necessarily show that
4 Next page Answer starting at line 4 And then he drops down to line eleven
5 six Idontthink that existed then In the 5 on page 155 All I can say is I think there is
6 literature today I dontthink it exists except in 6 an association between the condition she now has
7 the preponderance of evidence and it may be very 7 and that exposure At this point hestalking
8 well that otherpeople dontbelieve that thats 8 about a causation issue
9 the case but I do And so you know blame is 9 Then he goes on and then the
10 for thejury to decide 10 question goes on to say And thatsbased upon
11 And the next question Well do you 11 your manyyears of experience as a toxicologist
12 think people that were trained in toxicology such 12 Answer Yes Question Based upon its
13 as yourselfwould have been able to review the 13 based on your extrapolation of a number of
14 medical literature and the scientific literature 14 scientific papers and your weighing of the
15 that existed on or prior to March of 20o8 and have 15 evidence is that right Answer Yes
16 been able to determine that there would have been 16 Andfinally we have the definitive
17 a life threatening orImsorry 17 question againat page 155 line 20 But you
18 life altering condition that resulted from pepper 18 cantcite me to one specific paper out there that
19 spray exposure 19 existedprior to March of 2oo8 that specifically
20 And the answer is I dontsee 20 would have put lay persons without your background
21 evidence that the normal ways for industrial 21 on notice that the exposure to their product could
22 hygiene officers and personnel to evaluate such 22 have caused longterm health conditions
23 kinds of exposure may or maynot have existed at 23 Answer No
24 that time I haventseen it 24 Your Honor we come at this at
25 Then he drops down to pay 155 line 12s different ways We talked about his expertise
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1 one. I've got some pen markings on that one. 1 page. It starts at line 21, page 101. The 
2 THE C : Okay. 2 question there is, "Have you in your review of 
3 MR BUR E: All right. So the first quote 3 p er-reviewed publications seen any articles that 
4 that we rely upon is on page 100. And it starts 4 focus on the duration of time after exposure to 
5 at line 22 and will just read here the pertinent 5 D.C. that adverse health effects are custo arily 
6 parts. "Question: All right. Do you recall 6 dee ed persistent in hu ans?" 
7 having -- in your review of the scientific and 7 oing n to the next pa , 1 . 
8 edical literature seeing any peer-reviewed 8 "Answe : I would say y general o inion is that 
9 publications that specifically address the 9 general conclusion from the literature is that 
10 association between D.C. exposure on the one hand 10 t ey're transitory and that ould generally , 
11 and long-term chronic adverse health effects on 11 you k , ore than a inute and proba ly less 
12 the other?" "Answer: ell, that's hat I as  than a da  r t .  I think th r 's s sta tial 
13 referring to before, that I don't think the  e idence that the p , irrita , la i , 
 studies have been done or published that  et etera that e talked t re is t lo , 
15 definitively - well, that provide robust data  it esn't ersist f r ee s a  ths." 
 about that scenario, that exposure. o  I'm  uote  three is the  that 
17 talking about exposure in a chronic sense,  starts t age . n    n  t  art 
 multiple cases of exposure."  rea ing ere t line  here  stion's 
19 And you drop down to line 12, "And, no,  , "In  ion   arc   00  as 
20 I d 't t i  that --  n't  ies   there t i  fi itively published i  t  
 made that, that come to that conclusion that there  - ie ed ic   iterature 
22 are adverse effects because I don't think people     t      
23 have done the studies." kay. That's quote  r cts     tice t t re t  
24  .  their products by so ebody ith chronic health 
25 Quote NO.2 is actually on the sa e  tions  .       
 18 
 exacerbated response which would have included  , "But         
2 ongoing chronic cough for a subsequent period of        l    
 ti .      ssaril   at. " 
 Next page. Answer starting at line          
 six, "I don't think that existed then. In the    55. "All    i   t i  t  i  
6 literature today I don't think it exists except in   ssoci ti  t  t  iti  s   s 
7 the preponderance of evidence and it may be very  a  t at exposure." t t is i t e's tal i  
8 well that other people don't believe that that's    ati  ue. 
9 the case, but I do. And so, you know, blame is      - and then the 
10 for the jury to decide."  q sti    t  say, "An  that's   
11 And the next question, "Well, do you  r  rs of experi  a  a t i l ist?" 
12 think people that were trained in toxicology such  "An r: es." "Q ti n:   -- it's 
13 as yourself would have been able to review the 13 s  o  y r extr polati  of a nu r f 
14 edical literature and the scientific literature 14 scientifi  rs an  y r i i  f t  
15 that existed on or prior to March of 2008 and have 15 evi ence; i  t t ri ht?" " n er: Yes." 
16 been able to deter ine that there ould have been 16  fi ll   h  t  definiti  
17 a life threatening" -- or, I'm sorry, 17 questi  again at pag  155, li  20, "But you 
18 "life-altering condition that resulted from pepper 18 can't cit  e to one specific paper out there that 
19 spray exposure?" 19 existed pri r to rc  of 200  t at specificall  
20 And the answer is, "I don't see 20 would have put lay persons without your background 
21 evidence that the nor al ways for industrial 21 on notice that the exposure to their product could 
22 hygiene officers and personnel to evaluate such 22 have caused long-t  health conditi ?" 
23 kinds of exposure mayor may not have existed at 23 " wer: No." 
24 that time. I haven't seen it." 24 Your Honor, we come at this at 
25 Then he drops down to pay 155, line 25 different ways. We talked about his expertise, 
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1 the expertise of toxicologists the just
2 laymen what anybody would know in the industry
















































And in fact he quotes theliterature
and says the literature says just the opposite
that its transitory That is indirect
contradiction of paragraph nine where hes making
this conclusory statement
And I think it is a sham affidavit and
if the court is inclinedto go as far as to say
that it can use that alone as grounds to get rid
of the affidavit or strike those quotes thatare
not proper
But I think in addition to that because
you have conclusory statements and as you
pointed out the very literature that he relies
upon doesn say it So that means there is no
foundational basis
THE COURT Well I think whats interesting
heres heres the concern I have Because
the deposition makes it really clear that his
understanding of the literature and when he
says that he doesntsay theresnot one specific
study He says my understanding ofthe
21
so I I dontknowwhere hes getting that
In fact the more recent literature
he had something in there from 2009 2010
suggests that at this point nobody has a clear
understanding of the roleof this TrpV1 I cant
remember what its called this kind of receptor
because it seems to also have a protective
mechanism as well It plays a lot of roles
And so Imnot sure where he comes from
where he gets his conclusion
MR BURKE Well heres anotherthing along
those same lines and I think youregetting where
I was going here He tends to blur the line
between medical causation on the one hand and
foreseeability of a risk of injury on the other
And I think the way to really best illustrate that
is to look atwhat is his ultimate opinion I
mean its in there now It wasn in the other
one Its in paragraph eleven And this is
interesting andIm going to quote from this Do
you have it there
THE COURT Yeah
MR BURKE Itis reasonable to expect the
multiple TRP channels to act in concert with each
other to result in higher acute respiratory
20
1 literature is that the exposure toOC and
2 capsacinoids by humans are generally deemed to be
3 temporary and reversible and not long term And
4 he says yes And all the way through thatswhat
5 he says I mean youveleft out quite a few of
6 the things
7 MR BURKE I did
8 THE COURT But he makes it clear that
9 everything that he looked at said acute
10 And my concern after looking at these
11 studies is that he has a I donthave any
12 problem with an expert having a conclusion where
13 he gives the foundation for the conclusion and
14 says based on the following thatswhere I made
15 these determinations But my concern here is when
16 he has this list those things like I said they
17 seem because I went through all of the stuff
18 that he gave us all ofthe literature and he
19 picked out the ones where the word chronic
20 appears
21 And I it bothered me because when
22 you go back and looked at it the word chronic
23 was not was not related to the creation of a
24 chronic condition by the exposure to capsacin It
25 was a completely different use of the word And
22
1 responses to a multitudeof respiratory irritants
2 particularly people with increased sensitivity to
3 pepper sprays
4 And then Im skipping ahead a little
5 bit Once the TRP receptor population is
6 regulated and hypersensitivity occurs the
7 individual will thereafter experience acute
8 respiratory responses to respiratory irritants at
9 exposures thatwould not evoke a major response in
10 persons who have not been similarly sensitized
11 The hypersensitivity of affected individuals to a
12 whole array of respiratory irritants would be
13 expected to elicit respiratory symptoms that are
14 for all intents and purposes chronic due to the
15 frequency of recurrence of acute respiratory
16 responses to irritants typically encountered in
17 everyday life
18 Well Your Honor this is akin to a
19 medical opinion and hesnot a medical doctor so
20 Im not sure hes even qualified to give this
21 opinion but even if he is this is not an opinion
22 on foreseeable risk
23 And whatsmore significant is none of
24 the articles
25 THE COURT Well its not
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1 the expertise of toxicologists, the -- just 1 literature is that the e posure to .C. and 
2 lay e , hat anybody ould kno  in the industry. 2 ca s noids by hu ans are  dee ed to e 
3 He says it's not out there. They haven't done the 3 te porary a d re ersible and t long ter . nd 
4 st e . 4 he says yes. nd all the ay through that's hat 
5 n , in fact, he quotes the literature 5 e sa s. I ea , ou've left out quite a fe  of 
6 and says the literature says just the opposite, 6 the t in . 
7 that it's transitory. That is in direct 7 . : I i . 
a contradiction of paragraph nine where he's aking 8 E T: t e es it e  that 
9 this conclusory state ent. 9 t ing that he looked t i  t . 
 nd I think it is  s a  a fida it   nd  cern a ter loo ing t t es  
 if the court is inclined to go as far as to say  st ies is t at  as  -- I 't a e a  
 that, it can use that alone as grOlIDds to get rid  r le  ith  ert i   l si  here 
3 of the affidavit or strike those quotes that are  he gives the foundation for the conclusion and 
 not proper.  sa s based  the f ll i , t at's here I a e 
5 ut  t in  in tion t  t at a se  es  . t   re is  
6 you have conclusory statements, and, as you  e as this lis , se , ike I i ,  
 pointed out, the very literature that he relies   --   ent    e  
8 upon doesn't say it. So that eans there is no  t t e a e s, all f t e literat re, a  e 
  i .  picked out the ones here the ord "chronic" 
 T E C RT: ell, I think hat's interesting  rs. 
 -- re's -- re's t e r  I . ecause   I -- it t ere  e eca se e  
 the deposition makes it really clear that his  you go back and looked at it, the ord "chronic" 
 understanding of the literature --     as t -- s t r l t  t  t e r ti  f  
 says that, he doesn't say there's not one specific   ion     ci .  
 study. He says, my understanding of the     fere    e   
 22 
   -- I don't kno  here he's getting that.  res ses t  a ltit e f res irat r  irrita ts, 
 I  fact, t e re rece t literature --  rti l rl  l  it  i reas  nsiti it  t  
 he had so ething in there fro  2009, 2010 --  pepper sprays." 
 suggests that at this point nobody has a clear    'm    le 
 understanding of the role ofthis rp 1--  n't  it. "Once t   r t r l ti  is 
6   t's l  --      l t   nsiti it  rs, t  
7 because it seems to also have a protective  id  ill    
a echanis  as well. It plays a lot of roles. a respiratory responses t  respiratory irritants at 
   'm        exposures that ould not evoke a ajor response in 
10 -- where he gets his conclusion.  persons ho have not been si ilarly sensitized. 
 . E: ell, here's another thing along   rsensitivit  f ff t  i i i ls t   
 those sa e lines and I think you're getting where  hole array of respiratory irritants ould be 
 I was going here. He tends to blur the line  expected to elicit respiratory sy pto s that are 
 t  i l s ti   t      f r all i te ts  r ses c r ic e t  t e 
 foreseeability of a risk of injury on the other.  f cy f r  f c t  pir t r  
 And I think the way to really best illustrate that  responses to irritants typically encountered in 
 is to look at hat is his ulti ate opinion. I 17 r  life." 
 ean, it's in there now. It asn't in the other 1a ell, r nor, t i  i  aki  t  a 
19 one. It's in paragraph eleven. And this is 19 edical opinion and he's not a edical doctor, so 
 interesting and I'm going to quote from this. Do 20 'm t  he's v  ali  t  gi  t i  
 you have it there? 21 opinion, but even if he is, this is not an opinion 
  URT: ah. 22  f eable risk. 
23 R. BURKE: "It is reasonable to expect the 23  hat's or  signifi t i   of 
24 ultiple TRP channels to act in concert with each 24 t  arti l s --
5 ot r t  r sult i  hi r c t  respiratory 25  URT: ell, it's not just t at. e's 
. , 
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not saying that the exposure to capsacin is the
cause of this All hes saying is that once a
person has become hypersensitive and they can be
and by by and as I understand the
plaintiff in this case she came in
hypersensitive Hes not sayingthat capsacin
itself causes the hypersensitivity but its once
you are that way for example once yourean
asthmatic you are more you are going to be
more susceptible to cigarette smoke setting off an
acute response
MR BURKE Correct
THE COURT And all hes really saying is
that once you are in that situation onceyoure
an asthmatic for example or have COPD your
exposure to irritants is chronic you have a
chronic response to the exposure to irritants
Thatsall hessaying
MR BURKE I agree but hereswhatseven
more interesting Ifyou take this opinion that
hes come to andyou go back and look at all of
those articles he cited and you read them not one
of those authors came to that exact same opinion
And thats whatIm saying here you
know at the risk of overexaggeration he may be
25
causation on the one hand and foreseeability of
injury on the other
Imprepared to address the other
issues if you want to go on but if you
THE COURT No because I think once we
decide the issue of whether this affidavit is
is to be struck then it has a real sort of
cascading impact on the rest of the motions
MR BURKE Yeah at that point there really
isntmuch left after this SoIllreserve
argument on the other issues if we need to later
on
THE COURT Mr Overson you can see wer
sort of you got a
MR OVERSON I got an uphill battle
THE COURT Well and I you know I
to be honest with you I would like nothing better
to be in aposition where there reallywas a
dispute of fact thatsmaterial to the issue
because its wer not at the causation issue
at this point I tend we really are at that
issue ofwhether the companyshould have known
MR OVERSON Uhhuh
THE COURT that this was a risk And I
point out that that even in his affidavit he
VVr IVVJCIIP
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1 the only one in the world thatsever come to this
2 opinion
3 THE COURT Well Im
4 MR BURKE at least in writing And Im
5 not saying its necessarily wrong or right The
6 point is that a medical causation issue and
7 thats not relevant to these motions here today
8 Whats relevant is what was known or what should
9 have been known by SEC prior to 2oo8 and that has
1 o nothing to dowith that issue
11 And so to the extent that he expounds
12 on that I think if we were sitting in a courtroom
13 today andwe had a jury there and he was trying to
14 explain his views as what caused this that
15 literature may actuallybe used to help support an
16 opinion on causation but its not good enough to
17 support an opinion on risk of foreseeable disease
18 in this case the chronic condition that Ms Major
19 complains of
20 So I guess for all ofthose reasons
21 Your Honor we say this affidavit has to be
22 rejected as either being sham having conclusory
23 statements having a lack of complete foundation
24 for any of the conclusory statements and
25 absolutely confusing the issues of medical
26
1 he says things and its it wasn because
2 Imconfused by his affidavit Thatsnot what
3 the problem was
4 But for example in paragraph 12 he
5 goes he goes on and counsel didnttalk
6 about this but he says this The pre2008
7 articles previously identified upon which I base
8 my conclusion that the MK Fogger product posed a
9 risk of respiratory injury such as experienced are
10 as follows And counsel for SEC has apoint it
11 appears that hesmixing his opinion that this
12 caused her chronic condition with whether the
13 literature at the time would have put the company
14 on notice of this potential cause And I think
15 thatstheproblem I have with his entire
16 affidavit is there does seem to be that failure
17 to see that hes got that one role And hes got
18 really two roles here
19 And I read his expert report His
20 expert report is really just directed at the
21 causation issue and really theresnothing in
22 there that really goes into what the state of the
23 literature was
24 And so thats where Ithink the problem
25 here is with Dr Yost He doesnthave a clear
103120 102247PM Kim Madsen Official Court Reporter Boise Ioano
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 not saying that the exposure to capsacin is the 1 the ly ne in t e rld t at's er  t  t is 
 cause of this. ll he's saying is that once a  o inion --
 person as beco e h perse sitive a d the  can e  E : ll, 'm --
4 -- and by -- by -- d   e sta d the 4 . : -- t least in . nd 'm 
5 plaintiff in this case, she came in  not saying it's necessarily rong or right. he 
6 ersensiti e. e's t sa i  that ca saci   int is t at's a e ical ca sati  iss e a  
7 itself causes the hypersensitivity, but it's once  t at's  e a   es  tions ere . 
8 you are that way, for example, once you're an  at's r l t is t as  r t l  
9 asth atic, you are ore -- you are going to be  a e e     ri r to 00   t t  
 ore suscepible to cigarette s oke setting off an 0 nothing to do ith that issue. 
 acute response.      tent  e  
 . :   n t t, I t in  if  ere itting i   rtroo  
 THE COURT: And all he's really saying is  today and e had a jury there and he as trying to 
 that once you are in that situation, once you're 14 explain his vie s as hat caused this, that 
 an asth atic, for exa ple, or have , your  literature  t l      t  
 exposure to irritants is chronic -- you have a  i i   s ti , t it's t   t  
 chronic response to the exposure to irritants.  support an opinion on risk of foreseeable disease, 
 hat's all he's saying.  in is      . ajor 
 R. BURKE: I agree, but here's what's even  c lains f. 
 ore interesting. If you take this opinion that   I ss f r ll f t se r sons, 
 he's come to and you go back and look at all of  our onor, e say this affidavit has to be 
 those articles he cited and you read the , not one  rejected as either being sha , having conclusory 
 of those authors ca e to that exact sa e opinion.  t t nts, i   l  f l t  f ti  
 And that's what I'm saying here, you  for any of the conclusory state ents and 
 kno , at the risk of overexaggeration, he ay be  a s l tel  c f si  t e iss es f e ical 
  
 causation on the one hand and foreseeability of  --   t i   it's -- t sn't  
 injury on the other.  I'm confused by his affidavit. That's not hat 
 I'm prepared to address the other  t  r le  s. 
 issues if you ant to go on, but if you --  t, f r ple, i  r r  ,  
  T: o, because I think once e  goes -- he goes on -- d, l idn't t l  
  e    s f   --  t t is -- t e sa s t is, "The re-2008 
 is t   str k, t  it s  r l --  f  rti l s r i sl  i tifie   i  I s  
 cascading impact on the rest of the motions.  y conclusion that the  Fogger product posed a 
 R. BURKE: Yeah, at that point there really  ris  f r s ir t r  i j r  s  s ri  r  
 n't    i .  'll    f llows."  l f r    i t; it 
11 argu ent on the other issues if we need to later  appears that he's ixing his opinion that this 
 .    r i  i     
 THE COURT: Mr. Overson, you can see we're  liter t r  t t  ti  l   t t   
  f -- you got a --   ti  f t is t ti l se.  I t i  
 . ON: I got an uphill battle.  that's the proble  I have ith his entire 
16  RT: ll,  I -- you know, I --  ff vit,  t    t   t t f i  
 to be honest ith you, I ould like nothing better  t  see t at e's t t at e r le.  e's t 
 to be in a position where there really was a  really t o roles here. 
 dispute of fact that's material to the issue  nd I read his expert report. is 
  t's -- e're  t  t  i   expert report is really just directed at the 
21 at this point. I tend -- e really are at that  ca sati  iss e a  reall  there's t i  i  
 issue of whether the company should have known --  t r  t t r ally s i t  t t  st t  f t  
 . ON: -h .  l  as. 
  URT: -- t    ri k.    nd so that's here I think the proble  
 point out that -- t at e e  i  is affi avit, e 25  i  i  r. st.  oesn't h  a cl r 
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1 statement that in fact the literature and 1 THE COURT Except where hes being asked
2 really if you go back to his affidavit Imean 2 about I mean they do followup with the lay
3 his deposition hes talking about the totality of 3 person And I agree with you that you got to look
4 the literature the totality of the studies 4 at it from what what was the technical
5 Thatsreally the deposition is in opposite to 5 knowledge at thetime because the company does
6 what hestrying to say here and thatsI think 6 have a responsibility to be aware
7 the major problem thatyouvegot 7 MROVERSON Right
8 MR OVERSON Okay Lets let me back 8 THE COURT The problem though hes asked
9 up 9 whether there were any studies Hes not saying
10 THE COURT Okay 10 studies for lay people Hes saying that as far
11 MR OVERSON Okay One is I think the 11 as he knows therewere no studies that the
12 standard thatsbeing applied the knewor should 12 general view was that they are shortterm effects
13 have known is the wrong standard The standard 13 andacute
14 is not whether your typical SEC manufacturer would 14 And actually the studies that he cites
15 have been able to grab that a study off the 15 I could go through a whole bunch of these where
16 shelf that said if you expose people to capsacin 16 they actually say the same thing
17 theresa risk they might end up with chronic 17 MROVERSON Let if we couldmaybe
18 respiratory illness That is not the standard 18 THE COURT Yeah
19 We imply in product liability cases the standard 19 MROVERSON compartmentalize this a
20 of knowledge that the expert would have in the 20 little bit
21 scientific area the relevant scientific area 21 THE COURT Okay
22 that is and the questions that were put to Dr 22 MR OVERSON When I read his deposition
23 Yost in his deposition many of them were framed 23 okay hereswhat I read This is my
24 in terms of the lay person or a manufacturer of 24 interpretation of what hessaying is he is asked
25 OC spray products 25 are there do you know of any studies where
29 30
1 human beings are exposed to capsacin and the 1 THE COURT peer reviewed literature is
2 result is that the persons in the study endup 2 transitory and the studies thathe cited to say
3 with chronic respiratory illness and he says no 3 that
4 THE COURT Well he doesntactually 4 MROVERSON Okay Lets go to thatpoint
5 thats notwhat the questionsactually are 5 THE COURT Okay
6 Theyr really looking he says for example 6 MROVERSON What he what I hear him
7 Question Have you in your reviewof 7 saying is that generally that is the rule We
8 peer reviewed publications 8 have people exposed toOC spray day in and day
9 MR OVERSON Im sorry Where are you 9 out in this country and itsused a lot And for
10 THE COURT Imsorry Page ioi starting at 10 the vast majority of individuals it doesn pose a
11 line 21 Seen any articles that focus on the 11 problem particularly when itsused out on the
12 duration of time after exposure toOCthat 12 street because those I mean how many times
13 adverse health effects are customarily deemed 13 does your average person have exposure to OC
14 persistent in humans 14 spray
15 And then he goes on in the next thing 15 Thatsnot whatwer talking about
16 and he says Iwould say my general opinion is 16 here though Wer talking about somebody who
17 that the general conclusion from literature is 17 one did havesome level of sensitization purely
18 that they are transitory 18 because she came into the work forcewith a
19 MR OVERSON Right 19 respiratory illness of some level but she could
20 THE COURT And he goes on from that 20 work Okay She wasntlike she is today Then
21 MROVERSON Uhhuh 21 she has some level of chronic exposure while she
22 THE COURT Okay Thatsnot hesnot 22 working there
23 saying that a lay person would say it was 23 THE COURT Its a pretty minimal level
24 transitory Hessaying 24 MR OVERSON Okay
25 MR OVERSON Absolutely 125 THE COURT Ive read
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 state ent that, in fact, the literature --   E :  here e's   
 really if you go back to his affidavit -- I e  2 about -- I , t   ll  p ith t e la  
 his deposition, he's talking about the totality of  ers . n  I a ree ith ou that ou t to l  
4 the iterature -- the totality of the studies.  at it fro   -- at as the c  
5 hat's really -- the deposition is in opposite to  ledge t t  time ecause the  es 
6 hat he's trying to say here and that's I think 6 a e a res si ilit  to e a are. 
7 the ajor problem that you've got.  . : t. 
8 . : . t's --  e   E : he r l , t , 's  
9 up.  hether t ere ere  . e's t  
 T E C RT: kay.  st ies for la  l . e's s i  t t  far 
 . : a . e is I t i  t e    s  ere  , at e 
 standard that's being applied, the kne  or should  r l ie   t at t  re rt-ter  ff t  
 have kno n, is the rong standard. he standard   t . 
 is not whether your typical SEC anufacturer would   act all  the st ies t at e cites, 
 have been able to grab that -- a study off the  I l   t r   le ch f t es  re 
 shelf that said if you expose people to capsacin,  t e  l     i . 
 there's a risk they might end up with chronic 17 . : et -- f e  e --
 respiratory illness. That is not the standard.   : h. 
 e i ply in product liability cases the standard  . : -- t t lize t i   
 of knowledge that the expert would have in the 20 little it. 
 i tific r , t e rele a t i tifi  r ,  U T: y. 
  s -- and the questions that were put to Dr.  . :     siti , 
 ost in his deposition, any of the  ere fra ed  ay, ere's at I read. is is  
 in ter s of the lay person or a anufacturer of  interpretation of hat he's saying, is he is asked 
 O.C. spray products.   t  --      es re 
  
 hu an beings are exposed to capsacin and the   T: -- peer-revie ed literature is 
 result is that the persons in the study end up  tr sit r   t  st i s t t  it  t  s  
 with chronic respiratory illness and he says no.  t at. 
 THE COURT: ell, he doesn't actually--  . : y. et's   t i t. 
 that's not hat the questions actually are.   T: ay. 
 They're really looking -- he says, for exa ple,  . :   --    i  
 "Question: Have you in your review of  saying is that generally that is the rule. e 
 peer-revie ed publications" --  a e e le e se  t  .C. s ra  a  i  a  a  
 . E S : I'm sorry. here are you?     tr   t's   t.   
  T: I'm sorry. Page 101 starting at  the vast ajority of individuals it doesn't pose a 
 line 21. "Seen any articles that focus on the  r le  artic larl  e  it's se  t  t e 
 duration oftime after exposure to O.C. that    t  -- I an,   ti  
 adverse health effects are custo arily dee ed  does your average person have exposure to .C. 
 persistent in humans?"  spray. 
 nd then he goes on in the next thing  hat's t at e're tal i  a t 
 and he says, "I ould say y general opinion is  re, t ugh. e're t l i  t s  o, 
17 that the general conclusion from literature is  e, i    l l  sensiti ti  l  
 that they are transitory."      t  r  f    
 R. ERS : Right.  res irat r  illness f s e level, t s e c ul  
 T E RT: nd he goes on fro  that.  ork. kay. She asn't like she is today. Then 
 . : -h .     l l of chr ni   i  he's 
22  URT: kay. hat's t -- e's  22 orking there. 
 saying that a lay person would say it was 23  T: It's  r tt  i i l l vel. 
 transitory. He's saying -- 24 . ON: kay. 
 R. ERS : bsolutely. 25  URT: 've  --
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1 MR OVERSON Okay 1 before magnitude increases
2 THE COURT Ive read the stuff I mean 2 Now my point of walking through this
3 its 3 whole thing is that Dr Yost is saying not that
4 MR OVERSON But thats a factual 4 youre generally generally yes its acute
5 conclusion for the jury 5 It will go away andyoullbe fine But theresa
6 THE COURT I understand that but Im 6 segment of the population thatOCspray poses a
7 looking at her own statements 7 more significant risk of serious chronic injury
8 MR OVERSON Right 8 and he explains in his affidavit the mechanism by
9 THE COURT Theres 9 which that take place
10 MROVERSON But then 10 And the oddity about capsacin is its
11 THE COURT 15 seconds here a few places 11 is it you put it on a chart and people who
12 where she touching it Most of the things she 12 are exposed to it chronically some of them are
13 in classrooms So its not a huge amount and its 13 desensitized while others are hypersensitized
14 not chronic 14 And its not known what factors put you in the
15 MR OVERSON That that overlooks the 15 desensitization crowd and which ones put you in
16 clothing issue though and the one study that 16 the hypersensitive crowd But what is known is
17 defense counsel asked Dr Yost about did indicate 17 the exposure chronic exposure and even acute
18 that you know this stuffstays on your clothing 18 high levels of overexposure would upregulate the
19 But that aside thenwe have this very 19 TrpV1 receptors which at thatpoint once those
20 different type of exposure that takes place during 20 are upregulated and populations within your body
21 the training Wer talking about microsized 21 are higher than they were before youregoing to
22 particulate a mist if you will Now wer 22 be more susceptible to other irritant exposures
23 getting deeper into the lungs Okay 23 and youregoing to have repeated chronic
24 From that point on she is experiencing 24 responses I mean excuse me repeated acute
25 a significantly different respiratory illness than 25 responses
33 34
1 For instance if ifIm allergic to 1 different But he doesntdo that In fact this
2 peanuts and I eat a bag of peanuts Imgoing to 2 second affidavit is more about him trying to
3 have an acute response I think that thats 3 explain to me why Ididntunderstand his first
4 common sense Okay But ifIm allergic to 4 affidavit And thatsreally because he says
5 something that I run into every single day Im 5 over and over again I was informed that it was
6 going to have repeated acute responses that are 6 perceived that
7 going to look like and forall intents and 7 MROVERSON I think the acknowledgment is
8 purposes just like he said a chronic condition 8 that it was just poorly drafted and that falls on
9 And you know so thats what I hear him saying in 9 us not you
10 his affidavit 10 THE COURT I understand no I understand
11 Now back to the deposition all of 11 that The problem is hesspending time
12 those questions Mr Burke put the word in 12 explaining his last affidavit He hasnt
13 specifically over and over again and then turns to 13 explained why thataffidavit this now affidavit
14 generally He never asks him about the bodyof 14 is inconsistent with his deposition I mean if
15 literature in terms of at the time did it was 15 he had done exactly what youre doing see
16 there an understanding of the mechanism by which 16 youreexplaining his affidavits but hes not
17 this could happen in a select group of people 17 MR OVERSON And see perhaps that a
18 THE COURT Well let me ask you a question 18 requirement that should have I mean maybe that
19 Why in hissecond affidavit doesn he explain why 19 needs to be in there okay and obviously the
20 his testimony in his deposition has changed 20 court believes thatstrue But
21 Because it has changed And if he had come 21 THE COURT Thatswhat the law says
22 through in his second it has Imsorry it 22 MROVERSON Well letsback up because
23 has Ifhe if he would explain that and say 23 were on a motion for summaryjudgment
24 well heres the problem He was asking me this 24 THE COURT No right nowwer on motion to
25 this is what Iwas answering Then thats 125 strike
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1 M . O ERS : Okay.  before, magnitude increas s. 
2 THE : -- I've read the st ff. I e , 2 'No , y p int f alking through this 
3 i 's -- 3 hole thing is that . ost is s ing not that 
4 . E : But t t's a factual 4 y u're ge r lly -- rall , e , it's a t . 
5 conclusion for the jury.  It ill  a a  a  y u'll e fin . ut t re's a 
6 THE : I understand th , t I'm  se ent of the po lation that .C. a  oses a 
7 looking at her o n state ents.  ore significant risk f ious c ronic injury 
8 . E S : ight.  a d he lains in his id t the e a is   
9 HE : r 's--  hich t at ta e pla . 
10 . E : t then--  nd the o ity ut  is i 's 
11 HE : -- 15 sec s ere, a fe  laces 11 -- is it -- ou t it   art  le h  
 where she's touching it. ost of the things she's  are posed to t i ll , s e    
 in classroo s. So it's not a huge a ount and it's  des tized ile thers re it . 
 not c .  nd it's t no n hat a tors ut  in e 
 . : hat -- t at e looks the  i on d  ich s t   
 clothing issue, though, and the one study that  the e s e . t at is n s 
 defense s   . ost ut  icate  the posure -- ronic s re  e  t  
 that, you kno , this stuff stays on your clothing.  igh l l  f ere pos re l  r l t  t e 
 ut that aside, then e have this very  rpVl t rs, c  t    se 
20 different t pe f e osure t at ta es lace ring   ate   lations t i    
 the training. We're talking about micro-sized  r  i r t  t  r  f r , ou're i  t  
 particulate, a mist, if you will. Nowwe're  e e ti le t  t  i ita t  
 getting deeper into the lungs. Okay.  and you're going to have repeated chronic 
 Fro  that point on she is experiencing  r s s s --  n, s  ,   
 a significantly different respiratory illness than  s. 
  
 r i st , if -- if I'm ll r i  t   t.   esn't  t.  t,  
 peanuts and I eat a bag of peanuts, I'm going to        in   
 have a  acute response. I think t at -- at's  l i  t     idn't t  i  i t 
 co on sense. Okay. But if I'm allergic to 4 f vit.  at's l  --    
 so ething that I run into every single day, I'm  r  r i  I  i f r  t t it  
 going to have repeated acute responses that are   t--
 going to look like and for all intents and  . :      
 purposes, just like he said, a chronic condition.  t t it s j st rl  r ft   t t f lls  
 And, you know, so that's what I hear him saying in  , t u. 
  ff vit.   T:   -- ,   
11 , ac  t  t e e siti , all f  t.   i  e's pendi   
 those questions Mr. Burke put the word in  l i i  i  l t ffi avit.  asn't 
 specifically over and over again and then turns to  explained hy t at affidavit - t i   ffi it 
 generally. He never asks hi  about the body of   i i    positi n. I an, if 
 lite t  i  t   t t  ti  i  it --      ctl   ou're i  -- ee, 
 there an understanding of the mechanism by which  ou're x l i i  is ffi avits, t e's ot. 
 this could happen in a select group of people.  R. ON: , ee, r  that's  
 THE COURT: ell, let e ask you a question. 1  i  t t shoul   -- I an,  t t 
 hy in his second affidavit doesn't he explain why 1  ee s t  e i  t ere, kay, a  bvi sly t e 
 his testimony in his deposition has changed? 20 rt l  that's tr e. --
 Because it has changed. nd if he had co e 21  URT: hat's  t  l  says. 
 through in his second -- it has. I'm sorry, it 22 R. ON: ell, let's  u  b  
23 s. If  -- if he ould explain that and say, 23 e're o  a ti  f r su ary j ent. 
24 well, here's the problem. He was asking me this, 24 T  URT: o, ri t n  e're o  ti  t  
25 this is hat I as answering. hen that's 25 strike. 
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MR OVERSON Well thatstrue But even
when youreon motion to strike when yourein
context of the motion for summary judgment which
we are because its an affidavit filed in support
of a motion to reconsider this court grant of
summaryjudgment you have to look at the facts
and the record in a light most favorable to the
non moving party which would be us
THE COURT I understand that but that
doesntmean that I overlook the fact that your
affidavit is inconsistent with the deposition
MROVERSON Well and thatswhatIve
been trying to explain is my view reading the two
documents is theyr not And what I hear the
court saying is that there should have been
inclusion in the affidavit as to any potential
conflict between the affidavit and what he said in
his deposition It should have been explained in
his affidavit
And let me just stop here because if
this is the case I easily could have asked Dr
Yost about that and included it in his affidavit
I didntsee that as the issue particularly given
the statements of this court at the last hearing
with regard to the hesitancy the court should have
37
theyr two separate concepts
MR OVERSON I agree
THE COURT This isnta this isnta
well because itsa products liability case you
have to show that they had it was foreseeable
to them that this injury could occur And you
have to do that both for just the straight
products liability butalso for the failure to
warn Itsessential to both cases
MR OVERSON Iunderstand that And I
think that is what hessaying in paragraph nine
that Mr Burke pointed to and read for the court
is he is addressing that issue I think he
does talk about the causation in the deposition
Okay Myreading of his affidavit is he is
focused on the relevant issue Okay He may talk
about yes this is causal but the focus of the
affidavit is that heresthe mechanism bywhich
this type of injury was knownto be a risk due to
exposure to capsacin forcertain populations
Okay Andheres how the mechanism works and here
is some of the literature in a larger body of
literature And based on my education training
and experience this is what was known at the time
I fully agree that they are two separate issues
36
1 when deciding the issue of sham affidavit which I
2 agree is a totally terrible name for the doctrine
3 And Iwould ask in the interest of
4 justice Your Honor let me go back to Dr Yost
5 let me have an opportunity to see if he can tell
6 me what he meant what he and resolve any
7 conflict between his deposition and his affidavit
8 and submit a third affidavit
9 And I know you youre probably
10 reticent because we are bumping up against trial
11 But my client is seriously injured and she has a
12 right to recovery Iwould throwmyself on the
13 you know on the court and ask in the interest of
14 justice that we be given that opportunity before
15 you ruleon the motion for summary judgment and
16 motion for reconsideration
17 THE COURT Well do you understand my
18 what
19 MROVERSON I do
20 THE COURT whatIm struggling with is
21 and even in this affidavit I tend to agree
22 with opposing counsel that he he seems to mix
23 up the concept of causation medical causation
24 with the concept of what was the state of the
25 literature at the time that she was exposed and
38
1 THE COURT Can you explain to me his
2 statements at page 153 Look at those
3 MR OVERSON Okay Let me just back up and
4 read a littlebit here first
5 THE COURT Okay
6 MR OVERSON AndImlooking at 153 and I
7 see his statements But ifwe go to 152 the
8 question is causal Mr Burke is asking him a
9 question about causation with regard to Ms Major
1 o specifically and then Mr Burke follows up with
11 the questionon 153 And thatsbased on medical
12 records Yes And is there anything else
13 that you base that opinion on Well a little
14 bit on her deposition and what she describes as
15 you know her condition before and after
16 THE COURT Well with due respect
17 counsel
18 MROVERSON MaybeIm missing your
19 question
20 THE COURT Okay The question at the
21 bottom of page 153 has nothing to do with
22 causation What he says
23 MROVERSON Oh Imsorry Thatswhat
24 THE COURT I apologize then
25 MR OVERSON Okay
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1  : ell, t at's tr e. t e en 
2 hen you're on otion to strike hen you're in 
3 context of the otion for su ary judg ent, hich 
4 we are, because it's an affidavit filed in support 
5 f  tion to re sider t is urt's ra t f 
6 s  jud t, ou a e t  loo  t the a ts 
7 a  the rec r  in a light ost fa ora le to the 
8 - ing rt , hich ld e s. 
9 E :  nderstand t t, t t at 
 doesn't ean that I overlook the fact that your 
 ffid it is inconsistent ith the siti . 
  : ell--  t at's  've 
 been trying to explain, is my view reading the two 
 cu ents is t ey're t. nd at I ear t e 
 rt i  is that t  l  e een 
 inclusion i  t e affida it as t  a  te tial 
 ict e  t e ida it      
 his deposition. It should have been explained in 
 s it. 
0 
 
 l t  j st st  r  s  if 
this is the case, I easily could have asked r. 
2 s     lude  t n is vit. 
 I didn't see that as the issue particularly given 
 
 
the state ents of this court at the last hearing 
it  re ar  t  t e esita c  t e c rt s l  a e 
 
 they're t o separate concepts. 
 . E S : I agree. 
  RT: s n't  --  n't  --
 well, because it's a products liability case, you 
 have to sho  that they had --   res  
 to the  that this injury could occur. nd you 
 have to do that both for just the straight 
8 products liability, but also for the failure to 
 r . t's senti l   . 
  N:   at.   
 think that is hat he's saying in paragraph nine 
 that r. urke pointed to and read for the court, 
 is he is addressing that issue. I think --  
 does talk about the causation in the deposition. 
 kay. y reading of his affidavit is he is 
 focused on the relevant issue. kay. e ay talk 
 about yes, this is causal, but the focus of the 
 affidavit is that here's the echanis  by hich 
 this type of injury was known to be a risk due to 
 exposure to capsacin for certain populations. 
 kay. nd here's ho  the echanis  orks and here 
 is so e of the literature in a larger body of 
 literature. And based on my education, training 
 and experience this is what was known at the time. 





e  n  e issue   ,   
re  is  t t ll  t rrible a e for the tri . 
 n  I o ld  i  the interest  
 justice, our onor, let e go back to r. ost, 
let e a e a  rt it  t  see if e ca  tell 
e   t,   --  re e  
ict ee  s ion d  ida it 





 nd I   -- u're l  
 ice t a se  e    l. 
11 ut  lie t is s ri sl  i jure   s e s  
 right t  r ry. I l  t r  lf  t e --
  ,   rt   i  e te   
 justice that e e i e  t t rt it  f re 
  l   t  ti    j t  
 tion f r r si rati n. 
 E T: l ,    --
 at--
  :  o. 
 E T: ---  'm t    
 --    is i ,     
 ith opposing counsel t at he --  s t  i  
  t e c ce t f ca sation, e ical ca sation, 
 it  t  t  t  t  t t  t  
 iterature   e      
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  T: a   e lai  t  e is 
 t t t  t  .  t t . 
  N: y.       
      t. 
  T: y. 
 . N:  'm l i  t    
  i  t t ents.     t  2,  
 esti  is ca sal. r. r e is as i  i  a 
 question about causation ith regard to s. ajor 
0 specifically and then r. urke follo s up ith 
 t  sti   53, "An  that's s   i l 
 ?" "Y s." "An     l  
 t t  s  t t i i  ?" " l ,  l  
 it  r e siti   at s e escri es as, 
 you kno , her condition before and after." 
  URT: ell, it   spect, 
  --
 R. ON:  I'm issi  r 
 question. 
  URT: y.  sti  t t  
 tt    l?-  ot i  t   it  
 usation. t  say  --
 R. N: h, I'm sorry. hat's t--
  URT:  pologize, t en. 
  SON: kay. 
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1 THE COURT Lookat the question at the
2 bottom of page 153 and then look at his answer
3 MR OVERSON Right Okay
4 THE COURT And thats and itsclear
5 that counsel is asking him about causation at one
6 point but then hesasking him very clearly would
7 amanufacturer have known about this
8 MR OVERSON Right And I when you said
9 statement on this
10 THE COURT I apologize Iwas not being
11 accurate
12 MR OVERSON Well thatsokay So the
13 question is In your opinion as of March 2008
14 was there anything definitively published in the
15 peer reviewed scientific and medical literature
16 that would have put a manufacturer of a pepper
17 spray product such as SEC on notice of the of
18 the exposure and risks of chronic injury
19 Therestwo parts there One
20 Mr Burke phrases it in the specific is there a
21 specific study that studies exactly that And
22 two the question is framed in terms of well
23 would ithave put
24 THE COURT Actually he doesntsay that
25 You know letsread what it says
41
1 literature today I dontthink it exists except
2 through the preponderance of evidence and it may
3 very well be that other people dontbelieve
4 thatsthe case but I do
5 MR OVERSON Thatsthe linchpin is he
6 does reference the preponderance of the scientific
7 evidence
8 THE COURT Today Today
9 MR OVERSON No the question is aimed at
10 during that time period
11 THE COURT Idontthink that existed then
12 In the literature today I dontthink it exists
13 MR OVERSON He says to either one And
14 the question is Your Honor I see youre
15 getting frustrated
is THE COURT WellIm not frustrated Its
17 just that youre really playing games with what
18 hessaying Hesvery specific the literature
19 at the time didntexist In fact Imnot sure
20 it exists now But for the for him the
21 preponderance of the evidence now is that he would
22 come to that conclusion although other people
23 would disagree Thatswhat hessaying
24 MR OVERSON Okay Let me back up because
25 it is were backto that standard
40
1 MR OVERSON Okay
2 THE COURT In your opinion as ofMarch of
3 2oo8 was there anything definitively published in
4 the peer reviewed scientific and medical
5 literature that would have put a manufacturer of a
6 pepper spray product such as SEC on notice that
7 exposure to their products by somebody with the
8 chronic health conditionsof Ms Major would have
9 caused her an exacerbated response et cetera et
10 cetera He doesntlimit it to one He doesnt
11 say is there just one study
12 MROVERSON But
13 THE COURT Then why in the world
14 MROVERSON Ididntmean
15 THE COURT didn didntDrYost
16 come back and say ifyou look at the totality of
17 the peer reviewed literature like hestrying to
18 say now yes it would have put him on notice his
19 response was no
20 MR OVERSON I dontthink itspossible
21 for me to place him as far as intent The
22 question this goes back to where I started is
23
24 THE COURT Then he stays he goes on and
25 says I dontthink that existed then In the
42
1 THE COURT Let me just stop You know
2 what its your responsibility to have him in
3 his new in this last affidavit to have him come
4 forward and explain it He doesntexplain
5 anything about the conflict between his deposition
6 testimony and his affidavit Instead he spends
7 all of his time adding to his old affidavit and
8 hes still using imprecise language where it seems
9 to me hestalking about causation more than he is
10 talking about anything else
11 MROVERSON And you know I respectfully
12 disagree And I didntask him to include that
13 information in the affidavit because I didntsee
14 it as in conflict I we didn address this at
15 the last hearing
16 THE COURT Yes we did
17 MROVERSON No I mean we didntaddress
18 you found that they were not in conflict
19 THE COURT And I explainedwhy
20 MROVERSON You did
21 THE COURT I did I explained that he very
22 carefully in his first affidavit never ever ever
23 said that therewas that literature had a link
24 between an exposure to capsacin and chronic
25 effects only acute And in fact thatswhat
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1 E :  t the uestion t the  . : . 
2 tto  f a e 53 d then lo  t is .  E : n  ion   arch  
3 . : ight. kay.  008 as  t ing tively ishe   
 E : nd t at's --  t's lear 4 t e r-r ie ed i tifi   i l 
 that unsel is i  i  t ti  t e 5 literature that  e t  a turer   
 , t e  e's  i  er       t     ice  
  a acturer e  t i .  s re t   cts   t  e 
 . : i t. nd  -- hen you said  ic lt  iti   . ajor l   
   s -- 9 s  r   ,  r ,  
  : I l i . I as t i   . e sn't t t  .  esn't 
 .     just e . 
 . : ell, t at's a .  t e  . : t--
 tion i : "In r i ion s   8   :    e  --
 as there ing i e  lished  t e  . : I i n't --
 r-r ie ed s i tifi   i l literature   : -- i n't -- i n't r. st 
 t at l   t  f t rer f  r  e         l   
 spray product such as  on notice of the --   t  - i e  lite t , li  e's t i  t  
 the exposure and risks of chronic injury?"  say no , yes, it ould have put hi  on notice, his 
 ere's t  arts t ere. e,  r s s  s . 
 . e ases it  t e cifi , is t    . : I n't t i  it's i le 
 specific study t at studies exactly that. nd,   e       t.  
 t , t e ti n i  ra e  in t s f, ll,  ti  -- t is   t    t rt d, i  
 ould it have put --  --
  T: t ll   esn't s  t t.   RT:   s --     
 ou kno , let's read hat it says.    on't    n.   
41  
 literature t y,  n't t i  it i t  t   T: t  -- just t .   
 t r  t e re era ce f e i e ce a  it a   at, it's r responsibilit  t  a e i  -- in 
 very ell be that other people don't believe    --         
 that's the case, but I do.  r ard  l i  it.  esn't l i  
 . : at's t e li i , is e  t i  t t  fli t t e  is siti  
 does reference the preponderance of the scientific     it.    
  --  l           
 THE COURT: Today. Today.  he's still using i precise language where it see s 
 R. ERS : o, the question is ai ed at  t   e's t l i  t s ti  r  t   is 
 during that ti e period.  t l in  t t i  l . 
  RT:  on't    n.  . : ,  ,  pectful  
 In the literature today I don't think it exists.  disagree. And I didn't ask hi  to include that 
 . S : e says to either one. nd     f    idn't  
 the question is -- our onor, I see you're     nflict.  --  idn't    
 etti  fr strate .  t e last eari . 
16 T E RT: ell, I'm not frustrated. It's   RT: s,  id. 
 just that you're really playing ga es ith hat  . : . I an,  i n't r  
 he's saying. e's very specific, the literature  -- you found that they ere not in conflict. 
 t t  ti e i n't xist. I  f t, I'm t s r    RT:   l  . 
 t  .   e --     . N:  id. 
 preponderance of the evidence now is that he would   RT: I i . I l i  t t  r  
 co e to that conclusion although other people  carefully in his first affidavit never, ever, ever 
 would disagree. That's what he's saying.  i     --  l     
 . : . t    s   bet een an exposure to capsacin and chronic 
   -- 're   t t ndard.  effects, l  acute. d, i  fact, t at's at 
10/31/2011 02:24:27 PM i  , ffiCi l rt eporter, Oi , I  




















































his past affidavit said
Now what were doing iswere going
throughiterations of the affidavit where hes
trying to get closer to what he thinksIm getting
at in order to overcome the summary judgment And
thatsmy concern He still doesn explain how
his how his affidavit especially this most
recent one which is in conflict why hehasn
explainedwhy theresthe difference and thats
the concern
Andwith due respect the last motion
to strikewas very clear as to what the law is and
including all of the information about the fact
thatits not a sham if in fact the person says
Ididn remember at the timeor I at least
Iverethought or theres new theresnew
studies that Ivelooked at or something to
explain why theres the inconsistency And there
in my view its clearly inconsistent
MROVERSON Okay
THE COURT in a very material way
MROVERSON Uhhuh I I see where the
courtscoming from and thatswhyImasking time
to approach him and see if that he can explain
the contradiction that the courtsconcerned with
45
know before he testifies they should have an
opportunity to redepose him
THE COURT Well assuminghes going to
testify But this this deposition though is
kind of replete with these kinds of things Look
at page 1o1 thatcounselsalready read Look at
the bottom It says Question its at line
21 Have you in your review of peer reviewed
publications seen any articles that focus on the
duration of time after exposure to OC that
adverse health effects are customarily deemed
persistent in humans And his response is I
would say my general opinion is that general
conclusion from literature is that they are
transitory And that would generallymean you
know more than a minute and probably less than a
day or two And he goes on Itdoesn persist
for weeks and months
So thatshim talking about the
peer reviewed literature Hesnot saying there
isntone definitive study and the question wasnt
that This isnta problem of the question being
too narrow This is his response And thats
thatswhereIm really having a concern
MR OVERSON So you know I would
44
1 THE COURT WellImjust Imalittle
2 worried at this point because it seems to me its
3 only fair to the other side that if he is going to
4 reexplain it again that they have the
5 opportunity to cross examine him which is not in
6 an affidavit form
7 AndImconcerned because at some point
8 Im going to have to say lets see Ive got a
9 deposition Then I have an affidavit that doesn
10 reallyaddress this issue Now I have an
11 affidavit thatsdirectly thatsdirectly
12 contradictory to his deposition
13 At what point do we stop Atwhat
14 point do I say Im sorry this affidavit should be
15 stricken Because its its in conflict with
16 his earlier affidavit
17 MR OVERSON Well and in all fairness
18 the court should be aware that I have offered
19 repeatedly to make Dr Yost available for further
20 deposition
21 THE COURT Well I understand that but the
22 burden is on you not on the defense so
23 MR OVERSON I meanImjust addressing
24 the one issue thatyou raised in terms of fairness
25 to opposing counsel because I do agree that you
46
1 reiterate Mr Burke follows up Okay So is
2 basically your understanding that the adverse
3 health effects to acute exposure to OCare
4 generally deemed to be temporary reversible and
5 recoverable And he answers In general I think
6 thatstrue It does not mean that they cant
7 that they cantexacerbate an underlying condition
8 for someone who is highly sensitized and thats
9 what I opined in my statement But certainly in a
10 majority of the cases a large majority of the
11 cases the effects are temporary and reversible
12 yes from an acute exposure So he does make
13 that he does make that clear that hestalking
14 about
15 THE COURT Butwhats the standard for
16 foreseeability
17 MR OVERSON But thatswhat
18 THE COURT Foreseeability that there is one
19 person out there thats going to be affected Is
20 that the standard
21 MR OVERSON If first of all
22 THE COURT Because if thats the case l
23 dontknow whywe bother with products liability
24 law at all because I can tell you that probably
25 everything potentially could happen And if I
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1 his past affidavit said. 1 THE C : l , I'm just -- I'm a little 
2 Now what e're doing is we're ing 2 orried at this nt because it s s to e i 's 
3 through iterations ofthe affidavit here he's 3 o ly fair to the other side that if e is ing to 
4 trying to get closer to what he thinks I'm getting 4 r -e plain it a , that they have the 
5 at in order to overcome the s ary judg e t. nd 5 rt ity t  cross-e a ine hi , hich is not in 
6 that's y concern. e still doesn't explain ho  6  a fida it f . 
7 his -- ho  his affida it, es ecially this ost 7 nd I'm concerned because t s e nt 
8 recent one, hich is in conflict, hy -- he h 't 8 I'm ing to e t  s , l t's , I've t  
9 explained why there's the differeIX!e and that's 9 e siti . en I a e  affida it that esn't 
10 the c r .  re ll  address t is iss . o  I e n 
11 nd ith due respect, the last otion 11 a fida it t t's re  -- t t's re ly 
12 to strike as very clear as to hat the la  is and  c tra ct ry to is i . 
13 including all of the information about the fact  t at   e t p? t hat 
14 that it's not a sha  if, in fact, the person says  point do I say I'm sorry, this affidavit should be 
15 I 't re e ber  the i e r I --    stri . ecause it's -- it's i  fli t ith 
16 I've rethought or there's ne  -- t re's   is lier i vit. 
17 studies that I've looked at r so ething to  . : ll--  in  , 
 explain why there's the inconsistency. And there  e   e are   e fere  
 -- in y vie  it's clearly inconsistent --  repeatedly to ake r. ost available for further 
2  . S : kay.  siti . 
21 E T: -- in  ery t ri l .   T: l ,  ta  t,   
2  . : -hu .  --   re   de  i   , t  t  ,  --
2  court's coming from and that's why I'm asking time  . :  an, 'm just  
 to approach hi  and see if that -- e ca  e lai   t  e iss  t t  r is  i  t r s f f irness 
  ion  e ourt's  .  to opposing counsel because I do agree that, you 
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 kno , before he testifies, they should have an  t , r.   , "Ok .   
 opportunity to re-depose hi .  si ll  r rst i  t t t  rs  
  T: ell, assu ing he's going to   e t      .C.  
 testify. But this -- this deposition, though, is  r ll     orary,   
 kind of replete with these kinds of things. Look  ?"   rs, "In r l I t i  
 at page 101 that counsel's already read. Look at  at's . I       an't--
 the botto . It says, "Question:" -- it's t lin     an't   rl  it  
  -- "Have you in your review of peer-reviewed     i  i  i   that's 
 publications seen any articles that focus on the  hat I opined in y state ent. ut certainly in a 
 duration of ti e after exposure to .C. that  ajority of the cases, a large ajority of the 
11 a erse ealt  effects are c st aril  ee e   s,      rsible, 
 persistent in humans?" And his response is, "I  yes, fro  an acute exposure." So he does ake 
 would say my general opinion is that general  t -       e's t l  
 conclusion fro  literature is that they are   --
 transitory. nd that ould generally ean, you   RT: t hat's t  st  r 
 know, more than a minute and probably less than a  seeability? 
17 day or two." And he goes on, "It doesn't persist  . SON:  t at's t--
 f r s  t s.   RT: r seeabilit  t t t r  is  
 So that's hi  talking about the  r  t t r  that's goi  t  b  affected? I  
 peer-reviewed literature. He's not saying there  t t t  standard? 
21 isn't one definitive study and the question wasn't  . SON: I  -- first of all--
22 that. This isn't a problem of the question being 22  URT:  if that's t  case, 1 
3 too narrow. This is his response. And that's --  don't know why we bother with products liability 
 that's here I'm really having a concern. 24 l  t all  I c  tell y  t t r abl  
25 . SON: o -- you know, I ould 25 everything potentially could happen. nd if I 
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remember my Palagrafcorrectly I dontthink
thatsthe standard
MR OVERSON The standard is going to be
whether or not its a significant risk Okay
THE COURT Right but if hes saying that
in general its temporary and reversible
MR OVERSON Okay Thats right
THE COURT from acute exposure if hes
saying that then it seems tome that hes saying
that foreseeability is generally itsgoing to
be acute and not chronic
MROVERSON The same thing is true if I
sell a product that has peanuts in it and I dont
just put a warning on it that it has peanuts in it
knowing that theres there is aportion of a
significant portion of society thats allergic to
peanuts Im going to get sued in a products
liability case whensome kid swells up and dies
THE COURT Idontthink thats a good
example but
MROVERSON Well and what it does
though is thereis a significant portion of
society thatsallergic to peanuts
My in this case were talking about
individuals with respiratory illness at some level
49
MR OVERSON Well I again respectfully
ask an opportunity to approach DrYost and be
able to cure the problem that has been presented
And if he cantcure it then he cantcure it I
wontfile a sham a true sham affidavit
But I would like an opportunity to ask
him about the points that the court has raised
the points that Mr Burke has raised And if he
can present an affidavit that resolves those
conflicts Id like an opportunity to do so
THE COURT Allright Let me hear from
Mr Burke because Ithink this is the issue today
MR BURKE Your Honor there really isnt
much else to say I thinkyouvegot a good a
handle onwhatall of the issues are
THE COURT Well dontassume that I have a
good handle on the issues
MRBURKE Well I can justtellby the way
youre asking these questions that I think youdo
you have studied this very well and I commend you
for it
THE COURT Well dont dontdothat
because that will actually push me the other way
So dontdoit
MRBURKE Well my concern is theyr now
lyrl VU130 10
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1 who are sensitized Now IdontthinkIm
2 required to provemy case bybringing in a
3 statistician saying howmany people would be
4 hypersensitized to capsacin in order for thejury
5 to conclude that it was reasonable or that they
6 should have put that type ofwarning on there and
7 that it was causal and that they should have known
8 about it based on the literature I thinkthats
9 a different issue But I thinkwe need to
1 o understand that the relevant standard here is not
11 what SECknew
12 THE COURT I I know that counsel I
13 know that it is what is foreseeable for a
14 manufacturer
15 MR OVERSON No its not It I I
16 cited the cases The majority view is that it is
17 within the expert in the area and itsnot the
18 manufacturer The manufacturer is obligated to
19 test research hire people and thatwasn done
20 here And the questions are framed many of
21 these questions are framed in reference to lay
22 persons and manufacturers and
23 THE COURT Right but the ones thataren
24 not all of them arentIwould agreewith you
25 about the lay person stuff
50
1 asking for more timeand here we are on the second
2 affidavit the second round ofmotions We vegot
3 a trial datein amonth
4 THE COURT I understand that Lds stick
5 to what he says are what hes trying to explain
6 away that these arent wherehes complaining
7 that some of the questions are directed toward lay
8 persons as opposed to other experts in the area
9 MR BURKE Ithinkthe court hit the nail
10 on the head in every respect I mean every
11 question talks abort peer reviewed literature and
12 his responsescome back from there And I can go
13 over it again If you want to start on page
14 100
15 THE COURT No youdonthave to read them
16 MR BURKE Idontneed to read it again
17 but the questions are all focused on peer reviewed
18 literature and his answers are theresnothing out
19 there theresnothingout there that shows this
20 In fact to contrary thepeer reviewed literature
21 shows that its transitory So thatswhat he
22 says on ioo and1o1 On pages 153 to 156 all of
23 the material questions say peer reviewed
24 scientific and medical literature and his
25 responses no theresnothingout there that
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1 re e ber y alagraf correctly, I don't think    siti . , on't  'm 
2 that's the standard. 2 re ire  t  r e  case  ri in  i  a 
 . S : he standard is going 10 be  t ti ti ia  i    le l   
    t's  ica t k. amy.  hypersensitized to capsacin in order for the jury 
 T EC Rf: Right, but if he's saying that  t  c cl e t t it as rea!!l>na le r t t t e  
 i  e eral it's te rar  a  re ersi le --  l  e t t t t   i   t   
 . N: y. at's ri t.  t at it as ca sal a  t at t e  s l  a e  
  f: -- r  te ure, i  e's  t     t .   at's 
 sa i  t at, t e  it see s t  e t t e's sa i    fere  e.       
 t t f r s abilit  is r ll  -- it's i  t  0   e      
     ic.    . 
 . :  e    -- if I   RT:  --   t t, el.  
 ll  r t t t  ts i  it  I n't 13  t. I  s   l    
 just put a arning on itthat it has peanuts in it  f ct r r. 
 i  t at t ere's -- t ere is a rti  f --   . N: , t's t.  -- I -- I 
 si ificant c.rti  f s i t  t at's ll r i  t   it  t  s s.  j rit  i  is t t it is 
 peanuts, I'm going to get sued in a products  it i  t  t  t    it's t t  
 liability case hen so e kid s ells up and dies  anufacturer. he anufacturer is obligated to 
  f: I n't t i  t at's a   test, research, ire e le a  t at asn't e 
 l , t --  r .  t  ti   fr  --   
 . : ll--  at t s,  these questions are fra ed i  reference to lay 
 though, is thereis a significant portion of  r s  f t rers  --
 s i t  t ts ll r i  t  ts.  T E C RT: Right, but the ones that aren't 
  --  s  're in  t  -- not all of the  aren't. I ould agree ith you 
 i i iduals it  res irat r  illness at s e le el  t t  l  rs  st i. 
  
 . : ell, I, a ai ,respectf ll   asking for ore ti e and here e are on the second 
   t it  t  IX'oa  r. t    affidavit, the second round of otions. e've got 
 a le t  c re t e r le  t at as ee  rese ted.  a trial ate i  a nth. 
 nd f  n't  , m  n't e .    :   at. a's  
 n't il    --  t e  i it.  to hat he says are -- hat he's trying to explain 
 t I l  li e  rt it  t  as   a a , t at t ese aren't -- ere e's c lai in  
 i  t t  ints t t t  rt s r is ,  that so e of the questions are directtrl to ard lay 
 t e i ts t t r. r  s r i d.  if   persons as opposed to other ecperts in the area. 
 can present an affidavit that resolves those  . :  i    i   il 
 conflic1s, I'd like an opportunity to do so.  on the head in every respect. I mean, every 
  f: ll ri t. t e r fr   question talks abott peer-revie ed litff'ature and 
 r. urke because I think this is the issue today.  his responses co e back fro  there. nd I can go 
 R. BURKE: Your Honor, there really isn't  over it again If you want to start on page 
 uch else to say. I think you've got a good a  00--
 le   l  e ss es .   T: o, you don't have to read the . 
  f: el , n't       . : I don't need to read it again, 
 good handle on the issues.  but the questions are all focused on peer-revie ed 
 . : ll, I  j st tell  t    literature and his ansW!rs are there's nothing out 
 you're asking these questions that I think you do,  there, there's nothing out there that sho s this. 
  a e st ied t is ery ell a  I c e    In fact, to contrary, the peer-revie ed literature 
  .  s s t at it's tra sit r .  t at's at e 
  : ll, on't -- on't    says on 100 and 101. On pages 153 to 156, all of 
 because that ill actually push e the other ay.  the aterial questions say peer-revie ed 
  n't  .  i ti   i 11iterature  s 
 . : ell,  c cer  is t ey're   responses, no, there's nothing out there that 




















































would have put these guys on notice
And then he says then I ask him
well what about a trained toxicologist such as
yourself Thatswho you are Is there anything
out there that would put you on notice Thats
the question that starts at page 154 line 12 He
says I dontsee it No there isnt
And then he switches to the whole
concept of causation again But basically he says
to that response Imnot aware of anything
myself And then he kind of switches at the end
and says Im not aware of anything that would tip
off the normal lay person I think at this point
hesthinking about manufacturers of pepper spray
products
THE COURT Right but the point that
Mr Oversonsmaking is that its not the ordinary
lay person Thats notthe standard for a
products liability
MR BURKE Well the standard is the
manufacturer and the manufacturer is charged with
the knowledgeof experts in the field But he
hasn he may be an expert in the field in
terms of toxicology and he may have the expertise
to give his opinion as to what he thinks from the
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to bleed It couldprick the fabric that youre
working on and cause damage to the fabric But
its certainlynot foreseeable that that pin is
going to get jammed into a bone and shatter the
bone
And the court said that reasonable
minds could not differ on that point and
therefore as a matter of law it was not
foreseeable that that would cause that type of
injury So thatsexactly what wer talking
about here
And you go back to the peanut analogy
you know maybe the peanut will cause one acute
reaction but the point is is it going to cause
somebody down the road necessarily to have a
chronic reaction that will last for years and
years and years and never stop even though the
residue of the peanut has already left the body
In this case this woman hasntbeen
exposed toOCsince March of 2008 yet she
continues to have chronic cough
So I mean itsthe itsthe same
issue I think the Sidwell case is exactly on
point Its a failure to warn case They look at
it in terof negligence and strict products
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1 literature caused this person disease but hes
2 certainly not in a position any more than the
3 authors of all of the articles that he wrote to
4 suggest that there should be some foreseeability
5 there You have to go look at the articles and
s hessaying the articles dontexist so he gave
7 us the articles
8 THE COURT Well hes with Mr Overson
9 he indicated that he used his peanuts allergic
10 to peanuts
11 MR BURKE Yes Ive got a good example
12 for you I was thinking about that when you said
13 it Its a case in Idaho
14 THE COURT Ididntsay it
15 MR BURKE right on point Its the
16 Sidwell versusPrym Inc case We cited this in
17 our brief a number of times Its 112 Idaho 76
18 This was the pin case Classic failure to warn
19 case you know have itskind of like a sewing
20 needle or a safety pin
21 And what the courts saying and the
22 court this was something that came out in a
23 directed verdict Okay And the court upheld the
24 directed verdict and said that its foreseeable
25 that that pin could prick your skin and cause you
54
1 liability and they are very clear that
2 foreseeability of that injury and risk is
3 essential to maintain that cause of action and
4 they heldas a matter of law it wasn
5 So I really have nothing further to
6 say I think the court has really hit all of
7 issues with the questions that you asked Unless
8 you have another question ofme I think I will
9 stand onwhere we are
10 THE COURT No Im going to take a brief
11 recess I just want to look over the affidavit
12 again Stand in recess
13 Recess
14 THE COURT Imjust going to concentrate a
15 littlebit on the new affidavit and point out a
16 couple things AndIm doing this but Im not
17 inviting a new affidavit to respond to it
18 And the reason that in both casesIve
19 spent a lot of time with the affidavit is because
20 we do have a deposition and on its surface I think
21 its very clear that there is a change in the
22 testimony
23 So I just want to talk about a couple
24 of things He lets start at paragraph number
25 nine Hes submitting this affidavit to clarify
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1 would have put these guys on notice. 1 literature caused this p on's diseas , but h 's 
2 And then he says -- then I ask hi , 2 certainly not in a pos tion any ore than the 
3 well, what about a trained toxicologist such as 3 authors of all of the a ticles that he rote to 
4 yourself? That's who you are. Is there anything 4 suggest that there should e s e fores i t  
5 out there that ould put you on notice? That's 5 there. You have to go look t the a ticles a d 
6 the question that starts at page 154, line 12. He 6 h 's s ing the articles d 't e i t, so he gave 
7 says, I don't see it. No, there isn't. 1 us the article . 
8 nd then he s itches to the hole 8 HE : l , h 's -- ith r. ers , 
9 concept of causation again. But basically he says 9 e indicated that -- he se  his pe , le c 
10 to that response, I'm not aware of anything  to pe . 
11 myself. And then he kind of switches at the end  . : . I've t a ood e a ple 
12 and says, I'm not aware of anything that would tip  o  . I as thinking a out at hen  d 
13 off the normal lay person. I think at this point 3 i . It's a case in da  --
14 he's thinking about manufacturers of pepper spray  E : I di n't  it. 
15 products.  . : -- right  i t. It's e 
16 THE T: ight, but the point that   s s , I . . e ited is  
 r. verson's aking is that it's not the ordinary  ur i   er  ti . t's  da o . 
18 lay person. That's not the standard for a  his as the pin case. lassic failure to arn 
 products liability.  case,  , a e -- t's n  l    
 . : ll, the t r  is t e  e le   f t  i . 
21 manufacturer and the manufacturer is charged with   t t e urt's i  -- and the 
 the knowledge of experts in the field. But he   -- s a        
 sn't -- he ay be an expert in the field in  ire te  i t. y.  t e t ld t  
 terms of toxicology and he may have the expertise  re te      t's  
 to give his opinion as to what he thinks from the  t at t t i  l  ri  r i     
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 to bleed. It could prick the fabric that you're  liability and they are very clear that 
 working on and cause damage to the fabric. But  eabili        
 it's certainly not foreseeable that that pin is  esse tial t  i t i  t t ca se f acti  a  
 going to get jammed into a bone and shatter the  t  l    tt r fl  it asn't. 
 .    ll   t    
6  t  rt i  t t r l   s y. I t i  t  rt s r ll  it ll f 
 minds could not differ on that point, and, 1 i  it  t  sti  t t  sked. l  
 therefore, as a matter of law it was not     ti   ,    i  
 foreseeable that that would cause that type of  t     re. 
10 injury. So that's exactly what we're talking   T: . I'm i  t  t  a ri f 
11 about here. 11 recess. I just ant to look over the affidavit 
 nd you go back to the peanut analogy, 12 gain. t  i  r ss. 
 you know, maybe the peanut will cause one acute 13 (Re s) 
14 reaction, but the point is is it going to cause 14  RT: I'm j t goi  t  t t  a 
5 somebody down the road necessarily to have a 15 l  i  o  t   af i vit n  oi t  a 
16 chronic reaction that will last for years and 16 l  thi gs.  I'm doi  this, t I'm not 
1  years and years and never stop even though the 11 inviting a ne  affidavit t  respond to it. 
18 residue of the peanut has already left the body. 18  t  r ason t t i  bot  cases I'v  
19 I  t i  s  t is  hasn't been 19 spent a lot of ti e ith the affidavit is because 
20 exposed to O.C. since March of 2008, yet she 20  d  have a depositi  an  o  it  surf  I thi  
21 continues to have chronic cough. 21 it's very clear that there is a change in the 
22 So, I mean, it's the -- it's t  sa  22 testimony. 
23 issue. I think the Sidwell case is exactly on 23 So I j st ant to talk about a couple 
24 point. It's a failure to warn case. They look at 24 of things. e --let's start at paragrap  nu ber 
25 it in terms of negligence and strict products 25 nine. e's submitting this affidavit to clarify 
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1 his opinion that he gave in his last affidavit 1 literature says And it did say that prior to
2 And at the end what and nine he says I 2 2008
3 believe it best to state unequivocally itsmy 3 Then he goes on and he says Once a
4 expert opinion based on my education et cetera 4 higher sensitivity develops in an affected
5 et cetera it was known that a product such as 5 individual the neurogenic inflammatory response
6 SEC fogger posed a risk of both acute and chronic 6 in the respiratory tissues will occur at a lower
7 respiratory injury such as that described in her 7 threshold than in the general non sensitized
8 medical records 8 population Again this is not in reference to
9 Then he goes on in paragraph ten He 9 any kind of chronic the creation of any chronic
10 says There is no doubt that the literature and 10 disease He is simply saying that they are more
11 studies have established prior to 2oo8 within a 11 likely to have an acute response to exposure to
12 reasonable degree of scientific certainty that the 12 capsacin or a more acute response than a
13 inflammatory properties associated with exposure 13 nonsensitized individual
14 to capsacinoids greatly enhances the sensitivity 14 He then goes on and he says Once an
15 of neuronal and respiratory tissues to an array of 15 individual has become sensitized to capsacin the
16 irritants by an increase in number and 16 threshold for activation of the neurogenic
17 responsiveness to the TRP receptors populating 17 inflammatory response by exposure to irritants
18 those tissues 18 other than capsacin is also lowered In other
19 NowIm going to stop for a second 19 words once somebody has once the threshold for
20 He does not this sentence has nothing to do 20 activation has been created and been desensitized
21 with the creation of a chronic coughing condition 21 theyr going to become more sensitive to other
22 It simply says it enhances the sensitivity of 22 things besides capsacin Capsacin and its
23 these receptors And then he goes on and I 23 involvement in the sensitization process was well
24 think thats clear in the literature that he used 24 understood prior to 20o8 Thus even prior to 2008
25 in support of his affidavit that is what that 125 people with asthma andor chronic cough including
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1 Ms Major would have been expected to be much more
2 sensitive to the pathological effects of pepper
3 spray
4 And he goes on In other words she
5 already sensitized Shedbe expected to become
6 increasingly sensitized And he goes on and
7 says People with asthma and chronic cough are
8 simply more sensitive to the effects of pepper
9 spray than others with normal respiratory
10 function
11 Again hes not saying that the studies
12 existed at the time that people like Ms Majorwho
13 were exposed to capsacin develop a chronic
14 respiratory response related to that exposure
15 Hessimply saying that they are more sensitive to
16 the effects of pepper spray
17 He goes and in the next one he talks
18 about people with greater sensitivity to capsacin
19 are expected to have increased TrpV1 receptor
20 populations Okay Well all of thatsfine
21 That may go to whether she in fact whether this
22 caused her condition but he is not saying that
23 the literature indicated at the time that that
24 it was foreseeable that someone would develop a
25 chronic condition They simply would have more
1 acute responses
2 Same thing in paragraph 12 He goes on
3 and he says the pre so he goes and looks for
4 additional literature and studies that were
5 published prior to 20o8 to support his
6 conclusions So he does that And he says The
7 pre2008 articles previously identified upon which
8 I base my conclusion that this Fogger product
9 posed a risk of respiratory injury such as
10 experienced by MsMajor Again thatsthe
11 medical causation That is not the foreseeability
12 issue the issue of whether the manufacturer
13 should have known that it was foreseeable that she
14 would develop a chronic condition as a result of
15 her exposure to the to the capsacin and the
16 product produced by this company
17 And I think thats where thatsthe
18 problem that I have with his affidavit If you go
19 back and look at the question that he is asked he
20 does spend and Iwent back and looked at the
21 entire deposition He spends quite abit of time
22 talking about the medical causation Andwer
23 not here for that because that clearly would be a
24 jury question as towhether it was whether
25 this exposure caused it
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1 his opinion that he gave in his last affidavit. 1 literature says. And it did say that prior to 
2 And at the end what -- and nine he says, "I 2 200 . 
3 believe it best to state unequivocally it's my 3 Then he goes on and he sa s, "Once a 
4 expert opinion based on my education," et cetera, 4 higher se sitivity develops in an affected 
5 et cetera, "it was known that a product such as 5 individual, the neurogenic inflammatory response 
6 SEC fogger posed a risk of both acute and chronic 6 in the respiratory ti sues i l occur at a lower 
7 respiratory injury such as that described in her 7 threshold than in the general non-s tized 
8 medical records." 8 p l tion." Agai , this is not in reference to 
9 Then he goes on in paragraph ten. e 9 any kind of chronic -- the creation of any chronic 
10 says, "There is no doubt that the literature and 10 disea . e is si ply sa ing that the  are ore 
11 studies have established prior to 2008 within a 11 likely to have an acute response to exposure to 
12 reasonable degree of scientific certainty that the 12 capsacin r a ore te res onse than a 
13 inflammatory properties associated with exposure 13 n -s itized in i id l. 
14 to capsacinoids greatly enhances the sensitivity 14 e then oes n and e s , "Once n 
15 of neuronal and respiratory tissues to an array of  individual has e e s tized to i , the 
16 irritants by an increase in number and  t res ld for a ion e ic 
17 responsiveness to the TRP receptors populating  inflam at ry es onse  osure to irritants 
18 those tissues."  ther than s n s s  . n  
19 Now, I'm going to stop for a second.  , nce   -- once the threshold for 
20 e does not -- this sentence has nothing t  do  ation   eated   nsiti , 
 ith the creation of a chronic coughing condition.  t ey're i  t  e re iti e t  t r 
22 It simply says it enhances the sensitivity of  things besides capsacin. apsacin and it's 
23 these receptors. And then he goes on --    n olve ent in e i on rocess   
24  at's  in e iterature   s   s    0 . s     
25 in support of his affidavit, that is what that 25 le it  t  /or r i   i l i  
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1 Ms. Major would have been expected to be much more 1  s. 
 sensitive to the pathological effects of pepper      .    
 spray."      re- --       
 And he goes on, "In other words, she's  i  te      
5 already sensitized. She'd be expected to become  lis e  ri r t  0  t  s rt is 
6 increasingly sensitized." And he goes on and  l i .    t t.   ays, "Th  
7 says, "People with asthma and chronic cough are  r -200  rti l  r i l  i tifi   i  
8 simply more sensitive to the effects of pepper  I   cl i  t t t i   t 
9 spray than others with normal respiratory 9 posed a risk of respiratory injury such as 
10 f nction."  experienced by s. ajor." gain, that's the 
11 Again, he's not saying that the studies  di l ausation.  i  not t  f eeabilit  
12 existed at the time that people like s. ajor who  i sue, t  i  f t  t  f t  
3 were exposed to capsacin develop a chronic 13 shoul  hav   t t it  f bl  t t she 
14 respiratory response related to that exposure. 14 l  v l  a chr i  conditi  a  a result of 
15 He's simply saying that they are more sensitive to 15  ex  t  th  -- to t  capsaci  and t  
16 the effects of pepper spray. 16 pr t produced by this company. 
17 He goes -- an  i  t  next  h  talk  17  I t i k that's ere -- that's the 
18 about people with greater sensitivity to capsacin 18 proble  that I have ith his affidavit. If you go 
19 are expected to have increased TrpV1 receptor 19 bac  and l k at the question that he is asked, h  
20 populations. Okay. Well, all of that's fine. 20 does spend -- and I went back and l d at the 
21 That may go to whether she in fact -- whether this 21 entir  deposit on. He spend  quite a bit of ti e 
22 caused her condition, but he is not saying that 22 talking about t  edical causation. And we're 
23 the literature indicated at the time that -- that 23 not here for that because that clearly would be a 
24 it was foreseeable that someone would develop a 24 jury question as to whether it was -- whether 
25 chronic condition. They simply would have more 25 this exposure caused it 
.. 
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But when hes asked about the
peer reviewed literature and hes askedwould it
put a manufacturer of pepper spray on notice he
says no He makes it to me its about as clear
as it can be that in fact it didn exist at
that time And he even asked heseven asked
Is it your understanding that the adverse human
health effects that exposure to 0C and
capsacinoids by humans are generally deemed to be
temporary reversible and not long term And he
says I think thats fair yes So he agrees
with that
If this were a straight negligence
question duty breach of duty et cetera that
would be probably enough But here wer talking
about a manufacturer who whenyou get to the
foreseeability issue it has to be foreseeable to
thatperson that manufacturer that in fact this
could cause this chroniccondition and thats
where it all falls apart
I am not inclinedto tell the plaintiff
in this case that she can have yet a third
affidavit because its reallya third You have
the first the second and the third to try and
explain what should have been explained inthe
61
foreseeability and whether the manufacturer could
have foreseen that thiswould be the case
And the case cited the Sidwell case
cited bydefense is it exactly on point Almost
anything could happen with the product thats out
there That doesn make a product the
manufacturer liable It has to be something
thats reasonably foreseeable not just anything
anyplace anywhere
Andso I am granting the motion to
strike And I think it has unfortunately it
has a huge impact on the restof the case because
I thinkwe all understand that the Federal
Hazardous Substance Act doesn create a private
cause of action
And so the question thenbecomes
whether your clientsgoing to be able to come
forth and show that in fact there was some
problem with the warning label So I havent
decided that issue but I think that clearly not
having this expert has a huge impact So I dont
know if you want to go ahead and proceed on your
on the rest of your motions
MR BURKE Ican
THE COURT Okay BecauseIm denying the
Lvri wuaoio
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1 verybeginning in the first affidavit to explain
2 why his testimony seems at least to have changed
3 So Im going to strike the affidavit
4 I just think at this point I cantrely on it to
5 create a dispute of material fact which is really
6 which is its therefor Obviously I dontknow
7 which side is right but I do know that the burden
8 is on the plaintiff to bring forth an expert to
9 create a material dispute of fact and the problem
10 1 have is that the deposition suggests that the
11 defendant is in fact correct and is consistent
12 with the testimony that they have from their
13 expert
14 So now for to allow the the
15 plaintiff to come inand have their same expert
16 refute what he saidwithout reallyan explanation
17 as to why whatsreally different what caused
18 him to change his opinion and again I dont
19 like the word shambecause it and I noticedDr
20 Yost is very fond of the word nefarious and I
21 think this is more appropriate use of the word
22 nefarious because sham affidavit suggests
23 something nefarious and I dontthink thatsthe
24 case Itsjust it seems to me that he hasa
25 tendency to confuse medical causationwith
62
1 motion for reconsideration because itsbased on
2 the newaffidavit
3 MR BURKE Iwill try to be brief here
4 because I think wer reallyback to where we were
5 at the time we had the first summary judgment
6 motion The issues are exactly the same at this
7 pointwhen we donthave the benefit of the Yost
8 affidavit
9 As the court pointed out inthe first
10 summary judgment hearing a manufacturersduty is
11 only to design a product to eliminate unreasonable
12 riskof foreseeable injury and that is that the
13 legal duty to warn only applieswhere the supplier
14 knows or should have known of the unsafe condition
15 which is at issue And even whenyouretalking
16 about a warning situation if the product is
17 without an adequate warning its still only
is defective if the supplier has reason to know of
19 the danger
20 So the only relevant question that we
21 have on these motions is whether the chronic
22 irreversible health conditions that MsMajor
23 complains of were known or reasonably foreseeable
24 in terms of a risk of exposure to pepper spray and
25 that was prior to 2oo8 There simply is no
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1 ut when h 's asked about the 1 vel)' beginning in the first affida it to lain 
2 peer-reviewed literature and he's asked ould it 2 hy his testi ony see s at least to have c a . 
3 put a manufacturer of pepper spray on notice, he 3  I'm going to strike the a id . 
4 says no. He makes it -- to e i 's about as clear 4 I just think at this int le  't rely on it to 
5 as it can e tha , in fa , it d 't e ist at 5 create  ispute f te ial fa t, hich is re lly 
6 that time. nd he even as ed -- h 's e en , 6 hich is i 's there f . iously  n't  
7 "Is it your understanding that the adverse hu an 7 hich ide is rig t, t I  kno  t t the rden 
8 health effects that exposure to O.C. and 8 is n the f to bring orth n t to 
9 capsacinoids by hu ans are generally dee ed to be 9 create  al dispute f a t  the le  
10 te porary, reversible and not long ter ?" nd he  I a e is that the ition s gests t t the 
11 says, "I think that's fair, yes." So he agrees  e da t is, in fa , re t  is consistent 
12 ith t t.  ith t e te  t   e ro  r 
13 If this ere a straight negligence  rt. 
14 question, duty, breach of duty, et cetera, that    f r -- t  llo  the -- the 
15 ould be probably enough. ut here e're talking  l i tiff t  e i   a e t ir e rt 
16 about a manufacturer who, when you get to the  ute at   ithout l   la ion 
17 foreseeability issue, it has to be foreseeable to   t  , at's re ll  i fe t, t s  
 that person, that manufacturer that, in fact, this  hi  to change his opinion -- , i ,  on't 
 ld se t is  tion  at's  ike the   e ause t --  I tic  r. 
 here it all falls apart.  ost is l)' f  ft e r  f rious  I 
21 I a  not inclined to tell the plaintiff   is is  a      
 in this case that she can have yet a third  ous a se  ida it  
2  affidavit because it's really a third. ou have  s et i  efarious a  I n't t ink t at's t e 
 the first, the second and the third to try and  . It's j t -- t s       
 explain what should have been explained in the    s   ti  th 
  
 foreseeability and hether the anufacturer could  ion    t's   
 e f res  t t t is l   t e .  t e  i vit. 
 nd t e case cited, t e i ll case  . :  il       
 cited by defense, is it exactly on point. Al ost     e're ll       
 anything could happen ith the product that's out  t t  ti    t  fir t r  j t 
 there. That doesn't make a product --   .         
 a fact rer lia le. It as t  e s et i   i t e  e on't a e t e e efit f t e st 
 that's reasonably foreseeable, not just anything,  ff vit. 
 anyplace, anywhere.   t  t i t  t i  t  i t 
10 And so I a  granting the otion to  su ary judg ent hearing, a anufacturer's duty is 
11 tri .  I t i  it  -- f rt t l  it  l  t  si   r t t  li i t  r s l  
12 has a huge impact on the rest of the case because     i jUI    i    
 I t i  e all rst  t t t  e eral  le al t  t  r  l  applies ere t e supplier 
 Hazardous Substance Act doesn't create a private    l    f   condit  
   ction.  i  is t issue.    ou're t l i  
16 And so the question then becomes     sit ation, i  t   i  
 whether your client's going to be able to co e  i t   r i , t's stil  l  
 forth and sho  that, in fact, there as so e 18   t  l   r son t   of 
 problem with the warning label. So I haven't 9 t  danger. 
20 eci e  t at iss e, t I t i  t at clearl  t   t  onl  r l t sti  t t e 
21 having this expert has a huge impact. So I don't    t  oti  i  t r t  chr i  
 know if you want to go ahead and proceed on your  i  alt  conditi  t t s. j  
 -- on the rest of your motions.  c lai s f ere  r reasonably f reseeable 
  KE: I can.  i  ter s of a ris  of exp s re t  pe er spray and 
25 T E OURT: kay. ecause I'm denying the  that  ri  t  2008. T r  si ply i  n  
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1 evidence in the record at this point that says 1 issue offact
2 that And for that reason alone this motion 2 Now as the court indicated Ithink
3 should be granted I guess what wer talking 3 both parties are in agreement that theres no
4 about is two separate motions there is a motion 4 independent cause of action under FHSA So thats
5 a second motion for summaryjudgment That 5 not the issue Although I meanwere going to
6 motion should be granted The motion for 6 have to wait for counsel to respond But the way
7 reconsideration of the first order on summary 7 I read their briefs on this issue they are
8 judgment should be denied 8 basically agreeing with us that this isnta
9 So let me talk about the FHSA claim 9 negligence per se situation Its more of a
10 just briefly And I guess the only reason we 10 situation where the FHSA may be used as evidence
11 brought the second motion is that the court 11 of negligence but not necessarily negligence per
12 invited it on thegrounds that the first that 12 se
13 that issue the FHSA was not really teed up Im 13 And Ithinkthats that would be
14 still not thinking itsnecessary for two reasons 14 accurately stated because ifyou look at the
15 Number one it was really never pled 15 standard the labeling standard it doesn
16 THE COURT Right 16 specifically come out and say this is what the
17 MRBURKE But even ifyou get beyond that 17 warning label shall state at least as to this
18 number two we stillcome back to the same 18 this particular hazard And what it talks about
19 underlying issue and that is this is a negligent 19 is you must have some explanation of the principal
20 failure towarn case and you still have to have a 20 hazard but it doesn define what that principal
21 known or foreseeable risk of injury And no 21 hazard is Excuse me It doesn distinguish
22 matter howyou characterize this in terms of FHSA 22 between what is a principal hazard and a secondary
23 you still have that same issue to overcome andwe 23 hazard and it doesn actually tell you the words
24 dontthink that that has been done There hasnt 24 that you must use It just sayshere some
25 been sufficient evidence to even raise a triable 25 samples of the kind of thing that you may do
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1 So unlike the Idaho cases which we 1 what the acute responses were And so even
2 must look to because were really talking about 2 even if that was at issue there reallywould be
3 Idaho tort law now unlike the cases where the 3 no issue of fact on proximate cause because that
4 court has said yup thatsa negligence per se 4 would basically be therewould be no proximate
5 situation this isntit The type of things that 5 causes as amatter law
6 the Idaho cases are saying is where you have a 6 So therefore the labeling of acute
7 statute that says you cantgo over 55 miles per 7 respiratory response is simply not relevant to
8 hour ifitsposted Well thatspretty clear 8 these motions
9 youreeither over it or youreunder it and so 9 So where does that leave us The same
10 its easy to saywhen you violate Here thats 10 place At the end of the day as with the
11 not clearlydefined so I dontthink we have a 11 negligence and strict liability claims generally
12 negligence per se issue 12 the key to negligence liability under the FHSA is
13 Ialso dontthinkthatwe have an 13 still whether or not SEC had notice prior to2oo8
14 issue here of labeling for acute responses toOC 14 of the risk of chronic irreversible respiratory
15 exposure I think the court recognized that 15 disease And aswev stated many times here
16 during our last hearing If this was the issue 16 today that evidence just isn there And the
17 we wouldntbe here today because the acute 17 burdens on the plaintiff to come forward and
18 response would already be gone andwer nothere 18 produce that evidence The affidavit ofMr or
19 Clearly wer talking about a longterm chronic 19 Dr Yost is stricken Thatsnot applicable
20 disease 20 Theres nothing else in the record that would
21 And more to the point MsMajor was 21 support that claim Thank you
22 trainedby IDOC on what these acute respiratory 22 THE COURT Thank you Mr Overson
23 responses are and she actually had acute responses 23 MROVERSON Your Honor I do want to make
24 to exposures before she ever got exposed to any 24 two points and then Iwill submit it on the
25 OC products from SEC so she was well aware of 25 briefing
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1 evidence in the record at this point that says 1 issue  f t. 
2 th . nd for that reas n , this otion 2 , s the t in ic t ,  think 
3 should be granted. I guess hat e're talking 3 th ties e in e t that t re's  
4 about is t o separate otions; there is a otion  independent cause f a tion der .  t at's 
5 -- a second otion for su ary judg ent. hat  not t e iss . lthough --  , 're   
6 otion s ld e r t . he tion for  ave to ait r s l to . t e  
7 rec sideration f the first rder  s ar     the r riefs  is , t e  re 
8 judgment should be denied.   re ing t   that this is 't  
9  let e talk t the  lai   ligence er s  it ti . It's r  f  
 just briefly. nd I guess the only reason e  it ti   t       i e e 
 ro t t e sec nd tion is t at t e c rt 11 of negligence, but not necessarily negligence per 
 invited it on the grounds that the first --  12 . 
 that issue, the F S , as not really teed up. I'm  n    at's -- that ould be 
 still t t in ing it's ecessar  for t o reas s:   te  se      
 u ber , it as r ll  e er l .  , e  ,  sn't 
  T: ight.  ifi ll  e t   t i  i  t t  
 . : ut e  if ou t  t t,  ing a el    e t   s --
 nu ber t o, e still co e back to the sa e  t is rtic lar r . n  at it t l s t 
 underlying issue and that is this is a negligent  is you ust have so e explanation ofthe principal 
 failure to arn case and you still have to have a  rd,  t sn't     
 kno n or foreseeable risk of injury. nd no   . c s  .  sn't is  
 atter ho  you characterize this in ter s of F S ,  t  t is  ri i l r    s r  
 you still have that same issue to overcome and we    it esn't t ll  t ll  t e rds 
 n't   t as  .  sn't  that you ust use. It just says here's so e 
  f     ise  riable  s les f t  i  f t i  t t   . 
  
 o unlike the Idaho cases, hich e  hat the acute responses ere. nd so even --
 ust look to because e're really talking about    t   ,  l    
 Idaho tort la  no , unlike the cases here the           
 court has said, yup, that's a negligence per se  ould basically be -- t      
 situation, this isn't it. The type of things that      . 
 the Idaho cases are saying is here you have a  , t r f r , t  l li  f t  
 statute that says you can't go over 55 iles per  respiratory response is si ply not relevant to 
 hour if it's posted. ell, that's pretty clear;   ti ns. 
 you're either over it or you're under it and so       s?   
 it's easy to say when you violate. Here that's  place. t the end of the day, as ith the 
 not clearly defined, so I don't think we have a  negligence and strict liability clai s generally, 
 negligence per se issue.  the key to negligence liability under the F S  is 
13  l  on't i       till      e ri  t  00  
 issue here oflabeling for acute responses to O.C.   t  i   r nic, i i l  pi t  
 exposure. I think the court recognized that  disease. nd as e've stated any ti es here 
 during our last hearing. If this as the issue,  today, that evidence just isn't there. And the 
 e ouldn't be here today because the acute  burden's on the plaintiff to co e for ard and 
 response would already be gone and we're not here. 18 produce that evidence. he affidavit of r. -- r 
 Clearly we're talking about a long-term chronic 19 r.   stri ken. hat's  applicable. 
 .  There's nothing else in the record that ould 
 And more to the point, s. ajor was  support that clai . Thank you. 
22 trained by IDOC on what these acute respiratory   URT:  u. r. r on. 
 responses are and she actually had acute responses  R. ON:  nor, I d   t   
 to exposures before she ever got exposed to any 24 two points and then I will sub it it on the 
 O.c. products from SEC, so she was well aware of 25 briefing. 
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1 First of all itsnot my position that 1 damages She certainly has an expert who can
2 FHSA cannot give rise to a negligence per se I 2 testify that she did have some effects of this
3 believe that if the FHSA is violated the jury 3 So I agree with you Mr Overson
4 finds that thatsnegligence per se 4 Negligence per se I think sometimes is
5 Two is even without the chronic 5 terribly misunderstood Its not a substitute for
6 evidence the evidence ofpotential chronic 6 the for the plaintiff having to prove their
7 injury she still has a claimfor the extreme 7 case It simply is away in which the duty is
8 acute experience that she had The record is 8 established and the breach of the duty
9 indicative thatshe after the training she 9 Mr Burke is correct however the
10 continued on into the next day to have problems 10 standard has to be such that it doesn require
11 and had to go see her doctor the next day 11 the jury to have to weigh anything Its like the
12 Damages are smaller obviously butwe still have a 12 speeding violation And I like to use two
13 triable issue 13 examples If theresa speed limit that says you
14 THE COURT Okay Any response to that 14 cantgo over 55 and youre going 65 thats
15 MR BURKE No I thinkwev beat a dead 15 negligence per se but it only establishes the
16 horse to death 16 duty thebreach of the duty It doesn
17 THE COURT Well I mean he has a point 17 establish proximate cause or anything like that
18 If the whole thrust of everything has been 18 Where however the person is charged
19 about chronic Ithasn been aboutacute And 19 with reckless driving or driving in excess of
20 theresplenty of evidence that theres that 20 conditions that is not a standard that you would
21 there are acute effects from capsacin So I think 21 give an instruction on negligence per se because
22 hesgot a point I just don know that you are 22 in fact the jurysgoing to have engage in pretty
23 going to want to go to trial over it but thats 23 much the same gyrations they would have to engage
24 between the two of you because I dontthink 24 in anyway
25 summaryjudgment is on the basis that she has no 25 The if you look at the standard in
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1 the Federal Hazardous FH
2 MRBURKE Substance
3 THE COURT Substance When you ifyou
4 look at that it really isntcreating a standard
5 It simply requires it gives sort of an example
6 ofwhat needs to go on the warning label
7 SoIm Iwould not find that this
8 was a negligence per se situation I would not
9 give a jury instruction along those lines because
10 I just don think its a standard thatsbeen
11 clearly established
12 Imnot going to go into the proximate
13 cause or any of that other business I dont
14 think itsreally relevant to the courts
15 decision
16 I do agree with Mr Overson clearly he
17 the issue of the acute exposure is thats
18 still there and if the parties want to go forward
19 on that they certainly can
20 Mr Overson I need you to understand
21 I donttake pleasure in agreeing And for
22 whatever itsworth Ivebeen an attorney for 38
23 years Ive been both a plaintiffs counsel and
24 defensecounsel Plaintiffis much more fun
25 because youre on the side of right with due
1 respect
2 But unfortunately this is a situation
3 that I really think that summary judgment for
4 Security Equipment Corporation is appropriate on
5 the chronic issue But I want you to know I I
6 spent a lot of time reading this and really
7 thinking about it a lot and especially looking at
8 very carefully what was said in the depositions
9 and whats said in the affidavits And I
10 understand your argument I just don agree with
11 it So but it was not done lightly Theres
12 been a lot ofwork put into it
13 MR OVERSON I understand that and I
14 appreciate the courtsattention
15 THE COURT And I thinkboth sides have done
16 a really excellent job of addressing this issue
17 Its not an easy issue and you clearly have a
18 client whosgot some significant mental
19 medical health situation I understand that
20 Itsjust I I just don feel that summary
21 judgment is inappropriate in this case SoIm
22 going to grant it
23 I would askMr Burke to prepare the
24 appropriate orders Please run them by
25 Mr Overson first so that he can lookat them and
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 s  f , it's t   t at  .  t i l    t   
  a not e rise t   ligence  .   ti     e  fects  . 
 believe that if the F S  is violated, the jury     th , r. . 
4 finds that that's negligence per se. 4 e ligence er    es  
  is e  itho t t e c  t i l  is t . t's t  tit t   
 e i e ce, t e e idence f te tial c r ic  t  --  the      
 i j r , e till   l i  f r t e tre   case. It si l  is a a  i  ic  t e t  is 
 acute experience that she had. he record is  s   e    t . 
   e -- after the trai ing s e  r.   ct, , e 
 tinue   i t  t e t  t   le s   s  e h  t sn't re 
1 a  a  t  go see er ctor the e t ay.  t  j r  t   t  i  t i . It's like t  
 s re s ll r i sl , t e still     . nd  e  s   
 triable s .  l . If t re's   li it t t   
  : a .  res onse t  t at?  n't     ou're  , at's 
 . : ,   e've    15 lige ce r s , t it l  st lishes t  
 s  t  t .  ty, t  r  f t  ty. It sn't 
  T: ll, I ,  s  i t.  establish proxi ate cause or anything like that. 
  -- t e h le t rust f r t i  s een  r , r, e    
 t i .  sn't   .   it  les  i i   i i  i  ess  
 t ere's le t  f e i e ce t at t ere's --   i ,         
 there are acute effects fro  capsacin. So I think  i   i str ti   lige ce r s  se, 
 he's got a point. I just don't kno  that you are  i  t, t  j ry's i  t    i  tt  
 i  t  a t t   t  trial er it, t t at's  uch the sa e gyrations they ould have to engage 
 t e  t  t  f  s  I n't t i   i  y y. 
  udg e t    s       -- if  l  t t  t r  i  
  
   s --  --  ect. 
 . : . 2      i t  
  T: ubstance. hen you --    that I really think that su ary judg ent for 
 l  t t t, it r ll  isn't r ti   st r .  ecurity quip ent orporation is appropriate on 
 It si ply requires -- it gives sort of an exa ple  t  r i  i . t I t  t   I -- I 
 of hat needs to go on the arning label.      e    l  
  'm --        t i i  a t it a l t a  es eciall  l i  at 
 was a negligence per se situation. I would not  very carefully what was said in the depositions 
 give a jury instruction along those lines because   at's i    ffi vits.   
 I just don't think it's a standard that's been    t.   n't   
 clearly established.  t.  -- t it  t  li tly. ere's 
 I'm t going t  go into the proxi ate         . 
 cause or any of that other business. I don't  . N:      
 think it's really relevant to the court's  r iate t  urt's tt nti n. 
 i ion.   URT:   i      
 I  a ree it  r. erson, clearl  e   l     i   e. 
 -- the issue of the acute exposure is -- at's  It's not an easy issue and you clearly have a 
 still there and if the parties ant to go for ard  client ho's got so e significant ental --
 on that, they certainly can.   l  it ation.   t at. 
 r. ers , I ee   t  erstand,  It's just I --   on't l   
 I on't t  l s r  i  r eing.  f r  j e t is i a r riate i  t is case.  I'm 
 hatever it's orth, I've been an attorney for 38  i  t  r t it. 
 years. I've been both a plaintiffs counsel and  I l  s  r. r  t  r r  t  
  el. l i tiff      appropriate orders. Please run the  by 
 eca se ou're  t e si e f ri t it  e  r.  t  t       
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1 if he has any objection he can file that 1 BOISE IDAHO OCTOBER 177M 2011
2 objection Wellstand in recess 2 THE COURT Do you have you heard from
3 MR OVERSON Thankyou Your Honor 3 opposing counsel
4 MR BURKE Thank you 4 MR BURKE No but I will say that traffic
5 5 is extremely backed up at the parking lot so
s s THE COURT Oh is it
7 7 MR BURKE Yeah
8 8 THE COURT Oh okay
9 9 MR BURKE Theresno parking except for
10 10 way down inside the parking garage
11 11 THE COURT All right All right
12 12 Mr Overson is present
13 13 Ive read all of the material I do
14 14 have a couple of questions before we get into
15 15 this I went and rereadthe complaint And the
16 16 complaint I think can be read to include acute
17 17 effects Now I know that all of the discovery
18 18 has really is reallyat the chronic I frankly
19 19 dontknowwhat in damages I I
20 20 Mr Overson with due respectIveread your
21 21 brief about the idea that you can somehow find
22 22 liability on acute and somehowget damages on the
23 23 chronic I dontthink you can do that I think
24 24 I want you to know whenyou get up to argue
25 25 counsel I think has correctly pointed out that
73 74
1 almost all of the cases that you cite are from 1 that she was well aware ofthe acute effects
2 what we call railroad cases The standard is 2 But I dontthink youregoing to be
3 completely different and if you read all of the 3 able to back door from what I read of your
4 case law it identifies it as being very 4 argument back door into those chronic the
5 different 5 chronic effects that you tried to do
8 And so I tend to agreewith him that s Furthermore I know that you use for
7 what wer really looking at is I can 7 example as an example a medical dictionary
8 remember the name of the case its the safety 8 The problem thatyou have with that as to a
9 its the pin case 9 medical definition ofacuteversus chronic is
10 MR BURKE Sidwell 1 o this All of the expert testimony that I read had
11 THE COURT Sidwell thatwer really 11 made it really clear that the acute effects in
12 looking at Sidwell You cantuse damages to 12 this particular case is only a couple of days at
13 find liability You have to find liability first 13 most and thats what the studies show I didnt
14 AndIve already ruled that theresno liability 14 see anything in there that showed the acute
15 for the chronic allegations that you have because 15 effects would last for three month So I dont
16 there was no duty to warn 16 know that Imnot sure what relevance it is to
17 Now this case has never been teed up 17 have the medical dictionary thing
18 as an acute case andI dontknow whether given 18 With all of that in mind andIm not
19 whatIve read if this if I were to rule in 19 going to just point directlyat Mr OversonIm
20 your favor it seems to me thatwer going to be 20 also appointing Imgoing to be pointing to
21 therewill be a number of other motion practice 21 Mr Burke it seems to me that this is not a
22 becauseof the question ofwhether the warnings 22 judicial estoppel issue because I dontknow that
23 adequate as to acute acute effects and whether 23 anybody I dontknow that the court that
24 those whether your client was sufficiently 24 they gain any benefit or the court has allowed
25 warned And theresa lot ofevidence to suggest 25 them to you know gain anything from clearly what
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 if e as  j ti , e an file that  ! !  11l!  
 jecti . e'll stand i  recess.   T:   --     
3  :  , our r.  sing sel? 
  : ha k .  . : , t I ill s  t t tr ffi  
  i  tre l  acked  t t  r i  l t,  --
6 6  T: , s t? 
 7 . : . 
   : , . 
   : here's no parking except for 
    i i e t  r i  r . 
   :  t.  t. 
  r. ers  is r s nt. 
  've  l   e t ri l.   
  have a couple f questions before e get into 
  t is. I e t a  rerea  t e c lai t.  t e 
  l int, I t i ,   r  t  i l  t  
  . ,        
    -- is really at t e chronic. I frankly 
  n't  at i  a a es -- I --  --
  r. n, it   ect, 've   
  rief a t t e i ea t at  ca  s e  fin  
  lia ilit   t    t a es  t  
  chronic. I don't think you can do that. I think 
  -- I a t  t   e   et  t  ar e, 
  sel, I t i   rr tl  i t  t t t 
  
 al ost all of the cases that you cite are fro     as ll  f e  f cts. 
    lroa  s.     t I on't t i  ou're i  t  e 
 co pletely different and if you read all of the  e    --       
 case la , it identifies it as being very  ar e t, ac  r i t  t se c r ic -- t  
 t.  r ic ff ts t t  trie  t  . 
6 nd so I tend to agree ith hi  that 6 Further ore, I kno  that you use, for 
 hat e're really looking at is --  an't  exa ple -- as an exa ple a edical dictionary. 
  t    t   - it's the safety  e r le  t at  a e it  t at as t  a 
 -- it's the pin case.   tion f     
  : i el . 0 this: ll of the expert testi ony that I read had 
  T: Sid ell that e're really  ade it really clear that the acute effects in 
 looking at. Sid ell. ou can't use da ages to  t is rti lar s  is l   l  f s t 
 find liability. ou have to find liability first.    at's t  t  o .  i n't 
 nd I've already ruled that there's no liability  see anything in there that sho ed the acute 
 for the chronic allegations that you have because       th.   on't 
 there as no duty to arn.    -- 'm   t r l  i    
 o , this case has never been teed up    i  i  i g. 
 as a  ac te case a  I on't  et er i e    ll    i d,  'm  
  've    --        i  t  j st i t ir tl  t r. rson, I'm 
 your favor, it see s to e that e're going to be  also appointing -- fm going to be pointing to 
 -- there ill be a nu ber of other otion practice  r. ,      t  i    
 because of the question of whether the warning's  judicial estoppel issue because I don't kno  that 
 adequate as to acute --       --  on't    rt -- t  
 s  -- hether your client as sufficiently  they gain any benefit or the court has allo ed 
 arned. nd there's a lot of evidence to suggest  the  to, you kno , gain anything fro  clearly hat 
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1 has always been a chronic issue So I understand 1 uphill argument with you because a seeing it thus
2 I understand your arguments ButIm sort of 2 far anyway as SEC sees it
3 inclined to say thatyou know thatImnot going 3 However in that case what the court
4 to dismiss Im not going to find that they 4 was saying is that it wasn foreseeable that the
5 cantpursue the acute I dontknow what theyd 5 waythe injury occurredwould occur The injury
6 get from it But in any event I thatskind 6 wasntthe foreseeable pin prick that the court
7 ofwhereIm thinking right now 7 acknowledged It was thrust through the body into
8 So if I can make everyone focus and 8 a bone and shattered causing complications with
9 just give ten minutes to either side because 9 the bone Whereas had there been the simple pin
10 obviously this has been kind ofworked to death lo prick and assuming youknow that theywere
11 And I understand itsyour motion for 11 obligated to warn against that foreseeable injury
12 clarification but really what Mr Oversonhas 12 and the finger became infected and the person lost
13 done is filed a motion for reconsideration and 13 the finger potentially they could be held liable
14 thats the way I read it So Mr Overson you 14 for that type of injury
15 can have a ten minute total that means opening 15 And I would say that our case falls
16 and closing 16 closer to that scenario than the scenario with the
17 MR OVERSON All right Imreally Im 17 needle going and shattering inside the bone
18 prepared to submitwith the exception of maybe 18 The acute injury is an aggravation of
19 answering a few of the courts questions or as 19 an existing respiratory bronchitis and even if
20 manyquestions as the court has But 20 its just for two days That should establish the
21 THE COURT Which are usually to your 21 liability that that type they understood that
22 advantage just so you know 22 that was a complication According to the
23 MR OVERSON Yes I appreciate that I 23 vicepresident of this company in his deposition
24 would like to point out though that the pin case 24 said that a person with respiratory illness
25 1 think is different And I knowIvegot an 25 exposed to this material would have an aggravated
77 78
1 situation or it would take longer for them to 1 looking at it since the time of that pretrial
2 heal you know the effect would be greater So 2 conference
3 boom 3 THE COURT Well the only I just want to
4 THE COURT Yeah but he didntsay that it 4 explain The only reason that I did that is that
5 wouldbecome a chronic condition 5 the thrust of everything that wev been talking
6 MROVERSON Well right right but nobody 6 about here in court was on the chronic issue All
7 7 of the expert testimony was on the chronic issue
8 THE COURT Thats an issue 8 And actually the expert testimony also did
9 MROVERSON But nobody said nobody 9 establish that there are acute effects And in
10 anticipated that the hypothetical plaintiff in the 1o fact the warning label says there are acute
11 in the pin prick case would lose their finger 11 effects
12 But it was foreseeable that theydhave the acute 12 So with the clarification which was
13 injury of a pin prick So theres the distinction 13 directed at as I understand it directed at
14 thatIm drawing Okay 14 saying that the plaintiff no longer had a claim in
15 With that unless the court has any 15 that area because they had not pursued it in
16 further questionsImgoing to submit 16 fact it was your judicial estoppel issue that 1
17 THE COURT Mr Burke 17 thatI in fairness to bothsides I wanted to
18 MR BURKE Your Honor let me address the 18 treat it more like a summary judgment that in
19 contention that there is still a theory of 19 fact she didnthave that claim left sort of
20 liability on failure to warn of an acute 20 like a request for the court to say that she
21 respiratory reaction And thats really the focus 21 doesnthave that claim So thatswhy I did it
22 of our motion for clarification which as 1 22 MR BURKE Okay Well I agree and wer
23 understand I wasnthere the last time but the 23 proceeding today as if thats the issue and we
24 court decided to deemthat as a renewed motion for 24 think that that issue can be laid to rest today
25 summaryjudgment So thatsthe waywev been 25 And the reason we say that is itsnot
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 has al ays been a chronic issue. So I understand  l ent ith ou s    it t s 
2 -- I understand your argu ents. ut I'm sort of  far any ay as  sees it. 
3 inclined to say that, you kno , that I'm not going 3 ,   ase at  rt 
4 to is iss -- I'm not going to find that they  a   is that t n't res  that t  
5 can't pursue the acute. I don't know what they'd   the j   o ld . he injur  
6 get fro  it. ut, in any event, I -- t at's   n't t e forese le in ric  that t e rt 
7  here I'm t in ing right .  . t as rust    t  
8  if I can ake e eryone f c s a    ne    ications  
9 just give ten inutes to either side because  t e . hereas  there  t  i l  i  
 obviously this has been kind of orked to death. 10 prick, and assu ing, you kno , that they ere 
 nd I derstand it's r tion f r  ligate  to r  i st t t f rese le i j r , 
 clarification, but really hat r. verson has    inge  e fected   s   
 e  ile   tion     t e fin r, t ti ll  t e  l   l  lia l  
 that's the ay I read it. So, r. verson, you  for that type of injury. 
 can have a ten inute total, that eans opening       r se  
 a  cl si . 16 loser    a   r  th  
  : ll ri t. I'm r ll  -- 'm  le   t    . 
 prepared to submit with the exception of maybe  e t  i j  is  ti   
 answering a few of the court's questions or as   e isti  res irat r  r c itis  --  if 
 any questions as the court has. ut--  it's just  t  . t l  t li  t  
  T: hich are usually to your  ia ity  t  --   t 
 advantage, just so you know.  t t a   pli ti n. r i  t  t  
  S : es. I appreciate that. I  vice-president of this co pany in his deposition 
 l  li e t  i t t, t h, t at t e in case  s i  t t  rs  it  r s ir t r  illness 
 I think is different. nd I kno  I've got an   t  t i  t i l l    t  
  
 situation or it ould take longer for the  to  l i  t it i  t  ti   t t -trial 
 heal; you kno , the effect ould be greater. So  f r nce. 
 .   T: l ,   --    t  
  T: , t  i n't  t t it  xplain.  l  r  t t I i  t t i  t t 
 l    i  diti .     r   e've   
  E S : ell, right, right, but nobody         c . ll 
 --  of the expert testi ony as on the chronic issue. 
  : at's  e.   act all  t e e ert testi  als  i  
  ERS : But nobody said --   t l      f ts. ,  
 anticipated that the hypothetical plaintiff in the 0 fact, the arning label says there are acute 
 -- in the pin prick case would lose their finger.  f cts. 
 But it was foreseeable that they'd have the acute     l ri ti ,   
 injury of a pin prick. So there's the distinction   t --  I  it,  t 
 that I'm dra ing. kay.  saying that the plaintiff no longer had a clai  in 
 ith that, unless the court has any  that area because they had not pursued it, in 
 further questions, I'm going to submit.  fact, it s r j icial estoppel issue, t at I 
  URT: r. rke.  -- t t  -- i  e  t  t  i   t  t  
  E: our onor, let e address the  t  i   l  a su r  j  at,  
 contention t at there is still a theory f  f ct, s  idn't  t t l i  l ft, s rt f 
 liability on failure to warn of an acute  li   r t f r t  rt t   t t  
 respiratory reaction. nd that's really the focus 21 esn't v  t  laim.  that's  I i  it. 
 of our otion for clarification, hich as I 2 . KE: kay. ell, I agr   e're 
  -- I asn't ere t e last ti e, t t e 3 proceeding today as if that's the issue and e 
 urt ci        t    t i  t t t t i    l i  t  t t day. 
 su ary judg ent. So that's the way we've been 5  t  reaso  e say t t is it's t 
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riskofwhether whether there is a risk is so
80
1 a viable theory as a matter of law andthats 1 this acute reversible adverse reaction and they
2 because reasonable minds cantdiffer on this 2 want to have it temporarily incapacitate either a
3 point where the risk of acute adverse health 3 criminal or inmate whatever the situation is so
4 effects is known open and obvious It can give 4 they can avoid having to use the alternative
5 rise to a legal duty to warn 5 which is a lethal form offorce
s THE COURT And the products liability s So the point is these are acute
7 situation 7 temporary adverse reactions and they are known
8 MR BURKE Yes wer back to the products 8 and they are obvious to everyone and that includes
9 liability Werejust looking at in a different 9 Ms Major
10 framework Wer forgetting about the condition 10 Theresno dispute that she trained on
11 that she has right now and wer looking at the 11 acute respiratory reactions by through the
12 hypothetical condition that she has an acute 12 IDOC Theresno dispute that she was exposed to
13 injury 13 OCduring her trainings and she experienced
14 So let me start first ofall with the 14 those effects and she also observed others who
15 basic undisputed facts because this is where it 15 experienced those effects around her
16 always comes downto 16 Shesadmitted in two ofher affidavits
17 This is a pepper spray product Its 17 that she knew that exposure caused acute
18 designed and intended to cause acute reversible 18 temporary reversible reactions including
19 temporary adverse health effects And those 19 respiratory inflammation and coughing So
2o effects include acute adverse inflammation ofthe 20 THE COURT Well also test results show
21 respiratory tract Werenot talking about a side 21 that too
22 effect here that is not known generally to the 22 MR BURKE Yeah thetest results show that
23 population This is what this product is sold 23 she knows it
24 for This is why law enforcement agencies buy it 24 So what wer doing here Your Honor
25 and this is why they use it They want to provoke 25 iswer standing back and wer saying while the
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1 1
2 obvious to require a warning in the first place or 2
3 whether it may be a proximate cause of damage are 3
4 generally questions of fact for the jury Where 4
5 the facts are undisputed and where reasonable 5
s minds may not differ theybecome questions in law s
7 for the court Wer saying thats the situation 7
s here 8
9 Let me cite you to a number of Idaho 9
1 o cases that have so held as matter of law that 10
11 there is no duty to warn where the risk is 11
12 obvious Puckett versus Oakfabco132Idaho 816 12
13 Corbridge versus Clark Equipment 112 Idaho 145 13
14 Tattle versus Sudenga Industries Inc 125 Idaho 14
15 145 And finally we get back to ourkey case 15
16 here Sidwell versusPrym112Idaho 76 1s
17 I want to stop and talk about the 17
18 Sidweli case again because its it was 18
19 definitely on point whenwe were here last time 19
20 discussing it Its on point on this issue of the 20
21 acute injury also 21
22 Ifyou recall its the pin case So 22
23 we have twocomponents here We have what is 23
24 foreseeable is that a pin will prick the skin 24
25 It will prick clothing It might tear something 125
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1 a viable theory as a matter oflaw and that's 1 this ac t , reversible adverse reaction and they 
2 because reasonable inds ca 't di fer on this 2 ant to have it te p ra ily incapacitate either a 
3 point where the risk of acute adverse health 3 criminal or in at , hatever the situation is, s  
4 effects is kno n, open and obvious. It can't give 4 they can a id having to use the alter , 
5 rise to a legal duty to warn. 5 hich is a lethal form of forc . 
6 THE C RT: And the products liability 6 So the point is these are a , 
7 situation. 7 te r r , a verse reactions and they are kno n 
8 . : Yes, e're back to the products  and they are obvious to e eryone  that includes 
9 liability. We're just looking at in a different 9 s. aj r. 
10 fra e ork. e're forgetting about the condition  re's  dispute that s  trained n 
11 that she has right now and we're looking at the 1 te re irat r  re tions by -- through the 
12 hypothetical condition that she has an acute  I . re's  ispute at s e as ose  t  
13 injury.  .C. d ring her trainings a d e e ience  
14 So let e start, first of all, ith the  those e fects d s e s  bserved t ers ho 
15 basic undisputed facts because this is here it 15 e erience  those effects around er. 
16 always comes down to.  e's ted    r ida ts 
17 This is a pepper spray product. It's  t e   s re s  , 
 designed and intended to cause acute, reversible,  te porary, reversible reactions including 
19 temporary adverse health effects. And those  r s ir t r  infla ation  i . --
20 effects include acute, adverse infla ation of the  E : l ,     
 respiratory tract. We're not talking about a side  , . 
 effect here that is not kno n generally to the  . : ,      
 population. This is what this product is sold    i . 
24 for. This is why law enforce ent agencies buy it    e're  r ,  r, 
 and this is hy they use it. They ant to provoke  is e're st i    e're s i  il  t  
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1 s    --   s      It might actually enter an object. But what the 
2 obvious to require a warning in the first place or 2 court found was not foreseeable was that it would 
3 hether it ay be a proxi ate cause of da age are  be used with such a force to actually invade or 
4 generally questions of fact for the jury. Where  pierce the bone and shatter. 
 the facts are undisputed and here reasonable  And so for those reasons, as we 
6 minds may not differ, they become questions in law 6 discussed the last time, the court said that it's 
7 for the court. e're saying that's the situation  not foreseeable that that would happen. It wasn't 
8 re.  known or shouldn't have been known to the 
 Let me cite you to a number of Idaho  manufacturer that that would happen, and, 
10 cases that have so held as atter ofla  that  therefore, for that reason there was no duty to 
11 there is no duty to warn where the risk is  warn of that more chronic, permanent type of 
 obvious. Puekett versus akfabeD, 132 Idaho 816.  injury. 
 Corbridge versus Clark Equipment, 112 Idaho 145. 1  But the court didn't stop there. 
14 Thttle versus Sudenga Industries, Inc., 125 Idaho 14 Actually if you read the case, they actually 
15 145. And, finally we get back to our key case 15 talked about the foreseeability of the acute 
16 here, Sidwell versus Prym, 112 Idaho 76. 16 injury, that is the pin prick. And the court 
17 I want to stop and talk about the 17 said, well, yeah, it's certainly foreseeable that 
18 Sidwell case again because it's -- i   18 that might cause a pin prick on any users, but 
19 definitely on point when we were here last time 1  that was equally known to the manufacturer as it 
20 discussing it. It's on point on this issue of the 20 was to the user. And so the court said --
21 acute injury also. 21 THE COURT: There was no duty to warn. 
22 If you recall, it's the pin case. So 22 MR. BURKE: For a second reason there's no 
23 we have two components here. e have what is 23 duty to warn. So you have two components of duty 
24 foreseeable, is that a pin will prick the skin. 24 to warn here. The first component has to do with 
25 It will prick clothing. It might tear something. 25 lack offoreseeability for the more permanent 
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longterm damage the shattering ofthe knee bone
And the second has to dowith the more acute pin
prick injury which was so fore or so it
was foreseeable but itwas so foreseeable that it
was obvious And the court specifically said that
a manufacturer only has a duty to warn of
foreseeable risks that are not obvious
And thatswherewe get down to where
we are today Your Honor In this particular case
wethink the same rules should apply here because
that case is exactly on point The risk ofacute
temporary reversible respiratory reaction is
known and obvious It was to MsMajor Shes
admitted such
And so under the circumstances ifwere
only talking about acute injury there is no duty
to warn ofthat risk as a matter of lawbecause we
contend Your Honor like those other Idaho cases
I cited reasonable minds cannot differ on this
point
So heresa variation of the theme
The plaintiff argues that SEC should have warned
people with pre existing respiratory conditions
that their acute reactions maybe more severe
Well this is nothing more than an argument about
85
24 hours at the end ofthe day itsacute its
temporary and its recoverable
And so if we eliminate fora minute all
of this discussion about the chronic if we just
forget about those facts thatswhat any person
using this productor being exposed to this
product would know Its going to hurt like hell
for awhile itsnot going to be comfortable but
its going to be acute andIm going to be done
with it in a period of time
Manufacturers cantpredict
variability I mean itsgoingto be variable
depending upon all ofthose factors that we
indicated Butwhat they can do is consider that
it is still going to be acute temporary and
reversible And because that is what is at the
end of the day open and obvious our contention is
that there is no duty to warn ofthat as a matter
of law
Im prepared to address the other
arguments about bootstrapping what is chronic or
something thats


















































MR BURKE Okay Thankyou unless you 25
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the degree of acute reaction Acute reactions to
OCexposure will always be variable depending
upon the circumstances and the persons The
reaction may varydepending on the type of spray
the potency ofthe spray the brand of the spray
the length of time of exposure to the spray
whether the exposure is direct or indirect
whether the person has been decontaminated
Thatsabig factor Or whether theres
ventilation in the area where the exposure occurs
Whether the person exposed is allergic or more
sensitive than other persons We have testimony
in the record that some people dont react at all
Very few but some people dont And then some
people are just more sensitive
And finally you have the situation
that theyr contending here where someone may
have a pre existing respiratory condition or some
other medical condition that somehow makes the
situation more acutely severe or slightly longer
in terms of recovery period
So I guess what wer saying here that
at the end of the day its still temporary its
still acute and itsstill recoverable So
whether youretalking 20 minutes an hour oreven
86
have any other questions
THE COURT No MrOverson do you have
anything further
MR OVERSON Just one We just heard a
litany of factors controlling the degree of the
acute reaction None of that is on the label
None of that Andnone of it was in the training
Theresnothing in the training that says youre
going to have an exacerbated effect acute or
otherwise from this product if you have a
respiratory illness Theres nothing in her
training that says ifyoureexposed for ten
minutes as opposed to one minute none of those
factors that were laid out are theresno
warning on the product
THE COURT Okay
MR OVERSON Thank you
THE COURT GentlemenIm going to rule
from the bench That probably doesntcome as a
big surprise
Ive read all ofthe material I first
want to point out that Im not Imnot going to
go down the path ofjudicial estoppel as I
indicated I think that the more validpoint here
is the one that was raised in the opposition
I nizi nni 0774PM
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1 long-term damage, the shattering of the knee bone. 
2 And the second has to do with the more acute pin 
3 prick injury, which was so fore- -- or so -- it 
4 was foreseeable, but it was so foreseeable that it 
5 was obvious. And the court specifically said that 
6 a manufacturer only has a duty to warn of 
7 foreseeable risks that are not obvious. 
8 And that's where we get down to where 
9 we are today, Your Honor. In this particular case 
10 we think the same rules should apply here because 
11 that case is exactly on point. The risk of acute, 
12 temporary, reversible respiratory reaction is 
13 kno n and ob io s. It as to s. aj r. e's 
14 a itted s . 
15 nd so under the circumstances if 're 
16 only talking about acute injury, there is no duty 
17 to ar  f that risk s a atter f la  because e 
8 contend, Your Honor, like those other Idaho cases 
19 I cited, reasonable minds cannot differ on this 
20 point. 
21 So here's a variation of the the e. 
22 The plaintiff argues that SEC should have warned 
23 people with pre-existing respiratory conditions 
24 that their acute reactions may be more severe. 
25 ell, this is nothing ore than an argu ent about 
 
1 24 hours, at the end of the day it's acute, it's 
2 temporary and it's recoverable. 
3  s  if e eli i ate f r a i te all 
4 of this discussion about the chronic, if e just 
5 forget about those facts, that's what any person 
6 using this product or being exposed to this 
7 product would know. It's going to hurt like hen 
8 for a while, it's not going to be comfortable, but 
9 it's going to be acute and I'm going to be done 
10 with it in a period of time. 
11 Manufacturers can't predict 
12 variability. I mean, it's going to be variable 
13 depending upon all of those factors that we 
14 indicated. But what they can do is consider that 
15 it is still going to be acute, temporary and 
16 reversible. A  beca se that is at is at the 
17 end of the day open and obvious, our contention is 
18 that there is no duty to warn of that as a matter 
19 oflaw. 
20 I'm prepared to address the other 
21 arguments about bootstrapping, what is chronic or 
CVP11003515 
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1 the degr e of acute reactio . Acute reactions to 
2 O.C. exposure will always be variable depending 
3 upon the circumstances and the persons. The 
4 reaction may vary depending on the type of spra , 
5 the potency of the spra , the brand of the spr , 
6 the length of time of exposure to the s , 
7 whether the exposure is direct or indirect, 
8 whether the person has b en deco ta inate . 
9 Th t's a big fa . r whether th re's 
10 ventilation in the area here the exposure oc . 
11 hether the person exposed is a lergic or more 
12 se tive than ther ers . e have testimony 
13 in the rec rd that so e e le 't react at a . 
14 ery fe , but s e people n't. nd then  
 people are just ore s iti . 
 , i l , you e the s tuation 
 that t ey're c te ing ere here e ne  
 a e  - sting  tion r e 
 t er  o    es  
 t  ore  ere r Hghtl   
 in er s   . 
   ess  e're  ere  
  e   e  t's ti  r , t's 
 til  te  t's til  r bl .  





  t r sti s. 
 T: . r. r on,    
t  ther? 
. :  ne.   r   
 lita  f f t r  tr lli  t  r  f t  
t  r action.   t t i   t  l el. 
 
 
   t at.   f i   i  t  training. 
s here's t i  i  t  tr i i  t t  ou're 
 goi  t  v  a  x c r t  f ct, c t  or 
1  
11 
otherwise, f  t i  pr ct if y   a 
r spiratory ill s. here's nothi  i  her 
1  tr i i  t t say  if you're ex  for ten 
1  i t s as o  t  o  inute, n  of t e 
14 f ct r  t t r  l i  out are -- there's no 
15 arni  o  the product. 
16 T  COURT: Okay. 
17 R. V SON: Thank you. 
18 T  COURT: Gentlemen, I'  going to rule 
19 fro  the bench. That probably doesn't come as a 
20 big surprise. 
21 I'v  read all ofthe material. I first 
22 something that's -- 2  want to point out that I'm not -- I'  not going to 
23 THE COURT: No, I don't think you need to do 23 go down the path of judicial estop el, as I 
24 that. 24 indicated. I think that the more valid point here 
25 MR BURKE: Okay. Thankyou, unless you 25 is the one that was raised in the op osit on. 
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1 Now I do find this is very similar to 1 negligence case
2 SidweH And what Iwant to pointout is Sidwell 2 Lets talkabout the pin Did the
3 clearly covers this in all of its aspects First 3 manufacturer have to put a warning that ifyoure
4 because itmade it clear that a manufacturer does 4 a hemophiliac and youprick your finger it could
5 not have towarn for those things thatare not 5 be deadly And obviously no Andreally thats
6 foreseeable We already dealt with the chronic 6 what the plaintiff inthis case is arguing Im
7 Ive made a ruling that the chronic effects were 7 unusual Im different They should have warned
8 not foreseeable at that time And therefore 8 And this product is functioning as it
9 there was no duty to warn 9 was designed to function The purpose behind
10 LikeSidwell and itsamazing how 10 pepper spray is to do exactly vhat the plaintiff
11 similar they really are there is also m duty to 11 is complaining about in the sense that its
12 warn where the danger is obvious 12 causing an acute reaction That is its purpose
13 Now Mr Overson argues thatthe acute 13 Its purpose is to cause that acute reaction
14 reactions oould have been more severe and 14 The warning label is clear that thats
15 therefore they should have warned about that 15 what its purpose is The the plaintiff in
16 Well lets take the pin analogy because I think 16 this case not only was trained but she took tests
17 its a good one The SupremeCourt saidthere was 17 where she identifieswhatthose acute reactions
18 no duty to warn that a pin couldprick Likewise 18 would be So she was well aware of these things
19 there was no duty to warn that it could prick and 19 And the Supreme Court in my view has
20 also infect 20 made it clear thatwhere theundisputed facts lead
21 Letsassume because were I think 21 to only one conclusion then the court can rule as
22 what MrOverson is overlooking is hessuggesting 22 a matter of law This product is the purpose
23 we have the thinskinned plaintiff Thatswhat 23 is to do exactly what it did
24 we have Eggshell plaintiff Thatsnot a 24 Now if it caused a chronic reaction
25 products liability case Thatsyour traditional 25 and thats I know theresa dispute so Im
89 90
1 but for the purposes of thisImgoing to assume
2 that it did The court has already ruled based on
3 the expert testimony that in fact the
4 manufacturer did nothave a duty to warn of that
5 because itwas not foreseeable that it could cause
6 a chronic reaction that it could cause an acute
7 clearly it was foreseeable and in fact all of
8 the parties recognized that
9 So in this case it is not the failure
10 to warn that caused her acute reactions Her
11 acute reactions she knew about it that it was
12 going to happen So because this is a products
13 liability case the standards really are quite
14 different
15 So I am going to grantsummary judgment
16 in this caseto the defendant and I would ask the
17 defendant to prepare the appropriate judgment
18 form
19 I believe that resolves all ofthe
20 issues that remain inthe case IfIm wrong the
21 parties need to let me know And therefore I
22 dontthink we need a 54bto make this a viable
23 appealable judgment
24 So I would ask Mr Burke ifyou would
25 go ahead and prepare that order I have not yet
1 signed the order thatyou had previously prepared
2 I would prefer to havean order that covers all of
3 these things
4 MR BURKE Okay I was going bring that
5 up Okay Ill just redraft that and incorporate
6 what we have today and what wehad the last time
7 THE COURT I thinkthatsabetter
8 approach And then you need to preparea final
9 judgment
10 MR BURKE And a final judgment
11 THE COURT Because I hope everyonesaware
12 that the SupremeCourt changed thecivil ruleson
13 the judgment form
14 MR BURKE Yeah
15 THE COURT And we theresawhole lot of
16 attorneys I know you guys knowbut we get into
17 arguments with attorneys that theres supposed to
18 be nothing in the judgment other than judgment for
19 whomever
20 MR BURKE Right Wer aware of that
21 THE COURT Im glad There is there is
22 a firm out of Colorado thatwev just had this
23 ongoing argument with I keep saying look I
24 cantsign this judgment because its not
25 appropriate
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1 o , I do find this is very si ilar to  ne ligence . 
2 Si ell. nd hat I a t to i t t is i ell  t's ta  t the . id the 
3 clearly covers this in all of its aspects. First, 3 a facturer ave t  t  r i  t at if u're 
4 because it ade it clear that a a turer oes   iliac   rick our fin r, it l  
 not have to warn for those things that are not 5 be dly? nd io s  .  re  t at's 
6 foreseeabe. e already dealt ith the chronic. 6 hat the lai tiff i  t is case is ar i . I'm 
 I've ade a ruling that the chronic effects ere  l. I'm fe t.   e d. 
 not foresee le at t at ti . , thertf r ,  nd this rod ct is u ioning  t 
9 there as no duty to arn.  as e igned t  ti . e Clle ind 
 ike Sid ell, and it's a azing ho   pepper spray is to do exactly vhat the plaintiff 
 si ilar h~ reall  are, t ere is als  IX) t  t   is l i ing t i  t e s s  t at it's 
 arn here the danger is obvious.  i   t  r ti . hat is its r . 
 o , r. verson argues t atthe acute  Its purpose is to cause t at acute reaction. 
 re tions c  a e  re ere   he a n   s ear t a  at's 
 therefore h~ should have arned about that.  hat it's purpose is. he --    
 ell, let's take the pin analogy breause I think  t is ase t l  s tr i , t s  t  t sts 
 it's a good one. he Supre e ourt said there as    i ti ies t t ose t  ti  
 no duty to warn that a pin could prick. Likewise,   .     e  ese . 
 there as no duty to arn that it could prick and   t e re e rt i   ie  as 
 s  e   e it l  t t e t  is t  t  l  
 et's assu e, because e're --  t i      l i ,       
 hat r. verson is merlooking is he's suggesting   tter f l . is r t is --  s  
 e have the thin-skinned plaintiff. That's hat  is to do exactly hat it did. 
 e have. Eggshell plaintiff. That's not a  ,     c  
 products liability case. That's your traditional  a  t at's -- I  t ere's  is ute, s  I'm --
  
 but for the purposes of this I'm going to assume  i  t   t t   i l  r d. 
 that it did. The court has already ruled based on  I l  refer t  a e  r er t at c ers all f 
 the expert testi ony that, in fact, the  t  t i . 
 anufacturer did not have a duty to arn of that   : y. I  i  ri  t t 
   as  e   t    up. kay. I'll just redraft t at a  incorporate 
 a c r ic reacti , t t it c l  ca se a  ac te,  at e a e t a   at e a  t e last ti e. 
 clearly it as foreseeable, and, in fact, all of   T.  i  at's   
 the parties recognized that.  approach. nd then you need to prepare a final 
        e   judg ent 
 t   t t   t  cti ns.    :   fi l u~ent 
 ac te reacti s, s e e  a t it, t at it as   T: ecause I hope everyone's a are 
 going to happen. So because this is a products  t t t  r  rt al t  i il r l s  
 liability case, the standards really are quite   j t r . 
 i nt.   : ah. 
 So I am going to grant summary judgment   T:   -- t ere's  l  l t f 
     t     l     att r e s -- I   s ow, t e et i t  
 defendant to prepare the appropriate judgment  r ts it  att r s t t t ere's su s  t  
 r .   t i  i  t  j t t r t  j t f r 
  li   l  l  f   ver. 
 issues that re ain in the case. If I'm rong, the   KE: ight. e're a are ofthat. 
 parties neal to let e know. nd, therefore, I   RT: I'm glad. r  is -- t ere is 
22 don't think we need a 54(b) to rmke this a viable   fir  t f l r  t t e've j st  t is 
 appealable judgment  ongoing argument with. I keep saying, look, I 
 So I would ask, r. Burke, if you would  can't sign this judg ent because it's not 
 go ahead and prepare that order. I have not yet 25 appropriate. 
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1 MR OVERSON Im not going to Colorado to 92
2 argue with the judge over what the judgment shouldIR S P O R T R RS C R R T I P I C A T E
3 look like in Colorado 2
4 THE COURT I know Its pretty it 3
5 actually gets to be quite amusing sometimes 1 RIM I MADSEN Official Court
6 So thankyou gentlemen
5 Reporter County of Ada State of Idaho hereby
7 MR BURKE Thank you Your Honor 6
certify
That I m the reporter wbo took the
8 R proceedings had in the above entitled action in
9
9 machine shorthand and thereafter the sane was
10 reduced Snto typewr i tang under my direct
10
11 supervision and
11 12 Tbat the foregoing transcript contain
12 13 a full true and accurate record of the
13 14 proceeding had in the above and foregoing cause
14
15 which was heard at No ee Idaho
16 IN WIT10 SS R ROp I have hereunto at
15
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MR OVERSON: I'm not going to Colorado to 
2 argue with the judge over what the judgment should 
3 l ok like in Colorad . 
4 THE COURT: I know. It's pretty -- it 
5 actually gets to be quite amusing sometimes. 
6 So, thank you, gentlemen. 
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SUPPORT OF SECURITY EQUIPMENT
CORPORATION MOTIONS TO STRIKE
THIRD AFFIDAVIT OF GAROLD YOST
AND 3 FOR RULE 56cAWARD OF
ATTORNEYS FEES AND COSTS
Defendant Security Equipment Corporation Defendant or SEC by and through its
5
attorneys of record Greener Burke Shoemaker PA hereby submits this Memorandum both in
Opposition to Plaintiffs third Motion for Reconsideration filed on October 24 2011 and in
Support of its Motions to Strike the Third Affidavit of Dr Garold Yost and for an order
pursuant to Rule 56c of the Idaho Rules of Civil Procedure awarding it reasonable attorneys
fees and costs in the form of sanctions imposed against Plaintiff and her attorneys for
disregarding the Courts order denying Plaintiffs request to file a third affidavit of Dr Yost for
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I IE J  J , an individual, 
Plaintiff, 
v. 
SECURITY EQUIP ENT 
C RP RATI , a issouri corporation, 
nt. 
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 (1) I  I I   
I TIFF'S    
I   (2)  
  I   
PORATION'S   I  
 I     
 (3)   56(c)   
'    
efendant Security Equip ent Corporation ("Defendant" or "SEC"),   t r  its 
attorneys of record, Greener Burke Shoe aker P.A., hereby sub its this e orandu  both in 
pposition to Plaintiff s third otion for econsideration, filed on ctober 24, 2011, and in 
Support of its otions to Strike the Third Affidavit of Dr. Garold Yost, and for an order, 
pursuant to Rule 56(c) of the Idaho Rules of Civil Procedure, awarding it reasonable attorneys' 
fees a  c sts i  t e f r  f sa cti s i se  a ai st laintiff a  er att r e s f r 
disregarding the ourt's order denying Plaintiffs request to file a third affidavit of r. ost, for 
 I  S PP  F S U I  IP  RPORA TION'S I S  ST I  
THIRD AFFIDAVIT OF GAROLD YOST AND FOR RULE 56( c) A ARD OF ATTORNEYS' FEES AND 
 - Page 1 14542-  ( 24316 doc) 
filing an improper motion for reconsideration of orders entered before final judgment was
entered and for failing to timely and efficiently respond to Defendants summary judgment
motions In addition to this Memorandum SEC relies on the Affidavit of Counsel in Support of
Security Equipment CorporationsMotion for Rule 56c Award of Attorneys Fees and Costs
Counsel Aff the pleadings and record in this case and applicable law as discussed herein
I INTRODUCTION
By now the Court is well acquainted with the factual and procedural background in this
case As a complete historical recitation would therefore be repetitive SEC will merely
incorporate herein by this reference the factual and procedural background previously set forth in
its prior motions for summary judgment filed April 22 2011 July 22 2011 and September 20
2011 1 and its opposition to Plaintiffs prior motions to reconsider filed July 26 2011 and
October 4 2011
At the October 17 2011 hearing on SECs third motion for summary judgment and
Plaintiffs second motion for reconsideration this Court found in favor of SEC on all issues and
thereafter issued an Order Granting DefendantsMotions for Summary Judgment Striking
Affidavit of Garold Yost and Denying PlaintiffsMotions for Reconsideration filed October 20
2011 On the same day the Court issued a final Judgment in this action pursuant toIRCP
54a
Three days later on October 24 2011 Plaintiff filed her third Motion for
Reconsideration by which she has asked the Court to reconsider its prior prejudgment orders
granting summary judgment to SEC and striking the second Affidavit of Garold Yost In support
As the Court will recall the third motion for summary judgment filed by SEC originated as a
Motion for Clarification and was later converted to a motion for summary judgment at the request of the
Court
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filing an improper motion for reconsideration of orders entered before final judgment was 
entered, and for failing to timely and efficiently respond to Defendant's summary judgment 
tio s. In ad ition to this e ora ,  relies on the ffidavit of ounsel in pport of 
Security Equipment Corporation's Motion for Rule 56(c) Award of Attorneys' Fees and Costs 
("Counsel ff."), the pleadings and record in this case, and applicable law as discussed herein. 
. I TR I  
By now, the Court is well-acquainted with the factual and procedural background in this 
case. s a co plete historical recitation ould therefore be repetitive, SEC ill erely 
incorporate herein by this reference the factual and procedural background previously set forth in 
its prior motions for summary judgment (filed April 22, 2011, July 22, 2011, and September 20, 
2011 1) and its opposition to Plaintiffs prior motions to reconsider (filed July 26, 2011 and 
ctober 4, 2011). 
t the ctober 17, 2011 hearing on SEC's third otion for su ary judg ent and 
l intif  s  ti   i rati , t is t  i      ll i ,  
thereafter issued an Order Granting Defendant's otions for Summary Judgment, Striking 
Affidavit of Garo1d Yost and Denying Plaintiffs otions for Reconsideration (filed October 20, 
2011). On the same day, the Court issued a final Judgment in this action, pursuant to I.R.C.P. 
54(a). 
Three days later,   , 11, laintiff   i   f r 
Reconsideration, by which she has asked the Court to reconsider its prior prejudgment orders 
granting summary judgment to SEC and striking the second Affidavit of Garold Yost. In support 
1 s the ourt ill recall, the third otion for su ary judg ent filed by SE  originated as a 
otion for larification, and as later converted to a otion for su ary judg ent at the request of the 
ourt. 
A U  I  SUPPO  OF SECURITY EQUI  CORPORATION'S I  T  STRIK  
THIRD AFFIDAVIT OF GAROLD YOST AND FOR RULE 56(c) A ARD OF ATTORNEYS' FEES AND 
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of this latest motion Plaintiff has filed a third Affidavit of Garold Yost despite previously
having asked for and being denied permission to file such a third Affidavit See Transcript of
Proceedings Sept 14 2011 and October 17 2011 Trans attached as Exhibit 5 to the
Affidavit of Counsel filed herewith Counsel Aff pp 5921 602
It should be also noted that since Plaintiff filed her latest motion for reconsideration
which is the subject of this opposition she has also filed her Notice ofAppeal of virtually all of
this Court decisions to date While the effect of filing a Notice of Appeal would normally
divest this Court of further jurisdiction over the matterIAR13 there is a limited set of actions
that the Court may rule upon during the pendency of Plaintiffs appeal IAR 13b Among
those actions is a Rule 60b Motion for Relief from Judgment Id For the reasons noted herein
SEC contends that it is appropriate and necessary for this Court to treat Plaintiffs improperly
filed Rule 11 motion for reconsideration as a properlyfiled Rule 60bmotion and thus this
Court retains jurisdiction to decide this final matter during the pendency of Plaintiff s appeal
Plaintiffs Motion for Reconsideration brought pursuant to IRCP 11a2 is
procedurally improper because Plaintiff did not file it until after this Court entered final
Judgment and because Plaintiff cannot and did not show that she is entitled to relief under the
proper and applicable Rule of Civil ProcedureIRCP60b For these reasons discussed in
greater detail herein Plaintiffs motion should be denied In the alternative if the Court is
inclined to consider Plaintiff s motion despite its procedural defects the third Affidavit on which
Plaintiff bases her latest Motion for Reconsideration does not warrant the relief sought by
Plaintiff and on that basis as well Plaintiff s motion ought to be denied
II ARGUMENT
A A Rule 11 Motion For Reconsideration After Final Judgment Is Not Proper
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of this latest motion, Plaintiff has filed a third ffidavit of arold Yost, despite previously 
having asked for and being denied permission to file such a third Affidavit. (See Transcript of 
Proceedings (Sept. 14, 2011, and October 17, 2011) ("Trans."), attached as ibit 5 to the 
ffidavit of ounsel filed her ith ("Counsel ff."), p . 9:21 - 60:2.) 
It s ld be also noted that since P a ff filed er latest otion for re , 
which is the subject of this opposition, she has also filed her Notice of Appeal of virtually all of 
this rt's e isions to . hile t e fect f ilin  a otice  ppeal ld  
divest this Court of further jurisdiction over the atter, I.A.R. 13, there is a limited set of actions 
that the Court may rule upon during the pendency of Plaintiffs appeal. I.A.R. l3(b). Among 
those actions is a ule 60(b) otion for elief fro  Judg ent. Id. or the reasons noted herein, 
SEC contends that it is appropriate and necessary for this Court to treat Plaintiffs improperly-
file  l   ti  f r r si r ti  s  r rl -filed l  0(b) ti ,  t s t is 
Court retains jurisdiction to decide this final atter during the pendency of Plaintiff s appeal. 
l i tiffs ti  f r si eration, r t r t t  I.R.C.P.  1 (a)(2), IS 
procedurally improper because Plaintiff did not file it until after this Court entered final 
Judgment, and because Plaintiff cannot and did not show that she is entitled to relief under the 
proper and applicable Rule of Civil Procedure, I.R.c.P. 60(b). For these reasons, discussed in 
greater detail herein, Plaintiff s motion should be denied. I  t  lternative, i  t  rt i  
inclined to consider Plaintiff s otion despite its procedural defects, the third ffidavit on hich 
laintiff ases er latest ti  f r econsi erati  es ot arra t t e relief sought by 
Plaintiff and, on that basis as ell, Plaintiff s otion ought to be denied. 
II. U T 
.  l  11 ti  r econsiderati  ft r i l Judg ent Is t Proper. 
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Plaintiff has brought her third Motion for Reconsideration according to the same Rule of
Civil Procedure on which she based her two prior motions That Rule reads in relevant part
A motion for reconsideration of any interlocutory orders of the trial
court may be made at any time before the entry of final judgment
but not later than fourteen 14 days after the entry of the final
judgment A motion for reconsideration of any order of the trial
court made after entry of final judgment may be filed within
fourteen 14 days from the entry of such order provided there
shall be no motion for reconsideration of an order of the trial court
entered on any motion filed under Rules 50a52b55c59a
59e59160a or60b
IRCPIIa2B The operative difference between Plaintiffs earlier attempts to achieve
reconsideration under this Rule is that the latest motion was filed after the entry of final
Judgment
Until a final judgment has been entered an order granting summary judgment is an
interlocutory order and subject to reconsideration pursuant toIRCP Ia2BPuckett v
Verska 144 Idaho 161 166 158 P3d 937 942 2007 citing Idaho First NatlBank v David
Steed Assocs 121 Idaho 356 825 P2d 79 1992 Conversely when a final judgment has
been entered an order on summary judgment ceases to be interlocutory and becomes final and
appealable Id A party may only make a motion to reconsider interlocutory orders or orders
entered after the entry of final judgment Straub v Smith 145 Idaho 65 71 175 P3d 754 760
2007 citingIRCP Ia2emphasis added Following entry of final judgment though a
motion to reconsider should be treated as a motion to modify or amend the judgment Id A
motion to modify or amend a final judgment is governed by Rule 59e
Under Rule 59 however a movant is not entitled to offer additional evidence
beyond that introduced prior to the final judgment Pulley v Sand Hollow Ditch Co Ltd 125
Idaho 237 245 869 P2d 554 562 1993 citing Marcher v Butler 113 Idaho 867 870 749
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Plaintiff has brought her third otion for econsideration according to the sa e ule of 
i il r re n ich s  ase  r t  rior ti s. hat l  r s, i  r le ant rt: 
 tion  re e ion   inte  r ers    
court ay be ade at any ti e before the entry of final judg ent 
t t later t a  o rtee  (1 )  te  t e t   t e in l 
judg ent.  otion for reconsideration of any order of the trial 
rt  fter tr  f fi l judg e t   file  it i  
f rtee  (1 ) a s fr  t e e tr  f s c  r er; r i e , t ere 
        er     
t re    o  iled  es 0(a), 2(b), 5(c), 9(a), 
59(e), 59.1, 60(a), or 60(b). 
I.R.C.P. 1 1 (a)(2)(B). The operative difference bet een Plaintiffs earlier atte pts to achieve 
i ti  e  t i  l  is t t t  lat t tio  a  ile  ft  t  t   i l 
Judgment. 
"[U]ntil a fi al judg e t as ee  e tere , a  r er ra ti  s ar  jud e t is an 
interlocutory order and subject to reconsideration pursuant to I.R.C.P. II(a)(2)(B)." Puckett v. 
rs a,  I  , ,  .3d ,  (20 ) (citin  I  irst at 'I  v. i  
 & Assocs., 121 Idaho 356, 825 P.2d 79 (1992)). Conversely, hen a final judg ent has 
been entered, an order on su ary judg ent ceases to be interlocutory, and beco es final and 
appealable. !d. "[A] party ay only ake a otion to reconsider interlocutory orders or orders 
entered after the entry of final judg ent." Straub v. Smith, 145 Idaho 65, 71,175 P.3d 754, 760 
(2007) (citing I.R.C.P. II(a)(2)) (e phasis added). Following entry of final judg ent, though, a 
"motio  t  r i r l   tr t    ti  t  if  r end" t  j nt. I .  
motion to modify or amend a final judgment is governed by Rule 59( e). 
"[U]nder Rule 59( e)," ho ever, "a ovant is not entitled to offer additional evidence 
beyond that introduced" prior to the final judgment. Pulley v. Sand Hollow Ditch Co., Ltd., 125 
I  , 5,  .2d 54,  (1 3) (citi  r . utler, 1  I  67, 70,  
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P2d 486 489 1988 Where as in this case the motion for reconsideration raises new
issues or presents new information not addressed to the court prior to the decision which
resulted in the judgment the proper analogy is to a motion for relief from judgment under Rule
60b Lowe v Lym 103 Idaho 259 263 646 P2d 1030 1034 Ct App 1982 see also
Marcher 113 Idaho at 870 Because this motion attempts to present new information which the
trial court did not have before it when rendering its decision granting summary judgment the
motion must be considered a motion for relief from judgment underIRCP60b
Here the decision which resulted in the judgment Lowe supra was this Court
October 20 2011 Order granting summary judgment in all respects disposing of all of
Plaintiffsclaims by this and its prior orders including all prior Orders granting SECsmotions
for partial summary judgment denying Plaintiffs motions for reconsideration and granting
SECs motion to strike the Second Affidavit of Garold Yost See October 20 2011 Order
Concurrently therewith this Court entered the final Judgment in this action See October 20
2011 Judgment At that point on October 20 2011 those decision which resulted in the
judgment ceased to be interlocutory orders Puckett 144 Idaho at 166 It was not until after the
entry of final Judgment that Plaintiff filed and served its new motion for reconsideration and
thus per the Civil Rules and relevant case law cited herein Plaintiffs reliance on Rule
I Ia2Bis inappropriate
B Plaintiff Cannot Establish The Necessary Grounds For Relief Under Rule 60b
Based on the foregoing case law and given that a motion for reconsideration under Rule
I Ia2Bis improper at this stage the Court must determine whether to treat Plaintiff s motion
as one to alter or amend the judgment under Rule 59eor as one seeking relief from judgment
under Rule 60b Accord Marcher 113 Idaho at 870 and Lowe 103 Idaho at 263 A review of
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P.2d 486, 489 (1988». "[W]here - as in this case - the motion for 'reconside ' raises ne  
issues, or presents new information, not addressed to the court prior to the decision which 
resulted in the judg ent, the proper analogy is to a otion for relief fro  judgment under Rule 
60(b)." Lowe v. Lym, 103 Idaho 259, 263, 646 P.2d 1030, 1034 (Ct. App. 1982); see also 
Marcher, 113 Idaho at 870 ("Because this motion attempts to present new information which the 
trial t id t have ore it he  re  ts ision  ary jud , the 
otion ust e c sidere  a tion for relief fro  judg ent er LR.C.P. 0(b)."). 
ere, the "decision hich resulted in the judg ent," Lo e, supra, as this ourt's 
ctober 20, 2011, rder granting su ary judg ent "in all respects ... ispos[ing]    
Plaintiffs claims by this and it's prior orders," including all prior Orders granting SEC's motions 
for partial summary judgment, denying Plaintiffs motions for reconsideration, and granting 
C's      fida t   t. (Se  er ,  r er.) 
Concurrently therewith, this Court entered the final Judgment in this action. (See October 20, 
2011 Judgment.) At that point, on October 20, 2011, those "decision[s] which resulted in the 
judgment" ceased to be interlocutory orders. Puckett, 144 Idaho at 166. It was not until after the 
entry of final Judgment that Plaintiff filed and served its new "motion for reconsideration," and 
thus, per the Civil Rules and relevant case law cited herein, Plaintiffs reliance on Rule 
11 (a)(2)(B) is inappropriate. 
. l i ti   t l   ar   r li f r l  0(b}. 
Based on the foregoing case law, and given that a motion for reconsideration under Rule 
11(a)(2)(B) is i proper at this stage, the Court ust deter ine whether to treat Plaintiffs otion 
as one to alter or a end the judg ent, under Rule 59( e), or as one seeking relief fro  judg ent, 
under Rule 60(b). Accord Marcher, 113 Idaho at 870 and Lowe, 103 Idaho at 263. A review of 
E RA  I  SUPPORT F SECURITY EQUIPMENT CORPORATION'S M TI S TO STRIKE 
I  AFFIDA VI  F GA L  Y ST A D F  RUL  56( c)   OF ATT RNEYS' FE S AND 
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Plaintiff s motion and accompanying documents demonstrates that Plaintiff seeks reversal of this
Courts rulings on summary judgment by relying exclusively on the new evidence contained
within the third affidavit of Garold Yost Now that Dr Yost has clarified any perceived
conflicts between his deposition testimony and his affidavits and has provided additional
support for his opinions a material issue of fact exists that would prevent summary judgment
Plaintiffs October 24 2011 Memorandum p 4 emphasis added Accordingly the proper
analogy is undeniably to a motion for relief from judgment under Rule 60b Lowe 103
Idaho at 263
As with Rule 59eproceedings the right to grant or deny relief under the provisions of
Rule 60b is a discretionary one with the trial court Lowe 103 Idaho at 263 citing Johnston
v Pascoe 100 Idaho 414 599 P2d 985 1979 A determination under Rule 60b turns
largely on questions of fact to be determined by the trial court Waller v State Dept ofHealth
Welfare 146 Idaho 234 23738 192 P3d 1058 1061 62 2008 citing Idaho State Police ex
rel Russell v Real Property Situated in the County of Cassia 144 Idaho 60 62 156 P3d 561
563 2007 Although courts have broad discretion in granting or denying such motions that
discretion is bounded by the requirement that the party seeking relief demonstrate unique and
compelling circumstances which justify relief Maynard v Nguyen No 37335 2011 WL
3904099 Idaho Sept 7 2011 emphasis added citing Miller v Haller 129 Idaho 345 349
924 P2d 607 611 1996 Those factual findings will be upheld unless they are clearly
erroneous Waller 146 Idaho at 238 If the trial court makes findings of fact that are not
clearly erroneous applies to those facts the proper criteria under Rule 60b1and reaches a
decision that follows logically from the application of such legal criteria to the facts found then
the trial court will be found to have properly exercised its discretion Danz v Lockhart 132
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Plai tiff s motion and a ing documents de onstrates that l i tiff s s reversal of this 
Court's rulings on su ary judgment by relying exclusively on the new evidence contained 
ithin the third affidavit of Garold o t: "Now that . ost has clarified a  e  
conflicts bet een his deposition testi ony and his affidavits, and has provided additional 
support for his opinions, a material issue of fact exists that would prevent summary judgment." 
(Plaintiffs October 24, 2011 e orandu , p. 4 (emphasis added).) Accordingly, "the proper 
analogy is," undeniably, "to a motion for relief from judgment under Rule 60(b)." Lowe, 103 
Idaho at . 
"As ith ule 59(e) proceedings, the right to grant, or deny, relief under the provisions of 
Rule 60(b) is a discretionary one with the trial court." Lowe, 103 Idaho at 263 (citing Johnston 
v. ascoe, 100 Idaho 414, 599 .2d 985 (1979)). "A    0(b)  
largely on questions of fact to be determined by the trial court." Waller v. State, Dept. of Health 
& elfare, 146 Idaho 234, 237-38, 192 P.3d 1058, 1061-62 (2008) (citing Idaho State Police ex 
reI. ussell v. eal roperty Situated in the ounty f assia, 144 Idaho 60, 62, 156 P .3d 561, 
563 (2007)). "Although courts have broad discretion in granting or denying such motions, that 
discretion is bounded by the require ent that the party seeking relief de onstrate 'unique and 
compelling circumstances' which justifY relief."  . yen, o. 7335,   
3904099 (Idaho Sept. 7, 2011) (e phasis added) (citing iller v. aller, 129 Idaho 345, 349, 
924 P.2d 607, 611 (1996)). "Those factual findings will be upheld unless they are clearly 
rroneous." aller, 146 Idaho at 238. "If the trial court akes findings of fact that are not 
clearly erroneous, applies to those facts the proper criteria under Rule 60(b)(1), and reaches a 
decision that follows logically from the application of such legal criteria to the facts found, then 
the trial court ill be found to have properly exercised its discretion." anz v. Lockhart, 132 
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Idaho 113 11415 967P2d 1075 107677 Ct App 1998
Rule 60b establishes a different and higher burden for Plaintiff than the relaxed burden
afforded byIRCPIa2Bas it requires a showing of good cause and specifies particular
grounds upon which reliefmay be afforded Id In relevant part Rule 60b reads
On motion and upon such terms as are just the court may relieve a
party or his legal representative from a final judgment order or
proceeding for the following reasons 1 mistake inadvertence
surprise or excusable neglect 2 newly discovered evidence
which by due diligence could not have been discovered in time to
move for a new trial under Rule 59b 3 fraud whether
heretofore denominated intrinsic or extrinsic misrepresentation
or other misconduct of an adverse party 4 the judgment is void
5 the judgment has been satisfied released or discharged or a
prior judgment upon which it is based has been reversed or
otherwise vacated or it is no longer equitable that the judgment
should have prospective application or 6 any other reason
justifying relief from the operation of the judgment
IRCP60b Based on the record in this case Plaintiff cannot establish entitlement to relief
from judgment on any of the six 6 grounds covered byIRCP60b and the Court would be
wellwithin its discretion to deny Plaintiffsmotion
1 Mistake Inadvertence Surprise or Excusable Neglect
As noted above Rule 60b identifies as the first justification for relief from judgment
mistake inadvertence surprise or excusable neglect Id In ruling on a Rule 60b motion
2 Plaintiff has not heretofore presented any evidence or argument to satisfy any of the concerns
addressed by Rule 60b SEC therefore submits this opposition to the arguments that it anticipates
Plaintiff may attempt to craft in its final reply brief However because SEC does not anticipate any
argument from Plaintiff that it has committed fraud on the CourtIRCP60b3that the judgment is
voidIRCP60b4or that there is an equitable basis for the judgment to no longer have prospective
applicationLRCP60b5those aspects of Rule 60bwill not be addressed in this memorandum
SEC does not anticipate after now three rounds of summary judgment that Plaintiff will claim
surprise as a basis for relief from this Court judgment In the event that she does this Court should
reject such an attempt based on the simple fact that Plaintiff had multiple opportunities to remedy the
deficiencies in her argument prior to entry of Judgment and on that basis alone there is no legitimate
argument that she was surprised by any argument evidence or position advanced by SEC
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 , -15,  .2d ,1 -7  (Ct. p. 998). 
l  0(b) st lis s  iff r t  i r r  f r l i tiff t  t  r l  r  
  LR.C.P. 11(a)(2)(B),   "requires       ci  rti  
r   i  r li f   fforded." ! . I  r l t art, l  0(b) r ds: 
 ti  a   s c  ter s as are j st, t e c rt a  relie e a 
art  r is le al re rese tati e fr  a fi al j e t, r er, r 
proceeding for the follo ing reasons: (1) istake, inadvertence, 
surprise, or excusable neglect; (2) ne ly discovered evidence 
i    iligence l  t   i r  i  ti  t  
 f r   tri l r l  9(b); (3) fr  (wheth r 
eret f re e i ate  i tri sic r extrinsic), isre resentation, 
r t er isc ct f a  a erse arty; (4) t e j e t is i ; 
(5) t  j t   ti fi , r l , r i r d, r  
ri r j e t  i  it is s  s  r rs  r 
t er ise acated, r it is  l er e ita le t at t e j e t 
s l   r s ti e pli ti n; r (6)  t r r s  
justifying relief fro  the operation f the judg ent. 
LR.C.P. 0(b).   t   i  t i  , l i ti  t t li  titl t t  li  
fr  j e t  a  f t e si  (6) r s c ere   LR.C.P. 0(b)2, a  t e rt l  e 
ll- it in its i ti  t   l intif s ti . 
(1) ista e, I a verte ce, ur rise, or xc sa le eglect 
s te  a ve, le 0(b) i e tifies as t e first j stificati  f r relief fr  j e t 
"mistake, inadvertence, surprise, or excusable neglect.,,3 Id. In ruling on a ule 60(b) otion 
2 Plaintiff has not heretofore presented any evidence or argu ent to satisfy any of the concerns 
addressed by Rule 60(b). SEC therefore sub its this "opposition" to the argu ents that it anticipates 
Plaintiff ay atte pt to craft in its final reply brief. o ever, because SE  does not anticipate any 
argu ent fro  Plaintiff that it has co itted fraud on the Court (I.R.C.P. 60(b)(3», that the judg ent is 
void (I.R.C.P. 60(b)( 4», or that there is an equitable basis for the judgment to no longer have prospective 
application (I.R.C.P. 60(b )(5», those aspects of ule 60(b) ill not be addressed in this e orandu . 
3 S  does not anticipate, after no  three rounds of su ary judg ent, that Plaintiff ill clai  
"surprise" as a asis f r relief fr  t is ourt's j e t. I  t e e e t t at s e es, t is rt s l  
reject such an attempt based on the simple fact that Plaintiff had multiple opportunities to remedy the 
deficiencies in her argu ent prior to entry of Judg ent, and on that basis alone there is no legiti ate 
argu ent that she as surprised by any argu ent, evidence, or position advanced by . 
 I  S PP  F S I  IP  PORATION'S IONS  S I  
T IR  FFI IT F R L  OST  F R R LE 56( c)  R  F TT R E S' FEES  
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based on this basis it is important for the Court to recognize that the Rule is not intended to act
as an unguarded door for unsuccessful parties to reopen the litigation Indeed a motion to set
aside should not be used to remedy the inadvertence or oversight of one of the parties to the
original action Flood v Katz 143 Idaho 454 457 147 P3d 86 89 2006 internal citations
omitted
Under Rule 60b1a mistake sufficient to warrant setting aside a default judgment
must be of fact and not of law Cuevas v Barraza 146 Idaho 511 515516 198 P3d 740 744
745 Ct App 2008 Mistake or inadvertence referred to in Rule 60b1applies primarily to
errors or omissions committed by an attorney or by the court that are not apparent in the record
Berg v Kendall 147 Idaho 571 576577 212 P3d 1001 1006007 2009 citing Silsby v
Kepner 140 Idaho 410 411 95P3d 28 29 2004 To determine whether a mistake of fact is
sufficient to set aside a judgment a court should look to what a reasonably prudent person would
do under similar circumstances In other words the mistake cannot be due to willful ignorance
LeaseFirst v Burns 131 Idaho 158 161 162 953 P2d 598 601 602 1998 internal citations
omitted
In addition the party claiming excusable neglect must have exercised due diligence in
the prosecution of his rights LeaseFirst 131 Idaho at 162 quoting Olson v Kirkham 111
Idaho 34 38 720P2d 217 221CtApp 1986 The claimedneglect must be excusable and
to be of that calibre must be conduct that might be expected of a reasonably prudent person
under the same circumstances Cuevas 146 Idaho at 515516 see also Suitts v Nix 141 Idaho
706 709 117 P3d 120 123 2005 The conduct constituting excusable neglect must be that
which would be expected of a reasonably prudent person under the same circumstances
When the deficiencies in the moving partyscase are a result of carelessness by counsel relief
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   i ,                 
as an unguarded door for unsuccessful parties to reopen the litigation. Indeed, "[a] otion to set 
i  l  t   t  r  t  i rt  r r i t f  f t  rties t  t  
ri i al action." l  v. tz, 143 I a  , ,  .3d ,  (2 6) (inter al citati s 
o itted). 
 l  0(b)(1), "[a] i t  i ie t t  t tti  i   lt j t 
t   f t  t  l w."  . r ,  I  , -5 ,  .3d , 4-
 (CL . 08). "Mistake r i a erte ce referre  t  i  le 0(b)(1) a lies ri aril  t  
errors or o issions co itted by an attorney or by the court that are not apparent in the record." 
er  v. e dall,  I a  , -5 ,  .3d , -00  (20 ) (citin  ils y v. 
epner, 140 Idaho 410, 411, 95 .3d 28, 29 (2004)). "To deter ine hether a istake f fact is 
i ie t t  t i   j t,  t l  l  t  t  l  t  l  
do under si ilar circu stances. In other ords, the istake cannot be due to illful ignorance." 
s  . ,   , 1-162,  .2d , -60  (1 ) (inter   
itted). 
"In a iti , '[t]he art  clai i  e c sa le e lect st a e e ercise  e ilige ce i  
the prosecution of his rights .... '" e seFirst, 131 I a  at  (quotin  ls  v. irk , 111 
Idaho 34, 38, 720 P.2d 217,221 (CLApp. 1986)). The claimed "[n]eglect must be excusable and, 
to be of that calibre, ust be conduct that ight be expected of a reasonably prudent person 
r t   ir stances." vas,  I  t -5 ;  l  itt  . i ,  I  
706, 709, 117 P.3d 120, 123 (2005) ("The conduct constituting excusable neglect ust be that 
hich ould be expected of a reasonably prudent person under the sa e circu stances."). 
hen the deficiencies in the oving party's case are "a result of carelessness" by counsel, relief 
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is not justified Pullin v City ofKimberly 100 Idaho 34 37 592P2d 849 852 1979
In this case the errors committed by Plaintiff in her presentation of evidence offered to
oppose SECsmotions for summary judgment do not qualify as grounds for relief under the
foregoing case law interpreting Rule 60b1Relevant to this discussion are the primary legal
issues raised by SEC throughout this lengthy motion practice to wit 1 that in order to render
admissible affidavit testimony that contradicts prior deposition testimony the declarant must
provide an explanation for the changed testimony accord Cleveland v Policy Mgmt Sys Corp
526US 795 806 1999 Courts have held with virtual unanimity that a party cannot create
a genuine issue of fact sufficient to survive summary judgment simply by contradicting his or her
own previous sworn statement by say filing a later affidavit that flatly contradicts that partys
earlier sworn deposition without explaining the contradiction or attempting to resolve the
disparity and 2 that liability for an allegedly defective product will not be found if the
manufacturer could not have been on notice of the risk of the alleged injuries sustained by the
plaintiff accord Sidwell v William Prym Inc 112 Idaho 76 730 P2d 996 1986 Nothing in
the record suggests that Plaintiff is entitled to relief from her failure to achieve resolution of
these issues in her favor
As to the first issue regarding the sham affidavit rule Plaintiff has already conceded that
the deficiencies in the first and second Yost Affidavits were the result of her counsels
misunderstanding of the applicable legal issue presented
MR OVERSON Well and thatswhat Ive been trying
to explain is my view reading the two documents is theyr not
inconsistent And what I hear the court saying is that there
should have been inclusion in the affidavit as to any potential
conflict between the affidavit and what he said in his deposition
It should have been explained in his affidavit
And let me just stop here because if this is the case I
easily could have asked Dr Yost about that and included it in
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is t j stifie . lli  v. ity / i berly,  I a  , ,  .2d 9,  (1 9). 
I  t is case, t e err rs c itte   lai tiff i  er rese tati  f e i e ce ffere  t  
oppose S C's otions for su ary judg ent do not qualify as grounds for relief under the 
f r i   l  i t r r ti  l  0(b)(1). l t t  t is i i  r  t  ri r  l l 
iss es raise    t r t t is le t  ti  ractice, t  it: ) t at, i  r er t  re er 
ad issible affidavit testi ony that contradicts prior deposition testi ony, the declarant ust 
r i   l ti  f r t   t ti ,  l l  . li  t. s. orp., 
526 .S. 795, 806 (1999)) ("[Courts] have held ith virtual unani ity that a party cannot create 
a genuine issue f fact sufficient to survive su ary judg ent si ply by contradicting his or her 
 r i s s r  st t t (b , s y, fili   l t r ffi it t t fl tl  tr i ts t t rty's 
earlier s orn deposition) ithout explaining the contradiction or atte pting to resolve the 
i rit ."); and 2) that liability for an allegedly defective product ill not be found if the 
anufacturer could not have been on notice of the risk of the alleged injuries sustained by the 
laintiff, cc r  i ell v. illi  ry , I c.,  I a  ,  .2d  (1 6). t i  i  
the record suggests that laintiff is entitled to relief fro  her failure to achieve resolution of 
    r. 
s to the first issue, regarding the sha  affidavit rule, Plaintiff has already conceded that 
 ciencies   irs     fida ts      nsel's 
isunderstanding of the applicable legal issue presented: 
. : ll -- and that's hat I've been trying 
to explain, is y vie  reading the t o docu ents is they're not 
[inconsistent].  t I e r t e c rt s yi  is t t t ere 
s l  ve ee  i cl si  i  t e ffi vit s t  y te ti l 
conflict bet een the affidavit and hat he said in his deposition. 
It should have been explained in his affidavit. 
 let  j t st  r  s  if t is is t  s , I 
easily could have asked r. ost about that and included it in 
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his affidavit I didntsee that as the issue particularly given the
statements of this court at the last hearing with regard to the
hesitancy the court should have when deciding the issue of sham
affidavit which I agree is a totally terrible name for the doctrine
Trans pp 3512 362 By that time however Plaintiff and her counsel very clearly should
have perceived the issues that needed to have been addressed in the Second Yost Affidavit
THE COURT And with due respect the last motion to strike was very clear as to what the
law is Trans p 431112 Thus despite having been fully informed of the applicable
standard on sham affidavits Plaintiffs counsel admits to have been mistaken on the law and not
on the facts Id Considering Plaintiffs repeated attempts to hone Dr Yoststestimony to
conform to the legal burdens asserted by SEC and correctly demanded by the Court it is obvious
that Plaintiffs oversights have been legal in nature and due to counselsinadvertence thereby
disqualifying Plaintiff from entitlement to relief underIRCP60b1on the sham affidavit
issue Cuevas 146 Idaho at 515516
As to the other issue in the case for which Plaintiff may attempt to argue she was
mistaken regarding the foreseeability to SEC of her alleged injuries such an argument is equally
problematic under a Rule 60b1analysis Foreseeability of injury is an element of the legal
standard in products liability cases See Sidwell 112 Idaho 76 Instead of addressing the
foreseeability issue however Plaintiff and her expert have repeatedly focused their attention on
the separate legal element of causation
THE COURT what Im struggling with is and even
in this affidavit I tend to agree with opposing counsel that he he
seems to mix up the concept of causation medical causation with
the concept of what was the state of the literature at the time that
she was exposed and theyr two separate concepts
Trans pp 3512 371 There has been no contention by Plaintiff nor does SEC suspect there
will be that Dr Yost has been mistaken in his own opinion as to the causal connection between
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i  ffi avit. I idn't  t t  t  i  rti l rl  i  t  
st t ts f t is rt t t  l st ri  it  r r  t  t  
sit  t  rt s l    ci i  t  iss  f sha  
f i avit, i    i   t t ll  t rri l   r t  octrine. 
(Tr s., p. 5:12 - 36:2.) y that ti e, ho ever, Plaintiff and her counsel very clearly should 
a e ercei e  t e iss es t at ee e  t  a e ee  a resse  i  t e ec  st ffi avit: 
"[THE URT:]  it  e respect, t e last ti  t  stri e as er  clear as t  at t e 
l  is .... " (Trans., p. 43:11-12.) hus, despite having been fully infor ed of the applicable 
st r   s  ffi vits, l i tiffs s l its t    ist   t  l ,  t 
  ts. (I .) onsidering laintiffs repeated atte pts to hone r. ost's testi ony to 
confor  to the legal burdens asserted by SEC and correctly de anded by the Court, it is obvious 
that Plaintiff s oversights have been legal in nature, and due to counsel's inadvertence, thereby 
disqualifying Plaintiff fro  entitle ent to relief under I.R.C.P. 60(b)(l) on the sha  affidavit 
Is . ,    -5 . 
s to the other issue in the case for hich laintiff ay atte pt to argue she as 
istaken, regarding the foreseeability to S  of her alleged injuries, such an argu ent is equally 
proble atic under a Rule 60(b)(I) analysis. Foreseeability of injury is an ele ent of the legal 
 i  ts t  .  i el ,  a  . Instead of addressing the 
foreseeability issue, ho ever, Plaintiff and her expert have repeatedly focused their attention on 
t e se arate le al ele e t f ca sati : 
 : --- hat I'm struggling ith is --   
in this affidavit, I tend to agree ith opposing counsel that he --  
see s t  i   t e c ce t f ca sati , e ical ca sati , it  
the concept f hat as the state f the literature at the ti e that 
she as exposed and they're t o separate concepts. 
(Tra s., . 5: 12 - 7: 1.) r  s   t ti   l i tiff, r s  s s t t r  
will be, that Dr. Yost has been mistaken in his own opinion as to the causal connection between 
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Plaintiffsexposure to OC Spray and the injuries that she now claims From the record this
appears to be his consistent opinion throughout all iterations of his affidavit However that
emphasis as well as the rest of Dr Yosts testimony simply failed to sufficiently address the
relevant legal question on foreseeability Considering Plaintiffsrepeated attempts to hone Dr
Yoststestimony to conform to the legal burdens asserted by SEC and correctly demanded by
the Court even after the Judgment was entered it is obvious that Plaintiffs mistakes andor
oversights have been legal in nature not factual Accordingly Rule 60b1 relief is not
appropriate Cuevas 146 Idaho at 515516
The remaining question underIRCP60b1is whether Plaintiffs failures including
her failures to perceive andor address the legal issues raised by SEC should be considered by
this Court to be excusable neglect such as to warrant Rule 60b relief Again in order for
relief to be warranted under Rule 60b1 the requesting party must have exercised due
diligence in the prosecution of his rights LeaseFirst 131 Idaho at 162 In addition to the
multiple briefs filed by SEC throughout this case each articulating the basis and the case law
relied upon in arguing both that SEC was not on notice of any risks of injury akin to that which
Plaintiff claims in this action and that the Yost affidavits constituted inadmissible sham
testimony Plaintiff has also had the benefit of this Court own thoughts on the record on
multiple occasions Plaintiffs failures to meet the relevant legal burdens prior to entry of
Judgment strongly suggests something other than an exercise of due diligence on Plaintiff s part
The burdens imposed on Plaintiff in this products liability action have been no secret nor
have they been veiled in any way Plaintiffs failure to present any evidence that would be
sufficient to withstand SECs motion for summary judgment prior to entry of Judgment in this
case was not the conduct of a reasonably prudent person nor was it the product of due
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l intif  s       ie     i .   ord,  
appears to be his consistent opinion throughout all iterations of his affidavit. r,  
e phasis (as ell as the rest of r. ost's testi ony) si ply failed to sufficiently address the 
rele a t le al esti   f reseeability. si eri  laintiff's re eate  atte ts t  e r. 
ost's testi ony to confor  to the legal burdens asserted by S  and correctly de anded by 
t e rt (eve  ft r t  t  tered), it i  i  t t l i tiff  i t  /or 
oversights have been legal in nature, not factual. ccordingly, ule 60(b)(1) relief is not 
appropriate. uevas, 146 Idaho at 515-516. 
e re ai i  esti  er LR.C.P. 0(b)(1) is et er laintiff's fail res, i cl i  
her failures to perceive and/or address the legal issues raised by , should be considered by 
t i  rt t   "excusa le lect"   t  rr t l  0(b) r li f. i , i  r r f r 
relief to be arranted under ule 60(b)(1), the requesting party "must have exercised due 
diligence in the prosecution of his rights .... " eFirst,   t .  iti  t  t  
ultiple briefs filed by SE  throughout this case, each articulating the basis and the case la  
relied upon in arguing both that SE  as not on notice of any risks of injury akin to that hich 
i ti          f  t  s e  
testi ony, Plaintiff has also had the benefit of this Court's o n thoughts on the record on 
ultiple occasions. Plaintiff s failures to eet the relevant legal burdens prior to entry of 
Judg ent strongly suggests so ething other than an exercise of due diligence on Plaintiff s part. 
The burdens i posed on Plaintiff in this products liability action have been no secret, nor 
 t   il  i   y. l i ti  il  t  t  i  t t l   
s fficie t t  it sta  EC's ti  f r s ar  j e t ri r t  e tr  f J e t i  t is 
case as not the conduct of a "reasonably prudent" person, nor as it the product of "due 
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diligence Accord LeaseFirst 131 Idaho at 162 and Cuevas 146 Idaho at 515516 SEC
contends and the Court has already recognized that Plaintiff should have acquired from Dr
Yost an affidavit that both a explained the contradictions between his affidavit and deposition
testimony and b adequately explained how Plaintiffsalleged injuries were foreseeable to SEC
prior to March 2008 These two burdens are well established in relevant case law as presented
in the earlier motion practice and Plaintiffs failure to meet those burdens simply cannot be
considered excusable Any claim for relief from judgment advanced by Plaintiff based on
IRCP60b1should therefore be rejected by this Court
2 Newly Discovered Evidence
The second basis suggested by Rule 60b for relief from judgment arises when the
moving party presents newly discovered evidence which by due diligence could not have been
discovered in time to move for a new trial under Rule 59b IRCP60b2 By the plain
language of this Rule relief is not warranted simply because the moving party presents evidence
that it did not previously offer as would be appropriate under a Rule 11 motion for
reconsideration Id Rather the ability of a party to present evidence after entry of Judgment is
limited to that which by due diligence could not have been discovered previously Id See
also Savage Lateral Ditch Water Users Assn v Pulley 125 Idaho 237 869 P2d 554 1993
These affidavits were not newly discovered evidence in the usual sense under Rule 60b2
ie they did not disclose information in existence at the time of trial but not discoverable with
due diligence Obendorfv Terra Hug Spray Co Inc 145 Idaho 892 902 188 P3d 834 844
2008 Newly discovered evidence must be information in existence at the time of summary
judgment but not discoverable with due diligence Marcher 113 Idaho at 871 There has
been no good cause shown for the failure to make the new evidence a part of the record for
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diligence."  Fir t,      s,    -5 .  
t s,  t  rt s lre  r i d, t t l i tiff s l   ir  fr  r. 
ost a  affi a it t at t  a) e lai e  t e c tra ictions et ee  is affi a it a  e siti  
testi , a  ) a e atel  e lai e   laintiff s alle e  i j ries ere f reseea le t   
prior to arch, 2008. hese t o burdens are ell-established in relevant case la , as presented 
i  t  rli r tion r ti ,  l i tiffs f il r  t  t t s  r s si l  t  
i  "exc able."  clai  f r relief fr  j e t a a ce   lai tiff ase   
I.R.C.P. 60(b)(l), should therefore be rejected by this ourt. 
(2) l  is ere  i e  
The second basis suggested by Rule 60(b) for relief from judgment arises when the 
oving party presents "ne ly discovered evidence hich by due diligence could not have been 
discovered in ti e to ove for a new trial under Rule 59(b)." I.R.C.P. 60(b)(2). By the plain 
language of this Rule, relief is not warranted simply because the moving party presents evidence 
t t it i  t r iously ff r (as l   r ri t  r  l   ti  f r 
reconsideration). Id. Rather, the ability of a party to present evidence after entry of Judg ent is 
li ited to that hich "by due diligence could not have been discovered" previously. Id. See 
also Savage Lateral itch ater sers ss 'n v. ulley, 125 Idaho 237, 869 P.2d 554 (1993) 
("These affidavits were not 'newly discovered' evidence in the usual sense under Rule 60(b )(2), 
i.e., they did not disclose infor ation in existence at the ti e f trial but not discoverable ith 
due diligence."); bendorfv. Terra ug Spray Co., Inc., 145 Idaho 892, 902, 188 P.3d 834,844 
(2008) ("Ne ly discovered evidence ust be infor ation in existence at the ti e of [su ary 
judg ent] but not discoverable ith due diligence."); r er,  I  t  ("The   
been no good cause sho n for the failure to ake the [ne  evidence] a part of the record for ... 
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the motion for summary judgment Therefore the trial court was not required to consider these
materials when it ruled upon the Rule 60b motion
Here Plaintiff cannot make any argument that the evidence she would seek to rely on to
justify relief from the Judgment is newly discovered in the sense necessary for Rule 60b2
relief By the very nature of this case arising from Plaintiffsexposure to OC Spray sold by
SEC on or prior to March 2008 the evidence required to meet Plaintiffs burden on
foreseeability is by now over three years old Neither Plaintiff nor Dr Yost has explained why
the additional information that Plaintiff now seeks to rely on was not available at the time that
Plaintiff responded to SECs first or second motions for summary judgment Instead Dr Yost
merely explains These are articles and literature that I did not have at the time of my deposition
and which were located after my second affidavit in this case Third Yost Af 13 Plaintiff
does not provide any explanation as to why Dr Yost did not have the additional articles and
information now presented nor can she The relevant information and documents were all in
existence prior to March 2008 It appears as though Dr Yost merely performed some additional
research which with due diligence could have easily been done earlier and found the additional
information that he now relies upon This is quite plainly not the situation contemplated by
IRCP60b2and therefore Plaintiffsrequest for relief should be denied Accord Marcher
113 Idaho at 871
3 Any Other Reason Justifying Relief
The final grounds for relief underIRCP60b that Plaintiff may attempt to argue is
applicable in this case permits the Court to grant a Rule 60b motion for any other reason
justifying relief from the operation of the judgment IRCP60b Despite its broad
language however the Idaho Supreme Court has held that the Rule is not designed to function as
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the otion for su ary judg ent. herefore, the trial court as not required to consider these 
aterials hen it ruled upon the [Rule 60(b) otion]."). 
ere, Plaintiff cannot ake any argu ent that the evidence she ould seek to rely on to 
justify relief from the Judgment is "newly discovered" in the sense necessary for Rule 60(b )(2) 
relief. y the very nature of this case, arising fro  Plaintiffs exposure to  Spray sold by 
SEC on or prior to arch 2008, the evidence required to eet Plaintiff s burden on 
f reseeabilit  is,  , er t ree ears l . either lai tiff r r. st as e laine   
t  iti l i r atio  t t l i ti    t  l    t il le t t  ti  t t 
Plaintiff respi:mded to SEC's first or second motions for summary judgment. Instead, Dr. Yost 
erely explains, "These are articles and literature that I did not have at the ti e of y deposition 
 i  r  l cat  ft r  s  ffi it i  t is se." (Third st ff., ~ .) l i tiff 
does not provide any explanation as to why Dr. Yost "did not have" the additional articles and 
infor ation no  presented, nor can she. The relevant infor ation and docu ents ere all in 
existence prior to arch 2008. It appears as though Dr. Yost erely perfor ed so e additional 
research, hich ith due diligence could have easily been done earlier, and found the additional 
infor ation that he no  relies upon. is is it  l i l  t t  sit ti  t l t   
I.R.C.P. 60(b)(2), and therefore Plaintiffs request for relief should be denied. Accord archer, 
   . 
(3) ny ther eason Justifying elief 
 fi l r  f r r li f r I.R.C.P 0(b) t t l intiff  tt t t  r  is 
applicable in this case per its the Court to grant a Rule 60(b) otion for "any other reason 
justifying relief from the operation of the judgment." 1.R.c.P. 60(b)(6). espite its broad 
la age, ever, t e I a  re e rt as el  t at t e le is t esi e  t  f cti  as 
E  I  S PP T F SE IT  E IP E T RPORATION'S TI S T  ST I E 
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an open door through which non prevailing parties may avoid or delay the finality of a judgment
Rule 60bhas clearly defined limits Matter ofEstate ofBagley 117 Idaho 1091 1093
793 P2d 1263 1265 Ct App 1990 Although the court is vested with broad discretion in
determining whether to grant or deny a Rule 60b motion its discretion is limited and the
motion may be granted only on a showing of unique and compelling circumstances justifying
relief Miller v Haller 129 Idaho 345 349 924 P2d 607 611 1996 as quoted in Dawson v
Cheyovich Family Trust 149 Idaho 375 234 P3d 699 2010 Additionally the moving party
must present some argument that is based on reasons other than which would fall under the other
categories of relief under Rule 60b See Tyler v Keeney 128 Idaho 524 528 915 P2d 1382
1386 Ct App 1996 Where the facts asserted fall fairly under Rule 60b1and no other
facts have been argued Tyler cannot be granted relief under Rule 60b The burden for
the moving party on a Rule 60bmotion is high andthe appellate courts of this state have
infrequently granted relief under Rule 60bBerg v Kendall 147 Idaho 571 578 212P3d
1001 1008 2009
Precedent from the Idaho Supreme Court is useful in determining what constitutes
unique and compelling circumstances justifying relief See Berg 147 Idaho at 578579 When
the circumstances arise from a partys own failure to abide by the Rules of Civil Procedure relief
is not warranted Id In contrast in extraordinary circumstances such as where the plaintiff by
no fault of her own is deprived of an opportunity to present her claim courts are within their
discretion granting Rule 60b relief Id
Here any claimed deficiencies in the defense mounted by Plaintiff against SECs
motions for summary judgment cannot be said to be the fault of anyone but her She has had a
full opportunity to present the evidence necessary to protect her claims including multiple
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an open door through which non-prevailing parties ay avoid or delay the finality of a judg ent: 
"Rule 60(b)(6) has clearly defined li its." atter of Estate of Bagley, 117 Idaho 1091, 1093, 
793 P.2d 1263, 1265 (Ct. pp. 1990). "[A]lthough the court is vested ith broad discretion in 
determining whether to grant or deny a Rule 60(b) motion, its discretion is limited and [the 
motion] may be granted only on a showing of 'unique and compelling circumstances' justifying 
relief." iller v. aller, 129 Idaho , ,  .2d 607, 611 (1996) (as quoted in awson v. 
Cheyovich Family Trust, 149 Idaho 375, 234 P.3d 699 (2010». Additionally, the moving party 
must present some argument that is based on reasons other than which would fall under the other 
categories of relief under Rule 60(b). See Tyler v. Keeney, 128 Idaho 524, 528, 915 P.2d 1382, 
1386 (Ct. App. 1996) ("Where the facts asserted fall fairly under Rule 60(b)(1), and no other 
facts have been argued, Tyler cannot be granted relief under Rule 60(b)(6)."). he burden for 
the moving party on a Rule 60(b)(6) motion is high, and "[t]he appellate courts of this state have 
infrequently granted relief under ule 60(b)(6)." Berg v. Kendall, 147 Idaho 571, 578, 212 P.3d 
1001, 1008 (2009). 
recedent fro  the Idaho upre e ourt is useful in deter ining hat constitutes 
"unique and compelling circumstances" justifying relief. See Berg, 147 Idaho at 578-579. hen 
t e circ stances arise fr  a arty's  fail re to a i e  t e les f i il r cedure, relief 
is not arranted. Id. In contrast, in extraordinary circu stances, such as here the plaintiff by 
"no fault of her o n" is deprived of an "opportunity to present her claim," courts are ithin their 
discretion granting Rule 60(b) relief. Id. 
ere, any clai ed deficiencies m the defense ounted by Plaintiff against SEC's 
otions for su ary judg ent cannot be said to be the fault of anyone but her. She has had a 
full opportunity to present the evidence necessary to protect her claims, including multiple 
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rounds of summary judgment and motions for reconsideration There is simply nothing unique
about this rather runofthemill products liability case with the exception of perhaps the
uncommonly large number of chances that Plaintiff has taken in her attempts to resist andor
avoid the Judgment that was ultimately entered Similarly no argument can be had that there are
compelling circumstances justifying relief as Plaintiff has not been deprived any fundamental
or fair right to present her claim Plainly stated Plaintiff had ample opportunity to argue her
case and after doing so the Court rightfully rejected Plaintiffsclaims on the basis that SEC
could not be held liable for risks that were not and could not have been foreseen at the time of
Plaintiffsalleged injuries
Moreover while SEC cannot forecast all of the potential arguments that Plaintiff could
andor may attempt to set forth in her attempt to seek relief under Rule 60bthe record
presented by Plaintiff thus far suggests that any claim for relief would be more appropriately
brought under one of the other five bases for relief under Rule 60b Plaintiffsjustification for
relief will be based either in the mistake of her counsel in not adequately addressing the legal
issues presented or in her experts belated discovery of existing evidence These issues have
been addressed above Since the grounds for relief under Rule 60b are mutually exclusive
provisions Plaintiff cannot assert any additional claim for relief under Rule 60bbased on
the same arguments that would be properly classified in one of the other provisions of Rule
60b Pullin 100 Idaho at 37 n2
C The Third Yost Affidavit Fails To Establish Any Reason For This Court To Reverse
Its Prior Decisions
For the following reasons SEC urges the Court to reject the Third Yost Affidavit but if
the Court should consider the Affidavit it should strike it because the evidence presented therein
still fails to accomplish that which would be necessary for Plaintiff to meet the legal burdens
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rounds of su ary judgment and motions for reconsideration. There is si ply nothing "unique" 
about this rather run-of-the-mill products liability case, with the e ce tion f perhaps the 
uncommonly large number of chances that Plaintiff has taken in her attempts to resist and/or 
avoid the Judgment that was ultimately entered. Similarly, no argument can be had that there are 
"compelling" circumstances justifying relief, as Plaintiff has not been deprived any funda ental 
or fair right to present her claim. Plainly stated, Plaintiff had ample opportunity to argue her 
case and, after doing so, the ourt rightfully rejected laintiffs clai s on the basis that  
c ld t e l  liable f r ris s t at ere t  ld t a e  foresee  t t  ti e f 
Plaintiffs alleged injuries. 
oreover, hile SE  cannot forecast all of the potential argu ents that Plaintiff could 
and/or may attempt to set forth in her attempt to seek relief under Rule 60(b)(6), the record 
presented by Plaintiff thus far suggests that any claim for relief would be more appropriately 
brought under one of the other five bases for relief under Rule 60(b). Plaintiffs justification for 
             t l  i   l 
issues presented, or in her expert's belated discovery of existing evidence. These issues have 
been addressed, above. Since the grounds for relief under Rule 60(b) are "mutually exclusive 
provisions," Plaintiff cannot assert any additional claim for relief under Rule 60(b)(6) based on 
the same arguments that would be properly classified in one of the other provisions of Rule 
60(b). Pullin, 100 Idaho at 37, n.2. 
. he hird ost ffidavit ails o stablish ny eason or his ourt o everse 
It  ri r i i s. 
For the follo ing reasons, SEC urges the Court to reject the Third ost ffidavit, but if 
t  rt h l  i r t  ffi avit, it sho l  stri  it  the evi  pr sented therein 
still fails to accomplish that which would be necessary for Plaintiff to meet the legal burdens 
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required in this case and is otherwise just as objectionable as the prior iterations of the Yost
affidavits
1 Plaintiffsfiling of the new affidavit is in direct contravention of this Court
direction during the September 14 2011 oral argument On at least two occasions during that
hearing counsel for Plaintiff begged leave from the Court to file a third Yost Affidavit Trans
pp 3616 49110 In response to those requests the Court twice indicated that it would not
welcome a third Yost Affidavit Id at pp541 17 Im not inviting a new affidavit to
respond 5921 602 I am not inclined to tell the plaintiff in this case that she can have
yet a third affidavit to try and explain what should have been explained in the very beginning
Despite those directions Plaintiff has nevertheless done exactly what the Court told her
would not be permitted and has filed a new Affidavit attempting to explain what should have
been explained in the very beginning In addition to the jurisprudence cited above regarding the
appropriate grounds for Rule 60b relief discussing excusable neglect and the propriety of
evidence that could have been discovered earlier through due diligence the Courts own
direction in this matter is conclusive on the propriety and admissibility of the third Yost
Affidavit at this posthumous stage of the litigation
2 The evidence presented by way of the third Yost Affidavit fails to present any
new or groundbreaking evidence that would tend to show any error in the Courts Orders In
examining a partys new evidence underIRCP60b2in addition to the threshold question
discussed above whether the evidence is in fact new in the proper sense the Court is
permitted to determine whether that evidence if accepted would probably change the result of
the litigation Obendorf 145 Idaho at 902 As a party resisting summary judgment bears the
burden of identifying specifically what evidence in the record creates genuine issues of material
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required in this case, and is otherwise just as objectionable as the prior iterations of the Yost 
a fid : 
1. laintiffs filing of the ne  affidavit is in direct contravention of this ourt's 
direction during the September 14, 2011 oral argument. On at least two occasions during that 
hearing, counsel for Plaintiff begged leave from the Court to file a third Yost Affidavit. (Trans., 
pp. 36:3-16; 49:1-10.) In response to those requests, the Court twice indicated that it would not 
elco e a third ost ffidavit. (Id. at pp.54:14-17 (" ... I'm t in iting  e  i  to 
respond .... "); 9:21 - 0:2 ("I  t incline  t  tell the l i ti f in t is s  that e   
yet a third affidavit ... to try and explain hat should have been explained in the very beginning 
.... ").) Despite those directions, Plaintiff has nevertheless done exactly what the Court told her 
would not be permitted, and has filed a new Affidavit attempting to explain what should have 
been explained in the very beginning. In addition to the jurisprudence cited above, regarding the 
appropriate grounds for Rule 60(b) relief (discussing excusable neglect and the propriety of 
idence t t l    i r  rli r t r   ili nce), t  ourt's  
irecti  i  t is atter is c cl si e  t e r riet  a  a issibilit  f t e t ir  st 
Affidavit at this posthumous stage of the litigation. 
. The evidence presented by way of the third Yost Affidavit fails to present any 
new or groundbreaking evidence that would tend to show any error in the Court's Orders. In 
examining a party's new evidence under LR.C.P. 60(b)(2), in addition to the threshold question 
discussed above (whether the evidence is, in fact, "new" in the proper sense), the Court is 
permitted to determine whether that evidence, if accepted, would "probably change the result" of 
the litigation. Obendorf, 145 Idaho at 902. As a party resisting summary judgment bears the 
burden of identifying specifically what evidence in the record creates genuine issues of material 
E ORANDUM IN SUPPORT OF SECURITY EQUIP ENT CORPORATION'S OTIONS TO STRIKE 
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fact this Court is not required to dig through the voluminous articles jointly labeled as Exhibit
A to the third Yost Affidavit to ascertain whether any such evidence exists Vreeken v
Lockwood EnggBV 148 Idaho 89 104 218 P3d 1150 1165 2009 Rather Plaintiff bears
the burden of identifying the evidence most helpful to her case Id
With the third Yost Affidavit Plaintiff has produced a number of articles that she asserts
support the claim that her alleged injuries should have been foreseeable to SEC in March 2008
Notably in her memorandum in support of the socalled motion for reconsideration Plaintiff
does not point to any specific evidence out of any of the articles She does not even provide this
Court the courtesy of identifying the titles authors or number of articles that make up the 251
page Exhibit A Indeed the only discussion regarding the content of the additional articles
presented is contained within the third Yost Affidavit which itself only addresses two of the
many articles attached thereto
To the extent that Dr Yost discusses the content of the newly produced articles which
discussion this Court may assume contains the best that Plaintiff can find in all of the articles
presented that discussion still fails to bring to light any evidence warranting a reversal of this
Courtsprior Orders or the Judgment Principally the articles have the exact same deficiency
that was the object of this Court criticisms against the earlier articles presented they simply do
not state any conclusion regarding long term andor chronic adverse respiratory effects of
exposure to OC Spray These are simply additional articles that support Dr Yostspersonal
opinion on the element of medical causation in this case they fail to present any facts that
suggest that anyone in 2008 foresaw alleged risks of chronic injuries resulting from exposure to
4 Even as Dr Yost directs this Courts attention to the content of the articles produced his
citations are unreliable By way of example Dr Yost quotes the Cohen article as saying For some
symptoms persisted for weeks or more Third Yost Aff 11 while the article actually says For
some symptoms persisted for a week or more In this case that difference is significant
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fact, this Court is not required to dig through the voluminous articles Gointly labeled as "Exhibit 
" to the third ost ffida it) to ascertain hether any such e idence e ists. reeken v. 
Lockwood Eng'g, .V., 148 Idaho 89,104,218 P.3d 1150, 1165 (2009). ather, Plaintiff bears 
the burden of identifying the evidence most helpful to her case. ld. 
ith the third ost ffida it, lai tiff as roduce  a nu ber f articles that s e asserts 
support the claim that her alleged injuries should have been foreseeable to SEC in March, 2008. 
Notably, in her memorandum in support of the so-called motion for reconsideration, Plaintiff 
does not point to any specific evidence out of any of the articles. She does not even provide this 
Court the courtesy of identifying the titles, authors, or number of articles that make up the 251-
page "Exhibit A." Indeed, the only discussion regarding the content of the additional articles 
presented is contained within the third Yost Affidavit, which itself only addresses two of the 
many articles attached thereto. 
    r.  s ss   te t   -  ti l s,  
discussion this ourt ay assu e contains the best that laintiff can find in all of the articles 
presented, that discussion still fails to bring to light any evidence arranting a reversal of this 
Court's prior Orders or the Judgment. Principally, the articles have the exact same deficiency 
that was the object of this Court's criticisms against the earlier articles presented: they simply do 
not state any conclusion regarding long-term and/or chronic adverse respiratory effects of 
exposure to OC Spray.4 These are simply additional articles that support Dr. Yost's personal 
opinion on the ele ent of edical causation in this case; they fail to present any facts that 
suggest that anyone in 2008 foresaw alleged risks of chronic injuries resulting from exposure to 
4   r. t i t  t i  ourt's attenti  t  t  t t f t  rti l  r uced, i  
citations are unreliable. y ay of exa ple, r. ost quotes the ohen article as saying, "For some, 
symptoms persisted for weeks or more" (Third Yost A ff., ~ 11), hile the article actually says, "For 
some, symptoms persisted for a week or more." In this case, that difference is significant. 
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OC Spray Even the best evidence presented by Dr Yost confirms that there is no known long
term adverse respiratory health risk associated with exposure to OC Spray There is
insufficient data currently available to fully define the health risks of pepperspray Third
Yost Aff 11 In short Dr Yost is apparently still unable to provide any literature study
article reference or other evidence that established existing prior to March 2008 that a risk of
longterm andor chronic adverse respiratory health effects from exposure to OC Spray was
known to anyone in the world
3 The new affidavit suffers from virtually all of the same defects as the prior two
affidavits and on that basis may also be stricken from the record As the Court has made clear
during at least two of the earlier hearings in this case all of Dr Yosts affidavit testimony to date
has been burdened by problems greater than and beyond its contradictions with his deposition
testimony Just as he had done with his prior Affidavits which resulted in alternate grounds for
the Court to strike andor disregard his testimony Dr Yost continues in the third Affidavit to
confuse medical causation with foreseeability of harm to make conclusory statements and to
fail to provide an adequate foundation for his statements See Third Yost Af 3 4 7 8 9
11 12 13 14 15 By way of example though Dr Yost cannot point this Court to any evidence
showing longterm adverse health effects he nevertheless would have this Court take his
unsupported word for it that enough was understood in 2008 about the toxicology of
capsaicinoids such that SEC should have been on notice of Plaintiffs alleged variation of the
potentially many toxicological effects of OC Spray Id at 7 The conclusory nature of this
statement is underscored by Dr Yosts failure to identify any evidence that one of the possible
s It should be noted that the new MSDS sheet provided and relied upon by Dr Yost from
October 2004 is for a product entirely different in chemical makeup than SECs OC Spray Dr Yosts
new MSDS sheet is for pure Capsaicin which is only one of three chemicals that together comprise a
mere133 of the OC Spray formula manufactured by SEC Accordingly that MSDS sheet is irrelevant
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OC Spray. Even the best evidence presented by Dr. Yost confirms that there is no known, long-
term adverse respiratory health risk associated with exposure to OC Spray: [T]here is 
insufficient data currently available to fully define the health risks of pepperspray .... " (Third 
ost ff., ~ 11.) In short, Dr. Yost is apparently still unable to provide any literature, study, 
article, reference, or other evidence that established, existing prior to arch, 2008, that a risk of 
long-term and/or chronic adverse respiratory health effects from exposure to OC Spray was 
known to anyone in the world. 5 
. e e  id it s fers fro  irt ll  ll  t e  e ts  t e ior t  
affidavits, and on that basis ay also be stricken fro  the record. s the Court has ade clear 
during at least two of the earlier hearings in this case, all of Dr. Yost's affidavit testimony to date 
has been burdened by proble s greater than and beyond its contradictions ith his deposition 
testimony. Just as he had done with his prior Affidavits, which resulted in alternate grounds for 
the Court to strike and/or disregard his testi ony, Dr. Yost continues in the third Affidavit to 
f s  i l ti  it  f r abilit  f r , t   l r  t t nts,  t  
fail to provide an adequate foundation for his statements. (See Third Yost Aff., ~~ , , , , , 
11, 12, 13, 14, 15.) By way of example, though Dr. Yost cannot point this Court to any evidence 
"showing long-term adverse health effects," he nevertheless would have this Court take his 
unsupported word for it that "enough was understood" in 2008 "about the toxicology of 
capsaicinoids," such that SEC should have been on notice of Plaintiffs alleged variation of the 
potentially many toxicological effects of OC Spray. (Id. at ~ .)  cl sor  t r  f t is 
state ent is underscored by r. ost's failure to identify any evidence that one f the possible 
5 It should be noted that the new SDS sheet provided and relied upon by Dr. Yost, fro  
October, 2004, is for a product entirely different in chemical makeup than SEC's OC Spray. Dr. Yost's 
new SDS sheet is for pure Capsaicin, which is only one of three chemicals that together co prise a 
mere 1.33% ofthe OC Spray formula manufactured by SEC. Accordingly, that SDS sheet is irrelevant. 
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toxicological effects of OC is a longterm or chronic adverse respiratory illness or injury
Similar problems are prevalent throughout the third Yost Affidavit and SEC submits that the
Court should either strike or disregard the entirety of the Affidavit on that basis
4 Dr Yosts belated attempt to explain the discrepancies between his affidavit
testimony and his deposition testimony is insufficient to justify relief from the Judgment First
for the reasons previously stated Dr Yoststestimony is not newly discovered in the proper
sense of Rule 60b2 Whatever explanation Dr Yost now has for the inconsistencies in his
testimony presumably would have existed when he made the first inconsistent statements
several months ago Additionally based on the record in this case it is clear that Plaintiff was
informed as early as July 14 2011 of the inconsistencies and potential problems with the Yost
affidavits as well as the applicable law governing sham affidavits There is no reasonable
explanation as to why Plaintiff would not have presented Dr Yosts explanation earlier or
avoided the inconsistencies in the Second Yost Affidavit all together A reasonably prudent
person would not have waited until after Judgment was entered to raise these issues and no
excuse exists for Plaintiffsdelay
D Sanctions Are Warranted Against Plaintiff And Her Attorneys For Disregarding
The Courts Order Denying Plaintiffs Request To File A Third Affidavit Of Garold
Yost For Filing An Improper Motion For Reconsideration Of Orders Entered
Before Entry Of Final Judgment And For Failing To Timely And Efficiently
Respond To DefendantsSummary Judgment Motions
Idaho Rule of Civil Procedure 56cprovides that a trial court may in the exercise of its
discretion impose sanctions upon a party or hisher attorneys for failure to comply with the
summary judgment rules and procedures Gem State Insurance Co v Hutchison 145 Idaho 10
14 175 P3d 172 176 2007 Rule 56c governs summary judgment proceedings It provides
that the party opposing summary judgment must serve opposing affidavits and briefs within
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t icological effects f D  is a l -ter  r c r ic a erse res irat r  illness r i j r . 
Similar problems are prevalent throughout the third Yost Affidavit, and SEC submits that the 
rt s l  it r stri  r isr r  t  tir t  f t  ffida it  t t sis. 
. r. st's ate     e s e ies e  s f i  
testi ony and his deposition testi ony is insufficient to justify relief fro  the Judg ent. irst, 
f r t  r s r i l  t t d, r. st's t ti  is t "ne ly i red" i  t  r r 
se se f le 0(b )(2). hate er e la ati  r. st  as f r t e i c siste cies i  is 
testi ony presu ably ould have existed hen he ade the first inconsistent state ents, 
r l t s . iti ll ,   t  r r  i  t is , it i  l r t t l i tiff  
i f r e  as earl  as J l  ,  f t e i c siste cies a  te tial r le s it  t e st 
affidavits, as ell as the applicable la  governing sha  affidavits.     
explanation as to hy Plaintiff ould not have presented r. ost's "explanation" earlier, or 
avoided the inconsistencies in the econd ost ffidavit all together.  reasonably prudent 
ers  l  t a e aite  til after J e t as e tere  t  raise t ese iss es, a  no 
excuse exists for Plaintiffs delay. 
. Sanctions re arranted gainst Plaintiff nd er ttorneys For isregarding 
e ourt's r r e i  laintiff's e est  ile  ir  ffi a it f ar l  
ost, or Filing n I proper otion or econsideration f rders ntered 
efore ntry f Final Judg ent, nd or Failing o i ely nd fficiently 
espond To efendant's Su ary Judg ent otions. 
I a  le f i il r ce re 6( c) r i es t at a trial c rt ay, i  t e e ercise f its 
discretion, i pose sanctions upon a party or his/her attorneys for failure to co ply ith the 
su ary judg ent rules and procedures. e  State Insurance o. v. utchison, 145 Idaho 10, 
14, 175 P.3d 172, 176 (2007). Rule 56(c) governs su ary judg ent proceedings. It provides 
that the party opposing su ary judg ent ust serve opposing affidavits and briefs ithin 
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fourteen 14 days prior to the date of the summary judgment hearing It also allows the court to
alter or shorten time periods and requirements of the rule for good cause shown to continue
summary judgment hearings and to impose costs attorney fees and sanctions against a party or
the partys attorney or both Rule 56c
SEC contends that sanctions are warranted in this case and urges the Court to impose
sanctions against both Plaintiff and her attorneys in the form of an award of attorney fees and
costs to SEC for the following reasons
1 Plaintiff had more than sufficient time to fully respond to SECs Motion for
Summary Judgment SECsMotion and support her own Cross Motion for Summary
Judgment Plaintiffs Cross Motion prior to the hearing on those motions on July 15 2011
July 15 2011 Hearing SEC filed its Motion on April 22 2011 and Plaintiff filed her
opposition to that motion and her Cross Motion on June 10 2011 Nonetheless Plaintiff failed
to file any affidavit ofBillie Jo Major in relation to the first round Motions and her first affidavit
of her expert Dr Garold Yost First Yost Affidavit was inadequate to create a dispute of
facts sufficient to preclude summary judgment as the Court concluded in the July 15 2011
Hearing
2 Undaunted in the second round of motions which took place between July 16
2011 and September 15 2011 Plaintiff filed her first Motion for Reconsideration seeking a
reconsideration of the Courts grant to SEC of summary judgment To support that Motion
Plaintiff filed the first Affidavit of Billie Jo Major First Major Affidavit and the Second
Affidavit of Dr Yost Second Yost Affidavit Plaintiff and Dr Yost conceded that the
Second Yost Affidavit was intended to remedy the defects in the First Yost Affidavit which
defects were pointed out by the Court in the July 15 2011 Hearing See Second Yost Affidavit
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fourteen (14) days prior to the date of the summary judgment hearing. It also allows the court to 
alter or shorten time periods and requirements of the rule for good cause shown, to continue 
summary judgment hearings, and "to impose costs, attorney fees and sanctions against a party or 
the party's attorney, or both." Rule 56(c). 
 ntends that ons are arrante  i  this ca ,  rges t e o rt t  i pose 
sanctions against both Plaintiff and her attorneys in the form of an award of attorney fees and 
costs to S , for the follo ing reasons: 
.  a  ore than icie t i e   e   C's otion  
Summary Judgment ("S 's tion") and support her o n ross- otion for Su ary 
Judgment ("Plaintiffs Cross-Motion") prior to the hearing on those otions on July 15, 2011 
("July 15, 2011 Hearing").  ile  it  otion  il , ,  l i ti  ile   
opposition to that motion and her Cross-Motion on June 10, 2011. Nonetheless, Plaintiff failed 
to file any affidavit of Billie Jo Major in relation to the first round Motions, and her first affidavit 
of her expert, Dr. Garold Yost ("First Yost Affidavit"), as i a e ate t  create a is te f 
facts sufficient to preclude summary judgment, as the Court concluded in the July 15, 2011 
Hearing. 
. ndaunted, in the second round of otions, hich took place bet een July 16, 
2011 and September 15, 2011, Plaintiff filed her first Motion for Reconsideration, seeking a 
reconsideration of the Court's grant to SEC of su ary judg ent.  upport  tion, 
l i tiff fil  t  first ffi it f illi  Jo j r ("First j r ffi it") and t  eco  
ffidavit f r. ost ("Se  t i "). laintiff  r. t  t t t  
Second ost ffidavit as intended to re edy the defects in the First ost ffidavit hich 
defects were pointed out by the Court in the July 15,2011 Hearing. (See Second Yost Affidavit 
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T 8 All of the information and documents which were the subject of the Second Yost Affidavit
and the First Major Affidavit were readily available and could have been incorporated into
affidavits and made part of the record prior to the July 15 2011 Hearing Moreover
notwithstanding the arguments of SEC and the comments by the Court during the July 15 2011
Hearing regarding the showing necessary to overcome a charge of a sham affidavit Plaintiff
neglected to include in the Second Yost Affidavit any discussion explaining Dr Yosts
deposition testimony which was in direct conflict with statements in the Second Yost Affidavit
For that reason among others the Court struck the Second Yost Affidavit in the September 15
2011 on PlaintiffsFirst Motion for Reconsideration and SECsSecond Motion for Summary
Judgment September 15 2011 Hearing
3 During the September 15 2011 Hearing after the Court expressed its intention to
strike the Second Yost Affidavit Plaintiffs counsel made repeated requests of the Court to be
permitted to file a third corrected affidavit of Dr Yost See Trans pp 3613 49110 This
Court rejected those requests stating that it was not inclined to invite or permit Plaintiff to file a
third Yost Affidavit Id at pp 54 5960 The CourtsOrder Granting DefendantsMotion for
Summary Judgment Striking Affidavit of Garold Yost and Denying PlaintiffsMotions for
Reconsideration entered October 20 2011 provides that the Court denied Plaintiff s request for
permission to file a third Affidavit of Garold Yost October 20 2011 Order p 2
4 Having previously granted Defendant summary judgment twice having declared
the First Yost Affidavit deficient having granted DefendantsMotion to Strike the Second Yost
Affidavit and having denied Plaintiffs First Motion for Reconsideration the Court invited
Defendant to pursue a third Summary Judgment Motion SECs Third Motion to address the
limited acute injury issue raised by Plaintiff for the first time during oral argument on the
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~ 8.) All of the information and documents which were the subject of the Second Yost Affidavit 
and the First ajor ffidavit ere readily available, and could have been incorporated into 
affidavits, and ade part of the record, prior to the July 15, 2011 earing. oreo e , 
notwithstanding the arguments of SEC, and the comments by the Court during the July 15,2011 
earing regarding the sho ing necessary to overco e a charge of a "sham affidavit," Plaintiff 
neglected to include in the Second ost ffidavit any discussion explaining r. ost's 
deposition testimony which was in direct conflict with statements in the Second Yost Affidavit. 
r that r s , a ong t rs, the rt str ck t   ost ffida it i  t e t ber , 
  l intiffs irst otio  f r i r ti   C's  otion f r r  
Judg ent ("Septe ber 15, 2011 Hearing"). 
. During the Septe ber 15,2011 Hearing, after the Court expressed its intention to 
strike the Second ost ffidavit, Plaintiff s counsel ade repeated requests of the ourt to be 
permitted to file a third, corrected affidavit of Dr. Yost. (See Trans., pp. 36:3-13; 49:1-10.) This 
Court rejected those requests, stating that it was not inclined to invite or permit Plaintiff to file a 
third ost ffidavit. (Jd. at pp. 54, 59-60.) The ourt's rder ranting efendant's otion for 
Su ary Judg ent, Striking Affidavit of Garold Yost, and Denying Plaintiffs otions for 
econsideration entered ctober 20, 2011 provides that "the ourt denied Plaintiffs request for 
permission to file a third Affidavit of Garold Yost." (October 20,2011 Order, p. 2.) 
. Having previously granted Defendant summary judgment twice, having declared 
the First ost ffidavit deficient, having granted efendant's otion to Strike the Second ost 
Affidavit, and having denied Plaintiffs First otion for Reconsideration, the Court invited 
efendant to pursue a third Su ary Judg ent otion ("SEC's Third otion") to addr s the 
li ited acute injury issue raised by Plaintiff for the first ti e during oral argu ent on the 
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September 15 2011 Hearing During this third round of motions which was briefed and argued
during the time period between September 16 2011 and October 19 2011 Plaintiff filed a
Second Motion for Reconsideration asking the Court to reconsider its rulings granting
Defendant summary judgment and striking the Second Yost Affidavit and denying Plaintiffs
First Motion for Reconsideration In support of her Second Motion for Reconsideration Plaintiff
filed a Second Affidavit of Billie Jo Major Second Major Affidavit repeating and expanding
on the same facts which were presented in the First Major Affidavit All of the facts contained in
the Second Major Affidavit were available and known to Major prior to the July 15 2011
Hearing and could have been made part of the record prior to that hearing Plaintiff also
asserted a new legal theory based on damages which legal theory was also available and could
have been incorporated into Plaintiffs original summary judgment pleadings prior to the July 15
2011 Hearing
5 On October 24 2011 after the Court denied Plaintiff s Second Motion for
Reconsideration granted SECsMotion for Summary Judgment on all issues and entered a Final
Judgment in favor of SEC and in disregard of the CourtsSeptember 15 2011 ruling denying
Plaintiffs request for another Yost affidavit Plaintiff filed a Third Motion for Reconsideration
supported by a third Affidavit of Dr Yost Third Yost Affidavit This Third Yost Affidavit
was offered in order to overcome the defects noted by the Court in the First and Second Yost
Affidavits and to clarify and explain the conflicts between Dr Yostsdeposition and affidavit
testimony See Third Yost Affidavit 2 All of the facts information and articles cited in the
Third Yost Affidavit were available to Dr Yost and Plaintiff prior to the July 15 2011 Hearing
and could have been incorporated into pleadings in advance of that hearing They also could
have been incorporated into the Second Yost Affidavit but were not notwithstanding the
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September 15, 2011 Hearing. During this third round of motions, which was briefed and argued 
during the time period between September 16, 2011 and October 19, 2011, Plaintiff filed a 
Se nd otion for si r ti , as ing the rt to reconsider its rulings r ti  
Defendant su ary judg ent and striking the Second Yost Affidavit, and denying Plaintiff s 
irst otion for e i ti .  t f her  otion  e i ti , l i ti f 
file   e nd ffida it f illie J  ajor ("Secon  aj r ffida it"),    
on the sa e facts hich ere presented in the irst ajor ffidavit. ll of the facts contained in 
the Second ajor ffidavit ere available and kno n to ajor prior to the July 15, 2011 
Hearing, and could have been made part of the record prior to that hearing. i   
asserted a ne  legal theory based on da ages, hich legal theory as also available and could 
have been incorporated into Plaintiffs original su ary judg ent pleadings prior to the July 15, 
2011 Hearing. 
.  t  , 1, t  t  t i  l i ti   ti   
econsideration, granted SEC's otion for Su ary Judg ent on all issues and entered a Final 
Judg ent in favor of SEC, and in disregard of the Court's Septe ber 15, 2011 ruling denying 
Plaintiffs request for another Yost affidavit, Plaintiff filed a Third otion for Reconsideration 
supported by a third Affidavit of Dr. Yost ("Third Yost Affidavit"). i  i  t i it 
       f      i     ec   
Affidavits, and to clarify and explain the conflicts between Dr. Yost's deposition and affidavit 
testi ony. (See Third ost ffidavit ~ .) ll f t e facts, i f r ati  a  articles cite  i  t e 
i  t i it  il l  t  r. t  l i tif  i  t  t  ul  ,20  ri  
and could have been incorporated into pleadings in advance of that hearing. They also could 
have been incorporated into the Second ost ffidavit, but ere not, not ithstanding the 
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discussion between the Court and the parties about sham affidavits in the July 15 2011
Hearing
6 The Courts final Judgment in this case was entered on October 20 2011
Nonetheless Plaintiff seeks by her third Motion for Reconsideration to have the Court reconsider
orders that were entered prior to the entry of final judgment As stated in Argument sections A
and B above those pre judgment orders became part of the final judgment once it was entered
and cannot be the subject of a motion for reconsideration filed after entry offinal judgment The
proper procedure for obtaining relief from a final judgment is through a motion for relief from
judgment under Idaho Rules of Civil Procedure Rule 60b Plaintiff has not filed such a motion
or satisfied the requirements for obtaining relief under such rule
7 Proper and complete affidavits of Dr Yost and Major could and should have been
served by Plaintiff on or prior to fourteen 14 days before the July 15 2011 Hearing but they
were not Because they werentSEC has incurred substantial additional expense after the July
15 2011 Hearing in having to defend three motions for reconsideration and to prosecute three
motions to strike three successive affidavits of Dr Yost the last of which was not permitted by
the Court Defendant has also incurred additional expenses in having to defend an improper
third Motion for Reconsideration after entry of final judgment The nature and extent of those
additional fees and costs are outlined in the Affidavit of Counsel As that Affidavit indicates the
total additional expenses in fees and costs incurred by SEC after July 15 2011 in dealing with
the defects in the Yost Affidavits and in responding to three successive motions for
reconsideration are around375650
8 IRCPRule 56c is intended to address the type of abuse and disregard of
summary judgment procedures which have been perpetrated by Plaintiff and her attorneys in this
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discussion bet een the ourt and the parties a out "sham affid its" in the J l  ,  
earing. 
. he urt's final t in this case as t re   ctober , . 
onet l ss, Plai tiff s e s by her t ird otion f r e si r ti  t  have the rt reconsider 
orders that ere entered prior to the entry f final judg ent. s stated in rgu ent sections  
and , above, those pre-judgment orders beca e part of the final judg ent once it as entered, 
and cannot be the subject of a otion for reconsideration filed after entry of final judg ent. he 
proper procedure for obtaining relief fro  a final jUdgment is through a otion for relief fro  
judgment under Idaho Rules of Civil Procedure Rule 60(b). Plaintiff has not filed such a motion 
or satisfied the require ents for obtaining relief under such rule. 
. Proper and co plete affidavits of r. ost and ajor could and should have been 
served by Plaintiff on or prior to fourteen (14) days before the July 15, 2011 Hearing, but they 
ere not. ecause they eren't, SE  has incurred substantial additional expense after the July 
15,2011 earing in having to defend three otions for reconsideration and to prosecute three 
tions    i  ts  r. t,       r i   
 urt. f t s ls  i rr  iti l s s i  i  t  f   i r r 
third otion for Reconsideration after entry of final judg ent. The nature and extent of those 
i l        ida   sel.    t s,  
total additional expenses in fees and costs incurred by SEC, after July 15, 2011, in dealing ith 
t e efects i  t e st ffida its a  i  res i  t  t ree s ccessi e ti s f r 
r sideration, r  r  $37,565. 0. 
. I.R.C.P. le 6(c) is i te e  t  a ress t e t e f a se an  isre ar  f 
summary judgment procedures which have been perpetrated by Plaintiff and her attorneys in this 
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case The rules do not permit the party opposing summary judgment to get a do over every
time that party receives an adverse summary judgment ruling andor fails to get it right the first
time around Neither do the rules permit a party to obtain reconsideration of a prejudgment
interlocutory order after final judgment is entered For the reasons stated herein this Court
should exercise its discretion pursuant to Rule 56cand impose sanctions on both Plaintiff and
her attorneys by awarding SEC its additional costs and fees unnecessarily incurred due to
Plaintiffsconduct in the amount of375650
III CONCLUSION
For the reasons stated herein Plaintiffs motion for reconsideration under IRCP
I Ia2 is procedurally improper given that Judgment was entered prior to Plaintiff s filing of
that motion and the Court should therefore treat Plaintiff s motion as one brought underIRCP
60b Because Plaintiff cannot justify relief from judgment under the provisions of Rule 60b
her motion should be denied Further even if this Court were to consider the additional evidence
presented by Plaintiff that evidence still fails to meet the burdens imposed by relevant products
liability law and Plaintiff has therefore failed to adequately justify her attempt to seek relief
from the Judgment Accordingly SEC respectfully requests that this Court deny Plaintiffs so
called motion for reconsideration strike or not consider the third Yost Affidavit award SEC
attorney fees underIRCP56cand allow this case to run its course through appeal
DATED this day of December 2011
GKI R BURKE SH EM ERPA
istopher C Burke
Thomas J Lloyd III
Attorneys for Defendant
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case. The rules do not pennit the party opposing su ary judgment to get a "do over" every 
time that party receives an adverse summary judgment ruling, andlor fails to get it right the first 
ti e around. either do the rules pennit a party to obtain reconsideration f a pre-judgment 
interlocutory order after final judg ent is entered. r the e  te  i , t is o rt 
should exercise its discretion pursuant to ule 56( c), and i pose sanctions on both Plaintiff and 
er att rne s  a ar ing  its a itional c sts a  fees, ecessaril  inc rre  e t  
laintiffs c ct, i  t e a t f$37,565.50. 
I.  
  s  i , fs     .R.C.P. 
I I (a)(2) is procedurally improper, given that Judgment was entered prior to Plaintiffs filing of 
t at ti ,  t  rt s l  t r fore tr t l i tiffs ti  s  r t r I.R.C.P. 
60(b). Because Plaintiff cannot justify relief from judgment under the provisions of Rule 60(b), 
    i d. r,   s      i   
presented by Plaintiff, that evidence still fails to eet the burdens i posed by relevant products 
liability law, and Plaintiff has therefore failed to adequately justify her attempt to seek relief 
fro  the Judg ent. ccordingly, SE  respectfully requests that this ourt deny Plaintiffs so-
ll  ti  f r r sideration, stri  r t si r t  t ir  st ffi vit, r   
attorney fees under I.R.c.P. 56(c), and allo  this case to run its course through appeal. 
 t i  J;k'day of December, 2011. 
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing Memorandum in Support of
Security Equipment CorporationsMotions to Strike Third Affidavit of Garold Yost and
for Rule 56c Award of Attorneys Fees and Costs on the following named personson the
date indicated below in the manner indicated below
Darwin Overson Esq ViaUS Mail
Eric B Swartz Esq LVia Hand Delivery
JONES SWARTZ PLLC VI Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O BOX 7808
Boise Idaho 83707
DATED this day of December 2011
Christopher C Burke
Thomas J Lloyd III
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THIRD AFFIDAVIT OF GAROLD YOST AND FOR RULE 56c AWARD OF ATTORNEYS FEES AND




CE IFICATE OF S ICE 
I hereby certify that I caused to be served the foregoing emorandum in Support of 
Security Equipment Corporation's otions to Strike Third Affidavit of Garold Yost and 
for Rule 56(c) Award of Attorneys' Fees and Costs on the following named person(s) on the 
date indicated belo , in the anner indicated belo : 
Darwin Overson, Esq. 
Eric B. Swartz, Esq. 
J ES & S ARTZ, PLLC 
1673 . reline riv , ite 220 
. . ox  
Boise, Idaho 83707 
TE  t is J..&tday of December, 2011. 
[ ] ia .S. il 
[ :VVia and elivery 
[ v1 ia i ile (208/489-89 ) 
[ ] ia er ight ivery 
rist er . r e 
ho as 1. loyd III 
RANDUM I  SUPPORT OF SECURITY EQUIPMENT CORPORATION'S MOTI S TO STRIKE 
THIRD AFFIDAVIT OF GAROLD YOST AND FOR RULE 56(c) A ARD OF ATTORNEYS' FEES AND 
C STS - Page 25 14542-011 
(424316.doc) 
Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKERPA








CHRISTOPHER D RICH Clerk
By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA




CORPORATION a Missouri corporation
Case No CVPI1003515
NOTICE OF HEARING RE SEC
MOTIONS TO STRIKE THIRD
AFFIDAVIT OF GAROLD YOSTPhD
AND FOR RULE 56c ATTORNEYS
FEES AND COSTS
Defendant
PLEASE TAKENOTICE that Defendant Security Equipment Corporation SEC by
and through its attorney of record Greener Burke Shoemaker PA shall call up for hearing its
Motions to Strike Third Affidavit of Garold Yost PhDand for Rule 56c Attorneys Fees
and Costs Said hearing shall be held on December 15 2011 at 400pm or as soon
thereafter as counsel can be heard before the Honorable Cheri C Copsey at the Ada County
Courthouse located at 200 West Front Avenue Boise Idaho
DATED this A day of r 2011 GR N BURKE HO AKE A
Christopher C Burke Thomas J Lloyd III
Attorneys for Defendant
NOTICE OF HEARING RE SEC MOTION TO STRIKE THIRD AFFIDAVITOF GAROLD YOST PhDAND
FOR RULE 56cATTORNEYS FEES AND COSTS PAGE 1 14542 011 425274doc
002193
Christopher C. Burke, ISB #2098 
Tho as 1. Lloyd III, ISB #7772 
 E E  .A. 
 e t  t t, ite  
oise, Idaho 83702 
el: (208) 319-2600 
x: (20 ) -2601 
Attorneys for Defendant 
f\ r: 1 r', 
; I l '-; 
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I  . I , l  
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       I     
  ,        
I IE J  J , a  i i i al, 
laintiff, 
v. 
I  I  
A I ,  iss ri r r ti , 
nt. 
 o.: -PI-  
    EC'S 
IO S    
I    T, h.D. 
   6(c) ' 
   
P S   I  that efendant Security quip ent orporation ("SE "), by 
a  t r  its att r e  f record, ree er r e e a er .A., s all call  f r eari  its 
tions t  tri  ir  ffid it f r l  st, h.D.  f r l  6(c) tt r s' ees 
and Costs. Said hearing shall be held on December 15, 2011, at 4:00 p.m., or as soon 
t ereafter as c sel ca  e eard, ef re t e ra le eri . se  at t e a t  
ourthouse, located at 200 est Front venue, oise, Idaho. 
 s JL  f~r, . 
hristopher . urke / ho as J. loyd III 
tt r s f r f t 
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing NOTICE OF HEARING RE
SEC MOTION TO STRIKE THIRD AFFIDAVIT OF GAROLD YOST PhD AND FOR RULE
56cATTORNEYS FEES AND COSTS on the following named personson the date indicated
below in the manner indicated below
Darwin Overson Esq ViaUSMail
Eric B Swartz Esq ViaHand Delivery
JONES SWARTZ PLLC XVia Facsimile 2084898988
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Thomas J Lloyd III
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IC TE F S ICE 
I hereby certify that I caused to be served the foregoing TICE F E RING RE 
C'S ION  E IR  IT   , h.D.    
56(c) TTOR E S' FEES  C STS on the follo ing na ed person(s) on the date indicated 
belo , in the anner indicated belo : 
ar in verson, Esq. 
Eric . S artz, Esq. 
J ES & S , P C 
1673 . Shoreline r., Suite 220 
.O. ox  
oise,I  83707 
 is Y  f~.ffi~"', . 
~. 
[ ] ia .S.  
[ ] ia a  eli er  
[X] ia i e (20 - 9-89 ) 
[ ] ia r i t liver  
  I   EC'S  T  STRI  I  I I   L  ST, h.D.  
F  LE 56(c) TT E S' FEES  STS - PA E 2 14542- 1  ( 25274 doc) 
Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKER PA






DEC 0 5 2011
CHRISTOPHER D NCH Clerk
By ELYSHIA HOLMES
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA










TO THE ABOVENAMED APPELLANT AND THE PARTYSATTORNEY AND THE
CLERK OF THE ABOVE ENTITLED COURT
NOTICE IS HEREBY GIVEN that the Respondent Security Equipment Corporation
SEC or Respondent by and through its counsel of record Greener Burke Shoemaker PA
in the above entitled proceeding hereby requests pursuant to Rule 19IARthe inclusion of the
following material in the Clerksrecord in addition to that required to be included by theIAR
and the notice of appeal
1 ClerksRecord
a May 7 2010 Stipulation for Scheduling and Planning
b May 28 2010 Order Governing Proceedings and Trial Setting
0 R I G 1IN
SECURITY EQUIPMENT CORPORATIONSREQUEST FOR ADDITIONAL RECORD Page 1
14542011 429168doc
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hristopher C. urke, IS  #2098 
Tho as J. Lloyd III, IS  #7772 
  ER  
 .  t, te  
ise, I a   
    
 . RI , lm  
   
 
l: (20 ) -2600 
: (20 ) -2601 
ttorneys for efendant 
           
  ,        
I IE J  J , an individual, 
l intiff, 
v. 
I  I  
C RPORATI N, a issouri corporation, 
ant. 
 o.: -PI-I  
I  I  
RPORATION'S   
I I   
:  -NAME     RTY'S ,   
   -   
TICE IS EREB  I E , that the Respondent, Security Equip ent Corporation 
("SEC" or "Respondent"), by and through its counsel f record, reener urke hoe aker P.A., 
in the above-entitled proceeding hereby requests, pursuant to ule 19, I.A.R., the inclusion of the 
f ll i  aterial i  t e lerk's rec r  i  a iti  t  t at re ire  t  e i cl e   t e I.A.R. 
and the notice of appeal. 
. lerk's cord: 
. ay 7, 2010 Stipulation for Scheduling and Planning; 
. ay 28,2010 rder overning roceedings and rial etting; 
SE IT  E IP E T RPORA nON'S E EST F  ITI L E  - Page 1 
-0  (4 9168.doc) 
C January 26 2011 Confidentiality Order and
d May 13 2011 Order Governing Proceedings and Setting Trial
Pursuant to Rule 27IARRespondent requests that the Clerk provided scanned copies
of the designated clerksrecord
2 I further certify that this request for additional record has been served upon the
Clerk of the District Court and upon all parties required to be served pursuant to Rule 20
DATED this day of December 2011
GRE E B KE S EMA R P
Christopher C Burke
Thomas J Lloyd III
Attorneys for Defendant
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c. Ja ar  ,  fide tiality r er; a  
. ay 13, 2011 rder overning Proceedings and Setting Trial. 
ursuant to ule 27, I.A.R., espondent requests that the lerk provided scanned copies 
of the designated clerk's record. 
. I further certify t at t is re est f r a iti al rec r  as ee  ser e   t e 
ler   t  ist ict t   ll ties ire  t  e  t t  l  . 
TE   S~ day of ece ber, 2011. 
hristopher . urke 
as 1.   
ttorne s  e  
SECURIT  E IP E T C RPORATION'S RE EST F R ITI L REC R  - Page 2 
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CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing Security Equipment
CorporationsRequest for Additional Record on the following named persons on the date
indicated below in themanner indicated below
Darwin Overson Esq yf ViaUS Mail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 ViaOvernight Delivery
P O Box 7808
Boise Idaho 83707
AttorneyforPlaintiff
Clerk of Court WiaUS Mail
FOURTH JUDICIAL DISTRICT ADA COUNTY Via Hand Delivery
200 W Front Street Via Facsimile
Boise Idaho 83702 ViaOvernight Delivery
DATED this Ju day of December 2011
V
C sizs opher C Burke
Thomas J Lloyd III
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I hereby certify that I caused to be served the foregoing Security Equip ent 
orporation's equest for dditional ecord on the follo ing na ed person(s) on the date 
indicated l , in t  a r i icate  l : 
ar in verson, sq. 
ric . S artz, sq. 
 & ,  
 . reline ri e, ite  
. .   
oise, Idaho 83707 
Attorney for Plaintiff 
   
FOURTH JUDICIAL ISTRICT,  COUNTY 
 .   
ise, I a   
TE  this ~ day of ece ber, 2011. 
/ 
[ f a .S.  
[ ] ia a  li r  
[ ] ia i ile (20 /489-89 ) 
[ ] ia er i t eli er  
[Jvi  .S.  
[ ia and elivery 
[ ]  i  
[ ] i  r i t li r  
~--f---L~' 8~ ( 
hrIS opher . urke 
Tho as J. Lloyd III 
I  I  RPORATION'S   I I   - Page 3 
14542-011 (429168 doc) 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA
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MOTION TO SHORTEN TIME FOR
CONSIDERATION OFPLAINTIFFS
MOTION FOR RECONSIDERATION
LIKELY TO BE TREATED AS AN
RCP60bMOTION OR IN THE
ALTERNATIVE FOR A
CONTINUANCE OF THE HEARING
Plaintiff respectfully moves underIRCP 6b and 7b3to shorten the time for
hearing Plaintiffsmotion for reconsideration supported by a recently submitted affidavit
showing mistake inadvertence or excusable neglect underIRCP60b1and for any other
reason justifying relief from operation of the judgment underIRCP60b
Plaintiff seeks to have heard at the December 15 2011 hearing her motion for
reconsideration with the Court considering the supporting affidavit of her counsel The affidavit
was not filed with the motion because counsel was unaware that the Court had entered final
MOTION TO SHORTEN TIME FOR CONSIDERATION OF PLAINTIFFSMOTION FOR
RECONSIDERATION LIKELY TO BE TREATED AS ANIRCP60b MOTION OR IN THE
ALTERNATIVE FOR A CONTINUANCE OF THE HEARING 1
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post Office Box 7808
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ar in vers , ISB #5 87 
ric . S rt , ISB #6396 
J ES & S RTZ P LC 
1673 . S reline ri e, Suite 200 [837 ] 
Post ffice o  7808 
oise, I  83707 
Telephone: (208) 489-8989 
Facsi ile: (208) 489-8988 
E ail: darwin jonesandswartzlaw.com 
eric jonesandswartzlaw.com 
Attorneys for Plaintiff, Billie Jo ajor 
tt;  2011 
CHRi';';T(;'i';~;:"i1 D. RICH lerk 
y KA"iHY BI  • 
~ 
 E         
   ,        
I IE  J ,  i i i l, 
Plaintiff, 
vs. 
SEC RIT  E IP E T C RP RATI , 
a issouri corporation, 
ant. 
s  .  I  
     
  I TIFF'S 
I   I I  
I       
I.R.C.P. 0(b) I , ,   
I ,  
    
Plaintiff respectfully moves under 1.R.c.P. 6(b) and 7(b)(3) to shorten the time for 
hearing Plaintiff s motion for reconsideration supported by a recently submitted affidavit 
showing mistake, inadvertence, or excusable neglect under I.R. c.P. 60(b)( 1) and for "any other 
reason justifying relief fro  operation of the judg ent" under I.R.C.P. 60(b)(6). 
l i ti        r 5,  ari  r ti  r 
reconsideration, ith the ourt considering the supporting affidavit of her counsel. he affidavit 
s t fil  it  t  ti  s  s l s r  t t t  rt  t r  fi l 
I    I   SI I   LAINTIF 'S I   
NSIDERATI  I       I.R.C.P. 60(b) TI N, R, I   
ALTERNATIVE, FORA CONTINUANCE OF THE HEARING -1 
judgment If the Court is inclined to deny the motion to shorten time the Plaintiff moves in the
alternative to vacate the hearing and reset to allow for the 14 days normally required prior to the
hearing
Good cause exists for allowing the Plaintiff to file an affidavit in support of Plaintiffs
motion for reconsideration which will likely be treated as anIRCP60bmotion Plaintiffs
counsel was unaware that judgment had been entered at the time he filed the PlaintiffsIRCP
1la2Bmotion for reconsideration
This motion is supported by the affidavit of counsel filed concurrently herewith along
with the pleadings affidavits and other documents of record
DATED this 8th day of December 2011
MOTION TO SHORTEN TIME FOR CONSIDERATION OF PLAINTIFFSMOTION FOR
RECONSIDERATION LIKELY TO BE TREATED AS ANIRCP60b MOTION OR IN THE
ALTERNATIVE FOR A CONTINUANCE OF THE HEARING 2
ERiCB SwARTz
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judgment. If the Court is inclined to deny the motion to shorten time, the Plaintiff moves in the 
alter ive to vacate the he ing and res t to lo  fo  the 4 s ly re re  rior to the 
hearing. 
ood cause e ists for allo ing t e lai tiff to file a  affida it in s rt f laintiffs 
otion for re ti , ich  likely  treate   a  I.R.C.P. 0(b) . l intif s 
counsel as una are that judg ent had been entered at the ti e he filed the Plaintiffs I.R.C.P. 
I 1 (a)(2)(B) motion for reconsideration. 
his otion is supported by the affidavit of counsel filed concurrently here ith along 
ith the pleadings, affidavits, and other docu ents of record. 
 t is t  a  f ece er, . 
I    I   I I   LAINTIF 'S I   
SI I  I     S  LR.C.P. 60(b) I N, R, I   
LTERNATIVE, F R  CONTI CE F T E E RI  -  
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 8th day of December 2011 a true and correct copy of
the foregoing document was served on the following individualsbythe method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA










MOTION TO SHORTEN TIME FOR CONSIDERATION OF PLAINTIFFSMOTION FOR
RECONSIDERATION LIKELY TO BE TREATED AS ANIRCP60bMOTION OR IN THE
ALTERNATIVE FOR A CONTINUANCE OF THE HEARING 3
002200
IFICATE F S  
I ERE Y IFY that n this 8th a  f e , 2 , a true d rect c y of 
the foregoing document was served on the following individua1(s) by the method indicated: 
hristopher . urke 
Tho as J. Lloyd III 
 E S ER   
 . a c  tr t, ite 900 
oise, I  83702 
~--'!~r1"1VIN . RSON 
I  .  
TI  T  S TE  TI E F  CONSI ERATI  F PLAINTIFF'S TI  F  
NSI I  I       I.R.C.P. 60(b) I , R, I  T  
ALTERNATIVE, FOR A CONTINUANCE OF THE HEARING - 3 
.co  
6th 08 2011
G PYBv r0 l D RICH CINk
y itATHY BIEHL
IN THE DISTRICT COURT OF THE FOURTH JUDICIALDISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA





Case No CV PI 1003515






Plaintiff respectfully moves underIRCP6b7b3and 60b to enlarge the time for
submitting an affidavit showing mistake inadvertence or excusable neglect under IRCP
60b1and for any other reason justifying relief from operation of the judgment under
IRCP60b
Good cause exists for allowing the Plaintiff to file an affidavit in support of Plaintiffs
motion for reconsideration which will likely be treated as anIRCP60bmotion Plaintiffs
counsel was unaware that judgment had been entered at the time he filed PlaintiffsIRCP
11a2Bmotion for reconsideration
PLAINTIFFSMOTION TO ENLARGE TIME FOR SUBMITTING AFFIDAVIT SHOWING MISTAKE
INADVERTENCE OR EXCUSABLE NEGLECT UNDERICP60b 1
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
Post OfficeBox 7808
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IoR.CoPo 0(b) 
Plaintiff respectfully oves under I.R.c.P. 6(b), 7(b)(3), and 60(b) to enlarge the ti e for 
submitting an affidavit showing mistake, inadvertence, or excusable neglect under I.R.C.P. 
60(b)(1) and for "any other reason justifying relief fro  operation of the judg ent" under 
I.R.C.P. 0(b)(6). 
ood cause exists for allo ing the laintiff to file an affidavit in support f laintiffs 
ti   i rati , i  ill li l   t t    .R.C.P. 0(b) ti . laintif s 
s l  r  t t ju t   t r  t t  ti   file  laintiffs I.R.C.P. 
11(a)(2)(B) otion for reconsideration. 
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I E ,  E   LR.C.P. 0(b) -  
This motion is supported by the affidavit of counsel filed concurrently herewith along
with the pleadings affidavits and other documents of record
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This otion is s ported by the a fida it f counsel filed conc rre tly it , along 
with the pleadings, affidavits, and other documents of record. 
TED this 8th day of ece ber, 2011. 
By ______ ~ __ ~~~ __________ ___ 
VERSON 
I  .  
   
I  I  t t  t i  t   f r, ,  tr   rr t  f 
the foregoing docu ent as served on the follo ing individual(s) by the ethod indicated: 
rist r . r e 
Tho as J. Lloyd ill 
     
950 . annock Street, Suite 900 
Boise, ID 83702 
[ ] .S. il 
[ ] x: -2  
[ ] essenger elivqy 




I  .  
I  .  
LAINTIF 'S I    I   UB I I  FIDA I  SH I  I TAKE, 
INADVERTENCE, OR EXCUSABLE NEGLECT UNDER I.R.C.P. 60(b) - 2 
2011
C ep 6 D RICH Clerk
Cy KAfHY BEEHL
UeNty
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA









Case No CV PI 1003515
AFFIDAVIT OF COUNSEL IN
SUPPORT OF PLAINTIFFSREPLY
RE THIRD MOTION FOR
RECONSIDERATION OPPOSITION
TO DEFENDANTMOTION TO
STRIKE AND OPPOSITION TO
DEFENDANTMOTION FORRULE
56c AWARD OFATTORNEY FEES
AND COSTS
I Darwin L Overson being first duly sworn upon oath depose and state upon my own
personal knowledge as follows
1 I am an attorney with the law firm of Jones Swartz PLLC and am authorized to
practice law before this and all courts of the State of Idaho
2 I am counsel of record for Plaintiff Billie Jo Major in the above action and have
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I, Darwin L. Overson, being first duly sworn upon oath, depose and state upon y own 
personal knowledge as follows: 
. I a  an attorney ith the la  fir  of Jones & rt  L ,   t ri  t  
practice la  before this and all courts of the State of Idaho. 
.   l    l intiff illie  j  i  t   ction,   
I       LAINTIF 'S L  E:    
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firsthand knowledge of the documents materials and all other discovery that has been produced
by either party in this case
3 At the July 14 2011 hearing when the Court denied the Defendantsmotion to
strike the affidavit ofDr Yost on the grounds that it was not a sham affidavit in conflict with his
deposition testimony the Courts comments left the distinct impression with me that after the
Court had reviewed the deposition testimony an affidavit that included the expert opinion of
Dr Yost that SEC knew or should have known of the risks associated with its product would not
be considered in conflict with his deposition testimony
4 When I was working with Dr Yost to prepare a second affidavit to cure the
problems identified by the Court in his first affidavit I did not attempt to include any
explanations by Dr Yost of any conflicts between his affidavit testimony and his deposition
testimony because I did not perceive any conflicts between the testimony Nonetheless this
Court granted the Defendantsmotion to strike the second affidavit of Dr Yost on the grounds
that it conflicted with his deposition testimony That hearing took place on September 15 2011
Given the Courts comments regarding sham affidavits during the prior hearing the
September 15 2011 ruling surprised me
5 Surprised by the CourtsSeptember 15 2011 ruling on the Defendantsmotion to
strike I immediately started working toward obtaining an affidavit that would satisfy the Court
that a genuine issue of material fact existed on the foreseeability of injury element of the
Plaintiffs causes of action I contacted Dr Pacheco to discuss whether she could review the
literature predating when SEC sold its SABRE Red product to IDOC I spoke with her on or
about September 21 2011 and she agreed to review the literature I repeatedly attempted to
follow up with Dr Pacheco and by October 4 2011 it was clear that she would not have time to
AFFIDAVIT OF COUNSEL IN SUPPORT OF PLAINTIFFSREPLY RE THIRD MOTION FOR
RECONSIDERATION OPPOSITION TO DEFENDANTMOTION TO STRIKE AND OPPOSITION TO
DEFENDANTSMOTION FOR RULE 56cAWARD OF ATTORNEY FEES AND COSTS 2
002204
firstha  no ledge f the ts, t ri ls,  ll t er is r  t at s  roduced 
by either party in this case. 
. t the July 14, 2011 hearing, hen the ourt denied the efendant's otion to 
e the   . ost  the rounds t  it a  t   i   ct ith is 
deposition testimony, the Court's comments left the distinct impression with me that, after the 
t a  ie e  t  ition t ti ,  i it t t i l  t e t i io   
r. ost t t  e        is s  t      
be considered in conflict ith his deposition testi ony. 
. hen I as orking ith r. ost to prepare a second affidavit to cure the 
problems identified by the Court in his first affidavit, I did not attempt to include any 
explanations by Dr. Yost of any conflicts between his affidavit testimony and his deposition 
testi  eca se I i  t ercei e a  c flicts et ee  t e testi ny. l s,  
Court granted the Defendant's motion to strike the second affidavit of Dr. Yost on the grounds 
that it conflicted ith his deposition testi ony. hat hearing took place on epte ber 15, 2011. 
iven the ourt's co ents regarding "sha  affidavits" during the prior hearing, the 
Septe ber 15, 2011 ruling surprised e. 
. urprised by the ourt's epte ber 15, 2011 ruling on the efendant's otion to 
strike, I i ediately started orking to ard obtaining an affidavit that ould satisfy the ourt 
that a genuine issue of material fact existed on the foreseeability of injury element of the 
laintiffs   ti n.   r.      l  i  t  
literature pre-dating when SEC sold its SABRE Red product to IDOC. I spoke with her on or 
about Septe ber 21, 2011, and she agreed to revie  the literature. I repeatedly atte pted to 
follow up with Dr. Pacheco and by October 4,2011, it was clear that she would not have ti e to 
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conduct a literature review I then contacted Dr Yost and asked him to conduct an additional
review of the literature On October 6 2011 I prepared a rough draft of the affidavit ofDr Yost
I had several discussions with Dr Yost regarding the literature review and he was able to identify
additional publications to support the foreseeability element of the Plaintiffsclaims I continued
to work with Dr Yost to finalize the affidavit but he became extremely ill and was hospitalized
According to his family there was concern that he may not survive He was not able to execute
the affidavit until October 20 2011
6 In the meantime I had prepared a motion to reconsider this Court prior orders
granting the Defendantsmotion to strike and motions for summary judgment The motion and
memorandum were ready to sign and file but for the affidavit ofDr Yost I received the affidavit
of Dr Yost on October 24 2011 through Federal Express and immediately filed the motion
memorandum and affidavit At the time I was not aware that the Court had entered a final
judgment A copy of the judgment was received in my office on October 24 2011 but it did not
come to my attention
7 When the judgment was received in my office my secretary calendared the dates
for filing posttrial motions The office relies on a computer program that automatically
calculates the deadlines based on current activity in the case and the Idaho Rules of Civil
Procedure The computer programs is Vision produced by CompuLaw The calendaring
system set the deadline for filing a motion for reconsideration in this case for November 11
2011 When the information is entered in Vision it updates my calendar to include the
appropriate deadlines It does not alert me that it has made the update Upon a later review of
my calendar and upon my earlier review ofIRCPIa2BI believed that the motion for
reconsideration was timely because it was within 14 days of the entry ofjudgment
AFFIDAVIT OF COUNSEL IN SUPPORT OF PLAINTIFFSREPLY RE THIRD MOTION FOR
RECONSIDERATION OPPOSITION TO DEFENDANTMOTION TO STRIKE AND OPPOSITION TO
DEFENDANTSMOTION FOR RULE 56cAWARD OF ATTORNEY FEES AND COSTS 3
002205
  iterature .  t  ta te  .        i  
re ie  f t e literat re.  ct ber , , I re are  a r  raft f t e affi a it f r. st. 
I  r l is i  it  r. st r r i  t  literat r  r i     l  t  i tif  
a iti al lications t  s rt t e f reseeabilit  ele e t f t e laintiffs clai s. I c ti e  
t   it  r. ost t  inalize t  i vit, t  e t l  ill  a  pit li d. 
r i  t  is f ily, t ere s r  t t   t s r i .  s t l  t  t  
   t er , . 
. I  t e ea ti e I a  re are  a ti  t  rec si er t is ourt's ri r r ers 
granting the efendant's otion to strike and otions for su ary judg ent. he otion and 
e orandu  ere ready to sign and file but for the affidavit of r. ost. I received the affidavit 
 r. ost   ,   l ,   le   ti , 
  f vit.   ,           l 
judg ent.  copy of the judg ent as received in y office on ctober 24,2011, but it did not 
 t   tt ti . 
. hen the judg ent as received in y office, y secretary calendared the dates 
for filing post-trial motions. e ffice relies  a c ter r ra  t at a t aticall  
calc lates t e ea lines ase   c rre t acti it  i  t e case a  t e I a  les f i il 
r . The co puter progra s is Vision© produced by Co puLaw. e cale ari  
syste  set the deadline for filing a otion for reconsideration in this case for Nove ber 11, 
1. hen the infor ation is entered in ision© it updates y calendar to include the 
appropriate deadlines. It does not alert e that it has ade the update. pon a later revie  of 
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FURTHER YOUR AFFIANT SAYETH NAUGHT
LIJ
SUBSCRIBED AND SWORN TO before me this 8th day ofDecember 2011
Notary Public for Idaho
a 0TARp MyCommission expires 7 zoz
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 8th day of December 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
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MOTION TO STRIKE AND
OPPOSITION TO DEFENDANT
MOTION FOR RULE 56c AWARD OF
ATTORNEY FEES AND COSTS
Plaintiff hereby submits her memorandum in reply to Defendantsopposition to
Plaintiffsmotion for reconsideration in opposition to Defendantsmotion to strike the affidavit
ofDr Yost and in opposition to DefendantsRule 56cmotion for attorney fees and costs
PLAINTIFF FILED HER MOTION FOR RECONSIDERATION FOUR DAYS AFTER
ENTRY OF THE ORDER GRANTING DEFENDANT SUMMARY JUDGMENT AND
THE FINAL JUDGMENT AND IS THEREFORE TIMELY
Defendantsposition is that a Rule I Ia2Bmotion to reconsider an interlocutory
order granting a motion for summary judgment must be filed before final judgment Defendants
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ttorneys for laintiff, illie Jo ajor 
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a issouri corporation, 
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Plaintiff hereby sub its her e orandu  in reply to efendant's opposition to 
Plaintiff's otion for reconsideration; in opposition to efendant's otion to strike the affidavit 
of r. ost; and in opposition to efendant's Rule 56(c) otion for attorney fees and costs. 
F      I     
         
 I  J T,  I   I  
efendant's position is that a Rule 11(a)(2)(B) otion to reconsider an interlocutory 
order granting a otion for su ary judg ent ust be filed before final judg ent. efendant's 
I TIFF'S  : I  I   NSIDERATION; SITI   FENDANT'S 
  I ;  SI I   FENDANT'S    6(c)   
    -  
position is contrary to the plain language of the rule Since the motion to reconsider was filed
four days after entry of the order granting summary judgment and entry of the final judgment the
motion was timely
Furthermore even if the rule were as the Defendant claims this Court must treat the
IRCP11a2Bmotion as analogous to anIRCP59e or 60b motion Straub v Smith
145 Idaho 65 71 2007 motion to reconsider brought after judgment treated as motion to alter
or amend judgment Lowe v Lym 103 Idaho 259 263 App 1982 where motion for
reconsideration raises new issues it should be treated by analogy as motion for relief from
judgment but see CoeurdAlene Mining Co v First National Bank of Northern Idaho 118
Idaho 812 82223 1990 when a motion is brought under IRCP11a2Beven after
judgment has been entered a trial court should consider new facts presented by the moving
party that bear on the correctness of the interlocutory order
Under Rule 59e this Court can consider the Third Affidavit ofDr Yost to correct legal
and factual errors occurring in the proceedings since the affidavit corrects this Courts
misapprehension of Dr Yostsearlier affidavits See Straub 145 Idaho at 71 finding an abuse
of discretion by the trial courtsrefusal to consider partysaffidavit clarifying factual error made
by the court Lowe 103 Idaho at 263 Rule 59e proceedings afford the trial court the
opportunity to correct errors both of fact or law that had occurred in its proceedings The
portion of Dr Yosts affidavit explaining that his prior affidavits were not conflicting with his
deposition testimony is the type of information that is appropriately considered when a motion
for reconsideration is treated as aIRCP59emotion See Straub 145 Idaho at 71 partys
affidavit explaining intent of a stipulation to dismiss
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sition is c trar  t  t e lai  la a e f t e r le. i ce t e ti  t  rec si er as file  
four days after entry f the order granting su ary judg ent and entry of the final judg ent, the 
otion as ti ely. 
rt r r ,  i  t  r le r   t  f t l i , t is rt t tr t t  
I.R.C.P 11(a)(2)(B) otion as analogous to an I.R.C.P. 59(e) or 60(b) otion. Straub v. S ith, 
  ,  (20 ) (motion t  i  t t  j t t t   ti  t  lt  
r  ju ent); e v. ,  I a  ,  (A . 82) (where ti  f r 
 s             l   
judg ent); but see oeur d'Alene ining o. v. First ational Bank of orthern Idaho, 118 
I  , -23 (19 ) (whe   ti  is r t r 1.R.c.P. 1 (a)(2)(B),  ft r 
judg ent has been entered, a trial court should consider "new facts presented by the oving 
party that bear on the correctness of the interlocutory order"). 
nder ule 59( e), this ourt can consider the hird ffidavit of r. ost "to correct legal 
 f t l rr r  rri  i  t  r edings" i  t  ffi it rr t  t i  ourt's 
is re si  f r. st's rli r ffi its.  tr ,  I  t  (findin   s  
of discretion by the trial court's refusal to consider party's affidavit clarifying factual error ade 
by the court); o e, 103 Idaho at 263 ("Rule 59(e) proceedings afford the trial court the 
opportunity to correct errors both of fact or law that had occurred in its proceedings").  
portion of Dr. Yost's affidavit explaining that his prior affidavits were not conflicting with his 
deposition testi ony is the type of infor ation that is appropriately considered hen a otion 
for reconsideration is treated as a I.R.C.P. 59(e) otion. See Straub, 145 Idaho at 71 (party's 
affidavit explaining intent of a stipulation to dis iss). 
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UnderIRCP60b this Court can reach the merits of the motion to reconsider by
relieving the Plaintiff of the operation of the judgment so far as this Court may find thatIRCP
IIa2Bdoes not allow a motion to reconsider after entry of final judgment Good cause
exists for doing so on the grounds that 1 counsel worked diligently to obtain a third affidavit
from Dr Yost but was hindered by Dr Yost becoming very ill and having to be hospitalizedi
was not clear whether he would survive at the time and 2 when the motion to reconsider was
filed counsel was not aware that this Court had entered the order and final judgment Aff ofD
Overson IT 37
Irrespective of whether the Court treats the motion as analogous to anIRCP59eor
60b motion it is still fundamentally anIRCP11a2Bmotion A motion to reconsider
filed within 14 days of entry of final judgment must be reviewed underIRCP11a2B
taking into account any new facts presented by the moving party that bear on the correctness of
the interlocutory order CoeurdAlene Mining Co v First National Bank ofNorthern Idaho
118 Idaho 812 823 1990
CDA could have brought this exhibit to the attention of the trial
court even after the judgment was entered IRCPIla213
entitled CDA to request reconsideration ofthe trial courtspretrial
order specifying the facts that would be deemed established for the
purposes of trial The rule states that a motion for
reconsideration of any interlocutory orders of the trial court
may be made at any time before the entry of final judgment
but not later than fourteen 14 days after the entry of the final
judgment CDAssecond motion for reconsideration was
filed on the fourteenth day after the entry of judgment
On a motion for reconsideration of the specification of facts
deemed established pursuant toIRCP56d the trial court
should reconsider those facts in light of any new or additional
facts that are submitted in support of the motion This view of
the effect ofIRCP11a2Bis consistent with the discussion
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r I.R.C.P. 60(b), t is rt  rea  the rits f the tion to re i er  
relieving the Plaintiff of the operation of the judg ent so far as this Court ay find that I.R.C.P. 
11(a)(2)(B) does not allo  a otion to reconsider after entry of final judg ent.  s  
exists for doing so on the grounds that (1) counsel orked diligently to obtain a third affidavit 
fr  r. st t as i dere   r. ost ec i  er  ill a  a i  t  e spitalized-it 
as   hether  ld   t e ;  (2) e   ion  der  
filed, counsel as not a are that this ourt had entered the order and final judg ent. f£ of . 
ers , ~~ -7. 
Irrespective of hether the Court treats the otion as analogous to an I.R.C.P. 59( e) or 
60(b) motion, it is still fundamentally an I.R.C.P. 11(a)(2)(B) motion. A motion to reconsider 
filed within 14 days of entry of final judgment must be reviewed under 1.R.c.P. 11(a)(2)(B) 
taking "into account any ne  facts presented by the oving party that bear on the correctness of 
the interlocutory order." oeur d 'Alene ining o. v. irst ational ank f orthern Idaho, 
118 Idaho 812, 823 (1990). 
 l   r t t is i it t  t  tt ti  f t  tri l 
rt,  ft r t  j t s t r d. I.R.C.P. II(a)(2)(B) 
entitled CDA to request reconsideration of the trial court's pre-trial 
order specifying the facts that would be dee ed established for the 
purposes  i l.    t t  t   
reconsideration "of any interlocutory orders of the trial court 
ay be ade at any ti e before the entry of final judg ent 
but not later than fourteen (14) days after the entry of the final 
judg ent." DA's    i r t   
file   t e f rtee t  a  after t e e tr  f j ent. 
n a otion for reconsideration of the specification of facts 
dee ed established pursuant to I.R.C.P. 56(d), the trial court 
should reconsider those facts in light of any ne  or additional 
facts that are sub itted in support of the otion. This vie  of 
t e effect f 1.R.c.P. II(a)(2)(B) is c siste t it  t e isc ssi  
LAINTIF 'S L  :    ONSIDERATION; POSITI   EFENDANT'S 
TI  T  ST I E;  PP SITI  T  EFENDANT'S TI  F  LE 56( c )  F 
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of reconsideration in JI Case Company v McDonald 76 Idaho
223 280P2d 1070 1955 There this Court said
A rehearing or reconsideration in the trial court
usually involves new or additional facts and a more
comprehensive presentation of both law and fact
Indeed the chief virtue of a reconsideration is to
obtain a full and complete presentation of all
available facts so that the truth may be ascertained
and justice done as nearly as may be Id at 229
280P2d at 1073
We acknowledge that before this Court had adopted IRCP
11a2Bwe had ruled that a trial court correctly treated a
motion for reconsideration of a memorandum decision following
trial as a motion to alter or amend judgment pursuant toIRCP
59e Obray v Mitchell 98 Idaho 533 539 567P2d 1284 1290
1977 As our Court of Appeals correctly pointed out in Lowe v
Lym 103 Idaho 259 263 646P2d 1030 1034 1982 citations
omitted A Rule 59emotion to amend a judgment is addressed
to the discretion of the court An order denying a motion made
under Rule 59e to alter or amend a judgment is appealable but
only on the question ofwhether there has been a manifest abuse of
discretion Rule 59e proceedings afford the trial court the
opportunity to correct errors both of fact or law that had occurred
in its proceedings it thereby provides a mechanism for corrective
action short of an appeal Such proceedings must of necessity
therefore be directed to the status of the case as it existed when the
court rendered the decision upon which thejudgment is based
However we view the function of the trial court to be different
when presented with a motion for reconsideration of an
interlocutory order pursuant toIRCP11a2B When
considering a motion of this type the trial court should take
into account any new facts presented by the moving party that
bear on the correctness of the interlocutory order The burden
is on the moving party to bring the trial courtsattention to the new
facts We will not require the trial court to search the record to
determine if there is any new information that might change the
specification of facts deemed to be established
CoeurdAlene Mining Co 118 Idaho at 82223 Thus this Court must review the Plaintiffs
motion for reconsideration and take into account Dr Yosts third affidavit where he clarifies his
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i terloc t r  r r r t t  I.R.C.P. 1 (a)(2)(B).  
considering a otion of this type, the trial court should take 
into account any ne  facts presented by the oving party that 
bear on the correctness of the interlocutory order. The burden 
is on the oving party to bring the trial court's attention to the ne  
facts. e ill t re ire t e trial c rt t  searc  t e rec r  t  
eter i e if t ere is a  e  i for ation t at i t c a e t e 
specification of facts dee ed to be established. 
r 'Alene ining o.,  I  t -2 . s, t is rt st r i  t  laintiffs 
    t e  t r. st's     ies  
I TIFF'S  : I  IO   SIDERATI N; I I   ENDANT'S 
OTION TO STRIKE; AND OPPOSITION TO DEFENDANT'S OTION FOR RULE 56( c ) A ARD OF 
TT  S   -  
prior deposition and affidavit testimony on record with this Court The Defendantsmotion to
strike should bedenied
MISTAKE INADVERTENCE SURPRISE OR EXCUSABLE NEGLECT EXIST
JUSTIFYING THIS COURT TO RELIEVE THE PLAINTIFF FROM THE FINAL
JUDGMENT
Plaintiff should be granted relief from operation of the judgment on the grounds of
mistake inadvertence surprise or excusable neglect under IRCP60b1or alternatively
underIRCP60bDuring the hearing on Defendantsfirst motion for summary judgment
this Court stated that the affidavit ofDr Yost did not establish a material issue of fact because it
did not sufficiently state that at the time the product was sold to IDOC it was known that the
product could cause the kinds of injuries suffered by the Plaintiff
Defendant had moved to strike the affidavit of Dr Yost claiming it to be a sham affidavit
Plaintiffscounsel argued that the deposition testimony did not conflict with the affidavit because
Defendantsattorney never asked the proper questions to illicit answers that would conflict with
the affidavit The Court at that time denied the Defendantsmotion to strike the affidavit on the
grounds that it was not a sham affidavit in conflict with his deposition testimony The Courts
comments left the distinct impression that after reviewing the deposition testimony an affidavit
that included the expert opinion ofDr Yost that SEC knew or should have known of the risks
associated with its product would not be considered in conflict with his deposition testimony
Aff ofD Overson 3
Plaintiff filed a second affidavit of Dr Yost wherein it was explained that the literature
within the scientific community was such that a manufacturer such as SEC should have known
that its product posed a risk of harm such as that suffered by the Plaintiff The affidavit pointed
out a litany of articles and publications supporting his views No effort was made to explain any
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ior n  id t    t  s rt.  f ndant's   
ike   . 
I , ,     S  
 S         
 
l i tiff s l   r t  r lief fr  r ti  f t  j t  t e r ds f 
ista e, i a erte ce, s r rise r e c sa le e lect er LR.C.P. 0(b)(1), r alter ati el  
 LR.C.P. 0(b)(6). ing    dant's irs     t, 
t is t    i   r. s    t l         
did not sufficiently state that at the ti e the product as sold to I , it as kno n that the 
product could cause the kinds of injuries suffered by the Plaintiff. 
efe a t a  e  t  stri e t e affi a it f r. st clai i  it t  e a s a  affi avit. 
laintiffs counsel argued that the deposition testi ony did not conflict ith the affidavit because 
efendant's attorney never asked the proper questions to illicit ans ers that ould conflict ith 
 it.  t   e   f ndant's   t      
r s t t it s t  s  ffi it i  fli t it  is siti  t sti ny.  ourt's 
co ents left the distinct i pression that, after revie ing the deposition testi ony, an affidavit 
that included the expert opinion of r. ost that SE  kne  or should have kno n of the risks 
ss i t  it  its r t l  t  si r  i  fli t it  is siti  t sti ony. 
ff. . , '11 . 
laintiff filed a second affidavit f r. ost herein it as explained that the literature 
ithin the scientific co unity as such that a anufacturer such as S  should have kno n 
that its product posed a risk of har  such as that suffered by the Plaintiff. The affidavit pointed 
out a litany of articles and pUblications supporting his views. No effort was made to explain any 
I TIFF'S  : I  I   SIDERATI N; SITI   FENDANT'S 
I   TRIKE;  SITI   FENDANT'S I    6( c )   
    -  
conflicts between his affidavit testimony and his deposition testimony because neither Dr Yost
nor Plaintiffscounsel perceived any conflicts Aff of D Overson 4 Aff ofDr Yost 3ra
610 Nonetheless this Court granted Defendantsmotion to strike the second affidavit of
Dr Yost on the grounds that it conflicted with his deposition testimony That hearing took place
on September 15 2011 Given the Courtscomments regarding sham affidavits during the
prior hearing that ruling surprised Plaintiffscounsel Aff of D Overson 4
In addition to granting Defendantsmotion to strike the Court still considered Dr Yosts
affidavit as lacking support for the proposition that it was known at the time SEC sold its product
to IDOC that it posed a risk of injury such as that suffered by the Plaintiff
Surprised by the Courts ruling granting Defendantsmotion to strike and summary
judgment Plaintiffs counsel immediately took steps to prepare an affidavit that would cure the
problems the Court found with Dr Yosts prior affidavits Aff of D Overson 5 Counsel
contacted Dr Pacheco on September 20 2011 to ask her to review the literature and she agreed
to do so Aff ofD Overson 5 However Dr Pacheco had not responded to several calls by
counsel following up with her and by October 4 2011 it was clear that Dr Pacheco would not
have time to perform the review Aff ofD Overson 5 On October 6 2011 counsel prepared
a rough draft affidavit for Dr Yost to review Aff of D Overson 5 Dr Yost conducted an
additional review of the literature in order to identify additional support showing that it was
known that SECsproduct posed a risk of injury Aff of D Overson 5 However the
following week Dr Yost became extremely ill and was hospitalized Aff of D Overson 5
Counsel was informed that Dr Yostscondition deteriorated and it was not clear whether he
would survive Aff of D Overson 5 Dr Yost was not able to sign the affidavit until
October 20 2011 Aff ofD Overson 5
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licts t ee  is id it testi o   is iti  te ti  a se it  . ost 
nor Plaintiffs counsel perceived any conflicts. ff. of . verson, ~ ; .  . st (3rd), 
~~ -1 . t l , t is rt r te  f dant's ti  t  tri e t e  ffi it f 
Dr. Yost on the grounds that it conflicted with his deposition testi ony. That hearing took place 
on September 15, 2011. i  t e urt's e ts i  "sha  i vits" i  t  
prior hearing, that ruling surprised laintiffs counsel. ff. of . verson, ~ . 
I  ition t  r ti  f ndant's tion t  stri , t  rt still si r  r. st's 
ffi it  l i  rt f r t  r iti  t t it   t t  ti   l  it  r t 
to IDOC that it posed a risk of injury such as that suffered by the Plaintiff. 
Surprised by the Court's ruling granting Defendant's motion to strike and summary 
judg ent, Plaintiffs counsel i ediately took steps to prepare an affidavit that ould cure the 
proble s the Court found ith r. ost's prior affidavits. ff. of . verson, ~ . l 
contacted r. Pacheco on Septe ber 20,2011, to ask her to revie  the literature, and she agreed 
  . ff. . , ~ 5. e er, r. ac ec  a  t res e  t  se eral calls  
counsel following up with her, and by October 4, 2011, it was clear that Dr. Pacheco would not 
have ti e to perfor  the revie . ff. of . verson, ~ .   ,2011,   
a rough draft affidavit for r. ost to review. ff. of . verson, ~ . r. t t   
a iti al re ie  f t e literat re i  r er t  i e tif  a iti al s rt s i  t at it as 
known that SEC's product posed a risk of injury. ff.  . r on, ~ . ver, t  
following week Dr. Yost became extremely ill and was hospitalized. Aff. of D. Overson, ~ . 
sel as i f r e  t at r. ost's c iti  eteri rate  a  it as t clear et er e 
l  r i . f .  . r on, ~ . r. t  t l  t  si  t  ffi vit til 
ctober 20, 2011. ff. of . verson, ~ . 
LAINTIF 'S PL  E: I  I   CONSIDERATION; SITI   EFENDANT'S 
OTION TO STRIKE; AND OPPOSITION TO DEFENDANT'S OTION FOR RULE 56(c) A ARD OF 
    -  
U
I
This Court signed the order granting Defendantsvarious summary judgment motions and
entered the final judgment on October 20 2011
Plaintiffs counsel had prepared the motion and memorandum for reconsideration and
awaited the receipt of Dr Yostsaffidavit to file the documents Aff of D Overson 6 At that
time counsel was unaware that the Court had already signed and entered the judgment on
October 20 2011 Aff ofD Overson 6 During the same period counsel was preparing for
trial in another case Aff of D Overson 6 When Dr Yostsaffidavit came into counsels
office on October 24 2011 counsel signed the motion for reconsideration and the memorandum
and filed all three documents Aff of D Overson 6 A copy of the judgment was received in
counselsoffice from the Court on that same day but it did not come to counselsattention Aff
ofD Overson 6
When the judgment was received in counsels office his staff calendared that date for
filing posttrial motions Aff of D Overson 7 The office relies on a computer program that
automatically calculates the deadlines based on current activity in the case and the Idaho Rules of
Civil Procedure Aff of D Overson 7 The computer program is Vision produced by
CompuLaw Aff of D Overson 7 The calendaring system set the deadline for filing a motion
for reconsideration in this case for November 11 2011 Aff ofD Overson 7 Upon a later
review of the calendar and upon an earlier review ofIRCP Ia2Bcounsel believed that
the motion for reconsideration was timely as it had been filed within 14 days of entry of
judgment Aff of D Overson 7
If the Court is inclined to find that Plaintiffsmotion for reconsideration must be treated
as aIRCP60bmotion the factual predicate for relief under 60b1and 60bhas been
set forth in counselsaffidavit filed concurrently herewith As such this Court should reach the
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This ourt signed the order granting efendant's various su ary judgment otions and 
entered the final judgment on ctober 20,2011. 
Plai tiff s counsel a  prepared t e tion and e orandu  for rec si eration a  
a aited the receipt f r. st's affida it to file the doc e ts. ff. f . ers , ~ 6. t that 
ti e, counsel as una are that the ourt had already signed and entered the judgment on 
ctober 20, 2011. ff. f . verson, ~ . uring t e s e ,  as   
trial in t er c . .  . , ~ .  . st's  a e t  sel's 
ffice n ct er , , c sel si e  t e ti  f r rec si erati  a  t e e ra , 
a d ile   t ree . .  . , ~ .    t  judg e t  i  i  
sel's ffice fr  t e rt  t t   t it i  t  t  nsel's tt ti . ff. 
of . verson, ~ . 
hen the judg ent as received in counsel's office, his staff calendared that date for 
filing post-trial otions. ff. of . verson, ~ .  ffic  r li s   t r r r  t t 
auto atically calculates the deadlines based on current activity in the case and the Idaho Rules of 
 . ff.  . , ~ .     ision©   
CompuLaw. Aff. ofD. Overson, ~ .  l ri  t  t t  li  f r fili   ti  
f r r i r ti  i  t i   f r r , . ff. f . r on, ~ .   l  
review of the calendar, and upon an earlier review ofLR.C.P. 11(a)(2)(B), counsel believed that 
the otion for reconsideration as ti ely as it had been filed ithin 14 days f entry f 
judgment. Aff. ofD. Overson, ~ . 
   i  i l  t  f  t t laintiff s   i  t  t t  
as a LR.C.P. 0(b) ti n, t e fact al re icate f r relief er 0(b)(1) a  0(b)(6) as ee  
set forth in counsel's affidavit filed concurrently herewith. s such, this ourt should reach the 
LAINTIF 'S L  E: I    ECONSIDERATION; POSITI   EFENDANT'S 
OTION TO STRIKE; AND OPPOSITION TO DEFENDANT'S OTION FOR RULE 56( c ) A ARD OF 
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merits of the Plaintiffsmotion to reconsider deny the Defendantsmotion to strike and set aside
the judgment
TO THE EXTENT THAT IDAHO CASES HAVE HELDIRCP11a2BMOTIONS
MUST BE FILED PRIOR TO ENTRY OF JUDGMENT THOSE CASE WERE
DECIDED INCORRECTLY
While there have been Idaho cases stating that a motion to reconsider filed after entry of
judgment should be treated as either an IRCP 59e or 60b motion those cases were
incorrectly decided without sufficient analysis of the history and purpose ofIRCP Ia2B
This Court is bound by Idaho precedent but the argument is set forth for overruling those case in
order to preserve the issue on appeal
In many of the cases that have statedIRCP Ia2Bgrants authority to reconsider
and vacate an interlocutory order so long as final judgment has not yet been ordered there was
no final judgment that had been ordered See eg Telford v Neibaur 130 Idaho 932 934
1998 In this case the district court reconsidered its ruling before the entry of final judgment
and therefore acted with authority under the rule Idaho First NatlBank v David Steed
Assoc 121 Idaho 356 361 Idaho 1992 In this case there was no judgment only an order
dismissing DSAscounterclaim Marcher v Butler 113 Idaho 867 86772 1988 noIRCP
11a2Bmotion brought Puckett v Verska 144 Idaho 161 164 43 2007 no final judgment
entered at time ofmotion for reconsideration As such those statements are dicta
To the extent that Straub holds that anIRCP11a2Bmotion for reconsideration of
an order granting summary judgment cannot be filed after entry of judgment the case was
decided wrong Plaintiff argues in good faith for a change in the law since the Straub decision is
contrary to the Courts holding in CoeurdAleneMining Co v First National Bank ofN Idaho
118 Idaho 812 1990 and the plain language ofIRCP11a2BandIC 1 16038
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it  f t  laintif s ti  t  r consider,  t  fendant's ti  t  stri   t i  
 nt. 
    I  S S   I.R.C.P. 1l(a)(2)(B) I S 
   I     T,    
I  I  
hile there have been Idaho cases stating that a otion to reconsider filed after entry of 
judg ent should be treated as either an LR.C.P. 59(e) or 60(b) otion, those cases ere 
i c rrectl  eci e  it t s fficie t a al sis f t e ist r  a  r se fLR.C.P. 11(a)(2)(B). 
This Court is bound by Idaho precedent, but the argument is set forth for overruling those case in 
      al. 
In any of the cases that have stated LR.C.P. 11(a)(2)(B) grants authority to reconsider 
 t   i t rl t r  r r "so l  s fi l j t s t t  r ered," t r  s 
no final judg ent that had been ordered. See, e.g., elford v. eibaur, 130 Idaho 932, 934 
(1998) ("In this case, the district court reconsidered its ruling before the entry of final judg ent 
and, therefore, acted ith authority under the rule.");  s  at'l  .   & 
ssoc., 121 Idaho 356, 361 (Idaho 1992) ("In this case, there as no judg ent, only an order 
is is i  A's t rcl i ."); archer v. Butler, 113 Idaho 867,867-72 (1988) (no LR.C.P. 
11(a)(2)(B) otion brought); Puckett v. Verska, 144 Idaho 161, 164-43 (2007) (no final judg ent 
entered at ti e of otion for reconsideration). s such, those state ents are dicta. 
o the extent that Straub holds that an LR.C.P. 11(a)(2)(B) otion for reconsideration of 
an order granting su ary judg ent cannot be filed after entry of judg ent, the case as 
eci e  r . lai tiff ar es in  fait  f r a c a e in the la  si ce t e tr  ecisi  is 
contrary to the Court's holding in Coeur d'Alene Mining Co. v. First National Bank ofN Idaho, 
118 Idaho 812, (1990), and the plain language ofl.R.C.P. 11(a)(2)(B) and I.C. § 1-1603(8). 
P I IFF'S P  : IR  IO  F  SI I ; PP SI I   F NDANT'S 
TIO  T  ST I E;  PP SITI  T  EFE DANT'S TIO  F  LE 56( c)  ARD F 
TTO  FEES  S S - 8 
The rule is contrary to the Courtsholding in CoeurdAlene Mining Co where the Court
explained that anIRCP11a2Bmotion for reconsideration could be filed up to 14 days
after entry ofjudgment
CDA could have brought this exhibit to the attention of the trial
court even after the judgment was entered IRCP11a2B
entitled CDA to request reconsideration of the trial courtspre
trial order specifying the facts that would be deemed established
for the purposes of trial The rule states that a motion for
reconsideration ofany interlocutory orders of the trial court may
be made at any time before the entry offinaljudgment but not later
than fourteen 14 days after the entry of the final judgment
CDAs second motion for reconsideration was filed on the
fourteenth day after the entry ofjudgment
On a motion for reconsideration of the specification of facts
deemed established pursuant toIRCP56d the trial court
should reconsider those facts in light of any new or additional facts
that are submitted in support of the motion This view of the effect
ofIRCP 11a2Bis consistent with the discussion of
reconsideration in JICase Company v McDonald 76 Idaho 223
280P2d 1070 1955 There this Court said
A rehearing or reconsideration in the trial court
usually involves new or additional facts and a more
comprehensive presentation of both law and fact
Indeed the chief virtue of a reconsideration is to
obtain a full and complete presentation of all
available facts so that the truth may be ascertained
and justice done as nearly as may be Id at 229
280P2dat 1073
We acknowledge that before this Court had adoptedIRCP
11a2Bwe had ruled that a trial court correctly treated a
motion for reconsideration of a memorandum decision following
trial as a motion to alter or amend judgment pursuant toIRCP
59e Obray v Mitchell 98 Idaho 533 539 567P2d 1284 1290
1977 As our Court of Appeals correctly pointed out in Lowe v
Lym 103 Idaho 259 263 646 P2d 1030 1034 1982 citations
omitted A Rule 59emotion to amend a judgment is addressed
to the discretion of the court An order denying a motion made
PLAINTIFFSREPLY RE THIRD MOTION FORRECONSIDERATION OPPOSITION TO DEFENDANTS
MOTION TO STRIKE AND OPPOSITION TO DEFENDANTSMOTION FOR RULE 56cAWARD OF
ATTORNEY FEES AND COSTS 9
002216
 l  i  t  t  t  ourt's l i  i  r 'Alene i i  o.,  t  t 
explained that an I.R.C.P. 11(a)(2)(B) otion for reconsideration could be filed up to 14 days 
after entry f judg ent: 
 could have brought this exhibit to the attention f the trial 
court, even after the judg ent as entered. JR. CP. 11 (a)(2)(B) 
entitled  to request reconsideration of the trial court's pre-
tri l r r s ifYi  t  f ts t t l    st lis  
f r t e rposes f tri l. e r le st tes t t  ti  f r 
reconsideration "of any interlocutory orders of the trial court ay 
e e t y ti e ef re t e e try f fi l j e t t t l ter 
than fourteen (14) days after the entry f the final judg ent. " 
A's second otion for reconsideration as filed on the 
fourteenth day after the entry f judg ent. 
  ti  f r r si r ti  f t  s cifi ti  f f ts 
ee e  esta lis e  rs a t t  I.R.C.P. 6(d), t e trial c rt 
should reconsider those facts in light f any ne  or additional facts 
t t  itt  i  t  t  ti . i  i   t  f t 
 1.R.c.P. II(a)(2)(B) is consistent ith the discussion of 
r i r tion i  J   . l ,  I  3, 
280 P.2d 1070 (1955). here, this ourt said: 
 rehearing or reconsideration in the trial court 
ll  i lves  r iti l f t ,   r  
co prehensive presentation of both la  and fact. 
I eed, t e c ief irt e f a rec si erati  is t  
tai  a f ll a  c lete rese tati  f all 
il le t ,  t t t  t t    ertai ed, 
and justice done, as nearly as ay be. !d. at 229, 
 .2d  3. 
e le  t t f r  t is rt  t  1.R.c.P. 
11 (a)(2)(B), e a  r le  t at a trial c rt c rrectl  treate  a 
otion for reconsideration of a e orandu  decision follo ing 
trial as a otion to alter or a end judg ent pursuant to I.R.C.P. 
59(e). bray v. itchell, 98 Idaho 533, 539, 567 .2d 1284, 1290 
(1 7).   t  l  tl  i t  t i   . 
Ly , 103 Idaho 259, 263, 646 P.2d 1030, 1034 (1982) (citations 
itted):  l  9( e) ti  t    j t is r ss  
     rt. An order denying a motion made 
I TIFF'S  : I    SIDERATION; SI I   FENDANT'S 
TI  T  ST I E;  PP SITI  T  EFENDANT'S TI  F  LE 56( c )  F 
    -  
under Rule 59e to alter or amend a judgment is appealable but
only on the question ofwhether there has been a manifest abuse of
discretion Rule 59e proceedings afford the trial court the
opportunity to correct errors both of fact or law that had occurred
in its proceedings it thereby provides a mechanism for corrective
action short of an appeal Such proceedings must of necessity
therefore be directed to the status of the case as it existed when the
court rendered the decision upon which the judgment is based
However we view the function of the trial court to be different
when presented with a motion for reconsideration of an
interlocutory order pursuant to IRCP 11a2B When
considering a motion of this type the trial court should take into
account any new facts presented by the moving party that bear on
the correctness of the interlocutory order The burden is on the
moving party to bring the trial courtsattention to the new facts
We will not require the trial court to search the record to determine
if there is any new information that might change the specification
of facts deemed to be established
CoeurdAlene Mining Co 118 Idaho at 822 823 emphasis added
By comparison to the thorough analysis in CoeurdAlene the Straub Court stated
However a party may only make a motion to reconsider interlocutory orders or orders entered
after the entry of final judgment Straub 145 Idaho at 71 In making the statement the Courts
only cited authority was toIRCP11a2BStraub 145 Idaho at 71 The Straub Court went
on to state that since the dismissal was a final judgment the motion to reconsider should be
treated as a motion to modify or amend the order of dismissal underIRCP59e Id at 71
Nevertheless the Straub Court then proceeded to consider the affidavit that was submitted with
the motion and reversed the district courtsdenial of the motion for reconsideration Id
Specifically the Court held that the district courts denial of the motion to reconsider on the
grounds that a specific rule had not been cited nor a basis for the motion was an abuse of
discretion sinceIRCPIIa2Bwas cited and an affidavit was submitted with the motion
Id
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r l  9(e) t  lt r r   j t i  appealable, t 
l   t  sti  f t r t r     anif t  f 
i r ti . l  9(e) r i s ff r  t  tri l rt t  
rt i   t r    t r l  t t d  
i  its r dings; it t r  r i s  is  f r rr ti  
t     peal. uch proceedings ust f necessity, 
t r f r ,  i t  t  t  t t  f t    it i t   t  
rt r r  t  i i   i  t  j t i  sed. 
er,     f t      e  
 r t  it   ti   i r ti  f  
i t rl t r  r r r t t  LRC.P. 11 (a)(2)(B).  
i ri   ti   t i  t , t  tri l rt l  t  i t  
t   f t  r t   t  i  rt  t t r  
t  rr t ss f t  i t rl t r  r r.      
i  rt  t  ri  t  tri l urt's tt ti  t  t   f ts. 
 ill t i  t  t i l t t   t   t  t i  
if there is any ne  infor ation that ight change the specification 
     stabli hed. 
e r 'Alene i i  o.,  I  at -8  (e phasis ded). 
 c aris  t  t e t r  a al sis i  e r  'Alene, t e tr  rt state  
"Howe er, a art  a  l  a e a ti  t  rec si er i terl c t r  r ers r r ers e tere  
after the entry of final judg ent." Straub, 145 Idaho at 71. In aking the state ent, the ourt's 
l  ite  t rit  s t  LRC.P. II(a)(2)(B). tr b,  I  t .  tr  rt t 
 t  state t at si ce t e is issal as a fi al ju e t, t e "motion t  rec si er s l  e 
treate  as a ti  t  if  r a e  t e r er f is issal" er LRC.P. 9(e). Id. at 71. 
e ert eless, t e tr  rt t e  r cee e  t  c si er t e affi a it t at as s itte  it  
 tion  erse   s ict urt's      i r ti . . 
cifi l ,  t  t    urt's    ion     
r nds that a s ecific r le a  t ee  cite  r a asis f r t e ti  as a  a se f 
discretion since LRC.P. 11(a)(2)(B) as cited and an affidavit as sub itted ith the otion. 
I . 
I TIFF'S  : I  OTION  I A I ; I ION  ENDANT'S 
IO  O I ;  I ION  NDANT'S OTION   56( c ) R   
TTOR  F ES  S S -  
The rule advanced in Straub is contrary to the plain language ofIRCP11a2B
Such a rule renders the second clause of the first sentence ofIRCP Ia2Bwithout any
effect or meaning and is therefore contrary to Idaho rules of statutory construction The Straub
interpretation ofIRCP11a2Balso presents an impracticality in applicationwhich is the
situation that arose in this case Since a party has no idea when a judge is going to sign and enter
a judgment there is no way to determine the deadline for filing themotion
Rule I la2Bmust be read in light of the context in which it was adopted As
recognized by the Idaho Supreme Court in JL Case Co v McDonald 76 Idaho 223 22934
1955 where a grievous wrong may be committed by some misapprehension or inadvertence
of the judge the common law recognized the inherent power ofthe courts to modify alter or
vacate its judgments at any time during the term Id at 230 quoting Occidental Life Ins Co v
Niendorf 55 Idaho 521 1935 Idaho adopted statutes early on that recognized the courts
inherent powers and provided for the method by which the inherent powers would be used to
reconsider orders and judgments See Id discussing inherent powers and IC 116038
Every court has power to amend and control its process and orders so as to make them
conformable to law and justice IC 116038
Even though the federal system does not have a rule similar toIRCP11a2Bthe
federal courts recognize the inherent powers of a trial court to reconsider its orders and
judgments A motion to reconsider a remand order is proper where the court has patently
misunderstood a party or has made a decision outside the adversarial issues presented to the
court by the parties which made an error not of reasoning but of apprehension Bank of
Waunakee v Rochester Cheese Sales Inc 906F2d 1185 1191 7th Cir 1990
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e r le a a ce  i  tr  is c trar  t  t e lai  la a e f I.R.c.P. 11 (a)(2)(B). 
uch a rule renders the second clause f the first sentence of I.R.C.P. II(a)(2)(B) ithout any 
ff t r i ,  i  t r f re tr r  t  I  r l  f t t t r  tr cti .  t  
inter retati  f I.R.C.P. II(a)(2)(B) als  rese ts a  i racticalit  i  a lication-which is t e 
sit ati  t at ar se i  t is case. i ce a art  as  i ea e  a j e is i  t  si  a  e ter 
 t,        l   i   ti . 
ule II(a)(2)(B) ust be read in light of the context in hich it as adopted.  
recognized by the Idaho Supre e ourt in I ase o. v. c onald, 76 Idaho 223, 229-34 
(19 5), ere a "'grievous r  a  e c itte   s e isa re e si  r i a erte ce 
of the judge,'" the co on la  recognized the inherent po er of the courts to "'modify, alter, or 
vacate its judg ents at any ti e during the term. '" ! . at 230 (quoting ccidental ife Ins. o. v. 
iendorf, 55 Idaho 521 (1935)). Idaho adopted statutes early on that recognized the court's 
inherent po ers and provided for the ethod by hich the inherent po ers ould be used to 
reconsider orders and judg ents. See Id. (discussing inherent po ers and I.c. § 1-1603(8)). 
"Ever  rt s r . . . t    tr l its r ss  r rs, s  s t   t  
conformable to law and justice." I.C. § 1-1603(8). 
ven though the federal syste  does not have a rule si ilar to I.R.C.P. 11(a)(2)(B), the 
federal courts recognize the inherent po ers of a trial court to reconsider its orders and 
judg ents.  otion to reconsider a re and order is proper here the court has patently 
is erst  a art , r as a e a ecisi  tsi e t e a ersarial iss es rese te  t  t e 
court by the parties, which made an error not of reasoning but of apprehension. Bank of 
aunakee v. ochester heese Sales, Inc., 906 F.2d 1185, 1191 (7th ir. 1990). 
I TIFF'S  :  I   I RATI N; I I   FENDANT'S 
TI  T  ST I E;  PP SITI  T  EFENDANT'S TI  F  LE 56(c)  F 
    -  
G
It was within this context that Idaho adopted IRCP11a2Bin 1987 The final
adopted rule was clear on its face that a motion to reconsider could be filed up to 14 days after
entry ofjudgment
A motion for reconsideration of any interlocutory orders of the trial
court may be made at any time before the entry of final judgment
but not later than fourteen 14 days after the entry of the final
Lmoment A motion for reconsideration of any order of the trial
court made after entry of final judgment may be filed within
fourteen 14 days from the entry of such order provided there
shall be no motion for reconsideration of an order of the trial court
entered on any motion filed under Rules 50a 52b55c59a
59e59160aor60b
Id emphasis added Applying a plain reading ofIRCPIIa2BPlaintiffsmotion for
reconsideration was filed timely on October 24 2011 The Judgment was entered on the same
day as the order granting Defendantsvarious motions for summary judgmentOctober 20
2011 Therefore Plaintiffsmotion for reconsideration was filed on the fourth day after entry of
the judgment and the order granting Defendantsmultiple motions for summary judgment As
such themotion was timely
DEFENDANTSMOTION FOR ATTORNEY FEES AND COSTS SHOULD BE DENIED
Defendantsrequest for fees and costs as sanctions should be denied for the reason that
this Court statements during prior summary judgment hearings that it was not inclined to
invite or permit additional affidavits were in relation to whether this Court was willing to delay
ruling on the Defendantsmotions for summary judgment and not whether the Court was
forbidding affidavits filed in support of a motion for reconsideration To the extent that counsel
misunderstood the Courtsstatements and the statements could be considered an order the order
was not clear Furthermore such an order would be contrary toIRCPI1a2B59e
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It s it i  t is t t t t I  t  I.R.C.P. 1(a)(2)(B) i  7.  l 
adopted rule as clear on its face that a otion to reconsider could be filed up to 14 days after 
  nt. 
 ti  f r rec si erati  f a  i terl c t r  r ers f t e trial 
court ay be ade at any ti e before the entry f final judg ent 
but not later than fourteen (J 4) days after the entry f the final 
judgment.  ti   i ti      t  t i l 
t  t  t   i l j t   il  it i  
fourteen (14) days fro  the entry of such order; provided, there 
l      i t         
t    ti  ile   le  0(a), 2(b), 5(c), 9(a), 
9(e), 9.1, 0(a),  0(b). 
! . (e phasis ded). l i   l i  r i  f 1.R.C.P. 11(a)(2)(B), laintiffs ti  f r 
r si r ti  s file  ti l   t r , 1.  J t s t r   t  s  
day as the order granting efendant's various otions for su ary judg ent-October 20, 
2011. herefore, Plaintiff s otion for reconsideration as filed on the fourth day after entry of 
the judg ent and the order granting efendant's ultiple otions for su ary judg ent. s 
,    l . 
ENDANT'S IO          
efendant's request for fees and costs as sanctions should be denied for the reason that 
this ourt's state ents during prior su ary judg ent hearings that it as not "inclined to 
invite or per it" additional affidavits ere in relation to hether this ourt as illing to delay 
ruling on the efendant's otions for su ary judg ent, and not hether the Court as 
r i i  id its ile  i  t   ti   i eration.  t  t t t t l 
isunderstood the ourt's state ents and the state ents could be considered an order, the order 
as t l r. rt er re, s c  a  r er l  e c trar  t  1.R.c.P. 11 (a)(2)(B), 9(e), 
I TIFF'S  : I  I   I RATI ; I I   FENDANT'S 
I   I ;  I I   ENDANT'S I    6(c)   
    -1  
60band the holding in Puckett v Verska 144 Idaho 161 166 2007 when reviewing a
motion for reconsideration the court should consider additional affidavits
Sanctions are not appropriate in this case since the Plaintiff has acted in good faith and
IRCP56cdoes not provide for sanctions under the circumstances of this case The sanctions
provided for under IRCP56c are for delays caused by untimely filings of memoranda
affidavits and depositions resulting in a hearing having to be continued
The court may alter or shorten the time periods and requirements of
this rule for good cause shown may continue the hearing and may
impose costs attorney fees and sanctions against a party or the
partys attorney or both
IRCP56c Sanctions under this provision are only appropriate for violations ofIRCP
56cand the Plaintiff has not violated any of the provisions ofthat rule
If the Plaintiff has violated any rules it would be solelyIRCP11a2Bby filing a
motion for reconsideration four days after entry of the final order That action was taken in good
faith since Plaintiffscounsel was not aware that the Court had entered judgment on October 20
2011 and for other reasons already stated Furthermore there has been no harm or prejudice to
the Defendant since the case law is clear that a motion to reconsider filed after judgment should
be treated as a motion brought under eitherIRCP59e or60basdiscussed above
Even ifan award of fees was allowed under the circumstances the Defendantsrequest is
for fees associated with each of its motions for summary judgment Defendant filed three
different motions for summary judgment The only fees incurred by the Defendant relating to the
motion to reconsider filed after the judgment was entered were those identified in paragraph 5 of
the Affidavit of Counsel in Support of SECsMotion for Rule 56cAward ofAttorneysFees
and Costs
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0(b),  t  l i  i  tt v. rska,  I  ,  (2 7) ( h  r i i   
otion for reconsideration the court should consider additional affidavits). 
ti s  t i t  i  t i   i  t  l i ti   t  i   it   
.RC.P. 6(c)  t ide  ti   t  i t   t i  e.  ti  
r i  f r r I.RC.P. 6(c) r  f r l    ti l  filings  r nda, 
ffi its  iti  r lti  i   ri  i  t   ti ed. 
 rt  lt r r s rt  t  ti  ri s  r ir ts f 
t is r l  f r  s  s own,  ti  t  aring,   
i pose costs, attorney fees and sanctions against a party or the 
arty's tt ,  th. 
I.RC.P. 6(c). ti s r t is r isi  r  l  r ri t  f r i l ti s f I.RC.P. 
6(c),  t  l i tiff s t i l t   f t  r isi s ft t r l . 
If the Plaintiff has violated any rules it ould be solely I.RC.P. 11(a)(2)(B) by filing a 
otion for reconsideration four days after entry of the final order. That action as taken in good 
fait  si ce laintiff s c sel as t a are t at t e rt a  e tere  j e t  ct er , 
2011, and for other reasons already stated. urther ore, there has been no har  or prejUdice to 
the efendant since the case la  is clear that a otion to reconsider filed after judg ent should 
 tre t  s  ti  r t r it r I.RC.P. 9(e) r 0(b)-as is ss  ve. 
ven if an a ard f fees as allo ed under the circu stances, the efendant's request is 
for fees associated ith each of its otions for su ary judg ent.  l   
iffere t tions f r s ar  j e t. e l  fees i c rre   t e efe a t relati  t  t e 
otion to reconsider filed after the judg ent was entered were those identified in paragraph 5 of 
t e ffida it f sel i  rt f C's ti  f r le 6(c) ar  f tt rney's ees 
 . 
P I TIFF'S P  : I  I  F  SI ERATI ; PP SI I   FENDANT'S 
I   S I ;  PP SI I   FENDANT'S I  F   56(c)  F 
    -  
Furthermore Defendantsrequest for attorneys fees and costs is untimely as to fees and
costs incurred prior to October 20 2011 SeeIRCP54d14 days to file cost memo
CONCLUSION
Plaintiffsmotion for reconsideration should be granted on the merits and Defendants
motion to strike and motion for attorney fees should be denied
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Furthennore, efendant's request for attorney's fees and costs is unti ely as to fees and 
costs incurred prior to ctober 20,2011. See LR.C.P. 54(d)(5) (14 days to file cost emo). 
I  
laintif s   i r ti       rits;  efendant's 
ti  t  tri e  ti  f r tt r  f  l   i d. 
E TF  I  t is t  a  f ece ber,  . ____ ~_ 
By ______ ~-=~~ ____________ __ 
 .  
 .  
I IFF'S  : IR  IO   I I ; I I   ENDANT'S 
OTION TO STRIKE; AND OPPOSITION TO DEFENDANT'S OTION FOR RULE 56( c ) A ARD OF 
TT  FEES   -  
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 8th day ofDecember 2011 a true and correct copy of
the foregoing document was served on the following individualsby the method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT
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PLEASE TAKE NOTICE That the Honorable Cheri C Copsey District Judge has reset
this matter for Oral Argument on the Motion to Reconsider Motion to Strike and Motion for
Rule 56cCosts and Fees from December 15 2011 to January 26 2012 at300pmat the
Ada County Courthouse 200W Front Boise Idaho
NO FURTHER DOCUMENTS ARE TO BE FILED except for Security Equipment















.M. 10::1-5 F'lE  .P.M. ___ _ 
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E   ,    E    
I LIE J  J , 
l i tiff,  .   -03515 
vs. I   I  
SECURITY EQUIP ENT CORP.,  
nt. 
PLE SE T E TICE That the onorable Cheri C. Copsey~ istrict Judge, has reset 
this atter for ral rgu ent on the otion to econsider, otion to Strike, and otion for 
le 6(c) sts  s fr  r ,  t  J r  ,  t : 0 .m., t t  
da ounty ourthouse, 200 . Front, oise, Idaho. 
      I , e ce t f r ec rit  i e t 
Corporation's reply to ajor's Opposition filed on December 8, 2011. 
  I  
 . I  
........ " 
"  J{J "" ....... ~/~ '" 
'. •••• / " 
--~~~--~~~r-~=-- • ~ ~ 
 HE S7'~ \,("" -:. ... .,.~ '=' ': 
CLERKSCERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this I day ofDecember 2011 a true and correct















Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
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copy of the foregoing docu ent as served on the follo ing individua1(s) by the ethod 
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i  . s  
 .  
 &  
 . r li  ri , it   
.O.   
,  -7808 
ounsel for laintiff 
hristopher . urke 
as J. l  ill 
    
 .  tr t, it   
i , I   
l f  f t 
[ ] .S. i  
b(I x: -89  
( j ss r li r  
[ ] E ail: darwin@jonesandswartzlaw.com 
eric jonesandswartz1aw.com 
[ ] .S. i  
j.q x: -26  
[ ] ess r li r  
[ ] ail: e gre nerlaw.com 
tlloyd@greenerlaw.com 
I  . I ,  
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Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKER PA
950W Bannock Street Suite 900
Boise Idaho 83702
Tel 208 3192600
Fax 208 319 2601
Attorneys for Defendant
DEC 13 2011
CHRISTOPHER D RICH Clerk
By STEPHANIE VIDAK
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA




CORPORATION a Missouri corporation
Defendant
Case No CVPI1003515
REPLY MEMORANDUM IN SUPPORT OF
SECURITY EQUIPMENT
CORPORATION MOTION TO STRIKE
THIRD AFFIDAVIT OF GAROLD YOST
Defendant Security Equipment Corporation Defendant or SEC by and through its
attorneys of record Greener Burke Shoemaker PA hereby submits this Reply Memorandum in
further Support of its Motion to Strike the Third Affidavit ofDr Garold Yost and in response to
PlaintiffsOpposition to that Motion filed on December 8 2011
ARGUMENT
I The Plain Language And Intent Of The Relevant Rules Of Civil Procedure
Cannot Be Ignored
Citing to the plain language of the rule Plaintiff quarrels with SECs contention that a
Rule IIa2Bmotion for reconsideration of a summary judgment order is improper when
filed after the entry of final judgment Plaintiffs Dec 8 2011 Memorandum pp 12
Ironically in order to make such an argument Plaintiff is forced to disregard and in fact to
REPLY MEMORANDUM IN SUPPORT OF SECURITY EQUIPMENT CORPORATIONSMOTION TO
STRIKE THIRD AFFIDAVIT OF GAROLD YOST Page 1
14542 011 432911
002225J 
Christopher C. Burke, ISB #2098 
Thomas J. Lloyd III, ISB #7772 
GREENER BURKE S E AKER PA 
9  . Bannock Stre t, S ite 900 
Boise, Idaho 83702 
Tel: (208) 319-2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
DEC  3 20 1 
CHRISTOPHER D. I , lerk 
By STEPHANIE VI  
DEPUTY 
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I  I  
PORATION'S    
     
Defendant Security Equipment Corporation ("Defendant" or "SEC"),     
attorneys of record, Greener Burke Shoemaker P.A., hereby submits this Reply Memorandum in 
further Support of its otion to Strike the Third Affidavit of Dr. Garold Yost, and in response to 
Plaintiffs Opposition to that otion, filed on December 8, 2011. 
 
I. The Plain Language nd Intent f The elevant ules f ivil Procedure 
Cannot Be Ignored. 
Citing to the "plain language of the rule," Plaintiff quarrels with SEC's contention that a 
Rule 11(a)(2)(B) motion for reconsideration of a summary judgment order is improper when 
filed after the entry of final judgment. (Plaintiffs ec. 8, 2011 e orandum, pp. 1-2.) 
Ironically, in order to make such an argument, Plaintiff is forced to disregard, and in fact to 
REPLY A  I  SU P  OF SECURITY EQUIP E T CORPORATION'S I  TO 
STRIKE T I  AFFIDAVIT OF GAROLD ST - Page 1 
14542-011 ( 3291 ) 
ignore without any analysis the qualifying adjectival use of the word interlocutory in the
relevant sentence ofIRCPIIa2BAmotion for reconsideration of any interlocutory
orders of the trial court may be made not later than fourteen 14 days after the entry of the
final judgment IRCP11a2Bemphasis added Plaintiff does not at any point offer any
analysis as to the distinction between an interlocutory order and a final order but instead
essentially reads the term out of the rule By Plaintiffsown suggestion that the Court adhere to
Idaho rules of statutory construction PlaintiffsDec 8 2011 Memorandum Plaintiffs
analysis is immediately suspect
Indeed it is necessary for the limiting terminology inIRCPI Ia2Bto be given
effect in order for that Rule to be read harmoniously with the other Rules of Civil Procedure
Coexistent with and long predating Rule I Ia2Bare Rules of Civil Procedure 59 and 60
which address the various ways that a party my alter amend or otherwise gain relief from a final
judgment Based largely on the policy interest in finality of judgments McBride v McBride
112 Idaho 959 963 739 P2d 258 262 1987 Rules 59 and 60 offer a more restricted avenue
for relief with respect to final judgments than does Rule 11 with respect to interlocutory orders
Given that a Rule 59e motion to alter or amend a judgment must be made within fourteen 14
days after entry of final judgment the same amount of time prescribed by Rule I Ia2B
Plaintiffs expansive reading of Rule 11a2Brenders Rule 59e and its attendant
restrictionslimitations meaningless As discussed below because an order granting summary
judgment ceases to be interlocutory in nature once judgment has been entered Rule I Ia2B
and Rules 59 60 continue to have distinct functions if and only if Rule I Ia2Bremains
limited to interlocutory orders not final ordersjudgments as is the case in this litigation See
State v Hartwig 150 Idaho 326 246 P3d 979 2011 We have stated that motions to
REPLY MEMORANDUM IN SUPPORT OF SECURITY EQUIPMENT CORPORATIONSMOTION TO
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ignore without any analysis, the qualifying, adjectival use of the word "interlocutory" in the 
relevant sentence of I.R.C.P. II(a)(2)(B): "A motion for reconsideration of any interlocutory 
orders of the trial court ay be ade . . . not later than fourt en (14) days after the e try f the 
final judgment." I.R.C.P. II(a)(2)(B) (emphasis added). Plaintiff does not at any point offer any 
analysis as to the distinction between an interlocutory order and a final order, but instead 
essentially reads the term out of the rule. By Plaintiffs own suggestion that the Court adhere to 
"Idaho rules of statutory construction" (Plaintiffs ec. 8, 2011 e orandum), Plaintiffs 
analysis is immediately suspect. 
Indeed, it is necessary for the li iting ter inology in I.R.C.P. II(a)(2)(B) to be given 
fect in er r t at le     t       . 
Coexistent with, and long pre-dating, Rule II(a)(2)(B), are Rules of Civil Procedure 59 and 60, 
hich address the various ays that a party y alter, a end, or other ise gain relief fro  a final 
judgment. Based largely on the policy interest in "finality of judgments," McBride v. McBride, 
112 Idaho 959, 963, 739 P.2d 258, 262 (1987), Rules 59 and 60 offer a ore restricted avenue 
for relief ith respect to final judg ents than does Rule 11 ith respect to interlocutory orders. 
iven that a ule 59(e) otion to alter or a end ajudg ent ust be ade ithin fourteen (14) 
days after entry of final judgment - t  s  t f ti  r s ri   l  11 (a)(2)(B) -
Plaintiffs expansive reading of Rule 11(a)(2)(B) renders Rule 59(e) (and its attendant 
restrictions/limitations) meaningless. As discussed below, because an order granting summary 
judgment ceases to be interlocutory in nature once judgment has been entered, Rule II(a)(2)(B) 
and l  59 &  c ti  t  have disti t f cti  if an  nl  if Rul  11(a)(2)(B) re ai  
li ited to interlocutory orders, not final orders/judg ents as is the case in this litigation. See 
State v. Hartwig, 150 Idaho 326, 246 P.3d 979 (2011) ("  have stated that oti s to 
REPLY MEMORANDUM I  SUPPORT OF SECURITY EQUIPMENT CORPORATION'S MOTI N TO 
STRIKE THIRD AFFIDAVIT OF GAROLD YOST - Page 2 
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reconsider when applied to final judgments are properly considered underIRCP59e
Important for the Court to note as it evaluates which Rulesshould apply to Plaintiffs
motion and the concurrent Third Yost Affidavit is that while Plaintiff claims to offer the Third
Yost Affidavit in support of her motion to reconsider the order striking the second Yost affidavit
the true and obvious object of Plaintiffsmotion is to reconsider the order granting summary
judgment In point of fact nothing in the Third Yost Affidavit suggests that this Court decision
striking the Second Yost Affidavit was wrong Rather the mere fact that Plaintiff has offered the
Third Affidavit of Dr Yost buttresses the fact that the Second Affidavit was deficient
objectionable and properly stricken Accordingly the true purpose of Plaintiffsmotion is to
simply replace andor supplement the Yost testimony in an effort to have the Court reconsider
the order on summary judgment As Plaintiff is therefore offering new evidence in an effort to
gain relief from the judgment the applicable Rule of Civil Procedure from which to assess the
propriety of Plaintiffslate submission of evidence is Rule 60b Savage Lateral Ditch Water
Users Assnv Pulley 125 Idaho 237 869P2d 554 1993 citing Lowe v Lym 103 Idaho 259
646P2d 1030CtApp 1982
To the extent that Plaintiff is asking this Court to rule contrary to relevant precedent and
expand the application of Rule11a2Bsuch a request must be rejected and SECsmotion to
strike ought to be granted See Noreen v Price Dev Co LtdPship 135 Idaho 816 820 25
P3d 129 132 2001 Hence if Noreensmotion for reconsideration is treated as a motion for
relief from an interlocutory order under Rule I Ia2BBarbers affidavit was appropriately
considered by the trial court but if the motion sought to alter or amend a final judgment under
Rule 59Pricesmotion to strike the affidavit should have been granted
REPLY MEMORANDUM IN SUPPORT OF SECURITY EQUIPMENT CORPORATIONSMOTION TO
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reconsider, when applied to final judgments, are properly considered under I.R.C.P. 59( e) .... "). 
Important for the Court to note as it evaluates which Rule(s) should apply to Plaintiffs 
otion and the concurrent Third Yost Affidavit is that, while Plai tiff claims to offer the hird 
Yost Affidavit in support of her motion to reconsider the order striking the second Yost affidavit, 
the true and obvious object of Plaintiffs otion is to reconsider the order granting su ary 
judgment. In point of fact, nothing in the Third Yost Affidavit suggests that this Court's decision 
striking the Second Yost Affidavit was wrong. Rather, the mere fact that Plaintiff has offered the 
hird ffida it f r. ost ttresses t e f t that t e  ffidavit  fi i t, 
objectionable, and properly stricken. Accordingly, the true purpose of Plaintiffs motion is to 
simply replace and/or supplement the Yost testimony in an effort to have the Court reconsider 
the order on summary jUdgment. As Plaintiff is therefore offering new evidence in an effort to 
gain relief from the judgment, the applicable Rule of Civil Procedure from which to assess the 
propriety of Plaintiff s late submission of evidence is Rule 60(b). Savage Lateral Ditch Water 
Users Ass'n v. Pulley, 125 Idaho 237,869 P.2d 554 (1993) (citing Lowe v. Lym, 103 Idaho 259, 
646 P.2d 1030 (Ct.App. 1982)). 
 t e e te t t at lai tiff is as i  t is rt t  r le c trar  t  rele a t rece e t a  
expand the application of Rule 11(a)(2)(B), such a request must be rejected, and SEC's motion to 
strike ought to be granted. See Noreen v. Price Dev. Co. Ltd. P'ship, 135 Idaho 816, 820, 25 
P.3d 129, 132 (2001) ("Hence, if Noreen's motion for reconsideration is treated as a motion for 
relief from an interlocutory order under Rule 11(a)(2)(B), Barber's affidavit was appropriately 
considered by the trial court, but if the motion sought to alter or amend a final judgment under 
Rule 59(e), Price's motion to strike the affidavit should have been granted."). 
III 
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II Plaintiff Presents No Compelling Argument To Overturn WellEstablished Case
Law Governing Post Judgment Motions
In an overt acknowledgement that Idaho case law does not support Plaintiffsargument
thatIRCPI Ia2Bshould allow a party to move to reconsider a final judgment and any
orders subsumed therein Plaintiff suggests that the case law cited by SEC was wrongly decided
However Plaintiffsargument as above is premised on a faulty analysis ofIRCPIIa2B
which fails to give proper meaning to each and every word contained within the rule Again
Plaintiff continues to disregard the adjectival use of the word interlocutory in IRCP
Ia2Bso her argument must be rejected as an inadequate and incomplete analysis of the
relevant Rules ofCivil Procedure now under consideration by this Court
As no definition for the word interlocutory exists in the Idaho Rules this Court must
look to the case law interpretingIRCPIIa2BRelevant to this case is the question of
whether a summary judgment order is interlocutory and if so whether it ever becomes final in
the course of litigation Applicable precedent plainly answers that question indicating that upon
entry of a final judgment a summary judgment order ceases to be interlocutoryUntilafinal
judgment has been entered an order granting summary judgment is an interlocutory order
Puckett v Verska 144 Idaho 161 166 158 P3d 937 942 2007 Plaintiff attempts to downplay
this and similar language from other supporting cases as mere dicta simply because the
procedural history of those several cases is not indistinguishably analogous to the facts presently
before this Court See Plaintiff s Dec 8 2011 Memorandum p 8 Plaintiffsunderstanding of
dicta is incorrect simply because a decision does not follow the same underlying factual andor
procedural background does not render the language of the decision mere dicta in a subsequent
case Rather American common law is founded on the application ofsimilar legal principles to
differing factual situations In the present case the case law is clear that a summary judgment
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II. Plaintiff Presents o Co pelling rgument To verturn ell-Established Case 
a  overning Post-Judgment otions. 
In an overt acknowledgement that Idaho case law does not support Plaintiffs argument 
that I.R.C.P. II(a)(2)(B) should allo  a party to ove to reconsider a final judgment (and any 
orders subsu ed therein), Plaintiff suggests that the case la  cited by SE  as rongly decided. 
o ever, Plaintiffs argu ent, as above, is pre ised on a faulty analysis ofl.R.C.P. II(a)(2)(B), 
hich fails to give proper eaning to each and every ord contained ithin the rule. gain, 
lai tiff c tinues to isre ar  t e a jecti al se f t e r  "interloc t ry" in I.R.C.P. 
11(a)(2)(B), so her argument must be rejected as an inadequate and incomplete analysis of the 
relevant les f i il r ce re  er c si erati   t is rt. 
s no definition for the ord "interlocutory" exists in the Idaho ules, this ourt ust 
look to the case la  interpreting I.R.C.P. 11 (a)(2)(B). elevant to this case is the question of 
hether a su ary judg ent order is interlocutory, and if so, hether it ever beco es final in 
the course of litigation. Applicable precedent plainly answers that question, indicating that upon 
entry of a final judgment, a summary judgment order ceases to be interlocutory: "{UJntil a final 
judgment has been entered, an order granting summary judgment is an interlocutory order .... " 
Puckett v. Verska, 144 Idaho 161, 166, 158 P.3d 937, 942 (2007). Plaintiff atte pts to do nplay 
this and si ilar language fro  other supporting cases as ere dicta, si ply because the 
procedural history of those several cases is not indistinguishably analogous to the facts presently 
before this ourt. (See Plaintiffs ec. 8,2011 e orandum, p. 8.) Plaintiffs understanding of 
dicta is incorrect: si ply because a decision does not follo  the sa e underlying factual and/or 
procedural background does not render the language of the decision mere dicta in a subsequent 
case. Rather, A erican co on law is founded on the application of si ilar legal principles to 
differing factual situations. In the present case, the case law is clear that a summary judgment 
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order is interlocutory in nature only until a final judgment has been entered Id The Puckett
case decided the propriety of a motion for reconsideration filed with a supporting affidavit in
the context of a motion being filed before rather than after entry of final judgment Id The
question was resolved as a result ofa specific argument asserted by the Respondent therein that
the prejudgment affidavit was improper under Rule Ia2B144 Idaho at 166 As opposed
to mere dicta the decision is directly on point and provides ample guidance for this Court
Following her improper dismissal of the several cases supporting the rule that a summary
judgment order is interlocutory only until entry of final judgment Plaintiff turns to Straub v
Smith 145 Idaho 65 175 P3d 754 2007 which she admits holds that anIRCP11a2B
motion for reconsideration of an order granting summary judgment cannot be filed after entry of
judgment PlaintiffsDec 8 2011 Memorandum p 8 Her argument is misguided
First Plaintiff argues that the 2007 Straub decision conflicts with the decision in Coeur
dAlene Mining Co v First National Bank ofNorth Idaho 118 Idaho 812 800 P2d 1026
1990 In fact the two decisions are consistent with each other and with the only plain reading
of the Rules that gives effect to the wording of the Rules The decision in Straub was that an
order of dismissal much like the judgment and subsumed summary judgment order here was a
final order not subject to the purview of Rule Ia2Bover interlocutory orders 145 Idaho at
71 In contrast the discussion in CoeurdAlene Mining Co quoted at length by Plaintiff
PlaintiffsDec 8 2011 Memorandum pp 910 related to a motion for reconsideration of an
interlocutory order made before the trial pursuant toIRCP56d Rather than resolving all
issues for trial as this Court summary judgment orders did the trial courts Rule 56dorder in
CoeurdAleneMining Co was truly an interlocutory order Accordingly per the law set forth in
Puckett when judgment was entered in this case Rule I Ia2Bceased to be applicable
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rder is interlocutory in nature only "until a final judgment has bee  t red." I . he uckett 
case decided the propriety of a otion for reconsideration, filed with a supporting affidavit, in 
the context of a otion being filed before, rather than after, entry of final judg ent. Id. he 
question was resolved as a result of a specific argument asserted by the Respondent therein, that 
the pre-judgment affidavit as i proper under Rule 11(a)(2)(B). 144 Idaho at 166. s opposed 
to ere ict , t e ecision is irectl   int a  rovides a le idance f r t is rt. 
ollo ing her i proper dis issal f the several cases supporting the rule that a su ary 
jUdgment order is interlocutory only until entry of final judg ent, Plaintiff turns to Straub v. 
S ith, 145 Idaho 65, 175 P.3d 754 (2007), which she ad its "holds that an LR.C.P. 11(a)(2)(B) 
otion for reconsideration f an order granting su ary judg ent cannot be filed after entry f 
judgment." (Plaintiffs Dec. 8,2011 emorandum, p. 8.) Her argument is misguided. 
First, Plaintiff argues that the 2007 Straub decision conflicts ith the decision in oeur 
d'Alene ining Co. v. First National Bank of North Idaho, 118 Idaho 812, 800 P.2d 1026 
(1990). In fact, the t o decisions are consistent ith each other and ith the only plain reading 
of the ules that gives effect to the ording f the ules. he decision in Straub as that an 
order of dis issal, uch like the judg ent (and subsu ed su ary judg ent order) here, as a 
final order not subject to the purview of Rule 11(a)(2)(B) over interlocutory orders. 145 Idaho at 
. In contrast, the discussion in oeur d'Alene ining o. quoted at length by laintiff 
(Plaintiffs Dec. 8, 2011 emorandum, pp. 9-10) related to a motion for reconsideration of an 
interlocutory order ade before the trial pursuant to LR.C.P. 56(d). ather than resolving all 
iss es f r trial, as t is ourt's s ar  j e t r ers i , t e trial court's le 6(d) r er i  
eur 'Alene i i  o. as tr l  a  i terl c t r  r er. ccordingly, er t e la  set f rt  i  
Puckett, when judgment was entered in this case, Rule 11(a)(2)(B) ceased to be applicable. 
L   I    ECURIT  EQUI  ORPORATION'S I  T  
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Next Plaintiff suggests that the Straub case renders the second clause of the first
sentence of Rule I Ia2Bmeaningless Plaintiff Dec 8 2011 Memorandum p 11 This
notion is simply not true as there are orders that remain interlocutory in nature even after entry
of final judgment including by way of example only that which was at issue in CoeurdAlene
Mining Co orders on nondispositive motions and orders regarding discovery The only orders
that are not subject to the first sentence of Rule IIa2Bare those that are dispositive and
final and not interlocutory such as what became of this Court orders on summary judgment
upon entry of final judgment
Finally Plaintiffsattempt to fitIRCPIa2Binto either a historical framework or
a framework analogous to the Federal Rules of Civil Procedure fails to take into account that
there are additional rules both at the state and federal levels that serve the important purposes
with which Plaintiff is concerned The case law cited by Plaintiff that predates the Idaho Rules
of Civil Procedure is consistent with SECs argument that Rules 59 and 60 which have
counterparts in the federal rules which have existed a great deal longer that Rule 11a2B
and which must not be practically read out of the rules by overextending the reach of Rule 11
provide the necessary remedy for amending andorgranting relief from a final judgment SeeJI
Case Co v McDonald 76 Idaho 223 280P2d 1070 1955 The intended purview of Rule 11
cannot be said to occupy the same function as these other long established rules which for good
reason are more restrained in what how and why they allow additional evidence to be presented
In short Plaintiff has not offered any cogent argument as to why Straub and the other
applicable precedent relied upon by SEC should be overturned or challenged by this Court
When every word of Rule I Ia2Bis given meaning there is harmony in the relevant Idaho
precedent and the remainder of the Idaho Rules As such this Court attention must turn to
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ext, Plaintiff suggests that the Straub case renders the second clause of the first 
se te ce f ule 11(a)(2)(B) ea i less. (Plai tiffs ec. ,  e ra , . 1.) is 
notion is si ply not true, as there are orders that re ain interlocutory in nature even after entry 
of final judg ent, including (by ay of exa ple only) that hich as at issue in oeur d'Alene 
ining o., orders on nondispositive otions, and orders regarding discovery. The only orders 
t at are t s ject t  t e first se te ce f le II(a)(2)(B) are t se t at are is siti e a  
final, and not interlocutory, such as hat beca e of this Court's orders on su ary judg ent 
upon entry of final judg ent. 
Finally, Plaintiffs atte pt to fit I.R.C.P. II(a)(2)(B) into either a historical fra e ork or 
a fra e ork analogous to the ederal ules f ivil rocedure fails to take into account that 
t   iti l l , t  t t  t t   l l l , t t  t  i t t s  
it  ic  l i tiff i  r d.   l  it   l i tiff t t r -date  t  I  l  
 i il  i  i t t it  C's t t t l    , i   
counterparts in the federal rules, hich have existed a great deal longer that Rule 11(a)(2)(B), 
and hich ust not be practically read out of the rules by overextending the reach of Rule 11, 
provide the necessary remedy for amending and/or granting relief from a final judgment. See JI 
 . . ld,  I  ,  .2d  (1 5).  i t  r i   l   
t  s i  t   t  s  f ti  s t s  t er, l - st lis  r l s, i  f r  
reas  are re restrai e  i  at,  a   t e  all  a iti al e i e ce t  e resented. 
In short, Plaintiff has not offered any cogent argu ent as to hy Straub and the other 
applicable precedent relied upon by SE  should be overturned or challenged by this ourt. 
hen every ord of Rule II(a)(2)(B) is given eaning, there is har ony in the relevant Idaho 
precedent and the remainder of the Idaho Rules. As such, this Court's attention must turn to 
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whether Plaintiff has satisfied the requirements of Rule 60b for considering the new evidence
in the Third Yost Affidavit after the judgment was entered
III Plaintiff Has Failed To Present Adequate Reason For Granting ReliefFrom The
Judgment UnderIRCP60b
In its opening brief on this motion SEC correctly anticipated that Plaintiff would attempt
to craft an argument that the Third Yost Affidavit should be admissible pursuant toIRCP
60b1or 6 Even though Plaintiff asserts an argument alternatively underIRCP
60bno argument is actually made to that effect See PlaintiffsDec 8 2011
Memorandum pp 58 As previously briefed by SEC a motion for relief from judgment
brought under Rule60bmust assert some grounds for relief that are not otherwise properly
categorized under one of the other Rule 60bbases Where the facts asserted fall fairly under
Rule60b1and no other facts have been argued aparty cannot be granted relief under Rule
60bTyler v Keeney 128 Idaho 524 528 915 P2d 1382 1386 CtApp 1986 Because
no separate or unique argument has been made under Rule 60bthe propriety of the Third
Yost Affidavit must be analyzed under Rule60b1and stricken accordingly
Plaintiffscounsel cannot legitimately claim that he was surprised within the meaning of
IRCP60b1by the Courts decision striking the Second Yost Affidavit As noted by the
Court the first time that Plaintiffs counsel claimed that the law on sham affidavits had not been
fully explained by the Court and SEC in its briefing
THE COURT And with due respect the first motion to strike
was very clear as to what the law is and including all of the
information about the fact that its not a sham if in fact the person
says I didnt remember at the time or I at least Ive rethought or
theres new theresnew studies that Ive looked at or something
to explain the inconsistency And there in my view its clearly
inconsistent in a very material way
SEC also anticipated an argument based on the newly discovered evidence provision ofIRCP
60b2Plaintiff did not make any such argument however and has therefore waived the same
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whether Plaintiff has satisfied the requirements of ule 60(b) for considering the ne  evidence 
in the Third ost ffidavit after the judgment as entered. 
III. Plai tiff as Failed o Prese t dequate eason For ranting lief Fro  he 
Judg ent nder I.R.C.P. 60(b). 
In its opening brief on this otion, SEC correctly anticipated that Plaintiff would atte pt 
to craft an argument that the Third Yost Affidavit should be admissible pursuant to I.R.C.P. 
60(b)(1) or (6).1 Even though Plaintiff asserts an argu ent "alternatively under I.R.C.P. 
60(b)(6)," no argument is actually made to that effect. (Se  l intif s . ,  
e orandu , pp. 5-8.) s previously briefed by SEC, a otion for relief fro  judg ent 
brought under Rule 60(b)(6) ust assert so e grounds for relief that are not otherwise properly 
categorized under one of the other Rule 60(b) bases: "Where the facts asserted fall fairly under 
Rule 60(b)(1), and no other facts have been argued, [a party] cannot be granted relief under Rule 
60(b)(6). Tyler v. Keeney, 128 Idaho 524, 528, 915 P.2d 1382, 1386 (Ct.App. 1986). Because 
no separate or unique argument has been made under Rule 60(b)( 6), the propriety of the Third 
ost ffidavit ust be analyzed under Rule 60(b)(1), and stricken accordingly. 
Plaintiff s counsel cannot legiti ately clai  that he as surprised, ithin the eaning of 
I.R.C.P. 60(b)(1), by the Court's decision striking the Second Yost Affidavit. As noted by the 
ourt the first ti e that laintiffs counsel clai ed that the la  on sha  affidavits had not been 
fully explained by the Court and SEC in its briefing: 
 OURT: ...  it  e respect, t e [first] ti  t  stri e 
was very clear as to what the law is and including all of the 
i   t  f t t t it's t  sha  if, i  fact, t  r  
says I didn't remember at the time or I - at least I've rethought or 
there's  - t ere's  studi s t t I've l  at r so ethi  
to explain the inconsistency. And there - i  y i  it's cl arly 
i i t t ... in a very material way. 
1 SEC also anticipated an argument based on the "newly discovered evidence" provision ofI.R.C.P. 
60(b )(2). Plaintiff did not make any such argument, however, and has therefore waived the same. 
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Sept 14 2011 Trans p 431121 The law of sham affidavits had been presented very clearly
to Plaintiff prior to her filing of the Second Yost Affidavit Simply stated this Court denied
SECs argument that the First Yost Affidavit was a sham based on the fact that the affidavit was
too vague to be considered in direct conflict with the deposition testimony Citing the exact
same vagueness the Court ruled that the First Yost Affidavit was insufficient to create a genuine
issue of material fact sufficient to withstand SECsmotion for summary judgment
As if using the Courtscomments as a blueprint Plaintiff s counsel went back to Dr Yost
with a revised Second Affidavit attempting to clear up the vagueness in a way that he perceived
would buffer Plaintiffs first motion for reconsideration What he failed to do was ensure that
the Second Yost Affidavit would not commit the very sins that the Court had already cautioned
would be susceptible to a sham affidavit attack In other words Plaintiffs counsel focused
entirely on his offense and completely neglected his defense Based on that history it is
disingenuous at best for Plaintiffs counsel to claim that he was surprised that the Second Yost
Affidavit was stricken as a sham simply because the First Yost Affidavit a completely different
affidavit was not Frankly what occurred with the First Yost Affidavit had little to do with
how the Second Yost Affidavit was analyzed other than to say that Plaintiff her counsel and
her expert should have been more aware of the law of sham affidavits
SEC has briefed at length all factors to be considered underIRCP60b1with the
exception of surprise and will rest its argument regarding those points mistake inadvertence
and excusable neglect on the briefing submitted and on the oral argument to be presented
Though Plaintiff has seemingly attempted to create some argument based on inadvertence or
excusable neglect the fact of the matter is that none of the explanations based on Dr Yosts
health unsubstantiated communications with Dr Pacheco or otherwise provide any
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(Sept. 14,2011 Trans., p. 43:11-21.) The law of sham affidavits had been presented very clearly 
to Plaintiff prior to her filing of the Second ost ffidavit. i l  t t , t is rt i  
SEC's argu ent that the First ost ffidavit as a sha , based on the fact that the affidavit as 
too vague to be considered in direct conflict with the deposition testi ony. i   a t 
sa e a e ess, t e rt r le  t at t e irst ost ffida it as i s fficie t t  create a e i e 
s  f  a  icient t  thst  C's    jUdg . 
 if i  t  ourt's e ts   l ri t, l i ti f  l t  t  r. t 
it   r is ,  ffid it, tt ti  t  l r  t  a ueness i    t t  r i  
  i  s irst   i ration. at        
t   ost ffid it l  t it t e r  i  t t t  rt  lr  ti  
ould be susceptible to a sha  affidavit attack. I  t r r s, l i tiff s s l f s  
entirely on his offense and co pletely neglected his defense. ase   t at ist ry, it is 
disingenuous, at best, for Plaintiff s counsel to clai  that he was surprised that the Second Yost 
ffidavit as stricken as a sha  si ply because the irst ost ffidavit - a co pletely different 
i  - as not. Frankly, hat occurred ith the First ost ffidavit had little to do ith 
 t   st ffida it s l , t r t  t  s  t t laintiff, r sel,  
her expert should have been ore aware of the law of sha  affidavits. 
SE  has briefed at length all factors to be considered under I.R.C.P. 60(b)(1), ith the 
exception of "surprise", a  ill rest its ar e t re ar i  t se i ts ( ista e, i a erte ce 
and excusable neglect) on the briefing sub itted and on the oral argu ent to be presented. 
Though Plaintiff has seemingly attempted to create some argument based on inadvertence or 
excusable neglect, the fact of the matter is that none of the explanations -  on r. ost's 
health, unsubstantiated co unications ith r. Pacheco, or other ise - r i  ny 
REPL  E R  I  S PP RT F SECURIT  E IP E T C RPORATION'S TI  T  
I  I  I I   L   - Page 8 
14542-  (4 11) 
explanation as to why the information sought to be included in the Third Yost Affidavit was not
included in the Second Yost Affidavit In other words Plaintiff counsel has merely attempted
to show why he didntbring another motion for reconsideration sooner prior to entry of
judgment he has made no showing as to why he didntinclude all necessary information in the
Second Yost Affidavit or the First Yost Affidavit in the first place To the extent that Plaintiff
is asking the Court to overturn its order striking the Second Yost Affidavit this new evidence
only demonstrates that the Courtsorder striking that affidavit was both proper and justified
As Plaintiff and her counsel have asserted surprise as a basis for relief SEC contends
that Plaintiff is relying on a type of surprise that is not contemplated byIRCP60b1The
term surprise was addressed in the context of Rule60b1in Nickles v Durban 118 Idaho
198 795 P2d 903 CtApp 1990 where the Court found that surprise in this context is
generally defined to be some condition or situation in which a party to an action unexpectedly
placed to his injury without any default or negligence ofhis own and which ordinary prudence
could not have guarded against 118 Idaho at 203 204 citing Mid Kansas Fed Say and Loan
Assoc of Witchita Kansas v Burke 233 Kan 796 666 P2d 203 1983 Applicable here
merely being surprised that the Court rules against a party is not grounds for relief Ordinary
prudence could have guarded against the surprise that Plaintiffscounsel now claims and the
negligence of her counsel andorexpert is not grounds for relief
IV Even If The Yost Affidavit Is Not Stricken As Improper Plaintiff Has Failed To
Address TheRemaining Deficiencies And Objectionable Content Therein
In SECs opening brief on this motion it addressed the same deficiencies which have
plagued the entire series of Yost Affidavits from the beginning Namely Dr Yost has continued
to confuse medical causation and foreseeability of risk of injury he has continued to testify with
conclusory statements drawing on his own unqualified legal analysis and he has continually
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explanation as to hy the information sought to be included in the hird ost ffidavit as not 
include  in the econd ost fida . In ther , l intif s s l as erely t te  
to sho  hy he didn't bring another otion for reconsideration sooner, prior to entry of 
judg ent; he has ade no showing as to why he didn't include all necessary infor ation in the 
econd ost ffidavit (or the irst ost ffidavit) in the first place. o the extent that laintiff 
is asking the ourt to overturn its order striking the Second ost ffidavit, this ne  evidence 
only demonstrates that the Court's order striking that affidavit was both proper and justified. 
s      te  "sur "   s  li f,   
that Plaintiff is relying on a type of surprise that is not conte plated by I.R.C.P. 60(b)(1). he 
term "surprise" was addressed in the context of Rule 60(b)(1) in Nickles v. Durbano, 118 Idaho 
198, 795 .2d 903 (Ct.App. 1990), here the ourt found that "'[ ]urpris '     
generally defined to be 'some condition or situation in which a party to an action unexpectedly 
placed to his injury, without any default or negligence of his own, and which ordinary prudence 
could not have guarded against." 118 Idaho at 203-204 (citing id ansas Fed. Sav. and Loan 
Assoc. of itchita, Kansas v. Burke, 233 an. 796, 666 P.2d 203 (1983). lic l  re, 
erely being 'surprised' that the Court rules against a party is not grounds for relief. Ordinary 
prudence could have guarded against the surprise that Plaintiff s counsel now claims, and the 
negligence of her counsel and/or expert is not grounds for relief. 
I .  If  st ffi it Is t tri  s I r per, l i tiff s il   
ress e e ai i  eficie cies  jecti a le te t erein. 
In SEC's opening brief on this otion, it addressed the sa e deficiencies hich have 
plagued the entire series of Yost Affidavits from the beginning. Namely, Dr. Yost has continued 
t  f s  i l sati   f r seeability f ris  f i jury,  s ti  t  t stif  it  
conclusory state ents drawing on his own, unqualified legal analysis, and he has continually 
L   I  S  OF SECURIT  EQUIP  ORPORATION'S I  T  
STRIKE THIRD AFFIDAVIT OF GAROLD YOST - Page 9 
1454 -  ( 911) 
failed to provide the requisite foundation for any of his opinions See SECsDec 1 2011
Memorandum pp 1819 Moreover the articles on which Dr Yost relies do not support his
conclusory opinions on foreseeability ofrisk ofchronic disease and are not sufficient as a matter
oflaw to have put SEC on notice that exposure to its products may cause chronic irreversible
respiratory disease of the type about which Plaintiff complains
Plaintiff has failed to address these deficiencies in the Third Yost Affidavit SEC urges
the Court to therefore consider the Third Yost Affidavit with the same critical analysis that it
applied to the first two Affidavits Under such analysis regardless of the Courtsdecision on the
propriety of the new Affidavit underIRCP60bversusIRCP11a2Bthe Court has
ample grounds to strike the Third Yost Affidavit and to uphold the earlier decisions on summary
judgment and the final judgment itself
CONCLUSION
For the reasons stated herein SEC respectfully requests that this Court strike the Third
Affidavit of Gerald Yost as filed in violation of the applicable Rules of Civil Procedure and
without the requisite good cause for a tardy submission of evidence In the alternative it should
be stricken on the grounds that it like its predecessors in this litigation is filled with legal
conclusions testimony lacking proper foundation and confusion of the issues as between
medical causation and foreseeability of risk of injury For any of these reasons the Court is
within its discretion to strike the Third Yost Affidavit and affirm the judgment
DATED this Vday ofDecember 2011 GREENER BURKE SHOEMAKERPA
Christopher C Burke Thomas J Lloyd III
Attorneys for Defendant
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failed to provide the requisite foundation for any of his opinions. (S e C's De . 1, 2011 
e orandu , pp. 18-19.) ore r, the articles n hich r. ost relies o not s port is 
conclusory opinions on foreseeability of risk of chronic disease, and are not sufficient as a atter 
of law to have put SEC on notice that exposure to its products may cause chronic, irreversible 
respiratory disease of the type about which Plaintiff complains. 
f has failed to ress t es  iciencies in the rd ost id i .  rges 
the t to therefore s der t e ird ost ffida it ith e e tical sis  t 
applied to the first two Affidavits. Under such analysis, regardless of the Court's decision on the 
propriety of the new Affidavit under I.R.c.P. 60(b) versus I.R.C.P. 11(a)(2)(B), the Court has 
a ple grounds to strike the Third ost ffidavit and to uphold the earlier decisions on su ary 
judgment and the final judgment, itself. 
 
For the reasons stated herein, S  respectfully requests that this ourt strike the hird 
ffida it f r l  t,  fil  i  i l ti  f t  li le l  f i il r r   
ithout the requisite good cause for a tardy sub ission of evidence. In the alternative, it should 
be stricken on the grounds that it, like its predecessors in this litigation, is filled with legal 
conclusions, testimony lacking proper foundation, and confusion of the issues as between 
edical causation and foreseeability of risk of injury. For any of these reasons, the ourt is 
it i  its iscreti  t  stri e t e ir  st ffi a it a  affir  t e j ent. 
. ~ 
 t i  (3 day of December, 2011. 
  SHOEM  .A. 
,- I L "3:. f?y£z&-=< 
rist er . r e / as J. l  III 
tt r e s f r efe a t 
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I hereby certify that I caused to be served the foregoing document on the following
named personson the date indicated below in the manner indicated below
Darwin Overson Esq ViaUS Mail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 ViaOvernight Delivery
P O Box 7808
Boise Idaho 83707
DATED this 1 day of December 2011
Christopher C Burke
Thomas J Lloyd III
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THIRD AFFIDAVIT OF GARALD YOST
DENYING DEFENDANTSMOTION
FOR RULE 56CATTORNEY FEES
AND AWARDING DEFENDANT COSTS
On October 20 2011 this Court entered Judgment in favor of Defendant Security
Equipment Corporation SEC against Plaintiff Billie Jo Major Major dismissing
Plaintiff s Complaint against SEC and awarding SEC its costs in an amount to be determined
pursuant to Rule 54 of the Idaho Rules of Civil Procedure
On October 24 2011 Plaintiff filed aMotion for Reconsideration of the CourtsOrders
granting Defendants1Motion to Strike the Affidavit of Dr Yost and 2 Motions for
Summary Judgment In support of that Motion Plaintiff filed a third Affidavit of Gerald S Yost
PhDin Support of Plaintiff s Motion for Reconsideration of the CourtsOrder Striking the
Second Affidavit of Dr Yost Third Yost Affidavit On December 1 2011 SEC filed a
Motion to Strike the Third Yost Affidavit and a Motion for Rule 56c Award of Attorney Fees
and Costs On December 8 2011 Plaintiff filed an Affidavit of Counsel in Support of Plaintiffs
Reply Regarding Third Motion for Reconsideration Opposition to DefendantsMotion to Strike
ORDER DENYING PLAINTIFFSTHIRD MOTION FORRECONSIDERATION DENYING DEFENDANTS
MOTION TO STRIKE THIRD AFFIDAVIT OF GARALD YOST DENYING DEFENDANTSMOTION FOR
RULE 56CATTORNEY FEES AND AWARDING DEFENDANT COSTS Page 1 14542 011 443880doc002236
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I  THE ISTRICT RT F E  J I I  IS I  O'iFH:E ,C;; .CY 
TE F ID , I  ND F R E    
I LIE J  J , a  indi id l, 
laintiff, 
v. 
I  I  
CORPORATION, a issouri corporation, 
t. 
ase .: - -I 5 
 I  I TIFF'S 
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ENDANT'S I    
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I  ENDANT'S I  
  6(C)  , 
   S 
 ct ber , , t is rt e tere  J e t i  fa r f efe a t ec rit  
Equipment Corporation ("SEC") against Plaintiff illie .10 ajor ("Major"), is is i  
Plaintiff's Complaint against SEC and awarding SEC its costs in an amount to be determined, 
pursuant to Rule 54 of the Idaho Rules of Civil Procedure. 
n ctober 24,2011, laintiff filed a otion for econsideration f the ourt's rders 
granting Defendant's (1) Motion to Strike the Affidavit of Dr. Yost, and (2) Motions for 
Summary Judgment. In support of that Motion, Plaintiff filed a third Affidavit of Gerald S. Yost, 
Ph.D. in Support of Plaintiff's otion for econsideration of the ourt's rder Striking the 
 ida   r.  ("Thir   id ").   ,2011,    
ti  t  tri  t  i  t i it   ti  f r l  6(c)   tt   
 sts.  r , 11, laintiff fil   ffi it f s l i  rt f laintiff's 
Reply Regarding Third otion for Reconsideration; Opposition to Defendant's otion to Strike; 
 I  LAINTIF 'S I  I  F R CONSIDERATION,  EFENDANT'S 
I   STRI  I  FI I  OF  ST, EN I  DEFENDANT'S I  FOR 
RULE 56(C) ATTORNEY FEES, AND A WARDING DEFENDANT COSTS - Page 1 14542- 1 ( 43880.doc) 
and Opposition to DefendantsMotion for Rule 56c Award of Attorney Fees and Costs The
parties filed briefs in support of and in opposition to these three 3 motions
On November 3 2011 SEC filed its Memorandum of Costs in the amount of Twenty
Two Thousand Six Hundred Fifty Dollars and ThirtySeven Cents2265037Plaintiff did not
file any objections to this Memorandum of Costs
After considering the written submissions of the parties and hearing oral argument by
counsel on the three 3 motions and the Memorandum of Costs on January 26 2012 and good
cause appearing the Court HEREBY ORDERS as follows
SECsMotion to Strike the Third Yost Affidavit is DENIED on the grounds and
for the reasons stated by the Court on the record during the January 26 2012 hearing on the
Motion
2 PlaintiffsMotion for Reconsideration of the CourtsOrders Granting
DefendantsMotion to Strike the Affidavit of Gerald Yost and Motions for Summary Judgment
is DENIED on the grounds and for the reasons stated by the Court on the record during the
January 26 2012 hearing on the Motion
3 SECsMotion for Rule 56cAttorney Fees and Costs is DENIED on the grounds
and for the reasons stated by the Court on the record during the January 26 2012 hearing on the
Motion and
4 Defendant SEC is hereby awarded costs as a matter ofright pursuant to Rule
54d1Cofthe Idaho Rules of Civil Procedure in the amount of2265037which amount
shall be added to the Judgment previously entered by the Court on November 20 2011
ORDER DENYING PLAINTIFFSTHIRD MOTION FOR RECONSIDERATION DENYING DEFENDANTS
MOTION TO STRIKE THIRD AFFIDAVIT OF GARALD YOST DENYING DEFENDANTSMOTION FOR
RULE 56CATTORNEY FEES AND AWARDING DEFENDANT COSTS Page 2 14542011 443880doc002237
and Opposition to Defendant's Motion for Rule 56(c) Award of Attorney Fees and Costs. The 
parties filed briefs in support of and in opposition to these three (3) motions. 
On November 3, 2011, SEC filed its emorandum of osts in the a ount of T enty-
Two Thousand Six Hundred Fifty ollars and Thirty-Seven Cents ($22,650.37). Plaintiff did not 
file any objections to this Memorandum of Costs. 
After considering the written submissions of the parties and hearing oral argument by 
counsel on the three (3) otions and the e orandum of Costs on January 26, 2012, and good 
cause appearing, the Court HEREBY ORDERS as follows: 
1. C's tion t  e  r  s  fida t    t  s  
for the reasons stated by the Court on the record during the January 26,2012 hearing on the 
otion; 
. l intif s io   i r ti    ourt's   
efendant's tio  t  tri e t e ffida it f eral  st a  tio s f r ar  J e t 
is DENIED on the grounds and for the reasons stated by the Court on the record during the 
January 26, 2012 hearing on the Motion; 
3. SEC's otion for Rule 56(c) ttorney Fees and Costs is E IE  on the grounds 
and for the reasons stated by the Court on the record during the January 26, 2012 hearing on the 
Motion; and 
. Defendant SEC is hereby awarded costs as a atter of right, pursuant to Rule 
54(d)(1)(C) of the Idaho Rules of Civil Procedure, in the amount of $22,650.37, which amount 
shall be added to the Judgment previously entered by the Court on November 20,2011. 
III 
ORDER DENYING PLAINTIFF'S THIRD MOTION FOR RECONSIDERATION, DENYING DEFENDANT'S 
MOTION TO STRIKE THIRD AFFIDAVIT OF GARALD YOST, DENYING DEFENDANT'S MOTION FOR 
RULE 56(C) ATTORNEY FEES, AND A  ARDlNG DEFENDANT COSTS - Page 2 14542-01  (443880.doc) 
IT IS SO ORDERED
DATED this 6pday of February 2012 044ee
Honorable Cheri C C4sey istrict Judge
Fourth Judicial District Ada County
ORDER DENYING PLAINTIFFSTHIRD MOTION FOR RECONSIDERATION DENYING DEFENDANTS
MOTION TO STRIKE THIRD AFFIDAVIT OF GARALD YOST DENYING DEFENDANTSMOTION FOR
RULE 56CATTORNEY FEES AND AWARDING DEFENDANT COSTS Page 3 14542 011 443880doe002238
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TE  thIS ~ day of ebruary, 2012. 
no~ .~istr ct  
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  LAINTIF 'S I    CONSIDERATION,  EFENDANT'S 
I   STRI  I  I I  OF A A  ST, I  DEFENDANT'S I  F  
RULE 56(C) ATTORNEY FEES, AND A WARDING DEFENDANT COSTS - Page 3 1454 -  ( 43880.doc) 
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing ORDER DENYING
PLAINTIFFSTHIRD MOTION FOR RECONSIDERATION DENYING DEFENDANTS
MOTION TO STRIKE THIRD AFFIDAVIT OF GAROLD YOST DENYING DEFENDANT
MOTION FOR RULE 56CATTORNEY FEES AND AWARDING DEFENDANT COSTS on
the following named personson the date indicated below in the manner indicated below
Darwin Overson Esq ViaUS Mail
Eric B Swartz Esq ViaHand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 ViaOvernight Delivery
P O Box 7808
Boise Idaho 83707
Christopher C Burke Esq ViaUSMail
Thomas J Lloyd III Esq Via Hand Delivery
GREENER BURKE SHOEMAKERPA Via Facsimile 2083192601
950W Bannock Street Suite 900 Via Overnight Delivery
Boise Idaho 83702
DATED this 3 day of February 2012
e 0009 G
Clerk of ourt of ryF 0
0




ORDER DENYING PLAINTIFFSTHIRD MOTION FOR RECONSIDERATION DENYING DEFENDANTS
MOTION TO STRIKE THIRD AFFIDAVIT OF GARALD YOST DENYING DEFENDANTSMOTION FOR
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CERTIFICATE OF S ICE 
I hereby certify that I caused to be served the foregoing ORDER DENYING 
PLAINTIFF'S THIRD MOTION FOR RECONSIDERATION, DENYING DEFENDANT'S 
OTION TO S IKE THIRD FFI IT F  YO , ING D DANT'S 
OTION FOR LE 56(C) TTORNEY FEES, AND ARDING EFE NT COSTS on 
the following named person(s) on the date indicated below, in the manner indicated below: 
Darwin Overson, Esq. fj ia .S. ail 
Eric B. Swartz, Esq. ia and liver  
J  & S ARTZ, PLLC [ ] ia ile (208/489-89 ) 
 . horeline rive, uite  [ ] ia g t ve  
. . ox 7808 
Boise, Idaho 83707 
Christopher C. Burke, Esq. 114-,via U.S. ail 
Thomas J. Lloyd III, Esq. [ ] ia  e  
GREENER BURKE SHOE AKER P.A. [ ]  le (208/319-26 ) 
950 . Bannock Street, Suite 900 [ ] i  r i t li r  
Boise, Idaho 83702 
TE  this ~ day of February, 2012. 
CHRISTOPH~a D. Bieri 
By: 
ORDER DENYING PLAINTIFF'S THIRD MOTION FOR RECONSIDERATION, DENYING DEFENDANT'S 
TI N TO STRIKE THIRD AFFIDAVIT OF GARALD YOST, DENYING DEFENDANT'S MOTION FOR 
RULE 56(C) ATTORNEY FEES, AND A WARDING DEFENDANT COSTS - Page 4 14542-01  ( 43880.doc) 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THL
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA






CORPORATION a Missouri corporation
Defendant
Pursuant to Rule 54aand Rule 54d1ofIdaho Rules of Civil Procedure and this
CourtsOrders entered July 19 2011 October 20 2011 and 4dr 3 2012 this
amended judgment is hereby entered in favor of Defendant Security Equipment Corporation
SEC against Plaintiff Billie Jo Major dismissing Plaintiffs Complaint against SEC and each
and every claim asserted therein with prejudice and awarding SEC its costs as a matter of right
in the amount of TwentyTwo Thousand Six Hundred Fifty Dollars and ThirtySeven Cents
2265037
DATED this J day of February 2012
ck44q
Honorable Cheri C Copsey D1Wrict Judge
Fourth Judicial District Ada County




JAN 3 0 2012 
Ada County Clerk 
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CHRISTOPHER (), filCH, lerk 
By JOHN WI;:!<THeR6Y 
IN THE DISTRICT COURT OF THE FOURTH J I I L ISTRICT OF THEfEPU(" 
S TE OF ID , IN AND FOR THE  F  
BILLIE JO AJ , an individual, 
Pl i tiff, 
v. 
SECURITY EQUIP ENT 
CORPORATION, a issouri corporation, 
t. 
ase .: -P - 03515 
ENDED J  
Pursuant to ule 54( a) and ule 54( d)(1) of Idaho ules of ivil Procedure, and this 
Court's rders entered July 19,2011, ctober 20,2011, and. ~  ,20 ,  
amended judgment is hereby entered in favor of Defendant Security Equipment Corporation 
("SE ") against Plaintiff Billie Jo ajor, dismissing Plaintiffs Complaint against SEC, and each 
and every claim asserted therein, with prejudice, and awarding SEC its costs as a matter of right 
in the a ount of Twenty-Two Thousand Six Hundred Fifty Dollars and Thirty-Seven Cents 
($22,650.37). 
'.I~ 
 this _;J_ day of February, 2012. 
AMENDED JUDGMENT - Page 1 
14542-011 (443881.doc) 
 ri . opsey,  nc  Jud  
rt  udi i l i trict,  ount  
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing AMENDED JUDGMENT on the
following named personson the date indicated below in the manner indicated below
Darwin Overson Esq ViaUSMail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 ViaOvernight Delivery
P O BOX 7808
Boise Idaho 83707
Christopher C Burke Esq ViaUSMail
Thomas J Lloyd III Esq Via Hand Delivery
GREENER BURKE SHOEMAKERPA Via Facsimile 2083192601
950 W Bannock Street Suite 900 ViaOvernight Delivery
Boise Idaho 83702
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FICATE   
I hereby certify that I caused to be served the foregoing ENDE  J E T on the 
follo ing na ed person(s) on the date indicated belo , in the anner indicated belo : 
ar in verson, Esq. 
Eric . S artz, Esq. 
J  & , P C 
673 . reline ri e, ite 220 
. . ox  
ise, Ida o  
Christopher C. Burke, Esq. 
ho as J. loyd III, sq. 
  E  .A. 
950 . annock Street, Suite 900 
oise, Idaho 83702 
  L day of February, 2012. 
AMENDED JUDGMENT - Page 2 
14542-011 (44388I.doc) 
[ ] ia .S. il 
[ ] ia a  ivery 
[ ] ia le (208/489-89 ) 
[ ] ia er i t eli er  
[ ] ia .S. il 
[ ] ia a  li e  
[ ] ia le (208/319-26 ) 
[ ] i  r i t li r  
y: 
FEB 17 2012
Darwin Overson ISB 5887
Eric B Swartz ISB 6396
JONES SWARTZ PLLC
1673 W Shoreline Drive Suite 200 83702
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Attorneys for Plaintiff Appellant Billie Jo Major
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
THE STATE OF IDAHO IN AND FOR THE COUNTY OF ADA






Case No CV PI 1003515
AMENDED NOTICE OFAPPEAL
TO The abovenamed Defendant SECURITY EQUIPMENT CORPORATION
and its
Attorneys of Record CHRISTOPHER C BURKE and THOMAS J LLOYD III GREENER
BURKE SHOEMAKER PA 950W Bannock Street Suite 900 Boise ID 83702 and the
CLERK of the above entitled Court
NOTICE IS HEREBY GIVEN THAT
1 The abovenamed Plaintiff Appellant BILLIE JO MAJOR appeals against the
0
above named Defendant Appellee to the Idaho Supreme Court from the October 20 2011
JUDGMENT the February 3 2012 AMENDED JUDGMENT and the following orders
AMENDED NOTICE OF APPEAL I
002242
Darwin Overso , ISB #5887 
Eric B. Swartz, ISB #6396 
JONES & S ARTZ P LC 
1673 W. Shoreline Drive, Suite 200 [83702] 
Post Office Box 7808 
Boise, ID 83707 
Telephone: (208) 489-8989 
Facsimile: (208) 489-8988 
Email: darwin@jonesandswartzlaw.com 
eric@jonesandswartzlaw.com 
Attorneys for Plaintiff-Appellant, Billie Jo Major 
: ":iI1ili~ 
FEB 1 7 2012 
CHRISTOPHER D. RIC . Clerk 
By JOANNA ORTEGA 
DEPUTY 
I  HE IS ICT RT  E  J I I  ISTRICT F 
E TE F I , I  ND  E    
BILLIE JO MAJOR, and individual, 
Plaintiff-Appellant, 
vs. 
SECURITY EQUIPMENT CORPORATION, 
a Missouri corporation, 
fendant-A ellee. 
ase .  I  
E E     
TO: he -na  f ndant, ECURIT  UIP NT RPORATION, and its 
Attorneys of Record, CHRISTOPHER C. BURKE and THOMAS J. LLOYD III, GREENER 
E S E E  PA, 950 . annock Street, Suite 900, oise, I  83702, and the 
LE  of the above-entitled ourt. 
TI E IS E E  I E  THAT: 
1. The above- a e  Plaintiff- pellant, I I  J  JOR, appeals against t e 
above-named Defendant-Appellee to the Idaho Supreme Court from the October 20, 2011 
JUDGMENT, the February 3, 2012 AMENDED JUDGMENT, and the following orders: 
AMENDED NOTICE OF APPEAL - 1 
July 19 2011 ORDER RE PENDING MOTIONS FOR SUMMARY JUDGMENT AND TO STRIKE
AFFIDAVIT OF GERALD YOST
October 20 2011 ORDER GRANTING DEFENDANTSMOTIONS FOR SUMMARY
JUDGMENT STRIKING AFFIDAVIT OF GAROLD YOST AND DENYING PLAINTIFF
MOTIONS FOR RECONSIDERATION and
February 3 2012 ORDER DENYING PLAINTIFFSTHIRD MOTION FOR
RECONSIDERATION DENYING DEFENDANTSMOTION TO STRIKE THIRD AFFIDAVIT
OF GARALD YOST DENYING DEFENDANT MOTION FOR RULE 56CATTORNEY
FEES AND AWARDING DEFENDANT COSTS
the Honorable Cheri C Copsey presiding
2 Appellant has a right to appeal to the Idaho Supreme Court and the Judgments
and Orders described in paragraph 1 above are appealable under and pursuant to Idaho Appellate
Rule 11a
3 Appellant requests a review ofthe following issues
a In granting the Defendants first motion for summary judgment did the
District Court err in its finding that there were no genuine issues of material fact as to the
foreseeability of injury element of each of the Plaintiffsproduct liability claims
b In granting the Defendantssecond motion for summary judgment and
denying the Plaintiffsmotion for reconsideration did the District Court err in its finding that
there were no genuine issues of material fact as to the foreseeability of injury element of the
Plaintiffsproduct liability case
c In granting the Defendantsthird motion for summary judgment and denying
the Plaintiffsmotion for reconsideration did the District Court err in its finding that the Plaintiff
could not proceed to trial on her acute injury claims because the risk of those injuries were
known to her and were disclosed on the product label
AMENDED NOTICE OF APPEAL 2
002243
• July 19, 2011 ORDER RE PENDING MOTIONS FOR SUMMARY JUDGMENT AND TO STRIKE 
A FIDAVIT OF GERALD YOS ; 
• October 20, 2011 ORDER GRANTING DEFE T'S MOTIONS FOR S ARY 
JUDG ENT, STRIKING AFFIDAVIT OF GAROLD YOST AND DENYING PL I TIFF'S 
OTIONS FOR REC I I ; and 
• February 3, 2012 ORDER DENYING PLAINTIFF'S THIRD MOTION FOR 
RE SI E TI , DE ING EFE DANT'S OTION TO ST IKE T IRD FFI IT 
OF G R LD YOST, DENYING DEFE DANT'S OTION FOR RULE 56(c) ATTORNEY 
FEES, AND AWARDING DEFENDANT COSTS, 
the onorable heri . opsey, presiding. 
. Appellant has a right to appeal to the Idaho Supreme Court, and the Judgments 
and Orders described in paragraph 1 above are appealable under and pursuant to Idaho Appellate 
Rule II(a)(1). 
3. Appellant requests a review of the following issues: 
(a) In granting the Defendant's first motion for summary judgment, did the 
District Court err in its finding that there were no genuine issues of aterial fact as to the 
foreseeability of injury element of each of the Plaintiff s product liability claims? 
(b) In granting the Defendant's second motion for summary judgment, and 
denying the Plaintiff s motion for reconsideration, did the District Court err in its finding that 
there were no genuine issues of material fact as to the foreseeability of injury element of the 
Plaintiffs product liability case? 
(c) In granting the Defendant's third motion for summary judgment, and denying 
the Plaintiffs otion for reconsideration, did the istrict Court err in its finding that the Plaintiff 
could not proceed to trial on her acute injury claims because the risk of those injuries were 
known to her and were disclosed on the product label? 
AMENDED NOTICE OF APPEAL - 2 
d In granting the Defendants third motion for summary judgment did the
District Court err in finding that the Plaintiff could only establish the foreseeability of injury
element of her claims by proof that it was known at the time the product was sold to Plaintiffs
employer that there was a risk of chronic injury when there was ample evidence in the record of
the thenknown acute injury risks
e In granting the Defendants motion to strike and denying the Plaintiffs
motion for reconsideration did the District Court err in finding that the second affidavit of
Plaintiffsexpert was in direct conflict with his prior deposition testimony and it was therefore a
sham affidavit
f Did the District Court apply the correct standard for admissibility of expert
testimony
g In denying the Plaintiffsmotion for partial summary judgment and granting
the Defendantsfirst motion for summary judgment did the District Court err in its finding that
the Federal Hazardous Substance Act preempted Occupational Safety and Health Act regulations
governing labeling requirements for products used in the workplace
h Did the District Court err by denying Plaintiffs motion for
reconsideration of its prior orders granting Defendants motion to strike the affidavit of
Plaintiffs expert based on the sham affidavit doctrine
i Did the District Court err by denying Plaintiffs motion for
reconsideration of its prior orders granting Defendantsmotions for summary judgment
j Did the District Court err by applying the wrong standard in a product
liability case for determining whether the manufacturer knew or should have known of the
risk of injury posed by its product at the time of sale
AMENDED NOTICE OF APPEAL 3
002244
(d) In granting the efendant's third otion for su ary judg ent, did the 
istrict rt rr in finding that t e l i tiff ld ly st lis  t  fores ilit  f i j r  
le ent f r laims  r f t t it as  t t e ti e t  r t s s l  t  l intiffs 
e ployer that there was a risk of chronic injury, when there was a ple evidence in the record of 
t e t e -kno  ac te i j r  ris s? 
( e) In granting the efendant's otion to strike, and denying the Plaintiff s 
tion for r si r ti , id t e istrict rt rr i  findin  t t t  s  ffid it f 
Plaintiffs expert as in direct conflict ith his prior deposition testi ony and it as therefore a 
 vit? 
(f) id the istrict ourt apply the correct standard for ad issibility of expert 
testi ony? 
(g) In denying the Plaintiffs otion for partial su ary judg ent, and granting 
t e efendant's first ti  f r s ar  j e t, i  t e istrict rt err i  its fi i  t at 
t  r l r s st  t r t  ti l f t   lt  t r l ti s 
governing labeling requirements for products used in the workplace? 
(h) id     by i  l intiff's   
reconsideration of its prior orders granting Defendant's motion to strike the affidavit of 
Plaintiff's expert based on the "sha  affidavit" doctrine? 
(i)     r   i  laintiff's ti   
rec si erati  f its ri r r ers ra ti  efendant's ti s f r s ar  j ent? 
(j) id the istrict ourt err by applying the rong standard in a product 
liability case for deter ining hether the anufacturer kne  or should have kno n of the 
risk of injury posed by its product at the ti e of sale? 
 I    -  
4 On January 25 2011 the District Court entered its Confidentiality Order relating
to certain documents produced by the Defendant in discovery Documents filed under seal
include the following
a Affidavit of Christopher A Reilly PhDin Support ofDefendantsMotion
for Summary Judgment filed April 22 2011
b Affidavit ofRobert Nance in Support of DefendantsMotion for Summary
Judgment filed April 22 2011
c Affidavit of Counsel in Support of DefendantsMotion for Summary
Judgment filed April 22 2011
d Affidavit of Counsel in Support of PlaintiffsOpposition to Defendants
Motion for Summary Judgment and in Support of Plaintiff Cross Motion
for Partial Summary Judgment filed June 10 2011
5 The following reporterstranscripts are requested
a The July 14 2011 hearing on DefendantsMotion for Summary Judgment
PlaintiffsCross Motion for Partial Summary Judgment and Defendants
Motion to Strike Portions of the Affidavit ofGarold Yost Reporter
estimated page length is less than 100 pages
b The September 15 2011 hearing on DefendantsSecond Motion for
Summary Judgment PlaintiffsMotion for Reconsideration and
DefendantsMotion to Strike Portions of the Second Affidavit ofGarold
Yost Reporter estimated page length is less than 100 pages
c The September 22 2011 Pretrial Hearing Conference Reportersestimated
page length is less than 100 pages
d The October 17 2011 hearing on DefendantsMotion for Clarification third
motion for summary judgment and Plaintiff Second Motion for
Reconsideration Reportersestimated page length is less than 100 pages
e The January 26 2012 hearing on Plaintiffs Motion for Reconsideration
of the CourtsOrders Granting Defendants1Motion to Strike the
Affidavit of Dr Yost and 2 Motions for Summary Judgment
Reportersestimated page length is less than 100 pages
6 Appellant requests the following documents to be included in the clerks record in
addition to the standard clerksrecord
AMENDED NOTICE OF APPEAL 4
002245
.  r  , , t e istrict rt t re  its fi ti lit  r er r l ti  
t  certain c e ts roduce   the efe a t in isc er . e t  ile   l 
include the follo ing: 
(a) ffidavit  rist er . ill , h.D. in rt  f dant's ti  
f r ary e t file  ril , . 
(b) ffida it  ert  i  rt  f ndant's ti  f r r  
Judg ent filed pril 22, 2011. 
(c) ffida it  l i  rt  f dant's tio  f r r  
Judg ent filed pril 22, 2011. 
(d) ffida it f s l i  rt f l intiffs siti  t  f dant's 
otion for u ary Judg ent and in upport of laintiffs ross otion 
 ti l  t ile   , . 
. The follo ing reporter's transcripts are requested: 
(a) The July 14, 2011 hearing on efendant's otion for Su ary Judg ent, 
l intiffs r ss ti  f r rti l r  J nt,  f ndant's 
tion      id    t. eporter's 
esti ated page length is less than 100 pages. 
(b) he Septe ber 15, 2011 hearing on efendant's Second otion for 
Su ary Judg ent, Plaintiffs otion for econsideration, and 
f ndant's        i    
ost. eporter's esti ated page length is less than 100 pages. 
(c) The September 22,2011 Pretrial Hearing Conference. Reporter's estimated 
page length is less than 100 pages. 
(d)  t r ,  ri   f ndant's ti  f r l rifi ti  (thir  
ti  f r s r  j ent),  laintiffs  ti  f r 
Reconsideration. Reporter's esti ated page length is less than 100 pages. 
(e) e Ja ar  ,  eari   lai tiff's ti  f r ec si erati  
 t  ourt's  ti  fendant's (1) ti  t  t i  t  
ffidavit of r. ost, and (2) otions for Su ary Judg ent. 
eporter's esti ated page length is less than 100 pages. 
. ppellant requests the follo ing docu ents to be included in the clerk's record in 
iti  t  t  t  lerk's cord: 
   EA  -  
a Register ofAction
b Table ofContents of each volume
c Complaint2410
d Answer to the Complaint4510
e SECsMotion for Summary Judgment42211
f Memorandum in Support of SECsMotion for Summary Judgment
42211
g Affidavit of Christopher A Reilly PhDin Support of DefendantsMotion
for Summary Judgment42211
h Affidavit ofRobert Nance in Support ofDefendantsMotion for Summary
Judgment42211
i Affidavit ofCounsel in Support of DefendantsMotion for Summary
Judgment42211
j Affidavit ofCounsel in Support ofPlaintiffsOpposition to Defendants
Motion for Summary Judgment and in Support ofPlaintiff Cross Motion
for Partial Summary Judgment42211
k Affidavit of Counsel in Support ofMotion for Summary Judgment52611
1 PlaintiffsCross Motion for Partial Summary Judgment6101
m PlaintiffsOpposition to Motion for Summary Judgment and Memorandum
in Support of Cross Motion for Partial Summary Judgment6101
n Affidavit ofCounsel in Opposition to SECsMotion for Summary Judgment
and In Support of Plaintiff Cross Motion for Partial Summary Judgment
6101
o Affidavit ofGarold S Yost PhDin Opposition to SECsMotion for
Summary Judgment6101
p Affidavit ofJP Purswell PhDin Opposition to SECsMotion for
Summary Judgment and in Support ofPlaintiff Cross Motion for Partial
Summary Judgment6101
q SECsMotion to Strike Portions of the Affidavit ofGarold S Yost PhD
62411
AMENDED NOTICE OF APPEAL 5
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(a) egister of ction 
(b) a le  ntents  e h lu e 
(c) o plaint (2124/1 0) 
(d) ns er to the o plaint (4/5/10) 
(e) C's otion for Su ary Judg ent (4122/11) 
(f) e orandu  in Support of S C's otion for Su ary Judg ent 
(4122/11) 
(g) ffida it f ristopher . ill , h.D. i  rt f f ndant's tio  
for Su ary Judg ent (4122/11) 
(h) ffidavit f obert ance in upport f efendant's otion for u ary 
Judg ent (4/22/11) 
(i) ffidavit f ounsel in upport f efendant's otion for u ary 
Judgment (4/22/11) 
(j) ffidavit of ounsel in Support of Plaintiffs pposition to efendant's 
otion for Su ary Judg ent and in Support of Plaintiffs ross otion 
for Partial Su ary Judg ent (4122/11) 
(k)· ffida it f s l i  rt f tio  f r r  J t (5/26/11) 
(1) l intiffs r  ti  f r rti l r  t (6/10/11) 
(m) Plaintiffs Opposition to otion for Summary Judgment and emorandum 
in Support of ross otion for Partial Su ary Judg ent (6/10/11) 
(n) ffidavit of Counsel in pposition to SEC's otion for Su ary Judg ent 
and In Support of Plaintiffs Cross otion for Partial Su ary Judg ent 
(6/10/11) 
(0) ffidavit f arold . ost, h.D. i  pposition to EC's otion for 
Summary Judgment (6/10/11) 
(p) ffidavit ofJ.P. Purswell, Ph.D., in pposition to EC's otion for 
Su ary Judg ent and in Support of Plaintiffs ross otion for Partial 
Su ary Judg ent (6/10/11) 
(q) EC's  t  tr  rt  f t  i  f r  . t, h.D. 
(6/24/11) 
 I    -  
r Affidavit of Thomas J Lloyd in Support ofSECsMotion to Strike Portions
of the Affidavit of Garold S Yost PhD62411
s SECsMemorandum in Support ofMotion to Strike Portions of Affidavit of
Garold S Yost PhD62411
t SECsReply Memorandum in Support ofDefendantsMotion for Summary
Judgment62411
u SECsMemorandum in Opposition to Cross Motion for Partial Summary
Judgment63011
v Affidavit of Chris Burke in Support of Opposition to PlaintiffsCross
Motion for Partial Summary Judgment63011
w Affidavit ofNicholas Roberts in Support of Opposition to PlaintiffsCross
Motion for Partial Summary Judgment63011
x Affidavit of Robert Nance in Support of Opposition to PlaintiffsCross
Motion for Partial Summary Judgment63011
y Second Affidavit of Robert Nance in Support of Opposition to Plaintiffs
Cross Motion for Partial Summary Judgment63011
z Affidavit of Thomas J Lloyd III in Support ofOpposition to Plaintiffs
Cross Motion for Partial Summary Judgment711
aa PlaintiffsOpposition to SECsMotion to Strike Portions of the Affidavit of
Garold S Yost PhD711
bb PlaintiffsReply to Opposition to Cross Motion for Summary Judgment
711
cc Amended Affidavit ofJP Purswell Filed in Opposition to SECsMotion
for Summary Judgment711
dd Ex Parte Motion to Strike Amended Affidavit ofJP Purswell Filed in
Opposition to Motion for Summary Judgment711
ee PlaintiffsMotion for Order Shortening Time for Filing Amended Affidavit
ofDr Purswell7121
ff Affidavit of Counsel in Opposition to DefendantsEx Parte Motion to Strike
Dr PurswellsAmended Affidavit and in Support of PlaintiffsMotion to
Shorten Time for Filing Amended Affidavit ofDr Purswell 7121
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(r) ffida it  ho as . l  in rt  C's tio  t  trike rti s 
 t  ffida t   . , h.D. (6/2 /11) 
(s) C's e ora   t  tio   e s  ida   
 . , h.D. (6/24111) 
(t) C's e l  e ra  i  rt f efendant's tion f r ar  
naent(6/24/11) 
(u) C's e orandu  in pposition to ross otion for artial u ary 
Judgnaent (6/30/11) 
(v) ffida it  is r e i  t  iti  t  l intif s s  
otion for Partial Su ary Judgnaent (6/30/11) 
(w) ffidavit of icholas oberts in upport of pposition to laintiffs ross 
otion for Partial Su ary Judgnaent (6/30/11) 
(x) ffida it f rt  i  rt f siti  t  l intiffs r ss 
tio  f r rti l r  J na t (6/30/11) 
(y) ec  ffida it f ert a ce i  rt f siti  t  laintiffs 
ross tion  rti l  na t (6/30/11) 
(z) ffidavit of Tho as J. Lloyd III in Support of pposition to Plaintiffs 
r  ti  f r rti l r  na t (7/1 11) 
(aa) Plaintiffs pposition to SEC's otion to Strike Portions ofthe ffidavit of 
arold S. ost, Ph.D. (7/1111) 
(bb) Plaintiffs Reply to Opposition to Cross otion for Su ary Judgnaent 
(717/11) 
(cc) ended ffidavit of J.P. Purs ell Filed in pposition to SEC's otion 
for Su ary Judgnaent (717/11) 
(dd) Ex Parte otion to Strike ended ffidavit of J.P. Purs ell Filed in 
Opposition to otion for Su ary Judgnaent (7/11111) 
(ee) Plaintiffs otion for Order Shortening Time for Filing Amended Affidavit 
of Dr. Purswell (7/12/11) 
(ft) ffida it f l i  iti  t  f ndant's  rt  ti  t  tri  
r. urswell's e e  ffi a it a  i  rt f laintiffs ti  t  
Shorten i e for Filing ended ffidavit of r. Purs ell (7/12/11) 
    -  
gg Order re Pending Motions for Summary Judgment and to Strike Affidavit of
Gerald Yost7191
hh SECsSecond Motion for Summary Judgment72211
ii Second Affidavit of Christopher Burke72211
Oj Memorandum in Support ofDefendantsSecond Motion for Summary
Judgment72211
kk PlaintiffsMotion for Reconsideration72611
11 Affidavit of Counsel in Support ofPlaintiffsMotion for Reconsideration
72611
mm Affidavit ofBillie Major in Support ofPlaintiffsMotion for
Reconsideration72611
nn Affidavit of Garold S Yost PhD in Support ofPlaintiffsMotion for
Reconsideration72611
oo Memorandum in Support ofPlaintiffsMotion for Reconsideration and in
Opposition to DefendantsSecond Motion for Summary Judgment72611
pp SECsMotion to Strike Portions of Second Affidavit ofGarold S Yost
PhD8181
qq Affidavit of Thomas J Lloyd III in Support of SECsMotion to Strike
Portions of Second Affidavit ofGarold S Yost PhD8181
rr Memorandum in Support of SECsMotion to Strike Portions of Second
Affidavit of Garold S Yost PhD8181
ss Reply Memorandum in Support ofDefendants SecondMotion for
Summary Judgment and in Opposition to PlaintiffsMotion for
Reconsideration82611
tt DefendantsMotion for Clarification treated as a third motion for summary
judgment92011
uu Affidavit ofCounsel in Support of SECsMotion for Clarification92011
vv Memorandum in Support of SECsMotion for Clarification92611
ww Plaintiff s Motion for Reconsideration of CourtsOrder Granting
DefendantsMotion for Summary Judgment 1041
AMENDED NOTICE OF APPEAL 7
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(g ) r er re e i  tions f r ar  J e t a  t  tri e ffida it f 
  (7119111) 
(hh) EC's Second otion for Su ary Judg ent (7122/11) 
(ii) econd ffidavit f hristopher urke (7122111) 
Gj) e orandu  in Support of efendant's Second otion for Su ary 
Judg ent (7/22/11) 
(k ) l intiffs ti  f r i r ti  (7126111) 
(11) fida t    t  laintif s   i r t  
(7126111) 
(m ) ffidavit of illie ajor in upport f laintiffs otion for 
econsideration (7126111) 
(n ) ffida it f r l  . st, h.D., i  rt f laintiffs ti  f r 
Reconsideration (7126111) 
(00) e orandu  in Support of Plaintiffs otion for Reconsideration, and in 
siti  t  efendant's ec  tio  f r ar  J e t (7/26 11) 
(pp) C's otion to trike ortions f econd ffidavit f arold . ost, 
Ph.D. (8118111) 
(qq) ffidavit of ho as J. loyd III in Support of SEC's otion to Strike 
Portions of Second ffidavit of arold S. ost, Ph.D. (8118111) 
(rr) e ra  i  rt f EC's ti  t  tri e rti s f ec  
ffidavit f arold S. ost, h.D. (8118/11) 
(s ) l   i  t  dant's  ti   
Su ary Judg ent, and in pposition to Plaintiffs otion for 
i r ti  (812 /11) 
(tt) efendant's otion for larification (treated as a third otion for su ary 
judg ent) (9120/11) 
(uu) Affidavit of Counsel in Support of SEC's otion for Clarification (9120/11) 
(vv) e orandu  in Support of SEC's otion for larification (9126/11) 
(ww) Plaintiffs otion for Reconsideration of Court's Order Granting 
Defendant's otion for Su ary Judg ent (10/4/11) 
    -  
xx Affidavit ofBillie Jo Major in Support of PlaintiffsMotion for
Reconsideration and in Opposition to Defendant Third Motion for
Summary Judgment 1041
yy Affidavit ofCounsel in Support ofPlaintiffsMotion for Reconsideration of
CourtsOrder Granting DefendantsMotions for Summary Judgment
1041
zz Memorandum in Support ofPlaintiffsMotion for Reconsideration of
CourtsOrder Granting DefendantsMotions for Summary Judgment
1041
aaa DefendantsMemorandum in Opposition to PlaintiffsSecond Motion for
Reconsideration and in Reply to Plaintiff Opposition to Defendants
Motion for Clarification 1011 11
bbb Order Granting DefendantsMotions for Summary Judgment Striking
Affidavit ofGarold Yost and Denying Plaintiff Motions for
Reconsideration 1021
ccc Judgment1021
ddd Plaintiffs Motion for Reconsideration of the CourtsOrders Granting
Defendants1Motion to Strike The Affidavit ofDr Yost and 2
Motions for Summary Judgment 10241
eee Memorandum In Support ofPlaintiffs Motion for Reconsideration of
the CourtsOrders Granting Defendants1Motion to Strike The
Affidavit of Dr Yost and 2 Motions for Summary Judgment
10241
fff Affidavit of Garold S Yost PhD In Support of Plaintiffs Motion for
Reconsideration of This Court Order Striking The Second Affidavit
of Dr Yost10241
ggg Errata Re Affidavit of Garold S Yost PhDIn Support of Plaintiffs
Motion for Reconsideration of This Court Order Striking The
Second Affidavit ofDr Yost10251
hhh Memorandum 1 in Opposition to Plaintiffs Third Motion for
Reconsideration and 2 in Support of Security Equipment
CorporationsMotions to Strike Third Affidavit ofGarold Yost and
3 for Rule 56c Award ofAttorneys Fees and Costs 121
7 I certify
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(xx) ffidavit of illie Jo ajor in Support of laintiffs otion for 
econsideration and in pposition to efendant's hird otion for 
u ary Judg ent (10/4111) 
(yy) ffidavit of ounsel in Support of Plaintiffs otion for econsideration of 
Court's rder ranting efendant's otions for Su ary Judg ent 
(10/4111) 
(zz) e orandu  in upport f laintiffs otion for econsideration f 
ourt's rder ranting efendant's otions for Su ary Judg ent 
(10/4/11) 
(aaa) efendant's e orandu  in pposition to laintiffs Second otion for 
econsideration and in eply to Plaintiffs pposition to efendant's 
otion for larification (10/11111) 
(bbb) rder ranting efendant's otions for u ary Judg ent, triking 
fida t  d s    laintiffs tions  
econsideration (10120111) 
(ccc) Judg ent (10120111) 
(ddd) laintiff's otion for econsideration ofthe ourt's rders ranting 
dant's (1) ti  t  t i  e id it  r. t,  (2) 
otions for u ary Judg ent. (10/24/11) 
(e ) e ra   rt f l i tiff's ti  f r i r ti  f 
t  ourt's r r  r ti  f ndant's (1) ti  t  tri   
ffida it f r. st,  (2) tio s f r r  J ent. 
(10/2 111) 
(fff) ffidavit of arold . ost, h.D., I  upport of laintiff's otion for 
i tion  i  ourt's  tri i    id it 
f r. ost. (10/24111) 
(ggg) rrata e: ffidavit of arold S. ost, Ph.D., In upport of Plaintiff's 
otion for econsideration of his ourt's rder Striking he 
 ffid it f r. st. (10/2 111) 
(hhh) e orandu  (1) in Opposition to Plaintiff's Third otion for 
econsideration and (2) in upport of ecurity quip ent 
orporation's otions to trike hird ffidavit of arold ost and 
(3) f r l  6(c) ar  f tt r '   t . (12/1/11) 
. I rtify: 
    -  
a That a copy of this Amended Notice of Appeal has been served on each




200 West Front Street
Boise ID 83702
b That the reporter has been paid the estimated fee for preparation of the
reporterstranscript
c That the estimated fee for preparation of the clerksrecord has been paid
d That the appellate filing fee has been paid
e That service has been made upon all parties required to be served pursuant to
Idaho Appellate Rule 20
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(a) hat a copy of this ended otice of ppeal has been served on each 
reporter f ho  a transcript has been requested as na ed and at the address set out below: 
 a s  
   
 t  rt s  
 t t t t 
ise, I   
(b) t t  r rt r s  i  t  sti t  f  f r r r ti  f t  
reporter's transcript. 
(c) hat the esti ated fee for preparation of the clerk's record has been paid. 
(d) t t  ll t  filin  f  s  i . 
(e) hat service has been ade upon all parties required to be served pursuant to 
Idaho ppellate ule 20. 
 this 17th day of February, 2012. 
 &   
~ 
 .  
Ic .  
    -  
CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 17th day of February 2012 a true and correct copy of
the foregoing document was served on the following individualsbythe method indicated
Christopher C Burke
Thomas J Lloyd III
GREENER BURKE SHOEMAKER PA
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I E E  E TIF  that on this 17th day of February, 2012, a true and correct copy of 
the foregoing docu ent as served on the follo ing individual(s) by the ethod indicated: 
Christopher C. Burke 
s J. l  III 
     
 .  tr t, it   
,   
 a se  
   
 t  rthouse 
    
i , I   
    -  
[X] .S. ail 
[ ] x: -26  
[ ]  e  
[ ] ail: c r e greenerlaw.com 
tlloyd greenerlaw.com 
[X] .S. il 
[ ] x: 
[ ] ss r li r  
[ ] Email: 
DARWIN L. OVERSON 





FES 2 4 2012
Christopher C Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKER PA




Attorneys for Cross Appellant
CHRMDPHER D RICH Clerk
ByJOANNA ORTEAA
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA




CORPORATION a Missouri corporation
Case No CVPI 1003515
SECURITY EQUIPMENT
CORPORATION NOTICE OF CROSS
APPEAL
Defendant
TO THE ABOVENAMED CROSS RESPONDENT BILLIE JO MAJOR AND HER
ATTORNEYS OF RECORD DARWIN OVERSON AND ERIC B SWARTZ JONES
SWARTZ PLLC AND THE CLERK OF THE ABOVE ENTITLED COURT
NOTICE IS HEREBY GIVEN that
1 The abovenamed Cross Appellant Security Equipment Corporation SEC or
CrossAppellant appeals against the abovenamed Cross Respondent to the Idaho Supreme
Court from the Order Denying DefendantsMotion to Strike Third Affidavit of Garold Yost the
Order entered in the above entitled action on the 3 day of February 2012 the Honorable
Judge Cheri C Copsey presiding
SECURITY EQUIPMENT CORPORATIONSNOTICE OF CROSS APPEAL Page 1
14542011 448846doc
002252
hristopher . urke, IS  #2098 
ho as J. loyd III, IS  #7772 
ER E E   
 . a ock tr t, ite  
Boise, Idaho 83702 
el: (208) 319-2600 
Fax: (208) 319-2601 
ttorneys for ross- ppellant 
ORIGINAL : [rot: ~._. _ 
B   
ISTOPH  . ,  
  G  
 
           
  ,        
I IE J  J , an individual, 
Plaintiff, 
v. 
I  I  
CORPORATION, a issouri corporation, 
nt. 
 o.: - I-I0  
I  I  
PORATION'S   -
 
:  -NA E  - ONDENT, IE  ,   
S  D, I    I  . TZ, J  
& , ,      - I   
I  I   I , that: 
. he above-na ed ross- ppellant, Security quip ent orporation ("S " or 
"Cross-Appellant"), appeals against the above-na ed Cross-Respondent to the Idaho Supre e 
ourt fro  the rder enying efendant's otion to Strike hird ffidavit of arold ost (the 
"Ord "), e tere  i  t e a e-entitle  acti   t e  rd a  f ebr ary, 12, t e ra le 
Judge Cheri C. Copsey, presiding. 
SECURITY EQUIPMENT CORPORA nON'S NonCE OF CROSS-APPEAL - Page 1 
14542-011 (448846.doc) 
2 Cross Appellant SEC has a right to cross appeal to the Idaho Supreme Court and
the Order described in Paragraph 1 above is an appealable Order under and pursuant to Rule
I Ia7 ofIAR
3 Cross Appellant requests review of the following issue
a Did the District Court abuse its discretion in denying DefendantsMotion
to Strike Third Affidavit of Garold Yost
4 No additional reporterstranscript is requested other than that already requested
by AppellantsNotice and Amended Notice of Appeal
5 No additional clerks record is requested other than that previously requested by
Appellant in the Notice and Amended Notice of Appeal and by Respondent in its Request for
Additional Record and Supplemental Request for Additional Record
6 I certify that service has been made upon all parties required to be served
pursuant to Rule 20
DATED thisA day of February 2012
SECURITY EQUIPMENT CORPORATIONSNOTICE OF CROSS APPEAL Page 2
14542011 448846doc
Thomas J Lloyd III
Attorneys for Cross Appellant
002253
2. Cross-Appellant SEC has a right to cross-appeal to the Idaho Supreme Court, and 
the rder described in Paragraph 1 above is an appealable rder under and pursuant to ule 
11(a)(7) ofLA.R.. 
. ross- ppellant requests revie  of the follo ing issue: 
. d the ist ict t  ts s retion i   dant's tion 
 rike hird ffidavit  a ld t? 
. o additional reporter's transcript is requested, other than that already requested 
by Appellant's Notice and Amended Notice of Appeal. 
. o additional clerk's record is requested, other than that previously requested by 
Appellant in the Notice and Amended Notice of Appeal, and by Respondent in its Request for 
Additional Record and Supple ental Request for Additional Record. 
. I certify that service has been ade upon all parties required to be served, 
pursuant to Rule 20. 
 t i  ffi.y of February, 2012. 
Chn pher C. Burke 
Tho as 1. Lloyd III 
Attorneys for Cross-Appellant 
SECURITY EQUIP ENT CORPORATION'S NOTICE OF CROSS-APPEAL - Page 2 
14542-011 (448846.doc) 
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing Security Equipment
CorporationsNotice of Cross Appeal on the following named persons on the date indicated
below in the manner indicated below
Darwin Overson Esq ViaUS Mail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O BOX 7808
Boise Idaho 83707
AttorneyforPlaintiff
Clerk of Court ViaUS Mail
FOURTH JUDICIAL DISTRICT ADA COUNTY ViaHand Delivery
200 W Front Street Via Facsimile
Boise Idaho 83702 Via Overnight Delivery




Thomas J Lloyd III
SECURITY EQUIPMENT CORPORATIONSNOTICE OF CROSS APPEAL Page 3
14542011 448846doc
002254
E   
I hereby certify that I caused to be served the foregoing ec rity ip e t 
orporation's otice of ross- ppeal on the follo ing na ed person(s) on the date indicated 
b l , in t e r i icated l : 
ar in verson, Esq. 
ric . artz, s . 
 & S , PLL  
1673 . Shoreline rive, Suite 220 
. . ox  
Boise, Idaho 83707 
Attorney for Plaintiff 
e    
FOURTH JUDICIAL DISTRICT, ADA COUNTY 
 . t  
oise, Idaho 83702 
TE  this ffiay of February, 2012. 
/ 
[.f] ia .S.  
[ ] ia and  
[ ] ia le (20 /489-8 ) 
[ ] ia vernight elivery 
[ JVi  .S.  
[ ia and elivery 
[ ]  i  
[ ] ia vernight elivery 
i0(l . 0 ~ 
~HlJJ\J~k 
Christopher C. Burke 
Tho as 1. Lloyd III 




FEB 2 4 2011
ChristopherC Burke ISB 2098
Thomas J Lloyd III ISB 7772
GREENER BURKE SHOEMAKER PA





CHRISTOPHER D RICH Clerk
By JOANNA ORTEGA
DEPUTY
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO IN AND FOR THE COUNTY OF ADA












TO THE ABOVENAMED APPELLANT AND THE PARTYSATTORNEY AND THE
CLERK OF THE ABOVE ENTITLED COURT
NOTICE IS HEREBY GIVEN that the Respondent Security Equipment Corporation
SEC or Respondent by and through its counsel of record Greener Burke Shoemaker PA
in the above entitled proceeding hereby requests pursuant to Rule 19IARthe inclusion of the
following additional material in the Clerksrecord in addition to that required to be included by
theIARthe Notice of Appeal and the Amended Notice of Appeal
1 Clerks Record
a May 7 2010 Stipulation for Scheduling and Planning
b May 28 2010 Order Governing Proceedings and Trial Setting
SECURITY EQUIPMENT CORPORATIONSSUPPLEMENTAL REQUEST FOR ADDITIONAL RECORD
FOLLOWING APPELLANTSAMENDED NOTICE OF APPEAL Page 1 14542011 448845doc
002255
'. . , 
 
AM l&)6~, __ :_:_: 
hristopher . urke, IS  #2098 
ho as 1. loyd III, IS  #7772 
  ER P  
 . a  tr t, ite  
oise, Idaho 83702 
Tel: (208) 319-2600 
Fax: (208) 319-2601 
ttorneys for efendant 
EB  % 2 
I  . ,  
   
O  
           
  I , I        
I   J ,  i i i l, 
Plaintiff, 
v. 
S I  IP  
CORPORATION, a issouri corporation, 
nt. 
 .: -PI-I  
I  I  
PORATION'S L  
    
 PEL ANT'S  
   
:  -NAME  L    ARTY'S Y,   
   -   
I  IS  I , that the espondent, Security quip ent orporation 
("SEC" or "Respondent"),  a  t r  its c sel f rec rd, ree er r e e a er .A., 
i  t e a e-e title  r cee i  ere  re ests, rs a t t  le , I.A.R., t e i cl si  f t e 
following additional material in the Clerk's record in addition to that required to be included by 
the I.A.R., the Notice of Appeal and the A ended Notice of Appeal. 
. lerk's cord: 
. ay 7, 2010 Stipulation for Scheduling and Planning; 
. ay 28, 2010 rder overning Proceedings and Trial Setting; 
SECURITY EQUIP ENT CORPORA nON'S SUPPLE ENTAL REQUEST FOR ADDITIONAL RECORD 
I  PEL ANT'S  I    - age  14542-011 (448845.doc) 
r
January 26 2011 Confidentiality Order
d May 13 2011 Order Governing Proceedings and Setting Trial
e December 1 2011 DefendantsMotion to Strike Third Affidavit of
Garold Yost PhDfiled in support of Plaintiffs Motion for
Reconsideration
December S 2011 Affidavit of Counsel in Support of Plaintiffs Reply
g December 13 2011 Reply Memorandum in Support of Security
Equipment CorporationsMotion to Strike Third Affidavit ofGarold
Yost
h February 3 2012 Amended Judgment and
February 3 2012 Order Denying Plaintiffs Third Motion for
Reconsideration Denying DefendantsMotion to Strike Third Affidavit
of Garold Yost Denying DefendantsMotion for Rule 56cAttorney
Fees and Awarding Defendant Costs
Pursuant to Rule 27IARRespondent requests that the Clerk provide scanned copies of
the designated clerksrecord
2 I further certify that this request for additional record has been served upon the
Clerk of the District Court and upon all parties required to be served pursuant to Rule 20




Thomas J Lloyd III
Attorneys for Defendant
SECURITY EQUIPMENT CORPORATIONSSUPPLEMENTAL REQUEST FOR ADDITIONAL RECORD
FOLLOWING APPELLANTSAMENDED NOTICE OF APPEAL Page 2 14542011 448845doe
002256
c. January 26, 2011 Confidentiality rder; 
d. ay 13,2011 Order Governing Proceedings and Setting Trial; 
e. Dece ber 1, 2011 efendant's otion to Strike Third ffidavit of 
arold st, h.D., filed in s t f l i tiff's otion fo  
ec si er ti ; 
f. ece ber 8, 2011 ffidavit of ounsel in Support of Plaintiff's eply; 
g. e  , 11 e l  e o andum i  t f it  
Equipment Corporation's otion to Strike Third Affidavit of Garold 
ost; 
. February 3, 2012 A ended Judg ent; and 
1. February 3, 2012 Order Denying Plaintiff's Third otion for 
econsideration, enying efendant's otion to Strike Third ffidavit 
of arold ost, enying efendant's otion for ule 56(c) ttorney 
ees, and arding efendant osts. 
rs a t t  le , I.A.R., es e t re ests t at t e ler  r i e sca e  c ies f 
the designated clerk's record. 
. I further certify that this request for additional record has been served upon the 
Clerk ofthe District Court and upon all parties required to be served pursuant to Rule 20. 
 t i  Nday of February, 2012. 
Chri t r . Burke 
Tho as 1. Lloyd III 
Attorneys for efendant 
SECURITY EQUIPMENT CORPORATION'S SUPPLEMENTAL REQUEST FOR ADDITIONAL RECORD 
FOLLOWING APPELLANT'S AMENDED NOTICE OF APPEAL - Page 2 14542-011 ( 48845 doc) 
CERTIFICATE OF SERVICE
I hereby certify that I caused to be served the foregoing Security Equipment
CorporationsSupplemental Request for Additional Record Following Appellants
Amended Notice ofAppeal on the following named personson the date indicated below in
the manner indicated below
Darwin Overson Esq ViaUS Mail
Eric B Swartz Esq Via Hand Delivery
JONES SWARTZ PLLC Via Facsimile 2084898988
1673 W Shoreline Drive Suite 220 Via Overnight Delivery
P O Box 7808
Boise Idaho 83707
Attorneyfor Plaintiff
Clerk of Court ViaUSMail
FOURTH JUDICIAL DISTRICT ADA COUNTY Hand DeliveryVia
200 W Front Street Via Facsimile
Boise Idaho 83702 Via Overnight Delivery
DATED this 7 day of February 2012
Christopher C Burke
Thomas J Lloyd III
SECURITY EQUIPMENT CORPORATIONSSUPPLEMENTAL REQUEST FOR ADDITIONAL RECORD
FOLLOWING APPELLANTSAMENDED NOTICE OF APPEAL Page 3 14542 011 448845doc
002257
" . 
CE IFICATE F S ICE 
I hereby certify that I caused to be served the foregoing Security quipment 
Corporation's Supplemental Request for Additional Record Following Appellant's 
A ended Notice of Appeal on the following na ed person(s) on the date indicated below, in 
the a er indicated b l : 
Darwin Overson, Esq. 
Eric B. Swartz, Esq. 
 & S TZ, PLL  
 . reline ri e, ite  
. .   
Boise, Idaho 83707 
Attorney for Plaintifj 
l   t 
F RT  J ICI L ISTRICT,  C T  
200 . Front Street 
Boise, Idaho 83702 
 thIS 1~{."y of February, 2012. 
[.t1 ia .S. a l 
[ ] ia a  ivery 
[ ] ia ile (208/489-89 ) 
[ ] ia er i t eli er  
[ ); ia .S. il 
[/I Via  e  
[ ] ia si i  
[ ] Via r i t li r  
lQ· a l ~&tL 1!~L 
hristopher . urke 
as 1. l  III 
SECURITY EQUIPMENT CORPORATION'S SUPPLEMENTAL REQUEST FOR ADDITIONAL RECORD 




A.M. , ::,. 
MAR 06 2012 
CHRISTOPHER D. RICH, Clerk 
Christopher C. Burke, ISB #2098 By s"rEPHANIE VIDAK 
DEPUTYThomas 1. Lloyd III, ISB #7772 
GREENER BURKE SHOEMAKER PA 
950 W. Bannock Street, Suite 900 
Boise, Idaho 83702 
Tel: (208) 319-2600 
Fax: (208) 319-2601 
Attorneys for Defendant 
IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF ADA 




CORPORATION, a Missouri corporation, 
Defendant. 
Case No.: CY-PI-I003515 
NOTICE OF CHANGE OF ADDRESS 
TO: ALL COUNSEL OF RECORD 
YOU ARE HEREBY NOTIFIED that effective March 5, 2012, our office relocated to the 
following address (suite number is the only change): 
GREENER BURKE SHOEMAKER P.A.
 




Our phone and fax numbers will remain the same:
 
Telephone No. (208) 319-2600
 
Facsimile No. (208) 319-2601
 
Please direct all future communications, correspondence and court-related documentation 
to the above address as of March 5, 2012. 


















DATED this 6th day of March, 2012. 
(]::&tI:t:L
Chnstopher C. Burke 
Thomas 1. Lloyd III 
Attorneys for Defendant 
CERTIFICATE OF SERVICE 
I hereby certify that I caused to be served the foregoing Notice of Change of Address on 
the following named person(s) on the date indicated below, in the manner indicated below: 
/ 
Darwin Overson, Esq. [ I] Via U.S. Mail 
Eric B. Swartz, Esq. [ ] Via Hand Delivery 
JONES & SWARTZ, PLLC [ ] Via Facsimile (208/489-8988) 
1673 W. Shoreline Drive, Suite 220 [ ] Via Overnight Delivery 
P. O. Box 7808 
Boise, Idaho 83707 




Thomas J. Lloyd III
 

































NOTICE OF TRANSCRIPT LODGED 
39414-2011 
NO. FILED 
A.M.-!l" 'D y.MI --­
APR 02 2012 
CHRISTOPHER D. RICH, Clerk 









200 West Front Street 
Boise, Idaho 83702 
(208) 287-7583 
Clerk of the Court 
Idaho Supreme Court 
451 West State Street 
Boise, Idaho 83720 
TO: 
. . . . . . Se ptemb e r 1 5, 2 011 
. . . . . . Se ptemb e r 2 2, 2 011 
July 14, 2011 
Notice is hereby given that on January 11, 2012, I 
lodged an appeal transcript of 201 pages in length for 
the above-referenced appeal with the District Court 
Clerk of the County of Ada in the 4th Judicial 
District 
This transcript contains hearings held on 
October 17, 2011 
002260
A.M.-!' '. 'j) y.M ___ -
o
...... 
      




A.M.--/._ P.M, _ 
































 NOTICE OF TRANSCRIPT LODGED 
14
 This transcript contains hearings held on
 
15
































 Notice is hereby given that
 
lodged an appeal transcript
 
12
 the above-referenced appeal
 




on March 23, 2012, I
 
of 39 pages in length for
 
with the District Court
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF 
THE STATE OF IDAHO, IN AND FOR THE COUNTY OF ADA 
BILLIE JO MAJOR, an individual,
 





 CERTIFICATE OF EXHIBITS 





I, CHRISTOPHER D. RICH, Clerk ofthe District Court of the Fourth Judicial District of 
the State of Idaho in and for the County of Ada, do hereby certify: 
There were no exhibits offered for identification or admitted into evidence during the 
course of this action. 
I FURTHER CERTIFY, that the following documents will be submitted as 
CONFIDENTIAL EXHIBITS to the Record: 
1.	 Affidavit of Christopher A. Reilly, Ph.D. In Support ofDefendant's Motion for Summary
 
Judgment, filed April 22, 2011. (Filed Under Seal Pursuant To Confidentiality Order)
 
2.	 Affidavit of Robert Nance in Support ofDefendant's Motion for Summary Judgment,
 
filed April 22, 2011. (Filed Under Seal Pursuant to Confidentiality Order)
 
3.	 Affidavit of Counsel in Support of Defendant's Motion for Summary Judgment, Filed
 
April 22, 2011. (Filed Under Seal Pursuant to Confidentiality Order)
 
4.	 Affidavit of Counsel in Support ofPlaintiff's Opposition to Defendant's Motion for
 
Summary Judgment and In Support ofPlaintiffs Cross Motion for Partial Summary
 
Judgment, filed June 10,2011. (Filed Under Seal)
 
IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 
Court this 2nd day of April, 2012. 
"........",

~" .,. 4 'I,......~ a\)Rl TiI.I. ,,_, 
~~	 c.; ......••• &'<::> ." 
.... " •• e. % " "c..,. .C'''. 
: .... •• OF THE •• '. ­
CHRISTOPHER D.~r' - s?'''1l'~r~ ~ 
.,.,"...., 
--L.!..\J.44LAu.tl~~J.l!(lt\Jij~JA('.J 
Clerk of the Distric· ;'.) • ~ Op ~ : 2 :.', 
1/)-4/jO .: .-< " . ..­ ~ 
~.	 . .,...~ 
/or, •••• \. 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
 
THE STATE OF IDAHO, IN AND FOR THE COUNTY OF ADA
 
BILLIE JO MAJOR, an individual, 
Plaintiff-Appellant-Cross Respondent, 
vs. 
SECURITY EQUIPMENT CORPORATION, a 
Missouri corporation, 
Defendant-Respondent-Cross Appellant. 
Supreme Court Docket No. 39414-2011 
CERTIFICATE OF SERVICE 
I, CHRISTOPHER D. RICH, the undersigned authority, do hereby certify that I have 
personally served or mailed, by either United States Mail or Interdepartmental Mail, one copy of 
the following: 
CLERK'S RECORD AND REPORTER'S TRANSCRIPT 
to each of the Attorneys ofRecord in this cause as follows: 
DARWIN OVERSON CHRISTOPHER C. BURKE 
ATTORNEY FOR APPELLANT ATTORNEY FOR RESPONDENT 
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IN THE DISTRICT COURT OF THE FOURTH JUDICIAL DISTRICT OF
 
THE STATE OF IDAHO, IN AND FOR THE COUNTY OF ADA
 
BILLIE JO MAJOR, an individual, 
Plaintiff-Appellant-Cross Respondent, 
vs. 
SECURITY EQUIPMENT CORPORATION, a 
Missouri corporation, 
Defendant-Respondent-Cross Appellant. 
Supreme Court Docket No. 39414-2011 
CERTIFICATE TO RECORD 
I, CHRISTOPHER D. RICH, Clerk of the District Court of the Fourth Judicial District of the 
State of Idaho, in and for the County of Ada, do hereby certify that the above and foregoing record in 
the above-entitled cause was compiled under my direction as, and is a true and correct record of the 
pleadings and documents that are automatically required under Rule 28 of the Idaho Appellate Rules, 
as well as those requested by Counsels. 
I FURTHER CERTIFY, that the Notice of Appeal was filed in the District Court on the 
23rd day ofNovember, 2011. 
• '\ i;. ~ 
,-", \,R1 ." " 
...~.,. CO ••••••• J 
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